0	Reversed	transcription	1
1	transcription	(	2
2	(	<ROOT>	-1
3	RT	(	2
4	)	RT	3
5	-PCR	analysis	6
6	analysis	mRNA	9
7	demonstrated	analysis	6
8	GH	mRNA	9
9	mRNA	(	2
10	in	mRNA	9
11	neutrophils	in	10
12	.	(	2

0	An	element	2
1	enhancer-blocking	element	2
2	element	between	3
3	between	<ROOT>	-1
4	alpha	between	3
5	and	alpha	4
6	delta	segments	8
7	gene	segments	8
8	segments	and	5
9	within	and	5
10	the	cell	13
11	human	cell	13
12	T	cell	13
13	cell	within	9
14	receptor	alpha/delta	15
15	alpha/delta	locus	16
16	locus	cell	13
17	.	and	5

0	Thus	may	3
1	,	may	3
2	GATA-3	may	3
3	may	<ROOT>	-1
4	play	may	3
5	an	role	7
6	important	role	7
7	role	play	4
8	in	play	4
9	the	balance	10
10	balance	in	8
11	between	play	4
12	Th1	between	11
13	and	Th2	14
14	Th2	Th1	12
15	subsets	may	3
16	in	subsets	15
17	immune	responses	18
18	responses	in	16
19	.	may	3

0	This	review	1
1	review	discussed	15
2	outlines	review	1
3	general	features	4
4	features	outlines	2
5	of	features	4
6	signal	transduction	7
7	transduction	and	8
8	and	of	5
9	several	aspects	10
10	aspects	and	8
11	of	cytokine	12
12	cytokine	aspects	10
13	networks	are	14
14	are	review	1
15	discussed	the	32
16	with	discussed	15
17	emphasis	discussed	15
18	on	emphasis	17
19	:	on	18
20	transcriptional	regulation	21
21	regulation	on	18
22	of	regulation	21
23	Th1	of	22
24	and	Th1	23
25	Th2-specific	cytokine	26
26	cytokine	and	24
27	genes	Th1	23
28	in	T	29
29	T	genes	27
30	cells	discussed	15
31	,	the	32
32	the	<ROOT>	-1
33	roles	the	32
34	of	roles	33
35	cytokines	of	34
36	and	cytokines	35
37	their	and	36
38	receptors	their	37
39	in	their	37
40	growth	in	39
41	and	growth	40
42	differentiation	the	32
43	of	differentiation	42
44	hemopoietic	of	43
45	cells	hemopoietic	44
46	,	of	43
47	and	of	43
48	the	manipulation	49
49	manipulation	cytokine	51
50	of	cytokine	51
51	cytokine	and	47
52	networks	the	32
53	.	the	32

0	With	<ROOT>	-1
1	the	aim	2
2	aim	With	0
3	of	aim	2
4	gaining	of	3
5	insight	gaining	4
6	into	gaining	4
7	the	function	8
8	function	into	6
9	of	activation	11
10	context-dependent	activation	11
11	activation	function	8
12	domains	With	0
13	,	domains	12
14	we	ALY	16
15	cloned	ALY	16
16	ALY	,	13
17	,	ALY	16
18	a	protein	21
19	novel	protein	21
20	LEF-1-interacting	protein	21
21	protein	,	17
22	.	With	0

0	EBF	and	1
1	and	<ROOT>	-1
2	E47	and	1
3	collaborate	to	4
4	to	E47	2
5	induce	to	4
6	expression	of	7
7	of	induce	5
8	the	immunoglobulin	10
9	endogenous	immunoglobulin	10
10	immunoglobulin	of	7
11	surrogate	and	1
12	light	and	1
13	chain	and	1
14	genes	and	1
15	.	and	1

0	No	degradation	1
1	degradation	was	7
2	of	degradation	1
3	p105	of	2
4	and	p105	3
5	p100	inhibitors	6
6	inhibitors	and	4
7	was	<ROOT>	-1
8	observed	was	7
9	under	observed	8
10	these	conditions	11
11	conditions	under	9
12	.	was	7

0	The	receptor	2
1	prolactin	receptor	2
2	receptor	superfamily	10
3	,	receptor	2
4	a	member	5
5	member	receptor	9
6	of	receptor	9
7	the	receptor	9
8	hematopoietin/cytokine	receptor	9
9	receptor	receptor	2
10	superfamily	ubiquitously	13
11	,	superfamily	10
12	is	ubiquitously	13
13	ubiquitously	<ROOT>	-1
14	expressed	ubiquitously	13
15	by	expressed	14
16	cells	in	17
17	in	by	15
18	the	by	15
19	immune	.	21
20	system	.	21
21	.	the	18

0	In	<ROOT>	-1
1	contrast	In	0
2	,	cell	4
3	somatic	cell	4
4	cell	In	0
5	fusion	between	6
6	between	In	0
7	clone	between	6
8	13	In	0
9	and	In	0
10	RJ2.2.5	In	0
11	restored	In	0
12	expression	haplotype	16
13	of	haplotype	16
14	the	haplotype	16
15	HLA-DQ	haplotype	16
16	haplotype	restored	11
17	encoded	haplotype	16
18	by	encoded	17
19	the	by	18
20	RJ2.2.5	the	19
21	DQB	gene	22
22	gene	RJ2.2.5	20
23	.	gene	22

0	These	findings	1
1	findings	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	a	AP-2-like	6
5	novel	AP-2-like	6
6	AP-2-like	factor	8
7	transcription	factor	8
8	factor	is	9
9	is	that	3
10	responsible	is	9
11	for	responsible	10
12	V-ATPase	subunit	14
13	B	subunit	14
14	subunit	for	11
15	amplification	suggest	2
16	during	amplification	15
17	monocyte	amplification	15
18	differentiation	suggest	2
19	.	suggest	2

0	These	results	1
1	results	add	2
2	add	<ROOT>	-1
3	to	add	2
4	our	knowledge	5
5	knowledge	to	3
6	about	knowledge	5
7	the	molecules	8
8	molecules	implicated	9
9	implicated	about	6
10	along	monocytic	12
11	the	monocytic	12
12	monocytic	implicated	9
13	differentiation	implicated	9
14	and	implicated	9
15	growth	add	2
16	arrest	add	2
17	of	leukemic	18
18	leukemic	arrest	16
19	cells	add	2
20	and	add	2
21	provide	and	20
22	a	step	24
23	first	step	24
24	step	provide	21
25	in	step	24
26	the	study	27
27	study	in	25
28	of	study	27
29	their	respective	30
30	respective	of	28
31	roles	respective	30
32	.	roles	31

0	These	transcripts	1
1	transcripts	<ROOT>	-1
2	can	transcripts	1
3	encode	can	2
4	three	proteins	5
5	proteins	encode	3
6	of	calculated	7
7	calculated	proteins	5
8	molecular	kDa	11
9	mass	32.2	10
10	32.2	molecular	8
11	kDa	calculated	7
12	,	calculated	7
13	27.8	kDa	14
14	kDa	transcripts	1
15	,	transcripts	1
16	and	14.3	17
17	14.3	transcripts	1
18	kDa	transcripts	1
19	.	transcripts	1

0	The	mean	1
1	mean	concentrations	2
2	concentrations	<ROOT>	-1
3	necessary	concentrations	2
4	to	necessary	3
5	cause	%	7
6	50	%	7
7	%	to	4
8	inhibition	%	7
9	of	lymphocyte	10
10	lymphocyte	inhibition	8
11	proliferation	lymphocyte	10
12	(	to	4
13	IC50s	to	4
14	)	to	4
15	for	concentrations	2
16	the	group	18
17	steroid-sensitive	group	18
18	group	for	15
19	ranged	concentrations	2
20	from	10-LRB--10-RRB-	23
21	2	x	22
22	x	10-LRB--10-RRB-	23
23	10-LRB--10-RRB-	ranged	19
24	mol/L	10-LRB--10-RRB-	23
25	for	10-LRB--10-RRB-	23
26	budesonide	for	25
27	to	budesonide	26
28	7	budesonide	26
29	x	10-LRB--8-RRB-	30
30	10-LRB--8-RRB-	budesonide	26
31	mol/L	for	32
32	for	budesonide	26
33	hydrocortisone	concentrations	2
34	,	concentrations	2
35	whereas	concentrations	2
36	the	whereas	35
37	mean	the	36
38	IC50s	mean	37
39	for	IC50s	38
40	the	10-LRB--8-RRB-	48
41	steroid-resistant	10-LRB--8-RRB-	48
42	group	10-LRB--8-RRB-	48
43	ranged	approximately	45
44	from	approximately	45
45	approximately	10-LRB--8-RRB-	48
46	2	approximately	45
47	x	10-LRB--8-RRB-	48
48	10-LRB--8-RRB-	for	39
49	mol/L	IC50s	38
50	for	mol/L	49
51	budesonide	to	52
52	to	for	50
53	greater	to	52
54	than	greater	53
55	10-LRB--6-RRB-	than	54
56	mol/L	for	57
57	for	10-LRB--6-RRB-	55
58	hydrocortisone	concentrations	2
59	.	concentrations	2

0	Since	<ROOT>	-1
1	it	is	2
2	is	Since	0
3	known	is	2
4	that	known	3
5	PGE2	is	6
6	is	that	4
7	able	cAMP	10
8	to	able	7
9	increase	to	8
10	cAMP	is	6
11	levels	is	6
12	,	is	6
13	we	whether	15
14	investigated	whether	15
15	whether	is	6
16	it	whether	15
17	can	it	16
18	affect	can	17
19	gene	affect	18
20	expression	through	21
21	through	gene	19
22	the	activation	23
23	activation	gene	19
24	of	activation	23
25	the	factors	27
26	transcription	factors	27
27	factors	of	24
28	which	bind	29
29	bind	factors	27
30	enhancer	in	32
31	elements	in	32
32	in	bind	29
33	the	in	32
34	promoter	the	33
35	regions	promoter	34
36	of	regions	35
37	cAMP-regulated	genes	38
38	genes	of	36
39	.	of	36

0	Adherent	cells	1
1	cells	were	2
2	were	<ROOT>	-1
3	counted	were	2
4	by	counted	3
5	digital	by	4
6	image	analysis	7
7	analysis	digital	5
8	.	were	2

0	Induction	is	3
1	of	Induction	0
2	STAT3	of	1
3	is	<ROOT>	-1
4	inhibited	is	3
5	by	inhibited	4
6	both	protein	9
7	the	protein	9
8	serine/threonine	protein	9
9	protein	by	5
10	kinase	inhibited	4
11	inhibitor	H-7	12
12	H-7	the	14
13	and	the	14
14	the	inhibited	4
15	immunosuppressive	the	14
16	drug	rapamycin	17
17	rapamycin	immunosuppressive	15
18	and	requires	19
19	requires	rapamycin	17
20	de	immunosuppressive	15
21	novo	de	20
22	protein	novo	21
23	synthesis	protein	22
24	,	novel	26
25	demonstrating	novel	26
26	novel	synthesis	23
27	coupling	and	30
28	between	and	30
29	sIg	and	30
30	and	protein	22
31	STAT	and	30
32	proteins	is	3
33	that	differs	34
34	differs	is	3
35	from	is	3
36	the	paradigm	38
37	classical	paradigm	38
38	paradigm	from	35
39	for	STAT	40
40	STAT	paradigm	38
41	induction	by	42
42	by	paradigm	38
43	cytokine	paradigm	38
44	receptors	is	3
45	.	is	3

0	Thus	<ROOT>	-1
1	,	Thus	0
2	replication	,	1
3	of	replication	2
4	the	of	3
5	transcriptional	the	4
6	template	is	7
7	is	transcriptional	5
8	not	is	7
9	a	prerequisite	10
10	prerequisite	is	7
11	for	prerequisite	10
12	expression	with	13
13	with	for	11
14	late	kinetics	15
15	kinetics	with	13
16	,	is	7
17	a	,	16
18	finding	a	17
19	inconsistent	finding	18
20	with	inconsistent	19
21	the	with	20
22	current	the	21
23	models	posit	25
24	which	posit	25
25	posit	current	22
26	a	relationship	28
27	cis-active	relationship	28
28	relationship	lytic	30
29	between	lytic	30
30	lytic	posit	25
31	EBV	replication	33
32	DNA	replication	33
33	replication	lytic	30
34	and	replication	33
35	late	and	34
36	gene	late	35
37	expression	.	38
38	.	gene	36

0	Bacterial	induces	6
1	lipopolysaccharide	Bacterial	0
2	(	LPS	3
3	LPS	Bacterial	0
4	)	LPS	3
5	rapidly	induces	6
6	induces	<ROOT>	-1
7	TF	transcription	9
8	gene	transcription	9
9	transcription	induces	6
10	in	transcription	9
11	monocytes	induces	6
12	.	induces	6

0	This	report	1
1	report	provides	2
2	provides	are	21
3	the	demonstration	5
4	first	demonstration	5
5	demonstration	provides	2
6	that	demonstration	5
7	upon	that	6
8	fusion	upon	7
9	with	HeLa	10
10	HeLa	fusion	8
11	cells	provides	2
12	,	are	21
13	the	contents	15
14	nuclear	contents	15
15	contents	are	21
16	of	contents	15
17	B	factors	20
18	cell-expressed	factors	20
19	transcription	factors	20
20	factors	of	16
21	are	<ROOT>	-1
22	depleted	are	21
23	within	depleted	22
24	a	hours	26
25	few	hours	26
26	hours	within	23
27	with	depleted	22
28	kinetics	with	27
29	that	are	30
30	are	kinetics	28
31	as	fast	32
32	fast	are	30
33	or	fast	32
34	faster	or	33
35	than	faster	34
36	that	than	35
37	of	that	36
38	Ig	of	37
39	gene	.	41
40	extinction	.	41
41	.	Ig	38

0	Thus	is	9
1	,	is	9
2	the	sequence	4
3	GAS	sequence	4
4	sequence	is	9
5	in	sequence	4
6	the	LTR	8
7	CAEV	LTR	8
8	LTR	in	5
9	is	<ROOT>	-1
10	essential	is	9
11	for	is	9
12	the	and	16
13	response	the	12
14	to	response	13
15	IFN-gamma	the	12
16	and	for	11
17	a	factor	19
18	STAT1-like	factor	19
19	factor	and	16
20	binds	and	16
21	to	this	22
22	this	binds	20
23	site	is	9
24	.	is	9

0	Thus	Oct-2	1
1	Oct-2	plays	2
2	plays	<ROOT>	-1
3	an	role	5
4	important	role	5
5	role	plays	2
6	in	the	7
7	the	plays	2
8	regulation	of	9
9	of	the	7
10	cellular	in	13
11	gene	in	13
12	expression	in	13
13	in	of	9
14	both	B	15
15	B	in	13
16	cells	plays	2
17	and	plays	2
18	neuronal	plays	2
19	cells	plays	2
20	as	plays	2
21	well	plays	2
22	as	plays	2
23	in	as	22
24	the	in	23
25	control	the	24
26	of	viral	27
27	viral	control	25
28	latency	plays	2
29	.	plays	2

0	Suppression	<ROOT>	-1
1	of	Suppression	0
2	human	responses	6
3	anti-porcine	responses	6
4	T-cell	responses	6
5	immune	responses	6
6	responses	of	1
7	by	transactivator	13
8	major	transactivator	13
9	histocompatibility	transactivator	13
10	complex	transactivator	13
11	class	transactivator	13
12	II	transactivator	13
13	transactivator	Suppression	0
14	constructs	Suppression	0
15	lacking	constructs	14
16	the	domain	19
17	amino	domain	19
18	terminal	domain	19
19	domain	lacking	15
20	.	Suppression	0

0	Inhibition	observed	14
1	of	Inhibition	0
2	TF	induction	3
3	induction	of	1
4	in	the	5
5	the	of	1
6	presence	the	5
7	of	presence	6
8	high	concentrations	11
9	CsA	concentrations	11
10	blood	concentrations	11
11	concentrations	of	7
12	was	Inhibition	0
13	also	observed	14
14	observed	<ROOT>	-1
15	when	was	19
16	stimulation	was	19
17	of	stimulation	16
18	cells	of	17
19	was	observed	14
20	performed	was	19
21	with	performed	20
22	interferon-gamma	with	21
23	or	with	21
24	interleukin-1beta	or	23
25	.	observed	14

0	Transient	analyses	2
1	expression	analyses	2
2	analyses	demonstrated	10
3	in	analyses	2
4	cells	of	5
5	of	analyses	2
6	neuroglial	of	5
7	and	lymphocytic	8
8	lymphocytic	neuroglial	6
9	origin	analyses	2
10	demonstrated	<ROOT>	-1
11	that	demonstrated	10
12	some	had	16
13	of	some	12
14	these	LTRs	15
15	LTRs	of	13
16	had	that	11
17	activities	had	16
18	which	varied	19
19	varied	activities	17
20	significantly	varied	19
21	from	varied	19
22	the	LTR	24
23	LAI	LTR	24
24	LTR	from	21
25	in	MG	27
26	U-373	MG	27
27	MG	varied	19
28	cells	cell	32
29	(	cell	32
30	an	cell	32
31	astrocytoma	cell	32
32	cell	demonstrated	10
33	line	demonstrated	10
34	)	demonstrated	10
35	as	demonstrated	10
36	well	demonstrated	10
37	as	demonstrated	10
38	in	as	37
39	Jurkat	in	38
40	cells	(	41
41	(	Jurkat	39
42	a	(	41
43	CD4-	a	42
44	positive	CD4-	43
45	lymphocyte	positive	44
46	cell	lymphocyte	45
47	line	cell	46
48	)	line	47
49	.	)	48

0	Human	virus	2
1	immunodeficiency	virus	2
2	virus	long	5
3	type	1	4
4	1	long	5
5	long	<ROOT>	-1
6	terminal	differ	9
7	repeat	differ	9
8	quasispecies	differ	9
9	differ	long	5
10	in	differ	9
11	basal	in	10
12	transcription	long	5
13	and	long	5
14	nuclear	factor	15
15	factor	long	5
16	recruitment	long	5
17	in	glial	19
18	human	glial	19
19	glial	recruitment	16
20	cells	long	5
21	and	long	5
22	lymphocytes	long	5
23	.	long	5

0	Although	is	14
1	the	signals	3
2	activating	signals	3
3	signals	Although	0
4	leading	signals	3
5	to	Egr-1	6
6	Egr-1	induction	7
7	induction	leading	4
8	have	Although	0
9	been	have	8
10	studied	been	9
11	extensively	studied	10
12	,	is	14
13	little	is	14
14	is	<ROOT>	-1
15	known	is	14
16	about	known	15
17	the	genes	18
18	genes	about	16
19	that	are	20
20	are	genes	18
21	placed	are	20
22	further	placed	21
23	downstream	known	15
24	within	this	25
25	this	activation	26
26	activation	known	15
27	cascade	and	28
28	and	is	14
29	that	and	28
30	are	that	29
31	transcriptionally	are	30
32	regulated	transcriptionally	31
33	by	regulated	32
34	Egr-1	is	14
35	.	is	14

0	These	findings	1
1	findings	are	2
2	are	<ROOT>	-1
3	discussed	are	2
4	in	discussed	3
5	relation	in	4
6	to	relation	5
7	possible	approaches	9
8	therapeutic	approaches	9
9	approaches	relation	5
10	to	approaches	9
11	the	immunotherapy	12
12	immunotherapy	to	10
13	of	immunotherapy	12
14	APL	of	13
15	.	are	2

0	Inhibition	<ROOT>	-1
1	of	Inhibition	0
2	proliferation	of	1
3	and	of	1
4	apoptosis	of	5
5	of	Inhibition	0
6	human	Inhibition	0
7	and	rat	8
8	rat	T	9
9	T	human	6
10	lymphocytes	Inhibition	0
11	by	Inhibition	0
12	curcumin	by	11
13	,	pigment	16
14	a	pigment	16
15	curry	pigment	16
16	pigment	Inhibition	0
17	.	Inhibition	0

0	Also	shift	4
1	,	shift	4
2	gel	shift	4
3	mobility	shift	4
4	shift	revealed	9
5	analyses	using	6
6	using	shift	4
7	specific	antiserum	8
8	antiserum	shift	4
9	revealed	<ROOT>	-1
10	decrease	revealed	9
11	in	decrease	10
12	the	activity	14
13	DNA-binding	activity	14
14	activity	gene	18
15	of	gene	18
16	an	gene	18
17	insulin	gene	18
18	gene	in	11
19	transcription	gene	18
20	factor	revealed	9
21	,	revealed	9
22	PDX-1/IPF1/STF-1	revealed	9
23	.	revealed	9

0	The	treatment	1
1	treatment	<ROOT>	-1
2	with	treatment	1
3	anti-V3	with	2
4	loop	(	7
5	monoclonal	(	7
6	antibody	(	7
7	(	anti-V3	3
8	902	abolished	12
9	antibody	abolished	12
10	)	abolished	12
11	completely	abolished	12
12	abolished	anti-V3	3
13	the	effect	15
14	suppressive	effect	15
15	effect	abolished	12
16	of	effect	15
17	V3-BH10	of	16
18	.	treatment	1

0	APL	blasts	1
1	blasts	<ROOT>	-1
2	,	blasts	1
3	available	blasts	1
4	only	available	3
5	from	patients	6
6	patients	only	4
7	F.R.	blasts	1
8	and	F.R.	7
9	P.G.	and	8
10	,	F.R.	7
11	were	F.R.	7
12	not	were	11
13	lysed	were	11
14	by	lysed	13
15	C3/5	by	14
16	and	were	11
17	were	and	16
18	unable	were	17
19	to	unable	18
20	present	BCR1/25	22
21	peptide	BCR1/25	22
22	BCR1/25	to	19
23	.	blasts	1

0	Therefore	motif	23
1	,	to	2
2	to	Therefore	0
3	evaluate	the	4
4	the	to	2
5	mechanism	the	4
6	of	TPA	7
7	TPA	mechanism	5
8	responsiveness	TPA	7
9	of	SNE	11
10	the	SNE	11
11	SNE	responsiveness	8
12	motifs	TPA	7
13	and	the	4
14	of	and	13
15	a	of	14
16	related	16-bp	17
17	16-bp	SEE	18
18	SEE	a	15
19	(	)	22
20	SRF/ETS	)	22
21	element	)	22
22	)	SEE	18
23	motif	added	50
24	found	motif	23
25	in	found	24
26	the	HCMV	27
27	HCMV	in	25
28	and	HCMV	27
29	chimpanzee	enhancers	32
30	CMV	enhancers	32
31	MIE	enhancers	32
32	enhancers	and	28
33	,	motif	23
34	we	,	33
35	have	the	37
36	examined	the	37
37	the	we	34
38	functional	and	40
39	responses	and	40
40	and	protein	41
41	protein	the	37
42	binding	protein	41
43	properties	multimerized	45
44	of	multimerized	45
45	multimerized	binding	42
46	wild-type	the	37
47	and	motif	23
48	mutant	motif	23
49	elements	added	50
50	added	<ROOT>	-1
51	upstream	added	50
52	to	upstream	51
53	the	MIE	55
54	SCMV	MIE	55
55	MIE	to	52
56	or	simian	57
57	simian	MIE	55
58	virus	regions	62
59	40	regions	62
60	minimal	regions	62
61	promoter	regions	62
62	regions	simian	57
63	in	simian	57
64	the	in	63
65	U-937	the	64
66	,	U-937	65
67	K-562	,	66
68	,	K-562	67
69	HL-60	,	68
70	,	HL-60	69
71	THP-1	HL-60	69
72	,	THP-1	71
73	and	THP-1	71
74	Jurkat	and	73
75	cell	Jurkat	74
76	lines	cell	75
77	.	lines	76

0	However	were	5
1	,	were	5
2	the	colonies	4
3	EKLF-/-	colonies	4
4	colonies	were	5
5	were	<ROOT>	-1
6	poorly	were	5
7	hemoglobinized	poorly	6
8	and	hemoglobinized	7
9	enucleated	and	8
10	erythrocytes	in	11
11	in	enucleated	9
12	these	colonies	13
13	colonies	in	11
14	contained	Heinz	16
15	numerous	Heinz	16
16	Heinz	enucleated	9
17	bodies	Heinz	16
18	.	were	5

0	Inhibition	<ROOT>	-1
1	of	T	2
2	T	Inhibition	0
3	cell	Inhibition	0
4	and	cell	3
5	promotion	and	4
6	of	promotion	5
7	natural	of	6
8	killer	cell	9
9	cell	natural	7
10	development	cell	9
11	by	development	10
12	the	by	11
13	dominant	helix	15
14	negative	helix	15
15	helix	the	12
16	loop	helix	15
17	helix	loop	16
18	factor	helix	17
19	Id3	factor	18
20	.	Id3	19

0	The	correlation	1
1	correlation	is	2
2	is	<ROOT>	-1
3	specific	is	2
4	as	is	2
5	the	level	6
6	level	did	14
7	of	level	6
8	at	three	10
9	least	three	10
10	three	factors	13
11	other	factors	13
12	transcription	factors	13
13	factors	of	7
14	did	as	4
15	not	did	14
16	change	did	14
17	.	is	2

0	OBJECTIVE	<ROOT>	-1
1	:	OBJECTIVE	0
2	To	OBJECTIVE	0
3	identify	To	2
4	and	identify	3
5	characterize	(	8
6	estrogen	characterize	5
7	receptor	(	8
8	(	and	4
9	ER	OBJECTIVE	0
10	)	ER	9
11	transcripts	ER	9
12	expressed	transcripts	11
13	in	expressed	12
14	immune	in	13
15	cells	immune	14
16	of	cells	15
17	patients	of	16
18	with	lupus	20
19	systemic	lupus	20
20	lupus	patients	17
21	erythematosus	(	22
22	(	OBJECTIVE	0
23	SLE	(	22
24	)	OBJECTIVE	0
25	and	healthy	26
26	healthy	OBJECTIVE	0
27	donors	OBJECTIVE	0
28	.	OBJECTIVE	0

0	The	inhibition	1
1	inhibition	PDTC	6
2	of	NF-kappa	3
3	NF-kappa	inhibition	1
4	B	inhibition	1
5	by	B	4
6	PDTC	<ROOT>	-1
7	paralleled	PDTC	6
8	with	paralleled	7
9	an	inhibition	10
10	inhibition	with	8
11	of	spontaneous	12
12	spontaneous	inhibition	10
13	cytotoxicity	mediated	14
14	mediated	spontaneous	12
15	by	mediated	14
16	NK	cells	17
17	cells	by	15
18	.	cells	17

0	Thus	cells	27
1	,	substitutions	2
2	substitutions	Thus	0
3	within	substitutions	2
4	the	domain	6
5	ligand-binding	domain	6
6	domain	within	3
7	of	domain	6
8	the	receptor	12
9	squirrel	receptor	12
10	monkey	receptor	12
11	glucocorticoid	receptor	12
12	receptor	of	7
13	can	substitutions	2
14	not	can	13
15	account	for	16
16	for	can	13
17	the	affinity	20
18	decreased	affinity	20
19	binding	affinity	20
20	affinity	for	16
21	of	affinity	20
22	these	receptors	23
23	receptors	of	21
24	in	for	16
25	squirrel	cells	27
26	monkey	cells	27
27	cells	<ROOT>	-1
28	.	cells	27

0	Here	describe	2
1	we	describe	2
2	describe	<ROOT>	-1
3	the	characterization	5
4	functional	characterization	5
5	characterization	describe	2
6	of	this	7
7	this	and	9
8	promoter	and	9
9	and	characterization	5
10	identification	describe	2
11	of	identification	10
12	the	factors	13
13	factors	identification	10
14	in	factors	13
15	B	in	14
16	and	T	17
17	T	B	15
18	cells	describe	2
19	that	regulate	20
20	regulate	describe	2
21	its	activity	22
22	activity	regulate	20
23	.	describe	2

0	We	<ROOT>	-1
1	investigated	We	0
2	whether	investigated	1
3	this	may	4
4	may	whether	2
5	be	may	4
6	partly	be	5
7	explained	be	5
8	by	explained	7
9	changes	by	8
10	in	changes	9
11	expression	in	10
12	of	expression	11
13	NF-kappaB	explained	7
14	with	NF-kappaB	13
15	monocyte	differentiation	16
16	differentiation	NF-kappaB	13
17	.	differentiation	16

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	transient	transfection	3
3	transfection	line	8
4	of	line	8
5	the	line	8
6	porcine	line	8
7	B-cell	line	8
8	line	,	1
9	L23	showed	10
10	showed	Moreover	0
11	up	showed	10
12	to	up	11
13	90	to	12
14	%	90	13
15	suppression	of	16
16	of	constitutive	17
17	constitutive	%	14
18	SLA-DR	constitutive	17
19	and	SLA-DR	18
20	SLA-DQ	and	19
21	antigen	SLA-DQ	20
22	expression	antigen	21
23	in	and	19
24	5-8	days	25
25	days	in	23
26	.	Moreover	0

0	The	nature	1
1	nature	is	13
2	of	nature	1
3	the	factors	5
4	nuclear	factors	5
5	factors	of	2
6	involved	of	2
7	in	involved	6
8	regulation	in	7
9	of	cytokine	11
10	these	cytokine	11
11	cytokine	regulation	8
12	genes	nature	1
13	is	<ROOT>	-1
14	still	is	13
15	unknown	is	13
16	.	is	13

0	This	mutant	1
1	mutant	inhibited	2
2	inhibited	<ROOT>	-1
3	TCR-induced	activation	4
4	activation	inhibited	2
5	of	activation	4
6	nuclear	factor	7
7	factor	of	5
8	of	T	10
9	activated	T	10
10	T	factor	7
11	cells	inhibited	2
12	by	inhibited	2
13	interfering	by	12
14	with	interfering	13
15	both	increase	18
16	intracellular	increase	18
17	calcium	increase	18
18	increase	with	14
19	and	increase	18
20	Ras-regulated	signal-regulated	24
21	activation	of	22
22	of	Ras-regulated	20
23	extracellular	of	22
24	signal-regulated	and	19
25	kinases	inhibited	2
26	.	inhibited	2

0	We	reported	3
1	have	We	0
2	recently	reported	3
3	reported	<ROOT>	-1
4	a	series	5
5	series	reported	3
6	(	series	5
7	A	series	5
8	)	series	5
9	of	series	5
10	1,25D3-resistant	variants	11
11	variants	of	9
12	of	HL60	13
13	HL60	variants	11
14	cells	which	15
15	which	reported	3
16	proliferate	which	15
17	in	the	18
18	the	proliferate	16
19	presence	the	18
20	of	presence	19
21	1,25D3	reported	3
22	and	reported	3
23	do	and	22
24	not	do	23
25	express	differentiation	26
26	differentiation	do	23
27	markers	do	23
28	(	Res.	31
29	Exp.	Res.	31
30	Cell	Res.	31
31	Res.	markers	27
32	224	Res.	31
33	,	Res.	31
34	312	Res.	31
35	,	312	34
36	1996	312	34
37	)	Res.	31
38	.	reported	3

0	We	observed	1
1	observed	<ROOT>	-1
2	that	observed	1
3	dexamethasone	mRNA	7
4	dramatically	inhibited	5
5	inhibited	dexamethasone	3
6	RANTES	mRNA	7
7	mRNA	that	2
8	expression	mRNA	7
9	dose	expression	8
10	dependently	dose	9
11	in	T	15
12	anti-CD3	T	15
13	activated	T	15
14	Hut-78	T	15
15	T	dependently	10
16	cells	observed	1
17	and	observed	1
18	human	observed	1
19	PBMCs	observed	1
20	.	observed	1

0	The	protein	5
1	Epstein-Barr	virus	2
2	virus	latent	3
3	latent	membrane	4
4	membrane	The	0
5	protein	<ROOT>	-1
6	1	is	10
7	(	LMP1	8
8	LMP1	1	6
9	)	LMP1	8
10	is	protein	5
11	essential	is	10
12	for	is	10
13	the	transformation	14
14	transformation	for	12
15	of	B	16
16	B	transformation	14
17	lymphocytes	protein	5
18	into	protein	5
19	lymphoblastoid	cell	20
20	cell	into	18
21	lines	cell	20
22	.	lines	21

0	In	studied	5
1	this	paper	2
2	paper	In	0
3	,	studied	5
4	we	studied	5
5	studied	<ROOT>	-1
6	the	consequences	8
7	molecular	consequences	8
8	consequences	studied	5
9	of	consequences	8
10	PF	treatment	11
11	treatment	of	9
12	during	treatment	11
13	lymphocyte	studied	5
14	activation	studied	5
15	.	studied	5

0	Cyclin	<ROOT>	-1
1	A	Cyclin	0
2	transcription	A	1
3	is	transcription	2
4	cell	cycle	5
5	cycle	regulated	6
6	regulated	transcription	2
7	and	regulated	6
8	induced	and	7
9	by	induced	8
10	cell	by	9
11	proliferative	.	13
12	signals	.	13
13	.	cell	10

0	Both	MAP	1
1	MAP	ERK	2
2	ERK	kinase	3
3	kinase	kinase-1	4
4	kinase-1	are	10
5	(	MEKK1	6
6	MEKK1	kinase-1	4
7	)	MEKK1	6
8	and	kinase-1	4
9	Raf	and	8
10	are	<ROOT>	-1
11	activated	are	10
12	strongly	activated	11
13	by	strongly	12
14	FMLP	by	13
15	,	by	13
16	but	by	13
17	minimally	but	16
18	by	minimally	17
19	PAF	by	18
20	.	are	10

0	Furthermore	was	4
1	,	was	4
2	Egr-1	induction	3
3	induction	was	4
4	was	gene	10
5	required	was	4
6	for	B1	9
7	endogenous	B1	9
8	NF-kappa	B1	9
9	B1	required	5
10	gene	<ROOT>	-1
11	expression	gene	10
12	,	expression	11
13	since	,	12
14	PMA/PHA-stimulated	were	22
15	T	PMA/PHA-stimulated	14
16	cell	lines	17
17	lines	T	15
18	expressing	lines	17
19	antisense	RNA	21
20	Egr-1	RNA	21
21	RNA	expressing	18
22	were	since	13
23	inhibited	were	22
24	in	inhibited	23
25	their	ability	26
26	ability	in	24
27	to	upregulate	28
28	upregulate	ability	26
29	NF-kappa	B1	30
30	B1	upregulate	28
31	transcription	gene	10
32	.	gene	10

0	In	cDNA	10
1	addition	In	0
2	,	In	0
3	over-expression	,	2
4	of	over-expression	3
5	STAT2	of	4
6	by	over-expression	3
7	transfection	the	9
8	of	the	9
9	the	by	6
10	cDNA	<ROOT>	-1
11	prevented	cDNA	10
12	apoptosis	prevented	11
13	of	cell	16
14	the	cell	16
15	T	cell	16
16	cell	apoptosis	12
17	clones	cDNA	10
18	.	cDNA	10

0	Expression	<ROOT>	-1
1	of	Expression	0
2	BHRF1	of	1
3	in	Expression	0
4	MCF-Fas	cells	5
5	cells	in	3
6	conferred	cells	5
7	nearly	complete	8
8	complete	Expression	0
9	resistance	against	10
10	against	Expression	0
11	both	antibody	13
12	anti-Fas	antibody	13
13	antibody	against	10
14	and	Expression	0
15	TNF-mediated	Expression	0
16	apoptosis	Expression	0
17	.	Expression	0

0	4	were	8
1	.	4	0
2	When	lymphocytes	4
3	apoptotic	lymphocytes	4
4	lymphocytes	were	8
5	from	lymphocytes	4
6	exposed	from	5
7	individuals	exposed	6
8	were	were	24
9	compared	were	8
10	to	apoptotic	11
11	apoptotic	compared	9
12	lymphocytes	the	14
13	from	the	14
14	the	compared	9
15	control	were	8
16	group	were	8
17	,	were	8
18	statistically-significant	differences	19
19	differences	group	23
20	between	differences	19
21	each	mean	22
22	mean	between	20
23	group	were	8
24	were	<ROOT>	-1
25	detected	were	24
26	(	detected	25
27	26.4	detected	25
28	+/-	26.4	27
29	1.8	+/-	28
30	and	12.1	31
31	12.1	+/-	28
32	+/-	12.1	31
33	1.3	+/-	32
34	,	were	24
35	respectively	were	24
36	)	were	24
37	,	were	24
38	indicating	an	39
39	an	were	24
40	increased	rate	41
41	rate	an	39
42	of	rate	41
43	apoptosis	of	42
44	in	were	24
45	80.5	%	46
46	%	were	24
47	of	%	46
48	exposed	of	47
49	individuals	exposed	48
50	(	%	46
51	P	were	24
52	&lt;	were	24
53	0.0001	&lt;	52
54	,	0.0001	53
55	Mann-Whitney	U-Test	56
56	U-Test	0.0001	53
57	)	0.0001	53
58	.	were	24

0	Aberrant	splicing	1
1	splicing	occurs	8
2	of	splicing	1
3	the	TSG101	4
4	TSG101	of	2
5	and	TSG101	4
6	FHIT	and	5
7	genes	splicing	1
8	occurs	<ROOT>	-1
9	frequently	occurs	8
10	in	occurs	8
11	multiple	malignancies	12
12	malignancies	in	10
13	and	occurs	8
14	in	normal	15
15	normal	and	13
16	tissues	occurs	8
17	and	occurs	8
18	mimics	and	17
19	alterations	mimics	18
20	previously	described	21
21	described	alterations	19
22	in	described	21
23	tumours	in	22
24	.	occurs	8

0	Using	<ROOT>	-1
1	site-directed	Using	0
2	mutagenesis	Using	0
3	,	Using	0
4	we	found	5
5	found	Using	0
6	that	found	5
7	two	are	12
8	of	two	7
9	these	of	8
10	predicted	alpha-helices	11
11	alpha-helices	of	8
12	are	that	6
13	required	are	12
14	for	required	13
15	full	activation	17
16	transcriptional	activation	17
17	activation	for	14
18	by	required	13
19	CIITA	by	18
20	.	CIITA	19

0	Here	show	2
1	we	show	2
2	show	factors	23
3	that	show	2
4	ETS1	can	5
5	can	that	3
6	transactivate	can	5
7	a	GM-CSF	8
8	GM-CSF	transactivate	6
9	reporter	construct	10
10	construct	GM-CSF	8
11	in	Jurkat	13
12	unstimulated	in	11
13	Jurkat	transactivate	6
14	cells	show	2
15	,	show	2
16	providing	that	17
17	that	show	2
18	either	that	17
19	NFkappaB	show	2
20	or	transcription	22
21	AP1	transcription	22
22	transcription	NFkappaB	19
23	factors	<ROOT>	-1
24	are	factors	23
25	supplied	are	24
26	by	supplied	25
27	co-transfection	by	26
28	.	factors	23

0	This	mechanism	2
1	homologous	mechanism	2
2	mechanism	was	7
3	of	receptor	5
4	H2	receptor	5
5	receptor	mechanism	2
6	desensitization	mechanism	2
7	was	<ROOT>	-1
8	time	was	7
9	dependent	time	8
10	.	was	7

0	Unlike	<ROOT>	-1
1	this	Unlike	0
2	physiologically	relevant	3
3	relevant	stimulation	4
4	stimulation	productive	8
5	,	stimulation	4
6	PHA	productive	8
7	stimulates	productive	8
8	productive	this	1
9	LAI	replication	10
10	replication	productive	8
11	in	productive	8
12	both	naive	13
13	naive	T	16
14	and	T	16
15	memory	T	16
16	T	in	11
17	cells	Unlike	0
18	.	Unlike	0

0	In	CsA	3
1	vitro	In	0
2	,	In	0
3	CsA	gene	6
4	inhibits	lymphocyte	5
5	lymphocyte	CsA	3
6	gene	<ROOT>	-1
7	activation	by	8
8	by	gene	6
9	inhibiting	phosphatase	11
10	the	phosphatase	11
11	phosphatase	by	8
12	activity	gene	6
13	of	gene	6
14	calcineurin	gene	6
15	(	CN	16
16	CN	calcineurin	14
17	)	CN	16
18	.	gene	6

0	Serine	phosphorylation	1
1	phosphorylation	STAT3	5
2	of	phosphorylation	1
3	STAT1	of	2
4	and	of	2
5	STAT3	was	6
6	was	<ROOT>	-1
7	seen	was	6
8	occasionally	seen	7
9	in	seen	7
10	other	leukemias	11
11	leukemias	in	9
12	,	was	6
13	but	was	6
14	it	was	15
15	was	but	13
16	a	finding	18
17	universal	finding	18
18	finding	was	15
19	only	finding	18
20	in	only	19
21	CLL	in	20
22	.	was	6

0	Biphasic	expressed	13
1	control	Biphasic	0
2	of	NF-kappa	3
3	NF-kappa	control	1
4	B	Biphasic	0
5	activation	Biphasic	0
6	induced	activation	5
7	by	HLA-DR	11
8	the	triggering	9
9	triggering	HLA-DR	11
10	of	HLA-DR	11
11	HLA-DR	induced	6
12	antigens	Biphasic	0
13	expressed	<ROOT>	-1
14	on	B	15
15	B	expressed	13
16	cells	expressed	13
17	.	expressed	13

0	The	amount	1
1	amount	was	5
2	of	amount	1
3	vimentin	mRNA	4
4	mRNA	of	2
5	was	<ROOT>	-1
6	also	was	5
7	increased	was	5
8	during	increased	7
9	recovery	during	8
10	from	recovery	9
11	stress	from	10
12	,	was	5
13	indicating	was	5
14	that	vimentin	15
15	vimentin	expression	16
16	expression	was	17
17	was	indicating	13
18	not	was	17
19	exclusively	was	17
20	regulated	exclusively	19
21	at	regulated	20
22	the	at	21
23	protein	the	22
24	level	protein	23
25	.	level	24

0	They	fail	1
1	fail	<ROOT>	-1
2	to	fail	1
3	induce	to	2
4	mRNA	induce	3
5	of	induce	3
6	TNF-alpha	fail	1
7	after	fail	1
8	3	h	9
9	h	after	7
10	of	h	9
11	culture	of	10
12	.	fail	1

0	TRAF3	is	1
1	is	<ROOT>	-1
2	a	modulator	4
3	negative	modulator	4
4	modulator	is	1
5	of	modulator	4
6	LMP1-LRB-1-231-RRB--mediated	activation	8
7	NF-kappaB	activation	8
8	activation	of	5
9	.	is	1

0	Taken	<ROOT>	-1
1	together	Taken	0
2	these	Taken	0
3	results	that	5
4	demonstrate	that	5
5	that	protein	8
6	the	protein	8
7	IK	protein	8
8	protein	plays	9
9	plays	these	2
10	a	plays	9
11	key	a	10
12	role	key	11
13	in	role	12
14	the	expression	16
15	constitutive	expression	16
16	expression	MHC	18
17	of	MHC	18
18	MHC	in	13
19	class	antigens	21
20	II	antigens	21
21	antigens	role	12
22	and	plays	9
23	that	inhibition	24
24	inhibition	is	28
25	induced	inhibition	24
26	by	induced	25
27	IK	by	26
28	is	and	22
29	upstream	is	28
30	of	upstream	29
31	CIITA	of	30
32	in	of	30
33	this	pathway	35
34	regulatory	pathway	35
35	pathway	in	32
36	.	Taken	0

0	Here	motif	4
1	the	motif	4
2	wild	motif	4
3	type	motif	4
4	motif	gives	5
5	gives	is	12
6	efficient	binding	7
7	binding	gives	5
8	of	binding	7
9	p50p50	of	8
10	that	of	8
11	again	gives	5
12	is	<ROOT>	-1
13	upregulated	is	12
14	in	tolerant	15
15	tolerant	upregulated	13
16	cells	is	12
17	whereas	is	12
18	a	mutant	19
19	mutant	shows	24
20	with	mutant	19
21	a	G	23
22	3'	G	23
23	G	with	20
24	shows	whereas	17
25	hardly	shows	24
26	any	binding	27
27	binding	shows	24
28	of	binding	27
29	p50p50	of	28
30	.	is	12

0	This	study	1
1	study	<ROOT>	-1
2	evaluates	study	1
3	(	evaluates	2
4	i	(	3
5	)	constitutive	6
6	constitutive	i	4
7	levels	i	4
8	of	levels	7
9	oncogene	of	8
10	and	of	8
11	p53	and	10
12	transcripts	in	13
13	in	of	8
14	chronic	phase	15
15	phase	in	13
16	CML	patients	17
17	patients	phase	15
18	and	ii	20
19	(	and	18
20	ii	phase	15
21	)	ii	20
22	their	modulations	23
23	modulations	phase	15
24	subsequent	modulations	23
25	to	phase	15
26	in	to	25
27	vivo	therapy	28
28	therapy	in	26
29	with	therapy	28
30	rIFN-alpha	2c	31
31	2c	with	29
32	.	study	1

0	We	<ROOT>	-1
1	modeled	We	0
2	this	modeled	1
3	degree	of	4
4	of	this	2
5	CN	of	4
6	inhibition	in	7
7	in	CN	5
8	primary	in	7
9	human	in	7
10	leukocytes	in	11
11	in	human	9
12	vitro	We	0
13	in	We	0
14	order	in	13
15	to	in	13
16	study	to	15
17	the	effect	18
18	effect	study	16
19	of	effect	18
20	partial	of	19
21	CN	on	23
22	inhibition	on	23
23	on	partial	20
24	the	on	23
25	downstream	on	23
26	signaling	downstream	25
27	events	signaling	26
28	that	lead	29
29	lead	events	27
30	to	gene	31
31	gene	activation	32
32	activation	lead	29
33	.	activation	32

0	Associated	<ROOT>	-1
1	with	Associated	0
2	its	inhibitor	3
3	inhibitor	with	1
4	,	inhibitor	3
5	I	,	4
6	kappaB	,	7
7	,	I	5
8	NF-kappaB	I	5
9	resides	I	5
10	as	I	5
11	an	as	10
12	inactive	an	11
13	form	inactive	12
14	in	form	13
15	the	cytoplasm	16
16	cytoplasm	in	14
17	.	Associated	0

0	DNase	<ROOT>	-1
1	I	DNase	0
2	mapping	of	3
3	of	I	1
4	genomic	element	9
5	DNA	identified	6
6	identified	element	9
7	a	element	9
8	hypersensitive	element	9
9	element	of	3
10	near	the	11
11	the	of	3
12	transcription	I	1
13	initiation	site	14
14	site	transcription	12
15	.	site	14

0	Expression	were	15
1	of	Expression	0
2	other	molecules	4
3	adhesion	molecules	4
4	molecules	of	1
5	such	molecules	4
6	as	such	5
7	lymphocyte	associated-antigen-1	9
8	function	associated-antigen-1	9
9	associated-antigen-1	as	6
10	(	associated-antigen-1	9
11	CD11a/CD18	as	6
12	)	CD11a/CD18	11
13	and	)	12
14	CD54	)	12
15	were	<ROOT>	-1
16	unaffected	were	15
17	.	were	15

0	In	<ROOT>	-1
1	the	absence	2
2	absence	In	0
3	of	absence	2
4	tetracyclines	of	3
5	,	tetracyclines	4
6	the	cells	9
7	transfected	T	8
8	T	cells	9
9	cells	tetracyclines	4
10	were	In	0
11	shown	were	10
12	to	shown	11
13	express	the	14
14	the	to	12
15	chimeric	the	14
16	receptor	chimeric	15
17	on	receptor	16
18	the	surface	20
19	cell	surface	20
20	surface	on	17
21	and	surface	20
22	could	and	21
23	be	could	22
24	activated	be	23
25	by	activated	24
26	its	Ag	28
27	cognate	Ag	28
28	Ag	by	25
29	,	In	0
30	leading	,	29
31	to	leading	30
32	the	secretion	33
33	secretion	to	31
34	of	secretion	33
35	IL-2	of	34
36	.	In	0

0	Transcriptional	activation	1
1	activation	could	7
2	by	activation	1
3	the	protein	6
4	RFX5	protein	6
5	fusion	protein	6
6	protein	by	2
7	could	<ROOT>	-1
8	be	could	7
9	restored	be	8
10	in	restored	9
11	RJ2.2.5	in	10
12	by	restored	9
13	cotransfection	expression	17
14	with	expression	17
15	a	expression	17
16	CIITA	expression	17
17	expression	by	12
18	plasmid	could	7
19	.	could	7

0	Reverse	reaction	3
1	transcriptase-polymerase	reaction	3
2	chain	reaction	3
3	reaction	analyses	7
4	(	RT-PCR	5
5	RT-PCR	reaction	3
6	)	RT-PCR	5
7	analyses	revealed	8
8	revealed	<ROOT>	-1
9	that	revealed	8
10	adult	were	15
11	and	adult	10
12	embryonic	genes	14
13	globin	genes	14
14	genes	and	11
15	were	that	9
16	appropriately	were	15
17	regulated	were	15
18	,	were	15
19	with	the	20
20	the	were	15
21	exception	beta	23
22	of	exception	21
23	beta	the	20
24	h1-globin	were	15
25	,	revealed	8
26	which	continued	27
27	continued	,	25
28	to	continued	27
29	be	to	28
30	expressed	be	29
31	at	expressed	30
32	a	level	35
33	very	low	34
34	low	level	35
35	level	at	31
36	.	revealed	8

0	One	site	3
1	transformation	site	3
2	effector	site	3
3	site	proximal	12
4	(	TES1	5
5	TES1	site	3
6	)	TES1	5
7	,	site	3
8	located	proximal	12
9	within	membrane	11
10	the	membrane	11
11	membrane	proximal	12
12	proximal	factor	24
13	45	proximal	12
14	residues	45	13
15	of	residues	14
16	the	tail	18
17	cytoplasmic	tail	18
18	tail	of	15
19	,	proximal	12
20	constitutively	factor	24
21	engages	tumor	22
22	tumor	factor	24
23	necrosis	factor	24
24	factor	<ROOT>	-1
25	receptor-associated	factor	24
26	factors	factor	24
27	.	factor	24

0	The	recognizes	7
1	A6H	(	4
2	monoclonal	(	4
3	antibody	(	4
4	(	The	0
5	mAb	The	0
6	)	The	0
7	recognizes	<ROOT>	-1
8	a	antigen	11
9	120,000-140,000	antigen	11
10	MW	antigen	11
11	antigen	recognizes	7
12	that	is	13
13	is	antigen	11
14	expressed	is	13
15	at	expressed	14
16	similar	densities	17
17	densities	at	15
18	on	densities	17
19	85-90	%	20
20	%	on	18
21	of	human	22
22	human	%	20
23	CD4+	recognizes	7
24	and	recognizes	7
25	CD8+	recognizes	7
26	T	recognizes	7
27	cells	recognizes	7
28	and	recognizes	7
29	on	cell	31
30	renal	cell	31
31	cell	and	28
32	carcinomas	recognizes	7
33	.	recognizes	7

0	Vitamin	receptor	2
1	D	receptor	2
2	receptor	<ROOT>	-1
3	:	receptor	2
4	no	evidence	5
5	evidence	for	6
6	for	receptor	2
7	allele-specific	mRNA	8
8	mRNA	for	6
9	stability	in	10
10	in	for	6
11	cells	for	6
12	which	for	6
13	are	which	12
14	heterozygous	are	13
15	for	heterozygous	14
16	the	Taq	17
17	Taq	for	15
18	I	restriction	19
19	restriction	heterozygous	14
20	enzyme	restriction	19
21	polymorphism	receptor	2
22	.	receptor	2

0	The	factor	3
1	A-myb	factor	3
2	transcription	factor	3
3	factor	<ROOT>	-1
4	in	factor	3
5	neoplastic	in	4
6	and	neoplastic	5
7	normal	cells	9
8	B	cells	9
9	cells	and	6
10	.	factor	3

0	At	four	2
1	least	four	2
2	four	specific	4
3	different	four	2
4	specific	complexes	6
5	NF-kappaB	complexes	6
6	complexes	<ROOT>	-1
7	are	the	10
8	present	the	10
9	in	the	10
10	the	complexes	6
11	nucleus	these	13
12	of	these	13
13	these	complexes	6
14	cells	complexes	6
15	.	complexes	6

0	Using	generated	17
1	plasmids	Using	0
2	containing	sense	3
3	sense	plasmids	1
4	or	sense	3
5	antisense	Using	0
6	RXR-alpha	Using	0
7	sequences	under	8
8	under	Using	0
9	the	under	8
10	control	an	12
11	of	an	12
12	an	the	9
13	inducible	Using	0
14	promoter	Using	0
15	,	generated	17
16	we	generated	17
17	generated	transfected	19
18	stably	transfected	19
19	transfected	expressed	23
20	cell	transfected	19
21	lines	which	22
22	which	transfected	19
23	expressed	<ROOT>	-1
24	either	expressed	23
25	increased	or	26
26	or	either	24
27	decreased	either	24
28	levels	decreased	27
29	of	decreased	27
30	RXR-alpha	of	29
31	,	RXR-alpha	30
32	respectively	RXR-alpha	30
33	.	expressed	23

0	Hence	does	6
1	,	does	6
2	the	expression	3
3	expression	does	6
4	of	expression	3
5	LAZ3/BCL6	of	4
6	does	<ROOT>	-1
7	not	does	6
8	correlate	does	6
9	to	correlate	8
10	malignancy	to	9
11	,	does	6
12	but	does	6
13	reflects	but	12
14	the	origin	15
15	origin	reflects	13
16	of	B	17
17	B	origin	15
18	cells	from	19
19	from	does	6
20	the	germinal	21
21	germinal	from	19
22	centers	does	6
23	.	does	6

0	A	pattern	3
1	follicular	pattern	3
2	expression	pattern	3
3	pattern	was	4
4	was	<ROOT>	-1
5	also	was	4
6	found	was	4
7	in	found	6
8	all	non-malignant	9
9	non-malignant	in	7
10	reactive	lymph	11
11	lymph	found	6
12	nodes	.	13
13	.	lymph	11

0	Additional	<ROOT>	-1
1	size	Additional	0
2	heterogeneity	size	1
3	of	heterogeneity	2
4	both	NFATc	5
5	NFATc	of	3
6	and	NFATc	5
7	NFATp	and	6
8	results	from	9
9	from	heterogeneity	2
10	phosphorylation	size	1
11	.	Additional	0

0	Ro	09-2210	1
1	09-2210	was	2
2	was	<ROOT>	-1
3	also	was	2
4	able	was	2
5	to	able	4
6	block	IL-2	8
7	antigen-induced	IL-2	8
8	IL-2	to	5
9	secretion	IL-2	8
10	with	IL-2	8
11	an	with	10
12	IC50	an	11
13	=	IC50	12
14	30	,	16
15	nM	,	16
16	,	=	13
17	but	to	5
18	was	to	5
19	considerably	was	18
20	less	considerably	19
21	potent	less	20
22	at	blocking	23
23	blocking	potent	21
24	Ca2+	stimulated	26
25	flux	stimulated	26
26	stimulated	potent	21
27	by	stimulated	26
28	anti-CD3	treatment	29
29	treatment	by	27
30	.	was	2

0	Rabbit	antiserum	1
1	antiserum	SRG3	9
2	raised	antiserum	1
3	against	raised	2
4	a	polypeptide	6
5	COOH-terminal	polypeptide	6
6	polypeptide	the	8
7	of	the	8
8	the	against	3
9	SRG3	<ROOT>	-1
10	recognized	SRG3	9
11	a	SRG3	9
12	protein	with	13
13	with	a	11
14	an	mass	17
15	apparent	mass	17
16	molecular	mass	17
17	mass	with	13
18	of	mass	17
19	155	of	18
20	kD	.	21
21	.	155	19

0	Immunoblot	analysis	1
1	analysis	showed	2
2	showed	<ROOT>	-1
3	that	showed	2
4	the	subunit	6
5	p50	subunit	6
6	subunit	was	7
7	was	that	3
8	constitutively	was	7
9	expressed	constitutively	8
10	in	expressed	9
11	monocytes	in	10
12	and	monocytes	11
13	MDMs	monocytes	11
14	.	showed	2

0	TCF/LEF	proteins	1
1	proteins	have	2
2	have	<ROOT>	-1
3	recently	have	2
4	been	have	2
5	found	been	4
6	to	found	5
7	constitute	to	6
8	a	constitute	7
9	downstream	a	8
10	component	downstream	9
11	of	component	10
12	the	pathway	16
13	Wingless/Wnt	pathway	16
14	signal	pathway	16
15	transduction	pathway	16
16	pathway	of	11
17	.	have	2

0	Our	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	G0S2	expression	5
5	expression	is	6
6	is	that	3
7	required	is	6
8	to	required	7
9	commit	to	8
10	cells	commit	9
11	to	cells	10
12	enter	cells	10
13	the	cells	10
14	G1	of	16
15	phase	of	16
16	of	the	13
17	the	cells	10
18	cell	cells	10
19	cycle	suggest	2
20	,	suggest	2
21	and	suggest	2
22	that	suggest	2
23	,	suggest	2
24	while	suggest	2
25	not	other	27
26	excluding	other	27
27	other	,	30
28	possible	,	30
29	targets	,	30
30	,	while	24
31	early	inhibition	32
32	inhibition	,	30
33	of	,	30
34	G0S2	of	33
35	expression	by	36
36	by	of	33
37	CsA	be	39
38	may	be	39
39	be	suggest	2
40	important	be	39
41	in	important	40
42	achieving	in	41
43	immunosuppression	achieving	42
44	.	suggest	2

0	A	analysis	3
1	sucrose	analysis	3
2	gradient	analysis	3
3	analysis	indicated	4
4	indicated	<ROOT>	-1
5	the	presence	7
6	simultaneous	presence	7
7	presence	indicated	4
8	of	presence	7
9	two	kinds	10
10	kinds	of	8
11	of	receptor	12
12	receptor	kinds	10
13	complexes	:	14
14	:	indicated	4
15	the	complex	17
16	steroid-MR	complex	17
17	complex	:	14
18	and	indicated	4
19	the	complex	21
20	antibody-MR	complex	21
21	complex	and	18
22	.	indicated	4

0	In	<ROOT>	-1
1	support	In	0
2	of	support	1
3	this	interpretation	4
4	interpretation	of	2
5	,	mutation	6
6	mutation	putative	8
7	of	mutation	6
8	putative	In	0
9	nuclear	sequences	11
10	localization	sequences	11
11	sequences	putative	8
12	decreased	localization	14
13	nuclear	localization	14
14	localization	putative	8
15	and	localization	14
16	increased	activation	18
17	transcriptional	activation	18
18	activation	and	15
19	by	activation	18
20	membrane-bound	DeltaE	21
21	DeltaE	by	19
22	.	In	0

0	MATERIALS	were	26
1	AND	MATERIALS	0
2	METHODS	AND	1
3	:	METHODS	2
4	Eleven	patients	5
5	patients	MATERIALS	0
6	with	MATERIALS	0
7	ulcerative	MATERIALS	0
8	colitis	MATERIALS	0
9	(	MATERIALS	0
10	5	(	9
11	who	responded	12
12	responded	MATERIALS	0
13	to	responded	12
14	intravenous	glucocorticoids	15
15	glucocorticoids	to	13
16	and	6	17
17	6	glucocorticoids	15
18	who	6	17
19	did	6	17
20	not	did	19
21	)	6	17
22	and	responded	12
23	ten	subjects	25
24	control	subjects	25
25	subjects	and	22
26	were	<ROOT>	-1
27	studied	were	26
28	.	were	26

0	To	have	6
1	test	To	0
2	this	hypothesis	3
3	hypothesis	test	1
4	,	have	6
5	we	have	6
6	have	<ROOT>	-1
7	been	have	6
8	interested	been	7
9	to	interested	8
10	determine	to	9
11	which	cycle	17
12	,	if	13
13	if	cycle	17
14	any	if	13
15	,	if	13
16	cell	cycle	17
17	cycle	entry	18
18	entry	determine	10
19	events	entry	18
20	are	events	19
21	affected	are	20
22	by	affected	21
23	oxidative	signalling	24
24	signalling	by	22
25	.	have	6

0	New	World	1
1	World	primates	2
2	primates	have	8
3	such	as	4
4	as	primates	2
5	the	monkey	7
6	squirrel	monkey	7
7	monkey	as	4
8	have	<ROOT>	-1
9	elevated	cortisol	10
10	cortisol	have	8
11	levels	cortisol	10
12	and	have	8
13	glucocorticoid	have	8
14	resistance	have	8
15	.	have	8

0	Chemokines	refer	1
1	refer	<ROOT>	-1
2	to	refer	1
3	a	family	6
4	rapidly	expanding	5
5	expanding	family	6
6	family	to	2
7	of	family	6
8	small	cytokines	9
9	cytokines	of	7
10	whose	cytokines	9
11	primary	is	13
12	function	is	13
13	is	recruitment	14
14	recruitment	cytokines	9
15	of	cytokines	9
16	leukocytes	cytokines	9
17	to	leukocytes	16
18	inflammatory	sites	19
19	sites	leukocytes	16
20	.	sites	19

0	Thus	seems	3
1	,	seems	3
2	Egr-1	seems	3
3	seems	<ROOT>	-1
4	to	seems	3
5	control	to	4
6	the	expression	7
7	expression	control	5
8	of	downstream	9
9	downstream	expression	7
10	target	downstream	9
11	genes	seems	3
12	not	seems	3
13	only	not	12
14	as	seems	3
15	a	activator	17
16	transcriptional	activator	17
17	activator	as	14
18	,	seems	3
19	but	seems	3
20	also	but	19
21	as	repressor	23
22	a	repressor	23
23	repressor	but	19
24	molecule	seems	3
25	.	seems	3

0	Retinoic	acid	1
1	acid	caused	2
2	caused	<ROOT>	-1
3	the	caused	2
4	leukemic	to	6
5	cells	to	6
6	to	differentiate	7
7	differentiate	the	3
8	in	and	10
9	vitro	in	8
10	and	differentiate	7
11	in	and	10
12	vivo	caused	2
13	,	caused	2
14	eliciting	remissions	15
15	remissions	,	13
16	of	remissions	15
17	both	state	20
18	the	state	20
19	preleukemic	state	20
20	state	APL	22
21	and	state	20
22	APL	of	16
23	in	APL	22
24	mice	in	23
25	.	caused	2

0	In	did	3
1	vitro	In	0
2	stimulation	did	3
3	did	<ROOT>	-1
4	not	did	3
5	affect	did	3
6	ER	affect	5
7	mRNA	ER	6
8	expression	.	9
9	.	mRNA	7

0	Incubation	<ROOT>	-1
1	of	Incubation	0
2	APL	cells	3
3	cells	of	1
4	with	Incubation	0
5	IFN-gamma	with	4
6	failed	Incubation	0
7	to	failed	6
8	induce	to	7
9	HLA	molecules	12
10	class	molecules	12
11	II	molecules	12
12	molecules	induce	8
13	and	Incubation	0
14	recognition	Incubation	0
15	by	Incubation	0
16	the	clone	18
17	C3/5	clone	18
18	clone	by	15
19	.	Incubation	0

0	This	result	1
1	result	demonstrates	2
2	demonstrates	<ROOT>	-1
3	that	demonstrates	2
4	Tyr-492	are	7
5	and	Tyr-492	4
6	Tyr-493	and	5
7	are	that	3
8	not	are	7
9	responsible	are	7
10	for	responsible	9
11	the	domain	14
12	Src	domain	14
13	homology	domain	14
14	domain	for	10
15	2-mediated	association	16
16	association	are	7
17	of	association	16
18	p56-LRB-lck-RRB-	of	17
19	with	are	7
20	ZAP-70	are	7
21	.	demonstrates	2

0	Using	motif	21
1	a	mutant	6
2	mitogenically	mutant	6
3	incompetent	mutant	6
4	human	mutant	6
5	G-CSFR	mutant	6
6	mutant	Using	0
7	in	were	12
8	which	in	7
9	Pro639	were	12
10	and	Pro639	9
11	Pro641	and	10
12	were	Using	0
13	substituted	were	12
14	by	substituted	13
15	alanine	Using	0
16	,	Using	0
17	the	,	16
18	box	1	19
19	1	the	17
20	PDP	Using	0
21	motif	was	22
22	was	tyrosine	33
23	found	was	22
24	to	found	23
25	be	to	24
26	required	be	25
27	for	required	26
28	activation	for	27
29	of	activation	28
30	Jak	kinases	31
31	kinases	of	29
32	,	was	22
33	tyrosine	<ROOT>	-1
34	phosphorylation	tyrosine	33
35	of	the	36
36	the	phosphorylation	34
37	G-CSFR	tyrosine	33
38	,	G-CSFR	37
39	and	,	38
40	recruitment	and	39
41	of	recruitment	40
42	Stat	proteins	43
43	proteins	of	41
44	.	of	41

0	Addition	had	7
1	of	Addition	0
2	activated	platelets	3
3	platelets	of	1
4	to	Addition	0
5	adherent	to	4
6	monocytes	adherent	5
7	had	<ROOT>	-1
8	a	had	7
9	similar	and	11
10	effect	and	11
11	and	a	8
12	was	had	7
13	associated	was	12
14	with	associated	13
15	nuclear	activation	18
16	factor-kappa	activation	18
17	B	activation	18
18	activation	with	14
19	.	had	7

0	Studies	are	1
1	are	<ROOT>	-1
2	in	are	1
3	progress	in	2
4	to	are	1
5	investigate	to	4
6	the	relationship	8
7	functional	relationship	8
8	relationship	investigate	5
9	between	relationship	8
10	A-myb	between	9
11	and	A-myb	10
12	c-myc	and	11
13	,	are	1
14	particularly	in	15
15	in	are	1
16	the	context	17
17	context	in	15
18	of	BL	19
19	BL	context	17
20	cells	are	1
21	and	are	1
22	to	are	1
23	determine	to	22
24	whether	determine	23
25	A-myb	is	26
26	is	whether	24
27	deregulated	is	26
28	in	these	29
29	these	deregulated	27
30	cells	are	1
31	.	are	1

0	Induction	cytokine	2
1	of	cytokine	2
2	cytokine	<ROOT>	-1
3	expression	cytokine	2
4	in	expression	3
5	leukocytes	cytokine	2
6	by	cytokine	2
7	binding	by	6
8	of	binding	7
9	thrombin-stimulated	platelets	10
10	platelets	of	8
11	.	cytokine	2

0	In	observed	5
1	this	study	2
2	study	In	0
3	,	observed	5
4	we	observed	5
5	observed	<ROOT>	-1
6	that	observed	5
7	curcumin	inhibited	12
8	(	microM	10
9	50	microM	10
10	microM	inhibited	12
11	)	microM	10
12	inhibited	that	6
13	proliferation	of	14
14	of	inhibited	12
15	rat	of	14
16	thymocytes	stimulated	17
17	stimulated	observed	5
18	with	observed	5
19	concanavalin	A	20
20	A	(	21
21	(	with	18
22	Con	A	23
23	A	(	21
24	)	(	21
25	as	observed	5
26	well	as	25
27	as	as	25
28	that	as	25
29	of	human	30
30	human	lymphoblastoid	32
31	Jurkat	lymphoblastoid	32
32	lymphoblastoid	that	28
33	cells	observed	5
34	in	observed	5
35	the	phase	38
36	logarithmic	growth	37
37	growth	phase	38
38	phase	in	34
39	.	observed	5

0	The	is	7
1	nuclear	kappaB	3
2	factor	nuclear	1
3	kappaB	(	4
4	(	The	0
5	NF-kappaB	)	6
6	)	The	0
7	is	alpha	25
8	thought	is	7
9	to	thought	8
10	be	to	9
11	crucially	be	10
12	involved	crucially	11
13	in	involved	12
14	the	tumor	22
15	gene	the	14
16	activation	of	17
17	of	gene	15
18	several	of	17
19	cytokines	tumor	22
20	,	cytokines	19
21	including	tumor	22
22	tumor	in	13
23	necrosis	factor	24
24	factor	in	13
25	alpha	<ROOT>	-1
26	(	alpha	25
27	TNF	alpha	25
28	)	TNF	27
29	.	)	28

0	It	remains	1
1	remains	<ROOT>	-1
2	to	remains	1
3	be	to	2
4	shown	which	5
5	which	be	3
6	molecular	events	7
7	events	be	3
8	lead	to	2
9	to	lead	8
10	the	pre-activation	13
11	specific	pre-activation	13
12	'	pre-activation	13
13	pre-activation	to	9
14	'	pre-activation	13
15	,	remains	1
16	i.e.	constitutive	17
17	constitutive	and	20
18	nuclear	translocation	19
19	translocation	and	20
20	and	remains	1
21	DNA	binding	22
22	binding	remains	1
23	,	of	24
24	of	remains	1
25	these	of	24
26	members	of	24
27	of	members	26
28	NF-AT	of	27
29	,	remains	1
30	NF-kB	remains	1
31	and	remains	1
32	AP-1	factor	33
33	factor	remains	1
34	families	remains	1
35	.	remains	1

0	In	may	6
1	HIV-infected	patients	2
2	patients	In	0
3	,	may	6
4	such	enhancement	5
5	enhancement	may	6
6	may	<ROOT>	-1
7	further	may	6
8	impair	immunity	10
9	host	immunity	10
10	immunity	may	6
11	and	may	6
12	could	and	11
13	accelerate	could	12
14	the	course	15
15	course	accelerate	13
16	of	course	15
17	HIV	disease	18
18	disease	of	16
19	.	disease	18

0	Glucocorticoid	<ROOT>	-1
1	(	GC	2
2	GC	Glucocorticoid	0
3	)	GC	2
4	resistance	Glucocorticoid	0
5	in	Glucocorticoid	0
6	patients	in	5
7	with	patients	6
8	chronic	renal	9
9	renal	impairs	15
10	failure	renal	9
11	(	CRF	12
12	CRF	renal	9
13	)	CRF	12
14	seriously	impairs	15
15	impairs	GC	17
16	successive	impairs	15
17	GC	with	7
18	therapy	GC	17
19	after	GC	17
20	renal	GC	17
21	transplantation	GC	17
22	.	Glucocorticoid	0

0	Finally	demethylation	16
1	,	Finally	0
2	reactivation	,	1
3	of	reactivation	2
4	tumor-suppressor	of	3
5	gene	tumor-suppressor	4
6	expression	through	7
7	through	gene	5
8	pharmacologic	Finally	0
9	inhibition	Finally	0
10	of	inhibition	9
11	DNA	methyltransferase	12
12	methyltransferase	of	10
13	and	Finally	0
14	resultant	demethylation	16
15	DNA	demethylation	16
16	demethylation	appears	17
17	appears	<ROOT>	-1
18	to	appears	17
19	be	to	18
20	a	be	19
21	promising	a	20
22	new	avenue	23
23	avenue	promising	21
24	of	avenue	23
25	therapy	of	24
26	in	avenue	23
27	acute	in	26
28	leukemia	acute	27
29	.	leukemia	28

0	In	showed	6
1	the	study	3
2	present	study	3
3	study	In	0
4	,	showed	6
5	we	showed	6
6	showed	<ROOT>	-1
7	that	showed	6
8	CD14+	adherent	9
9	adherent	can	12
10	human	monocytes	11
11	monocytes	adherent	9
12	can	that	7
13	differentiate	can	12
14	into	dendritic	16
15	CD1+relB+	dendritic	16
16	dendritic	differentiate	13
17	cells	(	18
18	(	showed	6
19	DC	(	18
20	)	showed	6
21	by	showed	6
22	the	combination	23
23	combination	by	21
24	of	combination	23
25	GM-CSF	of	24
26	plus	of	24
27	interleukin-4	showed	6
28	(	showed	6
29	IL-4	showed	6
30	)	showed	6
31	and	showed	6
32	that	and	31
33	they	differentiate	34
34	differentiate	that	32
35	into	differentiate	34
36	tartrate-resistant	phosphatase	38
37	acid	phosphatase	38
38	phosphatase	into	35
39	(	TRAP	40
40	TRAP	phosphatase	38
41	)	TRAP	40
42	-positive	giant	45
43	osteoclast-like	giant	45
44	multinucleated	giant	45
45	giant	phosphatase	38
46	cells	giant	45
47	(	giant	45
48	MGC	showed	6
49	)	showed	6
50	by	showed	6
51	the	combination	52
52	combination	by	50
53	of	combination	52
54	M-CSF	of	53
55	plus	M-CSF	54
56	IL-4	plus	55
57	.	showed	6

0	The	protein	1
1	protein	was	2
2	was	<ROOT>	-1
3	found	was	2
4	in	untreated	5
5	untreated	found	3
6	cells	was	2
7	at	was	2
8	low	levels	9
9	levels	at	7
10	,	was	2
11	whereas	was	2
12	induction	whereas	11
13	of	induction	12
14	the	cycle	17
15	lytic	cycle	17
16	replication	cycle	17
17	cycle	of	13
18	by	induction	12
19	TPA	treatment	20
20	treatment	by	18
21	or	treatment	20
22	by	treatment	20
23	providing	transactivator	27
24	the	transactivator	27
25	immediate	transactivator	27
26	early	transactivator	27
27	transactivator	by	22
28	BZLF1	transactivator	27
29	in	BZLF1	28
30	trans	transactivator	27
31	resulted	trans	30
32	in	transactivator	27
33	increased	in	32
34	expression	.	35
35	.	increased	33

0	The	results	1
1	results	showed	2
2	showed	<ROOT>	-1
3	that	showed	2
4	intense	that	3
5	physical	led	7
6	exercise	physical	5
7	led	intense	4
8	not	to	10
9	only	not	8
10	to	led	7
11	increases	to	10
12	in	blood	13
13	blood	increases	11
14	hormone	concentrations	15
15	concentrations	blood	13
16	but	concentrations	15
17	also	but	16
18	to	but	16
19	an	increase	20
20	increase	to	18
21	in	the	22
22	the	increase	20
23	density	the	22
24	of	glucocorticoid	25
25	glucocorticoid	density	23
26	receptors	showed	2
27	in	showed	2
28	lymphocytes	showed	2
29	.	showed	2

0	Decreased	activation	2
1	transcriptional	activation	2
2	activation	N-terminal	4
3	by	activation	2
4	N-terminal	is	8
5	deletions	N-terminal	4
6	of	deletions	5
7	CIITA	of	6
8	is	<ROOT>	-1
9	correlated	is	8
10	directly	correlated	9
11	with	correlated	9
12	their	with	11
13	reduced	their	12
14	binding	to	15
15	to	reduced	13
16	TAFII32	reduced	13
17	.	is	8

0	NF-kappa	B	1
1	B	was	2
2	was	<ROOT>	-1
3	examined	was	2
4	as	examined	3
5	one	as	4
6	of	one	5
7	the	mechanisms	10
8	many	mechanisms	10
9	molecular	mechanisms	10
10	mechanisms	of	6
11	for	mechanisms	10
12	mediating	for	11
13	cell	death	14
14	death	mediating	12
15	by	death	14
16	MTBE	by	15
17	and	MTBE	16
18	benzene	and	17
19	.	was	2

0	Messenger	RNA	1
1	RNA	granulocyte-macrophage	16
2	(	mRNA	3
3	mRNA	RNA	1
4	)	mRNA	3
5	levels	RNA	1
6	for	levels	5
7	the	for	6
8	granulocyte-colony	(	11
9	stimulating	factor	10
10	factor	(	11
11	(	the	7
12	G-CSF	the	7
13	)	G-CSF	12
14	receptor	)	13
15	,	)	13
16	granulocyte-macrophage	receptor	21
17	(	GM	18
18	GM	granulocyte-macrophage	16
19	)	GM	18
20	-CSF	receptor	21
21	receptor	were	41
22	alpha	receptor	21
23	subunit	receptor	21
24	and	subunit	23
25	tumor	factor	27
26	necrosis	factor	27
27	factor	and	24
28	(	subunit	23
29	TNF	receptor	21
30	)	receptor	21
31	receptors	receptor	21
32	I	(	33
33	(	receptor	21
34	p55	receptor	21
35	)	receptor	21
36	and	(	38
37	II	and	36
38	(	receptor	21
39	p75	(	38
40	)	receptor	21
41	were	<ROOT>	-1
42	also	were	41
43	detected	were	41
44	in	detected	43
45	this	subset	46
46	subset	in	44
47	in	detected	43
48	addition	in	47
49	to	addition	48
50	c-kit	to	49
51	and	to	49
52	flt-3	were	41
53	,	were	41
54	receptors	were	41
55	known	receptors	54
56	to	known	55
57	be	to	56
58	expressed	be	57
59	on	progenitor	60
60	progenitor	expressed	58
61	cells	were	41
62	.	were	41

0	Reactive	species	2
1	oxygen	species	2
2	species	are	3
3	are	<ROOT>	-1
4	involved	are	3
5	in	involved	4
6	signal	in	5
7	transduction	pathways	8
8	pathways	signal	6
9	leading	pathways	8
10	to	leading	9
11	nuclear	B	14
12	factor	B	14
13	kappa	B	14
14	B	to	10
15	(	NF-kappa	16
16	NF-kappa	to	10
17	B	to	10
18	)	are	3
19	activation	are	3
20	which	has	21
21	has	are	3
22	been	has	21
23	implicated	the	25
24	in	implicated	23
25	the	been	22
26	regulation	been	22
27	of	gene	28
28	gene	regulation	26
29	transcription	are	3
30	.	are	3

0	In	toxic	13
1	fact	In	0
2	,	mAb	3
3	mAb	In	0
4	L243	In	0
5	but	L243	4
6	not	superantigens	9
7	the	superantigens	9
8	staphylococcal	superantigens	9
9	superantigens	but	5
10	,	In	0
11	staphylococcal	exotoxin	12
12	exotoxin	toxic	13
13	toxic	shock	14
14	shock	<ROOT>	-1
15	syndrome	shock	14
16	toxin-I	staphylococcal	18
17	or	staphylococcal	18
18	staphylococcal	enterotoxin	19
19	enterotoxin	shock	14
20	B	shock	14
21	,	shock	14
22	regulate	the	23
23	the	shock	14
24	NF-kappa	B	25
25	B	the	23
26	binding	B	25
27	activity	shock	14
28	.	shock	14

0	STAT1	pathway	1
1	pathway	is	2
2	is	<ROOT>	-1
3	involved	is	2
4	in	involved	3
5	activation	terminal	11
6	of	terminal	11
7	caprine	terminal	11
8	arthritis-encephalitis	terminal	11
9	virus	terminal	11
10	long	terminal	11
11	terminal	in	4
12	repeat	is	2
13	in	repeat	12
14	monocytes	in	13
15	.	is	2

0	This	gene	1
1	gene	is	7
2	,	gene	1
3	originally	named	4
4	named	gene	1
5	AML1	named	4
6	,	gene	1
7	is	<ROOT>	-1
8	a	homologue	10
9	human	homologue	10
10	homologue	is	7
11	of	homologue	10
12	the	runt	15
13	Drosophila	gene	14
14	gene	runt	15
15	runt	of	11
16	that	controls	17
17	controls	runt	15
18	early	controls	17
19	events	early	18
20	in	events	19
21	fly	in	20
22	embryogenesis	.	23
23	.	fly	21

0	These	<ROOT>	-1
1	data	These	0
2	identify	LDL	3
3	LDL	data	1
4	as	LDL	3
5	a	LDL	3
6	VCAM-inducer	a	5
7	possibly	VCAM-inducer	6
8	distinct	possibly	7
9	from	cytokines	10
10	cytokines	distinct	8
11	and	possibly	7
12	endotoxin	LDL	3
13	.	These	0

0	Tumor	factor	2
1	necrosis	factor	2
2	factor	<ROOT>	-1
3	receptor-1	factor	2
4	(	TNFR-1	5
5	TNFR-1	receptor-1	3
6	)	TNFR-1	5
7	and	receptor-1	3
8	CD95	called	11
9	(	CD95	8
10	also	called	11
11	called	and	7
12	Fas	called	11
13	or	Fas	12
14	APO-1	are	16
15	)	are	16
16	are	factor	2
17	cytokine	factor	2
18	receptors	factor	2
19	that	engage	20
20	engage	factor	2
21	the	pathway	23
22	apoptosis	pathway	23
23	pathway	engage	20
24	through	a	25
25	a	factor	2
26	region	a	25
27	of	intracellular	28
28	intracellular	region	26
29	homology	factor	2
30	,	designated	31
31	designated	factor	2
32	the	designated	31
33	``	death	34
34	death	the	32
35	domain	death	34
36	.	domain	35

0	T	receptor	2
1	cell	receptor	2
2	receptor	(	3
3	(	TCR	4
4	TCR	)	5
5	)	<ROOT>	-1
6	alpha	)	5
7	and	alpha	6
8	delta	and	7
9	gene	delta	8
10	segments	are	11
11	are	gene	9
12	organized	are	11
13	within	T	23
14	a	within	13
15	single	but	18
16	genetic	but	18
17	locus	but	18
18	but	a	14
19	are	T	23
20	differentially	T	23
21	regulated	differentially	20
22	during	T	23
23	T	organized	12
24	cell	T	23
25	development	gene	9
26	.	and	7

0	Cotransfection	experiments	1
1	experiments	revealed	2
2	revealed	<ROOT>	-1
3	that	revealed	2
4	both	hGATA-4	5
5	hGATA-4	stimulation	8
6	and	hGATA-4	5
7	PMA/A23187	and	6
8	stimulation	that	3
9	are	stimulation	8
10	necessary	stimulation	8
11	for	necessary	10
12	the	for	11
13	IL-5	activation	15
14	promoter	activation	15
15	activation	the	12
16	.	revealed	2

0	The	antibodies	2
1	monoclonal	antibodies	2
2	antibodies	were	3
3	were	<ROOT>	-1
4	able	were	3
5	to	able	4
6	discriminate	to	5
7	between	discriminate	6
8	the	between	7
9	cells	of	10
10	of	the	8
11	Categories	Va	12
12	Va	of	10
13	,	Va	12
14	VI	Va	12
15	and	VI	14
16	DFR	and	15
17	but	DFR	16
18	not	Category	19
19	Category	and	15
20	III	the	8
21	cells	were	3
22	.	were	3

0	These	results	1
1	results	confirm	2
2	confirm	<ROOT>	-1
3	at	confirm	2
4	a	level	6
5	molecular	level	6
6	level	at	3
7	the	ability	8
8	ability	confirm	2
9	of	ability	8
10	HIV-1	of	9
11	to	ability	8
12	replicate	to	11
13	in	replicate	12
14	B	cells	15
15	cells	in	13
16	and	confirm	2
17	that	and	16
18	this	activity	19
19	activity	is	20
20	is	that	17
21	strongly	is	20
22	associated	is	20
23	with	associated	22
24	NF-kappaB	confirm	2
25	.	confirm	2

0	Variation	has	9
1	of	Variation	0
2	glucocorticoids	of	1
3	in	Variation	0
4	healthy	aged	5
5	aged	in	3
6	subjects	aged	5
7	and	Variation	0
8	athletes	Variation	0
9	has	<ROOT>	-1
10	been	has	9
11	shown	been	10
12	.	has	9

0	Its	property	2
1	immunosuppressive	property	2
2	property	is	3
3	is	<ROOT>	-1
4	distinct	is	3
5	from	distinct	4
6	cyclosporin	from	5
7	because	distinct	4
8	only	tepoxalin	9
9	tepoxalin	because	7
10	,	tepoxalin	9
11	but	tepoxalin	9
12	not	cyclosporin	13
13	cyclosporin	but	11
14	,	tepoxalin	9
15	suppresses	tepoxalin	9
16	NF-kappa	tepoxalin	9
17	B	activation	18
18	activation	NF-kappa	16
19	.	is	3

0	An	overexpression	1
1	overexpression	has	4
2	of	overexpression	1
3	p50	of	2
4	has	<ROOT>	-1
5	been	has	4
6	described	been	5
7	in	described	6
8	follicular	cells	10
9	dendritic	cells	10
10	cells	in	7
11	(	FDC	12
12	FDC	described	6
13	)	FDC	12
14	.	has	4

0	The	increase	1
1	increase	is	4
2	of	increase	1
3	cortisol	of	2
4	is	<ROOT>	-1
5	immunosuppressive	is	4
6	and	reduces	7
7	reduces	immunosuppressive	5
8	GR	reduces	7
9	concentration	both	10
10	both	in	11
11	in	GR	8
12	nervous	GR	8
13	and	nervous	12
14	immune	and	13
15	systems	and	13
16	.	systems	15

0	In	<ROOT>	-1
1	contrast	In	0
2	,	In	0
3	expression	In	0
4	of	expression	3
5	B	genes	7
6	cell-expressed	genes	7
7	genes	of	4
8	that	are	9
9	are	of	4
10	not	are	9
11	dependent	are	9
12	on	cell-specific	13
13	cell-specific	dependent	11
14	controls	cell-specific	13
15	is	In	0
16	unaffected	In	0
17	.	In	0

0	In	was	9
1	peripheral	In	0
2	blood	In	0
3	lymphocytes	In	0
4	,	expression	5
5	expression	In	0
6	of	Trident	7
7	Trident	expression	5
8	mRNA	In	0
9	was	<ROOT>	-1
10	absent	was	9
11	,	was	9
12	but	was	9
13	could	but	12
14	be	could	13
15	induced	be	14
16	upon	induced	15
17	stimulation	upon	16
18	with	stimulation	17
19	mitogens	with	18
20	in	mitogens	19
21	vitro	with	18
22	.	was	9

0	The	number	1
1	number	may	4
2	of	number	1
3	GCR	of	2
4	may	<ROOT>	-1
5	be	may	4
6	improved	be	5
7	by	be	5
8	inhalation	by	7
9	of	inhalation	8
10	oxygen	may	4
11	.	may	4

0	Our	are	2
1	data	are	2
2	are	allows	14
3	most	consistent	4
4	consistent	are	2
5	with	are	2
6	a	model	7
7	model	with	5
8	in	recruitment	10
9	which	in	8
10	recruitment	model	7
11	to	recruitment	10
12	the	TCR	13
13	TCR	to	11
14	allows	<ROOT>	-1
15	ZAP-70	allows	14
16	autophosphorylation	ZAP-70	15
17	and	autophosphorylation	16
18	binding	allows	14
19	to	allows	14
20	p56-LRB-lck-RRB-	phosphorylates	25
21	,	phosphorylates	25
22	which	phosphorylates	25
23	in	phosphorylates	25
24	turn	in	23
25	phosphorylates	to	19
26	Tyr-492	Tyr-493	28
27	and/or	Tyr-492	26
28	Tyr-493	phosphorylates	25
29	with	phosphorylates	25
30	consequent	up-regulation	31
31	up-regulation	kinase	35
32	of	kinase	35
33	the	kinase	35
34	ZAP-70	kinase	35
35	kinase	phosphorylates	25
36	activity	allows	14
37	.	allows	14

0	The	expression	1
1	expression	patterns	2
2	patterns	<ROOT>	-1
3	suggest	that	4
4	that	patterns	2
5	RBTN-2	interacts	7
6	normally	interacts	7
7	interacts	that	4
8	equally	interacts	7
9	with	interacts	7
10	elf-2a	with	9
11	and	elf-2a	10
12	elf-2b	and	11
13	.	patterns	2

0	Energy	substrates	1
1	substrates	<ROOT>	-1
2	,	substrates	1
3	hormone	responses	4
4	responses	substrates	1
5	and	glucocorticoid	6
6	glucocorticoid	responses	4
7	binding	substrates	1
8	in	binding	7
9	lymphocytes	substrates	1
10	during	substrates	1
11	intense	substrates	1
12	physical	intense	11
13	exercise	physical	12
14	in	humans	15
15	humans	exercise	13
16	following	physical	12
17	phosphocreatine	administration	18
18	administration	following	16
19	.	substrates	1

0	G28-5	IgG	1
1	IgG	blocked	3
2	partially	blocked	3
3	blocked	<ROOT>	-1
4	,	blocked	3
5	whereas	G28-5	6
6	G28-5	augmented	8
7	sFv	augmented	8
8	augmented	blocked	3
9	CD40	augmented	8
10	responses	CD40	9
11	during	augmented	8
12	stimulation	ligand	15
13	with	natural	14
14	natural	stimulation	12
15	ligand	(	16
16	(	protein	19
17	gp39-CD8	protein	19
18	fusion	protein	19
19	protein	during	11
20	)	blocked	3
21	.	blocked	3

0	To	characterized	11
1	analyze	To	0
2	the	analyze	1
3	regulatory	the	2
4	mechanisms	controlling	5
5	controlling	regulatory	3
6	p27Kip1	controlling	5
7	gene	expression	8
8	expression	p27Kip1	6
9	,	characterized	11
10	we	characterized	11
11	characterized	<ROOT>	-1
12	the	5'-flanking	13
13	5'-flanking	region	14
14	region	characterized	11
15	from	nt	16
16	nt	region	14
17	-1609	nt	16
18	to	nt	16
19	+178	to	18
20	.	characterized	11

0	Human	<ROOT>	-1
1	LDL	Human	0
2	induces	the	3
3	the	LDL	1
4	vascular	the	3
5	cell	(	8
6	adhesion	molecule-1	7
7	molecule-1	(	8
8	(	vascular	4
9	VCAM-1	the	3
10	)	the	3
11	transcriptionally	the	3
12	with	transcriptionally	11
13	an	increase	14
14	increase	with	12
15	in	increase	14
16	mRNA	in	15
17	levels	through	18
18	through	increase	14
19	activation	through	18
20	of	activation	19
21	the	of	20
22	VCAM	.	24
23	promoter	.	24
24	.	the	21

0	Here	demonstrate	2
1	we	demonstrate	2
2	demonstrate	<ROOT>	-1
3	that	demonstrate	2
4	B-1	lymphocytes	5
5	lymphocytes	express	7
6	constitutively	express	7
7	express	that	3
8	nuclear	express	7
9	activated	nuclear	8
10	STAT3	activated	9
11	,	STAT3	10
12	which	is	13
13	is	STAT3	10
14	not	is	13
15	expressed	is	13
16	by	expressed	15
17	unmanipulated	)	21
18	conventional	B-2	20
19	(	conventional	18
20	B-2	)	21
21	)	by	16
22	lymphocytes	demonstrate	2
23	.	demonstrate	2

0	We	hypothesize	1
1	hypothesize	proteins	11
2	that	interference	3
3	interference	hypothesize	1
4	in	DNA-binding	5
5	DNA-binding	interference	3
6	activities	DNA-binding	5
7	of	activities	6
8	GATA-1	activities	6
9	and	GATA-1	8
10	CACCC-binding	hypothesize	1
11	proteins	<ROOT>	-1
12	is	proteins	11
13	the	mechanism	14
14	mechanism	is	12
15	by	inhibits	19
16	which	by	15
17	the	ER	18
18	ER	inhibits	19
19	inhibits	is	12
20	regulation	inhibits	19
21	of	these	22
22	these	regulation	20
23	genes	proteins	11
24	.	proteins	11

0	Confirmed	mutations	1
1	mutations	were	2
2	were	<ROOT>	-1
3	identified	were	2
4	in	identified	3
5	28	%	6
6	%	in	4
7	of	%	6
8	the	families	9
9	families	of	7
10	studied	were	2
11	and	were	2
12	on	and	11
13	the	assumption	14
14	assumption	on	12
15	that	assumption	14
16	half	should	21
17	of	half	16
18	the	cases	20
19	sporadic	cases	20
20	cases	of	17
21	should	that	15
22	have	TSC2	23
23	TSC2	should	21
24	mutations	should	21
25	,	mutations	24
26	a	estimate	28
27	crude	estimate	28
28	estimate	would	33
29	of	estimate	28
30	the	rate	32
31	detection	rate	32
32	rate	of	29
33	would	mutations	24
34	be	would	33
35	60	%	36
36	%	be	34
37	.	were	2

0	However	IL-4-induced	2
1	,	IL-4-induced	2
2	IL-4-induced	effects	3
3	effects	were	4
4	were	<ROOT>	-1
5	clearly	were	4
6	improved	were	4
7	following	improved	6
8	JAK3	expression	9
9	expression	following	7
10	.	were	4

0	METHODS	days	20
1	AND	METHODS	0
2	RESULTS	AND	1
3	:	RESULTS	2
4	We	METHODS	0
5	obtained	venous	7
6	peripheral	venous	7
7	venous	METHODS	0
8	blood	METHODS	0
9	samples	blood	8
10	in	samples	9
11	20	patients	12
12	patients	in	10
13	with	patients	12
14	AMI	with	13
15	before	samples	9
16	and	before	15
17	daily	METHODS	0
18	for	METHODS	0
19	5	METHODS	0
20	days	<ROOT>	-1
21	after	days	20
22	direct	after	21
23	percutaneous	direct	22
24	transluminal	percutaneous	23
25	coronary	transluminal	24
26	angioplasty	coronary	25
27	(	PTCA	28
28	PTCA	angioplasty	26
29	)	PTCA	28
30	and	angioplasty	26
31	in	and	30
32	20	patients	33
33	patients	in	31
34	undergoing	in	31
35	elective	PTCA	36
36	PTCA	undergoing	34
37	.	days	20

0	Purified	<ROOT>	-1
1	SR-BP	Purified	0
2	retained	its	3
3	its	SR-BP	1
4	binding	migrated	7
5	properties	and	6
6	and	binding	4
7	migrated	its	3
8	on	migrated	7
9	SDS-polyacrylamide	on	8
10	gel	SDS-polyacrylamide	9
11	as	gel	10
12	a	protein	15
13	Mr	protein	15
14	28,000	protein	15
15	protein	as	11
16	.	Purified	0

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	a	variation	4
4	variation	indicate	2
5	in	transcriptional	6
6	transcriptional	variation	4
7	regulation	indicate	2
8	rather	regulation	7
9	than	rather	8
10	mRNA	stability	11
11	stability	rather	8
12	between	indicate	2
13	the	alleles	14
14	alleles	between	12
15	.	indicate	2

0	Functional	IL-12	1
1	IL-12	is	2
2	is	<ROOT>	-1
3	a	heterodimer	4
4	heterodimer	is	2
5	composed	heterodimer	4
6	of	composed	5
7	two	subunits	9
8	distinct	subunits	9
9	subunits	of	6
10	that	subunits	9
11	are	that	10
12	encoded	are	11
13	by	encoded	12
14	separate	genes	15
15	genes	by	13
16	on	genes	15
17	different	chromosomes	18
18	chromosomes	on	16
19	.	is	2

0	In	<ROOT>	-1
1	particular	In	0
2	,	In	0
3	the	part	4
4	part	,	2
5	played	part	4
6	by	played	5
7	the	receptors	10
8	retinoid	receptors	10
9	X	receptors	10
10	receptors	by	6
11	(	RXRs	12
12	RXRs	receptors	10
13	)	RXRs	12
14	,	part	4
15	which	are	16
16	are	part	4
17	members	receptor	23
18	of	receptor	23
19	the	receptor	23
20	steroid/thyroid	receptor	23
21	hormone	receptor	23
22	nuclear	receptor	23
23	receptor	are	16
24	family	part	4
25	,	part	4
26	has	not	27
27	not	,	25
28	been	not	27
29	explored	been	28
30	.	In	0

0	Thus	elevated	6
1	,	in	2
2	in	HIV	3
3	HIV	Thus	0
4	infection	Thus	0
5	,	elevated	6
6	elevated	<ROOT>	-1
7	cortisol	elevated	6
8	levels	cortisol	7
9	suppress	elevated	6
10	cell-mediated	immunity	11
11	immunity	elevated	6
12	and	elevated	6
13	stimulate	and	12
14	humoral	stimulate	13
15	immunity	is	20
16	,	is	20
17	whereas	this	18
18	this	is	20
19	response	this	18
20	is	humoral	14
21	not	is	20
22	detected	is	20
23	in	cortisol-resistant	24
24	cortisol-resistant	detected	22
25	patients	cortisol-resistant	24
26	.	elevated	6

0	The	<ROOT>	-1
1	data	The	0
2	demonstrate	that	3
3	that	data	1
4	the	subunit	6
5	p65	subunit	6
6	subunit	that	3
7	of	NF-kappa	8
8	NF-kappa	subunit	6
9	B	is	10
10	is	The	0
11	inhibited	by	12
12	by	is	10
13	salicylate	The	0
14	treatment	The	0
15	and	The	0
16	highlight	The	0
17	the	of	19
18	role	of	19
19	of	The	0
20	salicylate	of	19
21	in	The	0
22	the	in	21
23	control	of	24
24	of	the	22
25	gene	of	24
26	expression	gene	25
27	of	expression	26
28	inflammatory	of	27
29	mediators	.	30
30	.	inflammatory	28

0	Late	expression	2
1	gene	expression	2
2	expression	follows	3
3	follows	<ROOT>	-1
4	and	follows	3
5	is	and	4
6	dependent	is	5
7	upon	dependent	6
8	lytic	replication	9
9	replication	upon	7
10	of	replication	9
11	the	genome	13
12	viral	genome	13
13	genome	of	10
14	.	follows	3

0	Pretreatment	caused	12
1	with	protein	3
2	a	protein	3
3	protein	Pretreatment	0
4	kinase	Pretreatment	0
5	C	kinase	4
6	activator	Pretreatment	0
7	,	Pretreatment	0
8	phorbol	12-myristate	9
9	12-myristate	Pretreatment	0
10	13-acetate	Pretreatment	0
11	,	caused	12
12	caused	<ROOT>	-1
13	almost	complete	14
14	complete	histamine-induced	17
15	inhibition	of	16
16	of	complete	14
17	histamine-induced	caused	12
18	-LSB-Ca2+-RSB-i	caused	12
19	rise	caused	12
20	,	caused	12
21	but	caused	12
22	did	but	21
23	not	did	22
24	do	did	22
25	so	do	24
26	by	do	24
27	activators	do	24
28	of	activators	27
29	cAMP-	activators	27
30	and	cAMP-	29
31	cGMP-dependent	.	34
32	protein	.	34
33	kinases	.	34
34	.	and	30

0	These	changes	2
1	initial	changes	2
2	changes	are	3
3	are	<ROOT>	-1
4	followed	are	3
5	by	followed	4
6	the	loss	8
7	eventual	loss	8
8	loss	TCR	10
9	of	TCR	10
10	TCR	by	5
11	zeta	chain	12
12	chain	(	15
13	and	(	15
14	p56	(	15
15	(	TCR	10
16	lck	are	3
17	)	are	3
18	and	are	3
19	a	and	18
20	marked	in	22
21	decrease	in	22
22	in	a	19
23	cytotoxic	a	19
24	function	.	25
25	.	cytotoxic	23

0	There	was	1
1	was	<ROOT>	-1
2	a	correlation	4
3	direct	correlation	4
4	correlation	was	1
5	between	correlation	4
6	the	rate	7
7	rate	between	5
8	of	rate	7
9	lymphocyte	infiltration	10
10	infiltration	of	8
11	and	infiltration	10
12	the	level	13
13	level	and	11
14	of	level	13
15	progesterone	of	14
16	receptors	progesterone	15
17	in	receptors	16
18	tumor	in	17
19	.	was	1

0	A	motif	1
1	motif	presenting	2
2	presenting	strong	4
3	a	strong	4
4	strong	was	9
5	similarity	strong	4
6	to	an	7
7	an	similarity	5
8	initiator	an	7
9	was	<ROOT>	-1
10	detected	was	9
11	,	was	9
12	as	was	9
13	well	as	12
14	as	as	12
15	putative	sites	17
16	binding	sites	17
17	sites	as	12
18	for	as	12
19	Sp1	was	9
20	,	was	9
21	GATA-2	was	9
22	,	GATA-2	21
23	LyF-1	GATA-2	21
24	,	LyF-1	23
25	ets-1	LyF-1	23
26	,	ets-1	25
27	AP1	,	26
28	,	AP1	27
29	and	,	28
30	MZF1	factors	32
31	transcription	factors	32
32	factors	and	29
33	,	and	29
34	and	,	33
35	two	GAS	36
36	GAS	and	34
37	motifs	GAS	36
38	.	was	9

0	BACKGROUND	that	16
1	:	BACKGROUND	0
2	The	transactivator	5
3	class	transactivator	5
4	II	transactivator	5
5	transactivator	is	9
6	(	CIITA	7
7	CIITA	transactivator	5
8	)	CIITA	7
9	is	BACKGROUND	0
10	a	bi-	11
11	bi-	is	9
12	or	multifunctional	13
13	multifunctional	domain	14
14	domain	bi-	11
15	protein	BACKGROUND	0
16	that	<ROOT>	-1
17	acts	that	16
18	as	that	16
19	a	activator	21
20	transcriptional	activator	21
21	activator	as	18
22	and	that	16
23	plays	critical	25
24	a	critical	25
25	critical	and	22
26	role	in	27
27	in	that	16
28	the	expression	29
29	expression	MHC	31
30	of	MHC	31
31	MHC	in	27
32	class	II	33
33	II	in	27
34	genes	.	35
35	.	II	33

0	It	predicts	1
1	predicts	<ROOT>	-1
2	for	predicts	1
3	two	reading	5
4	open	reading	5
5	reading	for	2
6	frames	reading	5
7	(	ORFs	8
8	ORFs	reading	5
9	)	ORFs	8
10	.	predicts	1

0	These	<ROOT>	-1
1	data	These	0
2	demonstrate	that	3
3	that	data	1
4	PML-RAR	alpha	5
5	alpha	that	3
6	and	alpha	5
7	PLZF-RAR	have	9
8	alpha	PLZF-RAR	7
9	have	alpha	5
10	similar	(	11
11	(	)	13
12	inhibitory	(	11
13	)	have	9
14	effects	These	0
15	on	RA-independent	16
16	RA-independent	effects	14
17	differentiation	These	0
18	and	These	0
19	opposite	)	24
20	(	stimulatory	21
21	stimulatory	opposite	19
22	or	stimulatory	21
23	inhibitory	opposite	19
24	)	and	18
25	effects	These	0
26	on	RA-dependent	27
27	RA-dependent	These	0
28	differentiation	These	0
29	and	These	0
30	that	and	29
31	they	that	30
32	behave	they	31
33	in	behave	32
34	vivo	in	33
35	as	behave	32
36	RA-dependent	as	35
37	enhancers	or	38
38	or	RA-dependent	36
39	inhibitors	or	38
40	of	inhibitors	39
41	RA-responsive	genes	42
42	genes	of	40
43	,	of	40
44	respectively	behave	32
45	.	These	0

0	In	present	4
1	this	report	2
2	report	In	0
3	we	present	4
4	present	<ROOT>	-1
5	the	characterisation	6
6	characterisation	of	7
7	of	present	4
8	NF-kappaB	subunits	9
9	subunits	of	7
10	engaged	complexes	12
11	in	complexes	12
12	complexes	of	7
13	binding	present	4
14	to	binding	13
15	the	site	18
16	HIV-1	site	18
17	NF-kappaB	site	18
18	site	to	14
19	in	to	14
20	human	8e51	21
21	8e51	in	19
22	T-cells	present	4
23	,	present	4
24	that	,	23
25	harbour	that	24
26	a	defective	27
27	defective	harbour	25
28	HIV-1	defective	27
29	.	HIV-1	28

0	It	is	1
1	is	<ROOT>	-1
2	directly	implicated	3
3	implicated	is	1
4	in	implicated	3
5	the	emergence	6
6	emergence	implicated	3
7	of	emergence	6
8	the	of	7
9	age-related	.	12
10	immune	.	12
11	deficiency	.	12
12	.	the	8

0	In	LAI	3
1	contrast	In	0
2	,	LAI	3
3	LAI	<ROOT>	-1
4	replicates	LAI	3
5	well	replicates	4
6	in	T	9
7	memory	T	9
8	CD4	T	9
9	T	well	5
10	cells	stimulated	11
11	stimulated	LAI	3
12	in	LAI	3
13	the	way	15
14	same	way	15
15	way	in	12
16	.	LAI	3

0	The	<ROOT>	-1
1	leukocyte-specific	The	0
2	,	leukocyte-specific	1
3	cytoskeleton-binding	leukocyte-specific	1
4	pp52	cytoskeleton-binding	3
5	(	expressed	13
6	LSP-1	(	5
7	,	LSP-1	6
8	WP-34	LSP-1	6
9	)	WP-34	8
10	protein	WP-34	8
11	is	(	5
12	widely	expressed	13
13	expressed	pp52	4
14	in	multiple	15
15	multiple	expressed	13
16	leukocyte	multiple	15
17	lineages	including	19
18	,	including	19
19	including	leukocyte	16
20	B	leukocyte-specific	1
21	and	T	22
22	T	leukocyte-specific	1
23	lymphocytes	The	0
24	,	The	0
25	granulocytes	The	0
26	,	The	0
27	and	The	0
28	macrophages	The	0
29	.	The	0

0	Involvement	<ROOT>	-1
1	of	Involvement	0
2	different	pathways	4
3	transduction	pathways	4
4	pathways	of	1
5	in	Involvement	0
6	NF-kappa	B	7
7	B	in	5
8	activation	B	7
9	by	several	10
10	several	Involvement	0
11	inducers	Involvement	0
12	.	Involvement	0

0	As	World	14
1	a	step	3
2	first	step	3
3	step	As	0
4	in	affinity	11
5	understanding	affinity	11
6	the	mechanism	7
7	mechanism	affinity	11
8	of	decreased	9
9	decreased	affinity	11
10	binding	affinity	11
11	affinity	step	3
12	in	New	13
13	New	affinity	11
14	World	<ROOT>	-1
15	primates	World	14
16	,	World	14
17	we	World	14
18	used	we	17
19	reverse	transcription-PCR	20
20	transcription-PCR	used	18
21	to	used	18
22	clone	to	21
23	the	glucocorticoid	24
24	glucocorticoid	receptor	25
25	receptor	clone	22
26	from	receptor	25
27	squirrel	from	26
28	monkey	squirrel	27
29	liver	monkey	28
30	and	liver	29
31	have	the	33
32	compared	the	33
33	the	and	30
34	sequence	the	33
35	to	liver	29
36	receptor	sequences	37
37	sequences	to	35
38	obtained	World	14
39	from	obtained	38
40	owl	,	43
41	monkey	,	43
42	liver	,	43
43	,	from	39
44	cotton-top	World	14
45	tamarin	World	14
46	B95-8	World	14
47	cells	World	14
48	,	World	14
49	and	,	48
50	human	lymphocytes	51
51	lymphocytes	and	49
52	.	World	14

0	Cotransfection	<ROOT>	-1
1	with	Cotransfection	0
2	a	mutant	5
3	transdominant	mutant	5
4	negative	mutant	5
5	mutant	abolishes	10
6	of	mutant	5
7	the	subunit	9
8	NF-YA	subunit	9
9	subunit	of	6
10	abolishes	with	1
11	the	activation	13
12	transcriptional	activation	13
13	activation	abolishes	10
14	by	abolishes	10
15	heme	by	14
16	,	heme	15
17	indicating	heme	15
18	that	plays	20
19	NF-Y	plays	20
20	plays	essential	22
21	an	essential	22
22	essential	indicating	17
23	role	heme	15
24	in	this	25
25	this	role	23
26	activation	Cotransfection	0
27	.	Cotransfection	0

0	We	studied	2
1	then	studied	2
2	studied	<ROOT>	-1
3	the	effect	4
4	effect	studied	2
5	of	effect	4
6	the	antibody	7
7	antibody	of	5
8	on	progesterone	11
9	aldosterone	progesterone	11
10	and	progesterone	11
11	progesterone	effect	4
12	binding	studied	2
13	to	binding	12
14	the	hMR	15
15	hMR	to	13
16	.	studied	2

0	We	reported	2
1	previously	reported	2
2	reported	<ROOT>	-1
3	that	reported	2
4	dexamethasone	is	28
5	(	DEX	6
6	DEX	dexamethasone	4
7	)	DEX	6
8	,	dexamethasone	4
9	a	synthetic	10
10	synthetic	dexamethasone	4
11	glucocorticoid	synthetic	10
12	,	causes	13
13	causes	glucocorticoid	11
14	apoptosis	causes	13
15	in	apoptosis	14
16	mature	lines	19
17	Th	lines	19
18	cell	lines	19
19	lines	in	15
20	,	causes	13
21	and	dexamethasone	4
22	that	and	21
23	this	induction	24
24	induction	cell	26
25	of	cell	26
26	cell	that	22
27	death	dexamethasone	4
28	is	that	3
29	prevented	is	28
30	by	specific	31
31	specific	,	33
32	cytokines	,	33
33	,	prevented	29
34	namely	is	28
35	,	reported	2
36	by	IL-2	37
37	IL-2	reported	2
38	in	reported	2
39	Th1	reported	2
40	cells	reported	2
41	and	reported	2
42	by	reported	2
43	IL-4	in	44
44	in	reported	2
45	Th2	reported	2
46	cells	reported	2
47	.	reported	2

0	However	IL2	2
1	,	IL2	2
2	IL2	does	3
3	does	<ROOT>	-1
4	not	does	3
5	reverse	does	3
6	CsA	inhibition	7
7	inhibition	reverse	5
8	,	does	3
9	suggesting	does	3
10	that	suggesting	9
11	at	one	13
12	least	one	13
13	one	gene	16
14	other	gene	16
15	NFAT-sensitive	gene	16
16	gene	may	17
17	may	that	10
18	be	may	17
19	involved	be	18
20	.	does	3

0	These	findings	1
1	findings	show	2
2	show	<ROOT>	-1
3	that	show	2
4	the	that	3
5	nuclear	is	12
6	accumulation	is	12
7	of	accumulation	6
8	NFAT4	of	7
9	promoted	accumulation	6
10	by	promoted	9
11	calcineurin	by	10
12	is	the	4
13	opposed	is	12
14	by	opposed	13
15	the	pathway	19
16	JNK	pathway	19
17	signal	pathway	19
18	transduction	pathway	19
19	pathway	by	14
20	.	show	2

0	By	we	7
1	competition	experiments	2
2	experiments	By	0
3	and	By	0
4	supershift	and	3
5	assays	By	0
6	,	we	7
7	we	<ROOT>	-1
8	identified	we	7
9	the	we	7
10	induced	the	9
11	HRF	induced	10
12	as	HRF	11
13	containing	as	12
14	at	factor	19
15	least	at	14
16	the	factor	19
17	ubiquitous	factor	19
18	transcription	factor	19
19	factor	containing	13
20	NF-Y	.	21
21	.	containing	13

0	The	sites	3
1	two	sites	3
2	AP-1	sites	3
3	sites	bound	4
4	bound	<ROOT>	-1
5	c-Fos/c-Jun	heterodimers	6
6	heterodimers	bound	4
7	in	both	8
8	both	bound	4
9	unstimulated	bound	4
10	and	bound	4
11	LPS-stimulated	bound	4
12	cells	bound	4
13	.	bound	4

0	Immunoblot	analysis	1
1	analysis	monolayers	8
2	and	analysis	1
3	immunoperoxidase	staining	4
4	staining	infected	6
5	of	infected	6
6	infected	and	2
7	cell	analysis	1
8	monolayers	demonstrated	9
9	demonstrated	<ROOT>	-1
10	vector	expression	11
11	expression	demonstrated	9
12	of	expression	11
13	VZV	.	15
14	proteins	.	15
15	.	of	12

0	Furthermore	NF-kappaB	9
1	,	Furthermore	0
2	prolonged	degradation	3
3	degradation	,	1
4	of	degradation	3
5	IkappaB-alpha	of	4
6	and	degradation	3
7	activation	and	6
8	of	and	6
9	NF-kappaB	were	10
10	were	<ROOT>	-1
11	demonstrated	were	10
12	in	demonstrated	11
13	THP-1	cells	14
14	cells	demonstrated	11
15	exposed	anti-E.	17
16	to	anti-E.	17
17	anti-E.	demonstrated	11
18	chaffeensis	serum	19
19	serum	anti-E.	17
20	and	were	10
21	E.	were	10
22	chaffeensis	were	10
23	.	were	10

0	Activated	neutrophils	1
1	neutrophils	have	2
2	have	<ROOT>	-1
3	the	ability	4
4	ability	have	2
5	to	ability	4
6	upregulate	to	5
7	the	expression	8
8	expression	upregulate	6
9	of	expression	8
10	many	genes	11
11	genes	of	9
12	,	have	2
13	in	have	2
14	particular	in	13
15	those	in	13
16	encoding	those	15
17	cytokines	encoding	16
18	and	cytokines	17
19	chemokines	cytokines	17
20	,	encoding	16
21	and	have	2
22	to	and	21
23	subsequently	to	22
24	release	to	22
25	the	proteins	27
26	corresponding	proteins	27
27	proteins	release	24
28	.	have	2

0	Two	regions	1
1	regions	<ROOT>	-1
2	,	regions	1
3	DP1	regions	1
4	(	DP1	3
5	-140	(	4
6	to	-92	7
7	-92	-140	5
8	bp	-92	7
9	)	bp	8
10	and	)	9
11	DP2	and	10
12	(	were	21
13	-353	were	21
14	to	-304	15
15	-304	-353	13
16	bp	-304	15
17	)	bp	16
18	of	)	17
19	the	promoter	20
20	promoter	of	18
21	were	DP2	11
22	essential	were	21
23	for	were	21
24	transcription	and	10
25	in	HeLa	26
26	HeLa	transcription	24
27	cells	regions	1
28	and	regions	1
29	human	regions	1
30	peripheral	regions	1
31	monocytes	regions	1
32	.	regions	1

0	Cyclosporin	<ROOT>	-1
1	A	Cyclosporin	0
2	inhibits	A	1
3	monocyte	inhibits	2
4	tissue	monocyte	3
5	factor	tissue	4
6	activation	in	7
7	in	cardiac	8
8	cardiac	factor	5
9	transplant	A	1
10	recipients	Cyclosporin	0
11	.	Cyclosporin	0

0	Electrophoretic	assay	3
1	mobility	assay	3
2	shift	assay	3
3	assay	revealed	4
4	revealed	binding	9
5	that	binding	9
6	the	binding	9
7	potential	binding	9
8	NF-kappaB	binding	9
9	binding	formed	29
10	sequence	which	11
11	which	binding	9
12	is	which	11
13	located	is	12
14	around	located	13
15	120	around	14
16	bp	120	15
17	upstream	bp	16
18	of	upstream	17
19	the	of	18
20	transcription	in	23
21	initiation	in	23
22	site	in	23
23	in	the	19
24	murine	in	23
25	and	binding	9
26	human	binding	9
27	p40	binding	9
28	genes	formed	29
29	formed	<ROOT>	-1
30	an	complex	32
31	NF-kappaB	complex	32
32	complex	formed	29
33	with	formed	29
34	nuclear	extract	35
35	extract	Daudi	37
36	from	extract	35
37	Daudi	with	33
38	cells	formed	29
39	stimulated	formed	29
40	by	formed	29
41	CD40	formed	29
42	ligation	formed	29
43	.	formed	29

0	Biosynthesis	<ROOT>	-1
1	of	tumor	2
2	tumor	Biosynthesis	0
3	necrosis	factor-alpha	4
4	factor-alpha	Biosynthesis	0
5	(	factor-alpha	4
6	TNF-alpha	)	7
7	)	Biosynthesis	0
8	is	)	7
9	predominantly	is	8
10	by	predominantly	9
11	cells	Biosynthesis	0
12	of	cells	11
13	the	lineage	15
14	monocytic	lineage	15
15	lineage	of	12
16	.	Biosynthesis	0

0	We	reported	2
1	previously	reported	2
2	reported	increased	16
3	that	reported	2
4	monocyte	adhesion	5
5	adhesion	that	3
6	to	adhesion	5
7	tumor	necrosis	8
8	necrosis	factor-alpha	9
9	factor-alpha	to	6
10	(	factor-alpha	9
11	TNF-alpha	factor-alpha	9
12	)	reported	2
13	-treated	endothelial	14
14	endothelial	reported	2
15	cells	reported	2
16	increased	<ROOT>	-1
17	expression	of	18
18	of	increased	16
19	tissue	factor	20
20	factor	increased	16
21	and	increased	16
22	CD36	and	21
23	on	increased	16
24	monocytes	increased	16
25	.	increased	16

0	Adenovirus	can	1
1	can	<ROOT>	-1
2	establish	may	6
3	persistent	infections	4
4	infections	establish	2
5	which	infections	4
6	may	can	1
7	reactivate	may	6
8	and	reactivate	7
9	cause	and	8
10	disease	cause	9
11	in	disease	10
12	immunocompromised	hosts	13
13	hosts	in	11
14	.	can	1

0	Transient	transfection	1
1	transfection	lymphoma	5
2	of	lymphoma	5
3	a	lymphoma	5
4	B	lymphoma	5
5	lymphoma	resulted	7
6	line	lymphoma	5
7	resulted	days	22
8	in	resulted	7
9	up	in	8
10	to	%	12
11	89	%	12
12	%	up	9
13	reduction	%	12
14	of	II	18
15	constitutive	II	18
16	MHC	II	18
17	class	II	18
18	II	reduction	13
19	expression	resulted	7
20	within	expression	19
21	5	resulted	7
22	days	<ROOT>	-1
23	and	days	22
24	suppression	and	23
25	of	suppression	24
26	HLA-DRA	mRNA	27
27	mRNA	of	25
28	synthesis	mRNA	27
29	.	days	22

0	Upon	precursor	4
1	antigen	precursor	4
2	stimulation	precursor	4
3	,	precursor	4
4	precursor	<ROOT>	-1
5	CD4+	T	6
6	T	helper	7
7	helper	(	8
8	(	precursor	4
9	pTh	(	8
10	)	and	13
11	cells	and	13
12	proliferate	and	13
13	and	pTh	9
14	differentiate	precursor	4
15	into	differentiate	14
16	two	into	15
17	populations	two	16
18	of	effector	19
19	effector	populations	17
20	cells	effector	19
21	(	effector	19
22	eTh1	effector	19
23	and	eTh1	22
24	eTh2	effector	19
25	)	effector	19
26	,	precursor	4
27	each	precursor	4
28	one	expressing	29
29	expressing	precursor	4
30	a	expressing	29
31	specific	a	30
32	pattern	cytokines	34
33	of	cytokines	34
34	cytokines	specific	31
35	that	distinguishes	36
36	distinguishes	cytokines	34
37	them	distinguishes	36
38	from	distinguishes	36
39	their	precursors	40
40	precursors	from	38
41	.	precursor	4

0	Many	aspects	1
1	aspects	of	2
2	of	are	5
3	leukocyte	of	2
4	function	of	2
5	are	<ROOT>	-1
6	regulated	are	5
7	by	regulated	6
8	both	heterotrimeric	9
9	heterotrimeric	by	7
10	and	heterotrimeric	9
11	Ras-related	proteins	13
12	GTP-binding	proteins	13
13	proteins	and	10
14	,	are	5
15	but	are	5
16	there	is	17
17	is	but	15
18	little	is	17
19	definite	little	18
20	information	definite	19
21	about	information	20
22	their	about	21
23	roles	their	22
24	in	roles	23
25	the	processes	27
26	specialized	processes	27
27	processes	in	24
28	utilized	processes	27
29	by	utilized	28
30	leukocytes	cell	32
31	for	cell	32
32	cell	is	17
33	killing	is	17
34	.	are	5

0	In	were	10
1	contrast	In	0
2	,	were	10
3	proviruses	carrying	4
4	carrying	were	10
5	mutations	carrying	4
6	in	mutations	5
7	the	sites	9
8	Sp1	sites	9
9	sites	in	6
10	were	<ROOT>	-1
11	totally	defective	12
12	defective	were	10
13	in	defective	12
14	terms	of	15
15	of	in	13
16	replication	of	15
17	.	were	10

0	METHODS	<ROOT>	-1
1	:	METHODS	0
2	The	authors	3
3	authors	METHODS	0
4	evaluated	METHODS	0
5	tarsal	evaluated	4
6	and	tarsal	5
7	bulbar	and	6
8	conjunctival	biopsies	9
9	biopsies	bulbar	7
10	from	tarsal	5
11	seven	patients	12
12	patients	from	10
13	with	patients	12
14	severe	with	13
15	and	severe	14
16	symptomatic	VKC	17
17	VKC	severe	14
18	for	severe	14
19	the	presence	20
20	presence	for	18
21	of	presence	20
22	estrogen	presence	20
23	and	severe	14
24	progesterone	severe	14
25	receptors	severe	14
26	by	severe	14
27	using	by	26
28	monoclonal	antibodies	29
29	antibodies	using	27
30	with	using	27
31	a	technique	33
32	peroxidase-antiperoxidase	technique	33
33	technique	with	30
34	.	METHODS	0

0	It	is	1
1	is	<ROOT>	-1
2	clear	is	1
3	from	clear	2
4	various	from	3
5	studies	various	4
6	that	studies	5
7	the	activity	8
8	activity	that	6
9	of	activity	8
10	the	of	9
11	NADPH	the	10
12	oxidase	NADPH	11
13	can	oxidase	12
14	be	can	13
15	modulated	be	14
16	through	modulated	15
17	the	regulation	18
18	regulation	through	16
19	of	regulation	18
20	the	state	22
21	GTP-GDP	state	22
22	state	of	19
23	of	state	22
24	Rac	of	23
25	.	is	1

0	We	generated	2
1	then	generated	2
2	generated	<ROOT>	-1
3	new	anti-pml/RAR-alpha	5
4	donor	anti-pml/RAR-alpha	5
5	anti-pml/RAR-alpha	generated	2
6	CD4-LRB-+-RRB-	clones	8
7	T-cell	clones	8
8	clones	generated	2
9	.	generated	2

0	Activation	B	5
1	and	Activation	0
2	regulation	and	1
3	of	NF-kappa	4
4	NF-kappa	Activation	0
5	B	<ROOT>	-1
6	are	B	5
7	tightly	are	6
8	controlled	tightly	7
9	by	controlled	8
10	a	group	11
11	group	by	9
12	of	inhibitory	13
13	inhibitory	group	11
14	proteins	(	15
15	(	B	5
16	I	(	15
17	kappa	I	16
18	B	B	5
19	)	B	5
20	that	B	5
21	sequester	NF-kappa	22
22	NF-kappa	B	23
23	B	that	20
24	in	B	23
25	the	in	24
26	cytoplasm	the	25
27	of	effector	29
28	immune/inflammatory	effector	29
29	effector	cytoplasm	26
30	cells	B	5
31	.	B	5

0	This	result	1
1	result	<ROOT>	-1
2	,	result	1
3	confirmed	,	2
4	by	confirmed	3
5	competitions	by	4
6	with	competitions	5
7	each	site	9
8	GATA	site	9
9	site	with	6
10	,	demonstrated	11
11	demonstrated	confirmed	3
12	the	demonstrated	11
13	higher	affinity	15
14	relative	affinity	15
15	affinity	the	12
16	(	at	17
17	at	affinity	15
18	least	at	17
19	sevenfold	at	17
20	)	at	17
21	of	site	22
22	site	affinity	15
23	3	site	22
24	.	result	1

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	fluorescent	,	2
4	in	(	7
5	situ	(	7
6	hybridization	(	7
7	(	fluorescent	3
8	FISH	In	0
9	)	In	0
10	results	In	0
11	refined	previous	13
12	the	previous	13
13	previous	In	0
14	localization	previous	13
15	of	localization	14
16	15-LO	of	15
17	to	15-LO	16
18	human	to	17
19	chromosome	human	18
20	17p13.3	In	0
21	.	In	0

0	The	distribution	2
1	spatial	distribution	2
2	distribution	immunoglobulin	5
3	of	human	4
4	human	distribution	2
5	immunoglobulin	<ROOT>	-1
6	genes	immunoglobulin	5
7	within	immunoglobulin	5
8	the	nucleus	9
9	nucleus	within	7
10	:	immunoglobulin	5
11	evidence	immunoglobulin	5
12	for	evidence	11
13	gene	topography	14
14	topography	for	12
15	independent	topography	14
16	of	cell	17
17	cell	independent	15
18	type	and	19
19	and	independent	15
20	transcriptional	immunoglobulin	5
21	activity	immunoglobulin	5
22	.	immunoglobulin	5

0	These	<ROOT>	-1
1	data	are	2
2	are	These	0
3	most	consistent	4
4	consistent	are	2
5	with	are	2
6	NOTCH1	oncogenesis	7
7	oncogenesis	with	5
8	and	oncogenesis	7
9	transcriptional	are	2
10	activation	being	11
11	being	transcriptional	9
12	independent	transcriptional	9
13	of	independent	12
14	association	of	13
15	with	association	14
16	RBP-Jkappa	with	15
17	at	RBP-Jkappa	16
18	promoter	sites	19
19	sites	RBP-Jkappa	16
20	.	sites	19

0	Moderate	ubiquitous	1
1	ubiquitous	is	3
2	activation	is	3
3	is	<ROOT>	-1
4	further	is	3
5	induced	and	8
6	by	induced	5
7	CREB/ATF	by	6
8	and	is	3
9	Sp1	and	8
10	factors	through	11
11	through	proximal	12
12	proximal	is	3
13	upstream	elements	14
14	elements	proximal	12
15	.	is	3

0	Activation	inflammatory	6
1	of	Activation	0
2	the	pathway	4
3	NF-kappaB	pathway	4
4	pathway	of	1
5	by	inflammatory	6
6	inflammatory	<ROOT>	-1
7	stimuli	inflammatory	6
8	in	stimuli	7
9	human	in	8
10	neutrophils	.	11
11	.	human	9

0	The	factor	5
1	natural	factor	5
2	dominant	factor	5
3	negative	factor	5
4	HLH	factor	5
5	factor	Id3	6
6	Id3	transcriptional	10
7	,	Id3	6
8	which	blocks	9
9	blocks	transcriptional	10
10	transcriptional	was	20
11	activity	transcriptional	10
12	of	activity	11
13	a	number	14
14	number	of	12
15	of	number	14
16	known	factors	18
17	bHLH	factors	18
18	factors	of	15
19	,	transcriptional	10
20	was	<ROOT>	-1
21	expressed	was	20
22	in	progenitor	24
23	CD34+	progenitor	24
24	progenitor	expressed	21
25	cells	was	20
26	by	was	20
27	retrovirus-mediated	transfer	29
28	gene	transfer	29
29	transfer	by	26
30	.	was	20

0	Taken	<ROOT>	-1
1	together	Taken	0
2	,	Taken	0
3	these	,	2
4	data	these	3
5	demonstrate	the	6
6	the	data	4
7	existence	the	6
8	of	existence	7
9	an	of	8
10	HLA-DQ	an	9
11	isotype-specific	trans-acting	12
12	trans-acting	HLA-DQ	10
13	factor	functions	16
14	,	functions	16
15	which	functions	16
16	functions	trans-acting	12
17	independently	functions	16
18	of	independently	17
19	CIITA	of	18
20	.	Taken	0

0	Active	differentiated	10
1	nuclear	Active	0
2	RelB	was	3
3	was	nuclear	1
4	detected	was	3
5	by	detected	4
6	supershift	by	5
7	assay	only	8
8	only	supershift	6
9	in	detected	4
10	differentiated	<ROOT>	-1
11	DC	derived	12
12	derived	differentiated	10
13	from	derived	12
14	either	PB	15
15	PB	or	17
16	precursors	PB	15
17	or	from	13
18	monocytes	differentiated	10
19	and	differentiated	10
20	in	differentiated	10
21	activated	differentiated	10
22	B	differentiated	10
23	cells	differentiated	10
24	.	differentiated	10

0	Regulation	of	1
1	of	<ROOT>	-1
2	-LSB-Ca2+-RSB-i	of	1
3	rise	of	1
4	activated	rise	3
5	by	activated	4
6	doxepin-sensitive	by	5
7	H1-histamine	doxepin-sensitive	6
8	receptors	H1-histamine	7
9	in	doxepin-sensitive	6
10	Jurkat	in	9
11	cells	Jurkat	10
12	,	cells	11
13	cloned	T	15
14	human	T	15
15	T	,	12
16	lymphocytes	of	1
17	.	of	1

0	Our	results	1
1	results	indicated	2
2	indicated	<ROOT>	-1
3	that	indicated	2
4	the	epitope	5
5	epitope	was	9
6	recognized	epitope	5
7	by	recognized	6
8	18C7	by	7
9	was	that	3
10	directly	implicated	11
11	implicated	was	9
12	in	hormone	13
13	hormone	implicated	11
14	binding	implicated	11
15	.	indicated	2

0	Requirement	cell	8
1	of	monocytic	4
2	prestimulated	monocytic	4
3	THP-1	monocytic	4
4	monocytic	Requirement	0
5	cells	Requirement	0
6	for	cell	8
7	endothelial	cell	8
8	cell	<ROOT>	-1
9	activation	cell	8
10	.	activation	9

0	Regulation	<ROOT>	-1
1	of	Regulation	0
2	cytokine	of	1
3	and	cytokine	4
4	cytokine	of	1
5	receptor	expression	6
6	expression	cytokine	4
7	by	of	1
8	glucocorticoids	by	7
9	.	Regulation	0

0	The	receptor	2
1	estrogen	receptor	2
2	receptor	<ROOT>	-1
3	(	ER	4
4	ER	receptor	2
5	)	ER	4
6	repressed	receptor	2
7	erythroid	differentiation	8
8	differentiation	repressed	6
9	and	receptor	2
10	erythroid-specific	and	9
11	gene	and	9
12	expression	.	13
13	.	gene	11

0	These	<ROOT>	-1
1	studies	These	0
2	examined	the	3
3	the	studies	1
4	ability	the	3
5	of	ability	4
6	CMV	products	9
7	IE	products	9
8	gene	products	9
9	products	of	5
10	to	ability	4
11	modulate	to	10
12	IL-6	modulate	11
13	production	.	14
14	.	IL-6	12

0	By	show	6
1	promoter	analysis	3
2	function	analysis	3
3	analysis	By	0
4	,	show	6
5	we	show	6
6	show	promoter	10
7	that	promoter	10
8	the	promoter	10
9	SAA	promoter	10
10	promoter	confer	17
11	sequence	between	12
12	between	promoter	10
13	-280	between	12
14	and	-280	13
15	-226	and	14
16	can	-226	15
17	confer	<ROOT>	-1
18	LPS	confer	17
19	responsiveness	.	20
20	.	LPS	18

0	Human	promoter	3
1	15-lipoxygenase	promoter	3
2	gene	promoter	3
3	promoter	analysis	5
4	:	promoter	3
5	analysis	<ROOT>	-1
6	and	analysis	5
7	identification	and	6
8	of	DNA	9
9	DNA	analysis	5
10	binding	analysis	5
11	sites	analysis	5
12	for	regulatory	14
13	IL-13-induced	regulatory	14
14	regulatory	analysis	5
15	factors	regulatory	14
16	in	factors	15
17	monocytes	in	16
18	.	analysis	5

0	Cytokine-stimulated	expression	3
1	cell	expression	3
2	surface	expression	3
3	expression	<ROOT>	-1
4	of	expression	3
5	vascular	of	4
6	cell	(	9
7	adhesion	molecule-1	8
8	molecule-1	(	9
9	(	vascular	5
10	VCAM-1	of	4
11	,	of	4
12	CD106	expression	3
13	)	expression	3
14	and	expression	3
15	E-selectin	expression	3
16	(	E-selectin	15
17	ELAM-1	expression	3
18	,	expression	3
19	CD62E	expression	3
20	)	expression	3
21	,	expression	3
22	but	expression	3
23	not	adhesion	26
24	of	intercellular	25
25	intercellular	not	23
26	adhesion	but	22
27	molecule-1	adhesion	26
28	(	adhesion	26
29	ICAM-1	adhesion	26
30	,	ICAM-1	29
31	CD54	,	30
32	)	,	30
33	,	,	30
34	was	expression	3
35	time-	and	36
36	and	expression	3
37	dose-	dependently	38
38	dependently	inhibited	39
39	inhibited	and	36
40	by	inhibited	39
41	TCP	expression	3
42	succinate	expression	3
43	but	expression	3
44	not	by	45
45	by	but	43
46	TCP	by	45
47	or	TCP	46
48	TCP	acetate	49
49	acetate	or	47
50	.	acetate	49

0	Measurement	showed	23
1	of	Measurement	0
2	the	of	1
3	transcriptional	after	9
4	activity	transcriptional	3
5	of	activity	4
6	the	promoter	8
7	HIV-1	promoter	8
8	promoter	of	5
9	after	transient	10
10	transient	the	2
11	transfection	provirus	15
12	of	provirus	15
13	the	provirus	15
14	HIV-1	provirus	15
15	provirus	transient	10
16	DNA	or	17
17	or	Measurement	0
18	of	Measurement	0
19	long	repeat-luciferase	21
20	terminal	repeat-luciferase	21
21	repeat-luciferase	of	18
22	constructs	repeat-luciferase	21
23	showed	<ROOT>	-1
24	a	correlation	26
25	positive	correlation	26
26	correlation	showed	23
27	between	showed	23
28	the	transcriptional	29
29	transcriptional	and	30
30	and	between	27
31	the	replication	32
32	replication	and	30
33	defects	showed	23
34	for	most	35
35	most	defects	33
36	mutants	most	35
37	.	mutants	36

0	Eight	male	3
1	healthy	male	3
2	untrained	male	3
3	male	volunteers	4
4	volunteers	prolonged	31
5	pedalled	volunteers	4
6	a	pedalled	5
7	cycle	a	6
8	ergometer	cycle	7
9	according	ergometer	8
10	to	according	9
11	two	to	10
12	exercise	two	11
13	protocols	exercise	12
14	:	first	16
15	the	first	16
16	first	protocols	13
17	involved	first	16
18	step-wise	increasing	19
19	increasing	protocols	13
20	physical	increasing	19
21	exercise	physical	20
22	to	exercise	21
23	maximal	(	24
24	(	exercise	21
25	MPE	(	24
26	)	MPE	25
27	;	)	26
28	the	second	29
29	second	;	27
30	involved	second	29
31	prolonged	<ROOT>	-1
32	(	prolonged	31
33	35	(	32
34	min	35	33
35	)	min	34
36	submaximal	min	34
37	physical	(	39
38	exercise	(	39
39	(	submaximal	36
40	PPE	prolonged	31
41	)	prolonged	31
42	at	prolonged	31
43	70	%	44
44	%	at	42
45	of	%	44
46	the	individual	47
47	individual	of	45
48	's	individual	47
49	maximal	oxygen	50
50	oxygen	individual	47
51	uptake	oxygen	50
52	.	uptake	51

0	Induction	was	6
1	of	Induction	0
2	HIV	of	1
3	by	Induction	0
4	C.	neoformans	5
5	neoformans	by	3
6	was	<ROOT>	-1
7	enhanced	was	6
8	by	enhanced	7
9	anti-capsular	by	8
10	antibody	anti-capsular	9
11	,	antibody	10
12	while	antibody	10
13	induction	was	17
14	by	induction	13
15	both	organisms	16
16	organisms	by	14
17	was	while	12
18	inhibited	was	17
19	by	inhibited	18
20	anti-TNF-alpha	antibody	21
21	antibody	by	19
22	.	was	6

0	In	STAT3	10
1	summary	In	0
2	,	In	0
3	the	phosphorylation	6
4	constitutive	phosphorylation	6
5	serine	phosphorylation	6
6	phosphorylation	,	2
7	of	phosphorylation	6
8	STAT1	of	7
9	and	of	7
10	STAT3	is	11
11	is	<ROOT>	-1
12	present	is	11
13	in	present	12
14	all	CLL	15
15	CLL	in	13
16	samples	CLL	15
17	tested	samples	16
18	to	tested	17
19	date	to	18
20	,	is	11
21	although	is	11
22	the	although	21
23	physiologic	the	22
24	significance	this	26
25	of	this	26
26	this	physiologic	23
27	modification	be	30
28	remains	to	29
29	to	modification	27
30	be	this	26
31	determined	be	30
32	.	is	11

0	We	have	1
1	have	<ROOT>	-1
2	also	have	1
3	observed	have	1
4	a	expression	6
5	differential	expression	6
6	expression	observed	3
7	of	expression	6
8	the	subunit	10
9	NF-YA	subunit	10
10	subunit	of	7
11	in	subunit	10
12	heme-treated	in	11
13	and	heme-treated	12
14	control	and	13
15	FLCs	control	14
16	and	during	17
17	during	have	1
18	monocyte-to-macrophage	have	1
19	differentiation	have	1
20	.	have	1

0	None	matched	8
1	of	None	0
2	the	substitutions	3
3	substitutions	of	1
4	in	None	0
5	the	domain	7
6	ligand-binding	domain	7
7	domain	in	4
8	matched	<ROOT>	-1
9	mutations	matched	8
10	known	mutations	9
11	to	known	10
12	influence	to	11
13	binding	affinity	14
14	affinity	influence	12
15	in	affinity	14
16	other	species	17
17	species	in	15
18	.	matched	8

0	We	demonstrated	3
1	have	demonstrated	3
2	previously	demonstrated	3
3	demonstrated	<ROOT>	-1
4	that	demonstrated	3
5	experimental	expression	6
6	expression	factor	11
7	of	factor	11
8	the	factor	11
9	polyomavirus	factor	11
10	transcription	factor	11
11	factor	that	4
12	T-antigen	demonstrated	3
13	has	the	14
14	the	demonstrated	3
15	potential	the	14
16	to	potential	15
17	induce	anti-DNA	18
18	anti-DNA	to	16
19	antibodies	to	16
20	in	antibodies	19
21	mice	demonstrated	3
22	.	demonstrated	3

0	Generation	<ROOT>	-1
1	of	Generation	0
2	CD1+RelB+	dendritic	3
3	dendritic	cells	4
4	cells	of	1
5	and	Generation	0
6	tartrate-resistant	and	5
7	acid	phosphatase-positive	8
8	phosphatase-positive	tartrate-resistant	6
9	osteoclast-like	giant	11
10	multinucleated	giant	11
11	giant	cells	12
12	cells	Generation	0
13	from	Generation	0
14	human	Generation	0
15	monocytes	Generation	0
16	.	Generation	0

0	Freshly	expressed	4
1	isolated	expressed	4
2	monocytes	constitutively	3
3	constitutively	expressed	4
4	expressed	<ROOT>	-1
5	high	expressed	4
6	levels	of	7
7	of	transcriptionally	8
8	transcriptionally	expressed	4
9	inactive	which	12
10	p50	which	12
11	homodimer	which	12
12	which	expressed	4
13	decreased	which	12
14	with	decreased	13
15	time	with	14
16	in	time	15
17	culture	in	16
18	in	culture	17
19	favor	culture	17
20	of	favor	19
21	the	of	20
22	transcriptionally	the	21
23	active	transcriptionally	22
24	p50/p65	active	23
25	and	p50/p65	24
26	p50/RelB	heterodimers	27
27	heterodimers	and	25
28	.	p50/p65	24

0	The	combination	2
1	mitogenic	combination	2
2	combination	were	14
3	of	combination	2
4	anti	CD2	5
5	CD2	of	3
6	+	CD2	5
7	anti	released	9
8	CD28	released	9
9	released	+	6
10	the	footprint	11
11	footprint	of	3
12	as	combination	2
13	cells	combination	2
14	were	<ROOT>	-1
15	committed	were	14
16	to	committed	15
17	proliferation	to	16
18	.	were	14

0	In	<ROOT>	-1
1	the	mutants	4
2	four	mutants	4
3	representative	mutants	4
4	mutants	In	0
5	investigated	mutants	4
6	,	In	0
7	the	reiterations	9
8	DNA	reiterations	9
9	reiterations	G	18
10	all	started	11
11	started	reiterations	9
12	within	started	11
13	a	consensus	15
14	six-base-pair	consensus	15
15	consensus	within	12
16	sequence	consensus	15
17	,	reiterations	9
18	G	,	6
19	(	G	18
20	or	(	19
21	C	or	20
22	)	(	19
23	CTGTG	In	0
24	,	In	0
25	located	,	24
26	in	located	25
27	the	exon	29
28	second	exon	29
29	exon	in	26
30	of	exon	29
31	the	of	30
32	E1a	the	31
33	region	(	34
34	(	E1a	32
35	at	nt	36
36	nt	(	34
37	1333	In	0
38	,	1367	39
39	1367	In	0
40	,	1367	39
41	or	1367	39
42	1419	or	41
43	)	In	0
44	.	In	0

0	Higher-molecular-weight	species	1
1	species	<ROOT>	-1
2	of	species	1
3	NFATc	of	2
4	(	NFATc	3
5	of	(	4
6	110	of	5
7	and	110	6
8	140	kDa	9
9	kDa	and	7
10	)	kDa	9
11	were	(	4
12	also	species	1
13	detected	species	1
14	.	species	1

0	In	<ROOT>	-1
1	addition	In	0
2	,	BHRF1	3
3	BHRF1	In	0
4	protected	BHRF1	3
5	these	protected	4
6	cells	from	7
7	from	monocyte-mediated	8
8	monocyte-mediated	these	5
9	killing	but	10
10	but	these	5
11	failed	these	5
12	to	failed	11
13	protect	to	12
14	them	protect	13
15	from	them	14
16	killing	from	15
17	mediated	killing	16
18	by	mediated	17
19	lymphokine-activated	mediated	17
20	killer	cells	21
21	cells	lymphokine-activated	19
22	.	cells	21

0	Role	<ROOT>	-1
1	of	Role	0
2	GATA-1	of	1
3	in	Role	0
4	proliferation	in	3
5	and	in	3
6	differentiation	Role	0
7	of	definitive	8
8	definitive	differentiation	6
9	erythroid	definitive	8
10	and	erythroid	9
11	megakaryocytic	Role	0
12	cells	Role	0
13	in	cells	12
14	vivo	Role	0
15	.	Role	0

0	There	was	1
1	was	<ROOT>	-1
2	not	was	1
3	any	homology	5
4	DNA	homology	5
5	homology	was	1
6	between	homology	5
7	the	breakpoints	8
8	breakpoints	between	6
9	in	breakpoints	8
10	the	exon	12
11	second	exon	12
12	exon	in	9
13	and	breakpoints	8
14	the	sequences	16
15	inserting	sequences	16
16	sequences	and	13
17	(	starting	18
18	starting	sequences	16
19	at	nt	20
20	nt	starting	18
21	532	sequences	16
22	,	was	1
23	710	was	1
24	,	was	1
25	or	was	1
26	792	or	25
27	)	was	1
28	.	was	1

0	Concomitant	downregulation	1
1	downregulation	of	2
2	of	<ROOT>	-1
3	IgH	3'	4
4	3'	of	2
5	enhancer	of	2
6	activity	of	2
7	and	of	2
8	c-myc	expression	9
9	expression	of	2
10	in	of	2
11	a	environment	15
12	plasmacytoma	x	13
13	x	fibroblast	14
14	fibroblast	environment	15
15	environment	in	10
16	:	of	2
17	implications	of	2
18	for	implications	17
19	dysregulation	for	18
20	of	dysregulation	19
21	translocated	c-myc	22
22	c-myc	of	20
23	.	of	2

0	The	response	4
1	local	response	4
2	cellular	response	4
3	immune	response	4
4	response	<ROOT>	-1
5	to	response	4
6	herpes	to	5
7	simplex	virus	8
8	virus	(	9
9	(	herpes	6
10	HSV	is	12
11	)	is	12
12	is	response	4
13	important	is	12
14	in	important	13
15	the	in	14
16	control	the	15
17	of	control	16
18	recurrent	of	17
19	HSV	recurrent	18
20	infection	HSV	19
21	.	infection	20

0	LPS	tolerance	1
1	tolerance	<ROOT>	-1
2	in	tolerance	1
3	monocytes/macrophages	in	2
4	:	tolerance	1
5	three	cytosins	7
6	3'	cytosins	7
7	cytosins	are	8
8	are	tolerance	1
9	required	binding	13
10	in	binding	13
11	the	binding	13
12	DNA	binding	13
13	binding	are	8
14	motif	tolerance	1
15	for	tolerance	1
16	detection	for	15
17	of	detection	16
18	upregulated	p50	21
19	NF-kappa	p50	21
20	B	p50	21
21	p50	of	17
22	homodimers	tolerance	1
23	.	tolerance	1

0	The	<ROOT>	-1
1	GC-R	The	0
2	Bmax	and	3
3	and	GC-R	1
4	Kd	and	3
5	in	and	3
6	quiescent	in	5
7	PBMC	quiescent	6
8	of	quiescent	6
9	the	group	11
10	GC-resistant	group	11
11	group	of	8
12	were	The	0
13	5.33	were	12
14	+/-	5.33	13
15	1.37	+/-	14
16	fmol/10-LRB-6-RRB-	+/-	14
17	cells	and	18
18	and	fmol/10-LRB-6-RRB-	16
19	3.20	+/-	20
20	+/-	1.39	21
21	1.39	5.33	13
22	nM	1.39	21
23	,	5.33	13
24	respectively	5.33	13
25	.	The	0

0	Pretreatment	did	8
1	with	Pretreatment	0
2	B.pertussis	with	1
3	,	B.pertussis	2
4	V.cholera.	B.pertussis	2
5	or	C.botulinum	6
6	C.botulinum	V.cholera.	4
7	toxin	Pretreatment	0
8	did	<ROOT>	-1
9	not	did	8
10	influence	did	8
11	histamine-induced	rise	13
12	-LSB-Ca2+-RSB-i	rise	13
13	rise	influence	10
14	.	did	8

0	DNA	changes	2
1	methylation	changes	2
2	changes	<ROOT>	-1
3	in	changes	2
4	hematologic	malignancies	5
5	malignancies	in	3
6	:	changes	2
7	biologic	and	8
8	and	changes	2
9	clinical	and	8
10	implications	changes	2
11	.	changes	2

0	In	a	6
1	addition	In	0
2	,	a	6
3	we	a	6
4	have	a	6
5	isolated	a	6
6	a	<ROOT>	-1
7	third	NF-kappa	8
8	NF-kappa	a	6
9	B	inhibitor	10
10	inhibitor	a	6
11	,	B	14
12	I	B	14
13	kappa	I	12
14	B	epsilon	15
15	epsilon	a	6
16	(	1	17
17	1	epsilon	15
18	)	1	17
19	.	a	6

0	Anti-intercellular	adhesion	1
1	adhesion	molecule-1	2
2	molecule-1	(	3
3	(	antibodies	8
4	ICAM-1	(	3
5	)	(	3
6	and	anti-P-selectin	7
7	anti-P-selectin	)	5
8	antibodies	adhesion	19
9	(	[	12
10	monoclonal	antibodies	11
11	antibodies	[	12
12	[	antibodies	8
13	mAbs	antibodies	8
14	]	antibodies	8
15	)	antibodies	8
16	attenuated	antibodies	8
17	phase-1	adhesion	19
18	neutrophil	adhesion	19
19	adhesion	<ROOT>	-1
20	,	adhesion	19
21	consistent	with	22
22	with	adhesion	19
23	roles	constitutively	25
24	for	constitutively	25
25	constitutively	expressed	26
26	expressed	with	22
27	ICAM-1	with	22
28	and	ICAM-1	27
29	enhanced	and	28
30	surface	adhesion	19
31	expression	adhesion	19
32	of	expression	31
33	preformed	of	32
34	P-selectin	adhesion	19
35	.	adhesion	19

0	We	demonstrated	1
1	demonstrated	changed	11
2	that	demonstrated	1
3	constitutive	expression	4
4	expression	that	2
5	of	expression	4
6	NF-kappaB	expression	4
7	in	primary	8
8	primary	NF-kappaB	6
9	human	demonstrated	1
10	monocytes	demonstrated	1
11	changed	<ROOT>	-1
12	significantly	changed	11
13	with	changed	11
14	differentiation	with	13
15	in	changed	11
16	vitro	changed	11
17	to	changed	11
18	monocyte-derived	macrophages	19
19	macrophages	to	17
20	(	MDMs	21
21	MDMs	macrophages	19
22	)	MDMs	21
23	and	changed	11
24	differentiation	changed	11
25	in	changed	11
26	vivo	changed	11
27	to	vivo	26
28	alveolar	changed	11
29	macrophages	changed	11
30	(	macrophages	29
31	AMs	macrophages	29
32	)	changed	11
33	.	changed	11

0	In	LAZ3/BCL6	7
1	the	samples	3
2	tumor	samples	3
3	samples	In	0
4	,	expression	5
5	expression	In	0
6	of	expression	5
7	LAZ3/BCL6	was	8
8	was	<ROOT>	-1
9	observed	was	8
10	in	observed	9
11	68	%	12
12	%	cell	16
13	of	cell	16
14	all	cell	16
15	B	cell	16
16	cell	in	10
17	NHL	observed	9
18	and	NHL	17
19	none	non-B	22
20	of	non-B	22
21	the	non-B	22
22	non-B	and	18
23	lymphomas	was	8
24	.	was	8

0	It	is	1
1	is	<ROOT>	-1
2	remarkable	is	1
3	that	remarkable	2
4	in	that	3
5	B-CLL	in	4
6	cells	B-CLL	5
7	the	appearance	9
8	nuclear	appearance	9
9	appearance	that	3
10	and	DNA	11
11	DNA	that	3
12	binding	DNA	11
13	of	binding	12
14	specific	factors	16
15	transcription	factors	16
16	factors	of	13
17	is	is	1
18	dramatically	is	17
19	affected	dramatically	18
20	whereas	remained	28
21	other	whereas	20
22	members	other	21
23	of	members	22
24	the	family	27
25	same	family	27
26	factor	family	27
27	family	of	23
28	remained	affected	19
29	unaltered	remained	28
30	in	unaltered	29
31	these	cells	33
32	leukemic	cells	33
33	cells	in	30
34	.	cells	33

0	CONCLUSION	<ROOT>	-1
1	:	CONCLUSION	0
2	These	CONCLUSION	0
3	data	These	2
4	suggest	that	5
5	that	data	3
6	glucocorticoids	such	7
7	such	as	8
8	as	that	5
9	budesonide	as	8
10	,	budesonide	9
11	by	budesonide	9
12	virtue	budesonide	9
13	of	virtue	12
14	their	of	13
15	high	their	14
16	GCR	high	15
17	binding	GCR	16
18	affinities	binding	17
19	and	greater	20
20	greater	ability	21
21	ability	affinities	18
22	to	suppress	23
23	suppress	ability	21
24	lymphocyte	may	27
25	proliferation	may	27
26	,	may	27
27	may	ability	21
28	therefore	may	27
29	be	ability	21
30	beneficial	be	29
31	in	beneficial	30
32	the	management	33
33	management	in	31
34	of	management	33
35	difficult-to-control	asthma	36
36	asthma	of	34
37	.	CONCLUSION	0

0	V3	loop	1
1	loop	virus	5
2	of	virus	5
3	human	virus	5
4	immunodeficiency	virus	5
5	virus	type	6
6	type	suppresses	8
7	1	suppresses	8
8	suppresses	2-induced	10
9	interleukin	2-induced	10
10	2-induced	erratum	16
11	T	growth	13
12	cell	growth	13
13	growth	2-induced	10
14	[	2-induced	10
15	published	[	14
16	erratum	appears	17
17	appears	<ROOT>	-1
18	in	appears	17
19	AIDS	1997	23
20	Res	Retroviruses	22
21	Hum	Retroviruses	22
22	Retroviruses	1997	23
23	1997	in	18
24	May	appears	17
25	1	May	24
26	;	appears	17
27	13	(	28
28	(	:	31
29	7	(	28
30	)	(	28
31	:	appears	17
32	633	:	31
33	]	:	31

0	There	was	1
1	was	<ROOT>	-1
2	a	was	1
3	significant	a	2
4	negative	between	6
5	correlation	between	6
6	between	significant	3
7	IC50S	between	6
8	of	IC50S	7
9	prednisolone	of	8
10	and	between	6
11	increase-ratios	and	10
12	(	increase-ratios	11
13	post/pre	(	12
14	ratio	)	15
15	)	post/pre	13
16	of	)	15
17	Bmax	(	12
18	after	(	12
19	mitogen	stimulation	20
20	stimulation	increase-ratios	11
21	(	between	6
22	p	between	6
23	&lt;	0.05	24
24	0.05	between	6
25	)	between	6
26	.	between	6

0	The	hypothesis	1
1	hypothesis	may	13
2	that	hypothesis	1
3	the	factor	5
4	nuclear	factor	5
5	factor	that	2
6	of	T	8
7	activated	T	8
8	T	factor	5
9	cells	hypothesis	1
10	(	NF-AT	11
11	NF-AT	hypothesis	1
12	)	NF-AT	11
13	may	is	17
14	influence	may	13
15	HIV-1	replication	16
16	replication	influence	14
17	is	<ROOT>	-1
18	therefore	compelling	19
19	compelling	given	20
20	given	is	17
21	the	correlation	23
22	tight	correlation	23
23	correlation	given	20
24	of	correlation	23
25	HIV-1	induction	27
26	transcriptional	induction	27
27	induction	of	24
28	to	cell	30
29	T	cell	30
30	cell	given	20
31	activation	is	17
32	.	is	17

0	These	cells	1
1	cells	were	2
2	were	<ROOT>	-1
3	examined	were	2
4	for	examined	3
5	ER	mRNA	6
6	mRNA	for	4
7	by	for	4
8	reverse	reaction	13
9	transcription	reaction	13
10	nested	reaction	13
11	polymerase	reaction	13
12	chain	reaction	13
13	reaction	by	7
14	.	were	2

0	The	domain	2
1	extracellular	domain	2
2	domain	was	8
3	of	domain	2
4	the	receptor	7
5	murine	receptor	7
6	G-CSF	receptor	7
7	receptor	of	3
8	was	<ROOT>	-1
9	required	was	8
10	for	required	9
11	the	activity	12
12	activity	for	10
13	of	activity	12
14	SB	247464	15
15	247464	of	13
16	,	247464	15
17	suggesting	247464	15
18	that	suggesting	17
19	the	compound	20
20	compound	acts	21
21	acts	that	18
22	by	acts	21
23	oligomerizing	chains	25
24	receptor	chains	25
25	chains	by	22
26	.	was	8

0	These	<ROOT>	-1
1	data	These	0
2	show	that	3
3	that	data	1
4	the	detection	5
5	detection	that	3
6	of	detection	5
7	upregulated	of	6
8	p50	in	10
9	homodimers	in	10
10	in	upregulated	7
11	LPS	cells	13
12	tolerant	cells	13
13	cells	upregulated	7
14	is	that	3
15	dependent	is	14
16	on	dependent	15
17	subtle	differences	18
18	differences	on	16
19	in	differences	18
20	the	binding	25
21	sequence	of	22
22	of	binding	25
23	the	binding	25
24	DNA	binding	25
25	binding	in	19
26	motif	These	0
27	.	These	0

0	Extracts	prepared	1
1	prepared	cells	7
2	from	prepared	1
3	XP-B	from	2
4	and	XP-B	3
5	XP-D	prepared	1
6	lymphoblastoid	prepared	1
7	cells	<ROOT>	-1
8	exhibited	cells	7
9	similar	activity	11
10	transcription	activity	11
11	activity	exhibited	8
12	from	cells	7
13	the	promoter	17
14	adenovirus	major	15
15	major	promoter	17
16	late	promoter	17
17	promoter	from	12
18	when	cells	7
19	compared	cells	7
20	to	compared	19
21	that	to	20
22	in	that	21
23	extracts	in	22
24	from	normal	25
25	normal	in	22
26	cells	cells	7
27	.	cells	7

0	To	<ROOT>	-1
1	determine	To	0
2	whether	determine	1
3	the	substitutions	4
4	substitutions	were	7
5	per	substitutions	4
6	se	per	5
7	were	whether	2
8	responsible	were	7
9	for	responsible	8
10	decreased	affinity	11
11	affinity	for	9
12	,	To	0
13	squirrel	To	0
14	monkey	and	15
15	and	squirrel	13
16	human	and	15
17	glucocorticoid	human	16
18	receptors	expressed	20
19	were	expressed	20
20	expressed	glucocorticoid	17
21	in	expressed	20
22	the	System	27
23	TNT	System	27
24	Coupled	System	27
25	Reticulocyte	System	27
26	Lysate	System	27
27	System	in	21
28	.	To	0

0	Reduction	<ROOT>	-1
1	of	IL-2	2
2	IL-2	Reduction	0
3	production	is	4
4	is	Reduction	0
5	secondary	is	4
6	to	secondary	5
7	the	inability	8
8	inability	to	6
9	to	element	14
10	phosphorylate	response	13
11	the	cAMP	12
12	cAMP	response	13
13	response	element	14
14	element	inability	8
15	binding	element	14
16	protein	binding	15
17	,	protein	16
18	CREB	,	17
19	,	CREB	18
20	and	,	19
21	induce	,	19
22	expression	induce	21
23	of	expression	22
24	the	genes	27
25	immediate	genes	27
26	early	genes	27
27	genes	of	23
28	such	as	29
29	as	genes	27
30	Fos	B	31
31	B	that	32
32	that	as	29
33	are	that	32
34	required	are	33
35	to	required	34
36	transactivate	IL-2	38
37	the	IL-2	38
38	IL-2	to	6
39	promoter	Reduction	0
40	.	Reduction	0

0	In	<ROOT>	-1
1	fact	In	0
2	,	cells	4
3	8e51	cells	4
4	cells	that	5
5	that	In	0
6	had	that	5
7	almost	had	6
8	lost	almost	7
9	their	capacity	11
10	syncytia-forming	capacity	11
11	capacity	lost	8
12	were	capacity	11
13	found	that	5
14	to	found	13
15	contain	to	14
16	at	contain	15
17	least	less	20
18	10	less	20
19	times	less	20
20	less	cells	29
21	active	the	26
22	NF-kappaB	the	26
23	DNA-binding	the	26
24	complex	the	26
25	than	the	26
26	the	less	20
27	actively	cells	29
28	fusing	cells	29
29	cells	at	16
30	.	cells	29

0	A	combination	1
1	combination	<ROOT>	-1
2	of	combination	1
3	differential	splicing	4
4	splicing	of	2
5	and	combination	1
6	alternative	and	5
7	use	alternative	6
8	of	use	7
9	promoters	of	8
10	generates	of	8
11	four	isoforms	13
12	mRNA	isoforms	13
13	isoforms	generates	10
14	,	combination	1
15	of	2.6	16
16	2.6	combination	1
17	kb	combination	1
18	and	kb	17
19	1.3-1.5	kb	20
20	kb	combination	1
21	in	combination	1
22	size	combination	1
23	.	combination	1

0	This	review	1
1	review	will	2
2	will	<ROOT>	-1
3	cover	will	2
4	the	mechanisms	6
5	molecular	mechanisms	6
6	mechanisms	cover	3
7	that	are	8
8	are	mechanisms	6
9	utilized	are	8
10	by	utilized	9
11	mammalian	viruses	13
12	oncogenic	viruses	13
13	viruses	by	10
14	to	utilized	9
15	affect	to	14
16	the	activity	17
17	activity	affect	15
18	of	activity	17
19	Rel/NF-kappa	B	20
20	B	of	18
21	transcription	B	20
22	factors	cover	3
23	and	factors	22
24	the	and	23
25	role	of	26
26	of	the	24
27	Rel/NF-kappa	B	28
28	B	of	26
29	in	the	30
30	the	of	26
31	regulation	of	32
32	of	will	2
33	viral	expression	35
34	gene	expression	35
35	expression	of	32
36	and	will	2
37	replication	will	2
38	.	will	2

0	Thus	is	3
1	,	is	3
2	BOB.1/OBF.1	is	3
3	is	<ROOT>	-1
4	a	coactivator	6
5	transcriptional	coactivator	6
6	coactivator	is	3
7	that	is	8
8	is	coactivator	6
9	critically	is	8
10	regulated	critically	9
11	by	regulated	10
12	posttranslational	by	11
13	modifications	posttranslational	12
14	to	modifications	13
15	mediate	cell	16
16	cell	to	14
17	type-specific	cell	16
18	gene	type-specific	17
19	expression	.	20
20	.	gene	18

0	We	demonstrate	1
1	demonstrate	<ROOT>	-1
2	that	demonstrate	1
3	expression	that	2
4	of	expression	3
5	Tax	of	4
6	can	expression	3
7	induce	DNA-binding	10
8	the	DNA-binding	10
9	E2F-containing	DNA-binding	10
10	DNA-binding	can	6
11	complexes	can	6
12	in	T	14
13	Jurkat	T	14
14	T	complexes	11
15	cells	demonstrate	1
16	.	demonstrate	1

0	IL-2R	alpha	1
1	alpha	<ROOT>	-1
2	transcription	is	3
3	is	alpha	1
4	at	alpha	1
5	least	at	4
6	in	controlled	8
7	part	in	6
8	controlled	alpha	1
9	by	controlled	8
10	two	by	9
11	positive	two	10
12	regulatory	,	14
13	regions	,	14
14	,	positive	11
15	PRRI	positive	11
16	and	PRRI	15
17	PRRII	and	16
18	.	alpha	1

0	Treatment	activator	9
1	of	T	2
2	T	Treatment	0
3	cells	Treatment	0
4	with	activator	9
5	the	activator	9
6	protein	activator	9
7	kinase	activator	9
8	C	kinase	7
9	activator	<ROOT>	-1
10	PMA	activator	9
11	in	activator	9
12	combination	activator	9
13	with	Ca2+	14
14	Ca2+	combination	12
15	ionophores	activator	9
16	mimics	activator	9
17	this	process	18
18	process	mimics	16
19	,	activator	9
20	and	activator	9
21	the	agents	23
22	two	agents	23
23	agents	are	24
24	are	and	20
25	often	are	24
26	substituted	are	24
27	for	TCR	28
28	TCR	substituted	26
29	stimulation	activator	9
30	,	activator	9
31	bypassing	the	32
32	the	TCR	33
33	TCR	activator	9
34	.	activator	9

0	Thus	results	2
1	these	Thus	0
2	results	suggest	3
3	suggest	<ROOT>	-1
4	a	contribution	6
5	direct	contribution	6
6	contribution	suggest	3
7	of	contribution	6
8	EBV	of	7
9	to	contribution	6
10	chronic	pathogenesis	13
11	rheumatoid	pathogenesis	13
12	arthritis	pathogenesis	13
13	pathogenesis	to	9
14	.	suggest	3

0	The	phosphorylation	2
1	serine	phosphorylation	2
2	phosphorylation	was	6
3	of	phosphorylation	2
4	these	STATs	5
5	STATs	of	3
6	was	<ROOT>	-1
7	a	process	9
8	continuous	process	9
9	process	was	6
10	,	was	6
11	as	was	6
12	incubation	inhibitor	19
13	of	incubation	12
14	CLL	cells	15
15	cells	of	13
16	with	inhibitor	19
17	the	inhibitor	19
18	kinase	inhibitor	19
19	inhibitor	as	11
20	H7	led	21
21	led	was	6
22	to	led	21
23	the	dephosphorylation	24
24	dephosphorylation	serine	27
25	of	serine	27
26	these	serine	27
27	serine	to	22
28	residues	was	6
29	.	was	6

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	activation	T	11
5	of	activation	4
6	NF-AT1	of	5
7	in	activation	4
8	Tax-expressing	in	7
9	and	in	7
10	HTLV-I-transformed	T	11
11	T	that	3
12	cells	suggest	2
13	results	suggest	2
14	from	suggest	2
15	its	dephosphorylation	16
16	dephosphorylation	from	14
17	,	suggest	2
18	which	may	21
19	in	may	21
20	turn	in	19
21	may	suggest	2
22	be	may	21
23	due	be	22
24	to	due	23
25	deregulation	to	24
26	of	deregulation	25
27	calcineurin	of	26
28	.	suggest	2

0	We	conclude	1
1	conclude	polymorphism	4
2	that	polymorphism	4
3	VDR	polymorphism	4
4	polymorphism	<ROOT>	-1
5	does	polymorphism	4
6	not	does	5
7	affect	the	8
8	the	does	5
9	abundance	the	8
10	of	abundance	9
11	the	VDR	12
12	VDR	of	10
13	mRNA	VDR	12
14	.	polymorphism	4

0	Later	established	2
1	we	established	2
2	established	<ROOT>	-1
3	spontaneously	formed	4
4	formed	B-lymphoblastoid	5
5	B-lymphoblastoid	established	2
6	cell	(	8
7	lines	(	8
8	(	B-lymphoblastoid	5
9	LCLs	)	10
10	)	established	2
11	from	a	12
12	a	)	10
13	patient	established	2
14	with	established	2
15	an	disease	17
16	MS-like	disease	17
17	disease	with	14
18	and	established	2
19	from	and	18
20	another	patient	21
21	patient	from	19
22	with	patient	21
23	MS	with	22
24	who	had	25
25	had	MS	23
26	a	had	25
27	reactivated	a	26
28	Epstein-Barr	virus	29
29	virus	reactivated	27
30	(	EBV	31
31	EBV	virus	29
32	)	EBV	31
33	infection	)	32
34	.	infection	33

0	The	same	1
1	same	was	2
2	was	<ROOT>	-1
3	found	was	2
4	for	found	3
5	RXR-beta	mRNA	6
6	mRNA	for	4
7	.	was	2

0	Ad2	infection	1
1	infection	induced	2
2	induced	<ROOT>	-1
3	transient	increase	4
4	increase	induced	2
5	in	mRNA	7
6	the	mRNA	7
7	mRNA	increase	4
8	levels	induced	2
9	for	induced	2
10	TNF-alpha	for	9
11	and	for	9
12	IL-1	and	11
13	beta	for	9
14	in	beta	13
15	both	in	14
16	monocytes	and	17
17	and	both	15
18	in	and	17
19	macrophages	induced	2
20	,	induced	2
21	although	induced	2
22	the	although	21
23	kinetics	the	22
24	of	kinetics	23
25	the	of	24
26	transcription	was	27
27	was	the	25
28	slightly	different	29
29	different	the	25
30	.	induced	2

0	Moreover	released	9
1	,	Moreover	0
2	ACH-2	cells	3
3	cells	treated	4
4	treated	,	1
5	with	treated	4
6	HOCl	Moreover	0
7	or	HOCl	6
8	H2O2	Moreover	0
9	released	tumour	10
10	tumour	<ROOT>	-1
11	necrosis	factor-alpha	12
12	factor-alpha	tumour	10
13	(	factor-alpha	12
14	TNF-alpha	tumour	10
15	)	TNF-alpha	14
16	in	)	15
17	the	supernatants	18
18	supernatants	in	16
19	.	tumour	10

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	,	In	0
4	we	,	3
5	examined	we	4
6	early	events	8
7	signaling	events	8
8	events	examined	5
9	in	examined	5
10	proliferating	in	9
11	and	proliferating	10
12	terminally	and	11
13	differentiated	terminally	12
14	cells	G-CSF	16
15	following	G-CSF	16
16	G-CSF	differentiated	13
17	stimulation	differentiated	13
18	to	terminally	12
19	determine	to	18
20	whether	determine	19
21	identical	whether	20
22	signaling	are	24
23	cascades	are	24
24	are	identical	21
25	activated	are	24
26	.	In	0

0	It	was	1
1	was	<ROOT>	-1
2	possible	was	1
3	that	was	1
4	one	bore	11
5	of	one	4
6	the	clone	7
7	clone	alleles	10
8	13	alleles	10
9	CIITA	alleles	10
10	alleles	of	5
11	bore	that	3
12	a	mutation	13
13	mutation	bore	11
14	that	allowed	15
15	allowed	mutation	13
16	HLA-DQ	allowed	15
17	,	bore	11
18	but	bore	11
19	not	but	18
20	HLA-DR	but	18
21	or	-DP	22
22	-DP	HLA-DR	20
23	transcription	was	1
24	.	was	1

0	Collectively	shows	3
1	this	study	2
2	study	Collectively	0
3	shows	<ROOT>	-1
4	that	shows	3
5	expression	is	10
6	of	expression	5
7	the	gene	9
8	Btk	gene	9
9	gene	of	6
10	is	that	4
11	regulated	is	10
12	by	combined	14
13	the	combined	14
14	combined	regulated	11
15	action	combined	14
16	of	action	15
17	Sp1-	members	20
18	and	Sp1-	17
19	PU.1-family	and	18
20	members	of	16
21	.	shows	3

0	Interestingly	was	6
1	,	was	6
2	the	induction	5
3	DEX-mediated	induction	5
4	IkappaBalpha	induction	5
5	induction	was	6
6	was	<ROOT>	-1
7	completely	was	6
8	inhibited	completely	7
9	by	inhibited	8
10	IL-2	by	9
11	,	IL-2	10
12	but	by	9
13	not	but	12
14	IL-4	not	13
15	,	was	6
16	in	Th1	17
17	Th1	was	6
18	cells	was	6
19	,	was	6
20	while	was	6
21	the	profile	23
22	reverse	profile	23
23	profile	was	24
24	was	while	20
25	seen	was	24
26	in	Th2	27
27	Th2	seen	25
28	cells	was	6
29	.	was	6

0	Ascorbate	had	4
1	and	Ascorbate	0
2	AZT	and	1
3	also	had	4
4	had	<ROOT>	-1
5	no	effect	6
6	effect	had	4
7	on	effect	6
8	NF-kappa	activation	10
9	B	activation	10
10	activation	on	7
11	following	had	4
12	TNF-alpha-	following	11
13	or	cells	19
14	PMA-induced	or	13
15	stimulation	of	16
16	of	PMA-induced	14
17	U1	cells	19
18	promonocytic	cells	19
19	cells	TNF-alpha-	12
20	.	cells	19

0	We	using	18
1	have	We	0
2	therefore	have	1
3	investigated	therefore	2
4	the	investigated	3
5	transcriptional	the	4
6	activity	transcriptional	5
7	of	A-MYB	8
8	A-MYB	activity	6
9	and	A-MYB	8
10	its	and	9
11	regulation	in	12
12	in	the	4
13	several	in	12
14	human	We	0
15	lymphoid	We	0
16	cell	We	0
17	lines	We	0
18	using	<ROOT>	-1
19	co-transfection	using	18
20	assays	co-transfection	19
21	and	using	18
22	show	that	23
23	that	and	21
24	A-MYB	that	23
25	is	using	18
26	transcriptionally	is	25
27	active	in	28
28	in	transcriptionally	26
29	all	the	30
30	the	in	28
31	B	,	35
32	cell	,	35
33	lines	,	35
34	studied	,	35
35	,	in	28
36	but	in	28
37	not	in	28
38	in	T	39
39	T	using	18
40	cells	using	18
41	.	using	18

0	We	have	1
1	have	<ROOT>	-1
2	examined	have	1
3	the	effect	4
4	effect	examined	2
5	of	effect	4
6	cytokines	of	5
7	on	effect	4
8	IL-2	deprivation-induced	9
9	deprivation-induced	human	12
10	apoptosis	of	11
11	of	deprivation-induced	9
12	human	on	7
13	antigen-specific	T	14
14	T	helper	15
15	helper	have	1
16	clones	have	1
17	with	different	18
18	different	have	1
19	cytokine	have	1
20	production	have	1
21	profiles	have	1
22	.	have	1

0	The	range	1
1	range	was	6
2	of	G-LRB-S-RRB-alpha	3
3	G-LRB-S-RRB-alpha	range	1
4	expression	produced	5
5	produced	G-LRB-S-RRB-alpha	3
6	was	<ROOT>	-1
7	found	was	6
8	to	found	7
9	mimic	to	8
10	a	spectrum	13
11	physiologically	relevant	12
12	relevant	spectrum	13
13	spectrum	mimic	9
14	of	G-LRB-S-RRB-alpha	15
15	G-LRB-S-RRB-alpha	spectrum	13
16	expression	in	17
17	in	G-LRB-S-RRB-alpha	15
18	membranes	was	6
19	derived	was	6
20	from	human	21
21	human	derived	19
22	tissues	was	6
23	and	was	6
24	rat	was	6
25	brain	was	6
26	.	was	6

0	In	<ROOT>	-1
1	cells	In	0
2	preincubated	In	0
3	for	preincubated	2
4	a	day	5
5	day	for	3
6	,	In	0
7	levels	In	0
8	of	levels	7
9	FOS	mRNA	10
10	mRNA	of	8
11	reach	In	0
12	a	reach	11
13	maximum	a	12
14	20	maximum	13
15	min	20	14
16	after	the	17
17	the	min	15
18	addition	min	15
19	of	addition	18
20	lectin	of	19
21	and	lectin	20
22	decline	and	21
23	to	decline	22
24	control	decline	22
25	levels	decline	22
26	over	levels	25
27	the	over	26
28	next	3	29
29	3	the	27
30	hr	3	29
31	.	hr	30

0	In	are	11
1	this	system	3
2	model	system	3
3	system	In	0
4	,	are	11
5	the	activities	6
6	activities	are	11
7	of	activities	6
8	late	promoter-reporter	9
9	promoter-reporter	of	7
10	fusions	are	11
11	are	<ROOT>	-1
12	measured	are	11
13	following	transfection	15
14	transient	transfection	15
15	transfection	measured	12
16	into	measured	12
17	tissue	cells	19
18	culture	cells	19
19	cells	into	16
20	expressing	measured	12
21	EBV	measured	12
22	during	measured	12
23	different	during	22
24	stages	different	23
25	of	stages	24
26	the	of	25
27	lytic	.	29
28	cycle	.	29
29	.	the	26

0	Our	observations	1
1	observations	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	both	enhancer	6
5	the	enhancer	6
6	enhancer	have	10
7	and	enhancer	6
8	the	promoter	9
9	promoter	and	7
10	have	that	3
11	a	have	10
12	complex	whose	15
13	tissue-specific	whose	15
14	structure	whose	15
15	whose	functional	16
16	functional	potentiates	18
17	interplay	potentiates	18
18	potentiates	a	11
19	T-cell-specific	transcription	20
20	transcription	a	11
21	.	suggest	2

0	Pancreas	organogenesis	1
1	organogenesis	is	2
2	is	<ROOT>	-1
3	a	process	6
4	highly	regulated	5
5	regulated	process	6
6	process	is	2
7	,	is	2
8	in	is	2
9	which	in	8
10	two	evaginate	12
11	anlage	evaginate	12
12	evaginate	in	8
13	from	evaginate	12
14	the	primitive	15
15	primitive	from	13
16	gut	primitive	15
17	.	is	2

0	We	investigated	2
1	have	investigated	2
2	investigated	<ROOT>	-1
3	the	effects	4
4	effects	investigated	2
5	of	effects	4
6	acetylsalicylic	acid	7
7	acid	of	5
8	and	investigated	2
9	sodium	and	8
10	salicylate	on	11
11	on	sodium	9
12	the	sodium	9
13	LPS-induced	the	12
14	synthesis	LPS-induced	13
15	of	synthesis	14
16	the	of	15
17	pro-coagulant	factor	20
18	protein	factor	20
19	tissue	factor	20
20	factor	the	16
21	(	factor	20
22	TF	)	23
23	)	the	16
24	and	)	23
25	the	)	23
26	pro-inflammatory	protein	27
27	protein	tumor	28
28	tumor	factor-alpha	30
29	necrosis	factor-alpha	30
30	factor-alpha	the	25
31	(	factor-alpha	30
32	TNF-alpha	investigated	2
33	)	investigated	2
34	,	investigated	2
35	as	investigated	2
36	well	investigated	2
37	as	prostaglandin	39
38	the	prostaglandin	39
39	prostaglandin	investigated	2
40	PGE2	prostaglandin	39
41	in	human	42
42	human	prostaglandin	39
43	monocytes	investigated	2
44	.	investigated	2

0	METHODS	<ROOT>	-1
1	AND	METHODS	0
2	RESULTS	AND	1
3	:	RESULTS	2
4	We	METHODS	0
5	measured	We	4
6	levels	measured	5
7	of	levels	6
8	TF	of	7
9	activity	METHODS	0
10	in	METHODS	0
11	peripheral	METHODS	0
12	blood	METHODS	0
13	mononuclear	METHODS	0
14	cells	METHODS	0
15	and	METHODS	0
16	highly	purified	17
17	purified	and	15
18	monocytes/macrophages	METHODS	0
19	from	METHODS	0
20	10	cardiac	22
21	consecutive	cardiac	22
22	cardiac	METHODS	0
23	transplant	and	25
24	recipients	and	25
25	and	cardiac	22
26	10	and	25
27	healthy	METHODS	0
28	control	METHODS	0
29	subjects	METHODS	0
30	.	METHODS	0

0	Activated	B	2
1	NF-kappa	B	2
2	B	was	6
3	in	B	2
4	nuclear	extracts	5
5	extracts	in	3
6	was	<ROOT>	-1
7	measured	was	6
8	by	measured	7
9	an	assay	13
10	electrophoretic	assay	13
11	mobility	assay	13
12	shift	assay	13
13	assay	by	8
14	using	32P-labeled	15
15	32P-labeled	assay	13
16	probe	was	6
17	.	was	6

0	The	mechanisms	2
1	underlying	mechanisms	2
2	mechanisms	are	14
3	by	are	8
4	which	by	3
5	the	genes	7
6	corresponding	genes	7
7	genes	are	8
8	are	mechanisms	2
9	transcriptionally	are	8
10	initiated	transcriptionally	9
11	after	transcriptionally	9
12	virus	infection	13
13	infection	after	11
14	are	<ROOT>	-1
15	still	are	14
16	poorly	understood	17
17	understood	are	14
18	.	are	14

0	The	factor	3
1	winged-helix	factor	3
2	transcription	factor	3
3	factor	is	5
4	Trident	factor	3
5	is	<ROOT>	-1
6	expressed	is	5
7	in	expressed	6
8	actively	lymphocytes	10
9	dividing	lymphocytes	10
10	lymphocytes	in	7
11	.	is	5

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	on	In	0
4	the	number	5
5	number	on	3
6	and	number	5
7	function	and	6
8	of	number	5
9	GR	of	8
10	in	number	5
11	lymphocytes	In	0
12	,	In	0
13	we	were	14
14	were	In	0
15	unable	were	14
16	to	unable	15
17	find	to	16
18	a	relation	19
19	relation	find	17
20	between	relation	19
21	the	functionality	22
22	functionality	between	20
23	of	functionality	22
24	the	GR	25
25	GR	of	23
26	and	functionality	22
27	the	development	28
28	development	and	26
29	of	development	28
30	NRDS	of	29
31	.	In	0

0	Interleukin-6	levels	1
1	levels	are	2
2	are	<ROOT>	-1
3	increased	are	2
4	in	increased	3
5	lung	in	4
6	transplant	patients	7
7	patients	lung	5
8	clinically	patients	7
9	diagnosed	clinically	8
10	with	CMV	11
11	CMV	lung	5
12	pneumonitis	in	4
13	.	are	2

0	The	change	1
1	change	may	10
2	in	change	1
3	NF-kappaB	components	4
4	components	in	2
5	with	monocyte	6
6	monocyte	change	1
7	differentiation	change	1
8	in	change	1
9	vivo	change	1
10	may	<ROOT>	-1
11	also	may	10
12	explain	may	10
13	the	different	14
14	different	transcriptional	15
15	transcriptional	explain	12
16	activities	of	17
17	of	transcriptional	15
18	these	of	17
19	cell	in	21
20	populations	in	21
21	in	these	18
22	HIV-infected	may	10
23	individuals	may	10
24	.	may	10

0	Anti-E.	antibody	2
1	chaffeensis	antibody	2
2	antibody	<ROOT>	-1
3	complexed	antibody	2
4	with	complexed	3
5	E.	chaffeensis	6
6	chaffeensis	with	4
7	significantly	chaffeensis	6
8	enhanced	chaffeensis	6
9	mRNA	expression	10
10	expression	enhanced	8
11	of	expression	10
12	IL-1beta	in	13
13	in	of	11
14	THP-1	chaffeensis	6
15	cells	antibody	2
16	.	antibody	2

0	These	findings	1
1	findings	reveal	2
2	reveal	<ROOT>	-1
3	the	features	4
4	features	reveal	2
5	controlling	the	6
6	the	promoter	8
7	pp52	promoter	8
8	promoter	features	4
9	in	promoter	8
10	B	in	9
11	and	T	12
12	T	B	10
13	cells	reveal	2
14	and	reveal	2
15	provide	and	14
16	the	foundation	17
17	foundation	provide	15
18	for	provide	15
19	determining	for	18
20	the	regulation	21
21	regulation	this	23
22	of	this	23
23	this	determining	19
24	promoter	in	25
25	in	reveal	2
26	other	leukocyte	27
27	leukocyte	in	25
28	lineages	leukocyte	27
29	.	lineages	28

0	CONCLUSIONS	<ROOT>	-1
1	:	CONCLUSIONS	0
2	Sexual	hormones	3
3	hormones	may	9
4	,	hormones	3
5	through	hormones	3
6	their	receptors	7
7	receptors	through	5
8	,	hormones	3
9	may	CONCLUSIONS	0
10	influence	may	9
11	the	activity	12
12	activity	influence	10
13	of	activity	12
14	eosinophils	of	13
15	in	activity	12
16	patients	in	15
17	with	patients	16
18	VKC	patients	16
19	.	CONCLUSIONS	0

0	These	differences	1
1	differences	suggest	8
2	in	differences	1
3	expression	of	4
4	of	in	2
5	FOS	of	4
6	and	of	4
7	FOSB	differences	1
8	suggest	<ROOT>	-1
9	different	roles	10
10	roles	suggest	8
11	and	roles	10
12	regulation	and	11
13	.	suggest	8

0	Transient	tranfection	1
1	tranfection	cell	5
2	of	cell	5
3	a	cell	5
4	promyelocyte	cell	5
5	cell	line	6
6	line	expression	13
7	(	line	6
8	NB4	line	6
9	)	line	6
10	with	expression	13
11	a	expression	13
12	C/EBP-epsilon	expression	13
13	expression	increased	15
14	plasmid	expression	13
15	increased	<ROOT>	-1
16	cell	growth	17
17	growth	increased	15
18	by	increased	15
19	sevenfold	by	18
20	,	sevenfold	19
21	while	sevenfold	19
22	antisense	sevenfold	19
23	C/EBP-epsilon	caused	24
24	caused	antisense	22
25	a	caused	24
26	fivefold	in	28
27	decrease	in	28
28	in	a	25
29	clonal	in	28
30	growth	of	31
31	of	clonal	29
32	these	cells	33
33	cells	of	31
34	.	cells	33

0	In	showed	7
1	keeping	In	0
2	with	keeping	1
3	this	finding	4
4	finding	with	2
5	,	showed	7
6	we	showed	7
7	showed	cells	12
8	that	showed	7
9	apoptosis	that	8
10	of	U937	11
11	U937	apoptosis	9
12	cells	<ROOT>	-1
13	is	cells	12
14	characterized	cells	12
15	by	characterized	14
16	the	disappearance	18
17	rapid	disappearance	18
18	disappearance	by	15
19	of	disappearance	18
20	the	105,000-	21
21	105,000-	of	19
22	to	110,000-molecular-weight	23
23	110,000-molecular-weight	disappearance	18
24	pRB	cells	12
25	forms	cells	12
26	concomitantly	cells	12
27	with	concomitantly	26
28	the	appearance	29
29	appearance	of	30
30	of	with	27
31	a	smear	32
32	smear	molecular	38
33	of	smear	32
34	immunoreactive	products	35
35	products	of	33
36	with	molecular	38
37	a	molecular	38
38	molecular	of	30
39	weight	cells	12
40	of	cells	12
41	greater	than	42
42	than	of	40
43	250,000	than	42
44	.	cells	12

0	Nuclear	run-off	1
1	run-off	was	16
2	assays	run-off	1
3	and	run-off	1
4	half-life	studies	5
5	studies	and	3
6	showed	studies	5
7	that	accumulation	8
8	accumulation	run-off	1
9	of	accumulation	8
10	C/EBP	mRNA	12
11	epsilon	mRNA	12
12	mRNA	of	9
13	by	run-off	1
14	9-cis	RA	15
15	RA	by	13
16	was	<ROOT>	-1
17	due	was	16
18	to	due	17
19	enhanced	transcription	20
20	transcription	to	18
21	.	was	16

0	Electrophoretic	<ROOT>	-1
1	mobility	Electrophoretic	0
2	shift	mobility	1
3	assays	indicate	4
4	indicate	Electrophoretic	0
5	that	indicate	4
6	MS-2beta	that	5
7	and	MS-2beta	6
8	MS-2gamma	and	7
9	interact	MS-2gamma	8
10	with	interact	9
11	nuclear	factors	12
12	factors	with	10
13	that	are	14
14	are	factors	12
15	induced	during	16
16	during	are	14
17	U937	differentiation	18
18	differentiation	during	16
19	.	differentiation	18

0	We	suspect	1
1	suspect	<ROOT>	-1
2	that	epsilon	5
3	the	epsilon	5
4	C/EBP	epsilon	5
5	epsilon	suspect	1
6	promoter/enhancer	contains	7
7	contains	epsilon	5
8	a	element	11
9	retinoic	element	11
10	acid-response	element	11
11	element	contains	7
12	that	is	13
13	is	element	11
14	directly	is	13
15	stimulated	directly	14
16	by	stimulated	15
17	retinoids	by	16
18	.	suspect	1

0	The	levels	1
1	levels	were	10
2	of	levels	1
3	the	of	2
4	apoptosis	proteins	6
5	effector	proteins	6
6	proteins	the	3
7	Bak	levels	1
8	and	Bak	7
9	Bad	and	8
10	were	<ROOT>	-1
11	enhanced	were	10
12	,	were	10
13	whereas	were	10
14	there	was	15
15	was	whereas	13
16	a	down-regulation	18
17	slight	down-regulation	18
18	down-regulation	suppressor	22
19	of	suppressor	22
20	the	suppressor	22
21	apoptosis	suppressor	22
22	suppressor	was	15
23	protein	were	10
24	Bcl-2	were	10
25	after	were	10
26	treatment	were	10
27	of	treatment	26
28	the	cells	29
29	cells	of	27
30	with	were	10
31	PDBu	with	30
32	and	PDBu	31
33	DMSO	and	32
34	.	were	10

0	Transcription	<ROOT>	-1
1	factor	Transcription	0
2	E2F	binds	3
3	binds	factor	1
4	to	cellular	5
5	cellular	binds	3
6	promoters	Transcription	0
7	of	promoters	6
8	certain	of	7
9	growth-	certain	8
10	and	cell	11
11	cell	growth-	9
12	cycle-controlling	cell	11
13	genes	Transcription	0
14	and	Transcription	0
15	forms	complexes	18
16	distinct	complexes	18
17	heteromeric	complexes	18
18	complexes	and	14
19	with	and	14
20	other	with	19
21	nuclear	.	23
22	proteins	.	23
23	.	other	20

0	Recent	points	3
1	molecular	points	3
2	evidence	molecular	1
3	points	to	4
4	to	<ROOT>	-1
5	transient	expression	8
6	and/or	stage-specific	7
7	stage-specific	expression	8
8	expression	to	4
9	of	expression	8
10	delta-	of	9
11	and	delta-	10
12	kappa-opioid	and	11
13	receptors	kappa-opioid	12
14	by	kappa-opioid	12
15	thymic	T	18
16	and	T	18
17	peripheral	T	18
18	T	by	14
19	lymphocytes	to	4
20	.	to	4

0	The	enzyme	2
1	active	enzyme	2
2	enzyme	was	3
3	was	<ROOT>	-1
4	expressed	was	3
5	in	expressed	4
6	Escherichia	coli	7
7	coli	in	5
8	and	was	3
9	in	and	8
10	insect	cells	11
11	cells	in	9
12	as	in	9
13	a	protein	15
14	non-fusion	protein	15
15	protein	as	12
16	.	was	3

0	The	identification	2
1	recent	identification	2
2	identification	has	10
3	and	identification	2
4	characterization	and	3
5	of	characterization	4
6	several	factors	9
7	key	factors	9
8	transcription	factors	9
9	factors	characterization	4
10	has	<ROOT>	-1
11	helped	has	10
12	to	helped	11
13	elucidate	to	12
14	the	mechanisms	16
15	molecular	mechanisms	16
16	mechanisms	elucidate	13
17	of	T	18
18	T	mechanisms	16
19	helper	T	18
20	cell	helper	19
21	cytokine	cell	20
22	gene	cytokine	21
23	expression	.	24
24	.	gene	22

0	Switching	gears	1
1	gears	<ROOT>	-1
2	during	gears	1
3	T-cell	maturation	4
4	maturation	during	2
5	:	maturation	4
6	RANTES	maturation	4
7	and	maturation	4
8	late	and	7
9	transcription	.	10
10	.	late	8

0	Interleukin-5	is	4
1	(	IL-5	2
2	IL-5	Interleukin-5	0
3	)	IL-5	2
4	is	<ROOT>	-1
5	produced	is	4
6	by	T	7
7	T	produced	5
8	lymphocytes	is	4
9	and	is	4
10	known	is	4
11	to	known	10
12	support	to	11
13	B	support	12
14	cell	growth	15
15	growth	B	13
16	and	B	13
17	eosinophilic	and	16
18	differentiation	of	19
19	of	eosinophilic	17
20	the	is	4
21	progenitor	is	4
22	cells	is	4
23	.	is	4

0	Regions	<ROOT>	-1
1	of	Regions	0
2	low	of	1
3	base	low	2
4	order-dependent	stem-loop	5
5	stem-loop	potential	6
6	potential	base	3
7	in	potential	6
8	the	region	9
9	region	in	7
10	of	region	9
11	the	gene	12
12	gene	of	10
13	are	base	3
14	defined	.	15
15	.	are	13

0	G28-5	sFv	1
1	sFv	was	2
2	was	<ROOT>	-1
3	a	agonist	6
4	more	potent	5
5	potent	agonist	6
6	agonist	was	2
7	than	agonist	6
8	G28-5	IgG	9
9	IgG	than	7
10	and	IgG	9
11	was	was	2
12	able	was	11
13	to	able	12
14	stimulate	by	17
15	CD40	by	17
16	responses	by	17
17	by	to	13
18	B	was	2
19	cells	was	2
20	and	was	2
21	monocytes	was	2
22	.	was	2

0	Immunoprecipitation	<ROOT>	-1
1	of	Immunoprecipitation	0
2	cell	extract	3
3	extract	of	1
4	with	brought	12
5	the	antiserum	6
6	antiserum	with	4
7	against	antiserum	6
8	the	SRG3	10
9	mouse	SRG3	10
10	SRG3	against	7
11	also	brought	12
12	brought	Immunoprecipitation	0
13	down	brought	12
14	a	protein	16
15	195-kD	protein	16
16	protein	down	13
17	that	could	18
18	could	brought	12
19	be	could	18
20	recognized	be	19
21	by	recognized	20
22	an	antiserum	23
23	antiserum	by	21
24	raised	recognized	20
25	against	raised	24
26	human	raised	24
27	SWI2	protein	28
28	protein	human	26
29	.	protein	28

0	Similar	<ROOT>	-1
1	to	Similar	0
2	LEF-1	to	1
3	,	Similar	0
4	ALY	,	3
5	can	ALY	4
6	stimulate	can	5
7	transcription	stimulate	6
8	in	stimulate	6
9	the	context	10
10	context	TCR	13
11	of	TCR	13
12	the	TCR	13
13	TCR	in	8
14	alpha	Similar	0
15	enhancer	apparently	17
16	but	enhancer	15
17	apparently	Similar	0
18	not	apparently	17
19	when	tethered	20
20	tethered	apparently	17
21	to	tethered	20
22	DNA	through	23
23	through	to	21
24	an	through	23
25	heterologous	an	24
26	DNA-binding	an	24
27	domain	DNA-binding	26
28	.	domain	27

0	S-allyl	cysteine	1
1	cysteine	inhibits	2
2	inhibits	<ROOT>	-1
3	activation	of	4
4	of	inhibits	2
5	nuclear	B	8
6	factor	B	8
7	kappa	B	8
8	B	of	4
9	in	human	10
10	human	of	4
11	T	inhibits	2
12	cells	inhibits	2
13	.	inhibits	2

0	Taken	<ROOT>	-1
1	together	Taken	0
2	,	Taken	0
3	these	,	2
4	data	suggest	5
5	suggest	these	3
6	the	existence	7
7	existence	these	3
8	of	existence	7
9	an	promoter	11
10	intragenic	promoter	11
11	promoter	of	8
12	driving	of	8
13	an	expression	15
14	IFN-gamma-inducible	expression	15
15	expression	driving	12
16	of	expression	15
17	CIITA	of	16
18	.	Taken	0

0	The	molecule	1
1	molecule	bound	2
2	bound	<ROOT>	-1
3	CD40	bound	2
4	with	CD40	3
5	a	with	4
6	high	a	5
7	affinity	(	8
8	(	high	6
9	2.2	(	8
10	nM	)	11
11	)	(	8
12	and	a	5
13	was	and	12
14	a	monomer	15
15	monomer	was	13
16	in	monomer	15
17	solution	.	18
18	.	in	16

0	In	controls	5
1	flies	In	0
2	,	controls	5
3	this	pathway	4
4	pathway	controls	5
5	controls	<ROOT>	-1
6	segment	polarity	7
7	polarity	controls	5
8	;	polarity	7
9	in	;	8
10	Xenopus	;	8
11	it	Xenopus	10
12	controls	;	8
13	the	definition	14
14	definition	controls	12
15	of	definition	14
16	the	axis	18
17	body	axis	18
18	axis	of	15
19	.	controls	5

0	Cytokine	<ROOT>	-1
1	signal	Cytokine	0
2	networks	and	3
3	and	signal	1
4	a	in	7
5	new	in	7
6	era	in	7
7	in	and	3
8	biomedical	research	9
9	research	in	7
10	.	Cytokine	0

0	We	generated	1
1	generated	<ROOT>	-1
2	a	mutant	4
3	point	mutant	4
4	mutant	generated	1
5	of	mutant	4
6	ZEBRA	of	5
7	,	generated	1
8	Z	,	7
9	(	S186A	10
10	S186A	,	7
11	)	S186A	10
12	,	,	7
13	that	was	14
14	was	,	7
15	not	was	14
16	impaired	in	17
17	in	its	18
18	its	was	14
19	ability	this	26
20	to	ability	19
21	activate	;	23
22	transcription	activate	21
23	;	ability	19
24	however	;	23
25	,	;	23
26	this	its	18
27	mutation	abolished	28
28	abolished	generated	1
29	its	ability	30
30	ability	abolished	28
31	to	ability	30
32	initiate	to	31
33	the	initiate	32
34	viral	.	37
35	lytic	.	37
36	cascade	.	37
37	.	the	33

0	Transactivation	is	7
1	by	Transactivation	0
2	ETS1	by	1
3	,	Transactivation	0
4	NFkappaB	Transactivation	0
5	and	NFkappaB	4
6	AP1	and	5
7	is	<ROOT>	-1
8	synergistic	is	7
9	,	and	10
10	and	synergistic	8
11	mutation	and	10
12	of	mutation	11
13	the	of	12
14	individual	reveals	17
15	binding	reveals	17
16	sites	reveals	17
17	reveals	the	13
18	that	and	10
19	the	that	18
20	transcriptional	of	22
21	activities	of	22
22	of	the	19
23	these	factors	24
24	factors	are	25
25	are	of	22
26	interdependent	are	25
27	.	is	7

0	The	effects	1
1	effects	may	7
2	of	effects	1
3	Ara-C	of	2
4	on	JNK	5
5	JNK	activity	6
6	activity	effects	1
7	may	<ROOT>	-1
8	be	may	7
9	mediated	be	8
10	through	mediated	9
11	secondary	pathways	13
12	response	pathways	13
13	pathways	through	10
14	.	may	7

0	Recently	was	6
1	,	was	6
2	fibromyalgia	was	6
3	(	FMS	4
4	FMS	fibromyalgia	2
5	)	FMS	4
6	was	<ROOT>	-1
7	shown	was	6
8	to	shown	7
9	be	to	8
10	a	disorder	11
11	disorder	be	9
12	associated	disorder	11
13	with	associated	12
14	an	functioning	16
15	altered	functioning	16
16	functioning	with	13
17	of	functioning	16
18	the	of	17
19	stress	.	22
20	response	.	22
21	system	.	22
22	.	the	18

0	AML1a	<ROOT>	-1
1	but	AML1a	0
2	not	differentiation	6
3	AML1b	not	2
4	inhibits	not	2
5	erythroid	not	2
6	differentiation	but	1
7	induced	by	8
8	by	differentiation	6
9	sodium	AML1a	0
10	butyrate	AML1a	0
11	and	AML1a	0
12	enhances	AML1a	0
13	the	AML1a	0
14	megakaryocytic	the	13
15	differentiation	of	16
16	of	leukemia	18
17	K562	leukemia	18
18	leukemia	megakaryocytic	14
19	cells	AML1a	0
20	.	AML1a	0

0	AML1a	expression	1
1	expression	was	2
2	was	<ROOT>	-1
3	associated	was	2
4	with	associated	3
5	enhanced	sensitivity	6
6	sensitivity	with	4
7	to	differentiation	9
8	megakaryocytic	differentiation	9
9	differentiation	sensitivity	6
10	induced	by	11
11	by	was	2
12	phorbol	was	2
13	ester	was	2
14	.	was	2

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	transcripts	In	0
4	from	transcripts	3
5	TSG101	were	12
6	,	were	12
7	FHIT	were	12
8	and	FHIT	7
9	seven	genes	11
10	other	genes	11
11	genes	and	8
12	were	In	0
13	analysed	were	12
14	in	analysed	13
15	RNA	isolated	16
16	isolated	in	14
17	from	peripheral	19
18	normal	peripheral	19
19	peripheral	analysed	13
20	blood	In	0
21	lymphocytes	In	0
22	.	In	0

0	Accumulation	<ROOT>	-1
1	of	Accumulation	0
2	C/EBP	of	1
3	epsilon	mRNA	4
4	mRNA	C/EBP	2
5	occurred	mRNA	4
6	as	of	1
7	early	as	6
8	as	as	6
9	1	as	8
10	hour	after	11
11	after	1	9
12	exposure	1	9
13	of	exposure	12
14	NB4	1	9
15	cells	Accumulation	0
16	to	9-cis	17
17	9-cis	Accumulation	0
18	RA	Accumulation	0
19	(	x	21
20	5	x	21
21	x	RA	18
22	10-LRB--7-RRB-	Accumulation	0
23	mol/L	Accumulation	0
24	)	Accumulation	0
25	;	Accumulation	0
26	and	Accumulation	0
27	at	were	32
28	48	hours	29
29	hours	at	27
30	,	were	32
31	levels	were	32
32	were	and	26
33	increased	were	32
34	by	increased	33
35	5.1-fold	by	34
36	.	Accumulation	0

0	Spontaneous	occurrence	1
1	occurrence	<ROOT>	-1
2	of	occurrence	1
3	early	region	4
4	region	of	2
5	1A	occurrence	1
6	reiteration	1A	5
7	mutants	reiteration	6
8	of	mutants	7
9	type	of	8
10	5	adenovirus	11
11	adenovirus	type	9
12	in	infected	14
13	persistently	infected	14
14	infected	adenovirus	11
15	human	T-lymphocytes	16
16	T-lymphocytes	adenovirus	11
17	.	occurrence	1

0	The	same	1
1	same	is	2
2	is	<ROOT>	-1
3	true	is	2
4	for	is	2
5	nuclear	extracts	6
6	extracts	for	4
7	taken	extracts	6
8	from	P388D1	11
9	the	P388D1	11
10	murine	P388D1	11
11	P388D1	taken	7
12	macrophage	is	2
13	cell	macrophage	12
14	line	cell	13
15	when	line	14
16	tested	when	15
17	with	tested	16
18	the	motif	20
19	-516	motif	20
20	motif	with	17
21	of	motif	20
22	the	of	21
23	murine	(	26
24	TNF	(	26
25	promoter	(	26
26	(	the	22
27	GGGGGCTTTCCC	is	2
28	)	is	2
29	.	is	2

0	In	induced	5
1	addition	In	0
2	,	LPS	3
3	LPS	In	0
4	stimulation	induced	5
5	induced	<ROOT>	-1
6	the	binding	7
7	binding	induced	5
8	of	binding	7
9	cognate	factors	11
10	nuclear	factors	11
11	factors	of	8
12	to	the	13
13	the	induced	5
14	Egr-1	induced	5
15	and	induced	5
16	kappaB3	induced	5
17	sites	induced	5
18	,	which	19
19	which	induced	5
20	were	which	19
21	identified	were	20
22	as	identified	21
23	Egr-1	identified	21
24	and	were	20
25	p50/p65	and	24
26	,	induced	5
27	respectively	induced	5
28	.	induced	5

0	Transient	were	13
1	transfectants	line	6
2	of	line	6
3	the	line	6
4	porcine	line	6
5	B-cell	line	6
6	line	Transient	0
7	L23	Transient	0
8	with	Transient	0
9	the	constructs	12
10	mutated	constructs	12
11	CIITA	constructs	12
12	constructs	with	8
13	were	<ROOT>	-1
14	tested	were	13
15	for	tested	14
16	the	suppression	17
17	suppression	for	15
18	of	suppression	17
19	constitutive	SLA-DR	20
20	SLA-DR	of	18
21	and	SLA-DQ	22
22	SLA-DQ	SLA-DR	20
23	expression	were	13
24	.	were	13

0	Cell	specific	1
1	specific	expression	2
2	expression	human	4
3	of	human	4
4	human	gene	10
5	Bruton	human	4
6	's	Bruton	5
7	agammaglobulinemia	tyrosine	8
8	tyrosine	Bruton	5
9	kinase	human	4
10	gene	<ROOT>	-1
11	(	gene	10
12	Btk	gene	10
13	)	Btk	12
14	is	)	13
15	regulated	is	14
16	by	regulated	15
17	Sp1-	members	20
18	and	Sp1-	17
19	Spi-1/PU.1-family	and	18
20	members	by	16
21	.	gene	10

0	In	respond	5
1	addition	In	0
2	,	these	3
3	these	promoters	4
4	promoters	respond	5
5	respond	<ROOT>	-1
6	only	respond	5
7	indirectly	respond	5
8	to	respond	5
9	the	transactivator	12
10	viral	transactivator	12
11	immediate-early	transactivator	12
12	transactivator	to	8
13	,	respond	5
14	ZEBRA	respond	5
15	.	respond	5

0	Human	<ROOT>	-1
1	immunodeficiency	virus-type	2
2	virus-type	Human	0
3	1	virus-type	2
4	(	1	3
5	HIV-1	)	6
6	)	1	3
7	infection	characterized	9
8	is	infection	7
9	characterized	)	6
10	by	characterized	9
11	a	state	13
12	chronic	state	13
13	state	by	10
14	of	state	13
15	immune	hyperactivation	16
16	hyperactivation	of	14
17	in	state	13
18	patients	in	17
19	.	Human	0

0	Thus	is	3
1	,	is	3
2	ceramide	is	3
3	is	<ROOT>	-1
4	not	is	3
5	a	signal	7
6	positive	signal	7
7	signal	is	3
8	for	ERK	9
9	ERK	signal	7
10	activation	ERK	9
11	in	T-cell	12
12	T-cell	activation	10
13	lines	is	3
14	.	is	3

0	The	capacity	1
1	capacity	<ROOT>	-1
2	of	capacity	1
3	curcumin	of	2
4	to	curcumin	3
5	inhibit	curcumin	3
6	both	growth	8
7	cell	growth	8
8	growth	inhibit	5
9	and	growth	8
10	death	and	9
11	strongly	death	10
12	implies	strongly	11
13	that	strongly	11
14	these	biological	16
15	two	biological	16
16	biological	that	13
17	processes	biological	16
18	share	processes	17
19	a	pathway	21
20	common	pathway	21
21	pathway	share	18
22	at	biological	16
23	some	point	24
24	point	at	22
25	and	biological	16
26	that	and	25
27	curcumin	presumably	33
28	affects	curcumin	27
29	a	step	31
30	common	step	31
31	step	affects	28
32	,	presumably	33
33	presumably	that	26
34	involving	presumably	33
35	a	modulation	36
36	modulation	involving	34
37	of	modulation	36
38	the	of	37
39	AP-1	transcription	40
40	transcription	the	38
41	factor	transcription	40
42	.	factor	41

0	Fragments	were	12
1	of	Fragments	0
2	a	sequence	5
3	3.6	kb	4
4	kb	sequence	5
5	sequence	of	1
6	of	sequence	5
7	the	promoter	11
8	human	promoter	11
9	CRH	promoter	11
10	gene	promoter	11
11	promoter	of	6
12	were	<ROOT>	-1
13	amplified	were	12
14	by	amplified	13
15	PCR	by	14
16	and	amplified	13
17	ligated	and	16
18	upstream	ligated	17
19	of	upstream	18
20	a	reporter	22
21	CAT	reporter	22
22	reporter	of	19
23	.	were	12

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	the	protein	6
5	SRG3	protein	6
6	protein	is	7
7	is	that	3
8	involved	is	7
9	in	involved	8
10	the	glucocorticoid-induced	11
11	glucocorticoid-induced	in	9
12	apoptosis	glucocorticoid-induced	11
13	in	involved	8
14	the	cell	16
15	thymoma	cell	16
16	cell	in	13
17	line	cell	16
18	.	line	17

0	The	purpose	1
1	purpose	is	5
2	of	purpose	1
3	this	review	4
4	review	of	2
5	is	<ROOT>	-1
6	to	is	5
7	show	to	6
8	how	leads	18
9	the	accumulation	10
10	accumulation	leads	18
11	of	accumulation	10
12	various	lesions	14
13	biochemical	lesions	14
14	lesions	of	11
15	with	accumulation	10
16	advancing	age	17
17	age	with	15
18	leads	show	7
19	to	leads	18
20	the	to	19
21	failure	leads	18
22	of	failure	21
23	a	of	22
24	critical	a	23
25	cell	namely	28
26	function	namely	28
27	,	namely	28
28	namely	critical	24
29	the	namely	28
30	activation-induced	.	33
31	lymphocyte	.	33
32	proliferation	.	33
33	.	the	29

0	Cytokine	rescue	1
1	rescue	is	9
2	from	rescue	1
3	glucocorticoid	from	2
4	induced	apoptosis	5
5	apoptosis	from	2
6	in	T	7
7	T	from	2
8	cells	rescue	1
9	is	<ROOT>	-1
10	mediated	is	9
11	through	mediated	10
12	inhibition	through	11
13	of	inhibition	12
14	IkappaBalpha	of	13
15	.	is	9

0	Among	target	2
1	these	Among	0
2	target	is	4
3	genes	target	2
4	is	<ROOT>	-1
5	the	gene	6
6	gene	is	4
7	encoding	interleukin-2	8
8	interleukin-2	IL2	10
9	(	IL2	10
10	IL2	gene	6
11	)	IL2	10
12	,	a	13
13	a	cytokine	14
14	cytokine	is	4
15	facilitating	is	4
16	progression	is	4
17	through	progression	16
18	the	through	17
19	G1	of	21
20	phase	of	21
21	of	the	18
22	the	cycle	24
23	cell	cycle	24
24	cycle	through	17
25	.	is	4

0	The	kinase	3
1	STAT	kinase	3
2	serine	kinase	3
3	kinase	has	7
4	in	kinase	3
5	CLL	cells	6
6	cells	in	4
7	has	<ROOT>	-1
8	not	has	7
9	been	has	7
10	identified	been	9
11	,	has	7
12	and	has	7
13	appears	and	12
14	to	appears	13
15	be	to	14
16	neither	be	15
17	mitogen-activated	nor	20
18	protein	nor	20
19	kinase	nor	20
20	nor	neither	16
21	pp70-LRB-s6k-RRB-	has	7
22	.	has	7

0	The	virus	2
1	Epstein-Barr	virus	2
2	virus	protein	7
3	(	EBV	4
4	EBV	virus	2
5	)	EBV	4
6	transforming	protein	7
7	protein	LMP1	8
8	LMP1	appears	9
9	appears	terminus	42
10	to	factor	17
11	be	factor	17
12	a	factor	17
13	constitutively	factor	17
14	activated	factor	17
15	tumor	factor	17
16	necrosis	factor	17
17	factor	appears	9
18	receptor	(	19
19	(	factor	17
20	TNFR	appears	9
21	)	appears	9
22	on	appears	9
23	the	basis	24
24	basis	on	22
25	of	basis	24
26	an	ability	28
27	intrinsic	ability	28
28	ability	of	25
29	to	ability	28
30	aggregate	to	29
31	in	ability	28
32	the	membrane	34
33	plasma	membrane	34
34	membrane	in	31
35	and	an	36
36	an	on	22
37	association	an	36
38	of	carboxyl	41
39	its	carboxyl	41
40	cytoplasmic	carboxyl	41
41	carboxyl	an	36
42	terminus	<ROOT>	-1
43	(	terminus	42
44	CT	terminus	42
45	)	terminus	42
46	with	terminus	42
47	TNFR-associated	factors	48
48	factors	with	46
49	(	factors	48
50	TRAFs	)	51
51	)	factors	48
52	.	terminus	42

0	Previously	have	5
1	,	have	5
2	we	have	5
3	and	we	2
4	others	and	3
5	have	<ROOT>	-1
6	demonstrated	have	5
7	that	demonstrated	6
8	NF-kappa	B	9
9	B	regulates	10
10	regulates	that	7
11	the	regulates	10
12	NF-kappa	B1	13
13	B1	gene	14
14	gene	the	11
15	.	gene	14

0	Scatchard	plot	1
1	plot	<ROOT>	-1
2	analysis	revealed	3
3	revealed	plot	1
4	Kd	plot	1
5	values	plot	1
6	of	values	5
7	7.1	nM	8
8	nM	of	6
9	and	plot	1
10	0.15	plot	1
11	nM	plot	1
12	for	and	14
13	-LRB-+-RRB--pentazocine	and	14
14	and	plot	1
15	SR	plot	1
16	31747A	plot	1
17	,	plot	1
18	respectively	plot	1
19	,	plot	1
20	indicating	SR	28
21	an	affinity	22
22	affinity	indicating	20
23	of	affinity	22
24	SR-BP	of	23
25	50-fold	for	27
26	higher	50-fold	25
27	for	SR-BP	24
28	SR	plot	1
29	31747A	plot	1
30	than	31747A	29
31	for	than	30
32	pentazocine	for	31
33	.	plot	1

0	In	describe	4
1	this	review	2
2	review	In	0
3	we	describe	4
4	describe	<ROOT>	-1
5	the	defects	6
6	defects	describe	4
7	in	B-	8
8	B-	describe	4
9	and	B-	8
10	T-lymphocyte	describe	4
11	development	describe	4
12	in	describe	4
13	mice	carrying	14
14	carrying	targeted	15
15	targeted	in	12
16	mutations	targeted	15
17	in	mutations	16
18	the	genes	20
19	E-protein	genes	20
20	genes	in	17
21	and	describe	4
22	discuss	and	21
23	our	current	24
24	current	describe	4
25	understanding	current	24
26	of	the	27
27	the	understanding	25
28	role	the	27
29	of	these	30
30	these	role	28
31	proteins	describe	4
32	in	describe	4
33	lymphoid	describe	4
34	development	describe	4
35	.	describe	4

0	Addition	was	5
1	of	Addition	0
2	prestimulated	cells	4
3	THP-1	cells	4
4	cells	of	1
5	was	<ROOT>	-1
6	followed	was	5
7	by	followed	6
8	a	adhesion	10
9	noticeable	adhesion	10
10	adhesion	by	7
11	after	adhesion	10
12	3	h	13
13	h	adhesion	10
14	which	reversed	15
15	reversed	adhesion	10
16	to	reversed	15
17	basal	values	18
18	values	to	16
19	within	reversed	15
20	24	h	21
21	h	within	19
22	.	was	5

0	At	was	5
1	the	time	3
2	same	time	3
3	time	At	0
4	there	was	5
5	was	<ROOT>	-1
6	no	change	7
7	change	was	5
8	in	change	7
9	the	level	10
10	level	in	8
11	of	level	10
12	expression	of	11
13	of	of	11
14	the	of	13
15	cell	antigenes	17
16	surface	antigenes	17
17	antigenes	the	14
18	CD33	the	14
19	,	was	5
20	CD34	was	5
21	,	was	5
22	CD45	was	5
23	,	was	5
24	CD71	was	5
25	and	was	5
26	glycophorin	A	27
27	A	was	5
28	.	was	5

0	The	results	1
1	results	indicate	2
2	indicate	long-term	20
3	that	indicate	2
4	stimulation	that	3
5	of	NK	6
6	NK	stimulation	4
7	cells	indicate	2
8	,	indicate	2
9	either	indicate	2
10	freshly	either	9
11	isolated	peripheral	13
12	from	peripheral	13
13	peripheral	blood	14
14	blood	freshly	10
15	lymphocytes	(	16
16	(	indicate	2
17	PBL	indicate	2
18	)	indicate	2
19	or	long-term	20
20	long-term	measured	42
21	cultured	clones	23
22	NK	clones	23
23	clones	long-term	20
24	,	long-term	20
25	with	specific	26
26	specific	long-term	20
27	cell	specific	26
28	targets	long-term	20
29	results	targets	28
30	in	results	29
31	an	in	30
32	increased	an	31
33	binding	increased	32
34	activity	NF-kappa	36
35	of	NF-kappa	36
36	NF-kappa	increased	32
37	B	long-term	20
38	and	long-term	20
39	AP-1	transcription	40
40	transcription	factors	41
41	factors	long-term	20
42	measured	<ROOT>	-1
43	by	gel	44
44	gel	measured	42
45	retardation	measured	42
46	.	measured	42

0	Uncoupling	cycle	3
1	of	cycle	3
2	cell	cycle	3
3	cycle	arrest	4
4	arrest	<ROOT>	-1
5	from	arrest	4
6	the	expression	7
7	expression	from	5
8	of	monocytic	9
9	monocytic	expression	7
10	differentiation	arrest	4
11	markers	arrest	4
12	in	HL60	13
13	HL60	markers	11
14	cell	arrest	4
15	variants	arrest	4
16	.	arrest	4

0	The	CRE	2
1	tandem	CRE	2
2	CRE	are	6
3	and	CRE	2
4	POS	sites	5
5	sites	and	3
6	are	<ROOT>	-1
7	of	are	6
8	major	functional	9
9	functional	of	7
10	importance	functional	9
11	as	are	6
12	judged	shift	18
13	by	judged	12
14	mutational	by	13
15	and	mutational	14
16	electrophoretic	and	15
17	mobility	shift	18
18	shift	as	11
19	analyses	shift	18
20	.	are	6

0	The	<ROOT>	-1
1	transcription	B	4
2	factor	B	4
3	NF-kappa	B	4
4	B	The	0
5	is	The	0
6	maintained	is	5
7	in	maintained	6
8	an	cytoplasmic	10
9	inactive	cytoplasmic	10
10	cytoplasmic	in	7
11	state	cytoplasmic	10
12	by	maintained	6
13	I	by	12
14	kappa	The	0
15	B	The	0
16	inhibitors	The	0
17	.	The	0

0	As	<ROOT>	-1
1	determined	RNA	6
2	by	transient	3
3	transient	RNA	6
4	expression	and	5
5	and	transient	3
6	RNA	As	0
7	analyses	As	0
8	,	As	0
9	the	activation	10
10	activation	,	8
11	of	kinase	13
12	protein	of	11
13	kinase	activation	10
14	C	(	15
15	(	As	0
16	PKC	As	0
17	)	As	0
18	also	As	0
19	increased	rates	20
20	rates	also	18
21	of	rates	20
22	transcription	the	24
23	from	the	24
24	the	DRA	26
25	wild-type	DRA	26
26	DRA	of	21
27	promoter	As	0
28	but	As	0
29	not	As	0
30	from	a	31
31	a	As	0
32	DRA	As	0
33	promoter	bearing	34
34	bearing	As	0
35	clustered	point	36
36	point	bearing	34
37	mutations	point	36
38	in	mutations	37
39	the	X2	40
40	X2	in	38
41	box	X2	40
42	.	As	0

0	The	process	1
1	process	is	4
2	of	process	1
3	apoptosis	of	2
4	is	<ROOT>	-1
5	used	is	4
6	to	used	5
7	eliminate	to	6
8	unwanted	eliminate	7
9	cells	from	10
10	from	unwanted	8
11	a	from	10
12	wide	a	11
13	variety	organisms	15
14	of	organisms	15
15	organisms	wide	12
16	.	organisms	15

0	The	<ROOT>	-1
1	other	The	0
2	,	other	1
3	CIITA	encodes	5
4	,	encodes	5
5	encodes	other	1
6	a	protein	8
7	large	protein	8
8	protein	encodes	5
9	with	a	10
10	a	protein	8
11	defined	a	10
12	acidic	transcriptional	13
13	transcriptional	defined	11
14	activation	domain	15
15	domain	protein	18
16	;	domain	15
17	this	protein	18
18	protein	a	10
19	does	The	0
20	not	does	19
21	interact	does	19
22	with	interact	21
23	DNA	with	22
24	.	The	0

0	However	<ROOT>	-1
1	,	an	2
2	an	However	0
3	induction	was	9
4	of	induction	3
5	the	gene	8
6	human	gene	8
7	CIITA	gene	8
8	gene	of	4
9	was	an	2
10	observed	was	9
11	in	observed	10
12	mouse	macrophage	13
13	macrophage	in	11
14	and	macrophage	13
15	fibrosarcoma	lines	17
16	cell	lines	17
17	lines	and	14
18	,	However	0
19	when	were	22
20	the	cells	21
21	cells	were	22
22	were	However	0
23	transfected	were	22
24	with	transfected	23
25	a	cosmid	26
26	cosmid	with	24
27	containing	cosmid	26
28	the	gene	31
29	human	gene	31
30	CIITA	gene	31
31	gene	containing	27
32	,	with	24
33	but	with	24
34	lacking	but	33
35	the	lacking	34
36	1.8	kb	37
37	kb	described	39
38	promoter	described	39
39	described	the	35
40	above	described	39
41	.	However	0

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	amino	,	2
4	acids	amino	3
5	346	acids	4
6	to	346	5
7	543	to	6
8	,	acids	4
9	which	were	10
10	were	acids	4
11	previously	were	10
12	defined	as	13
13	as	were	10
14	important	the	16
15	for	the	16
16	the	as	13
17	repressor	the	16
18	activity	repressor	17
19	of	activity	18
20	the	proteins	23
21	GAL4-EBNA3C	proteins	23
22	fusion	proteins	23
23	proteins	of	19
24	,	also	25
25	also	In	0
26	appear	also	25
27	to	appear	26
28	be	to	27
29	necessary	be	28
30	for	be	28
31	the	repression	32
32	repression	for	30
33	of	repression	32
34	Cp	of	33
35	.	In	0

0	A	putative	1
1	putative	may	9
2	function	of	3
3	of	putative	1
4	BHRF1	of	3
5	in	BHRF1	4
6	EBV-infected	in	5
7	epithelial	putative	1
8	cells	putative	1
9	may	<ROOT>	-1
10	be	may	9
11	to	be	10
12	protect	to	11
13	virus-infected	protect	12
14	cells	from	15
15	from	virus-infected	13
16	TNF-	cell	19
17	and/or	cell	19
18	anti-Fas-induced	cell	19
19	cell	may	9
20	death	may	9
21	in	death	20
22	order	in	21
23	to	maximize	24
24	maximize	in	21
25	virus	may	9
26	production	may	9
27	.	may	9

0	No	defect	2
1	RNA-packaging	defect	2
2	defect	could	3
3	could	<ROOT>	-1
4	be	could	3
5	measured	be	4
6	for	measured	5
7	any	for	6
8	of	any	7
9	the	viruses	11
10	mutant	viruses	11
11	viruses	of	8
12	as	measured	5
13	determined	as	12
14	by	determined	13
15	quantification	by	14
16	of	quantification	15
17	their	of	16
18	HIV	.	21
19	genomic	.	21
20	RNA	.	21
21	.	their	17

0	The	transactivator	3
1	class	transactivator	3
2	II	transactivator	3
3	transactivator	is	7
4	(	CIITA	5
5	CIITA	transactivator	3
6	)	CIITA	5
7	is	<ROOT>	-1
8	essential	the	10
9	for	the	10
10	the	is	7
11	expression	class	19
12	of	class	19
13	major	class	19
14	histocompatibility	complex	15
15	complex	(	16
16	(	class	19
17	MHC	class	19
18	)	class	19
19	class	the	10
20	II	is	7
21	antigens	is	7
22	.	is	7

0	Mutations	are	12
1	that	abolish	2
2	abolish	Mutations	0
3	the	binding	4
4	binding	abolish	2
5	of	binding	4
6	each	factor	7
7	factor	of	5
8	to	abolish	2
9	its	site	11
10	cognate	site	11
11	site	to	8
12	are	<ROOT>	-1
13	introduced	are	12
14	in	introduced	13
15	an	clone	19
16	infectious	clone	19
17	HIV-1	clone	19
18	molecular	clone	19
19	clone	in	14
20	to	introduced	13
21	study	to	20
22	their	study	21
23	effect	HIV-1	25
24	on	HIV-1	25
25	HIV-1	their	22
26	transcription	their	22
27	and	are	12
28	replication	are	12
29	.	are	12

0	Three	products	3
1	overlapping	products	3
2	PCR	products	3
3	products	were	13
4	,	products	3
5	covering	products	3
6	the	sequence	9
7	complete	sequence	9
8	coding	sequence	9
9	sequence	covering	5
10	of	sequence	9
11	mRNA	of	10
12	,	products	3
13	were	<ROOT>	-1
14	generated	lymphoblastoid	16
15	from	lymphoblastoid	16
16	lymphoblastoid	were	13
17	cell	lines	18
18	lines	lymphoblastoid	16
19	,	were	13
20	translated	were	13
21	into	translated	20
22	35S-methionine	protein	24
23	labelled	protein	24
24	protein	into	21
25	,	were	13
26	and	were	13
27	analysed	and	26
28	by	analysed	27
29	SDS-PAGE	and	26
30	.	SDS-PAGE	29

0	The	results	1
1	results	showed	2
2	showed	<ROOT>	-1
3	that	showed	2
4	the	number	5
5	number	that	3
6	of	number	5
7	GCR	of	6
8	in	of	6
9	the	patients	10
10	patients	in	8
11	was	number	5
12	significantly	number	5
13	reduced	significantly	12
14	(	P	15
15	P	reduced	13
16	&lt;	)	18
17	0.01	)	18
18	)	P	15
19	and	showed	2
20	it	was	21
21	was	and	19
22	increased	was	21
23	when	state	26
24	their	state	26
25	health	state	26
26	state	increased	22
27	was	state	26
28	improved	state	26
29	.	showed	2

0	Suppression	trans-activator	10
1	of	MHC	2
2	MHC	II	4
3	class	II	4
4	II	Suppression	0
5	expression	by	6
6	by	Suppression	0
7	human	trans-activator	10
8	class	trans-activator	10
9	II	trans-activator	10
10	trans-activator	<ROOT>	-1
11	constructs	trans-activator	10
12	lacking	trans-activator	10
13	the	domain	15
14	N-terminal	domain	15
15	domain	lacking	12
16	.	trans-activator	10

0	Signal	transducer	1
1	transducer	<ROOT>	-1
2	and	transducer	1
3	activator	and	2
4	of	and	2
5	transcription-3	transducer	1
6	(	STAT3	7
7	STAT3	transcription-3	5
8	)	STAT3	7
9	is	constitutively	10
10	constitutively	transducer	1
11	activated	transducer	1
12	in	activated	11
13	normal	in	12
14	,	transducer	1
15	self-renewing	transducer	1
16	B-1	transducer	1
17	cells	transducer	1
18	but	transducer	1
19	only	but	18
20	inducibly	transducer	1
21	expressed	transducer	1
22	in	expressed	21
23	conventional	in	22
24	B	lymphocytes	25
25	lymphocytes	conventional	23
26	[	lymphocytes	25
27	see	in	22
28	comments	transducer	1
29	]	transducer	1

0	ALY	is	1
1	is	<ROOT>	-1
2	a	ubiquitously	3
3	ubiquitously	is	1
4	expressed	ubiquitously	3
5	,	is	1
6	nuclear	that	8
7	protein	nuclear	6
8	that	,	5
9	specifically	associates	10
10	associates	that	8
11	with	the	12
12	the	associates	10
13	activation	the	12
14	domains	is	1
15	of	domains	14
16	LEF-1	of	15
17	and	LEF-1	16
18	AML-1	LEF-1	16
19	(	AML-1	18
20	CBF	is	1
21	alpha2	is	1
22	,	is	1
23	PEBP2	,	22
24	alpha	(	25
25	(	is	1
26	B	is	1
27	)	is	1
28	,	which	29
29	which	is	1
30	is	which	29
31	another	is	30
32	protein	is	30
33	component	protein	32
34	of	TCR	36
35	the	TCR	36
36	TCR	component	33
37	alpha	is	1
38	enhancer	is	1
39	complex	is	1
40	.	is	1

0	Basal	promoter	7
1	activity	bp	5
2	of	bp	5
3	a	bp	5
4	3070	bp	5
5	bp	Basal	0
6	CRH	promoter	7
7	promoter	fragment	8
8	fragment	was	9
9	was	<ROOT>	-1
10	only	was	9
11	seen	only	10
12	in	seen	11
13	neuronal	in	12
14	and	in	12
15	lymphoblastoid	cell	16
16	cell	and	14
17	lines	cell	16
18	.	lines	17

0	However	although	2
1	,	although	2
2	although	is	6
3	NFAT	binding	5
4	DNA	binding	5
5	binding	although	2
6	is	upon	15
7	similarly	is	6
8	induced	both	10
9	in	both	10
10	both	similarly	7
11	eTh1	is	6
12	and	is	6
13	eTh2	is	6
14	cells	is	6
15	upon	<ROOT>	-1
16	antigen	upon	15
17	stimulation	upon	15
18	,	upon	15
19	only	,	18
20	the	only	19
21	NFAT	present	23
22	complexes	present	23
23	present	able	28
24	in	present	23
25	eTh2	in	24
26	cells	are	27
27	are	eTh2	25
28	able	the	20
29	to	able	28
30	mediate	to	29
31	high-level	mediate	30
32	transcription	high-level	31
33	,	transcription	32
34	and	was	40
35	relatively	little	36
36	little	and	34
37	NFAT	was	40
38	transcriptional	was	40
39	activity	was	40
40	was	transcription	32
41	induced	was	40
42	in	eTh1	43
43	eTh1	induced	41
44	cells	upon	15
45	.	upon	15

0	Tumor	factor-alpha	2
1	necrosis	factor-alpha	2
2	factor-alpha	<ROOT>	-1
3	(	factor-alpha	2
4	TNF-alpha	factor-alpha	2
5	)	stimulated	6
6	stimulated	factor-alpha	2
7	the	differentiation	9
8	terminal	differentiation	9
9	differentiation	the	11
10	of	the	11
11	the	stimulated	6
12	DC	factor-alpha	2
13	by	factor-alpha	2
14	downregulating	by	13
15	the	expression	16
16	expression	downregulating	14
17	of	expression	16
18	the	receptor	20
19	M-CSF	receptor	20
20	receptor	of	17
21	,	factor-alpha	2
22	cfms	factor-alpha	2
23	mRNA	factor-alpha	2
24	,	factor-alpha	2
25	and	factor-alpha	2
26	aborting	factor-alpha	2
27	the	potential	28
28	potential	aborting	26
29	to	aborting	26
30	convert	to	29
31	to	convert	30
32	macrophages	factor-alpha	2
33	.	factor-alpha	2

0	Significant	progress	1
1	progress	has	2
2	has	<ROOT>	-1
3	been	has	2
4	made	been	3
5	in	made	4
6	gaining	in	5
7	a	gaining	6
8	detailed	a	7
9	understanding	detailed	8
10	of	understanding	9
11	the	regulation	13
12	transcriptional	regulation	13
13	regulation	of	10
14	of	the	15
15	the	regulation	13
16	interleukin-4	of	10
17	gene	in	5
18	.	has	2

0	Gel	assay	4
1	electrophoretic	assay	4
2	mobility	assay	4
3	shift	assay	4
4	assay	an	6
5	detected	assay	4
6	an	induced	7
7	induced	<ROOT>	-1
8	DNA-binding	activity	9
9	activity	induced	7
10	in	these	11
11	these	induced	7
12	cells	induced	7
13	in	induced	7
14	response	in	13
15	to	response	14
16	LPS	induced	7
17	.	induced	7

0	ETS1	is	1
1	is	<ROOT>	-1
2	a	factor	4
3	transcription	factor	4
4	factor	is	1
5	of	factor	4
6	the	family	8
7	ETS	family	8
8	family	of	5
9	that	is	10
10	is	factor	4
11	expressed	is	10
12	in	T	13
13	T	expressed	11
14	cells	is	1
15	.	is	1

0	Thrombopoietin	acts	4
1	(	TPO	2
2	TPO	Thrombopoietin	0
3	)	TPO	2
4	acts	<ROOT>	-1
5	on	acts	4
6	megakaryopoiesis	on	5
7	and	megakaryopoiesis	6
8	erythropoiesis	and	7
9	in	erythropoiesis	8
10	vitro	megakaryopoiesis	6
11	and	vitro	10
12	in	vitro	10
13	vivo	in	12
14	.	acts	4

0	We	<ROOT>	-1
1	have	We	0
2	employed	have	1
3	an	employed	2
4	optimized	an	3
5	cell-free	optimized	4
6	RNA	cell-free	5
7	transcription	RNA	6
8	assay	transcription	7
9	to	assay	8
10	analyze	to	9
11	transcription	analyze	10
12	activity	transcription	11
13	of	activity	12
14	XP-B	of	13
15	and	XP-B	14
16	XP-D	transcription	11
17	.	We	0

0	Triggering	factor	29
1	of	Triggering	0
2	HLA	antigens	5
3	class	antigens	5
4	II	antigens	5
5	antigens	of	1
6	by	Triggering	0
7	the	by	6
8	anti-HLA-DR	(	11
9	monoclonal	(	11
10	antibody	(	11
11	(	the	7
12	mAb	(	11
13	)	(	11
14	L243	(	11
15	significantly	(	11
16	(	significantly	15
17	P	Triggering	0
18	&lt;	0.05	19
19	0.05	Triggering	0
20	)	Triggering	0
21	and	tumor	27
22	differentially	enhanced	23
23	enhanced	tumor	27
24	the	release	25
25	release	tumor	27
26	of	tumor	27
27	tumor	Triggering	0
28	necrosis	Triggering	0
29	factor	<ROOT>	-1
30	alpha	(	31
31	(	factor	29
32	TNF-alpha	)	33
33	)	factor	29
34	by	lymphoma	38
35	the	non-Hodgkin	36
36	non-Hodgkin	lymphoma	38
37	's	non-Hodgkin	36
38	lymphoma	factor	29
39	cells	factor	29
40	Ri-I	factor	29
41	,	factor	29
42	Ci-I	factor	29
43	,	factor	29
44	and	factor	29
45	Sc-I	factor	29
46	,	factor	29
47	which	are	48
48	are	factor	29
49	at	distinct	51
50	a	distinct	51
51	distinct	are	48
52	stage	distinct	51
53	of	stage	52
54	B-cell	differentiation	55
55	differentiation	of	53
56	,	differentiation	55
57	and	,	56
58	by	differentiation	55
59	the	more	60
60	more	mature	61
61	mature	by	58
62	Burkitt	lymphoma	63
63	lymphoma	cell	64
64	cell	mature	61
65	Raji	factor	29
66	;	factor	29
67	in	did	71
68	contrast	in	67
69	,	did	71
70	it	did	71
71	did	factor	29
72	not	did	71
73	induce	did	71
74	TNF-alpha	release	75
75	release	induce	73
76	by	leukemia	79
77	the	leukemia	79
78	pre-B	leukemia	79
79	leukemia	release	75
80	cells	factor	29
81	Nalm-6	factor	29
82	and	factor	29
83	BV173	factor	29
84	.	factor	29

0	IFN-alpha/beta	tyrosine	3
1	specifically	induced	2
2	induced	tyrosine	3
3	tyrosine	<ROOT>	-1
4	phosphorylation	tyrosine	3
5	and	tyrosine	3
6	translocation	tyrosine	3
7	into	translocation	6
8	nucleus	into	7
9	of	nucleus	8
10	signal	of	9
11	transducers	signal	10
12	and	transducers	11
13	activators	and	12
14	of	activators	13
15	transcription	of	14
16	(	of	14
17	STAT	2	19
18	)	2	19
19	2	of	14
20	protein	and	12
21	in	cell	24
22	the	cell	24
23	T	cell	24
24	cell	and	12
25	clones	transducers	11
26	.	tyrosine	3

0	Fab	fragment	1
1	fragment	induce	13
2	of	fragment	1
3	anti-E.	G	6
4	chaffeensis	G	6
5	immunoglobulin	G	6
6	G	of	2
7	complexed	fragment	1
8	with	complexed	7
9	E.	chaffeensis	10
10	chaffeensis	with	8
11	did	induce	13
12	not	induce	13
13	induce	receptor	41
14	any	induce	13
15	of	any	14
16	these	cytokines	18
17	three	cytokines	18
18	cytokines	of	15
19	,	induce	13
20	indicating	induce	13
21	that	indicating	20
22	ehrlichial	binding	23
23	binding	is	24
24	is	that	21
25	required	is	24
26	for	required	25
27	IL-1beta	for	26
28	mRNA	IL-1beta	27
29	expression	mRNA	28
30	and	expression	29
31	that	and	30
32	binding	Fc	39
33	of	binding	32
34	the	complex	36
35	immune	complex	36
36	complex	of	33
37	to	the	38
38	the	binding	32
39	Fc	that	31
40	gamma	induce	13
41	receptor	required	43
42	is	receptor	41
43	required	<ROOT>	-1
44	for	required	43
45	TNF-alpha	required	43
46	and	required	43
47	IL-6	required	43
48	mRNA	required	43
49	expression	required	43
50	and	expression	49
51	enhanced	and	50
52	IL-1beta	enhanced	51
53	mRNA	IL-1beta	52
54	expression	.	55
55	.	mRNA	53

0	This	activity	1
1	activity	seems	2
2	seems	<ROOT>	-1
3	to	seems	2
4	be	to	3
5	due	be	4
6	to	cAMP	8
7	increased	to	6
8	cAMP	due	5
9	levels	cAMP	8
10	because	be	4
11	forskolin	because	10
12	and	forskolin	11
13	IBMX	the	15
14	mimic	the	15
15	the	because	10
16	effects	of	17
17	of	seems	2
18	PGE2	of	17
19	.	PGE2	18

0	Both	drugs	1
1	drugs	dose-dependently	2
2	dose-dependently	inhibited	3
3	inhibited	<ROOT>	-1
4	LPS-induced	TF	5
5	TF	inhibited	3
6	and	TF	5
7	TNF-alpha	and	6
8	synthesis	TNF-alpha	7
9	at	synthesis	8
10	the	at	9
11	mRNA	the	10
12	and	mRNA	11
13	the	protein	14
14	protein	and	12
15	level	protein	14
16	,	inhibited	3
17	and	inhibited	3
18	reduced	and	17
19	PGE2	.	21
20	production	.	21
21	.	reduced	18

0	The	loss	1
1	loss	<ROOT>	-1
2	of	proliferative	3
3	proliferative	loss	1
4	potential	proliferative	3
5	in	potential	4
6	response	characteristic	12
7	to	response	6
8	antigenic	challenge	9
9	challenge	is	10
10	is	response	6
11	a	is	10
12	characteristic	in	5
13	feature	immune	15
14	of	immune	15
15	immune	senescence	16
16	senescence	characteristic	12
17	.	senescence	16

0	PMA	acted	1
1	acted	<ROOT>	-1
2	synergistically	acted	1
3	with	synergistically	2
4	ionomycin	with	3
5	to	ionomycin	4
6	activate	with	3
7	JNK	MAPKs	8
8	MAPKs	activate	6
9	in	with	3
10	Jurkat	in	9
11	and	in	9
12	EL4	with	3
13	within	EL4	12
14	10	minutes	15
15	minutes	within	13
16	.	acted	1

0	Inducible	expression	1
1	expression	<ROOT>	-1
2	and	expression	1
3	phosphorylation	and	2
4	of	phosphorylation	3
5	coactivator	of	4
6	BOB.1/OBF.1	expression	1
7	in	T	8
8	T	BOB.1/OBF.1	6
9	cells	expression	1
10	[	expression	1
11	see	expression	1
12	comments	expression	1
13	]	expression	1

0	Common	human	7
1	and	Common	0
2	distinct	pathways	5
3	intracellular	pathways	5
4	signaling	pathways	5
5	pathways	and	1
6	in	human	7
7	human	<ROOT>	-1
8	neutrophils	human	7
9	utilized	human	7
10	by	human	7
11	platelet	activating	12
12	activating	factor	13
13	factor	by	10
14	and	human	7
15	FMLP	human	7
16	.	human	7

0	3	lymphocytes	4
1	.	3	0
2	Peripheral	lymphocytes	4
3	blood	lymphocytes	4
4	lymphocytes	were	11
5	(	lymphocytes	4
6	PBL	lymphocytes	4
7	)	lymphocytes	4
8	of	lymphocytes	4
9	both	groups	10
10	groups	of	8
11	were	<ROOT>	-1
12	tested	were	11
13	for	tested	12
14	the	percentage	15
15	percentage	for	13
16	of	percentage	15
17	apoptotic	of	16
18	cells	cycle	21
19	and	cycle	21
20	cell	cycle	21
21	cycle	apoptotic	17
22	progression	were	11
23	using	were	11
24	flow	using	23
25	cytometry	flow	24
26	.	cytometry	25

0	Significance	blood	9
1	of	Significance	0
2	quantitative	of	4
3	analysis	of	4
4	of	AML1/ETO	5
5	AML1/ETO	of	1
6	transcripts	Significance	0
7	in	peripheral	8
8	peripheral	Significance	0
9	blood	<ROOT>	-1
10	stem	blood	9
11	cells	from	12
12	from	blood	9
13	t-LRB-8;21-RRB-	blood	9
14	acute	blood	9
15	myelogenous	blood	9
16	leukemia	blood	9
17	.	blood	9

0	This	led	1
1	led	<ROOT>	-1
2	to	led	1
3	the	hypothesis	4
4	hypothesis	to	2
5	that	hypothesis	4
6	some	were	12
7	of	some	6
8	the	proteins	11
9	Rel/NF-kappa	proteins	11
10	B	proteins	11
11	proteins	of	7
12	were	that	5
13	key	factors	15
14	nuclear	factors	15
15	factors	were	12
16	in	factors	15
17	functions	factors	15
18	of	accessory	19
19	accessory	functions	17
20	cells	led	1
21	of	cells	20
22	the	response	24
23	immune	response	24
24	response	of	21
25	.	led	1

0	IL-2	induced	1
1	induced	<ROOT>	-1
2	the	binding	3
3	binding	of	4
4	of	induced	1
5	Stat5a	of	4
6	and	Stat5a	5
7	b	and	6
8	proteins	induced	1
9	to	induced	1
10	the	element	13
11	human	element	13
12	GASd	element	13
13	element	to	9
14	.	induced	1

0	Because	conclude	11
1	of	Because	0
2	the	behaviours	4
3	similar	behaviours	4
4	behaviours	Because	0
5	of	behaviours	4
6	aldosterone	of	5
7	and	aldosterone	6
8	progesterone	and	7
9	,	conclude	11
10	we	conclude	11
11	conclude	<ROOT>	-1
12	that	conclude	11
13	the	N-terminal	14
14	N-terminal	is	20
15	Thr729-Leu765	N-terminal	14
16	region	Thr729-Leu765	15
17	of	region	16
18	the	HBD	19
19	HBD	of	17
20	is	that	12
21	similarly	is	20
22	involved	similarly	21
23	in	involved	22
24	the	binding	25
25	binding	in	23
26	of	binding	25
27	both	.	29
28	hormones	.	29
29	.	of	26

0	Cytomegalovirus	<ROOT>	-1
1	(	Cytomegalovirus	0
2	CMV	(	1
3	)	CMV	2
4	infection	)	3
5	is	)	3
6	nonpermissive	persistent	8
7	or	persistent	8
8	persistent	is	5
9	in	)	3
10	many	lymphoid	11
11	lymphoid	in	9
12	and	lymphoid	11
13	myeloid	types	15
14	cell	types	15
15	types	and	12
16	but	in	9
17	can	be	18
18	be	but	16
19	activated	be	18
20	in	differentiated	21
21	differentiated	activated	19
22	macrophages	Cytomegalovirus	0
23	.	Cytomegalovirus	0

0	Thrombopoietin	supports	1
1	supports	<ROOT>	-1
2	in	vitro	3
3	vitro	supports	1
4	erythroid	vitro	3
5	differentiation	erythroid	4
6	via	supports	1
7	its	c-Mpl	10
8	specific	c-Mpl	10
9	receptor	c-Mpl	10
10	c-Mpl	via	6
11	in	c-Mpl	10
12	a	in	11
13	human	cell	15
14	leukemia	cell	15
15	cell	a	12
16	line	cell	15
17	.	line	16

0	Indeed	was	7
1	,	was	7
2	IL-10	was	7
3	,	IL-10	2
4	like	IL-10	2
5	IFN-gamma	like	4
6	,	IL-10	2
7	was	<ROOT>	-1
8	able	was	7
9	to	able	8
10	significantly	to	9
11	reduce	to	9
12	the	amount	13
13	amount	cell	16
14	of	cell	16
15	B-CLL	cell	16
16	cell	reduce	11
17	death	caused	18
18	caused	reduce	11
19	by	caused	18
20	hydrocortisone-induced	apoptosis	21
21	apoptosis	by	19
22	.	apoptosis	21

0	The	<ROOT>	-1
1	ED50	The	0
2	(	ED50	1
3	the	was	18
4	cortisol	giving	6
5	concentration	giving	6
6	giving	the	3
7	50	%	8
8	%	giving	6
9	inhibition	the	3
10	of	inhibition	9
11	the	of	10
12	thymidine	,	15
13	incorporation	,	15
14	)	,	15
15	,	the	11
16	however	the	11
17	,	was	18
18	was	(	2
19	identical	was	18
20	in	identical	19
21	all	groups	23
22	three	groups	23
23	groups	in	20
24	.	The	0

0	This	review	1
1	review	will	2
2	will	<ROOT>	-1
3	concentrate	will	2
4	on	concentrate	3
5	this	topic	6
6	topic	on	4
7	and	topic	6
8	on	and	7
9	its	role	10
10	role	on	8
11	for	the	12
12	the	role	10
13	regulation	the	12
14	of	regulation	13
15	eosinophil	apoptosis	16
16	apoptosis	of	14
17	.	will	2

0	For	were	34
1	this	purpose	2
2	purpose	For	0
3	,	human	4
4	human	For	0
5	GATA-3	human	4
6	,	GATA-3	5
7	either	recombinant	8
8	recombinant	GATA-3	5
9	or	For	0
10	in	or	9
11	nuclear	extracts	12
12	extracts	in	10
13	,	For	0
14	and	For	0
15	three	For	0
16	natural	For	0
17	GATA	elements	18
18	elements	natural	16
19	of	long	22
20	the	long	22
21	HIV-1	long	22
22	long	elements	18
23	terminal	(	25
24	repeat	(	25
25	(	For	0
26	sites	For	0
27	1	For	0
28	,	For	0
29	2	For	0
30	,	For	0
31	and	For	0
32	3	For	0
33	)	For	0
34	were	<ROOT>	-1
35	chosen	were	34
36	,	is	42
37	in	is	42
38	which	in	37
39	only	site	40
40	site	is	42
41	2	site	40
42	is	chosen	35
43	a	site	46
44	noncanonical	site	46
45	GATA	site	46
46	site	is	42
47	.	site	46

0	Mutations	prevented	9
1	which	abrogated	2
2	abrogated	Mutations	0
3	the	abrogated	2
4	gene-suppressive	the	3
5	activity	gene-suppressive	4
6	of	activity	5
7	NRE	gamma	8
8	gamma	prevented	9
9	prevented	<ROOT>	-1
10	RFX1	prevented	9
11	from	RFX1	10
12	binding	from	11
13	to	binding	12
14	NRE	prevented	9
15	gamma	prevented	9
16	.	prevented	9

0	Lipopolysaccharide	one	2
1	is	Lipopolysaccharide	0
2	one	<ROOT>	-1
3	of	one	2
4	the	trigger	7
5	most	potent	6
6	potent	trigger	7
7	trigger	of	3
8	substances	trigger	7
9	for	trigger	7
10	monocytes	one	2
11	and	monocytes	10
12	macrophages	and	11
13	causing	one	2
14	secretion	one	2
15	of	secretion	14
16	inflammatory	mediators	17
17	mediators	of	15
18	such	as	19
19	as	mediators	17
20	tumor	factor	22
21	necrosis	factor	22
22	factor	as	19
23	and	one	2
24	interleukin-1	one	2
25	.	one	2

0	Individual	mutation	1
1	mutation	did	15
2	of	mutation	1
3	the	DBF	4
4	DBF	of	2
5	or	DBF	4
6	AP3-L	site	7
7	site	or	5
8	as	mutation	1
9	well	as	8
10	as	as	8
11	the	mutation	13
12	double	mutation	13
13	mutation	as	8
14	AP-1-LRB-III-RRB-/AP3-L	mutation	1
15	did	<ROOT>	-1
16	not	did	15
17	affect	did	15
18	HIV-1	replication	19
19	replication	affect	17
20	compared	affect	17
21	to	compared	20
22	that	to	21
23	of	that	22
24	the	of	23
25	wild-type	virus	26
26	virus	the	24
27	.	virus	26

0	The	inability	1
1	inability	<ROOT>	-1
2	of	inability	1
3	prolonged	stimulation	4
4	stimulation	of	2
5	of	stimulation	4
6	conventional	cells	8
7	B-2	cells	8
8	cells	of	5
9	with	stimulation	4
10	anti-Ig	with	9
11	,	inability	1
12	a	treatment	13
13	treatment	inability	1
14	sufficient	treatment	13
15	to	sufficient	14
16	induce	to	15
17	CD5	expression	18
18	expression	induce	16
19	,	inability	1
20	to	inability	1
21	result	to	20
22	in	STAT3	24
23	sustained	STAT3	24
24	STAT3	result	21
25	activation	inability	1
26	suggests	inability	1
27	that	suggests	26
28	STAT3	is	29
29	is	that	27
30	a	marker	33
31	specific	marker	33
32	nuclear	marker	33
33	marker	is	29
34	for	marker	33
35	B-1	cells	36
36	cells	for	34
37	.	inability	1

0	Since	have	9
1	sequence	variations	2
2	variations	Since	0
3	in	3'	5
4	the	3'	5
5	3'	Since	0
6	UTR	Since	0
7	of	UTR	6
8	VDR	Since	0
9	have	<ROOT>	-1
10	been	have	9
11	linked	been	10
12	to	linked	11
13	the	haplotypes	15
14	different	haplotypes	15
15	haplotypes	to	12
16	,	have	9
17	investigators	proposed	19
18	have	proposed	19
19	proposed	have	9
20	that	proposed	19
21	the	stability	22
22	stability	influenced	27
23	of	stability	22
24	VDR	of	23
25	mRNA	is	26
26	is	VDR	24
27	influenced	that	20
28	by	influenced	27
29	allelic	by	28
30	variations	.	31
31	.	allelic	29

0	The	distribution	1
1	distribution	cytokine	5
2	of	cytokine	5
3	myeloid	cytokine	5
4	lineage-associated	cytokine	5
5	cytokine	proteins	9
6	receptors	and	7
7	and	cytokine	5
8	lysosomal	cytokine	5
9	proteins	was	10
10	was	<ROOT>	-1
11	analyzed	blood	16
12	in	blood	16
13	human	blood	16
14	CD34+	blood	16
15	cord	blood	16
16	blood	was	10
17	cell	subsets	21
18	(	CB	19
19	CB	subsets	21
20	)	CB	19
21	subsets	was	10
22	at	was	10
23	different	of	25
24	stages	of	25
25	of	commitment	27
26	myeloid	of	25
27	commitment	at	22
28	by	commitment	27
29	reverse-transcriptase	reaction	32
30	polymerase	reaction	32
31	chain	reaction	32
32	reaction	by	28
33	(	RT-PCR	34
34	RT-PCR	reaction	32
35	)	RT-PCR	34
36	.	was	10

0	An	regulates	8
1	acute	An	0
2	myeloid	,	5
3	leukemia	,	5
4	gene	,	5
5	,	acute	1
6	AML1	An	0
7	,	An	0
8	regulates	<ROOT>	-1
9	transcriptional	activation	10
10	activation	regulates	8
11	and	activation	10
12	hemopoietic	regulates	8
13	myeloid	regulates	8
14	cell	differentiation	15
15	differentiation	myeloid	13
16	antagonistically	differentiation	15
17	by	antagonistically	16
18	two	forms	21
19	alternative	forms	21
20	spliced	forms	21
21	forms	by	17
22	.	forms	21

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	we	,	2
4	investigated	the	5
5	the	blot	11
6	expression	the	5
7	of	expression	6
8	LAZ3/BCL6	of	7
9	by	blot	11
10	Northern	blot	11
11	blot	we	3
12	analysis	blot	11
13	on	blot	11
14	multiple	on	13
15	human	multiple	14
16	tissues	.	17
17	.	human	15

0	The	methodology	1
1	methodology	employed	2
2	employed	<ROOT>	-1
3	transient	transfection	4
4	transfection	employed	2
5	of	transfection	4
6	HEK	cells	8
7	293	cells	8
8	cells	of	5
9	with	a	10
10	a	employed	2
11	cDNA	a	10
12	for	cDNA	11
13	the	form	15
14	52-kDa	form	15
15	form	for	12
16	of	form	15
17	G-LRB-S-RRB-alpha	of	16
18	under	form	15
19	regulation	under	18
20	by	metallothionein	22
21	inducible	metallothionein	22
22	metallothionein	regulation	19
23	promoters	for	12
24	.	employed	2

0	To	raised	16
1	assess	To	0
2	the	phosphorylation	3
3	phosphorylation	assess	1
4	of	serine	5
5	serine	phosphorylation	3
6	residues	serine	5
7	of	residues	6
8	STAT1	To	0
9	and	To	0
10	STAT3	To	0
11	in	To	0
12	CLL	To	0
13	cells	To	0
14	,	raised	16
15	we	raised	16
16	raised	<ROOT>	-1
17	antibodies	raised	16
18	that	antibodies	17
19	specifically	recognize	20
20	recognize	that	18
21	the	form	22
22	form	recognize	20
23	of	form	22
24	STAT1	phosphorylated	25
25	phosphorylated	of	23
26	on	recognize	20
27	ser-727	on	26
28	and	ser-727	27
29	the	form	30
30	form	and	28
31	of	form	30
32	STAT3	phosphorylated	33
33	phosphorylated	of	31
34	on	form	30
35	ser-727	on	34
36	.	raised	16

0	Transcription	factors	1
1	factors	<ROOT>	-1
2	of	factors	1
3	the	of	2
4	NFAT	the	3
5	(	NFAT	4
6	nuclear	factor	7
7	factor	(	5
8	of	T	10
9	activated	T	10
10	T	factor	7
11	cells	factors	1
12	)	factors	1
13	family	)	12
14	play	family	13
15	important	play	14
16	roles	important	15
17	in	roles	16
18	immune	roles	16
19	and	immune	18
20	inflammatory	and	19
21	responses	roles	16
22	by	responses	21
23	regulating	the	24
24	the	by	22
25	expression	genes	27
26	of	expression	25
27	genes	the	24
28	encoding	the	24
29	cytokines	encoding	28
30	and	cytokines	29
31	immunoregulatory	and	30
32	proteins	immunoregulatory	31
33	.	factors	1

0	Primer	analysis	2
1	extension	analysis	2
2	analysis	<ROOT>	-1
3	of	analysis	2
4	C/EBP-epsilon	mRNA	5
5	mRNA	detected	6
6	detected	of	3
7	a	detected	6
8	single	a	7
9	major	approximately	13
10	transcription	approximately	13
11	start	approximately	13
12	site	approximately	13
13	approximately	single	8
14	200	single	8
15	bp	200	14
16	upstream	bp	15
17	of	upstream	16
18	the	start	19
19	start	of	17
20	codon	start	19
21	.	analysis	2

0	Hence	decreased	2
1	,	decreased	2
2	decreased	is	6
3	sensitivity	to	4
4	to	decreased	2
5	cortisol	decreased	2
6	is	<ROOT>	-1
7	associated	is	6
8	with	associated	7
9	renin	suppression	10
10	suppression	with	8
11	.	is	6

0	These	contained	1
1	contained	<ROOT>	-1
2	the	contained	1
3	luciferase	the	2
4	gene	under	5
5	under	luciferase	3
6	the	under	5
7	control	the	6
8	of	control	7
9	either	of	8
10	the	either	9
11	human	the	10
12	IL2	human	11
13	upstream	(	16
14	enhancer	(	16
15	region	(	16
16	(	IL2	12
17	segments	the	10
18	-326	the	10
19	to	-326	18
20	+45	to	19
21	)	+45	20
22	or	)	21
23	three	or	22
24	repeats	)	21
25	of	repeats	24
26	the	element	28
27	NFAT	element	28
28	element	of	25
29	contained	+45	20
30	within	+45	20
31	it	within	30
32	(	under	5
33	segments	luciferase	3
34	-255	segments	33
35	to	-255	34
36	-285	)	37
37	)	to	35
38	.	)	37

0	Characterization	<ROOT>	-1
1	of	Characterization	0
2	interleukin-10	of	1
3	receptor	expression	4
4	expression	of	1
5	on	leukemia	9
6	B-cell	leukemia	9
7	chronic	leukemia	9
8	lymphocytic	leukemia	9
9	leukemia	of	1
10	cells	Characterization	0
11	.	Characterization	0

0	On	was	6
1	the	hand	3
2	other	hand	3
3	hand	On	0
4	,	was	6
5	Ad2	was	6
6	was	<ROOT>	-1
7	internalized	was	6
8	by	internalized	7
9	macrophages	by	8
10	.	was	6

0	Using	is	18
1	a	panel	2
2	panel	Using	0
3	of	panel	2
4	specific	antisera	5
5	antisera	of	3
6	in	antisera	5
7	immunoprecipitation	of	3
8	assays	,	9
9	,	immunoprecipitation	7
10	we	of	3
11	found	that	12
12	that	of	3
13	NFATp	(	14
14	(	kDa	16
15	135	(	14
16	kDa	that	12
17	)	Using	0
18	is	86	35
19	constitutively	is	18
20	expressed	constitutively	19
21	in	normal	22
22	normal	expressed	20
23	human	normal	22
24	T	,	26
25	cells	,	26
26	,	human	23
27	while	is	18
28	synthesis	while	27
29	of	while	27
30	NFATc	(	31
31	(	is	18
32	predominant	is	18
33	form	of	34
34	of	is	18
35	86	kDa	36
36	kDa	is	38
37	)	kDa	36
38	is	<ROOT>	-1
39	induced	by	40
40	by	is	38
41	ionomycin	is	38
42	treatment	is	38
43	.	is	38

0	The	kinetics	1
1	kinetics	suggest	4
2	of	kinetics	1
3	expression	of	2
4	suggest	<ROOT>	-1
5	that	suggest	4
6	the	levels	9
7	high	levels	9
8	initial	levels	9
9	levels	are	10
10	are	that	5
11	caused	are	10
12	by	caused	11
13	the	procedure	15
14	isolation	procedure	15
15	procedure	by	12
16	,	suggest	4
17	and	suggest	4
18	do	and	17
19	not	do	18
20	reflect	expression	22
21	constitutive	expression	22
22	expression	do	18
23	.	suggest	4

0	This	effect	1
1	effect	is	2
2	is	<ROOT>	-1
3	blocked	is	2
4	by	blocked	3
5	anti-VCAM	antibodies	6
6	antibodies	by	4
7	.	is	2

0	Only	patients	2
1	FMS	Only	0
2	patients	displayed	3
3	displayed	<ROOT>	-1
4	lower	and	6
5	CBG	lower	4
6	and	displayed	3
7	basal	and	6
8	serum	displayed	3
9	cortisol	displayed	3
10	concentrations	displayed	3
11	when	compared	12
12	compared	displayed	3
13	to	compared	12
14	controls	to	13
15	.	displayed	3

0	As	appears	20
1	a	target	2
2	target	As	0
3	for	target	2
4	DNA	methylation	5
5	methylation	for	3
6	and	As	0
7	for	and	6
8	binding	for	7
9	of	that	12
10	transcription	factors	11
11	factors	of	9
12	that	binding	8
13	mediate	As	0
14	or	As	0
15	impede	As	0
16	transcription	As	0
17	,	appears	20
18	this	element	19
19	element	appears	20
20	appears	<ROOT>	-1
21	to	appears	20
22	play	to	21
23	a	IFN-gamma	28
24	central	in	26
25	role	in	26
26	in	a	23
27	controlling	IFN-gamma	28
28	IFN-gamma	play	22
29	expression	to	21
30	.	appears	20

0	Mutations	result	6
1	in	Mutations	0
2	these	factors	5
3	liver-enriched	factors	5
4	transcription	factors	5
5	factors	in	1
6	result	<ROOT>	-1
7	in	2	13
8	two	forms	9
9	forms	2	13
10	of	2	13
11	early-onset	type	12
12	type	2	13
13	2	result	6
14	diabetes	result	6
15	(	diabetes	14
16	maturity-onset	diabetes	17
17	diabetes	(	15
18	of	diabetes	17
19	the	of	18
20	young	[	21
21	[	the	19
22	MODY	[	21
23	]	)	24
24	)	[	21
25	,	diabetes	17
26	MODY3	diabetes	17
27	and	MODY3	26
28	MODY1	and	27
29	,	diabetes	17
30	which	are	31
31	are	diabetes	17
32	characterized	are	31
33	by	characterized	32
34	impaired	insulin	36
35	glucose-stimulated	insulin	36
36	insulin	by	33
37	secretion	are	31
38	,	diabetes	17
39	early	diabetes	17
40	disease	result	6
41	onset	result	6
42	,	result	6
43	and	result	6
44	autosomal	dominant	45
45	dominant	and	43
46	inheritance	result	6
47	.	result	6

0	Our	data	1
1	data	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	although	that	3
5	PBSC	although	4
6	harvests	PBSC	5
7	collected	harvests	6
8	after	collected	7
9	consolidation	chemotherapy	10
10	chemotherapy	are	11
11	are	after	8
12	contaminated	are	11
13	by	contaminated	12
14	leukemic	by	13
15	cells	,	16
16	,	leukemic	14
17	the	leukemic	14
18	degree	of	19
19	of	cell	21
20	leukemic	cell	21
21	cell	the	17
22	contamination	decreases	23
23	decreases	cell	21
24	with	decreases	23
25	repeated	cycles	26
26	cycles	after	8
27	of	cycles	26
28	chemotherapy	of	27
29	.	indicate	2

0	Amino	sequence	2
1	acid	sequence	2
2	sequence	comparison	3
3	comparison	shows	4
4	shows	<ROOT>	-1
5	that	shows	4
6	CHEMR1	is	7
7	is	that	5
8	84	%	9
9	%	is	7
10	identical	is	7
11	to	identical	10
12	human	CCR-4	13
13	CCR-4	to	11
14	,	shows	4
15	indicating	shows	4
16	that	indicating	15
17	CHEMR1	is	18
18	is	that	16
19	likely	is	18
20	to	likely	19
21	be	mouse	23
22	a	mouse	23
23	mouse	to	20
24	CCR-4	mouse	23
25	.	shows	4

0	In	suggests	5
1	addition	In	0
2	,	suggests	5
3	this	analysis	4
4	analysis	suggests	5
5	suggests	<ROOT>	-1
6	a	step	8
7	common	step	8
8	step	suggests	5
9	in	step	8
10	the	in	9
11	signaling	that	13
12	pathways	that	13
13	that	the	10
14	trigger	that	13
15	I	alpha	17
16	kappaB	alpha	17
17	alpha	trigger	14
18	,	suggests	5
19	I	suggests	5
20	kappaB	beta	21
21	beta	suggests	5
22	,	suggests	5
23	and	epsilon	26
24	I	epsilon	26
25	kappaB	epsilon	26
26	epsilon	suggests	5
27	degradation	suggests	5
28	.	suggests	5

0	These	studies	1
1	studies	were	2
2	were	T	13
3	conducted	were	2
4	with	(	7
5	highly	purified	6
6	purified	with	4
7	(	conducted	3
8	FACS-isolated	(	7
9	)	of	11
10	subsets	of	11
11	of	(	7
12	CD4	T	13
13	T	identified	15
14	cells	T	13
15	identified	<ROOT>	-1
16	by	identified	15
17	expression	of	18
18	of	by	16
19	both	CD45RA	20
20	CD45RA	of	18
21	and	CD45RA	20
22	CD62L	and	21
23	.	identified	15

0	We	report	1
1	report	<ROOT>	-1
2	that	report	1
3	removal	that	2
4	of	removal	3
5	the	amino	8
6	N-terminal	amino	8
7	151	amino	8
8	amino	of	4
9	acids	amino	8
10	,	removal	3
11	encompassing	removal	3
12	all	encompassing	11
13	of	all	12
14	the	domain	16
15	acidic	domain	16
16	domain	of	13
17	but	all	12
18	leaving	but	17
19	intact	domain	22
20	the	domain	22
21	proline/serine/threonine-rich	domain	22
22	domain	leaving	18
23	,	removal	3
24	results	removal	3
25	in	potent	30
26	a	potent	30
27	mutant	potent	30
28	protein	potent	30
29	with	potent	30
30	potent	results	24
31	suppressive	MHC	34
32	properties	MHC	34
33	for	MHC	34
34	MHC	potent	30
35	class	II	36
36	II	potent	30
37	expression	.	38
38	.	II	36

0	Further	coimmunoprecipitated	3
1	,	coimmunoprecipitated	3
2	Tax1	coimmunoprecipitated	3
3	coimmunoprecipitated	<ROOT>	-1
4	with	coimmunoprecipitated	3
5	NF-Y	with	4
6	from	NF-Y	5
7	nuclear	extracts	8
8	extracts	from	6
9	of	extracts	8
10	HTLV-1-transformed	of	9
11	cells	HTLV-1-transformed	10
12	,	providing	13
13	providing	cells	11
14	evidence	providing	13
15	for	providing	13
16	in	providing	13
17	vivo	interaction	18
18	interaction	in	16
19	of	interaction	18
20	Tax1	of	19
21	and	providing	13
22	NF-YB	and	21
23	.	coimmunoprecipitated	3

0	Transcriptional	activity	1
1	activity	<ROOT>	-1
2	and	activity	1
3	constitutive	localization	5
4	nuclear	localization	5
5	localization	and	2
6	of	activity	1
7	the	protein	9
8	ETS	protein	9
9	protein	of	6
10	Elf-1	activity	1
11	.	activity	1

0	Truncated	forms	1
1	forms	<ROOT>	-1
2	of	forms	1
3	the	of	2
4	NOTCH1	the	3
5	transmembrane	engineered	7
6	receptor	engineered	7
7	engineered	NOTCH1	4
8	to	engineered	7
9	resemble	forms	11
10	mutant	forms	11
11	forms	to	8
12	of	NOTCH1	13
13	NOTCH1	certain	16
14	found	NOTCH1	13
15	in	found	14
16	certain	forms	11
17	cases	certain	16
18	of	human	19
19	human	cases	17
20	T	cell	21
21	cell	forms	11
22	leukemia/lymphoma	forms	1
23	(	T-ALL	24
24	T-ALL	leukemia/lymphoma	22
25	)	T-ALL	24
26	efficiently	induce	27
27	induce	forms	1
28	T-ALL	induce	27
29	when	expressed	30
30	expressed	induce	27
31	in	bone	33
32	the	bone	33
33	bone	expressed	30
34	marrow	forms	1
35	of	marrow	34
36	mice	of	35
37	.	forms	1

0	Activation	induces	10
1	of	the	2
2	the	Activation	0
3	granulocyte	receptor	6
4	colony-stimulating	receptor	6
5	factor	receptor	6
6	receptor	(	7
7	(	Activation	0
8	G-CSFR	(	7
9	)	Activation	0
10	induces	tyrosine	12
11	rapid	tyrosine	12
12	tyrosine	<ROOT>	-1
13	phosphorylation	tyrosine	12
14	of	phosphorylation	13
15	multiple	substrates	17
16	intracellular	substrates	17
17	substrates	of	14
18	in	tyrosine	12
19	proliferating	tyrosine	12
20	cells	tyrosine	12
21	and	tyrosine	12
22	nonproliferating	tyrosine	12
23	,	tyrosine	12
24	terminally	tyrosine	12
25	differentiated	tyrosine	12
26	neutrophils	tyrosine	12
27	.	tyrosine	12

0	In	suggested	15
1	contrast	In	0
2	,	suggested	15
3	semiquantitative	analysis	5
4	RT-PCR	analysis	5
5	analysis	suggested	15
6	of	analysis	5
7	RNA	of	6
8	from	analysis	5
9	reticulocytes	from	8
10	of	reticulocytes	9
11	the	animals	14
12	same	animals	14
13	chimeric	animals	14
14	animals	of	10
15	suggested	<ROOT>	-1
16	that	suggested	15
17	the	ES	18
18	ES	cell-derived	19
19	cell-derived	that	16
20	reticulocytes	were	21
21	were	cell-derived	19
22	present	were	21
23	at	cell-derived	19
24	a	level	25
25	level	at	23
26	of	level	25
27	6	%	28
28	%	of	26
29	to	at	23
30	8	%	31
31	%	to	29
32	.	suggested	15

0	The	subunit	2
1	gamma-LRB-c-RRB-	subunit	2
2	subunit	can	3
3	can	<ROOT>	-1
4	be	can	3
5	employed	be	4
6	in	employed	5
7	receptor	in	6
8	complexes	receptor	7
9	for	in	6
10	IL-2	employed	5
11	,	IL-2	10
12	-4	be	4
13	,	can	3
14	-7	can	3
15	,	can	3
16	-9	can	3
17	,	can	3
18	and	can	3
19	-15	can	3
20	,	can	3
21	and	can	3
22	the	defects	25
23	multiple	defects	25
24	signaling	defects	25
25	defects	and	21
26	that	would	27
27	would	defects	25
28	result	would	27
29	from	result	28
30	a	chain	33
31	defective	chain	33
32	gamma-LRB-c-RRB-	chain	33
33	chain	from	29
34	in	these	35
35	these	from	29
36	receptors	are	37
37	are	can	3
38	proposed	are	37
39	to	proposed	38
40	cause	severe	42
41	the	severe	42
42	severe	to	39
43	phenotype	severe	42
44	of	X-SCID	45
45	X-SCID	phenotype	43
46	patients	can	3
47	.	can	3

0	We	identified	2
1	also	identified	2
2	identified	<ROOT>	-1
3	a	sequence	6
4	potent	sequence	6
5	inhibitory	sequence	6
6	sequence	identified	2
7	within	N-terminal	9
8	its	N-terminal	9
9	N-terminal	identified	2
10	domain	identified	2
11	.	identified	2

0	These	<ROOT>	-1
1	data	These	0
2	suggest	that	3
3	that	activated	4
4	activated	data	1
5	NFAT	data	1
6	is	These	0
7	involved	is	6
8	in	involved	7
9	the	in	8
10	effector	the	9
11	function	effector	10
12	of	eTh2	13
13	eTh2	function	11
14	cells	These	0
15	and	These	0
16	that	and	15
17	the	failure	18
18	failure	that	16
19	of	eTh1	20
20	eTh1	failure	18
21	cells	These	0
22	to	These	0
23	produce	These	0
24	IL-4	These	0
25	in	These	0
26	response	in	25
27	to	response	26
28	an	to	27
29	antigen	is	30
30	is	an	28
31	due	an	28
32	,	These	0
33	at	partially	35
34	least	at	33
35	partially	These	0
36	,	These	0
37	to	These	0
38	a	to	37
39	failure	These	0
40	to	failure	39
41	induce	These	0
42	high-level	These	0
43	transcription	high-level	42
44	of	transcription	43
45	the	gene	47
46	IL-4	gene	47
47	gene	of	44
48	by	high-level	42
49	NFAT	These	0
50	.	These	0

0	For	are	5
1	example	For	0
2	,	are	5
3	certain	oxidants	4
4	oxidants	are	5
5	are	<ROOT>	-1
6	known	are	5
7	to	known	6
8	activate	to	7
9	the	B	14
10	nuclear	B	14
11	transcription	B	14
12	factor	B	14
13	kappa	B	14
14	B	activate	8
15	,	are	5
16	which	regulates	17
17	regulates	are	5
18	the	expression	19
19	expression	regulates	17
20	of	expression	19
21	a	variety	22
22	variety	of	20
23	of	adhesion	25
24	different	adhesion	25
25	adhesion	variety	22
26	molecules	are	5
27	,	are	5
28	cytokines	are	5
29	,	cytokines	28
30	and	,	29
31	enzymes	are	5
32	.	are	5

0	There	is	1
1	is	<ROOT>	-1
2	general	agreement	3
3	agreement	is	1
4	on	agreement	3
5	the	pathogenesis	7
6	inflammatory	pathogenesis	7
7	pathogenesis	on	4
8	of	pathogenesis	7
9	bronchial	asthma	10
10	asthma	of	8
11	:	pathogenesis	7
12	an	accumulation	13
13	accumulation	pathogenesis	7
14	of	accumulation	13
15	activated	,	17
16	eosinophils	,	17
17	,	of	14
18	degranulated	pathogenesis	7
19	mast	agreement	3
20	cells	is	1
21	,	is	1
22	T	is	1
23	lymphocytes	T	22
24	and	T	22
25	in	and	24
26	very	severe	27
27	severe	forms	28
28	forms	in	25
29	,	is	1
30	granulocytes	has	31
31	has	is	1
32	constantly	has	31
33	been	has	31
34	found	been	33
35	in	been	33
36	the	in	35
37	bronchial	the	36
38	mucosa	bronchial	37
39	.	mucosa	38

0	These	observations	1
1	observations	implicated	2
2	implicated	was	14
3	c-Rel	implicated	2
4	as	c-Rel	3
5	an	factor	8
6	IL-2	factor	8
7	promoter	factor	8
8	factor	as	4
9	,	implicated	2
10	for	implicated	2
11	which	support	13
12	experimental	support	13
13	support	for	10
14	was	<ROOT>	-1
15	obtained	transient	17
16	from	transient	17
17	transient	was	14
18	transfection	experiments	19
19	experiments	was	14
20	.	was	14

0	In	have	4
1	UCSD-AML1	In	0
2	,	have	4
3	we	have	4
4	have	<ROOT>	-1
5	also	have	4
6	identified	have	4
7	fusion	transcripts	8
8	transcripts	identified	6
9	between	insertion	13
10	the	insertion	13
11	ecotropic	insertion	13
12	viral	insertion	13
13	insertion	identified	6
14	site	have	4
15	I	(	16
16	(	EVI1	17
17	EVI1	have	4
18	)	have	4
19	gene	have	4
20	in	gene	19
21	3q26	in	20
22	and	3q26	21
23	GR6	and	22
24	and	GR6	23
25	between	and	24
26	EVI1	between	25
27	and	EVI1	26
28	Ribophorin	and	27
29	I	Ribophorin	28
30	that	Ribophorin	28
31	maps	that	30
32	30	kb	33
33	kb	maps	31
34	telomeric	maps	31
35	to	telomeric	34
36	GR6	to	35
37	in	GR6	36
38	3q21	in	37
39	.	have	4

0	Transcriptional	regulation	1
1	regulation	<ROOT>	-1
2	during	regulation	1
3	myelopoiesis	during	2
4	.	regulation	1

0	For	recruited	4
1	comparison	For	0
2	,	recruited	4
3	we	recruited	4
4	recruited	<ROOT>	-1
5	a	group	7
6	control	group	7
7	group	recruited	4
8	consisting	recruited	4
9	of	healthy	11
10	32	healthy	11
11	healthy	consisting	8
12	males	consisting	8
13	and	males	12
14	females	and	13
15	with	age	17
16	similar	age	17
17	age	recruited	4
18	distribution	age	17
19	and	recruited	4
20	without	recruited	4
21	a	history	22
22	history	without	20
23	of	history	22
24	exposure	of	23
25	to	exposure	24
26	MTBE	to	25
27	or	MTBE	26
28	benzene	or	27
29	.	recruited	4

0	Both	FMLP	1
1	FMLP	activated	4
2	and	FMLP	1
3	PAF	and	2
4	activated	<ROOT>	-1
5	MAP	activated	4
6	kinase	kinase-3	7
7	kinase-3	activated	4
8	(	MKK3	9
9	MKK3	kinase-3	7
10	)	MKK3	9
11	,	activated	4
12	a	activated	4
13	known	a	12
14	activator	known	13
15	of	activator	14
16	p38	activated	4
17	MAPk	.	18
18	.	p38	16

0	Stimulation	<ROOT>	-1
1	of	Stimulation	0
2	DND39	cells	3
3	cells	of	1
4	with	of	1
5	IL-4	with	4
6	or	IL-4	5
7	anti-CD40	Stimulation	0
8	monoclonal	Stimulation	0
9	antibody	(	10
10	(	Stimulation	0
11	mAb	Stimulation	0
12	)	Stimulation	0
13	activated	Stimulation	0
14	phosphatidylinositol	Stimulation	0
15	3-kinase	Stimulation	0
16	and	subsequently	17
17	subsequently	Stimulation	0
18	induced	Stimulation	0
19	nuclear	expression	20
20	expression	NF-kappa	22
21	of	NF-kappa	22
22	NF-kappa	was	26
23	B	,	24
24	,	NF-kappa	22
25	which	NF-kappa	22
26	was	induced	18
27	identified	was	26
28	by	identified	27
29	electrophoretic	mobility	30
30	mobility	by	28
31	shift	mobility	30
32	assays	identified	27
33	.	Stimulation	0

0	Thus	<ROOT>	-1
1	,	Thus	0
2	GATA-1	plays	3
3	plays	,	1
4	important	plays	3
5	in	important	4
6	vivo	in	5
7	roles	vivo	6
8	for	roles	7
9	directing	for	8
10	definitive	directing	9
11	hematopoietic	differentiate	14
12	progenitors	differentiate	14
13	to	differentiate	14
14	differentiate	definitive	10
15	along	differentiate	14
16	both	differentiate	14
17	the	both	16
18	erythroid	the	17
19	and	erythroid	18
20	megakaryocytic	erythroid	18
21	pathways	.	22
22	.	megakaryocytic	20

0	Because	were	17
1	cell	analysis	3
2	cycle	analysis	3
3	analysis	showed	4
4	showed	Because	0
5	that	showed	4
6	in	that	5
7	PBL	in	6
8	from	in	6
9	chemically-exposed	from	8
10	individuals	in	6
11	,	were	17
12	between	were	17
13	20-50	%	14
14	%	were	17
15	of	%	14
16	cells	of	15
17	were	<ROOT>	-1
18	accumulated	were	17
19	at	accumulated	18
20	the	boundaries	22
21	S-G2/M	boundaries	22
22	boundaries	at	19
23	.	were	17

0	Therefore	:	7
1	,	:	7
2	while	:	7
3	the	:	7
4	total	sialyltransferase	6
5	plasma	sialyltransferase	6
6	sialyltransferase	the	3
7	:	<ROOT>	-1
8	cortisol	ratio	9
9	ratio	reflects	10
10	reflects	:	7
11	HPA	function	13
12	axis	function	13
13	function	reflects	10
14	,	reflects	10
15	alterations	:	7
16	in	alterations	15
17	specific	activity	19
18	isozyme	activity	19
19	activity	in	16
20	may	:	7
21	also	be	22
22	be	:	7
23	associated	be	22
24	with	associated	23
25	other	states	28
26	CNS	states	28
27	disease	states	28
28	states	with	24
29	.	:	7

0	TRADD	was	1
1	was	<ROOT>	-1
2	the	protein	4
3	only	protein	4
4	protein	was	1
5	that	interacted	6
6	interacted	protein	4
7	with	interacted	6
8	wild-type	TES2	9
9	TES2	with	7
10	and	was	1
11	not	and	10
12	with	not	11
13	isoleucine-mutated	TES2	14
14	TES2	with	12
15	.	was	1

0	Interactions	were	12
1	between	Interactions	0
2	the	canonical	3
3	canonical	between	1
4	and	site	7
5	unique	and	4
6	GATA	site	7
7	site	canonical	3
8	3	site	7
9	and	canonical	3
10	nuclear	extracts	11
11	extracts	and	9
12	were	<ROOT>	-1
13	also	were	12
14	studied	were	12
15	in	studied	14
16	real	time	17
17	time	in	15
18	and	in	15
19	provided	and	18
20	information	provided	19
21	on	information	20
22	its	and	24
23	association	and	24
24	and	on	21
25	dissociation	rates	26
26	rates	and	24
27	for	and	24
28	native	huGATA-3	29
29	huGATA-3	for	27
30	.	were	12

0	PMLRAR	<ROOT>	-1
1	alpha	exhibited	4
2	transgenic	exhibited	4
3	mice	exhibited	4
4	exhibited	PMLRAR	0
5	impaired	neutrophil	6
6	neutrophil	exhibited	4
7	maturation	neutrophil	6
8	early	maturation	7
9	in	early	8
10	life	in	9
11	,	PMLRAR	0
12	which	progressed	13
13	progressed	,	11
14	at	progressed	13
15	a	at	14
16	low	a	15
17	frequency	low	16
18	over	frequency	17
19	the	course	20
20	course	over	18
21	of	course	20
22	several	months	23
23	months	of	21
24	to	course	20
25	overt	APL	26
26	APL	to	24
27	.	PMLRAR	0

0	p27Kip1	inhibits	2
1	directly	inhibits	2
2	inhibits	<ROOT>	-1
3	the	inhibits	2
4	catalytic	the	3
5	activity	and/or	13
6	of	activity	5
7	cyclin/cdks	of	6
8	(	activity	5
9	cyclin-dependent	kinase	10
10	kinase	activity	5
11	)	activity	5
12	complexes	and/or	13
13	and/or	catalytic	4
14	interferes	and/or	13
15	physically	inhibits	2
16	with	cyclin/cdks	17
17	cyclin/cdks	physically	15
18	activation	inhibits	2
19	by	inhibits	2
20	CAK	by	19
21	.	inhibits	2

0	Therefore	compared	3
1	,	compared	3
2	we	compared	3
3	compared	<ROOT>	-1
4	the	sequences	6
5	nucleotide	sequences	6
6	sequences	compared	3
7	of	sequences	6
8	the	CD11a	9
9	CD11a	of	7
10	,	compared	3
11	CD11b	compared	3
12	,	compared	3
13	and	promoters	16
14	CD11c	and	13
15	gene	promoters	16
16	promoters	compared	3
17	to	compared	3
18	identify	to	17
19	common	elements	20
20	elements	identify	18
21	that	might	22
22	might	elements	20
23	contribute	might	22
24	to	contribute	23
25	inducible	expression	26
26	expression	to	24
27	.	compared	3

0	In	can	4
1	addition	In	0
2	,	can	4
3	ALY	can	4
4	can	<ROOT>	-1
5	increase	can	4
6	DNA	binding	7
7	binding	increase	5
8	by	LEF-1	10
9	both	LEF-1	10
10	LEF-1	increase	5
11	and	LEF-1	10
12	AML	and	11
13	proteins	can	4
14	.	can	4

0	Expressions	<ROOT>	-1
1	of	Expressions	0
2	human	of	1
3	and	human	2
4	squirrel	and	3
5	monkey	squirrel	4
6	glucocorticoid	monkey	5
7	receptors	glucocorticoid	6
8	and	receptors	7
9	a	receptor	12
10	squirrel	receptor	12
11	monkey	receptor	12
12	receptor	were	23
13	in	was	16
14	which	in	13
15	Phe774	was	16
16	was	receptor	12
17	mutated	was	16
18	to	mutated	17
19	Leu	to	18
20	(	F774L	21
21	F774L	Leu	19
22	)	F774L	21
23	were	and	8
24	similar	were	23
25	.	Expressions	0

0	Our	results	1
1	results	lend	2
2	lend	<ROOT>	-1
3	further	support	4
4	support	lend	2
5	to	lend	2
6	the	hypothesis	7
7	hypothesis	to	5
8	that	hypothesis	7
9	inflammatory	may	15
10	and	inflammatory	9
11	immune	responses	12
12	responses	and	10
13	of	inflammatory	9
14	monocytes/macrophages	of	13
15	may	that	8
16	be	may	15
17	modulated	be	16
18	at	modulated	17
19	the	level	21
20	molecular	level	21
21	level	at	18
22	by	modulated	17
23	signals	by	22
24	originating	signals	23
25	from	originating	24
26	tissue	structural	27
27	structural	from	25
28	cells	such	29
29	such	as	30
30	as	lend	2
31	fibroblasts	lend	2
32	.	lend	2

0	To	was	22
1	study	To	0
2	the	influence	3
3	influence	study	1
4	of	NFkappaB	5
5	NFkappaB	influence	3
6	activity	To	0
7	on	To	0
8	apoptosis	mediated	9
9	mediated	To	0
10	by	To	0
11	TRAIL	by	10
12	,	TRAIL	11
13	CD95	TRAIL	11
14	,	CD95	13
15	TNFalpha	To	0
16	,	To	0
17	or	To	0
18	doxorubicin	or	17
19	,	NFkappaB	20
20	NFkappaB	To	0
21	activation	NFkappaB	20
22	was	<ROOT>	-1
23	inhibited	was	22
24	using	proteasome	26
25	the	proteasome	26
26	proteasome	inhibited	23
27	inhibitor	was	22
28	N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	inhibitor	27
29	or	transient	30
30	transient	inhibitor	27
31	overexpression	transient	30
32	of	overexpression	31
33	mutant	IkappaBalpha	34
34	IkappaBalpha	of	32
35	.	was	22

0	Serum	cortisol	1
1	cortisol	were	6
2	and	cortisol	1
3	urinary	cortisol	5
4	free	cortisol	5
5	cortisol	and	2
6	were	<ROOT>	-1
7	measured	were	6
8	by	measured	7
9	RIA	by	8
10	.	were	6

0	Abnormal	apoptosis	1
1	apoptosis	cycle	4
2	and	cycle	4
3	cell	cycle	4
4	cycle	<ROOT>	-1
5	progression	cycle	4
6	in	cycle	4
7	humans	exposed	8
8	exposed	in	6
9	to	exposed	8
10	methyl	ether	12
11	tertiary-butyl	ether	12
12	ether	contaminating	15
13	and	ether	12
14	benzene	and	13
15	contaminating	to	9
16	water	contaminating	15
17	.	cycle	4

0	CCAAT/enhancer	epsilon	3
1	binding	epsilon	3
2	protein	epsilon	3
3	epsilon	is	4
4	is	<ROOT>	-1
5	preferentially	is	4
6	up-regulated	is	4
7	during	granulocytic	8
8	granulocytic	differentiation	9
9	differentiation	up-regulated	6
10	and	up-regulated	6
11	its	versatility	13
12	functional	versatility	13
13	versatility	and	10
14	is	determined	15
15	determined	is	4
16	by	determined	15
17	alternative	by	16
18	use	alternative	17
19	of	use	18
20	promoters	of	19
21	and	use	18
22	differential	splicing	23
23	splicing	and	21
24	.	is	4

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	We	RESULTS	0
3	identified	We	2
4	peptides	identified	3
5	derived	peptides	4
6	from	derived	5
7	EWS/FLI-1	protein	9
8	fusion	protein	9
9	protein	from	6
10	and	from	6
11	from	mutated	12
12	mutated	and	10
13	K-RAS	protein	14
14	protein	(	15
15	(	RESULTS	0
16	encompassing	RESULTS	0
17	respectively	RESULTS	0
18	the	point	20
19	fusion	point	20
20	point	RESULTS	0
21	and	the	22
22	the	RESULTS	0
23	mutation	the	22
24	at	mutation	23
25	position	RESULTS	0
26	12	RESULTS	0
27	)	RESULTS	0
28	that	showed	29
29	showed	RESULTS	0
30	binding	motif	31
31	motif	showed	29
32	for	showed	29
33	HLA-Cw*0702	for	32
34	and	HLA-Cw*0702	33
35	HLA-A3	HLA-Cw*0702	33
36	respectively	RESULTS	0
37	.	RESULTS	0

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	the	upregulation	3
3	upregulation	,	1
4	of	NF-kappa	5
5	NF-kappa	upregulation	3
6	B	Moreover	0
7	binding	Moreover	0
8	activity	Moreover	0
9	is	activity	8
10	regulated	is	9
11	by	regulated	10
12	the	triggering	13
13	triggering	by	11
14	of	triggering	13
15	selected	epitopes	16
16	epitopes	HLA-DR	18
17	of	HLA-DR	18
18	HLA-DR	of	14
19	antigens	Moreover	0
20	.	Moreover	0

0	Moreover	was	17
1	,	TCR-induced	2
2	TCR-induced	was	17
3	phosphorylation	TCR-induced	2
4	of	phosphorylation	3
5	pp36-38	of	4
6	,	pp36-38	5
7	thought	pp36-38	5
8	to	thought	7
9	play	to	8
10	a	upstream	12
11	role	upstream	12
12	upstream	play	9
13	of	upstream	12
14	these	pathways	15
15	pathways	of	13
16	,	pp36-38	5
17	was	<ROOT>	-1
18	found	was	17
19	to	found	18
20	be	to	19
21	reduced	be	20
22	.	was	17

0	A	clone	2
1	cDNA	clone	2
2	clone	was	13
3	,	clone	2
4	CHEMR1	clone	2
5	,	clone	2
6	resembling	clone	2
7	the	receptor	11
8	typical	receptor	11
9	G	receptor	11
10	protein-coupled	receptor	11
11	receptor	resembling	6
12	,	clone	2
13	was	<ROOT>	-1
14	isolated	was	13
15	from	cytotoxic	18
16	a	cytotoxic	18
17	mouse	cytotoxic	18
18	cytotoxic	isolated	14
19	T-lymphocyte	cytotoxic	18
20	(	CTL	21
21	CTL	T-lymphocyte	19
22	)	CTL	21
23	library	T-lymphocyte	19
24	.	library	23

0	Recognition	<ROOT>	-1
1	of	simplex	3
2	herpes	simplex	3
3	simplex	Recognition	0
4	virus	type	5
5	type	tegument	7
6	2	tegument	7
7	tegument	simplex	3
8	proteins	Recognition	0
9	by	T	11
10	CD4	T	11
11	T	Recognition	0
12	cells	Recognition	0
13	infiltrating	Recognition	0
14	human	Recognition	0
15	genital	Recognition	0
16	herpes	Recognition	0
17	lesions	Recognition	0
18	.	Recognition	0

0	One	possibility	1
1	possibility	is	5
2	toward	possibility	1
3	this	goal	4
4	goal	toward	2
5	is	<ROOT>	-1
6	to	is	5
7	try	to	6
8	to	try	7
9	dissociate	main	11
10	two	main	11
11	main	to	8
12	activities	main	11
13	of	activities	12
14	glucocorticoids	to	8
15	,	glucocorticoids	14
16	i.e.	,	15
17	transactivation	i.e.	16
18	and	transactivation	17
19	transrepression	to	8
20	.	is	5

0	In	investigated	5
1	this	study	2
2	study	In	0
3	we	investigated	5
4	have	investigated	5
5	investigated	<ROOT>	-1
6	the	effect	7
7	effect	investigated	5
8	of	effect	7
9	FCM	of	8
10	on	investigated	5
11	the	on	10
12	LPS-induced	DNA-binding	13
13	DNA-binding	the	11
14	activity	the	11
15	of	activity	14
16	NF-kappaB	,	17
17	,	investigated	5
18	by	,	17
19	means	shift	22
20	of	shift	22
21	electrophoretic	of	20
22	shift	investigated	5
23	assay	investigated	5
24	(	investigated	5
25	EMSA	investigated	5
26	)	investigated	5
27	.	investigated	5

0	Several	could	3
1	neuroendocrine-immune	could	3
2	interactions	could	3
3	could	be	4
4	be	<ROOT>	-1
5	responsible	be	4
6	for	with	10
7	reduced	levels	9
8	GR	levels	9
9	levels	for	6
10	with	responsible	5
11	age	be	4
12	and	sport	13
13	sport	age	11
14	activity	be	4
15	in	activity	14
16	man	in	15
17	.	be	4

0	Activation	<ROOT>	-1
1	of	Activation	0
2	mature	B	3
3	B	of	1
4	cells	Activation	0
5	via	Activation	0
6	Ag	via	5
7	receptor	induces	9
8	cross-linking	induces	9
9	induces	transient	10
10	transient	Ag	6
11	expression	Ag	6
12	of	transcription	14
13	the	transcription	14
14	transcription	expression	11
15	factor	transcription	14
16	Egr-1	Activation	0
17	.	Activation	0

0	In	have	11
1	order	In	0
2	to	In	0
3	dissect	to	2
4	the	mechanisms	6
5	molecular	mechanisms	6
6	mechanisms	dissect	3
7	of	monocytic	8
8	monocytic	mechanisms	6
9	differentiation	In	0
10	we	have	11
11	have	<ROOT>	-1
12	developed	have	11
13	a	based	17
14	subtractive	based	17
15	hybridisation	based	17
16	method	based	17
17	based	developed	12
18	on	developed	12
19	a	on	18
20	simplified	a	19
21	'	simplified	20
22	representational	simplified	20
23	difference	representational	22
24	analysis	difference	23
25	'	analysis	24
26	.	analysis	24

0	A	clinically	1
1	clinically	dose	3
2	relevant	dose	3
3	dose	<ROOT>	-1
4	(	mM	6
5	25	mM	6
6	mM	dose	3
7	)	mM	6
8	of	dose	3
9	acute	of	8
10	ethanol	treatment	11
11	treatment	in	12
12	in	acute	9
13	vitro	in	12
14	increased	in	12
15	NF-kappa	increased	14
16	B	in	12
17	binding	B	16
18	activity	dose	3
19	in	dose	3
20	monocytes	in	19
21	with	dose	3
22	a	induction	24
23	preferential	induction	24
24	induction	with	21
25	of	induction	24
26	the	inhibitory	27
27	inhibitory	of	25
28	,	dose	3
29	p50/p50	,	30
30	,	,	28
31	NF-kappa	dose	3
32	B/Rel	dose	3
33	homodimer	B/Rel	32
34	,	homodimer	33
35	and	,	34
36	resulted	and	35
37	in	and	35
38	no	in	37
39	induction	no	38
40	of	induction	39
41	the	heterodimer	43
42	p65/p50	heterodimer	43
43	heterodimer	of	40
44	.	heterodimer	43

0	By	was	12
1	contrast	By	0
2	,	By	0
3	the	factor	7
4	monocyte-macrophage	factor	7
5	colony	factor	7
6	stimulating	factor	7
7	factor	,	2
8	(	factor	7
9	M-CSF	factor	7
10	)	receptor	11
11	receptor	By	0
12	was	<ROOT>	-1
13	largely	was	12
14	absent	was	12
15	at	absent	14
16	this	stage	17
17	stage	at	15
18	and	was	12
19	in	and	18
20	the	subsets	22
21	CD34+Thy-1-CD45RA-	subsets	22
22	subsets	in	19
23	.	was	12

0	ATRA	<ROOT>	-1
1	also	induced	2
2	induced	ATRA	0
3	expression	ATRA	0
4	of	expression	3
5	C/EBP	protein	7
6	epsilon	protein	7
7	protein	of	4
8	in	of	4
9	NB4	in	8
10	cells	ATRA	0
11	,	ATRA	0
12	as	ATRA	0
13	shown	as	12
14	by	shown	13
15	Western	blotting	16
16	blotting	by	14
17	.	ATRA	0

0	Recent	<ROOT>	-1
1	work	has	5
2	from	work	1
3	several	laboratories	4
4	laboratories	from	2
5	has	Recent	0
6	demonstrated	has	5
7	that	demonstrated	6
8	Rel/NF-kappa	B	9
9	B	regulate	12
10	transcription	B	9
11	factors	regulate	12
12	regulate	that	7
13	apoptosis	Recent	0
14	in	Recent	0
15	many	types	17
16	cell	types	17
17	types	in	14
18	.	Recent	0

0	Based	propose	8
1	upon	Based	0
2	work	upon	1
3	from	work	2
4	our	laboratory	5
5	laboratory	from	3
6	,	propose	8
7	we	propose	8
8	propose	<ROOT>	-1
9	that	propose	8
10	inhibition	of	11
11	of	produces	15
12	NF-kappa	B	13
13	B	produces	15
14	activation	B	13
15	produces	that	9
16	significant	anti	17
17	anti	produces	15
18	inflammatory	anti	17
19	activity	which	20
20	which	be	22
21	may	be	22
22	be	propose	8
23	mediated	be	22
24	by	mediated	23
25	the	inhibition	26
26	inhibition	by	24
27	of	inhibition	26
28	transcription	of	27
29	of	inhibition	26
30	certain	mediators	32
31	pro-inflammatory	mediators	32
32	mediators	of	29
33	and	adhesion	34
34	adhesion	inhibition	26
35	molecules	propose	8
36	.	propose	8

0	The	expression	1
1	expression	class	9
2	of	class	9
3	major	class	9
4	histocompatibility	complex	5
5	complex	(	6
6	(	class	9
7	MHC	class	9
8	)	class	9
9	class	is	12
10	II	antigens	11
11	antigens	class	9
12	is	be	25
13	constitutive	is	12
14	in	constitutive	13
15	professional	in	14
16	antigen	(	19
17	presenting	(	19
18	cells	(	19
19	(	professional	15
20	APCs	in	14
21	)	is	12
22	but	also	24
23	can	but	22
24	also	be	25
25	be	<ROOT>	-1
26	induced	be	25
27	by	induced	26
28	interferon-gamma	by	27
29	(	be	25
30	IFN-gamma	be	25
31	)	be	25
32	on	be	25
33	the	majority	34
34	majority	on	32
35	of	majority	34
36	the	APCs	39
37	non	APCs	39
38	professional	APCs	39
39	APCs	of	35
40	(	fibroblasts	42
41	e.g.	fibroblasts	42
42	fibroblasts	APCs	39
43	)	fibroblasts	42
44	.	be	25

0	Normal	specimens	2
1	artery	specimens	2
2	specimens	reveal	8
3	(	=	5
4	n	=	5
5	=	specimens	2
6	6	=	5
7	)	=	5
8	reveal	<ROOT>	-1
9	minimal	PPARgamma	11
10	immunoreactive	PPARgamma	11
11	PPARgamma	reveal	8
12	.	reveal	8

0	Gene	experiments	2
1	targeting	experiments	2
2	experiments	revealed	6
3	in	experiments	2
4	the	mouse	5
5	mouse	in	3
6	revealed	<ROOT>	-1
7	a	dependency	9
8	differential	dependency	9
9	dependency	revealed	6
10	of	dependency	9
11	fetal	of	10
12	and	of	10
13	adult	B-lymphopoiesis	14
14	B-lymphopoiesis	and	12
15	on	transcription	17
16	this	transcription	17
17	transcription	revealed	6
18	factor	revealed	6
19	.	revealed	6

0	The	<ROOT>	-1
1	ZEBRA	The	0
2	protein	ZEBRA	1
3	from	protein	2
4	Epstein-Barr	virus	5
5	virus	from	3
6	(	EBV	7
7	EBV	virus	5
8	)	EBV	7
9	activates	EBV	7
10	a	activates	9
11	switch	activates	9
12	from	the	13
13	the	switch	11
14	latent	the	13
15	to	the	16
16	the	latent	14
17	lytic	activates	9
18	expression	EBV	7
19	program	EBV	7
20	of	program	19
21	the	virus	22
22	virus	of	20
23	.	The	0

0	NF-kappa	B	1
1	B	is	2
2	is	<ROOT>	-1
3	an	factor	6
4	important	factor	6
5	transcription	factor	6
6	factor	is	2
7	required	cell	10
8	for	cell	10
9	T	cell	10
10	cell	factor	6
11	proliferation	is	2
12	and	is	2
13	other	functions	15
14	immunological	functions	15
15	functions	and	12
16	.	is	2

0	Binding	is	13
1	of	Binding	0
2	the	factor	4
3	nuclear	factor	4
4	factor	of	1
5	to	Binding	0
6	the	element	8
7	GAS	element	8
8	element	to	5
9	in	Binding	0
10	the	LTR	12
11	CAEV	LTR	12
12	LTR	in	9
13	is	<ROOT>	-1
14	inhibited	by	15
15	by	is	13
16	antibody	directed	17
17	directed	by	15
18	against	directed	17
19	STAT1	(	20
20	(	against	18
21	p91/84	(	20
22	)	is	13
23	.	is	13

0	The	promoter	3
1	human	promoter	3
2	TF	promoter	3
3	promoter	contains	4
4	contains	<ROOT>	-1
5	binding	sites	6
6	sites	contains	4
7	for	sites	6
8	the	factors	10
9	transcription	factors	10
10	factors	for	7
11	AP-1	for	7
12	,	contains	4
13	c-Rel/p65	contains	4
14	,	contains	4
15	Egr-1	contains	4
16	,	contains	4
17	and	contains	4
18	Sp1	and	17
19	.	contains	4

0	The	Wilms	1
1	Wilms	gene	5
2	'	Wilms	1
3	tumor	gene	5
4	suppressor	gene	5
5	gene	was	9
6	(	WT1	7
7	WT1	gene	5
8	)	WT1	7
9	was	<ROOT>	-1
10	previously	was	9
11	identified	was	9
12	as	identified	11
13	being	as	12
14	imprinted	being	13
15	,	was	9
16	with	was	9
17	frequent	expression	19
18	maternal	expression	19
19	expression	with	16
20	in	with	16
21	human	placentae	22
22	placentae	in	20
23	and	was	9
24	fetal	and	23
25	brains	and	23
26	.	was	9

0	Although	differs	16
1	corticosteroids	are	2
2	are	Although	0
3	the	agents	7
4	most	potent	5
5	potent	agents	7
6	therapeutic	agents	7
7	agents	are	2
8	used	agents	7
9	for	used	8
10	this	disease	11
11	disease	for	9
12	,	differs	16
13	their	effect	15
14	anti-inflammatory	effect	15
15	effect	differs	16
16	differs	<ROOT>	-1
17	from	differs	16
18	patient	from	17
19	to	patient	18
20	patient	to	19
21	.	patient	20

0	One	<ROOT>	-1
1	of	One	0
2	these	subregions	3
3	subregions	of	1
4	,	One	0
5	NRE	gamma	6
6	gamma	is	8
7	,	is	8
8	is	One	0
9	active	is	8
10	in	carcinoma	14
11	both	carcinoma	14
12	HeLa	cervical	13
13	cervical	carcinoma	14
14	carcinoma	is	8
15	cells	and	16
16	and	One	0
17	Huh7	One	0
18	hepatoma	One	0
19	cells	One	0
20	and	One	0
21	was	and	20
22	found	was	21
23	to	found	22
24	be	to	23
25	bound	be	24
26	by	bound	25
27	a	factor	29
28	protein	factor	29
29	factor	by	26
30	present	in	31
31	in	types	34
32	both	types	34
33	cell	types	34
34	types	factor	29
35	.	One	0

0	Induction	<ROOT>	-1
1	of	Induction	0
2	interleukin-12	of	1
3	p40	transcript	4
4	transcript	of	1
5	by	CD40	6
6	CD40	transcript	4
7	ligation	of	1
8	via	ligation	7
9	activation	of	10
10	of	Induction	0
11	nuclear	factor-kappaB	12
12	factor-kappaB	of	10
13	.	factor-kappaB	12

0	Virus	production	1
1	production	occurred	2
2	occurred	<ROOT>	-1
3	with	delayed	5
4	slightly	delayed	5
5	delayed	occurred	2
6	kinetics	for	7
7	for	occurred	2
8	viruses	for	7
9	containing	combined	10
10	combined	occurred	2
11	mutations	occurred	2
12	in	mutations	11
13	the	AP-1-LRB-III-RRB-	14
14	AP-1-LRB-III-RRB-	in	12
15	,	occurred	2
16	AP3-L	occurred	2
17	,	occurred	2
18	and	occurred	2
19	DBF	exhibited	47
20	sites	DBF	19
21	and	sites	20
22	in	and	21
23	the	AP3-L	24
24	AP3-L	in	22
25	and	AP3-L	24
26	DBF-sites	and	25
27	,	DBF	19
28	whereas	viruses	29
29	viruses	DBF	19
30	mutated	DBF	19
31	in	DBF	19
32	the	AP-1-LRB-I,II,III-RRB-	33
33	AP-1-LRB-I,II,III-RRB-	in	31
34	and	AP-1-LRB-I,II,III-RRB-	33
35	AP3-L	sites	36
36	sites	and	34
37	and	DBF	19
38	in	and	37
39	the	AP-1-LRB-I,II,III-RRB-	40
40	AP-1-LRB-I,II,III-RRB-	in	38
41	,	DBF	19
42	AP3-L	DBF	19
43	,	DBF	19
44	and	DBF	19
45	DBF	sites	46
46	sites	and	44
47	exhibited	and	18
48	a	exhibited	47
49	severely	defective	50
50	defective	a	48
51	replicative	.	53
52	phenotype	.	53
53	.	defective	50

0	A-myb	is	1
1	is	<ROOT>	-1
2	strongly	is	1
3	expressed	is	1
4	in	Burkitt	5
5	Burkitt	(	8
6	's	Burkitt	5
7	lymphomas	(	8
8	(	expressed	3
9	BL	is	1
10	)	is	1
11	and	is	1
12	slg+	is	1
13	B-acute	is	1
14	lymphoblastic	B-acute	13
15	leukaemias	lymphoblastic	14
16	(	B-ALL	17
17	B-ALL	leukaemias	15
18	)	B-ALL	17
19	and	leukaemias	15
20	not	in	21
21	in	and	19
22	all	in	21
23	other	all	22
24	leukaemias/lymphomas	other	23
25	tested	leukaemias/lymphomas	24
26	,	tested	25
27	with	the	28
28	the	tested	25
29	exception	the	28
30	of	exception	29
31	a	subset	32
32	subset	of	30
33	of	subset	32
34	CLL	of	33
35	(	subset	32
36	about	%	38
37	25	about	36
38	%	exception	29
39	of	%	38
40	cases	of	39
41	)	cases	40
42	.	is	1

0	Dibutyryl	cAMP	1
1	cAMP	increased	3
2	also	increased	3
3	increased	<ROOT>	-1
4	c-fos	mRNA	5
5	mRNA	increased	3
6	and	increased	3
7	protein	and	6
8	,	increased	3
9	and	increased	3
10	levels	remained	11
11	remained	elevated	12
12	elevated	and	9
13	even	12	15
14	after	12	15
15	12	elevated	12
16	hr	12	15
17	of	hr	16
18	treatment	increased	3
19	.	increased	3

0	Thymocytes	expressed	1
1	expressed	<ROOT>	-1
2	four-	expressed	1
3	to	four-	2
4	10-fold	to	3
5	greater	10-fold	4
6	amounts	greater	5
7	of	amounts	6
8	the	of	7
9	3.5	than	12
10	kb	than	12
11	transcript	than	12
12	than	other	13
13	other	the	8
14	tissues	expressed	1
15	.	expressed	1

0	Constitutive	expression	1
1	expression	isolated	7
2	of	expression	1
3	p50	homodimer	4
4	homodimer	of	2
5	in	of	2
6	freshly	expression	1
7	isolated	<ROOT>	-1
8	human	isolated	7
9	monocytes	decreases	10
10	decreases	isolated	7
11	with	decreases	10
12	in	decreases	10
13	vitro	in	12
14	and	isolated	7
15	in	isolated	7
16	vivo	isolated	7
17	differentiation	isolated	7
18	:	isolated	7
19	a	:	18
20	possible	mechanism	21
21	mechanism	a	19
22	influencing	mechanism	21
23	human	influencing	22
24	immunodeficiency	virus	25
25	virus	human	23
26	replication	virus	25
27	in	and	29
28	monocytes	and	29
29	and	replication	26
30	mature	a	19
31	macrophages	isolated	7
32	.	isolated	7

0	Histamine	modulates	1
1	modulates	<ROOT>	-1
2	the	expression	3
3	expression	modulates	1
4	of	expression	3
5	c-fos	of	4
6	through	AMP	8
7	cyclic	AMP	8
8	AMP	modulates	1
9	production	modulates	1
10	via	production	9
11	the	receptor	13
12	H2	receptor	13
13	receptor	via	10
14	in	receptor	13
15	the	U937	20
16	human	U937	20
17	promonocytic	U937	20
18	cell	U937	20
19	line	U937	20
20	U937	in	14
21	.	modulates	1

0	However	did	3
1	,	did	3
2	NF-YB	did	3
3	did	<ROOT>	-1
4	interact	did	3
5	with	interact	4
6	the	mutants	9
7	C-terminal	mutants	9
8	Tax1	mutants	9
9	mutants	with	5
10	M22	with	5
11	(	130TL-AS	12
12	130TL-AS	M22	10
13	)	130TL-AS	12
14	and	M22	10
15	M47	and	14
16	(	319LL-RS	17
17	319LL-RS	M47	15
18	)	319LL-RS	17
19	.	did	3

0	No	<ROOT>	-1
1	statistically	significant	2
2	significant	was	4
3	correlation	was	4
4	was	No	0
5	found	was	4
6	between	found	5
7	c-Jun-	between	6
8	and	c-Jun-	7
9	GST-pi-positive	cells	11
10	plasma	cells	11
11	cells	and	8
12	.	cells	11

0	Thus	conclude	3
1	,	conclude	3
2	we	conclude	3
3	conclude	transcription	16
4	that	conclude	3
5	the	XP-B	6
6	XP-B	that	4
7	and	lymphoblastoid	9
8	XP-D	lymphoblastoid	9
9	lymphoblastoid	XP-B	6
10	cells	conclude	3
11	do	conclude	3
12	not	conclude	3
13	have	transcription	16
14	impaired	RNA	15
15	RNA	transcription	16
16	transcription	<ROOT>	-1
17	activity	transcription	16
18	.	transcription	16

0	In	was	13
1	mobility	In	0
2	shift	mobility	1
3	assays	In	0
4	,	In	0
5	a	factor	7
6	nuclear	factor	7
7	factor	,	4
8	from	factor	7
9	THP-1	from	8
10	and	U-937	11
11	U-937	factor	7
12	cells	In	0
13	was	binding	40
14	identified	was	13
15	that	binds	16
16	binds	identified	14
17	to	binds	16
18	several	elements	21
19	AP-2	elements	21
20	response	elements	21
21	elements	to	17
22	within	binds	16
23	the	promoter	25
24	B2	promoter	25
25	promoter	within	22
26	,	binds	16
27	but	binds	16
28	does	but	27
29	not	does	28
30	react	does	28
31	with	react	30
32	AP-2	antibodies	33
33	antibodies	with	31
34	,	was	13
35	and	sequence	39
36	has	sequence	39
37	a	sequence	39
38	DNA	sequence	39
39	sequence	was	13
40	binding	<ROOT>	-1
41	affinity	binding	40
42	profile	that	43
43	that	binding	40
44	differs	that	43
45	from	differs	44
46	AP-2	binding	40
47	.	binding	40

0	These	regulators	2
1	transcriptional	regulators	2
2	regulators	trigger	5
3	in	regulators	2
4	turn	in	3
5	trigger	<ROOT>	-1
6	a	cascade	7
7	cascade	trigger	5
8	of	cascade	7
9	genetic	changes	10
10	changes	of	8
11	that	determine	13
12	ultimately	determine	13
13	determine	changes	10
14	the	course	15
15	course	determine	13
16	of	course	15
17	the	of	16
18	cells	the	17
19	during	cells	18
20	differentiation	during	19
21	.	trigger	5

0	In	has	7
1	the	years	4
2	past	years	4
3	few	years	4
4	years	In	0
5	,	has	7
6	there	has	7
7	has	<ROOT>	-1
8	been	has	7
9	some	progress	10
10	progress	been	8
11	in	progress	10
12	defining	in	11
13	the	kinases	15
14	tyrosine	kinases	15
15	kinases	defining	12
16	that	are	17
17	are	kinases	15
18	activated	are	17
19	by	activated	18
20	the	receptor	22
21	IL-3/IL-5/GM-CSF	receptor	22
22	receptor	by	19
23	beta-subunit	receptor	22
24	in	activated	18
25	eosinophils	in	24
26	.	has	7

0	The	regulation	1
1	regulation	<ROOT>	-1
2	of	NF-kappa	3
3	NF-kappa	regulation	1
4	B	regulation	1
5	activation	regulation	1
6	following	regulation	1
7	the	triggering	8
8	triggering	HLA-DR	10
9	of	HLA-DR	10
10	HLA-DR	has	15
11	antigens	HLA-DR	10
12	by	HLA-DR	10
13	mAb	L243	14
14	L243	by	12
15	has	following	6
16	been	has	15
17	studied	been	16
18	at	studied	17
19	various	times	20
20	times	cells	23
21	in	times	20
22	Raji	cells	23
23	cells	at	18
24	.	cells	23

0	Expression	<ROOT>	-1
1	of	Expression	0
2	transcription	factors	3
3	factors	of	1
4	during	Expression	0
5	sodium	phenylacetate	6
6	phenylacetate	induced	7
7	induced	during	4
8	erythroid	differentiation	9
9	differentiation	induced	7
10	in	K562	11
11	K562	induced	7
12	cells	Expression	0
13	.	Expression	0

0	We	show	2
1	now	show	2
2	show	<ROOT>	-1
3	that	differential	5
4	this	differential	5
5	differential	show	2
6	rescue	differential	5
7	by	specific	8
8	specific	differential	5
9	cytokines	show	2
10	in	cytokines	9
11	Th	in	10
12	cells	Th	11
13	correlates	show	2
14	with	show	2
15	the	level	16
16	level	with	14
17	of	level	16
18	IkappaBalpha	of	17
19	that	is	20
20	is	level	16
21	regulated	is	20
22	by	regulated	21
23	DEX	regulated	21
24	and	DEX	23
25	cytokines	DEX	23
26	.	show	2

0	The	effect	1
1	effect	posttranslational	5
2	of	posttranslational	5
3	the	pRB	4
4	pRB	posttranslational	5
5	posttranslational	was	9
6	modification	posttranslational	5
7	during	posttranslational	5
8	apoptosis	during	7
9	was	<ROOT>	-1
10	investigated	was	9
11	by	investigated	10
12	determining	by	11
13	the	levels	15
14	E2F-1	levels	15
15	levels	determining	12
16	and	determining	12
17	by	determining	12
18	isolating	by	17
19	and	isolating	18
20	characterizing	clones	22
21	pRB-null	clones	22
22	clones	and	19
23	from	U937	24
24	U937	determining	12
25	cells	was	9
26	.	was	9

0	A	<ROOT>	-1
1	small	A	0
2	,	see	9
3	nonpeptidyl	see	9
4	mimic	nonpeptidyl	3
5	of	factor	7
6	granulocyte-colony-stimulating	factor	7
7	factor	mimic	4
8	[	factor	7
9	see	small	1
10	commetns	small	1
11	]	commetns	10

0	In	were	5
1	humans	In	0
2	,	were	5
3	similar	effects	4
4	effects	were	5
5	were	<ROOT>	-1
6	observed	with	7
7	with	were	5
8	homologous	with	7
9	members	homologous	8
10	of	(	14
11	the	protein	13
12	CCAAT/enhancer-binding	protein	13
13	protein	of	10
14	(	members	9
15	C/EBP	(	14
16	)	members	9
17	family	members	9
18	of	transcriptional	19
19	transcriptional	family	17
20	regulators	were	5
21	,	human	24
22	especially	human	24
23	the	human	24
24	human	were	5
25	homolog	human	24
26	of	chicken	27
27	chicken	homolog	25
28	NF-M	were	5
29	,	were	5
30	C/EBP-beta	were	5
31	(	NF-IL6	32
32	NF-IL6	C/EBP-beta	30
33	)	NF-IL6	32
34	.	were	5

0	These	<ROOT>	-1
1	data	These	0
2	suggest	data	1
3	that	suggest	2
4	a	number	6
5	small	number	6
6	number	that	3
7	of	progenitor	11
8	GATA-1.05	progenitor	11
9	mutant	progenitor	11
10	hematopoietic	progenitor	11
11	progenitor	number	6
12	cells	begin	13
13	begin	These	0
14	to	proliferate	15
15	proliferate	begin	13
16	vigorously	during	17
17	during	These	0
18	early	adulthood	19
19	adulthood	during	17
20	,	These	0
21	but	These	0
22	because	the	23
23	the	but	21
24	cells	These	0
25	are	These	0
26	unable	are	25
27	to	unable	26
28	terminally	this	31
29	differentiate	terminally	28
30	,	terminally	28
31	this	to	27
32	leads	this	31
33	to	progenitor	34
34	progenitor	leads	32
35	proliferation	the	37
36	in	the	37
37	the	progenitor	34
38	spleen	progenitor	34
39	and	consequently	40
40	consequently	spleen	38
41	death	These	0
42	.	These	0

0	AP-1	derived	1
1	derived	21	14
2	from	mature	3
3	mature	derived	1
4	monocytes	derived	1
5	and	monocytes	4
6	astrocytes	derived	1
7	preferentially	interacts	8
8	interacts	derived	1
9	with	interacts	8
10	the	promoter	12
11	HTLV-I	promoter	12
12	promoter	with	9
13	central	derived	1
14	21	<ROOT>	-1
15	bp	repeat	16
16	repeat	21	14
17	.	21	14

0	To	(	22
1	explore	To	0
2	the	modifications	3
3	modifications	of	4
4	of	explore	1
5	not	of	4
6	reproductive	target	7
7	target	of	4
8	tissues	target	7
9	as	explore	1
10	ovulation	markers	11
11	markers	as	9
12	we	markers	11
13	studied	markers	11
14	the	behaviour	15
15	behaviour	studied	13
16	of	behaviour	15
17	Albuminemia	of	16
18	,	Albuminemia	17
19	Platelet	Albuminemia	17
20	Factor	markers	11
21	IV	(	22
22	(	<ROOT>	-1
23	as	(	22
24	indicator	)	28
25	of	indicator	24
26	Platelet	Aggregation	27
27	Aggregation	of	25
28	)	as	23
29	,	Type	30
30	Type	)	28
31	II	(	22
32	estrogenic	(	22
33	receptors	(	22
34	in	(	22
35	42	ovulation	36
36	ovulation	induced	37
37	induced	in	34
38	women	induced	37
39	,	undergoing	40
40	undergoing	in	34
41	our	observation	42
42	observation	undergoing	40
43	.	(	22

0	Although	<ROOT>	-1
1	experimental	evidence	2
2	evidence	is	3
3	is	Although	0
4	lacking	is	3
5	,	Although	0
6	lytic	replication	9
7	viral	replication	9
8	DNA	replication	9
9	replication	,	5
10	is	Although	0
11	believed	is	10
12	to	believed	11
13	remove	to	12
14	modifications	or	15
15	or	remove	13
16	binding	or	15
17	factors	Although	0
18	from	the	19
19	the	factors	17
20	genome	the	19
21	which	serve	22
22	serve	the	19
23	to	serve	22
24	repress	to	23
25	late	expression	27
26	gene	expression	27
27	expression	repress	24
28	during	repress	24
29	latency	during	28
30	or	during	28
31	the	or	30
32	early	the	31
33	lytic	.	35
34	cycle	.	35
35	.	early	32

0	RFX5	<ROOT>	-1
1	and	RFX5	0
2	CIITA	and	1
3	associate	RFX5	0
4	to	associate	3
5	form	to	4
6	a	capable	8
7	complex	capable	8
8	capable	form	5
9	of	capable	8
10	activating	transcription	11
11	transcription	of	9
12	from	promoters	18
13	class	from	12
14	II	promoters	18
15	major	promoters	18
16	histocompatibility	promoters	18
17	complex	promoters	18
18	promoters	capable	8
19	.	RFX5	0

0	Although	is	17
1	NF-kappa	B	2
2	B	activates	3
3	activates	Although	0
4	the	expression	5
5	expression	activates	3
6	of	expression	5
7	many	genes	8
8	genes	of	6
9	involved	Although	0
10	in	Although	0
11	immune	in	10
12	and	immune	11
13	inflammatory	and	12
14	responses	Although	0
15	,	is	17
16	little	is	17
17	is	<ROOT>	-1
18	known	is	17
19	about	known	18
20	the	about	19
21	role	of	22
22	of	the	20
23	NF-kappa	B	24
24	B	of	22
25	activation	B	24
26	in	the	27
27	the	of	22
28	induction	IgE	30
29	of	IgE	30
30	IgE	the	27
31	synthesis	is	17
32	in	B	34
33	human	B	34
34	B	synthesis	31
35	cells	is	17
36	.	is	17

0	Whereas	T	1
1	T	<ROOT>	-1
2	cells	from	3
3	from	T	1
4	young	T	1
5	subjects	T	1
6	stimulated	T	1
7	with	stimulated	6
8	cross-linked	markedly	37
9	anti-CD3epsilon	cross-linked	8
10	mAb	anti-CD3epsilon	9
11	OKT3	mAb	10
12	plus	OKT3	11
13	PMA	plus	12
14	or	demonstrated	21
15	with	or	14
16	the	with	15
17	lectin	PMA	20
18	PHA	PMA	20
19	plus	PMA	20
20	PMA	demonstrated	21
21	demonstrated	plus	12
22	considerable	demonstrated	21
23	increases	considerable	22
24	in	increases	23
25	c-Fos	in	24
26	protein	c-Fos	25
27	expression	was	36
28	,	was	36
29	the	expression	30
30	expression	was	36
31	of	expression	30
32	c-Fos	c-Jun	35
33	but	not	34
34	not	c-Jun	35
35	c-Jun	of	31
36	was	OKT3	11
37	markedly	with	7
38	reduced	markedly	37
39	in	reduced	38
40	stimulated	T	41
41	T	in	39
42	cells	in	39
43	from	certain	44
44	certain	cells	42
45	elderly	certain	44
46	subjects	.	47
47	.	elderly	45

0	We	suggest	1
1	suggest	<ROOT>	-1
2	that	suggest	1
3	the	specific	6
4	T	cell-	5
5	cell-	specific	6
6	specific	is	12
7	expression	specific	6
8	of	expression	7
9	the	gene	11
10	IL-3	gene	11
11	gene	of	8
12	is	that	2
13	partly	is	12
14	controlled	is	12
15	through	the	16
16	the	is	12
17	enhancer	suggest	1
18	by	enhancer	17
19	cooperation	by	18
20	between	cooperation	19
21	Oct	between	20
22	and	family	24
23	NFAT	family	24
24	family	Oct	21
25	proteins	suggest	1
26	.	suggest	1

0	The	MPO	8
1	highly	specific	2
2	specific	granulomonocyte-associated	3
3	granulomonocyte-associated	lysosomal	4
4	lysosomal	The	0
5	proteins	myeloperoxidase	6
6	myeloperoxidase	The	0
7	(	myeloperoxidase	6
8	MPO	<ROOT>	-1
9	)	MPO	8
10	and	MPO	8
11	lysozyme	MPO	8
12	(	LZ	13
13	LZ	lysozyme	11
14	)	LZ	13
15	,	MPO	8
16	as	MPO	8
17	well	MPO	8
18	as	MPO	8
19	the	as	18
20	transcription	the	19
21	factor	PU.1	22
22	PU.1	transcription	20
23	,	PU.1	22
24	were	MPO	8
25	already	detectable	26
26	detectable	MPO	8
27	in	detectable	26
28	the	subset	32
29	most	immature	30
30	immature	subset	32
31	CD34+Thy-1+	subset	32
32	subset	in	27
33	.	MPO	8

0	Murine	<ROOT>	-1
1	and	Murine	0
2	human	and	1
3	MZF-2	proteins	4
4	proteins	human	2
5	consisted	proteins	4
6	of	consisted	5
7	814	consisted	5
8	and	814	7
9	775	amino	10
10	amino	and	8
11	acids	amino	10
12	,	Murine	0
13	respectively	Murine	0
14	,	Murine	0
15	and	Murine	0
16	have	and	15
17	identity	have	16
18	of	identity	17
19	75.3	%	20
20	%	of	18
21	between	identity	17
22	them	between	21
23	.	them	22

0	Here	show	2
1	we	show	2
2	show	<ROOT>	-1
3	that	show	2
4	the	factor	6
5	transcription	factor	6
6	factor	that	3
7	RFX1	factor	6
8	can	bind	9
9	bind	RFX1	7
10	to	NRE	11
11	NRE	bind	9
12	gamma	and	13
13	and	NRE	11
14	transactivate	NRE	11
15	the	transactivate	14
16	core	through	18
17	promoter	through	18
18	through	the	15
19	this	site	20
20	site	the	15
21	.	show	2

0	Since	demonstrated	18
1	these	compounds	3
2	latter	compounds	3
3	compounds	were	4
4	were	Since	0
5	known	were	4
6	to	known	5
7	activate	to	6
8	NF-kappa	B	9
9	B	activate	7
10	translocation	in	11
11	in	Since	0
12	a	way	14
13	redox-sensitive	way	14
14	way	in	11
15	,	demonstrated	18
16	we	demonstrated	18
17	have	demonstrated	18
18	demonstrated	was	25
19	that	B	21
20	NF-kappa	B	21
21	B	demonstrated	18
22	activation	B	21
23	by	PMA	24
24	PMA	B	21
25	was	<ROOT>	-1
26	resistant	was	25
27	to	resistant	26
28	antioxidant	(	30
29	N-acetyl-L-cysteine	(	30
30	(	to	27
31	NAC	(	30
32	)	(	30
33	and	was	25
34	sensitive	was	25
35	to	kinase	36
36	kinase	sensitive	34
37	inhibitors	staurosporine	38
38	staurosporine	kinase	36
39	and	staurosporine	38
40	H7	and	39
41	while	kinase	36
42	activation	was	25
43	by	was	25
44	H2O2	was	25
45	or	H2O2	44
46	TNF-alpha	was	25
47	were	TNF-alpha	46
48	not	TNF-alpha	46
49	.	was	25

0	Chloramphenicol	acetyltransferase	1
1	acetyltransferase	expression	2
2	expression	constructs	3
3	constructs	containing	4
4	containing	were	11
5	regions	containing	4
6	of	regions	5
7	the	promoter	10
8	human	promoter	10
9	collagenase-1	promoter	10
10	promoter	of	6
11	were	was	23
12	stably	were	11
13	or	stably	12
14	transiently	or	13
15	transfected	transiently	14
16	into	were	11
17	U937	,	19
18	cells	,	19
19	,	into	16
20	and	were	11
21	reporter	were	11
22	activity	was	23
23	was	<ROOT>	-1
24	assessed	was	23
25	at	assessed	24
26	various	at	25
27	times	after	28
28	after	the	29
29	the	various	26
30	onset	the	29
31	of	onset	30
32	phorbol	12-myristate	33
33	12-myristate	of	31
34	13-acetate	(	35
35	(	12-myristate	33
36	PMA	(	35
37	)	12-myristate	33
38	-mediated	the	29
39	differentiation	the	29
40	.	was	23

0	To	<ROOT>	-1
1	understand	To	0
2	the	understand	1
3	molecular	the	2
4	mechanisms	controlling	5
5	controlling	molecular	3
6	CD19	expression	8
7	gene	expression	8
8	expression	the	2
9	,	To	0
10	we	,	9
11	isolated	we	10
12	and	functionally	13
13	functionally	isolated	11
14	characterized	functionally	13
15	the	CD19	16
16	CD19	characterized	14
17	promoter	isolated	11
18	using	promoter	17
19	in	using	18
20	vivo	in	19
21	footprinting	vivo	20
22	,	footprinting	21
23	gel	shift	24
24	shift	footprinting	21
25	assays	in	19
26	,	To	0
27	and	To	0
28	transfection	To	0
29	studies	To	0
30	.	To	0

0	When	challenged	1
1	challenged	<ROOT>	-1
2	with	challenged	1
3	an	stimulus	5
4	activating	stimulus	5
5	stimulus	with	2
6	such	as	7
7	as	stimulus	5
8	alpha-CD3	as	7
9	or	alpha-CD3	8
10	a	combination	11
11	combination	or	9
12	of	phorbol	13
13	phorbol	combination	11
14	ester	phorbol	13
15	plus	phorbol	13
16	ionophore	plus	15
17	,	challenged	1
18	the	,	17
19	cells	are	20
20	are	the	18
21	severely	are	20
22	compromised	severely	21
23	in	compromised	22
24	their	ability	25
25	ability	in	23
26	to	ability	25
27	produce	to	26
28	the	produce	27
29	cytokine	interleukin-2	30
30	interleukin-2	the	28
31	(	interleukin-2	30
32	IL-2	interleukin-2	30
33	)	interleukin-2	30
34	.	challenged	1

0	These	observations	1
1	observations	imply	2
2	imply	<ROOT>	-1
3	a	function	4
4	function	imply	2
5	for	function	4
6	Trident	for	5
7	in	imply	2
8	dividing	lymphocytes	9
9	lymphocytes	imply	2
10	.	imply	2

0	Notably	<ROOT>	-1
1	,	Notably	0
2	the	lack	3
3	lack	,	1
4	of	lack	3
5	pRB	of	4
6	in	lack	3
7	these	clones	9
8	U937-derived	clones	9
9	clones	in	6
10	renders	these	11
11	these	lack	3
12	p53-null	these	11
13	cells	resistant	15
14	highly	resistant	15
15	resistant	p53-null	12
16	to	Notably	0
17	apoptosis	induced	18
18	induced	to	16
19	by	serum	20
20	serum	induced	18
21	withdrawal	serum	20
22	,	serum	20
23	calphostin	Notably	0
24	C	Notably	0
25	,	Notably	0
26	and	Notably	0
27	ceramide	and	26
28	.	Notably	0

0	The	presence	1
1	presence	protein	4
2	of	protein	4
3	this	protein	4
4	protein	<ROOT>	-1
5	results	protein	4
6	in	results	5
7	a	in	6
8	markedly	thymic	10
9	reduced	thymic	10
10	thymic	a	7
11	cellularity	thymic	10
12	,	protein	4
13	although	protein	4
14	the	distribution	15
15	distribution	although	13
16	of	distribution	15
17	the	of	16
18	remaining	is	20
19	cells	is	20
20	is	the	17
21	normal	is	20
22	based	is	20
23	on	based	22
24	evaluation	on	23
25	of	the	26
26	the	evaluation	24
27	CD4	the	26
28	and	cell	30
29	CD8	cell	30
30	cell	CD4	27
31	surface	cell	30
32	antigens	that	33
33	that	the	26
34	are	that	33
35	used	are	34
36	to	used	35
37	gauge	cell	39
38	T	cell	39
39	cell	to	36
40	development	to	36
41	.	protein	4

0	In	kappa	4
1	contrast	In	0
2	,	kappa	4
3	I	kappa	4
4	kappa	were	21
5	B-alpha	kappa	4
6	levels	B-alpha	5
7	in	levels	6
8	PBMC	in	7
9	and	in	7
10	monocytes	subjects	13
11	from	healthy	12
12	healthy	subjects	13
13	subjects	kappa	4
14	or	subjects	13
15	from	kappa	4
16	patients	kappa	4
17	with	kappa	4
18	nontuberculous	kappa	4
19	pulmonary	kappa	4
20	conditions	kappa	4
21	were	<ROOT>	-1
22	intact	were	21
23	.	were	21

0	The	hierarchy	2
1	transcriptional	hierarchy	2
2	hierarchy	suggests	5
3	of	hierarchy	2
4	HNFs	of	3
5	suggests	<ROOT>	-1
6	that	suggests	5
7	other	proteins	8
8	proteins	might	13
9	of	proteins	8
10	the	cascade	12
11	regulatory	cascade	12
12	cascade	of	9
13	might	that	6
14	be	might	13
15	responsible	be	14
16	for	responsible	15
17	other	forms	18
18	forms	for	16
19	of	forms	18
20	MODY	late-onset	22
21	and/or	MODY	20
22	late-onset	type	23
23	type	of	19
24	2	diabetes	25
25	diabetes	type	23
26	.	diabetes	25

0	Peripheral	mononuclear	2
1	blood	mononuclear	2
2	mononuclear	were	14
3	cells	mononuclear	2
4	(	mononuclear	2
5	pbmc	mononuclear	2
6	)	mononuclear	2
7	and	mononuclear	2
8	bone	cells	10
9	marrow	cells	10
10	cells	and	7
11	of	mononuclear	2
12	26	mononuclear	2
13	patients	mononuclear	2
14	were	<ROOT>	-1
15	examined	were	14
16	for	examined	15
17	c-fos	for	16
18	,	for	16
19	c-myc	,	18
20	,	,	18
21	p53	,	20
22	and	mRNA	26
23	the	mRNA	26
24	hybrid	mRNA	26
25	bcr/abl	mRNA	26
26	mRNA	p53	21
27	levels	were	14
28	.	were	14

0	Human	virus	3
1	T-cell	leukemia	2
2	leukemia	virus	3
3	virus	type	4
4	type	is	9
5	I	(	6
6	(	type	4
7	HTLV-I	(	6
8	)	(	6
9	is	<ROOT>	-1
10	an	is	9
11	etiological	(	17
12	agent	adult	14
13	of	adult	14
14	adult	(	17
15	T-cell	leukemia	16
16	leukemia	(	17
17	(	an	10
18	ATL	(	17
19	)	(	17
20	.	is	9

0	The	Bmax	1
1	Bmax	<ROOT>	-1
2	and	Bmax	1
3	Kd	and	2
4	were	Kd	3
5	not	Kd	3
6	significantly	changed	7
7	changed	not	5
8	after	changed	7
9	mitogen	after	8
10	stimulation	mitogen	9
11	in	stimulation	10
12	both	subgroups	13
13	subgroups	in	11
14	of	subgroups	13
15	CRF	of	14
16	.	Bmax	1

0	The	protein	1
1	protein	expressed	2
2	expressed	was	6
3	in	expressed	2
4	insect	cells	5
5	cells	in	3
6	was	<ROOT>	-1
7	used	was	6
8	to	used	7
9	test	to	8
10	for	test	9
11	the	for	10
12	presence	specific	14
13	of	specific	14
14	specific	the	11
15	antibodies	was	6
16	in	was	6
17	sera	was	6
18	from	was	6
19	normal	was	6
20	,	was	6
21	healthy	was	6
22	carriers	was	6
23	and	carriers	22
24	from	and	23
25	patients	from	24
26	with	patients	25
27	various	with	26
28	diseases	.	29
29	.	various	27

0	Treatment	resulted	3
1	with	Treatment	0
2	DMSO	with	1
3	resulted	<ROOT>	-1
4	in	resulted	3
5	the	elevation	6
6	elevation	in	4
7	of	elevation	6
8	the	of	7
9	apoptosis	effector	10
10	effector	Bax	11
11	Bax	the	8
12	,	resulted	3
13	whereas	resulted	3
14	treatment	resulted	3
15	with	resulted	3
16	PDBu	with	15
17	did	resulted	3
18	not	did	17
19	significantly	did	17
20	alter	did	17
21	the	alter	20
22	levels	the	21
23	of	levels	22
24	this	of	23
25	protein	.	26
26	.	this	24

0	Activation	intergenic	10
1	of	Activation	0
2	a	gene	4
3	novel	gene	4
4	gene	of	1
5	in	gene	4
6	3q21	in	5
7	and	3q21	6
8	identification	Activation	0
9	of	identification	8
10	intergenic	<ROOT>	-1
11	fusion	transcripts	12
12	transcripts	intergenic	10
13	with	insertion	16
14	ecotropic	insertion	16
15	viral	insertion	16
16	insertion	intergenic	10
17	site	intergenic	10
18	I	intergenic	10
19	in	intergenic	10
20	leukemia	in	19
21	.	intergenic	10

0	Patients	have	4
1	with	Patients	0
2	steroid-resistant	asthma	3
3	asthma	with	1
4	have	<ROOT>	-1
5	been	have	4
6	shown	been	5
7	to	shown	6
8	have	GCR	11
9	a	GCR	11
10	reduced	GCR	11
11	GCR	to	7
12	binding	affinity	13
13	affinity	GCR	11
14	.	have	4

0	Several	forms	1
1	forms	of	2
2	of	are	5
3	EGR-1	of	2
4	protein	of	2
5	are	sequences	22
6	found	are	5
7	within	found	6
8	the	groups	10
9	different	groups	10
10	groups	within	7
11	of	groups	10
12	cell	lines	13
13	lines	of	11
14	,	are	5
15	and	the	16
16	the	are	5
17	binding	the	16
18	activity	are	5
19	to	are	5
20	DNA	consensus	21
21	consensus	to	19
22	sequences	was	23
23	was	<ROOT>	-1
24	investigated	was	23
25	.	was	23

0	However	had	7
1	,	mutation	2
2	mutation	had	7
3	of	mutation	2
4	the	box	6
5	PU	box	6
6	box	of	3
7	had	<ROOT>	-1
8	no	effect	9
9	effect	had	7
10	in	had	7
11	the	line	13
12	T-cell	line	13
13	line	in	10
14	Jurkat	had	7
15	,	had	7
16	where	is	23
17	none	is	23
18	of	none	17
19	the	members	22
20	Spi-1	members	22
21	family	members	22
22	members	of	18
23	is	had	7
24	expressed	is	23
25	.	had	7

0	Consistent	was	9
1	with	Consistent	0
2	this	hypothesis	3
3	hypothesis	with	1
4	,	was	9
5	the	span	8
6	short	span	8
7	life	span	8
8	span	was	9
9	was	<ROOT>	-1
10	ameliorated	was	9
11	by	ES	16
12	introduction	ES	16
13	into	ES	16
14	the	ES	16
15	EKLF-/-	ES	16
16	ES	ameliorated	10
17	cells	was	9
18	of	cells	17
19	a	gene	22
20	human	gene	22
21	LCR/gamma-globin	gene	22
22	gene	of	18
23	,	was	9
24	as	was	9
25	evidenced	as	24
26	by	evidenced	25
27	the	by	26
28	presence	of	29
29	of	cell-derived	31
30	ES	of	29
31	cell-derived	the	27
32	reticulocytes	by	26
33	as	by	26
34	well	by	26
35	as	by	26
36	mature	by	26
37	erythrocytes	was	9
38	in	was	9
39	the	blood	40
40	blood	the	42
41	of	the	42
42	the	in	38
43	chimeric	was	9
44	animals	was	9
45	.	was	9

0	Throughout	<ROOT>	-1
1	the	Throughout	0
2	study	mean	26
3	period	study	2
4	,	period	3
5	CD41	immunofluorescence	6
6	immunofluorescence	flow	10
7	of	flow	10
8	leukocytes	flow	10
9	(	flow	10
10	flow	period	3
11	cytometry	period	3
12	)	revealed	13
13	revealed	cytometry	11
14	increased	adhesion	16
15	leukocyte-platelet	adhesion	16
16	adhesion	period	3
17	in	adhesion	16
18	patients	in	17
19	with	patients	18
20	AMI	with	19
21	compared	period	3
22	with	period	3
23	control	period	3
24	patients	period	3
25	(	study	2
26	mean	the	1
27	+/-	mean	26
28	SE	+/-	27
29	of	+/-	27
30	fluorescence	of	29
31	[	fluorescence	30
32	channels	Throughout	0
33	]	Throughout	0
34	before	Throughout	0
35	PTCA	Throughout	0
36	:	Throughout	0
37	77	+/-	38
38	+/-	Throughout	0
39	16	+/-	38
40	versus	35	41
41	35	+/-	38
42	+/-	+/-	38
43	9	+/-	38
44	;	9	43
45	P	9	43
46	=	.003	47
47	.003	P	45
48	)	9	43
49	.	Throughout	0

0	The	show	3
1	data	show	3
2	further	show	3
3	show	<ROOT>	-1
4	that	show	3
5	these	distributions	8
6	overall	distributions	8
7	topographical	distributions	8
8	distributions	are	9
9	are	that	4
10	independent	are	9
11	of	independent	10
12	gene	activity	14
13	transcriptional	activity	14
14	activity	of	11
15	and	are	9
16	are	and	15
17	conserved	are	16
18	in	conserved	17
19	different	types	21
20	cell	types	21
21	types	in	18
22	.	show	3

0	In	does	15
1	conclusion	In	0
2	,	does	15
3	the	does	15
4	presence	the	3
5	of	presence	4
6	myeloid-associated	factor	8
7	growth	factor	8
8	factor	of	5
9	receptor	transcripts	10
10	transcripts	factor	8
11	in	of	5
12	CD34+	subsets	14
13	CB	subsets	14
14	subsets	in	11
15	does	<ROOT>	-1
16	not	does	15
17	discriminate	does	15
18	the	discriminate	17
19	various	the	18
20	stages	of	21
21	of	various	19
22	differentiation	of	21
23	,	differentiation	22
24	with	the	25
25	the	,	23
26	exception	the	25
27	of	exception	26
28	the	receptor	30
29	M-CSF	receptor	30
30	receptor	of	27
31	.	of	21

0	Few	factors	2
1	host	factors	2
2	factors	<ROOT>	-1
3	that	factors	2
4	directly	transcription	7
5	limit	transcription	7
6	HIV-1	transcription	7
7	transcription	could	9
8	and	could	9
9	could	that	3
10	support	could	9
11	this	support	10
12	state	this	11
13	of	state	12
14	nonproductive	HIV-1	15
15	HIV-1	of	13
16	infection	HIV-1	15
17	have	infection	16
18	been	have	17
19	described	been	18
20	.	factors	2

0	Expression	correlates	3
1	of	Expression	0
2	c-fos	of	1
3	correlates	<ROOT>	-1
4	with	correlates	3
5	IFN-alpha	responsiveness	6
6	responsiveness	myelogenous	12
7	in	myelogenous	12
8	Philadelphia	chromosome	9
9	chromosome	myelogenous	12
10	positive	myelogenous	12
11	chronic	myelogenous	12
12	myelogenous	with	4
13	leukemia	correlates	3
14	.	correlates	3

0	Furthermore	did	7
1	,	did	7
2	this	accumulation	6
3	C/EBP	accumulation	6
4	epsilon	accumulation	6
5	mRNA	accumulation	6
6	accumulation	did	7
7	did	<ROOT>	-1
8	not	did	7
9	require	did	7
10	synthesis	require	9
11	of	synthesis	10
12	new	of	11
13	protein	new	12
14	factors	protein	13
15	because	factors	14
16	9-cis	because	15
17	RA	9-cis	16
18	induced	RA	17
19	C/EBP	epsilon	20
20	epsilon	induced	18
21	mRNA	accumulation	22
22	accumulation	epsilon	20
23	in	9-cis	16
24	the	absence	25
25	absence	in	23
26	of	protein	28
27	new	protein	28
28	protein	absence	25
29	synthesis	factors	14
30	.	did	7

0	Nuclear	accumulation	1
1	accumulation	opposed	4
2	of	accumulation	1
3	NFAT4	of	2
4	opposed	<ROOT>	-1
5	by	opposed	4
6	the	pathway	10
7	JNK	pathway	10
8	signal	pathway	10
9	transduction	pathway	10
10	pathway	by	5
11	.	opposed	4

0	The	<ROOT>	-1
1	interleukin-10	has	21
2	(	IL-10	3
3	IL-10	receptor	5
4	)	IL-10	3
5	receptor	is	6
6	is	has	21
7	another	member	8
8	member	is	6
9	of	member	8
10	the	of	9
11	IFN	the	10
12	receptor	IFN	11
13	family	,	14
14	,	receptor	12
15	but	is	6
16	its	but	15
17	ligand	,	18
18	,	its	16
19	IL-10	,	18
20	,	is	6
21	has	The	0
22	been	has	21
23	reported	been	22
24	to	in	27
25	induce	in	27
26	apoptosis	induce	25
27	in	reported	23
28	B-CLL	reported	23
29	cells	B-CLL	28
30	.	The	0

0	Mutational	analysis	1
1	analysis	showed	2
2	showed	<ROOT>	-1
3	that	showed	2
4	optimal	transcriptional	5
5	transcriptional	activity	6
6	activity	required	7
7	required	that	3
8	the	required	7
9	GATA	at	11
10	sequence	at	11
11	at	the	8
12	position	-24	13
13	-24	showed	2
14	,	showed	2
15	and	showed	2
16	gel-shift	and	15
17	assays	and	15
18	further	showed	2
19	showed	showed	2
20	that	showed	19
21	the	factor	24
22	GATA-2	factor	24
23	transcription	factor	24
24	factor	that	20
25	,	factor	24
26	but	factor	24
27	not	GATA-1	28
28	GATA-1	but	26
29	,	GATA-1	28
30	bound	GATA-1	28
31	to	bound	30
32	this	bound	30
33	region	bound	30
34	of	region	33
35	the	promoter	37
36	PECAM-1	promoter	37
37	promoter	of	34
38	.	showed	2

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	,	In	0
4	we	,	3
5	investigated	we	4
6	the	investigated	5
7	role	the	6
8	of	transcription	10
9	these	transcription	10
10	transcription	role	7
11	factors	in	12
12	in	the	6
13	uninduced	the	6
14	and	uninduced	13
15	LPS-induced	human	20
16	TF	in	19
17	gene	in	19
18	expression	in	19
19	in	LPS-induced	15
20	human	and	14
21	monocytic	THP-1	22
22	THP-1	human	20
23	cells	THP-1	22
24	.	In	0

0	Characterization	<ROOT>	-1
1	of	Characterization	0
2	the	of	1
3	murine	the	2
4	cyclin-dependent	murine	3
5	kinase	cyclin-dependent	4
6	inhibitor	p27Kip1	8
7	gene	p27Kip1	8
8	p27Kip1	kinase	5
9	.	cyclin-dependent	4

0	During	<ROOT>	-1
1	the	differentiation	2
2	differentiation	During	0
3	of	T	6
4	naive	T	6
5	CD4-LRB-+-RRB-	T	6
6	T	differentiation	2
7	cells	During	0
8	isolated	During	0
9	from	isolated	8
10	T	During	0
11	cell	During	0
12	receptor	During	0
13	transgenic	During	0
14	mice	During	0
15	,	expression	18
16	GATA-3	expression	18
17	gene	expression	18
18	expression	During	0
19	was	During	0
20	up-regulated	During	0
21	in	up-regulated	20
22	developing	in	21
23	Th2	developing	22
24	cells	Th2	23
25	,	During	0
26	but	During	0
27	was	but	26
28	down-regulated	was	27
29	in	Th1	30
30	Th1	down-regulated	28
31	cells	During	0
32	,	During	0
33	and	During	0
34	antigen-	During	0
35	or	During	0
36	cAMP-activated	During	0
37	Th2	During	0
38	cells	During	0
39	(	cells	38
40	but	Th1	42
41	not	but	40
42	Th1	(	39
43	cells	During	0
44	)	During	0
45	expressed	GATA-3	47
46	the	GATA-3	47
47	GATA-3	During	0
48	protein	During	0
49	.	During	0

0	Potential	elements	2
1	cis-acting	elements	2
2	elements	were	3
3	were	<ROOT>	-1
4	identified	were	3
5	in	identified	4
6	the	in	5
7	promoter	the	6
8	region	promoter	7
9	of	region	8
10	the	gene	12
11	NGAL	gene	12
12	gene	of	9
13	by	promoter	7
14	computer	analysis	15
15	analysis	by	13
16	and	analysis	15
17	include	by	13
18	binding	sites	19
19	sites	include	17
20	for	include	17
21	CTF/CBP	transcription	25
22	,	CTF/CBP	21
23	the	transcription	25
24	hematopoietic	transcription	25
25	transcription	for	20
26	factors	transcription	25
27	GATA-1	were	3
28	and	were	3
29	PU.1	were	3
30	,	PU.1	29
31	and	PU.1	29
32	the	and	31
33	LPS-inducible	B	36
34	factor	B	36
35	NF-kappa	B	36
36	B	the	32
37	.	were	3

0	DNA-binding	activities	1
1	activities	were	22
2	(	determined	3
3	determined	activities	1
4	by	determined	3
5	the	assay	9
6	electrophoretic	assay	9
7	mobility	assay	9
8	shift	assay	9
9	assay	by	4
10	)	determined	3
11	of	activities	1
12	three	factors	14
13	transcription	factors	14
14	factors	of	11
15	:	factors	14
16	NFkappaB	activities	1
17	,	activities	1
18	AP-1	,	17
19	and	,	17
20	NFAT	activities	1
21	,	activities	1
22	were	<ROOT>	-1
23	abolished	were	22
24	in	abolished	23
25	the	lymphocytes	26
26	lymphocytes	in	24
27	by	abolished	23
28	all	modes	30
29	three	modes	30
30	modes	by	27
31	of	modes	30
32	oxidative	of	31
33	stress	were	22
34	.	were	22

0	IL-4	is	1
1	is	plays	11
2	secreted	is	1
3	by	activated	4
4	activated	secreted	2
5	Th2	is	1
6	but	Th1	8
7	not	but	6
8	Th1	is	1
9	cells	is	1
10	and	is	1
11	plays	<ROOT>	-1
12	a	plays	11
13	major	a	12
14	role	major	13
15	in	role	14
16	the	response	18
17	immune	response	18
18	response	in	15
19	by	response	18
20	modulating	the	21
21	the	by	19
22	differentiation	of	23
23	of	the	21
24	naive	of	23
25	Th	of	23
26	cells	plays	11
27	toward	plays	11
28	the	phenotype	30
29	Th2	phenotype	30
30	phenotype	toward	27
31	.	plays	11

0	Unexpectedly	CD4	3
1	,	Unexpectedly	0
2	the	CD4	3
3	CD4	silencer	4
4	silencer	is	5
5	is	<ROOT>	-1
6	also	is	5
7	active	also	6
8	in	active	7
9	CD4+	in	8
10	CD8int/-	CD4+	9
11	cells	CD8int/-	10
12	of	cells	11
13	the	of	12
14	thymus	,	15
15	,	the	13
16	implying	,	15
17	that	implying	16
18	an	that	17
19	anti-silencer	may	20
20	may	an	18
21	be	may	20
22	required	be	21
23	to	required	22
24	resume	to	23
25	CD4	in	27
26	expression	CD4	25
27	in	resume	24
28	this	cell	29
29	cell	in	27
30	population	is	5
31	.	is	5

0	Therefore	is	4
1	,	is	4
2	monokine	induction	3
3	induction	is	4
4	is	<ROOT>	-1
5	a	effect	7
6	zinc-specific	effect	7
7	effect	is	4
8	influenced	effect	7
9	by	influenced	8
10	the	properties	12
11	physicochemical	properties	12
12	properties	by	9
13	of	properties	12
14	the	ion	15
15	ion	of	13
16	.	is	4

0	These	results	1
1	results	provide	2
2	provide	<ROOT>	-1
3	evidence	provide	2
4	that	evidence	3
5	AML1	proteins	6
6	proteins	play	7
7	play	a	8
8	a	that	4
9	role	evidence	3
10	in	role	9
11	erythroid	in	10
12	and	erythroid	11
13	megakaryocytic	erythroid	11
14	differentiation	megakaryocytic	13
15	.	differentiation	14

0	Activation	<ROOT>	-1
1	of	Activation	0
2	signaling	pathways	3
3	pathways	of	1
4	and	pathways	3
5	prevention	Activation	0
6	of	prevention	5
7	apoptosis	Activation	0
8	by	Activation	0
9	cytokines	by	8
10	in	by	8
11	eosinophils	Activation	0
12	.	Activation	0

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	No	RESULTS	0
3	significant	No	2
4	partial	active	61
5	correlations	partial	4
6	of	correlations	5
7	the	number	8
8	number	of	6
9	of	number	8
10	the	of	9
11	peripheral	the	10
12	blood	peripheral	11
13	mononuclear	blood	12
14	cell	mononuclear	13
15	glucocorticoid	receptors	16
16	receptors	(	17
17	(	cell	14
18	6821	sites	22
19	+/-	5669	20
20	5669	binding	21
21	binding	sites	22
22	sites	(	17
23	per	cell	24
24	cell	sites	22
25	)	(	17
26	and	(	17
27	the	and	26
28	affinity	(	29
29	(	the	27
30	Kd	(	29
31	:	(	29
32	16.5	(	29
33	+/-	(	29
34	13.51	cell	14
35	nmol/L	13.51	34
36	)	nmol/L	35
37	for	)	36
38	the	glucocorticoid	39
39	glucocorticoid	for	37
40	receptors	for	37
41	with	)	36
42	the	score	44
43	symptom	score	44
44	score	with	41
45	(	the	10
46	placebo	correlations	5
47	:	partial	4
48	4.3	+/-	49
49	+/-	partial	4
50	2.45	+/-	49
51	pts	partial	4
52	;	partial	4
53	fluticasone	:	54
54	:	+/-	56
55	2.4	:	54
56	+/-	pts	58
57	1.55	pts	58
58	pts	partial	4
59	)	partial	4
60	after	active	61
61	active	significant	3
62	treatment	were	63
63	were	active	61
64	found	active	61
65	.	active	61

0	A	obstacle	2
1	major	obstacle	2
2	obstacle	results	11
3	in	obstacle	2
4	designing	in	3
5	a	vector	6
6	vector	designing	4
7	to	designing	4
8	deliver	these	9
9	these	designing	4
10	genes	designing	4
11	results	<ROOT>	-1
12	from	results	11
13	the	structure	14
14	structure	from	12
15	of	structure	14
16	IL-12	of	15
17	.	results	11

0	Some	criteria	1
1	criteria	<ROOT>	-1
2	which	can	3
3	can	criteria	1
4	be	can	3
5	used	be	4
6	to	used	5
7	define	to	6
8	steroid-resistant	asthma	10
9	bronchial	asthma	10
10	asthma	define	7
11	are	criteria	1
12	listed	criteria	1
13	here	listed	12
14	.	criteria	1

0	T-cell	proliferation	1
1	proliferation	studies	2
2	studies	were	3
3	were	<ROOT>	-1
4	performed	T	10
5	using	human	8
6	highly	purified	7
7	purified	using	5
8	human	performed	4
9	CD4+	T	10
10	T	were	3
11	cells	were	3
12	.	were	3

0	We	<ROOT>	-1
1	analysed	We	0
2	mRNA	TSC2	10
3	from	mRNA	2
4	18	from	3
5	unrelated	18	4
6	cases	of	7
7	of	unrelated	5
8	TSC	unrelated	5
9	for	TSC	8
10	TSC2	analysed	1
11	mutations	We	0
12	using	We	0
13	the	using	12
14	protein	(	17
15	truncation	test	16
16	test	(	17
17	(	the	13
18	PTT	the	13
19	)	We	0
20	.	We	0

0	Genomic	organization	1
1	organization	<ROOT>	-1
2	,	organization	1
3	sequence	organization	1
4	,	sequence	3
5	and	,	4
6	transcriptional	regulation	7
7	regulation	,	4
8	of	regulation	7
9	the	gene	12
10	human	gene	12
11	eotaxin	gene	12
12	gene	of	8
13	.	organization	1

0	In	identified	6
1	earlier	studies	2
2	studies	In	0
3	,	identified	6
4	we	identified	6
5	have	identified	6
6	identified	<ROOT>	-1
7	the	factors	9
8	transcription	factors	9
9	factors	identified	6
10	NF-kappa	B	11
11	B	factors	9
12	and	identified	6
13	AP-1	identified	6
14	as	identified	6
15	molecular	targets	16
16	targets	cycle	23
17	for	oxidative	18
18	oxidative	cycle	23
19	signalling	cycle	23
20	processes	cycle	23
21	during	cycle	23
22	cell	cycle	23
23	cycle	as	14
24	entry	identified	6
25	,	identified	6
26	and	identified	6
27	have	shown	28
28	shown	and	26
29	that	signalling	31
30	oxidative	signalling	31
31	signalling	shown	28
32	is	identified	6
33	involved	is	32
34	in	the	35
35	the	involved	33
36	regulation	the	35
37	of	regulation	36
38	early	the	35
39	changes	gene	41
40	in	gene	41
41	gene	involved	33
42	expression	identified	6
43	during	expression	42
44	the	G0	45
45	G0	phase	48
46	to	G0	45
47	G1	to	46
48	phase	during	43
49	transition	phase	48
50	.	identified	6

0	NAC	was	1
1	was	epsilon	7
2	effective	epsilon	7
3	in	epsilon	7
4	inhibiting	epsilon	7
5	mature	epsilon	7
6	C	epsilon	7
7	epsilon	<ROOT>	-1
8	transcription	epsilon	7
9	and	epsilon	7
10	IgE	epsilon	7
11	synthesis	epsilon	7
12	in	epsilon	7
13	the	in	12
14	T	system	17
15	cell-independent	system	17
16	culture	system	17
17	system	the	13
18	.	epsilon	7

0	Tissue	factor	1
1	factor	<ROOT>	-1
2	(	factor	1
3	TF	factor	1
4	)	factor	1
5	expression	factor	1
6	by	peripheral	7
7	peripheral	expression	5
8	blood	monocytes	9
9	monocytes	peripheral	7
10	during	factor	1
11	sepsis	factor	1
12	initiates	factor	1
13	intravascular	factor	1
14	thrombosis	factor	1
15	.	factor	1

0	Recently	<ROOT>	-1
1	,	Recently	0
2	several	groups	3
3	groups	,	1
4	have	groups	3
5	described	have	4
6	marked	alterations	7
7	alterations	described	5
8	in	described	5
9	signal	transduction	10
10	transduction	in	8
11	elements	transduction	10
12	in	T	13
13	T	elements	11
14	cells	from	15
15	from	Recently	0
16	cancer	from	15
17	patients	Recently	0
18	or	Recently	0
19	in	Recently	0
20	mice	bearing	21
21	bearing	Recently	0
22	tumor	for	23
23	for	bearing	21
24	a	weeks	26
25	few	weeks	26
26	weeks	for	23
27	(	&gt;	28
28	&gt;	days	30
29	26	&gt;	28
30	days	bearing	21
31	)	Recently	0
32	.	Recently	0

0	A	promyelocytic	6
1	PMLRARalpha	promyelocytic	6
2	transgene	initiates	3
3	initiates	promyelocytic	6
4	murine	promyelocytic	6
5	acute	promyelocytic	6
6	promyelocytic	<ROOT>	-1
7	leukemia	promyelocytic	6
8	.	promyelocytic	6

0	Thus	play	4
1	,	play	4
2	STAT3	may	3
3	may	play	4
4	play	<ROOT>	-1
5	a	play	4
6	role	in	7
7	in	a	5
8	B	cell	9
9	cell	in	7
10	antigen-specific	play	4
11	signaling	responses	12
12	responses	play	4
13	,	play	4
14	and	play	4
15	its	activation	17
16	constitutive	activation	17
17	activation	is	18
18	is	and	14
19	associated	exhibiting	25
20	with	exhibiting	25
21	a	exhibiting	25
22	normal	exhibiting	25
23	cell	exhibiting	25
24	population	exhibiting	25
25	exhibiting	is	18
26	intrinsic	exhibiting	25
27	proliferative	behavior	28
28	behavior	intrinsic	26
29	.	behavior	28

0	Human	was	9
1	IL-5	transfected	5
2	promoter/enhancer-luciferase	transfected	5
3	gene	transfected	5
4	construct	transfected	5
5	transfected	Human	0
6	to	transfected	5
7	T-cell	clones	8
8	clones	Human	0
9	was	was	18
10	transcribed	was	9
11	on	transcribed	10
12	either	TCR	13
13	TCR	or	14
14	or	on	11
15	IL-2R	on	11
16	stimulation	and	17
17	and	IL-2R	15
18	was	<ROOT>	-1
19	clearly	was	18
20	downregulated	was	18
21	by	downregulated	20
22	dexamethasone	by	21
23	,	dexamethasone	22
24	indicating	,	23
25	that	was	18
26	the	upstream	35
27	approximately	located	33
28	500-bp	human	29
29	human	located	33
30	IL-5	segment	32
31	gene	segment	32
32	segment	located	33
33	located	5'	34
34	5'	upstream	35
35	upstream	that	25
36	of	coding	38
37	the	coding	38
38	coding	upstream	35
39	region	contains	40
40	contains	was	18
41	activation-inducible	was	18
42	enhancer	elements	43
43	elements	was	18
44	responsible	elements	43
45	for	the	46
46	the	responsible	44
47	regulation	the	46
48	by	regulation	47
49	GC	by	48
50	.	was	18

0	We	<ROOT>	-1
1	therefore	We	0
2	investigated	therefore	1
3	whether	investigated	2
4	NF-kappaB/Rel	whether	3
5	proteins	are	6
6	are	NF-kappaB/Rel	4
7	expressed	are	6
8	in	expressed	7
9	human	in	8
10	neutrophils	,	11
11	,	human	9
12	as	expressed	7
13	well	as	12
14	as	as	12
15	their	fate	16
16	fate	as	14
17	on	fate	16
18	cell	on	17
19	activation	cell	18
20	.	activation	19

0	The	promoter	2
1	15-LO	promoter	2
2	promoter	is	3
3	is	Ap2	23
4	associated	is	3
5	with	associated	4
6	a	island	8
7	CpG	island	8
8	island	with	5
9	at	island	8
10	the	5'-end	11
11	5'-end	at	9
12	of	5'-end	11
13	the	gene	14
14	gene	of	12
15	,	is	3
16	and	is	3
17	sequence	analysis	18
18	analysis	reveals	19
19	reveals	and	16
20	putative	and	16
21	Sp1	is	3
22	and	Sp1	21
23	Ap2	<ROOT>	-1
24	binding	Ap2	23
25	site/s	binding	24
26	and	Ap2	23
27	absence	Ap2	23
28	of	Ap2	23
29	TATA	of	28
30	or	of	28
31	CAAT	or	30
32	motifs	of	28
33	.	Ap2	23

0	Primer	extension	1
1	extension	<ROOT>	-1
2	and	extension	1
3	nuclease	and	2
4	S1	nuclease	3
5	protection	S1	4
6	analysis	protection	5
7	revealed	analysis	6
8	two	sites	12
9	major	transcription	10
10	transcription	sites	12
11	initiation	sites	12
12	sites	revealed	7
13	.	sites	12

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	a	,	1
3	CIITA	a	2
4	protein	in	5
5	in	CIITA	3
6	which	in	5
7	both	alpha-helices	9
8	functional	alpha-helices	9
9	alpha-helices	have	10
10	have	in	5
11	been	have	10
12	deleted	displays	13
13	displays	been	11
14	a	displays	13
15	dominant	.	18
16	negative	.	18
17	phenotype	.	18
18	.	displays	13

0	NFAT	activation	1
1	activation	is	2
2	is	<ROOT>	-1
3	mediated	is	2
4	in	mediated	3
5	part	in	4
6	by	mediated	3
7	induced	import	9
8	nuclear	import	9
9	import	by	6
10	.	is	2

0	Early	buds	1
1	buds	are	2
2	are	<ROOT>	-1
3	characterized	are	2
4	by	characterized	3
5	a	morphogenesis	7
6	branching	morphogenesis	7
7	morphogenesis	by	4
8	of	morphogenesis	7
9	the	epithelium	11
10	ductal	epithelium	11
11	epithelium	of	8
12	from	morphogenesis	7
13	which	from	12
14	endocrine	precursor	17
15	and	endocrine	14
16	exocrine	precursor	17
17	precursor	from	12
18	cells	are	2
19	bud	are	2
20	to	are	2
21	eventually	to	20
22	form	are	2
23	the	compartments	26
24	two	compartments	26
25	other	compartments	26
26	compartments	form	22
27	.	are	2

0	c-Jun	<ROOT>	-1
1	and	c-Jun	0
2	GST-pi	expression	3
3	expression	c-Jun	0
4	in	plasma	6
5	human	plasma	6
6	plasma	c-Jun	0
7	cells	c-Jun	0
8	.	c-Jun	0

0	While	were	16
1	there	was	2
2	was	While	0
3	a	increase	5
4	significant	increase	5
5	increase	was	2
6	in	increase	5
7	plasma	cortisol	8
8	cortisol	in	6
9	levels	was	2
10	in	was	2
11	the	group	13
12	depressed	group	13
13	group	in	10
14	,	were	16
15	there	were	16
16	were	<ROOT>	-1
17	no	changes	18
18	changes	were	16
19	in	changes	18
20	the	parameters	24
21	lymphocyte	parameters	24
22	GR	parameters	24
23	binding	parameters	24
24	parameters	in	19
25	(	were	16
26	K	(	27
27	(	(	25
28	m	(	27
29	)	(	25
30	and	were	16
31	Bmax	were	16
32	)	were	16
33	.	were	16

0	Moreover	blocked	17
1	,	blocked	17
2	the	inhibitors	3
3	inhibitors	blocked	17
4	of	inhibitors	3
5	serine	proteases	6
6	proteases	of	4
7	,	inhibitors	3
8	N-alpha-tosyl-L-lysine	ketone	10
9	chloromethyl	ketone	10
10	ketone	inhibitors	3
11	and	ketone	10
12	N-alpha-tosyl-L-phenylalanine	ketone	14
13	chloromethyl	ketone	14
14	ketone	and	11
15	,	inhibitors	3
16	also	blocked	17
17	blocked	<ROOT>	-1
18	the	activity	20
19	cytolytic	activity	20
20	activity	blocked	17
21	of	NK	22
22	NK	activity	20
23	cells	blocked	17
24	against	cells	23
25	the	K562	28
26	sensitive	K562	28
27	target	K562	28
28	K562	against	24
29	.	blocked	17

0	To	was	35
1	investigate	To	0
2	further	investigate	1
3	,	To	0
4	we	,	3
5	then	purified	6
6	purified	a	7
7	a	we	4
8	number	different	10
9	of	different	10
10	different	a	7
11	kinases	To	0
12	,	was	35
13	including	was	35
14	PKC	including	13
15	,	was	35
16	PhK	ZAP-70	18
17	,	ZAP-70	18
18	ZAP-70	ERK	20
19	,	ZAP-70	18
20	ERK	09-2210	34
21	,	ERK	20
22	and	ERK	20
23	MEK	and	22
24	1	MEK	23
25	(	MKK	27
26	a	MKK	27
27	MKK	MEK	23
28	)	MKK	27
29	,	ERK	20
30	and	ERK	20
31	showed	that	32
32	that	and	30
33	Ro	that	32
34	09-2210	was	35
35	was	<ROOT>	-1
36	a	inhibitor	38
37	selective	inhibitor	38
38	inhibitor	was	35
39	of	inhibitor	38
40	MEK1	of	39
41	in	(	43
42	vitro	in	41
43	(	inhibitor	38
44	IC50	(	43
45	=	59	46
46	59	IC50	44
47	nM	)	48
48	)	59	46
49	.	was	35

0	The	domain	2
1	DNA-binding	domain	2
2	domain	<ROOT>	-1
3	(	domain	2
4	amino	(	3
5	acids	amino	4
6	421-486	conserved	10
7	)	421-486	6
8	is	)	7
9	completely	)	7
10	conserved	acids	5
11	among	conserved	10
12	human	among	11
13	,	squirrel	14
14	squirrel	human	12
15	monkey	human	12
16	,	monkey	15
17	owl	monkey	18
18	monkey	monkey	15
19	,	monkey	18
20	and	monkey	18
21	cotton-top	and	20
22	tamarin	cotton-top	21
23	receptors	tamarin	22
24	.	receptors	23

0	Paternal	expression	1
1	expression	human	5
2	of	expression	1
3	WT1	of	2
4	in	human	5
5	human	<ROOT>	-1
6	fibroblasts	human	5
7	and	human	5
8	lymphocytes	human	5
9	.	human	5

0	However	were	5
1	,	were	5
2	the	DC	4
3	monocyte-derived	DC	4
4	DC	were	5
5	were	<ROOT>	-1
6	not	were	5
7	terminally	were	5
8	differentiated	terminally	7
9	cells	;	10
10	;	differentiated	8
11	they	differentiated	8
12	could	still	13
13	still	differentiated	8
14	convert	still	13
15	to	still	13
16	macrophages	were	5
17	in	macrophages	16
18	response	were	5
19	to	were	5
20	M-CSF	to	19
21	.	were	5

0	In	therefore	5
1	B	cells	2
2	cells	In	0
3	,	therefore	5
4	Egr-1	therefore	5
5	therefore	plays	6
6	plays	critical	8
7	a	critical	8
8	critical	<ROOT>	-1
9	role	in	10
10	in	critical	8
11	integrating	in	10
12	the	integrating	11
13	short-lived	delivered	15
14	signal	delivered	15
15	delivered	the	12
16	by	delivered	15
17	triggering	by	16
18	of	triggering	17
19	the	of	18
20	Ag	into	22
21	receptor	into	22
22	into	the	19
23	phenotypic	changes	24
24	changes	into	22
25	,	into	22
26	including	into	22
27	repression	including	26
28	of	repression	27
29	CD95	of	28
30	and	CD95	29
31	CD23	and	30
32	transcription	.	33
33	.	CD95	29

0	Nuclear	p65	1
1	p65	<ROOT>	-1
2	and	p65	1
3	c-Rel	and	2
4	proteins	p65	1
5	were	proteins	4
6	found	were	5
7	in	cell	9
8	all	cell	9
9	cell	found	6
10	types	lymphocytes	12
11	including	lymphocytes	12
12	lymphocytes	were	5
13	.	p65	1

0	Contrary	staurosporine	19
1	to	Contrary	0
2	the	to	1
3	idea	that	4
4	that	the	2
5	protein	that	4
6	kinase	is	8
7	C	is	8
8	is	protein	5
9	involved	is	8
10	in	TCR-mediated	11
11	TCR-mediated	involved	9
12	activation	of	13
13	of	Contrary	0
14	NF-kappaB	of	13
15	,	NF-kappaB	14
16	high	Contrary	0
17	doses	Contrary	0
18	of	Contrary	0
19	staurosporine	<ROOT>	-1
20	did	staurosporine	19
21	not	did	20
22	interfere	did	20
23	with	interfere	22
24	activation	of	25
25	of	with	23
26	NF-kappaB	of	25
27	by	NF-kappaB	26
28	PHA	staurosporine	19
29	,	staurosporine	19
30	while	staurosporine	19
31	the	dose	33
32	same	dose	33
33	dose	blocked	37
34	of	dose	33
35	staurosporine	of	34
36	completely	blocked	37
37	blocked	while	30
38	activation	blocked	37
39	by	activation	38
40	PMA	blocked	37
41	.	staurosporine	19

0	BACKGROUND	<ROOT>	-1
1	:	BACKGROUND	0
2	Myeloid	development	4
3	cell	development	4
4	development	is	5
5	is	BACKGROUND	0
6	controlled	is	5
7	by	controlled	6
8	tissue-specific	factors	10
9	transcription	factors	10
10	factors	by	7
11	.	BACKGROUND	0

0	Receptor/Stat	interaction	1
1	interaction	is	2
2	is	<ROOT>	-1
3	mediated	is	2
4	by	mediated	3
5	the	by	4
6	src	the	5
7	homology	src	6
8	2	homology	7
9	(	2	8
10	SH2	2	8
11	)	2	8
12	domain	is	2
13	of	corresponding	15
14	the	corresponding	15
15	corresponding	domain	12
16	Stat	is	2
17	protein	is	2
18	.	is	2

0	Analyses	predict	11
1	of	Analyses	0
2	the	sequence	6
3	primary	sequence	6
4	amino	sequence	6
5	acid	sequence	6
6	sequence	of	1
7	of	activation	9
8	the	activation	9
9	activation	sequence	6
10	domain	Analyses	0
11	predict	<ROOT>	-1
12	the	predict	11
13	presence	the	12
14	of	presence	13
15	three	alpha-helices	16
16	alpha-helices	of	14
17	,	alpha-helices	16
18	each	with	19
19	with	alpha-helices	16
20	a	with	19
21	high	of	23
22	proportion	of	23
23	of	a	20
24	acidic	of	23
25	residues	.	26
26	.	acidic	24

0	Of	<ROOT>	-1
1	the	proteins	3
2	GATA-binding	proteins	3
3	proteins	Of	0
4	,	Of	0
5	only	,	4
6	GATA-4	regulates	8
7	selectively	regulates	8
8	regulates	,	4
9	the	regulates	8
10	human	the	9
11	IL-5	human	10
12	gene	producing	16
13	promoter	gene	12
14	in	IL-5	15
15	IL-5	promoter	13
16	producing	IL-5	11
17	cells	Of	0
18	which	express	19
19	express	Of	0
20	multiple	GATA-binding	21
21	GATA-binding	express	19
22	proteins	Of	0
23	.	Of	0

0	However	possibilities	2
1	other	possibilities	2
2	possibilities	<ROOT>	-1
3	,	possibilities	2
4	such	as	5
5	as	possibilities	2
6	altered	distribution	7
7	distribution	as	5
8	of	lymphocyte	9
9	lymphocyte	different	12
10	subpopulations	different	12
11	with	different	12
12	different	distribution	7
13	receptor	distribution	7
14	concentrations	possibilities	2
15	and	possibilities	2
16	with	different	17
17	different	and	15
18	cytokine	possibilities	2
19	production	possibilities	2
20	,	can	21
21	can	possibilities	2
22	not	can	21
23	be	can	21
24	excluded	be	23
25	.	possibilities	2

0	By	established	8
1	promoter	deletion	2
2	deletion	By	0
3	and	By	0
4	mutation	By	0
5	analyses	By	0
6	,	established	8
7	we	established	8
8	established	<ROOT>	-1
9	this	region	10
10	region	established	8
11	as	established	8
12	a	element	15
13	positive	element	15
14	regulatory	element	15
15	element	as	11
16	.	established	8

0	Molecular	analysis	1
1	analysis	<ROOT>	-1
2	of	the	3
3	the	analysis	1
4	cDNA	genomic	6
5	and	genomic	6
6	genomic	indicated	8
7	clones	genomic	6
8	indicated	analysis	1
9	the	indicated	8
10	presence	the	9
11	of	presence	10
12	two	of	11
13	exons	two	12
14	encoding	a	15
15	a	protein	16
16	protein	exons	13
17	with	protein	16
18	an	mass	21
19	apparent	mass	21
20	molecular	mass	21
21	mass	with	17
22	of	mass	21
23	32	kDa	24
24	kDa	of	22
25	and	kDa	24
26	a	pI	27
27	pI	kDa	24
28	of	pI	27
29	9.5	of	28
30	.	analysis	1

0	OCA-B	associates	1
1	associates	domain	6
2	with	associates	1
3	the	associates	1
4	Oct-1	domain	6
5	POU	domain	6
6	domain	<ROOT>	-1
7	,	domain	6
8	a	structure	11
9	bipartite	structure	11
10	DNA-binding	structure	11
11	structure	,	7
12	containing	POU-specific	14
13	a	POU-specific	14
14	POU-specific	domain	6
15	(	POU-LSB-S-RSB-	16
16	POU-LSB-S-RSB-	POU-specific	14
17	)	POU-LSB-S-RSB-	16
18	domain	domain	6
19	joined	domain	18
20	by	joined	19
21	a	by	20
22	flexible	a	21
23	linker	flexible	22
24	to	linker	23
25	a	homeodomain	27
26	POU	homeodomain	27
27	homeodomain	to	24
28	(	POU-LSB-H-RSB-	29
29	POU-LSB-H-RSB-	domain	18
30	)	POU-LSB-H-RSB-	29
31	.	domain	6

0	Although	of	2
1	inhibition	of	2
2	of	C	5
3	IL-4-driven	germline	4
4	germline	C	5
5	C	was	10
6	epsilon	C	5
7	transcription	C	5
8	by	C	5
9	NAC	by	8
10	was	remarkably	16
11	not	was	10
12	sufficient	was	10
13	,	remarkably	16
14	the	agent	15
15	agent	remarkably	16
16	remarkably	<ROOT>	-1
17	diminished	anti-CD40	18
18	anti-CD40	mAb-mediated	19
19	mAb-mediated	epsilon	24
20	up-regulation	of	21
21	of	mAb-mediated	19
22	germline	of	21
23	C	of	21
24	epsilon	remarkably	16
25	transcription	remarkably	16
26	.	remarkably	16

0	c-Rel	subunits	3
1	and	c-Rel	0
2	p65	subunits	3
3	subunits	bind	4
4	bind	<ROOT>	-1
5	to	bind	4
6	an	site	9
7	upstream	site	9
8	NF-kappaB	site	9
9	site	to	5
10	in	human	11
11	human	bind	4
12	granulocyte	bind	4
13	macrophage-colony	bind	4
14	stimulating	bind	4
15	factor	bind	4
16	promoter	in	18
17	involved	in	18
18	in	bind	4
19	phorbol	bind	4
20	ester	bind	4
21	response	ester	20
22	in	response	21
23	5637	cells	24
24	cells	in	22
25	.	cells	24

0	By	<ROOT>	-1
1	contrast	By	0
2	,	ICRF-193	3
3	ICRF-193	By	0
4	only	provoked	5
5	provoked	By	0
6	a	activation	8
7	late	activation	8
8	activation	provoked	5
9	(	activation	8
10	from	hours	11
11	hours	(	9
12	72	hours	11
13	to	72	12
14	96	hours	11
15	)	(	9
16	of	activation	8
17	the	enzyme	19
18	total	enzyme	19
19	enzyme	of	16
20	.	By	0

0	1	<ROOT>	-1
1	.	1	0
2	In	1	0
3	this	study	4
4	study	In	2
5	we	that	7
6	hypothesized	that	7
7	that	1	0
8	in	that	7
9	individuals	in	8
10	with	individuals	9
11	certain	makeup	13
12	genetic	makeup	13
13	makeup	with	10
14	,	1	0
15	MTBE	,	14
16	,	MTBE	15
17	benzene	MTBE	15
18	or	benzene	17
19	their	metabolites	20
20	metabolites	or	18
21	act	metabolites	20
22	as	1	0
23	adducts	as	22
24	and	programmed	27
25	may	and	24
26	induce	programmed	27
27	programmed	adducts	23
28	cell	1	0
29	death	1	0
30	.	1	0

0	However	is	15
1	,	is	15
2	the	progression	3
3	progression	is	15
4	to	progression	3
5	subsequent	events	6
6	events	to	4
7	which	comprise	8
8	comprise	terminal	9
9	terminal	events	6
10	differentiation	terminal	9
11	and	cycle	13
12	cell	cycle	13
13	cycle	events	6
14	arrest	progression	3
15	is	<ROOT>	-1
16	halted	is	15
17	during	halted	16
18	the	adaptation	19
19	adaptation	during	17
20	to	during	17
21	the	to	20
22	presence	the	21
23	of	presence	22
24	1,25D3	is	15
25	in	these	26
26	these	1,25D3	24
27	cells	is	15
28	.	is	15

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	the	expression	5
5	expression	may	9
6	of	expression	5
7	bcl-6	protein	8
8	protein	of	6
9	may	that	3
10	be	may	9
11	associated	be	10
12	with	associated	11
13	morphological	differentiation	14
14	differentiation	with	12
15	in	be	10
16	normal	in	15
17	and	may	9
18	neoplastic	may	9
19	epidermal	cells	20
20	cells	may	9
21	.	cells	20

0	Sequence	analysis	1
1	analysis	revealed	13
2	of	analysis	1
3	nineteen	LTRs	4
4	LTRs	of	2
5	cloned	of	2
6	from	2	7
7	2	cloned	5
8	adult	analysis	1
9	and	analysis	1
10	3	analysis	1
11	pediatric	analysis	1
12	patients	analysis	1
13	revealed	<ROOT>	-1
14	an	average	15
15	average	nucleotide	18
16	of	nucleotide	18
17	33	nucleotide	18
18	nucleotide	revealed	13
19	changes	nucleotide	18
20	(	nucleotide	18
21	with	(	20
22	respect	with	21
23	to	respect	22
24	the	to	23
25	sequence	of	26
26	of	LTR	29
27	the	LTR	29
28	LAI	LTR	29
29	LTR	the	24
30	)	respect	22
31	within	)	30
32	the	within	31
33	455-bp	the	32
34	U3	455-bp	33
35	region	U3	34
36	.	region	35

0	In	infected	1
1	infected	<ROOT>	-1
2	monocytes	infected	1
3	,	infected	1
4	which	die	5
5	die	infected	1
6	by	die	5
7	apoptosis	by	6
8	,	infected	1
9	the	expression	10
10	expression	,	8
11	of	expression	10
12	CREB	of	11
13	,	CTF	14
14	CTF	CREB	12
15	,	CTF	14
16	and	CTF	14
17	OTF-2	and	16
18	was	OTF-2	17
19	rather	suppressed	20
20	suppressed	infected	1
21	8	infected	1
22	hours	infected	1
23	after	infection	24
24	infection	hours	22
25	.	infected	1

0	Autologous	peripheral	1
1	peripheral	blood	2
2	blood	stem	3
3	stem	transplantation	5
4	cell	stem	3
5	transplantation	is	9
6	(	PBSCT	7
7	PBSCT	transplantation	5
8	)	PBSCT	7
9	is	<ROOT>	-1
10	replacing	is	9
11	autologous	replacing	10
12	bone	(	15
13	marrow	(	15
14	transplantation	(	15
15	(	autologous	11
16	BMT	is	9
17	)	is	9
18	in	is	9
19	the	treatment	20
20	treatment	in	18
21	of	treatment	20
22	leukemia	of	21
23	.	is	9

0	However	<ROOT>	-1
1	,	However	0
2	induction	,	1
3	of	induction	2
4	NF-AT	of	3
5	,	induction	2
6	which	has	7
7	has	induction	2
8	the	requirements	11
9	same	requirements	11
10	signaling	requirements	11
11	requirements	has	7
12	as	c-Rel	13
13	c-Rel	was	16
14	induction	c-Rel	13
15	,	c-Rel	13
16	was	has	7
17	not	was	16
18	inhibited	was	16
19	by	inhibited	18
20	PF	by	19
21	.	However	0

0	T	cells	1
1	cells	were	2
2	were	<ROOT>	-1
3	separated	were	2
4	into	separated	3
5	CD4	into	4
6	and	into	4
7	CD8	were	2
8	.	were	2

0	Mutations	<ROOT>	-1
1	in	Mutations	0
2	the	gene	4
3	TSC2	gene	4
4	gene	in	1
5	:	Mutations	0
6	analysis	Mutations	0
7	of	analysis	6
8	the	sequence	11
9	complete	sequence	11
10	coding	sequence	11
11	sequence	of	7
12	using	analysis	6
13	the	using	12
14	protein	(	17
15	truncation	test	16
16	test	(	17
17	(	the	13
18	PTT	the	13
19	)	Mutations	0
20	.	Mutations	0

0	While	<ROOT>	-1
1	we	can	2
2	can	While	0
3	not	can	2
4	exclude	can	2
5	that	exclude	4
6	alterations	that	5
7	in	occur	11
8	TSG101	in	7
9	and	TSG101	8
10	FHIT	and	9
11	occur	alterations	6
12	during	occur	11
13	cancer	development	14
14	development	during	12
15	,	alterations	6
16	our	data	17
17	data	indicate	18
18	indicate	alterations	6
19	that	indicate	18
20	in	transcript	26
21	this	context	22
22	context	in	20
23	the	transcript	26
24	commonly	observed	25
25	observed	transcript	26
26	transcript	that	19
27	abnormalities	transcript	26
28	are	abnormalities	27
29	misleading	are	28
30	.	While	0

0	Infected	AML	1
1	AML	blasts	2
2	blasts	produced	3
3	produced	<ROOT>	-1
4	between	produced	3
5	2	between	4
6	and	2	5
7	6	ng	8
8	ng	and	6
9	of	ng	8
10	IL-12/10	of	9
11	(	6	12
12	6	ng	8
13	)	6	12
14	cells	per	15
15	per	produced	3
16	ml	per	17
17	per	produced	3
18	48	produced	3
19	hr	produced	3
20	.	produced	3

0	As	leads	18
1	shown	As	0
2	by	shown	1
3	reverse	by	2
4	transcription-polymerase	reverse	3
5	chain	transcription-polymerase	4
6	reaction	chain	5
7	and	reaction	6
8	electrophoretic	and	7
9	mobility	chain	5
10	shift	,	12
11	assay	,	12
12	,	mobility	9
13	respectively	transcription-polymerase	4
14	,	leads	18
15	treatment	leads	18
16	with	treatment	15
17	CsA	with	16
18	leads	<ROOT>	-1
19	to	mRNA	22
20	decreased	mRNA	22
21	TF	mRNA	22
22	mRNA	leads	18
23	expression	and	24
24	and	leads	18
25	reduced	and	24
26	activation	leads	18
27	of	leads	18
28	the	factor	31
29	NF-kappaB	factor	31
30	transcription	factor	31
31	factor	of	27
32	,	which	33
33	which	leads	18
34	is	which	33
35	known	is	34
36	to	known	35
37	contribute	to	36
38	to	the	39
39	the	contribute	37
40	induction	the	39
41	of	TF	43
42	the	TF	43
43	TF	induction	40
44	promotor	the	39
45	in	human	46
46	human	promotor	44
47	monocytes	leads	18
48	.	leads	18

0	The	<ROOT>	-1
1	present	The	0
2	review	summarizes	3
3	summarizes	these	4
4	these	present	1
5	findings	,	6
6	,	these	4
7	with	,	6
8	a	with	7
9	special	a	8
10	focus	special	9
11	on	focus	10
12	our	studies	14
13	own	studies	14
14	studies	on	11
15	on	pluripotent	16
16	pluripotent	studies	14
17	endocrine	rat	20
18	cultures	rat	20
19	of	rat	20
20	rat	pluripotent	16
21	pancreas	studies	14
22	.	The	0

0	Stimulation	gives	18
1	of	T	3
2	purified	T	3
3	T	Stimulation	0
4	lymphocytes	Stimulation	0
5	by	Stimulation	0
6	a	combination	7
7	combination	molecules	17
8	of	combination	7
9	monoclonal	antibodies	10
10	antibodies	of	8
11	directed	combination	7
12	at	combination	7
13	CD2	at	12
14	and	at	12
15	CD28	at	12
16	adhesion	combination	7
17	molecules	by	5
18	gives	<ROOT>	-1
19	rise	gives	18
20	to	rise	19
21	a	proliferation	24
22	long	proliferation	24
23	lasting	proliferation	24
24	proliferation	to	20
25	in	proliferation	24
26	the	absence	27
27	absence	in	25
28	of	accessory	29
29	accessory	absence	27
30	cells	gives	18
31	.	gives	18

0	Transfectants	were	1
1	were	<ROOT>	-1
2	exposed	were	1
3	to	varying	4
4	varying	exposed	2
5	concentrations	(	6
6	(	varying	4
7	0-125	were	1
8	microM	were	1
9	)	of	10
10	of	zinc	11
11	zinc	were	1
12	sulfate	zinc	11
13	that	produced	14
14	produced	sulfate	12
15	a	produced	14
16	3-fold	a	15
17	range	3-fold	16
18	of	membrane	19
19	membrane	range	17
20	G-LRB-S-RRB-alpha	were	1
21	expression	were	1
22	.	were	1

0	On	does	12
1	the	hand	3
2	other	hand	3
3	hand	On	0
4	,	On	0
5	FCM	,	4
6	produced	FCM	5
7	in	the	8
8	the	produced	6
9	presence	the	8
10	of	presence	9
11	indomethacin	On	0
12	does	<ROOT>	-1
13	not	does	12
14	inhibit	does	12
15	NF-kappaB	activation	16
16	activation	inhibit	14
17	by	activation	16
18	LPS	by	17
19	.	does	12

0	Differential	localization	2
1	nuclear	localization	2
2	localization	RelB	9
3	of	localization	2
4	p50	of	3
5	,	localization	2
6	p52	localization	2
7	,	localization	2
8	and	localization	2
9	RelB	<ROOT>	-1
10	proteins	RelB	9
11	in	proteins	10
12	human	cells	14
13	accessory	cells	14
14	cells	in	11
15	of	proteins	10
16	the	response	18
17	immune	response	18
18	response	of	15
19	in	response	18
20	situ	in	19
21	.	situ	20

0	Furthermore	<ROOT>	-1
1	,	Furthermore	0
2	studies	,	1
3	carried	kinase	12
4	out	carried	3
5	using	carried	3
6	H7	using	5
7	,	carried	3
8	a	protein	9
9	protein	,	7
10	kinase	A/protein	11
11	A/protein	carried	3
12	kinase	blocked	16
13	C	kinase	12
14	inhibitor	kinase	12
15	,	kinase	12
16	blocked	studies	2
17	c-fos	Furthermore	0
18	induction	,	19
19	,	c-fos	17
20	whereas	no	21
21	no	Furthermore	0
22	effect	was	23
23	was	observed	24
24	observed	no	21
25	with	Furthermore	0
26	bisindolylmaleimide	Furthermore	0
27	,	Furthermore	0
28	a	protein	30
29	specific	protein	30
30	protein	,	27
31	kinase	Furthermore	0
32	C	inhibitor	33
33	inhibitor	Furthermore	0
34	.	inhibitor	33

0	Both	IL-2	1
1	IL-2	bind	4
2	and	IL-2	1
3	IL-4	and	2
4	bind	<ROOT>	-1
5	to	receptors	6
6	receptors	bind	4
7	containing	gamma	10
8	the	gamma	10
9	common	gamma	10
10	gamma	receptors	6
11	chain	bind	4
12	and	bind	4
13	JAK3	bind	4
14	.	bind	4

0	Inefficient	DNA	1
1	DNA	replication	2
2	replication	is	3
3	is	also	4
4	also	<ROOT>	-1
5	found	also	4
6	in	found	5
7	another	line	10
8	monocyte	line	10
9	cell	line	10
10	line	in	6
11	,	line	10
12	THP-1	also	4
13	.	also	4

0	ZEBRA	is	12
1	,	ZEBRA	0
2	a	member	3
3	member	ZEBRA	0
4	of	member	3
5	the	family	7
6	bZIP	family	7
7	family	of	4
8	of	family	7
9	DNA-binding	proteins	10
10	proteins	of	8
11	,	ZEBRA	0
12	is	<ROOT>	-1
13	a	activator	15
14	transcriptional	activator	15
15	activator	is	12
16	capable	is	12
17	of	capable	16
18	inducing	expression	19
19	expression	of	17
20	from	of	17
21	viral	promoters	24
22	lytic	promoters	24
23	cycle	promoters	24
24	promoters	from	20
25	.	is	12

0	Late	expression	2
1	gene	expression	2
2	expression	does	11
3	from	virus	6
4	the	virus	6
5	Epstein-Barr	virus	6
6	virus	expression	2
7	BcLF1	expression	2
8	and	BFRF3	9
9	BFRF3	BcLF1	7
10	promoters	expression	2
11	does	<ROOT>	-1
12	not	does	11
13	require	does	11
14	DNA	replication	15
15	replication	require	13
16	in	require	13
17	cis	does	11
18	.	does	11

0	Endothelial	cells	1
1	cells	were	2
2	were	<ROOT>	-1
3	treated	were	2
4	with	treated	3
5	TCP	with	4
6	,	were	2
7	alpha-tocopherol	acetate	8
8	acetate	were	2
9	(	TCP	10
10	TCP	acetate	8
11	acetate	TCP	10
12	)	TCP	10
13	,	acetate	8
14	or	acetate	8
15	alpha-tocopheryl	succinate	16
16	succinate	or	14
17	(	TCP	18
18	TCP	succinate	16
19	succinate	TCP	18
20	)	TCP	18
21	before	were	2
22	stimulation	necrosis	25
23	with	necrosis	25
24	tumor	necrosis	25
25	necrosis	before	21
26	factor-alpha	were	2
27	(	interleukin-1	37
28	TNF-alpha	;	29
29	;	(	27
30	10	;	29
31	U/ml	;	29
32	,	;	29
33	6	(	27
34	h	)	35
35	)	6	33
36	or	interleukin-1	37
37	interleukin-1	were	2
38	beta	IL-1	40
39	(	IL-1	40
40	IL-1	beta	41
41	beta	were	2
42	;	were	2
43	10	,	45
44	U/ml	,	45
45	,	were	2
46	6	,	45
47	h	)	48
48	)	6	46
49	.	were	2

0	These	observations	1
1	observations	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	a	site	7
5	so-far-unrecognized	site	7
6	SP-1	site	7
7	site	that	3
8	in	site	7
9	the	promoter	12
10	human	promoter	12
11	IL-1beta	promoter	12
12	promoter	in	8
13	may	site	7
14	participate	may	13
15	in	may	13
16	the	regulation	18
17	transcriptional	regulation	18
18	regulation	in	15
19	of	regulation	18
20	this	gene	21
21	gene	of	19
22	in	site	7
23	keratinocytes	in	22
24	.	suggest	2

0	The	coupling	2
1	direct	coupling	2
2	coupling	receptor	5
3	between	receptor	5
4	cytokine	receptor	5
5	receptor	helps	9
6	and	receptor	5
7	transcription	factor	8
8	factor	receptor	5
9	helps	<ROOT>	-1
10	to	helps	9
11	explain	to	10
12	how	explain	11
13	different	how	12
14	cytokines	distinct	16
15	elicit	distinct	16
16	distinct	how	12
17	patterns	of	18
18	of	how	12
19	gene	of	18
20	expression	.	21
21	.	gene	19

0	Direct	sensorgrams	3
1	analysis	sensorgrams	3
2	of	sensorgrams	3
3	sensorgrams	<ROOT>	-1
4	,	sensorgrams	3
5	with	sensorgrams	3
6	recombinant	allowed	9
7	huGATA-3	allowed	9
8	,	allowed	9
9	allowed	and	14
10	the	comparison	11
11	comparison	and	14
12	of	and	14
13	association	and	14
14	and	sensorgrams	3
15	dissociation	sensorgrams	3
16	profiles	sensorgrams	3
17	of	profiles	16
18	the	of	17
19	three	regions	21
20	DNA	regions	21
21	regions	the	18
22	and	regions	21
23	their	ranking	24
24	ranking	and	22
25	according	ranking	24
26	to	according	25
27	their	affinities	29
28	relative	affinities	29
29	affinities	to	26
30	.	sensorgrams	3

0	Reporter	constructs	2
1	gene	constructs	2
2	constructs	were	3
3	were	<ROOT>	-1
4	used	were	3
5	to	map	6
6	map	used	4
7	this	map	6
8	effect	of	9
9	of	map	6
10	deltorphin	map	6
11	to	map	6
12	the	AP-1-	13
13	AP-1-	to	11
14	and	AP-1-	13
15	NF-AT/AP-1-binding	sites	16
16	sites	and	14
17	of	IL-2	19
18	the	IL-2	19
19	IL-2	AP-1-	13
20	promoter	were	3
21	.	were	3

0	We	overexpressed	1
1	overexpressed	<ROOT>	-1
2	AML1a	overexpressed	1
3	(	without	4
4	without	overexpressed	1
5	the	domain	7
6	transcription-activating	domain	7
7	domain	without	4
8	)	without	4
9	and	overexpressed	1
10	AML1b	the	13
11	(	with	12
12	with	the	13
13	the	and	9
14	domain	the	13
15	)	and	9
16	proteins	overexpressed	1
17	in	leukemia	19
18	K562	leukemia	19
19	leukemia	overexpressed	1
20	cells	overexpressed	1
21	,	which	22
22	which	overexpressed	1
23	can	which	22
24	be	can	23
25	induced	be	24
26	to	induced	25
27	differentiate	to	26
28	into	differentiate	27
29	hemoglobin-producing	cells	30
30	cells	into	28
31	and	differentiate	27
32	megakaryocytes	and	31
33	.	overexpressed	1

0	Increased	expression	1
1	expression	<ROOT>	-1
2	of	expression	1
3	Gs-LRB-alpha-RRB-	activation	5
4	enhances	Gs-LRB-alpha-RRB-	3
5	activation	of	2
6	of	activation	5
7	the	of	6
8	adenylyl	the	7
9	cyclase	adenylyl	8
10	signal	cyclase	9
11	transduction	.	13
12	cascade	.	13
13	.	signal	10

0	We	hypothesize	1
1	hypothesize	is	13
2	that	hypothesize	1
3	an	that	2
4	unknown	an	3
5	gene	an	3
6	or	gene	5
7	genes	hypothesize	1
8	in	hypothesize	1
9	linkage	in	8
10	with	linkage	9
11	the	polymorphisms	12
12	polymorphisms	with	10
13	is	<ROOT>	-1
14	(	are	15
15	are	is	13
16	)	are	15
17	responsible	are	15
18	for	responsible	17
19	the	relationship	20
20	relationship	for	18
21	between	relationship	20
22	risk	between	21
23	of	risk	22
24	prostate	cancer	25
25	cancer	of	23
26	and	cancer	25
27	VDR	cancer	25
28	polymorphisms	.	29
29	.	VDR	27

0	Peripheral	mononuclear	2
1	blood	mononuclear	2
2	mononuclear	are	7
3	cells	mononuclear	2
4	(	mononuclear	2
5	PBMCs	mononuclear	2
6	)	mononuclear	2
7	are	<ROOT>	-1
8	a	model	10
9	good	model	10
10	model	are	7
11	for	model	10
12	studies	for	11
13	of	studies	12
14	GR	of	13
15	in	of	13
16	humans	are	7
17	.	are	7

0	c-Rel	is	1
1	is	<ROOT>	-1
2	a	target	3
3	target	is	1
4	of	target	3
5	pentoxifylline-mediated	of	4
6	inhibition	pentoxifylline-mediated	5
7	of	lymphocyte	9
8	T	lymphocyte	9
9	lymphocyte	inhibition	6
10	activation	is	1
11	.	is	1

0	Analysis	revealed	7
1	of	(	3
2	RelA	of	1
3	(	Analysis	0
4	p65	(	3
5	)	Analysis	0
6	mRNA	Analysis	0
7	revealed	<ROOT>	-1
8	that	revealed	7
9	the	stability	10
10	stability	that	8
11	of	(	13
12	RelA	of	11
13	(	stability	10
14	p65	(	13
15	)	mRNA	16
16	mRNA	stability	10
17	was	mRNA	16
18	significantly	higher	19
19	higher	stability	10
20	in	stability	10
21	MDMs	stability	10
22	,	stability	10
23	compared	stability	10
24	with	compared	23
25	monocytes	revealed	7
26	.	revealed	7

0	The	role	1
1	role	remains	19
2	of	role	1
3	the	GR	4
4	GR	of	2
5	and	mineralocorticoid	6
6	mineralocorticoid	receptor	7
7	receptor	(	8
8	(	role	1
9	MR	(	8
10	)	(	8
11	in	)	10
12	the	regulation	14
13	CRH	regulation	14
14	regulation	in	11
15	in	(	8
16	the	patients	18
17	FMS	patients	18
18	patients	in	15
19	remains	<ROOT>	-1
20	to	remains	19
21	be	to	20
22	solved	be	21
23	.	remains	19

0	Biological	<ROOT>	-1
1	markers	Biological	0
2	of	markers	1
3	ovulation	of	2
4	,	Biological	0
5	after	Biological	0
6	a	great	7
7	great	after	5
8	in	great	7
9	the	past	10
10	past	in	8
11	,	Biological	0
12	have	Biological	0
13	been	have	12
14	fallen	been	13
15	into	fallen	14
16	disuse	into	15
17	for	fallen	14
18	the	diffusion	20
19	large	diffusion	20
20	diffusion	for	17
21	of	diffusion	20
22	biochemical	of	21
23	and	of	21
24	biophysical	ones	25
25	ones	have	12
26	.	Biological	0

0	The	sites	3
1	transcriptional	sites	3
2	start	sites	3
3	sites	were	4
4	were	<ROOT>	-1
5	identified	were	4
6	by	identified	5
7	an	by	6
8	RNase	.	11
9	protection	.	11
10	assay	.	11
11	.	an	7

0	The	importance	1
1	importance	of	2
2	of	was	12
3	TNF-alpha	of	2
4	release	of	2
5	in	release	4
6	NF-kappaB	induction	7
7	induction	of	2
8	by	of	2
9	HOCl	by	8
10	or	HOCl	9
11	H2O2	of	2
12	was	was	42
13	demonstrated	was	12
14	by	demonstrated	13
15	the	fact	16
16	fact	by	14
17	that	fact	16
18	:	fact	16
19	(	1	20
20	1	was	27
21	)	1	20
22	the	appearance	24
23	nuclear	appearance	24
24	appearance	was	27
25	of	appearance	24
26	NF-kappaB	of	25
27	was	fact	16
28	promoted	in	29
29	in	was	27
30	untreated	was	27
31	cells	untreated	30
32	;	was	27
33	and	(	34
34	(	was	27
35	2	(	34
36	)	was	27
37	synergism	was	27
38	between	synergism	37
39	TNF-alpha	between	38
40	and	TNF-alpha	39
41	HOCl	was	12
42	was	<ROOT>	-1
43	detected	was	42
44	.	was	42

0	This	silencer	1
1	silencer	is	2
2	is	<ROOT>	-1
3	inactive	is	2
4	in	is	2
5	the	thymocytes	9
6	most	immature	7
7	immature	thymocytes	9
8	DN	thymocytes	9
9	thymocytes	in	4
10	,	is	2
11	which	probably	12
12	probably	is	2
13	use	silencer	16
14	a	silencer	16
15	distinct	silencer	16
16	silencer	probably	12
17	mechanism	probably	12
18	to	mechanism	17
19	down-regulate	to	18
20	CD4	down-regulate	19
21	gene	CD4	20
22	expression	.	23
23	.	gene	21

0	The	identical	15
1	C-terminal	The	0
2	half	C-terminal	1
3	of	half	2
4	human	MZF-2	5
5	MZF-2	of	3
6	,	MZF-2	5
7	carrying	half	2
8	the	carrying	7
9	zinc	,	12
10	finger	,	12
11	domains	,	12
12	,	the	8
13	was	The	0
14	completely	identical	15
15	identical	<ROOT>	-1
16	with	identical	15
17	that	with	16
18	of	human	19
19	human	that	17
20	MZF-1	identical	15
21	,	identical	15
22	whereas	identical	15
23	the	MZF-2	27
24	N-terminal	MZF-2	27
25	half	MZF-2	27
26	of	MZF-2	27
27	MZF-2	was	28
28	was	whereas	22
29	different	was	28
30	from	different	29
31	the	from	30
32	corresponding	human	35
33	region	human	35
34	of	human	35
35	human	the	31
36	MZF-1	the	31
37	,	MZF-1	36
38	and	,	37
39	was	and	38
40	coded	was	39
41	by	coded	40
42	distinct	by	41
43	exons	.	44
44	.	distinct	42

0	AIMS	<ROOT>	-1
1	AND	AIMS	0
2	BACKGROUND	AND	1
3	:	BACKGROUND	2
4	Structurally	AIMS	0
5	altered	AIMS	0
6	proteins	altered	5
7	(	proteins	6
8	derived	(	7
9	from	derived	8
10	chromosomal	from	9
11	translocations	chromosomal	10
12	or	gene	13
13	gene	be	17
14	mutations	gene	13
15	)	can	16
16	can	mutations	14
17	be	translocations	11
18	considered	be	17
19	tumor	specific	20
20	specific	considered	18
21	antigens	specific	20
22	and	an	24
23	represent	an	24
24	an	antigens	21
25	attractive	target	26
26	target	T-cell	29
27	for	T-cell	29
28	a	T-cell	29
29	T-cell	mediated	30
30	mediated	an	24
31	response	from	9
32	.	AIMS	0

0	We	find	2
1	now	find	2
2	find	<ROOT>	-1
3	that	mutating	4
4	mutating	find	2
5	two	tyrosines	6
6	tyrosines	mutating	4
7	to	tyrosines	6
8	an	isoleucine	9
9	isoleucine	to	7
10	at	find	2
11	the	end	13
12	carboxyl	end	13
13	end	at	10
14	of	end	13
15	the	tail	17
16	cytoplasmic	tail	17
17	tail	of	14
18	cripples	find	2
19	the	ability	20
20	ability	cripples	18
21	of	ability	20
22	EBV	of	21
23	to	ability	20
24	cause	to	23
25	lymphoblastoid	cause	24
26	cell	marking	30
27	outgrowth	marking	30
28	,	marking	30
29	thereby	marking	30
30	marking	lymphoblastoid	25
31	a	site	35
32	second	site	35
33	transformation	site	35
34	effector	site	35
35	site	marking	30
36	,	find	2
37	TES2	find	2
38	.	find	2

0	Co-ligation	proteins	32
1	of	Co-ligation	0
2	the	antigen	4
3	A6H	antigen	4
4	antigen	of	1
5	and	antigen	4
6	the	and	5
7	CD3	induced	9
8	complex	induced	9
9	induced	the	6
10	expression	of	11
11	of	the	6
12	the	factor	14
13	transcription	factor	14
14	factor	of	11
15	AP-1	Co-ligation	0
16	in	AP-1	15
17	CD4+	Co-ligation	0
18	T	Co-ligation	0
19	cells	Co-ligation	0
20	,	Co-ligation	0
21	whereas	Co-ligation	0
22	no	increase	23
23	increase	whereas	21
24	in	increase	23
25	NF-kappa	B	26
26	B	in	24
27	and	increase	23
28	octamer-binding	(	29
29	(	and	27
30	Oct	(	29
31	)	(	29
32	proteins	<ROOT>	-1
33	was	proteins	32
34	seen	was	33
35	compared	seen	34
36	to	T	37
37	T	compared	35
38	cells	proteins	32
39	stimulated	proteins	32
40	with	proteins	32
41	anti-CD3	proteins	32
42	alone	proteins	32
43	.	proteins	32

0	None	was	7
1	of	None	0
2	the	putative	4
3	other	putative	4
4	putative	of	1
5	regulatory	sites	6
6	sites	putative	4
7	was	<ROOT>	-1
8	occupied	was	7
9	in	occupied	8
10	vivo	in	9
11	,	was	7
12	indicating	was	7
13	that	indicating	12
14	they	may	15
15	may	that	13
16	not	may	15
17	be	may	15
18	functional	be	17
19	.	was	7

0	B-cell	leukemia	3
1	chronic	leukemia	3
2	lymphocytic	leukemia	3
3	leukemia	<ROOT>	-1
4	(	leukemia	3
5	B-CLL	leukemia	3
6	)	cells	7
7	cells	leukemia	3
8	accumulate	leukemia	3
9	in	leukemia	3
10	vivo	leukemia	3
11	in	vivo	10
12	the	in	11
13	G0/G1	leukemia	3
14	phase	of	15
15	of	leukemia	3
16	the	cycle	18
17	cell	cycle	18
18	cycle	of	15
19	,	leukemia	3
20	suggesting	leukemia	3
21	that	suggesting	20
22	their	that	21
23	malignant	their	22
24	expansion	is	25
25	is	malignant	23
26	due	is	25
27	,	is	25
28	at	in	30
29	least	at	28
30	in	is	25
31	part	in	30
32	,	malignant	23
33	to	malignant	23
34	a	delay	35
35	delay	to	33
36	in	cell	37
37	cell	delay	35
38	death	malignant	23
39	.	leukemia	3

0	The	dinucleotide	2
1	CpG	dinucleotide	2
2	dinucleotide	is	6
3	in	dinucleotide	2
4	this	element	5
5	element	in	3
6	is	<ROOT>	-1
7	selectively	methylated	8
8	methylated	is	6
9	in	T	11
10	Th2	T	11
11	T	methylated	8
12	cells	is	6
13	and	other	14
14	other	is	6
15	cells	is	6
16	that	do	17
17	do	is	6
18	not	do	17
19	express	do	17
20	IFN-gamma	express	19
21	,	is	6
22	and	transcription	26
23	methylation	transcription	26
24	markedly	reduces	25
25	reduces	transcription	26
26	transcription	is	6
27	factor	transcription	26
28	binding	is	6
29	.	is	6

0	A	<ROOT>	-1
1	similar	A	0
2	adhesive	was	4
3	response	was	4
4	was	similar	1
5	elicited	was	4
6	by	elicited	5
7	TNF	was	4
8	alpha	(	9
9	(	was	4
10	100	)	12
11	U/ml	)	12
12	)	(	9
13	,	)	12
14	one	was	4
15	of	one	14
16	the	inducers	19
17	most	potent	18
18	potent	inducers	19
19	inducers	of	15
20	of	inducers	19
21	endothelial	properties	24
22	cell	properties	24
23	adhesive	properties	24
24	properties	of	20
25	,	A	0
26	here	A	0
27	used	here	26
28	as	used	27
29	positive	as	28
30	control	positive	29
31	.	control	30

0	We	show	1
1	show	<ROOT>	-1
2	that	interacts	4
3	PRE-I	interacts	4
4	interacts	show	1
5	with	interacts	4
6	PMA-	with	5
7	and	PMA-	6
8	PMA/ionomycin-inducible	interacts	4
9	,	interacts	4
10	cyclosporin	interacts	4
11	A-sensitive	cyclosporin	10
12	nuclear	factors	13
13	factors	interacts	4
14	.	show	1

0	An	element	2
1	enhancer-blocking	element	2
2	element	was	12
3	(	element	2
4	BEAD-1	element	2
5	,	BEAD-1	4
6	for	,	5
7	blocking	alpha/delta	9
8	element	alpha/delta	9
9	alpha/delta	,	5
10	1	,	5
11	)	,	5
12	was	<ROOT>	-1
13	localized	was	12
14	to	localized	13
15	a	3'	18
16	2.0-kb	3'	18
17	region	3'	18
18	3'	to	14
19	of	3'	18
20	TCR	delta	21
21	delta	of	19
22	gene	segments	23
23	segments	delta	21
24	and	segments	23
25	5'	was	12
26	of	TCR	27
27	TCR	5'	25
28	alpha	was	12
29	joining	was	12
30	gene	was	12
31	segments	within	32
32	within	was	12
33	this	locus	34
34	locus	within	32
35	.	was	12

0	Association	<ROOT>	-1
1	of	Association	0
2	TRAF1	of	1
3	,	Association	0
4	TRAF2	Association	0
5	,	TRAF2	4
6	and	,	5
7	TRAF3	Association	0
8	with	Association	0
9	an	domain	13
10	Epstein-Barr	domain	13
11	virus	domain	13
12	LMP1	domain	13
13	domain	with	8
14	important	domain	13
15	for	important	14
16	B-lymphocyte	transformation	17
17	transformation	for	15
18	:	transformation	17
19	role	for	15
20	in	for	15
21	NF-kappaB	Association	0
22	activation	Association	0
23	.	Association	0

0	The	compound	1
1	compound	induced	2
2	induced	<ROOT>	-1
3	G1	arrest	4
4	arrest	induced	2
5	and	granulocytic	6
6	granulocytic	of	8
7	differentiation	granulocytic	6
8	of	arrest	4
9	HL-60	of	8
10	cells	,	11
11	,	HL-60	9
12	although	induced	2
13	the	effect	15
14	differentiation-inducing	effect	15
15	effect	was	16
16	was	although	12
17	modest	was	16
18	.	induced	2

0	In	transfected	4
1	murine	In	0
2	Ba/F3	cells	3
3	cells	In	0
4	transfected	human	7
5	with	human	7
6	the	human	7
7	human	<ROOT>	-1
8	G-CSFR	human	7
9	and	G-CSFR	8
10	NFS-60	and	9
11	cells	human	7
12	constitutively	expressing	13
13	expressing	murine	15
14	the	murine	15
15	murine	human	7
16	G-CSFR	human	7
17	,	human	7
18	G-CSF	induced	19
19	induced	tyrosine	20
20	tyrosine	human	7
21	phosphorylation	human	7
22	and	human	7
23	activation	human	7
24	of	activation	23
25	Jak1	human	7
26	,	human	7
27	Jak2	human	7
28	,	human	7
29	and	human	7
30	Tyk2	human	7
31	.	human	7

0	By	HeLa	4
1	isolating	HeLa	4
2	Daudi	HeLa	4
3	x	HeLa	4
4	HeLa	<ROOT>	-1
5	heterokaryons	HeLa	4
6	a	hours	8
7	few	hours	8
8	hours	after	9
9	after	heterokaryons	5
10	fusion	after	9
11	,	fusion	10
12	we	heterokaryons	5
13	have	studied	14
14	studied	we	12
15	the	studied	14
16	initial	the	15
17	fate	initial	16
18	of	fate	17
19	two	factors	23
20	B	factors	23
21	cell-specific	factors	23
22	transcription	factors	23
23	factors	of	18
24	involved	of	18
25	in	involved	24
26	Ig	gene	27
27	gene	in	25
28	transcription	gene	27
29	,	initial	16
30	Oct-2	initial	16
31	and	Oct-2	30
32	NF-kappa	B	33
33	B	and	31
34	.	HeLa	4

0	Early	<ROOT>	-1
1	B	Early	0
2	cell	B	1
3	factor	(	4
4	(	cell	2
5	EBF	(	4
6	)	(	4
7	and	)	6
8	E47	)	6
9	participate	B	1
10	in	transcriptional	12
11	the	transcriptional	12
12	transcriptional	participate	9
13	control	transcriptional	12
14	of	control	13
15	early	of	14
16	B	early	15
17	lymphocyte	B	16
18	differentiation	lymphocyte	17
19	.	differentiation	18

0	Thus	is	3
1	,	is	3
2	C/EBPepsilon	is	3
3	is	<ROOT>	-1
4	regulated	is	3
5	in	regulated	4
6	a	fashion	8
7	complex	fashion	8
8	fashion	in	5
9	and	regulated	4
10	may	and	9
11	play	may	10
12	a	play	11
13	role	a	12
14	in	the	15
15	the	role	13
16	regulation	the	15
17	of	regulation	16
18	genes	is	3
19	involved	is	3
20	in	involved	19
21	myeloid	differentiation	22
22	differentiation	involved	19
23	.	is	3

0	In	was	7
1	one	case	2
2	case	In	0
3	,	was	7
4	the	shift	6
5	PTT	shift	6
6	shift	was	7
7	was	<ROOT>	-1
8	explained	was	7
9	by	explained	8
10	in-frame	splicing	11
11	splicing	by	9
12	out	explained	8
13	of	out	12
14	exon	was	7
15	10	was	7
16	,	10	15
17	in	the	18
18	the	,	16
19	presence	normal	22
20	of	normal	22
21	a	normal	22
22	normal	the	18
23	exon	normal	22
24	10	,	16
25	genomic	,	16
26	sequence	was	7
27	.	was	7

0	Deregulation	occurs	4
1	of	Deregulation	0
2	the	pathway	3
3	pathway	of	1
4	occurs	<ROOT>	-1
5	in	occurs	4
6	several	tumors	8
7	human	tumors	8
8	tumors	in	5
9	.	occurs	4

0	We	show	1
1	show	gene	26
2	here	show	1
3	that	show	1
4	the	region	6
5	minimum	region	6
6	region	that	3
7	of	region	6
8	the	promoter	11
9	ferritin	promoter	11
10	H-gene	promoter	11
11	promoter	of	7
12	that	is	13
13	is	promoter	11
14	able	is	13
15	to	able	14
16	confer	transcriptional	17
17	transcriptional	to	15
18	regulation	to	15
19	by	regulation	18
20	heme	is	13
21	in	is	13
22	FLCs	a	24
23	to	a	24
24	a	in	21
25	reporter	show	1
26	gene	<ROOT>	-1
27	is	gene	26
28	77	nucleotides	29
29	nucleotides	is	27
30	upstream	nucleotides	29
31	of	TATA	33
32	the	TATA	33
33	TATA	upstream	30
34	box	gene	26
35	.	gene	26

0	In	<ROOT>	-1
1	addition	In	0
2	,	mutation	3
3	mutation	In	0
4	of	mutation	3
5	the	element	7
6	Y-box	element	7
7	element	of	4
8	alone	Tax1-mediated	10
9	abrogated	Tax1-mediated	10
10	Tax1-mediated	mutation	3
11	activation	In	0
12	.	In	0

0	Because	females	20
1	the	gene	3
2	GATA-1	gene	3
3	gene	is	4
4	is	Because	0
5	located	is	4
6	on	located	5
7	the	chromosome	9
8	X	chromosome	9
9	chromosome	on	6
10	,	which	11
11	which	heterozygous	19
12	is	which	11
13	randomly	is	12
14	inactivated	every	16
15	in	inactivated	14
16	every	randomly	13
17	cell	every	16
18	,	which	11
19	heterozygous	Because	0
20	females	can	21
21	can	active	25
22	bear	can	21
23	either	active	25
24	an	active	25
25	active	wild-type	26
26	wild-type	<ROOT>	-1
27	or	wild-type	26
28	mutant	wild-type	26
29	(	mutant	28
30	referred	(	29
31	to	(	29
32	as	to	31
33	GATA-1.05	as	32
34	)	as	32
35	GATA-1	allele	36
36	allele	)	34
37	,	wild-type	26
38	consequently	,	37
39	leading	consequently	38
40	to	leading	39
41	variable	severity	43
42	anemic	severity	43
43	severity	to	40
44	.	wild-type	26

0	The	disease	4
1	human	disease	4
2	autosomal	disease	4
3	recessive	disease	4
4	disease	<ROOT>	-1
5	,	disease	4
6	xeroderma	pigmentosum	7
7	pigmentosum	disease	4
8	(	XP	9
9	XP	pigmentosum	7
10	)	XP	9
11	,	result	13
12	can	,	11
13	result	pigmentosum	7
14	from	result	13
15	mutations	from	14
16	in	mutations	15
17	any	in	16
18	one	any	17
19	of	one	18
20	seven	of	19
21	genes	,	22
22	,	seven	20
23	designated	seven	20
24	XPA	disease	4
25	through	XPA	24
26	XPG	through	25
27	.	disease	4

0	The	amino-terminal	2
1	c-Jun	amino-terminal	2
2	amino-terminal	kinase	3
3	kinase	(	4
4	(	phosphorylates	7
5	JNK	(	4
6	)	(	4
7	phosphorylates	<ROOT>	-1
8	NFAT4	phosphorylates	7
9	on	NFAT4	8
10	two	sites	11
11	sites	on	9
12	.	phosphorylates	7

0	Induction	depends	6
1	of	Induction	0
2	the	response	5
3	adaptive	response	5
4	immune	response	5
5	response	of	1
6	depends	<ROOT>	-1
7	on	the	8
8	the	depends	6
9	expression	the	8
10	of	co-stimulatory	11
11	co-stimulatory	expression	9
12	molecules	depends	6
13	and	depends	6
14	cytokines	depends	6
15	by	depends	6
16	antigen-presenting	depends	6
17	cells	depends	6
18	.	depends	6

0	Sensitivity	was	5
1	for	Sensitivity	0
2	induction	for	1
3	of	induction	2
4	apoptosis	of	3
5	was	<ROOT>	-1
6	markedly	was	5
7	increased	markedly	6
8	by	increased	7
9	these	treatments	10
10	treatments	by	8
11	in	increased	7
12	apoptosis	in	11
13	sensitive	apoptosis	12
14	cell	sensitive	13
15	lines	cell	14
16	.	lines	15

0	In	,	3
1	functional	studies	2
2	studies	In	0
3	,	construct	12
4	interferon-gamma-stimulated	clones	6
5	PIEC	clones	6
6	clones	,	3
7	transfected	,	3
8	with	mutated	10
9	this	mutated	10
10	mutated	transfected	7
11	CIITA	,	3
12	construct	failed	13
13	failed	<ROOT>	-1
14	to	failed	13
15	stimulate	to	14
16	purified	T	19
17	human	T	19
18	CD4+	T	19
19	T	stimulate	15
20	lymphocytes	failed	13
21	.	failed	13

0	These	factors	2
1	transcription	factors	2
2	factors	are	3
3	are	<ROOT>	-1
4	either	are	3
5	not	are	3
6	produced	are	3
7	due	produced	6
8	to	due	7
9	block	to	8
10	of	block	9
11	transcription	of	10
12	of	of	10
13	their	genes	15
14	respective	genes	15
15	genes	of	12
16	(	Oct-2	17
17	Oct-2	genes	15
18	,	Oct-2	17
19	OBF-1	Oct-2	17
20	,	OBF-1	19
21	PU.1	OBF-1	19
22	)	PU.1	21
23	,	)	22
24	or	)	22
25	are	or	24
26	rendered	posttranslationally	28
27	inactive	posttranslationally	28
28	posttranslationally	NF-kappa	30
29	(	NF-kappa	30
30	NF-kappa	are	25
31	B	NF-kappa	30
32	,	E47	33
33	E47	NF-kappa	30
34	)	E47	33
35	.	are	3

0	Binding	was	8
1	of	Binding	0
2	ER	of	1
3	to	Binding	0
4	an	element	7
5	estrogen	element	7
6	response	element	7
7	element	to	3
8	was	<ROOT>	-1
9	enhanced	was	8
10	by	enhanced	9
11	addition	by	10
12	of	by	10
13	rabbit	lysate	15
14	reticulocyte	lysate	15
15	lysate	of	12
16	.	was	8

0	Reporter	constructs	1
1	constructs	<ROOT>	-1
2	spanning	portions	3
3	portions	constructs	1
4	of	promoter	6
5	the	promoter	6
6	promoter	portions	3
7	identified	constructs	1
8	a	region	9
9	region	constructs	1
10	between	constructs	1
11	-85	between	10
12	and	-85	11
13	-200	and	12
14	that	produced	15
15	produced	constructs	1
16	high	produced	15
17	levels	high	16
18	of	levels	17
19	reporter	of	18
20	gene	activity	21
21	activity	reporter	19
22	in	activity	21
23	lymphoid	constructs	1
24	cells	constructs	1
25	.	constructs	1

0	The	adenovirus	1
1	adenovirus	19K	3
2	E1B	19K	3
3	19K	gene	4
4	gene	plays	5
5	plays	essential	7
6	an	essential	7
7	essential	<ROOT>	-1
8	role	essential	7
9	in	essential	7
10	transformation	in	9
11	of	transformation	10
12	primary	of	11
13	rodent	in	15
14	cells	in	15
15	in	primary	12
16	cooperation	in	15
17	with	cooperation	16
18	E1A	with	17
19	and	E1A	18
20	in	and	19
21	the	inhibition	22
22	inhibition	in	20
23	of	inhibition	22
24	apoptosis	of	23
25	during	in	20
26	lytic	during	25
27	infection	lytic	26
28	.	infection	27

0	The	cellularity	2
1	thymic	cellularity	2
2	cellularity	was	6
3	of	cellularity	2
4	these	mice	5
5	mice	of	3
6	was	<ROOT>	-1
7	significantly	was	6
8	decreased	significantly	7
9	.	decreased	8

0	Tax1	does	1
1	does	<ROOT>	-1
2	not	does	1
3	bind	does	1
4	DNA	bind	3
5	directly	DNA	4
6	but	directly	5
7	regulates	but	6
8	transcription	regulates	7
9	through	transcription	8
10	protein-protein	transcription	8
11	interactions	protein-protein	10
12	with	interactions	11
13	sequence-specific	factors	15
14	transcription	factors	15
15	factors	with	12
16	.	does	1

0	Interestingly	<ROOT>	-1
1	,	Interestingly	0
2	the	activation	4
3	constitutive	activation	4
4	activation	,	1
5	of	activation	4
6	NF-AT1	of	5
7	in	T	9
8	these	T	9
9	T	activation	4
10	cells	Interestingly	0
11	is	cells	10
12	associated	is	11
13	with	associated	12
14	its	dephosphorylation	15
15	dephosphorylation	with	13
16	.	Interestingly	0

0	Six	shifts	2
1	PTT	shifts	2
2	shifts	were	3
3	were	<ROOT>	-1
4	identified	were	3
5	.	were	3

0	This	analysis	1
1	analysis	identified	2
2	identified	<ROOT>	-1
3	one	element	5
4	such	element	5
5	element	identified	2
6	repeated	identified	2
7	four	times	8
8	times	repeated	6
9	within	CD11b	11
10	the	CD11b	11
11	CD11b	repeated	6
12	promoter	repeated	6
13	.	identified	2

0	Crkl	becomes	7
1	,	Crkl	0
2	an	protein	5
3	SH2/SH3	protein	5
4	adapter	protein	5
5	protein	Crkl	0
6	,	Crkl	0
7	becomes	<ROOT>	-1
8	coimmunoprecipitated	becomes	7
9	specifically	coimmunoprecipitated	8
10	with	coimmunoprecipitated	8
11	STAT5	erythropoietin-stimulated	13
12	from	erythropoietin-stimulated	13
13	erythropoietin-stimulated	becomes	7
14	erythroid	becomes	7
15	cells	becomes	7
16	;	becomes	7
17	although	becomes	7
18	it	was	19
19	was	although	17
20	shown	was	19
21	to	shown	20
22	become	to	21
23	associated	become	22
24	with	associated	23
25	c-Cbl	with	24
26	in	c-Cbl	25
27	the	in	26
28	studies	the	27
29	using	cell	30
30	cell	studies	28
31	lines	cell	30
32	.	lines	31

0	In	show	5
1	summary	In	0
2	,	show	5
3	these	studies	4
4	studies	show	5
5	show	<ROOT>	-1
6	that	show	5
7	the	amount	8
8	amount	that	6
9	of	G-LRB-S-RRB-alpha	10
10	G-LRB-S-RRB-alpha	amount	8
11	expression	G-LRB-S-RRB-alpha	10
12	has	amount	8
13	a	impact	15
14	marked	impact	15
15	impact	amount	8
16	on	impact	15
17	the	level	18
18	level	on	16
19	of	level	18
20	activity	of	19
21	of	activity	20
22	the	cascade	24
23	AC	cascade	24
24	cascade	of	21
25	from	activity	20
26	the	membrane	27
27	membrane	from	25
28	through	from	25
29	to	the	30
30	the	through	28
31	nucleus	amount	8
32	.	show	5

0	Synergistic	transactivation	1
1	transactivation	<ROOT>	-1
2	of	response	5
3	the	response	5
4	LPS	response	5
5	response	transactivation	1
6	element	transactivation	1
7	in	transactivation	1
8	Drosophila	in	7
9	Schneider	transactivation	1
10	cells	transactivation	1
11	by	transactivation	1
12	coexpression	by	11
13	of	coexpression	12
14	c-Fos	of	13
15	,	transactivation	1
16	c-Jun	transactivation	1
17	,	transactivation	1
18	c-Rel	transactivation	1
19	,	transactivation	1
20	and	transactivation	1
21	p65	c-Jun	23
22	or	c-Jun	23
23	c-Jun	transactivation	1
24	and	transactivation	1
25	p65	transactivation	1
26	required	the	27
27	the	transactivation	1
28	transactivation	domains	29
29	domains	the	27
30	of	domains	29
31	c-Jun	transactivation	1
32	and	transactivation	1
33	p65	transactivation	1
34	.	transactivation	1

0	CONCLUSION	<ROOT>	-1
1	:	CONCLUSION	0
2	Monocytes	CONCLUSION	0
3	,	Monocytes	2
4	T	,	6
5	cells	,	6
6	,	Monocytes	2
7	and	,	6
8	B	cells	9
9	cells	Monocytes	2
10	in	Monocytes	2
11	patients	CONCLUSION	0
12	express	patients	11
13	transcripts	express	12
14	of	wild	17
15	the	wild	17
16	normal	wild	17
17	wild	transcripts	13
18	type	wild	17
19	ER	CONCLUSION	0
20	and	binding	23
21	the	binding	23
22	hormone	binding	23
23	binding	CONCLUSION	0
24	domain	variants	25
25	variants	CONCLUSION	0
26	in	variants	25
27	vivo	in	26
28	.	CONCLUSION	0

0	We	concluded	1
1	concluded	is	19
2	that	concluded	1
3	,	decreased	8
4	in	decreased	8
5	healthy	subjects	6
6	subjects	in	4
7	,	subjects	6
8	decreased	GC-R	13
9	PBMC	capacity	10
10	capacity	GC-R	13
11	to	GC-R	13
12	amplify	GC-R	13
13	GC-R	that	2
14	numbers	concluded	1
15	in	concluded	1
16	response	in	15
17	to	response	16
18	mitogen	in	15
19	is	<ROOT>	-1
20	correlated	with	21
21	with	is	19
22	GC	is	19
23	resistance	is	19
24	,	is	19
25	whereas	is	19
26	in	CRF	27
27	CRF	whereas	25
28	patients	is	19
29	the	mechanism	31
30	resistant	mechanism	31
31	mechanism	is	32
32	is	is	19
33	not	is	32
34	correlated	with	35
35	with	is	32
36	GC-R	with	35
37	parameters	GC-R	36
38	.	is	19

0	Pancreatic	development	1
1	development	B	7
2	and	development	1
3	maturation	and	2
4	of	B	7
5	the	B	7
6	islet	B	7
7	B	<ROOT>	-1
8	cell	B	7
9	.	B	7

0	The	dysfunction	3
1	age-associated	dysfunction	3
2	immune	dysfunction	3
3	dysfunction	may	4
4	may	<ROOT>	-1
5	be	may	4
6	implicated	be	5
7	to	implicated	6
8	some	degree	9
9	degree	to	7
10	in	degree	9
11	the	in	10
12	extreme	of	14
13	susceptibility	of	14
14	of	the	11
15	the	elderly	16
16	elderly	of	14
17	to	elderly	16
18	infection	to	17
19	and	to	17
20	neoplasia	to	17
21	and	neoplasia	20
22	may	neoplasia	20
23	even	may	22
24	participate	may	22
25	in	participate	24
26	various	aspects	27
27	aspects	in	25
28	of	aspects	27
29	senescence	of	28
30	.	may	4

0	The	element	3
1	negative	element	3
2	regulatory	element	3
3	element	<ROOT>	-1
4	(	element	3
5	NRE	element	3
6	)	element	3
7	of	contains	17
8	the	promoter	16
9	hepatitis	HBV	13
10	B	virus	11
11	virus	(	12
12	(	hepatitis	9
13	HBV	core	15
14	)	HBV	13
15	core	the	8
16	promoter	of	7
17	contains	element	3
18	three	element	3
19	subregions	act	21
20	which	act	21
21	act	element	3
22	synergistically	element	3
23	to	synergistically	22
24	suppress	to	23
25	core	suppress	24
26	promoter	core	25
27	activity	suppress	24
28	.	element	3

0	BSAP	failed	1
1	failed	<ROOT>	-1
2	to	failed	1
3	trans-activate	to	2
4	CD19	constructs	6
5	promoter	constructs	6
6	constructs	trans-activate	3
7	in	trans-activate	3
8	B	cells	9
9	cells	in	7
10	or	trans-activate	3
11	non-B	failed	1
12	cells	failed	1
13	,	failed	1
14	suggesting	failed	1
15	that	suggesting	14
16	cis	elements	17
17	elements	are	25
18	such	as	19
19	as	elements	17
20	the	PyG	21
21	PyG	as	19
22	and	PyG	21
23	GC	boxes	24
24	boxes	and	22
25	are	that	15
26	also	are	25
27	necessary	are	25
28	for	promoter	32
29	high	promoter	32
30	level	promoter	32
31	CD19	promoter	32
32	promoter	are	25
33	expression	failed	1
34	.	failed	1

0	Isolation	<ROOT>	-1
1	of	Isolation	0
2	a	promoter	4
3	B-cell-specific	promoter	4
4	promoter	of	1
5	for	promoter	4
6	the	transactivator	10
7	human	transactivator	10
8	class	transactivator	10
9	II	transactivator	10
10	transactivator	for	5
11	.	Isolation	0

0	The	onset	1
1	onset	both	3
2	of	both	3
3	both	processes	4
4	processes	was	5
5	was	<ROOT>	-1
6	found	was	5
7	to	found	6
8	be	to	7
9	closely	paralleled	10
10	paralleled	be	8
11	by	paralleled	10
12	,	by	11
13	and	by	11
14	dependent	and	13
15	on	dependent	14
16	,	on	15
17	IkappaB-alpha	on	15
18	degradation	IkappaB-alpha	17
19	.	degradation	18

0	Copyright	1997	1
1	1997	<ROOT>	-1
2	Academic	1997	1
3	Press	1997	1
4	.	1997	1

0	Activation	B	3
1	of	NF-kappa	2
2	NF-kappa	Activation	0
3	B	<ROOT>	-1
4	seems	B	3
5	to	seems	4
6	play	to	5
7	an	role	9
8	important	role	9
9	role	play	6
10	in	the	11
11	the	play	6
12	regulation	the	11
13	of	regulation	12
14	many	of	13
15	proinflammatory	many	14
16	cytokine	proinflammatory	15
17	genes	cytokine	16
18	,	genes	17
19	but	,	18
20	can	but	19
21	not	can	20
22	be	can	20
23	the	mechanism	25
24	only	mechanism	25
25	mechanism	be	22
26	,	but	19
27	since	but	19
28	several	since	27
29	cytokine	several	28
30	genes	cytokine	29
31	lack	respective	32
32	respective	binding	33
33	binding	genes	30
34	sites	in	35
35	in	binding	33
36	their	binding	33
37	promoter	.	39
38	regions	.	39
39	.	their	36

0	Similar	alterations	1
1	alterations	were	2
2	were	which	11
3	not	were	2
4	detected	were	2
5	in	detected	4
6	transcripts	in	5
7	of	other	9
8	the	other	9
9	other	in	5
10	genes	which	11
11	which	<ROOT>	-1
12	were	which	11
13	analysed	which	11
14	.	which	11

0	EBNA3C	is	1
1	is	<ROOT>	-1
2	a	is	1
3	potent	a	2
4	repressor	potent	3
5	of	repressor	4
6	transcription	of	5
7	when	bound	8
8	bound	of	5
9	to	bound	8
10	DNA	to	9
11	as	DNA	10
12	a	DNA	10
13	fusion	a	12
14	with	binding	17
15	the	binding	17
16	DNA	binding	17
17	binding	fusion	13
18	domain	(	19
19	(	a	12
20	DBD	is	1
21	)	is	1
22	of	)	21
23	GALA	of	22
24	.	is	1

0	Both	Kd	1
1	Kd	<ROOT>	-1
2	(	Kd	1
3	30.3+/-2.5	(	2
4	versus	30.3+/-2.5	3
5	19.2+/-2.4	versus	4
6	nmol/L	19.2+/-2.4	5
7	)	nmol/L	6
8	and	)	7
9	IC50	and	8
10	values	(	11
11	(	IC50	9
12	15.5+/-1.8	and	8
13	versus	15.5+/-1.8	12
14	8.9+/-1.2	versus	13
15	nmol/L	8.9+/-1.2	14
16	)	for	17
17	for	nmol/L	15
18	cortisol	30.3+/-2.5	3
19	were	cortisol	18
20	significantly	higher	21
21	higher	Kd	1
22	in	Kd	1
23	patients	in	22
24	with	patients	23
25	lower	values	27
26	renin	values	27
27	values	with	24
28	(	Kd	1
29	P	Kd	1
30	&lt;	P	29
31	.03	Kd	1
32	)	Kd	1
33	.	Kd	1

0	The	number	1
1	number	<ROOT>	-1
2	of	number	1
3	GR	of	2
4	and	of	2
5	the	Kd	6
6	Kd	similar	8
7	were	Kd	6
8	similar	and	4
9	in	similar	8
10	the	term	11
11	term	in	9
12	and	similar	8
13	preterm	and	12
14	(	with	15
15	with	preterm	13
16	and	with	15
17	without	and	16
18	NRDS	without	17
19	)	with	15
20	babies	similar	8
21	.	number	1

0	The	analysis	2
1	functional	analysis	2
2	analysis	revealed	7
3	of	analysis	2
4	the	gene	6
5	IL-8	gene	6
6	gene	of	3
7	revealed	<ROOT>	-1
8	that	revealed	7
9	both	AP-1-	10
10	AP-1-	were	15
11	and	AP-1-	10
12	NF-kappaB	elements	14
13	factor-binding	elements	14
14	elements	and	11
15	were	that	8
16	involved	were	15
17	in	involved	16
18	conferring	in	17
19	the	responsiveness	20
20	responsiveness	conferring	18
21	to	responsiveness	20
22	CMV	to	21
23	.	CMV	22

0	To	we	16
1	clarify	To	0
2	the	clarify	1
3	presence	the	2
4	of	presence	3
5	histamine	receptor	6
6	receptor	To	0
7	and	transmembrane	9
8	its	transmembrane	9
9	transmembrane	To	0
10	mechanism	transmembrane	9
11	in	human	12
12	human	T	13
13	T	transmembrane	9
14	lymphocytes	To	0
15	,	To	0
16	we	investigated	17
17	investigated	<ROOT>	-1
18	the	effects	19
19	effects	investigated	17
20	of	effects	19
21	agonists	of	20
22	or	agonists	21
23	antagonists	or	22
24	of	antagonists	23
25	histamine	or	22
26	receptor	subtypes	27
27	subtypes	histamine	25
28	and	or	22
29	bacterial	investigated	17
30	toxins	investigated	17
31	on	intracellular	32
32	intracellular	investigated	17
33	concentration	investigated	17
34	of	investigated	17
35	Ca2+	investigated	17
36	-LSB-Ca2+-RSB-i	investigated	17
37	)	investigated	17
38	,	-LSB-3H-RSB-pyrilamine	39
39	-LSB-3H-RSB-pyrilamine	investigated	17
40	binding	-LSB-3H-RSB-pyrilamine	39
41	and	binding	40
42	c-fos	investigated	17
43	mRNA	investigated	17
44	expression	investigated	17
45	in	expression	44
46	Jurkat	in	45
47	cells	Jurkat	46
48	,	cells	47
49	cloned	T	51
50	human	T	51
51	T	,	48
52	lymphocytes	investigated	17
53	.	investigated	17

0	Rhombotin-2	is	4
1	(	RBTN-2	2
2	RBTN-2	Rhombotin-2	0
3	)	RBTN-2	2
4	is	<ROOT>	-1
5	a	proto-oncogene	6
6	proto-oncogene	is	4
7	only	in	8
8	in	proto-oncogene	6
9	the	context	10
10	context	T	12
11	of	T	12
12	T	in	8
13	lymphocytes	is	4
14	.	is	4

0	Nonetheless	is	12
1	,	is	12
2	only	portion	5
3	a	portion	5
4	limited	portion	5
5	portion	is	12
6	of	portion	5
7	the	domain	9
8	cytoplasmic	domain	9
9	domain	of	6
10	of	domain	9
11	gamma-LRB-c-RRB-	of	10
12	is	<ROOT>	-1
13	necessary	is	12
14	for	necessary	13
15	IL-7R	for	14
16	signal	transduction	17
17	transduction	for	14
18	.	is	12

0	Stimulation	<ROOT>	-1
1	of	blood	2
2	blood	Stimulation	0
3	platelets	Stimulation	0
4	with	Stimulation	0
5	alpha-thrombin	caused	10
6	or	alpha-thrombin	5
7	other	activators	9
8	platelet	activators	9
9	activators	or	6
10	caused	Stimulation	0
11	a	caused	10
12	rapid	and	13
13	and	a	11
14	strong	and	13
15	induction	strong	14
16	of	induction	15
17	Rap1	of	16
18	that	Rap1	17
19	associated	Rap1	17
20	with	associated	19
21	RBD	with	20
22	in	RBD	21
23	vitro	in	22
24	.	Stimulation	0

0	NFAT	proteins	1
1	proteins	constitute	2
2	constitute	<ROOT>	-1
3	a	family	4
4	family	constitute	2
5	of	family	4
6	transcription	factors	7
7	factors	of	5
8	involved	family	4
9	in	involved	8
10	mediating	transduction	12
11	signal	transduction	12
12	transduction	in	9
13	.	constitute	2

0	Biochemical	analysis	1
1	analysis	shows	11
2	by	analysis	1
3	Western	blotting	4
4	blotting	by	2
5	of	hematopoietic	9
6	fetal	of	5
7	and	hematopoietic	9
8	adult	hematopoietic	9
9	hematopoietic	blotting	4
10	populations	analysis	1
11	shows	<ROOT>	-1
12	several	isoforms	14
13	runt	isoforms	14
14	isoforms	shows	11
15	.	shows	11

0	The	effect	1
1	effect	was	7
2	of	effect	1
3	18C7	of	2
4	on	effect	1
5	the	binding	6
6	binding	on	4
7	was	<ROOT>	-1
8	similar	was	7
9	with	similar	8
10	both	.	12
11	hormones	.	12
12	.	with	9

0	It	is	1
1	is	<ROOT>	-1
2	intriguing	is	1
3	that	is	1
4	the	genome	6
5	A-myb	genome	6
6	genome	has	7
7	has	that	3
8	been	has	7
9	localised	been	8
10	relatively	close	11
11	close	localised	9
12	to	close	11
13	the	to	12
14	c-myc	gene	15
15	gene	to	12
16	on	gene	15
17	chromosome	on	16
18	8	chromosome	17
19	,	is	1
20	suggesting	is	1
21	that	suggesting	20
22	the	translocation	24
23	c-myc	translocation	24
24	translocation	that	21
25	in	translocation	24
26	BL	in	25
27	and	translocation	24
28	B-ALL	and	27
29	may	B-ALL	28
30	affect	A-myb	31
31	A-myb	may	29
32	transcription	is	1
33	.	is	1

0	Infection	induces	8
1	of	human	2
2	human	Infection	0
3	monocytes	Infection	0
4	with	monocytes	3
5	influenza	virus	7
6	A	virus	7
7	virus	with	4
8	induces	<ROOT>	-1
9	a	range	11
10	broad	range	11
11	range	induces	8
12	of	range	11
13	proinflammatory	cytokines	14
14	cytokines	of	12
15	and	induces	8
16	mononuclear	induces	8
17	cell	induces	8
18	attracting	cell	17
19	chemokines	attracting	18
20	before	chemokines	19
21	the	before	20
22	infected	undergo	24
23	cells	undergo	24
24	undergo	the	21
25	apoptosis	undergo	24
26	.	induces	8

0	Involvement	B1	14
1	of	Involvement	0
2	Egr-1/RelA	synergy	3
3	synergy	of	1
4	in	cell	7
5	distinguishing	cell	7
6	T	cell	7
7	cell	synergy	3
8	activation	Involvement	0
9	from	NF-kappa	13
10	tumor	NF-kappa	13
11	necrosis	NF-kappa	13
12	factor-alpha-induced	NF-kappa	13
13	NF-kappa	Involvement	0
14	B1	<ROOT>	-1
15	transcription	B1	14
16	.	B1	14

0	Diffusible	proteins	2
1	endothelial	proteins	2
2	proteins	<ROOT>	-1
3	such	as	4
4	as	proteins	2
5	soluble	E-selectin	6
6	E-selectin	as	4
7	,	E-selectin	6
8	PAI-1	E-selectin	6
9	and	PAI-1	8
10	vWf	and	9
11	to	vWf	10
12	a	extent	14
13	minimal	extent	14
14	extent	to	11
15	,	proteins	2
16	increased	proteins	2
17	in	increased	16
18	supernatants	in	17
19	from	increased	16
20	HUVEC	cocultured	21
21	cocultured	from	19
22	for	increased	16
23	24	h	24
24	h	for	22
25	with	increased	16
26	prestimulated	with	25
27	THP-1	prestimulated	26
28	cells	THP-1	27
29	.	proteins	2

0	Induction	<ROOT>	-1
1	of	Induction	0
2	vascular	of	1
3	cell	vascular	2
4	adhesion	by	6
5	molecule-1	by	6
6	by	cell	3
7	low-density	cell	3
8	lipoprotein	vascular	2
9	.	Induction	0

0	This	report	1
1	report	describes	2
2	describes	<ROOT>	-1
3	studies	describes	2
4	indicating	studies	3
5	that	indicating	4
6	the	proximal	8
7	most	proximal	8
8	proximal	is	14
9	of	proximal	8
10	these	elements	13
11	two	elements	13
12	regulatory	elements	13
13	elements	of	9
14	is	that	5
15	an	determinant	17
16	important	determinant	17
17	determinant	is	14
18	of	determinant	17
19	its	expression	21
20	restricted	expression	21
21	expression	of	18
22	.	describes	2

0	Repression	required	4
1	of	Repression	0
2	Cp	activity	3
3	activity	of	1
4	required	<ROOT>	-1
5	amino	to	8
6	acids	to	8
7	207	to	8
8	to	required	4
9	368	required	4
10	,	required	4
11	which	encompasses	12
12	encompasses	required	4
13	a	encompasses	12
14	region	a	13
15	resembling	region	14
16	a	DBD	18
17	basic	DBD	18
18	DBD	resembling	15
19	adjacent	required	4
20	to	binding	25
21	a	binding	25
22	leucine	binding	25
23	zipper	binding	25
24	DNA	binding	25
25	binding	adjacent	19
26	motif	required	4
27	and	required	4
28	a	site	29
29	site	and	27
30	which	binds	31
31	binds	site	29
32	to	cellular	34
33	the	cellular	34
34	cellular	binds	31
35	factor	cellular	34
36	CBF1/RBP-Jkappa	site	29
37	.	required	4

0	Thus	may	13
1	,	may	13
2	Tax	may	13
3	,	Tax	2
4	through	Tax	2
5	enhancement	through	4
6	of	enhancement	5
7	the	activity	9
8	DNA-binding	activity	9
9	activity	of	6
10	of	activity	9
11	E2F	of	10
12	,	Tax	2
13	may	<ROOT>	-1
14	be	may	13
15	capable	be	14
16	of	capable	15
17	regulating	of	16
18	cellular	expression	20
19	gene	expression	20
20	expression	regulating	17
21	implicated	expression	20
22	in	implicated	21
23	the	proliferation	24
24	proliferation	implicated	21
25	and	proliferation	24
26	transformation	and	25
27	of	transformation	26
28	T	cells	29
29	cells	transformation	26
30	in	implicated	21
31	ATL	be	14
32	.	may	13

0	It	has	1
1	has	<ROOT>	-1
2	therefore	has	1
3	been	has	1
4	proposed	E2F	6
5	that	E2F	6
6	E2F	been	3
7	is	cellular	10
8	involved	cellular	10
9	in	cellular	10
10	cellular	has	1
11	proliferation	has	1
12	control	has	1
13	.	has	1

0	The	described	3
1	transgenic	mice	2
2	mice	described	3
3	described	provide	5
4	here	described	3
5	provide	<ROOT>	-1
6	an	model	9
7	apparently	accurate	8
8	accurate	model	9
9	model	provide	5
10	for	model	9
11	human	APL	12
12	APL	for	10
13	that	includes	14
14	includes	model	9
15	clear	evidence	16
16	evidence	includes	14
17	of	tumor	18
18	tumor	evidence	16
19	progression	provide	5
20	.	provide	5

0	In	have	7
1	fact	In	0
2	,	have	7
3	the	offspring	4
4	offspring	have	7
5	of	offspring	4
6	alcoholics	of	5
7	have	<ROOT>	-1
8	higher	levels	9
9	levels	have	7
10	of	G-LRB-S-RRB-alpha	11
11	G-LRB-S-RRB-alpha	levels	9
12	expression	in	13
13	in	have	7
14	certain	tissues	15
15	tissues	in	13
16	compared	have	7
17	with	compared	16
18	the	offspring	19
19	offspring	with	17
20	of	offspring	19
21	nonalcoholics	of	20
22	.	have	7

0	The	element	3
1	proximal	element	3
2	regulatory	element	3
3	element	mediates	8
4	of	element	3
5	the	promoter	7
6	interferon-gamma	promoter	7
7	promoter	of	4
8	mediates	<ROOT>	-1
9	selective	expression	10
10	expression	mediates	8
11	in	T	12
12	T	mediates	8
13	cells	mediates	8
14	.	mediates	8

0	The	data	1
1	data	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	cellular	genes	5
5	genes	might	6
6	might	that	3
7	be	might	6
8	activated	be	7
9	by	activated	8
10	Ad2	virus	11
11	virus	by	9
12	infection	virus	11
13	in	nonpermissive	14
14	nonpermissive	be	7
15	cells	where	16
16	where	indicate	2
17	no	products	20
18	viral	products	20
19	gene	products	20
20	products	where	16
21	could	indicate	2
22	be	could	21
23	detected	be	22
24	.	indicate	2

0	New	knowledge	1
1	knowledge	may	8
2	on	knowledge	1
3	the	mechanism	4
4	mechanism	on	2
5	of	mechanism	4
6	steroid	resistance	7
7	resistance	of	5
8	may	<ROOT>	-1
9	have	may	8
10	important	implications	11
11	implications	have	9
12	for	implications	11
13	the	treatment	14
14	treatment	for	12
15	of	treatment	14
16	chronic	asthma	17
17	asthma	of	15
18	and	may	8
19	other	and	18
20	diseases	.	21
21	.	other	19

0	Rheumatoid	is	2
1	arthritis	is	2
2	is	<ROOT>	-1
3	a	disorder	5
4	multistep	disorder	5
5	disorder	is	2
6	associated	disorder	5
7	with	associated	6
8	autoimmune	features	9
9	features	with	7
10	of	features	9
11	yet	of	10
12	unknown	etiology	13
13	etiology	of	10
14	.	is	2

0	The	network	2
1	complex	network	2
2	network	are	6
3	of	cytokines	4
4	cytokines	that	5
5	that	network	2
6	are	responses	12
7	involved	are	6
8	in	involved	7
9	inflammatory	and	10
10	and	involved	7
11	immunoregulatory	are	6
12	responses	plays	13
13	plays	critical	15
14	a	critical	15
15	critical	<ROOT>	-1
16	role	critical	15
17	in	role	16
18	the	pathogenesis	19
19	pathogenesis	HIV	21
20	of	HIV	21
21	HIV	in	17
22	infection	HIV	21
23	.	infection	22

0	In	<ROOT>	-1
1	addition	In	0
2	to	addition	1
3	the	to	2
4	CD11b	gene	5
5	gene	also	14
6	,	the	7
7	the	gene	5
8	homologous	genes	9
9	genes	the	7
10	encoding	CD11a	11
11	CD11a	the	7
12	and	CD11a	11
13	CD11c	and	12
14	also	the	3
15	exhibit	also	14
16	inducible	In	0
17	expression	In	0
18	during	expression	17
19	myeloid	In	0
20	differentiation	In	0
21	.	In	0

0	Here	demonstrate	2
1	we	demonstrate	2
2	demonstrate	<ROOT>	-1
3	that	demonstrate	2
4	AML1a	that	3
5	,	AML1a	4
6	which	has	8
7	solely	has	8
8	has	AML1a	4
9	no	effects	10
10	effects	has	8
11	as	effects	10
12	a	regulator	14
13	transcriptional	regulator	14
14	regulator	as	11
15	,	AML1a	4
16	dominantly	AML1a	4
17	suppresses	transcriptional	18
18	transcriptional	dominantly	16
19	activation	demonstrate	2
20	by	demonstrate	2
21	AML1b	by	20
22	,	demonstrate	2
23	and	demonstrate	2
24	that	exhibits	26
25	AML1a	exhibits	26
26	exhibits	and	23
27	the	affinity	29
28	higher	affinity	29
29	affinity	exhibits	26
30	for	affinity	29
31	DNA-binding	for	30
32	than	affinity	29
33	AML1b	than	32
34	.	demonstrate	2

0	Furthermore	show	3
1	,	show	3
2	we	show	3
3	show	<ROOT>	-1
4	that	show	3
5	patients	have	9
6	with	patients	5
7	GC-insensitive	asthma	8
8	asthma	with	6
9	have	that	4
10	cytokine-induced	have	9
11	abnormalities	cytokine-induced	10
12	in	abnormalities	11
13	the	in	12
14	DNA	binding	15
15	binding	the	13
16	capability	the	18
17	of	the	18
18	the	the	13
19	GCR	show	3
20	.	show	3

0	At	one	2
1	least	one	2
2	one	appears	5
3	of	one	2
4	them	of	3
5	appears	<ROOT>	-1
6	to	appears	5
7	be	to	6
8	myeloid	specific	9
9	specific	be	7
10	.	specific	9

0	Nuclear	is	9
1	factor-kappaB	Nuclear	0
2	activation	in	3
3	in	factor-kappaB	1
4	human	in	3
5	monocytes	stimulated	6
6	stimulated	human	4
7	with	stimulated	6
8	lipopolysaccharide	stimulated	6
9	is	<ROOT>	-1
10	inhibited	is	9
11	by	inhibited	10
12	fibroblast	and	15
13	conditioned	and	15
14	medium	and	15
15	and	by	11
16	exogenous	PGE2	17
17	PGE2	and	15
18	.	is	9

0	This	complex	2
1	protein	complex	2
2	complex	was	3
3	was	<ROOT>	-1
4	more	abundant	5
5	abundant	was	3
6	in	was	3
7	U-937	in	6
8	,	was	3
9	K-562	was	3
10	,	was	3
11	and	HeLa	12
12	HeLa	was	3
13	cell	extracts	14
14	extracts	HeLa	12
15	than	HeLa	12
16	in	than	15
17	Raji	in	16
18	,	was	3
19	HF	was	3
20	,	was	3
21	BALB/c	3T3	22
22	3T3	was	3
23	,	was	3
24	or	HL-60	25
25	HL-60	was	3
26	cells	was	3
27	,	was	3
28	but	was	3
29	the	activity	31
30	binding	the	29
31	activity	was	32
32	was	but	28
33	altered	twofold	35
34	only	twofold	35
35	twofold	was	32
36	after	twofold	35
37	TPA	twofold	35
38	treatment	.	39
39	.	TPA	37

0	This	spontaneous	2
1	``	spontaneous	2
2	spontaneous	is	4
3	stimulation	spontaneous	2
4	is	<ROOT>	-1
5	also	noted	6
6	noted	is	4
7	with	noted	6
8	some	genes	11
9	other	genes	11
10	G0S	genes	11
11	genes	with	7
12	and	genes	11
13	has	and	12
14	been	has	13
15	attributed	been	14
16	to	attributed	15
17	some	to	16
18	aspect	some	17
19	of	the	20
20	the	procedure	22
21	isolation	procedure	22
22	procedure	aspect	18
23	.	procedure	22

0	TRAMP	is	1
1	is	<ROOT>	-1
2	abundantly	is	1
3	expressed	abundantly	2
4	on	expressed	3
5	thymocytes	on	4
6	and	thymocytes	5
7	lymphocytes	and	6
8	.	and	6

0	Therefore	(	11
1	we	Therefore	0
2	investigated	the	3
3	the	we	1
4	properties	and	5
5	and	the	3
6	function	of	7
7	of	and	5
8	the	glucocorticoid	9
9	glucocorticoid	of	7
10	receptors	(	11
11	(	<ROOT>	-1
12	GR	(	11
13	)	(	11
14	in	(	11
15	FMS	(	11
16	patients	(	11
17	and	(	11
18	compared	(	11
19	the	results	20
20	results	compared	18
21	with	results	20
22	those	with	21
23	of	those	22
24	healthy	of	23
25	persons	healthy	24
26	and	persons	25
27	patients	and	26
28	with	patients	27
29	chronic	pain	32
30	low	pain	32
31	back	pain	32
32	pain	with	28
33	(	pain	32
34	LBP	a	35
35	a	(	33
36	localized	condition	38
37	pain	condition	38
38	condition	a	35
39	)	condition	38
40	.	(	11

0	We	<ROOT>	-1
1	have	We	0
2	packaged	Flexi-12	3
3	Flexi-12	have	1
4	into	Flexi-12	3
5	a	virus	8
6	recombinant	virus	8
7	adeno-associated	virus	8
8	virus	into	4
9	(	AAV	10
10	AAV	Flexi-12	3
11	)	AAV	10
12	and	Flexi-12	3
13	used	this	14
14	this	and	12
15	vector	and	12
16	to	vector	15
17	infect	leukemic	20
18	acute	leukemic	20
19	myeloid	leukemic	20
20	leukemic	to	16
21	(	AML	22
22	AML	leukemic	20
23	)	AML	22
24	blasts	leukemic	20
25	.	We	0

0	Thus	may	8
1	the	suppression	2
2	suppression	may	8
3	of	suppression	2
4	CD11b/CD18	expression	5
5	expression	of	3
6	by	suppression	2
7	tepoxalin	by	6
8	may	involve	9
9	involve	<ROOT>	-1
10	IL-8	involve	9
11	.	IL-8	10

0	While	infection	46
1	the	sera	2
2	sera	individuals	5
3	of	sera	2
4	EBV-negative	of	3
5	individuals	did	15
6	(	0/3	7
7	0/3	individuals	5
8	)	0/3	7
9	or	individuals	5
10	healthy	carriers	11
11	carriers	or	9
12	(	0/33	13
13	0/33	carriers	11
14	)	0/33	13
15	did	While	0
16	not	did	15
17	contain	did	15
18	detectable	of	20
19	levels	detectable	18
20	of	contain	17
21	antibodies	While	0
22	,	While	0
23	patients	While	0
24	with	patients	23
25	mononucleosis	While	0
26	(	5/18	27
27	5/18	mononucleosis	25
28	)	5/18	27
29	,	mononucleosis	25
30	chronic	infection	32
31	EBV	infection	32
32	infection	mononucleosis	25
33	(	infection	32
34	2/7	infection	32
35	)	,	36
36	,	2/7	34
37	EBV	reactivation	38
38	reactivation	,	36
39	(	reactivation	38
40	7/20	While	0
41	)	While	0
42	and	While	0
43	human	While	0
44	immunodeficiency	infection	46
45	virus	infection	46
46	infection	titres	53
47	(	5/24	48
48	5/24	infection	46
49	)	5/24	48
50	showed	infection	46
51	elevated	titres	53
52	antibody	titres	53
53	titres	<ROOT>	-1
54	against	titres	53
55	the	enzyme	56
56	enzyme	against	54
57	.	titres	53

0	Addition	<ROOT>	-1
1	of	Addition	0
2	an	antibody	5
3	anti-TNF	alpha	4
4	alpha	antibody	5
5	antibody	of	1
6	decreased	antibody	5
7	by	decreased	6
8	40	by	7
9	%	E-selectin	10
10	E-selectin	40	8
11	and	40	8
12	ICAM-1	Addition	0
13	induction	and	14
14	and	ICAM-1	12
15	suppressed	ICAM-1	12
16	PAI-1	overproduction	17
17	overproduction	suppressed	15
18	with	suppressed	15
19	a	with	18
20	weak	a	19
21	effect	weak	20
22	on	effect	21
23	vWf	on	22
24	.	Addition	0

0	In	subsets	16
1	contrast	In	0
2	,	In	0
3	the	characterization	4
4	characterization	,	2
5	of	characterization	4
6	transcription	factors	7
7	factors	of	5
8	selectively	characterization	4
9	regulating	selectively	8
10	cytokine	T	14
11	production	by	12
12	by	T	14
13	CD4+	T	14
14	T	regulating	9
15	cell	T	14
16	subsets	is	17
17	is	<ROOT>	-1
18	at	is	17
19	a	at	18
20	very	a	19
21	early	.	23
22	stage	.	23
23	.	very	20

0	Functional	synergy	1
1	synergy	<ROOT>	-1
2	between	synergy	1
3	Raf	and	4
4	and	between	2
5	calcineurin	between	2
6	.	synergy	1

0	Specific	lymphocytes	1
1	lymphocytes	were	2
2	were	<ROOT>	-1
3	induced	were	2
4	by	induced	3
5	in	by	4
6	vitro	in	5
7	peptide	and	9
8	sensitization	and	9
9	and	induced	3
10	screened	were	2
11	by	screened	10
12	thymidine	were	2
13	uptake	were	2
14	or	were	2
15	cellular	or	14
16	cytotoxic	cellular	15
17	assays	cytotoxic	16
18	.	were	2

0	TSC2	is	1
1	is	<ROOT>	-1
2	a	gene	3
3	gene	is	1
4	on	gene	3
5	chromosome	on	4
6	16p13.3	chromosome	5
7	associated	16p13.3	6
8	with	associated	7
9	the	neurocutaneous	12
10	autosomal	neurocutaneous	12
11	dominant	neurocutaneous	12
12	neurocutaneous	with	8
13	disorder	is	1
14	,	is	1
15	tuberous	,	14
16	sclerosis	(	18
17	complex	(	18
18	(	tuberous	15
19	TSC	is	1
20	)	is	1
21	.	is	1

0	Rescue	<ROOT>	-1
1	by	Rescue	0
2	cytokines	by	1
3	of	apoptotic	4
4	apoptotic	Rescue	0
5	cell	Rescue	0
6	death	Rescue	0
7	induced	Rescue	0
8	by	induced	7
9	IL-2	deprivation	10
10	deprivation	by	8
11	of	human	12
12	human	deprivation	10
13	antigen-specific	Rescue	0
14	T	Rescue	0
15	cell	Rescue	0
16	clones	Rescue	0
17	.	Rescue	0

0	These	findings	1
1	findings	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	cortisol	are	8
5	and	cortisol	4
6	its	receptors	7
7	receptors	and	5
8	are	that	3
9	critically	are	8
10	involved	are	8
11	in	the	12
12	the	involved	10
13	regulation	the	12
14	of	regulation	13
15	immune	function	16
16	function	of	14
17	in	HIV	18
18	HIV	of	14
19	infection	indicate	2
20	.	indicate	2

0	To	was	26
1	determine	To	0
2	whether	determine	1
3	the	genes	5
4	DM	genes	5
5	genes	are	6
6	are	whether	2
7	regulated	are	6
8	in	regulated	7
9	a	manner	11
10	similar	manner	11
11	manner	in	8
12	as	II	14
13	class	II	14
14	II	in	8
15	genes	To	0
16	,	To	0
17	a	series	18
18	series	,	16
19	of	series	18
20	in	and	22
21	vivo	in	20
22	and	of	19
23	in	vitro	24
24	vitro	and	22
25	analyses	To	0
26	was	<ROOT>	-1
27	performed	was	26
28	.	was	26

0	The	<ROOT>	-1
1	results	The	0
2	demonstrate	that	3
3	that	results	1
4	alterations	that	3
5	in	family	8
6	NF	family	8
7	kappaB	family	8
8	family	alterations	4
9	proteins	,	10
10	,	The	0
11	specifically	failure	13
12	the	failure	13
13	failure	,	10
14	of	p65	15
15	p65	failure	13
16	translocation	The	0
17	to	the	18
18	the	translocation	16
19	nucleus	the	18
20	,	nucleus	19
21	occur	,	20
22	earlier	The	0
23	and	The	0
24	more	and	23
25	frequently	more	24
26	than	the	27
27	the	frequently	25
28	decrease	the	27
29	in	decrease	28
30	zeta-chain	in	29
31	.	The	0

0	Blood	monocytes	1
1	monocytes	<ROOT>	-1
2	spontaneously	activate	3
3	activate	monocytes	1
4	endothelial	activate	3
5	cells	in	6
6	in	endothelial	4
7	culture	activate	3
8	,	monocytes	1
9	leading	monocytes	1
10	to	leading	9
11	adhesion	to	10
12	of	monocytic	13
13	monocytic	to	10
14	cells	monocytes	1
15	onto	the	16
16	the	monocytes	1
17	endothelial	surface	18
18	surface	the	16
19	and	surface	18
20	overproduction	and	19
21	of	overproduction	20
22	endothelial	proteins	23
23	proteins	of	21
24	such	monocytes	1
25	as	monocytes	1
26	von	factor	28
27	Willebrand	factor	28
28	factor	as	25
29	(	factor	28
30	vWf	factor	28
31	)	factor	28
32	and	monocytes	1
33	plasminogen	monocytes	1
34	activator	monocytes	1
35	inhibitor	monocytes	1
36	type	inhibitor	35
37	1	type	36
38	(	1	37
39	PAI-1	1	37
40	)	1	37
41	.	1	37

0	Expression	studies	1
1	studies	have	10
2	as	studies	1
3	well	as	2
4	as	as	2
5	the	use	6
6	use	as	2
7	of	use	6
8	transgenic	animals	9
9	animals	of	7
10	have	<ROOT>	-1
11	demonstrated	have	10
12	that	demonstrated	11
13	the	factor	16
14	A-MYB	factor	16
15	transcription	factor	16
16	factor	plays	17
17	plays	that	12
18	central	plays	17
19	and	plays	17
20	specific	and	19
21	role	the	23
22	in	the	23
23	the	plays	17
24	regulation	the	23
25	of	regulation	24
26	mature	cell	28
27	B	cell	28
28	cell	of	25
29	proliferation	have	10
30	and/or	have	10
31	differentiation	have	10
32	.	have	10

0	To	<ROOT>	-1
1	test	To	0
2	the	hypothesis	3
3	hypothesis	test	1
4	that	hypothesis	3
5	the	alpha	8
6	chimera	alpha	8
7	PMLRAR	alpha	8
8	alpha	plays	9
9	plays	that	4
10	a	plays	9
11	role	in	12
12	in	a	10
13	leukemogenesis	in	12
14	,	leukemogenesis	13
15	we	expressed	16
16	expressed	leukemogenesis	13
17	a	alpha	19
18	PMLRAR	alpha	19
19	alpha	expressed	16
20	cDNA	To	0
21	in	myeloid	22
22	myeloid	cDNA	20
23	cells	To	0
24	of	To	0
25	transgenic	To	0
26	mice	To	0
27	.	To	0

0	None	for	23
1	of	None	0
2	33	specimens	4
3	PBMC	specimens	4
4	specimens	of	1
5	from	healthy	6
6	healthy	of	1
7	adults	None	0
8	and	None	0
9	only	one	10
10	one	positive	16
11	of	one	10
12	40	samples	14
13	pediatric	samples	14
14	samples	of	11
15	was	one	10
16	positive	and	8
17	(	None	0
18	at	None	0
19	a	level	21
20	low	level	21
21	level	at	18
22	)	None	0
23	for	<ROOT>	-1
24	adenovirus	for	23
25	DNA	by	26
26	by	adenovirus	24
27	nested	for	23
28	PCR	.	30
29	assay	.	30
30	.	nested	27

0	CONCLUSIONS	<ROOT>	-1
1	:	CONCLUSIONS	0
2	The	number	4
3	increased	number	4
4	number	CONCLUSIONS	0
5	and	number	4
6	apparent	and	5
7	dissociation	of	9
8	constant	of	9
9	of	receptor	11
10	glucocorticoid	of	9
11	receptor	are	12
12	are	apparent	6
13	closely	are	12
14	associated	are	12
15	with	associated	14
16	the	effectiveness	17
17	effectiveness	with	15
18	of	glucocorticoid	19
19	glucocorticoid	effectiveness	17
20	therapy	with	15
21	.	CONCLUSIONS	0

0	Ras-related	proteins	2
1	GTP-binding	proteins	2
2	proteins	<ROOT>	-1
3	and	proteins	2
4	leukocyte	and	3
5	signal	transduction	6
6	transduction	and	3
7	.	proteins	2

0	These	defects	1
1	defects	are	2
2	are	<ROOT>	-1
3	paralleled	are	2
4	by	paralleled	3
5	an	ability	7
6	impaired	ability	7
7	ability	by	4
8	to	produce	9
9	produce	ability	7
10	Th1	produce	9
11	cytokines	ability	7
12	(	cytokines	11
13	IL-2	ability	7
14	and	IL-2	13
15	IFN-gamma	and	14
16	)	IL-2	13
17	.	are	2

0	However	<ROOT>	-1
1	,	However	0
2	the	nature	3
3	nature	mechanism	10
4	of	nature	3
5	the	subunit	6
6	subunit	of	4
7	involved	nature	3
8	in	this	9
9	this	involved	7
10	mechanism	,	1
11	has	not	12
12	not	mechanism	10
13	been	mechanism	10
14	defined	been	13
15	.	However	0

0	The	pathway	2
1	transduction	pathway	2
2	pathway	<ROOT>	-1
3	leading	pathway	2
4	to	NF-kappaB	5
5	NF-kappaB	leading	3
6	activation	in	7
7	in	NF-kappaB	5
8	U937	pathway	2
9	cells	involved	10
10	involved	pathway	2
11	the	species	17
12	intracellular	of	14
13	generation	of	14
14	of	species	17
15	reactive	species	17
16	oxygen	species	17
17	species	involved	10
18	(	ROS	19
19	ROS	species	17
20	)	ROS	19
21	,	pathway	2
22	as	pathway	2
23	demonstrated	as	22
24	by	inhibitory	27
25	the	inhibitory	27
26	concomitant	inhibitory	27
27	inhibitory	demonstrated	23
28	effects	pathway	2
29	of	pathway	2
30	antioxidants	pathway	2
31	on	NF-kappaB	32
32	NF-kappaB	pathway	2
33	activation	pathway	2
34	and	pathway	2
35	the	emission	36
36	emission	and	34
37	of	emission	36
38	a	of	37
39	fluorescent	reacting	41
40	probe	reacting	41
41	reacting	a	38
42	intracellularly	reacting	41
43	with	reacting	41
44	hydrogen	with	43
45	peroxide	hydrogen	44
46	.	peroxide	45

0	The	gene	2
1	AML1	gene	2
2	gene	is	6
3	on	gene	2
4	chromosome	on	3
5	21	chromosome	4
6	is	<ROOT>	-1
7	disrupted	is	6
8	in	disrupted	7
9	the	-LRB-8;21-RRB--LRB-q22;q22-RRB-	10
10	-LRB-8;21-RRB--LRB-q22;q22-RRB-	in	8
11	and	-LRB-8;21-RRB--LRB-q22;q22-RRB-	10
12	-LRB-3;21-RRB--LRB-q26;q22-RRB-	and	11
13	translocations	-LRB-3;21-RRB--LRB-q26;q22-RRB-	12
14	associated	with	15
15	with	translocations	13
16	myelogenous	with	15
17	leukemias	is	6
18	and	is	6
19	encodes	and	18
20	a	protein	22
21	DNA-binding	protein	22
22	protein	encodes	19
23	.	is	6

0	Deletion	partially	6
1	of	Deletion	0
2	the	domain	5
3	PLZF	domain	5
4	POZ	domain	5
5	domain	of	1
6	partially	abrogated	7
7	abrogated	<ROOT>	-1
8	the	inhibitory	9
9	inhibitory	effect	10
10	effect	abrogated	7
11	of	effect	10
12	PLZF-RAR	abrogated	7
13	alpha	abrogated	7
14	on	RA-induced	15
15	RA-induced	abrogated	7
16	differentiation	abrogated	7
17	and	abrogated	7
18	on	and	17
19	RA-mediated	type	20
20	type	up-regulation	23
21	II	up-regulation	23
22	TGase	up-regulation	23
23	up-regulation	on	18
24	,	abrogated	7
25	suggesting	that	26
26	that	abrogated	7
27	POZ-mediated	that	26
28	protein	POZ-mediated	27
29	interactions	might	30
30	might	be	31
31	be	protein	28
32	responsible	be	31
33	for	responsible	32
34	the	for	33
35	inhibitory	of	38
36	transcriptional	of	38
37	activities	of	38
38	of	the	34
39	PLZF-RAR	abrogated	7
40	alpha	abrogated	7
41	.	abrogated	7

0	This	inhibition	1
1	inhibition	correlates	2
2	correlates	<ROOT>	-1
3	with	correlates	2
4	decreased	secretion	6
5	MMP-9	secretion	6
6	secretion	with	3
7	as	correlates	2
8	determined	as	7
9	by	determined	8
10	Western	blotting	11
11	blotting	by	9
12	.	correlates	2

0	Differential	interaction	1
1	interaction	<ROOT>	-1
2	of	interaction	1
3	nuclear	factors	4
4	factors	of	2
5	with	factors	4
6	the	factors	4
7	PRE-I	the	6
8	enhancer	PRE-I	7
9	element	enhancer	8
10	of	human	12
11	the	human	12
12	human	element	9
13	IL-4	interaction	1
14	promoter	in	15
15	in	interaction	1
16	different	subsets	19
17	T	subsets	19
18	cell	subsets	19
19	subsets	in	15
20	.	interaction	1

0	The	ability	1
1	ability	is	7
2	of	ability	1
3	BHRF1	of	2
4	to	ability	1
5	inhibit	to	4
6	apoptosis	inhibit	5
7	is	<ROOT>	-1
8	dependent	is	7
9	on	dependent	8
10	stimulus	on	9
11	and	stimulus	10
12	cell	and	11
13	type	cell	12
14	.	type	13

0	In	STAT3	3
1	contrast	In	0
2	,	In	0
3	STAT3	is	5
4	activation	STAT3	3
5	is	<ROOT>	-1
6	induced	receptor	12
7	in	induced	6
8	B-2	cells	9
9	cells	in	7
10	after	receptor	12
11	antigen	receptor	12
12	receptor	is	5
13	engagement	is	5
14	in	engagement	13
15	a	delayed	16
16	delayed	fashion	17
17	fashion	in	14
18	(	engagement	13
19	after	is	5
20	3	is	5
21	h	is	5
22	)	is	5
23	.	is	5

0	The	association	2
1	constitutive	association	2
2	association	implicates	25
3	of	association	2
4	TRAFs	of	3
5	with	association	2
6	LMP1	with	5
7	through	with	5
8	the	aa	9
9	aa	through	7
10	187	aa	9
11	to	aa	9
12	231	to	11
13	domain	association	2
14	which	association	2
15	is	association	2
16	important	is	15
17	in	NF-kappaB	18
18	NF-kappaB	important	16
19	activation	association	2
20	and	association	2
21	primary	association	2
22	B-lymphocyte	association	2
23	growth	association	2
24	transformation	association	2
25	implicates	<ROOT>	-1
26	TRAF	aggregation	27
27	aggregation	implicates	25
28	in	LMP1	29
29	LMP1	aggregation	27
30	signaling	implicates	25
31	.	implicates	25

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	,	In	0
4	we	,	3
5	have	we	4
6	characterized	have	5
7	a	characterized	6
8	cellular	a	7
9	mutant	cellular	8
10	,	cell	16
11	the	cell	16
12	70/Z3-derived	cell	16
13	1.3E2	cell	16
14	murine	cell	16
15	pre-B	cell	16
16	cell	mutant	9
17	line	cell	16
18	,	we	4
19	that	does	20
20	does	we	4
21	not	does	20
22	activate	does	20
23	NF-kappaB	activate	22
24	in	activate	22
25	response	in	24
26	to	several	27
27	several	response	25
28	stimuli	,	3
29	.	,	3

0	Mononuclear	play	2
1	phagocytes	Mononuclear	0
2	play	<ROOT>	-1
3	an	role	5
4	important	role	5
5	role	play	2
6	in	play	2
7	atherosclerosis	in	6
8	and	atherosclerosis	7
9	its	rupture	12
10	sequela	rupture	12
11	plaque	rupture	12
12	rupture	and	8
13	in	play	2
14	part	in	13
15	by	play	2
16	their	secretion	17
17	secretion	by	15
18	of	secretion	17
19	matrix	of	18
20	metalloproteinases	secretion	17
21	(	MMPs	22
22	MMPs	metalloproteinases	20
23	)	MMPs	22
24	,	secretion	17
25	including	,	24
26	MMP-9	including	25
27	.	play	2

0	The	measurement	1
1	measurement	<ROOT>	-1
2	of	measurement	1
3	the	number	4
4	number	of	2
5	and	number	4
6	apparent	and	5
7	dissociation	of	9
8	constant	of	9
9	of	receptor	11
10	glucocorticoid	of	9
11	receptor	may	12
12	may	apparent	6
13	be	may	12
14	useful	be	13
15	in	be	13
16	predicting	response	17
17	response	in	15
18	to	response	17
19	glucocorticoids	measurement	1
20	.	measurement	1

0	We	show	1
1	show	ligands	13
2	that	show	1
3	triggering	that	2
4	of	signaling	6
5	CD40	of	4
6	signaling	triggering	3
7	pathway	(	8
8	(	show	1
9	s	show	1
10	)	show	1
11	by	CD40	12
12	CD40	)	10
13	ligands	<ROOT>	-1
14	expressed	on	15
15	on	ligands	13
16	L	ligands	13
17	cells	ligands	13
18	led	ligands	13
19	to	strong	20
20	strong	led	18
21	activation	strong	20
22	of	an	23
23	an	activation	21
24	NF-kappaB-controlled	reporter	26
25	beta-globin	reporter	26
26	reporter	an	23
27	gene	strong	20
28	in	B	30
29	primary	B	30
30	B	gene	27
31	lymphocytes	ligands	13
32	from	ligands	13
33	transgenic	ligands	13
34	mice	ligands	13
35	.	ligands	13

0	Like	<ROOT>	-1
1	the	Like	0
2	class	II	3
3	II	the	1
4	genes	II	3
5	,	genes	4
6	the	genes	8
7	HLA-DM	genes	8
8	genes	,	5
9	contain	genes	8
10	upstream	sequences	12
11	regulatory	sequences	12
12	sequences	genes	8
13	similar	sequences	12
14	to	similar	13
15	the	region	18
16	S-X-Y	region	18
17	regulatory	region	18
18	region	to	14
19	as	genes	8
20	well	genes	8
21	as	additional	22
22	additional	putative	23
23	putative	genes	8
24	regulatory	putative	23
25	sites	Like	0
26	.	Like	0

0	The	increase	1
1	increase	IL-6	3
2	in	IL-6	3
3	IL-6	<ROOT>	-1
4	luciferase	activity	5
5	activity	occurs	6
6	occurs	IL-6	3
7	in	occurs	6
8	the	absence	9
9	absence	in	7
10	of	absence	9
11	the	region	14
12	multiple	region	14
13	response	region	14
14	region	of	10
15	,	IL-6	3
16	the	area	17
17	area	,	15
18	of	IL-6	20
19	the	IL-6	20
20	IL-6	area	17
21	promoter	IL-6	3
22	responsive	IL-6	3
23	to	IL-1	24
24	IL-1	IL-6	3
25	,	IL-1	24
26	TNF	alpha	27
27	alpha	IL-1	24
28	,	alpha	27
29	cyclic	alpha	27
30	amp	cyclic	29
31	,	amp	30
32	and	amp	30
33	phorbol	12-myristate	34
34	12-myristate	and	32
35	13-acetate	12-myristate	34
36	.	IL-6	3

0	During	are	7
1	inflammatory	reactions	2
2	reactions	During	0
3	,	are	7
4	many	species	6
5	oxidative	species	6
6	species	are	7
7	are	<ROOT>	-1
8	produced	are	7
9	,	are	7
10	one	is	13
11	of	one	10
12	which	of	11
13	is	are	7
14	hypochlorous	acid	15
15	acid	is	13
16	(	HOCl	17
17	HOCl	acid	15
18	)	HOCl	17
19	,	acid	15
20	which	acid	15
21	is	which	20
22	responsible	is	21
23	for	responsible	22
24	the	effects	26
25	microbicidal	effects	26
26	effects	for	23
27	of	polymorphonuclear	30
28	activated	polymorphonuclear	30
29	human	polymorphonuclear	30
30	polymorphonuclear	effects	26
31	leukocytes	are	7
32	.	are	7

0	Two	been	23
1	of	Two	0
2	the	genes	3
3	genes	of	1
4	defective	Two	0
5	in	mutants	21
6	the	groups	9
7	five	groups	9
8	complementation	groups	9
9	groups	in	5
10	identified	groups	9
11	in	identified	10
12	the	in	11
13	class	II-negative	14
14	II-negative	or	18
15	bare	or	18
16	lymphocyte	or	18
17	syndrome	or	18
18	or	the	12
19	corresponding	or	18
20	laboratory	corresponding	19
21	mutants	have	22
22	have	defective	4
23	been	<ROOT>	-1
24	cloned	been	23
25	.	been	23

0	The	lack	1
1	lack	<ROOT>	-1
2	of	lack	1
3	steroid	binding	4
4	binding	of	2
5	of	HBD	6
6	HBD	binding	4
7	mutants	lack	1
8	with	lack	1
9	the	sequence	11
10	Thr729-Leu765	sequence	11
11	sequence	with	8
12	deleted	lack	1
13	[	lack	1
14	Jalaguier	lack	1
15	,	lack	1
16	Mesnier	lack	1
17	,	lack	1
18	Leger	lack	1
19	and	lack	1
20	Auzou	lack	1
21	(	Auzou	20
22	1996	lack	1
23	)	lack	1
24	J.Steroid	lack	1
25	Biochem.Mol.Biol.57	lack	1
26	,	lack	1
27	43-50	lack	1
28	]	supports	29
29	supports	lack	1
30	this	hypothesis	31
31	hypothesis	supports	29
32	.	lack	1

0	Furthermore	demonstrate	3
1	,	demonstrate	3
2	we	demonstrate	3
3	demonstrate	is	20
4	that	demonstrate	3
5	binding	for	14
6	of	binding	5
7	several	factors	11
8	B	factors	11
9	cell-specific	factors	11
10	transcription	factors	11
11	factors	of	6
12	,	for	14
13	essential	for	14
14	for	that	4
15	IgH	3'	16
16	3'	for	14
17	enhancer	for	14
18	activity	demonstrate	3
19	,	demonstrate	3
20	is	<ROOT>	-1
21	lacking	is	20
22	,	which	23
23	which	3'	26
24	may	3'	26
25	explain	may	24
26	3'	enhancer	27
27	enhancer	is	20
28	inactivity	is	20
29	,	is	20
30	although	is	20
31	the	binding	32
32	binding	although	30
33	of	repressors	34
34	repressors	binding	32
35	can	repressors	34
36	not	can	35
37	be	can	35
38	excluded	be	37
39	.	is	20

0	Deletion	analysis	1
1	analysis	showed	2
2	showed	<ROOT>	-1
3	that	expression	4
4	expression	is	9
5	from	expression	4
6	the	promoters	8
7	DM	promoters	8
8	promoters	from	5
9	is	showed	2
10	dependent	is	9
11	on	dependent	10
12	the	region	15
13	conserved	region	15
14	S-X-Y	region	15
15	region	on	11
16	.	showed	2

0	The	Pax-5	3
1	transcription	Pax-5	3
2	factor	Pax-5	3
3	Pax-5	is	4
4	is	<ROOT>	-1
5	expressed	is	4
6	during	expressed	5
7	the	stages	9
8	early	stages	9
9	stages	during	6
10	of	stages	9
11	B-cell	differentiation	12
12	differentiation	of	10
13	and	during	6
14	influences	during	6
15	the	expression	16
16	expression	influences	14
17	of	expression	16
18	several	of	17
19	B-cell-specific	several	18
20	genes	.	21
21	.	B-cell-specific	19

0	The	proportion	1
1	proportion	TCRhigh	5
2	of	TCRhigh	5
3	mature	TCRhigh	5
4	,	TCRhigh	5
5	TCRhigh	was	11
6	thymocytes	TCRhigh	5
7	of	thymocytes	6
8	the	lineage	10
9	alphabeta	lineage	10
10	lineage	of	7
11	was	<ROOT>	-1
12	reduced	was	11
13	,	was	11
14	and	was	11
15	the	population	18
16	remaining	population	18
17	TCRhigh	population	18
18	population	contained	19
19	contained	and	14
20	an	proportion	23
21	unusually	high	22
22	high	proportion	23
23	proportion	contained	19
24	of	proportion	23
25	double-positive	cells	26
26	cells	of	24
27	.	cells	26

0	Most	interestingly	1
1	interestingly	<ROOT>	-1
2	,	interestingly	1
3	expression	interestingly	1
4	of	expression	3
5	CD95	interestingly	1
6	(	Fas/Apo-1	7
7	Fas/Apo-1	CD95	5
8	)	Fas/Apo-1	7
9	and	CD95	5
10	of	and	9
11	CD23	of	10
12	was	interestingly	1
13	down-regulated	interestingly	1
14	in	down-regulated	13
15	all	transfectants	17
16	K46	transfectants	17
17	transfectants	in	14
18	.	interestingly	1

0	It	is	1
1	is	<ROOT>	-1
2	hypothesized	is	1
3	that	hypothesized	2
4	individuals	may	10
5	who	differ	6
6	differ	individuals	4
7	in	differ	6
8	G-LRB-S-RRB-alpha	expression	9
9	expression	in	7
10	may	that	3
11	also	may	10
12	differ	may	10
13	in	differ	12
14	the	expression	15
15	expression	in	13
16	of	expression	15
17	certain	genes	19
18	cAMP-dependent	genes	19
19	genes	of	16
20	.	is	1

0	Nonresponders	had	1
1	had	<ROOT>	-1
2	a	increase	4
3	significant	increase	4
4	increase	had	1
5	both	increase	4
6	in	both	5
7	the	number	8
8	number	in	6
9	of	binding	10
10	binding	number	8
11	sites	number	8
12	and	had	1
13	in	and	12
14	the	in	13
15	apparent	compared	18
16	dissociation	compared	18
17	constant	compared	18
18	compared	the	14
19	with	compared	18
20	responders	with	19
21	(	responders	20
22	P	with	19
23	=	had	1
24	0.045	had	1
25	;	had	1
26	P	had	1
27	=	0.029	28
28	0.029	P	26
29	)	had	1
30	.	had	1

0	HIV-1	LTR	1
1	LTR	is	3
2	transcription	is	3
3	is	<ROOT>	-1
4	controlled	is	3
5	by	controlled	4
6	a	array	8
7	complex	array	8
8	array	by	5
9	of	array	8
10	virus-encoded	of	9
11	and	virus-encoded	10
12	cellular	and	11
13	proteins	cellular	12
14	.	is	3

0	Urinary	cortisol	2
1	free	cortisol	2
2	cortisol	was	9
3	excretion	cortisol	2
4	in	cortisol	2
5	FMS	in	4
6	and	in	4
7	LBP	patients	8
8	patients	in	4
9	was	<ROOT>	-1
10	lower	was	9
11	compared	was	9
12	to	compared	11
13	controls	was	9
14	.	was	9

0	METHODS	<ROOT>	-1
1	:	METHODS	0
2	During	METHODS	0
3	a	study	7
4	double-blind	crossover	6
5	placebo-controlled	crossover	6
6	crossover	study	7
7	study	During	2
8	,	200	9
9	200	During	2
10	micrograms	spray	15
11	fluticasone	spray	15
12	propionate	spray	15
13	aqueous	spray	15
14	nasal	spray	15
15	spray	200	9
16	(	treatment	20
17	in	treatment	20
18	the	treatment	20
19	active	treatment	20
20	treatment	spray	15
21	period	treatment	20
22	)	treatment	20
23	and	spray	15
24	placebo	and	23
25	(	and	23
26	in	(	25
27	the	in	26
28	placebo	)	31
29	treatment	period	30
30	period	placebo	28
31	)	the	27
32	were	administered	33
33	administered	in	26
34	twice	administered	33
35	daily	in	26
36	for	in	26
37	2	weeks	38
38	weeks	in	26
39	to	in	26
40	22	patients	41
41	patients	to	39
42	allergic	patients	41
43	to	allergic	42
44	house	mite	46
45	dust	mite	46
46	mite	to	43
47	.	METHODS	0

0	Since	has	10
1	the	human	2
2	human	genomic	3
3	genomic	Since	0
4	sterol	element	6
5	regulatory	element	6
6	element	has	10
7	(	SRE	8
8	SRE	element	6
9	)	SRE	8
10	has	revealed	26
11	been	has	10
12	shown	been	11
13	to	shown	12
14	regulate	to	13
15	various	genes	17
16	key	genes	17
17	genes	to	13
18	involved	genes	17
19	in	involved	18
20	this	phenomenon	21
21	phenomenon	in	19
22	,	revealed	26
23	the	study	25
24	present	study	25
25	study	revealed	26
26	revealed	<ROOT>	-1
27	the	existence	28
28	existence	protein	34
29	of	protein	34
30	a	protein	34
31	unique	protein	34
32	47	kDa	33
33	kDa	protein	34
34	protein	revealed	26
35	factor	having	36
36	having	protein	34
37	affinity	having	36
38	for	affinity	37
39	this	SRE	40
40	SRE	for	38
41	sequence	SRE	40
42	in	revealed	26
43	lymphocytes	revealed	26
44	from	revealed	26
45	normal	revealed	26
46	subjects	revealed	26
47	,	revealed	26
48	as	revealed	26
49	well	revealed	26
50	as	revealed	26
51	its	as	50
52	absence	its	51
53	in	revealed	26
54	lymphocytes	revealed	26
55	from	revealed	26
56	untreated	patients	58
57	CML	patients	58
58	patients	revealed	26
59	.	revealed	26

0	We	measured	1
1	measured	<ROOT>	-1
2	plasma	by	4
3	hormones	by	4
4	by	measured	1
5	radioimmunoassay	by	4
6	.	measured	1

0	In	stably	3
1	S107	stably	3
2	cells	stably	3
3	stably	was	16
4	transfected	with	5
5	with	genes	7
6	relB	genes	7
7	genes	stably	3
8	,	stably	3
9	stimulation	stably	3
10	of	stably	3
11	nuclear	translocation	13
12	RelB	translocation	13
13	translocation	of	10
14	by	translocation	13
15	CD40	stably	3
16	was	<ROOT>	-1
17	observed	was	16
18	.	was	16

0	When	cells	4
1	mouse	cells	4
2	MPC11	plasmacytoma	3
3	plasmacytoma	cells	4
4	cells	are	15
5	,	cells	4
6	in	3'	10
7	which	in	6
8	the	3'	10
9	IgH	3'	10
10	3'	enhancer	11
11	enhancer	cells	4
12	is	cells	4
13	active	are	15
14	,	are	15
15	are	<ROOT>	-1
16	fused	are	15
17	with	fused	16
18	fibroblasts	with	17
19	,	are	15
20	Ig	expression	21
21	expression	is	22
22	is	are	15
23	extinguished	is	22
24	at	extinguished	23
25	the	level	26
26	level	at	24
27	of	level	26
28	transcription	of	27
29	.	are	15

0	Based	upon	1
1	upon	<ROOT>	-1
2	these	upon	1
3	results	upon	1
4	we	propose	5
5	propose	upon	1
6	that	propose	5
7	this	factor	8
8	factor	may	9
9	may	a	11
10	have	a	11
11	a	that	6
12	role	in	13
13	in	that	6
14	pathophysiology	in	13
15	of	pathophysiology	14
16	chronic	leukaemia	18
17	myeloid	leukaemia	18
18	leukaemia	of	15
19	.	leukaemia	18

0	We	<ROOT>	-1
1	and	We	0
2	others	and	1
3	have	shown	4
4	shown	We	0
5	that	shown	4
6	SAA	gene	7
7	gene	is	8
8	is	that	5
9	induced	is	8
10	in	monocyte/macrophage	11
11	monocyte/macrophage	induced	9
12	cells	We	0
13	by	We	0
14	lipopolysaccharide	LPS	16
15	(	LPS	16
16	LPS	We	0
17	)	We	0
18	.	We	0

0	Seven	were	5
1	of	Seven	0
2	15	lines	4
3	fibroblast	lines	4
4	lines	of	1
5	were	patterns	14
6	heterozygous	were	5
7	for	heterozygous	6
8	polymorphic	for	7
9	alleles	,	10
10	,	polymorphic	8
11	and	the	12
12	the	,	10
13	expression	patterns	14
14	patterns	were	15
15	were	<ROOT>	-1
16	variable	were	15
17	,	were	15
18	i.e.	were	15
19	,	were	15
20	equal	were	15
21	,	equal	20
22	unequal	,	21
23	or	unequal	22
24	monoallelic	expression	26
25	paternal	expression	26
26	expression	or	23
27	in	unequal	22
28	three	in	27
29	,	unequal	22
30	two	unequal	22
31	and	two	30
32	two	cases	33
33	cases	and	31
34	,	unequal	22
35	respectively	unequal	22
36	.	were	15

0	Analysis	does	7
1	of	Analysis	0
2	the	status	4
3	redox	status	4
4	status	of	1
5	of	status	4
6	1.3E2	of	5
7	does	<ROOT>	-1
8	not	does	7
9	reveal	does	7
10	any	difference	11
11	difference	wild-type	13
12	from	wild-type	13
13	wild-type	reveal	9
14	70Z/3	reveal	9
15	.	does	7

0	Our	findings	1
1	findings	suggest	2
2	suggest	adhesion	5
3	that	adhesion	5
4	leukocyte-platelet	adhesion	5
5	adhesion	<ROOT>	-1
6	contributes	adhesion	5
7	to	the	8
8	the	contributes	6
9	regulation	the	8
10	of	regulation	9
11	inflammatory	regulation	9
12	responses	inflammatory	11
13	in	inflammatory	11
14	AMI	in	13
15	.	adhesion	5

0	We	<ROOT>	-1
1	have	We	0
2	used	have	1
3	a	used	2
4	somatic	to	8
5	cell	to	8
6	hybridization	to	8
7	approach	to	8
8	to	a	3
9	genetically	analyse	10
10	analyse	a	3
11	regulation	of	12
12	of	We	0
13	the	activity	14
14	activity	3'	18
15	of	3'	18
16	the	3'	18
17	IgH	3'	18
18	3'	of	12
19	enhancer	We	0
20	.	We	0

0	In	<ROOT>	-1
1	the	study	3
2	present	study	3
3	study	In	0
4	,	In	0
5	structure/function	,	4
6	analyses	structure/function	5
7	of	the	8
8	the	analyses	6
9	IL-7R	using	11
10	complex	using	11
11	using	the	8
12	a	the	8
13	chimeric	system	15
14	receptor	system	15
15	system	demonstrated	16
16	demonstrated	In	0
17	that	demonstrated	16
18	gamma-LRB-c-RRB-	is	19
19	is	that	17
20	indeed	is	19
21	critical	indeed	20
22	for	critical	21
23	IL-7R	for	22
24	function	.	25
25	.	IL-7R	23

0	The	expression	1
1	expression	Evi-1	6
2	of	expression	1
3	the	factors	5
4	nuclear	factors	5
5	factors	of	2
6	Evi-1	<ROOT>	-1
7	and	Evi-1	6
8	c-myb	Evi-1	6
9	,	Evi-1	6
10	known	Evi-1	6
11	to	known	10
12	inhibit	erythroid	13
13	erythroid	to	11
14	differentiation	erythroid	13
15	,	Evi-1	6
16	did	Evi-1	6
17	not	did	16
18	decrease	did	16
19	.	Evi-1	6

0	Unlike	were	33
1	full-sized	NOTCH1	2
2	NOTCH1	Unlike	0
3	,	Unlike	0
4	two	,	3
5	such	truncated	6
6	truncated	forms	7
7	forms	two	4
8	of	forms	7
9	the	of	8
10	protein	either	11
11	either	the	9
12	lacking	the	9
13	a	portion	15
14	major	portion	15
15	portion	extracellular	18
16	of	extracellular	18
17	the	extracellular	18
18	extracellular	lacking	12
19	domain	(	20
20	(	Unlike	0
21	DeltaE	Unlike	0
22	)	DeltaE	21
23	or	)	22
24	consisting	or	23
25	only	consisting	24
26	of	intracellular	28
27	the	intracellular	28
28	intracellular	only	25
29	domain	(	30
30	(	intracellular	28
31	ICN	(	30
32	)	intracellular	28
33	were	<ROOT>	-1
34	found	were	33
35	to	found	34
36	activate	to	35
37	transcription	activate	36
38	in	cultured	39
39	cultured	activate	36
40	cells	were	33
41	,	were	33
42	presumably	were	33
43	through	presumably	42
44	RBP-Jkappa	elements	46
45	response	elements	46
46	elements	through	43
47	within	through	43
48	DNA	were	33
49	.	were	33

0	The	<ROOT>	-1
1	squirrel	The	0
2	monkey	squirrel	1
3	glucocorticoid	monkey	2
4	receptor	glucocorticoid	3
5	is	receptor	4
6	approximately	97	7
7	97	identical	9
8	%	97	7
9	identical	is	5
10	in	identical	9
11	nucleotide	in	10
12	and	nucleotide	11
13	amino	sequence	15
14	acid	sequence	15
15	sequence	and	12
16	to	and	12
17	the	receptor	19
18	human	receptor	19
19	receptor	to	16
20	.	receptor	4

0	Although	<ROOT>	-1
1	DOR1	signaling	2
2	signaling	Although	0
3	increased	signaling	2
4	-LSB-Ca2+-RSB-i	increased	3
5	,	-LSB-Ca2+-RSB-i	4
6	deltorphin	,	5
7	enhanced	transcriptional	8
8	transcriptional	deltorphin	6
9	activity	,	5
10	of	activity	9
11	the	site	13
12	NF-AT/AP-1-binding	site	13
13	site	of	10
14	via	mechanism	16
15	a	mechanism	16
16	mechanism	activity	9
17	independent	mechanism	16
18	of	calcineurin	19
19	calcineurin	independent	17
20	and	calcineurin	19
21	distinct	and	20
22	from	the	23
23	the	distinct	21
24	effects	the	23
25	of	effects	24
26	elevated	of	25
27	-LSB-Ca2+-RSB-i	.	28
28	.	elevated	26

0	Our	<ROOT>	-1
1	results	Our	0
2	demonstrate	that	3
3	that	results	1
4	1.3E2	is	5
5	is	that	3
6	a	is	5
7	cellular	exhibiting	10
8	transduction	exhibiting	10
9	mutant	exhibiting	10
10	exhibiting	a	6
11	a	exhibiting	10
12	defect	a	11
13	in	defect	12
14	a	step	15
15	step	in	13
16	that	is	17
17	is	step	15
18	required	is	17
19	by	required	18
20	several	stimuli	22
21	different	stimuli	22
22	stimuli	by	19
23	to	required	18
24	activate	to	23
25	NF-kappaB	activate	24
26	.	NF-kappaB	25

0	In	expression	9
1	these	cases	2
2	cases	In	0
3	,	expression	9
4	at	expression	9
5	least	at	4
6	,	expression	9
7	the	expression	9
8	AML1	expression	9
9	expression	level	10
10	level	is	11
11	is	<ROOT>	-1
12	a	regulator	14
13	potential	regulator	14
14	regulator	cell	17
15	for	cell	17
16	myeloid	cell	17
17	cell	is	11
18	differentiation	cell	17
19	.	differentiation	18

0	It	can	1
1	can	<ROOT>	-1
2	bind	to	3
3	to	can	1
4	DNA	target	5
5	target	to	3
6	sequences	within	7
7	within	a	8
8	a	can	1
9	variety	can	1
10	of	cytokine	11
11	cytokine	variety	9
12	genes	can	1
13	.	can	1

0	The	Scya3r2	3
1	CHEMR1	Scya3r2	3
2	gene	Scya3r2	3
3	Scya3r2	is	4
4	is	<ROOT>	-1
5	a	gene	7
6	single-copy	gene	7
7	gene	is	4
8	whose	gene	7
9	open	whose	8
10	reading	open	9
11	frame	reading	10
12	may	frame	11
13	be	may	12
14	in	be	13
15	a	in	14
16	single	a	15
17	exon	single	16
18	and	exon	17
19	maps	and	18
20	to	maps	19
21	the	to	20
22	distal	the	21
23	region	mouse	25
24	of	mouse	25
25	mouse	distal	22
26	Chr	distal	22
27	9	Chr	26
28	where	9	27
29	the	where	28
30	mouse	the	29
31	macrophage	chemokine	44
32	inflammatory	protein-1alpha	33
33	protein-1alpha	(	34
34	(	macrophage	31
35	MIP-1alpha	(	34
36	)	(	34
37	receptor	gene	38
38	gene	(	34
39	Scya3r	macrophage	31
40	and	macrophage	31
41	two	chemokine	44
42	related	C-C	43
43	C-C	chemokine	44
44	chemokine	mouse	30
45	receptor-like	exon	17
46	genes	is	4
47	reside	is	4
48	.	is	4

0	PRRI	is	1
1	is	proximal	4
2	an	proximal	4
3	inducible	proximal	4
4	proximal	<ROOT>	-1
5	enhancer	proximal	4
6	,	enhancer	5
7	located	,	6
8	between	located	7
9	nucleotides	-276	10
10	-276	between	8
11	and	-276	10
12	-244	proximal	4
13	,	proximal	4
14	which	contains	15
15	contains	proximal	4
16	NF-kappaB	and	17
17	and	contains	15
18	SRE/CArG	motifs	19
19	motifs	contains	15
20	.	proximal	4

0	In	luciferase	3
1	contrast	In	0
2	,	In	0
3	luciferase	expression	4
4	expression	was	5
5	was	was	14
6	not	was	5
7	stimulated	IFN-gamma	9
8	after	stimulated	7
9	IFN-gamma	was	5
10	treatment	when	11
11	when	the	12
12	the	was	5
13	construct	was	5
14	was	<ROOT>	-1
15	transfected	in	16
16	in	macrophage	17
17	macrophage	was	14
18	or	macrophage	17
19	in	macrophage	17
20	epithelial	was	14
21	cell	was	14
22	lines	was	14
23	.	was	14

0	Thus	<ROOT>	-1
1	,	Thus	0
2	RFX5	,	1
3	can	RFX5	2
4	activate	can	3
5	transcription	activate	4
6	only	in	7
7	in	activate	4
8	cooperation	in	7
9	with	cooperation	8
10	CIITA	with	9
11	.	Thus	0

0	Recently	been	7
1	,	B	5
2	activation	,	1
3	of	NF-kappa	4
4	NF-kappa	activation	2
5	B	Recently	0
6	has	been	7
7	been	<ROOT>	-1
8	linked	been	7
9	to	linked	8
10	ARDS	to	9
11	and	ARDS	10
12	has	and	11
13	been	has	12
14	shown	been	13
15	to	shown	14
16	be	to	15
17	a	step	20
18	critical	step	20
19	proximal	step	20
20	step	be	16
21	in	be	16
22	the	in	21
23	initiation	neutrophilic	25
24	of	neutrophilic	25
25	neutrophilic	the	22
26	inflammation	neutrophilic	25
27	in	animal	28
28	animal	inflammation	26
29	models	neutrophilic	25
30	.	been	7

0	A	site	3
1	novel	site	3
2	SP-1	site	3
3	site	beta	8
4	in	beta	8
5	the	beta	8
6	human	interleukin-1	7
7	interleukin-1	beta	8
8	beta	confers	10
9	promoter	confers	10
10	confers	<ROOT>	-1
11	preferential	transcriptional	12
12	transcriptional	confers	10
13	activity	confers	10
14	in	confers	10
15	keratinocytes	confers	10
16	.	confers	10

0	An	beta	2
1	anti-IL-1	beta	2
2	beta	antibody	3
3	antibody	had	4
4	had	<ROOT>	-1
5	negligible	effects	6
6	effects	had	4
7	on	effects	6
8	HUVEC	molecules	10
9	adhesion	molecules	10
10	molecules	on	7
11	,	had	4
12	PAI-1	had	4
13	or	PAI-1	12
14	vWf	production	15
15	production	or	13
16	.	had	4

0	In	initiates	8
1	addition	In	0
2	,	initiates	8
3	translation	initiates	8
4	of	translation	3
5	NFATc	mRNA	6
6	mRNA	of	4
7	apparently	initiates	8
8	initiates	<ROOT>	-1
9	at	initiates	8
10	two	codons	13
11	different	codons	13
12	AUG	codons	13
13	codons	at	9
14	,	initiates	8
15	giving	initiates	8
16	rise	giving	15
17	to	giving	15
18	proteins	to	17
19	that	differ	20
20	differ	proteins	18
21	in	differ	20
22	size	in	21
23	by	differ	20
24	36	amino	25
25	amino	by	23
26	acids	amino	25
27	.	initiates	8

0	This	translocation	1
1	translocation	is	2
2	is	<ROOT>	-1
3	characteristic	is	2
4	of	characteristic	3
5	a	subset	7
6	small	subset	7
7	subset	of	4
8	of	non-Hodgkin	9
9	non-Hodgkin	subset	7
10	lymphomas	is	2
11	exhibiting	is	2
12	plasmacytoid	is	2
13	differentiation	is	2
14	.	is	2

0	Interleukin-4	<ROOT>	-1
1	(	IL-4	2
2	IL-4	Interleukin-4	0
3	)	IL-4	2
4	and	(	6
5	interleukin-12	and	4
6	(	Interleukin-4	0
7	IL-12	(	6
8	)	(	6
9	control	Interleukin-4	0
10	the	differentiation	11
11	differentiation	control	9
12	of	T-helper	13
13	T-helper	differentiation	11
14	cells	Interleukin-4	0
15	.	Interleukin-4	0

0	Thus	likely	3
1	,	DR3	2
2	DR3	Thus	0
3	likely	plays	4
4	plays	<ROOT>	-1
5	a	plays	4
6	role	in	7
7	in	a	5
8	regulating	in	7
9	lymphocyte	regulating	8
10	homeostasis	.	11
11	.	lymphocyte	9

0	Notably	no	2
1	,	Notably	0
2	no	Stat3	14
3	activation	no	2
4	of	activation	3
5	Jak1	no	2
6	,	Jak1	5
7	Jak2	no	2
8	,	no	2
9	Tyk2	no	2
10	,	no	2
11	Stat1	no	2
12	,	Stat1	11
13	or	no	2
14	Stat3	was	15
15	was	<ROOT>	-1
16	observed	was	15
17	in	observed	16
18	neutrophils	in	17
19	following	G-CSF	20
20	G-CSF	observed	16
21	stimulation	G-CSF	20
22	.	was	15

0	Since	are	21
1	the	acid	3
2	okadaic	acid	3
3	acid	Since	0
4	,	Since	0
5	a	phosphatase	8
6	potent	phosphatase	8
7	protein	phosphatase	8
8	phosphatase	,	4
9	inhibitor	phosphatase	8
10	,	Since	0
11	prolongs	Since	0
12	the	induction	13
13	induction	the	15
14	of	the	15
15	the	Since	0
16	binding	the	15
17	activity	Since	0
18	,	are	21
19	phosphorylation	events	20
20	events	are	21
21	are	<ROOT>	-1
22	likely	are	21
23	to	likely	22
24	occur	to	23
25	.	are	21

0	Glucocorticoid	receptors	1
1	receptors	(	2
2	(	)	4
3	GR	)	4
4	)	<ROOT>	-1
5	are	)	4
6	ubiquitous	molecules	7
7	molecules	)	4
8	and	molecules	7
9	are	and	8
10	present	are	9
11	also	present	10
12	in	present	10
13	the	hippocampus	14
14	hippocampus	in	12
15	and	hippocampus	14
16	in	other	18
17	several	other	18
18	other	and	15
19	nervous	present	10
20	and	immune	21
21	immune	nervous	19
22	tissues	present	10
23	.	)	4

0	TRAMP	<ROOT>	-1
1	,	TRAMP	0
2	a	receptor	5
3	novel	receptor	5
4	apoptosis-mediating	receptor	5
5	receptor	TRAMP	0
6	with	sequence	7
7	sequence	receptor	5
8	homology	sequence	7
9	to	factor	12
10	tumor	factor	12
11	necrosis	factor	12
12	factor	TRAMP	0
13	receptor	TRAMP	0
14	1	TRAMP	0
15	and	Fas	16
16	Fas	TRAMP	0
17	(	Apo-1/CD95	18
18	Apo-1/CD95	Fas	16
19	)	Apo-1/CD95	18
20	.	TRAMP	0

0	Furthermore	<ROOT>	-1
1	,	Furthermore	0
2	the	domains	4
3	functional	domains	4
4	domains	,	1
5	responsible	domains	4
6	for	DNA	7
7	DNA	responsible	5
8	binding	were	23
9	,	were	23
10	transactivation	were	23
11	,	transactivation	10
12	and	transactivation	10
13	negative	and	12
14	regulation	transactivation	10
15	,	transactivation	10
16	previously	characterized	17
17	characterized	transactivation	10
18	in	characterized	17
19	a	context	21
20	fibroblast	context	21
21	context	in	18
22	,	transactivation	10
23	were	DNA	7
24	found	were	23
25	to	found	24
26	have	to	25
27	similar	activity	28
28	activity	have	26
29	in	have	26
30	B	cells	31
31	cells	in	29
32	.	Furthermore	0

0	Such	differentiation	1
1	differentiation	block	2
2	block	was	5
3	by	block	2
4	AML1a	by	3
5	was	<ROOT>	-1
6	canceled	was	5
7	by	canceled	6
8	the	overexpression	10
9	concomitant	overexpression	10
10	overexpression	by	7
11	of	overexpression	10
12	AML1b	of	11
13	.	was	5

0	The	<ROOT>	-1
1	human	exhibited	4
2	C/EBP-epsilon	protein	3
3	protein	exhibited	4
4	exhibited	The	0
5	strong	exhibited	4
6	and	strong	5
7	specific	and	6
8	binding	double-stranded	10
9	to	binding	8
10	double-stranded	C/EBP	14
11	DNA	C/EBP	14
12	containing	consensus	13
13	consensus	C/EBP	14
14	C/EBP	specific	7
15	sites	C/EBP	14
16	.	sites	15

0	Interestingly	gene	2
1	,	Interestingly	0
2	gene	(	11
3	disruption	(	11
4	of	either	5
5	either	(	11
6	IL-7	(	11
7	or	(	11
8	the	IL-7	9
9	IL-7	receptor	10
10	receptor	or	7
11	(	mice	17
12	IL-7R	(	11
13	)	(	11
14	alpha	(	11
15	subunit	(	11
16	in	subunit	15
17	mice	leads	18
18	leads	<ROOT>	-1
19	to	leads	18
20	immunological	defects	21
21	defects	to	19
22	that	are	23
23	are	defects	21
24	similar	are	23
25	to	similar	24
26	human	to	25
27	X-SCID	human	26
28	.	X-SCID	27

0	The	sense	1
1	sense	U	5
2	cell	(	4
3	lines	(	4
4	(	sense	1
5	U	showed	15
6	alpha	U	5
7	S	alpha	6
8	and	S	7
9	its	alpha	12
10	clonal	derivative	11
11	derivative	its	9
12	alpha	and	8
13	G2S	U	5
14	)	G2S	13
15	showed	<ROOT>	-1
16	increased	sensitivity	17
17	sensitivity	showed	15
18	to	sensitivity	17
19	RA	to	18
20	,	showed	15
21	while	showed	15
22	the	alpha	28
23	antisense	(	26
24	cell	(	26
25	lines	(	26
26	(	the	22
27	U	alpha	28
28	alpha	while	21
29	A	showed	15
30	and	A	29
31	its	alpha	34
32	clonal	derivative	33
33	derivative	its	31
34	alpha	and	30
35	B5A	showed	15
36	)	showed	15
37	showed	showed	15
38	decreased	showed	15
39	sensitivity	showed	15
40	to	sensitivity	39
41	RA	showed	15
42	,	showed	15
43	as	showed	15
44	demonstrated	as	43
45	by	demonstrated	44
46	growth	inhibition	47
47	inhibition	by	45
48	and	inhibition	47
49	by	inhibition	47
50	regulation	by	49
51	of	reporter	54
52	an	reporter	54
53	RA-responsive	reporter	54
54	reporter	regulation	50
55	gene	showed	15
56	.	showed	15

0	NF-AT	were	3
1	and	NF-AT	0
2	NF-kappaB	and	1
3	were	<ROOT>	-1
4	not	were	3
5	significantly	were	3
6	induced	significantly	5
7	by	IL-2	8
8	IL-2	induced	6
9	stimulation	were	3
10	.	were	3

0	Molecular	cloning	1
1	cloning	CCR-4	24
2	and	cloning	1
3	characterization	and	2
4	of	characterization	3
5	a	cloning	1
6	cDNA	cloning	1
7	,	cloning	1
8	CHEMR1	,	7
9	,	CHEMR1	8
10	encoding	a	11
11	a	chemokine	12
12	chemokine	receptor	13
13	receptor	a	15
14	with	a	15
15	a	,	9
16	homology	C-C	20
17	to	C-C	20
18	the	C-C	20
19	human	C-C	20
20	C-C	cloning	1
21	chemokine	cloning	1
22	receptor	cloning	1
23	,	CCR-4	24
24	CCR-4	<ROOT>	-1
25	.	CCR-4	24

0	Based	<ROOT>	-1
1	on	Based	0
2	nucleotide	requirements	4
3	sequence	requirements	4
4	requirements	on	1
5	and	requirements	4
6	immunoreactivity	and	5
7	,	Based	0
8	we	demonstrate	9
9	demonstrate	Based	0
10	that	demonstrate	9
11	this	that	10
12	DNA-protein	is	14
13	complex	is	14
14	is	this	11
15	comprised	is	14
16	of	comprised	15
17	the	components	19
18	AP-1	components	19
19	components	of	16
20	,	components	19
21	Fos	components	19
22	and	Fos	21
23	Jun	that	10
24	.	Based	0

0	During	T	1
1	T	<ROOT>	-1
2	cell	T	1
3	differentiation	cell	2
4	,	differentiation	3
5	expression	peaked	6
6	peaked	T	1
7	in	positive	13
8	the	immature	11
9	actively	immature	11
10	dividing	immature	11
11	immature	in	7
12	single	positive	13
13	positive	T	1
14	cells	positive	13
15	.	cells	14

0	Levels	reach	4
1	of	Levels	0
2	FOSB	mRNA	3
3	mRNA	of	1
4	reach	<ROOT>	-1
5	a	reach	4
6	maximum	a	5
7	40	maximum	6
8	min	40	7
9	after	the	10
10	the	min	8
11	addition	min	8
12	of	addition	11
13	lectin	of	12
14	and	lectin	13
15	decline	and	14
16	to	decline	15
17	control	decline	15
18	levels	decline	15
19	over	levels	18
20	the	over	19
21	next	6	22
22	6	the	20
23	hr	over	19
24	.	hr	23

0	In	<ROOT>	-1
1	order	In	0
2	to	In	0
3	elucidate	to	2
4	possible	elucidate	3
5	mechanisms	possible	4
6	underlying	mechanisms	5
7	endothelial	mechanisms	5
8	cell	by	10
9	activation	by	10
10	by	endothelial	7
11	xenogeneic	serum	12
12	serum	by	10
13	,	serum	12
14	we	serum	12
15	focussed	on	16
16	on	we	14
17	transcription	B	20
18	factor	B	20
19	NF-kappa	B	20
20	B	on	16
21	,	serum	12
22	a	regulator	24
23	central	regulator	24
24	regulator	serum	12
25	for	the	26
26	the	serum	12
27	induction	the	26
28	of	induction	27
29	different	genes	30
30	genes	of	28
31	,	In	0
32	including	adhesive	33
33	adhesive	,	31
34	molecules	adhesive	33
35	and	molecules	34
36	chemoattractants	adhesive	33
37	.	In	0

0	In	could	4
1	vivo	In	0
2	,	could	4
3	this	could	4
4	could	<ROOT>	-1
5	lead	could	4
6	to	inappropriate	7
7	inappropriate	of	9
8	binding	of	9
9	of	lead	5
10	cortisol	lead	5
11	to	lead	5
12	mineralocorticoid	receptors	13
13	receptors	to	11
14	.	could	4

0	Squamous	carcinomas	2
1	cell	carcinomas	2
2	carcinomas	showed	3
3	showed	<ROOT>	-1
4	a	variety	5
5	variety	of	6
6	of	showed	3
7	expression	of	6
8	levels	showed	3
9	,	showed	3
10	while	showed	3
11	two	undifferentiated	12
12	undifferentiated	SCC	18
13	spindle-shaped	carcinomas	14
14	carcinomas	undifferentiated	12
15	and	SCC	18
16	one	undifferentiated	17
17	undifferentiated	SCC	18
18	SCC	while	10
19	cell	remained	21
20	line	remained	21
21	remained	SCC	18
22	unstained	showed	3
23	.	showed	3

0	TRADD	associated	1
1	associated	with	2
2	with	<ROOT>	-1
3	wild-type	with	2
4	LMP1	wild-type	3
5	but	LMP1	4
6	not	but	5
7	with	not	6
8	isoleucine-mutated	LMP1	9
9	LMP1	with	7
10	in	LMP1	9
11	mammalian	in	10
12	cells	,	13
13	,	mammalian	11
14	and	not	6
15	TRADD	associated	17
16	constitutively	associated	17
17	associated	and	14
18	with	associated	17
19	LMP1	in	20
20	in	associated	17
21	EBV-transformed	associated	17
22	cells	with	2
23	.	with	2

0	This	factor	2
1	transcription	factor	2
2	factor	is	3
3	is	<ROOT>	-1
4	activated	is	3
5	via	activated	4
6	the	phosphorylation	8
7	selective	phosphorylation	8
8	phosphorylation	via	5
9	,	is	3
10	ubiquination	is	3
11	and	ubiquination	10
12	degradation	is	3
13	of	degradation	12
14	its	inhibitor	15
15	inhibitor	of	13
16	protein	I-kB	17
17	I-kB	inhibitor	15
18	thereby	inhibitor	15
19	allowing	of	21
20	translocation	of	21
21	of	is	3
22	NF-kappa	of	21
23	B	into	24
24	into	NF-kappa	22
25	the	is	3
26	nucleus	where	27
27	where	the	25
28	it	upregulates	29
29	upregulates	where	27
30	the	transcription	31
31	transcription	(	38
32	of	(	38
33	a	variety	34
34	variety	(	38
35	of	(	38
36	adhesion	molecules	37
37	molecules	of	35
38	(	upregulates	29
39	e.g.	(	38
40	ICAM-1	(	38
41	,	is	3
42	VCAM-1	is	3
43	)	is	3
44	,	is	3
45	cytokines	(	46
46	(	,	44
47	TNF	(	46
48	,	TNF	47
49	IL-1	(	46
50	,	(	46
51	IL-6	is	3
52	)	is	3
53	and	is	3
54	enzymes	is	3
55	(	is	3
56	iNOS	is	3
57	)	is	3
58	.	is	3

0	Characterization	does	7
1	of	Characterization	0
2	a	that	6
3	mutant	that	6
4	cell	that	6
5	line	that	6
6	that	of	1
7	does	<ROOT>	-1
8	not	does	7
9	activate	does	7
10	NF-kappaB	activate	9
11	in	activate	9
12	response	in	11
13	to	multiple	14
14	multiple	response	12
15	stimuli	does	7
16	.	does	7

0	However	gamma	15
1	,	produced	4
2	these	plasmids	3
3	plasmids	produced	4
4	produced	However	0
5	transcriptional	However	0
6	activity	However	0
7	in	HeLa	8
8	HeLa	activity	6
9	cells	only	10
10	only	However	0
11	in	However	0
12	conjunction	However	0
13	with	conjunction	12
14	interferon	However	0
15	gamma	proteins	33
16	stimulation	gamma	15
17	,	gamma	15
18	a	condition	19
19	condition	,	17
20	in	condition	19
21	which	expression	22
22	expression	of	23
23	of	in	20
24	both	CIITA	25
25	CIITA	of	23
26	and	of	23
27	class	II	28
28	II	and	26
29	major	of	23
30	histocompatibility	surface	32
31	complex	surface	32
32	surface	in	20
33	proteins	<ROOT>	-1
34	are	proteins	33
35	induced.	are	34

0	Moreover	are	12
1	,	Moreover	0
2	both	,	1
3	in	both	2
4	cell	lines	5
5	lines	in	3
6	and	both	2
7	in	leukemia	9
8	primary	leukemia	9
9	leukemia	and	6
10	cells	Moreover	0
11	that	are	12
12	are	<ROOT>	-1
13	resistant	are	12
14	towards	are	12
15	induction	towards	14
16	of	induction	15
17	apoptosis	of	16
18	by	are	12
19	DILs	by	18
20	and	DILs	19
21	doxorubicin	and	20
22	,	are	12
23	antagonization	are	12
24	of	NFkappaB	25
25	NFkappaB	antagonization	23
26	activity	partially	27
27	partially	are	12
28	restored	sensitivity	30
29	apoptosis	sensitivity	30
30	sensitivity	are	12
31	.	are	12

0	SR	31747A	1
1	31747A	is	9
2	,	31747A	1
3	defined	31747A	1
4	as	defined	3
5	a	ligand	7
6	sigma	ligand	7
7	ligand	as	4
8	,	31747A	1
9	is	<ROOT>	-1
10	a	novel	11
11	novel	is	9
12	immunosuppressive	that	14
13	agent	that	14
14	that	novel	11
15	blocks	that	14
16	proliferation	blocks	15
17	of	proliferation	16
18	human	of	17
19	and	human	18
20	mouse	and	19
21	lymphocytes	.	22
22	.	and	19

0	After	eventually	6
1	DMSO	treatment	2
2	treatment	After	0
3	,	eventually	6
4	HL-60	cells	5
5	cells	eventually	6
6	eventually	<ROOT>	-1
7	died	eventually	6
8	via	died	7
9	apoptosis	via	8
10	,	eventually	6
11	whereas	eventually	6
12	the	viability	13
13	viability	was	17
14	of	viability	13
15	PDBu-treated	cells	16
16	cells	of	14
17	was	whereas	11
18	not	was	17
19	affected	was	17
20	during	affected	19
21	the	interval	23
22	same	interval	23
23	interval	during	20
24	.	eventually	6

0	The	gene	1
1	gene	is	2
2	is	<ROOT>	-1
3	expressed	is	2
4	in	expressed	3
5	all	cells	7
6	hematopoietic	cells	7
7	cells	in	4
8	with	the	9
9	the	in	4
10	exception	the	9
11	of	exception	10
12	T-cells	is	2
13	and	is	2
14	plasma	is	2
15	cells	is	2
16	.	is	2

0	Although	have	22
1	JAK3	is	2
2	is	Although	0
3	required	is	2
4	for	required	3
5	proper	development	7
6	lymphoid	development	7
7	development	for	4
8	,	Although	0
9	the	roles	11
10	precise	roles	11
11	roles	,	8
12	of	roles	11
13	this	kinase	14
14	kinase	of	12
15	in	roles	11
16	IL-2	in	15
17	and	in	15
18	IL-4	Although	0
19	signaling	Although	0
20	in	Although	0
21	lymphocytes	Although	0
22	have	<ROOT>	-1
23	not	have	22
24	been	have	22
25	defined	been	24
26	.	have	22

0	In	<ROOT>	-1
1	order	In	0
2	to	In	0
3	investigate	to	2
4	the	nature	5
5	nature	investigate	3
6	of	nature	5
7	the	of	6
8	A6H	level	14
9	mAb	level	14
10	costimulus	level	14
11	at	transcriptional	13
12	the	transcriptional	13
13	transcriptional	costimulus	10
14	level	the	7
15	we	In	0
16	have	we	15
17	examined	induction	18
18	induction	have	16
19	of	induction	18
20	the	of	19
21	transcription	the	20
22	factors	transcription	21
23	OCT-1	factors	22
24	,	OCT-1	23
25	AP-1	,	24
26	and	,	24
27	NF-kappa	B	28
28	B	and	26
29	which	known	31
30	are	which	29
31	known	OCT-1	23
32	to	the	20
33	be	to	32
34	transcriptional	regulators	35
35	regulators	several	37
36	of	several	37
37	several	be	33
38	cytokine	and	39
39	and	cytokine	40
40	cytokine	be	33
41	receptor	have	16
42	genes	In	0
43	,	In	0
44	including	,	43
45	the	including	44
46	IL-2	and	47
47	and	the	45
48	IL-2R	and	47
49	genes	IL-2R	48
50	.	In	0

0	Emphasis	is	1
1	is	<ROOT>	-1
2	given	is	1
3	to	given	2
4	recent	to	3
5	information	recent	4
6	about	information	5
7	the	mechanisms	9
8	molecular	mechanisms	9
9	mechanisms	about	6
10	of	prolactin	11
11	prolactin	mechanisms	9
12	receptor	prolactin	11
13	signal	transduction	14
14	transduction	prolactin	11
15	,	is	1
16	and	is	1
17	the	and	16
18	signaling	the	17
19	molecules	signaling	18
20	and	prolactin-inducible	21
21	prolactin-inducible	molecules	19
22	target	prolactin-inducible	21
23	genes	that	24
24	that	is	1
25	participate	that	24
26	in	participate	25
27	these	responses	28
28	responses	in	26
29	.	is	1

0	To	<ROOT>	-1
1	overcome	To	0
2	the	difficulty	3
3	difficulty	overcome	1
4	in	obtaining	5
5	obtaining	difficulty	3
6	quiescent	obtaining	5
7	monocytes	To	0
8	,	To	0
9	we	,	8
10	studied	the	11
11	the	we	9
12	ability	the	11
13	of	ability	12
14	promonocytic	of	13
15	THP-1	to	17
16	cells	to	17
17	to	promonocytic	14
18	activate	of	13
19	endothelial	cells	20
20	cells	activate	18
21	.	cells	20

0	A	factor	1
1	factor	<ROOT>	-1
2	in	factor	1
3	bovine	in	2
4	colostrum	factor	8
5	(	factor	8
6	colostrum	factor	8
7	inhibitory	factor	8
8	factor	bovine	3
9	,	factor	8
10	CIF	factor	8
11	)	factor	1
12	inhibits	factor	1
13	interleukin	factor	1
14	2	interleukin	13
15	(	IL2	16
16	IL2	interleukin	13
17	)	IL2	16
18	production	factor	1
19	in	activated	20
20	activated	production	18
21	T	factor	1
22	helper	factor	1
23	cells	factor	1
24	by	factor	1
25	blocking	by	24
26	the	accumulation	27
27	accumulation	blocking	25
28	of	accumulation	27
29	IL2	mRNA	30
30	mRNA	of	28
31	.	factor	1

0	CIF	inhibited	1
1	inhibited	as	6
2	induction	inhibited	1
3	of	either	4
4	either	induction	2
5	construct	inhibited	1
6	as	did	7
7	did	<ROOT>	-1
8	cyclosporine	did	7
9	,	cyclosporine	8
10	which	known	12
11	is	which	10
12	known	cyclosporine	8
13	to	known	12
14	block	to	13
15	activation	block	14
16	of	activation	15
17	the	element	19
18	NFAT	element	19
19	element	of	16
20	.	did	7

0	The	incorporation	3
1	maximum	incorporation	3
2	-LRB-3H-RRB--thymidine	incorporation	3
3	incorporation	was	18
4	into	incorporation	3
5	DNA	into	4
6	of	blood	8
7	cord	blood	8
8	blood	DNA	5
9	lymphocytes	incorporation	3
10	from	incorporation	3
11	all	preterms	12
12	preterms	from	10
13	,	incorporation	3
14	with	incorporation	3
15	or	with	14
16	without	or	15
17	NRDS	without	16
18	was	<ROOT>	-1
19	suppressed	was	18
20	when	compared	21
21	compared	suppressed	19
22	to	compared	21
23	that	to	22
24	from	that	23
25	term	babies	26
26	babies	that	23
27	or	that	23
28	adults	compared	21
29	.	was	18

0	Northern	analyses	2
1	blot	analyses	2
2	analyses	indicated	3
3	indicated	<ROOT>	-1
4	a	indicated	3
5	highly	restricted	6
6	restricted	a	4
7	mRNA	pattern	9
8	expression	pattern	9
9	pattern	restricted	6
10	,	restricted	6
11	with	restricted	6
12	the	expression	14
13	strongest	expression	14
14	expression	with	11
15	occurring	expression	14
16	in	occurring	15
17	promyelocyte	in	16
18	and	promyelocyte	17
19	late-myeloblast-like	and	18
20	cell	late-myeloblast-like	19
21	lines	cell	20
22	.	lines	21

0	In	is	5
1	contrast	In	0
2	,	is	5
3	when	RBTN-2	4
4	RBTN-2	is	5
5	is	would	13
6	inappropriately	is	5
7	expressed	inappropriately	6
8	in	T	9
9	T	expressed	7
10	cells	is	5
11	,	would	13
12	RBTN-2	would	13
13	would	<ROOT>	-1
14	interact	predominantly	15
15	predominantly	would	13
16	with	predominantly	15
17	elf-2b	predominantly	15
18	;	would	13
19	this	interaction	20
20	interaction	may	21
21	may	would	13
22	lead	cell	25
23	to	cell	25
24	T	cell	25
25	cell	may	21
26	proliferation	would	13
27	.	would	13

0	Studies	<ROOT>	-1
1	of	Studies	0
2	pluripotent	cultures	4
3	islet	cultures	4
4	cultures	of	1
5	.	Studies	0

0	This	process	1
1	process	requires	2
2	requires	<ROOT>	-1
3	calcium-dependent	dephosphorylation	4
4	dephosphorylation	requires	2
5	of	dephosphorylation	4
6	NFAT	of	5
7	caused	dephosphorylation	4
8	by	caused	7
9	the	phosphatase	10
10	phosphatase	by	8
11	calcineurin	caused	7
12	.	requires	2

0	We	show	2
1	now	show	2
2	show	<ROOT>	-1
3	that	show	2
4	in	that	3
5	EBV-transformed	lymphocytes	7
6	B	lymphocytes	7
7	lymphocytes	in	4
8	most	in	4
9	of	most	8
10	TRAF1	of	9
11	or	of	9
12	TRAF3	show	2
13	and	show	2
14	5	%	15
15	%	are	18
16	of	%	15
17	TRAF2	of	16
18	are	and	13
19	associated	are	18
20	with	associated	19
21	LMP1	with	20
22	and	are	18
23	that	and	22
24	most	is	27
25	of	most	24
26	LMP1	of	25
27	is	that	23
28	associated	is	27
29	with	associated	28
30	TRAF1	with	29
31	or	TRAF1	30
32	TRAF3	or	31
33	.	show	2

0	Our	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	constitutive	ETS1	5
5	ETS1	cooperate	13
6	,	ETS1	5
7	and	inducible	8
8	inducible	ETS1	5
9	NFkappaB	inducible	8
10	and	NFkappaB	9
11	AP1	and	10
12	,	ETS1	5
13	cooperate	that	3
14	as	cooperate	13
15	part	as	14
16	of	part	15
17	a	higher	18
18	higher	of	16
19	order	higher	18
20	transcriptional	complex	21
21	complex	order	19
22	in	complex	21
23	activated	T	24
24	T	complex	21
25	cells	suggest	2
26	.	suggest	2

0	Jak1	expression	1
1	expression	is	2
2	is	receptor	11
3	required	insulin	10
4	for	insulin	10
5	mediating	insulin	10
6	interleukin-4-induced	tyrosine	7
7	tyrosine	insulin	10
8	phosphorylation	of	9
9	of	insulin	10
10	insulin	is	2
11	receptor	<ROOT>	-1
12	substrate	receptor	11
13	and	receptor	11
14	Stat6	receptor	11
15	signaling	receptor	11
16	molecules	receptor	11
17	.	receptor	11

0	Our	<ROOT>	-1
1	results	Our	0
2	imply	that	3
3	that	T	4
4	T	results	1
5	cells	need	6
6	need	Our	0
7	to	need	6
8	maintain	to	7
9	a	maintain	8
10	certain	NF-kappaB	13
11	level	of	12
12	of	certain	10
13	NF-kappaB	a	9
14	transcriptional	a	9
15	activity	Our	0
16	in	Our	0
17	order	Our	0
18	to	Our	0
19	survive	to	18
20	;	Our	0
21	up-	Our	0
22	or	up-	21
23	down-regulation	up-	21
24	of	down-regulation	23
25	nuclear	of	24
26	NF	Our	0
27	kappaB	NF	26
28	through	kappaB	27
29	modulation	through	28
30	of	modulation	29
31	IkappaBalpha	of	30
32	expression	IkappaBalpha	31
33	by	cytokines	34
34	cytokines	expression	32
35	or	expression	32
36	DEX	expression	32
37	may	Our	0
38	lead	may	37
39	to	lead	38
40	cell	survival	41
41	survival	or	42
42	or	to	39
43	cell	or	42
44	death	Our	0
45	,	Our	0
46	respectively	Our	0
47	.	Our	0

0	Molecular	differences	1
1	differences	may	16
2	of	differences	1
3	the	molecule	5
4	A6H	molecule	5
5	molecule	of	2
6	or	distinct	7
7	distinct	differences	1
8	regulation	of	9
9	of	activation	14
10	the	A6H	11
11	A6H	activation	14
12	transduced	activation	14
13	AP-1	activation	14
14	activation	differences	1
15	pathway	differences	1
16	may	<ROOT>	-1
17	exist	may	16
18	in	exist	17
19	CD4+	in	18
20	and	T	22
21	CD8+	T	22
22	T	in	18
23	cell	.	25
24	subpopulations	.	25
25	.	in	18

0	These	results	1
1	results	provide	2
2	provide	<ROOT>	-1
3	evidence	provide	2
4	that	evidence	3
5	promonocytic	that	4
6	THP-1	require	8
7	cells	require	8
8	require	promonocytic	5
9	prestimulation	promonocytic	5
10	in	prestimulation	9
11	order	in	10
12	to	in	10
13	activate	to	12
14	HUVEC	activate	13
15	and	HUVEC	14
16	that	alpha	18
17	TNF	alpha	18
18	alpha	and	15
19	contributes	provide	2
20	to	contributes	19
21	this	phenomenon	22
22	phenomenon	to	20
23	.	provide	2

0	Xenogeneic	serum	2
1	human	serum	2
2	serum	promotes	3
3	promotes	<ROOT>	-1
4	leukocyte	adhesion	5
5	adhesion	promotes	3
6	to	adhesion	5
7	porcine	endothelium	8
8	endothelium	to	6
9	under	flow	10
10	flow	promotes	3
11	conditions	promotes	3
12	,	promotes	3
13	possibly	through	14
14	through	promotes	3
15	the	activation	16
16	activation	through	14
17	of	activation	16
18	the	of	17
19	transcription	B	22
20	factor	B	22
21	NF-kappa	B	22
22	B	the	18
23	.	promotes	3

0	The	N-terminal	2
1	distinct	N-terminal	2
2	N-terminal	carries	6
3	half	N-terminal	2
4	of	half	3
5	MZF-2	of	4
6	carries	<ROOT>	-1
7	two	domains	9
8	characteristic	domains	9
9	domains	carries	6
10	,	carries	6
11	a	domain	13
12	leucine-rich	domain	13
13	domain	,	10
14	called	domain	13
15	LeR	called	14
16	and	domain	13
17	an	domain	19
18	acidic	domain	19
19	domain	and	16
20	,	domain	13
21	which	suggests	22
22	suggests	domain	13
23	a	suggests	22
24	unique	of	26
25	function	of	26
26	of	a	23
27	MZF-2	of	26
28	in	MZF-2	27
29	neutrophil	carries	6
30	development	carries	6
31	.	carries	6

0	GR6	is	1
1	is	<ROOT>	-1
2	activated	is	1
3	in	cell	6
4	the	cell	6
5	UCSD-AML1	cell	6
6	cell	activated	2
7	line	is	1
8	and	is	1
9	in	is	1
10	a	sample	12
11	leukemic	sample	12
12	sample	in	9
13	,	is	1
14	both	is	1
15	of	both	14
16	which	carry	17
17	carry	of	15
18	a	t-LRB-3;3-RRB--LRB-q21;q26-RRB-	19
19	t-LRB-3;3-RRB--LRB-q21;q26-RRB-	carry	17
20	.	is	1

0	Deltorphin	increased	2
1	also	increased	2
2	increased	<ROOT>	-1
3	accumulation	of	4
4	of	transcription	6
5	AP-1	transcription	6
6	transcription	factor	7
7	factor	increased	2
8	complexes	increased	2
9	,	complexes	8
10	suggesting	,	9
11	that	suggesting	10
12	DOR1	IL-2	14
13	augments	IL-2	14
14	IL-2	that	11
15	secretion	by	16
16	by	IL-2	14
17	increasing	by	16
18	the	component	20
19	AP-1	component	20
20	component	increasing	17
21	of	component	20
22	the	factor	25
23	NF-AT/AP-1	factor	25
24	transcription	factor	25
25	factor	of	21
26	.	increased	2

0	BEAD-1	blocked	1
1	blocked	<ROOT>	-1
2	the	ability	3
3	ability	delta	7
4	of	delta	7
5	the	delta	7
6	TCR	delta	7
7	delta	blocked	1
8	enhancer	(	9
9	(	blocked	1
10	Edelta	(	9
11	)	blocked	1
12	to	blocked	1
13	activate	to	12
14	a	promoter	15
15	promoter	activate	13
16	when	located	17
17	located	activate	13
18	between	located	17
19	the	two	20
20	two	between	18
21	in	two	20
22	a	construct	24
23	chromatin-integrated	construct	24
24	construct	in	21
25	.	blocked	1

0	These	constructs	1
1	constructs	were	2
2	were	<ROOT>	-1
3	transfected	with	16
4	into	with	16
5	a	variety	6
6	variety	into	4
7	of	variety	6
8	cell	lines	9
9	lines	of	7
10	,	into	4
11	either	alone	12
12	alone	into	4
13	or	alone	12
14	together	or	13
15	,	into	4
16	with	were	2
17	transcription	with	16
18	factor	transcription	17
19	expression	with	16
20	vectors	were	2
21	.	were	2

0	Our	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	CaMKIV	may	5
5	may	that	3
6	represent	may	5
7	a	represent	6
8	physiologically	relevant	9
9	relevant	a	7
10	CREB	kinase	11
11	kinase	relevant	9
12	in	T	13
13	T	kinase	11
14	cells	suggest	2
15	and	suggest	2
16	that	and	15
17	the	enzyme	18
18	enzyme	is	19
19	is	that	16
20	also	is	19
21	required	is	19
22	to	required	21
23	ensure	to	22
24	normal	ensure	23
25	expansion	normal	24
26	of	T	27
27	T	expansion	25
28	cells	suggest	2
29	in	suggest	2
30	the	in	29
31	thymus	.	32
32	.	the	30

0	In	<ROOT>	-1
1	order	In	0
2	to	transcriptional	5
3	study	transcriptional	5
4	the	transcriptional	5
5	transcriptional	In	0
6	control	of	7
7	of	In	0
8	15-LO	of	7
9	expression	,	10
10	,	15-LO	8
11	we	and	14
12	have	and	14
13	cloned	and	14
14	and	,	10
15	sequenced	and	14
16	the	sequenced	15
17	human	the	16
18	15-LO	human	17
19	promoter	region	20
20	region	15-LO	18
21	.	region	20

0	By	<ROOT>	-1
1	immunocytochemistry	By	0
2	,	By	0
3	25	%	6
4	+/-	%	6
5	7	+/-	4
6	%	,	2
7	of	%	6
8	the	of	7
9	human	were	11
10	neutrophils	were	11
11	were	the	8
12	shown	of	7
13	to	shown	12
14	express	to	13
15	immunoreactive	express	14
16	GH	,	17
17	,	immunoreactive	15
18	whereas	of	7
19	eosinophils	were	20
20	were	of	7
21	negative	were	20
22	.	By	0

0	These	<ROOT>	-1
1	data	These	0
2	provide	direct	3
3	direct	data	1
4	evidence	direct	3
5	for	evidence	4
6	the	involvement	7
7	involvement	for	5
8	of	involvement	7
9	NF-kappaB/Rel	of	8
10	family	in	12
11	proteins	in	12
12	in	NF-kappaB/Rel	9
13	late	T	16
14	stages	of	15
15	of	T	16
16	T	direct	3
17	lymphocyte	direct	3
18	development	lymphocyte	17
19	,	coincident	20
20	coincident	development	18
21	with	lymphocyte	17
22	positive	and	23
23	and	with	21
24	negative	.	26
25	selection	.	26
26	.	and	23

0	Human	virus	2
1	immunodeficiency	virus	2
2	virus	<ROOT>	-1
3	type	virus	2
4	1	)	7
5	(	1	4
6	HIV-1	)	7
7	)	replicates	8
8	replicates	type	3
9	more	replicates	8
10	efficiently	virus	2
11	in	efficiently	10
12	vitro	in	11
13	in	differentiated	14
14	differentiated	virus	2
15	macrophages	virus	2
16	than	macrophages	15
17	in	than	16
18	freshly	in	17
19	isolated	freshly	18
20	monocytes	isolated	19
21	.	monocytes	20

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	RNase	,	2
4	protection	RNase	3
5	assays	revealed	6
6	revealed	protection	4
7	that	T	9
8	anti-CD3/PMA-stimulated	T	9
9	T	revealed	6
10	cells	revealed	6
11	from	revealed	6
12	a	from	11
13	substantial	of	15
14	proportion	of	15
15	of	a	12
16	elderly	of	15
17	subjects	exhibited	18
18	exhibited	elderly	16
19	decreased	a	12
20	levels	of	21
21	of	a	12
22	c-fos	of	21
23	and/or	c-fos	22
24	c-jun	mRNA	25
25	mRNA	c-fos	22
26	compared	a	12
27	to	T	28
28	T	compared	26
29	cells	In	0
30	from	young	31
31	young	In	0
32	subjects	In	0
33	.	In	0

0	We	suggested	1
1	suggested	<ROOT>	-1
2	that	suggested	1
3	negative	feedback	4
4	feedback	could	7
5	of	feedback	4
6	cortisol	of	5
7	could	that	2
8	be	could	7
9	deranged	be	8
10	.	suggested	1

0	Implication	has	14
1	of	Implication	0
2	viruses	of	1
3	such	as	4
4	as	of	1
5	Epstein-Barr	virus	6
6	virus	as	4
7	(	EBV	8
8	EBV	virus	6
9	)	EBV	8
10	in	virus	6
11	rheumatoid	in	10
12	arthritis	pathogenesis	13
13	pathogenesis	rheumatoid	11
14	has	<ROOT>	-1
15	been	has	14
16	suspected	been	15
17	on	suspected	16
18	the	basis	19
19	basis	on	17
20	of	basis	19
21	several	observations	23
22	indirect	observations	23
23	observations	of	20
24	,	been	39
25	but	been	39
26	thus	but	25
27	far	thus	26
28	,	been	39
29	a	EBV	33
30	direct	a	29
31	link	a	29
32	between	EBV	33
33	EBV	been	39
34	and	EBV	33
35	rheumatoid	and	34
36	arthritis	rheumatoid	35
37	has	not	38
38	not	arthritis	36
39	been	observations	23
40	provided	has	14
41	.	has	14

0	The	enhancer	2
1	IL-3	enhancer	2
2	enhancer	spanned	3
3	spanned	an	4
4	an	inducible	5
5	inducible	I-hypersensitive	9
6	cyclosporin	I-hypersensitive	9
7	A-sensitive	I-hypersensitive	9
8	DNase	I-hypersensitive	9
9	I-hypersensitive	found	11
10	site	I-hypersensitive	9
11	found	<ROOT>	-1
12	only	found	11
13	in	T	14
14	T	only	12
15	cells	found	11
16	.	found	11

0	Our	studies	2
1	previous	studies	2
2	studies	showed	3
3	showed	<ROOT>	-1
4	that	showed	3
5	the	exposure	6
6	exposure	that	4
7	of	human	8
8	human	exposure	6
9	monocytes	showed	3
10	to	showed	3
11	E.	chaffeensis	12
12	chaffeensis	showed	3
13	induces	the	14
14	the	showed	3
15	expression	of	16
16	of	the	14
17	interleukin-1beta	of	16
18	(	of	16
19	IL-1beta	showed	3
20	)	showed	3
21	,	showed	3
22	IL-8	showed	3
23	,	and	24
24	and	IL-8	22
25	IL-10	showed	3
26	genes	showed	3
27	in	showed	3
28	vitro	tumor	34
29	but	tumor	34
30	not	the	31
31	the	tumor	34
32	expression	tumor	34
33	of	tumor	34
34	tumor	showed	3
35	necrosis	factor	36
36	factor	showed	3
37	alpha	(	38
38	(	showed	3
39	TNF-alpha	(	38
40	)	showed	3
41	and	showed	3
42	IL-6	showed	3
43	mRNAs	showed	3
44	.	showed	3

0	[	Correlation	1
1	Correlation	<ROOT>	-1
2	of	Correlation	1
3	lymphocytic	infiltration	4
4	infiltration	of	2
5	of	infiltration	4
6	tumor	tissue	7
7	tissue	of	5
8	with	infiltration	4
9	the	state	13
10	hormonal	state	13
11	and	hormonal	10
12	metabolic	and	11
13	state	with	8
14	in	state	13
15	patients	in	14
16	with	patients	15
17	breast	with	16
18	cancer	]	19
19	]	breast	17

0	Finally	were	3
1	,	were	3
2	we	were	3
3	were	<ROOT>	-1
4	able	were	3
5	to	able	4
6	generate	to	5
7	a	generate	6
8	specific	a	7
9	CD8+	specific	8
10	CTL	CD8+	9
11	line	CTL	10
12	against	line	11
13	a	against	12
14	K-RAS	.	17
15	mutated	.	17
16	peptide	.	17
17	.	a	13

0	Using	was	8
1	a	Using	0
2	nuclear	a	1
3	run-on	nuclear	2
4	assay	run-on	3
5	,	assay	4
6	IL-4	Using	0
7	stimulation	Using	0
8	was	<ROOT>	-1
9	shown	was	8
10	to	shown	9
11	enhance	to	10
12	transcription	enhance	11
13	by	enhance	11
14	two-	by	13
15	to	enhance	11
16	threefold	to	15
17	.	was	8

0	In	was	22
1	contrast	In	0
2	,	In	0
3	IFN-alpha/beta	T	5
4	rescued	T	5
5	T	,	2
6	cell	from	8
7	clones	from	8
8	from	T	5
9	apoptosis	In	0
10	without	apoptosis	9
11	active	,	13
12	proliferation	,	13
13	,	In	0
14	and	,	13
15	expression	In	0
16	of	In	0
17	apoptosis-associated	proteins	18
18	proteins	of	16
19	tested	In	0
20	so	In	0
21	far	so	20
22	was	<ROOT>	-1
23	unaffected	was	22
24	.	was	22

0	High	levels	1
1	levels	virus	16
2	of	levels	1
3	the	activity	5
4	DNA-binding	activity	5
5	activity	of	2
6	of	activity	5
7	E2F	of	6
8	in	adult	9
9	adult	levels	1
10	T-cell	leukemia	11
11	leukemia	adult	9
12	and	virus	16
13	human	virus	16
14	T-cell	leukemia	15
15	leukemia	virus	16
16	virus	<ROOT>	-1
17	type	virus	16
18	I-infected	virus	16
19	cells	virus	16
20	:	virus	16
21	possible	enhancement	22
22	enhancement	virus	16
23	of	enhancement	22
24	DNA-binding	of	23
25	of	DNA-binding	24
26	E2F	of	25
27	by	enhancement	22
28	the	by	27
29	human	transactivating	34
30	T-cell	leukemia	31
31	leukemia	transactivating	34
32	virus	transactivating	34
33	I	transactivating	34
34	transactivating	the	28
35	protein	the	28
36	,	protein	35
37	Tax	virus	16
38	.	virus	16

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	herpes	proteins	7
5	simplex	proteins	7
6	tegument	proteins	7
7	proteins	are	8
8	are	that	3
9	processed	presentation	12
10	for	antigen	11
11	antigen	processed	9
12	presentation	are	8
13	in	presentation	12
14	vivo	in	13
15	and	in	13
16	are	and	15
17	possible	are	16
18	candidate	possible	17
19	compounds	candidate	18
20	for	compounds	19
21	herpes	for	20
22	simplex	herpes	21
23	vaccines	.	24
24	.	simplex	22

0	These	data	1
1	data	indicate	2
2	indicate	<ROOT>	-1
3	that	occurs	6
4	IL-4	signaling	5
5	signaling	occurs	6
6	occurs	indicate	2
7	in	occurs	6
8	the	absence	9
9	absence	in	7
10	of	absence	9
11	of	of	10
12	JAK3	of	11
13	,	JAK3	12
14	but	of	10
15	is	indicate	2
16	comparatively	indicate	2
17	inefficient	.	18
18	.	comparatively	16

0	A	novel	1
1	novel	factor	3
2	immunosuppressive	factor	3
3	factor	<ROOT>	-1
4	in	factor	3
5	bovine	factor	3
6	colostrum	bovine	5
7	blocks	colostrum	6
8	activation	bovine	5
9	of	activation	8
10	the	enhancer	14
11	interleukin	2	12
12	2	enhancer	14
13	gene	enhancer	14
14	enhancer	of	9
15	at	of	9
16	the	site	18
17	NFAT	site	18
18	site	at	15
19	.	site	18

0	CD4+	T	1
1	T	cells	2
2	cells	costimulated	3
3	costimulated	<ROOT>	-1
4	with	costimulated	3
5	the	with	4
6	A6H	upregulated	8
7	mAb	upregulated	8
8	upregulated	the	5
9	CD80	upregulated	8
10	,	upregulated	8
11	CD86	upregulated	8
12	,	upregulated	8
13	CD71	IL-2R	22
14	,	CD71	13
15	interleukin-2	alpha	20
16	(	IL-2	17
17	IL-2	alpha	20
18	)	IL-2	17
19	R	alpha	20
20	alpha	CD71	13
21	,	alpha	20
22	IL-2R	upregulated	8
23	beta	upregulated	8
24	and	upregulated	8
25	IL-2R	upregulated	8
26	gamma	upregulated	8
27	,	upregulated	8
28	while	upregulated	8
29	no	while	28
30	corresponding	of	32
31	up-regulation	of	32
32	of	no	29
33	these	molecules	36
34	cell	molecules	36
35	surface	molecules	36
36	molecules	of	32
37	was	no	29
38	seen	was	37
39	in	T	41
40	CD8+	T	41
41	T	seen	38
42	cells	costimulated	3
43	.	costimulated	3

0	Although	were	23
1	there	was	2
2	was	Although	0
3	an	increase	4
4	increase	was	2
5	in	increase	4
6	the	activity	8
7	plasma	activity	8
8	activity	in	5
9	of	activity	8
10	the	sialyltransferase	13
11	alpha	2,6	12
12	2,6	sialyltransferase	13
13	sialyltransferase	of	9
14	isozyme	sialyltransferase	13
15	in	sialyltransferase	13
16	the	group	18
17	schizophrenic	group	18
18	group	in	15
19	,	were	23
20	no	other	21
21	other	changes	22
22	changes	were	23
23	were	<ROOT>	-1
24	determined	were	23
25	.	were	23

0	Activation	requirements	2
1	domain	requirements	2
2	requirements	<ROOT>	-1
3	for	requirements	2
4	disruption	for	3
5	of	disruption	4
6	Epstein-Barr	latency	8
7	virus	latency	8
8	latency	of	5
9	by	disruption	4
10	ZEBRA	by	9
11	.	requirements	2

0	This	implicates	1
1	implicates	<ROOT>	-1
2	that	implicates	1
3	the	SRG3	4
4	SRG3	may	5
5	may	that	2
6	play	may	5
7	an	play	6
8	important	cell	13
9	regulatory	during	11
10	role	during	11
11	during	important	8
12	T	cell	13
13	cell	an	7
14	development	an	7
15	in	play	6
16	thymus	implicates	1
17	.	implicates	1

0	The	development	1
1	development	is	6
2	of	eosinophilic	4
3	chronic	eosinophilic	4
4	eosinophilic	development	1
5	inflammation	development	1
6	is	<ROOT>	-1
7	dependent	is	6
8	on	dependent	7
9	interleukin-5	on	8
10	(	IL-5	11
11	IL-5	interleukin-5	9
12	)	IL-5	11
13	,	interleukin-5	9
14	a	factor	17
15	selective	factor	17
16	eosinophil-activating	factor	17
17	factor	interleukin-5	9
18	,	interleukin-5	9
19	produced	is	6
20	by	T	22
21	helper	T	22
22	T	produced	19
23	cells	is	6
24	.	is	6

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	,	In	0
4	we	,	3
5	used	we	4
6	a	approach	9
7	RT-PCR	approach	9
8	based	approach	9
9	approach	used	5
10	to	used	5
11	compare	to	10
12	the	stability	13
13	stability	compare	11
14	of	stability	13
15	the	T	17
16	big	T	17
17	T	of	14
18	and	stability	13
19	small	allele	21
20	t	allele	21
21	allele	and	18
22	in	heterozygous	24
23	normal	heterozygous	24
24	heterozygous	stability	13
25	lymphocytes	used	5
26	and	myeloid	33
27	the	heterozygous	28
28	heterozygous	lines	30
29	cell	lines	30
30	lines	and	26
31	NB4	myeloid	33
32	(	myeloid	33
33	myeloid	In	0
34	leukemia	In	0
35	)	In	0
36	and	In	0
37	PC-3	In	0
38	and	In	0
39	DU	145	40
40	145	In	0
41	(	prostate	42
42	prostate	145	40
43	cancers	prostate	42
44	)	prostate	42
45	.	In	0

0	Signal	transduction	1
1	transduction	<ROOT>	-1
2	by	transduction	1
3	DR3	by	2
4	,	transduction	1
5	a	death	6
6	death	,	4
7	domain-containing	receptor	8
8	receptor	related	9
9	related	death	6
10	to	related	9
11	TNFR-1	to	10
12	and	TNFR-1	11
13	CD95	and	12
14	.	transduction	1

0	The	role	1
1	role	was	21
2	of	role	1
3	cellular	status	5
4	redox	status	5
5	status	of	2
6	in	role	1
7	both	cytotoxic	8
8	cytotoxic	in	6
9	activity	cytotoxic	8
10	and	role	1
11	NF-kappa	B	12
12	B	and	10
13	activation	B	12
14	in	role	1
15	natural	killer	16
16	killer	in	14
17	(	NK	18
18	NK	killer	16
19	)	NK	18
20	cells	role	1
21	was	<ROOT>	-1
22	investigated	was	21
23	.	was	21

0	By	<ROOT>	-1
1	transfecting	cells	3
2	tumor	cells	3
3	cells	By	0
4	with	By	0
5	both	IL-12	6
6	IL-12	with	4
7	and	IL-12	6
8	B7.1	and	7
9	cDNAs	may	12
10	,	may	12
11	it	may	12
12	may	B7.1	8
13	be	may	12
14	possible	be	13
15	to	be	13
16	use	to	15
17	these	targets	19
18	modified	targets	19
19	targets	use	16
20	as	use	16
21	vaccines	as	20
22	.	By	0

0	The	expression	1
1	expression	was	7
2	of	expression	1
3	TNF-alpha	of	2
4	and	of	2
5	IL-6	expression	1
6	mRNAs	expression	1
7	was	<ROOT>	-1
8	also	was	7
9	induced	was	7
10	.	was	7

0	To	<ROOT>	-1
1	determine	To	0
2	whether	determine	1
3	CIF	blocks	4
4	blocks	whether	2
5	at	whether	2
6	the	level	7
7	level	at	5
8	of	IL2	9
9	IL2	level	7
10	transcription	at	5
11	,	transcription	10
12	we	reporter	14
13	introduced	reporter	14
14	reporter	at	5
15	plasmids	reporter	14
16	into	leukemia	20
17	the	leukemia	20
18	human	leukemia	20
19	T	leukemia	20
20	leukemia	plasmids	15
21	cell	reporter	14
22	line	transient	25
23	Jurkat	transient	25
24	by	transient	25
25	transient	cell	21
26	transfection	To	0
27	.	To	0

0	Sterol	element	2
1	regulatory	element	2
2	element	has	6
3	(	SRE	4
4	SRE	element	2
5	)	SRE	4
6	has	<ROOT>	-1
7	been	has	6
8	recognized	been	7
9	to	recognized	8
10	regulate	to	9
11	various	to	9
12	key	genes	13
13	genes	coding	14
14	coding	various	11
15	for	especially	16
16	especially	(	20
17	low	density	18
18	density	(	20
19	lipoprotein	(	20
20	(	coding	14
21	LDL	)	22
22	)	coding	14
23	-receptor	)	22
24	,	)	22
25	3-hydroxy-3-methylglutaryl	coenzyme	26
26	coenzyme	)	22
27	A	coenzyme	26
28	(	HMG-CoA	29
29	HMG-CoA	coenzyme	26
30	)	HMG-CoA	29
31	reductase	coding	14
32	and	coding	14
33	HMG-CoA	coding	14
34	synthase	coding	14
35	known	coding	14
36	to	known	35
37	play	a	38
38	a	to	36
39	crucial	to	36
40	role	crucial	39
41	in	role	40
42	the	mechanism	45
43	cholesterol	mechanism	45
44	feedback	mechanism	45
45	mechanism	in	41
46	.	has	6

0	A	spectrum	2
1	similar	spectrum	2
2	spectrum	transcript	4
3	of	transcript	4
4	transcript	deletions	5
5	deletions	<ROOT>	-1
6	has	deletions	5
7	previously	has	6
8	been	has	6
9	described	in	10
10	in	been	8
11	the	putative	12
12	putative	gene	15
13	tumour	gene	15
14	suppressor	gene	15
15	gene	in	10
16	FHIT	deletions	5
17	.	deletions	5

0	In	alpha	3
1	addition	In	0
2	,	In	0
3	alpha	G2S	4
4	G2S	exhibited	5
5	exhibited	<ROOT>	-1
6	increased	of	8
7	expression	of	8
8	of	exhibited	5
9	CD11b	exhibited	5
10	and	CD11b	9
11	CD54	and	10
12	,	exhibited	5
13	while	exhibited	5
14	alpha	B5A	15
15	B5A	cells	16
16	cells	while	13
17	showed	cells	16
18	increased	cells	16
19	expression	increased	18
20	of	expression	19
21	CD102	of	20
22	,	CD102	21
23	suggesting	cells	16
24	that	cells	16
25	RXR-alpha	that	24
26	has	a	27
27	a	RXR-alpha	25
28	role	in	29
29	in	a	27
30	regulating	in	29
31	expression	regulating	30
32	of	cell	33
33	cell	adhesion	34
34	adhesion	expression	31
35	molecules	in	36
36	in	exhibited	5
37	U937	exhibited	5
38	cells	exhibited	5
39	.	exhibited	5

0	Immune	hyperactivation	1
1	hyperactivation	<ROOT>	-1
2	of	T	4
3	HIV-1-infected	of	2
4	T	hyperactivation	1
5	cells	T	4
6	mediated	hyperactivation	1
7	by	mediated	6
8	Tat	the	10
9	and	the	10
10	the	mediated	6
11	CD28	hyperactivation	1
12	pathway	hyperactivation	1
13	.	hyperactivation	1

0	Curcumin	<ROOT>	-1
1	(	diferuoylmethane	2
2	diferuoylmethane	Curcumin	0
3	)	diferuoylmethane	2
4	,	Curcumin	0
5	the	pigment	7
6	yellow	pigment	7
7	pigment	Curcumin	0
8	in	pigment	7
9	the	rhizome	10
10	rhizome	in	8
11	of	rhizome	10
12	tumeric	of	11
13	(	longa	15
14	Curcuma	longa	15
15	longa	pigment	7
16	)	longa	15
17	,	pigment	7
18	an	ingredient	19
19	ingredient	pigment	7
20	of	ingredient	19
21	curry	of	20
22	spice	ingredient	19
23	,	known	25
24	is	,	23
25	known	spice	22
26	to	known	25
27	exhibit	to	26
28	a	variety	29
29	variety	exhibit	27
30	of	pharmacological	31
31	pharmacological	variety	29
32	effects	Curcumin	0
33	including	effects	32
34	antitumor	including	33
35	,	Curcumin	0
36	antiinflammatory	Curcumin	0
37	,	Curcumin	0
38	and	Curcumin	0
39	antiinfectious	activities	40
40	activities	and	38
41	.	Curcumin	0

0	We	<ROOT>	-1
1	have	We	0
2	performed	have	1
3	domain	of	5
4	analysis	of	5
5	of	performed	2
6	NFATx1	of	5
7	by	the	9
8	examining	by	7
9	the	performed	2
10	effects	the	9
11	of	deletion	12
12	deletion	effects	10
13	mutations	We	0
14	.	We	0

0	The	<ROOT>	-1
1	tax	The	0
2	gene	product	3
3	product	tax	1
4	of	product	3
5	the	type	6
6	type	of	4
7	I	product	3
8	human	tax	1
9	T-cell	leukemia	10
10	leukemia	virus	11
11	virus	(	12
12	(	human	8
13	HTLV-I	(	12
14	)	transactivates	15
15	transactivates	interleukin-2	16
16	interleukin-2	HTLV-I	13
17	(	IL-2	18
18	IL-2	interleukin-2	16
19	)	IL-2	18
20	gene	through	21
21	through	The	0
22	activation	The	0
23	of	an	24
24	an	The	0
25	enhancer	termed	26
26	termed	an	24
27	CD28	The	0
28	responsive	The	0
29	element	The	0
30	(	CD28RE	31
31	CD28RE	The	0
32	)	CD28RE	31
33	.	The	0

0	Mobility	shift	1
1	shift	showed	3
2	assays	shift	1
3	showed	<ROOT>	-1
4	that	showed	3
5	in	translated	7
6	vitro	in	5
7	translated	that	4
8	Pax-5a	translated	7
9	and	Pax-5a	8
10	Pax-5d	and	9
11	,	showed	3
12	but	showed	3
13	not	but	12
14	Pax-5b	not	13
15	or	not	13
16	Pax-5e	or	15
17	,	showed	3
18	could	showed	3
19	interact	protein-binding	24
20	with	protein-binding	24
21	a	protein-binding	24
22	B-cell-specific	activator	23
23	activator	protein-binding	24
24	protein-binding	could	18
25	site	could	18
26	on	blk	28
27	the	blk	28
28	blk	site	25
29	promoter	.	30
30	.	site	25

0	Experimental	expression	1
1	expression	<ROOT>	-1
2	in	expression	1
3	mice	in	2
4	and	spontaneous	5
5	spontaneous	expression	1
6	expression	in	7
7	in	human	8
8	human	expression	1
9	SLE	expression	1
10	of	expression	1
11	polyomavirus	expression	1
12	T-antigen	expression	1
13	.	expression	1

0	The	visualization	1
1	visualization	showed	11
2	of	visualization	1
3	heavy	chain	6
4	and	chain	6
5	light	and	4
6	chain	of	2
7	genes	visualization	1
8	in	B-lymphoid	9
9	B-lymphoid	genes	7
10	cells	visualization	1
11	showed	genes	29
12	that	showed	11
13	the	genes	16
14	three	genes	16
15	Ig	genes	16
16	genes	are	17
17	are	that	12
18	differentially	are	17
19	and	differentially	18
20	nonrandomly	and	19
21	distributed	nonrandomly	20
22	in	nonrandomly	20
23	different	in	22
24	nuclear	different	23
25	subvolumes	the	27
26	:	the	27
27	the	nuclear	24
28	kappa	and	19
29	genes	were	30
30	were	<ROOT>	-1
31	found	were	30
32	to	found	31
33	be	to	32
34	preferentially	be	33
35	confined	preferentially	34
36	to	confined	35
37	an	volume	40
38	outer	volume	40
39	nuclear	volume	40
40	volume	to	36
41	,	were	30
42	whereas	the	43
43	the	were	30
44	gamma	central	51
45	and	gamma	44
46	lambda	genes	47
47	genes	and	45
48	consistently	central	51
49	occupied	consistently	48
50	more	central	51
51	central	the	43
52	positions	were	30
53	within	positions	52
54	the	within	53
55	nucleus	,	56
56	,	the	54
57	the	genes	59
58	lambda	genes	59
59	genes	,	56
60	being	genes	59
61	more	being	60
62	interior	when	63
63	when	more	61
64	compared	more	61
65	with	compared	64
66	the	with	65
67	gamma	.	69
68	genes	.	69
69	.	the	66

0	We	<ROOT>	-1
1	examined	signaling	2
2	signaling	We	0
3	by	signaling	2
4	erythropoietin	signaling	2
5	in	erythropoietin	4
6	highly	purified	7
7	purified	We	0
8	human	colony	9
9	colony	We	0
10	forming	We	0
11	unit-erythroid	We	0
12	cells	We	0
13	,	We	0
14	generated	We	0
15	in	generated	14
16	vitro	in	15
17	from	CD34-LRB-+-RRB-	18
18	CD34-LRB-+-RRB-	generated	14
19	cells	We	0
20	.	We	0

0	We	tested	1
1	tested	<ROOT>	-1
2	the	effect	3
3	effect	tested	1
4	of	effect	3
5	three	of	4
6	linear	three	5
7	or	linear	6
8	two	or	7
9	loop	two	8
10	peptides	loop	9
11	derived	peptides	10
12	from	derived	11
13	the	from	12
14	V3	type	29
15	region	V3	14
16	of	region	15
17	the	of	16
18	HTLV-III	the	17
19	BH10	virus	28
20	clone	virus	28
21	or	virus	28
22	the	strain	24
23	SF2	strain	24
24	strain	virus	28
25	of	virus	28
26	human	virus	28
27	immunodeficiency	virus	28
28	virus	HTLV-III	18
29	type	the	13
30	1	type	29
31	on	cell	34
32	IL-2-driven	cell	34
33	T	cell	34
34	cell	type	29
35	proliferation	tested	1
36	.	tested	1

0	However	are	10
1	,	However	0
2	the	mechanisms	4
3	intracellular	mechanisms	4
4	mechanisms	,	1
5	for	these	6
6	these	mechanisms	4
7	effects	are	10
8	of	effects	7
9	ethanol	of	8
10	are	<ROOT>	-1
11	yet	are	10
12	to	are	10
13	be	to	12
14	understood	be	13
15	.	are	10

0	Thus	proposed	2
1	we	proposed	2
2	proposed	<ROOT>	-1
3	that	proposed	2
4	ETS1	that	3
5	,	ETS1	4
6	which	is	7
7	is	ETS1	4
8	expressed	is	7
9	constitutively	expressed	8
10	in	constitutively	9
11	Jurkat	in	10
12	cells	,	13
13	,	Jurkat	11
14	may	expressed	8
15	act	expressed	8
16	in	act	15
17	concert	in	16
18	with	concert	17
19	PMA/ionomycin	factors	21
20	inducible	factors	21
21	factors	with	18
22	.	proposed	2

0	The	kinases	1
1	kinases	<ROOT>	-1
2	that	kinases	1
3	couple	ligand	4
4	ligand	that	2
5	binding	ligand	4
6	to	tyrosine	7
7	tyrosine	binding	5
8	phosphorylation	of	9
9	of	ligand	4
10	cellular	of	9
11	substrates	by	12
12	by	cellular	10
13	the	G-CSFR	14
14	G-CSFR	by	12
15	with	G-CSFR	14
16	activation	of	17
17	of	are	21
18	specific	programs	20
19	functional	programs	20
20	programs	are	21
21	are	with	15
22	largely	unknown	23
23	unknown	are	21
24	.	kinases	1

0	In	has	13
1	this	study	2
2	study	In	0
3	,	has	13
4	therefore	has	13
5	,	has	13
6	the	U937	12
7	human	U937	12
8	monoblastic	U937	12
9	leukemia	U937	12
10	cell	U937	12
11	line	U937	12
12	U937	has	13
13	has	<ROOT>	-1
14	been	has	13
15	used	been	14
16	as	used	15
17	a	system	19
18	model	system	19
19	system	as	16
20	to	system	19
21	investigate	to	20
22	the	of	24
23	role	of	24
24	of	investigate	21
25	one	of	24
26	of	one	25
27	the	RXRs	28
28	RXRs	of	26
29	,	of	24
30	RXR-alpha	of	24
31	,	RXR-alpha	30
32	in	,	31
33	monoblast	differentiation	34
34	differentiation	in	32
35	.	differentiation	34

0	The	shift	1
1	shift	pRB	3
2	in	pRB	3
3	pRB	molecular	4
4	molecular	was	6
5	weight	molecular	4
6	was	was	21
7	reproduced	was	6
8	by	reproduced	7
9	adding	by	8
10	exogenous	purified	11
11	purified	adding	9
12	tTG	adding	9
13	to	adding	9
14	extracts	to	13
15	obtained	extracts	14
16	from	U937	18
17	viable	U937	18
18	U937	obtained	15
19	cells	was	6
20	and	was	6
21	was	<ROOT>	-1
22	prevented	was	21
23	by	prevented	22
24	dansylcadaverine	by	23
25	,	dansylcadaverine	24
26	a	inhibitor	29
27	potent	inhibitor	29
28	enzyme	inhibitor	29
29	inhibitor	dansylcadaverine	24
30	.	was	21

0	Taken	<ROOT>	-1
1	together	Taken	0
2	,	Taken	0
3	these	,	2
4	data	these	3
5	suggest	that	6
6	that	data	4
7	EBF	and	8
8	and	that	6
9	E47	synergize	10
10	synergize	and	8
11	to	synergize	10
12	activate	to	11
13	expression	activate	12
14	of	expression	13
15	a	subset	16
16	subset	of	14
17	of	subset	16
18	genes	of	17
19	that	subset	16
20	define	that	19
21	an	define	20
22	early	of	24
23	stage	of	24
24	of	an	21
25	the	of	24
26	B	cell	27
27	cell	the	25
28	lineage	an	21
29	.	Taken	0

0	CONCLUSIONS	<ROOT>	-1
1	:	CONCLUSIONS	0
2	This	study	3
3	study	demonstrates	4
4	demonstrates	CONCLUSIONS	0
5	that	demonstrates	4
6	TF	activation	7
7	activation	is	18
8	,	activation	7
9	occurring	activation	7
10	in	occurring	9
11	mononuclear	cells	12
12	cells	in	10
13	of	cells	12
14	cardiac	recipients	16
15	transplant	recipients	16
16	recipients	of	13
17	,	recipients	16
18	is	that	5
19	inhibited	is	18
20	by	inhibited	19
21	treatment	by	20
22	with	treatment	21
23	CsA	with	22
24	.	CONCLUSIONS	0

0	The	results	1
1	results	demonstrate	3
2	clearly	demonstrate	3
3	demonstrate	<ROOT>	-1
4	that	demonstrate	3
5	anoxia/reoxygenation	leads	9
6	(	A/R	7
7	A/R	anoxia/reoxygenation	5
8	)	A/R	7
9	leads	that	4
10	to	leads	9
11	a	increase	13
12	biphasic	increase	13
13	increase	to	10
14	in	neutrophil	15
15	neutrophil	increase	13
16	adhesion	neutrophil	15
17	to	adhesion	16
18	HUVECs	to	17
19	,	adhesion	16
20	with	peak	21
21	peak	responses	22
22	responses	adhesion	16
23	occurring	responses	22
24	at	occurring	23
25	30	minutes	26
26	minutes	at	24
27	(	occurring	23
28	phase	(	27
29	1	(	27
30	)	(	27
31	and	occurring	23
32	240	minutes	33
33	minutes	and	31
34	(	minutes	33
35	phase	minutes	33
36	2	minutes	33
37	)	minutes	33
38	after	leads	9
39	reoxygenation	after	38
40	.	demonstrate	3

0	NF-kappaB	activation	2
1	nuclear	activation	2
2	activation	was	3
3	was	<ROOT>	-1
4	not	was	3
5	detectable	before	6
6	before	was	3
7	1	h	8
8	h	before	6
9	after	cell	10
10	cell	was	3
11	contact	cell	10
12	and	was	3
13	was	and	12
14	dependent	was	13
15	on	dependent	14
16	protein	on	15
17	synthesis	on	15
18	.	synthesis	17

0	Cotransfection	luciferase	15
1	of	Cotransfection	0
2	CMV	genes	4
3	IE	genes	4
4	genes	of	1
5	and	(	10
6	IL-6	transferase	9
7	chloramphenicol	transferase	9
8	acetyl	transferase	9
9	transferase	and	5
10	(	Cotransfection	0
11	CAT	(	10
12	)	(	10
13	or	)	12
14	IL-6	Cotransfection	0
15	luciferase	<ROOT>	-1
16	constructs	were	17
17	were	luciferase	15
18	used	were	17
19	to	promoter	22
20	study	promoter	22
21	IL-6	promoter	22
22	promoter	used	18
23	activity	used	18
24	.	luciferase	15

0	The	<ROOT>	-1
1	observed	The	0
2	E1a	understanding	11
3	reiterations	understanding	11
4	provide	a	5
5	a	understanding	11
6	model	gain	8
7	to	gain	8
8	gain	into	10
9	insight	gain	8
10	into	a	5
11	understanding	observed	1
12	the	evolutionary	13
13	evolutionary	understanding	11
14	events	evolutionary	13
15	of	events	14
16	some	evolutionary	13
17	,	some	16
18	if	not	19
19	not	some	16
20	all	not	19
21	,	some	16
22	adenovirus	evolutionary	13
23	types	during	24
24	during	observed	1
25	many	during	24
26	years	many	25
27	of	years	26
28	symbiotic	,	29
29	,	relationship	31
30	persistent	,	29
31	relationship	of	27
32	in	human	33
33	human	relationship	31
34	tonsils	The	0
35	and	The	0
36	adenoids	The	0
37	and	The	0
38	possibly	other	39
39	other	The	0
40	lymphoid	The	0
41	organs	The	0
42	.	The	0

0	Finally	recovered	2
1	,	recovered	2
2	recovered	protein	3
3	protein	was	4
4	was	<ROOT>	-1
5	identified	was	4
6	as	identified	5
7	genuine	huGATA-3	8
8	huGATA-3	as	6
9	by	huGATA-3	8
10	SDS-PAGE	huGATA-3	8
11	,	SDS-PAGE	10
12	Western	blotting	13
13	blotting	SDS-PAGE	10
14	,	blotting	13
15	and	,	14
16	bandshift	and	15
17	assays	,	14
18	.	was	4

0	The	factors	2
1	transcription	factors	2
2	factors	CD11b	8
3	Sp1	factors	2
4	and	Sp1	3
5	PU.1	factors	2
6	prime	CD11b	8
7	the	CD11b	8
8	CD11b	<ROOT>	-1
9	promoter	CD11b	8
10	,	CD11b	8
11	but	CD11b	8
12	the	nature	13
13	nature	are	22
14	of	nature	13
15	the	factors	16
16	factors	of	14
17	responsible	factors	16
18	for	responsible	17
19	its	expression	21
20	inducible	expression	21
21	expression	for	18
22	are	but	11
23	unknown	are	22
24	.	CD11b	8

0	The	patterns	2
1	tissular	patterns	2
2	patterns	II	8
3	of	patterns	2
4	CIITA	of	3
5	and	II	8
6	MHC	II	8
7	class	II	8
8	II	gene	9
9	gene	expression	10
10	expression	gamma	29
11	are	expression	10
12	tightly	are	11
13	correlated	tightly	12
14	:	correlated	13
15	CIITA	:	14
16	mRNA	CIITA	15
17	is	highly	18
18	highly	expressed	19
19	expressed	CIITA	15
20	in	expressed	19
21	B	cells	22
22	cells	in	20
23	,	expression	10
24	and	expression	10
25	is	and	24
26	induced	is	25
27	by	induced	26
28	interferon	expression	10
29	gamma	<ROOT>	-1
30	(	gamma	29
31	IFN-gamma	gamma	29
32	)	gamma	29
33	in	gamma	29
34	macrophage	gamma	29
35	and	macrophage	34
36	epithelial	cell	37
37	cell	and	35
38	lines	cell	37
39	.	lines	38

0	This	antibody	1
1	antibody	recognized	2
2	recognized	<ROOT>	-1
3	both	denatured	5
4	the	denatured	5
5	denatured	MR	8
6	and	MR	8
7	native	and	6
8	MR	recognized	2
9	forms	recognized	2
10	,	recognized	2
11	as	MR	16
12	well	as	11
13	as	as	11
14	the	MR	16
15	hetero-oligomeric	MR	16
16	MR	recognized	2
17	form	recognized	2
18	and	recognized	2
19	the	state	22
20	transformed	MR	21
21	MR	state	22
22	state	and	18
23	.	recognized	2

0	Functional	analysis	1
1	analysis	required	33
2	of	analysis	1
3	monocytic	THP-1	4
4	THP-1	of	2
5	cells	transfected	6
6	transfected	THP-1	4
7	with	analysis	1
8	plasmids	with	7
9	containing	various	10
10	various	plasmids	8
11	lengths	various	10
12	of	TNF-alpha	13
13	TNF-alpha	lengths	11
14	promoter	analysis	1
15	localized	in	18
16	enhancer	in	18
17	elements	in	18
18	in	analysis	1
19	a	analysis	1
20	region	(	21
21	(	a	19
22	-182	(	21
23	to	-182	22
24	-37	(	27
25	base	(	27
26	pairs	(	27
27	(	to	23
28	bp	(	27
29	)	bp	28
30	)	that	31
31	that	)	29
32	were	analysis	1
33	required	<ROOT>	-1
34	for	required	33
35	optimal	for	34
36	transcription	optimal	35
37	of	transcription	36
38	the	of	37
39	TNF-alpha	the	38
40	gene	in	41
41	in	TNF-alpha	39
42	response	in	41
43	to	response	42
44	LPS	TNF-alpha	39
45	.	required	33

0	Involvement	<ROOT>	-1
1	of	Involvement	0
2	an	factor	5
3	SAF-like	factor	5
4	transcription	factor	5
5	factor	of	1
6	in	Involvement	0
7	the	activation	8
8	activation	in	6
9	of	activation	8
10	serum	gene	13
11	amyloid	gene	13
12	A	gene	13
13	gene	of	9
14	in	monocyte/macrophage	15
15	monocyte/macrophage	activation	8
16	cells	Involvement	0
17	by	Involvement	0
18	lipopolysaccharide	by	17
19	.	Involvement	0

0	In	protein	11
1	both	types	3
2	cell	types	3
3	types	In	0
4	the	levels	6
5	cellular	levels	6
6	levels	In	0
7	of	levels	6
8	IkappaBalpha	mRNA	9
9	mRNA	of	7
10	and	In	0
11	protein	were	12
12	were	<ROOT>	-1
13	evaluated	were	12
14	by	evaluated	13
15	DEX	treatment	16
16	treatment	by	14
17	.	were	12

0	Previously	showed	3
1	,	showed	3
2	we	showed	3
3	showed	<ROOT>	-1
4	that	showed	3
5	fibroblast	medium	7
6	conditioned	medium	7
7	medium	that	4
8	(	FCM	9
9	FCM	medium	7
10	)	FCM	9
11	is	medium	7
12	able	is	11
13	to	able	12
14	inhibit	both	15
15	both	to	13
16	TNF	both	15
17	mRNA	and	19
18	accumulation	and	19
19	and	TNF	16
20	protein	showed	3
21	release	in	22
22	in	showed	3
23	peripheral	showed	3
24	blood-derived	showed	3
25	human	showed	3
26	monocytes	showed	3
27	(	showed	3
28	PBM	showed	3
29	)	showed	3
30	stimulated	showed	3
31	with	showed	3
32	lipopolysaccharide	LPS	34
33	(	LPS	34
34	LPS	showed	3
35	)	showed	3
36	.	showed	3

0	METHODS	were	16
1	:	METHODS	0
2	Stable	METHODS	0
3	transfectants	METHODS	0
4	of	transfectants	3
5	the	line	10
6	porcine	line	10
7	vascular	line	10
8	endothelial	line	10
9	cell	line	10
10	line	of	4
11	PIEC	of	4
12	with	PIEC	11
13	mutated	constructs	15
14	CIITA	constructs	15
15	constructs	with	12
16	were	<ROOT>	-1
17	tested	were	16
18	for	tested	17
19	SLA-DR	for	18
20	and	SLA-DQ	21
21	SLA-DQ	SLA-DR	19
22	induction	SLA-DQ	21
23	by	recombinant	24
24	recombinant	for	18
25	porcine	interferon-gamma	26
26	interferon-gamma	recombinant	24
27	.	interferon-gamma	26

0	The	ciprofloxacin	3
1	fluoroquinolone	ciprofloxacin	3
2	antibiotic	ciprofloxacin	3
3	ciprofloxacin	has	4
4	has	<ROOT>	-1
5	recently	has	4
6	been	has	4
7	reported	been	6
8	to	reported	7
9	upregulate	to	8
10	interleukin-2	upregulate	9
11	(	IL-2	12
12	IL-2	interleukin-2	10
13	)	IL-2	12
14	gene	induction	15
15	induction	interleukin-2	10
16	.	has	4

0	PRRIII	contains	1
1	contains	<ROOT>	-1
2	a	site	6
3	Stat	site	6
4	protein	site	6
5	binding	site	6
6	site	contains	1
7	that	overlaps	8
8	overlaps	site	6
9	with	overlaps	8
10	an	motif	12
11	EBS	motif	12
12	motif	with	9
13	(	GASd/EBSd	14
14	GASd/EBSd	contains	1
15	)	GASd/EBSd	14
16	.	contains	1

0	Here	show	3
1	,	show	3
2	we	show	3
3	show	alpha	32
4	that	show	3
5	zinc	addition	6
6	addition	leads	15
7	in	addition	6
8	a	serum-	9
9	serum-	in	7
10	and	addition	6
11	lipopolysaccharide-free	system	14
12	cell	system	14
13	culture	system	14
14	system	and	10
15	leads	that	4
16	to	leads	15
17	significantly	to	16
18	enhanced	significantly	17
19	levels	of	20
20	of	1	22
21	interleukin	1	22
22	1	enhanced	18
23	beta	1	22
24	(	IL-1	25
25	IL-1	show	3
26	beta	IL-1	25
27	)	show	3
28	and	factor	31
29	tumour	factor	31
30	necrosis	factor	31
31	factor	show	3
32	alpha	<ROOT>	-1
33	(	alpha	32
34	TNF-alpha	alpha	32
35	)	alpha	32
36	and	alpha	32
37	to	and	36
38	expression	to	37
39	of	expression	38
40	the	mRNA	42
41	corresponding	mRNA	42
42	mRNA	of	39
43	in	peripheral	45
44	human	peripheral	45
45	peripheral	of	39
46	blood	alpha	32
47	mononuclear	alpha	32
48	cells	alpha	32
49	(	alpha	32
50	PBMC	alpha	32
51	)	alpha	32
52	.	alpha	32

0	The	inhibitor	3
1	NF-kappa	B	2
2	B	inhibitor	3
3	inhibitor	suppresses	7
4	,	inhibitor	3
5	tepoxalin	inhibitor	3
6	,	inhibitor	3
7	suppresses	<ROOT>	-1
8	surface	expression	9
9	expression	suppresses	7
10	of	expression	9
11	the	molecules	14
12	cell	molecules	14
13	adhesion	molecules	14
14	molecules	of	10
15	CD62E	suppresses	7
16	,	suppresses	7
17	CD11b/CD18	,	16
18	and	CD11b/CD18	17
19	CD106	and	18
20	.	suppresses	7

0	Using	shift	3
1	electrophoretic	Using	0
2	mobility	shift	3
3	shift	we	5
4	analysis	shift	3
5	we	demonstrated	6
6	demonstrated	is	28
7	that	demonstrated	6
8	the	region	10
9	promoter	region	10
10	region	that	7
11	spanning	region	10
12	base	spanning	11
13	pairs	base	12
14	-1	pairs	13
15	to	-1	14
16	-275	to	15
17	,	which	18
18	which	demonstrated	6
19	contains	which	18
20	several	sites	23
21	putative	sites	23
22	binding	sites	23
23	sites	contains	19
24	for	transcription	25
25	transcription	contains	19
26	factors	demonstrated	6
27	,	demonstrated	6
28	is	<ROOT>	-1
29	bound	by	30
30	by	is	28
31	nuclear	factors	32
32	factors	by	30
33	Sp1	is	28
34	and	is	28
35	IRBP	is	28
36	but	IRBP	35
37	not	IRBP	35
38	by	not	37
39	C/EBPs	by	38
40	.	is	28

0	Further	induced	12
1	,	induced	12
2	M.	tuberculosis	3
3	tuberculosis	induced	12
4	and	tuberculosis	3
5	its	protein	9
6	tuberculin	,	7
7	,	protein	9
8	purified	protein	9
9	protein	and	4
10	derivative	protein	9
11	,	tuberculosis	3
12	induced	kappa	24
13	the	degradation	14
14	degradation	kappa	17
15	of	kappa	17
16	I	of	15
17	kappa	induced	12
18	B-alpha	the	20
19	and	the	20
20	the	kappa	17
21	expression	the	20
22	of	expression	21
23	I	induced	12
24	kappa	protein	30
25	B-alpha	kappa	24
26	mRNA	kappa	24
27	,	kappa	24
28	and	protein	30
29	purified	protein	30
30	protein	<ROOT>	-1
31	derivative	induced	32
32	induced	NF-kappa	36
33	the	activation	34
34	activation	NF-kappa	36
35	of	NF-kappa	36
36	NF-kappa	protein	30
37	B	protein	30
38	in	protein	30
39	monocytes	protein	30
40	.	protein	30

0	These	results	1
1	results	may	2
2	may	<ROOT>	-1
3	also	may	2
4	relate	may	2
5	to	cycle	15
6	recent	to	5
7	data	GATA-1	9
8	implicating	GATA-1	9
9	GATA-1	recent	6
10	function	in	11
11	in	GATA-1	9
12	apoptosis	GATA-1	9
13	and	apoptosis	12
14	cell	cycle	15
15	cycle	relate	4
16	progression	may	2
17	.	may	2

0	We	<ROOT>	-1
1	detected	We	0
2	binding	detected	1
3	for	binding	2
4	the	peptide	6
5	EWS/FLI-1	peptide	6
6	peptide	for	3
7	and	binding	2
8	for	peptides	11
9	5	peptides	11
10	RAS	peptides	11
11	peptides	type	15
12	(	wild	14
13	1	wild	14
14	wild	peptides	11
15	type	and	7
16	and	We	0
17	4	We	0
18	mutated	We	0
19	)	We	0
20	.	We	0

0	ZEBRA	activation	1
1	activation	<ROOT>	-1
2	can	activation	1
3	be	can	2
4	replaced	be	3
5	by	replaced	4
6	a	acidic	8
7	heterologous	acidic	8
8	acidic	by	5
9	,	activation	1
10	proline-rich	activation	1
11	,	activation	1
12	or	glutamine-rich	13
13	glutamine-rich	activation	1
14	activation	domain	15
15	domain	activation	1
16	.	domain	15

0	The	concentration	1
1	concentration	was	6
2	of	concentration	1
3	the	VDR	4
4	VDR	mRNA	5
5	mRNA	of	2
6	was	<ROOT>	-1
7	10-LRB--8-RRB-	was	6
8	to	10-LRB--8-RRB-	7
9	10-LRB--7-RRB-	to	8
10	g/g	10-LRB--7-RRB-	9
11	of	g/g	10
12	total	RNA	13
13	RNA	of	11
14	in	g/g	10
15	cell-sorted	in	14
16	monocytes	and	17
17	and	cell-sorted	15
18	in	g/g	10
19	in	in	18
20	vitro	in	19
21	activated	,	23
22	lymphocytes	,	23
23	,	vitro	20
24	but	was	6
25	only	but	24
26	10-LRB--12-RRB-	was	6
27	g/g	was	6
28	of	was	6
29	total	was	6
30	mRNA	was	6
31	in	resting	32
32	resting	was	6
33	lymphocytes	was	6
34	,	was	6
35	establishing	was	6
36	that	establishing	35
37	the	VDR	38
38	VDR	determined	40
39	mRNA	VDR	38
40	determined	that	36
41	by	determined	40
42	our	method	43
43	method	by	41
44	in	method	43
45	PBMCs	in	44
46	is	determined	40
47	due	determined	40
48	to	constitutive	49
49	constitutive	due	47
50	expression	in	51
51	in	due	47
52	monocytes	was	6
53	.	was	6

0	This	indicated	1
1	indicated	<ROOT>	-1
2	that	indicated	1
3	the	erythrocytes	5
4	EKLF-/-	erythrocytes	5
5	erythrocytes	must	9
6	in	erythrocytes	5
7	adult	animals	8
8	animals	in	6
9	must	that	2
10	be	must	9
11	short-lived	be	10
12	,	indicated	1
13	apparently	indicated	1
14	due	apparently	13
15	to	due	14
16	the	imbalance	17
17	imbalance	to	15
18	of	imbalance	17
19	beta-	of	18
20	versus	beta-	19
21	alpha-globin	versus	20
22	chains	,	23
23	,	alpha-globin	21
24	leading	,	23
25	to	beta-	19
26	the	precipitation	27
27	precipitation	to	25
28	of	precipitation	27
29	excess	of	28
30	alpha-globin	excess	29
31	chains	alpha-globin	30
32	to	chains	31
33	form	to	32
34	Heinz	form	33
35	bodies	.	36
36	.	Heinz	34

0	Fine	mapping	1
1	mapping	<ROOT>	-1
2	by	mapping	1
3	in	by	2
4	vivo	in	3
5	footprinting	demonstrated	6
6	demonstrated	vivo	4
7	five	demonstrated	6
8	transcription	five	7
9	factor	transcription	8
10	binding	sites	11
11	sites	transcription	8
12	that	sites	11
13	are	that	12
14	occupied	are	13
15	in	both	16
16	both	occupied	14
17	resting	both	16
18	and	resting	17
19	activated	and	18
20	peripheral	activated	19
21	blood	T	22
22	T	occupied	14
23	lymphocytes	mapping	1
24	;	mapping	1
25	these	are	26
26	are	mapping	1
27	tandem	motifs	29
28	CRE	motifs	29
29	motifs	are	26
30	,	motifs	29
31	a	site	33
32	Sp1	site	33
33	site	motifs	29
34	,	motifs	29
35	an	site	38
36	overlapping	site	38
37	Egr-1/Sp1	site	38
38	site	motifs	29
39	,	mapping	1
40	and	palindromic	43
41	a	palindromic	43
42	novel	palindromic	43
43	palindromic	mapping	1
44	octamer	sequence	45
45	sequence	mapping	1
46	(	sequence	45
47	POS	)	48
48	)	mapping	1
49	.	)	48

0	It	is	1
1	is	<ROOT>	-1
2	likely	that	3
3	that	is	1
4	several	mechanisms	5
5	mechanisms	are	6
6	are	that	3
7	involved	are	6
8	.	is	1

0	The	combination	1
1	combination	inhibited	7
2	of	combination	1
3	RA	of	2
4	and	of	2
5	DHCC	of	2
6	together	inhibited	7
7	inhibited	<ROOT>	-1
8	growth	inhibited	7
9	of	growth	8
10	both	sense	11
11	sense	of	9
12	and	of	9
13	antisense	and	12
14	cell	antisense	13
15	lines	cell	14
16	.	lines	15

0	Differentiation	<ROOT>	-1
1	of	Differentiation	0
2	U-937	cells	4
3	promonocytic	cells	4
4	cells	of	1
5	by	Differentiation	0
6	etoposide	by	5
7	and	by	5
8	ICRF-193	Differentiation	0
9	,	Differentiation	0
10	two	DNA	12
11	antitumour	DNA	12
12	DNA	Differentiation	0
13	topoisomerase	Differentiation	0
14	II	Differentiation	0
15	inhibitors	Differentiation	0
16	with	different	17
17	different	inhibitors	15
18	mechanisms	different	17
19	of	mechanisms	18
20	action	Differentiation	0
21	.	Differentiation	0

0	Elf-2b	lacks	1
1	lacks	<ROOT>	-1
2	a	domain	5
3	putative	domain	5
4	transactivation	domain	5
5	domain	lacks	1
6	.	lacks	1

0	Dendritic	(	2
1	cells	(	2
2	(	are	5
3	DC	(	2
4	)	(	2
5	are	<ROOT>	-1
6	potent	APCs	7
7	APCs	are	5
8	that	enter	9
9	enter	APCs	7
10	resting	tissues	11
11	tissues	enter	9
12	as	APCs	7
13	precursors	as	12
14	and	as	12
15	,	are	5
16	after	Ag	17
17	Ag	are	5
18	exposure	are	5
19	,	are	5
20	differentiate	are	5
21	and	differentiate	20
22	migrate	and	21
23	to	migrate	22
24	draining	nodes	26
25	lymph	nodes	26
26	nodes	to	23
27	.	are	5

0	Western	and	1
1	and	<ROOT>	-1
2	supershift	and	1
3	analyses	and	1
4	indicated	and	1
5	that	proteins	10
6	functional	Jun	7
7	Jun	and	8
8	and	that	5
9	Fos	and	8
10	proteins	indicated	4
11	were	proteins	10
12	present	were	11
13	in	present	12
14	nuclear	extracts	15
15	extracts	in	13
16	of	U937	18
17	PMA-differentiated	U937	18
18	U937	extracts	15
19	cells	and	1
20	.	and	1

0	The	antigens	1
1	antigens	cells	8
2	recognized	antigens	1
3	by	recognized	2
4	many	T	7
5	HSV-specific	T	7
6	CD4	T	7
7	T	by	3
8	cells	lesions	13
9	localizing	cells	8
10	to	genital	11
11	genital	localizing	9
12	HSV-2	cells	8
13	lesions	are	14
14	are	<ROOT>	-1
15	unknown	are	14
16	.	are	14

0	The	proteins	3
1	Rel/NF-kappa	proteins	3
2	B	proteins	3
3	proteins	<ROOT>	-1
4	,	proteins	3
5	p50	,	4
6	,	p50	5
7	p52	,	4
8	,	proteins	3
9	p65	proteins	3
10	,	p65	9
11	c-Rel	proteins	3
12	,	c-Rel	11
13	and	proteins	3
14	RelB	proteins	3
15	,	proteins	3
16	constitute	proteins	3
17	a	family	18
18	family	constitute	16
19	of	family	18
20	transcription	factors	21
21	factors	of	19
22	involved	family	18
23	in	involved	22
24	the	regulation	26
25	positive	regulation	26
26	regulation	in	23
27	of	regulation	26
28	a	variety	29
29	variety	of	27
30	of	variety	29
31	genes	of	30
32	during	regulation	26
33	the	response	35
34	immune	response	35
35	response	during	32
36	.	proteins	3

0	Cells	pretreated	1
1	pretreated	showed	4
2	with	pretreated	1
3	dimaprit	pretreated	1
4	showed	<ROOT>	-1
5	a	decrease	6
6	decrease	showed	4
7	in	decrease	6
8	the	cAMP	9
9	cAMP	in	7
10	response	to	11
11	to	cAMP	9
12	subsequent	addition	13
13	addition	cAMP	9
14	of	addition	13
15	H2	of	14
16	agonists	showed	4
17	,	showed	4
18	whereas	showed	4
19	the	cAMP	20
20	cAMP	whereas	18
21	response	cAMP	20
22	to	response	21
23	prostaglandin	unaltered	26
24	E2	prostaglandin	23
25	remained	E2	24
26	unaltered	response	21
27	.	showed	4

0	Since	is	11
1	medical	treatments	2
2	treatments	increase	6
3	or	treatments	2
4	stress	or	3
5	commonly	increase	6
6	increase	Since	0
7	opioid	levels	8
8	levels	increase	6
9	,	is	11
10	it	is	11
11	is	<ROOT>	-1
12	important	is	11
13	to	important	12
14	understand	to	13
15	the	mechanisms	16
16	mechanisms	understand	14
17	by	understand	14
18	which	by	17
19	opioids	by	17
20	affect	opioids	19
21	T	opioids	19
22	lymphocyte	functions	23
23	functions	T	21
24	.	functions	23

0	The	induced	1
1	induced	complexes	2
2	complexes	were	3
3	were	anti-class	11
4	detectable	were	3
5	in	detectable	4
6	extracts	in	5
7	of	in	5
8	cells	were	3
9	incubated	with	10
10	with	were	3
11	anti-class	(	15
12	I	anti-class	11
13	monoclonal	(	15
14	antibody	(	15
15	(	<ROOT>	-1
16	mAb	(	15
17	)	(	15
18	for	(	15
19	1.5	(	15
20	h	(	15
21	;	(	15
22	the	induction	23
23	induction	was	24
24	was	(	15
25	maximal	was	24
26	at	was	24
27	5	h	28
28	h	at	26
29	,	was	24
30	persistent	was	24
31	at	16	32
32	16	persistent	30
33	h	(	15
34	and	no	35
35	no	(	15
36	longer	(	15
37	observed	at	38
38	at	(	15
39	40	(	15
40	h	(	15
41	.	(	15

0	In	may	9
1	addition	In	0
2	to	addition	1
3	its	CD15	8
4	well-recognized	CD15	8
5	adhesive	,	7
6	role	,	7
7	,	well-recognized	4
8	CD15	to	2
9	may	<ROOT>	-1
10	function	may	9
11	as	function	10
12	an	as	11
13	important	an	12
14	signaling	important	13
15	molecule	capable	16
16	capable	signaling	14
17	of	capable	16
18	initiating	of	17
19	proinflammatory	initiating	18
20	events	proinflammatory	19
21	in	events	20
22	monocytes	proinflammatory	19
23	that	come	24
24	come	proinflammatory	19
25	into	come	24
26	contact	into	25
27	with	activated	28
28	activated	contact	26
29	endothelium	may	9
30	.	may	9

0	Eotaxin	is	1
1	is	<ROOT>	-1
2	an	beta-chemokine	5
3	eosinophil	beta-chemokine	5
4	specific	beta-chemokine	5
5	beta-chemokine	is	1
6	assumed	beta-chemokine	5
7	to	assumed	6
8	be	to	7
9	involved	be	8
10	in	involved	9
11	eosinophilic	in	10
12	inflammatory	eosinophilic	11
13	diseases	such	14
14	such	inflammatory	12
15	as	atopic	16
16	atopic	such	14
17	dermatitis	atopic	16
18	,	dermatitis	17
19	allergic	rhinitis	20
20	rhinitis	dermatitis	17
21	,	rhinitis	20
22	asthma	rhinitis	20
23	and	asthma	22
24	parasitic	and	23
25	infections	parasitic	24
26	.	is	1

0	We	consider	1
1	consider	<ROOT>	-1
2	the	consequences	4
3	possible	consequences	4
4	consequences	consider	1
5	of	consequences	4
6	the	content	9
7	reduced	content	9
8	cellular	content	9
9	content	of	5
10	of	content	9
11	TFIIH	of	10
12	for	consequences	4
13	the	for	12
14	clinical	the	13
15	symptoms	clinical	14
16	in	symptoms	15
17	XP-B	in	16
18	or	XP-B	17
19	XP-D	consider	1
20	patients	consider	1
21	,	consider	1
22	and	consider	1
23	discuss	and	22
24	a	phenotype	27
25	'	phenotype	27
26	conditional	phenotype	27
27	phenotype	and	22
28	'	phenotype	27
29	that	may	30
30	may	phenotype	27
31	involve	may	30
32	an	impairment	33
33	impairment	involve	31
34	of	impairment	33
35	cellular	function	36
36	function	of	34
37	only	impairment	33
38	under	only	37
39	certain	conditions	41
40	growth	conditions	41
41	conditions	under	38
42	.	conditions	41

0	This	study	1
1	study	examined	2
2	examined	<ROOT>	-1
3	the	examined	2
4	role	of	5
5	of	the	3
6	various	of	5
7	cis-acting	various	6
8	regulatory	elements	9
9	elements	cis-acting	7
10	in	elements	9
11	the	lipopolysaccharide	12
12	lipopolysaccharide	in	10
13	(	LPS	14
14	LPS	elements	9
15	)	LPS	14
16	induction	elements	9
17	of	induction	16
18	the	promoter	21
19	human	promoter	21
20	TNF-alpha	promoter	21
21	promoter	of	17
22	in	of	17
23	cells	of	24
24	of	cis-acting	7
25	monocytic	cis-acting	7
26	lineage	examined	2
27	.	examined	2

0	We	conclude	1
1	conclude	<ROOT>	-1
2	that	conclude	1
3	sodium	treatment	5
4	phenylacetate	treatment	5
5	treatment	increases	9
6	of	treatment	5
7	K562	cells	8
8	cells	of	6
9	increases	that	2
10	gamma-globin	mRNA	11
11	mRNA	increases	9
12	and	increases	9
13	induces	and	12
14	cell	maturation	15
15	maturation	induces	13
16	as	induces	13
17	judged	induces	13
18	by	judged	17
19	morphology	by	18
20	without	morphology	19
21	affecting	the	22
22	the	by	18
23	expression	the	22
24	of	expression	23
25	the	factors	28
26	erythroid	factors	28
27	transcription	factors	28
28	factors	of	24
29	,	conclude	1
30	some	,	29
31	of	some	30
32	which	of	31
33	are	which	32
34	known	some	30
35	to	known	34
36	be	to	35
37	involved	be	36
38	in	the	39
39	the	involved	37
40	regulation	of	41
41	of	the	39
42	beta-like	the	39
43	globin	.	45
44	genes	.	45
45	.	beta-like	42

0	These	are	1
1	are	<ROOT>	-1
2	essential	IL-2	4
3	for	IL-2	4
4	IL-2	are	1
5	inducibility	IL-2	4
6	of	reporter	8
7	PRRIII/CAT	reporter	8
8	reporter	inducibility	5
9	constructs	are	1
10	.	are	1

0	In	selected	29
1	order	In	0
2	to	In	0
3	evaluate	to	2
4	the	conditions	5
5	conditions	evaluate	3
6	for	optimal	7
7	optimal	conditions	5
8	expression	and	9
9	and	optimal	7
10	immunogenicity	(	14
11	of	(	14
12	varicella-zoster	virus	13
13	virus	(	14
14	(	In	0
15	VZV	In	0
16	)	In	0
17	proteins	In	0
18	in	proteins	17
19	a	in	18
20	herpes	a	19
21	simplex	(	23
22	virus-1	(	23
23	(	herpes	20
24	HSV-1	a	19
25	)	In	0
26	vector	In	0
27	,	selected	29
28	we	selected	29
29	selected	<ROOT>	-1
30	the	selected	29
31	VZV	the	30
32	glycoprotein	E	33
33	E	VZV	31
34	(	E	33
35	gE	E	33
36	)	gE	35
37	,	gE	35
38	encoded	selected	29
39	by	selected	29
40	ORF	by	39
41	68	ORF	40
42	and	68	41
43	the	ORF	47
44	VZV	ORF	47
45	product	of	46
46	of	VZV	44
47	ORF	and	42
48	62	ORF	47
49	,	selected	29
50	an	(	55
51	immediate-early	major	52
52	major	protein	54
53	tegument	protein	54
54	protein	an	50
55	(	,	49
56	IE62	selected	29
57	)	selected	29
58	.	selected	29

0	Transient	<ROOT>	-1
1	transfection	experiments	2
2	experiments	Transient	0
3	with	Transient	0
4	expression	vectors	5
5	vectors	with	3
6	for	Transient	0
7	two	for	6
8	of	the	9
9	the	two	7
10	isoforms	Transient	0
11	demonstrated	Transient	0
12	that	demonstrated	11
13	the	protein	15
14	32.2-kDa	protein	15
15	protein	is	16
16	is	that	12
17	an	activator	18
18	activator	is	16
19	of	activator	18
20	transcription	of	19
21	of	of	19
22	granulocyte	factor	24
23	colony-stimulating	factor	24
24	factor	of	21
25	receptor	factor	24
26	promoter	,	27
27	,	receptor	25
28	while	of	19
29	the	protein	31
30	14.3-kDa	protein	31
31	protein	is	32
32	is	while	28
33	not	is	32
34	.	Transient	0

0	In	development	3
1	contrast	In	0
2	,	development	3
3	development	<ROOT>	-1
4	into	NK	5
5	NK	development	3
6	cells	development	3
7	in	development	3
8	an	in	7
9	FTOC	is	10
10	is	an	8
11	enhanced	is	10
12	.	development	3

0	The	expression	1
1	expression	kappa	4
2	of	kappa	4
3	I	of	2
4	kappa	was	17
5	B-alpha	kappa	4
6	gene	kappa	4
7	,	which	8
8	which	kappa	4
9	is	which	8
10	responsive	is	9
11	to	responsive	10
12	activation	by	13
13	by	B	15
14	NF-kappa	B	15
15	B	responsive	10
16	,	kappa	4
17	was	<ROOT>	-1
18	up-regulated	was	17
19	in	up-regulated	18
20	PBMC	in	19
21	and	in	19
22	monocytes	was	17
23	from	monocytes	22
24	patients	from	23
25	,	patients	24
26	but	in	28
27	not	in	28
28	in	patients	24
29	mononuclear	cells	30
30	cells	in	28
31	from	healthy	32
32	healthy	cells	30
33	subjects	was	17
34	or	was	17
35	those	or	34
36	with	those	35
37	nontuberculous	with	36
38	lung	.	40
39	diseases	.	40
40	.	nontuberculous	37

0	An	increase	1
1	increase	is	7
2	in	increase	1
3	the	concentration	6
4	intracellular	concentration	6
5	Ca2+	concentration	6
6	concentration	in	2
7	is	<ROOT>	-1
8	both	necessary	9
9	necessary	is	7
10	and	necessary	9
11	sufficient	and	10
12	for	Rap1	13
13	Rap1	sufficient	11
14	activation	Rap1	13
15	since	is	7
16	it	was	17
17	was	since	15
18	induced	was	17
19	by	induced	18
20	agents	by	19
21	that	increase	22
22	increase	agents	20
23	intracellular	increase	22
24	Ca2+	and	25
25	and	intracellular	23
26	inhibited	and	25
27	by	inhibited	26
28	a	agent	30
29	Ca2+-chelating	agent	30
30	agent	by	27
31	.	agent	30

0	Because	was	30
1	candidiasis	are	4
2	and	candidiasis	1
3	cryptococcosis	and	2
4	are	Because	0
5	common	are	4
6	in	are	4
7	human	in	6
8	immunodeficiency	human	7
9	virus	(	10
10	(	immunodeficiency	8
11	HIV	)	12
12	)	(	10
13	-infected	persons	14
14	persons	immunodeficiency	8
15	,	Because	0
16	the	effect	17
17	effect	,	15
18	of	effect	17
19	Cryptococcus	neoformans	20
20	neoformans	of	18
21	and	neoformans	20
22	Candida	albicans	23
23	albicans	and	21
24	on	HIV	25
25	HIV	effect	17
26	expression	HIV	25
27	in	monocytic	28
28	monocytic	expression	26
29	cells	Because	0
30	was	<ROOT>	-1
31	examined	was	30
32	.	was	30

0	G0S2	may	1
1	may	<ROOT>	-1
2	be	may	1
3	of	be	2
4	value	of	3
5	as	value	4
6	a	as	5
7	reporter	a	6
8	gene	reporter	7
9	for	gene	8
10	analyzing	for	9
11	the	mechanism	12
12	mechanism	analyzing	10
13	of	mechanism	12
14	action	of	13
15	of	action	14
16	CsA	of	15
17	and	analyzing	10
18	its	influence	19
19	influence	and	17
20	on	influence	19
21	the	on	20
22	positive	and	23
23	and	the	21
24	negative	and	23
25	selection	negative	24
26	of	the	21
27	lymphocytes	the	21
28	in	lymphocytes	27
29	response	in	28
30	to	response	29
31	self	response	29
32	and	self	31
33	not-self	the	21
34	antigens	reporter	7
35	.	may	1

0	Heat-shock	increase	4
1	and	Heat-shock	0
2	cadmium	and	1
3	chloride	increase	4
4	increase	<ROOT>	-1
5	the	mRNA	7
6	vimentin	mRNA	7
7	mRNA	increase	4
8	and	protein	9
9	protein	increase	4
10	levels	human	13
11	in	U-937	12
12	U-937	human	13
13	human	promonocytic	14
14	promonocytic	increase	4
15	cells	increase	4
16	.	increase	4

0	Collectively	indicate	4
1	,	indicate	4
2	these	findings	3
3	findings	indicate	4
4	indicate	<ROOT>	-1
5	that	indicate	4
6	A/R	elicits	7
7	elicits	adhesion	12
8	a	adhesion	12
9	two-phase	adhesion	12
10	neutrophil-endothelial	adhesion	12
11	cell	adhesion	12
12	adhesion	that	14
13	response	that	14
14	that	that	5
15	involves	that	14
16	transcription-independent	that	14
17	and	transcription-independent	16
18	transcription-dependent	and	17
19	surface	expression	20
20	expression	transcription-dependent	18
21	of	expression	20
22	different	molecules	26
23	endothelial	molecules	26
24	cell	molecules	26
25	adhesion	molecules	26
26	molecules	of	21
27	.	indicate	4

0	This	result	1
1	result	implies	2
2	implies	<ROOT>	-1
3	that	implies	2
4	development	can	11
5	of	development	4
6	anti-E.	antibody	8
7	chaffeensis	antibody	8
8	antibody	of	5
9	in	development	4
10	patients	in	9
11	can	that	3
12	result	can	11
13	in	result	12
14	the	production	15
15	production	in	13
16	of	production	15
17	major	cytokines	19
18	proinflammatory	cytokines	19
19	cytokines	of	16
20	,	implies	2
21	which	may	22
22	may	implies	2
23	play	may	22
24	an	role	26
25	important	role	26
26	role	play	23
27	in	play	23
28	the	pathophysiology	29
29	pathophysiology	in	27
30	of	pathophysiology	29
31	ehrlichiosis	of	30
32	and	ehrlichiosis	31
33	immune	responses	34
34	responses	of	30
35	to	responses	34
36	it	to	35
37	.	implies	2

0	Characterization	platelet/endothelial	4
1	of	platelet/endothelial	4
2	the	platelet/endothelial	4
3	human	platelet/endothelial	4
4	platelet/endothelial	adhesion	6
5	cell	platelet/endothelial	4
6	adhesion	<ROOT>	-1
7	molecule-1	promoter	8
8	promoter	adhesion	6
9	:	adhesion	6
10	identification	adhesion	6
11	of	transcriptional	19
12	a	element	15
13	GATA-2	element	15
14	binding	element	15
15	element	transcriptional	19
16	required	transcriptional	19
17	for	transcriptional	19
18	optimal	transcriptional	19
19	transcriptional	identification	10
20	activity	adhesion	6
21	.	adhesion	6

0	The	stability	1
1	stability	of	2
2	of	was	6
3	already	of	2
4	formed	of	2
5	complexed	formed	4
6	was	<ROOT>	-1
7	somewhat	different	8
8	different	was	6
9	in	was	6
10	the	HLA-A3	11
11	HLA-A3	in	9
12	and	HLA-A3	11
13	HLA-Cw*0702	and	12
14	system	was	6
15	:	was	6
16	both	were	17
17	were	was	6
18	more	stable	19
19	stable	were	17
20	at	degrees	22
21	26	degrees	22
22	degrees	stable	19
23	C	than	24
24	than	degrees	22
25	at	37	26
26	37	than	24
27	degrees	degrees	22
28	C	stable	19
29	but	C	28
30	while	seemed	47
31	the	2-m	33
32	beta	2-m	33
33	2-m	did	36
34	and	2-m	33
35	FCS	and	34
36	did	while	30
37	not	did	36
38	influence	did	36
39	the	stability	40
40	stability	influence	38
41	of	stability	40
42	the	complex	44
43	HLA-A3/peptide	complex	44
44	complex	of	41
45	,	seemed	47
46	they	seemed	47
47	seemed	but	29
48	to	seemed	47
49	cause	opposite	50
50	opposite	to	48
51	effects	opposite	50
52	in	opposite	50
53	the	in	52
54	HLA-Cw*0702	(	56
55	system	(	56
56	(	the	53
57	beta	(	56
58	2-m	(	56
59	stabilized	and	60
60	and	the	53
61	FCS	seemed	47
62	destabilized	FCS	61
63	the	complex	64
64	complex	destabilized	62
65	)	seemed	47
66	.	was	6

0	The	proteolytic	1
1	proteolytic	degradation	2
2	degradation	is	9
3	of	degradation	2
4	the	B	8
5	post-translationally	B	8
6	modified	B	8
7	I-kappa	B	8
8	B	of	3
9	is	<ROOT>	-1
10	known	is	9
11	to	known	10
12	be	to	11
13	mediated	be	12
14	by	mediated	13
15	the	proteasome	17
16	26S	proteasome	17
17	proteasome	complex	18
18	complex	by	14
19	.	is	9

0	Since	was	5
1	repression	Since	0
2	by	these	3
3	these	Since	0
4	fusions	Since	0
5	was	seems	14
6	not	observed	7
7	observed	was	5
8	in	was	5
9	all	cell	10
10	cell	was	5
11	types	was	5
12	,	seems	14
13	it	seems	14
14	seems	<ROOT>	-1
15	likely	that	16
16	that	seems	14
17	EBNA3C	depends	19
18	either	depends	19
19	depends	that	16
20	on	depends	19
21	a	corepressor	22
22	corepressor	on	20
23	which	may	24
24	may	corepressor	22
25	interact	with	26
26	with	may	24
27	amino	with	26
28	acids	amino	27
29	346	acids	28
30	to	346	29
31	543	to	30
32	or	543	31
33	is	with	26
34	modified	may	24
35	in	modified	34
36	a	manner	38
37	cell-specific	manner	38
38	manner	in	35
39	in	modified	34
40	order	in	39
41	to	in	39
42	repress	to	41
43	.	seems	14

0	The	pathway	3
1	STAT-1	pathway	3
2	signaling	pathway	3
3	pathway	provides	4
4	provides	<ROOT>	-1
5	at	one	7
6	least	one	7
7	one	mechanism	8
8	mechanism	provides	4
9	for	mechanism	8
10	activation	for	9
11	of	activation	10
12	the	LTR	14
13	CAEV	LTR	14
14	LTR	of	11
15	by	for	9
16	IFN-gamma	for	9
17	in	IFN-gamma	16
18	monocytes	provides	4
19	.	provides	4

0	BSAP	is	1
1	is	<ROOT>	-1
2	required	is	1
3	for	required	2
4	B-lineage	commitment	5
5	commitment	for	3
6	in	commitment	5
7	the	liver	9
8	fetal	liver	9
9	liver	in	6
10	and	commitment	5
11	for	pro-B	16
12	progression	for	11
13	beyond	pro-B	16
14	an	pro-B	16
15	early	pro-B	16
16	pro-B	and	10
17	cell	in	19
18	stage	in	19
19	in	pro-B	16
20	adult	is	1
21	bone	is	1
22	marrow	is	1
23	.	is	1

0	The	ability	1
1	ability	<ROOT>	-1
2	of	ability	1
3	RFX1	of	2
4	to	RFX1	3
5	transactivate	RFX1	3
6	the	transactivate	5
7	core	raises	9
8	promoter	raises	9
9	raises	the	6
10	the	possibility	11
11	possibility	RFX1	3
12	that	possibility	11
13	RFX1	that	12
14	may	RFX1	13
15	play	may	14
16	a	play	15
17	dual	a	16
18	role	in	19
19	in	dual	17
20	regulating	in	19
21	HBV	regulating	20
22	gene	HBV	21
23	expression	.	24
24	.	gene	22

0	These	data	1
1	data	indicated	2
2	indicated	<ROOT>	-1
3	that	indicated	2
4	c-Fos/c-Jun	that	3
5	,	c-Fos/c-Jun	4
6	c-Rel/p65	c-Fos/c-Jun	4
7	,	c-Fos/c-Jun	4
8	and	c-Fos/c-Jun	4
9	Sp1	regulate	10
10	regulate	and	8
11	TF	in	14
12	gene	in	14
13	expression	in	14
14	in	regulate	10
15	human	monocytic	16
16	monocytic	cells	17
17	cells	regulate	10
18	.	cells	17

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	RFX1	,	2
4	can	RFX1	3
5	bind	can	4
6	simultaneously	bind	5
7	,	simultaneously	6
8	most	simultaneously	6
9	likely	simultaneously	6
10	as	likely	9
11	a	as	10
12	heterodimer	a	11
13	,	with	14
14	with	heterodimer	12
15	the	factor	17
16	transcription	factor	17
17	factor	with	14
18	MIBP1	to	19
19	to	with	14
20	NRE	with	14
21	gamma	can	4
22	.	In	0

0	Our	<ROOT>	-1
1	results	Our	0
2	demonstrate	that	3
3	that	results	1
4	PMLRAR	alpha	5
5	alpha	that	3
6	impairs	alpha	5
7	neutrophil	impairs	6
8	differentiation	neutrophil	7
9	and	differentiation	8
10	initiates	and	9
11	the	development	12
12	development	initiates	10
13	of	development	12
14	APL	of	13
15	.	Our	0

0	METHODS	were	8
1	:	METHODS	0
2	Peripheral	blood	3
3	blood	METHODS	0
4	monocytes	METHODS	0
5	and	monocytes	4
6	T	cells	7
7	cells	monocytes	4
8	were	prepared	9
9	prepared	<ROOT>	-1
10	from	prepared	9
11	patients	from	10
12	with	patients	11
13	SLE	with	12
14	(	=	16
15	n	=	16
16	=	from	10
17	6	=	16
18	)	=	16
19	and	healthy	20
20	healthy	from	10
21	donors	healthy	20
22	(	=	24
23	n	=	24
24	=	donors	21
25	8	=	24
26	)	=	24
27	.	prepared	9

0	Epstein-Barr	B	2
1	virus-transformed	B	2
2	B	<ROOT>	-1
3	cell	(	5
4	lines	(	5
5	(	B	2
6	n	(	5
7	=	n	6
8	7	cell	12
9	)	and	10
10	and	cell	12
11	B	cell	12
12	cell	=	7
13	hybridomas	B	2
14	(	hybridomas	13
15	n	=	16
16	=	hybridomas	13
17	2	hybridomas	13
18	)	hybridomas	13
19	established	B	2
20	from	established	19
21	patients	from	20
22	with	patients	21
23	SLE	with	22
24	and	SLE	23
25	a	with	22
26	healthy	a	25
27	individual	were	28
28	were	a	31
29	used	a	31
30	as	a	31
31	a	cell	33
32	B	a	31
33	cell	healthy	26
34	source	cell	33
35	.	source	34

0	Triggering	alpha	9
1	of	HLA-DR	2
2	HLA-DR	Triggering	0
3	antigens	Triggering	0
4	differentially	antigens	3
5	modulates	tumor	6
6	tumor	factor	8
7	necrosis	factor	8
8	factor	Triggering	0
9	alpha	<ROOT>	-1
10	release	alpha	9
11	by	B	12
12	B	alpha	9
13	cells	alpha	9
14	at	distinct	15
15	distinct	alpha	9
16	stage	alpha	9
17	of	alpha	9
18	maturation	alpha	9
19	.	alpha	9

0	In	determined	4
1	this	study	2
2	study	In	0
3	we	determined	4
4	determined	<ROOT>	-1
5	the	effects	6
6	effects	determined	4
7	of	effects	6
8	SAC	of	7
9	on	determined	4
10	NF-kappa	B	11
11	B	on	9
12	activation	B	11
13	in	human	14
14	human	T	15
15	T	determined	4
16	lymphocytes	(	17
17	(	Jurkat	18
18	Jurkat	determined	4
19	cells	determined	4
20	)	determined	4
21	induced	by	22
22	by	determined	4
23	tumor	by	22
24	necrosis	factor	25
25	factor	tumor	23
26	alpha	(	27
27	(	determined	4
28	TNF-alpha	determined	4
29	)	determined	4
30	and	determined	4
31	H2O2	determined	4
32	.	determined	4

0	Glucocorticoids	inhibit	5
1	(	GCS	2
2	GCS	Glucocorticoids	0
3	)	GCS	2
4	profoundly	inhibit	5
5	inhibit	<ROOT>	-1
6	several	aspects	7
7	aspects	T	9
8	of	T	9
9	T	inhibit	5
10	cell	inhibit	5
11	immunity	inhibit	5
12	largely	through	13
13	through	immunity	11
14	inhibition	through	13
15	of	cytokine	16
16	cytokine	inhibition	14
17	expression	inhibit	5
18	at	inhibit	5
19	the	transcriptional	20
20	transcriptional	at	18
21	and	inhibit	5
22	posttranscriptional	inhibit	5
23	levels	inhibit	5
24	.	inhibit	5

0	The	protein	9
1	different	The	0
2	patterns	of	3
3	of	different	1
4	p50	of	3
5	,	The	0
6	p52	The	0
7	and	p52	6
8	RelB	The	0
9	protein	<ROOT>	-1
10	nuclear	localization	11
11	localization	may	12
12	may	protein	9
13	provide	may	12
14	insight	provide	13
15	into	different	17
16	their	different	17
17	different	provide	13
18	roles	protein	9
19	during	roles	18
20	the	response	22
21	immune	response	22
22	response	during	19
23	in	response	22
24	vivo	in	23
25	.	protein	9

0	The	basis	2
1	molecular	basis	2
2	basis	is	9
3	of	basis	2
4	GC	insensitivity	5
5	insensitivity	of	3
6	,	is	9
7	however	is	9
8	,	is	9
9	is	<ROOT>	-1
10	unknown	is	9
11	.	is	9

0	Fusion	proteins	1
1	proteins	RAR	9
2	involving	proteins	1
3	the	retinoic	4
4	retinoic	involving	2
5	acid	receptor	6
6	receptor	retinoic	4
7	alpha	(	8
8	(	proteins	1
9	RAR	<ROOT>	-1
10	alpha	RAR	9
11	)	alpha	10
12	and	)	11
13	the	PML	14
14	PML	and	12
15	or	PML	14
16	PLZF	acute	24
17	nuclear	acute	24
18	protein	acute	24
19	are	acute	24
20	the	markers	22
21	genetic	markers	22
22	markers	acute	24
23	of	acute	24
24	acute	or	15
25	promyelocytic	PML	14
26	leukemias	APLs	28
27	(	APLs	28
28	APLs	promyelocytic	25
29	)	promyelocytic	25
30	.	RAR	9

0	Nuclear	extracts	1
1	extracts	demonstrated	6
2	of	extracts	1
3	anti-CD15	cross-linked	4
4	cross-linked	cells	5
5	cells	of	2
6	demonstrated	<ROOT>	-1
7	enhanced	demonstrated	6
8	levels	enhanced	7
9	of	the	10
10	the	levels	8
11	transcriptional	factor	12
12	factor	activator	13
13	activator	the	10
14	protein-1	the	10
15	,	protein-1	14
16	minimally	changed	17
17	changed	B	20
18	nuclear	B	20
19	factor-kappa	B	20
20	B	demonstrated	6
21	,	demonstrated	6
22	and	demonstrated	6
23	did	and	22
24	not	did	23
25	affect	not	24
26	SV40	not	24
27	promoter	specific	28
28	specific	SV40	26
29	protein-1	not	24
30	.	demonstrated	6

0	During	<ROOT>	-1
1	the	course	2
2	course	During	0
3	of	course	2
4	serious	bacterial	5
5	bacterial	of	3
6	infections	bacterial	5
7	,	During	0
8	lipopolysaccharide	LPS	10
9	(	LPS	10
10	LPS	)	11
11	)	,	7
12	interacts	,	7
13	with	interacts	12
14	monocyte/macrophage	receptors	15
15	receptors	with	13
16	,	with	13
17	resulting	,	16
18	in	During	0
19	the	generation	20
20	generation	in	18
21	of	generation	20
22	inflammatory	cytokines	23
23	cytokines	of	21
24	.	During	0

0	Interleukin-12	IL-12	2
1	(	IL-12	2
2	IL-12	plays	16
3	)	IL-12	2
4	,	plays	16
5	a	cytokine	7
6	heterodimeric	cytokine	7
7	cytokine	plays	16
8	produced	cytokine	7
9	by	produced	8
10	activated	monocytes	11
11	monocytes	by	9
12	and	monocytes	11
13	dendritic	and	12
14	cells	dendritic	13
15	,	cytokine	7
16	plays	<ROOT>	-1
17	a	interferon	22
18	crucial	in	20
19	role	in	20
20	in	a	17
21	regulating	interferon	22
22	interferon	plays	16
23	(	plays	16
24	IFN	(	23
25	)	IFN	24
26	-gamma	)	25
27	production	-gamma	26
28	and	production	27
29	in	and	28
30	the	generation	31
31	generation	in	29
32	of	generation	31
33	IFN-gamma-producing	T	34
34	T	1	36
35	helper	1	36
36	1	Th1	38
37	(	1	36
38	Th1	of	32
39	)	-gamma	26
40	cells	plays	16
41	.	plays	16

0	Consequently	suggest	4
1	,	suggest	4
2	these	results	3
3	results	suggest	4
4	suggest	<ROOT>	-1
5	that	suggest	4
6	physiologically	relevant	7
7	relevant	concentrations	8
8	concentrations	may	11
9	of	concentrations	8
10	ethanol	of	9
11	may	that	5
12	affect	may	11
13	production	affect	12
14	of	production	13
15	inflammatory	cytokines	16
16	cytokines	of	14
17	,	such	18
18	such	production	13
19	as	necrosis	21
20	tumor	necrosis	21
21	necrosis	such	18
22	factor-alpha	necrosis	21
23	,	interleukin-1	24
24	interleukin-1	necrosis	21
25	beta	interleukin-1	24
26	,	interleukin-1	24
27	and	,	26
28	interleukin-6	suggest	4
29	by	suggest	4
30	disrupting	NF-kappa	31
31	NF-kappa	by	29
32	B	suggest	4
33	signaling	B	32
34	in	B	32
35	monocytes	in	34
36	.	suggest	4

0	Overexpression	stimulates	3
1	of	Overexpression	0
2	ALY	of	1
3	stimulates	enhancer	30
4	the	activity	5
5	activity	TCR	8
6	of	TCR	8
7	the	TCR	8
8	TCR	stimulates	3
9	alpha	stimulates	3
10	enhancer	reconstituted	12
11	complex	reconstituted	12
12	reconstituted	stimulates	3
13	in	transfected	14
14	transfected	HeLa	16
15	nonlymphoid	HeLa	16
16	HeLa	reconstituted	12
17	cells	stimulates	3
18	,	stimulates	3
19	whereas	stimulates	3
20	down-regulation	eliminates	27
21	of	down-regulation	20
22	ALY	of	21
23	by	ALY	22
24	anti-sense	by	23
25	oligonucleotides	virtually	26
26	virtually	anti-sense	24
27	eliminates	whereas	19
28	TCR	stimulates	3
29	alpha	stimulates	3
30	enhancer	<ROOT>	-1
31	activity	enhancer	30
32	in	T	33
33	T	activity	31
34	cells	enhancer	30
35	.	enhancer	30

0	In	is	6
1	this	complex	2
2	complex	In	0
3	,	is	6
4	promoter	specificity	5
5	specificity	is	6
6	is	is	20
7	determined	is	6
8	by	binding	11
9	the	binding	11
10	DNA	binding	11
11	binding	determined	7
12	domain	is	6
13	of	domain	12
14	RFX5	of	13
15	and	RFX5	14
16	the	apparatus	19
17	general	apparatus	19
18	transcription	apparatus	19
19	apparatus	and	15
20	is	<ROOT>	-1
21	recruited	is	20
22	by	activation	25
23	the	activation	25
24	acidic	activation	25
25	activation	recruited	21
26	domain	of	27
27	of	is	20
28	CIITA	of	27
29	.	CIITA	28

0	Blood	monocytes	1
1	monocytes	are	7
2	from	monocytes	1
3	patients	from	2
4	with	patients	3
5	active	tuberculosis	6
6	tuberculosis	with	4
7	are	<ROOT>	-1
8	activated	are	7
9	in	activated	8
10	vivo	in	9
11	,	are	7
12	as	are	7
13	evidenced	as	12
14	by	evidenced	13
15	an	increase	16
16	increase	by	14
17	in	increase	16
18	the	release	20
19	stimulated	release	20
20	release	in	17
21	of	release	20
22	proinflammatory	cytokines	23
23	cytokines	of	21
24	,	are	7
25	such	as	26
26	as	are	7
27	TNF-alpha	as	26
28	,	are	7
29	and	spontaneous	31
30	the	spontaneous	31
31	spontaneous	are	7
32	expression	spontaneous	31
33	of	expression	32
34	IL-2R	are	7
35	.	are	7

0	Two	enhancer	3
1	multicopy	enhancer	3
2	basal	enhancer	3
3	enhancer	<ROOT>	-1
4	motifs	enhancer	3
5	within	enhancer	3
6	the	MIE	8
7	SCMV	MIE	8
8	MIE	within	5
9	enhancer	,	10
10	,	MIE	8
11	namely	,	10
12	,	enhancer	3
13	11	enhancer	3
14	copies	enhancer	3
15	of	copies	14
16	the	of	15
17	16-bp	the	16
18	cyclic	(	22
19	AMP	(	22
20	response	(	22
21	element	(	22
22	(	16-bp	17
23	CRE	(	22
24	)	16-bp	17
25	and	)	36
26	3	)	36
27	copies	3	26
28	of	(	34
29	novel	factor	33
30	17-bp	factor	33
31	serum	response	32
32	response	factor	33
33	factor	of	28
34	(	copies	27
35	SRF	(	34
36	)	16-bp	17
37	binding	enhancer	3
38	sites	binding	37
39	referred	enhancer	3
40	to	referred	39
41	as	enhancer	3
42	the	SNE	43
43	SNE	as	41
44	(	SNE	43
45	SRF/NFkappaB-like	SNE	43
46	element	SNE	43
47	)	SNE	43
48	,	enhancer	3
49	as	enhancer	3
50	well	enhancer	3
51	as	classical	53
52	four	classical	53
53	classical	enhancer	3
54	NFkappaB	enhancer	3
55	sites	NFkappaB	54
56	within	sites	55
57	the	version	59
58	HCMV	version	59
59	version	within	56
60	,	enhancer	3
61	contribute	enhancer	3
62	to	contribute	61
63	TPA	responsiveness	64
64	responsiveness	to	62
65	in	responsiveness	64
66	transient	in	65
67	assays	in	68
68	in	transient	66
69	monocyte	in	68
70	and	monocyte	69
71	T-cell	and	70
72	types	and	70
73	.	types	72

0	Hela	extracts	2
1	nuclear	extracts	2
2	extracts	)	10
3	contained	)	10
4	a	)	10
5	specific	)	10
6	nuclear	factor	7
7	factor	(	8
8	(	)	10
9	s	(	8
10	)	<ROOT>	-1
11	binding	to	12
12	to	)	10
13	15-LO	to	12
14	promoter	which	16
15	DNA	which	16
16	which	15-LO	13
17	are	)	10
18	distinct	are	17
19	from	distinct	18
20	those	from	19
21	derived	those	20
22	from	derived	21
23	IL-13-treated	extracts	28
24	human	extracts	28
25	peripheral	extracts	28
26	monocyte	extracts	28
27	nuclear	extracts	28
28	extracts	from	22
29	.	)	10

0	They	fuse	2
1	later	fuse	2
2	fuse	<ROOT>	-1
3	,	fuse	2
4	and	fuse	2
5	,	and	4
6	under	,	5
7	the	influence	8
8	influence	under	6
9	of	influence	8
10	the	of	9
11	surrounding	the	10
12	mesenchyme	surrounding	11
13	,	mesenchyme	12
14	the	mesenchyme	12
15	mature	organ	16
16	organ	develops	17
17	develops	the	14
18	,	develops	17
19	being	,	18
20	mainly	being	19
21	composed	mainly	20
22	of	composed	21
23	ductal	of	22
24	,	of	22
25	exocrine	,	24
26	and	exocrine	25
27	endocrine	and	26
28	compartments	endocrine	27
29	.	fuse	2

0	During	<ROOT>	-1
1	myelopoiesis	During	0
2	,	During	0
3	which	includes	4
4	includes	,	2
5	the	development	6
6	development	includes	4
7	of	development	6
8	granulocytic	of	7
9	and	monocytic	10
10	monocytic	development	6
11	lineages	During	0
12	,	During	0
13	transcription	factors	14
14	factors	,	12
15	from	factors	14
16	several	from	15
17	families	are	18
18	are	several	16
19	active	are	18
20	,	are	18
21	including	several	16
22	AML1/CBF	including	21
23	beta	,	24
24	,	AML1/CBF	22
25	C/EBP	,	24
26	,	C/EBP	25
27	Ets	C/EBP	25
28	,	C/EBP	25
29	c-Myb	,	24
30	,	factors	14
31	HOX	factors	14
32	,	factors	14
33	and	factors	14
34	MZF-1	and	33
35	.	During	0

0	Lack	<ROOT>	-1
1	of	Lack	0
2	T-cell-mediated	recognition	3
3	recognition	of	1
4	of	recognition	3
5	the	region	7
6	fusion	region	7
7	region	of	4
8	of	hybrid	11
9	the	hybrid	11
10	pml/RAR-alpha	hybrid	11
11	hybrid	region	7
12	protein	Lack	0
13	by	protein	12
14	lymphocytes	Lack	0
15	of	Lack	0
16	acute	Lack	0
17	promyelocytic	Lack	0
18	leukemia	Lack	0
19	patients	Lack	0
20	.	Lack	0

0	Peroxisomal	<ROOT>	-1
1	proliferator-activated	Peroxisomal	0
2	receptor	proliferator-activated	1
3	gamma	receptor	2
4	(	gamma	3
5	PPARgamma	)	6
6	)	(	4
7	,	)	6
8	a	factor	10
9	transcription	factor	10
10	factor	(	4
11	in	factor	10
12	the	superfamily	15
13	nuclear	superfamily	15
14	receptor	superfamily	15
15	superfamily	in	11
16	,	regulates	17
17	regulates	(	4
18	gene	regulates	17
19	expression	in	20
20	in	(	4
21	response	Peroxisomal	0
22	to	response	21
23	various	Peroxisomal	0
24	activators	Peroxisomal	0
25	,	activators	24
26	including	activators	24
27	15-deoxy-delta12,14-prostaglandin	J2	28
28	J2	including	26
29	and	J2	28
30	the	troglitazone	33
31	antidiabetic	troglitazone	33
32	agent	troglitazone	33
33	troglitazone	and	29
34	.	Peroxisomal	0

0	However	resembled	5
1	,	resembled	5
2	B	cells	4
3	series	cells	4
4	cells	resembled	5
5	resembled	<ROOT>	-1
6	the	cells	9
7	A	cells	9
8	series	cells	9
9	cells	resembled	5
10	in	resembled	5
11	exhibiting	in	10
12	faster	exhibiting	11
13	growth	faster	12
14	rates	growth	13
15	than	rates	14
16	the	than	15
17	parental	the	16
18	HL60	parental	17
19	cells	HL60	18
20	and	rates	14
21	showed	and	20
22	high	of	24
23	levels	of	24
24	of	showed	21
25	vitamin	receptor	27
26	D	receptor	27
27	receptor	showed	21
28	and	receptor	27
29	retinoid	proteins	32
30	receptor	proteins	32
31	X	proteins	32
32	proteins	and	28
33	.	resembled	5

0	Although	is	16
1	little	is	2
2	is	Although	0
3	known	is	2
4	to	known	3
5	date	to	4
6	concerning	date	5
7	the	regulation	8
8	regulation	gene	10
9	of	gene	10
10	gene	date	5
11	transcription	Although	0
12	in	transcription	11
13	neutrophils	in	12
14	,	is	16
15	it	is	16
16	is	<ROOT>	-1
17	noteworthy	is	16
18	that	noteworthy	17
19	many	that	18
20	of	these	21
21	these	many	19
22	genes	these	21
23	depend	genes	22
24	on	the	25
25	the	depend	23
26	activation	the	25
27	of	activation	26
28	transcription	factors	29
29	factors	of	27
30	,	such	31
31	such	of	27
32	as	such	31
33	NF-kappaB	such	31
34	,	for	35
35	for	NF-kappaB	33
36	inducible	expression	37
37	expression	for	35
38	.	is	16

0	Alteration	<ROOT>	-1
1	of	Alteration	0
2	a	serine	4
3	single	serine	4
4	serine	of	1
5	in	serine	4
6	the	domain	8
7	basic	domain	8
8	domain	in	5
9	of	domain	8
10	the	of	9
11	Epstein-Barr	the	10
12	virus	Epstein-Barr	11
13	ZEBRA	virus	12
14	protein	ZEBRA	13
15	separates	protein	14
16	its	functions	17
17	functions	separates	15
18	of	transcriptional	19
19	transcriptional	functions	17
20	activation	and	21
21	and	disruption	22
22	disruption	the	10
23	of	disruption	22
24	latency	of	23
25	.	Alteration	0

0	We	<ROOT>	-1
1	compared	We	0
2	glucocorticoid	and	6
3	receptor	and	6
4	binding	and	6
5	characteristics	and	6
6	and	compared	1
7	glucocorticoid	and	6
8	responsiveness	We	0
9	of	human	10
10	human	responsiveness	8
11	mononuclear	(	13
12	leukocytes	(	13
13	(	human	10
14	HML	We	0
15	)	We	0
16	from	We	0
17	hypertensive	We	0
18	patients	We	0
19	and	We	0
20	matched	and	19
21	normotensive	volunteers	22
22	volunteers	matched	20
23	.	We	0

0	We	conclude	1
1	conclude	<ROOT>	-1
2	that	conclude	1
3	engagement	that	2
4	of	engagement	3
5	CD15	of	4
6	on	engagement	3
7	monocytes	results	8
8	results	on	6
9	in	monocyte	10
10	monocyte	results	8
11	activation	conclude	1
12	.	conclude	1

0	Mutation	abolished	10
1	of	Mutation	0
2	this	motif	3
3	motif	of	1
4	almost	Mutation	0
5	completely	almost	4
6	,	Mutation	0
7	and	Mutation	0
8	specifically	and	7
9	,	Mutation	0
10	abolished	<ROOT>	-1
11	the	binding	12
12	binding	abolished	10
13	of	binding	12
14	two	complexes	16
15	low-mobility	complexes	16
16	complexes	of	13
17	and	abolished	10
18	led	and	17
19	to	led	18
20	a	decrease	23
21	95	decrease	23
22	%	decrease	23
23	decrease	to	19
24	of	decrease	23
25	constitutive	activation	27
26	transcriptional	activation	27
27	activation	of	24
28	of	decrease	23
29	a	IL-1beta	32
30	reporter	IL-1beta	32
31	construct	IL-1beta	32
32	IL-1beta	of	28
33	(	-170/+108	34
34	-170/+108	decrease	23
35	)	-170/+108	34
36	.	abolished	10

0	Analysis	<ROOT>	-1
1	of	Analysis	0
2	myeloid-associated	genes	3
3	genes	of	1
4	in	progenitor	7
5	human	progenitor	7
6	hematopoietic	progenitor	7
7	progenitor	of	1
8	cells	Analysis	0
9	.	Analysis	0

0	Isoforms	Pax-5d	1
1	Pax-5d	have	4
2	and	Pax-5d	1
3	Pax-5e	and	2
4	have	<ROOT>	-1
5	deleted	have	4
6	the	3'-region	7
7	3'-region	deleted	5
8	,	deleted	5
9	which	encodes	10
10	encodes	transactivating	12
11	the	transactivating	12
12	transactivating	deleted	5
13	domain	transactivating	12
14	,	domain	13
15	and	,	14
16	replaced	and	15
17	it	replaced	16
18	with	replaced	16
19	a	sequence	21
20	novel	sequence	21
21	sequence	with	18
22	.	have	4

0	Consequently	was	5
1	,	was	5
2	the	study	4
3	present	study	4
4	study	was	5
5	was	<ROOT>	-1
6	addressed	was	5
7	to	addressed	6
8	understand	to	7
9	this	phenomenon	10
10	phenomenon	understand	8
11	and	was	5
12	revealed	protein	20
13	the	existence	14
14	existence	protein	20
15	of	protein	20
16	a	protein	20
17	unique	protein	20
18	47	kDa	19
19	kDa	protein	20
20	protein	and	11
21	factor	was	5
22	having	affinity	23
23	affinity	was	5
24	for	affinity	23
25	this	SRE	26
26	SRE	for	24
27	sequence	SRE	26
28	in	was	5
29	lymphocytes	was	5
30	from	was	5
31	normal	was	5
32	subjects	was	5
33	as	was	5
34	well	was	5
35	as	was	5
36	its	as	35
37	absence	its	36
38	in	was	5
39	lymphocytes	from	40
40	from	was	5
41	untreated	patients	43
42	CML	patients	43
43	patients	from	40
44	.	was	5

0	This	domain	2
1	activation	domain	2
2	domain	interacts	5
3	of	domain	2
4	CIITA	of	3
5	interacts	<ROOT>	-1
6	with	kDa	9
7	the	kDa	9
8	32	kDa	9
9	kDa	interacts	5
10	subunit	kDa	9
11	of	subunit	10
12	the	of	11
13	general	TFIID	16
14	transcription	TFIID	16
15	complex	TFIID	16
16	TFIID	the	12
17	,	TAFII32	18
18	TAFII32	TFIID	16
19	.	TAFII32	18

0	Whereas	is	8
1	the	pathway	2
2	pathway	is	8
3	responsible	pathway	2
4	for	responsible	3
5	this	role	7
6	latter	role	7
7	role	for	4
8	is	is	15
9	yet	is	8
10	to	is	8
11	be	to	10
12	elucidated	be	11
13	,	is	15
14	it	is	15
15	is	<ROOT>	-1
16	unlikely	is	15
17	to	unlikely	16
18	include	to	17
19	CREB	phosphorylation	20
20	phosphorylation	include	18
21	.	is	15

0	Here	show	3
1	,	show	3
2	we	show	3
3	show	<ROOT>	-1
4	that	show	3
5	the	site	7
6	DBF	site	7
7	site	is	8
8	is	factor	11
9	an	factor	11
10	interferon-responsive	factor	11
11	factor	that	4
12	(	IRF	13
13	IRF	factor	11
14	)	IRF	13
15	binding	show	3
16	site	show	3
17	and	show	3
18	that	and	17
19	the	motif	21
20	AP3-L	motif	21
21	motif	binds	22
22	binds	that	18
23	the	binds	22
24	T-cell-specific	the	23
25	factor	T-cell-specific	24
26	NF-AT	factor	25
27	.	NF-AT	26

0	Some	clones	4
1	tegument-specific	clones	4
2	CD4	clones	4
3	T-cell	clones	4
4	clones	exhibited	5
5	exhibited	<ROOT>	-1
6	cytotoxic	exhibited	5
7	activity	cytotoxic	6
8	against	cytotoxic	6
9	HSV-infected	cells	10
10	cells	against	8
11	.	cells	10

0	Despite	<ROOT>	-1
1	this	are	4
2	,	are	4
3	there	are	4
4	are	Despite	0
5	still	are	4
6	significant	gaps	7
7	gaps	are	4
8	in	our	9
9	our	gaps	7
10	understanding	our	9
11	of	understanding	10
12	this	process	13
13	process	of	11
14	and	are	4
15	its	consequences	16
16	consequences	and	14
17	.	Despite	0

0	To	was	30
1	explore	To	0
2	the	pathogenesis	3
3	pathogenesis	explore	1
4	of	pathogenesis	3
5	chronic	leukemia	7
6	lymphocytic	leukemia	7
7	leukemia	of	4
8	(	leukemia	7
9	CLL	of	4
10	)	explore	1
11	,	To	0
12	we	,	11
13	examined	whether	14
14	whether	we	12
15	phosphorylation	whether	14
16	of	phosphorylation	15
17	one	of	16
18	or	more	19
19	more	one	17
20	signal	more	19
21	transducer	more	19
22	and	transducer	21
23	activator	and	22
24	of	and	22
25	transcription	(	26
26	(	and	22
27	STAT	(	26
28	)	STAT	27
29	factors	To	0
30	was	<ROOT>	-1
31	abnormal	was	30
32	in	from	34
33	cells	from	34
34	from	abnormal	31
35	CLL	from	34
36	patients	was	30
37	.	was	30

0	It	elevated	2
1	also	elevated	2
2	elevated	<ROOT>	-1
3	peripheral	blood	4
4	blood	elevated	2
5	neutrophil	blood	4
6	counts	neutrophil	5
7	in	counts	6
8	mice	in	7
9	.	elevated	2

0	Induction	I	17
1	of	factor	3
2	nuclear	factor	3
3	factor	Induction	0
4	kappa	B/Rel	5
5	B/Rel	factor	3
6	nuclear	B/Rel	5
7	activity	Induction	0
8	in	peripheral	10
9	human	peripheral	10
10	peripheral	activity	7
11	blood	T	12
12	T	Induction	0
13	lymphocytes	Induction	0
14	by	I	17
15	anti-HLA	I	17
16	class	I	17
17	I	<ROOT>	-1
18	monoclonal	I	17
19	antibodies	I	17
20	.	I	17

0	Isoelectric	focusing	1
1	focusing	<ROOT>	-1
2	demonstrated	focusing	1
3	that	demonstrated	2
4	TPO	that	3
5	induced	TPO	4
6	fetal	induced	5
7	and	fetal	6
8	adult	synthesis	10
9	Hb	synthesis	10
10	synthesis	and	7
11	,	TPO	4
12	whereas	TPO	4
13	EPO	induced	14
14	induced	whereas	12
15	embryonic	TPO	4
16	,	TPO	4
17	fetal	TPO	4
18	,	TPO	4
19	and	TPO	4
20	adult	and	19
21	Hb	synthesis	22
22	synthesis	adult	20
23	.	synthesis	22

0	Transcriptional	activation	1
1	activation	DeltaE	8
2	by	activation	1
3	this	form	5
4	mutant	form	5
5	form	by	2
6	of	form	5
7	membrane-bound	of	6
8	DeltaE	was	9
9	was	<ROOT>	-1
10	approximately	equivalent	11
11	equivalent	was	9
12	to	equivalent	11
13	that	to	12
14	produced	that	13
15	by	produced	14
16	intranuclear	ICN	17
17	ICN	by	15
18	.	was	9

0	Some	were	5
1	monocytes	Some	0
2	and	monocytes	1
3	T	cells	4
4	cells	monocytes	1
5	were	<ROOT>	-1
6	stimulated	were	5
7	with	stimulated	6
8	estradiol	with	7
9	,	were	5
10	PMA	were	5
11	,	were	5
12	and	were	5
13	ionomycin	were	5
14	.	were	5

0	Sequence	cDNA	3
1	analyses	of	2
2	of	Sequence	0
3	cDNA	clones	4
4	clones	indicated	5
5	indicated	and	18
6	that	indicated	5
7	these	transcripts	8
8	transcripts	that	6
9	encode	transcripts	8
10	proteins	encode	9
11	differing	only	12
12	only	at	13
13	at	proteins	10
14	their	termini	16
15	amino	termini	16
16	termini	at	13
17	,	indicated	5
18	and	<ROOT>	-1
19	likely	and	18
20	represent	and	18
21	alternatively	represent	20
22	spliced	isoforms	23
23	isoforms	alternatively	21
24	.	and	18

0	In	transcription	2
1	vitro	In	0
2	transcription	<ROOT>	-1
3	assays	showed	4
4	showed	Tax	6
5	that	Tax	6
6	Tax	transcription	2
7	was	transcription	2
8	able	was	7
9	to	able	8
10	significantly	to	9
11	increase	significantly	10
12	the	to	9
13	transcriptional	the	12
14	activity	transcriptional	13
15	of	activity	14
16	a	template	17
17	template	of	15
18	containing	template	17
19	the	-257	20
20	-257	containing	18
21	to	transcriptional	13
22	+74	to	21
23	region	+74	22
24	of	region	23
25	the	of	24
26	c-sis/PDGF-B	.	28
27	promoter	.	28
28	.	the	25

0	Nonetheless	<ROOT>	-1
1	,	Nonetheless	0
2	CREB	,	1
3	,	CREB	2
4	Ets-1	,	3
5	,	Ets-1	4
6	and	Ets-1	4
7	AML1	and	6
8	bind	Ets-1	4
9	and	Ets-1	4
10	activate	and	9
11	cooperatively	activate	10
12	and	activate	10
13	very	and	12
14	efficiently	and	12
15	through	activate	10
16	the	through	15
17	nonconsensus	promoter	23
18	binding	promoter	23
19	sites	promoter	23
20	at	promoter	23
21	the	promoter	23
22	core	promoter	23
23	promoter	the	16
24	region	Nonetheless	0
25	.	Nonetheless	0

0	Cloning	<ROOT>	-1
1	and	Cloning	0
2	expression	Cloning	0
3	of	expression	2
4	the	dUTPase	7
5	Epstein-Barr	dUTPase	7
6	virus-encoded	dUTPase	7
7	dUTPase	of	3
8	:	Cloning	0
9	patients	Cloning	0
10	with	patients	9
11	acute	with	10
12	,	patients	9
13	reactivated	patients	9
14	or	reactivated	13
15	chronic	infection	17
16	virus	infection	17
17	infection	Cloning	0
18	develop	Cloning	0
19	antibodies	develop	18
20	against	antibodies	19
21	the	enzyme	22
22	enzyme	antibodies	19
23	.	Cloning	0

0	Binding	capacity	1
1	capacity	<ROOT>	-1
2	(	capacity	1
3	4978+/-391	(	2
4	versus	4978+/-391	3
5	4131+/-321	versus	4
6	sites/cell	)	7
7	)	4131+/-321	5
8	,	4978+/-391	3
9	Kd	(	2
10	values	for	11
11	for	(	2
12	dexamethasone	for	11
13	(	dexamethasone	12
14	6.7+/-0.5	capacity	1
15	versus	capacity	1
16	5.7+/-0.3	capacity	1
17	nmol/L	5.7+/-0.3	16
18	)	nmol/L	17
19	,	)	18
20	and	,	19
21	IC50	capacity	1
22	values	for	23
23	for	capacity	1
24	dexamethasone	for	23
25	(	dexamethasone	24
26	3.4+/-0.3	capacity	1
27	versus	capacity	1
28	3.1+/-0.2	capacity	1
29	nmol/L	3.1+/-0.2	28
30	)	and	31
31	and	nmol/L	29
32	cortisol	3.1+/-0.2	28
33	(	cortisol	32
34	12.2+/-1.6	(	33
35	versus	12.2+/-1.6	34
36	9.5+/-0.3	versus	35
37	nmol/L	)	38
38	)	9.5+/-0.3	36
39	were	versus	35
40	not	versus	35
41	significantly	not	40
42	different	significantly	41
43	.	capacity	1

0	Peripheral	T	2
1	blood	T	2
2	T	<ROOT>	-1
3	cells	T	2
4	and	T	2
5	monocytes	T	2
6	and	T	2
7	B	T	2
8	cell	T	2
9	lines	T	2
10	derived	T	2
11	from	T	2
12	patients	express	15
13	with	express	15
14	lupus	express	15
15	express	T	2
16	estrogen	express	15
17	receptor	T	2
18	transcripts	similar	19
19	similar	T	2
20	to	T	2
21	those	to	20
22	of	normal	23
23	normal	those	21
24	cells	T	2
25	.	T	2

0	Although	has	6
1	retinoic	(	3
2	acid	(	3
3	(	Although	0
4	RA	(	3
5	)	Although	0
6	has	<ROOT>	-1
7	been	has	6
8	known	been	7
9	for	known	8
10	many	years	11
11	years	for	9
12	to	known	8
13	be	to	12
14	a	plays	18
15	modulating	that	17
16	agent	that	17
17	that	plays	18
18	plays	be	13
19	a	be	13
20	role	a	19
21	in	both	23
22	generating	both	23
23	both	role	20
24	granulocytes	has	6
25	and	has	6
26	monocytes	has	6
27	,	mechanism	30
28	the	mechanism	30
29	molecular	mechanism	30
30	mechanism	has	6
31	underlying	mechanism	30
32	this	underlying	31
33	role	has	34
34	has	mechanism	30
35	not	has	34
36	been	has	34
37	defined	been	36
38	in	defined	37
39	the	lineage	41
40	monoblast	lineage	41
41	lineage	in	38
42	.	has	6

0	Responses	were	15
1	to	Responses	0
2	these	antigens	4
3	EBV	antigens	4
4	antigens	to	1
5	by	synovial	6
6	synovial	Responses	0
7	lymphocytes	Responses	0
8	from	Responses	0
9	several	patients	14
10	other	patients	14
11	chronic	patients	14
12	rheumatoid	patients	14
13	arthritis	patients	14
14	patients	from	8
15	were	<ROOT>	-1
16	readily	detectable	17
17	detectable	were	15
18	.	were	15

0	Temporal	<ROOT>	-1
1	control	Temporal	0
2	of	control	1
3	IgH	of	2
4	gene	expression	5
5	expression	IgH	3
6	in	expression	5
7	developing	IgH	3
8	B	cells	9
9	cells	developing	7
10	by	control	14
11	the	control	14
12	3'	locus	13
13	locus	control	14
14	control	Temporal	0
15	region	Temporal	0
16	.	Temporal	0

0	Oxidant-regulation	<ROOT>	-1
1	of	gene	2
2	gene	Oxidant-regulation	0
3	expression	Oxidant-regulation	0
4	in	inflamed	7
5	the	inflamed	7
6	chronically	inflamed	7
7	inflamed	expression	3
8	intestine	Oxidant-regulation	0
9	.	Oxidant-regulation	0

0	Interleukin-12	IL-12	2
1	(	IL-12	2
2	IL-12	is	4
3	)	IL-12	2
4	is	<ROOT>	-1
5	a	cytokine	6
6	cytokine	is	4
7	that	cytokine	6
8	exhibits	that	7
9	pleiotropic	exhibits	8
10	effects	on	11
11	on	pleiotropic	9
12	lymphocytes	pleiotropic	9
13	and	killer	15
14	natural	killer	15
15	killer	pleiotropic	9
16	cells	is	4
17	and	is	4
18	has	and	17
19	been	has	18
20	shown	been	19
21	to	shown	20
22	have	to	21
23	promise	have	22
24	for	promise	23
25	the	immunotherapy	26
26	immunotherapy	for	24
27	of	immunotherapy	26
28	cancer	of	27
29	.	is	4

0	The	sequence	1
1	sequence	is	7
2	in	develop	6
3	which	in	2
4	these	alterations	5
5	alterations	develop	6
6	develop	sequence	1
7	is	<ROOT>	-1
8	unknown	is	7
9	.	is	7

0	During	observed	13
1	the	process	3
2	differentiation	process	3
3	process	During	0
4	of	process	3
5	cells	from	6
6	from	of	4
7	the	cell	9
8	monocytic	cell	9
9	cell	During	0
10	line	During	0
11	THP-1	During	0
12	we	observed	13
13	observed	<ROOT>	-1
14	a	transcriptional	16
15	transient	transcriptional	16
16	transcriptional	observed	13
17	upregulation	observed	13
18	of	upregulation	17
19	a	carboxylesterase	21
20	human	carboxylesterase	21
21	carboxylesterase	of	18
22	analyzed	by	23
23	by	carboxylesterase	21
24	means	observed	13
25	of	means	24
26	Northern	of	25
27	blots	.	28
28	.	Northern	26

0	The	interaction	1
1	interaction	NF-YB	5
2	of	interaction	1
3	Tax1	of	2
4	with	Tax1	3
5	NF-YB	<ROOT>	-1
6	was	NF-YB	5
7	specific	NF-YB	5
8	in	did	11
9	that	NF-YB	10
10	NF-YB	in	8
11	did	NF-YB	5
12	not	did	11
13	interact	did	11
14	with	interact	13
15	a	variety	16
16	variety	with	14
17	of	variety	16
18	other	factors	20
19	transcription	factors	20
20	factors	of	17
21	,	NF-YB	5
22	including	NF-YB	5
23	human	Tat	26
24	immunodeficiency	virus	25
25	virus	Tat	26
26	Tat	including	22
27	,	NF-YB	5
28	human	NF-YB	5
29	papillomavirus	human	28
30	E6	human	28
31	,	E6	30
32	and	,	31
33	Bicoid	and	32
34	,	,	31
35	or	,	31
36	with	or	35
37	the	M7	38
38	M7	)	43
39	(	)	43
40	amino	)	43
41	acids	)	43
42	29CP-AS	)	43
43	)	with	36
44	Tax1	)	43
45	mutant	)	43
46	.	NF-YB	5

0	Elf-1	bind	3
1	and	Elf-1	0
2	Stat5	and	1
3	bind	erratum	21
4	to	bind	3
5	a	element	7
6	critical	element	7
7	element	to	4
8	in	bind	3
9	a	enhancer	11
10	new	enhancer	11
11	enhancer	receptor	16
12	of	receptor	16
13	the	receptor	16
14	human	interleukin-2	15
15	interleukin-2	receptor	16
16	receptor	in	8
17	alpha	bind	3
18	gene	bind	3
19	[	bind	3
20	published	erratum	21
21	erratum	appears	22
22	appears	<ROOT>	-1
23	in	appears	22
24	Mol	Cell	25
25	Cell	in	23
26	Biol	1997	27
27	1997	Cell	25
28	Apr	Cell	25
29	;	appears	22
30	17	(	31
31	(	:	34
32	4	(	31
33	)	(	31
34	:	appears	22
35	2351	:	34
36	]	:	34

0	The	transcript	3
1	primary	transcript	3
2	RNA	transcript	3
3	transcript	is	7
4	of	transcript	3
5	the	gene	6
6	gene	of	4
7	is	<ROOT>	-1
8	subject	is	7
9	to	subject	8
10	alternative	splicing	11
11	splicing	to	9
12	to	subject	8
13	yield	to	12
14	different	yield	13
15	variants	different	14
16	which	can	17
17	can	variants	15
18	either	can	17
19	activate	can	17
20	or	activate	19
21	repress	or	20
22	gene	repress	21
23	expression	.	24
24	.	repress	21

0	Immediate	are	7
1	early	Immediate	0
2	and	early	1
3	early	proteins	6
4	lytic	proteins	6
5	cycle	proteins	6
6	proteins	and	2
7	are	<ROOT>	-1
8	frequent	targets	9
9	targets	are	7
10	of	virus-induced	13
11	the	virus-induced	13
12	Epstein-Barr	virus-induced	13
13	virus-induced	targets	9
14	cytotoxic	T	15
15	T	are	7
16	cell	T	15
17	response	are	7
18	.	are	7

0	This	lysate	1
1	lysate	was	2
2	was	<ROOT>	-1
3	also	was	2
4	necessary	was	2
5	for	was	2
6	ER	for	5
7	to	ER	6
8	diminish	to	7
9	the	activity	11
10	DNA-binding	activity	11
11	activity	diminish	8
12	of	activity	11
13	GATA-1	of	12
14	.	was	2

0	We	show	1
1	show	<ROOT>	-1
2	that	show	1
3	the	translocation	6
4	constitutive	translocation	6
5	nuclear	translocation	6
6	translocation	that	2
7	of	translocation	6
8	NF-ATp	of	7
9	,	NF-ATp	8
10	a	member	11
11	member	NF-ATp	8
12	of	growing	14
13	the	growing	14
14	growing	member	11
15	family	growing	14
16	of	family	15
17	NF-AT	factors	18
18	factors	of	16
19	,	is	20
20	is	of	16
21	a	hallmark	22
22	hallmark	is	20
23	of	B	25
24	nonstimulated	B	25
25	B	hallmark	22
26	cells	show	1
27	from	show	1
28	CLL	show	1
29	patients	show	1
30	that	patients	29
31	distinguishes	that	30
32	B-CLL	distinguishes	31
33	cells	'	35
34	from	'	35
35	'	B-CLL	32
36	normal	'	35
37	'	B-CLL	32
38	B	lymphocytes	39
39	lymphocytes	'	37
40	.	show	1

0	Human	protein	4
1	myeloid	protein	4
2	zinc	protein	4
3	finger	protein	4
4	protein	is	8
5	(	protein	4
6	MZF-1	protein	4
7	)	protein	4
8	is	<ROOT>	-1
9	a	factor	12
10	putative	factor	12
11	transcription	factor	12
12	factor	is	8
13	containing	fingers	16
14	13	fingers	16
15	zinc	fingers	16
16	fingers	factor	12
17	,	factor	12
18	and	factor	12
19	has	and	18
20	been	has	19
21	suggested	has	19
22	that	suggested	21
23	it	regulates	24
24	regulates	that	22
25	the	development	26
26	development	regulates	24
27	of	development	26
28	neutrophilic	of	27
29	granulocytes	neutrophilic	28
30	.	granulocytes	29

0	The	exception	2
1	only	exception	2
2	exception	was	3
3	was	<ROOT>	-1
4	hydrogen	peroxide	5
5	peroxide	was	3
6	at	peroxide	5
7	20	at	6
8	microM	,	9
9	,	20	7
10	which	did	11
11	did	,	9
12	not	did	11
13	induce	catalase	14
14	catalase	did	11
15	activity	did	11
16	.	was	3

0	Its	has	6
1	normal	c-myb	4
2	cellular	c-myb	4
3	equivalent	c-myb	4
4	c-myb	Its	0
5	,	Its	0
6	has	<ROOT>	-1
7	been	has	6
8	shown	been	7
9	to	shown	8
10	promote	to	9
11	the	proliferation	12
12	proliferation	promote	10
13	and	proliferation	12
14	block	the	15
15	the	and	13
16	differentiation	the	15
17	of	differentiation	16
18	haematopoietic	of	17
19	cells	in	20
20	in	haematopoietic	18
21	several	in	20
22	experimental	models	23
23	models	several	21
24	and	models	23
25	is	and	24
26	required	fetal	28
27	for	fetal	28
28	fetal	is	25
29	haematopoiesis	is	25
30	.	has	6

0	In	complexes	14
1	unstimulated	In	0
2	THP-1	In	0
3	,	In	0
4	CRE-binding	protein	5
5	protein	In	0
6	and	protein	5
7	,	In	0
8	to	In	0
9	a	lesser	10
10	lesser	to	8
11	extent	to	8
12	,	In	0
13	c-Jun	complexes	14
14	complexes	were	15
15	were	<ROOT>	-1
16	found	were	15
17	to	found	16
18	bind	to	17
19	to	bind	18
20	the	site	22
21	CRE	site	22
22	site	to	19
23	.	site	22

0	Acetylsalicylic	acid	1
1	acid	inhibit	5
2	and	acid	1
3	sodium	salicylate	4
4	salicylate	and	2
5	inhibit	<ROOT>	-1
6	LPS-induced	translocation	10
7	NF-kappa	B/c-Rel	8
8	B/c-Rel	translocation	10
9	nuclear	translocation	10
10	translocation	inhibit	5
11	,	inhibit	5
12	and	inhibit	5
13	synthesis	and	12
14	of	inhibit	5
15	tissue	factor	16
16	factor	inhibit	5
17	(	factor	16
18	TF	inhibit	5
19	)	inhibit	5
20	and	inhibit	5
21	tumor	factor	23
22	necrosis	factor	23
23	factor	and	20
24	alfa	inhibit	5
25	(	TNF-alpha	26
26	TNF-alpha	alfa	24
27	)	TNF-alpha	26
28	in	human	29
29	human	alfa	24
30	monocytes	inhibit	5
31	.	inhibit	5

0	Findings	<ROOT>	-1
1	that	Findings	0
2	xenogeneic	serum	3
3	serum	promotes	4
4	promotes	leukocyte-endothelium	5
5	leukocyte-endothelium	that	1
6	interaction	leukocyte-endothelium	5
7	possibly	interaction	6
8	through	interaction	6
9	NF-kappa	B	10
10	B	might	12
11	activation	B	10
12	might	leukocyte-endothelium	5
13	be	might	12
14	relevant	be	13
15	for	be	13
16	designing	for	15
17	future	designing	16
18	therapeutic	strategies	19
19	strategies	future	17
20	aimed	strategies	19
21	at	xenograft	23
22	prolonging	xenograft	23
23	xenograft	aimed	20
24	survival	xenograft	23
25	.	Findings	0

0	Zinc	is	1
1	is	<ROOT>	-1
2	an	element	5
3	important	element	5
4	trace	element	5
5	element	is	1
6	for	element	5
7	immune	function	8
8	function	for	6
9	.	is	1

0	The	gene	3
1	human	gene	3
2	PAX-5	gene	3
3	gene	was	4
4	was	<ROOT>	-1
5	recently	was	4
6	shown	was	4
7	to	shown	6
8	participate	to	7
9	together	shown	6
10	with	shown	6
11	the	locus	13
12	IgH	locus	13
13	locus	with	10
14	in	chromosomal	16
15	the	chromosomal	16
16	chromosomal	shown	6
17	translocation	t-LRB-9;14-RRB--LRB-p13;q32-RRB-	18
18	t-LRB-9;14-RRB--LRB-p13;q32-RRB-	was	4
19	.	was	4

0	The	work	1
1	work	suggests	3
2	strongly	suggests	3
3	suggests	<ROOT>	-1
4	that	suggests	3
5	EBV-replicative	lesions	6
6	lesions	are	7
7	are	that	4
8	subject	are	7
9	to	subject	8
10	direct	control	12
11	CTL	control	12
12	control	to	9
13	in	subject	8
14	vivo	suggests	3
15	and	vivo	14
16	that	and	15
17	immediate	early	18
18	early	are	22
19	and	early	18
20	early	proteins	21
21	proteins	and	19
22	are	that	16
23	frequently	are	22
24	the	targets	26
25	immunodominant	targets	26
26	targets	are	22
27	.	suggests	3

0	RelB	protein	1
1	protein	<ROOT>	-1
2	and	protein	1
3	mRNA	were	4
4	were	and	2
5	detected	were	4
6	constitutively	detected	5
7	in	detected	5
8	lymphocytes	in	7
9	and	in	7
10	in	activated	11
11	activated	and	9
12	monocytes	protein	1
13	,	protein	1
14	differentiated	protein	1
15	DC	protein	1
16	,	protein	1
17	and	monocyte-derived	18
18	monocyte-derived	protein	1
19	DC	protein	1
20	.	protein	1

0	Macrophages	<ROOT>	-1
1	in	Macrophages	0
2	human	:	6
3	atheroma	:	6
4	contain	atheroma	3
5	PPARgamma	:	6
6	:	in	1
7	differentiation-dependent	)	14
8	peroxisomal	)	14
9	proliferator-activated	)	14
10	receptor	)	14
11	gamma	)	14
12	(	)	14
13	PPARgamma	)	14
14	)	Macrophages	0
15	expression	Macrophages	0
16	and	Macrophages	0
17	reduction	and	16
18	of	Macrophages	0
19	MMP-9	Macrophages	0
20	activity	Macrophages	0
21	through	activity	20
22	PPARgamma	activation	23
23	activation	Macrophages	0
24	in	activation	23
25	mononuclear	phagocytes	26
26	phagocytes	in	24
27	in	activation	23
28	vitro	in	27
29	.	Macrophages	0

0	We	show	2
1	also	show	2
2	show	<ROOT>	-1
3	that	show	2
4	calcineurin	associated	5
5	associated	that	3
6	with	associated	5
7	the	domain	9
8	N-terminal	domain	9
9	domain	with	6
10	of	domain	9
11	NFATx1	of	10
12	at	associated	5
13	multiple	sites	15
14	docking	sites	15
15	sites	at	12
16	and	associated	5
17	caused	and	16
18	a	reduction	19
19	reduction	caused	17
20	of	reduction	19
21	size	of	20
22	,	show	2
23	indicative	show	2
24	of	indicative	23
25	dephosphorylation	show	2
26	,	show	2
27	in	show	2
28	NFATx1	in	27
29	.	show	2

0	By	was	10
1	using	By	0
2	several	using	1
3	HBD	several	2
4	subfragments	HBD	3
5	,	subfragments	4
6	the	subfragments	4
7	mAb	epitope	9
8	18C7	epitope	9
9	epitope	the	6
10	was	<ROOT>	-1
11	located	was	10
12	in	located	11
13	the	region	15
14	N-terminal	region	15
15	region	in	12
16	of	region	15
17	the	HBD	18
18	HBD	of	16
19	from	region	15
20	Thr729	from	19
21	to	located	11
22	Leu765	to	21
23	.	was	10

0	Induction	<ROOT>	-1
1	of	Induction	0
2	IL-5	mRNA	3
3	mRNA	of	1
4	upon	Induction	0
5	TCR	was	9
6	and	TCR	5
7	IL-2R	stimulation	8
8	stimulation	and	6
9	was	upon	4
10	totally	inhibited	11
11	inhibited	by	12
12	by	was	9
13	dexamethasone	was	9
14	.	Induction	0

0	Here	<ROOT>	-1
1	we	summarize	2
2	summarize	Here	0
3	studies	summarize	2
4	which	studies	3
5	investigate	which	4
6	the	mechanism	7
7	mechanism	investigate	5
8	by	investigate	5
9	which	by	8
10	these	cytokines	11
11	cytokines	by	8
12	selectively	cytokines	11
13	reprogramme	selectively	12
14	gene	reprogramme	13
15	expression	gene	14
16	in	expression	15
17	T-lymphocytes	in	16
18	.	Here	0

0	The	development	1
1	development	<ROOT>	-1
2	of	development	1
3	resistance	of	2
4	to	resistance	3
5	host	mechanisms	7
6	defense	mechanisms	7
7	mechanisms	to	4
8	such	as	9
9	as	factor	12
10	tumor	factor	12
11	necrosis	factor	12
12	factor	mechanisms	7
13	(	TNF	14
14	TNF	mechanisms	7
15	)	TNF	14
16	-	to	4
17	and	to	4
18	Fas-mediated	to	4
19	apoptosis	development	1
20	of	apoptosis	19
21	transformed	of	20
22	or	transformed	21
23	virus-infected	or	22
24	cells	may	25
25	may	virus-infected	23
26	be	transformed	21
27	a	of	20
28	critical	a	27
29	component	critical	28
30	in	component	29
31	the	development	32
32	development	in	30
33	of	development	32
34	disease	of	33
35	.	development	1

0	Acute	exposure	2
1	ethanol	exposure	2
2	exposure	has	3
3	has	<ROOT>	-1
4	the	capacity	5
5	capacity	has	3
6	to	capacity	5
7	modulate	to	6
8	immune	functions	9
9	functions	modulate	7
10	,	has	3
11	particularly	to	13
12	,	to	13
13	to	has	3
14	down	regulate	15
15	regulate	to	13
16	monocyte	regulate	15
17	production	monocyte	16
18	of	production	17
19	inflammatory	cytokines	20
20	cytokines	of	18
21	.	has	3

0	Increased	TF	2
1	monocyte	TF	2
2	TF	was	7
3	expression	TF	2
4	in	transplant	5
5	transplant	expression	3
6	recipients	TF	2
7	was	induction	19
8	shown	was	7
9	to	shown	8
10	be	to	9
11	adversely	be	10
12	affected	adversely	11
13	by	affected	12
14	treatment	by	13
15	with	treatment	14
16	CsA	with	15
17	:	CsA	16
18	TF	affected	12
19	induction	was	20
20	was	<ROOT>	-1
21	markedly	was	20
22	reduced	markedly	21
23	by	reduced	22
24	CsA	by	23
25	serum	concentrations	26
26	concentrations	CsA	24
27	reaching	concentrations	26
28	peak	levels	31
29	CsA	levels	31
30	drug	levels	31
31	levels	reaching	27
32	.	was	20

0	The	<ROOT>	-1
1	possible	The	0
2	clinical	possible	1
3	use	clinical	2
4	of	use	3
5	the	derivative	8
6	methyl	derivative	8
7	xanthine	derivative	8
8	derivative	of	4
9	,	clinical	2
10	pentoxifylline	clinical	2
11	(	PF	12
12	PF	pentoxifylline	10
13	)	PF	12
14	,	pentoxifylline	10
15	for	pentoxifylline	10
16	the	treatment	17
17	treatment	for	15
18	of	treatment	17
19	T	diseases	21
20	cell-dependent	diseases	21
21	diseases	of	18
22	is	The	0
23	being	with	25
24	noted	being	23
25	with	The	0
26	increasing	with	25
27	interest	increasing	26
28	.	The	0

0	Regions	suggest	13
1	of	Regions	0
2	low	potential	3
3	potential	of	1
4	in	potential	3
5	a	potential	3
6	68.5-kb	containing	9
7	genomic	containing	9
8	segment	containing	9
9	containing	a	5
10	the	gene	12
11	FOSB	gene	12
12	gene	containing	9
13	suggest	<ROOT>	-1
14	that	suggest	13
15	the	potential	16
16	potential	may	17
17	may	that	14
18	help	may	17
19	locate	genes	20
20	genes	help	18
21	in	DNA	23
22	uncharted	DNA	23
23	DNA	genes	20
24	sequences	suggest	13
25	.	suggest	13

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	macrophage	4
4	macrophage	suggest	2
5	differentiation	macrophage	4
6	results	differentiation	5
7	in	results	6
8	the	expression	9
9	expression	in	7
10	of	p50/RelA	12
11	active	of	10
12	p50/RelA	expression	9
13	(	results	6
14	p65	)	15
15	)	macrophage	4
16	heterodimers	suggest	2
17	with	heterodimers	16
18	the	capacity	19
19	capacity	with	17
20	to	capacity	19
21	activate	to	20
22	target	activate	21
23	gene	target	22
24	expression	.	25
25	.	gene	23

0	Ara-C	<ROOT>	-1
1	activated	Ara-C	0
2	JNKs	activated	1
3	only	after	4
4	after	JNKs	2
5	prolonged	incubation	6
6	incubation	after	4
7	(	incubation	6
8	90-120	(	7
9	minutes	90-120	8
10	)	minutes	9
11	.	)	10

0	Further	optimization	1
1	optimization	<ROOT>	-1
2	of	optimization	1
3	culture	conditions	4
4	conditions	of	2
5	,	optimization	1
6	type	,	5
7	of	type	6
8	Antigen	Cells	10
9	Presenting	Cells	10
10	Cells	of	7
11	(	APC	12
12	APC	Cells	10
13	)	APC	12
14	,	type	6
15	peptides	optimization	1
16	,	optimization	1
17	use	,	16
18	of	use	17
19	stabilizers	of	18
20	like	stabilizers	19
21	beta	like	20
22	2-m	are	23
23	are	beta	21
24	still	are	23
25	needed	of	18
26	.	optimization	1

0	The	pigment	1
1	pigment	inhibited	3
2	also	inhibited	3
3	inhibited	morphological	22
4	apoptosis	in	5
5	in	inhibited	3
6	dexamethasone-treated	rat	7
7	rat	inhibited	3
8	thymocytes	inhibited	3
9	and	thymocytes	8
10	in	Jurkat	12
11	UV-irradiated	Jurkat	12
12	Jurkat	and	9
13	cells	inhibited	3
14	as	inhibited	3
15	judged	inhibited	3
16	by	judged	15
17	DNA	formation	19
18	ladder	formation	19
19	formation	by	16
20	,	morphological	22
21	cellular	morphological	22
22	morphological	<ROOT>	-1
23	changes	morphological	22
24	,	changes	23
25	and	flow	26
26	flow	changes	23
27	cytometry	flow	26
28	analysis	.	29
29	.	cytometry	27

0	A	factor	3
1	novel	factor	3
2	transcription	factor	3
3	factor	regulates	4
4	regulates	<ROOT>	-1
5	expression	regulates	4
6	of	expression	5
7	the	subunit	11
8	vacuolar	subunit	11
9	H+-ATPase	subunit	11
10	B2	subunit	11
11	subunit	of	6
12	through	of	6
13	AP-2	sites	14
14	sites	through	12
15	during	monocytic	16
16	monocytic	of	6
17	differentiation	regulates	4
18	.	regulates	4

0	Recent	evidence	1
1	evidence	has	2
2	has	<ROOT>	-1
3	implicated	has	2
4	components	implicated	3
5	of	components	4
6	the	system	8
7	immune	system	8
8	system	of	5
9	in	implicated	3
10	the	pathogenesis	11
11	pathogenesis	in	9
12	of	pathogenesis	11
13	endometriosis	of	12
14	.	has	2

0	Electrophoretic	analysis	4
1	mobility	analysis	4
2	shift	analysis	4
3	assay	analysis	4
4	analysis	suggested	5
5	suggested	<ROOT>	-1
6	that	suggested	5
7	AP-1	and	8
8	and	are	10
9	NF-kappaB	and	8
10	are	that	6
11	among	are	10
12	the	among	11
13	possible	the	12
14	targets	GC	16
15	of	GC	16
16	GC	possible	13
17	actions	the	12
18	on	T	20
19	TCR-stimulated	T	20
20	T	actions	17
21	cells	suggested	5
22	.	suggested	5

0	Freshly	<ROOT>	-1
1	isolated	Freshly	0
2	cells	show	3
3	show	high	4
4	high	isolated	1
5	levels	high	4
6	of	levels	5
7	FOSB/G0S3	of	6
8	and	FOSB/G0S3	7
9	FOS/G0S7	mRNAs	10
10	mRNAs	and	8
11	,	decline	13
12	which	decline	13
13	decline	isolated	1
14	rapidly	decline	13
15	during	decline	13
16	incubation	during	15
17	in	incubation	16
18	culture	in	17
19	medium	.	20
20	.	culture	18

0	LPS	stimulation	1
1	stimulation	increased	2
2	increased	<ROOT>	-1
3	the	binding	4
4	binding	increased	2
5	of	binding	4
6	c-Jun-containing	.	8
7	complexes	.	8
8	.	of	5

0	The	gene	2
1	NGAL	gene	2
2	gene	is	3
3	is	<ROOT>	-1
4	highly	homologous	5
5	homologous	is	3
6	to	homologous	5
7	the	24p3	10
8	mouse	24p3	10
9	gene	24p3	10
10	24p3	to	6
11	.	is	3

0	The	family	2
1	myb	family	2
2	family	has	6
3	of	family	2
4	transcription	factors	5
5	factors	of	3
6	has	<ROOT>	-1
7	been	has	6
8	strongly	implicated	9
9	implicated	been	7
10	in	implicated	9
11	the	regulation	12
12	regulation	implicated	9
13	of	regulation	12
14	cell	growth	15
15	growth	of	13
16	and	has	6
17	differentiation	in	18
18	in	has	6
19	the	in	18
20	haematopoietic	.	22
21	system	.	22
22	.	the	19

0	Using	was	14
1	TNF-alpha-activity	neutralizing	2
2	neutralizing	antibodies	3
3	antibodies	Using	0
4	,	Using	0
5	the	demonstrated	7
6	authors	demonstrated	7
7	demonstrated	,	4
8	that	demonstrated	7
9	the	upregulation	10
10	upregulation	that	8
11	of	NF-kappa	12
12	NF-kappa	upregulation	10
13	B	Using	0
14	was	<ROOT>	-1
15	found	was	14
16	to	found	15
17	depend	to	16
18	,	depend	17
19	at	time	21
20	later	time	21
21	time	point	22
22	point	depend	17
23	,	point	22
24	on	autocrine	26
25	an	autocrine	26
26	autocrine	point	22
27	effect	autocrine	26
28	of	effect	27
29	TNF-alpha	was	14
30	secreted	was	14
31	following	triggering	32
32	triggering	was	14
33	of	HLA-DR	34
34	HLA-DR	was	14
35	antigens	was	14
36	.	was	14

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	Dose-dependent	inhibition	3
3	inhibition	was	4
4	was	RESULTS	0
5	demonstrated	was	4
6	for	demonstrated	5
7	all	for	6
8	glucocorticoids	in	9
9	in	all	7
10	both	in	9
11	patient	in	9
12	groups	patient	11
13	,	groups	12
14	with	groups	12
15	the	group	17
16	steroid-resistant	group	17
17	group	with	14
18	requiring	approximately	19
19	approximately	groups	12
20	2	log-fold	21
21	log-fold	approximately	19
22	more	log-fold	21
23	glucocorticoids	more	22
24	for	more	22
25	an	equivalent	26
26	equivalent	for	24
27	degree	of	28
28	of	equivalent	26
29	inhibition	equivalent	26
30	.	RESULTS	0

0	Alcohol-induced	regulation	1
1	regulation	regulatory	4
2	of	regulatory	4
3	nuclear	regulatory	4
4	regulatory	<ROOT>	-1
5	factor-kappa	regulatory	4
6	beta	human	8
7	in	human	8
8	human	regulatory	4
9	monocytes	regulatory	4
10	.	regulatory	4

0	CD40-stimulated	B	2
1	human	B	2
2	B	lymphocytes	3
3	lymphocytes	<ROOT>	-1
4	are	lymphocytes	3
5	highly	permissive	6
6	permissive	are	4
7	to	permissive	6
8	a	infection	10
9	productive	infection	10
10	infection	virus	15
11	by	virus	15
12	the	virus	15
13	human	virus	15
14	immunodeficiency	virus	15
15	virus	to	7
16	type	lymphocytes	3
17	1	lymphocytes	3
18	.	lymphocytes	3

0	This	response	2
1	indirect	response	2
2	response	is	3
3	is	<ROOT>	-1
4	mediated	is	3
5	by	mediated	4
6	other	viral	7
7	viral	by	5
8	or	virally	9
9	virally	viral	7
10	induced	virally	9
11	activities	is	3
12	downstream	of	13
13	of	is	3
14	ZEBRA	of	13
15	in	of	13
16	the	in	15
17	lytic	.	19
18	cascade	.	19
19	.	the	16

0	Here	demonstrate	2
1	we	demonstrate	2
2	demonstrate	GAS	6
3	that	GAS	6
4	the	putative	5
5	putative	GAS	6
6	GAS	<ROOT>	-1
7	element	in	8
8	in	GAS	6
9	the	LTR	11
10	CAEV	LTR	11
11	LTR	in	8
12	binds	in	8
13	specifically	in	8
14	to	specifically	13
15	a	factor	17
16	cellular	factor	17
17	factor	to	14
18	induced	to	14
19	by	IFN-gamma	20
20	IFN-gamma	induced	18
21	in	promonocytic	22
22	promonocytic	induced	18
23	cells	GAS	6
24	.	GAS	6

0	Porcine	antigens	4
1	MHC	antigens	4
2	class	antigens	4
3	II	antigens	4
4	antigens	are	5
5	are	<ROOT>	-1
6	potent	are	5
7	stimulators	potent	6
8	of	stimulators	7
9	direct	recognition	11
10	T-cell	recognition	11
11	recognition	of	8
12	by	T	15
13	human	T	15
14	CD4+	T	15
15	T	potent	6
16	cells	are	5
17	and	are	5
18	are	and	17
19	,	are	18
20	therefore	are	18
21	,	are	18
22	likely	are	18
23	to	likely	22
24	play	to	23
25	an	role	27
26	important	role	27
27	role	play	24
28	in	play	24
29	the	responses	31
30	rejection	responses	31
31	responses	in	28
32	to	responses	31
33	transgenic	donors	35
34	pig	donors	35
35	donors	to	32
36	in	responses	31
37	clinical	xenotransplantation	38
38	xenotransplantation	in	36
39	.	are	5

0	In	<ROOT>	-1
1	the	majority	2
2	majority	In	0
3	of	majority	2
4	cell	of	3
5	lines	the	8
6	studied	the	8
7	,	studied	6
8	the	cell	4
9	regulation	was	13
10	of	regulation	9
11	ferritin	expression	12
12	expression	of	10
13	was	the	8
14	exerted	was	13
15	mostly	exerted	14
16	at	translational	18
17	the	translational	18
18	translational	exerted	14
19	level	translational	18
20	.	In	0

0	The	functions	2
1	antiviral	functions	2
2	functions	may	8
3	of	T	6
4	infiltrating	T	6
5	CD4-bearing	T	6
6	T	functions	2
7	cells	functions	2
8	may	lymphokine	17
9	include	may	8
10	cytotoxicity	include	9
11	,	may	8
12	inhibition	may	8
13	of	inhibition	12
14	viral	growth	15
15	growth	of	13
16	,	may	8
17	lymphokine	<ROOT>	-1
18	secretion	lymphokine	17
19	,	secretion	18
20	and	secretion	18
21	support	and	20
22	of	secretion	18
23	humoral	of	22
24	and	secretion	18
25	CD8	responses	26
26	responses	and	24
27	.	lymphokine	17

0	To	have	23
1	further	To	0
2	elucidate	To	0
3	the	role	4
4	role	elucidate	2
5	of	role	4
6	this	motif	9
7	variant	motif	9
8	octamer	motif	9
9	motif	of	5
10	in	the	11
11	the	role	4
12	regulation	the	11
13	of	regulation	12
14	germline	transcription	15
15	transcription	of	13
16	from	unrearranged	18
17	the	unrearranged	18
18	unrearranged	of	13
19	kappa	To	0
20	locus	To	0
21	,	have	23
22	we	have	23
23	have	<ROOT>	-1
24	quantitated	have	23
25	the	affinity	28
26	relative	affinity	28
27	binding	affinity	28
28	affinity	quantitated	24
29	of	affinity	28
30	Oct-1	of	29
31	and	have	23
32	Oct-2	and	31
33	for	and	31
34	the	variant	35
35	variant	for	33
36	octamer	motif	37
37	motif	for	33
38	and	motif	37
39	determined	and	38
40	the	determined	39
41	functional	the	40
42	role	functional	41
43	of	role	42
44	this	motif	46
45	octamer	motif	46
46	motif	of	43
47	in	transcriptional	48
48	transcriptional	role	42
49	activation	the	40
50	.	have	23

0	In	<ROOT>	-1
1	vivo	In	0
2	footprinting	identified	3
3	identified	protected	4
4	protected	vivo	1
5	regions	protected	4
6	over	regions	5
7	the	over	6
8	known	the	7
9	high	protein	15
10	affinity	protein	15
11	B	protein	15
12	cell	protein	15
13	lineage-specific	protein	15
14	activator	protein	15
15	protein	known	8
16	(	BSAP	17
17	BSAP	In	0
18	)	BSAP	17
19	site	BSAP	17
20	,	In	0
21	the	affinity	23
22	low	affinity	23
23	affinity	,	20
24	BSAP	site	25
25	site	affinity	23
26	,	affinity	23
27	a	site	29
28	SP1/Egr-1	site	29
29	site	affinity	23
30	termed	site	29
31	the	termed	30
32	CD19	the	31
33	GC	CD19	32
34	box	PyG	45
35	,	sites	39
36	and	novel	38
37	two	novel	38
38	novel	sites	39
39	sites	box	34
40	named	sites	39
41	the	box	43
42	AT	box	43
43	box	named	40
44	and	box	43
45	PyG	GC	33
46	box	In	0
47	.	In	0

0	There	are	1
1	are	<ROOT>	-1
2	many	hypotheses	3
3	hypotheses	are	1
4	concerning	hypotheses	3
5	the	pathogenesis	6
6	pathogenesis	concerning	4
7	of	pathogenesis	6
8	endometriosis	of	7
9	,	are	1
10	though	are	1
11	no	theory	13
12	single	theory	13
13	theory	can	14
14	can	though	10
15	explain	can	14
16	all	cases	17
17	cases	explain	15
18	.	are	1

0	ZEBRA	domain	2
1	activation	domain	2
2	domain	constructs	4
3	swap	constructs	4
4	constructs	<ROOT>	-1
5	retain	constructs	4
6	ZEBRA	abilities	9
7	's	ZEBRA	6
8	native	abilities	9
9	abilities	retain	5
10	to	constructs	4
11	activate	to	10
12	specific	promoters	14
13	EBV	promoters	14
14	promoters	activate	11
15	,	constructs	4
16	to	constructs	4
17	disrupt	to	16
18	EBV	disrupt	17
19	latency	EBV	18
20	,	latency	19
21	and	,	20
22	to	stimulate	23
23	stimulate	and	21
24	replication	constructs	4
25	at	constructs	4
26	the	at	25
27	EBV	the	26
28	lytic	EBV	27
29	origin	lytic	28
30	.	origin	29

0	The	match	2
1	closest	match	2
2	match	consensus	7
3	to	consensus	7
4	the	consensus	7
5	known	consensus	7
6	SP-1	consensus	7
7	consensus	is	13
8	sequence	within	9
9	within	consensus	7
10	the	region	12
11	respective	region	12
12	region	within	9
13	is	<ROOT>	-1
14	a	motif	16
15	TCCCCTCCCCT	motif	16
16	motif	is	13
17	.	is	13

0	Genes	<ROOT>	-1
1	that	regulate	2
2	regulate	Genes	0
3	interleukin-4	expression	4
4	expression	Genes	0
5	in	T	6
6	T	Genes	0
7	cells	Genes	0
8	.	Genes	0

0	Northern	analyses	1
1	analyses	showed	2
2	showed	<ROOT>	-1
3	similar	levels	4
4	levels	showed	2
5	of	levels	4
6	two	transcripts	8
7	elf-2	transcripts	8
8	transcripts	of	5
9	(	kb	11
10	3.5	kb	11
11	kb	transcripts	8
12	and	kb	11
13	3.8	kb	14
14	kb	and	12
15	)	kb	14
16	in	)	15
17	all	)	15
18	tissues	kb	11
19	except	levels	4
20	thymus	showed	2
21	.	showed	2

0	Furthermore	was	5
1	,	was	5
2	an	relationship	4
3	inverse	relationship	4
4	relationship	was	5
5	was	<ROOT>	-1
6	also	was	5
7	observed	was	5
8	between	observed	7
9	the	LDL	10
10	LDL	between	8
11	receptor	expression	13
12	gene	expression	13
13	expression	LDL	10
14	at	transcriptional	16
15	the	transcriptional	16
16	transcriptional	observed	7
17	level	observed	7
18	and	binding	20
19	the	binding	20
20	binding	was	5
21	affinity	protein	26
22	of	protein	26
23	this	protein	26
24	47	kDa	25
25	kDa	protein	26
26	protein	was	5
27	factor	protein	26
28	to	factor	27
29	the	SRE	30
30	SRE	to	28
31	sequence	SRE	30
32	.	was	5

0	These	<ROOT>	-1
1	data	These	0
2	strongly	data	1
3	suggest	strongly	2
4	that	suggest	3
5	a	that	4
6	transcriptionally	of	9
7	active	form	8
8	form	of	9
9	of	a	5
10	AML1	of	9
11	is	AML1	10
12	essential	of	9
13	for	essential	12
14	the	cell	16
15	myeloid	cell	16
16	cell	for	13
17	differentiation	cell	16
18	.	differentiation	17

0	These	observations	1
1	observations	suggest	2
2	suggest	<ROOT>	-1
3	the	importance	5
4	functional	importance	5
5	importance	suggest	2
6	of	importance	5
7	gamma-LRB-c-RRB-	of	6
8	in	importance	5
9	the	in	8
10	IL-7R	complex	11
11	complex	the	9
12	.	complex	11

0	Finally	showed	5
1	,	showed	5
2	gel	showed	5
3	shift	showed	5
4	analysis	showed	5
5	showed	<ROOT>	-1
6	synergistic	formation	8
7	complex	formation	8
8	formation	showed	5
9	between	formation	8
10	proteins	between	9
11	that	bind	12
12	bind	formation	8
13	to	X	16
14	the	X	16
15	putative	X	16
16	X	bind	12
17	boxes	X	16
18	of	X	16
19	the	genes	21
20	DM	genes	21
21	genes	of	18
22	,	showed	5
23	as	showed	5
24	is	as	23
25	found	is	24
26	for	found	25
27	the	gene	29
28	DRA	gene	29
29	gene	for	26
30	.	showed	5

0	In	efficient	7
1	combination	In	0
2	,	efficient	7
3	EBF	and	4
4	and	efficient	7
5	E47	efficient	7
6	induce	E47	5
7	efficient	<ROOT>	-1
8	expression	of	9
9	of	efficient	7
10	the	immunoglobulin	12
11	endogenous	immunoglobulin	12
12	immunoglobulin	of	9
13	surrogate	,	17
14	light	,	17
15	chain	,	17
16	genes	,	17
17	,	efficient	7
18	lambda5	efficient	7
19	and	efficient	7
20	VpreB	efficient	7
21	,	efficient	7
22	whereas	efficient	7
23	other	genes	26
24	pre-B	genes	26
25	cell-specific	genes	26
26	genes	remain	27
27	remain	whereas	22
28	silent	remain	27
29	.	efficient	7

0	We	found	1
1	found	were	19
2	that	found	1
3	in	that	2
4	100	%	5
5	%	in	3
6	of	%	5
7	patients	of	6
8	with	patients	7
9	CLL	with	8
10	(	%	5
11	n	(	10
12	=	n	11
13	32	)	14
14	)	=	12
15	,	n	11
16	STAT1	found	1
17	and	found	1
18	STAT3	found	1
19	were	<ROOT>	-1
20	constitutively	phosphorylated	21
21	phosphorylated	on	22
22	on	were	19
23	serine	were	19
24	.	were	19

0	Elf-2	transcription	6
1	,	Elf-2	0
2	a	transcription	6
3	rhombotin-2	binding	4
4	binding	transcription	6
5	ets	transcription	6
6	transcription	<ROOT>	-1
7	factor	transcription	6
8	:	transcription	6
9	discovery	and	10
10	and	transcription	6
11	potential	and	10
12	role	in	13
13	in	T	14
14	T	and	10
15	cell	transcription	6
16	leukemia	transcription	6
17	.	transcription	6

0	IL-4	stimulated	1
1	stimulated	factor-kappaB	3
2	nuclear	factor-kappaB	3
3	factor-kappaB	<ROOT>	-1
4	nuclear	translocation	5
5	translocation	factor-kappaB	3
6	and	translocation	5
7	binding	factor-kappaB	3
8	before	factor-kappaB	3
9	enhancement	before	8
10	of	RNA	12
11	HIV	RNA	12
12	RNA	enhancement	9
13	expression	factor-kappaB	3
14	.	factor-kappaB	3

0	Indirect	suggested	2
1	evidence	Indirect	0
2	suggested	<ROOT>	-1
3	that	suggested	2
4	allele	T	5
5	T	is	6
6	is	that	3
7	less	stable	8
8	stable	is	6
9	than	stable	8
10	allele	t	11
11	t	than	9
12	.	suggested	2

0	The	critical	14
1	genes	The	0
2	encoding	the	3
3	the	factors	8
4	functionally	factors	8
5	related	hepatocyte	6
6	hepatocyte	factors	8
7	nuclear	factors	8
8	factors	genes	1
9	HNF-1alpha	The	0
10	and	HNF-1alpha	9
11	HNF-4alpha	play	12
12	play	and	10
13	a	critical	14
14	critical	<ROOT>	-1
15	role	in	16
16	in	critical	14
17	normal	in	16
18	pancreatic	.	21
19	beta-cell	.	21
20	function	.	21
21	.	normal	17

0	In	produced	7
1	addition	In	0
2	,	produced	7
3	both	heat	4
4	heat	produced	7
5	and	heat	4
6	cadmium	and	5
7	produced	<ROOT>	-1
8	an	increase	9
9	increase	produced	7
10	in	increase	9
11	the	amount	12
12	amount	in	10
13	of	amount	12
14	the	of	13
15	intermediate	the	14
16	filament	intermediate	15
17	protein	filament	16
18	vimentin	,	19
19	,	as	20
20	as	protein	17
21	determined	the	14
22	by	determined	21
23	immunoblot	by	22
24	and	immunoblot	23
25	immunofluorescence	and	24
26	assays	.	27
27	.	immunofluorescence	25

0	MAbs	reacted	4
1	against	MAbs	0
2	the	dUTPase	3
3	dUTPase	against	1
4	reacted	type	22
5	with	reacted	4
6	a	protein	7
7	protein	with	5
8	of	protein	7
9	approximately	kDa	11
10	31	approximately	9
11	kDa	of	8
12	in	protein	7
13	12-O-tetradecanoyl-phorbol-13-acetate	in	12
14	(	12-O-tetradecanoyl-phorbol-13-acetate	13
15	TPA	(	14
16	)	TPA	15
17	-stimulated	B	18
18	B	(	14
19	cells	reacted	4
20	harbouring	reacted	4
21	either	reacted	4
22	type	<ROOT>	-1
23	1	type	22
24	or	1	23
25	type	EBV	27
26	2	type	25
27	EBV	or	24
28	.	type	22

0	We	report	1
1	report	<ROOT>	-1
2	here	report	1
3	that	ectopic	4
4	ectopic	expression	5
5	expression	report	1
6	of	expression	5
7	CIITA	of	6
8	cDNAs	CIITA	7
9	derived	cDNAs	8
10	by	derived	9
11	reverse	reaction	15
12	transcriptase	reaction	15
13	polymerase	reaction	15
14	chain	reaction	15
15	reaction	do	19
16	from	reaction	15
17	clone	from	16
18	13	clone	17
19	do	by	10
20	not	do	19
21	restore	do	19
22	expression	of	23
23	of	restore	21
24	HLA-DQ	of	23
25	in	cell	28
26	another	cell	28
27	CIITA-deficient	cell	28
28	cell	HLA-DQ	24
29	line	by	10
30	,	report	1
31	RJ2.2.5	report	1
32	.	report	1

0	The	ratio	1
1	ratio	was	11
2	of	ratio	1
3	adult	mRNA	5
4	beta-globin/alpha-globin	mRNA	5
5	mRNA	of	2
6	in	ES	9
7	the	ES	9
8	mutant	ES	9
9	ES	ratio	1
10	cells	ratio	1
11	was	<ROOT>	-1
12	1/15	was	11
13	of	1/15	12
14	that	of	13
15	in	ES	17
16	wild-type	ES	17
17	ES	that	14
18	cells	was	11
19	.	was	11

0	GC	efficiently	1
1	efficiently	suppressed	2
2	suppressed	<ROOT>	-1
3	IL-5	synthesis	4
4	synthesis	suppressed	2
5	of	T-cell	6
6	T-cell	synthesis	4
7	clones	suppressed	2
8	activated	suppressed	2
9	via	(	13
10	either	receptor	12
11	T-cell	receptor	12
12	receptor	via	9
13	(	suppressed	2
14	TCR	(	13
15	)	suppressed	2
16	or	suppressed	2
17	IL-2	suppressed	2
18	receptor	(	19
19	(	suppressed	2
20	IL-2R	suppressed	2
21	)	suppressed	2
22	.	suppressed	2

0	Taken	could	21
1	together	Taken	0
2	,	Taken	0
3	these	,	2
4	findings	strongly	5
5	strongly	that	7
6	suggest	that	7
7	that	these	3
8	SR-BP	that	7
9	represents	the	10
10	the	target	12
11	molecular	target	12
12	target	SR-BP	8
13	for	SR	14
14	SR	target	12
15	31747A	Taken	0
16	in	Taken	0
17	mammalian	in	16
18	tissues	Taken	0
19	,	could	21
20	which	could	21
21	could	<ROOT>	-1
22	be	could	21
23	critical	be	22
24	for	cell	26
25	T	cell	26
26	cell	be	22
27	proliferation	could	21
28	.	could	21

0	Among	<ROOT>	-1
1	these	sequences	2
2	sequences	Among	0
3	we	identified	5
4	have	identified	5
5	identified	Among	0
6	the	alpha-tubulin	7
7	alpha-tubulin	identified	5
8	,	protein	11
9	the	protein	11
10	TaxREB	protein	11
11	protein	identified	5
12	and	protein	15
13	two	protein	15
14	ribosomal	protein	15
15	protein	identified	5
16	sequences	Among	0
17	which	had	18
18	had	sequences	16
19	not	had	18
20	been	had	18
21	previously	described	22
22	described	been	20
23	as	described	22
24	differentially	expressed	25
25	expressed	as	23
26	.	expressed	25

0	Jurkat	T	1
1	T	cells	2
2	cells	were	3
3	were	stably	4
4	stably	<ROOT>	-1
5	transfected	stably	4
6	with	transfected	5
7	a	with	6
8	single	a	7
9	vector	single	8
10	encoding	vector	9
11	the	encoding	10
12	tetracycline	the	11
13	trans-activator	tetracycline	12
14	protein	trans-activator	13
15	,	protein	14
16	controlled	,	15
17	by	controlled	16
18	a	promoter	20
19	constitutive	promoter	20
20	promoter	by	17
21	,	by	17
22	and	,	21
23	the	and	22
24	chimeric	the	23
25	TCR	chimeric	24
26	,	TCR	25
27	under	,	26
28	the	under	27
29	control	the	28
30	of	control	29
31	a	of	30
32	trans-activator	a	31
33	protein-responsive	.	35
34	promoter	.	35
35	.	trans-activator	32

0	The	presence	1
1	presence	did	4
2	of	presence	1
3	variants	of	2
4	did	<ROOT>	-1
5	not	did	4
6	correlate	did	4
7	with	correlate	6
8	disease	activity	9
9	activity	with	7
10	or	activity	9
11	medication	or	10
12	.	did	4

0	Our	results	1
1	results	seem	2
2	seem	<ROOT>	-1
3	to	seem	2
4	confirm	to	3
5	a	confirm	4
6	possible	a	5
7	role	possible	6
8	of	role	7
9	the	of	8
10	transcriptional	the	9
11	complex	transcriptional	10
12	AP-1	complex	11
13	in	AP-1	12
14	activating	AP-1	12
15	GST-pi	seem	2
16	promoter	in	17
17	in	seem	2
18	human	seem	2
19	plasma	seem	2
20	cells	seem	2
21	.	seem	2

0	Purified	T	4
1	quiescent	human	2
2	human	Purified	0
3	blood	T	4
4	T	were	6
5	lymphocytes	T	4
6	were	<ROOT>	-1
7	subjected	were	6
8	to	subjected	7
9	:	to	8
10	(	exposure	14
11	i	)	12
12	)	exposure	14
13	acute	)	12
14	exposure	to	8
15	to	exposure	14
16	hydrogen	exposure	14
17	peroxide	exposure	14
18	;	exposure	14
19	(	ii	20
20	ii	exposure	23
21	)	ii	20
22	chronic	exposure	23
23	exposure	exposure	14
24	to	hydrogen	25
25	hydrogen	exposure	23
26	peroxide	hydrogen	25
27	;	peroxide	26
28	and	peroxide	26
29	(	iii	30
30	iii	and	28
31	)	iii	30
32	acute	were	6
33	exposure	were	6
34	to	ionizing	35
35	ionizing	exposure	33
36	radiation	were	6
37	.	were	6

0	These	<ROOT>	-1
1	data	These	0
2	are	the	3
3	the	data	1
4	first	of	6
5	demonstration	of	6
6	of	the	3
7	a	of	6
8	role	a	7
9	for	role	8
10	a	for	9
11	STAT	a	10
12	family	STAT	11
13	member	family	12
14	in	the	15
15	the	member	13
16	regulation	of	17
17	of	the	15
18	a	promoter	20
19	viral	promoter	20
20	promoter	of	17
21	.	These	0

0	There	was	1
1	was	<ROOT>	-1
2	no	competition	3
3	competition	was	1
4	between	competition	3
5	TPO	between	4
6	and	TPO	5
7	EPO	and	6
8	for	competition	3
9	binding	for	8
10	to	binding	9
11	EPO	receptor	12
12	receptor	to	10
13	.	was	1

0	On	observed	5
1	several	occasions	2
2	occasions	On	0
3	we	observed	5
4	have	observed	5
5	observed	<ROOT>	-1
6	retrovirus-like	particles	7
7	particles	observed	5
8	(	RVLPs	9
9	RVLPs	particles	7
10	)	RVLPs	9
11	by	observed	5
12	transmission	microscopy	14
13	electron	microscopy	14
14	microscopy	by	11
15	(	EM	16
16	EM	microscopy	14
17	)	EM	16
18	of	microscopy	14
19	cultured	of	18
20	T	observed	5
21	cells	observed	5
22	from	a	23
23	a	observed	5
24	patient	observed	5
25	with	patient	24
26	MS	observed	5
27	.	observed	5

0	The	concentration	1
1	concentration	was	14
2	of	concentration	1
3	the	VDR	4
4	VDR	of	2
5	mRNA	VDR	4
6	,	concentration	1
7	corrected	concentration	1
8	for	corrected	7
9	the	number	10
10	number	for	8
11	of	number	10
12	monocytes	of	11
13	,	concentration	1
14	was	<ROOT>	-1
15	similar	was	14
16	among	similar	15
17	the	groups	20
18	three	groups	20
19	genotype	groups	20
20	groups	among	16
21	,	was	14
22	as	was	14
23	were	as	22
24	the	were	23
25	other	examined	27
26	variables	examined	27
27	examined	:	28
28	:	the	24
29	serum	calcitriol	30
30	calcitriol	was	14
31	,	calcitriol	30
32	serum	osteocalcin	33
33	osteocalcin	calcitriol	30
34	,	osteocalcin	33
35	and	osteocalcin	33
36	vertebral	and	35
37	and	vertebral	36
38	hip	density	40
39	bone	density	40
40	density	and	37
41	.	was	14

0	Our	studies	1
1	studies	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	transcriptional	synergy	5
5	synergy	that	3
6	mediated	by	7
7	by	synergy	5
8	activation	both	10
9	of	both	10
10	both	indicate	2
11	Egr-1	indicate	2
12	and	indicate	2
13	NF-kappa	indicate	2
14	B	indicate	2
15	may	indicate	2
16	have	indicate	2
17	important	ramifications	18
18	ramifications	have	16
19	in	T	20
20	T	have	16
21	cell	indicate	2
22	development	indicate	2
23	by	development	22
24	upregulating	NF-kappa	25
25	NF-kappa	B1	26
26	B1	by	23
27	gene	B1	26
28	expression	.	29
29	.	gene	27

0	Whether	is	16
1	the	putative	2
2	putative	have	10
3	new	retrovirus	4
4	retrovirus	putative	2
5	(	es	6
6	es	retrovirus	4
7	)	es	6
8	and	putative	2
9	EBV	and	8
10	have	Whether	0
11	any	relationship	13
12	causal	relationship	13
13	relationship	have	10
14	to	relationship	13
15	MS	to	14
16	is	<ROOT>	-1
17	still	is	16
18	not	is	16
19	known	is	16
20	,	is	16
21	but	is	16
22	the	findings	23
23	findings	support	24
24	support	but	21
25	this	possibility	26
26	possibility	support	24
27	.	is	16

0	We	conclude	1
1	conclude	<ROOT>	-1
2	that	conclude	1
3	interactions	are	8
4	between	interactions	3
5	TAFII32	between	4
6	and	TAFII32	5
7	CIITA	and	6
8	are	that	2
9	responsible	for	10
10	for	are	8
11	activation	conclude	1
12	of	II	14
13	class	II	14
14	II	activation	11
15	genes	conclude	1
16	.	conclude	1

0	In	<ROOT>	-1
1	contrast	In	0
2	,	stimuli	3
3	stimuli	In	0
4	such	as	5
5	as	stimuli	3
6	hyperosmotic	shock	7
7	shock	as	5
8	or	phosphatase	9
9	phosphatase	shock	7
10	inhibitors	In	0
11	,	which	12
12	which	In	0
13	use	which	12
14	PDTC-insensitive	pathways	15
15	pathways	use	13
16	,	pathways	15
17	induce	I	18
18	I	pathways	15
19	kappaB	alpha	20
20	alpha	I	18
21	degradation	pathways	15
22	in	degradation	21
23	1.3E2	in	22
24	.	In	0

0	Control	NF-kappa	2
1	of	NF-kappa	2
2	NF-kappa	<ROOT>	-1
3	B	NF-kappa	2
4	activity	NF-kappa	2
5	by	NF-kappa	2
6	the	by	5
7	I	B	9
8	kappa	I	7
9	B	beta	10
10	beta	the	6
11	inhibitor	the	6
12	.	NF-kappa	2

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	we	In	0
4	examined	we	3
5	the	basis	6
6	basis	examined	4
7	of	basis	6
8	activation	of	7
9	of	basis	6
10	monocytes	of	9
11	during	examined	4
12	active	tuberculosis	13
13	tuberculosis	during	11
14	and	tuberculosis	13
15	by	tuberculosis	13
16	M.	tuberculosis	17
17	tuberculosis	by	15
18	.	In	0

0	HIV	infection	1
1	infection	is	2
2	is	<ROOT>	-1
3	also	is	2
4	associated	is	2
5	with	associated	4
6	activation	with	5
7	of	activation	6
8	the	of	7
9	hypothalamo-pituitary-adrenal	the	8
10	axis	hypothalamo-pituitary-adrenal	9
11	function	axis	10
12	and	function	11
13	increased	plasma	14
14	plasma	and	12
15	and	plasma	14
16	urinary	concentrations	18
17	cortisol	concentrations	18
18	concentrations	and	15
19	.	is	2

0	Ascorbic	acid	1
1	acid	has	8
2	(	ascorbate	3
3	ascorbate	acid	1
4	or	ascorbate	3
5	vitamin	ascorbate	3
6	C	acid	1
7	)	C	6
8	has	<ROOT>	-1
9	been	has	8
10	shown	been	9
11	to	shown	10
12	suppress	to	11
13	the	induction	14
14	induction	suppress	12
15	of	induction	14
16	HIV	of	15
17	in	suppress	12
18	latently	infected	19
19	infected	suppress	12
20	T	cells	22
21	lymphocytic	cells	22
22	cells	infected	19
23	following	cells	22
24	stimulation	has	8
25	with	stimulation	24
26	a	cytokine	34
27	tumor	promoter	28
28	promoter	a	26
29	(	promoter	28
30	PMA	a	26
31	)	PMA	30
32	and	a	26
33	inflammatory	a	26
34	cytokine	with	25
35	(	with	25
36	TNF-alpha	with	25
37	)	with	25
38	.	has	8

0	Tyrosine	phosphorylation	1
1	phosphorylation	<ROOT>	-1
2	of	phosphorylation	1
3	Jak2	of	2
4	reaches	Jak2	3
5	a	peak	6
6	peak	Jak2	3
7	around	peak	6
8	10	minutes	9
9	minutes	around	7
10	after	stimulation	11
11	stimulation	phosphorylation	1
12	and	stimulation	11
13	is	and	12
14	maximum	is	13
15	at	is	13
16	5	U/mL	17
17	U/mL	at	15
18	of	U/mL	17
19	erythropoietin	of	18
20	.	phosphorylation	1

0	NF-kappa	proteins	2
1	B/Rel	proteins	2
2	proteins	have	3
3	have	<ROOT>	-1
4	been	have	3
5	shown	been	4
6	to	shown	5
7	physically	to	6
8	interact	physically	7
9	with	shown	5
10	both	AP-1	11
11	AP-1	and	12
12	and	with	9
13	Sp1	and	12
14	proteins	have	3
15	.	have	3

0	The	function	1
1	function	is	4
2	of	function	1
3	LEF-1	of	2
4	is	<ROOT>	-1
5	dependent	is	4
6	,	is	4
7	in	is	4
8	part	in	7
9	,	is	4
10	on	is	4
11	the	domain	13
12	HMG	domain	13
13	domain	on	10
14	that	induces	15
15	induces	is	4
16	a	bend	18
17	sharp	bend	18
18	bend	induces	15
19	in	bend	18
20	the	helix	22
21	DNA	helix	22
22	helix	in	19
23	,	is	4
24	and	is	4
25	on	and	24
26	an	on	25
27	activation	an	26
28	domain	that	29
29	that	activation	27
30	stimulates	that	29
31	transcription	only	32
32	only	an	26
33	in	only	32
34	a	context	36
35	specific	context	36
36	context	in	33
37	of	context	36
38	other	proteins	40
39	enhancer-binding	proteins	40
40	proteins	of	37
41	.	is	4

0	Induction	virus	4
1	of	virus	4
2	human	virus	4
3	immunodeficiency	virus	4
4	virus	type	5
5	type	1	6
6	1	<ROOT>	-1
7	expression	1	6
8	in	monocytic	9
9	monocytic	expression	7
10	cells	1	6
11	by	1	6
12	Cryptococcus	neoformans	13
13	neoformans	by	11
14	and	by	11
15	Candida	albicans	16
16	albicans	and	14
17	.	1	6

0	The	down-regulation	1
1	down-regulation	may	10
2	of	down-regulation	1
3	RANTES	expression	4
4	expression	of	2
5	by	down-regulation	1
6	glucocorticoids	by	5
7	in	T	8
8	T	by	5
9	cells	down-regulation	1
10	may	<ROOT>	-1
11	directly	may	10
12	contribute	may	10
13	to	contribute	12
14	the	efficacy	15
15	efficacy	of	16
16	of	to	13
17	these	of	16
18	agents	contribute	12
19	in	agents	18
20	suppressing	cellular	21
21	cellular	in	19
22	infiltration	may	10
23	and	infiltration	22
24	to	and	23
25	their	properties	27
26	anti-inflammatory	properties	27
27	properties	to	24
28	.	may	10

0	Three	define	9
1	RFLPs	TaqI	3
2	(	TaqI	3
3	TaqI	define	9
4	,	TaqI	3
5	ApaI	)	8
6	,	ApaI	5
7	BsmI	)	8
8	)	TaqI	3
9	define	<ROOT>	-1
10	two	define	9
11	common	:	13
12	haplotypes	:	13
13	:	two	10
14	BAt	define	9
15	and	BAt	14
16	baT	and	15
17	.	define	9

0	Variant	transcripts	2
1	receptor	transcripts	2
2	transcripts	lacking	3
3	lacking	were	17
4	exon	lacking	3
5	5	or	6
6	or	exon	4
7	exon	or	6
8	7	or	6
9	,	which	10
10	which	lacking	3
11	encodes	binding	14
12	the	binding	14
13	hormone	binding	14
14	binding	which	10
15	domain	lacking	3
16	,	were	17
17	were	<ROOT>	-1
18	identified	were	17
19	in	identified	18
20	the	majority	21
21	majority	in	19
22	of	majority	21
23	the	cells	24
24	cells	of	22
25	.	cells	24

0	Moreover	mobility	3
1	,	mobility	3
2	electrophoretic	mobility	3
3	mobility	<ROOT>	-1
4	shift	mobility	3
5	assays	demonstrated	6
6	demonstrated	mobility	3
7	that	demonstrated	6
8	CMV	induced	9
9	induced	that	7
10	the	formation	11
11	formation	induced	9
12	of	formation	11
13	NF-kappaB	of	12
14	and	induced	9
15	AP-1	mobility	3
16	complexes	mobility	3
17	.	mobility	3

0	Deranged	homeostasis	3
1	cellular	homeostasis	3
2	cholesterol	homeostasis	3
3	homeostasis	has	4
4	has	<ROOT>	-1
5	been	has	4
6	widely	been	5
7	recognized	widely	6
8	in	recognized	7
9	the	in	8
10	initiation	the	9
11	as	initiation	10
12	well	as	11
13	as	as	11
14	progression	types	17
15	of	progression	14
16	various	of	15
17	types	as	11
18	of	cancers	19
19	cancers	types	17
20	including	cancers	19
21	chronic	including	20
22	myeloid	cancers	19
23	leukaemia	CML	25
24	(	CML	25
25	CML	myeloid	22
26	)	CML	25
27	.	has	4

0	The	binding	1
1	binding	induced	6
2	of	binding	1
3	the	mAb	5
4	A6H	mAb	5
5	mAb	of	2
6	induced	<ROOT>	-1
7	a	signal	9
8	costimulatory	signal	9
9	signal	induced	6
10	in	T	13
11	anti-CD3	T	13
12	activated	T	13
13	T	signal	9
14	cells	induced	6
15	.	induced	6

0	A	subpopulation	1
1	subpopulation	<ROOT>	-1
2	of	subpopulation	1
3	stably	infected	4
4	infected	of	2
5	CD4+	infected	4
6	cells	capable	7
7	capable	producing	9
8	of	capable	7
9	producing	CD4+	5
10	virus	producing	9
11	upon	virus	10
12	stimulation	upon	11
13	has	stimulation	12
14	been	stimulation	12
15	identified	producing	9
16	in	identified	15
17	human	in	16
18	immunodeficiency	human	17
19	virus	(	20
20	(	individuals	24
21	HIV	)	22
22	)	(	20
23	-positive	(	20
24	individuals	immunodeficiency	18
25	(	individuals	24
26	T.-W.Chun	individuals	24
27	,	T.-W.Chun	26
28	D.Finzi	T.-W.Chun	26
29	,	D.Finzi	28
30	J.Margolick	D.Finzi	28
31	,	J.Margolick	30
32	K.Chadwick	J.Margolick	30
33	,	K.Chadwick	32
34	D.Schwartz	K.Chadwick	32
35	,	D.Schwartz	34
36	and	D.Schwartz	34
37	R.F.Siliciano	and	36
38	,	individuals	24
39	Nat.Med.1	subpopulation	1
40	:	subpopulation	1
41	1284-1290	subpopulation	1
42	,	1284-1290	41
43	1995	)	44
44	)	,	42
45	.	)	44

0	We	investigated	1
1	investigated	<ROOT>	-1
2	the	function	3
3	function	investigated	1
4	of	function	3
5	the	of	4
6	evolutionary	conserved	7
7	conserved	the	5
8	X2	conserved	7
9	box	X2	8
10	in	conserved	7
11	the	promoter	12
12	promoter	in	10
13	of	promoter	12
14	the	gene	16
15	HLA-DRA	gene	16
16	gene	of	13
17	from	the	18
18	the	conserved	7
19	human	major	20
20	major	the	18
21	histocompatibility	complex	22
22	complex	(	23
23	(	investigated	1
24	MHC	(	23
25	)	MHC	24
26	in	)	25
27	resting	in	26
28	and	B	30
29	activated	B	30
30	B	in	26
31	cells	investigated	1
32	.	investigated	1

0	In	anti-CD28	17
1	contrast	In	0
2	to	ionomycin	3
3	ionomycin	contrast	1
4	treatment	In	0
5	,	In	0
6	exposure	,	5
7	of	exposure	6
8	cells	of	7
9	to	myristate	11
10	phorbol	myristate	11
11	myristate	cells	8
12	acetate	(	13
13	(	myristate	11
14	PMA	(	13
15	)	PMA	14
16	plus	)	15
17	anti-CD28	<ROOT>	-1
18	did	anti-CD28	17
19	not	induce	20
20	induce	did	18
21	NFATc	induce	20
22	,	NFATc	21
23	indicating	,	22
24	that	induce	20
25	under	that	24
26	these	conditions	27
27	conditions	under	25
28	,	interleukin-2	29
29	interleukin-2	under	25
30	synthesis	by	31
31	by	interleukin-2	29
32	these	by	31
33	cells	is	34
34	is	these	32
35	apparently	independent	36
36	independent	anti-CD28	17
37	of	independent	36
38	NFATc	anti-CD28	17
39	.	anti-CD28	17

0	Stable	transfection	1
1	transfection	suggests	11
2	of	U937	3
3	U937	transfection	1
4	cells	with	5
5	with	transfection	1
6	sense	transfection	1
7	or	transfection	1
8	antisense	transfection	1
9	RXR-alpha	transfection	1
10	cDNA	transfection	1
11	suggests	<ROOT>	-1
12	a	suggests	11
13	role	for	14
14	for	a	12
15	RXR-alpha	for	14
16	in	RXR-alpha	15
17	the	in	16
18	control	the	17
19	of	control	18
20	monoblastic	differentiation	21
21	differentiation	of	19
22	induced	by	23
23	by	of	19
24	retinoic	acid	25
25	acid	by	23
26	and	acid	25
27	vitamin	.	29
28	D	.	29
29	.	and	26

0	Cytomegalovirus	<ROOT>	-1
1	(	Cytomegalovirus	0
2	CMV	(	1
3	)	induced	5
4	infection	)	3
5	induced	CMV	2
6	interleukin-8	cell	16
7	(	cell	16
8	IL-8	cell	16
9	)	cell	16
10	gene	cell	16
11	transcription	cell	16
12	in	cell	16
13	a	cell	16
14	human	cell	16
15	monocytic	cell	16
16	cell	induced	5
17	line	induced	5
18	,	(	1
19	THP-1	Cytomegalovirus	0
20	cells	Cytomegalovirus	0
21	,	IL-8	24
22	leading	IL-8	24
23	to	IL-8	24
24	IL-8	Cytomegalovirus	0
25	secretion	IL-8	24
26	.	Cytomegalovirus	0

0	The	E1A	1
1	E1A	<ROOT>	-1
2	and	E1A	1
3	hexon	primers	4
4	primers	and	2
5	amplified	DNA	6
6	DNA	E1A	1
7	from	six	13
8	representative	six	13
9	adenoviral	serotypes	10
10	serotypes	representative	8
11	in	six	13
12	all	in	11
13	six	E1A	1
14	adenoviral	groups	15
15	groups	E1A	1
16	(	A-F	17
17	A-F	groups	15
18	)	A-F	17
19	.	E1A	1

0	Thus	patients	10
1	,	Thus	0
2	the	reduction	3
3	reduction	,	1
4	of	reduction	3
5	CN	activity	6
6	activity	of	4
7	observed	reduction	3
8	in	CsA-treated	9
9	CsA-treated	observed	7
10	patients	is	11
11	is	<ROOT>	-1
12	accompanied	is	11
13	by	accompanied	12
14	a	degree	16
15	similar	degree	16
16	degree	by	13
17	of	degree	16
18	reduction	of	17
19	in	degree	16
20	lymphocyte	degree	16
21	gene	activation	22
22	activation	lymphocyte	20
23	,	is	11
24	and	is	11
25	accounts	and	24
26	for	accounts	25
27	the	observed	29
28	immunosuppression	observed	29
29	observed	for	26
30	.	is	11

0	IL-2R	alpha	1
1	alpha	is	2
2	is	<ROOT>	-1
3	rapidly	is	2
4	and	is	2
5	potently	is	2
6	induced	is	2
7	in	T	8
8	T	induced	6
9	cells	in	10
10	in	is	2
11	response	is	2
12	to	is	2
13	mitogenic	stimuli	14
14	stimuli	to	12
15	.	stimuli	14

0	Peculiarly	were	10
1	,	Peculiarly	0
2	eccrine	poromas	3
3	poromas	basal	7
4	and	basal	7
5	undifferentiated	basal	7
6	spindle-shaped	undifferentiated	5
7	basal	Peculiarly	0
8	cell	epitheliomas	9
9	epitheliomas	Peculiarly	0
10	were	<ROOT>	-1
11	totally	unstained	12
12	unstained	were	10
13	.	were	10

0	Thus	is	9
1	,	is	9
2	the	activity	3
3	activity	is	9
4	of	activity	3
5	a	factor	8
6	bHLH	factor	8
7	transcription	factor	8
8	factor	of	4
9	is	is	32
10	necessary	is	9
11	for	necessary	10
12	T	differentiation	14
13	lineage	differentiation	14
14	differentiation	for	11
15	of	differentiation	14
16	bipotential	precursors	17
17	precursors	of	15
18	,	is	9
19	in	is	9
20	the	absence	21
21	absence	in	19
22	of	absence	21
23	which	of	22
24	a	of	22
25	default	pathway	26
26	pathway	a	24
27	leading	pathway	26
28	to	leading	27
29	NK	to	28
30	cell	development	31
31	development	NK	29
32	is	<ROOT>	-1
33	chosen	is	32
34	.	is	32

0	For	were	5
1	this	purpose	2
2	purpose	For	0
3	,	were	5
4	mice	were	5
5	were	<ROOT>	-1
6	immunized	were	5
7	with	immunized	6
8	a	protein	10
9	fusion	protein	10
10	protein	with	7
11	including	protein	10
12	the	including	11
13	sequence	the	12
14	Thr729-Lys984	sequence	13
15	of	Thr729-Lys984	14
16	hMR	of	15
17	.	were	5

0	Although	has	10
1	its	remains	6
2	precise	its	1
3	mode	precise	2
4	of	mode	3
5	action	of	4
6	remains	Although	0
7	elusive	remains	6
8	,	has	10
9	curcumin	has	10
10	has	<ROOT>	-1
11	been	has	10
12	shown	been	11
13	to	shown	12
14	suppress	to	13
15	the	activity	16
16	activity	suppress	14
17	of	activity	16
18	the	of	17
19	AP-1	transcription	20
20	transcription	the	18
21	factor	transcription	20
22	in	factor	21
23	cells	stimulated	24
24	stimulated	has	10
25	to	stimulated	24
26	proliferate	has	10
27	.	has	10

0	The	generality	1
1	generality	was	5
2	of	generality	1
3	this	finding	4
4	finding	of	2
5	was	<ROOT>	-1
6	confirmed	was	5
7	by	confirmed	6
8	the	induction	9
9	induction	by	7
10	of	induction	9
11	Bcl-xL	of	10
12	in	human	13
13	human	induction	9
14	myeloid	by	7
15	U-937	by	7
16	cells	was	5
17	,	was	5
18	human	peripheral	19
19	peripheral	was	5
20	blood	was	5
21	monocytes	was	5
22	exposed	to	23
23	to	was	5
24	phorbol	ester	25
25	ester	was	5
26	,	ester	25
27	and	ester	25
28	mouse	and	27
29	thioglycollate-activated	and	27
30	and	thioglycollate-activated	29
31	resident	macrophages	33
32	peritoneal	macrophages	33
33	macrophages	and	30
34	.	was	5

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	stress	cause	6
5	treatments	cause	6
6	cause	that	3
7	an	increase	8
8	increase	cause	6
9	in	increase	8
10	vimentin	levels	11
11	levels	in	9
12	in	promonocytic	13
13	promonocytic	cause	6
14	cells	indicate	2
15	,	which	16
16	which	indicate	2
17	may	be	18
18	be	which	16
19	explained	be	18
20	at	in	22
21	least	at	20
22	in	explained	19
23	part	in	22
24	by	explained	19
25	transcript	.	27
26	stabilization	.	27
27	.	by	24

0	The	frequencies	4
1	RAKFKQLLQ-specific	frequencies	4
2	CTL	frequencies	4
3	precursor	frequencies	4
4	frequencies	were	9
5	in	frequencies	4
6	all	in	5
7	5	persons	8
8	persons	were	9
9	were	<ROOT>	-1
10	at	were	9
11	least	at	10
12	as	were	9
13	dominant	as	12
14	as	dominant	13
15	those	as	14
16	observed	those	15
17	with	observed	16
18	two	EBV-associated	20
19	other	EBV-associated	20
20	EBV-associated	with	17
21	,	were	9
22	HLA-B8-restricted	latent	23
23	latent	were	9
24	epitopes	latent	23
25	,	epitopes	24
26	FLRGRAYGL	were	9
27	and	were	9
28	QAKWRLQTL	were	9
29	.	were	9

0	The	understanding	2
1	current	understanding	2
2	understanding	<ROOT>	-1
3	of	understanding	2
4	the	mechanisms	6
5	molecular	mechanisms	6
6	mechanisms	of	3
7	underlying	immunosenescence	8
8	immunosenescence	is	9
9	is	of	3
10	still	is	9
11	fragmentary	is	9
12	.	understanding	2

0	Here	<ROOT>	-1
1	we	identify	2
2	identify	Here	0
3	intracellular	identify	2
4	signaling	intracellular	3
5	components	signaling	4
6	involved	components	5
7	in	involved	6
8	activation	of	9
9	of	in	7
10	NF-kappaB	TCR	12
11	following	NF-kappaB	10
12	TCR	of	9
13	stimulation	Here	0
14	.	Here	0

0	Nevertheless	induced	4
1	,	induced	4
2	dibutyryl	cAMP	3
3	cAMP	induced	4
4	induced	<ROOT>	-1
5	a	induced	4
6	down-regulation	a	5
7	of	down-regulation	6
8	the	levels	9
9	levels	of	7
10	of	levels	9
11	this	proto-oncogene	12
12	proto-oncogene	of	10
13	.	induced	4

0	All	<ROOT>	-1
1	fusions	All	0
2	splice	the	3
3	the	fusions	1
4	5'	ends	5
5	ends	the	3
6	of	ends	5
7	the	genes	9
8	3q21	genes	9
9	genes	of	6
10	into	ends	5
11	exon	into	10
12	2	exon	11
13	of	2	12
14	the	of	13
15	EVI1	the	14
16	gene	EVI1	15
17	,	gene	16
18	an	event	19
19	event	,	17
20	that	event	19
21	is	similar	22
22	similar	that	20
23	to	similar	22
24	the	splicing	27
25	normal	splicing	27
26	intergenic	splicing	27
27	splicing	to	23
28	of	splicing	27
29	MDS1-EVI1	of	28
30	and	MDS1-EVI1	29
31	to	and	30
32	those	previously	33
33	previously	to	31
34	documented	previously	33
35	in	MDS1-EVI1	29
36	leukemias	in	35
37	with	MDS1-EVI1	29
38	t-LRB-3;21-RRB-	with	37
39	and	t-LRB-3;21-RRB-	38
40	t-LRB-3;12-RRB-	and	39
41	,	event	19
42	in	leukemia	46
43	which	in	42
44	acute	leukemia	46
45	myelogenous	leukemia	46
46	leukemia	event	19
47	1-EVI1	event	19
48	fusions	event	19
49	and	event	19
50	ETV6-EVI1	All	0
51	fusions	All	0
52	,	All	0
53	respectively	All	0
54	,	All	0
55	occur	All	0
56	.	All	0

0	Thirteen	preterms	1
1	preterms	prenatal	7
2	of	preterms	1
3	the	group	5
4	latter	group	5
5	group	of	2
6	received	group	5
7	prenatal	<ROOT>	-1
8	steroid	treatment	9
9	treatment	prenatal	7
10	.	prenatal	7

0	IL-12	<ROOT>	-1
1	and	cell	21
2	type	II	7
3	I	type	2
4	but	type	2
5	not	type	6
6	type	II	7
7	II	and	1
8	interferons	expression	10
9	induce	expression	10
10	expression	beta	14
11	of	IL-12R	13
12	the	IL-12R	13
13	IL-12R	expression	10
14	beta	II	7
15	2	beta	14
16	chain	during	17
17	during	2	15
18	in	vitro	19
19	vitro	during	17
20	T	cell	21
21	cell	IL-12	0
22	differentiation	cell	21
23	after	receptor	25
24	antigen	receptor	25
25	receptor	differentiation	22
26	triggering	IL-12	0
27	.	IL-12	0

0	In	<ROOT>	-1
1	summary	In	0
2	,	In	0
3	we	,	2
4	have	we	3
5	discovered	have	4
6	that	discovered	5
7	expression	is	12
8	of	expression	7
9	C/EBP	mRNA	11
10	epsilon	mRNA	11
11	mRNA	of	8
12	is	that	6
13	markedly	are	19
14	enhanced	markedly	13
15	as	enhanced	14
16	the	promyelocytes	18
17	NB4	promyelocytes	18
18	promyelocytes	as	15
19	are	is	12
20	induced	are	19
21	by	induced	20
22	retinoids	discovered	5
23	to	retinoids	22
24	differentiate	towards	25
25	towards	to	23
26	granulocytes	discovered	5
27	.	In	0

0	The	sites	3
1	SCMV	sites	3
2	SNE	sites	3
3	sites	contain	4
4	contain	<ROOT>	-1
5	potential	motifs	10
6	overlapping	motifs	10
7	core	motifs	10
8	recognition	motifs	10
9	binding	motifs	10
10	motifs	contain	4
11	for	contain	4
12	SRF	for	11
13	,	SRF	12
14	Rel/NFkappaB	ETS	16
15	,	ETS	16
16	ETS	transcription	21
17	,	ETS	16
18	and	ETS	16
19	YY1	and	18
20	class	YY1	19
21	transcription	,	13
22	factors	contain	4
23	but	contain	4
24	fail	but	23
25	to	fail	24
26	respond	to	25
27	to	respond	26
28	either	serum	29
29	serum	tumor	31
30	or	tumor	31
31	tumor	to	27
32	necrosis	factor	33
33	factor	tumor	31
34	alpha	contain	4
35	.	contain	4

0	Additionally	have	7
1	,	Additionally	0
2	proposed	pathways	3
3	pathways	,	1
4	of	NF-kappaB	5
5	NF-kappaB	pathways	3
6	activation	Additionally	0
7	have	<ROOT>	-1
8	been	have	7
9	based	been	8
10	on	based	9
11	indirect	evidence	12
12	evidence	on	10
13	provided	on	10
14	by	provided	13
15	experiments	which	16
16	which	by	14
17	used	which	16
18	antioxidants	which	16
19	to	provided	13
20	inhibit	NF-kappaB	22
21	active	NF-kappaB	22
22	NF-kappaB	to	19
23	formation	have	7
24	.	have	7

0	Direct	is	10
1	analysis	Direct	0
2	of	analysis	1
3	these	of	2
4	modified	these	3
5	cells	acting	6
6	acting	modified	4
7	as	modified	4
8	tumor	vaccines	9
9	vaccines	as	7
10	is	<ROOT>	-1
11	underway	is	10
12	.	is	10

0	To	<ROOT>	-1
1	investigate	To	0
2	whether	retained	5
3	dissociated	retained	5
4	glucocorticoids	retained	5
5	retained	investigate	1
6	the	antiinflammatory	7
7	antiinflammatory	retained	5
8	and	retained	5
9	immunosuppressive	and	8
10	potential	and	8
11	of	potential	10
12	classic	glucocorticoids	13
13	glucocorticoids	of	11
14	,	of	11
15	several	,	14
16	in	and	18
17	vitro	in	16
18	and	several	15
19	in	and	18
20	vivo	To	0
21	models	vivo	20
22	were	models	21
23	used	.	24
24	.	were	22

0	Cell-to-cell	contact	1
1	contact	activates	2
2	activates	terminal	5
3	the	terminal	5
4	long	terminal	5
5	terminal	<ROOT>	-1
6	repeat	terminal	5
7	of	repeat	6
8	human	of	7
9	immunodeficiency	human	8
10	virus	immunodeficiency	9
11	1	virus	10
12	through	1	11
13	its	motif	15
14	kappaB	motif	15
15	motif	through	12
16	.	terminal	5

0	Moreover	resembled	8
1	,	resembled	8
2	the	mechanism	3
3	mechanism	resembled	8
4	of	mechanism	3
5	action	of	4
6	of	action	5
7	BHRF1	of	6
8	resembled	<ROOT>	-1
9	that	resembled	8
10	of	that	9
11	Bcl-2	of	10
12	and	of	10
13	Bcl-xL	resembled	8
14	as	resembled	8
15	it	inhibited	16
16	inhibited	as	14
17	TNF-	inhibited	16
18	and	TNF-	17
19	anti-Fas-induced	and	18
20	activation	two	22
21	of	two	22
22	two	anti-Fas-induced	19
23	enzymes	resembled	8
24	participating	resembled	8
25	in	participating	24
26	the	pathway	28
27	apoptosis	pathway	28
28	pathway	in	25
29	,	phospholipase	31
30	cytosolic	phospholipase	31
31	phospholipase	resembled	8
32	A2	phospholipase	31
33	and	A2	32
34	caspase-3/CPP32	and	33
35	,	resembled	8
36	but	resembled	8
37	did	but	36
38	not	did	37
39	interfere	did	37
40	with	the	41
41	the	interfere	39
42	activation	the	41
43	of	activation	42
44	NF-kappaB-like	factors	46
45	transcription	factors	46
46	factors	of	43
47	.	of	43

0	The	roles	2
1	suggested	roles	2
2	roles	acting	8
3	of	roles	2
4	the	regions	7
5	downstream	regions	7
6	3'	regions	7
7	regions	of	3
8	acting	<ROOT>	-1
9	as	acting	8
10	a	Region	13
11	Locus	Region	13
12	Control	Region	13
13	Region	as	9
14	(	LCR	15
15	LCR	Region	13
16	)	LCR	15
17	,	acting	8
18	have	acting	8
19	allowed	have	18
20	comparisons	allowed	19
21	to	comparisons	20
22	be	to	21
23	made	be	22
24	between	made	23
25	the	regulation	26
26	regulation	between	24
27	of	regulation	26
28	the	locus	30
29	IgH	locus	30
30	locus	of	27
31	with	regulation	26
32	other	systems	34
33	model	systems	34
34	systems	with	31
35	whose	expression	37
36	gene	expression	37
37	expression	is	38
38	is	systems	34
39	governed	is	38
40	by	governed	39
41	LCR	activity	42
42	activity	by	40
43	.	acting	8

0	Despite	appears	12
1	its	Despite	0
2	reported	Ig/EBP-1	11
3	role	reported	2
4	as	role	3
5	a	regulator	7
6	negative	regulator	7
7	regulator	as	4
8	of	regulator	7
9	transcription	of	8
10	,	reported	2
11	Ig/EBP-1	its	1
12	appears	<ROOT>	-1
13	to	appears	12
14	exert	to	13
15	a	effect	17
16	stimulatory	effect	17
17	effect	exert	14
18	on	effect	17
19	this	on	18
20	promoter	.	21
21	.	this	19

0	Molecular	to	6
1	mechanisms	of	2
2	of	to	6
3	anoxia/reoxygenation-induced	to	6
4	neutrophil	to	6
5	adherence	to	6
6	to	<ROOT>	-1
7	cultured	to	6
8	endothelial	to	6
9	cells	to	6
10	.	to	6

0	Aging	is	1
1	is	<ROOT>	-1
2	classically	is	1
3	accompanied	classically	2
4	by	accompanied	3
5	a	by	4
6	dysregulation	a	5
7	of	dysregulation	6
8	the	of	7
9	immunologic	.	11
10	machinery	.	11
11	.	the	8

0	In	we	4
1	previous	In	0
2	work	In	0
3	,	we	4
4	we	<ROOT>	-1
5	identified	we	4
6	an	site	8
7	essential	site	8
8	site	identified	5
9	in	identified	5
10	the	promoter	12
11	c-sis/PDGF-B	promoter	12
12	promoter	in	9
13	,	we	4
14	Tax-responsive	we	4
15	element	1	16
16	1	(	17
17	(	we	4
18	TRE1	we	4
19	)	TRE1	18
20	,	)	19
21	necessary	for	22
22	for	)	19
23	transactivation	we	4
24	by	we	4
25	Tax	by	24
26	.	we	4

0	The	reversal	1
1	reversal	occurred	6
2	from	reversal	1
3	stimulation	from	2
4	to	reversal	1
5	inhibition	to	4
6	occurred	<ROOT>	-1
7	after	occurred	6
8	3	5	10
9	to	5	10
10	5	days	11
11	days	after	7
12	of	days	11
13	adherence	of	12
14	to	occurred	6
15	plastic	to	14
16	.	occurred	6

0	However	free	3
1	,	plasma	2
2	plasma	free	3
3	free	<ROOT>	-1
4	cortisol	concentrations	5
5	concentrations	free	3
6	were	free	3
7	similar	were	6
8	in	similar	7
9	the	three	10
10	three	groups	11
11	groups	in	8
12	.	groups	11

0	This	factor	2
1	transcription	factor	2
2	factor	is	3
3	is	<ROOT>	-1
4	composed	is	3
5	of	composed	4
6	products	of	5
7	from	of	5
8	the	fos	9
9	fos	from	7
10	and	fos	9
11	jun	and	10
12	proto-oncogene	family	13
13	family	from	7
14	and	from	7
15	is	and	14
16	believed	is	15
17	to	believed	16
18	be	to	17
19	important	be	18
20	in	important	19
21	regulating	cell	22
22	cell	in	20
23	growth	cell	22
24	and	growth	23
25	proliferation	and	24
26	.	is	3

0	Similar	results	1
1	results	were	2
2	were	<ROOT>	-1
3	obtained	were	2
4	in	obtained	3
5	hepatic	cells	7
6	HTC	cells	7
7	cells	in	4
8	for	obtained	3
9	the	transactivation	10
10	transactivation	endogenous	13
11	of	endogenous	13
12	the	endogenous	13
13	endogenous	for	8
14	tyrosine	amino	15
15	amino	endogenous	13
16	transferase	were	2
17	gene	(	18
18	(	were	2
19	TAT	were	2
20	)	were	2
21	,	which	22
22	which	were	2
23	encodes	which	22
24	one	encodes	23
25	of	one	24
26	the	of	25
27	enzymes	the	26
28	involved	enzymes	27
29	in	involved	28
30	the	glucocorticoid-dependent	31
31	glucocorticoid-dependent	in	29
32	stimulation	were	2
33	of	stimulation	32
34	neoglucogenesis	of	33
35	.	were	2

0	This	review	1
1	review	considers	2
2	considers	<ROOT>	-1
3	the	evidence	4
4	evidence	considers	2
5	for	evidence	4
6	different	theories	7
7	theories	for	5
8	of	theories	7
9	the	histogenesis	10
10	histogenesis	of	8
11	of	histogenesis	10
12	endometriosis	of	11
13	and	endometriosis	12
14	discusses	immune	16
15	possible	immune	16
16	immune	considers	2
17	factors	considers	2
18	that	may	19
19	may	factors	17
20	be	may	19
21	involved	be	20
22	in	involved	21
23	the	pathophysiology	24
24	pathophysiology	in	22
25	of	the	26
26	the	pathophysiology	24
27	disease	considers	2
28	.	considers	2

0	Activation	<ROOT>	-1
1	of	T	3
2	helper	T	3
3	T	Activation	0
4	cells	Activation	0
5	results	in	6
6	in	Activation	0
7	coordinate	in	6
8	expression	in	6
9	of	expression	8
10	a	number	11
11	number	of	9
12	of	cytokines	13
13	cytokines	number	11
14	involved	cytokines	13
15	in	number	11
16	differentiation	in	15
17	,	Activation	0
18	proliferation	Activation	0
19	and	Activation	0
20	activation	Activation	0
21	of	Activation	0
22	the	of	21
23	haematopoietic	.	25
24	system	.	25
25	.	the	22

0	The	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	a	molecule	6
5	small	molecule	6
6	molecule	can	7
7	can	that	3
8	activate	can	7
9	a	receptor	10
10	receptor	activate	8
11	that	binds	13
12	normally	binds	13
13	binds	receptor	10
14	a	ligand	18
15	relatively	large	16
16	large	ligand	18
17	protein	ligand	18
18	ligand	binds	13
19	.	indicate	2

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	transfection	,	1
3	of	Daudi	4
4	Daudi	transfection	2
5	cells	with	6
6	with	NF-kappaB	9
7	the	NF-kappaB	9
8	polymerized	NF-kappaB	9
9	NF-kappaB	Moreover	0
10	binding	Moreover	0
11	sequence	Moreover	0
12	ligated	Moreover	0
13	to	ligated	12
14	a	acetyltransferase	17
15	thymidine	acetyltransferase	17
16	kinase/chloramphenicol	acetyltransferase	17
17	acetyltransferase	(	18
18	(	to	13
19	CAT	(	18
20	)	ligated	12
21	reporter	Moreover	0
22	plasmid	greatly	23
23	greatly	induced	24
24	induced	Moreover	0
25	CAT	Moreover	0
26	activity	Moreover	0
27	,	Moreover	0
28	but	Moreover	0
29	transfection	Moreover	0
30	with	NF-kappaB	34
31	the	NF-kappaB	34
32	polymerized	NF-kappaB	34
33	mutated	NF-kappaB	34
34	NF-kappaB	transfection	29
35	binding	Moreover	0
36	sequence	Moreover	0
37	did	Moreover	0
38	not	did	37
39	.	Moreover	0

0	Further	demonstrate	5
1	,	Further	0
2	monocytes	demonstrate	5
3	from	demonstrate	5
4	patients	from	3
5	demonstrate	<ROOT>	-1
6	an	susceptibility	8
7	augmented	susceptibility	8
8	susceptibility	demonstrate	5
9	to	susceptibility	8
10	a	infection	12
11	productive	infection	12
12	infection	to	9
13	with	infection	12
14	HIV-1	with	13
15	in	infection	12
16	vitro	in	15
17	.	demonstrate	5

0	Neutral	SMase	1
1	SMase	was	3
2	activity	SMase	1
3	was	<ROOT>	-1
4	assessed	was	3
5	in	assessed	4
6	membranes	in	5
7	from	in	5
8	Jurkat	line	13
9	,	line	13
10	a	line	13
11	human	line	13
12	T-cell	line	13
13	line	assessed	4
14	,	line	13
15	and	line	13
16	EL4	and	15
17	,	EL4	16
18	a	line	21
19	murine	line	21
20	T-cell	line	21
21	line	EL4	16
22	.	was	3

0	We	have	1
1	have	<ROOT>	-1
2	previously	have	1
3	identified	an	4
4	an	have	1
5	enhancer	an	4
6	element	enhancer	5
7	,	element	6
8	PRE-I	is	11
9	,	is	11
10	that	is	11
11	is	element	6
12	essential	is	11
13	for	essential	12
14	the	function	15
15	function	human	18
16	of	human	18
17	the	human	18
18	human	for	13
19	IL-4	is	11
20	promoter	is	11
21	.	have	1

0	This	contrasts	1
1	contrasts	<ROOT>	-1
2	with	contrasts	1
3	findings	with	2
4	in	(	9
5	alpha-	in	4
6	and	alpha-	5
7	beta-herpesvirus	systems	8
8	systems	alpha-	5
9	(	contrasts	1
10	herpes	(	9
11	simplex	contrasts	1
12	,	contrasts	1
13	cytomegalovirus	,	12
14	)	where	15
15	where	cytomegalovirus	13
16	viral	where	15
17	interference	viral	16
18	with	interference	17
19	the	with	18
20	antigen-processing	the	19
21	pathway	during	22
22	during	antigen-processing	20
23	lytic	during	22
24	infection	renders	25
25	renders	lytic	23
26	immediate	renders	25
27	early	renders	25
28	and	early	27
29	early	proteins	30
30	proteins	and	28
31	much	during	22
32	less	the	19
33	immunogenic	less	32
34	.	contrasts	1

0	Thus	<ROOT>	-1
1	,	Thus	0
2	the	,	1
3	cooperation	may	10
4	of	cooperation	3
5	two	factors	9
6	general	factors	9
7	cellular	factors	9
8	transcription	factors	9
9	factors	of	4
10	may	the	2
11	allow	may	10
12	for	allow	11
13	the	downregulation	15
14	selective	downregulation	15
15	downregulation	for	12
16	of	downregulation	15
17	HIV	transcription	18
18	transcription	of	16
19	.	Thus	0

0	The	protein	2
1	SRG3	protein	2
2	protein	contains	3
3	contains	DNA	11
4	an	terminus	7
5	acidic	terminus	7
6	NH2	terminus	7
7	terminus	contains	3
8	,	DNA	11
9	a	DNA	11
10	myb-like	DNA	11
11	DNA	<ROOT>	-1
12	binding	domain	13
13	domain	DNA	11
14	,	motif	17
15	a	motif	17
16	leucine-zipper	motif	17
17	motif	DNA	11
18	,	motif	17
19	and	,	18
20	a	proline-	21
21	proline-	region	24
22	and	proline-	21
23	glutamine-rich	and	22
24	region	and	19
25	at	region	24
26	its	terminus	28
27	COOH	terminus	28
28	terminus	at	25
29	.	DNA	11

0	ATF/CREB	family	3
1	and	family	3
2	Sp	family	3
3	family	interacted	5
4	members	family	3
5	interacted	bp	9
6	with	bp	9
7	the	bp	9
8	21	bp	9
9	bp	types	19
10	repeats	bp	9
11	to	bp	9
12	form	to	11
13	DNA-protein	complexes	14
14	complexes	form	12
15	common	complexes	14
16	to	cell	18
17	all	cell	18
18	cell	complexes	14
19	types	<ROOT>	-1
20	examined	types	19
21	.	types	19

0	C/EBPepsilon	mRNA	1
1	mRNA	was	2
2	was	<ROOT>	-1
3	greatly	was	2
4	induced	was	2
5	during	granulocytic	8
6	in	granulocytic	8
7	vitro	in	6
8	granulocytic	induced	4
9	differentiation	was	2
10	of	human	11
11	human	cells	14
12	primary	cells	14
13	CD34-LRB-+-RRB-	cells	14
14	cells	differentiation	9
15	.	cells	14

0	Interestingly	revealed	5
1	,	revealed	5
2	co-immunoprecipitation	analysis	3
3	analysis	revealed	5
4	also	revealed	5
5	revealed	<ROOT>	-1
6	that	revealed	5
7	Tax	mutant	8
8	mutant	is	10
9	IEXC29S	mutant	8
10	is	that	6
11	unable	is	10
12	to	unable	11
13	interact	to	12
14	with	interact	13
15	NGFI-A/Egr-1	with	14
16	,	is	10
17	whereas	is	10
18	Tax	mutant	19
19	mutant	is	21
20	IEXL320G	mutant	19
21	is	whereas	17
22	able	is	21
23	to	able	22
24	interact	to	23
25	with	interact	24
26	NGFI-A/Egr-1	with	25
27	.	revealed	5

0	Translocations	have	6
1	involving	Translocations	0
2	the	locus	5
3	human	locus	5
4	CBFA2	locus	5
5	locus	involving	1
6	have	<ROOT>	-1
7	been	have	6
8	associated	been	7
9	with	associated	8
10	leukemia	with	9
11	.	have	6

0	Analyses	showed	17
1	of	Analyses	0
2	nuclear	translocation	3
3	translocation	of	1
4	of	translocation	3
5	individual	members	6
6	members	of	4
7	of	members	6
8	Rel	proteins	9
9	proteins	of	7
10	after	CD40	11
11	CD40	of	1
12	induction	of	1
13	of	B	15
14	primary	B	15
15	B	induction	12
16	cells	Analyses	0
17	showed	<ROOT>	-1
18	a	showed	17
19	strong	a	18
20	and	strong	19
21	long-lasting	of	23
22	accumulation	long-lasting	21
23	of	and	20
24	RelB	of	23
25	and	RelB	24
26	,	and	25
27	less	and	25
28	pronounced	less	27
29	,	less	27
30	of	,	29
31	c-Rel	of	30
32	.	of	30

0	To	<ROOT>	-1
1	delineate	To	0
2	the	mechanisms	4
3	regulatory	mechanisms	4
4	mechanisms	delineate	1
5	of	human	6
6	human	IL-5	7
7	IL-5	mechanisms	4
8	synthesis	To	0
9	,	To	0
10	we	,	9
11	established	CD4+	13
12	allergen-specific	CD4+	13
13	CD4+	we	10
14	T-cell	clones	15
15	clones	CD4+	13
16	from	CD4+	13
17	asthmatic	from	16
18	patients	.	19
19	.	asthmatic	17

0	In	does	4
1	addition	In	0
2	,	does	4
3	TRAMP	does	4
4	does	<ROOT>	-1
5	not	does	4
6	appear	does	4
7	to	appear	6
8	interact	to	7
9	with	interact	8
10	any	with	9
11	of	any	10
12	the	ligands	15
13	known	ligands	15
14	apoptosis-inducing	ligands	15
15	ligands	of	11
16	of	ligands	15
17	the	of	16
18	TNF	the	17
19	family	.	20
20	.	TNF	18

0	Furthermore	<ROOT>	-1
1	,	Furthermore	0
2	increasing	,	1
3	the	spacing	4
4	spacing	LPS	14
5	between	spacing	4
6	the	CRE	7
7	CRE	between	5
8	and	CRE	7
9	the	sites	11
10	kappaB3	sites	11
11	sites	and	8
12	completely	sites	11
13	abolished	spacing	4
14	LPS	increasing	2
15	induction	LPS	14
16	,	induction	15
17	suggesting	,	16
18	a	interaction	20
19	cooperative	interaction	20
20	interaction	suggesting	17
21	between	complexes	23
22	c-Jun	complexes	23
23	complexes	interaction	20
24	and	complexes	23
25	p50/p65	complexes	23
26	.	Furthermore	0

0	C3/5	cells	1
1	cells	developed	2
2	developed	<ROOT>	-1
3	specific	proliferation	4
4	proliferation	developed	2
5	and	developed	2
6	cytotoxicity	and	5
7	when	challenged	8
8	challenged	developed	2
9	with	challenged	8
10	peptide-pulsed	with	9
11	lymphoblastic	lines	13
12	cell	lines	13
13	lines	peptide-pulsed	10
14	and	developed	2
15	peripheral	and	14
16	blood	lymphocytes	17
17	lymphocytes	and	14
18	from	developed	2
19	the	DR11-LRB-+-RRB-	21
20	four	DR11-LRB-+-RRB-	21
21	DR11-LRB-+-RRB-	from	18
22	APL	patients	23
23	patients	DR11-LRB-+-RRB-	21
24	.	developed	2

0	In	demonstrate	4
1	conclusion	In	0
2	,	demonstrate	4
3	we	demonstrate	4
4	demonstrate	<ROOT>	-1
5	that	demonstrate	4
6	the	succinate	11
7	vitamin	succinate	11
8	E	succinate	11
9	derivative	TCP	10
10	TCP	succinate	11
11	succinate	prevents	12
12	prevents	cell	14
13	monocytic	cell	14
14	cell	that	5
15	adhesion	endothelial	18
16	to	endothelial	18
17	cytokine-stimulated	endothelial	18
18	endothelial	cell	14
19	cells	demonstrate	4
20	by	inhibiting	21
21	inhibiting	demonstrate	4
22	the	activation	23
23	activation	NF-kappa	25
24	of	NF-kappa	25
25	NF-kappa	inhibiting	21
26	B	demonstrate	4
27	,	further	28
28	further	demonstrate	4
29	emphasizing	further	28
30	the	potential	32
31	antiatherosclerotic	potential	32
32	potential	emphasizing	29
33	of	lipid	34
34	lipid	potential	32
35	soluble	antioxidants	36
36	antioxidants	lipid	34
37	.	demonstrate	4

0	Analysis	showed	4
1	of	Analysis	0
2	Tax	mutants	3
3	mutants	of	1
4	showed	<ROOT>	-1
5	that	showed	4
6	two	mutants	7
7	mutants	were	13
8	,	mutants	7
9	IEXC29S	mutants	7
10	and	IEXC29S	9
11	IEXL320G	and	10
12	,	mutants	7
13	were	that	5
14	unable	were	13
15	to	unable	14
16	significantly	to	15
17	transactivate	to	15
18	the	transactivate	17
19	c-sis/PDGF-B	.	21
20	promoter	.	21
21	.	the	18

0	We	identified	2
1	also	identified	2
2	identified	<ROOT>	-1
3	Sp1	identified	2
4	,	Sp1	3
5	Sp3	identified	2
6	,	Sp3	5
7	and	Sp3	5
8	NGFI-A/Egr-1	and	7
9	as	identified	2
10	the	as	9
11	primary	the	10
12	nuclear	primary	11
13	transcription	to	16
14	factors	to	16
15	binding	to	16
16	to	nuclear	12
17	TRE1	nuclear	12
18	which	mediate	19
19	mediate	TRE1	17
20	Tax	responsiveness	21
21	responsiveness	mediate	19
22	.	identified	2

0	Since	<ROOT>	-1
1	GH	stimulates	2
2	stimulates	Since	0
3	the	development	4
4	development	stimulates	2
5	and	stimulates	2
6	function	and	5
7	of	and	5
8	granulocytes	and	5
9	,	Since	0
10	we	,	9
11	investigated	the	12
12	the	we	10
13	expression	the	12
14	of	expression	13
15	GH	of	14
16	in	granulocyte	17
17	granulocyte	we	10
18	subsets	we	10
19	.	Since	0

0	Dissociation	<ROOT>	-1
1	of	Dissociation	0
2	the	of	1
3	Jak	the	2
4	kinase	from	6
5	pathway	from	6
6	from	Jak	3
7	G-CSF	signaling	9
8	receptor	signaling	9
9	signaling	the	2
10	in	signaling	9
11	neutrophils	Dissociation	0
12	.	Dissociation	0

0	Similarly	showed	6
1	,	showed	6
2	the	cells	5
3	Egr-1-expressing	cells	5
4	Ramos	cells	5
5	cells	showed	6
6	showed	<ROOT>	-1
7	reduced	showed	6
8	levels	reduced	7
9	of	levels	8
10	CD95	expression	11
11	expression	of	9
12	.	of	9

0	These	<ROOT>	-1
1	data	These	0
2	show	that	3
3	that	data	1
4	some	that	3
5	transcription	associated	7
6	factors	associated	7
7	associated	can	11
8	with	associated	7
9	cytokine	signalling	10
10	signalling	with	8
11	can	some	4
12	also	activate	13
13	activate	data	1
14	the	activate	13
15	CRH	.	17
16	promoter	.	17
17	.	the	14

0	These	results	1
1	results	demonstrated	2
2	demonstrated	<ROOT>	-1
3	that	demonstrated	2
4	LPS-mediated	SAA	5
5	SAA	that	3
6	gene	induction	7
7	induction	SAA	5
8	in	SAA	5
9	monocyte/macrophage	SAA	5
10	cells	demonstrated	2
11	is	demonstrated	2
12	primarily	demonstrated	2
13	due	primarily	12
14	to	the	15
15	the	due	13
16	induction	of	17
17	of	the	15
18	SAF	activity	19
19	activity	of	17
20	.	demonstrated	2

0	This	element	2
1	cis	element	2
2	element	binds	3
3	binds	protein	5
4	a	protein	5
5	protein	<ROOT>	-1
6	complex	protein	5
7	referred	protein	5
8	to	protein	5
9	as	to	8
10	HRF	as	9
11	(	HRF	10
12	heme-responsive	(	11
13	factor	)	14
14	)	heme-responsive	12
15	,	which	16
16	which	heme-responsive	12
17	is	which	16
18	greatly	is	17
19	enhanced	greatly	18
20	both	enhanced	19
21	in	both	20
22	heme-treated	FLCs	23
23	FLCs	in	21
24	and	during	25
25	during	monocyte-to-macrophage	26
26	monocyte-to-macrophage	FLCs	23
27	differentiation	in	21
28	.	protein	5

0	Analysis	revealed	5
1	of	Analysis	0
2	Gal4-Elf-1	proteins	4
3	fusion	proteins	4
4	proteins	of	1
5	revealed	contain	14
6	that	revealed	5
7	the	amino	10
8	N-terminal	amino	10
9	86	amino	10
10	amino	that	6
11	acids	amino	10
12	of	acids	11
13	Elf-1	revealed	5
14	contain	activation	17
15	a	activation	17
16	transcriptional	activation	17
17	activation	is	24
18	domain	activation	17
19	,	is	24
20	the	activity	21
21	activity	is	24
22	of	activity	21
23	which	of	22
24	is	<ROOT>	-1
25	attenuated	is	24
26	by	repression	29
27	an	repression	29
28	internal	repression	29
29	repression	attenuated	25
30	domain	is	24
31	.	is	24

0	T	lymphocytes	1
1	lymphocytes	<ROOT>	-1
2	recognize	lymphocytes	1
3	antigens	recognize	2
4	in	antigens	3
5	the	form	6
6	form	in	4
7	of	form	6
8	peptides	bound	9
9	bound	of	7
10	to	bound	9
11	HLA-molecules	to	10
12	.	lymphocytes	1

0	Morphological	studies	1
1	studies	demonstrated	2
2	demonstrated	<ROOT>	-1
3	characteristic	features	4
4	features	demonstrated	2
5	of	erythroid	6
6	erythroid	features	4
7	differentiation	demonstrated	2
8	and	demonstrated	2
9	maturation	demonstrated	2
10	.	demonstrated	2

0	Some	are	9
1	of	Some	0
2	the	antiinflammatory	5
3	most	potent	4
4	potent	antiinflammatory	5
5	antiinflammatory	of	1
6	and	antiinflammatory	5
7	immunosuppressive	and	6
8	agents	and	6
9	are	<ROOT>	-1
10	synthetic	glucocorticoids	11
11	glucocorticoids	are	9
12	.	are	9

0	The	assay	4
1	electrophoretic	assay	4
2	mobility	assay	4
3	shift	assay	4
4	assay	<ROOT>	-1
5	with	assay	4
6	extracts	expressing	10
7	of	extracts	6
8	COS	cells	9
9	cells	of	7
10	expressing	with	5
11	GATA-binding	proteins	12
12	proteins	showed	13
13	showed	expressing	10
14	that	showed	13
15	GATA-4	that	14
16	has	GATA-4	15
17	the	affinity	20
18	highest	binding	19
19	binding	affinity	20
20	affinity	has	16
21	to	affinity	20
22	the	site	25
23	-70	site	25
24	GATA	site	25
25	site	to	21
26	among	affinity	20
27	the	proteins	30
28	three	proteins	30
29	GATA-binding	proteins	30
30	proteins	among	26
31	.	assay	4

0	Three	proteins	2
1	interacting	proteins	2
2	proteins	<ROOT>	-1
3	have	proteins	2
4	recently	proteins	2
5	been	recently	4
6	shown	been	5
7	to	shown	6
8	contribute	to	7
9	to	contribute	8
10	subset-restricted	expression	11
11	expression	to	9
12	of	expression	11
13	the	gene	15
14	IL-4	gene	15
15	gene	of	12
16	.	proteins	2

0	Seven	preterms	1
1	preterms	developed	2
2	developed	<ROOT>	-1
3	neonatal	distress	5
4	respiratory	distress	5
5	distress	developed	2
6	syndrome	developed	2
7	(	NRDS	8
8	NRDS	developed	2
9	)	NRDS	8
10	.	developed	2

0	Thus	<ROOT>	-1
1	,	Thus	0
2	the	,	1
3	protective	of	5
4	role	of	5
5	of	the	2
6	BHRF1	of	5
7	against	BHRF1	6
8	apoptosis	against	7
9	resembles	apoptosis	8
10	that	apoptosis	8
11	of	that	10
12	Bcl-2	of	11
13	in	of	11
14	being	in	13
15	cell	being	14
16	type	cell	15
17	specific	type	16
18	and	specific	17
19	dependent	and	18
20	on	dependent	19
21	the	stimulus	23
22	apoptotic	stimulus	23
23	stimulus	on	20
24	.	Thus	0

0	The	protein	4
1	PLZF-RAR	alpha	2
2	alpha	protein	4
3	fusion	protein	4
4	protein	contains	5
5	contains	<ROOT>	-1
6	an	N-terminal	9
7	approximately	120-amino-acid	8
8	120-amino-acid	N-terminal	9
9	N-terminal	motif	10
10	motif	contains	5
11	(	motif	10
12	called	(	11
13	the	domain	15
14	POZ	domain	15
15	domain	called	12
16	)	(	11
17	,	motif	10
18	which	is	19
19	is	protein-protein	38
20	also	is	19
21	found	is	19
22	in	found	21
23	a	variety	24
24	variety	in	22
25	of	variety	24
26	zinc	proteins	28
27	finger	proteins	28
28	proteins	of	25
29	and	proteins	28
30	a	group	31
31	group	variety	24
32	of	group	31
33	poxvirus	proteins	34
34	proteins	of	32
35	and	in	22
36	which	and	35
37	mediates	protein-protein	38
38	protein-protein	motif	10
39	interactions	motif	10
40	.	contains	5

0	Interleukin-5	plays	24
1	(	IL-5	2
2	IL-5	Interleukin-5	0
3	)	IL-5	2
4	,	Interleukin-5	0
5	which	is	6
6	is	Interleukin-5	0
7	produced	is	6
8	by	produced	7
9	CD4-LRB-+-RRB-	Th2	14
10	T	helper	11
11	helper	2	12
12	2	(	13
13	(	CD4-LRB-+-RRB-	9
14	Th2	by	8
15	)	Th2	14
16	cells	Interleukin-5	0
17	,	Interleukin-5	0
18	but	Interleukin-5	0
19	not	but	18
20	by	Th1	21
21	Th1	not	19
22	cells	Interleukin-5	0
23	,	Interleukin-5	0
24	plays	<ROOT>	-1
25	a	plays	24
26	key	a	25
27	role	key	26
28	in	role	27
29	the	development	30
30	development	in	28
31	of	development	30
32	eosinophilia	of	31
33	in	development	30
34	asthma	in	33
35	.	plays	24

0	Cytokine	stimulation	1
1	stimulation	leads	2
2	leads	the	4
3	to	the	4
4	the	<ROOT>	-1
5	phosphorylation	the	4
6	of	tyrosine	8
7	specific	tyrosine	8
8	tyrosine	phosphorylation	5
9	residues	tyrosine	8
10	within	intracellular	12
11	the	intracellular	12
12	intracellular	residues	9
13	domain	the	4
14	of	the	4
15	the	receptor	18
16	corresponding	cytokine	17
17	cytokine	receptor	18
18	receptor	of	14
19	.	the	4

0	Finally	demonstrate	3
1	,	demonstrate	3
2	we	demonstrate	3
3	demonstrate	<ROOT>	-1
4	that	deletion	5
5	deletion	demonstrate	3
6	in	deletion	5
7	NFATx1	in	6
8	of	NFATx1	7
9	the	mapped	10
10	mapped	60	11
11	60	of	8
12	residues	leads	13
13	leads	demonstrate	3
14	to	nuclear	16
15	its	nuclear	16
16	nuclear	leads	13
17	translocation	nuclear	16
18	independent	translocation	17
19	of	calcium	20
20	calcium	independent	18
21	signaling	demonstrate	3
22	.	demonstrate	3

0	This	pathway	2
1	ROS	pathway	2
2	pathway	was	3
3	was	<ROOT>	-1
4	also	was	3
5	characterized	was	3
6	by	characterized	5
7	the	use	8
8	use	by	6
9	of	use	8
10	other	inhibitors	11
11	inhibitors	of	9
12	.	was	3

0	Alternative	splicing	1
1	splicing	<ROOT>	-1
2	of	splicing	1
3	exon	of	2
4	10	exon	3
5	of	exon	3
6	the	of	5
7	TSC2	the	6
8	gene	TSC2	7
9	may	gene	8
10	be	may	9
11	a	be	10
12	normal	.	14
13	variant	.	14
14	.	a	11

0	When	are	3
1	endothelial	cells	2
2	cells	are	3
3	are	<ROOT>	-1
4	incubated	are	3
5	with	incubated	4
6	this	lipoprotein	7
7	lipoprotein	with	5
8	in	pathophysiologic	9
9	pathophysiologic	are	3
10	amounts	are	3
11	,	are	3
12	the	,	11
13	cells	the	12
14	are	activated	15
15	activated	cells	13
16	.	are	3

0	By	observed	6
1	confocal	microscopy	3
2	fluorescence	microscopy	3
3	microscopy	By	0
4	,	observed	6
5	we	observed	6
6	observed	(	13
7	a	staining	9
8	positive	staining	9
9	staining	observed	6
10	for	NF-kappa	11
11	NF-kappa	observed	6
12	B	(	13
13	(	<ROOT>	-1
14	p65	(	13
15	subunit	(	13
16	)	(	13
17	in	(	13
18	the	nuclei	19
19	nuclei	of	20
20	of	in	17
21	PAEC	of	20
22	exposed	for	23
23	for	of	20
24	1	(	13
25	hr	(	13
26	30	(	13
27	min	to	28
28	to	30	26
29	human	(	13
30	serum	(	13
31	,	NF-kappa	34
32	which	,	31
33	indicated	NF-kappa	34
34	NF-kappa	(	13
35	B	(	13
36	activation	in	37
37	in	(	13
38	this	setting	39
39	setting	in	37
40	.	setting	39

0	One	hour	1
1	hour	<ROOT>	-1
2	pulse-treatment	hour	1
3	with	pulse-treatment	2
4	3	topoisomerase	8
5	microM	3	4
6	etoposide	caused	7
7	caused	microM	5
8	topoisomerase	with	3
9	associated	topoisomerase	8
10	,	hour	1
11	primary	breakage	13
12	DNA	breakage	13
13	breakage	,	10
14	,	breakage	13
15	which	was	16
16	was	breakage	13
17	rapidly	was	16
18	followed	was	16
19	by	followed	18
20	apoptosis	by	19
21	.	apoptosis	20

0	Those	cytokines	1
1	cytokines	may	2
2	may	<ROOT>	-1
3	modulate	may	2
4	the	differentiation	5
5	differentiation	modulate	3
6	of	differentiation	5
7	monocytes	of	6
8	by	modulate	3
9	CSFs	by	8
10	.	may	2

0	BOB.1/OBF.1	is	1
1	is	<ROOT>	-1
2	a	coactivator	4
3	transcriptional	coactivator	4
4	coactivator	is	1
5	that	is	6
6	is	coactivator	4
7	constitutively	is	6
8	expressed	constitutively	7
9	in	expressed	8
10	B	cells	11
11	cells	in	9
12	and	in	9
13	interacts	and	12
14	with	interacts	13
15	the	Oct1	16
16	Oct1	with	14
17	and	Oct1	16
18	Oct2	factors	20
19	transcription	factors	20
20	factors	and	17
21	.	is	1

0	Thus	)	16
1	,	Thus	0
2	the	binding	3
3	binding	,	1
4	of	binding	3
5	V3	loop	6
6	loop	of	4
7	of	loop	6
8	gp120	of	7
9	to	binding	3
10	the	to	9
11	cell	the	10
12	surface	molecule	13
13	molecule	cell	11
14	(	binding	3
15	s	Thus	0
16	)	appears	17
17	appears	<ROOT>	-1
18	to	appears	17
19	affect	to	18
20	intracellular	IL-2	21
21	IL-2	affect	19
22	signaling	,	23
23	,	IL-2	21
24	which	leads	25
25	leads	appears	17
26	to	leads	25
27	the	suppression	28
28	suppression	T	31
29	of	T	31
30	IL-2-induced	T	31
31	T	to	26
32	cell	appears	17
33	growth	appears	17
34	.	appears	17

0	The	gene	9
1	interleukin	IL-2R	6
2	2	(	5
3	receptor	alpha-chain	4
4	alpha-chain	(	5
5	(	interleukin	1
6	IL-2R	alpha	7
7	alpha	The	0
8	)	The	0
9	gene	<ROOT>	-1
10	is	gene	9
11	a	regulator	13
12	key	regulator	13
13	regulator	is	10
14	of	lymphocyte	15
15	lymphocyte	regulator	13
16	proliferation	lymphocyte	15
17	.	gene	9

0	Gel	demonstrated	3
1	shift	Gel	0
2	assays	demonstrated	3
3	demonstrated	<ROOT>	-1
4	SP1	demonstrated	3
5	and	demonstrated	3
6	Egr-1	demonstrated	3
7	binding	Egr-1	6
8	to	the	9
9	the	binding	7
10	CD19	demonstrated	3
11	GC	demonstrated	3
12	box	demonstrated	3
13	,	demonstrated	3
14	while	unknown	15
15	unknown	demonstrated	3
16	nuclear	unknown	15
17	proteins	the	19
18	bound	the	19
19	the	nuclear	16
20	PyG	the	19
21	and	PyG	20
22	AT	boxes	23
23	boxes	and	21
24	.	demonstrated	3

0	We	show	1
1	show	<ROOT>	-1
2	that	show	1
3	the	mechanism	5
4	molecular	mechanism	5
5	mechanism	that	2
6	(	mechanism	5
7	s	mechanism	5
8	)	mechanism	5
9	underlying	)	8
10	Ig	extinction	12
11	gene	extinction	12
12	extinction	underlying	9
13	can	be	14
14	be	mechanism	5
15	explained	be	14
16	,	in	19
17	at	in	19
18	least	at	17
19	in	explained	15
20	part	in	19
21	,	in	19
22	by	in	19
23	a	lack	24
24	lack	by	22
25	of	lack	24
26	transcription	factors	27
27	factors	of	25
28	that	are	29
29	are	lack	24
30	essential	are	29
31	for	essential	30
32	Ig	for	31
33	gene	Ig	32
34	transcription	.	35
35	.	gene	33

0	These	results	1
1	results	suggest	2
2	suggest	TMD	8
3	that	suggest	2
4	blasts	that	3
5	in	blasts	4
6	M7	in	5
7	and	in	5
8	TMD	<ROOT>	-1
9	may	TMD	8
10	correspond	may	9
11	to	correspond	10
12	progenitors	to	11
13	of	both	14
14	both	progenitors	12
15	erythroid	both	14
16	and	erythroid	15
17	megakaryocytic	TMD	8
18	lineages	TMD	8
19	.	TMD	8

0	Exclusive	expression	2
1	paternal	expression	2
2	expression	was	5
3	of	expression	2
4	WT1	of	3
5	was	<ROOT>	-1
6	also	was	5
7	shown	was	5
8	in	shown	7
9	non-cultured	lymphocytes	11
10	peripheral	lymphocytes	11
11	lymphocytes	in	8
12	from	two	15
13	the	two	15
14	latter	two	15
15	two	in	8
16	individuals	was	5
17	.	was	5

0	Bruton	(	5
1	's	Bruton	0
2	agammaglobulinemia	tyrosine	3
3	tyrosine	Bruton	0
4	kinase	(	5
5	(	is	8
6	Btk	(	5
7	)	(	5
8	is	<ROOT>	-1
9	a	kinase	12
10	cytoplasmic	kinase	12
11	tyrosine	kinase	12
12	kinase	is	8
13	involved	kinase	12
14	in	involved	13
15	the	agammaglobulinemia	19
16	human	agammaglobulinemia	19
17	disease	agammaglobulinemia	19
18	X-linked	agammaglobulinemia	19
19	agammaglobulinemia	in	14
20	(	XLA	21
21	XLA	agammaglobulinemia	19
22	)	XLA	21
23	.	is	8

0	Regulation	could	3
1	of	Regulation	0
2	NFAT	of	1
3	could	<ROOT>	-1
4	be	could	3
5	therefore	be	4
6	a	element	8
7	critical	element	8
8	element	be	4
9	in	be	4
10	the	polarization	11
11	polarization	in	9
12	to	polarization	11
13	eTh1	could	3
14	or	eTh1	13
15	eTh2	could	3
16	.	could	3

0	Effect	<ROOT>	-1
1	of	Effect	0
2	adenovirus	of	1
3	2	adenovirus	2
4	on	Effect	0
5	cellular	activation	7
6	gene	activation	7
7	activation	on	4
8	in	Effect	0
9	blood-derived	in	8
10	monocytes	blood-derived	9
11	and	monocytes	10
12	macrophages	and	11
13	.	Effect	0

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	activates	5
4	histamine	activates	5
5	activates	several	6
6	several	indicate	2
7	mechanisms	several	6
8	involved	mechanisms	7
9	in	the	10
10	the	involved	8
11	induction	the	10
12	of	induction	11
13	differentiation	of	12
14	,	indicate	2
15	such	as	16
16	as	indicate	2
17	cAMP	as	16
18	and	c-fos	19
19	c-fos	cAMP	17
20	production	cAMP	17
21	,	cAMP	17
22	but	,	21
23	fails	but	22
24	to	fails	23
25	promote	to	24
26	differentiation	to	24
27	of	U937	28
28	U937	differentiation	26
29	cells	indicate	2
30	,	indicate	2
31	apparently	,	30
32	due	apparently	31
33	to	due	32
34	the	to	33
35	rapid	the	34
36	desensitization	rapid	35
37	of	desensitization	36
38	H2	receptors	39
39	receptors	rapid	35
40	.	indicate	2

0	Large	deletions	2
1	germline	deletions	2
2	deletions	occur	5
3	of	deletions	2
4	TSC2	of	3
5	occur	<ROOT>	-1
6	in	occur	5
7	&lt;	in	6
8	5	%	9
9	%	&lt;	7
10	of	%	9
11	cases	of	10
12	,	%	9
13	and	%	9
14	a	number	15
15	number	been	21
16	of	number	15
17	small	of	16
18	intragenic	have	20
19	mutations	have	20
20	have	small	17
21	been	and	13
22	described	been	21
23	.	occur	5

0	Signals	are	3
1	from	Signals	0
2	TES1	from	1
3	are	<ROOT>	-1
4	sufficient	are	3
5	to	sufficient	4
6	drive	initial	7
7	initial	to	5
8	proliferation	initial	7
9	of	infected	10
10	infected	proliferation	8
11	resting	B	12
12	B	are	3
13	lymphocytes	B	12
14	,	are	3
15	but	are	3
16	most	lymphoblastoid	17
17	lymphoblastoid	but	15
18	cells	infected	19
19	infected	are	3
20	with	are	3
21	a	virus	22
22	virus	with	20
23	that	does	24
24	does	virus	22
25	not	does	24
26	express	does	24
27	the	express	26
28	155	the	27
29	residues	beyond	30
30	beyond	155	28
31	TES1	beyond	30
32	fail	beyond	30
33	to	fail	32
34	grow	to	33
35	as	grow	34
36	long-term	grow	34
37	cell	long-term	36
38	lines	cell	37
39	.	lines	38

0	Inhibition	<ROOT>	-1
1	of	Inhibition	0
2	nuclear	of	1
3	factor	nuclear	2
4	kappaB	nuclear	2
5	activation	kappaB	4
6	attenuates	apoptosis	7
7	apoptosis	activation	5
8	resistance	apoptosis	7
9	in	lymphoid	10
10	lymphoid	apoptosis	7
11	cells	Inhibition	0
12	.	Inhibition	0

0	The	compartments	2
1	three	compartments	2
2	compartments	are	3
3	are	<ROOT>	-1
4	thought	are	3
5	to	thought	4
6	be	to	5
7	of	be	6
8	common	origin	10
9	endodermal	origin	10
10	origin	of	7
11	;	are	3
12	in	are	3
13	contrast	in	12
14	to	contrast	13
15	earlier	hypotheses	16
16	hypotheses	to	14
17	,	hypotheses	16
18	which	suggested	19
19	suggested	hypotheses	16
20	that	suggested	19
21	the	compartment	23
22	endocrine	compartment	23
23	compartment	was	24
24	was	that	20
25	of	was	24
26	neuroectodermal	origin	27
27	origin	of	25
28	.	are	3

0	The	synthesis	1
1	synthesis	<ROOT>	-1
2	and	synthesis	1
3	immunogenicity	and	2
4	of	immunogenicity	3
5	varicella-zoster	E	8
6	virus	E	8
7	glycoprotein	E	8
8	E	of	4
9	and	E	8
10	immediate-early	protein	11
11	protein	(	12
12	(	herpes	18
13	IE62	)	14
14	)	(	12
15	expressed	in	16
16	in	)	14
17	recombinant	herpes	18
18	herpes	and	9
19	simplex	herpes	18
20	virus-1	simplex	19
21	.	virus-1	20

0	Induction	<ROOT>	-1
1	of	(	3
2	relA	of	1
3	(	Induction	0
4	p65	(	3
5	)	Induction	0
6	and	)	5
7	I	B	9
8	kappa	I	7
9	B	and	6
10	alpha	Induction	0
11	subunit	Induction	0
12	expression	peripheral	17
13	during	expression	12
14	differentiation	during	13
15	of	peripheral	17
16	human	peripheral	17
17	peripheral	Induction	0
18	blood	Induction	0
19	monocytes	Induction	0
20	to	Induction	0
21	macrophages	Induction	0
22	.	Induction	0

0	Regulation	type	4
1	of	type	4
2	inosine-5'-monophosphate	dehydrogenase	3
3	dehydrogenase	type	4
4	type	<ROOT>	-1
5	II	type	4
6	gene	in	8
7	expression	in	8
8	in	II	5
9	human	type	4
10	T	cells	11
11	cells	human	9
12	.	cells	11

0	We	hypothesize	1
1	hypothesize	<ROOT>	-1
2	that	hypothesize	1
3	this	protein	5
4	110-kDa	protein	5
5	protein	may	6
6	may	that	2
7	be	may	6
8	a	functionally	9
9	functionally	cell-specific	12
10	important	cell-specific	12
11	B	cell-specific	12
12	cell-specific	be	7
13	co-activator	hypothesize	1
14	of	co-activator	13
15	A-MYB	of	14
16	.	hypothesize	1

0	We	agents	29
1	have	We	0
2	previously	shown	3
3	shown	have	1
4	that	shown	3
5	ETS1	can	6
6	can	that	4
7	transactivate	can	6
8	GM-CSF	transactivate	7
9	in	T	11
10	Jurkat	T	11
11	T	transactivate	7
12	cells	We	0
13	,	We	0
14	but	,	13
15	only	after	16
16	after	,	13
17	the	after	16
18	cells	the	17
19	have	cells	18
20	been	have	19
21	stimulated	been	20
22	by	stimulated	21
23	treatment	by	22
24	with	treatment	23
25	PMA	with	24
26	and	PMA	25
27	ionomycin	We	0
28	,	agents	29
29	agents	<ROOT>	-1
30	that	mimic	31
31	mimic	cell	33
32	T	cell	33
33	cell	agents	29
34	activation	agents	29
35	.	agents	29

0	The	studies	1
1	studies	described	2
2	described	<ROOT>	-1
3	herein	described	2
4	demonstrate	that	5
5	that	activation	7
6	the	activation	7
7	activation	herein	3
8	domain	described	2
9	.	described	2

0	ZAP-70	will	1
1	will	<ROOT>	-1
2	then	will	1
3	be	will	1
4	able	be	3
5	to	able	4
6	effectively	to	5
7	control	effectively	6
8	phosphorylation	control	7
9	of	phosphorylation	8
10	its	substrates	11
11	substrates	of	9
12	and	substrates	11
13	lead	control	7
14	to	gene	15
15	gene	activation	16
16	activation	lead	13
17	.	activation	16

0	NGAL	was	1
1	was	<ROOT>	-1
2	expressed	was	1
3	in	bone	4
4	bone	expressed	2
5	marrow	was	1
6	and	was	1
7	in	and	6
8	tissues	was	1
9	that	are	10
10	are	was	1
11	prone	are	10
12	to	prone	11
13	exposure	to	12
14	to	exposure	13
15	microorganisms	exposure	13
16	.	was	1

0	Selection	of	1
1	of	<ROOT>	-1
2	down-regulated	of	1
3	sequences	along	4
4	along	monocytic	6
5	the	monocytic	6
6	monocytic	of	1
7	differentiation	of	1
8	of	of	1
9	leukemic	of	1
10	HL60	of	1
11	cells	of	1
12	.	of	1

0	Ten	patients	2
1	HIV-infected	patients	2
2	patients	<ROOT>	-1
3	with	patients	2
4	normal	affinity	6
5	receptor	affinity	6
6	affinity	with	3
7	to	patients	2
8	glucocorticoids	to	7
9	(	AIDS-C	10
10	AIDS-C	glucocorticoids	8
11	)	AIDS-C	10
12	,	patients	2
13	10	patients	15
14	HIV-infected	patients	15
15	patients	low	17
16	with	low	17
17	low	patients	2
18	receptor	affinity	19
19	affinity	patients	2
20	to	patients	2
21	glucocorticoids	to	20
22	(	AIDS-GR	23
23	AIDS-GR	glucocorticoids	21
24	)	AIDS-GR	23
25	,	patients	2
26	and	patients	2
27	20	and	26
28	healthy	subjects	29
29	subjects	were	30
30	were	patients	2
31	studied	were	30
32	.	patients	2

0	These	<ROOT>	-1
1	results	These	0
2	imply	that	3
3	that	results	1
4	E1B	19K	5
5	19K	that	3
6	is	that	3
7	required	is	6
8	for	required	7
9	efficient	for	8
10	viral	replication	12
11	DNA	replication	12
12	replication	efficient	9
13	in	efficient	9
14	U937	efficient	9
15	cells	These	0
16	.	These	0

0	In	was	17
1	fetal	In	0
2	liver	mice	5
3	of	mice	5
4	PU.1-/-	mice	5
5	mice	fetal	1
6	,	mice	5
7	which	lack	8
8	lack	mice	5
9	lymphoid	and	10
10	and	lack	8
11	myeloid	and	10
12	cells	lack	8
13	,	mice	5
14	expression	of	15
15	of	was	17
16	Btk	of	15
17	was	<ROOT>	-1
18	reduced	two-	19
19	two-	was	17
20	to	two-	19
21	threefold	to	20
22	but	threefold	21
23	not	abolished	24
24	abolished	but	22
25	.	was	17

0	Cytomegalovirus	genes	3
1	immediate	genes	3
2	early	genes	3
3	genes	upregulate	4
4	upregulate	<ROOT>	-1
5	interleukin-6	upregulate	4
6	gene	interleukin-6	5
7	expression	.	8
8	.	gene	6

0	In	was	7
1	smoking	patients	3
2	menopausal	patients	3
3	patients	In	0
4	,	was	7
5	lymphocyte	infiltration	6
6	infiltration	was	7
7	was	<ROOT>	-1
8	found	was	7
9	to	found	8
10	be	to	9
11	higher	be	10
12	than	higher	11
13	in	than	12
14	non-smokers	in	13
15	(	non-smokers	14
16	p	(	15
17	&lt;	0.05	18
18	0.05	p	16
19	)	p	16
20	.	was	7

0	These	findings	1
1	findings	may	2
2	may	<ROOT>	-1
3	help	may	2
4	in	help	3
5	understanding	in	4
6	the	pathogenesis	7
7	pathogenesis	understanding	5
8	of	pathogenesis	7
9	the	immunodeficiency	10
10	immunodeficiency	of	8
11	that	occurs	12
12	occurs	pathogenesis	7
13	with	occurs	12
14	mutations	with	13
15	of	mutations	14
16	JAK3	of	15
17	and	JAK3	16
18	may	and	17
19	suggest	may	18
20	a	mechanism	21
21	mechanism	suggest	19
22	for	mechanism	21
23	the	effects	25
24	pleiotropic	effects	25
25	effects	for	22
26	of	effects	25
27	IL-4	of	26
28	.	may	2

0	Construction	<ROOT>	-1
1	and	Construction	0
2	biological	characterization	3
3	characterization	and	1
4	of	Construction	0
5	an	protein	8
6	interleukin-12	protein	8
7	fusion	protein	8
8	protein	of	4
9	(	Flexi-12	10
10	Flexi-12	protein	8
11	)	Flexi-12	10
12	:	protein	8
13	delivery	protein	8
14	to	blasts	18
15	acute	blasts	18
16	myeloid	blasts	18
17	leukemic	blasts	18
18	blasts	delivery	13
19	using	Construction	0
20	adeno-associated	virus	21
21	virus	using	19
22	.	Construction	0

0	Glucocorticoid	receptors	1
1	receptors	<ROOT>	-1
2	in	peripheral	4
3	human	peripheral	4
4	peripheral	receptors	1
5	blood	receptors	1
6	mononuclear	cells	7
7	cells	receptors	1
8	in	receptors	1
9	relation	in	8
10	to	relation	9
11	age	to	10
12	and	age	11
13	to	sport	14
14	sport	and	12
15	activity	receptors	1
16	.	receptors	1

0	Regulation	<ROOT>	-1
1	of	Regulation	0
2	the	gene	5
3	tissue	gene	5
4	factor	gene	5
5	gene	of	1
6	in	human	7
7	human	of	1
8	monocytic	of	1
9	cells	Regulation	0
10	.	Regulation	0

0	Inhibition	mRNA	8
1	of	nuclear	2
2	nuclear	Inhibition	0
3	factor	subunit	6
4	kappa	subunit	6
5	B	subunit	6
6	subunit	nuclear	2
7	p65	Inhibition	0
8	mRNA	<ROOT>	-1
9	accumulation	in	10
10	in	mRNA	8
11	lipopolysaccharide-stimulated	human	12
12	human	monocytic	13
13	monocytic	mRNA	8
14	cells	with	16
15	treated	with	16
16	with	mRNA	8
17	sodium	mRNA	8
18	salicylate	mRNA	8
19	.	mRNA	8

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	In	expressed	10
3	all	ER	7
4	cells	ER	7
5	tested	,	6
6	,	cells	4
7	ER	In	2
8	mRNA	was	9
9	was	expressed	10
10	expressed	RESULTS	0
11	without	RESULTS	0
12	prior	RESULTS	0
13	in	prior	12
14	vitro	in	13
15	stimulation	RESULTS	0
16	.	RESULTS	0

0	The	virus	3
1	caprine	virus	3
2	arthritis-encephalitis	virus	3
3	virus	<ROOT>	-1
4	(	)	6
5	CAEV	)	6
6	)	virus	3
7	long	)	6
8	terminal	)	6
9	repeat	terminal	8
10	(	repeat	9
11	LTR	(	10
12	)	is	13
13	is	LTR	11
14	activated	is	13
15	by	in	21
16	gamma	by	15
17	interferon	gamma	16
18	(	IFN-gamma	19
19	IFN-gamma	interferon	17
20	)	interferon	17
21	in	cells	23
22	promonocytic	cells	23
23	cells	LTR	11
24	.	cells	23

0	Southern	hybridization	2
1	blot	hybridization	2
2	hybridization	bands	23
3	showed	hybridization	2
4	that	hybridization	2
5	only	bands	9
6	two	only	5
7	and	only	5
8	four	only	5
9	bands	that	4
10	were	bands	9
11	found	were	10
12	in	found	11
13	ILT-mat	in	12
14	and	ILT-mat	13
15	ATL16T-LRB---RRB-	and	14
16	cells	,	17
17	,	and	14
18	respectively	hybridization	2
19	,	hybridization	2
20	whereas	&gt;	21
21	&gt;	hybridization	2
22	10	hybridization	2
23	bands	were	24
24	were	<ROOT>	-1
25	detected	were	24
26	in	detected	25
27	other	cells	29
28	ATL	cells	29
29	cells	in	26
30	.	cells	29

0	Inhibition	<ROOT>	-1
1	of	Inhibition	0
2	binding	of	1
3	by	selectin	5
4	anti-P	selectin	5
5	selectin	of	1
6	antibodies	Inhibition	0
7	reduced	Inhibition	0
8	the	effect	9
9	effect	reduced	7
10	of	effect	9
11	activated	platelets	12
12	platelets	of	10
13	on	cytokine	14
14	cytokine	effect	9
15	production	effect	9
16	.	Inhibition	0

0	Additionally	showed	3
1	,	showed	3
2	we	showed	3
3	showed	of	20
4	that	showed	3
5	pentazocine	competitive	8
6	,	pentazocine	5
7	a	competitive	8
8	competitive	that	4
9	inhibitor	of	10
10	of	also	15
11	SR	31747A	12
12	31747A	of	10
13	binding	of	10
14	,	binding	13
15	also	that	4
16	prevents	the	17
17	the	immunosuppressive	18
18	immunosuppressive	showed	3
19	effect	of	20
20	of	<ROOT>	-1
21	SR	of	20
22	31747A	of	20
23	.	of	20

0	Impaired	induction	1
1	induction	<ROOT>	-1
2	of	induction	1
3	c-fos/c-jun	genes	4
4	genes	of	2
5	and	induction	1
6	of	and	5
7	transcriptional	regulatory	8
8	regulatory	of	6
9	proteins	binding	10
10	binding	regulatory	8
11	distinct	binding	10
12	c-fos/c-jun	induction	1
13	promoter	induction	1
14	elements	induction	1
15	in	induction	1
16	activated	in	15
17	human	activated	16
18	T	during	20
19	cells	during	20
20	during	human	17
21	aging	human	17
22	.	induction	1

0	In	have	12
1	particular	In	0
2	,	have	12
3	one	class	4
4	class	have	12
5	of	class	4
6	helix-loop-helix	proteins	7
7	proteins	of	5
8	,	class	4
9	termed	class	4
10	E-proteins	termed	9
11	,	class	4
12	have	<ROOT>	-1
13	been	have	12
14	implicated	the	16
15	in	implicated	14
16	the	been	13
17	regulation	have	12
18	of	gene	19
19	gene	regulation	17
20	expression	have	12
21	during	expression	20
22	B-cell	have	12
23	development	.	24
24	.	B-cell	22

0	A	population	2
1	small	population	2
2	population	<ROOT>	-1
3	of	population	2
4	UT-7/GM	cells	5
5	cells	of	3
6	positively	cells	5
7	stained	for	8
8	for	population	2
9	hemoglobin	population	2
10	(	Hb	11
11	Hb	hemoglobin	9
12	)	Hb	11
13	after	hemoglobin	9
14	a	after	13
15	7-day	to	17
16	exposure	to	17
17	to	a	14
18	TPO	to	17
19	.	population	2

0	Similarly	indicates	4
1	,	indicates	4
2	substantial	evidence	3
3	evidence	indicates	4
4	indicates	<ROOT>	-1
5	that	indicates	4
6	full	activation	7
7	activation	requires	10
8	of	activation	7
9	NF-kappaB	of	8
10	requires	that	5
11	dual	signals	12
12	signals	requires	10
13	.	indicates	4

0	APLs	are	11
1	with	APLs	0
2	the	alpha	4
3	PML-RAR	alpha	4
4	alpha	with	1
5	or	alpha	4
6	the	protein	10
7	PLZF-RAR	alpha	8
8	alpha	protein	10
9	fusion	protein	10
10	protein	or	5
11	are	blasts	32
12	phenotypically	indistinguishable	13
13	indistinguishable	are	11
14	except	indistinguishable	13
15	that	except	14
16	they	differ	17
17	differ	that	15
18	in	differ	17
19	their	to	21
20	sensitivity	to	21
21	to	in	18
22	retinoic	(	24
23	acid	(	24
24	(	to	21
25	RA	(	24
26	)	-induced	27
27	-induced	that	15
28	differentiation	are	11
29	:	are	11
30	PML-RAR	alpha	31
31	alpha	blasts	32
32	blasts	alpha	50
33	are	blasts	32
34	sensitive	are	33
35	to	sensitive	34
36	RA	to	35
37	and	RA	36
38	patients	sensitive	34
39	enter	blasts	32
40	disease	blasts	32
41	remission	blasts	32
42	after	RA	43
43	RA	blasts	32
44	treatment	,	45
45	,	blasts	32
46	while	blasts	32
47	patients	while	46
48	with	patients	47
49	PLZF-RAR	with	48
50	alpha	<ROOT>	-1
51	do	alpha	50
52	not	alpha	50
53	.	alpha	50

0	Maximal	induction	2
1	LPS	induction	2
2	induction	required	7
3	of	induction	2
4	the	promoter	6
5	TF	promoter	6
6	promoter	of	3
7	required	<ROOT>	-1
8	the	sites	11
9	two	sites	11
10	AP-1	sites	11
11	sites	required	7
12	and	B	15
13	the	B	15
14	kappa	B	15
15	B	sites	11
16	site	required	7
17	within	response	20
18	the	response	20
19	LPS	response	20
20	response	site	16
21	element	required	7
22	.	required	7

0	GATA-1	protein	1
1	protein	vary	4
2	and	protein	1
3	mRNA	and	2
4	vary	<ROOT>	-1
5	in	vary	4
6	a	manner	8
7	similar	manner	8
8	manner	in	5
9	through	vary	4
10	the	cycle	12
11	cell	cycle	12
12	cycle	through	9
13	,	vary	4
14	suggesting	vary	4
15	that	suggesting	14
16	the	expression	17
17	expression	is	27
18	of	expression	17
19	the	of	18
20	gene	the	19
21	or	gene	20
22	the	stability	23
23	stability	or	21
24	of	stability	23
25	its	message	26
26	message	of	24
27	is	that	15
28	regulated	is	27
29	.	vary	4

0	Among	is	7
1	the	Among	0
2	documented	the	1
3	cellular	to	5
4	responses	cellular	3
5	to	documented	2
6	LDL	the	1
7	is	<ROOT>	-1
8	increased	recruitment	9
9	recruitment	is	7
10	of	recruitment	9
11	monocytes	of	10
12	,	which	13
13	which	recruitment	9
14	are	which	13
15	believed	are	14
16	to	believed	15
17	play	to	16
18	a	play	17
19	major	a	18
20	role	in	21
21	in	major	19
22	promoting	in	21
23	intimal	formation	25
24	plaque	formation	25
25	formation	in	21
26	.	is	7

0	Taken	provide	5
1	together	Taken	0
2	,	provide	5
3	these	results	4
4	results	provide	5
5	provide	are	21
6	a	aspect	8
7	new	aspect	8
8	aspect	provide	5
9	to	aspect	8
10	our	to	9
11	knowledge	of	12
12	of	our	10
13	monocyte	evidence	17
14	differentiation	monocyte	13
15	and	differentiation	14
16	provide	and	15
17	evidence	of	12
18	that	evidence	17
19	human	of	12
20	monocytes	provide	5
21	are	<ROOT>	-1
22	flexible	are	21
23	in	flexible	22
24	their	in	23
25	differentiation	their	24
26	potential	differentiation	25
27	and	potential	26
28	are	and	27
29	precursors	are	28
30	not	macrophages	33
31	only	not	30
32	of	not	30
33	macrophages	are	28
34	but	macrophages	33
35	also	differentiation	25
36	of	also	35
37	CD1+relB+DC	of	36
38	and	CD1+relB+DC	37
39	TRAP-positive	MGC	40
40	MGC	and	38
41	.	are	21

0	This	system	1
1	system	<ROOT>	-1
2	faithfully	recapitulates	3
3	recapitulates	system	1
4	late	patterns	6
5	expression	patterns	6
6	patterns	recapitulates	3
7	from	endogenous	9
8	the	endogenous	9
9	endogenous	recapitulates	3
10	virus	system	1
11	,	system	1
12	implicating	system	1
13	specific	sequences	15
14	cis-active	sequences	15
15	sequences	implicating	12
16	in	implicating	12
17	the	in	16
18	control	the	17
19	of	control	18
20	late	of	19
21	gene	late	20
22	expression	.	23
23	.	gene	21

0	After	<ROOT>	-1
1	exercise	After	0
2	following	exercise	1
3	placebo	following	2
4	administration	we	5
5	we	placebo	3
6	observed	in	8
7	increases	in	8
8	in	placebo	3
9	concentrations	placebo	3
10	of	blood	11
11	blood	concentrations	9
12	substrates	blood	11
13	,	blood	11
14	plasma	adrenocorticotropin	15
15	adrenocorticotropin	(	16
16	(	After	0
17	ACTH	(	16
18	)	(	16
19	,	hormone	21
20	growth	hormone	21
21	hormone	(	16
22	and	hormone	21
23	cortisol	and	22
24	and	and	22
25	in	and	24
26	the	number	27
27	number	in	25
28	of	glucocorticoid	29
29	glucocorticoid	number	27
30	receptors	After	0
31	in	After	0
32	lymphocytes	After	0
33	without	After	0
34	changes	After	0
35	in	changes	34
36	the	in	35
37	dissociation	.	39
38	constant	.	39
39	.	the	36

0	Therefore	<ROOT>	-1
1	oxygen	therapy	2
2	therapy	is	3
3	is	Therefore	0
4	helpful	is	3
5	in	helpful	4
6	raising	in	5
7	the	activity	8
8	activity	raising	6
9	of	glucocorticoid	10
10	glucocorticoid	activity	8
11	receptors	Therefore	0
12	and	Therefore	0
13	controlling	and	12
14	the	development	15
15	development	controlling	13
16	of	the	17
17	the	development	15
18	disease	Therefore	0
19	.	Therefore	0

0	Expression	<ROOT>	-1
1	of	Expression	0
2	bcl-6	protein	3
3	protein	of	1
4	in	normal	5
5	normal	of	1
6	skin	Expression	0
7	and	Expression	0
8	epidermal	Expression	0
9	neoplasms	Expression	0
10	.	Expression	0

0	In	hypothesize	13
1	the	absence	2
2	absence	In	0
3	of	absence	2
4	a	gene	7
5	cloned	gene	7
6	MIBP1	gene	7
7	gene	of	3
8	for	further	9
9	further	absence	2
10	studies	In	0
11	,	hypothesize	13
12	we	hypothesize	13
13	hypothesize	<ROOT>	-1
14	that	acts	16
15	RFX1	acts	16
16	acts	hypothesize	13
17	with	acts	16
18	MIBP1	with	17
19	to	acts	16
20	negatively	regulate	21
21	regulate	the	22
22	the	to	19
23	core	the	22
24	promoter	core	23
25	activity	the	22
26	through	activity	25
27	the	gamma	29
28	NRE	gamma	29
29	gamma	through	26
30	site	gamma	29
31	.	hypothesize	13

0	By	<ROOT>	-1
1	using	By	0
2	a	using	1
3	reverse	a	2
4	transcription-PCR-based	approach	5
5	approach	reverse	3
6	and	approach	5
7	a	set	8
8	set	and	6
9	of	set	8
10	primers	of	9
11	specific	set	8
12	for	DNA-binding	14
13	the	DNA-binding	14
14	DNA-binding	specific	11
15	domains	By	0
16	of	highly	17
17	highly	homologous	18
18	homologous	domains	15
19	members	homologous	18
20	of	members	19
21	the	of	20
22	C/EBP	the	21
23	family	C/EBP	22
24	of	transcriptional	25
25	transcriptional	family	23
26	regulators	C/EBP	22
27	,	regulators	26
28	we	regulators	26
29	have	we	28
30	cloned	have	29
31	a	cloned	30
32	novel	a	31
33	human	novel	32
34	gene	human	33
35	encoding	a	36
36	a	member	37
37	member	gene	34
38	of	member	37
39	the	of	38
40	C/EBP	gene	41
41	gene	the	39
42	family	,	43
43	,	gene	41
44	identified	have	29
45	as	human	47
46	the	human	47
47	human	identified	44
48	homolog	human	47
49	of	homolog	48
50	CRP1	of	49
51	,	CRP1	50
52	C/EBP-epsilon	By	0
53	.	By	0

0	Constitutive	expression	1
1	expression	<ROOT>	-1
2	of	expression	1
3	Id3	development	6
4	completely	Id3	3
5	blocks	development	6
6	development	of	2
7	of	development	6
8	CD34+	of	7
9	cells	CD34+	8
10	into	T	11
11	T	cells	9
12	cells	in	13
13	in	expression	1
14	a	expression	1
15	fetal	expression	1
16	thymic	expression	1
17	organ	expression	1
18	culture	(	19
19	(	expression	1
20	FTOC	expression	1
21	)	expression	1
22	.	expression	1

0	NFATx1	is	14
1	,	NFATx1	0
2	which	preferentially	4
3	is	preferentially	4
4	preferentially	NFATx1	0
5	expressed	preferentially	4
6	in	expressed	5
7	the	in	6
8	thymus	and	9
9	and	blood	11
10	peripheral	blood	11
11	blood	the	7
12	leukocytes	blood	11
13	,	NFATx1	0
14	is	<ROOT>	-1
15	one	is	14
16	of	one	15
17	four	of	16
18	members	four	17
19	of	members	18
20	the	of	19
21	NFAT	of	23
22	family	of	23
23	of	the	20
24	transcription	factors	25
25	factors	of	23
26	.	is	14

0	CD19	expression	1
1	expression	begins	2
2	begins	<ROOT>	-1
3	at	begins	2
4	the	stage	7
5	pro-B	stage	7
6	cell	stage	7
7	stage	at	3
8	of	B	9
9	B	stage	7
10	cell	.	12
11	development	.	12
12	.	B	9

0	Further	complete	2
1	,	Further	0
2	complete	cells	6
3	activation	complete	2
4	of	T	5
5	T	activation	3
6	cells	requires	7
7	requires	<ROOT>	-1
8	at	two	10
9	least	two	10
10	two	signals	11
11	signals	requires	7
12	,	one	13
13	one	requires	7
14	that	stimulates	15
15	stimulates	one	13
16	an	increase	17
17	increase	stimulates	15
18	in	intracellular	19
19	intracellular	increase	17
20	calcium	intracellular	19
21	and	stimulates	15
22	one	and	21
23	that	one	22
24	stimulates	processes	26
25	enzymatic	stimulates	24
26	processes	that	23
27	including	kinases	28
28	kinases	processes	26
29	.	requires	7

0	In	was	24
1	this	study	2
2	study	In	0
3	,	In	0
4	the	effect	5
5	effect	,	3
6	of	effect	5
7	anti-E.	antibody	9
8	chaffeensis	antibody	9
9	antibody	of	6
10	complexed	of	6
11	with	complexed	10
12	E.	chaffeensis	13
13	chaffeensis	with	11
14	on	the	15
15	the	effect	5
16	expression	the	15
17	of	expression	16
18	major	cytokines	20
19	proinflammatory	cytokines	20
20	cytokines	of	17
21	in	human	22
22	human	of	17
23	monocytes	In	0
24	was	<ROOT>	-1
25	examined	was	24
26	.	was	24

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	in	,	1
3	two	in	2
4	in	in	2
5	vivo	Moreover	0
6	models	vivo	5
7	,	exerted	10
8	these	compounds	9
9	compounds	exerted	10
10	exerted	models	6
11	an	antiinflammatory	12
12	antiinflammatory	exerted	10
13	and	antiinflammatory	12
14	immunosuppressive	and	13
15	activity	and	13
16	as	potent	17
17	potent	and	13
18	as	potent	17
19	that	as	18
20	of	that	19
21	the	of	20
22	classic	the	21
23	glucocorticoid	prednisolone	24
24	prednisolone	classic	22
25	.	prednisolone	24

0	Accordingly	<ROOT>	-1
1	,	Accordingly	0
2	Western	blots	3
3	blots	with	4
4	with	,	1
5	antibodies	with	4
6	specific	with	4
7	for	specific	6
8	the	domain	10
9	DNA-binding	domain	10
10	domain	for	7
11	,	with	4
12	that	with	4
13	is	common	14
14	common	that	12
15	to	that	12
16	all	forms	17
17	forms	to	15
18	,	with	4
19	identify	with	4
20	multiple	proteins	21
21	proteins	identify	19
22	.	Accordingly	0

0	Interleukin-6	protein	1
1	protein	were	5
2	and	protein	1
3	IL-6	mRNA	4
4	mRNA	and	2
5	were	<ROOT>	-1
6	measured	in	7
7	in	were	5
8	control	in	7
9	and	CMV	10
10	CMV	early	12
11	immediate	early	12
12	early	in	7
13	transfected	were	5
14	cells	were	5
15	.	were	5

0	ORF1	consists	1
1	consists	<ROOT>	-1
2	of	consists	1
3	240	bp	4
4	bp	of	2
5	that	would	6
6	would	consists	1
7	encode	80	8
8	80	would	6
9	amino	would	6
10	acids	amino	9
11	,	consists	1
12	while	consists	1
13	the	while	12
14	major	the	13
15	ORF2	consists	16
16	consists	major	14
17	of	648	18
18	648	consists	16
19	bp	capable	20
20	capable	648	18
21	of	capable	20
22	coding	of	21
23	for	coding	22
24	216	coding	22
25	amino	216	24
26	acids	amino	25
27	.	consists	1

0	The	factors	3
1	following	factors	3
2	transcription	factors	3
3	factors	were	4
4	were	<ROOT>	-1
5	studied	were	4
6	:	were	4
7	the	factors	9
8	Octamer	factors	9
9	factors	were	4
10	Oct-1	factors	9
11	and	factors	9
12	Oct-2	factors	9
13	,	factors	9
14	members	factor	18
15	of	factor	18
16	the	factor	18
17	AP-1	factor	18
18	factor	factors	9
19	family	factors	9
20	,	NF-AT	21
21	NF-AT	factors	9
22	factors	factors	9
23	,	factors	9
24	in	factors	9
25	particular	in	24
26	NF-ATp	particular	25
27	,	NF-ATp	26
28	and	particular	25
29	members	and	28
30	of	members	29
31	the	family	33
32	Rel/NF-kB	family	33
33	family	of	30
34	.	were	4

0	The	prevalence	2
1	high	prevalence	2
2	prevalence	suggests	6
3	of	prevalence	2
4	promoter	methylation	5
5	methylation	of	3
6	suggests	<ROOT>	-1
7	that	suggests	6
8	this	abnormality	10
9	molecular	abnormality	10
10	abnormality	can	11
11	can	that	7
12	be	can	11
13	used	be	12
14	to	used	13
15	monitor	to	14
16	disease	activity	17
17	activity	to	14
18	during	used	13
19	therapy	during	18
20	.	suggests	6

0	In	demonstrate	5
1	this	paper	2
2	paper	In	0
3	,	demonstrate	5
4	we	demonstrate	5
5	demonstrate	)	20
6	that	demonstrate	5
7	the	activation	8
8	activation	that	6
9	of	activation	8
10	NF-kappaB	of	9
11	by	activation	8
12	LPS	by	11
13	in	activation	8
14	a	in	13
15	promonocytic	(	18
16	cell	(	18
17	line	(	18
18	(	a	14
19	U937	demonstrate	5
20	)	followed	21
21	followed	<ROOT>	-1
22	a	kinetics	25
23	rather	kinetics	25
24	slow	rather	23
25	kinetics	followed	21
26	,	followed	21
27	depending	followed	21
28	on	depending	27
29	the	rate	30
30	rate	inhibitor	33
31	of	inhibitor	33
32	IkappaB-alpha	inhibitor	33
33	inhibitor	on	28
34	hydrolysis	followed	21
35	.	followed	21

0	To	<ROOT>	-1
1	help	To	0
2	elucidate	help	1
3	further	elucidate	2
4	the	mechanism	5
5	mechanism	elucidate	2
6	by	elucidate	2
7	which	regulates	9
8	ZAP-70	regulates	9
9	regulates	by	6
10	these	regulates	9
11	initial	events	12
12	events	regulates	9
13	,	elucidate	2
14	we	a	16
15	used	a	16
16	a	elucidate	2
17	dominant-negative	approach	19
18	mutant	approach	19
19	approach	a	16
20	.	To	0

0	We	observed	2
1	also	observed	2
2	observed	<ROOT>	-1
3	hematopoiesis	observed	2
4	outside	hematopoiesis	3
5	of	outside	4
6	the	bone	7
7	bone	of	5
8	marrow	hematopoiesis	3
9	in	the	10
10	the	marrow	8
11	affected	mutant	12
12	mutant	the	10
13	mice	observed	2
14	.	observed	2

0	Recent	progress	1
1	progress	provides	16
2	in	progress	1
3	understanding	in	2
4	the	regulation	5
5	regulation	understanding	3
6	of	regulation	5
7	the	oxidase	10
8	phagocyte	oxidase	10
9	NADPH	oxidase	10
10	oxidase	of	6
11	by	understanding	3
12	the	Rac	13
13	Rac	GTP-binding	14
14	GTP-binding	by	11
15	proteins	GTP-binding	14
16	provides	<ROOT>	-1
17	a	basis	18
18	basis	provides	16
19	for	basis	18
20	defining	for	19
21	the	characteristics	23
22	operational	characteristics	23
23	characteristics	defining	20
24	of	characteristics	23
25	one	system	28
26	such	system	28
27	phagocyte	system	28
28	system	of	24
29	.	provides	16

0	We	isolated	1
1	isolated	<ROOT>	-1
2	a	gene	5
3	new	gene	5
4	mouse	gene	5
5	gene	isolated	1
6	that	is	7
7	is	gene	5
8	highly	is	7
9	expressed	highly	8
10	in	expressed	9
11	thymocytes	in	10
12	,	thymocytes	11
13	testis	in	10
14	,	isolated	1
15	and	isolated	1
16	brain	and	15
17	.	isolated	1

0	Finally	revealed	4
1	,	revealed	4
2	co-immunoprecipitation	analysis	3
3	analysis	revealed	4
4	revealed	<ROOT>	-1
5	that	revealed	4
6	Tax	is	7
7	is	that	5
8	able	is	7
9	to	able	8
10	stably	to	9
11	bind	to	9
12	to	bind	11
13	both	Sp1	14
14	Sp1	to	12
15	and	Sp1	14
16	NGFI-A/Egr-1	and	15
17	.	revealed	4

0	Here	describe	2
1	we	describe	2
2	describe	predicts	16
3	cloning	describe	2
4	and	cloning	3
5	characterization	and	4
6	of	characterization	5
7	full-length	of	6
8	cDNA	murine	10
9	encoding	murine	10
10	murine	describe	2
11	(	murine	10
12	m	describe	2
13	)	describe	2
14	NFATc	which	15
15	which	describe	2
16	predicts	<ROOT>	-1
17	that	predicts	16
18	the	protein	19
19	protein	has	20
20	has	that	17
21	all	motifs	25
22	the	motifs	25
23	conserved	motifs	25
24	structural	motifs	25
25	motifs	has	20
26	of	NFAT	27
27	NFAT	family	28
28	family	motifs	25
29	members	family	28
30	,	members	29
31	including	rel	33
32	the	rel	33
33	rel	members	29
34	homology	predicts	16
35	domain	predicts	16
36	,	NFAT	38
37	the	NFAT	38
38	NFAT	predicts	16
39	homology	NFAT	38
40	domain	homology	39
41	and	domain	40
42	the	signals	45
43	nuclear	signals	45
44	translocation	signals	45
45	signals	and	41
46	.	predicts	16

0	Stimulation	human	2
1	of	human	2
2	human	<ROOT>	-1
3	neutrophils	human	2
4	with	neutrophils	3
5	chemoattractants	FMLP	6
6	FMLP	with	4
7	or	activating	9
8	platelet	activating	9
9	activating	FMLP	6
10	factor	(	11
11	(	human	2
12	PAF	(	11
13	)	(	11
14	results	human	2
15	in	human	2
16	different	in	15
17	but	human	2
18	overlapping	human	2
19	functional	human	2
20	responses	human	2
21	.	human	2

0	Our	findings	1
1	findings	demonstrate	2
2	demonstrate	that	3
3	that	<ROOT>	-1
4	truncated	TSG101	5
5	TSG101	that	3
6	and	FHIT	7
7	FHIT	TSG101	5
8	transcripts	that	3
9	are	transcripts	8
10	commonly	are	9
11	detected	commonly	10
12	in	detected	11
13	both	in	12
14	normal	both	13
15	and	normal	14
16	malignant	both	13
17	tissues	that	3
18	and	that	3
19	that	and	18
20	a	fraction	22
21	significant	fraction	22
22	fraction	are	25
23	of	fraction	22
24	these	of	23
25	are	that	19
26	likely	are	25
27	to	likely	26
28	be	to	27
29	the	result	30
30	result	be	28
31	of	result	30
32	aberrant	splicing	33
33	splicing	of	31
34	.	that	3

0	Macrophage-differentiation	reduced	3
1	of	Macrophage-differentiation	0
2	NB4	of	1
3	reduced	<ROOT>	-1
4	levels	reduced	3
5	of	levels	4
6	C/EBP	mRNA	8
7	epsilon	mRNA	8
8	mRNA	of	5
9	.	reduced	3

0	All	modes	2
1	three	modes	2
2	modes	of	3
3	of	induced	6
4	oxidative	of	3
5	stress	of	3
6	induced	<ROOT>	-1
7	catalase	induced	6
8	activity	induced	6
9	in	activity	8
10	the	lymphocytes	11
11	lymphocytes	in	9
12	.	induced	6

0	This	<ROOT>	-1
1	review	This	0
2	focuses	review	1
3	on	focuses	2
4	the	on	3
5	molecular	of	7
6	actions	of	7
7	of	the	4
8	prolactin	of	7
9	in	prolactin	8
10	the	the	4
11	immune	the	4
12	system	the	4
13	.	This	0

0	Expression	cloning	1
1	cloning	tegument	10
2	with	cloning	1
3	this	region	4
4	region	cloning	1
5	of	region	4
6	DNA	of	5
7	now	cloning	1
8	shows	that	9
9	that	cloning	1
10	tegument	<ROOT>	-1
11	protein	tegument	10
12	VP22	protein	11
13	and	VP22	12
14	the	and	13
15	viral	the	14
16	dUTPase	are	27
17	,	are	27
18	encoded	are	27
19	by	encoded	18
20	genes	by	19
21	UL49	genes	20
22	and	UL49	21
23	UL50	and	22
24	,	encoded	18
25	respectively	encoded	18
26	,	encoded	18
27	are	viral	15
28	T-cell	antigens	29
29	antigens	viral	15
30	.	tegument	10

0	Modulation	of	1
1	of	<ROOT>	-1
2	mRNA	of	1
3	expression	CCAAT/enhancer	9
4	of	CCAAT/enhancer	9
5	a	CCAAT/enhancer	9
6	novel	CCAAT/enhancer	9
7	human	CCAAT/enhancer	9
8	myeloid-selective	CCAAT/enhancer	9
9	CCAAT/enhancer	of	1
10	binding	of	1
11	protein	of	1
12	gene	(	13
13	(	of	1
14	C/EBP	epsilon	15
15	epsilon	of	1
16	)	of	1
17	.	of	1

0	Clinical	deterioration	1
1	deterioration	virus	5
2	in	virus	5
3	human	virus	5
4	immunodeficiency	virus	5
5	virus	<ROOT>	-1
6	type	virus	5
7	1	type	6
8	(	1	7
9	HIV-1	)	10
10	)	1	7
11	infection	associated	13
12	is	infection	11
13	associated	)	10
14	with	associated	13
15	increased	with	14
16	levels	increased	15
17	of	levels	16
18	viral	replication	19
19	replication	of	17
20	and	of	17
21	burden	and	20
22	in	of	17
23	the	blood	25
24	peripheral	blood	25
25	blood	in	22
26	and	of	17
27	lymphoid	of	17
28	organs	1	7
29	.	virus	5

0	Under	<ROOT>	-1
1	these	conditions	2
2	conditions	Under	0
3	HUVEC	molecules	5
4	adhesion	molecules	5
5	molecules	Under	0
6	,	molecules	5
7	E-selectin	molecules	5
8	,	molecules	5
9	VCAM-1	molecules	5
10	and	VCAM-1	9
11	ICAM-1	were	13
12	,	ICAM-1	11
13	were	molecules	5
14	increased	were	13
15	at	increased	14
16	3	h	17
17	h	at	15
18	with	increased	14
19	only	with	18
20	ICAM-1	only	19
21	remaining	overexpressed	22
22	overexpressed	increased	14
23	at	overexpressed	22
24	24	h	25
25	h	at	23
26	.	Under	0

0	Pretreatment	T	3
1	of	T	3
2	ACH-2	of	1
3	T	resulted	21
4	cells	by	5
5	by	T	3
6	NAC	followed	7
7	followed	T	3
8	by	followed	7
9	stimulation	by	8
10	with	stimulation	9
11	PMA	T	3
12	,	T	3
13	TNF-alpha	T	3
14	,	T	3
15	or	T	3
16	hydrogen	T	3
17	peroxide	T	3
18	(	peroxide	17
19	H2O2	T	3
20	)	T	3
21	resulted	<ROOT>	-1
22	in	resulted	21
23	strong	suppression	24
24	suppression	in	22
25	of	NF-kappa	26
26	NF-kappa	suppression	24
27	B	resulted	21
28	activation	resulted	21
29	.	resulted	21

0	It	has	1
1	has	<ROOT>	-1
2	been	has	1
3	recently	claimed	4
4	claimed	been	2
5	that	polymorphism	6
6	polymorphism	claimed	4
7	for	polymorphism	6
8	the	receptor	11
9	vitamin	receptor	11
10	D	receptor	11
11	receptor	for	7
12	(	VDR	13
13	VDR	receptor	11
14	)	VDR	13
15	influences	)	14
16	several	aspects	17
17	aspects	bone	21
18	of	aspects	17
19	calcium	of	18
20	and	bone	21
21	bone	polymorphism	6
22	metabolism	been	2
23	.	has	1

0	Glucocorticoid-resistance	lymphocytes	3
1	in	peripheral-blood	2
2	peripheral-blood	Glucocorticoid-resistance	0
3	lymphocytes	does	4
4	does	<ROOT>	-1
5	not	does	4
6	correlate	does	4
7	with	correlate	6
8	number	with	7
9	of	number	8
10	affinity	of	9
11	of	of	9
12	glucocorticoid-receptors	of	9
13	in	chronic	14
14	chronic	of	9
15	renal	chronic	14
16	failure	does	4
17	patients	does	4
18	.	does	4

0	Intravenous	administration	1
1	administration	<ROOT>	-1
2	of	administration	1
3	PCr	of	2
4	(	starting	5
5	starting	administration	1
6	1	day	7
7	day	starting	5
8	before	exercise	9
9	exercise	administration	1
10	)	exercise	9
11	led	)	10
12	to	led	11
13	an	increase	14
14	increase	to	12
15	in	increase	14
16	the	total	17
17	total	in	15
18	workload	total	17
19	(	on	20
20	on	total	17
21	average	on	20
22	by	on	20
23	5.8	%	24
24	%	by	22
25	)	on	20
26	and	led	11
27	in	AT	28
28	AT	and	26
29	(	on	30
30	on	)	10
31	average	on	30
32	by	on	30
33	6.8	%	34
34	%	by	32
35	)	on	30
36	during	)	10
37	MPE	during	36
38	and	MPE	37
39	to	and	38
40	a	tolerance	42
41	better	tolerance	42
42	tolerance	to	39
43	of	tolerance	42
44	exercise	of	43
45	during	MPE	37
46	PPE	during	45
47	.	administration	1

0	As	the	31
1	well	as	2
2	as	As	0
3	culminating	As	0
4	in	culminating	3
5	the	phosphorylation	7
6	inducible	phosphorylation	7
7	phosphorylation	in	4
8	of	phosphorylation	7
9	I	alpha	11
10	kappaB	alpha	11
11	alpha	of	8
12	on	As	0
13	serines	on	12
14	32	serines	13
15	and	serines	13
16	36	and	15
17	,	serines	13
18	all	stimuli	20
19	the	stimuli	20
20	stimuli	serines	13
21	that	are	22
22	are	stimuli	20
23	inactive	are	22
24	on	1.3E2	25
25	1.3E2	are	22
26	cells	As	0
27	exhibit	a	28
28	a	As	0
29	sensitivity	to	30
30	to	the	31
31	the	<ROOT>	-1
32	antioxidant	the	31
33	pyrrolidine	the	31
34	dithiocarbamate	the	31
35	(	dithiocarbamate	34
36	PDTC	dithiocarbamate	34
37	)	dithiocarbamate	34
38	.	the	31

0	As	was	13
1	cortisol	is	2
2	is	As	0
3	involved	is	2
4	in	involved	3
5	the	regulation	7
6	physiological	regulation	7
7	regulation	in	4
8	of	regulation	7
9	cytokines	of	8
10	,	was	13
11	a	study	12
12	study	was	13
13	was	<ROOT>	-1
14	conducted	was	13
15	to	conducted	14
16	examine	to	15
17	cytokine	patterns	18
18	patterns	examine	16
19	in	patterns	18
20	two	groups	21
21	groups	patterns	18
22	of	hypercortisolemic	23
23	hypercortisolemic	groups	21
24	patients	was	13
25	,	was	13
26	one	,	25
27	with	normal	28
28	normal	one	26
29	sensitivity	was	13
30	to	sensitivity	29
31	glucocorticoids	was	13
32	and	was	13
33	the	other	34
34	other	and	32
35	with	glucocorticoid	36
36	glucocorticoid	other	34
37	resistance	was	13
38	.	was	13

0	By	beta-tubulin	8
1	contrast	By	0
2	,	By	0
3	the	amounts	4
4	amounts	,	2
5	of	amounts	4
6	actin	of	5
7	and	of	5
8	beta-tubulin	were	9
9	were	<ROOT>	-1
10	not	were	9
11	significantly	were	9
12	altered	significantly	11
13	.	altered	12

0	Amplified	cDNA	1
1	cDNA	were	2
2	were	<ROOT>	-1
3	sequenced	were	2
4	by	sequenced	3
5	standard	methods	6
6	methods	by	4
7	.	were	2

0	A	dysfunction	1
1	dysfunction	has	26
2	in	the	3
3	the	dysfunction	1
4	regulation	of	5
5	of	the	3
6	the	hypothalamic-pituitary-adrenal	7
7	hypothalamic-pituitary-adrenal	axis	11
8	(	HPA	9
9	HPA	hypothalamic-pituitary-adrenal	7
10	)	HPA	9
11	axis	of	5
12	,	dysfunction	1
13	possibly	dysfunction	1
14	attributed	dysfunction	1
15	to	attributed	14
16	a	change	17
17	change	to	15
18	in	glucocorticoid	19
19	glucocorticoid	(	21
20	receptor	(	21
21	(	change	17
22	GR	)	23
23	)	to	15
24	functionality	)	23
25	,	dysfunction	1
26	has	<ROOT>	-1
27	been	has	26
28	implicated	been	27
29	in	implicated	28
30	depression	in	29
31	.	has	26

0	However	<ROOT>	-1
1	,	p65	5
2	the	intensity	3
3	intensity	p65	5
4	of	p65	5
5	p65	However	0
6	labeling	was	7
7	was	However	0
8	much	higher	9
9	higher	was	7
10	in	higher	9
11	several	thymocytes	12
12	thymocytes	in	10
13	from	higher	9
14	the	medulla	15
15	medulla	from	13
16	.	However	0

0	Neutrophil	lipocalin	2
1	gelatinase-associated	lipocalin	2
2	lipocalin	is	6
3	(	NGAL	4
4	NGAL	lipocalin	2
5	)	NGAL	4
6	is	<ROOT>	-1
7	a	lipocalin	9
8	25-kDa	lipocalin	9
9	lipocalin	is	6
10	first	identified	11
11	identified	lipocalin	9
12	as	identified	11
13	a	as	12
14	protein	a	13
15	stored	protein	14
16	in	specific	17
17	specific	stored	15
18	granules	is	6
19	of	granules	18
20	the	neutrophil	22
21	human	neutrophil	22
22	neutrophil	of	19
23	.	is	6

0	Within	<ROOT>	-1
1	the	Within	0
2	nucleus	RelB	4
3	,	nucleus	2
4	RelB	may	5
5	may	the	1
6	specifically	may	5
7	transactivate	specifically	6
8	genes	that	9
9	that	Within	0
10	are	critical	11
11	critical	that	9
12	for	critical	11
13	APC	Within	0
14	function	Within	0
15	.	Within	0

0	These	results	1
1	results	provide	2
2	provide	<ROOT>	-1
3	evidence	expression	6
4	that	Jak1	5
5	Jak1	expression	6
6	expression	provide	2
7	is	provide	2
8	required	provide	2
9	for	required	8
10	mediating	phosphorylation	12
11	tyrosine	phosphorylation	12
12	phosphorylation	for	9
13	and	phosphorylation	12
14	activation	of	15
15	of	crucial	16
16	crucial	provide	2
17	molecules	provide	2
18	involved	provide	2
19	in	provide	2
20	IL-4	provide	2
21	signal	provide	2
22	transduction	provide	2
23	.	provide	2

0	Our	results	1
1	results	showing	2
2	showing	<ROOT>	-1
3	that	showing	2
4	GC	that	3
5	suppressed	GC	4
6	IL-5	production	7
7	production	T	11
8	by	T	11
9	human	T	11
10	CD4+	T	11
11	T	suppressed	5
12	cells	showing	2
13	activated	showing	2
14	by	showing	2
15	two	distinct	16
16	distinct	by	14
17	stimuli	showing	2
18	,	showing	2
19	TCR	,	18
20	and	TCR	19
21	IL-2R	stimulation	22
22	stimulation	and	20
23	,	showing	2
24	underscore	showing	2
25	the	efficacy	26
26	efficacy	underscore	24
27	of	efficacy	26
28	GC	of	27
29	in	GC	28
30	the	treatment	31
31	treatment	in	29
32	of	treatment	31
33	allergic	of	32
34	diseases	via	35
35	via	allergic	33
36	suppression	via	35
37	of	T-cell	38
38	T-cell	suppression	36
39	IL-5	showing	2
40	synthesis	showing	2
41	.	showing	2

0	Cyclosporine	is	4
1	(	CsA	2
2	CsA	Cyclosporine	0
3	)	CsA	2
4	is	<ROOT>	-1
5	both	is	4
6	a	both	5
7	clinical	immunosuppressive	8
8	immunosuppressive	a	6
9	drug	and	10
10	and	immunosuppressive	8
11	a	probe	12
12	probe	immunosuppressive	8
13	to	probe	12
14	dissect	pathways	17
15	intracellular	pathways	17
16	signaling	pathways	17
17	pathways	to	13
18	.	is	4

0	The	<ROOT>	-1
1	lymphocytes	lipid	3
2	exhibited	lipid	3
3	lipid	The	0
4	peroxidation	only	5
5	only	lipid	3
6	upon	The	0
7	exposure	upon	6
8	to	exposure	7
9	the	level	11
10	lowest	level	11
11	level	to	8
12	of	level	11
13	hydrogen	of	12
14	peroxide	used	15
15	used	hydrogen	13
16	(	level	11
17	20	)	19
18	microM	)	19
19	)	(	16
20	.	The	0

0	Since	conclude	15
1	the	co-expression	2
2	co-expression	abolished	8
3	with	co-expression	2
4	a	c-Fos	7
5	dominant	negative	6
6	negative	c-Fos	7
7	c-Fos	with	3
8	abolished	Since	0
9	the	responsiveness	10
10	responsiveness	abolished	8
11	to	responsiveness	10
12	TPA	to	11
13	,	conclude	15
14	we	conclude	15
15	conclude	<ROOT>	-1
16	that	conclude	15
17	activated	transcription	18
18	transcription	that	16
19	of	the	20
20	the	transcription	18
21	DRA	conclude	15
22	gene	depends	23
23	depends	conclude	15
24	on	depends	23
25	interactions	the	27
26	between	the	27
27	the	on	24
28	X2	the	27
29	box	X2	28
30	and	X2	28
31	NF-X2	and	30
32	,	conclude	15
33	which	contains	34
34	contains	conclude	15
35	c-Fos	contains	34
36	.	c-Fos	35

0	We	<ROOT>	-1
1	present	We	0
2	here	present	1
3	the	here	2
4	results	present	1
5	on	present	1
6	the	recognition	7
7	recognition	on	5
8	of	recognition	7
9	several	peptides	11
10	pml/RAR-alpha	peptides	11
11	peptides	of	8
12	by	recognition	7
13	APL	patients	14
14	patients	expressing	15
15	expressing	by	12
16	HLA	DR11	17
17	DR11	expressing	15
18	.	We	0

0	Prostaglandin	induction	2
1	E2	induction	2
2	induction	<ROOT>	-1
3	of	induction	2
4	binding	of	3
5	activity	of	3
6	to	activity	5
7	CRE	of	3
8	and	induction	2
9	AP-2	and	8
10	elements	induction	2
11	in	human	12
12	human	T	13
13	T	elements	10
14	lymphocytes	induction	2
15	.	induction	2

0	Interestingly	consistently	3
1	,	consistently	3
2	we	consistently	3
3	consistently	observed	4
4	observed	<ROOT>	-1
5	30	%	6
6	%	observed	4
7	less	%	6
8	RT-PCR	derived	10
9	product	derived	10
10	derived	less	7
11	from	derived	10
12	the	from	11
13	small	in	17
14	t	in	17
15	allele	in	17
16	mRNA	in	17
17	in	the	12
18	steady	state	19
19	state	in	17
20	,	state	19
21	a	finding	22
22	finding	speaks	25
23	which	finding	22
24	also	speaks	25
25	speaks	state	19
26	against	speaks	25
27	a	stability	29
28	higher	stability	29
29	stability	against	26
30	of	stability	29
31	the	of	30
32	small	the	31
33	t	small	32
34	allele	t	33
35	mRNA	allele	34
36	.	mRNA	35

0	CONCLUSION	<ROOT>	-1
1	:	CONCLUSION	0
2	Mutated	constructs	5
3	human	constructs	5
4	CIITA	constructs	5
5	constructs	are	6
6	are	CONCLUSION	0
7	potent	suppressors	8
8	suppressors	II	13
9	of	II	13
10	porcine	II	13
11	MHC	II	13
12	class	II	13
13	II	are	6
14	expression	CONCLUSION	0
15	.	CONCLUSION	0

0	Inhibition	may	12
1	of	Inhibition	0
2	apoptosis	of	1
3	in	Inhibition	0
4	eosinophils	in	3
5	by	eosinophils	4
6	cytokines	Inhibition	0
7	such	as	8
8	as	cytokines	6
9	IL-5	as	8
10	and	IL-5	9
11	GM-CSF	and	10
12	may	<ROOT>	-1
13	play	may	12
14	an	role	16
15	important	role	16
16	role	play	13
17	in	play	13
18	the	pathogenesis	19
19	pathogenesis	in	17
20	of	pathogenesis	19
21	allergic	of	20
22	and	of	20
23	parasitic	of	20
24	disorders	may	12
25	.	may	12

0	Within	hours	2
1	2	Within	0
2	hours	<ROOT>	-1
3	,	hours	2
4	this	resulted	5
5	resulted	hours	2
6	in	resulted	5
7	increased	(	11
8	mRNA	for	9
9	for	interleukin	10
10	interleukin	increased	7
11	(	in	6
12	IL	)	13
13	)	(	11
14	,	hours	2
15	1	,	19
16	beta	,	19
17	,	beta	16
18	IL-8	,	19
19	,	hours	2
20	and	,	19
21	monocyte	and	20
22	chemoattractant	monocyte	21
23	protein	(	24
24	(	hours	2
25	MCP	hours	2
26	)	MCP	25
27	-1	)	26
28	in	MCP	25
29	unfractionated	leukocytes	30
30	leukocytes	in	28
31	.	hours	2

0	Interleukin-6	<ROOT>	-1
1	(	IL-6	2
2	IL-6	Interleukin-6	0
3	)	IL-6	2
4	plays	IL-6	2
5	a	plays	4
6	central	in	8
7	role	in	8
8	in	a	5
9	numerous	processes	13
10	inflammatory	processes	13
11	and	inflammatory	10
12	immune	and	11
13	processes	a	5
14	.	Interleukin-6	0

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	PPARgamma	expression	5
4	mRNA	expression	5
5	expression	,	2
6	in	U937	7
7	U937	,	2
8	cells	In	0
9	increased	In	0
10	during	increased	9
11	phorbol	12-myristate	12
12	12-myristate	during	10
13	13	12-myristate	12
14	acetate-induced	differentiation	15
15	differentiation	12-myristate	12
16	.	differentiation	15

0	Prolonged	was	10
1	suppression	Prolonged	0
2	of	suppression	1
3	trans-gene	expression	4
4	expression	of	2
5	for	suppression	1
6	up	days	9
7	to	up	6
8	7	up	6
9	days	for	5
10	was	was	35
11	observed	was	10
12	after	observed	11
13	doxycycline	was	14
14	was	after	12
15	removed	was	14
16	from	the	17
17	the	removed	15
18	cultures	the	17
19	,	cultures	18
20	but	eventual	21
21	eventual	,	19
22	recovery	was	10
23	of	recovery	22
24	surface	expression	25
25	expression	of	23
26	was	was	10
27	complete	was	10
28	,	was	10
29	and	was	10
30	the	absolute	31
31	absolute	and	29
32	time	absolute	31
33	to	recovery	34
34	recovery	time	32
35	was	<ROOT>	-1
36	directly	proportional	37
37	proportional	was	35
38	to	initial	40
39	the	initial	40
40	initial	proportional	37
41	concentration	initial	40
42	of	concentration	41
43	the	drug	44
44	drug	of	42
45	.	was	35

0	In	was	27
1	addition	In	0
2	,	In	0
3	electrophoretic	shift	5
4	mobility	shift	5
5	shift	,	2
6	and	shift	5
7	supershift	and	6
8	assays	In	0
9	revealed	In	0
10	that	binding	13
11	important	binding	13
12	NF-kappaB	binding	13
13	binding	In	0
14	activity	composed	15
15	composed	In	0
16	of	composed	15
17	at	p50	19
18	least	p50	19
19	p50	of	16
20	,	p50	19
21	p65	p50	19
22	,	In	0
23	and	In	0
24	c-Rel	In	0
25	NF-kappaB	In	0
26	subunits	NF-kappaB	25
27	was	<ROOT>	-1
28	present	was	27
29	in	present	28
30	nuclei	in	29
31	of	B	33
32	CD40-stimulated	B	33
33	B	nuclei	30
34	cells	was	27
35	.	was	27

0	The	factor	2
1	transcription	factor	2
2	factor	Spi-1/PU.1	3
3	Spi-1/PU.1	<ROOT>	-1
4	as	Spi-1/PU.1	3
5	well	as	4
6	as	as	4
7	the	factor	10
8	closely	factor	10
9	related	factor	10
10	factor	as	4
11	Spi-B	bound	12
12	bound	factor	10
13	to	bound	12
14	the	PU-box	15
15	PU-box	to	13
16	in	bound	12
17	B-cells	in	16
18	.	Spi-1/PU.1	3

0	To	<ROOT>	-1
1	clarify	To	0
2	the	clarify	1
3	role	of	4
4	of	the	2
5	mammalian	of	4
6	runt	products	7
7	products	the	2
8	in	clarify	1
9	normal	in	8
10	and	clarify	1
11	leukemic	clarify	1
12	hematopoiesis	To	0
13	,	To	0
14	we	,	13
15	have	we	14
16	studied	have	15
17	their	studied	16
18	pattern	of	19
19	of	their	17
20	expression	of	19
21	in	expression	20
22	mouse	tissues	24
23	hematopoietic	tissues	24
24	tissues	of	19
25	in	tissues	24
26	the	in	25
27	adult	the	26
28	and	adult	27
29	during	and	28
30	ontogeny	during	29
31	using	ontogeny	30
32	an	box	34
33	anti-runt	box	34
34	box	using	31
35	antiserum	box	34
36	.	To	0

0	The	(	26
1	apparent	The	0
2	dissociation	apparent	1
3	constant	dissociation	2
4	of	constant	3
5	the	glucocorticoid	6
6	glucocorticoid	of	4
7	receptors	of	4
8	from	receptors	7
9	the	nonresponders	10
10	nonresponders	from	8
11	,	receptors	7
12	responders	,	11
13	,	and	14
14	and	responders	12
15	healthy	and	14
16	controls	were	17
17	were	The	0
18	7.03	(	19
19	(	The	0
20	range	(	19
21	,	The	0
22	5.66-10	The	0
23	)	The	0
24	,	(	26
25	4.27	(	26
26	(	<ROOT>	-1
27	range	(	26
28	,	(	26
29	4-5.13	(	26
30	)	(	26
31	,	(	26
32	and	(	26
33	6.18	(	34
34	(	(	26
35	range	(	26
36	,	(	26
37	5.86-6.74	,	36
38	)	(	26
39	nM	(	26
40	,	(	26
41	respectively	(	26
42	.	(	26

0	The	receptor	2
1	M-CSF	receptor	2
2	receptor	was	3
3	was	<ROOT>	-1
4	first	was	3
5	detectable	first	4
6	in	detectable	5
7	the	subset	10
8	myeloid-committed	subset	10
9	CD34+Thy-l-CD45RA+	subset	10
10	subset	in	6
11	.	was	3

0	We	measured	1
1	measured	<ROOT>	-1
2	the	number	3
3	number	measured	1
4	of	glucocorticoid	5
5	glucocorticoid	number	3
6	receptors	(	7
7	(	measured	1
8	GR	(	7
9	)	measured	1
10	in	blood	12
11	cord	blood	12
12	blood	)	9
13	lymphocytes	measured	1
14	and	binding	16
15	the	binding	16
16	binding	measured	1
17	affinity	(	18
18	(	binding	16
19	Kd	(	18
20	)	measured	1
21	in	15	22
22	15	measured	1
23	term	measured	1
24	and	measured	1
25	in	preterm	27
26	20	preterm	27
27	preterm	and	24
28	babies	measured	1
29	.	measured	1

0	It	is	1
1	is	adhesion	9
2	known	is	1
3	that	expression	5
4	the	expression	5
5	expression	is	1
6	levels	expression	5
7	of	levels	6
8	intercellular	is	1
9	adhesion	<ROOT>	-1
10	molecule-1	adhesion	9
11	(	adhesion	9
12	ICAM-1	adhesion	9
13	)	ICAM-1	12
14	in	T	16
15	adult	T	16
16	T	)	13
17	cell	leukemia	18
18	leukemia	(	19
19	(	ATL	20
20	ATL	)	13
21	)	ATL	20
22	cells	adhesion	9
23	are	adhesion	9
24	high	adhesion	9
25	,	adhesion	9
26	whereas	adhesion	9
27	those	whereas	26
28	in	T-lymphoid	29
29	T-lymphoid	those	27
30	cells	adhesion	9
31	are	cells	30
32	not	are	31
33	.	adhesion	9

0	Within	promoter	12
1	the	region	2
2	region	Within	0
3	between	Within	0
4	-108	base	7
5	and	-108	4
6	-40	and	5
7	base	between	3
8	pairs	base	7
9	of	IFN-gamma	11
10	the	IFN-gamma	11
11	IFN-gamma	pairs	8
12	promoter	<ROOT>	-1
13	are	promoter	12
14	two	promoter	12
15	conserved	two	14
16	and	conserved	15
17	essential	and	16
18	regulatory	elements	19
19	elements	and	16
20	,	which	21
21	which	promoter	12
22	confer	which	21
23	activation-specific	expression	24
24	expression	confer	22
25	in	T	26
26	T	confer	22
27	cells	promoter	12
28	.	promoter	12

0	The	factors	4
1	class	factors	4
2	II-specific	factors	4
3	transcription	factors	4
4	factors	<ROOT>	-1
5	RFX	and	6
6	and	factors	4
7	CIITA	factors	4
8	are	CIITA	7
9	also	required	10
10	required	factors	4
11	for	required	10
12	expression	,	13
13	,	for	11
14	as	factors	4
15	cell	factors	4
16	lines	deficient	17
17	deficient	factors	4
18	in	deficient	17
19	these	factors	20
20	factors	in	18
21	failed	factors	4
22	to	failed	21
23	allow	to	22
24	transcription	allow	23
25	from	transcription	24
26	the	from	25
27	DM	.	29
28	promoters	.	29
29	.	the	26

0	Binding	increased	3
1	to	Binding	0
2	RBD	to	1
3	increased	<ROOT>	-1
4	from	increased	3
5	undetectable	from	4
6	levels	undetectable	5
7	in	resting	8
8	resting	levels	6
9	platelets	increased	3
10	to	increased	3
11	&gt;	to	10
12	50	%	13
13	%	&gt;	11
14	of	%	13
15	total	Rap1	16
16	Rap1	of	14
17	within	&gt;	11
18	30	within	17
19	s	after	20
20	after	stimulation	21
21	stimulation	30	18
22	.	increased	3

0	Although	indicate	19
1	subtle	can	9
2	gene	movements	3
3	movements	subtle	1
4	within	subtle	1
5	those	regions	8
6	defined	regions	8
7	topographical	regions	8
8	regions	within	4
9	can	Although	0
10	not	can	9
11	be	can	9
12	excluded	be	11
13	by	excluded	12
14	this	study	15
15	study	by	13
16	,	indicate	19
17	the	results	18
18	results	indicate	19
19	indicate	<ROOT>	-1
20	that	indicate	19
21	tissue	specificity	22
22	specificity	gene	24
23	of	gene	24
24	gene	expression	25
25	expression	is	26
26	is	that	20
27	not	is	26
28	accompanied	is	26
29	by	accompanied	28
30	drastic	changes	31
31	changes	by	29
32	in	changes	31
33	gene	topography	35
34	nuclear	topography	35
35	topography	in	32
36	,	indicate	19
37	rather	that	39
38	suggesting	that	39
39	that	indicate	19
40	gene	within	42
41	organization	within	42
42	within	that	39
43	the	nucleus	44
44	nucleus	may	45
45	may	within	42
46	be	may	45
47	primarily	dependent	48
48	dependent	be	46
49	on	dependent	48
50	structural	on	49
51	constraints	structural	50
52	imposed	constraints	51
53	on	imposed	52
54	the	chromosomes	56
55	respective	chromosomes	56
56	chromosomes	on	53
57	.	indicate	19

0	[	bronchial	2
1	Cortisone-resistant	bronchial	2
2	bronchial	<ROOT>	-1
3	asthma	bronchial	2
4	]	bronchial	2

0	Two	have	6
1	other	members	2
2	members	have	6
3	of	members	2
4	the	family	5
5	family	of	3
6	have	<ROOT>	-1
7	been	have	6
8	cloned	show	17
9	more	recently	10
10	recently	cloned	8
11	,	cloned	8
12	A-myb	cloned	8
13	and	A-myb	12
14	B-myb	and	13
15	,	cloned	8
16	which	show	17
17	show	been	7
18	sequence	homology	19
19	homology	with	20
20	with	have	6
21	c-myb	have	6
22	in	have	6
23	several	in	22
24	domains	in	22
25	,	in	22
26	of	,	25
27	which	binding	30
28	the	binding	30
29	DNA	binding	30
30	binding	,	25
31	domain	have	6
32	as	have	6
33	well	have	6
34	as	have	6
35	other	as	34
36	regulatory	.	38
37	domains	.	38
38	.	other	35

0	Immunofluorescence	<ROOT>	-1
1	studies	Immunofluorescence	0
2	on	revealed	17
3	thymic	of	5
4	populations	of	5
5	of	on	2
6	mice	carrying	7
7	carrying	of	5
8	transgenes	carrying	7
9	in	transgenes	8
10	various	transgenes	8
11	combinations	various	10
12	of	combinations	11
13	these	elements	16
14	regulatory	elements	16
15	DNA	elements	16
16	elements	of	12
17	revealed	studies	1
18	that	revealed	17
19	thymocytes	control	20
20	control	CD4	22
21	the	CD4	22
22	CD4	that	18
23	gene	CD4	22
24	in	gene	23
25	a	manner	27
26	different	manner	27
27	manner	in	24
28	than	revealed	17
29	mature	T	31
30	peripheral	T	31
31	T	Immunofluorescence	0
32	lymphocytes	Immunofluorescence	0
33	.	Immunofluorescence	0

0	We	identified	2
1	recently	identified	2
2	identified	<ROOT>	-1
3	the	factor	6
4	winged-helix	factor	6
5	transcription	factor	6
6	factor	identified	2
7	Trident	factor	6
8	and	factor	6
9	described	pattern	12
10	its	pattern	12
11	expression	its	10
12	pattern	and	8
13	in	synchronized	14
14	synchronized	identified	2
15	fibroblasts	identified	2
16	.	identified	2

0	Northern	analyses	1
1	analyses	suggested	2
2	suggested	<ROOT>	-1
3	that	suggested	2
4	the	were	12
5	reiterated	the	4
6	splicing	sites	7
7	sites	mutants	11
8	of	sites	7
9	the	representative	10
10	representative	of	8
11	mutants	reiterated	5
12	were	that	3
13	all	were	12
14	used	were	12
15	in	used	14
16	RNA	splicing	17
17	splicing	in	15
18	,	suggested	2
19	and	suggested	2
20	the	and	19
21	closest	were	26
22	donor	were	26
23	and	donor	22
24	recipient	joints	25
25	joints	and	23
26	were	the	20
27	used	frequently	29
28	most	frequently	29
29	frequently	were	26
30	.	suggested	2

0	The	element	2
1	CCAAT	element	2
2	element	is	16
3	present	element	2
4	in	present	3
5	reverse	in	4
6	orientation	reverse	5
7	in	orientation	6
8	this	in	7
9	promoter	this	8
10	region	promoter	9
11	of	region	10
12	the	gene	15
13	ferritin	gene	15
14	H-chain	gene	15
15	gene	of	11
16	is	<ROOT>	-1
17	necessary	is	16
18	for	binding	19
19	binding	necessary	17
20	and	is	16
21	for	is	16
22	gene	is	16
23	activity	is	16
24	,	is	16
25	since	is	16
26	a	mutation	29
27	single	mutation	29
28	point	mutation	29
29	mutation	is	30
30	is	since	25
31	able	is	30
32	to	able	31
33	abolish	to	32
34	the	binding	35
35	binding	abolish	33
36	of	binding	35
37	HRF	of	36
38	and	HRF	37
39	the	activity	41
40	transcriptional	activity	41
41	activity	and	38
42	in	transfected	43
43	transfected	activity	41
44	cells	is	16
45	.	is	16

0	In	prostaglandin	3
1	contrast	In	0
2	,	prostaglandin	3
3	prostaglandin	<ROOT>	-1
4	I2	prostaglandin	3
5	(	PGI2	6
6	PGI2	I2	4
7	)	PGI2	6
8	,	prostaglandin	3
9	a	regulator	12
10	strong	regulator	12
11	negative	regulator	12
12	regulator	prostaglandin	3
13	of	regulator	12
14	platelet	function	15
15	function	of	13
16	,	prostaglandin	3
17	inhibited	prostaglandin	3
18	agonist-induced	prostaglandin	3
19	as	prostaglandin	3
20	well	as	19
21	as	as	19
22	Ca2+-induced	as	19
23	activation	Ca2+-induced	22
24	of	activation	23
25	Rap1	of	24
26	.	prostaglandin	3

0	One	interpretation	1
1	interpretation	of	2
2	of	<ROOT>	-1
3	these	of	2
4	data	of	2
5	leads	of	2
6	to	leads	5
7	a	model	8
8	model	to	6
9	in	amplifies	17
10	which	in	9
11	the	peak	12
12	peak	amplifies	17
13	in	peak	12
14	GATA-1	binding	16
15	DNA	binding	16
16	binding	in	13
17	amplifies	model	8
18	the	effect	19
19	effect	amplifies	17
20	of	effect	19
21	early	replication	22
22	replication	of	20
23	on	the	24
24	the	amplifies	17
25	activation	of	26
26	of	the	24
27	erythroid-specific	of	26
28	genes	of	2
29	at	of	2
30	the	time	32
31	same	time	32
32	time	at	29
33	as	of	2
34	preventing	activation	35
35	activation	as	33
36	of	activation	35
37	non-erythroid	genes	38
38	genes	of	36
39	containing	GATA-responsive	40
40	GATA-responsive	of	36
41	elements	of	2
42	.	of	2

0	The	identification	1
1	identification	has	8
2	of	identification	1
3	the	Sry	7
4	mammalian	Sry	7
5	sex-determining	Sry	7
6	gene	Sry	7
7	Sry	of	2
8	has	<ROOT>	-1
9	led	has	8
10	to	led	9
11	the	discovery	12
12	discovery	to	10
13	of	discovery	12
14	a	family	16
15	large	family	16
16	family	of	13
17	of	family	16
18	related	of	17
19	(	related	18
20	'	(	19
21	HMG	(	19
22	box	HMG	21
23	'	HMG	21
24	)	'	23
25	transcription	factors	26
26	factors	)	24
27	that	factors	26
28	control	has	8
29	developmental	control	28
30	events	developmental	29
31	in	yeast	32
32	yeast	events	30
33	,	yeast	32
34	C.	elegans	35
35	elegans	yeast	32
36	,	elegans	35
37	Drosophila	elegans	35
38	and	Drosophila	37
39	vertebrates	and	38
40	.	has	8

0	This	pattern	1
1	pattern	receptor	29
2	of	pattern	1
3	STAT	of	2
4	protein	STAT	3
5	phosphorylation	is	6
6	is	protein	4
7	identical	pattern	1
8	to	identical	7
9	IL-10	to	8
10	receptor	IL-10	9
11	activation	on	12
12	on	IL-10	9
13	normal	pattern	1
14	cells	pattern	1
15	and	pattern	1
16	similar	and	15
17	to	similar	16
18	IFN-alpha	(	19
19	(	to	17
20	STAT1	(	19
21	and	STAT1	20
22	STAT3	pattern	1
23	)	pattern	1
24	and	pattern	1
25	IFN-gamma	pattern	1
26	(	pattern	1
27	STAT1	pattern	1
28	)	pattern	1
29	receptor	<ROOT>	-1
30	activation	receptor	29
31	in	activation	30
32	CLL	in	31
33	.	receptor	29

0	Intimate	interactions	1
1	interactions	<ROOT>	-1
2	between	hemopoietic	4
3	multipotential	hemopoietic	4
4	hemopoietic	interactions	1
5	stem	hemopoietic	4
6	cells	interactions	1
7	and	interactions	1
8	their	and	7
9	microenvironment	their	8
10	work	their	8
11	towards	work	10
12	redefining	work	10
13	the	identity	14
14	identity	redefining	12
15	and	identity	14
16	the	fate	18
17	differentiative	fate	18
18	fate	and	15
19	of	fate	18
20	these	of	19
21	primitive	cells	22
22	cells	these	20
23	.	cells	22

0	To	<ROOT>	-1
1	investigate	To	0
2	the	mechanisms	3
3	mechanisms	investigate	1
4	of	transcriptional	5
5	transcriptional	mechanisms	3
6	activation	of	7
7	of	interleukin-1beta	8
8	interleukin-1beta	(	9
9	(	mechanisms	3
10	IL-1beta	To	0
11	)	To	0
12	in	To	0
13	non-monocytic	in	12
14	cells	,	15
15	,	non-monocytic	13
16	we	To	0
17	constructed	To	0
18	a	series	19
19	series	constructed	17
20	of	series	19
21	reporter	plasmids	22
22	plasmids	of	20
23	with	constructed	17
24	the	gene	28
25	bacterial	gene	28
26	chloramphenicol	gene	28
27	acetyltransferase	gene	28
28	gene	with	23
29	linked	gene	28
30	to	various	31
31	various	linked	29
32	parts	various	31
33	of	parts	32
34	the	promoter	37
35	human	promoter	37
36	IL-1beta	promoter	37
37	promoter	of	33
38	and	To	0
39	performed	To	0
40	transient	To	0
41	transfection	experiments	42
42	experiments	To	0
43	.	To	0

0	A	has	8
1	novel	B-cell	2
2	B-cell	A	0
3	derived	(	4
4	(	B-cell	2
5	Bcd	(	4
6	)	Bcd	5
7	oncogene	A	0
8	has	patient	25
9	been	has	8
10	isolated	been	9
11	from	blood	14
12	the	blood	14
13	peripheral	blood	14
14	blood	isolated	10
15	lymphocytes	has	8
16	of	has	8
17	one	leukemia	21
18	B-cell	leukemia	21
19	chronic	leukemia	21
20	lymphocytic	leukemia	21
21	leukemia	has	8
22	(	B-CLL	23
23	B-CLL	leukemia	21
24	)	B-CLL	23
25	patient	<ROOT>	-1
26	using	DNA	27
27	DNA	patient	25
28	transfer	patient	25
29	and	mouse	31
30	a	mouse	31
31	mouse	transfer	28
32	tumorigenicity	.	34
33	assay	.	34
34	.	mouse	31

0	The	core	1
1	core	<ROOT>	-1
2	of	core	1
3	the	promoter	4
4	promoter	of	2
5	(	promoter	4
6	positions	promoter	4
7	-42	positions	6
8	to	-42	7
9	+11	is	11
10	)	is	11
11	is	to	8
12	recognized	promoter	4
13	by	recognized	12
14	the	Ets-1	19
15	lymphoid	Ets-1	19
16	cell-specific	Ets-1	19
17	transcription	Ets-1	19
18	factors	Ets-1	19
19	Ets-1	by	13
20	,	promoter	4
21	LEF1	promoter	4
22	,	promoter	4
23	and	promoter	4
24	AML1	and	23
25	as	promoter	4
26	well	as	25
27	as	as	25
28	by	promoter	4
29	CREB/ATF-1	by	28
30	,	CREB/ATF-1	29
31	as	,	30
32	is	as	31
33	demonstrated	in	34
34	in	is	32
35	gel	shift	36
36	shift	in	34
37	and	shift	36
38	footprinting	core	1
39	experiments	core	1
40	.	core	1

0	The	aim	1
1	aim	was	5
2	of	aim	1
3	this	research	4
4	research	of	2
5	was	<ROOT>	-1
6	to	was	5
7	test	to	6
8	the	hypothesis	9
9	hypothesis	test	7
10	that	hypothesis	9
11	a	relationship	13
12	causal	relationship	13
13	relationship	exists	14
14	exists	that	10
15	between	exists	14
16	the	level	17
17	level	between	15
18	of	level	17
19	expression	of	18
20	of	of	18
21	G-LRB-S-RRB-alpha	was	5
22	and	was	5
23	induction	and	22
24	of	induction	23
25	the	cyclase	27
26	adenylyl	cyclase	27
27	cyclase	cascade	31
28	(	AC	29
29	AC	cyclase	27
30	)	AC	29
31	cascade	of	24
32	.	was	5

0	In	demonstrate	5
1	this	report	2
2	report	In	0
3	,	demonstrate	5
4	we	demonstrate	5
5	demonstrate	<ROOT>	-1
6	that	demonstrate	5
7	the	form	9
8	active	form	9
9	form	is	12
10	of	form	9
11	NF-AT1	of	10
12	is	that	6
13	also	is	12
14	present	is	12
15	in	present	14
16	the	nuclei	17
17	nuclei	T	20
18	of	T	20
19	HTLV-I-transformed	T	20
20	T	in	15
21	cells	demonstrate	5
22	that	express	23
23	express	demonstrate	5
24	the	protein	26
25	Tax	protein	26
26	protein	express	23
27	.	demonstrate	5

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	CMV	activates	5
5	activates	transcriptional	7
6	these	transcriptional	7
7	transcriptional	that	3
8	factors	transcriptional	7
9	,	transcriptional	7
10	resulting	transcriptional	7
11	in	resulting	10
12	IL-8	in	11
13	gene	IL-8	12
14	expression	.	15
15	.	gene	13

0	These	findings	1
1	findings	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	PRE-I	may	5
5	may	that	3
6	play	may	5
7	a	play	6
8	role	a	7
9	in	role	8
10	the	regulation	12
11	differential	regulation	12
12	regulation	expression	16
13	of	expression	16
14	IL-4	of	13
15	gene	expression	16
16	expression	in	9
17	levels	suggest	2
18	.	suggest	2

0	Promoter	activity	1
1	activity	was	2
2	was	<ROOT>	-1
3	increased	was	2
4	by	increased	3
5	the	factors	7
6	transcription	factors	7
7	factors	by	4
8	C/EBPbeta	by	4
9	(	C/EBPbeta	8
10	NF-IL6	was	2
11	)	was	2
12	and	was	2
13	more	strongly	14
14	strongly	and	12
15	,	was	2
16	by	,	15
17	C/EBPdelta	(	18
18	(	by	16
19	NF-IL6beta	(	18
20	)	was	2
21	.	was	2

0	In	<ROOT>	-1
1	contrast	In	0
2	,	In	0
3	overexpression	In	0
4	of	wild-type	5
5	wild-type	overexpression	3
6	ZAP-70	induced	7
7	induced	In	0
8	constitutive	activation	9
9	activation	In	0
10	of	activation	9
11	nuclear	factor	12
12	factor	of	10
13	of	T	15
14	activated	T	15
15	T	factor	12
16	cells	In	0
17	.	In	0

0	The	number	1
1	number	<ROOT>	-1
2	of	number	1
3	Type	I	4
4	I	of	2
5	and	number	1
6	Type	and	5
7	II	number	1
8	receptors	number	1
9	before	number	1
10	the	test	11
11	test	lower	13
12	was	test	11
13	lower	before	9
14	in	lower	13
15	elderly	lower	13
16	subjects	elderly	15
17	than	subjects	16
18	in	adults	19
19	adults	than	17
20	.	number	1

0	When	are	2
1	monocytes	are	2
2	are	is	24
3	stimulated	are	2
4	with	stimulated	3
5	LPS	with	4
6	(	lipopolysaccharide	7
7	lipopolysaccharide	LPS	5
8	)	lipopolysaccharide	7
9	repeatedly	LPS	5
10	then	repeatedly	9
11	the	expression	14
12	initially	high	13
13	high	expression	14
14	expression	LPS	5
15	of	expression	14
16	the	of	15
17	TNF	(	18
18	(	tumor	19
19	tumor	necrosis	20
20	necrosis	gene	23
21	factor	necrosis	20
22	)	factor	21
23	gene	the	16
24	is	<ROOT>	-1
25	only	very	26
26	very	is	24
27	low	very	26
28	,	is	24
29	i.e.	is	24
30	the	i.e.	29
31	cells	are	32
32	are	tolerant	33
33	tolerant	the	30
34	to	tolerant	33
35	LPS	tolerant	33
36	.	is	24

0	[	<ROOT>	-1
1	The	value	2
2	value	[	0
3	of	value	2
4	the	test	6
5	clinical	test	6
6	test	of	3
7	of	glucocorticoid	8
8	glucocorticoid	test	6
9	receptors	of	10
10	of	[	0
11	peripheral	[	0
12	blood	[	0
13	leukocytes	[	0
14	in	leukocytes	13
15	patients	pulmonary	18
16	with	pulmonary	18
17	chronic	pulmonary	18
18	pulmonary	in	14
19	heart	[	0
20	disease	[	0
21	]	[	0

0	We	report	1
1	report	<ROOT>	-1
2	here	report	1
3	the	cloning	4
4	cloning	protein	15
5	and	cloning	4
6	characterization	and	5
7	of	characterization	6
8	a	homologue	10
9	human	homologue	10
10	homologue	cloning	4
11	of	homologue	10
12	the	Drosophila	13
13	Drosophila	of	11
14	toll	cloning	4
15	protein	report	1
16	(	report	1
17	Toll	report	1
18	)	report	1
19	which	has	20
20	has	report	1
21	been	has	20
22	shown	been	21
23	to	shown	22
24	induce	adult	30
25	the	response	28
26	innate	response	28
27	immune	response	28
28	response	induce	24
29	in	adult	30
30	adult	to	23
31	Drosophila	to	23
32	.	report	1

0	Histamine	induced	1
1	induced	<ROOT>	-1
2	mRNA	induced	1
3	expression	mRNA	2
4	of	expression	3
5	an	of	4
6	immediate	an	5
7	early	immediate	6
8	gene	c-fos	9
9	c-fos	early	7
10	.	c-fos	9

0	Mutation	diminished	4
1	of	Mutation	0
2	Ser184	of	1
3	also	diminished	4
4	diminished	<ROOT>	-1
5	transactivation	function	6
6	function	diminished	4
7	in	function	6
8	B	cells	9
9	cells	in	7
10	,	diminished	4
11	suggesting	diminished	4
12	that	suggesting	11
13	the	phosphorylation	15
14	activating	phosphorylation	15
15	phosphorylation	is	22
16	that	is	17
17	is	phosphorylation	15
18	inducible	is	17
19	in	inducible	18
20	T	cells	21
21	cells	inducible	18
22	is	that	12
23	constitutively	diminished	4
24	present	constitutively	23
25	in	present	24
26	B	cells	27
27	cells	in	25
28	.	diminished	4

0	Cell-to-cell	contact	1
1	contact	activates	2
2	activates	<ROOT>	-1
3	in	activates	2
4	vitro	in	3
5	binding	of	6
6	of	activates	2
7	the	of	6
8	nuclear	kappaB	10
9	factor	nuclear	8
10	kappaB	(	11
11	(	the	7
12	NF-kappaB	(	11
13	)	of	6
14	p50/p65	activates	2
15	heterodimer	kappaB	19
16	to	kappaB	19
17	an	kappaB	19
18	HIV-1	kappaB	19
19	kappaB	activates	2
20	oligonucleotide	activates	2
21	.	activates	2

0	A	<ROOT>	-1
1	conserved	A	0
2	tissue-specific	conserved	1
3	structure	tissue-specific	2
4	at	structure	3
5	a	beta-chain	9
6	human	beta-chain	9
7	T-cell	beta-chain	9
8	receptor	beta-chain	9
9	beta-chain	at	4
10	core	promoter	11
11	promoter	structure	3
12	.	A	0

0	Interestingly	was	7
1	,	was	7
2	the	sequence	6
3	deduced	sequence	6
4	amino	sequence	6
5	acid	sequence	6
6	sequence	was	7
7	was	<ROOT>	-1
8	found	was	7
9	to	found	8
10	be	to	9
11	related	be	10
12	to	related	11
13	fungal	sterol	15
14	C8-C7	sterol	15
15	sterol	to	12
16	isomerase	be	10
17	,	isomerase	16
18	encoded	isomerase	16
19	by	encoded	18
20	the	gene	22
21	ERG2	gene	22
22	gene	by	19
23	.	was	7

0	In	<ROOT>	-1
1	vitro	In	0
2	,	In	0
3	thrombin-stimulated	to	7
4	fixed	to	7
5	platelets	bound	6
6	bound	to	7
7	to	,	2
8	neutrophils	to	7
9	and	neutrophils	8
10	monocytes	In	0
11	.	In	0

0	The	<ROOT>	-1
1	APL	The	0
2	recapitulated	features	3
3	features	APL	1
4	of	features	3
5	the	disease	7
6	human	disease	7
7	disease	of	4
8	,	APL	1
9	including	APL	1
10	a	response	11
11	response	including	9
12	to	response	11
13	retinoic	to	12
14	acid	retinoic	13
15	.	acid	14

0	The	mutated	1
1	mutated	human	2
2	human	constructs	4
3	CIITA	constructs	4
4	constructs	were	5
5	were	<ROOT>	-1
6	,	were	5
7	therefore	were	5
8	,	were	5
9	tested	were	5
10	in	tested	9
11	the	pig	12
12	pig	in	10
13	.	were	5

0	Preliminary	observations	1
1	observations	tend	2
2	tend	<ROOT>	-1
3	to	correlate	4
4	correlate	tend	2
5	this	cell	7
6	CREF	cell	7
7	cell	correlate	4
8	killing	tend	2
9	with	killing	8
10	the	accumulation	11
11	accumulation	with	9
12	of	accumulation	11
13	the	of	12
14	early	viral	15
15	viral	proteins	16
16	proteins	the	13
17	and/or	DNA	19
18	viral	DNA	19
19	DNA	proteins	16
20	in	the	13
21	the	cells	23
22	infected	cells	23
23	cells	in	20
24	.	tend	2

0	The	mAb	1
1	mAb	failed	2
2	failed	<ROOT>	-1
3	to	failed	2
4	induce	to	3
5	NF-kappa	activity	8
6	B/Rel	activity	8
7	nuclear	B/Rel	6
8	activity	induce	4
9	in	cells	10
10	cells	induce	4
11	incubated	cells	10
12	in	the	13
13	the	failed	2
14	presence	3,4-dichloroisocoumarin	16
15	of	3,4-dichloroisocoumarin	16
16	3,4-dichloroisocoumarin	failed	2
17	,	3,4-dichloroisocoumarin	16
18	an	inhibitor	19
19	inhibitor	kappa	22
20	of	inhibitor	19
21	I	of	20
22	kappa	3,4-dichloroisocoumarin	16
23	B-alpha	3,4-dichloroisocoumarin	16
24	degradation	failed	2
25	.	failed	2

0	Glucocorticoid-mediated	of	2
1	inhibition	of	2
2	of	<ROOT>	-1
3	RANTES	expression	4
4	expression	of	2
5	in	human	6
6	human	T	7
7	T	of	2
8	lymphocytes	of	2
9	.	of	2

0	In	<ROOT>	-1
1	the	In	0
2	IL-4-producing	Th0-like	3
3	Th0-like	human	4
4	human	the	1
5	Jurkat	In	0
6	and	Jurkat	5
7	mouse	and	6
8	EL-4	mouse	7
9	cells	,	10
10	,	EL-4	8
11	POS-1	)	15
12	(	)	15
13	designated	)	15
14	POS-1a	)	15
15	)	EL-4	8
16	contains	)	15
17	NF-IL6beta	In	0
18	and	In	0
19	Jun	In	0
20	.	In	0

0	To	<ROOT>	-1
1	understand	To	0
2	the	mechanisms	3
3	mechanisms	underlined	4
4	underlined	understand	1
5	in	this	6
6	this	underlined	4
7	regulation	normal	9
8	in	normal	9
9	normal	underlined	4
10	human	To	0
11	cells	To	0
12	,	To	0
13	we	,	12
14	have	we	13
15	analysed	have	14
16	in	analysed	15
17	vivo	in	16
18	protein-DNA	vivo	17
19	interactions	protein-DNA	18
20	at	interactions	19
21	the	Cyclin	22
22	Cyclin	at	20
23	A	Cyclin	22
24	locus	T	27
25	in	T	27
26	primary	T	27
27	T	Cyclin	22
28	lymphocytes	T	27
29	.	T	27

0	TNF-alpha	release	1
1	release	peaked	2
2	peaked	<ROOT>	-1
3	at	peaked	2
4	24	h	5
5	h	at	3
6	and	peaked	2
7	decreased	and	6
8	thereafter	and	6
9	,	peaked	2
10	and	peaked	2
11	it	was	12
12	was	and	10
13	dose	was	12
14	dependent	dose	13
15	and	was	12
16	preceded	and	15
17	by	preceded	16
18	an	increase	19
19	increase	by	17
20	of	TNF-alpha	21
21	TNF-alpha	increase	19
22	mRNA	peaked	2
23	detectable	peaked	2
24	after	peaked	2
25	3	peaked	2
26	h	peaked	2
27	of	h	26
28	stimulation	peaked	2
29	with	stimulation	28
30	mAb	L243	31
31	L243	with	29
32	.	peaked	2

0	Using	<ROOT>	-1
1	immunological	cross-linking	2
2	cross-linking	Using	0
3	to	Using	0
4	mimic	to	3
5	receptor	engagement	6
6	engagement	mimic	4
7	by	engagement	6
8	natural	ligands	9
9	ligands	by	7
10	,	Using	0
11	we	show	13
12	now	show	13
13	show	Using	0
14	that	show	13
15	CD15	that	14
16	(	Lewis	17
17	Lewis	CD15	15
18	X	Lewis	17
19	)	Lewis	17
20	,	CD15	15
21	a	counter-receptor	23
22	monocyte	counter-receptor	23
23	counter-receptor	CD15	15
24	for	counter-receptor	23
25	endothelial	selectins	26
26	selectins	for	24
27	may	counter-receptor	23
28	participate	may	27
29	in	may	27
30	this	in	29
31	response	.	32
32	.	this	30

0	This	suppressive	1
1	suppressive	effect	2
2	effect	was	3
3	was	<ROOT>	-1
4	also	was	3
5	seen	was	3
6	in	seen	5
7	IL-2-driven	growth	9
8	cell	growth	9
9	growth	in	6
10	of	growth	9
11	CD8-positive	lymphocytes	12
12	lymphocytes	of	10
13	purified	of	10
14	from	of	10
15	7-day	PHA-blasts	16
16	PHA-blasts	from	14
17	,	PHA-blasts	16
18	indicating	PHA-blasts	16
19	that	indicating	18
20	CD4	molecules	21
21	molecules	were	22
22	were	that	19
23	not	were	22
24	required	were	22
25	for	required	24
26	the	suppression	27
27	suppression	for	25
28	.	was	3

0	Binding	IL-1	5
1	of	IL-1	5
2	activated	IL-1	5
3	platelets	activated	2
4	induces	platelets	3
5	IL-1	<ROOT>	-1
6	beta	IL-1	5
7	,	IL-1	5
8	IL-8	IL-1	5
9	,	IL-8	8
10	and	,	9
11	MCP-1	IL-1	5
12	in	IL-1	5
13	leukocytes	in	12
14	.	IL-1	5

0	Ro	09-2210	1
1	09-2210	was	2
2	was	<ROOT>	-1
3	also	was	2
4	able	was	2
5	to	able	4
6	inhibit	to	5
7	phorbol	ester/ionomycin-induced	8
8	ester/ionomycin-induced	inhibit	6
9	activation	of	10
10	of	ester/ionomycin-induced	8
11	AP1	of	10
12	with	AP1	11
13	IC50	ester/ionomycin-induced	8
14	=	IC50	13
15	&lt;	nM	17
16	10	&lt;	15
17	nM	=	14
18	.	was	2

0	TCR	signaling	1
1	signaling	was	2
2	was	<ROOT>	-1
3	triggered	was	2
4	by	triggered	3
5	treating	T	7
6	Jurkat	T	7
7	T	by	4
8	cells	was	2
9	with	was	2
10	PHA	with	9
11	or	PHA	10
12	anti-CD3	or	11
13	Abs	was	2
14	,	was	2
15	and	was	2
16	NF-kappaB	activation	17
17	activation	was	2
18	was	was	2
19	monitored	was	18
20	by	monitored	19
21	electrophoretic	mobility	22
22	mobility	by	20
23	shift	mobility	22
24	assays	and/or	25
25	and/or	monitored	19
26	by	reporter	28
27	kappaB-dependent	reporter	28
28	reporter	and/or	25
29	assays	was	2
30	.	was	2

0	The	gene	3
1	NF-kappa	B1	2
2	B1	gene	3
3	gene	encodes	4
4	encodes	<ROOT>	-1
5	a	protein	7
6	105-kD	protein	7
7	protein	encodes	4
8	that	is	9
9	is	encodes	4
10	the	precursor	11
11	precursor	is	9
12	of	precursor	11
13	the	component	15
14	p50	component	15
15	component	of	12
16	of	NF-kappa	17
17	NF-kappa	component	15
18	B	encodes	4
19	.	encodes	4

0	Surprisingly	does	8
1	,	does	8
2	TRAF1	does	8
3	,	TRAF1	2
4	-2	TRAF1	2
5	,	TRAF1	2
6	or	TRAF1	2
7	-3	or	6
8	does	CT	15
9	not	does	8
10	interact	CT	15
11	with	CT	15
12	the	CT	15
13	terminal	CT	15
14	LMP1	CT	15
15	CT	<ROOT>	-1
16	aa	CT	15
17	333	aa	16
18	to	CT	15
19	386	to	18
20	which	386	19
21	can	CT	15
22	independently	can	21
23	mediate	independently	22
24	NF-kappaB	CT	15
25	activation	CT	15
26	.	CT	15

0	Involvement	<ROOT>	-1
1	of	Involvement	0
2	the	region	4
3	N-terminal	region	4
4	region	of	1
5	of	region	4
6	the	receptor	9
7	human	receptor	9
8	mineralocorticoid	receptor	9
9	receptor	of	5
10	hormone-binding	of	1
11	domain	Involvement	0
12	in	Involvement	0
13	agonist	in	12
14	and	in	12
15	antagonist	Involvement	0
16	binding	Involvement	0
17	as	Involvement	0
18	revealed	as	17
19	by	revealed	18
20	a	monoclonal	22
21	new	monoclonal	22
22	monoclonal	by	19
23	antibody	monoclonal	22
24	.	antibody	23

0	It	is	1
1	is	<ROOT>	-1
2	thus	is	1
3	generally	is	1
4	believed	is	1
5	that	believed	4
6	the	that	5
7	pancreatic	the	6
8	endocrine-lineage	possesses	9
9	possesses	pancreatic	7
10	the	ability	11
11	ability	possesses	9
12	to	ability	11
13	mature	to	12
14	along	mature	13
15	a	along	14
16	differentiation	that	18
17	pathway	that	18
18	that	along	14
19	shares	along	14
20	many	characteristics	21
21	characteristics	shares	19
22	with	along	14
23	those	with	22
24	of	those	23
25	neuronal	differentiation	26
26	differentiation	of	24
27	.	is	1

0	High-level	activation	2
1	NF-kappaB	activation	2
2	activation	appears	4
3	also	appears	4
4	appears	<ROOT>	-1
5	to	appears	4
6	be	to	5
7	a	component	9
8	critical	component	9
9	component	be	6
10	of	component	9
11	long-term	outgrowth	12
12	outgrowth	of	10
13	.	appears	4

0	The	effect	1
1	effect	was	26
2	of	effect	1
3	both	cytokines	4
4	cytokines	of	2
5	on	effect	1
6	the	on	5
7	monocyte	maturation/differentiation	8
8	maturation/differentiation	,	11
9	(	maturation/differentiation	8
10	CD11b	,	11
11	,	the	6
12	CD13	,	11
13	,	the	6
14	and	the	6
15	CD26	the	6
16	)	effect	1
17	and	effect	1
18	other	and	17
19	macrophage	markers	20
20	markers	effect	1
21	(	markers	20
22	CD14	effect	1
23	and	CD14	22
24	CD68	CD14	22
25	)	effect	1
26	was	<ROOT>	-1
27	examined	was	26
28	.	was	26

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	NF-kappa	B	5
5	B	is	7
6	activity	B	5
7	is	that	3
8	commonly	is	7
9	inducible	is	7
10	in	inducible	9
11	DND39	inducible	9
12	cells	indicate	2
13	by	indicate	2
14	IL-4	indicate	2
15	and	indicate	2
16	anti-CD40	indicate	2
17	mAb	indicate	2
18	and	indicate	2
19	suggest	that	20
20	that	indicate	2
21	NF-kappa	sensitive	23
22	B	sensitive	23
23	sensitive	that	20
24	to	indicate	2
25	NAC	to	24
26	may	indicate	2
27	play	may	26
28	a	play	27
29	role	in	30
30	in	a	28
31	regulating	IgE	32
32	IgE	in	30
33	synthesis	IgE	32
34	in	IgE	32
35	B	cells	36
36	cells	in	34
37	.	indicate	2

0	These	phenomena	1
1	phenomena	are	2
2	are	<ROOT>	-1
3	in	are	2
4	a	manner	6
5	dose-dependent	manner	6
6	manner	in	3
7	comparable	manner	6
8	to	manner	6
9	that	seen	10
10	seen	to	8
11	with	seen	10
12	rIL-12	with	11
13	.	are	2

0	OCA-B	is	1
1	is	<ROOT>	-1
2	a	analog	4
3	functional	analog	4
4	analog	is	1
5	of	analog	4
6	VP16	of	5
7	but	is	1
8	targets	but	7
9	a	surface	11
10	separate	surface	11
11	surface	targets	8
12	of	surface	11
13	the	domain	16
14	Oct-1	domain	16
15	POU	domain	16
16	domain	of	12
17	[	erratum	19
18	published	[	17
19	erratum	is	1
20	appears	erratum	19
21	in	appears	20
22	Mol	is	1
23	Cell	is	1
24	Biol	is	1
25	1998	Apr	26
26	Apr	is	1
27	;	Apr	26
28	18	(	29
29	(	Apr	26
30	4	(	29
31	)	Apr	26
32	:	Apr	26
33	2430	is	1
34	]	is	1

0	With	<ROOT>	-1
1	the	aim	2
2	aim	With	0
3	of	aim	2
4	identifying	of	3
5	genetic	targets	6
6	targets	identifying	4
7	for	transcription	9
8	these	transcription	9
9	transcription	identifying	4
10	factors	With	0
11	,	With	0
12	we	cDNAs	15
13	stably	transfected	14
14	transfected	cDNAs	15
15	cDNAs	,	11
16	encoding	EBF	17
17	EBF	cDNAs	15
18	or	EBF	17
19	a	homodimer	21
20	covalent	homodimer	21
21	homodimer	or	18
22	of	homodimer	21
23	E47	of	22
24	,	cDNAs	15
25	individually	With	0
26	or	With	0
27	together	With	0
28	,	With	0
29	into	which	35
30	immature	cells	33
31	hematopoietic	Ba/F3	32
32	Ba/F3	cells	33
33	cells	into	29
34	,	into	29
35	which	,	28
36	lack	both	37
37	both	which	35
38	factors	With	0
39	.	With	0

0	It	has	1
1	has	<ROOT>	-1
2	been	has	1
3	shown	been	2
4	that	been	2
5	this	E1B	6
6	E1B	19K	7
7	19K	protein	8
8	protein	is	9
9	is	that	4
10	not	is	9
11	necessary	for	12
12	for	is	9
13	viral	replication	15
14	DNA	replication	15
15	replication	for	12
16	in	human	17
17	human	for	12
18	cell	has	1
19	lines	has	1
20	,	such	21
21	such	has	1
22	as	such	21
23	HeLa	and	24
24	and	as	22
25	KB	such	21
26	.	has	1

0	The	protein	1
1	protein	is	2
2	is	<ROOT>	-1
3	believed	is	2
4	to	believed	3
5	bind	to	4
6	small	substances	8
7	lipophilic	substances	8
8	substances	bind	5
9	such	as	10
10	as	substances	8
11	bacterial	as	10
12	derived	bacterial	11
13	formylpeptides	derived	12
14	and	formylpeptides	13
15	lipopolysaccharides	and	14
16	(	LPS	17
17	LPS	lipopolysaccharides	15
18	)	LPS	17
19	and	formylpeptides	13
20	might	function	21
21	function	and	19
22	as	function	21
23	a	modulator	24
24	modulator	as	22
25	of	modulator	24
26	inflammation	of	25
27	.	inflammation	26

0	The	gene	1
1	gene	has	2
2	has	<ROOT>	-1
3	41	exons	5
4	small	exons	5
5	exons	has	2
6	spanning	exons	5
7	45	kb	8
8	kb	spanning	6
9	of	kb	8
10	genomic	of	9
11	DNA	of	9
12	and	DNA	11
13	encoding	a	14
14	a	kb	16
15	5.5	kb	16
16	kb	and	12
17	mRNA	has	2
18	.	has	2

0	We	<ROOT>	-1
1	have	We	0
2	generated	have	1
3	transgenic	mice	4
4	mice	generated	2
5	that	express	6
6	express	mice	4
7	a	form	10
8	catalytically	form	10
9	inactive	form	10
10	form	express	6
11	of	protein	13
12	Ca2+/calmodulin-dependent	protein	13
13	protein	form	10
14	kinase	IV	15
15	IV	mice	4
16	(	IV	15
17	CaMKIV	We	0
18	)	We	0
19	specifically	)	18
20	in	T	22
21	thymic	T	22
22	T	We	0
23	cells	We	0
24	.	We	0

0	Oxidants	are	1
1	are	<ROOT>	-1
2	also	are	1
3	known	are	1
4	to	known	3
5	activate	to	4
6	another	factor	8
7	transcription	factor	8
8	factor	activate	5
9	,	are	1
10	activator	are	1
11	protein-1	.	12
12	.	activator	10

0	We	analysed	1
1	analysed	and	10
2	FHIT	analysed	1
3	in	analysed	1
4	the	series	6
5	same	series	6
6	series	in	3
7	of	series	6
8	RNA	of	7
9	samples	analysed	1
10	and	<ROOT>	-1
11	detected	and	10
12	truncated	and	10
13	FHIT	and	10
14	transcripts	and	10
15	frequently	both	17
16	in	both	17
17	both	and	10
18	tumour	and	19
19	and	both	17
20	normal	both	17
21	tissues	and	10
22	.	and	10

0	Treatment	of	1
1	of	<ROOT>	-1
2	PAEC	of	1
3	exposed	of	1
4	to	exposed	3
5	xenogeneic	to	4
6	serum	xenogeneic	5
7	with	xenogeneic	5
8	the	with	7
9	NF-kappa	the	8
10	B	pyrrolidinedithiocarbamate	12
11	inhibitors	pyrrolidinedithiocarbamate	12
12	pyrrolidinedithiocarbamate	NF-kappa	9
13	(	to	4
14	PDTC	of	1
15	,	microM	17
16	25	microM	17
17	microM	of	1
18	)	of	1
19	and	of	1
20	tosyl-phechloromethylketone	of	1
21	(	tosyl-phechloromethylketone	20
22	TPCK	(	21
23	,	microM	25
24	25	microM	25
25	microM	(	21
26	)	(	21
27	significantly	)	26
28	(	significantly	27
29	P	of	1
30	&lt;	reduced	33
31	0.01	reduced	33
32	)	reduced	33
33	reduced	of	1
34	leukocyte	of	1
35	adhesion	of	1
36	in	adhesion	35
37	respect	in	36
38	to	respect	37
39	PAEC	treated	40
40	treated	to	38
41	with	human	42
42	human	treated	40
43	serum	human	42
44	alone	treated	40
45	.	of	1

0	This	could	1
1	could	<ROOT>	-1
2	partly	could	1
3	be	could	1
4	explained	be	3
5	by	explained	4
6	the	treatment	9
7	antenatal	treatment	9
8	steroid	treatment	9
9	treatment	by	5
10	.	could	1

0	LPS	stimulation	1
1	stimulation	did	2
2	did	<ROOT>	-1
3	not	did	2
4	give	did	2
5	rise	give	4
6	to	give	4
7	a	to	6
8	persistent	cell	27
9	nuclear	persistent	8
10	accumulation	nuclear	9
11	of	accumulation	10
12	RelB	of	11
13	and	RelB	12
14	c-Rel	and	13
15	,	persistent	8
16	whereas	c-Rel	18
17	nuclear	c-Rel	18
18	c-Rel	persistent	8
19	,	c-Rel	18
20	but	,	19
21	not	,	19
22	RelB	,	19
23	,	persistent	8
24	accumulated	cell	27
25	after	cell	27
26	B	cell	27
27	cell	a	7
28	receptor	did	2
29	stimulation	did	2
30	.	did	2

0	The	results	1
1	results	agree	4
2	for	results	1
3	athletes	for	2
4	agree	<ROOT>	-1
5	with	agree	4
6	their	with	5
7	lower	anabolic/catabolic	8
8	anabolic/catabolic	their	6
9	balance	anabolic/catabolic	8
10	.	balance	9

0	Under	resulted	9
1	identical	conditions	2
2	conditions	Under	0
3	,	resulted	9
4	FMLP	resulted	9
5	but	FMLP	4
6	not	PAF	7
7	PAF	but	5
8	,	FMLP	4
9	resulted	<ROOT>	-1
10	in	resulted	9
11	significant	p42/44	12
12	p42/44	in	10
13	(	ERK	14
14	ERK	activation	17
15	)	ERK	14
16	MAPk	activation	17
17	activation	resulted	9
18	.	resulted	9

0	Pharmacologic	will	9
1	control	Pharmacologic	0
2	of	control	1
3	trans-gene	expression	4
4	expression	of	2
5	in	T	7
6	gene-modified	T	7
7	T	of	2
8	cells	Pharmacologic	0
9	will	<ROOT>	-1
10	not	will	9
11	only	will	9
12	facilitate	new	13
13	new	will	9
14	approaches	the	16
15	to	the	16
16	the	new	13
17	study	different	19
18	of	different	19
19	different	the	16
20	aspects	T	22
21	of	T	22
22	T	different	19
23	cell	the	16
24	biology	will	9
25	,	will	9
26	but	will	9
27	will	but	26
28	also	but	26
29	provide	the	30
30	the	also	28
31	basis	gene	34
32	for	gene	34
33	new	gene	34
34	gene	also	28
35	therapy	will	9
36	strategies	will	9
37	.	will	9

0	Within	is	7
1	the	lineage	3
2	erythroid	lineage	3
3	lineage	Within	0
4	,	is	7
5	runt	expression	6
6	expression	is	7
7	is	<ROOT>	-1
8	biphasic	is	7
9	,	is	7
10	clearly	present	11
11	present	is	7
12	in	present	11
13	the	erythroblasts	14
14	erythroblasts	blood	17
15	of	blood	17
16	early	blood	17
17	blood	in	12
18	islands	is	7
19	and	islands	18
20	of	and	19
21	the	liver	23
22	fetal	liver	23
23	liver	of	20
24	,	is	7
25	but	is	7
26	absent	but	25
27	in	absent	26
28	the	adult	29
29	adult	in	27
30	.	is	7

0	We	identified	1
1	identified	that	5
2	a	segment	4
3	promoter	segment	4
4	segment	identified	1
5	that	<ROOT>	-1
6	activates	that	5
7	transcription	activates	6
8	most	that	5
9	efficiently	that	5
10	in	efficiently	9
11	keratinocytes	that	5
12	.	that	5

0	This	review	1
1	review	analyzes	2
2	analyzes	<ROOT>	-1
3	various	alterations	5
4	molecular	alterations	5
5	alterations	analyzes	2
6	responsible	alterations	5
7	for	responsible	6
8	the	response	10
9	deficient	response	10
10	response	for	7
11	to	response	10
12	corticosteroid	treatment	13
13	treatment	to	11
14	observed	treatment	13
15	in	response	10
16	steroid-resistant	response	10
17	bronchial	steroid-resistant	16
18	asthmatic	bronchial	17
19	subjects	analyzes	2
20	.	analyzes	2

0	Our	findings	1
1	findings	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	distinct	elements	6
5	regulatory	elements	6
6	elements	control	15
7	,	elements	6
8	acting	elements	6
9	somewhat	independently	10
10	independently	acting	8
11	of	independently	10
12	each	other	13
13	other	of	11
14	,	elements	6
15	control	that	3
16	expression	control	15
17	of	expression	16
18	collagenase-1	suggest	2
19	.	suggest	2

0	Oxidative	<ROOT>	-1
1	stress	Oxidative	0
2	suppresses	Oxidative	0
3	transcription	factor	4
4	factor	suppresses	2
5	activities	factor	4
6	in	stimulated	7
7	stimulated	suppresses	2
8	lymphocytes	Oxidative	0
9	.	Oxidative	0

0	These	<ROOT>	-1
1	blast	transcription	5
2	cells	express	3
3	express	blast	1
4	lineage-specific	transcription	5
5	transcription	These	0
6	factors	such	7
7	such	These	0
8	as	GATA-1	9
9	GATA-1	such	7
10	common	to	11
11	to	GATA-1	9
12	these	lineages	13
13	lineages	to	11
14	and	These	0
15	frequently	express	16
16	express	These	0
17	erythroid-specific	mRNAs	18
18	mRNAs	express	16
19	such	as	20
20	as	mRNAs	18
21	gamma-globin	and	22
22	and	as	20
23	erythroid	delta-aminolevulinate	24
24	delta-aminolevulinate	and	22
25	synthase	These	0
26	(	These	0
27	ALAS-E	These	0
28	)	These	0
29	,	These	0
30	indicating	These	0
31	that	indicating	30
32	most	have	41
33	of	most	32
34	the	blasts	35
35	blasts	of	33
36	in	blasts	35
37	M7	in	36
38	and	most	32
39	TMD	cases	40
40	cases	and	38
41	have	that	31
42	erythroid	have	41
43	and	erythroid	42
44	megakaryocytic	erythroid	42
45	phenotypes	.	46
46	.	megakaryocytic	44

0	FMS	patients	1
1	patients	display	2
2	display	<ROOT>	-1
3	a	hormone	7
4	hyperreactive	pituitary	5
5	pituitary	hormone	7
6	adrenocorticotropic	hormone	7
7	hormone	display	2
8	(	ACTH	9
9	ACTH	hormone	7
10	)	ACTH	9
11	release	display	2
12	in	display	2
13	response	in	12
14	to	response	13
15	corticotropin-releasing	hormone	16
16	hormone	(	17
17	(	CRH	18
18	CRH	to	14
19	)	CRH	18
20	and	display	2
21	to	and	20
22	insulin-induced	hypoglycemia	23
23	hypoglycemia	to	21
24	.	display	2

0	Stimulation	<ROOT>	-1
1	of	Stimulation	0
2	PPARgamma	of	1
3	with	Stimulation	0
4	troglitazone	with	3
5	or	troglitazone	4
6	15-deoxy-delta12,14-prostaglandin	J2	7
7	J2	or	5
8	in	troglitazone	4
9	human	monocyte-derived	10
10	monocyte-derived	in	8
11	macrophages	monocyte-derived	10
12	inhibited	troglitazone	4
13	MMP-9	troglitazone	4
14	gelatinolytic	MMP-9	13
15	activity	gelatinolytic	14
16	in	activity	15
17	a	in	16
18	concentration-dependent	as	20
19	fashion	as	20
20	as	a	17
21	revealed	as	20
22	by	a	17
23	zymography	by	22
24	.	Stimulation	0

0	Tissue	<ROOT>	-1
1	and	cell-type	2
2	cell-type	Tissue	0
3	specific	cell-type	2
4	expression	Tissue	0
5	of	expression	4
6	the	of	5
7	tuberous	the	6
8	sclerosis	tuberous	7
9	gene	sclerosis	8
10	,	gene	9
11	TSC2	,	10
12	,	TSC2	11
13	in	human	14
14	human	,	12
15	tissues	Tissue	0
16	.	Tissue	0

0	CONCLUSION	<ROOT>	-1
1	:	CONCLUSION	0
2	Cytomegalovirus	immediate	3
3	immediate	CONCLUSION	0
4	early	products	6
5	gene	products	6
6	products	immediate	3
7	significantly	immediate	3
8	enhanced	significantly	7
9	expression	enhanced	8
10	of	expression	9
11	IL-6	of	10
12	in	LPS-stimulated	13
13	LPS-stimulated	IL-6	11
14	cells	CONCLUSION	0
15	.	CONCLUSION	0

0	T	cells	1
1	cells	<ROOT>	-1
2	recognizing	cells	1
3	antigens	encoded	4
4	encoded	recognizing	2
5	within	encoded	4
6	map	within	5
7	units	map	6
8	0.67	map	6
9	to	0.67	8
10	0.73	to	9
11	of	0.73	10
12	HSV	of	11
13	DNA	are	14
14	are	HSV	12
15	frequently	recovered	16
16	recovered	encoded	4
17	from	recovered	16
18	herpetic	lesions	19
19	lesions	from	17
20	.	cells	1

0	Lipopolysaccharide	human	13
1	(	LPS	2
2	LPS	Lipopolysaccharide	0
3	)	LPS	2
4	-prestimulated	LPS	2
5	and	-prestimulated	4
6	untreated	and	5
7	THP-1	cells	8
8	cells	untreated	6
9	were	Lipopolysaccharide	0
10	cocultured	Lipopolysaccharide	0
11	with	cocultured	10
12	resting	Lipopolysaccharide	0
13	human	<ROOT>	-1
14	umbilical	(	18
15	vein	(	18
16	endothelial	(	18
17	cells	(	18
18	(	human	13
19	HUVEC	human	13
20	)	human	13
21	for	human	13
22	3	human	13
23	and	human	13
24	24	and	23
25	h	24	24
26	in	the	27
27	the	24	24
28	presence	the	27
29	of	presence	28
30	colimycin	of	29
31	to	the	27
32	neutralize	to	31
33	LPS	neutralize	32
34	traces	LPS	33
35	.	traces	34

0	When	was	4
1	the	ability	3
2	transactivation	ability	3
3	ability	was	4
4	was	showed	11
5	compared	was	4
6	among	compared	5
7	the	three	8
8	three	among	6
9	,	showed	11
10	GATA-4	showed	11
11	showed	<ROOT>	-1
12	the	activity	14
13	highest	activity	14
14	activity	showed	11
15	.	showed	11

0	Here	show	2
1	we	show	2
2	show	<ROOT>	-1
3	that	show	2
4	in	fibroblast	9
5	a	fibroblast	9
6	MPC11	plasmacytoma	7
7	plasmacytoma	fibroblast	9
8	x	fibroblast	9
9	fibroblast	that	3
10	environment	show	2
11	,	3'	14
12	the	3'	14
13	IgH	3'	14
14	3'	enhancer	15
15	enhancer	show	2
16	is	transcriptionally	17
17	transcriptionally	show	2
18	inactive	show	2
19	.	show	2

0	Taken	<ROOT>	-1
1	together	Taken	0
2	these	Taken	0
3	data	these	2
4	indicate	data	3
5	that	indicate	4
6	carboxylesterase	in	9
7	gene	in	9
8	transcription	in	9
9	in	that	5
10	THP-1	cells	11
11	cells	that	5
12	starts	that	5
13	at	initiation	15
14	multiple	initiation	15
15	initiation	starts	12
16	sites	Taken	0
17	and	Taken	0
18	that	and	17
19	Sp1	that	18
20	and	Sp1	19
21	IRBP	may	22
22	may	Sp1	19
23	be	may	22
24	critical	factors	25
25	factors	be	23
26	for	be	23
27	modulating	for	26
28	the	transcription	30
29	differentiation-dependent	transcription	30
30	transcription	modulating	27
31	of	carboxylesterase	34
32	this	carboxylesterase	34
33	human	carboxylesterase	34
34	carboxylesterase	transcription	30
35	gene	Taken	0
36	.	Taken	0

0	We	<ROOT>	-1
1	have	We	0
2	previously	demonstrated	3
3	demonstrated	have	1
4	an	requirement	6
5	obligatory	requirement	6
6	requirement	demonstrated	3
7	for	intracellular	8
8	intracellular	reactive	9
9	reactive	requirement	6
10	oxygen	demonstrated	3
11	species	lymphocyte	15
12	generation	lymphocyte	15
13	during	lymphocyte	15
14	T	lymphocyte	15
15	lymphocyte	oxygen	10
16	activation	lymphocyte	15
17	,	We	0
18	and	We	0
19	have	proposed	20
20	proposed	and	18
21	that	reactive	23
22	intracellular	reactive	23
23	reactive	proposed	20
24	oxygen	may	26
25	species	may	26
26	may	reactive	23
27	act	proposed	20
28	as	proposed	20
29	signalling	proposed	20
30	agents	We	0
31	in	the	32
32	the	agents	30
33	regulation	the	32
34	of	regulation	33
35	certain	cycle	44
36	cellular	certain	35
37	processes	,	38
38	,	cellular	36
39	for	cellular	36
40	example	for	39
41	,	certain	35
42	during	cycle	44
43	cell	cycle	44
44	cycle	of	34
45	entry	We	0
46	.	We	0

0	We	found	1
1	found	was	10
2	that	found	1
3	in	T	4
4	T	that	2
5	cells	found	1
6	,	found	1
7	anti-CD3-induced	found	1
8	c-Rel	expression	9
9	expression	found	1
10	was	<ROOT>	-1
11	blocked	was	10
12	by	blocked	11
13	PF	by	12
14	,	was	10
15	whereas	was	10
16	the	induction	17
17	induction	members	22
18	of	induction	17
19	other	family	21
20	NF-kappaB	family	21
21	family	of	18
22	members	was	23
23	was	whereas	15
24	not	was	23
25	significantly	was	23
26	affected	significantly	25
27	.	was	10

0	Molecular	cues	1
1	cues	act	7
2	delivered	cues	1
3	by	delivered	2
4	the	microenvironment	5
5	microenvironment	by	3
6	frequently	act	7
7	act	<ROOT>	-1
8	in	act	7
9	an	fashion	11
10	instructive	fashion	11
11	fashion	in	8
12	by	fashion	11
13	initiating	that	17
14	intracellular	that	17
15	signaling	that	17
16	pathways	that	17
17	that	fashion	11
18	ultimately	act	7
19	target	act	7
20	a	group	22
21	select	group	22
22	group	target	19
23	of	group	22
24	transcription	factors	25
25	factors	of	23
26	.	act	7

0	The	effect	3
1	GH-induced	inhibitory	2
2	inhibitory	effect	3
3	effect	was	4
4	was	<ROOT>	-1
5	also	was	4
6	observed	was	4
7	using	observed	6
8	normal	using	7
9	human	monocytes	10
10	monocytes	normal	8
11	and	observed	6
12	monocyte-derived	and	11
13	macrophages	monocyte-derived	12
14	.	was	4

0	Here	have	3
1	,	have	3
2	we	have	3
3	have	lacking	13
4	studied	IL-2	5
5	IL-2	have	3
6	and	IL-2	5
7	IL-4	and	6
8	signaling	B	10
9	in	B	10
10	B	have	3
11	cell	have	3
12	lines	have	3
13	lacking	<ROOT>	-1
14	JAK3	lacking	13
15	.	lacking	13

0	Constitutive	<ROOT>	-1
1	dephosphorylation	Constitutive	0
2	and	dephosphorylation	1
3	activation	Constitutive	0
4	of	Constitutive	0
5	a	member	6
6	member	of	4
7	of	member	6
8	the	factor	10
9	nuclear	factor	10
10	factor	of	7
11	of	T	13
12	activated	T	13
13	T	factor	10
14	cells	Constitutive	0
15	,	Constitutive	0
16	NF-AT1	Constitutive	0
17	,	Constitutive	0
18	in	T-cell	24
19	Tax-expressing	in	18
20	and	in	18
21	type	T-cell	24
22	I	type	21
23	human	T-cell	24
24	T-cell	Constitutive	0
25	leukemia	T-cell	24
26	virus-infected	Constitutive	0
27	human	Constitutive	0
28	T	cells	29
29	cells	human	27
30	.	cells	29

0	Interaction	of	1
1	of	<ROOT>	-1
2	transcription	factors	3
3	factors	of	1
4	RFX1	of	1
5	and	RFX1	4
6	MIBP1	of	1
7	with	of	1
8	the	motif	10
9	gamma	motif	10
10	motif	with	7
11	of	motif	10
12	the	element	15
13	negative	element	15
14	regulatory	element	15
15	element	core	21
16	of	core	21
17	the	core	21
18	hepatitis	core	21
19	B	virus	20
20	virus	core	21
21	core	of	11
22	promoter	of	1
23	.	of	1

0	Role	<ROOT>	-1
1	for	Role	0
2	a	sequence	7
3	novel	sequence	7
4	5'	sequence	7
5	palindromic	sequence	7
6	octamer	sequence	7
7	sequence	for	1
8	.	Role	0

0	In	demonstrate	5
1	this	report	2
2	report	In	0
3	,	demonstrate	5
4	we	demonstrate	5
5	demonstrate	<ROOT>	-1
6	that	demonstrate	5
7	the	site	9
8	AP-1	site	9
9	site	regulate	15
10	and	site	9
11	a	element	14
12	distal	element	14
13	promoter	element	14
14	element	and	10
15	regulate	that	6
16	transcriptional	induction	17
17	induction	regulate	15
18	of	induction	17
19	collagenase-1	of	18
20	during	monocytic	21
21	monocytic	regulate	15
22	differentiation	demonstrate	5
23	.	demonstrate	5

0	Furthermore	is	3
1	,	is	3
2	it	is	3
3	is	<ROOT>	-1
4	highly	is	3
5	expressed	highly	4
6	in	expressed	5
7	Burkitt	in	6
8	's	Burkitt	7
9	lymphoma	's	8
10	cells	and	11
11	and	's	8
12	may	highly	4
13	participate	may	12
14	in	may	12
15	the	pathogenesis	16
16	pathogenesis	in	14
17	of	this	18
18	this	pathogenesis	16
19	disease	is	3
20	.	is	3

0	Partial	sequences	1
1	sequences	<ROOT>	-1
2	from	sequences	1
3	exons	from	2
4	1-8	were	5
5	were	exons	3
6	nearly	identical	7
7	identical	were	5
8	to	identical	7
9	the	sequence	11
10	published	sequence	11
11	sequence	to	8
12	of	sequence	11
13	the	mRNA	16
14	human	mRNA	16
15	ER	mRNA	16
16	mRNA	of	12
17	.	sequences	1

0	Dose-response	studies	1
1	studies	that	3
2	showed	studies	1
3	that	resulted	14
4	10-LRB--7-RRB-	to	5
5	to	10-LRB--6-RRB-	6
6	10-LRB--6-RRB-	that	3
7	mol/L	(	10
8	9-cis	(	10
9	RA	(	10
10	(	10-LRB--6-RRB-	6
11	12	10-LRB--6-RRB-	6
12	hours	10-LRB--6-RRB-	6
13	)	that	3
14	resulted	<ROOT>	-1
15	in	resulted	14
16	peak	levels	17
17	levels	in	15
18	of	levels	17
19	C/EBP	mRNA	21
20	epsilon	mRNA	21
21	mRNA	of	18
22	;	resulted	14
23	but	resulted	14
24	even	but	23
25	10-LRB--10-RRB-	mol/L	26
26	mol/L	even	24
27	9-cis	these	32
28	RA	these	32
29	increased	these	32
30	levels	these	32
31	of	these	32
32	these	mol/L	26
33	transcripts	resulted	14
34	.	resulted	14

0	The	element	4
1	other	studied	2
2	studied	element	4
3	regulatory	element	4
4	element	is	5
5	is	<ROOT>	-1
6	the	CD4	8
7	minimal	CD4	8
8	CD4	silencer	9
9	silencer	is	5
10	which	inhibits	11
11	inhibits	silencer	9
12	CD4	inhibits	11
13	gene	expression	14
14	expression	CD4	12
15	in	peripheral	16
16	peripheral	expression	14
17	CD8	T	18
18	T	inhibits	11
19	lymphocytes	is	5
20	.	is	5

0	Expression	was	6
1	of	Expression	0
2	luciferase	of	1
3	in	these	4
4	these	Expression	0
5	cells	Expression	0
6	was	myristate	10
7	induced	by	8
8	by	was	6
9	phorbol	myristate	10
10	myristate	<ROOT>	-1
11	acetate	myristate	10
12	plus	acetate	11
13	a	calcium	14
14	calcium	plus	12
15	ionophore	myristate	10
16	.	myristate	10

0	Thus	is	3
1	,	is	3
2	it	is	3
3	is	<ROOT>	-1
4	not	is	3
5	unexpected	is	3
6	that	unexpected	5
7	this	switch	11
8	versatile	switch	11
9	cellular	switch	11
10	homeostatic	switch	11
11	switch	would	12
12	would	that	6
13	be	would	12
14	affected	be	13
15	by	affected	14
16	a	variety	17
17	variety	by	15
18	of	variety	17
19	viral	of	18
20	pathogens	,	21
21	,	viral	19
22	which	have	23
23	have	be	13
24	evolved	mechanisms	25
25	mechanisms	have	23
26	to	mechanisms	25
27	utilize	mechanisms	25
28	various	utilize	27
29	aspects	facilitate	35
30	of	aspects	29
31	Rel/NF-kappa	of	30
32	B	Rel/NF-kappa	31
33	activity	B	32
34	to	activity	33
35	facilitate	various	28
36	their	replication	37
37	replication	,	38
38	,	facilitate	35
39	cell	that	6
40	survival	is	3
41	and	is	3
42	possibly	evasion	43
43	evasion	is	3
44	of	immune	45
45	immune	evasion	43
46	responses	is	3
47	.	is	3

0	So	far	1
1	far	<ROOT>	-1
2	,	far	1
3	transcriptional	,	2
4	analyses	transcriptional	3
5	of	analyses	4
6	p40	have	7
7	have	far	1
8	been	have	7
9	carried	been	8
10	out	carried	9
11	only	carried	9
12	using	only	11
13	bacterial	using	12
14	constituents	using	12
15	such	constituents	14
16	as	such	15
17	LPS	as	16
18	as	stimuli	19
19	stimuli	LPS	17
20	.	stimuli	19

0	STAT3	expression	1
1	expression	has	4
2	in	expression	1
3	particular	in	2
4	has	<ROOT>	-1
5	been	has	4
6	associated	been	5
7	with	associated	6
8	Abl	with	7
9	,	Abl	8
10	Src	Abl	8
11	,	Src	10
12	and	,	11
13	HTLV-1	Src	10
14	transformation	HTLV-1	13
15	of	normal	16
16	normal	transformation	14
17	cells	has	4
18	.	has	4

0	We	report	1
1	report	<ROOT>	-1
2	that	report	1
3	both	YY1	4
4	YY1	participate	7
5	and	YY1	4
6	LSF	and	5
7	participate	that	2
8	in	participate	7
9	the	formation	10
10	formation	in	8
11	of	formation	10
12	a	of	11
13	complex	a	12
14	that	recognizes	15
15	recognizes	complex	13
16	the	region	18
17	initiation	region	18
18	region	recognizes	15
19	of	region	18
20	the	LTR	22
21	HIV-1	LTR	22
22	LTR	of	19
23	.	report	1

0	The	oncogene	2
1	v-myb	oncogene	2
2	oncogene	causes	10
3	,	oncogene	2
4	carried	oncogene	2
5	by	carried	4
6	avian	retroviruses	8
7	defective	retroviruses	8
8	retroviruses	by	5
9	,	oncogene	2
10	causes	<ROOT>	-1
11	leukaemias	causes	10
12	in	causes	10
13	the	chicken	14
14	chicken	in	12
15	and	chicken	14
16	transforms	causes	10
17	haematopoietic	causes	10
18	cells	haematopoietic	17
19	in	cells	18
20	vitro	in	19
21	.	causes	10

0	We	<ROOT>	-1
1	have	We	0
2	compared	human	7
3	the	action	4
4	action	human	7
5	on	human	7
6	U-937	human	7
7	human	have	1
8	promonocytic	cells	10
9	leukemia	cells	10
10	cells	topoisomerase	14
11	of	topoisomerase	14
12	two	topoisomerase	14
13	DNA	topoisomerase	14
14	topoisomerase	human	7
15	II	human	7
16	inhibitors	,	17
17	,	We	0
18	namely	,	17
19	the	etoposide	21
20	epipodophyllotoxin	etoposide	21
21	etoposide	,	17
22	and	etoposide	21
23	the	ICRF-193	25
24	bisdioxopiperazine	ICRF-193	25
25	ICRF-193	and	22
26	.	We	0

0	YY1	is	9
1	,	YY1	0
2	a	factor	7
3	widely	distributed	4
4	distributed	factor	7
5	human	factor	7
6	transcription	factor	7
7	factor	YY1	0
8	,	YY1	0
9	is	<ROOT>	-1
10	known	is	9
11	to	known	10
12	inhibit	to	11
13	HIV-1	long	14
14	long	inhibit	12
15	terminal	repeat	16
16	repeat	long	14
17	(	)	19
18	LTR	)	19
19	)	repeat	16
20	transcription	)	19
21	and	repeat	16
22	virus	and	21
23	production	.	24
24	.	virus	22

0	Cell-to-cell	HT29	13
1	contact	Cell-to-cell	0
2	between	contact	1
3	peripheral	blood	4
4	blood	between	2
5	lymphocytes	Cell-to-cell	0
6	and	Cell-to-cell	0
7	transfected	line	12
8	human	line	12
9	colonic	line	12
10	carcinoma	line	12
11	cell	line	12
12	line	and	6
13	HT29	activates	14
14	activates	<ROOT>	-1
15	transcription	terminal	19
16	of	terminal	19
17	the	terminal	19
18	long	terminal	19
19	terminal	activates	14
20	repeats	activates	14
21	(	repeats	20
22	LTR	(	21
23	)	LTR	22
24	of	)	23
25	human	virus	27
26	immunodeficiency	virus	27
27	virus	of	24
28	.	virus	27

0	Using	<ROOT>	-1
1	ATL-16T	cells	2
2	cells	Using	0
3	which	express	4
4	express	cells	2
5	IL-5	express	4
6	mRNA	IL-5	5
7	,	have	9
8	we	have	9
9	have	mRNA	6
10	identified	have	9
11	a	region	12
12	region	identified	10
13	,	Using	0
14	within	Using	0
15	the	promoter	19
16	human	promoter	19
17	IL-5	promoter	19
18	gene	promoter	19
19	promoter	within	14
20	,	regulates	22
21	that	regulates	22
22	regulates	Using	0
23	IL-5	regulates	22
24	gene	IL-5	23
25	transcription	.	26
26	.	gene	24

0	Ehrlichia	chaffeensis	1
1	chaffeensis	is	2
2	is	<ROOT>	-1
3	an	is	2
4	obligatory	an	3
5	intracellular	that	7
6	bacterium	that	7
7	that	obligatory	4
8	infects	that	7
9	monocytes	infects	8
10	and	monocytes	9
11	macrophages	and	10
12	and	that	7
13	is	and	12
14	the	is	13
15	etiologic	the	14
16	agent	etiologic	15
17	of	agent	16
18	human	ehrlichiosis	19
19	ehrlichiosis	of	17
20	in	agent	16
21	the	States	23
22	United	States	23
23	States	in	20
24	.	is	2

0	The	mutant	2
1	AP-1	mutant	2
2	mutant	constructs	3
3	constructs	showed	5
4	also	showed	5
5	showed	<ROOT>	-1
6	delayed	activation	8
7	transcriptional	activation	8
8	activation	showed	5
9	in	PMA-treated	10
10	PMA-treated	activation	8
11	fibroblasts	showed	5
12	.	showed	5

0	In	were	10
1	contrast	In	0
2	,	were	10
3	the	activities	5
4	binding	activities	5
5	activities	were	10
6	of	activities	5
7	NF1	of	6
8	and	NF1	7
9	Sp1	and	8
10	were	<ROOT>	-1
11	not	were	10
12	affected	were	10
13	by	affected	12
14	ER	by	13
15	.	ER	14

0	5'-serially	truncated	1
1	truncated	PECAM-1	2
2	PECAM-1	promoter	3
3	promoter	segments	4
4	segments	drove	12
5	cloned	segments	4
6	in	cloned	5
7	front	in	6
8	of	front	7
9	a	reporter	11
10	luciferase	reporter	11
11	reporter	of	8
12	drove	<ROOT>	-1
13	transcription	in	14
14	in	drove	12
15	both	lineage-	17
16	a	lineage-	17
17	lineage-	drove	12
18	and	lineage-	17
19	orientation-specific	and	18
20	manner	.	21
21	.	and	18

0	Therefore	enhancer	7
1	,	inactivation	2
2	inactivation	Therefore	0
3	of	3'	6
4	the	3'	6
5	IgH	3'	6
6	3'	inactivation	2
7	enhancer	is	8
8	is	<ROOT>	-1
9	a	process	11
10	multifactorial	process	11
11	process	is	8
12	affecting	that	16
13	several	factors	15
14	transcription	factors	15
15	factors	affecting	12
16	that	process	11
17	control	the	18
18	the	that	16
19	cell-specific	the	18
20	and	developmental	21
21	developmental	cell-specific	19
22	activity	developmental	21
23	of	developmental	21
24	the	enhancer	25
25	enhancer	of	23
26	.	is	8

0	We	have	1
1	have	<ROOT>	-1
2	now	have	1
3	studied	have	1
4	Trident	expression	5
5	expression	studied	3
6	in	studied	3
7	cell	lines	8
8	lines	in	6
9	,	have	1
10	differentiating	have	1
11	thymocytes	have	1
12	and	have	1
13	in	have	1
14	lymphocytes	derived	15
15	derived	have	1
16	from	peripheral	17
17	peripheral	derived	15
18	blood	have	1
19	.	have	1

0	As	<ROOT>	-1
1	evidenced	As	0
2	by	evidenced	1
3	electro	(	7
4	mobility	(	7
5	shift	(	7
6	assay	(	7
7	(	by	2
8	EMSA	As	0
9	)	As	0
10	and	As	0
11	the	use	12
12	use	probe	18
13	of	use	12
14	a	B	16
15	NF-kappa	B	16
16	B	of	13
17	prototypic	probe	18
18	probe	and	10
19	,	probe	18
20	these	drugs	21
21	drugs	probe	18
22	probably	probe	18
23	exert	probe	18
24	their	effects	26
25	inhibitory	effects	26
26	effects	exert	23
27	by	exert	23
28	interference	by	27
29	with	interference	28
30	the	translocation	32
31	nuclear	translocation	32
32	translocation	with	29
33	of	NF-kappa	34
34	NF-kappa	translocation	32
35	B/c-Rel	probe	18
36	proteins	probe	18
37	.	As	0

0	Monoclonal	antibodies	1
1	antibodies	<ROOT>	-1
2	against	antibodies	1
3	either	monomorphic	4
4	monomorphic	against	2
5	or	monomorphic	4
6	polymorphic	determinants	7
7	determinants	or	5
8	of	monomorphic	4
9	class	I	10
10	I	monomorphic	4
11	antigen	antibodies	1
12	induced	antibodies	1
13	in	induced	12
14	PBMC	in	13
15	and	in	13
16	highly	purified	17
17	purified	and	15
18	T	antibodies	1
19	lymphocytes	antibodies	1
20	the	activity	22
21	nuclear	activity	22
22	activity	antibodies	1
23	of	activity	22
24	NF-kappa	of	23
25	B/Rel	.	27
26	complexes	.	27
27	.	NF-kappa	24

0	Plasma	cortisol	1
1	cortisol	was	2
2	was	<ROOT>	-1
3	higher	was	2
4	and	was	2
5	testosterone	and	4
6	lower	testosterone	5
7	in	and	4
8	the	athletes	9
9	athletes	in	7
10	;	was	2
11	they	were	12
12	were	was	2
13	negatively	correlated	14
14	correlated	were	12
15	in	correlated	14
16	athletes	in	15
17	and	were	12
18	positively	and	17
19	correlated	positively	18
20	in	correlated	19
21	the	subjects	23
22	sedentary	subjects	23
23	subjects	in	20
24	.	was	2

0	Molecular	characterization	1
1	characterization	<ROOT>	-1
2	and	characterization	1
3	pattern	and	2
4	of	tissue	5
5	tissue	and	2
6	expression	characterization	1
7	of	expression	6
8	the	gene	9
9	gene	of	7
10	for	expression	6
11	neutrophil	lipocalin	13
12	gelatinase-associated	lipocalin	13
13	lipocalin	for	10
14	from	characterization	1
15	humans	characterization	1
16	.	characterization	1

0	Therefore	requires	12
1	,	requires	12
2	initiation	requires	12
3	of	initiation	2
4	the	cycle	7
5	EBV	cycle	7
6	lytic	cycle	7
7	cycle	of	3
8	by	initiation	2
9	the	protein	11
10	ZEBRA	protein	11
11	protein	by	8
12	requires	abolished	34
13	a	function	14
14	function	requires	12
15	in	function	14
16	addition	in	15
17	to	transcriptional	18
18	transcriptional	addition	16
19	activation	;	20
20	;	in	15
21	a	change	22
22	change	;	20
23	of	change	22
24	serine	of	23
25	186	in	15
26	to	186	25
27	alanine	to	26
28	in	alanine	27
29	the	domain	31
30	DNA-binding	domain	31
31	domain	in	28
32	of	ZEBRA	33
33	ZEBRA	domain	31
34	abolished	<ROOT>	-1
35	this	function	37
36	additional	function	37
37	function	abolished	34
38	and	abolished	34
39	uncovered	and	38
40	a	uncovered	39
41	new	a	40
42	role	new	41
43	for	role	42
44	the	for	43
45	ZEBRA	the	44
46	protein	ZEBRA	45
47	in	protein	46
48	disruption	EBV	50
49	of	EBV	50
50	EBV	protein	46
51	latency	abolished	34
52	.	abolished	34

0	n-Acetyl-L-cysteine	blocked	9
1	(	NAC	2
2	NAC	n-Acetyl-L-cysteine	0
3	)	NAC	2
4	,	n-Acetyl-L-cysteine	0
5	a	antioxidant	7
6	potent	antioxidant	7
7	antioxidant	n-Acetyl-L-cysteine	0
8	,	n-Acetyl-L-cysteine	0
9	blocked	<ROOT>	-1
10	NF-kappa	activation	12
11	B	activation	12
12	activation	caused	13
13	caused	blocked	9
14	by	blocked	9
15	IL-4	blocked	9
16	and	blocked	9
17	by	blocked	9
18	anti-CD40	blocked	9
19	mAb	blocked	9
20	.	blocked	9

0	Together	suggest	4
1	,	suggest	4
2	these	results	3
3	results	suggest	4
4	suggest	<ROOT>	-1
5	that	triggering	8
6	class	I	7
7	I	triggering	8
8	triggering	suggest	4
9	can	induce	10
10	induce	triggering	8
11	the	induce	10
12	activity	triggering	8
13	of	activity	12
14	NF-kappa	activity	17
15	B/Rel	activity	17
16	nuclear	B/Rel	15
17	activity	of	13
18	in	peripheral	19
19	peripheral	suggest	4
20	blood	T	21
21	T	suggest	4
22	lymphocytes	suggest	4
23	,	suggest	4
24	thereby	modulating	25
25	modulating	suggest	4
26	the	expression	27
27	expression	modulating	25
28	of	expression	27
29	genes	of	28
30	regulated	these	32
31	by	these	32
32	these	genes	29
33	transcription	suggest	4
34	factors	suggest	4
35	.	suggest	4

0	To	<ROOT>	-1
1	characterize	the	2
2	the	To	0
3	regulation	the	2
4	of	and	11
5	NGAL	of	4
6	further	NGAL	5
7	,	NGAL	5
8	we	and	11
9	have	and	11
10	cloned	and	11
11	and	regulation	3
12	sequenced	regulation	3
13	a	sequenced	12
14	5869-bp	a	13
15	region	5869-bp	14
16	of	region	15
17	the	of	16
18	NGAL	the	17
19	gene	NGAL	18
20	including	gene	19
21	1695	including	20
22	bp	1695	21
23	of	nontranscribed	26
24	the	nontranscribed	26
25	5'	nontranscribed	26
26	nontranscribed	bp	22
27	region	and	28
28	and	coding	31
29	a	coding	31
30	3696-bp	coding	31
31	coding	To	0
32	region	encompassing	33
33	encompassing	coding	31
34	seven	exons	35
35	exons	encompassing	33
36	and	exons	35
37	six	introns	38
38	introns	and	36
39	.	To	0

0	Further	relationship	4
1	,	Further	0
2	an	relationship	4
3	inverse	relationship	4
4	relationship	was	5
5	was	<ROOT>	-1
6	also	was	5
7	observed	was	5
8	between	observed	7
9	sterol	gene	12
10	modulated	gene	12
11	LDL-receptor	modulated	10
12	gene	between	8
13	transcription	gene	12
14	and	binding	16
15	the	binding	16
16	binding	observed	7
17	affinity	was	5
18	of	affinity	17
19	this	of	18
20	47	this	19
21	kDa	factor	22
22	factor	47	20
23	to	factor	22
24	the	SRE	25
25	SRE	to	23
26	sequence	SRE	25
27	.	was	5

0	Bone	<ROOT>	-1
1	marrow	samples	2
2	samples	Bone	0
3	from	Bone	0
4	33	patients	5
5	patients	from	3
6	affected	patients	5
7	by	affected	6
8	MM	by	7
9	and	by	7
10	MGUS	Bone	0
11	,	Bone	0
12	and	affected	16
13	8	patients	14
14	patients	and	12
15	not	affected	16
16	affected	Bone	0
17	by	affected	16
18	lymphoproliferative	diseases	19
19	diseases	by	17
20	were	Bone	0
21	studied	were	20
22	for	studied	21
23	expression	of	24
24	of	for	22
25	c-Jun	of	24
26	(	of	24
27	a	component	28
28	component	(	26
29	of	component	28
30	the	factor	32
31	transcription	factor	32
32	factor	of	29
33	AP-1	)	34
34	)	component	28
35	and	)	34
36	glutathione-S-transferase	pi	37
37	pi	component	28
38	(	pi	37
39	GST-pi	pi	37
40	)	pi	37
41	using	(	26
42	immunocytochemical	of	24
43	methods	for	22
44	.	Bone	0

0	Our	study	2
1	present	study	2
2	study	shows	3
3	shows	<ROOT>	-1
4	that	mediate	8
5	IFN-alpha	mediate	8
6	and	IFN-alpha	5
7	-beta	and	6
8	mediate	shows	3
9	anti-apoptotic	effect	10
10	effect	mediate	8
11	through	mediate	8
12	other	through	11
13	pathways	than	14
14	than	other	12
15	that	other	12
16	of	that	15
17	IL-2	of	16
18	in	of	16
19	growth	shows	3
20	factor	shows	3
21	deprivation	shows	3
22	apoptosis	shows	3
23	.	shows	3

0	Taken	suggest	5
1	together	Taken	0
2	,	suggest	5
3	these	observations	4
4	observations	suggest	5
5	suggest	<ROOT>	-1
6	that	suggest	5
7	nontoxic	concentrations	8
8	concentrations	that	6
9	of	concentrations	8
10	reactive	of	9
11	metabolites	reactive	10
12	of	metabolites	11
13	oxygen	of	12
14	and	oxygen	13
15	nitrogen	and	14
16	play	nitrogen	15
17	an	role	19
18	important	role	19
19	role	reactive	10
20	in	role	19
21	regulating	in	20
22	the	expression	23
23	expression	in	20
24	of	expression	23
25	genes	of	24
26	involved	of	24
27	in	involved	26
28	the	response	30
29	inflammatory	response	30
30	response	in	27
31	and	response	30
32	in	and	31
33	modulating	apoptosis	34
34	apoptosis	and	31
35	.	suggest	5

0	In	is	11
1	many	disorders	4
2	chronic	disorders	4
3	inflammatory	disorders	4
4	disorders	In	0
5	,	glucocorticoid	6
6	glucocorticoid	is	11
7	(	glucocorticoid	6
8	GC	glucocorticoid	6
9	)	insensitivity	10
10	insensitivity	glucocorticoid	6
11	is	<ROOT>	-1
12	a	is	11
13	challenging	a	12
14	clinical	associated	16
15	problem	associated	16
16	associated	challenging	13
17	with	associated	16
18	life-threatening	with	17
19	disease	.	21
20	progression	.	21
21	.	life-threatening	18

0	Activation	<ROOT>	-1
1	of	Activation	0
2	the	transcription	3
3	transcription	of	1
4	factor	transcription	3
5	NF-kappaB	transcription	3
6	in	of	1
7	lipopolysaccharide-stimulated	of	1
8	U937	Activation	0
9	cells	Activation	0
10	.	Activation	0

0	On	was	6
1	the	average	2
2	average	On	0
3	,	was	6
4	no	correlation	5
5	correlation	was	6
6	was	<ROOT>	-1
7	established	was	6
8	between	established	7
9	degree	of	10
10	of	between	8
11	lymphocyte	of	10
12	infiltration	lymphocyte	11
13	in	infiltration	12
14	breast	tumor	15
15	tumor	in	13
16	and	lymphocyte	11
17	age	and	16
18	and	age	17
19	menopause	and	18
20	onset	menopause	19
21	.	onset	20

0	In	is	7
1	this	system	2
2	system	In	0
3	,	is	7
4	late	expression	6
5	gene	expression	6
6	expression	,	3
7	is	<ROOT>	-1
8	sensitive	is	7
9	to	sensitive	8
10	inhibitors	to	9
11	of	inhibitors	10
12	the	polymerase	15
13	viral	polymerase	15
14	DNA	polymerase	15
15	polymerase	of	11
16	such	as	17
17	as	polymerase	15
18	phosphonoacetic	acid	19
19	acid	as	17
20	,	acid	19
21	although	,	20
22	the	reporters	23
23	reporters	although	21
24	lack	reporters	23
25	a	origin	27
26	eukaryotic	a	25
27	origin	lack	24
28	of	origin	27
29	replication	of	28
30	and	replication	29
31	are	and	30
32	not	are	31
33	replicated	are	31
34	under	replicated	33
35	the	under	34
36	assay	conditions	37
37	conditions	under	34
38	.	is	7

0	A	amount	2
1	large	amount	2
2	amount	has	22
3	of	amount	2
4	detailed	information	5
5	information	of	3
6	about	amount	2
7	the	proteins	9
8	intracellular	proteins	9
9	proteins	B	12
10	regulating	B	12
11	NF-kappa	B	12
12	B	about	6
13	activation	B	12
14	and	B	12
15	the	and	14
16	cellular	NF-kappa	19
17	response	NF-kappa	19
18	to	NF-kappa	19
19	NF-kappa	the	15
20	B	amount	2
21	activation	amount	2
22	has	<ROOT>	-1
23	emerged	has	22
24	recently	emerged	23
25	.	has	22

0	The	activation	1
1	activation	has	4
2	of	activation	1
3	NF-kappaB	of	2
4	has	<ROOT>	-1
5	been	has	4
6	recognized	responses	18
7	to	recognized	6
8	regulate	to	7
9	a	number	10
10	number	regulate	8
11	of	number	10
12	genes	of	11
13	necessary	T	16
14	for	T	16
15	normal	T	16
16	T	of	11
17	cell	recognized	6
18	responses	been	5
19	including	responses	18
20	IL-2	including	19
21	,	has	4
22	IL-6	has	4
23	,	has	4
24	IL-8	cell	29
25	,	cell	29
26	and	cell	29
27	several	cell	29
28	T	cell	29
29	cell	has	4
30	surface	has	4
31	receptors	has	4
32	.	has	4

0	The	unit	3
1	5'-positive	unit	3
2	regulatory	unit	3
3	unit	is	14
4	,	unit	3
5	consisting	unit	3
6	of	consisting	5
7	the	promoter	8
8	promoter	of	6
9	and	of	6
10	the	enhancer	12
11	5'	enhancer	12
12	enhancer	and	9
13	,	unit	3
14	is	<ROOT>	-1
15	already	is	14
16	active	of	24
17	at	active	16
18	the	CD4-CD8-double-negative	19
19	CD4-CD8-double-negative	at	17
20	(	DN	21
21	DN	CD4-CD8-double-negative	19
22	)	DN	21
23	stage	of	24
24	of	is	14
25	development	is	14
26	.	is	14

0	2	study	3
1	.	2	0
2	Our	2	0
3	study	involved	4
4	involved	<ROOT>	-1
5	a	group	6
6	group	involved	4
7	of	group	6
8	60	male	9
9	male	of	7
10	and	subjects	12
11	female	and	10
12	subjects	were	14
13	who	were	14
14	were	male	9
15	exposed	were	14
16	to	exposed	15
17	MTBE	to	16
18	and	MTBE	17
19	benzene-contaminated	and	18
20	water	benzene-contaminated	19
21	concentrations	water	20
22	up	water	20
23	to	76	24
24	76	up	22
25	PPB	76	24
26	for	water	20
27	MTBE	for	26
28	and	MTBE	27
29	14	and	28
30	PPB	14	29
31	for	water	20
32	benzene	for	31
33	,	involved	4
34	for	involved	4
35	a	period	36
36	period	for	34
37	of	period	36
38	5	of	37
39	to	5	38
40	8	years	41
41	years	to	39
42	.	involved	4

0	These	observations	1
1	observations	imply	2
2	imply	<ROOT>	-1
3	that	imply	2
4	during	that	3
5	persistent	during	4
6	infection	persistent	5
7	Ad5	infection	6
8	underwent	Ad5	7
9	spontaneous	mutations	10
10	mutations	underwent	8
11	by	mutations	10
12	sequence-specific	breakage	13
13	breakage	by	11
14	and	breakage	13
15	nonhomologous	joining	17
16	end-end	joining	17
17	joining	and	14
18	recombination	joining	17
19	events	recombination	18
20	.	events	19

0	A	molecule	3
1	nonpeptidyl	small	2
2	small	molecule	3
3	molecule	<ROOT>	-1
4	SB	247464	5
5	247464	molecule	3
6	,	247464	5
7	capable	was	19
8	of	(	12
9	activating	factor	11
10	granulocyte-colony-stimulating	factor	11
11	factor	(	12
12	(	capable	7
13	G-CSF	capable	7
14	)	pathways	17
15	signal	pathways	17
16	transduction	pathways	17
17	pathways	G-CSF	13
18	,	pathways	17
19	was	,	6
20	identified	molecule	3
21	in	identified	20
22	a	in	21
23	high-throughput	in	25
24	assay	in	25
25	in	a	22
26	cultured	in	25
27	cells	molecule	3
28	.	molecule	3

0	We	report	2
1	now	report	2
2	report	cytoplasmic	32
3	that	report	2
4	dimers	consisting	5
5	consisting	that	3
6	of	consisting	5
7	p50	NFkappaB1	8
8	NFkappaB1	of	6
9	,	consisting	5
10	p65	consisting	5
11	RelA	consisting	5
12	,	consisting	5
13	and/or	c-Rel	14
14	c-Rel	are	15
15	are	consisting	5
16	present	are	15
17	in	present	16
18	neutrophils	and	19
19	and	present	16
20	that	and	19
21	the	part	23
22	greater	part	23
23	part	these	25
24	of	these	25
25	these	that	20
26	protein	report	2
27	complexes	is	28
28	is	report	2
29	physically	associated	30
30	associated	report	2
31	with	report	2
32	cytoplasmic	<ROOT>	-1
33	IkappaB-alpha	cytoplasmic	32
34	in	cytoplasmic	32
35	resting	cells	36
36	cells	in	34
37	.	cells	36

0	Jun	is	1
1	is	and	6
2	essential	is	1
3	for	activation-induced	4
4	activation-induced	is	1
5	transcription	and	6
6	and	binds	7
7	binds	<ROOT>	-1
8	preferably	binds	7
9	as	binds	7
10	a	heterodimer	11
11	heterodimer	as	9
12	with	heterodimer	11
13	ATF-2	heterodimer	11
14	.	binds	7

0	A	protein	3
1	nuclear	protein	3
2	membrane	protein	3
3	protein	<ROOT>	-1
4	related	protein	3
5	to	related	4
6	yeast	isomerase	8
7	sterol	isomerase	8
8	isomerase	to	5
9	.	protein	3

0	We	found	1
1	found	were	12
2	that	binding	5
3	NFATx1	binding	5
4	DNA	binding	5
5	binding	found	1
6	activity	found	1
7	and	found	1
8	interaction	found	1
9	with	interaction	8
10	AP-1	polypeptides	11
11	polypeptides	with	9
12	were	was	24
13	dependent	were	12
14	on	dependent	13
15	its	region	19
16	central	region	19
17	Rel	region	19
18	similarity	region	19
19	region	on	14
20	and	region	19
21	that	activation	23
22	transcriptional	activation	23
23	activation	and	20
24	was	<ROOT>	-1
25	reduced	was	24
26	by	reduced	25
27	deletions	by	26
28	of	N-terminal	31
29	either	N-terminal	31
30	its	N-terminal	31
31	N-terminal	deletions	27
32	domain	was	24
33	or	was	24
34	its	or	33
35	C-terminal	,	37
36	domain	,	37
37	,	its	34
38	suggesting	was	24
39	the	was	24
40	presence	of	41
41	of	the	39
42	intrinsic	transcriptional	43
43	transcriptional	of	41
44	activation	was	24
45	motifs	was	24
46	in	was	24
47	both	regions	48
48	regions	in	46
49	.	was	24

0	Therefore	have	3
1	,	have	3
2	we	have	3
3	have	<ROOT>	-1
4	constructed	have	3
5	a	cDNA	7
6	single	cDNA	7
7	cDNA	constructed	4
8	that	encodes	9
9	encodes	cDNA	7
10	a	protein	12
11	single-chain	protein	12
12	protein	encodes	9
13	,	cDNA	7
14	called	cDNA	7
15	Flexi-12	called	14
16	,	cDNA	7
17	which	retains	18
18	retains	constructed	4
19	all	retains	18
20	of	biological	22
21	the	biological	22
22	biological	all	19
23	characteristics	biological	22
24	of	recombinant	25
25	recombinant	characteristics	23
26	IL-12	have	3
27	(	rIL-12	28
28	rIL-12	have	3
29	)	rIL-12	28
30	.	have	3

0	Rapid	<ROOT>	-1
1	Ca2+-mediated	Rapid	0
2	activation	Ca2+-mediated	1
3	of	activation	2
4	Rap1	of	3
5	in	Rap1	4
6	human	in	5
7	platelets	Rapid	0
8	.	Rapid	0

0	All	LCLs	1
1	LCLs	were	2
2	were	<ROOT>	-1
3	found	were	2
4	to	found	3
5	produce	to	4
6	both	RVLP	7
7	RVLP	produce	5
8	and	RVLP	7
9	EBV	particles	10
10	particles	and	8
11	by	produce	5
12	EM	by	11
13	.	were	2

0	These	<ROOT>	-1
1	data	These	0
2	are	consistent	3
3	consistent	data	1
4	with	consistent	3
5	EBNA3C	with	4
6	contributing	EBNA3C	5
7	to	the	8
8	the	contributing	6
9	regulation	the	8
10	of	EBNA	11
11	EBNA	regulation	9
12	expression	with	4
13	in	infected	15
14	latently	infected	15
15	infected	expression	12
16	B	data	1
17	cells	through	18
18	through	data	1
19	CBF1/RBP-Jkappa	These	0
20	and	CBF1/RBP-Jkappa	19
21	another	factor	22
22	factor	and	20
23	,	These	0
24	but	These	0
25	this	need	26
26	need	but	24
27	not	need	26
28	directly	need	26
29	involve	directly	28
30	EBNA2	involve	29
31	.	These	0

0	We	suggest	1
1	suggest	<ROOT>	-1
2	that	suggest	1
3	in	subjects	5
4	young	subjects	5
5	subjects	receptors	8
6	Type	subjects	5
7	II	subjects	5
8	receptors	that	2
9	are	receptors	8
10	initially	receptors	8
11	up-regulated	initially	10
12	by	up-regulated	11
13	dexamethasone	by	12
14	,	dexamethasone	13
15	and	dexamethasone	13
16	then	and	15
17	down-regulated	up-regulation	24
18	,	down-regulated	17
19	while	,	18
20	in	aged	21
21	aged	down-regulated	17
22	subjects	aged	21
23	an	aged	21
24	up-regulation	can	25
25	can	then	16
26	not	can	25
27	be	can	25
28	achieved	be	27
29	,	achieved	28
30	as	achieved	28
31	suggested	as	30
32	by	usually	39
33	the	values	35
34	higher	values	35
35	values	by	32
36	of	plasma	37
37	plasma	cortisol	38
38	cortisol	values	35
39	usually	suggested	31
40	found	usually	39
41	in	found	40
42	aging	suggest	1
43	subjects	suggest	1
44	.	suggest	1

0	In	was	7
1	the	group	3
2	sedentary	group	3
3	group	In	0
4	a	correlation	6
5	negative	correlation	6
6	correlation	was	7
7	was	<ROOT>	-1
8	present	binding	11
9	between	binding	11
10	GR	binding	11
11	binding	was	7
12	capacity	binding	11
13	and	capacity	12
14	age	was	7
15	.	was	7

0	Acute	leukemia	2
1	megakaryoblastic	leukemia	2
2	leukemia	are	17
3	(	AML-M7	4
4	AML-M7	leukemia	2
5	)	AML-M7	4
6	and	leukemia	2
7	transient	disorder	9
8	myeloproliferative	disorder	9
9	disorder	and	6
10	in	Down	11
11	Down	leukemia	2
12	's	Down	11
13	syndrome	leukemia	2
14	(	leukemia	2
15	TMD	leukemia	2
16	)	leukemia	2
17	are	<ROOT>	-1
18	characterized	are	17
19	by	characterized	18
20	rapid	growth	21
21	growth	by	19
22	of	growth	21
23	abnormal	of	22
24	blast	abnormal	23
25	cells	which	26
26	which	blast	24
27	express	blast	24
28	megakaryocytic	express	27
29	markers	.	30
30	.	megakaryocytic	28

0	The	class	2
1	MHC	class	2
2	class	homologous	4
3	II	class	2
4	homologous	<ROOT>	-1
5	proteins	homologous	4
6	HLA-DMA	proteins	5
7	and	HLA-DMA	6
8	HLA-DMB	and	7
9	function	HLA-DMA	6
10	in	homologous	4
11	the	in	10
12	loading	of	13
13	of	onto	15
14	peptides	of	13
15	onto	II	17
16	class	onto	15
17	II	the	11
18	molecules	homologous	4
19	.	homologous	4

0	Binding	parameters	1
1	parameters	were	5
2	of	-LSB-3H-RSB-pyrilamine	3
3	-LSB-3H-RSB-pyrilamine	parameters	1
4	binding	parameters	1
5	were	<ROOT>	-1
6	Kd	were	5
7	=	Kd	6
8	5.53	=	7
9	nM	5.53	8
10	and	nM	9
11	Bmax	and	10
12	=	2	13
13	2	and	10
14	,	and	10
15	647	sites/cell	16
16	sites/cell	were	5
17	.	were	5

0	Its	N-terminal	1
1	N-terminal	<ROOT>	-1
2	125	N-terminal	1
3	amino	125	2
4	acids	amino	3
5	function	acids	4
6	as	activation	10
7	an	independent	8
8	independent	activation	10
9	transcriptional	activation	10
10	activation	function	5
11	domain	N-terminal	1
12	.	N-terminal	1

0	We	have	1
1	have	<ROOT>	-1
2	developed	have	1
3	a	assay	5
4	reporter	assay	5
5	assay	developed	2
6	to	developed	2
7	begin	to	6
8	characterizing	begin	7
9	the	mechanisms	10
10	mechanisms	characterizing	8
11	that	regulate	12
12	regulate	mechanisms	10
13	late	in	16
14	gene	in	16
15	expression	in	16
16	in	regulate	12
17	Epstein-Barr	virus	18
18	virus	characterizing	8
19	(	EBV	20
20	EBV	virus	18
21	)	EBV	20
22	.	have	1

0	The	organization	2
1	structural	organization	2
2	organization	is	11
3	of	organization	2
4	the	of	3
5	393	long	8
6	amino	long	8
7	acid	long	8
8	long	the	4
9	human	TRAMP	10
10	TRAMP	organization	2
11	is	<ROOT>	-1
12	most	homologous	13
13	homologous	is	11
14	to	TNF	15
15	TNF	homologous	13
16	receptor	TNF	15
17	1	receptor	16
18	.	is	11

0	Early	patterns	4
1	viral	patterns	4
2	RNA	patterns	4
3	splicing	patterns	4
4	patterns	differ	6
5	also	differ	6
6	differ	<ROOT>	-1
7	between	differ	6
8	wild-type	cells	11
9	and	wild-type	8
10	dl337-infected	and	9
11	cells	between	7
12	.	cells	11

0	We	examined	1
1	examined	<ROOT>	-1
2	the	relationship	3
3	relationship	examined	1
4	between	GC-receptor	5
5	GC-receptor	relationship	3
6	(	GC-R	7
7	GC-R	GC-receptor	5
8	)	GC-R	7
9	parameters	in	10
10	in	GC-receptor	5
11	peripheral-blood	relationship	3
12	mononuclear	relationship	3
13	cells	examined	1
14	(	examined	1
15	PBMC	examined	1
16	)	examined	1
17	and	examined	1
18	PBMC	and	17
19	resistance	and	17
20	to	healthy	28
21	GC	to	20
22	in	GC	21
23	21	in	22
24	CRF	and	26
25	patients	and	26
26	and	21	23
27	18	to	20
28	healthy	resistance	19
29	subjects	examined	1
30	.	examined	1

0	Furthermore	protein	4
1	,	protein	4
2	the	protein	4
3	nuclear	protein	4
4	protein	complexes	5
5	complexes	binding	6
6	binding	<ROOT>	-1
7	the	binding	6
8	SRE	motif	9
9	motif	binding	6
10	induced	in	11
11	in	motif	9
12	activated	T	13
13	T	in	11
14	cells	binding	6
15	of	young	16
16	young	binding	6
17	and	contained	20
18	elderly	contained	20
19	subjects	contained	20
20	contained	young	16
21	serum	binding	6
22	response	binding	6
23	factor	binding	6
24	and	binding	6
25	Elk-1	binding	6
26	pointing	binding	6
27	toward	pointing	26
28	age-related	defects	29
29	defects	pointing	26
30	in	defects	29
31	the	activation	32
32	activation	in	30
33	of	activation	32
34	transcriptional	proteins	36
35	regulatory	proteins	36
36	proteins	of	33
37	distinct	pointing	26
38	from	distinct	37
39	c-jun/AP-1	from	38
40	.	binding	6

0	To	compared	10
1	evaluate	To	0
2	the	plausibility	4
3	physiologic	plausibility	4
4	plausibility	evaluate	1
5	of	plausibility	4
6	these	claims	7
7	claims	of	5
8	,	compared	10
9	we	compared	10
10	compared	<ROOT>	-1
11	the	abundance	12
12	abundance	compared	10
13	of	abundance	12
14	the	VDR	15
15	VDR	of	13
16	mRNA	VDR	15
17	in	peripheral	18
18	peripheral	compared	10
19	blood	compared	10
20	mononuclear	compared	10
21	cells	(	22
22	(	compared	10
23	PBMCs	compared	10
24	)	compared	10
25	between	compared	10
26	different	between	25
27	VDR	different	26
28	genotypes	VDR	27
29	using	a	30
30	a	genotypes	28
31	quantitative	a	30
32	reverse	transcribed	33
33	transcribed	a	30
34	polymerase	chain	35
35	chain	genotypes	28
36	reaction-based	method	37
37	method	different	26
38	.	method	37

0	By	was	18
1	contrast	By	0
2	,	By	0
3	the	expression	4
4	expression	,	2
5	of	expression	4
6	other	genes	9
7	adherence-associated	genes	9
8	early	genes	9
9	genes	of	5
10	,	expression	4
11	such	as	12
12	as	expression	4
13	IL-8	and	14
14	and	as	12
15	IL-1	and	14
16	beta	By	0
17	,	was	18
18	was	<ROOT>	-1
19	not	was	18
20	up-regulated	was	18
21	in	up-regulated	20
22	PBMC	in	21
23	of	in	21
24	tuberculous	was	18
25	patients	was	18
26	.	was	18

0	Preliminary	experiments	1
1	experiments	yielded	2
2	yielded	<ROOT>	-1
3	a	value	5
4	Km	value	5
5	value	yielded	2
6	of	value	5
7	about	of	6
8	0.8	about	7
9	microM	for	10
10	for	0.8	8
11	dUTP	yielded	2
12	.	yielded	2

0	Numerous	genes	1
1	genes	are	15
2	required	genes	1
3	during	required	2
4	the	immune	5
5	immune	during	3
6	or	immune	5
7	inflammation	response	8
8	response	or	6
9	as	or	6
10	well	or	6
11	as	adhesion	13
12	the	adhesion	13
13	adhesion	or	6
14	process	genes	1
15	are	<ROOT>	-1
16	regulated	are	15
17	by	regulated	16
18	nuclear	kappaB	20
19	factor	nuclear	18
20	kappaB	(	21
21	(	by	17
22	NF-kappaB	are	15
23	)	are	15
24	.	are	15

0	The	has	8
1	human	The	0
2	G0/G1	human	1
3	switch	G0/G1	2
4	gene	,	5
5	,	G0/G1	2
6	G0S2	,	5
7	,	The	0
8	has	<ROOT>	-1
9	potential	sites	11
10	NFAT-binding	sites	11
11	sites	has	8
12	in	has	8
13	the	in	12
14	5'	the	13
15	flank	5'	14
16	and	flank	15
17	encodes	and	16
18	a	phosphoprotein	22
19	small	phosphoprotein	22
20	basic	phosphoprotein	22
21	potential	phosphoprotein	22
22	phosphoprotein	encodes	17
23	of	unknown	24
24	unknown	phosphoprotein	22
25	function	.	26
26	.	unknown	24

0	These	observations	1
1	observations	provide	2
2	provide	<ROOT>	-1
3	further	evidence	4
4	evidence	provide	2
5	to	evidence	4
6	suggest	to	5
7	a	suggest	6
8	role	for	9
9	for	a	7
10	intracellular	cycle	19
11	oxidant	cycle	19
12	generation	as	13
13	as	mechanism	16
14	a	mechanism	16
15	regulatory	mechanism	16
16	mechanism	oxidant	11
17	during	cycle	19
18	cell	cycle	19
19	cycle	for	9
20	entry	for	9
21	,	a	7
22	and	a	7
23	establish	a	7
24	a	link	25
25	link	establish	23
26	between	link	25
27	oxidative	signalling	28
28	signalling	between	26
29	and	signalling	28
30	other	aspects	31
31	aspects	and	29
32	of	aspects	31
33	the	network	36
34	intracellular	network	36
35	signalling	network	36
36	network	of	32
37	that	is	38
38	is	network	36
39	activated	is	38
40	in	activated	39
41	response	in	40
42	to	response	41
43	mitogenic	response	41
44	stimulation	response	41
45	.	provide	2

0	Rather	has	6
1	,	has	6
2	analysis	has	6
3	of	analysis	2
4	this	system	5
5	system	of	3
6	has	<ROOT>	-1
7	revealed	has	6
8	a	relationship	10
9	trans	relationship	10
10	relationship	revealed	7
11	between	relationship	10
12	late	expression	14
13	gene	expression	14
14	expression	between	11
15	and	relationship	10
16	viral	replication	18
17	DNA	replication	18
18	replication	and	15
19	and	relationship	10
20	highlights	and	19
21	the	highlights	20
22	indirect	the	21
23	and	indirect	22
24	complex	these	27
25	link	complex	24
26	between	link	25
27	these	two	28
28	two	and	23
29	events	indirect	22
30	.	has	6

0	The	protein	2
1	tax	protein	2
2	protein	leukemia	6
3	of	human	4
4	human	protein	2
5	T-cell	leukemia	6
6	leukemia	1	9
7	virus	1	9
8	type	1	9
9	1	mediates	10
10	mediates	<ROOT>	-1
11	the	transactivation	12
12	transactivation	mediates	10
13	of	transactivation	12
14	the	promoter	18
15	c-sis/platelet-derived	growth	16
16	growth	promoter	18
17	factor-B	promoter	18
18	promoter	of	13
19	through	transactivation	12
20	interactions	through	19
21	with	interactions	20
22	the	with	21
23	zinc	the	22
24	finger	Sp1	27
25	transcription	factors	26
26	factors	Sp1	27
27	Sp1	zinc	23
28	and	the	22
29	NGFI-A/Egr-1	mediates	10
30	.	mediates	10

0	TCP	<ROOT>	-1
1	succinate	TCP	0
2	(	succinate	1
3	200	(	2
4	microM	,	5
5	,	200	3
6	24	,	5
7	h	24	6
8	)	24	6
9	reduced	VCAM-1	11
10	TNF-induced	VCAM-1	11
11	VCAM-1	E-selectin	13
12	and	E-selectin	13
13	E-selectin	)	8
14	expression	E-selectin	13
15	from	E-selectin	13
16	a	from	15
17	specific	mean	18
18	mean	a	16
19	fluorescence	intensity	20
20	intensity	mean	18
21	of	intensity	20
22	151	of	21
23	+/-	of	21
24	28	+/-	23
25	to	12	26
26	12	mean	18
27	+/-	12	26
28	4	+/-	27
29	channels	+/-	33
30	and	channels	29
31	from	225	32
32	225	and	30
33	+/-	TCP	0
34	38	TCP	0
35	to	TCP	0
36	79	+/-	37
37	+/-	to	35
38	21	+/-	37
39	channels	TCP	0
40	,	TCP	0
41	respectively	TCP	0
42	.	TCP	0

0	All	markers	2
1	the	markers	2
2	markers	considered	3
3	considered	were	4
4	were	<ROOT>	-1
5	sufficiently	were	4
6	sensitive	sufficiently	5
7	,	were	4
8	but	were	4
9	among	but	8
10	them	among	9
11	,	among	9
12	Platelet	,	11
13	Factor	most	17
14	IV	most	17
15	was	most	17
16	the	most	17
17	most	,	11
18	reliable	the	20
19	to	the	20
20	the	,	11
21	hormonal	were	4
22	ovulatory	were	4
23	situation	ovulatory	22
24	.	situation	23

0	MZF-2	mRNA	1
1	mRNA	was	2
2	was	<ROOT>	-1
3	expressed	was	2
4	in	myeloid	5
5	myeloid	expressed	3
6	cells	was	2
7	,	was	2
8	particularly	in	9
9	in	was	2
10	the	cells	11
11	cells	in	9
12	committed	was	2
13	to	committed	12
14	the	to	13
15	neutrophilic	the	14
16	lineage	neutrophilic	15
17	,	lineage	16
18	and	,	17
19	down-regulated	and	18
20	by	down-regulated	19
21	G-CSF	by	20
22	.	was	2

0	A	deletion	1
1	deletion	construct	2
2	construct	<ROOT>	-1
3	that	contains	4
4	contains	construct	2
5	a	site	8
6	NF-kappa	site	8
7	B	site	8
8	site	contains	4
9	but	contains	4
10	is	but	9
11	missing	region	15
12	the	region	15
13	multiple	region	15
14	response	region	15
15	region	is	10
16	demonstrated	increase	19
17	a	demonstrated	16
18	continued	increase	19
19	increase	is	10
20	in	IL-6	21
21	IL-6	increase	19
22	luciferase	increase	19
23	activity	LPS-stimulated	25
24	in	LPS-stimulated	25
25	LPS-stimulated	luciferase	22
26	CMV	construct	2
27	transfected	construct	2
28	cells	construct	2
29	.	construct	2

0	The	factor	3
1	Oct-2	factor	3
2	transcription	factor	3
3	factor	<ROOT>	-1
4	.	factor	3

0	In	<ROOT>	-1
1	contrast	In	0
2	to	contrast	1
3	activated	to	2
4	pTh	activated	3
5	cells	significant	13
6	,	produced	12
7	neither	eTh1	8
8	eTh1	produced	12
9	nor	eTh2	10
10	eTh2	produced	12
11	cells	eTh2	10
12	produced	cells	5
13	significant	pTh	4
14	IL-2	to	2
15	upon	IL-2	14
16	stimulation	In	0
17	,	high	20
18	but	high	20
19	the	high	20
20	high	In	0
21	levels	high	20
22	of	NFAT	23
23	NFAT	high	20
24	transcriptional	In	0
25	activities	correlate	27
26	directly	correlate	27
27	correlate	In	0
28	with	the	29
29	the	In	0
30	IL-4	the	29
31	production	IL-4	30
32	induced	production	31
33	in	induced	32
34	response	in	33
35	to	response	34
36	antigen	to	35
37	stimulation	antigen	36
38	in	stimulation	37
39	eTh2	cells	40
40	cells	in	38
41	.	cells	40

0	In	had	9
1	contrast	In	0
2	to	contrast	1
3	IL-4	to	2
4	,	had	9
5	interferon-gamma	,	4
6	(	IFN-gamma	7
7	IFN-gamma	,	4
8	)	IFN-gamma	7
9	had	<ROOT>	-1
10	no	effect	12
11	demonstrable	effect	12
12	effect	had	9
13	on	the	14
14	the	effect	12
15	differentiation	the	14
16	of	differentiation	15
17	monocytes	of	16
18	.	of	16

0	HeLa	cells	1
1	cells	stably	2
2	stably	showed	10
3	or	constructs	9
4	transiently	with	6
5	transfected	with	6
6	with	or	3
7	mutant	constructs	9
8	CIITA	constructs	9
9	constructs	stably	2
10	showed	<ROOT>	-1
11	up	showed	10
12	to	up	11
13	99	suppression	15
14	%	99	13
15	suppression	of	16
16	of	II	19
17	MHC	II	19
18	class	II	19
19	II	to	12
20	antigen	showed	10
21	induction	showed	10
22	by	induction	21
23	IFN-gamma	showed	10
24	and	showed	10
25	marked	suppression	26
26	suppression	HLA-DRA	28
27	of	HLA-DRA	28
28	HLA-DRA	and	24
29	mRNA	HLA-DRA	28
30	expression	showed	10
31	.	showed	10

0	These	<ROOT>	-1
1	data	is	13
2	provide	evidence	3
3	evidence	data	1
4	that	evidence	3
5	expression	human	8
6	of	human	8
7	the	human	8
8	human	that	4
9	IMPDH	type	10
10	type	human	8
11	II	evidence	3
12	gene	evidence	3
13	is	These	0
14	predominantly	regulated	15
15	regulated	is	13
16	by	regulated	15
17	the	factors	19
18	nuclear	factors	19
19	factors	by	16
20	ATF-2	factors	19
21	and	ATF-2	20
22	an	and	21
23	as	an	22
24	yet	as	23
25	unidentified	yet	24
26	POS-binding	protein	27
27	protein	unidentified	25
28	.	protein	27

0	In	(	5
1	contrast	In	0
2	,	(	5
3	the	RelA	4
4	RelA	(	5
5	(	subunit	8
6	p65	(	5
7	)	(	5
8	subunit	was	9
9	was	<ROOT>	-1
10	barely	detectable	11
11	detectable	was	9
12	in	was	9
13	monocytes	was	9
14	,	was	9
15	but	was	9
16	its	level	17
17	level	but	15
18	increased	level	17
19	markedly	increased	18
20	in	markedly	19
21	MDMs	markedly	19
22	.	MDMs	21

0	Although	is	21
1	much	is	2
2	is	Although	0
3	understood	is	2
4	about	understood	3
5	the	induction	6
6	induction	about	4
7	of	expressed	9
8	genes	of	7
9	expressed	induction	6
10	early	understood	3
11	(	within	12
12	within	early	10
13	24	within	12
14	h	24	13
15	)	within	12
16	after	T-cell	17
17	T-cell	understood	3
18	activation	Although	0
19	,	is	21
20	little	is	21
21	is	<ROOT>	-1
22	known	is	21
23	about	known	22
24	the	regulation	25
25	regulation	about	23
26	of	regulation	25
27	expression	of	26
28	of	of	26
29	genes	is	21
30	expressed	is	21
31	'	expressed	30
32	late	'	33
33	'	'	31
34	(	'	33
35	three	days	38
36	or	three	35
37	more	or	36
38	days	is	21
39	)	is	21
40	post-stimulation	is	21
41	.	is	21

0	These	cells	1
1	cells	<ROOT>	-1
2	,	cells	1
3	stimulated	cells	1
4	by	stimulated	3
5	an	antibody	8
6	agonistic	antibody	8
7	monoclonal	antibody	8
8	antibody	by	4
9	against	antibody	8
10	CD40	against	9
11	or	CD40	10
12	by	CD40	10
13	transfection	CD40	10
14	with	transfection	13
15	a	with	14
16	CD40L	expression	17
17	expression	,	19
18	vector	,	19
19	,	a	15
20	secreted	p40	21
21	p40	,	19
22	and	showed	23
23	showed	mRNA	26
24	enhanced	mRNA	26
25	p40	mRNA	26
26	mRNA	,	19
27	expression	.	28
28	.	mRNA	26

0	Abnormal	T	1
1	T	<ROOT>	-1
2	lymphocyte	induced	4
3	development	induced	4
4	induced	T	1
5	by	induced	4
6	targeted	by	5
7	overexpression	of	8
8	of	alpha	10
9	IkappaB	alpha	10
10	alpha	targeted	6
11	.	T	1

0	Three	epitopes	2
1	new	epitopes	2
2	epitopes	were	3
3	were	<ROOT>	-1
4	identified	were	3
5	in	identified	4
6	VP16	identified	4
7	,	VP16	6
8	a	VP16	6
9	tegument	a	8
10	protein	associated	11
11	associated	tegument	9
12	with	associated	11
13	VP22	with	12
14	.	were	3

0	The	motif	2
1	C/EBP	motif	2
2	motif	is	3
3	is	<ROOT>	-1
4	bound	pre-B	8
5	by	bound	4
6	Ig/EBP-1	by	5
7	in	pre-B	8
8	pre-B	is	3
9	cell	is	3
10	and	is	3
11	T	is	3
12	cell	is	3
13	extracts	is	3
14	,	is	3
15	but	is	3
16	is	but	15
17	replaced	is	16
18	by	replaced	17
19	nuclear	factor-IL-6beta	20
20	factor-IL-6beta	by	18
21	or	factor-IL-6beta	20
22	a	heterodimer	25
23	nuclear	heterodimer	25
24	factor-IL-6beta-Ig/EBP-1	heterodimer	25
25	heterodimer	or	21
26	in	replaced	17
27	plasmacytoma	extracts	29
28	cell	extracts	29
29	extracts	in	26
30	.	is	3

0	IL-4	had	1
1	had	<ROOT>	-1
2	no	effect	4
3	significant	effect	4
4	effect	had	1
5	on	effect	4
6	HIV	on	5
7	reverse	HIV	6
8	transcription	.	9
9	.	reverse	7

0	Monocytic	differentiation	1
1	differentiation	correlates	7
2	of	differentiation	1
3	HL-60	cells	6
4	promyelocytic	cells	6
5	leukemia	cells	6
6	cells	of	2
7	correlates	<ROOT>	-1
8	with	the	9
9	the	correlates	7
10	induction	of	11
11	of	the	9
12	Bcl-xL	of	11
13	.	correlates	7

0	Restriction	analysis	1
1	analysis	revealed	2
2	revealed	<ROOT>	-1
3	that	revealed	2
4	neutrophils	express	5
5	express	that	3
6	the	gene	8
7	GH-N	gene	8
8	gene	express	5
9	but	express	5
10	not	gene	13
11	the	gene	13
12	GH-V	gene	13
13	gene	but	9
14	.	revealed	2

0	Supershift	confirmed	8
1	with	specific	2
2	specific	Supershift	0
3	antibodies	Supershift	0
4	to	NF-kappa	5
5	NF-kappa	Supershift	0
6	B	subunits	7
7	subunits	Supershift	0
8	confirmed	<ROOT>	-1
9	that	confirmed	8
10	the	bands	13
11	inducible	bands	13
12	retarded	bands	13
13	bands	that	9
14	observed	bands	13
15	in	observed	14
16	the	EMSA	17
17	EMSA	in	15
18	and	bands	13
19	p65-p50	and	18
20	heterodimer	and	18
21	of	B/Rel	24
22	the	B/Rel	24
23	NF-kappa	B/Rel	24
24	B/Rel	heterodimer	20
25	protein	confirmed	8
26	.	confirmed	8

0	When	immunoglobulin	1
1	immunoglobulin	(	2
2	(	fused	9
3	Ig	(	2
4	)	expressing	5
5	expressing	Ig	3
6	B	(	2
7	cells	are	8
8	are	B	6
9	fused	is	16
10	with	non-B	11
11	non-B	fused	9
12	cells	fused	9
13	,	is	16
14	Ig	expression	15
15	expression	is	16
16	is	<ROOT>	-1
17	rapidly	suppressed	18
18	suppressed	is	16
19	at	suppressed	18
20	the	level	21
21	level	at	19
22	of	level	21
23	transcription	of	22
24	,	is	16
25	a	,	24
26	phenomenon	a	25
27	termed	phenomenon	26
28	extinction	.	29
29	.	termed	27

0	Human	cell	2
1	monocytic	cell	2
2	cell	line	3
3	line	THP-1	4
4	THP-1	was	5
5	was	were	29
6	treated	had	11
7	with	which	10
8	E.	chaffeensis	9
9	chaffeensis	with	7
10	which	had	11
11	had	was	5
12	been	was	5
13	preincubated	with	14
14	with	been	12
15	human	with	14
16	anti-E.	serum	18
17	chaffeensis	serum	18
18	serum	human	15
19	for	human	15
20	2	h	21
21	h	for	19
22	,	was	5
23	and	was	5
24	the	and	23
25	levels	the	24
26	of	cytokine	27
27	cytokine	levels	25
28	mRNAs	was	5
29	were	<ROOT>	-1
30	evaluated	reverse	33
31	by	reverse	33
32	competitive	reverse	33
33	reverse	were	29
34	transcription-PCR	were	29
35	.	were	29

0	In	response	6
1	preincubated	In	0
2	cells	,	3
3	,	preincubated	1
4	the	,	3
5	cycloheximide	response	6
6	response	is	7
7	is	<ROOT>	-1
8	decreased	is	7
9	,	is	7
10	especially	in	11
11	in	,	9
12	the	case	13
13	case	in	11
14	of	case	13
15	FOSB	of	14
16	.	is	7

0	Sequential	development	1
1	development	<ROOT>	-1
2	of	development	1
3	structural	of	2
4	and	functional	5
5	functional	of	2
6	alterations	development	1
7	in	T	8
8	T	alterations	6
9	cells	development	1
10	from	development	1
11	tumor-bearing	development	1
12	mice	development	1
13	.	development	1

0	Data	are	1
1	are	<ROOT>	-1
2	also	are	1
3	presented	are	1
4	to	presented	3
5	suggest	to	4
6	that	suggest	5
7	the	regulation	9
8	redox	regulation	9
9	regulation	that	6
10	in	NF-kappaB	11
11	NF-kappaB	regulation	9
12	activation	are	1
13	may	activation	12
14	be	may	13
15	relevant	be	14
16	to	relevant	15
17	immune-related	diseases	18
18	diseases	to	16
19	and	diseases	18
20	to	and	19
21	aging	to	20
22	.	are	1

0	Immunochemical	Abs	9
1	and	Immunochemical	0
2	immunofluorescent	staining	3
3	staining	and	1
4	of	thymus	5
5	thymus	staining	3
6	sections	thymus	5
7	using	specific	8
8	specific	staining	3
9	Abs	allowed	10
10	allowed	<ROOT>	-1
11	visualization	allowed	10
12	of	visualization	11
13	nuclear	proteins	16
14	NF-kappa	proteins	16
15	B	proteins	16
16	proteins	of	12
17	in	allowed	10
18	both	thymocytes	19
19	thymocytes	in	17
20	and	thymocytes	19
21	nonthymocyte	and	20
22	cells	allowed	10
23	.	allowed	10

0	It	was	1
1	was	<ROOT>	-1
2	recently	was	1
3	shown	was	1
4	by	shown	3
5	us	by	4
6	that	us	5
7	the	by	4
8	protein	is	9
9	is	the	7
10	located	is	9
11	in	located	10
12	germinal	center	13
13	center	in	11
14	B	by	4
15	cells	by	4
16	and	by	4
17	their	and	16
18	neoplastic	was	1
19	counterparts	was	1
20	.	was	1

0	Constitutive	binding	1
1	binding	factor	4
2	of	factor	4
3	further	of	2
4	factor	was	17
5	proteins	factor	4
6	to	factor	4
7	DNA	to	6
8	,	factor	4
9	such	as	10
10	as	factor	4
11	JunD	as	10
12	,	factor	4
13	c-Fos	,	12
14	and	c-Fos	13
15	FosB	factor	4
16	,	factor	4
17	was	<ROOT>	-1
18	detected	was	17
19	in	detected	18
20	several	patients	21
21	patients	in	19
22	whereas	DNA	26
23	the	localisation	24
24	localisation	DNA	26
25	and	DNA	26
26	DNA	detected	18
27	binding	was	17
28	of	binding	27
29	other	factors	30
30	factors	of	28
31	such	as	32
32	as	factors	30
33	c-Jun	as	32
34	,	c-Jun	33
35	RelA/p65	c-Jun	33
36	and	RelA/p65	35
37	c-Rel	and	36
38	was	c-Rel	37
39	unaltered	was	17
40	.	was	17

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	Here	RESULTS	0
3	,	Here	2
4	we	,	3
5	have	we	4
6	isolated	have	5
7	the	murine	8
8	murine	isolated	6
9	and	murine	8
10	human	and	9
11	cDNAs	human	10
12	which	cDNAs	11
13	encode	which	12
14	a	form	16
15	novel	form	16
16	form	cDNAs	11
17	of	(	20
18	MZF	protein	19
19	protein	of	17
20	(	form	16
21	MZF-2	(	20
22	)	cDNAs	11
23	.	RESULTS	0

0	Erythropoietin	induces	1
1	induces	tyrosine	2
2	tyrosine	<ROOT>	-1
3	phosphorylation	tyrosine	2
4	of	phosphorylation	3
5	Jak2	tyrosine	2
6	,	Jak2	5
7	STAT5A	Jak2	5
8	,	STAT5A	7
9	and	STAT5A	7
10	STAT5B	and	9
11	in	primary	12
12	primary	human	14
13	cultured	human	14
14	human	tyrosine	2
15	erythroid	tyrosine	2
16	precursors	tyrosine	2
17	.	tyrosine	2

0	Cloning	<ROOT>	-1
1	of	Cloning	0
2	the	of	1
3	novel	human	4
4	human	myeloid-cell-specific	5
5	myeloid-cell-specific	C/EBP-epsilon	6
6	C/EBP-epsilon	the	2
7	transcription	factor	8
8	factor	Cloning	0
9	.	Cloning	0

0	NF-kappaB	activation	1
1	activation	was	2
2	was	<ROOT>	-1
3	very	effective	4
4	effective	was	2
5	when	were	7
6	cells	were	7
7	were	was	2
8	subjected	were	7
9	to	subjected	8
10	hyperthermia	to	9
11	before	subjected	8
12	being	before	11
13	treated	being	12
14	with	treated	13
15	HOCl	was	2
16	.	was	2

0	To	<ROOT>	-1
1	investigate	To	0
2	the	relevance	4
3	potential	relevance	4
4	relevance	this	6
5	of	this	6
6	this	investigate	1
7	mechanism	this	6
8	in	mechanism	7
9	acute	this	6
10	myocardial	infarction	11
11	infarction	this	6
12	(	AMI	13
13	AMI	infarction	11
14	)	AMI	13
15	,	To	0
16	we	,	15
17	examined	we	16
18	cytokine	examined	17
19	induction	cytokine	18
20	by	leukocyte-platelet	21
21	leukocyte-platelet	induction	19
22	adhesion	and	23
23	and	cytokine	18
24	the	occurrence	25
25	occurrence	conjugates	28
26	of	occurrence	25
27	leukocyte-platelet	of	26
28	conjugates	and	23
29	in	conjugates	28
30	patients	in	29
31	with	patients	30
32	AMI	with	31
33	.	To	0

0	This	putative	1
1	putative	<ROOT>	-1
2	human	IL-2rE	3
3	IL-2rE	putative	1
4	,	putative	1
5	designated	PRRIII	6
6	PRRIII	putative	1
7	,	putative	1
8	confers	putative	1
9	IL-2	responsiveness	10
10	responsiveness	confers	8
11	on	responsiveness	10
12	a	on	11
13	heterologous	.	15
14	promoter	.	15
15	.	a	12

0	BOB.1/OBF.1	was	1
1	was	<ROOT>	-1
2	phosphorylated	was	1
3	at	was	1
4	Ser184	at	3
5	both	Ser184	4
6	in	both	5
7	vivo	in	6
8	and	in	6
9	in	and	8
10	vitro	in	9
11	,	was	1
12	and	this	13
13	this	was	1
14	modification	was	15
15	was	this	13
16	required	for	17
17	for	was	15
18	inducible	activation	19
19	activation	for	17
20	.	was	1

0	These	findings	1
1	findings	suggest	2
2	suggest	LTR	4
3	that	LTR	4
4	LTR	factor	15
5	sequence	LTR	4
6	changes	can	7
7	can	significantly	8
8	significantly	LTR	11
9	affect	LTR	11
10	basal	LTR	11
11	LTR	sequence	5
12	function	LTR	4
13	and	LTR	4
14	transcription	LTR	4
15	factor	<ROOT>	-1
16	recruitment	,	17
17	,	factor	15
18	which	may	19
19	may	factor	15
20	,	factor	15
21	in	factor	15
22	turn	in	21
23	,	factor	15
24	alter	factor	15
25	the	course	26
26	course	alter	24
27	of	course	26
28	viral	replication	29
29	replication	of	27
30	in	course	26
31	cells	in	30
32	of	alter	24
33	CNS	alter	24
34	and	factor	15
35	immune	factor	15
36	system	factor	15
37	origin	factor	15
38	.	factor	15

0	It	provides	1
1	provides	activation	4
2	a	activation	4
3	transcriptional	activation	4
4	activation	activates	11
5	domain	activation	4
6	which	domain	5
7	,	activates	11
8	unlike	activates	11
9	Oct-1	unlike	8
10	,	activates	11
11	activates	<ROOT>	-1
12	an	promoter	14
13	mRNA-type	promoter	14
14	promoter	activates	11
15	effectively	activates	11
16	,	activates	11
17	and	activates	11
18	it	and	17
19	stabilizes	it	18
20	Oct-1	stabilizes	19
21	on	Oct-1	20
22	the	Oct-1	20
23	Oct-1-responsive	ATGCAAAT	26
24	octamer	ATGCAAAT	26
25	sequence	ATGCAAAT	26
26	ATGCAAAT	the	22
27	.	activates	11

0	The	sequence	1
1	sequence	shows	2
2	shows	<ROOT>	-1
3	high	shows	2
4	homology	high	3
5	with	homology	4
6	the	with	5
7	murine	the	6
8	FOSB	which	11
9	gene	which	11
10	,	which	11
11	which	encodes	12
12	encodes	murine	7
13	a	component	14
14	component	encodes	12
15	of	transcriptional	18
16	the	transcriptional	18
17	AP1	transcriptional	18
18	transcriptional	component	14
19	regulator	shows	2
20	.	shows	2

0	Mutation	492/493	3
1	of	Mutation	0
2	tyrosines	of	1
3	492/493	signaling	14
4	in	kinase	6
5	the	kinase	6
6	kinase	492/493	3
7	domain	492/493	3
8	of	domain	7
9	ZAP-70	of	8
10	affects	492/493	3
11	multiple	signaling	14
12	T-cell	receptor	13
13	receptor	signaling	14
14	signaling	<ROOT>	-1
15	pathways	signaling	14
16	.	signaling	14

0	Therefore	<ROOT>	-1
1	,	Therefore	0
2	we	,	1
3	investigated	we	2
4	in	investigated	3
5	situ	in	4
6	the	localization	8
7	nuclear	localization	8
8	localization	investigated	3
9	of	localization	8
10	Rel/NF-kappa	proteins	12
11	B	proteins	12
12	proteins	of	9
13	in	accessory	14
14	accessory	investigated	3
15	cells	Therefore	0
16	of	cells	15
17	the	system	19
18	immune	system	19
19	system	of	16
20	by	Therefore	0
21	immunohistochemistry	by	20
22	and	Therefore	0
23	double	labeling	24
24	labeling	and	22
25	by	Therefore	0
26	immunofluorescence	by	25
27	from	normal	29
28	five	normal	29
29	normal	Therefore	0
30	human	Therefore	0
31	tonsils	Therefore	0
32	and	Therefore	0
33	five	lymph	34
34	lymph	and	32
35	nodes	Therefore	0
36	with	Therefore	0
37	follicular	hyperplasia	38
38	hyperplasia	with	36
39	.	Therefore	0

0	In	propose	4
1	conclusion	In	0
2	,	propose	4
3	we	propose	4
4	propose	<ROOT>	-1
5	that	propose	4
6	Bcl-xL	expression	7
7	expression	is	8
8	is	that	5
9	associated	is	8
10	with	associated	9
11	differentiation	with	10
12	and	with	10
13	survival	propose	4
14	of	hematopoietic	15
15	hematopoietic	survival	13
16	cells	propose	4
17	along	the	18
18	the	propose	4
19	monocyte/macrophage	propose	4
20	lineage	propose	4
21	.	propose	4

0	Expression	<ROOT>	-1
1	of	Expression	0
2	the	of	1
3	gene	human	5
4	encoding	human	5
5	human	the	2
6	inosine-5'-monophosphate	dehydrogenase	7
7	dehydrogenase	(	8
8	(	Expression	0
9	IMPDH	(	8
10	)	type	11
11	type	IMPDH	9
12	II	type	11
13	,	Expression	0
14	an	catalyzing	16
15	enzyme	catalyzing	16
16	catalyzing	,	13
17	the	step	19
18	rate-limiting	step	19
19	step	catalyzing	16
20	in	step	19
21	the	generation	22
22	generation	in	20
23	of	guanine	24
24	guanine	generation	22
25	nucleotides	guanine	24
26	,	is	27
27	is	nucleotides	25
28	increased	is	27
29	more	10-fold	31
30	than	10-fold	31
31	10-fold	catalyzing	16
32	in	activated	33
33	activated	catalyzing	16
34	peripheral	activated	33
35	blood	Expression	0
36	T	Expression	0
37	lymphocytes	Expression	0
38	and	Expression	0
39	is	cell	43
40	required	cell	43
41	for	cell	43
42	T	cell	43
43	cell	and	38
44	activation	cell	43
45	.	Expression	0

0	AML1	may	1
1	may	<ROOT>	-1
2	play	may	1
3	a	play	2
4	role	in	5
5	in	a	3
6	growth	in	5
7	and	growth	6
8	differentiation	may	1
9	of	may	1
10	cells	may	1
11	along	may	1
12	erythroid	may	1
13	and/or	may	1
14	megakaryocytic	may	1
15	lineages	may	1
16	,	lineages	15
17	because	lineages	15
18	a	level	20
19	significant	level	20
20	level	is	25
21	of	level	20
22	the	gene	24
23	AML1	gene	24
24	gene	of	21
25	is	because	17
26	expressed	is	25
27	in	these	28
28	these	expressed	26
29	cells	may	1
30	.	may	1

0	Examination	revealed	9
1	of	stably	6
2	CIITA	mRNA	3
3	mRNA	of	1
4	in	stably	6
5	IK	stably	6
6	stably	Examination	0
7	transfected	Examination	0
8	clones	Examination	0
9	revealed	<ROOT>	-1
10	a	reduction	12
11	marked	reduction	12
12	reduction	mRNA	15
13	of	mRNA	15
14	CIITA	mRNA	15
15	mRNA	revealed	9
16	transcription	revealed	9
17	.	revealed	9

0	Succinate	had	2
1	alone	Succinate	0
2	had	<ROOT>	-1
3	no	effect	4
4	effect	had	2
5	.	had	2

0	This	compares	1
1	compares	<ROOT>	-1
2	favourably	compares	1
3	with	favourably	2
4	other	with	3
5	screening	used	7
6	methods	used	7
7	used	other	4
8	for	used	7
9	TSC2	for	8
10	,	TSC2	9
11	notably	for	8
12	SSCP	for	8
13	,	SSCP	12
14	and	SSCP	12
15	since	and	14
16	PTT	since	15
17	involves	PTT	16
18	much	less	19
19	less	work	20
20	work	involves	17
21	it	may	22
22	may	work	20
23	be	may	22
24	the	method	25
25	method	be	23
26	of	method	25
27	choice	of	26
28	.	compares	1

0	The	role	1
1	role	<ROOT>	-1
2	of	role	1
3	Rel/NF-kappa	proteins	5
4	B	proteins	5
5	proteins	of	2
6	in	role	1
7	viral	oncogenesis	8
8	oncogenesis	in	6
9	and	the	10
10	the	role	1
11	regulation	of	12
12	of	the	10
13	viral	.	15
14	transcription	.	15
15	.	of	12

0	The	cell	2
1	T	cell	2
2	cell	factor	4
3	activation	factor	4
4	factor	<ROOT>	-1
5	NF-ATc	regulates	7
6	positively	regulates	7
7	regulates	factor	4
8	HIV-1	replication	9
9	replication	regulates	7
10	and	regulates	7
11	gene	factor	4
12	expression	gene	11
13	in	T	14
14	T	expression	12
15	cells	factor	4
16	.	factor	4

0	Carboxylesterases	play	1
1	play	<ROOT>	-1
2	an	role	4
3	important	role	4
4	role	play	1
5	in	play	1
6	defense	in	5
7	and	defense	6
8	clearance	and	7
9	mechanisms	clearance	8
10	of	mechanisms	9
11	the	of	10
12	monocyte/macrophage	.	14
13	system	.	14
14	.	the	11

0	Ciprofloxacin	induces	1
1	induces	<ROOT>	-1
2	an	induces	1
3	immunomodulatory	an	2
4	stress	immunomodulatory	3
5	response	stress	4
6	in	response	5
7	human	T	8
8	T	induces	1
9	lymphocytes	induces	1
10	.	induces	1

0	When	was	2
1	18C7	was	2
2	was	was	9
3	incubated	with	4
4	with	was	2
5	liganded	MR	6
6	MR	with	4
7	,	was	9
8	it	was	9
9	was	<ROOT>	-1
10	able	was	9
11	to	able	10
12	partly	displace	13
13	displace	hormone	19
14	(	displace	13
15	20	(	14
16	%	)	17
17	)	(	14
18	the	(	14
19	hormone	to	11
20	from	its	21
21	its	hormone	19
22	binding	site	23
23	site	its	21
24	.	site	23

0	Transcriptional	factors	1
1	factors	play	6
2	of	factors	1
3	the	family	5
4	NFAT	family	5
5	family	of	2
6	play	<ROOT>	-1
7	an	role	9
8	important	role	9
9	role	play	6
10	in	play	6
11	regulating	in	10
12	the	expression	13
13	expression	in	10
14	of	several	15
15	several	expression	13
16	cytokine	genes	17
17	genes	several	15
18	during	play	6
19	the	response	21
20	immune	response	21
21	response	during	18
22	,	play	6
23	such	as	24
24	as	play	6
25	the	genes	26
26	genes	as	24
27	for	genes	26
28	interleukin	for	27
29	2	interleukin	28
30	(	interleukin	28
31	IL-2	for	27
32	)	for	27
33	and	play	6
34	IL-4	play	6
35	,	play	6
36	among	play	6
37	others	among	36
38	.	play	6

0	Egr-1	expression	1
1	expression	correlates	2
2	correlates	<ROOT>	-1
3	with	correlates	2
4	the	phenotype	6
5	cellular	phenotype	6
6	phenotype	with	3
7	and	pattern	10
8	the	pattern	10
9	specific	pattern	10
10	pattern	correlates	2
11	of	viral	12
12	viral	pattern	10
13	latency	correlates	2
14	established	latency	13
15	within	established	14
16	the	within	15
17	individual	the	16
18	cell	individual	17
19	lines	cell	18
20	.	lines	19

0	One	is	11
1	of	One	0
2	the	elements	4
3	latter	elements	4
4	elements	of	1
5	,	One	0
6	the	3'	8
7	IgH	3'	8
8	3'	One	0
9	enhancer	3'	8
10	,	One	0
11	is	<ROOT>	-1
12	of	is	11
13	particular	interest	14
14	interest	of	12
15	:	is	11
16	(	1	17
17	1	is	20
18	)	1	17
19	it	is	20
20	is	is	11
21	B	cell-specific	22
22	cell-specific	is	20
23	and	cell-specific	22
24	active	and	23
25	only	and	23
26	in	is	20
27	late	in	26
28	B	(	32
29	cell	development	30
30	development	B	28
31	;	development	30
32	(	late	27
33	2	(	32
34	)	is	11
35	in	is	11
36	rodent	plasmacytomas	37
37	plasmacytomas	in	35
38	and	plasmacytomas	37
39	in	plasmacytomas	37
40	some	in	39
41	human	some	40
42	Burkitt	lymphomas	44
43	's	Burkitt	42
44	lymphomas	human	41
45	it	is	46
46	is	in	35
47	part	is	46
48	of	control	51
49	a	control	51
50	locus	control	51
51	control	part	47
52	region	(	53
53	(	is	11
54	LCR	is	11
55	)	is	11
56	that	is	57
57	is	is	11
58	involved	is	57
59	in	involved	58
60	deregulation	in	59
61	of	deregulation	60
62	the	oncogene	64
63	c-myc	oncogene	64
64	oncogene	of	61
65	as	is	11
66	a	result	67
67	result	as	65
68	of	result	67
69	translocation	of	68
70	into	translocation	69
71	the	locus	73
72	IgH	locus	73
73	locus	into	70
74	;	is	11
75	and	is	11
76	(	3	77
77	3	has	80
78	)	3	77
79	it	has	80
80	has	and	75
81	been	has	80
82	implicated	been	81
83	in	implicated	82
84	the	mechanisms	85
85	mechanisms	implicated	82
86	that	Ig	88
87	control	Ig	88
88	Ig	mechanisms	85
89	gene	switch	91
90	class	switch	91
91	switch	Ig	88
92	recombination	mechanisms	85
93	.	is	11

0	RXR-alpha	mRNA	1
1	mRNA	was	2
2	was	<ROOT>	-1
3	present	was	2
4	in	present	3
5	untreated	in	4
6	U937	,	8
7	cells	,	8
8	,	untreated	5
9	and	was	2
10	levels	was	2
11	increased	was	2
12	after	increased	11
13	induction	after	12
14	of	induction	13
15	differentiation	of	14
16	with	induction	13
17	phorbol	ester	18
18	ester	with	16
19	.	was	2

0	Its	expression	1
1	expression	is	2
2	is	<ROOT>	-1
3	stimulus-	is	2
4	and	is	2
5	cell-specific	and	4
6	.	is	2

0	In	seems	6
1	allergic	asthma	3
2	bronchial	asthma	3
3	asthma	In	0
4	,	seems	6
5	inflammation	seems	6
6	seems	<ROOT>	-1
7	to	seems	6
8	be	to	7
9	orchestrated	be	8
10	predominantly	orchestrated	9
11	by	be	8
12	a	subset	13
13	subset	by	11
14	of	T	15
15	T	subset	13
16	lymphocytes	seems	6
17	,	seems	6
18	with	seems	6
19	a	with	18
20	phenotype	a	19
21	similar	the	23
22	to	the	23
23	the	subset	25
24	Th2	subset	25
25	subset	able	26
26	able	phenotype	20
27	to	able	26
28	produce	able	26
29	IL-4	seems	6
30	and	seems	6
31	IL-5	seems	6
32	.	seems	6

0	However	appeared	4
1	,	appeared	4
2	this	factor	3
3	factor	appeared	4
4	appeared	<ROOT>	-1
5	when	achieved	9
6	these	patients	8
7	CML	patients	8
8	patients	achieved	9
9	achieved	haematological	11
10	complete	haematological	11
11	haematological	appeared	4
12	remission	(	13
13	(	appeared	4
14	CHR	appeared	4
15	)	appeared	4
16	through	)	15
17	alpha-interferon	therapy	18
18	therapy	through	16
19	.	appeared	4

0	Granulocyte-macrophage	factor	3
1	colony	factor	3
2	stimulating	factor	3
3	factor	is	7
4	(	GM-CSF	5
5	GM-CSF	factor	3
6	)	GM-CSF	5
7	is	<ROOT>	-1
8	one	cytokine	10
9	such	cytokine	10
10	cytokine	is	7
11	,	is	7
12	whose	is	7
13	increased	results	15
14	expression	results	15
15	results	whose	12
16	mostly	from	17
17	from	is	7
18	increases	from	17
19	in	increases	18
20	transcription	in	19
21	.	is	7

0	Here	demonstrate	3
1	,	demonstrate	3
2	we	demonstrate	3
3	demonstrate	<ROOT>	-1
4	a	role	6
5	novel	role	6
6	role	demonstrate	3
7	for	role	6
8	IK	for	7
9	in	IK	8
10	MHC	II	12
11	class	II	12
12	II	for	7
13	expression	since	14
14	since	for	7
15	over-expression	demonstrate	3
16	of	over-expression	15
17	this	protein	18
18	protein	of	16
19	by	stable	20
20	stable	demonstrate	3
21	transfection	into	22
22	into	demonstrate	3
23	human	B	24
24	B	demonstrate	3
25	cells	led	26
26	led	demonstrate	3
27	to	led	26
28	a	disappearance	30
29	total	disappearance	30
30	disappearance	II	35
31	of	II	35
32	constitutive	II	35
33	MHC	II	35
34	class	II	35
35	II	to	27
36	mRNA	demonstrate	3
37	expression	demonstrate	3
38	.	demonstrate	3

0	Glucocorticoids	are	1
1	are	<ROOT>	-1
2	important	are	1
3	for	important	2
4	maintaining	for	3
5	cellular	and	6
6	and	maintaining	4
7	humoral	and	6
8	homeostasis	are	1
9	and	are	1
10	are	and	9
11	key	are	10
12	mediators	key	11
13	of	mediators	12
14	neuroendocrine-immune	of	13
15	regulatory	.	17
16	interactions	.	17
17	.	neuroendocrine-immune	14

0	Pancreatic	expression	2
1	islet	expression	2
2	expression	<ROOT>	-1
3	studies	expression	2
4	and	studies	3
5	polymorphic	markers	7
6	DNA	markers	7
7	markers	and	4
8	in	genes	10
9	the	genes	10
10	genes	and	4
11	encoding	genes	10
12	hepatocyte	factor-3alpha	14
13	nuclear	factor-3alpha	14
14	factor-3alpha	encoding	11
15	,	factor-3alpha	14
16	-3beta	factor-3alpha	14
17	,	-3beta	16
18	-3gamma	-3beta	16
19	,	-3gamma	18
20	-4gamma	-3gamma	18
21	,	-4gamma	20
22	and	-4gamma	20
23	-6	and	22
24	.	expression	2

0	Our	observations	2
1	unexpected	observations	2
2	observations	<ROOT>	-1
3	of	observations	2
4	paternal	of	3
5	or	paternal	4
6	biallelic	expression	7
7	expression	or	5
8	of	expression	7
9	WT1	of	8
10	in	observations	2
11	fibroblasts	in	10
12	and	observations	2
13	lymphocytes	observations	2
14	,	observations	2
15	together	observations	2
16	with	observations	2
17	the	with	16
18	previous	of	20
19	findings	of	20
20	of	the	17
21	maternal	of	20
22	or	maternal	21
23	biallelic	expression	24
24	expression	or	22
25	in	or	22
26	placentae	in	25
27	and	placentae	26
28	brains	and	27
29	,	observations	2
30	suggest	observations	2
31	that	suggest	30
32	the	that	31
33	allele-specific	of	36
34	regulatory	of	36
35	system	of	36
36	of	the	32
37	WT1	the	32
38	is	WT1	37
39	unique	that	31
40	and	unique	39
41	may	be	42
42	be	and	40
43	controlled	be	42
44	by	controlled	43
45	a	tissue-	47
46	putative	tissue-	47
47	tissue-	by	44
48	and	tissue-	47
49	individual-specific	modifier	50
50	modifier	and	48
51	.	observations	2

0	A	TCR	2
1	chimeric	TCR	2
2	TCR	Ab	9
3	gene	single-chain	8
4	,	single-chain	8
5	comprising	single-chain	8
6	an	single-chain	8
7	anti-hapten	single-chain	8
8	single-chain	TCR	2
9	Ab	fragment	11
10	variable	fragment	11
11	fragment	was	25
12	fused	fragment	11
13	to	fused	12
14	the	to	13
15	transmembrane	the	14
16	and	transmembrane	15
17	cytoplasmic	and	16
18	regions	cytoplasmic	17
19	of	regions	18
20	the	zeta-chain	23
21	human	zeta-chain	23
22	TCR	zeta-chain	23
23	zeta-chain	of	19
24	,	fragment	11
25	was	<ROOT>	-1
26	used	was	25
27	to	used	26
28	determine	to	27
29	whether	determine	28
30	the	system	32
31	tetracycline-regulatable	system	32
32	system	could	33
33	could	whether	29
34	be	could	33
35	used	be	34
36	to	used	35
37	regulate	to	36
38	gene	regulate	37
39	expression	gene	38
40	in	T	41
41	T	expression	39
42	cells	was	25
43	.	was	25

0	Ro	<ROOT>	-1
1	09-2210	potent	3
2	exhibits	potent	3
3	potent	Ro	0
4	anti-proliferative	effects	5
5	effects	potent	3
6	on	effects	5
7	activated	T	8
8	T	Ro	0
9	cells	Ro	0
10	by	Ro	0
11	selectively	by	10
12	blocking	selectively	11
13	MKK	activity	14
14	activity	blocking	12
15	.	Ro	0

0	BACKGROUND	<ROOT>	-1
1	:	BACKGROUND	0
2	Fibrin	deposition	3
3	deposition	have	6
4	and	deposition	3
5	thrombosis	and	4
6	have	BACKGROUND	0
7	been	have	6
8	implicated	been	7
9	in	implicated	8
10	both	rejection	12
11	allograft	rejection	12
12	rejection	in	9
13	and	rejection	12
14	vasculopathy	and	13
15	after	implicated	8
16	cardiac	transplantation	17
17	transplantation	after	15
18	.	BACKGROUND	0

0	Effects	of	1
1	of	<ROOT>	-1
2	oxidative	of	1
3	stress	of	1
4	on	of	1
5	stimulation-dependent	transduction	7
6	signal	transduction	7
7	transduction	on	4
8	,	of	1
9	leading	of	1
10	to	IL-2	11
11	IL-2	leading	9
12	expression	of	1
13	,	of	1
14	were	studied	15
15	studied	of	1
16	.	studied	15

0	Among	<ROOT>	-1
1	the	Among	0
2	regulatory	the	1
3	promoter	elements	4
4	elements	potentially	5
5	potentially	regulatory	2
6	regulating	the	1
7	eotaxin	Among	0
8	gene	expression	9
9	expression	and/or	10
10	and/or	eotaxin	7
11	mediating	and/or	10
12	the	effects	13
13	effects	we	17
14	of	effects	13
15	anti-inflammatory	drugs	16
16	drugs	of	14
17	we	mediating	11
18	identified	we	17
19	consensus	Among	0
20	sequences	known	21
21	known	Among	0
22	to	known	21
23	interact	with	24
24	with	to	22
25	nuclear	factors	26
26	factors	with	24
27	like	factors	26
28	NF-IL6	like	27
29	,	with	24
30	AP-1	,	29
31	,	with	24
32	a	,	31
33	NF-kappa-B	like	34
34	like	a	32
35	consensus	like	34
36	sequence	like	34
37	and	like	34
38	gamma-interferon-	and	37
39	as	Among	0
40	well	Among	0
41	as	Among	0
42	glucocorticoid	Among	0
43	response	Among	0
44	elements	Among	0
45	.	Among	0

0	Epstein-Barr	virus	1
1	virus	can	10
2	(	EBV	3
3	EBV	virus	1
4	)	EBV	3
5	,	virus	1
6	a	gamma-herpesvirus	8
7	human	gamma-herpesvirus	8
8	gamma-herpesvirus	virus	1
9	,	virus	1
10	can	(	14
11	establish	(	14
12	both	nonproductive	13
13	nonproductive	establish	11
14	(	productive	18
15	latent	(	14
16	)	(	14
17	and	(	14
18	productive	<ROOT>	-1
19	(	productive	18
20	lytic	productive	18
21	)	productive	18
22	infections	productive	18
23	.	productive	18

0	The	<ROOT>	-1
1	TCR-mediated	The	0
2	activation	of	3
3	of	TCR-mediated	1
4	NF-kappaB	of	3
5	was	NF-kappaB	4
6	also	dependent	7
7	dependent	The	0
8	on	dependent	7
9	a	Ca2+	10
10	Ca2+	on	8
11	influx	dependent	7
12	,	influx	11
13	because	channel	16
14	the	Ca2+	15
15	Ca2+	channel	16
16	channel	influx	11
17	blocker	channel	16
18	,	influx	31
19	SK&amp;F	96365	20
20	96365	influx	31
21	,	96365	20
22	as	96365	20
23	well	as	22
24	as	as	22
25	other	agents	26
26	agents	as	22
27	that	prevented	28
28	prevented	agents	26
29	the	Ca2+	30
30	Ca2+	prevented	28
31	influx	blocker	17
32	,	The	0
33	inhibited	The	0
34	NF-kappaB	activation	35
35	activation	The	0
36	.	The	0

0	Adherence-isolated	monocytes	1
1	monocytes	showed	2
2	showed	<ROOT>	-1
3	constitutive	showed	2
4	DNA	binding	5
5	binding	constitutive	3
6	activity	NF-kappa	8
7	of	NF-kappa	8
8	NF-kappa	showed	2
9	B	showed	2
10	.	showed	2

0	IL-4-mediated	tyrosine	1
1	tyrosine	was	5
2	phosphorylation	was	5
3	of	phosphorylation	2
4	Stat6	of	3
5	was	was	16
6	pronounced	was	5
7	in	was	5
8	1D4	in	7
9	cells	,	10
10	,	1D4	8
11	while	was	5
12	no	phosphorylation	15
13	IL-4-induced	Stat6	14
14	Stat6	phosphorylation	15
15	phosphorylation	was	5
16	was	<ROOT>	-1
17	detected	was	16
18	in	E1C3	19
19	E1C3	detected	17
20	cells	was	16
21	.	was	16

0	Taken	<ROOT>	-1
1	together	Taken	0
2	,	Taken	0
3	these	,	2
4	data	these	3
5	suggest	that	6
6	that	data	4
7	tTG	might	15
8	,	tTG	7
9	acting	tTG	7
10	on	pRB	12
11	the	pRB	12
12	pRB	acting	9
13	protein	pRB	12
14	,	tTG	7
15	might	that	6
16	play	might	15
17	an	role	19
18	important	role	19
19	role	play	16
20	in	cell	22
21	the	cell	22
22	cell	play	16
23	progression	data	4
24	through	progression	23
25	the	program	27
26	death	program	27
27	program	through	24
28	.	Taken	0

0	Extinction	upon	8
1	of	Extinction	0
2	immunoglobulin	in	5
3	gene	in	5
4	expression	in	5
5	in	of	1
6	B	cells	7
7	cells	Extinction	0
8	upon	cells	12
9	fusion	upon	8
10	with	HeLa	11
11	HeLa	fusion	9
12	cells	is	13
13	is	<ROOT>	-1
14	preceded	is	13
15	by	preceded	14
16	rapid	depletion	18
17	nuclear	depletion	18
18	depletion	by	15
19	of	depletion	18
20	essential	factors	22
21	transcription	factors	22
22	factors	of	19
23	and	depletion	18
24	is	and	23
25	accompanied	is	24
26	by	accompanied	25
27	widespread	inactivation	28
28	inactivation	expressed	31
29	of	inactivation	28
30	genes	of	29
31	expressed	by	26
32	in	expressed	31
33	a	in	32
34	B	.	37
35	cell-specific	.	37
36	manner	.	37
37	.	a	33

0	Stimulation	peripheral	3
1	of	peripheral	3
2	human	peripheral	3
3	peripheral	blood	4
4	blood	<ROOT>	-1
5	mononuclear	cells	6
6	cells	blood	4
7	by	blood	4
8	zinc	by	7
9	and	zinc	8
10	related	cations	11
11	cations	and	9
12	.	blood	4

0	Kd	values	1
1	values	were	12
2	(	mean+/-SE	3
3	mean+/-SE	values	1
4	)	mean+/-SE	3
5	for	values	1
6	cortisol	for	5
7	in	values	1
8	HML	in	7
9	of	HML	8
10	hypertensive	patients	11
11	patients	of	9
12	were	<ROOT>	-1
13	higher	were	12
14	than	higher	13
15	in	than	14
16	control	in	15
17	subjects	control	16
18	(	were	12
19	24.6+/-2.4	(	18
20	versus	24.6+/-2.4	19
21	17.5+/-1.7	versus	20
22	nmol/L	17.5+/-1.7	21
23	,	nmol/L	22
24	P	nmol/L	22
25	&lt;	P	24
26	.04	)	27
27	)	nmol/L	22
28	.	)	27

0	Inhibition	did	4
1	of	Inhibition	0
2	RANTES	expression	3
3	expression	of	1
4	did	<ROOT>	-1
5	not	did	4
6	appear	did	4
7	to	appear	6
8	be	to	7
9	secondary	be	8
10	to	IL-2	11
11	IL-2	secondary	9
12	inhibition	and	13
13	and	required	14
14	required	secondary	9
15	binding	did	4
16	to	binding	15
17	the	receptor	20
18	intracellular	receptor	20
19	glucocorticoid	receptor	20
20	receptor	to	16
21	.	receptor	20

0	Interleukin-3	is	4
1	(	IL-3	2
2	IL-3	Interleukin-3	0
3	)	IL-3	2
4	is	<ROOT>	-1
5	a	cytokine	6
6	cytokine	is	4
7	that	is	8
8	is	cytokine	6
9	expressed	is	8
10	primarily	in	11
11	in	T	13
12	activated	T	13
13	T	expressed	9
14	cells	is	4
15	.	is	4

0	Sequence	<ROOT>	-1
1	analysis	and	2
2	and	Sequence	0
3	expression	in	4
4	in	Sequence	0
5	cultured	in	4
6	lymphocytes	Sequence	0
7	of	Sequence	0
8	the	of	7
9	human	the	8
10	FOSB	(	12
11	gene	(	12
12	(	human	9
13	G0S3	Sequence	0
14	)	Sequence	0
15	.	Sequence	0

0	Using	<ROOT>	-1
1	a	reaction	7
2	sensitive	reaction	7
3	,	reverse	4
4	reverse	reaction	7
5	transcription-polymerase	reaction	7
6	chain	reaction	7
7	reaction	Using	0
8	(	RT-PCR	9
9	RT-PCR	reaction	7
10	)	RT-PCR	9
11	assay	reaction	7
12	,	mRNA	14
13	G0S2	mRNA	14
14	mRNA	Using	0
15	levels	Using	0
16	were	assayed	17
17	assayed	blood	20
18	in	cultured	19
19	cultured	assayed	17
20	blood	Using	0
21	mononuclear	Using	0
22	cells	Using	0
23	.	Using	0

0	Using	mobility	2
1	electrophoretic	Using	0
2	mobility	found	7
3	shift	mobility	2
4	assays	mobility	2
5	,	found	7
6	we	found	7
7	found	<ROOT>	-1
8	that	found	7
9	in	the	10
10	the	that	8
11	presence	of	12
12	of	the	10
13	rabbit	the	10
14	reticulocyte	lysate	15
15	lysate	the	10
16	,	found	7
17	human	ER	18
18	ER	reduced	19
19	reduced	found	7
20	the	activities	22
21	binding	activities	22
22	activities	reduced	19
23	of	activities	22
24	chicken	proteins	29
25	immature	proteins	29
26	erythrocyte	proteins	29
27	nuclear	proteins	29
28	extracted	proteins	29
29	proteins	of	23
30	to	reduced	19
31	GATA	to	30
32	and	GATA	31
33	CACCC	GATA	31
34	sites	found	7
35	in	sites	34
36	the	promoter	38
37	H5	promoter	38
38	promoter	in	35
39	and	found	7
40	enhancer	found	7
41	.	found	7

0	We	mapped	2
1	have	mapped	2
2	mapped	<ROOT>	-1
3	the	inhibitory	4
4	inhibitory	mapped	2
5	activity	to	6
6	to	mapped	2
7	less	mapped	2
8	than	60	9
9	60	less	7
10	residues	,	11
11	,	60	9
12	containing	motifs	13
13	motifs	that	14
14	that	less	7
15	are	that	14
16	conserved	are	15
17	in	NFAT	19
18	all	NFAT	19
19	NFAT	conserved	16
20	proteins	mapped	2
21	.	mapped	2

0	Expression	activated	13
1	plasmids	Expression	0
2	encoding	regions	3
3	regions	plasmids	1
4	of	regions	3
5	RFX5	of	4
6	fused	plasmids	1
7	to	binding	11
8	the	binding	11
9	GAL4	binding	11
10	DNA	binding	11
11	binding	fused	6
12	domain	Expression	0
13	activated	<ROOT>	-1
14	transcription	activated	13
15	from	activated	13
16	a	construct	18
17	reporter	construct	18
18	construct	from	15
19	containing	GAL4	20
20	GAL4	from	15
21	sites	activated	13
22	in	activated	13
23	a	assay	25
24	cotransfection	assay	25
25	assay	B	30
26	in	B	30
27	the	Raji	28
28	Raji	B	30
29	human	B	30
30	B	in	22
31	cell	activated	13
32	line	activated	13
33	.	activated	13

0	Papillomas	<ROOT>	-1
1	and	Papillomas	0
2	keratoacanthomas	copied	3
3	copied	their	4
4	their	and	1
5	normal	counterparts	6
6	counterparts	their	4
7	in	their	4
8	the	in	7
9	mode	of	10
10	of	the	8
11	expression	.	12
12	.	of	10

0	The	TCR	1
1	TCR	beta	3
2	alpha	TCR	1
3	beta	bind	8
4	or	beta	3
5	-gamma	or	4
6	delta	chains	7
7	chains	or	4
8	bind	<ROOT>	-1
9	the	ligand	11
10	peptide	ligand	11
11	ligand	bind	8
12	,	bind	8
13	whereas	bind	8
14	the	whereas	13
15	associated	epsilon	18
16	CD3	epsilon	18
17	delta	epsilon	18
18	epsilon	the	14
19	gamma	bind	8
20	and	bind	8
21	TCR	bind	8
22	zeta	subunits	23
23	subunits	bind	8
24	couple	TCR	26
25	the	TCR	26
26	TCR	bind	8
27	to	bind	8
28	intracellular	signal	29
29	signal	to	27
30	transduction	components	31
31	components	signal	29
32	.	components	31

0	In	show	4
1	addition	In	0
2	,	show	4
3	we	show	4
4	show	<ROOT>	-1
5	that	show	4
6	TNF-alpha	is	7
7	is	that	5
8	a	factor	11
9	potent	factor	11
10	costimulatory	factor	11
11	factor	is	7
12	of	factor	11
13	the	CD34+Thy-1+	16
14	very	immature	15
15	immature	CD34+Thy-1+	16
16	CD34+Thy-1+	of	12
17	CB	subset	18
18	subset	CD34+Thy-1+	16
19	.	show	4

0	PURPOSE	<ROOT>	-1
1	:	PURPOSE	0
2	To	PURPOSE	0
3	clarify	To	2
4	the	relationship	5
5	relationship	clarify	3
6	between	relationship	5
7	the	glucocorticoid	8
8	glucocorticoid	between	6
9	receptor	glucocorticoid	8
10	and	receptor	9
11	the	effectiveness	12
12	effectiveness	and	10
13	of	glucocorticoid	14
14	glucocorticoid	effectiveness	12
15	therapy	PURPOSE	0
16	in	therapy	15
17	patients	in	16
18	with	patients	17
19	ulcerative	colitis	20
20	colitis	with	18
21	,	PURPOSE	0
22	we	PURPOSE	0
23	investigated	we	22
24	the	number	25
25	number	investigated	23
26	and	number	25
27	apparent	and	26
28	dissociation	of	30
29	constant	of	30
30	of	apparent	27
31	glucocorticoid	of	30
32	receptor	of	30
33	in	peripheral	34
34	peripheral	receptor	32
35	blood	PURPOSE	0
36	mononuclear	PURPOSE	0
37	leukocytes	PURPOSE	0
38	of	leukocytes	37
39	patients	of	38
40	with	patients	39
41	ulcerative	colitis	42
42	colitis	with	40
43	.	PURPOSE	0

0	Linked	to	1
1	to	<ROOT>	-1
2	these	to	1
3	events	to	1
4	,	to	1
5	antibodies	,	4
6	to	antibodies	5
7	T-antigen	to	6
8	,	antibodies	5
9	DNA	antibodies	5
10	,	DNA	9
11	TBP	DNA	9
12	,	TBP	11
13	and	TBP	11
14	CREB	and	13
15	were	CREB	14
16	detected	antibodies	5
17	,	antibodies	5
18	identical	antibodies	5
19	to	identical	18
20	what	observed	22
21	we	observed	22
22	observed	to	19
23	in	observed	22
24	mice	in	23
25	.	to	1

0	We	show	1
1	show	lines	14
2	that	show	1
3	a	mutant	6
4	constitutively	active	5
5	active	mutant	6
6	mutant	human	12
7	of	human	12
8	human	human	12
9	Toll	human	12
10	transfected	human	12
11	into	transfected	10
12	human	that	2
13	cell	show	1
14	lines	<ROOT>	-1
15	can	lines	14
16	induce	can	15
17	the	activation	18
18	activation	induce	16
19	of	activation	18
20	NF-kappaB	of	19
21	and	the	22
22	the	lines	14
23	expression	the	22
24	of	expression	23
25	NF-kappaB-controlled	genes	26
26	genes	of	24
27	for	cytokines	30
28	the	cytokines	30
29	inflammatory	cytokines	30
30	cytokines	of	24
31	IL-1	cytokines	30
32	,	IL-1	31
33	IL-6	IL-1	31
34	and	IL-6	33
35	IL-8	and	34
36	,	IL-8	35
37	as	IL-8	35
38	well	as	37
39	as	as	37
40	the	expression	41
41	expression	as	37
42	of	the	43
43	the	expression	41
44	co-stimulatory	and	34
45	molecule	lines	14
46	B7.1	lines	14
47	,	which	48
48	which	lines	14
49	is	which	48
50	required	is	49
51	for	required	50
52	the	activation	53
53	activation	T	56
54	of	T	56
55	naive	of	54
56	T	for	51
57	cells	lines	14
58	.	lines	14

0	Forty	patients	3
1	primary	patients	3
2	FMS	patients	3
3	patients	control	32
4	(	F	5
5	F	:	6
6	:	patients	3
7	M	:	6
8	=	36	9
9	36	M	7
10	:	36	9
11	4	36	9
12	)	36	9
13	,	patients	3
14	28	patients	16
15	LBP	patients	16
16	patients	patients	3
17	(	patients	16
18	25	(	17
19	:	3	20
20	3	(	17
21	)	3	20
22	and	patients	16
23	14	healthy	29
24	(	14	23
25	12	(	24
26	:	14	23
27	2	14	23
28	)	14	23
29	healthy	and	22
30	,	patients	3
31	sedentary	patients	3
32	control	were	34
33	persons	control	32
34	were	<ROOT>	-1
35	recruited	were	34
36	for	recruited	35
37	the	study	38
38	study	for	36
39	.	were	34

0	The	site	2
1	third	site	2
2	site	was	3
3	was	<ROOT>	-1
4	occupied	was	3
5	in	occupied	4
6	quiescent	cells	7
7	cells	in	5
8	or	cells	7
9	in	in	5
10	cells	was	3
11	stimulated	was	3
12	by	was	3
13	anti	was	3
14	CD2	was	3
15	or	was	3
16	anti	was	3
17	CD28	was	3
18	alone	CD28	17
19	.	was	3

0	In	<ROOT>	-1
1	addition	In	0
2	to	addition	1
3	the	isoform	5
4	existing	isoform	5
5	isoform	to	2
6	(	Pax-5	7
7	Pax-5	isoform	5
8	,	Pax-5	7
9	which	have	11
10	we	have	11
11	have	Pax-5	7
12	named	have	11
13	Pax-5a	named	12
14	)	Pax-5a	13
15	,	isolated	18
16	we	isolated	18
17	have	isolated	18
18	isolated	)	14
19	three	named	12
20	new	,	22
21	isoforms	,	22
22	,	three	19
23	Pax-5b	named	12
24	,	Pax-5	7
25	Pax-5d	isoform	5
26	,	isoform	5
27	and	isoform	5
28	Pax-5e	and	27
29	,	In	0
30	from	murine	31
31	murine	,	29
32	spleen	In	0
33	and	spleen	32
34	B-lymphoid	cell	35
35	cell	and	33
36	lines	using	37
37	using	library	38
38	library	cell	35
39	screenings	In	0
40	and	In	0
41	polymerase	In	0
42	chain	amplification	44
43	reaction	chain	42
44	amplification	In	0
45	.	In	0

0	Various	antioxidants	1
1	antioxidants	<ROOT>	-1
2	,	antioxidants	1
3	such	as	4
4	as	antioxidants	1
5	pyrrolidine	dithiocarbamate	6
6	dithiocarbamate	demonstrating	18
7	,	dithiocarbamate	6
8	p-bromophenacyl-bromide	dithiocarbamate	6
9	and	p-bromophenacyl-bromide	8
10	nordihydroguaiaretic	acid	11
11	acid	could	12
12	could	and	9
13	strongly	could	12
14	reduce	could	12
15	NF-kappaB	translocation	16
16	translocation	reduce	14
17	,	dithiocarbamate	6
18	demonstrating	as	4
19	the	importance	20
20	importance	demonstrating	18
21	of	oxidative	22
22	oxidative	importance	20
23	species	importance	20
24	in	importance	20
25	the	mechanism	27
26	transduction	mechanism	27
27	mechanism	in	24
28	.	antioxidants	1

0	Using	cell	3
1	an	cell	3
2	erythroid	cell	3
3	cell	<ROOT>	-1
4	line	cell	3
5	,	cell	3
6	we	,	5
7	have	we	6
8	tested	have	7
9	the	changes	10
10	changes	tested	8
11	in	tested	8
12	the	in	11
13	DNA	binding	14
14	binding	the	12
15	activity	the	12
16	of	activity	15
17	the	of	16
18	lineage-restricted	the	17
19	transcription	lineage-restricted	18
20	factor	transcription	19
21	GATA-1	transcription	19
22	through	GATA-1	21
23	the	cycle	25
24	cell	cycle	25
25	cycle	through	22
26	.	cell	3

0	We	found	1
1	found	<ROOT>	-1
2	a	degradation	4
3	constitutive	degradation	4
4	degradation	kappa	7
5	of	kappa	7
6	I	of	5
7	kappa	found	1
8	B-alpha	found	1
9	,	cytoplasmic	12
10	the	cytoplasmic	12
11	major	cytoplasmic	12
12	cytoplasmic	B-alpha	8
13	inhibitor	of	14
14	of	NF-kappa	20
15	nuclear	B	18
16	factor	B	18
17	kappa	B	18
18	B	of	14
19	(	NF-kappa	20
20	NF-kappa	cytoplasmic	12
21	B	found	1
22	)	found	1
23	,	found	1
24	in	,	23
25	freshly	in	24
26	isolated	freshly	25
27	PBMC	isolated	26
28	and	PBMC	27
29	monocytes	found	1
30	from	found	1
31	patients	found	1
32	with	found	1
33	tuberculosis	found	1
34	.	found	1

0	TPO	<ROOT>	-1
1	induced	tyrosine	2
2	tyrosine	TPO	0
3	phosphorylation	TPO	0
4	of	phosphorylation	3
5	the	receptor	7
6	TPO	receptor	7
7	receptor	of	4
8	but	phosphorylation	3
9	not	but	8
10	the	erythropoietin	11
11	erythropoietin	not	9
12	(	EPO	13
13	EPO	erythropoietin	11
14	)	EPO	13
15	receptor	erythropoietin	11
16	.	receptor	15

0	In	did	6
1	all	cases	3
2	three	cases	3
3	cases	In	0
4	,	did	6
5	we	did	6
6	did	<ROOT>	-1
7	not	did	6
8	find	did	6
9	a	difference	11
10	significant	difference	11
11	difference	find	8
12	in	difference	11
13	stability	in	12
14	.	did	6

0	Unexpectedly	T-cell	4
1	,	Unexpectedly	0
2	the	T-cell	4
3	CD8+	T-cell	4
4	T-cell	subpopulation	5
5	subpopulation	<ROOT>	-1
6	failed	subpopulation	5
7	to	failed	6
8	respond	to	7
9	.	subpopulation	5

0	When	used	1
1	used	caused	9
2	at	used	1
3	differentiation-inducing	concentrations	4
4	concentrations	at	2
5	,	caused	9
6	both	inhibitors	8
7	topoisomerase	inhibitors	8
8	inhibitors	caused	9
9	caused	AP-1	14
10	a	stimulation	12
11	great	stimulation	12
12	stimulation	AP-1	14
13	of	AP-1	14
14	AP-1	<ROOT>	-1
15	binding	AP-1	14
16	activity	AP-1	14
17	,	AP-1	14
18	with	AP-1	14
19	maximum	value	20
20	value	with	18
21	at	AP-1	14
22	hour	at	21
23	12	hour	22
24	in	AP-1	14
25	etoposide-treated	cells	26
26	cells	in	24
27	and	AP-1	14
28	at	and	27
29	hour	at	28
30	48	hour	29
31	in	and	27
32	ICRF-193-treated	cells	33
33	cells	in	31
34	.	cells	33

0	In	revealed	10
1	vitro	In	0
2	footprinting	analysis	3
3	analysis	In	0
4	within	In	0
5	this	part	6
6	part	within	4
7	of	part	6
8	the	promoter	9
9	promoter	of	7
10	revealed	<ROOT>	-1
11	two	binding	13
12	Sp1	binding	13
13	binding	revealed	10
14	sites	revealed	10
15	as	revealed	10
16	well	as	15
17	as	as	15
18	a	PU-box	19
19	PU-box	as	15
20	.	revealed	10

0	Evidence	calcineurin	2
1	that	calcineurin	2
2	calcineurin	<ROOT>	-1
3	is	calcineurin	2
4	rate-limiting	is	3
5	for	lymphocyte	8
6	primary	lymphocyte	8
7	human	lymphocyte	8
8	lymphocyte	rate-limiting	4
9	activation	calcineurin	2
10	.	calcineurin	2

0	Heat-shock	induced	29
1	for	Heat-shock	0
2	2	hours	3
3	hours	for	1
4	at	Heat-shock	0
5	42	degrees	6
6	degrees	C	7
7	C	at	4
8	,	Heat-shock	0
9	or	Heat-shock	0
10	the	administration	11
11	administration	or	9
12	for	3	13
13	3	or	9
14	hours	3	13
15	of	3	13
16	100	of	15
17	or	100	16
18	150	microM	19
19	microM	cadmium	20
20	cadmium	or	17
21	chloride	inhibited	23
22	,	inhibited	23
23	inhibited	cadmium	20
24	the	inhibited	23
25	subsequent	cadmium	20
26	proliferation	subsequent	25
27	activity	of	15
28	,	Heat-shock	0
29	induced	<ROOT>	-1
30	the	expression	31
31	expression	differentiation	34
32	of	differentiation	34
33	functional	differentiation	34
34	differentiation	induced	29
35	markers	induced	29
36	,	induced	29
37	and	caused	38
38	caused	induced	29
39	an	increase	40
40	increase	caused	38
41	in	increase	40
42	the	amount	43
43	amount	in	41
44	of	amount	43
45	the	protein	48
46	stress-responsive	protein	48
47	HSP70	protein	48
48	protein	of	44
49	in	U-937	50
50	U-937	human	51
51	human	promonocytic	52
52	promonocytic	amount	43
53	cells	induced	29
54	.	induced	29

0	When	introduced	1
1	introduced	<ROOT>	-1
2	in	introduced	1
3	front	in	2
4	of	front	3
5	a	of	4
6	luciferase	reporter	7
7	reporter	able	13
8	gene	is	12
9	,	is	12
10	this	promoter	11
11	promoter	is	12
12	is	reporter	7
13	able	a	5
14	to	able	13
15	direct	to	14
16	a	direct	15
17	high	a	16
18	luciferase	high	17
19	activity	luciferase	18
20	in	activity	19
21	a	B-LCL	23
22	human	B-LCL	23
23	B-LCL	in	20
24	.	introduced	1

0	NFkappaB	activity	1
1	activity	is	2
2	is	<ROOT>	-1
3	independent	is	2
4	from	independent	3
5	FADD	from	4
6	,	FADD	5
7	caspases	FADD	5
8	,	caspases	7
9	and	caspases	7
10	apoptosis	induction	11
11	induction	and	9
12	.	is	2

0	There	was	1
1	was	<ROOT>	-1
2	no	difference	3
3	difference	was	1
4	in	was	1
5	the	number	6
6	number	in	4
7	of	GR	8
8	GR	number	6
9	per	number	6
10	cell	among	11
11	among	per	9
12	the	three	13
13	three	groups	14
14	groups	among	11
15	(	:	17
16	FMS	:	17
17	:	groups	14
18	6498	+/-	19
19	+/-	252	20
20	252	:	17
21	,	:	17
22	LBP	:	17
23	:	:	17
24	6625	+/-	25
25	+/-	was	1
26	284	+/-	25
27	,	+/-	25
28	controls	was	1
29	:	was	1
30	6576	was	1
31	+/-	304	32
32	304	6576	30
33	)	304	32
34	,	)	33
35	but	was	1
36	the	was	1
37	dissociation	the	36
38	constant	dissociation	37
39	(	Kd	40
40	Kd	constant	38
41	)	Kd	40
42	of	Kd	40
43	the	FMS	44
44	FMS	of	42
45	(	14.5	46
46	14.5	FMS	44
47	+/-	14.5	46
48	0.9	nmol/l	49
49	nmol/l	+/-	47
50	)	14.5	46
51	and	of	42
52	LBP	subjects	59
53	(	+/-	55
54	14.7	+/-	55
55	+/-	subjects	59
56	1.3	+/-	55
57	nmol/l	+/-	55
58	)	+/-	55
59	subjects	was	60
60	was	and	51
61	significantly	higher	62
62	higher	was	60
63	than	higher	62
64	that	than	63
65	of	that	64
66	the	of	65
67	controls	(	68
68	(	+/-	70
69	10.9	(	68
70	+/-	the	66
71	0.8	+/-	70
72	nmol/l	the	66
73	)	nmol/l	72
74	(	)	73
75	p	was	60
76	&lt;	was	60
77	.05	)	78
78	)	&lt;	76
79	.	)	78

0	ETS1	transactivate	6
1	,	ETS1	0
2	NFkappaB	ETS1	0
3	and	NFkappaB	2
4	AP1	and	3
5	synergistically	transactivate	6
6	transactivate	<ROOT>	-1
7	the	promoter	10
8	human	promoter	10
9	GM-CSF	promoter	10
10	promoter	transactivate	6
11	.	transactivate	6

0	mNFATc	<ROOT>	-1
1	complexed	mNFATc	0
2	with	complexed	1
3	AP-1	bound	4
4	bound	with	2
5	specifically	bound	4
6	to	IL-2	9
7	the	IL-2	9
8	murine	IL-2	9
9	IL-2	mNFATc	0
10	NFAT	IL-2	9
11	recognition	mNFATc	0
12	sequence	mNFATc	0
13	and	mNFATc	0
14	activated	transcription	15
15	transcription	and	13
16	from	IL-2	19
17	the	IL-2	19
18	co-transfected	IL-2	19
19	IL-2	mNFATc	0
20	promoter	mNFATc	0
21	in	mNFATc	0
22	COS-7	cells	23
23	cells	in	21
24	.	cells	23

0	We	demonstrate	1
1	demonstrate	is	11
2	that	demonstrate	1
3	Elf-1	is	4
4	is	that	2
5	constitutively	is	4
6	localized	constitutively	5
7	in	the	8
8	the	localized	6
9	nucleus	which	10
10	which	the	8
11	is	<ROOT>	-1
12	dependent	is	11
13	on	dependent	12
14	the	on	13
15	presence	the	14
16	of	presence	15
17	amino	of	16
18	acids	amino	17
19	86-265	acids	18
20	.	is	11

0	CD15	engagement	1
1	engagement	<ROOT>	-1
2	by	engagement	1
3	monoclonal	antibody	4
4	antibody	by	2
5	also	engagement	1
6	attenuated	IL-1	7
7	IL-1	degradation	10
8	beta	degradation	10
9	transcript	degradation	10
10	degradation	engagement	1
11	,	engagement	1
12	demonstrating	,	11
13	that	demonstrating	12
14	signaling	that	13
15	via	signaling	14
16	CD15	also	17
17	also	via	15
18	had	also	17
19	posttranscriptional	effects	20
20	effects	via	15
21	.	engagement	1

0	The	region	2
1	promoter	region	2
2	region	lacked	3
3	lacked	NFkB	24
4	a	box	6
5	TATA	box	6
6	box	lacked	3
7	but	lacked	3
8	contained	but	7
9	potential	sites	11
10	binding	sites	11
11	sites	contained	8
12	for	contained	8
13	the	factors	15
14	transcriptional	factors	15
15	factors	for	12
16	including	factors	15
17	two	Sp1	18
18	Sp1	including	16
19	,	lacked	3
20	CRE	lacked	3
21	,	lacked	3
22	Myb	lacked	3
23	and	Myb	22
24	NFkB	<ROOT>	-1
25	located	NFkB	24
26	at	NFkB	24
27	positions	at	26
28	-153	NFkB	24
29	,	-153	28
30	-178	-153	28
31	,	-178	30
32	-286	-178	30
33	,	-286	32
34	-875	-286	32
35	,	-875	34
36	and	-875	34
37	-1011	and	36
38	,	NFkB	24
39	respectively	NFkB	24
40	.	NFkB	24

0	We	showed	2
1	previously	showed	2
2	showed	<ROOT>	-1
3	that	showed	2
4	granulocyte-macrophage	that	3
5	colony-stimulating	granulocyte-macrophage	4
6	factor	granulocyte-macrophage	4
7	(	GM-CSF	8
8	GM-CSF	factor	6
9	)	granulocyte-macrophage	4
10	and	showed	2
11	macrophage	showed	2
12	colony-stimulating	factor	13
13	factor	macrophage	11
14	(	factor	13
15	M-CSF	factor	13
16	)	factor	13
17	stimulate	factor	13
18	the	differentiation	19
19	differentiation	stimulate	17
20	of	human	21
21	human	differentiation	19
22	monocytes	into	23
23	into	showed	2
24	two	showed	2
25	phenotypically	distinct	26
26	distinct	two	24
27	types	distinct	26
28	of	types	27
29	macrophages	of	28
30	.	showed	2

0	We	suggested	2
1	previously	suggested	2
2	suggested	is	11
3	that	suggested	2
4	the	measurement	5
5	measurement	of	6
6	of	that	3
7	corticosteroid	of	6
8	receptors	of	6
9	in	of	6
10	lymphocytes	suggested	2
11	is	<ROOT>	-1
12	an	index	13
13	index	is	11
14	of	index	13
15	an	pattern	17
16	analogous	pattern	17
17	pattern	of	14
18	in	pattern	17
19	brain	in	18
20	.	is	11

0	We	<ROOT>	-1
1	used	We	0
2	cytokine	used	1
3	production	cytokine	2
4	as	readout	6
5	a	readout	6
6	readout	production	3
7	for	monocyte	8
8	monocyte	readout	6
9	activation	readout	6
10	and	activation	9
11	found	and	10
12	that	found	11
13	CD15	that	12
14	cross-linking	CD15	13
15	induced	cross-linking	14
16	TNF-alpha	release	17
17	release	from	18
18	from	induced	15
19	peripheral	blood	20
20	blood	from	18
21	monocytes	and	22
22	and	blood	20
23	cells	We	0
24	from	cell	27
25	the	cell	27
26	monocytic	cell	27
27	cell	We	0
28	line	We	0
29	MM6	We	0
30	.	We	0

0	Mycobacterium	tuberculosis	1
1	tuberculosis	are	5
2	and	tuberculosis	1
3	its	components	4
4	components	and	2
5	are	<ROOT>	-1
6	strong	signals	7
7	signals	are	5
8	to	signals	7
9	activate	to	8
10	monocytes	activate	9
11	to	activate	9
12	production	to	11
13	of	production	12
14	cytokines	of	13
15	.	are	5

0	After	<ROOT>	-1
1	a	incubation	3
2	2-day	incubation	3
3	incubation	After	0
4	in	incubation	3
5	LDL	in	4
6	,	After	0
7	the	binding	8
8	binding	NF-kappa	10
9	of	NF-kappa	10
10	NF-kappa	,	6
11	B	After	0
12	,	which	13
13	which	After	0
14	is	which	13
15	believed	is	14
16	to	believed	15
17	be	to	16
18	a	sensor	21
19	key	sensor	21
20	oxidative-stress	sensor	21
21	sensor	be	17
22	for	be	17
23	VCAM	regulation	24
24	regulation	for	22
25	,	is	14
26	remains	is	14
27	at	remains	26
28	basal	level	29
29	level	at	27
30	.	After	0

0	The	pattern	1
1	pattern	suggests	10
2	of	pattern	1
3	differential	expression	4
4	expression	of	2
5	of	expression	4
6	alternatively	isoforms	9
7	spliced	isoforms	9
8	Pax-5	isoforms	9
9	isoforms	of	5
10	suggests	<ROOT>	-1
11	that	suggests	10
12	they	may	13
13	may	that	11
14	be	regulators	16
15	important	be	14
16	regulators	may	13
17	of	regulators	16
18	transcription	suggests	10
19	during	suggests	10
20	B-cell	suggests	10
21	maturation	B-cell	20
22	.	maturation	21

0	Using	<ROOT>	-1
1	UT-7/GMT	Using	0
2	cells	,	3
3	,	UT-7/GMT	1
4	we	examined	5
5	examined	Using	0
6	how	TPO	7
7	TPO	examined	5
8	promotes	TPO	7
9	hemoglobinization	TPO	7
10	.	Using	0

0	A	cDNA	2
1	1.2-kb	cDNA	2
2	cDNA	encoding	3
3	encoding	C/EBP-epsilon	6
4	full-length	encoding	3
5	human	encoding	3
6	C/EBP-epsilon	was	7
7	was	<ROOT>	-1
8	cloned	was	7
9	from	cloned	8
10	a	lambda	13
11	promyelocyte-late	myeloblast-derived	12
12	myeloblast-derived	lambda	13
13	lambda	from	9
14	gt11	library	15
15	library	lambda	13
16	.	was	7

0	A-myb	is	1
1	is	<ROOT>	-1
2	expressed	is	1
3	in	expressed	2
4	a	subpopulation	5
5	subpopulation	in	3
6	of	lymphocytes	9
7	normal	lymphocytes	9
8	B	lymphocytes	9
9	lymphocytes	subpopulation	5
10	activated	is	1
11	in	activated	10
12	vivo	in	11
13	and	is	1
14	localised	is	1
15	in	is	1
16	the	center	18
17	germinal	center	18
18	center	in	15
19	of	lymphoid	21
20	peripheral	lymphoid	21
21	lymphoid	center	18
22	organs	is	1
23	and	is	1
24	is	is	1
25	not	is	1
26	detected	is	1
27	at	detected	26
28	significant	at	27
29	levels	significant	28
30	in	levels	29
31	all	other	32
32	other	in	30
33	mature	other	32
34	or	mature	33
35	immature	or	34
36	haematopoietic	bone	41
37	populations	studied	38
38	studied	haematopoietic	36
39	,	haematopoietic	36
40	including	bone	41
41	bone	immature	35
42	marrow	is	1
43	cells	is	1
44	,	is	1
45	T	is	1
46	lymphocytes	is	1
47	,	is	1
48	granulocytes	is	1
49	,	is	1
50	monocytes	is	1
51	,	is	1
52	either	at	53
53	at	is	1
54	rest	is	1
55	or	rest	54
56	after	or	55
57	in	is	1
58	vitro	is	1
59	activation	is	1
60	.	is	1

0	Low-density	lipoprotein	1
1	lipoprotein	is	5
2	(	LDL	3
3	LDL	lipoprotein	1
4	)	LDL	3
5	is	<ROOT>	-1
6	a	risk	8
7	well-established	risk	8
8	risk	is	5
9	factor	is	5
10	for	factor	9
11	atherosclerosis	for	10
12	.	is	5

0	Increased	treatment	7
1	CRH	activity	3
2	promoter	activity	3
3	activity	Increased	0
4	following	phorbol	5
5	phorbol	Increased	0
6	ester	treatment	7
7	treatment	was	8
8	was	<ROOT>	-1
9	inhibited	was	8
10	by	inhibited	9
11	a	mutant	15
12	dominant	mutant	15
13	negative	mutant	15
14	NF-IL6	mutant	15
15	mutant	by	10
16	,	was	8
17	showing	was	8
18	that	showing	17
19	the	effects	20
20	effects	were	24
21	of	phorbol	22
22	phorbol	effects	20
23	ester	phorbol	22
24	were	that	18
25	principally	mediated	26
26	mediated	were	24
27	by	mediated	26
28	C/EBP	by	27
29	.	C/EBP	28

0	The	number	1
1	number	was	7
2	of	number	1
3	GCR	of	2
4	in	number	1
5	the	patients	6
6	patients	in	4
7	was	<ROOT>	-1
8	greatly	was	7
9	increased	greatly	8
10	when	increased	9
11	these	when	10
12	patients	were	13
13	were	treated	14
14	treated	these	11
15	with	treated	14
16	oxygen	with	15
17	(	oxygen	16
18	P	oxygen	16
19	&lt;	oxygen	16
20	0.01	)	21
21	)	&lt;	19
22	.	)	21

0	The	contains	16
1	present	The	0
2	work	shows	3
3	shows	present	1
4	that	shows	3
5	the	that	4
6	primary	to	10
7	CD8+	to	10
8	CTL	to	10
9	response	to	10
10	to	the	5
11	EBV	to	10
12	in	EBV	11
13	infectious	in	12
14	mononucleosis	The	0
15	patients	The	0
16	contains	<ROOT>	-1
17	multiple	antigen-specific	19
18	lytic	antigen-specific	19
19	antigen-specific	contains	16
20	reactivities	contains	16
21	at	contains	16
22	levels	at	21
23	at	levels	22
24	least	at	23
25	as	at	23
26	high	as	25
27	as	at	23
28	those	as	27
29	seen	those	28
30	against	seen	29
31	latent	against	30
32	antigens	latent	31
33	;	similar	34
34	similar	are	36
35	reactivities	are	36
36	are	antigens	32
37	also	are	36
38	detectable	are	36
39	in	detectable	38
40	CTL	in	39
41	memory	CTL	40
42	.	memory	41

0	Considering	regulatory	3
1	that	regulatory	3
2	nuclear	regulatory	3
3	regulatory	/Rel	10
4	factor-kappa	regulatory	3
5	beta	(	6
6	(	regulatory	3
7	NF-kappa	(	6
8	B	regulatory	3
9	)	regulatory	3
10	/Rel	is	11
11	is	<ROOT>	-1
12	a	element	15
13	common	element	15
14	regulatory	element	15
15	element	is	11
16	of	element	15
17	the	of	16
18	promoter	the	17
19	region	promoter	18
20	of	cytokine	23
21	the	cytokine	23
22	inflammatory	cytokine	23
23	cytokine	region	19
24	genes	is	11
25	,	is	11
26	herein	,	25
27	,	herein	26
28	we	,	27
29	tested	we	28
30	the	hypothesis	31
31	hypothesis	tested	29
32	that	hypothesis	31
33	acute	ethanol	34
34	ethanol	that	32
35	affects	NF-kappa	36
36	NF-kappa	ethanol	34
37	B	that	32
38	activation	is	11
39	in	human	40
40	human	is	11
41	monocytes	is	11
42	.	is	11

0	High	doses	1
1	doses	oligonucleotide	23
2	of	doses	1
3	sodium	salicylate	4
4	salicylate	of	2
5	suppressed	p65	8
6	NF-kappa	p65	8
7	B	p65	8
8	p65	doses	1
9	mRNA	,	11
10	accumulation	,	11
11	,	doses	1
12	resulting	doses	1
13	in	doses	1
14	suppression	in	13
15	of	NF-kappa	17
16	total	NF-kappa	17
17	NF-kappa	suppression	14
18	B	doses	1
19	,	doses	1
20	p50	,	19
21	on	p50	20
22	tissue	doses	1
23	oligonucleotide	had	24
24	had	<ROOT>	-1
25	no	effects	26
26	effects	had	24
27	on	effects	26
28	lipopolysaccharide-induced	NF-kappa	29
29	NF-kappa	on	27
30	B	activation	31
31	activation	NF-kappa	29
32	.	had	24

0	Surprisingly	was	4
1	,	was	4
2	G28-5	sFv	3
3	sFv	was	4
4	was	<ROOT>	-1
5	a	agonist	8
6	potent	agonist	8
7	CD40	agonist	8
8	agonist	was	4
9	that	agonist	8
10	rapidly	crosslinked	11
11	crosslinked	that	9
12	CD40	crosslinked	11
13	on	CD40	12
14	the	surface	16
15	cell	surface	16
16	surface	CD40	12
17	but	crosslinked	11
18	did	crosslinked	11
19	not	did	18
20	crosslink	CD40-Ig	21
21	CD40-Ig	did	18
22	in	CD40-Ig	21
23	solution	.	24
24	.	in	22

0	We	report	2
1	also	report	2
2	report	<ROOT>	-1
3	that	report	2
4	the	virus	8
5	human	virus	8
6	T-cell	leukemia	7
7	leukemia	virus	8
8	virus	type	9
9	type	that	3
10	1	type	9
11	(	HTLV-1	12
12	HTLV-1	1	10
13	)	HTLV-1	12
14	-derived	Tax	15
15	Tax	type	9
16	trans-activator	Tax	15
17	induces	that	3
18	NF-kappaB	activity	19
19	activity	that	3
20	in	that	3
21	1.3E2	in	20
22	,	1.3E2	21
23	suggesting	1.3E2	21
24	that	suggesting	23
25	this	protein	27
26	viral	protein	27
27	protein	does	28
28	does	that	24
29	not	does	28
30	operate	does	28
31	via	operate	30
32	the	pathway	34
33	defective	pathway	34
34	pathway	via	31
35	.	report	2

0	Nuclear	B	2
1	factor-kappa	B	2
2	B	is	7
3	(	NF-kappa	4
4	NF-kappa	B	2
5	B	NF-kappa	4
6	)	NF-kappa	4
7	is	<ROOT>	-1
8	a	factor	10
9	transcription	factor	10
10	factor	is	7
11	that	binds	12
12	binds	factor	10
13	to	binds	12
14	the	sequence	17
15	consensus	sequence	17
16	DNA	sequence	17
17	sequence	to	13
18	in	cis-acting	20
19	the	cis-acting	20
20	cis-acting	binds	12
21	elements	is	7
22	of	elements	21
23	various	genes	24
24	genes	of	22
25	.	is	7

0	Considering	<ROOT>	-1
1	the	abovesaid	2
2	abovesaid	Considering	0
3	as	Considering	0
4	well	Considering	0
5	as	Considering	0
6	the	ability	8
7	lymphocyte	ability	8
8	ability	as	5
9	to	ability	8
10	perform	to	9
11	the	function	13
12	dual	function	13
13	function	perform	10
14	of	function	13
15	immunocytes	of	14
16	and	immunocytes	15
17	hormonocytes	and	16
18	,	Considering	0
19	it	is	20
20	is	Considering	0
21	suggested	is	20
22	that	suggested	21
23	the	results	24
24	results	may	25
25	may	that	22
26	be	may	25
27	used	be	26
28	in	used	27
29	both	study	31
30	the	study	31
31	study	in	28
32	of	study	31
33	lymphocyte	infiltration	34
34	infiltration	of	32
35	and	infiltration	34
36	research	in	28
37	in	research	36
38	means	that	22
39	of	its	40
40	its	means	38
41	control	Considering	0
42	.	Considering	0

0	Predicted	sequence	2
1	peptide	sequence	2
2	sequence	<ROOT>	-1
3	of	sequence	2
4	ORF2	a	6
5	contained	ORF2	4
6	a	of	3
7	zinc	which	10
8	finger	which	10
9	domain	which	10
10	which	a	6
11	showed	significant	12
12	significant	which	10
13	homology	to	14
14	to	sequence	2
15	GC	to	14
16	box	binding	17
17	binding	GC	15
18	proteins	binding	17
19	BTEB2	proteins	18
20	and	BTEB2	19
21	SP1	and	20
22	.	binding	17

0	These	findings	1
1	findings	show	2
2	show	to	18
3	that	healthy	4
4	healthy	virus	5
5	virus	show	2
6	carriers	maintain	7
7	maintain	show	2
8	a	maintain	7
9	high	a	8
10	frequency	high	9
11	of	T	14
12	BZLF1-specific	T	14
13	memory	T	14
14	T	frequency	10
15	cells	show	2
16	,	to	18
17	potentially	to	18
18	to	<ROOT>	-1
19	control	to	18
20	virus	spread	21
21	spread	to	18
22	from	infected	24
23	lytically	infected	24
24	infected	spread	21
25	cells	to	18
26	.	to	18

0	We	questioned	1
1	questioned	<ROOT>	-1
2	whether	questioned	1
3	these	differences	4
4	differences	might	5
5	might	whether	2
6	reflect	might	5
7	patterns	of	8
8	of	reflect	6
9	intracellular	transduction	11
10	signal	transduction	11
11	transduction	of	8
12	.	questioned	1

0	Differentiation	leads	2
1	generally	leads	2
2	leads	<ROOT>	-1
3	to	cycle	5
4	cell	cycle	5
5	cycle	leads	2
6	arrest	leads	2
7	.	leads	2

0	In	<ROOT>	-1
1	the	bone	3
2	adult	bone	3
3	bone	In	0
4	marrow	expression	8
5	,	found	7
6	we	found	7
7	found	marrow	4
8	expression	In	0
9	of	expression	8
10	runt	polypeptides	11
11	polypeptides	of	9
12	in	In	0
13	differentiating	in	12
14	myeloid	differentiating	13
15	cells	and	16
16	and	myeloid	14
17	in	B	18
18	B	differentiating	13
19	lymphocytes	In	0
20	.	In	0

0	Glucocorticoid	receptors	1
1	receptors	<ROOT>	-1
2	,	receptors	1
3	fibromyalgia	receptors	1
4	and	fibromyalgia	3
5	low	and	4
6	back	pain	7
7	pain	low	5
8	.	receptors	1

0	C/EBP	activates	1
1	activates	<ROOT>	-1
2	the	promoter	7
3	human	promoter	7
4	corticotropin-releasing	promoter	7
5	hormone	promoter	7
6	gene	promoter	7
7	promoter	activates	1
8	.	activates	1

0	One	is	8
1	of	One	0
2	the	advantages	4
3	potential	advantages	4
4	advantages	of	1
5	of	advantages	4
6	autologous	PBSCT	7
7	PBSCT	of	5
8	is	<ROOT>	-1
9	the	possibility	10
10	possibility	is	8
11	that	possibility	10
12	peripheral	blood	13
13	blood	that	11
14	stem	blood	13
15	cells	stem	14
16	(	blood	13
17	PBSC	is	8
18	)	is	8
19	are	is	8
20	less	likely	21
21	likely	are	19
22	to	likely	21
23	be	to	22
24	contaminated	be	23
25	by	contaminated	24
26	leukemic	cells	27
27	cells	by	25
28	than	contaminated	24
29	bone	be	23
30	marrow	grafts	31
31	grafts	bone	29
32	.	grafts	31

0	Precise	deletion	1
1	deletion	suggests	5
2	of	deletion	1
3	the	exons	4
4	exons	of	2
5	suggests	<ROOT>	-1
6	that	suggests	5
7	they	are	8
8	are	that	6
9	alternatively	are	8
10	spliced	alternatively	9
11	transcripts	.	12
12	.	spliced	10

0	LSF	also	2
1	(	LSF	0
2	also	known	3
3	known	<ROOT>	-1
4	as	known	3
5	LBP-1	as	4
6	,	LBP-1	5
7	UBP	LBP-1	5
8	,	UBP	7
9	and	UBP	7
10	CP-2	has	12
11	)	has	12
12	has	and	9
13	been	has	12
14	shown	been	13
15	to	LTR	17
16	repress	LTR	17
17	LTR	shown	14
18	transcription	in	19
19	in	LTR	17
20	vitro	LTR	17
21	,	known	3
22	but	known	3
23	transient	expression	24
24	expression	has	27
25	of	expression	24
26	LSF	of	25
27	has	but	22
28	no	effect	29
29	effect	LTR	31
30	on	LTR	31
31	LTR	has	27
32	activity	in	33
33	in	known	3
34	vivo	in	33
35	.	known	3

0	B-CLL	cells	1
1	cells	do	2
2	do	has	17
3	express	do	2
4	receptors	express	3
5	for	express	3
6	interferon-alpha	for	5
7	(	IFN-alpha	8
8	IFN-alpha	interferon-alpha	6
9	)	IFN-alpha	8
10	and	do	2
11	IFN-gamma	do	2
12	,	do	2
13	and	do	2
14	activation	and	13
15	of	and	13
16	both	of	15
17	has	<ROOT>	-1
18	been	has	17
19	shown	been	18
20	to	shown	19
21	promote	B-CLL	22
22	B-CLL	to	20
23	survival	to	20
24	in	survival	23
25	vitro	to	20
26	by	vitro	25
27	preventing	has	17
28	apoptosis	has	17
29	.	has	17

0	In	have	7
1	addition	In	0
2	,	have	7
3	aberrancies	in	4
4	in	have	7
5	NF-kappaB	in	4
6	activity	in	4
7	have	<ROOT>	-1
8	been	have	7
9	implicated	been	8
10	in	implicated	9
11	the	immunopathogenesis	12
12	immunopathogenesis	implicated	9
13	of	immunopathogenesis	12
14	diseases	of	13
15	involving	diseases	14
16	immune	involving	15
17	or	immune	16
18	inflammatory	or	17
19	processes	have	7
20	such	processes	19
21	as	and	23
22	atherosclerosis	and	23
23	and	such	20
24	HIV-1	infection	25
25	infection	and	23
26	.	have	7

0	The	ability	1
1	ability	is	19
2	of	ability	1
3	H2O2	of	2
4	or	H2O2	3
5	other	ROS	6
6	ROS	or	4
7	to	ability	1
8	induce	to	7
9	T	signals	11
10	cell	signals	11
11	signals	induce	8
12	and	ability	1
13	functional	responses	14
14	responses	and	12
15	by	ability	1
16	these	mechanisms	18
17	two	mechanisms	18
18	mechanisms	by	15
19	is	is	33
20	reviewed	is	19
21	and	reviewed	20
22	the	response	24
23	specific	response	24
24	response	and	21
25	of	response	24
26	NF-kappaB	of	25
27	to	response	24
28	redox	changes	29
29	changes	to	27
30	in	T	31
31	T	changes	29
32	cells	is	19
33	is	<ROOT>	-1
34	examined	is	33
35	.	is	33

0	PMA	MAPKS	10
1	,	PMA	0
2	but	PMA	0
3	not	Ara-C	4
4	Ara-C	but	2
5	or	Ara-C	4
6	ceramides	or	5
7	,	PMA	0
8	activated	MAPKS	10
9	ERK	MAPKS	10
10	MAPKS	<ROOT>	-1
11	,	MAPKS	10
12	in	MAPKS	10
13	Jurkat	in	12
14	and	in	12
15	EL4	in	12
16	.	MAPKS	10

0	The	presence	1
1	presence	suggests	24
2	of	presence	1
3	multiple	sites	6
4	potential	sites	6
5	binding	sites	6
6	sites	of	2
7	for	presence	1
8	MS-2	for	7
9	in	MS-2	8
10	the	in	9
11	promoter	regions	12
12	regions	the	10
13	of	regions	12
14	a	range	16
15	wide	range	16
16	range	of	13
17	of	range	16
18	genes	of	17
19	expressed	in	9
20	in	myeloid	22
21	mature	myeloid	22
22	myeloid	expressed	19
23	cells	presence	1
24	suggests	<ROOT>	-1
25	this	factor	26
26	factor	plays	27
27	plays	suggests	24
28	a	plays	27
29	general	differentiation	33
30	role	in	31
31	in	general	29
32	myeloid	in	31
33	differentiation	a	28
34	.	differentiation	33

0	After	was	6
1	ELISA	screening	2
2	screening	After	0
3	,	was	6
4	mAb	18C7	5
5	18C7	was	6
6	was	<ROOT>	-1
7	selected	was	6
8	for	selected	7
9	its	specificity	10
10	specificity	for	8
11	towards	specificity	10
12	the	HBD	13
13	HBD	towards	11
14	.	was	6

0	Leukotriene	B4	1
1	B4	produced	2
2	produced	and	7
3	by	produced	2
4	monocytes	produced	2
5	in	produced	2
6	vitro	and	7
7	and	receptor	10
8	soluble	and	7
9	interleukin-2	and	7
10	receptor	were	21
11	released	receptor	10
12	by	released	11
13	lymphocytes	receptor	10
14	in	receptor	10
15	vitro	receptor	10
16	and	receptor	10
17	cortisol	receptor	10
18	levels	receptor	10
19	in	receptor	10
20	plasma	receptor	10
21	were	<ROOT>	-1
22	determined	were	21
23	.	were	21

0	Electrophoretic	<ROOT>	-1
1	mobility	Electrophoretic	0
2	shift	mobility	1
3	assays	Electrophoretic	0
4	demonstrated	assays	3
5	a	demonstrated	4
6	strong	of	8
7	increase	of	8
8	of	a	5
9	NF-kappa	of	8
10	B	Electrophoretic	0
11	DNA	after	13
12	binding	DNA	11
13	after	Electrophoretic	0
14	triggering	after	13
15	of	HLA-DR	16
16	HLA-DR	triggering	14
17	antigens	Electrophoretic	0
18	.	Electrophoretic	0

0	When	transcriptionally	1
1	transcriptionally	promoter	11
2	active	transcriptionally	1
3	,	transcriptionally	1
4	the	,	3
5	human	the	4
6	immunodeficiency	human	5
7	virus	(	8
8	(	)	10
9	HIV	)	10
10	)	immunodeficiency	6
11	promoter	<ROOT>	-1
12	contains	promoter	11
13	a	contains	12
14	nucleosome-free	a	13
15	region	both	17
16	encompassing	both	17
17	both	nucleosome-free	14
18	the	nucleosome-free	14
19	promoter/enhancer	and	21
20	region	and	21
21	and	the	18
22	a	nucleosome-free	14
23	large	(	25
24	region	(	25
25	(	255	26
26	255	a	22
27	nucleotides	promoter	11
28	[	promoter	11
29	nt	promoter	11
30	]	)	31
31	)	nt	29
32	downstream	promoter	11
33	of	downstream	32
34	the	of	33
35	transcription	start	36
36	start	the	34
37	site	start	36
38	.	site	37

0	Rather	IFN-gamma	2
1	,	Rather	0
2	IFN-gamma	<ROOT>	-1
3	antagonized	IFN-gamma	2
4	the	effect	5
5	effect	antagonized	3
6	of	effect	5
7	IL-4	of	6
8	and	IFN-gamma	2
9	suppressed	and	8
10	the	DC	11
11	DC	formation	14
12	and	formation	14
13	MGC	and	12
14	formation	induced	15
15	induced	suppressed	9
16	by	induced	15
17	GM-CSF	by	16
18	+	GM-CSF	17
19	IL-4	GM-CSF	17
20	and	GM-CSF	17
21	M-CSF	IFN-gamma	2
22	+	M-CSF	21
23	IL-4	IFN-gamma	2
24	,	IFN-gamma	2
25	respectively	IFN-gamma	2
26	.	IFN-gamma	2

0	Lineage-	of	4
1	and	Lineage-	0
2	stage-specific	expression	3
3	expression	and	1
4	of	<ROOT>	-1
5	runt	box	6
6	box	of	4
7	polypeptides	of	4
8	in	polypeptides	7
9	primitive	in	8
10	and	primitive	9
11	definitive	hematopoiesis	12
12	hematopoiesis	and	10
13	.	of	4

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	a	lack	4
4	lack	indicate	2
5	of	lack	4
6	involvement	of	5
7	of	involvement	6
8	Jak	kinases	9
9	kinases	of	7
10	in	lack	4
11	signaling	in	10
12	by	in	10
13	the	G-CSFR	14
14	G-CSFR	by	12
15	in	lack	4
16	neutrophils	in	15
17	,	indicate	2
18	and	indicate	2
19	suggest	and	18
20	utilization	suggest	19
21	of	utilization	20
22	alternative	of	21
23	signal	alternative	22
24	transduction	pathways	25
25	pathways	distinct	26
26	distinct	signal	23
27	from	distinct	26
28	those	from	27
29	in	those	28
30	proliferating	cells	31
31	cells	in	29
32	.	cells	31

0	Another	death	1
1	death	domain-containing	2
2	domain-containing	member	3
3	member	was	16
4	of	member	3
5	the	family	7
6	TNFR	family	7
7	family	of	4
8	,	was	16
9	death	was	16
10	receptor	3	11
11	3	death	9
12	(	3	11
13	DR3	3	11
14	)	3	11
15	,	was	16
16	was	<ROOT>	-1
17	identified	was	16
18	and	was	16
19	was	and	18
20	shown	was	19
21	to	shown	20
22	induce	to	21
23	both	induce	22
24	apoptosis	both	23
25	and	apoptosis	24
26	activation	and	25
27	of	and	25
28	nuclear	of	27
29	factor	nuclear	28
30	kappaB	nuclear	28
31	.	kappaB	30

0	Molecular	cloning	1
1	cloning	cDNA	7
2	and	cloning	1
3	functional	characterization	4
4	characterization	and	2
5	of	murine	6
6	murine	cloning	1
7	cDNA	encoding	8
8	encoding	<ROOT>	-1
9	transcription	encoding	8
10	factor	transcription	9
11	NFATc	encoding	8
12	.	NFATc	11

0	Redox	regulation	1
1	regulation	of	2
2	of	<ROOT>	-1
3	the	mitogen-activated	4
4	mitogen-activated	protein	5
5	protein	of	2
6	kinase	of	2
7	pathway	kinase	6
8	during	lymphocyte	9
9	lymphocyte	pathway	7
10	activation	of	2
11	.	of	2

0	Our	results	1
1	results	support	2
2	support	<ROOT>	-1
3	the	model	4
4	model	proposing	5
5	proposing	support	2
6	that	proposing	5
7	the	domain	9
8	N-terminal	domain	9
9	domain	confers	10
10	confers	that	6
11	calcium-signaling	dependence	12
12	dependence	confers	10
13	on	transactivation	15
14	NFATx1	transactivation	15
15	transactivation	dependence	12
16	activity	support	2
17	by	support	2
18	regulating	by	17
19	its	localization	21
20	intracellular	localization	21
21	localization	regulating	18
22	through	regulating	18
23	a	module	25
24	protein	module	25
25	module	through	22
26	that	associates	27
27	associates	module	25
28	with	associates	27
29	calcineurin	associates	27
30	and	calcineurin	29
31	is	support	2
32	a	target	33
33	target	is	31
34	of	phosphatase	36
35	its	phosphatase	36
36	phosphatase	target	33
37	activity	phosphatase	36
38	.	support	2

0	To	was	13
1	investigate	To	0
2	the	mechanisms	4
3	molecular	mechanisms	4
4	mechanisms	investigate	1
5	of	mechanisms	4
6	RANTES	expression	7
7	expression	of	5
8	,	was	13
9	the	region	12
10	RANTES	region	12
11	promoter	region	12
12	region	was	13
13	was	<ROOT>	-1
14	analyzed	was	13
15	by	transient	16
16	transient	analyzed	14
17	expression	and	18
18	and	was	13
19	gel-mobility	was	13
20	shift	was	13
21	assays	was	13
22	.	was	13

0	In	investigated	7
1	the	work	3
2	present	work	3
3	work	In	0
4	,	investigated	7
5	we	investigated	7
6	have	investigated	7
7	investigated	Tax	14
8	the	mechanism	9
9	mechanism	investigated	7
10	(	mechanism	9
11	s	mechanism	9
12	)	mechanism	9
13	whereby	Tax	14
14	Tax	transactivates	15
15	transactivates	<ROOT>	-1
16	the	proto-oncogene	18
17	c-sis/PDGF-B	proto-oncogene	18
18	proto-oncogene	transactivates	15
19	.	transactivates	15

0	However	was	16
1	,	However	0
2	stimulation	,	1
3	of	stimulation	2
4	B-cells	of	3
5	from	B-CLL	6
6	B-CLL	of	3
7	patients	However	0
8	under	patients	7
9	conditions	which	10
10	which	under	8
11	induced	which	10
12	differentiation	into	13
13	into	which	10
14	plasma	However	0
15	cells	However	0
16	was	<ROOT>	-1
17	associated	was	16
18	with	associated	17
19	induction	with	18
20	of	induction	19
21	Bcd	of	20
22	gene	Bcd	21
23	expression	.	24
24	.	gene	22

0	Because	is	30
1	transgene	expression	2
2	expression	was	3
3	was	Because	0
4	regulated	was	3
5	by	regulated	4
6	the	promoter	8
7	proximal	promoter	8
8	promoter	by	5
9	of	promoter	8
10	the	gene	13
11	murine	gene	13
12	lck	gene	13
13	gene	of	9
14	and	this	15
15	this	Because	0
16	promoter	Because	0
17	is	promoter	16
18	inactivated	is	17
19	in	T	20
20	T	inactivated	18
21	cells	Because	0
22	that	Because	0
23	exit	the	24
24	the	Because	0
25	thymus	Because	0
26	,	mutant	28
27	the	mutant	28
28	mutant	is	30
29	hCaMKIV	mutant	28
30	is	<ROOT>	-1
31	not	is	30
32	present	is	30
33	in	present	32
34	peripheral	cells	36
35	T	cells	36
36	cells	in	33
37	.	cells	36

0	The	protein	2
1	Tax	protein	2
2	protein	is	8
3	,	protein	2
4	encoded	protein	2
5	by	encoded	4
6	HTLV-I	by	5
7	,	protein	2
8	is	<ROOT>	-1
9	a	activator	12
10	potent	activator	12
11	transcription	activator	12
12	activator	is	8
13	of	activator	12
14	viral	of	13
15	and	of	13
16	several	genes	18
17	cellular	genes	18
18	genes	and	15
19	.	is	8

0	In	<ROOT>	-1
1	the	study	3
2	present	study	3
3	study	In	0
4	,	In	0
5	we	,	4
6	investigated	we	5
7	whether	investigated	6
8	aberrancies	whether	7
9	in	the	10
10	the	aberrancies	8
11	regulation	the	15
12	of	regulation	11
13	c-fos/c-jun	of	12
14	at	the	15
15	the	the	10
16	mRNA	or	17
17	or	the	15
18	protein	In	0
19	level	In	0
20	might	In	0
21	underlie	might	20
22	the	underlie	21
23	age-associated	the	22
24	impairments	age-associated	23
25	of	impairments	24
26	AP-1	of	25
27	in	human	28
28	human	age-associated	23
29	T	cells	30
30	cells	human	28
31	.	cells	30

0	We	is	11
1	postulated	We	0
2	that	postulated	1
3	the	that	2
4	oncogenic	of	6
5	effect	of	6
6	of	the	3
7	RBTN-2	of	6
8	in	RBTN-2	7
9	T	of	6
10	cells	We	0
11	is	mediated	13
12	likely	mediated	13
13	mediated	(	17
14	by	mediated	13
15	binding	protein	16
16	protein	(	17
17	(	<ROOT>	-1
18	s	(	17
19	)	(	17
20	with	(	17
21	T	(	17
22	cell-specific	(	17
23	expression	(	17
24	.	(	17

0	Finally	was	3
1	,	was	3
2	it	was	3
3	was	<ROOT>	-1
4	observed	was	3
5	that	observed	4
6	the	rate	7
7	rate	D	15
8	of	rate	7
9	decay	of	8
10	of	decay	9
11	vimentin	mRNA	12
12	mRNA	of	10
13	upon	rate	7
14	actinomycin	D	15
15	D	that	5
16	administration	was	17
17	was	D	15
18	decreased	was	17
19	in	was	17
20	heat-	in	19
21	and	heat-	20
22	cadmium-pretreated	and	21
23	cells	in	24
24	in	and	21
25	comparison	was	3
26	to	comparison	25
27	untreated	to	26
28	cells	untreated	27
29	.	was	3

0	Finally	course	3
1	,	time	2
2	time	course	3
3	course	<ROOT>	-1
4	analysis	course	3
5	of	Egr-1	6
6	Egr-1	analysis	4
7	expression	course	3
8	during	expression	7
9	the	steps	11
10	early	steps	11
11	steps	during	8
12	of	steps	11
13	EBV	of	12
14	infection	EBV	13
15	in	demonstrated	17
16	vitro	in	15
17	demonstrated	steps	11
18	that	demonstrated	17
19	Egr-1	is	20
20	is	that	18
21	upregulated	is	20
22	within	upregulated	21
23	minutes	within	22
24	from	initial	26
25	the	initial	26
26	initial	within	22
27	interaction	initial	26
28	with	interaction	27
29	the	with	28
30	B	the	29
31	lymphocyte	B	30
32	.	lymphocyte	31

0	NF-X2	interacts	13
1	,	NF-X2	0
2	which	contains	3
3	contains	NF-X2	0
4	members	contains	3
5	of	members	4
6	the	families	8
7	AP-1/ATF/CREB	families	8
8	families	of	5
9	of	families	8
10	transcription	factors	11
11	factors	of	9
12	,	NF-X2	0
13	interacts	<ROOT>	-1
14	with	interacts	13
15	the	5'-TGCGTCA-3'	19
16	X2	(	18
17	box	(	18
18	(	the	15
19	5'-TGCGTCA-3'	with	14
20	)	5'-TGCGTCA-3'	19
21	from	5'-TGCGTCA-3'	19
22	positions	from	21
23	-97	from	21
24	to	from	21
25	-91	to	24
26	in	DRA	28
27	the	DRA	28
28	DRA	-91	25
29	promoter	interacts	13
30	.	interacts	13

0	In	appears	4
1	contrast	In	0
2	,	appears	4
3	CREB	appears	4
4	appears	<ROOT>	-1
5	to	appears	4
6	dampen	transcription	7
7	transcription	to	5
8	from	this	9
9	this	appears	4
10	element	appears	4
11	.	appears	4

0	Tissue	transglutaminase-dependent	1
1	transglutaminase-dependent	<ROOT>	-1
2	posttranslational	transglutaminase-dependent	1
3	modification	posttranslational	2
4	of	modification	3
5	the	product	8
6	retinoblastoma	product	8
7	gene	product	8
8	product	of	4
9	in	promonocytic	10
10	promonocytic	modification	3
11	cells	transglutaminase-dependent	1
12	undergoing	transglutaminase-dependent	1
13	apoptosis	transglutaminase-dependent	1
14	.	transglutaminase-dependent	1

0	METHODS	cell	7
1	:	METHODS	0
2	THP-1	,	4
3	cells	,	4
4	,	cell	7
5	a	,	4
6	monocytic	cell	7
7	cell	were	10
8	line	cell	7
9	,	cell	7
10	were	<ROOT>	-1
11	transfected	were	10
12	with	transfected	11
13	the	genes	16
14	CMV	genes	16
15	IE	genes	16
16	genes	with	12
17	.	were	10

0	This	presents	1
1	presents	<ROOT>	-1
2	several	problems	3
3	problems	presents	1
4	in	problems	3
5	vectors	in	4
6	,	vectors	5
7	particularly	those	8
8	those	vectors	5
9	in	those	8
10	which	in	9
11	additional	which	10
12	genes	,	13
13	,	which	10
14	either	,	13
15	a	which	10
16	co-stimulatory	a	15
17	gene	co-stimulatory	16
18	or	gene	17
19	a	or	18
20	selectable	,	22
21	marker	,	22
22	,	a	19
23	are	a	19
24	inserted	are	23
25	.	presents	1

0	A	temperature	2
1	low	temperature	2
2	temperature	<ROOT>	-1
3	(	degrees	5
4	26	degrees	5
5	degrees	temperature	2
6	C	degrees	5
7	)	C	6
8	increased	binding	10
9	the	binding	10
10	binding	C	6
11	both	degrees	5
12	in	temperature	2
13	HLA-A3	in	12
14	and	HLA-A3	13
15	HLA-Cw*0702	temperature	2
16	,	temperature	2
17	while	temperature	2
18	FCS	reduced	19
19	reduced	while	17
20	it	reduced	19
21	.	temperature	2

0	As	is	11
1	a	consequence	2
2	consequence	As	0
3	,	is	11
4	the	response	6
5	immune	response	6
6	response	is	11
7	developed	response	6
8	in	developed	7
9	senescent	organisms	10
10	organisms	in	8
11	is	<ROOT>	-1
12	usually	is	11
13	inappropriate	is	11
14	,	is	11
15	often	inefficient	16
16	inefficient	is	11
17	,	is	11
18	sometimes	is	11
19	aberrant	is	11
20	,	is	11
21	and	is	11
22	potentially	detrimental	23
23	detrimental	and	21
24	.	is	11

0	The	expression	1
1	expression	was	6
2	of	expression	1
3	these	proteins	5
4	two	proteins	5
5	proteins	of	2
6	was	<ROOT>	-1
7	not	was	6
8	related	was	6
9	to	related	8
10	clinical	or	11
11	or	to	9
12	laboratory	or	11
13	data	was	6
14	.	was	6

0	Double-stimulation	was	1
1	was	myristate	18
2	used	was	1
3	to	used	2
4	demonstrate	that	5
5	that	to	3
6	,	was	1
7	in	was	1
8	a	in	7
9	T	CEM	14
10	lymphocytic	T	9
11	cell	(	13
12	line	(	13
13	(	lymphocytic	10
14	CEM	a	8
15	)	CEM	14
16	,	was	1
17	phorbol	myristate	18
18	myristate	<ROOT>	-1
19	acetate	(	20
20	(	myristate	18
21	PMA	(	20
22	)	rapidly	23
23	rapidly	PMA	21
24	induced	myristate	18
25	NF-kappa	myristate	18
26	B	through	27
27	through	myristate	18
28	a	pathway	30
29	signaling	pathway	30
30	pathway	myristate	18
31	which	pathway	30
32	did	not	33
33	not	pathway	30
34	involve	not	33
35	reactive	myristate	18
36	oxygen	species	37
37	species	myristate	18
38	(	ROS	39
39	ROS	species	37
40	)	ROS	39
41	and	species	37
42	was	and	41
43	different	was	42
44	from	was	42
45	the	from	44
46	activation	triggered	47
47	triggered	the	45
48	by	triggered	47
49	either	H2O2	50
50	H2O2	by	48
51	or	H2O2	50
52	tumor	necrosis	53
53	necrosis	factor-alpha	54
54	factor-alpha	or	51
55	(	factor-alpha	54
56	TNF-alpha	factor-alpha	54
57	)	factor-alpha	54
58	.	myristate	18

0	This	research	1
1	research	may	2
2	may	<ROOT>	-1
3	make	may	2
4	feasible	make	3
5	manipulation	make	3
6	of	make	3
7	growth	make	3
8	and	make	3
9	differentiation	and	8
10	of	and	8
11	mammalian	,	13
12	cells	,	13
13	,	of	10
14	which	would	17
15	in	would	17
16	turn	in	15
17	would	may	2
18	have	profound	19
19	profound	would	17
20	implication	profound	19
21	in	biomedical	22
22	biomedical	profound	19
23	research	may	2
24	on	cell	25
25	cell	research	23
26	and	cell	25
27	gene	may	2
28	therapy	gene	27
29	,	gene	27
30	and	gene	27
31	development	and	30
32	of	gene	27
33	pharmaceutical	products	34
34	products	of	32
35	.	may	2

0	A	molecular	1
1	molecular	of	5
2	basis	for	3
3	for	molecular	1
4	induction	of	5
5	of	<ROOT>	-1
6	antibodies	of	5
7	to	antibodies	6
8	DNA	eukaryotic	10
9	and	eukaryotic	10
10	eukaryotic	to	7
11	transcription	of	5
12	factors	of	5
13	.	of	5

0	The	effect	1
1	effect	is	5
2	of	effect	1
3	the	steroid	4
4	steroid	of	2
5	is	<ROOT>	-1
6	mediated	is	5
7	by	mediated	6
8	its	binding	9
9	binding	to	10
10	to	by	7
11	corticosteroid	to	10
12	receptors	is	5
13	.	is	5

0	Here	summarize	2
1	we	summarize	2
2	summarize	<ROOT>	-1
3	the	importance	4
4	importance	summarize	2
5	of	importance	4
6	the	3'LCR	8
7	IgH	3'LCR	8
8	3'LCR	of	5
9	and	3'LCR	8
10	its	role	13
11	putative	role	13
12	functional	role	13
13	role	and	9
14	in	role	13
15	IgH	expression	17
16	gene	expression	17
17	expression	in	14
18	and	summarize	2
19	compare	and	18
20	it	compare	19
21	with	compare	19
22	the	with	21
23	5'LCR	the	22
24	regulatory	5'LCR	23
25	region	regulatory	24
26	of	region	25
27	the	of	26
28	human	.	31
29	beta-globin	.	31
30	locus	.	31
31	.	the	27

0	Several	molecules	2
1	small	molecules	2
2	molecules	antisense	5
3	,	molecules	2
4	an	molecules	2
5	antisense	<ROOT>	-1
6	oligonucleotide	,	7
7	,	antisense	5
8	and	,	7
9	gene	agents	11
10	therapeutic	agents	11
11	agents	antisense	5
12	that	agents	11
13	inhibit	b	15
14	NF-kappa	b	15
15	b	have	17
16	activation	b	15
17	have	that	12
18	been	have	17
19	described	been	18
20	.	antisense	5

0	Thus	<ROOT>	-1
1	,	Thus	0
2	C.	neoformans	3
3	neoformans	,	1
4	and	neoformans	3
5	C.	albicans	6
6	albicans	and	4
7	enhance	neoformans	3
8	HIV	expression	9
9	expression	enhance	7
10	in	monocytic	11
11	monocytic	expression	9
12	cells	through	13
13	through	Thus	0
14	a	TNF-alpha-	15
15	TNF-alpha-	through	13
16	and	Thus	0
17	NF-kappaB-dependent	mechanism	18
18	mechanism	Thus	0
19	.	Thus	0

0	These	findings	1
1	findings	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	TPO	that	3
5	has	direct	7
6	a	direct	7
7	direct	TPO	4
8	effect	direct	7
9	on	effect	8
10	hemoglobinization	on	9
11	via	effect	8
12	a	receptor	14
13	specific	receptor	14
14	receptor	via	11
15	on	receptor	14
16	UT-7/GMT	cells	17
17	cells	on	15
18	.	cells	17

0	Electrophoretic	(	4
1	mobility	Electrophoretic	0
2	shift	mobility	1
3	assays	(	4
4	(	<ROOT>	-1
5	EMSA	(	4
6	)	(	4
7	with	(	4
8	a	derived	11
9	43-mer	derived	11
10	oligonucleotide	derived	11
11	derived	revealed	18
12	from	derived	11
13	the	functionally	14
14	functionally	from	12
15	identified	functionally	14
16	cis-acting	element	17
17	element	functionally	14
18	revealed	with	7
19	specific	revealed	18
20	complexes	revealed	18
21	.	(	4

0	Conversely	IL-13	4
1	,	Conversely	0
2	IL-4	Conversely	0
3	and	IL-4	2
4	IL-13	<ROOT>	-1
5	markedly	IL-13	4
6	and	markedly	5
7	significantly	inhibited	8
8	inhibited	IL-13	4
9	HIV	inhibited	8
10	replication	level	14
11	at	transcriptional	13
12	the	transcriptional	13
13	transcriptional	level	14
14	level	HIV	9
15	in	IL-13	4
16	monocyte-derived	in	15
17	macrophages	monocyte-derived	16
18	,	IL-13	4
19	and	IL-13	4
20	this	occurred	21
21	occurred	and	19
22	whether	occurred	21
23	these	cytokines	24
24	cytokines	were	25
25	were	whether	22
26	added	after	29
27	before	added	26
28	or	added	26
29	after	were	25
30	HIV	were	25
31	infection	HIV	30
32	.	infection	31

0	To	<ROOT>	-1
1	elucidate	To	0
2	the	contributions	3
3	contributions	elucidate	1
4	of	contributions	3
5	GATA-1	of	4
6	to	definitive	7
7	definitive	elucidate	1
8	hematopoiesis	definitive	7
9	in	hematopoiesis	8
10	vivo	To	0
11	,	To	0
12	we	,	11
13	have	adult	15
14	examined	adult	15
15	adult	we	12
16	mice	adult	15
17	that	were	18
18	were	mice	16
19	rendered	genetically	20
20	genetically	were	18
21	defective	genetically	20
22	in	GATA-1	23
23	GATA-1	defective	21
24	synthesis	defective	21
25	(	defective	21
26	Takahashi	To	0
27	et	To	0
28	al	To	0
29	,	To	0
30	J	To	0
31	Biol	J	30
32	Chem	Biol	31
33	272	Chem	32
34	:	272	33
35	12611	,	36
36	,	272	33
37	1997	,	36
38	)	1997	37
39	.	)	38

0	Quantification	<ROOT>	-1
1	of	Quantification	0
2	vitamin	receptor	4
3	D	receptor	4
4	receptor	mRNA	5
5	mRNA	of	1
6	by	of	1
7	competitive	reaction	10
8	polymerase	reaction	10
9	chain	reaction	10
10	reaction	of	1
11	in	reaction	10
12	PBMC	in	11
13	:	reaction	10
14	lack	reaction	10
15	of	lack	14
16	correspondence	of	15
17	with	correspondence	16
18	common	variants	20
19	allelic	variants	20
20	variants	with	17
21	.	Quantification	0

0	Three	3rd	1
1	3rd	also	6
2	base	3rd	1
3	substitution	were	5
4	polymorphisms	were	5
5	were	base	2
6	also	<ROOT>	-1
7	detected	also	6
8	during	also	6
9	direct	during	8
10	sequencing	of	11
11	of	direct	9
12	PCR	of	11
13	products	.	14
14	.	PCR	12

0	Both	<ROOT>	-1
1	the	Both	0
2	preleukemic	the	1
3	state	preleukemic	2
4	and	state	3
5	the	leukemia	6
6	leukemia	could	7
7	could	and	4
8	be	could	7
9	transplanted	be	8
10	to	transplanted	9
11	nontransgenic	mice	12
12	mice	to	10
13	,	mice	12
14	and	mice	12
15	the	and	14
16	transplanted	could	18
17	preleukemia	could	18
18	could	the	15
19	progress	could	18
20	to	progress	19
21	APL	to	20
22	.	APL	21

0	In	<ROOT>	-1
1	particular	In	0
2	,	In	0
3	the	,	2
4	prolactin-inducible	the	3
5	interferon	prolactin-inducible	4
6	regulatory	factor-1	7
7	factor-1	interferon	5
8	gene	factor-1	7
9	and	gene	8
10	its	and	9
11	roles	its	10
12	in	roles	11
13	mediating	responses	16
14	diverse	responses	16
15	immune	responses	16
16	responses	in	12
17	.	interferon	5

0	We	describe	1
1	describe	<ROOT>	-1
2	here	describe	1
3	a	complex	6
4	heterodimeric	complex	6
5	binding	complex	6
6	complex	describe	1
7	of	(	10
8	NF-kappaB	subunits	9
9	subunits	of	7
10	(	complex	6
11	c-Rel	(	10
12	and	c-Rel	11
13	p65	describe	1
14	)	describe	1
15	which	)	14
16	is	identical	17
17	identical	which	15
18	to	identical	17
19	the	to	18
20	one	the	19
21	obtained	one	20
22	using	obtained	21
23	the	using	22
24	HIV-LTR-kappaB	the	23
25	site	recognition	27
26	as	recognition	27
27	recognition	HIV-LTR-kappaB	24
28	sequence	the	23
29	and	describe	1
30	different	from	31
31	from	describe	1
32	the	one	33
33	one	from	31
34	(	one	33
35	c-Rel	and	36
36	and	(	34
37	p50	and	36
38	)	p50	37
39	observed	with	40
40	with	from	31
41	nuclear	extracts	42
42	extracts	from	31
43	from	from	31
44	Mo	from	31
45	T-lymphoid	from	31
46	HTLV-II	describe	1
47	infected	describe	1
48	cells	describe	1
49	.	describe	1

0	The	Rh	1
1	Rh	:	2
2	:	<ROOT>	-1
3	33	cells	4
4	cells	:	2
5	behaved	(	9
6	as	(	9
7	normal	Rh	8
8	Rh	(	9
9	(	cells	4
10	D	:	2
11	)	:	2
12	positive	:	2
13	cells	positive	12
14	.	cells	13

0	In	determinant	9
1	several	cases	2
2	cases	In	0
3	,	determinant	9
4	the	epitope	6
5	peptide	epitope	6
6	epitope	determinant	9
7	and	epitope	6
8	HLA-restricting	and	7
9	determinant	<ROOT>	-1
10	recognized	has	14
11	by	recognized	10
12	these	CTLs	13
13	CTLs	by	11
14	has	determinant	9
15	been	has	14
16	defined	been	15
17	,	determinant	9
18	one	feature	20
19	unusual	feature	20
20	feature	determinant	9
21	being	determinant	9
22	the	number	23
23	number	being	21
24	of	responses	25
25	responses	number	23
26	restricted	responses	25
27	through	restricted	26
28	HLA-C	alleles	29
29	alleles	through	27
30	.	determinant	9

0	Surface	expression	1
1	expression	<ROOT>	-1
2	of	expression	1
3	ICAM-1	of	2
4	,	expression	1
5	P-selectin	,	4
6	,	P-selectin	5
7	and	,	6
8	E-selectin	,	6
9	on	P-selectin	5
10	HUVECs	on	9
11	correlated	P-selectin	5
12	with	correlated	11
13	the	phase-1	14
14	phase-1	with	12
15	and	adhesion	18
16	-2	adhesion	18
17	neutrophil	adhesion	18
18	adhesion	phase-1	14
19	responses	expression	1
20	.	expression	1

0	Glucocorticoids	have	4
1	(	GC	2
2	GC	Glucocorticoids	0
3	)	GC	2
4	have	<ROOT>	-1
5	long	have	4
6	been	have	4
7	used	been	6
8	as	used	7
9	the	agents	12
10	most	effective	11
11	effective	agents	12
12	agents	as	8
13	for	agents	12
14	the	treatment	15
15	treatment	for	13
16	of	treatment	15
17	allergic	diseases	18
18	diseases	of	16
19	accompanied	of	16
20	by	accompanied	19
21	eosinophilia	such	22
22	such	by	20
23	as	chronic	24
24	chronic	such	22
25	asthma	chronic	24
26	and	asthma	25
27	atopic	asthma	25
28	dermatitis	atopic	27
29	.	have	4

0	At	in	3
1	variance	At	0
2	,	in	3
3	in	was	13
4	PAEC	incubated	5
5	incubated	in	3
6	with	the	7
7	the	incubated	5
8	homologous	B	12
9	serum	B	12
10	,	NF-kappa	11
11	NF-kappa	B	12
12	B	the	7
13	was	<ROOT>	-1
14	strictly	localized	15
15	localized	was	13
16	in	localized	15
17	the	cytoplasm	19
18	cell	cytoplasm	19
19	cytoplasm	in	16
20	.	was	13

0	Both	have	1
1	have	<ROOT>	-1
2	been	have	1
3	shown	been	2
4	to	shown	3
5	be	to	4
6	transcription	factors	7
7	factors	be	5
8	.	have	1

0	Receptor	characteristics	1
1	characteristics	cells	6
2	of	characteristics	1
3	peripheral	mononuclear	5
4	blood	mononuclear	5
5	mononuclear	of	2
6	cells	were	7
7	were	<ROOT>	-1
8	evaluated	were	7
9	by	evaluated	8
10	-LSB-3H-RSB-dexamethasone	binding	11
11	binding	by	9
12	.	were	7

0	In	<ROOT>	-1
1	sharp	contrast	2
2	contrast	In	0
3	,	In	0
4	in	,	3
5	B	cells	6
6	cells	treated	7
7	treated	in	4
8	with	phorbol	10
9	the	phorbol	10
10	phorbol	treated	7
11	ester	In	0
12	12-O-tetradecanoylphorbol-13-acetate	strong	17
13	(	TPA	14
14	TPA	12-O-tetradecanoylphorbol-13-acetate	12
15	)	TPA	14
16	,	TPA	14
17	strong	ester	11
18	interactions	the	20
19	between	the	20
20	the	In	0
21	X2	the	20
22	box	X2	21
23	and	X2	21
24	NF-X2	and	23
25	containing	In	0
26	c-Fos	In	0
27	were	observed	28
28	observed	c-Fos	26
29	.	In	0

0	Rapid	was	7
1	and	Rapid	0
2	strong	activity	6
3	induction	of	4
4	of	activity	6
5	promoter	activity	6
6	activity	and	1
7	was	<ROOT>	-1
8	lost	in	9
9	in	was	7
10	constructs	was	7
11	with	constructs	10
12	a	element	15
13	mutant	AP-1	14
14	AP-1	element	15
15	element	with	11
16	;	was	7
17	however	was	7
18	,	was	7
19	at	collagenase-1	26
20	16-96	h	21
21	h	at	19
22	post-PMA	h	21
23	,	post-PMA	22
24	the	collagenase-1	26
25	mutant	collagenase-1	26
26	collagenase-1	was	7
27	promoter	displayed	28
28	displayed	was	7
29	AP-1	independent	30
30	independent	was	7
31	PMA-mediated	transactivation	32
32	transactivation	was	7
33	.	was	7

0	Since	in	13
1	APL	cells	2
2	cells	do	3
3	do	Since	0
4	not	do	3
5	express	do	3
6	HLA	molecules	9
7	class	molecules	9
8	II	molecules	9
9	molecules	express	5
10	,	in	13
11	we	in	13
12	tested	in	13
13	in	<ROOT>	-1
14	two	in	13
15	donors	(	16
16	(	two	14
17	D.E.	(	16
18	and	D.E.	17
19	C.H.R.	and	18
20	)	C.H.R.	19
21	and	)	20
22	in	)	20
23	patients	in	13
24	S.R.	in	13
25	and	S.R.	24
26	P.G.	would	36
27	whether	P.G.	26
28	the	use	29
29	use	P.G.	26
30	of	(	33
31	9-mer	peptides	32
32	peptides	of	30
33	(	use	29
34	BCR1/9	(	33
35	)	P.G.	26
36	would	and	25
37	generate	I-restricted	41
38	a	I-restricted	41
39	CD8/HLA	I-restricted	41
40	class	I-restricted	41
41	I-restricted	response	42
42	response	would	36
43	.	in	13

0	We	show	1
1	show	<ROOT>	-1
2	that	show	1
3	the	inactivation	4
4	inactivation	was	8
5	of	inactivation	4
6	the	inhibition	7
7	inhibition	of	5
8	was	calcium-calmodulin-dependent	17
9	dependent	was	8
10	on	dependent	9
11	the	activity	12
12	activity	on	10
13	of	activity	12
14	calcineurin	of	13
15	,	calcium-calmodulin-dependent	17
16	a	calcium-calmodulin-dependent	17
17	calcium-calmodulin-dependent	that	2
18	phosphatase	calcium-calmodulin-dependent	17
19	.	show	1

0	The	control	1
1	control	cell	3
2	of	cell	3
3	cell	cell	16
4	survival	cell	3
5	and	cell	6
6	cell	cell	3
7	death	cell	3
8	is	cell	3
9	of	is	8
10	central	importance	11
11	importance	of	9
12	in	importance	11
13	tissues	cell	3
14	with	cell	16
15	high	cell	16
16	cell	<ROOT>	-1
17	turnover	cell	16
18	such	cell	16
19	as	lymphoid	21
20	the	lymphoid	21
21	lymphoid	cell	16
22	system	cell	16
23	.	cell	16

0	H1-agonists	<ROOT>	-1
1	(	histamine	2
2	histamine	caused	6
3	and	histamine	2
4	2-methylhistamine	histamine	2
5	)	histamine	2
6	caused	H1-agonists	0
7	a	rise	9
8	transient	rise	9
9	rise	caused	6
10	of	rise	9
11	-LSB-Ca2+-RSB-	of	10
12	,	-LSB-Ca2+-RSB-	11
13	and	-LSB-Ca2+-RSB-	11
14	H1-antagonists	and	13
15	(	H1-antagonists	14
16	pyrilamine	(	15
17	and	pyrilamine	16
18	doxepin	and	17
19	)	doxepin	18
20	inhibited	)	19
21	the	more	25
22	histamine-induced	more	25
23	-LSB-Ca2+-RSB-i	more	25
24	rise	more	25
25	more	doxepin	18
26	potently	than	27
27	than	and	17
28	the	H2-antagonist	29
29	H2-antagonist	than	27
30	(	H2-antagonist	29
31	cimetidine	H2-antagonist	29
32	)	cimetidine	31
33	on	)	32
34	the	H3-antagonist	35
35	H3-antagonist	on	33
36	(	than	27
37	impromidine	)	38
38	)	-LSB-Ca2+-RSB-	11
39	.	)	38

0	Transcription	is	1
1	is	<ROOT>	-1
2	initiated	is	1
3	at	initiated	2
4	one	site	6
5	major	site	6
6	site	at	3
7	.	is	1

0	To	clarify	2
1	further	To	0
2	clarify	transcriptional	5
3	the	transcriptional	5
4	complex	transcriptional	5
5	transcriptional	extensively	15
6	regulation	of	7
7	of	GM-CSF	10
8	the	GM-CSF	10
9	human	GM-CSF	10
10	GM-CSF	transcriptional	5
11	gene	transcriptional	5
12	,	which	13
13	which	transcriptional	5
14	was	which	13
15	extensively	constitutively	47
16	investigated	extensively	15
17	in	activated	18
18	activated	investigated	16
19	T	,	21
20	cells	,	21
21	,	activated	18
22	we	activated	18
23	have	studied	24
24	studied	we	22
25	the	studied	24
26	role	of	27
27	of	the	25
28	an	NF-kappaB	30
29	upstream	NF-kappaB	30
30	NF-kappaB	of	27
31	like	of	27
32	site	cell	37
33	in	cell	37
34	the	cell	37
35	5637	cell	37
36	non-lymphoid	cell	37
37	cell	like	31
38	line	extensively	15
39	,	extensively	15
40	which	extensively	15
41	derives	extensively	15
42	from	derives	41
43	a	carcinoma	45
44	bladder	carcinoma	45
45	carcinoma	from	42
46	and	extensively	15
47	constitutively	<ROOT>	-1
48	produces	constitutively	47
49	GM-CSF	constitutively	47
50	.	constitutively	47

0	Synthetic	glucocorticoids	1
1	glucocorticoids	vary	2
2	vary	<ROOT>	-1
3	in	(	11
4	their	affinity	6
5	binding	affinity	6
6	affinity	in	3
7	for	affinity	6
8	the	glucocorticoid	9
9	glucocorticoid	for	7
10	receptor	(	11
11	(	vary	2
12	GCR	vary	2
13	)	vary	2
14	.	vary	2

0	B	lymphocytes	1
1	lymphocytes	were	15
2	from	lymphocytes	1
3	the	blood	5
4	peripheral	blood	5
5	blood	from	2
6	of	blood	5
7	patients	of	6
8	with	patients	7
9	chronic	leukaemia	11
10	lymphocytic	leukaemia	11
11	leukaemia	with	8
12	(	CLL	13
13	CLL	leukaemia	11
14	)	CLL	13
15	were	DNA	22
16	analysed	DNA	22
17	for	DNA	22
18	the	presence	20
19	nuclear	presence	20
20	presence	for	17
21	and	DNA	22
22	DNA	<ROOT>	-1
23	binding	DNA	22
24	of	binding	23
25	a	panel	26
26	panel	of	24
27	of	panel	26
28	transcription	factors	29
29	factors	of	27
30	which	are	31
31	are	panel	26
32	involved	are	31
33	in	gene	35
34	the	gene	35
35	gene	involved	32
36	control	DNA	22
37	of	lymphoid	38
38	lymphoid	control	36
39	cells	DNA	22
40	.	DNA	22

0	Nuclear	up-regulates	4
1	factor-kappa	Nuclear	0
2	B	potently	3
3	potently	factor-kappa	1
4	up-regulates	<ROOT>	-1
5	the	up-regulates	4
6	promoter	of	8
7	activity	of	8
8	of	the	5
9	RANTES	HIV	15
10	,	HIV	15
11	a	chemokine	12
12	chemokine	HIV	15
13	that	blocks	14
14	blocks	HIV	15
15	HIV	of	8
16	infection	HIV	15
17	.	infection	16

0	Oxypurinol	<ROOT>	-1
1	and	Oxypurinol	0
2	catalase	phase-1	4
3	inhibited	catalase	2
4	phase-1	and	1
5	adhesion	,	6
6	,	phase-1	4
7	suggesting	phase-1	4
8	a	Oxypurinol	0
9	role	for	10
10	for	a	8
11	xanthine	for	10
12	oxidase	xanthine	11
13	and	oxidase	12
14	H2O2	and	13
15	.	Oxypurinol	0

0	The	plays	7
1	retinoblastoma	(	4
2	gene	(	4
3	product	(	4
4	(	The	0
5	pRB	The	0
6	)	The	0
7	plays	<ROOT>	-1
8	an	role	10
9	important	role	10
10	role	plays	7
11	in	plays	7
12	controlling	in	11
13	both	controlling	12
14	cell	both	13
15	release	cell	14
16	from	release	15
17	the	from	16
18	G1	the	17
19	phase	G1	18
20	and	phase	19
21	apoptosis	the	17
22	.	plays	7

0	In	summarize	5
1	this	review	2
2	review	In	0
3	,	summarize	5
4	we	summarize	5
5	summarize	<ROOT>	-1
6	the	state	8
7	current	state	8
8	state	summarize	5
9	of	state	8
10	knowledge	of	9
11	of	knowledge	10
12	the	mechanism	13
13	mechanism	of	11
14	of	mechanism	13
15	action	of	14
16	of	action	15
17	GCS	of	16
18	,	summarize	5
19	including	summarize	5
20	the	phenomenon	21
21	phenomenon	including	19
22	of	phenomenon	21
23	steroid-induced	rebound	24
24	rebound	of	22
25	,	phenomenon	21
26	which	ensues	27
27	ensues	phenomenon	21
28	upon	GCS	29
29	GCS	withdrawal	30
30	withdrawal	ensues	27
31	.	summarize	5

0	Production	requires	4
1	of	Production	0
2	functional	IL-12	3
3	IL-12	of	1
4	requires	<ROOT>	-1
5	the	expression	7
6	coordinated	expression	7
7	expression	requires	4
8	of	expression	7
9	both	genes	10
10	genes	of	8
11	.	requires	4

0	Our	<ROOT>	-1
1	data	Our	0
2	demonstrate	a	3
3	a	data	1
4	major	a	3
5	role	major	4
6	of	role	5
7	the	of	6
8	GASd/EBSd	in	10
9	element	in	10
10	in	the	7
11	IL-2R	regulation	13
12	alpha	IL-2R	11
13	regulation	in	10
14	and	regulation	13
15	suggest	and	14
16	that	suggest	15
17	the	that	16
18	T-cell-specific	can	21
19	Elf-1	factor	20
20	factor	can	21
21	can	the	17
22	serve	can	21
23	as	serve	22
24	a	as	23
25	transcriptional	.	27
26	repressor	.	27
27	.	a	24

0	Thus	is	13
1	,	NF-kappa	2
2	NF-kappa	Thus	0
3	B	Thus	0
4	,	is	13
5	a	activator	8
6	potent	activator	8
7	transcriptional	activator	8
8	activator	is	13
9	of	activator	8
10	HIV	expression	11
11	expression	of	9
12	,	activator	8
13	is	<ROOT>	-1
14	also	is	13
15	involved	is	13
16	in	involved	15
17	the	expression	18
18	expression	in	16
19	of	expression	18
20	RANTES	of	19
21	,	is	13
22	a	chemokine	23
23	chemokine	,	21
24	that	chemokine	23
25	blocks	that	24
26	infection	blocks	25
27	by	macrophage-tropic	28
28	macrophage-tropic	infection	26
29	strains	macrophage-tropic	28
30	of	strains	29
31	HIV	is	13
32	.	is	13

0	The	absence	1
1	absence	suggests	13
2	of	absence	1
3	slow	of	2
4	migrating	slow	3
5	forms	migrating	4
6	of	B	9
7	I	of	6
8	kappa	B	9
9	B	migrating	4
10	beta	slow	3
11	following	beta	10
12	stimulation	absence	1
13	suggests	<ROOT>	-1
14	that	suggests	13
15	the	phosphorylation	16
16	phosphorylation	does	17
17	does	that	14
18	not	does	17
19	necessarily	does	17
20	constitute	does	17
21	the	event	23
22	signal-induced	event	23
23	event	constitute	20
24	which	event	23
25	targets	the	26
26	the	which	24
27	molecule	suggests	13
28	for	suggests	13
29	proteolysis	suggests	13
30	.	suggests	13

0	Human	epsilon	2
1	C/EBP	epsilon	2
2	epsilon	is	3
3	is	<ROOT>	-1
4	a	is	3
5	newly	cloned	6
6	cloned	a	4
7	gene	for	9
8	coding	for	9
9	for	cloned	6
10	a	for	9
11	CCAAT/enhancer	that	14
12	binding	that	14
13	protein	that	14
14	that	may	15
15	may	a	10
16	be	may	15
17	involved	be	16
18	in	the	19
19	the	involved	17
20	regulation	the	19
21	of	regulation	20
22	myeloid	is	3
23	differentiation	is	3
24	.	is	3

0	These	factors	1
1	factors	are	2
2	are	<ROOT>	-1
3	detected	are	2
4	at	detected	3
5	the	time	6
6	time	at	4
7	the	CD11b	8
8	CD11b	promoter	9
9	promoter	time	6
10	is	are	2
11	activated	are	2
12	.	are	2

0	Patients	cortisol	17
1	with	Patients	0
2	renin	values	3
3	values	with	1
4	less	values	3
5	than	less	4
6	0.13	ng	7
7	ng	angiotensin	8
8	angiotensin	than	5
9	I/L	angiotensin	8
10	per	I/L	9
11	second	per	10
12	were	I/L	9
13	markedly	less	14
14	less	to	16
15	sensitive	less	14
16	to	values	3
17	cortisol	<ROOT>	-1
18	than	cortisol	17
19	those	than	18
20	with	those	19
21	higher	values	22
22	values	with	20
23	.	cortisol	17

0	Rel/NF-kappa	B	1
1	B	<ROOT>	-1
2	transcription	B	1
3	factors	B	1
4	and	B	1
5	the	and	4
6	control	the	5
7	of	control	6
8	apoptosis	of	7
9	.	apoptosis	8

0	Loss-	<ROOT>	-1
1	and	Loss-	0
2	gain-of-function	mutations	3
3	mutations	and	1
4	reveal	Loss-	0
5	an	role	7
6	important	role	7
7	role	reveal	4
8	of	(	10
9	BSAP	of	8
10	(	role	7
11	Pax-5	(	10
12	)	Loss-	0
13	at	)	12
14	the	start	15
15	start	at	13
16	and	at	13
17	end	and	16
18	of	Loss-	0
19	B	Loss-	0
20	cell	Loss-	0
21	differentiation	Loss-	0
22	.	Loss-	0

0	This	activity	1
1	activity	may	2
2	may	<ROOT>	-1
3	be	may	2
4	relevant	be	3
5	to	relevant	4
6	the	mechanisms	7
7	mechanisms	to	5
8	whereby	does	11
9	HTLV-I	which	10
10	which	whereby	8
11	does	be	3
12	not	does	11
13	contain	does	11
14	oncogenes	does	11
15	induces	oncogenes	14
16	neoplasia	induces	15
17	.	may	2

0	Oxidants	are	5
1	such	as	2
2	as	Oxidants	0
3	hydrogen	peroxide	4
4	peroxide	as	2
5	are	<ROOT>	-1
6	known	are	5
7	to	known	6
8	activate	to	7
9	certain	factors	11
10	transcription	factors	11
11	factors	activate	8
12	such	as	13
13	as	factors	11
14	nuclear	factor	16
15	transcription	factor	16
16	factor	as	13
17	kappa	beta	18
18	beta	factor	16
19	.	are	5

0	Additional	<ROOT>	-1
1	major	Additional	0
2	protein-DNA	not	5
3	interactions	do	4
4	do	protein-DNA	2
5	not	major	1
6	occur	not	5
7	within	not	5
8	the	within	7
9	promoter	after	11
10	region	after	11
11	after	the	8
12	T	lymphocyte	13
13	lymphocyte	not	5
14	activation	lymphocyte	13
15	,	Additional	0
16	indicating	Additional	0
17	a	indicating	16
18	requirement	for	19
19	for	a	17
20	additional	a	17
21	protein-protein	additional	20
22	interactions	protein-protein	21
23	and/or	post-translational	24
24	post-translational	interactions	22
25	modifications	post-translational	24
26	of	modifications	25
27	pre-bound	factors	29
28	transcription	factors	29
29	factors	of	26
30	to	post-translational	24
31	account	to	30
32	for	account	31
33	the	for	32
34	observed	the	33
35	increase	observed	34
36	in	II	39
37	IMPDH	type	38
38	type	II	39
39	II	increase	35
40	gene	Additional	0
41	expression	Additional	0
42	.	Additional	0

0	IL-4	<ROOT>	-1
1	and	IL-4	0
2	IL-13	up-regulated	3
3	up-regulated	IL-4	0
4	the	expression	5
5	expression	of	6
6	of	up-regulated	3
7	both	of	6
8	genomic	IL-4	0
9	and	IL-4	0
10	spliced	IL-4	0
11	HIV	IL-4	0
12	mRNA	IL-4	0
13	in	mRNA	12
14	monocytes	IL-4	0
15	cultured	IL-4	0
16	on	IL-4	0
17	Teflon	on	16
18	,	Teflon	17
19	as	Teflon	17
20	determined	as	19
21	by	determined	20
22	Northern	analysis	23
23	analysis	by	21
24	and	analysis	23
25	p24	Ag	26
26	Ag	and	24
27	assay	Ag	26
28	.	IL-4	0

0	It	is	1
1	is	<ROOT>	-1
2	concluded	is	1
3	that	concluded	2
4	,	concluded	2
5	in	concluded	2
6	contrast	in	5
7	to	previous	9
8	a	previous	9
9	previous	contrast	6
10	study	PBMC	12
11	,	PBMC	12
12	PBMC	are	13
13	are	concluded	2
14	not	are	13
15	a	site	17
16	common	site	17
17	site	are	13
18	of	site	17
19	persistent	group	20
20	group	C	21
21	C	of	18
22	adenoviral	infection	23
23	infection	is	1
24	.	is	1

0	Transcription	factors	1
1	factors	<ROOT>	-1
2	in	factors	1
3	immune-mediated	disease	4
4	disease	in	2
5	.	disease	4

0	Transcriptional	induction	1
1	induction	<ROOT>	-1
2	of	induction	1
3	collagenase-1	of	2
4	in	collagenase-1	3
5	differentiated	in	4
6	monocyte-like	induction	1
7	(	U937	8
8	U937	monocyte-like	6
9	)	U937	8
10	cells	monocyte-like	6
11	is	cells	10
12	regulated	is	11
13	by	regulated	12
14	AP-1	by	13
15	and	by	13
16	an	site	19
17	upstream	site	19
18	C/EBP-beta	site	19
19	site	and	15
20	.	induction	1

0	No	difference	1
1	difference	was	5
2	in	difference	1
3	plasma	cortisol	4
4	cortisol	in	2
5	was	<ROOT>	-1
6	found	between	7
7	between	was	5
8	the	patients	9
9	patients	between	7
10	and	patients	9
11	the	subjects	13
12	healthy	subjects	13
13	subjects	and	10
14	(	subjects	13
15	P	&gt;	16
16	&gt;	between	7
17	0.05	between	7
18	)	was	5
19	.	was	5

0	The	generation	1
1	generation	of	2
2	of	<ROOT>	-1
3	genomic	of	2
4	diversity	of	2
5	during	of	2
6	the	course	7
7	course	during	5
8	of	course	7
9	infection	of	8
10	has	the	11
11	the	course	7
12	potential	the	11
13	to	potential	12
14	affect	to	13
15	all	aspects	16
16	aspects	affect	14
17	of	HIV-1	18
18	HIV-1	aspects	16
19	replication	,	20
20	,	aspects	16
21	including	,	20
22	expression	including	21
23	of	expression	22
24	the	of	23
25	proviral	the	24
26	genome	proviral	25
27	.	genome	26

0	The	combination	1
1	combination	has	10
2	of	combination	1
3	the	immune	4
4	immune	of	2
5	costimulatory	immune	4
6	molecule	costimulatory	5
7	B7.1	molecule	6
8	and	B7.1	7
9	IL-12	and	8
10	has	<ROOT>	-1
11	been	has	10
12	shown	been	11
13	to	shown	12
14	be	to	13
15	synergistic	be	14
16	for	cell	18
17	T	cell	18
18	cell	synergistic	15
19	activation	has	10
20	.	has	10

0	However	is	5
1	,	is	5
2	the	gene	4
3	NF-IL6	gene	4
4	gene	is	5
5	is	<ROOT>	-1
6	expressed	is	5
7	in	expressed	6
8	a	variety	9
9	variety	in	7
10	of	variety	9
11	nonmyeloid	types	13
12	cell	types	13
13	types	of	10
14	and	is	5
15	is	and	14
16	strongly	inducible	17
17	inducible	is	15
18	in	inducible	17
19	response	in	18
20	to	inflammatory	21
21	inflammatory	response	19
22	stimuli	is	5
23	,	stimuli	22
24	making	stimuli	22
25	it	making	24
26	an	candidate	28
27	unlikely	candidate	28
28	candidate	making	24
29	to	making	24
30	have	to	29
31	an	have	30
32	exclusive	an	31
33	role	exclusive	32
34	as	role	33
35	a	combinatorial	36
36	combinatorial	as	34
37	differentiation	combinatorial	36
38	switch	combinatorial	36
39	during	switch	38
40	myelopoiesis	during	39
41	in	human	42
42	human	myelopoiesis	40
43	cells	is	5
44	.	is	5

0	With	was	8
1	the	use	2
2	use	With	0
3	of	use	2
4	immunohistochemistry	of	3
5	,	was	8
6	bcl-6	protein	7
7	protein	was	8
8	was	<ROOT>	-1
9	shown	was	8
10	to	shown	9
11	stain	intensely	12
12	intensely	to	10
13	on	intensely	12
14	normal	on	13
15	prickle	normal	14
16	cells	,	17
17	,	prickle	15
18	but	normal	14
19	none	normal	14
20	to	none	19
21	only	none	19
22	slightly	epidermal	24
23	on	epidermal	24
24	epidermal	none	19
25	basal	normal	14
26	cells	normal	14
27	.	was	8

0	Likewise	<ROOT>	-1
1	,	Likewise	0
2	activation	Likewise	0
3	of	reporter	5
4	this	reporter	5
5	reporter	activation	2
6	construct	Likewise	0
7	by	necrosis	9
8	tumor	necrosis	9
9	necrosis	construct	6
10	factor-alpha	Likewise	0
11	depended	Likewise	0
12	on	depended	11
13	the	site	15
14	SP-1	site	15
15	site	on	12
16	.	Likewise	0

0	The	pathways	2
1	transduction	pathways	2
2	pathways	remain	9
3	that	lead	4
4	lead	kappaB	7
5	to	kappaB	7
6	I	kappaB	7
7	kappaB	pathways	2
8	inactivation	kappaB	7
9	remain	<ROOT>	-1
10	poorly	understood	11
11	understood	remain	9
12	.	remain	9

0	Furthermore	does	14
1	,	replacement	2
2	replacement	receptor	13
3	of	replacement	2
4	the	domain	7
5	gamma-LRB-c-RRB-	domain	7
6	cytoplasmic	domain	7
7	domain	of	3
8	by	erythropoeitin	12
9	a	erythropoeitin	12
10	severely	truncated	11
11	truncated	erythropoeitin	12
12	erythropoeitin	replacement	2
13	receptor	Furthermore	0
14	does	signaling	19
15	not	does	14
16	affect	signaling	19
17	measured	signaling	19
18	IL-7R	measured	17
19	signaling	<ROOT>	-1
20	events	signaling	19
21	.	signaling	19

0	Putative	cis-acting	1
1	cis-acting	control	2
2	control	elements	3
3	elements	included	10
4	present	elements	3
5	within	present	4
6	a	promoter	9
7	300-bp	promoter	9
8	core	promoter	9
9	promoter	within	5
10	included	<ROOT>	-1
11	two	sites	13
12	ets	sites	13
13	sites	GATA-associated	24
14	,	sites	13
15	an	site	17
16	Sp1	site	17
17	site	sites	13
18	,	sites	13
19	tandem	E-box	20
20	E-box	domains	21
21	domains	sites	13
22	,	sites	13
23	two	GATA-associated	24
24	GATA-associated	included	10
25	sites	(	26
26	(	included	10
27	CACCC	(	26
28	)	included	10
29	,	binding	32
30	an	binding	32
31	AP-2	binding	32
32	binding	included	10
33	site	included	10
34	,	included	10
35	and	included	10
36	a	GATA	37
37	GATA	and	35
38	element	GATA	37
39	at	included	10
40	-24	at	39
41	.	included	10

0	Differentiation-dependent	expression	1
1	expression	<ROOT>	-1
2	of	expression	1
3	a	carboxylesterase	5
4	human	carboxylesterase	5
5	carboxylesterase	of	2
6	in	monocytic	7
7	monocytic	expression	1
8	cells	expression	1
9	and	expression	1
10	transcription	expression	1
11	factor	transcription	10
12	binding	transcription	10
13	to	binding	12
14	the	promoter	15
15	promoter	to	13
16	.	expression	1

0	Here	demonstrate	2
1	we	demonstrate	2
2	demonstrate	(	15
3	that	fusion	4
4	fusion	demonstrate	2
5	of	HeLa	6
6	HeLa	fusion	4
7	cells	demonstrate	2
8	with	cells	7
9	either	cells	7
10	diploid	demonstrate	2
11	or	tetraploid	12
12	tetraploid	diploid	10
13	B	demonstrate	2
14	cells	demonstrate	2
15	(	results	18
16	Daudi	(	15
17	)	(	15
18	results	<ROOT>	-1
19	in	results	18
20	widespread	extinction	21
21	extinction	in	19
22	of	extinction	21
23	several	genes	27
24	other	genes	27
25	B	genes	27
26	cell-encoded	genes	27
27	genes	of	22
28	that	are	29
29	are	results	18
30	expressed	are	29
31	in	expressed	30
32	a	in	31
33	B	.	36
34	cell-specific	.	36
35	manner	.	36
36	.	a	32

0	To	was	32
1	examine	To	0
2	the	mechanisms	3
3	mechanisms	examine	1
4	by	examine	1
5	which	examine	1
6	salicylates	affect	7
7	affect	which	5
8	cytokine	gene	9
9	gene	affect	7
10	transcription	gene	9
11	,	To	0
12	the	amount	13
13	amount	,	11
14	of	amount	13
15	active	of	14
16	and	B	19
17	inactive	and	16
18	NF-kappa	B	19
19	B	amount	13
20	and	B	22
21	NF-kappa	B	22
22	B	amount	13
23	mRNA	To	0
24	,	To	0
25	in	human	29
26	Porphyromonas	gingivalis	27
27	gingivalis	human	29
28	lipopolysaccharide-stimulated	human	29
29	human	To	0
30	monocytic	To	0
31	cells	To	0
32	was	<ROOT>	-1
33	assessed	was	32
34	.	was	32

0	B	lymphocytes	1
1	lymphocytes	signal	9
2	from	lymphocytes	1
3	patients	from	2
4	with	patients	3
5	chronic	leukemia	7
6	lymphocytic	leukemia	7
7	leukemia	with	4
8	contain	leukemia	7
9	signal	<ROOT>	-1
10	transducer	signal	9
11	and	transducer	10
12	activator	and	11
13	of	and	11
14	transcription	(	15
15	(	and	11
16	STAT	(	15
17	)	1	18
18	1	on	23
19	and	on	23
20	STAT3	and	19
21	constitutively	STAT3	20
22	phosphorylated	STAT3	20
23	on	serine	24
24	serine	STAT	16
25	residues	signal	9
26	.	signal	9

0	This	degree	1
1	degree	was	5
2	of	degree	1
3	cell	damage	4
4	damage	of	2
5	was	<ROOT>	-1
6	not	was	5
7	observed	was	5
8	in	observed	7
9	Ad5wt	in	8
10	or	Ad5wt	9
11	H5sub304	infection	12
12	infection	or	10
13	of	infection	12
14	CREF	cells	15
15	cells	of	13
16	.	cells	15

0	Identification	terminal	14
1	of	that	4
2	nucleotide	sequences	3
3	sequences	of	1
4	that	Identification	0
5	regulate	murine	10
6	transcription	murine	10
7	of	murine	10
8	the	murine	10
9	MCF13	murine	10
10	murine	that	4
11	leukemia	Identification	0
12	virus	terminal	14
13	long	terminal	14
14	terminal	<ROOT>	-1
15	repeat	activated	17
16	in	activated	17
17	activated	terminal	14
18	T	terminal	14
19	cells	terminal	14
20	.	terminal	14

0	Expression	correlates	3
1	of	Expression	0
2	Egr-1	of	1
3	correlates	<ROOT>	-1
4	with	correlates	3
5	the	phenotype	7
6	transformed	phenotype	7
7	phenotype	with	4
8	and	correlates	3
9	the	type	10
10	type	and	8
11	of	viral	12
12	viral	type	10
13	latency	correlates	3
14	in	latency	13
15	EBV	in	14
16	genome	positive	17
17	positive	EBV	15
18	lymphoid	correlates	3
19	cell	correlates	3
20	lines	correlates	3
21	.	correlates	3

0	The	receptor	2
1	T-cell	receptor	2
2	receptor	(	3
3	(	TCR	4
4	TCR	)	5
5	)	have	8
6	beta-chain	)	5
7	promoters	)	5
8	have	<ROOT>	-1
9	been	have	8
10	characterized	been	9
11	as	characterized	10
12	nonstructured	promoters	14
13	basal	promoters	14
14	promoters	as	11
15	that	carry	16
16	carry	promoters	14
17	a	cyclic	21
18	single	cyclic	21
19	conserved	cyclic	21
20	ubiquitous	cyclic	21
21	cyclic	carry	16
22	AMP-responsive	cyclic	21
23	element	have	8
24	.	have	8

0	Specific	sites	2
1	docking	sites	2
2	sites	within	3
3	within	have	7
4	individual	cytokine	5
5	cytokine	within	3
6	receptors	within	3
7	have	<ROOT>	-1
8	been	have	7
9	identified	been	8
10	for	identified	9
11	almost	all	12
12	all	proteins	14
13	Stat	proteins	14
14	proteins	for	10
15	.	have	7

0	However	<ROOT>	-1
1	,	However	0
2	amino	to	5
3	acids	to	5
4	207	to	5
5	to	,	1
6	368	to	5
7	are	to	5
8	dispensable	are	7
9	when	are	7
10	the	when	9
11	protein	the	10
12	is	protein	11
13	bound	is	12
14	to	bound	13
15	DNA	to	14
16	as	DNA	15
17	a	DNA	15
18	fusion	a	17
19	with	fusion	18
20	the	with	19
21	GAL4	the	20
22	DBD	GAL4	21
23	,	DBD	22
24	thus	,	23
25	implicating	the	20
26	this	region	27
27	region	implicating	25
28	in	DNA	29
29	DNA	implicating	25
30	binding	However	0
31	.	However	0

0	Cotransfection	vectors	14
1	of	Cotransfection	0
2	the	sense	4
3	C/EBP-epsilon	sense	4
4	sense	of	1
5	and	expression	7
6	antisense	expression	7
7	expression	of	1
8	constructs	Cotransfection	0
9	together	Cotransfection	0
10	with	Cotransfection	0
11	chloramphenicol	reporter	13
12	acetyltransferase	reporter	13
13	reporter	Cotransfection	0
14	vectors	suggested	22
15	containing	myeloid-cell-specific	16
16	myeloid-cell-specific	vectors	14
17	c-mim	vectors	14
18	and	c-mim	17
19	human	and	18
20	myeloperoxidase	promoters	21
21	promoters	human	19
22	suggested	<ROOT>	-1
23	a	suggested	22
24	role	for	25
25	for	a	23
26	C/EBP-epsilon	factor	28
27	transcription	factor	28
28	factor	for	25
29	in	the	30
30	the	factor	28
31	regulation	of	32
32	of	the	30
33	a	subset	34
34	subset	of	32
35	of	subset	34
36	myeloid-cell-specific	genes	37
37	genes	of	35
38	.	suggested	22

0	We	report	1
1	report	<ROOT>	-1
2	here	report	1
3	that	report	1
4	monocytes/macrophages	that	3
5	in	monocytes/macrophages	4
6	human	in	5
7	atherosclerotic	lesions	8
8	lesions	human	6
9	(	lesions	8
10	n	=	11
11	=	(	9
12	12	=	11
13	)	(	9
14	express	in	5
15	immunostainable	in	5
16	PPARgamma	.	17
17	.	immunostainable	15

0	Inhibitor	induced	6
1	(	IK	2
2	IK	Inhibitor	0
3	)	IK	2
4	of	induced	6
5	IFN-gamma	of	4
6	induced	<ROOT>	-1
7	HLA	induced	6
8	class	induced	6
9	II	class	8
10	antigens	II	9
11	expression	also	12
12	also	inhibits	13
13	inhibits	II	16
14	HLA	inhibits	13
15	class	II	16
16	II	antigens	10
17	constitutive	expression	18
18	expression	II	16
19	in	II	9
20	the	in	19
21	human	B	23
22	Raji	B	23
23	B	the	20
24	cell	induced	6
25	line	induced	6
26	.	induced	6

0	In	NF-AT	21
1	addition	In	0
2	,	transcriptional	3
3	transcriptional	In	0
4	activity	transcriptional	3
5	of	activity	4
6	IL-2	of	5
7	and	of	5
8	metallothionein	enhancer	9
9	enhancer	In	0
10	and	enhancer	9
11	promoter	In	0
12	regions	promoter	11
13	and	In	0
14	transcription	In	0
15	factors	AP-1	16
16	AP-1	In	0
17	,	NF-kappaB	18
18	NF-kappaB	AP-1	16
19	,	In	0
20	and	In	0
21	NF-AT	were	22
22	were	<ROOT>	-1
23	analyzed	were	22
24	by	(	27
25	chloramphenicol	acetyltransferase	26
26	acetyltransferase	by	24
27	(	analyzed	23
28	CAT	(	27
29	)	were	22
30	and	were	22
31	electrophoretic	were	22
32	mobility	were	22
33	shift	mobility	32
34	assays	were	22
35	,	were	22
36	respectively	were	22
37	.	were	22

0	Rel/NF-kappa	B	1
1	B	is	2
2	is	<ROOT>	-1
3	a	factor	6
4	ubiquitous	factor	6
5	transcription	factor	6
6	factor	is	2
7	that	factor	6
8	consists	that	7
9	of	consists	8
10	multiple	of	9
11	polypeptide	ubiquitination	28
12	subunits	polypeptide	11
13	,	subunits	12
14	and	,	13
15	is	and	14
16	subject	is	15
17	to	subject	16
18	complex	mechanisms	20
19	regulatory	mechanisms	20
20	mechanisms	to	17
21	that	involve	22
22	involve	mechanisms	20
23	protein-protein	involve	22
24	interactions	protein-protein	23
25	,	interactions	24
26	phosphorylation	,	27
27	,	protein-protein	23
28	ubiquitination	multiple	10
29	,	proteolytic	30
30	proteolytic	ubiquitination	28
31	degradation	is	2
32	,	is	2
33	and	nucleocytoplasmic	34
34	nucleocytoplasmic	is	2
35	translocation	is	2
36	.	is	2

0	Nuclear	localization	1
1	localization	is	4
2	of	localization	1
3	RelB	of	2
4	is	<ROOT>	-1
5	associated	is	4
6	with	associated	5
7	effective	with	6
8	antigen-presenting	effective	7
9	cell	.	11
10	function	.	11
11	.	antigen-presenting	8

0	The	adherence	1
1	adherence	activated	5
2	of	adherence	1
3	monocytes	of	2
4	to	activated	5
5	activated	<ROOT>	-1
6	endothelium	is	7
7	is	activated	5
8	an	event	10
9	early	event	10
10	event	is	7
11	in	event	10
12	atherogenesis	in	11
13	.	activated	5

0	A	gene	3
1	new	gene	3
2	mouse	gene	3
3	gene	is	15
4	,	gene	3
5	SRG3	gene	3
6	,	gene	3
7	related	gene	3
8	to	related	7
9	the	SWI3	10
10	SWI3	to	8
11	of	SWI3	10
12	Saccharomyces	cerevisiae	13
13	cerevisiae	of	11
14	,	cerevisiae	13
15	is	<ROOT>	-1
16	required	is	15
17	for	required	16
18	apoptosis	induced	19
19	induced	for	17
20	by	induced	19
21	glucocorticoids	by	20
22	in	by	20
23	a	cell	25
24	thymoma	cell	25
25	cell	in	22
26	line	cell	25
27	.	line	26

0	The	mechanism	1
1	mechanism	is	4
2	of	mechanism	1
3	inhibition	of	2
4	is	<ROOT>	-1
5	related	is	4
6	to	related	5
7	the	expression	9
8	surface	expression	9
9	expression	to	6
10	of	expression	9
11	several	molecules	14
12	cell	molecules	14
13	adhesion	molecules	14
14	molecules	of	10
15	.	is	4

0	Evaluation	<ROOT>	-1
1	of	Evaluation	0
2	monoclonal	of	1
3	anti-D	monoclonal	2
4	reagents	anti-D	3
5	using	reagents	4
6	D	cells	8
7	variant	cells	8
8	cells	using	5
9	.	Evaluation	0

0	Rap1	is	1
1	is	<ROOT>	-1
2	a	GTPase	6
3	small	GTPase	6
4	,	GTPase	6
5	Ras-like	GTPase	6
6	GTPase	is	1
7	whose	function	8
8	function	are	11
9	and	function	8
10	regulation	and	9
11	are	GTPase	6
12	still	are	11
13	largely	unknown	14
14	unknown	are	11
15	.	is	1

0	Consistent	<ROOT>	-1
1	with	Consistent	0
2	the	binding	3
3	binding	with	1
4	data	binding	3
5	,	Consistent	0
6	the	,	5
7	same	the	6
8	mutations	same	7
9	in	mutations	8
10	the	responsiveness	14
11	GAS	the	10
12	element	eliminate	13
13	eliminate	GAS	11
14	responsiveness	in	9
15	to	responsiveness	14
16	IFN-gamma	to	15
17	in	to	15
18	the	context	19
19	context	in	17
20	of	context	19
21	both	a	22
22	a	of	20
23	functional	a	22
24	CAEV	functional	23
25	LTR	CAEV	24
26	and	LTR	25
27	a	and	26
28	heterologous	.	30
29	promoter	.	30
30	.	a	27

0	Anaerobic	threshold	1
1	threshold	was	5
2	(	AT	3
3	AT	threshold	1
4	)	AT	3
5	was	<ROOT>	-1
6	determined	was	5
7	from	determined	6
8	the	point	9
9	point	from	7
10	of	point	9
11	departure	of	10
12	of	departure	11
13	the	response	15
14	ventilatory	response	15
15	response	of	12
16	from	response	15
17	linearity	from	16
18	and	linearity	17
19	from	and	18
20	the	increase	22
21	sudden	increase	22
22	increase	from	19
23	in	venous	24
24	venous	blood	25
25	blood	increase	22
26	lactate	concentrations	27
27	concentrations	blood	25
28	during	increase	22
29	MPE	increase	22
30	.	was	5

0	However	was	6
1	,	was	6
2	a	complex	5
3	unique	complex	5
4	DNA-protein	complex	5
5	complex	was	6
6	was	<ROOT>	-1
7	detected	was	15
8	when	the	9
9	the	was	15
10	promoter	central	11
11	central	the	9
12	21	central	11
13	bp	repeat	14
14	repeat	the	9
15	was	was	6
16	reacted	was	15
17	with	the	30
18	nuclear	derived	20
19	extracts	derived	20
20	derived	with	17
21	from	glioblastoma	26
22	either	glioblastoma	26
23	the	glioblastoma	26
24	U-373	glioblastoma	26
25	MG	glioblastoma	26
26	glioblastoma	derived	20
27	cell	with	17
28	line	with	17
29	or	the	30
30	the	reacted	16
31	THP-1	mature	32
32	mature	the	30
33	monocytic	the	30
34	cell	the	30
35	line	the	30
36	.	was	6

0	In	inhibited	5
1	addition	In	0
2	,	inhibited	5
3	dibutyryl	cAMP	4
4	cAMP	inhibited	5
5	inhibited	histamine	14
6	cell	growth	7
7	growth	inhibited	5
8	in	inhibited	5
9	a	manner	11
10	dose-dependent	manner	11
11	manner	in	8
12	,	inhibited	5
13	whereas	histamine	14
14	histamine	<ROOT>	-1
15	failed	histamine	14
16	to	failed	15
17	affect	to	16
18	proliferation	affect	17
19	and	proliferation	18
20	differentiation	affect	17
21	of	U937	22
22	U937	differentiation	20
23	cells	histamine	14
24	.	histamine	14

0	Interleukin	stimulates	5
1	2	Interleukin	0
2	(	Interleukin	0
3	IL-2	Interleukin	0
4	)	IL-2	3
5	stimulates	<ROOT>	-1
6	IL-2R	alpha	7
7	alpha	stimulates	5
8	transcription	amplifying	11
9	,	transcription	8
10	thereby	amplifying	11
11	amplifying	stimulates	5
12	expression	amplifying	11
13	of	expression	12
14	its	receptor	17
15	own	receptor	17
16	high-affinity	receptor	17
17	receptor	of	13
18	.	stimulates	5

0	This	gene	1
1	gene	showed	5
2	,	gene	1
3	SRG3	gene	1
4	,	gene	1
5	showed	<ROOT>	-1
6	a	homology	9
7	significant	homology	9
8	sequence	homology	9
9	homology	showed	5
10	to	homology	9
11	SWI3	to	10
12	,	transcriptional	15
13	a	transcriptional	15
14	yeast	transcriptional	15
15	transcriptional	showed	5
16	activator	transcriptional	15
17	,	transcriptional	15
18	and	transcriptional	15
19	its	homolog	21
20	human	homolog	21
21	homolog	and	18
22	BAF155	showed	5
23	.	showed	5

0	Analysis	of	1
1	of	<ROOT>	-1
2	interactions	of	1
3	between	of	1
4	huGATA-3	factor	6
5	transcription	factor	6
6	factor	between	3
7	and	regulatory	10
8	three	regulatory	10
9	GATA	regulatory	10
10	regulatory	factor	6
11	elements	of	12
12	of	long	14
13	HIV-1	long	14
14	long	of	1
15	terminal	repeat	16
16	repeat	of	1
17	,	repeat	16
18	by	of	1
19	surface	plasmon	20
20	plasmon	by	18
21	resonance	plasmon	20
22	.	of	1

0	The	role	1
1	role	<ROOT>	-1
2	of	role	1
3	nuclear	B	5
4	factor-kappa	B	5
5	B	of	2
6	in	role	1
7	cytokine	regulation	9
8	gene	regulation	9
9	regulation	in	6
10	.	role	1

0	Both	LCLs	1
1	LCLs	were	2
2	were	<ROOT>	-1
3	found	were	2
4	by	found	3
5	EM	by	4
6	to	EM	5
7	produce	to	6
8	RVLP	produce	7
9	and	RVLP	8
10	EBV	particles	11
11	particles	and	9
12	.	were	2

0	We	demonstrated	1
1	demonstrated	is	10
2	that	demonstrated	1
3	the	that	2
4	virus	isolated	6
5	dUTPase	isolated	6
6	isolated	the	3
7	from	EBV-infected	8
8	EBV-infected	the	3
9	cells	demonstrated	1
10	is	<ROOT>	-1
11	a	phosphoprotein	12
12	phosphoprotein	is	10
13	.	is	10

0	Transcriptional	up-regulation	1
1	up-regulation	leukemia	18
2	of	up-regulation	1
3	the	of	2
4	c-sis/platelet-derived	growth	5
5	growth	the	3
6	factor-B	growth	5
7	(	PDGF-B	8
8	PDGF-B	proto-oncogene	10
9	)	PDGF-B	8
10	proto-oncogene	factor-B	6
11	by	proto-oncogene	10
12	the	protein	14
13	Tax	protein	14
14	protein	by	11
15	of	human	16
16	human	protein	14
17	T-cell	up-regulation	1
18	leukemia	virus	19
19	virus	type	20
20	type	has	22
21	1	type	20
22	has	<ROOT>	-1
23	been	has	22
24	implicated	been	23
25	as	implicated	24
26	one	mechanism	28
27	possible	mechanism	28
28	mechanism	as	25
29	of	mechanism	28
30	cellular	transformation	31
31	transformation	of	29
32	by	virus	36
33	human	virus	36
34	T-cell	leukemia	35
35	leukemia	virus	36
36	virus	of	29
37	type	has	22
38	1	has	22
39	.	has	22

0	Both	Drosophila	1
1	Drosophila	Toll	2
2	Toll	are	7
3	and	Toll	2
4	the	receptor	6
5	IL-1	receptor	6
6	receptor	and	3
7	are	<ROOT>	-1
8	known	are	7
9	to	known	8
10	signal	to	9
11	through	signal	10
12	the	pathway	14
13	NF-kappaB	pathway	14
14	pathway	through	11
15	.	are	7

0	Differanisole	A	1
1	A	cells	12
2	,	A	1
3	3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic	acid	4
4	acid	A	1
5	,	acid	4
6	inhibited	,	5
7	growth	human	9
8	of	human	9
9	human	,	5
10	myeloid	cells	12
11	leukemia	cells	12
12	cells	<ROOT>	-1
13	.	cells	12

0	In	could	5
1	PMA-treated	In	0
2	THP-1	cells	3
3	cells	PMA-treated	1
4	we	could	5
5	could	<ROOT>	-1
6	detect	could	5
7	three	sites	11
8	major	transcription	9
9	transcription	sites	11
10	initiation	sites	11
11	sites	detect	6
12	as	detect	6
13	revealed	as	12
14	by	revealed	13
15	Nuclease	Assay	17
16	Protection	Assay	17
17	Assay	by	14
18	carried	Assay	17
19	out	carried	18
20	with	carried	18
21	two	probes	25
22	overlapping	probes	25
23	antisense	probes	25
24	RNA	probes	25
25	probes	with	20
26	.	could	5

0	We	have	1
1	have	occurs	27
2	also	have	1
3	shown	tyrosine	5
4	that	tyrosine	5
5	tyrosine	have	1
6	phosphorylation	STAT	9
7	of	STAT	9
8	the	STAT	9
9	STAT	have	1
10	4	STAT	9
11	transcription	factor	12
12	factor	have	1
13	,	has	15
14	which	has	15
15	has	have	1
16	been	has	15
17	shown	been	16
18	to	shown	17
19	be	to	18
20	unique	be	19
21	to	IL-12	23
22	the	IL-12	23
23	IL-12	unique	20
24	signaling	IL-12	23
25	pathway	signaling	24
26	,	occurs	27
27	occurs	<ROOT>	-1
28	with	occurs	27
29	Flexi-12	with	28
30	at	Flexi-12	29
31	levels	at	30
32	similar	levels	31
33	to	similar	32
34	those	to	33
35	seen	those	34
36	with	seen	35
37	rIL-12	with	36
38	.	occurs	27

0	Competent	initiation	2
1	transcription	initiation	2
2	initiation	<ROOT>	-1
3	by	initiation	2
4	RNA	by	3
5	polymerase	RNA	4
6	II	in	7
7	in	polymerase	5
8	cell-free	initiation	2
9	extracts	from	10
10	from	cell-free	8
11	xeroderma	B	14
12	pigmentosum	groups	13
13	groups	B	14
14	B	cell-free	8
15	and	initiation	2
16	D	initiation	2
17	in	D	16
18	an	in	17
19	optimized	an	18
20	RNA	.	23
21	transcription	.	23
22	assay	.	23
23	.	optimized	19

0	This	finding	1
1	finding	indicates	2
2	indicates	<ROOT>	-1
3	that	indicates	2
4	phospholipase	A2	5
5	A2	are	8
6	and	A2	5
7	5-lipoxygenase	and	6
8	are	that	3
9	also	are	8
10	involved	are	8
11	.	indicates	2

0	Differanisole	A	1
1	A	inhibited	10
2	and	(	6
3	an	ligand	5
4	RXR-specific	ligand	5
5	ligand	and	2
6	(	A	1
7	Ro47-5944	(	6
8	)	A	1
9	cooperatively	inhibited	10
10	inhibited	<ROOT>	-1
11	the	growth	13
12	cell	growth	13
13	growth	inhibited	10
14	,	inhibited	10
15	while	inhibited	10
16	the	effect	18
17	combined	effect	18
18	effect	was	27
19	of	effect	18
20	differanisole	A	21
21	A	of	19
22	and	A	21
23	an	Am80	26
24	RAR-specific	Am80	26
25	ligand	Am80	26
26	Am80	and	22
27	was	while	15
28	just	was	27
29	additive	was	27
30	.	inhibited	10

0	Promoter	constructs	2
1	deletion	constructs	2
2	constructs	demonstrated	3
3	demonstrated	<ROOT>	-1
4	the	role	6
5	potential	role	6
6	role	demonstrated	3
7	of	role	6
8	distal	sequences	10
9	promoter	sequences	10
10	sequences	of	7
11	in	collagenase-1	13
12	regulating	collagenase-1	13
13	collagenase-1	demonstrated	3
14	transcription	demonstrated	3
15	.	demonstrated	3

0	It	had	1
1	had	<ROOT>	-1
2	previously	had	1
3	been	had	1
4	thought	been	3
5	that	thought	4
6	ZEBRA	capacity	8
7	's	ZEBRA	6
8	capacity	that	5
9	to	capacity	8
10	disrupt	to	9
11	EBV	disrupt	10
12	latency	EBV	11
13	resided	latency	12
14	primarily	in	15
15	in	its	16
16	its	latency	12
17	ability	its	16
18	to	ability	17
19	activate	ability	17
20	transcription	activate	19
21	of	transcription	20
22	genes	had	1
23	that	genes	22
24	encode	that	23
25	products	encode	24
26	required	products	25
27	for	required	26
28	lytic	.	30
29	replication	.	30
30	.	for	27

0	The	Bmax	1
1	Bmax	increased	6
2	in	Bmax	1
3	these	subjects	4
4	subjects	in	2
5	significantly	increased	6
6	increased	<ROOT>	-1
7	to	6.61	8
8	6.61	increased	6
9	+/-	2.02	10
10	2.02	6.61	8
11	(	2.02	10
12	257.7	(	11
13	+/-	257.7	12
14	107.8	%	15
15	%	+/-	13
16	)	(	11
17	after	2.02	10
18	24	increased	6
19	h	stimulation	20
20	stimulation	24	18
21	with	stimulation	20
22	concanavalin	A	23
23	A	with	21
24	(	A	23
25	p	A	23
26	&lt;	A	23
27	0.01	&lt;	26
28	)	,	29
29	,	0.01	27
30	while	0.01	27
31	the	change	33
32	Kd	change	33
33	change	was	34
34	was	while	30
35	not	was	34
36	significant	was	34
37	.	increased	6

0	Signaling	<ROOT>	-1
1	via	Signaling	0
2	IL-2	via	1
3	and	IL-2	2
4	IL-4	and	3
5	in	IL-2	2
6	JAK3-deficient	lymphocytes	10
7	severe	lymphocytes	10
8	combined	lymphocytes	10
9	immunodeficiency	lymphocytes	10
10	lymphocytes	in	5
11	:	Signaling	0
12	JAK3-dependent	Signaling	0
13	and	JAK3-dependent	12
14	independent	and	13
15	pathways	independent	14
16	.	Signaling	0

0	The	breakpoints	1
1	breakpoints	transcript	4
2	of	transcript	4
3	most	transcript	4
4	transcript	<ROOT>	-1
5	deletions	transcript	4
6	coincide	transcript	4
7	with	transcript	4
8	genuine	transcript	4
9	or	site	12
10	cryptic	or	9
11	splice	site	12
12	site	transcript	4
13	sequences	transcript	4
14	,	transcript	4
15	suggesting	transcript	4
16	that	suggesting	15
17	they	result	18
18	result	that	16
19	from	result	18
20	alternative	from	19
21	or	alternative	20
22	aberrant	splicing	23
23	splicing	or	21
24	.	transcript	4

0	Nuclear	<ROOT>	-1
1	transcription	Nuclear	0
2	factor	is	8
3	kB	is	8
4	(	NF-kappa	5
5	NF-kappa	kB	3
6	B	NF-kappa	5
7	)	NF-kappa	5
8	is	Nuclear	0
9	a	factor	12
10	ubiquitous	factor	12
11	transcription	factor	12
12	factor	is	8
13	and	pleiotropic	14
14	pleiotropic	is	8
15	regulator	Nuclear	0
16	of	regulator	15
17	numerous	genes	18
18	genes	of	16
19	involved	of	16
20	in	involved	19
21	the	immune	22
22	immune	in	20
23	and	immune	22
24	inflammatory	and	23
25	responses	Nuclear	0
26	.	Nuclear	0

0	Thus	suggest	4
1	,	suggest	4
2	our	data	3
3	data	suggest	4
4	suggest	<ROOT>	-1
5	that	suggest	4
6	TPO	that	5
7	has	distinct	9
8	a	distinct	9
9	distinct	action	10
10	action	TPO	6
11	on	action	10
12	erythropoiesis	on	11
13	.	suggest	4

0	The	replacement	1
1	replacement	may	13
2	of	replacement	1
3	p50	homodimers	4
4	homodimers	of	2
5	with	replacement	1
6	transcriptionally	active	7
7	active	with	5
8	heterodimers	replacement	1
9	following	heterodimers	8
10	time	following	9
11	in	time	10
12	culture	in	11
13	may	<ROOT>	-1
14	partially	may	13
15	explain	may	13
16	the	increase	18
17	progressive	increase	18
18	increase	explain	15
19	in	increase	18
20	susceptibility	in	19
21	of	susceptibility	20
22	monocytes	of	21
23	to	increase	18
24	HIV	infection	25
25	infection	vitro	28
26	during	infection	25
27	in	vitro	28
28	vitro	to	23
29	culture	increase	18
30	.	may	13

0	A	40-fold	1
1	40-fold	stimulation	2
2	stimulation	activity	6
3	of	stimulation	2
4	chloramphenicol	acetyltransferase	5
5	acetyltransferase	of	3
6	activity	could	15
7	mediated	activity	6
8	by	mediated	7
9	four	repeats	11
10	tandem	repeats	11
11	repeats	by	8
12	of	repeats	11
13	the	SNE	14
14	SNE	of	12
15	could	<ROOT>	-1
16	be	could	15
17	induced	be	16
18	within	induced	17
19	2	h	20
20	h	within	18
21	(	could	15
22	and	(	21
23	up	and	22
24	to	up	23
25	250-fold	to	24
26	within	250-fold	25
27	6	250-fold	25
28	h	)	29
29	)	6	27
30	after	250-fold	25
31	addition	after	30
32	of	addition	31
33	TPA	of	32
34	in	U-937	36
35	DNA-transfected	U-937	36
36	U-937	addition	31
37	cells	could	15
38	,	could	15
39	indicating	could	15
40	that	indicating	39
41	the	stimulation	42
42	stimulation	that	40
43	appeared	stimulation	42
44	likely	appeared	43
45	to	likely	44
46	be	to	45
47	a	protein	49
48	true	protein	49
49	protein	be	46
50	kinase	event	54
51	C-mediated	event	54
52	signal	event	54
53	transduction	event	54
54	event	stimulation	42
55	rather	differentiation	58
56	than	rather	55
57	a	differentiation	58
58	differentiation	event	54
59	response	.	60
60	.	differentiation	58

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	the	activity	6
5	functional	activity	6
6	activity	is	16
7	of	activity	6
8	ligands	of	7
9	built	of	7
10	from	the	11
11	the	built	9
12	binding	site	13
13	site	the	11
14	of	site	13
15	G28-5	of	14
16	is	that	3
17	highly	dependent	18
18	dependent	is	16
19	upon	is	16
20	the	size	21
21	size	upon	19
22	and	size	21
23	physical	and	22
24	properties	size	21
25	of	the	26
26	the	properties	24
27	molecule	both	28
28	both	is	16
29	in	both	28
30	solution	both	28
31	and	solution	30
32	on	and	31
33	the	surfaces	35
34	cell	surfaces	35
35	surfaces	on	32
36	.	indicate	2

0	Secondly	<ROOT>	-1
1	,	Secondly	0
2	we	,	1
3	investigated	we	2
4	whether	investigated	3
5	polyomavirus	whether	4
6	reactivation	polyomavirus	5
7	occurs	in	8
8	in	reactivation	6
9	SLE	in	8
10	patients	Secondly	0
11	,	Secondly	0
12	and	Secondly	0
13	whether	and	12
14	antibodies	are	25
15	to	antibodies	14
16	T-antigen	to	15
17	,	antibodies	14
18	DNA	antibodies	14
19	,	DNA	18
20	and	DNA	18
21	to	and	20
22	TBP	to	21
23	and	TBP	22
24	CREB	and	23
25	are	whether	13
26	linked	are	25
27	to	such	28
28	such	linked	26
29	events	linked	26
30	.	Secondly	0

0	GCS	were	1
1	were	<ROOT>	-1
2	also	were	1
3	reported	were	1
4	to	reported	3
5	act	to	4
6	indirectly	act	5
7	by	factor-beta	11
8	inducing	factor-beta	11
9	transforming	growth	10
10	growth	factor-beta	11
11	factor-beta	act	5
12	expression	,	13
13	,	to	4
14	which	,	13
15	in	T	18
16	turn	in	15
17	blocks	T	18
18	T	which	14
19	cell	which	14
20	immunity	were	1
21	.	were	1

0	Each	volunteer	1
1	volunteer	performed	2
2	performed	<ROOT>	-1
3	these	exercise	4
4	exercise	performed	2
5	twice	performed	2
6	,	performed	2
7	following	performed	2
8	either	injection	11
9	an	injection	11
10	intravenous	injection	11
11	injection	following	7
12	of	injection	11
13	phosphocreatine	of	12
14	(	PCr	15
15	PCr	injection	11
16	)	PCr	15
17	or	a	18
18	a	injection	11
19	placebo	performed	2
20	of	placebo	19
21	an	solution	24
22	isotonic	NaCl	23
23	NaCl	solution	24
24	solution	of	20
25	.	performed	2

0	Twenty-two	differences	1
1	differences	were	6
2	from	differences	1
3	the	sequence	5
4	human	sequence	5
5	sequence	from	2
6	were	<ROOT>	-1
7	found	were	6
8	in	found	7
9	the	in	8
10	N-terminal	(	12
11	region	(	12
12	(	the	9
13	amino	the	9
14	acids	amino	13
15	1-421	acids	14
16	)	1-421	15
17	of	)	16
18	the	receptor	21
19	squirrel	receptor	21
20	monkey	receptor	21
21	receptor	of	17
22	.	receptor	21

0	Opposite	effects	1
1	effects	promyelocytic	5
2	of	promyelocytic	5
3	the	promyelocytic	5
4	acute	promyelocytic	5
5	promyelocytic	receptor	9
6	leukemia	receptor	9
7	PML-retinoic	receptor	9
8	acid	receptor	9
9	receptor	RAR	12
10	alpha	(	11
11	(	receptor	9
12	RAR	alpha	17
13	alpha	RAR	12
14	)	alpha	13
15	and	)	14
16	PLZF-RAR	)	14
17	alpha	<ROOT>	-1
18	fusion	alpha	17
19	proteins	alpha	17
20	on	alpha	17
21	retinoic	signalling	23
22	acid	signalling	23
23	signalling	on	20
24	.	alpha	17

0	As	beta	15
1	a	step	2
2	step	As	0
3	toward	step	2
4	elucidating	toward	3
5	the	background	7
6	pathophysiological	background	7
7	background	elucidating	4
8	of	background	7
9	the	toxicity	12
10	so-called	toxicity	12
11	glucose	toxicity	12
12	toxicity	of	8
13	to	pancreatic	14
14	pancreatic	elucidating	4
15	beta	induced	19
16	cells	beta	15
17	,	induced	19
18	we	induced	19
19	induced	<ROOT>	-1
20	glycation	in	21
21	in	induced	19
22	HIT-T15	cells	23
23	cells	induced	19
24	using	induced	19
25	a	sugar	26
26	sugar	using	24
27	with	strong	28
28	strong	using	24
29	deoxidizing	strong	28
30	activity	induced	19
31	,	induced	19
32	D-ribose	,	31
33	,	D-ribose	32
34	and	D-ribose	32
35	examined	the	36
36	the	and	34
37	effects	the	36
38	on	effects	37
39	insulin	gene	40
40	gene	on	38
41	transcription	.	42
42	.	gene	40

0	These	<ROOT>	-1
1	results	These	0
2	demonstrate	distinct	3
3	distinct	results	1
4	patterns	of	5
5	of	distinct	3
6	intracellular	of	5
7	signaling	for	8
8	for	intracellular	6
9	two	distinct	3
10	chemoattractants	distinct	3
11	and	distinct	3
12	suggest	that	13
13	that	distinct	3
14	selective	of	16
15	activation	of	16
16	of	that	13
17	intracellular	of	16
18	signaling	may	20
19	cascades	may	20
20	may	These	0
21	underlie	may	20
22	different	underlie	21
23	patterns	of	24
24	of	different	22
25	functional	of	24
26	responses	.	27
27	.	functional	25

0	Regulation	,	3
1	by	Regulation	0
2	Egr-1	by	1
3	,	<ROOT>	-1
4	c-Jun	,	3
5	,	c-Jun	4
6	and	transcription	8
7	NF-kappaB	transcription	8
8	transcription	,	5
9	factors	,	3
10	.	,	3

0	While	also	11
1	LTRs	While	0
2	which	demonstrated	3
3	demonstrated	LTRs	1
4	the	activities	6
5	highest	activities	6
6	activities	demonstrated	3
7	in	MG	9
8	U-373	MG	9
9	MG	activities	6
10	cells	While	0
11	also	were	21
12	yielded	high	13
13	high	activities	14
14	activities	also	11
15	in	also	11
16	Jurkat	in	15
17	cells	,	18
18	,	LTRs	20
19	the	LTRs	20
20	LTRs	Jurkat	16
21	were	<ROOT>	-1
22	generally	were	21
23	more	were	21
24	active	more	23
25	in	active	24
26	Jurkat	in	25
27	cells	when	28
28	when	Jurkat	26
29	compared	were	21
30	to	compared	29
31	the	LTR	33
32	LAI	LTR	33
33	LTR	to	30
34	.	were	21

0	The	member	2
1	third	member	2
2	member	<ROOT>	-1
3	of	member	2
4	the	family	5
5	family	of	3
6	,	member	2
7	A-myb	,	6
8	,	A-myb	7
9	shows	,	8
10	the	shows	9
11	most	restricted	12
12	restricted	shows	9
13	pattern	of	14
14	of	restricted	12
15	expression	of	14
16	,	shows	9
17	suggesting	shows	9
18	a	suggesting	17
19	very	a	18
20	specific	role	21
21	role	a	18
22	for	this	23
23	this	role	21
24	transcription	factor	25
25	factor	role	21
26	.	member	2

0	An	rate	2
1	increased	rate	2
2	rate	degradation	5
3	of	lysosomal	4
4	lysosomal	rate	2
5	degradation	is	6
6	is	<ROOT>	-1
7	one	is	6
8	of	one	7
9	the	mechanisms	10
10	mechanisms	of	8
11	responsible	mechanisms	10
12	for	responsible	11
13	the	loss	14
14	loss	for	12
15	of	loss	14
16	zeta-chain	of	15
17	.	is	6

0	Our	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	the	promoters	6
5	germline	promoters	6
6	promoters	differ	11
7	and	promoters	6
8	V	promoters	10
9	region	promoters	10
10	promoters	and	7
11	differ	that	3
12	in	differ	11
13	their	dependence	14
14	dependence	in	12
15	on	dependence	14
16	octamer	on	15
17	for	differ	11
18	activation	and	19
19	and	for	17
20	respond	for	17
21	differently	respond	20
22	to	enhancer	23
23	enhancer	respond	20
24	activation	enhancer	23
25	.	activation	24

0	Cyclin	A	1
1	A	was	2
2	was	<ROOT>	-1
3	observed	was	2
4	after	observed	3
5	4	days	6
6	days	after	4
7	of	days	6
8	costimulation	of	7
9	with	costimulation	8
10	anti	CD2	11
11	CD2	with	9
12	+	CD2	11
13	CD28	+	12
14	whereas	of	7
15	stimulation	was	2
16	by	stimulation	15
17	anti	by	16
18	CD2	or	19
19	or	anti	17
20	anti	anti	17
21	CD28	anti	20
22	alone	was	23
23	was	CD28	21
24	not	was	2
25	effective	was	2
26	.	was	2

0	Regulation	(	5
1	of	heavy	3
2	immunoglobulin	heavy	3
3	heavy	Regulation	0
4	chain	Regulation	0
5	(	gene	8
6	IgH	(	5
7	)	(	5
8	gene	<ROOT>	-1
9	expression	gene	8
10	is	expression	9
11	controlled	is	10
12	by	controlled	11
13	a	intronic	18
14	B	intronic	18
15	cell-specific	intronic	18
16	promoter	intronic	18
17	,	intronic	18
18	intronic	by	12
19	enhancer	and	20
20	and	is	10
21	additional	B	22
22	B	and	20
23	cell-specific	gene	8
24	enhancer	recently	27
25	elements	recently	27
26	identified	recently	27
27	recently	gene	8
28	in	3'	30
29	the	3'	30
30	3'	recently	27
31	end	gene	8
32	of	end	31
33	the	locus	35
34	IgH	locus	35
35	locus	of	32
36	.	gene	8

0	Activation	correlates	5
1	of	Activation	0
2	the	pathway	4
3	Jak-Stat	pathway	4
4	pathway	of	1
5	correlates	<ROOT>	-1
6	with	correlates	5
7	proliferative	signaling	8
8	signaling	with	6
9	by	signaling	8
10	the	G-CSFR	11
11	G-CSFR	by	9
12	and	G-CSFR	11
13	requires	and	12
14	the	requires	13
15	membrane-proximal	1	17
16	box	1	17
17	1	the	14
18	PXP	correlates	5
19	motif	correlates	5
20	,	correlates	5
21	which	correlates	5
22	is	which	21
23	conserved	is	22
24	in	conserved	23
25	members	in	24
26	of	cytokine	28
27	the	cytokine	28
28	cytokine	members	25
29	receptor	correlates	5
30	superfamily	correlates	5
31	.	correlates	5

0	We	provide	1
1	provide	<ROOT>	-1
2	evidence	provide	1
3	that	evidence	2
4	FCM	inhibits	6
5	strongly	inhibits	6
6	inhibits	that	3
7	the	activation	10
8	LPS-induced	activation	10
9	NF-kappaB	activation	10
10	activation	inhibits	6
11	in	inhibits	6
12	PBM	inhibits	6
13	.	provide	1

0	IL-13	had	1
1	had	<ROOT>	-1
2	similar	effects	3
3	effects	had	1
4	on	had	1
5	CD11b	on	4
6	and	CD11b	5
7	CD13	and	6
8	,	had	1
9	but	had	1
10	no	effect	11
11	effect	but	9
12	on	effect	11
13	CD26	on	12
14	.	had	1

0	Agonistic	<ROOT>	-1
1	activity	Agonistic	0
2	of	activity	1
3	a	Fv	6
4	CD40-specific	Fv	6
5	single-chain	Fv	6
6	Fv	of	2
7	constructed	Fv	6
8	from	variable	10
9	the	variable	10
10	variable	constructed	7
11	regions	Agonistic	0
12	of	mAb	13
13	mAb	regions	11
14	G28-5	Agonistic	0
15	.	Agonistic	0

0	The	cells	1
1	cells	were	2
2	were	<ROOT>	-1
3	then	were	2
4	stimulated	were	2
5	for	stimulated	4
6	6	h	7
7	h	for	5
8	.	were	2

0	In	<ROOT>	-1
1	lymphocyte	In	0
2	differentiation	lymphocyte	1
3	,	play	8
4	several	proteins	7
5	HMG	proteins	7
6	box	proteins	7
7	proteins	play	8
8	play	differentiation	2
9	a	role	11
10	decisive	role	11
11	role	lymphocyte	1
12	.	In	0

0	The	phenotype	1
1	phenotype	knockout	4
2	of	knockout	4
3	RelB	knockout	4
4	knockout	implicates	6
5	mice	knockout	4
6	implicates	<ROOT>	-1
7	this	member	8
8	member	implicates	6
9	of	member	8
10	the	of	9
11	NF	kappa	12
12	kappa	the	10
13	B/Rel	family	14
14	family	the	10
15	in	the	10
16	DC	implicates	6
17	differentiation	implicates	6
18	.	implicates	6

0	Cytokines	<ROOT>	-1
1	:	Cytokines	0
2	shared	receptors	3
3	receptors	Cytokines	0
4	,	receptors	3
5	distinct	functions	6
6	functions	receptors	3
7	.	Cytokines	0

0	Cellular	status	2
1	redox	status	2
2	status	influences	3
3	influences	<ROOT>	-1
4	both	cytotoxic	5
5	cytotoxic	influences	3
6	and	cytotoxic	5
7	NF-kappa	B	8
8	B	and	6
9	activation	B	8
10	in	killer	12
11	natural	killer	12
12	killer	influences	3
13	cells	influences	3
14	.	influences	3

0	Two	regions	1
1	regions	were	2
2	were	<ROOT>	-1
3	identified	were	2
4	:	were	2
5	region	were	2
6	I	region	5
7	(	I	6
8	-182	(	7
9	to	-162	10
10	-162	-182	8
11	bp	)	12
12	)	-162	10
13	contained	-162	10
14	an	site	17
15	overlapping	site	17
16	Sp1/Egr-1	site	17
17	site	contained	13
18	,	-162	10
19	and	region	5
20	region	and	19
21	II	region	20
22	(	region	20
23	-119	(	22
24	to	)	26
25	-88	)	26
26	)	-119	23
27	contained	)	26
28	CRE	)	26
29	and	region	5
30	NF-kappaB	(	31
31	(	were	2
32	designated	(	31
33	kappaB3	were	2
34	)	were	2
35	sites	were	2
36	.	were	2

0	The	results	1
1	results	show	2
2	show	<ROOT>	-1
3	the	show	2
4	presence	the	3
5	of	family	8
6	several	family	8
7	NF-kappaB	family	8
8	family	presence	4
9	members	presence	4
10	,	members	9
11	with	,	10
12	the	RelA	14
13	transactivating	RelA	14
14	RelA	with	11
15	being	RelA	14
16	engaged	being	15
17	in	engaged	16
18	multiple	.	20
19	complexes	.	20
20	.	in	17

0	These	APC	2
1	RelB+	APC	2
2	APC	were	3
3	were	<ROOT>	-1
4	potent	were	3
5	stimulators	potent	4
6	of	stimulators	5
7	the	MLR	8
8	MLR	of	6
9	.	were	3

0	A	enhancer	3
1	T	enhancer	3
2	cell-specific	enhancer	3
3	enhancer	is	8
4	in	enhancer	3
5	the	locus	7
6	interleukin-3	locus	7
7	locus	in	4
8	is	<ROOT>	-1
9	activated	by	11
10	cooperatively	activated	9
11	by	is	8
12	Oct	by	11
13	and	by	11
14	NFAT	is	8
15	elements	within	16
16	within	a	17
17	a	is	8
18	DNase	I-hypersensitive	19
19	I-hypersensitive	site	20
20	site	a	17
21	.	is	8

0	The	<ROOT>	-1
1	synergistic	The	0
2	effect	synergistic	1
3	on	growth	4
4	growth	effect	2
5	inhibition	and	6
6	and	growth	4
7	induction	growth	4
8	of	induction	7
9	differentiation	of	8
10	required	effect	2
11	simultaneous	The	0
12	treatment	with	13
13	with	The	0
14	differanisole	A	15
15	A	with	13
16	and	A	15
17	9cisRA	and	16
18	.	The	0

0	At	<ROOT>	-1
1	the	end	3
2	5'	end	3
3	end	At	0
4	,	IFN-gamma	7
5	this	IFN-gamma	7
6	70-bp	IFN-gamma	7
7	IFN-gamma	sequence	11
8	response	element	9
9	element	contains	10
10	contains	IFN-gamma	7
11	sequence	At	0
12	similarity	At	0
13	to	activated	16
14	the	gamma	15
15	gamma	activated	16
16	activated	At	0
17	site	(	18
18	(	At	0
19	GAS	At	0
20	)	At	0
21	.	At	0

0	Interestingly	was	8
1	,	expression	3
2	the	expression	3
3	expression	Interestingly	0
4	level	of	5
5	of	mRNA	7
6	p27Kip1	mRNA	7
7	mRNA	was	8
8	was	declined	16
9	maximal	was	8
10	in	was	8
11	resting	in	10
12	Go	was	8
13	T-cells	and	14
14	and	Go	12
15	rapidly	was	8
16	declined	<ROOT>	-1
17	following	anti-CD3	18
18	anti-CD3	declined	16
19	activation	declined	16
20	.	declined	16

0	GATA-1	is	4
1	DNA	binding	2
2	binding	GATA-1	0
3	activity	GATA-1	0
4	is	<ROOT>	-1
5	down-regulated	is	4
6	in	down-regulated	5
7	late	phase	9
8	S	phase	9
9	phase	in	6
10	in	down-regulated	5
11	erythroid	cells	12
12	cells	in	10
13	.	is	4

0	Gene	studies	2
1	inactivation	studies	2
2	studies	genes	10
3	on	studies	2
4	the	PU.1	5
5	PU.1	on	3
6	,	studies	2
7	Ikaros	studies	2
8	and	GATA-3	9
9	GATA-3	Ikaros	7
10	genes	have	11
11	have	<ROOT>	-1
12	revealed	have	11
13	that	revealed	12
14	their	factors	16
15	encoded	factors	16
16	factors	are	17
17	are	that	13
18	essential	are	17
19	for	essential	18
20	the	step	23
21	earliest	step	23
22	commitment	step	23
23	step	for	19
24	into	the	25
25	the	step	23
26	B	T	28
27	and	T	28
28	T	revealed	12
29	lymphoid	have	11
30	lineages	have	11
31	.	have	11

0	To	<ROOT>	-1
1	validate	To	0
2	the	method	3
3	method	validate	1
4	,	To	0
5	we	,	4
6	made	binding	11
7	use	made	6
8	of	receptor	10
9	earlier	receptor	10
10	receptor	made	6
11	binding	we	5
12	studies	binding	11
13	indicating	that	14
14	that	binding	11
15	normal	binding	11
16	human	we	5
17	monocytes	and	18
18	and	we	5
19	activated	we	5
20	,	we	5
21	but	,	20
22	not	resting	23
23	resting	,	20
24	,	we	5
25	lymphocytes	To	0
26	expressed	To	0
27	the	expressed	26
28	VDR	To	0
29	.	To	0

0	Identification	<ROOT>	-1
1	of	Identification	0
2	Bcd	of	1
3	,	Identification	0
4	a	novel	5
5	novel	Identification	0
6	proto-oncogene	novel	5
7	expressed	proto-oncogene	6
8	in	expressed	7
9	B-cells	Identification	0
10	.	Identification	0

0	In	V3-BH10	3
1	addition	In	0
2	,	V3-BH10	3
3	V3-BH10	generated	4
4	generated	<ROOT>	-1
5	the	arrest	6
6	arrest	generated	4
7	of	arrest	6
8	Kit225	cells	9
9	cells	of	7
10	and	generated	4
11	also	and	10
12	purified	and	10
13	CD8-positive	generated	4
14	lymphocytes	generated	4
15	in	generated	4
16	G1	generated	4
17	phase	generated	4
18	in	the	19
19	the	generated	4
20	presence	the	19
21	of	presence	20
22	IL-2	generated	4
23	.	generated	4

0	Unexpectedly	was	27
1	,	Unexpectedly	0
2	a	site	7
3	second	site	7
4	,	site	7
5	stronger	site	7
6	RBP-Jkappa-binding	site	7
7	site	Unexpectedly	0
8	,	Unexpectedly	0
9	which	lies	10
10	lies	Unexpectedly	0
11	within	intracellular	13
12	the	intracellular	13
13	intracellular	lies	10
14	domain	close	15
15	close	intracellular	13
16	to	close	15
17	the	region	19
18	transmembrane	region	19
19	region	to	16
20	and	to	16
21	significantly	augments	22
22	augments	association	23
23	association	and	20
24	with	association	23
25	RBP-Jkappa	Unexpectedly	0
26	,	Unexpectedly	0
27	was	<ROOT>	-1
28	not	was	27
29	needed	was	27
30	for	needed	29
31	oncogenesis	for	30
32	or	oncogenesis	31
33	for	transcriptional	34
34	transcriptional	oncogenesis	31
35	activation	was	27
36	.	was	27

0	We	show	2
1	now	show	2
2	show	<ROOT>	-1
3	that	show	2
4	a	motif	6
5	mutant	motif	6
6	motif	Mac	31
7	that	motif	6
8	exchanges	C	12
9	the	C	12
10	terminal	3'	11
11	3'	C	12
12	C	fails	16
13	for	C	12
14	a	G	15
15	G	for	13
16	fails	that	7
17	to	fails	16
18	bind	to	17
19	the	homodimer	21
20	p50	homodimer	21
21	homodimer	bind	18
22	that	is	23
23	is	homodimer	21
24	upregulated	is	23
25	in	ant	28
26	LPS	ant	28
27	toler	ant	28
28	ant	upregulated	24
29	human	motif	6
30	Mono	Mac	31
31	Mac	that	3
32	6	Mac	31
33	cells	show	2
34	.	show	2

0	To	central	25
1	gain	To	0
2	a	understanding	4
3	better	understanding	4
4	understanding	sequence	15
5	of	repeat	11
6	the	impact	7
7	impact	terminal	10
8	of	terminal	10
9	long	terminal	10
10	terminal	of	5
11	repeat	understanding	4
12	(	understanding	4
13	LTR	understanding	4
14	)	understanding	4
15	sequence	gain	1
16	diversity	To	0
17	on	diversity	16
18	LTR-directed	on	17
19	gene	LTR-directed	18
20	expression	gene	19
21	in	expression	20
22	cells	To	0
23	of	central	25
24	the	central	25
25	central	(	28
26	nervous	central	25
27	system	central	25
28	(	<ROOT>	-1
29	CNS	(	28
30	)	(	28
31	and	(	28
32	immune	(	28
33	system	(	28
34	,	(	28
35	we	,	34
36	amplified	and	37
37	and	we	35
38	cloned	proviral	41
39	LTRs	proviral	41
40	from	LTRs	39
41	proviral	and	37
42	DNA	in	43
43	in	proviral	41
44	HIV-1-infected	proviral	41
45	peripheral	proviral	41
46	blood	proviral	41
47	.	(	28

0	G0S3	is	1
1	is	<ROOT>	-1
2	a	member	3
3	member	is	1
4	of	member	3
5	a	set	6
6	set	regulatory	11
7	of	regulatory	11
8	putative	regulatory	11
9	G0/G1	switch	10
10	switch	regulatory	11
11	regulatory	of	4
12	genes	(	13
13	(	is	1
14	G0S	genes	15
15	genes	(	13
16	)	is	1
17	selected	is	1
18	by	screening	19
19	screening	selected	17
20	cDNA	is	1
21	libraries	is	1
22	prepared	is	1
23	from	human	24
24	human	prepared	22
25	blood	is	1
26	mononuclear	is	1
27	cells	is	1
28	cultured	is	1
29	for	2	30
30	2	is	1
31	hr	is	1
32	with	hr	31
33	lectin	is	1
34	and	is	1
35	cycloheximide	is	1
36	.	is	1

0	Subcellular	protein	19
1	localization	Subcellular	0
2	analysis	localization	1
3	in	analysis	2
4	various	in	3
5	cells	monoclonal	10
6	,	monoclonal	10
7	using	monoclonal	10
8	a	monoclonal	10
9	specific	monoclonal	10
10	monoclonal	various	4
11	antibody	monoclonal	10
12	raised	Subcellular	0
13	against	raised	12
14	SR-BP	Subcellular	0
15	,	Subcellular	0
16	demonstrated	Subcellular	0
17	that	demonstrated	16
18	this	demonstrated	16
19	protein	was	20
20	was	<ROOT>	-1
21	associated	was	20
22	with	associated	21
23	the	envelope	25
24	nuclear	envelope	25
25	envelope	with	22
26	.	was	20

0	Epstein-Barr	virus	1
1	virus	<ROOT>	-1
2	EBNA3C	virus	1
3	represses	EBNA3C	2
4	Cp	,	5
5	,	represses	3
6	the	,	5
7	major	the	6
8	promoter	major	7
9	for	EBNA	10
10	EBNA	promoter	8
11	expression	,	12
12	,	EBNA	10
13	but	no	15
14	has	no	15
15	no	,	12
16	effect	promoter	8
17	on	effect	16
18	the	promoter	19
19	promoter	gene	23
20	of	gene	23
21	the	gene	23
22	cell	gene	23
23	gene	on	17
24	CD21	virus	1
25	.	virus	1

0	Both	responses	2
1	these	responses	2
2	responses	are	3
3	are	<ROOT>	-1
4	inhibited	are	3
5	by	inhibited	4
6	CsA	by	5
7	.	are	3

0	In	<ROOT>	-1
1	contrast	In	0
2	with	contrast	1
3	the	observation	4
4	observation	with	2
5	in	T	6
6	T	observation	4
7	cells	In	0
8	,	c-Rel	9
9	c-Rel	In	0
10	induction	c-Rel	9
11	was	induction	10
12	not	blocked	13
13	blocked	was	11
14	by	blocked	13
15	PF	by	14
16	in	blocked	13
17	B	cells	18
18	cells	in	16
19	.	In	0

0	The	study	2
1	present	study	2
2	study	demonstrates	3
3	demonstrates	,	31
4	that	binding	6
5	AP-2	binding	6
6	binding	demonstrates	3
7	sequences	are	8
8	are	demonstrates	3
9	essential	are	8
10	for	are	8
11	increased	for	10
12	transcription	the	14
13	from	the	14
14	the	increased	11
15	B2	promoter	16
16	promoter	the	14
17	during	increased	11
18	monocyte-macrophage	increased	11
19	differentiation	demonstrates	3
20	and	demonstrates	3
21	that	demonstrates	3
22	AP-2	,	23
23	,	expressed	24
24	expressed	that	21
25	exogenously	expressed	24
26	in	expressed	24
27	THP-1	in	26
28	and	other	29
29	other	expressed	24
30	cells	demonstrates	3
31	,	<ROOT>	-1
32	activates	the	35
33	transcription	the	35
34	from	the	35
35	the	,	31
36	B2	,	31
37	promoter	,	31
38	.	,	31

0	The	findings	1
1	findings	presented	2
2	presented	link	4
3	here	presented	2
4	link	lipoprotein	7
5	an	lipoprotein	7
6	atheogenic	lipoprotein	7
7	lipoprotein	<ROOT>	-1
8	,	lipoprotein	7
9	LDL	lipoprotein	7
10	,	lipoprotein	7
11	with	the	12
12	the	lipoprotein	7
13	induction	the	12
14	of	adhesion	16
15	an	adhesion	16
16	adhesion	induction	13
17	molecule	lipoprotein	7
18	important	lipoprotein	7
19	in	important	18
20	atherogenesis	in	19

0	Inhibition	THP-1-hGH	6
1	of	TNF-alpha	2
2	TNF-alpha	Inhibition	0
3	secretion	by	4
4	by	Inhibition	0
5	LPS-stimulated	THP-1-hGH	6
6	THP-1-hGH	was	8
7	cells	THP-1-hGH	6
8	was	<ROOT>	-1
9	associated	was	8
10	with	associated	9
11	a	decrease	12
12	decrease	with	10
13	in	decrease	12
14	nuclear	translocation	15
15	translocation	in	13
16	of	translocation	15
17	nuclear	factor-kappaB	18
18	factor-kappaB	of	16
19	.	was	8

0	The	mass	2
1	molecular	mass	2
2	mass	is	6
3	of	mass	2
4	these	factors	5
5	factors	of	3
6	is	characteristics	15
7	approximately	is	6
8	28	approximately	7
9	kDa	,	10
10	,	28	8
11	and	,	10
12	their	and	11
13	DNA	binding	14
14	binding	and	11
15	characteristics	<ROOT>	-1
16	are	indistinguishable	17
17	indistinguishable	characteristics	15
18	from	indistinguishable	17
19	those	factor	24
20	of	factor	24
21	the	factor	24
22	novel	factor	24
23	nuclear	factor	24
24	factor	from	18
25	MS-2	characteristics	15
26	.	characteristics	15

0	The	element	2
1	GAS	element	2
2	element	is	7
3	from	element	2
4	the	motif	6
5	70-bp	motif	6
6	motif	from	3
7	is	<ROOT>	-1
8	sufficient	is	7
9	to	sufficient	8
10	confer	to	9
11	responsiveness	to	12
12	to	confer	10
13	IFN-gamma	to	12
14	using	IFN-gamma	13
15	a	to	12
16	heterologous	a	15
17	minimal	promoter	18
18	promoter	is	7
19	.	is	7

0	Binding	indicated	9
1	assays	Binding	0
2	using	assays	1
3	125I-labeled	using	2
4	C-C	125I-labeled	3
5	chemokines	C-C	4
6	in	chemokines	5
7	mammalian	cells	8
8	cells	in	6
9	indicated	<ROOT>	-1
10	that	indicated	9
11	CHEMR1	did	12
12	did	that	10
13	not	did	12
14	bind	did	12
15	MIP-1alpha	bind	14
16	,	indicated	9
17	RANTES	indicated	9
18	,	indicated	9
19	or	indicated	9
20	MIP-1beta	or	19
21	,	indicated	9
22	whereas	binds	24
23	CCR-1	binds	24
24	binds	indicated	9
25	MIP-1alpha	indicated	9
26	and	indicated	9
27	RANTES	indicated	9
28	.	indicated	9

0	The	cytokine	2
1	immunomodulatory	cytokine	2
2	cytokine	affects	4
3	IL-4	cytokine	2
4	affects	<ROOT>	-1
5	cells	affects	4
6	of	cells	5
7	most	lineages	9
8	hemopoietic	lineages	9
9	lineages	of	6
10	.	lineages	9

0	The	levels	1
1	levels	mRNA	4
2	of	mRNA	4
3	ICAM-1	mRNA	4
4	mRNA	were	9
5	expression	mRNA	4
6	of	ATL	7
7	ATL	expression	5
8	cells	mRNA	4
9	were	<ROOT>	-1
10	generally	higher	11
11	higher	were	9
12	than	higher	11
13	those	than	12
14	of	T-lymphoid	15
15	T-lymphoid	those	13
16	cells	were	9
17	.	were	9

0	In	which	14
1	these	In	0
2	cells	,	3
3	,	factors	5
4	nuclear	factors	5
5	factors	these	1
6	involved	factors	5
7	in	involved	6
8	activation	in	7
9	of	activation	8
10	the	LTR	12
11	HIV-1	LTR	12
12	LTR	of	9
13	,	which	14
14	which	are	24
15	contains	transcriptional	17
16	the	transcriptional	17
17	transcriptional	control	18
18	control	which	14
19	elements	of	20
20	of	which	14
21	the	virus	22
22	virus	of	20
23	,	which	14
24	are	<ROOT>	-1
25	unknown	are	24
26	.	are	24

0	All	cases	1
1	cases	<ROOT>	-1
2	of	cases	1
3	follicular	of	2
4	,	cases	1
5	mixed	cases	1
6	small	mixed	5
7	and	small	6
8	large	and	7
9	cell	showed	11
10	lymphomas	showed	11
11	showed	large	8
12	LAZ3/BCL6	cases	1
13	expression	confined	14
14	confined	cases	1
15	to	the	16
16	the	confined	14
17	neoplastic	cases	1
18	follicles	cases	1
19	.	cases	1

0	Chromosomal	translocation	1
1	translocation	has	13
2	resulting	translocation	1
3	in	resulting	2
4	abnormal	expression	5
5	expression	in	3
6	of	expression	5
7	the	gene	9
8	LAZ3/BCL6	gene	9
9	gene	of	6
10	in	gene	9
11	B	cells	12
12	cells	in	10
13	has	<ROOT>	-1
14	been	has	13
15	implicated	been	14
16	in	implicated	15
17	the	tumorigenesis	18
18	tumorigenesis	implicated	15
19	of	tumorigenesis	18
20	non-Hodgkin	lymphoma	21
21	lymphoma	of	19
22	(	NHL	23
23	NHL	tumorigenesis	18
24	)	NHL	23
25	.	has	13

0	Transfection	cDNA	11
1	of	an	2
2	an	vector	4
3	expression	an	2
4	vector	Transfection	0
5	containing	vector	4
6	ORF2	containing	5
7	but	ORF2	6
8	not	Transfection	0
9	full	Transfection	0
10	length	Transfection	0
11	cDNA	was	12
12	was	<ROOT>	-1
13	able	was	12
14	to	able	13
15	transform	to	14
16	NIH3T3	cells	17
17	cells	transform	15
18	and	cells	17
19	induce	and	18
20	tumors	induce	19
21	in	tumors	20
22	nude	tumors	20
23	mice	.	24
24	.	nude	22

0	We	analyzed	1
1	analyzed	<ROOT>	-1
2	the	activity	3
3	activity	analyzed	1
4	of	activity	3
5	the	enhancer	6
6	enhancer	of	4
7	,	analyzed	1
8	the	promoter	9
9	promoter	the	11
10	and	the	11
11	the	,	7
12	silencer	analyzed	1
13	of	silencer	12
14	the	of	13
15	human	T	19
16	CD4	T	19
17	gene	T	19
18	during	T	19
19	T	the	14
20	cell	the	14
21	development	analyzed	1
22	using	analyzed	1
23	transgenic	analyzed	1
24	mice	analyzed	1
25	.	analyzed	1

0	These	<ROOT>	-1
1	phosphotyrosines	These	0
2	serve	phosphotyrosines	1
3	as	serve	2
4	docking	as	3
5	sites	latent	7
6	for	latent	7
7	latent	docking	4
8	,	latent	7
9	cytoplasmic	factors	11
10	transcription	factors	11
11	factors	known	12
12	known	latent	7
13	as	known	12
14	signal	as	13
15	transducers	signal	14
16	and	transducers	15
17	activators	and	16
18	of	(	20
19	transcription	of	18
20	(	activators	17
21	Stat	(	20
22	)	Stat	21
23	proteins	These	0
24	.	These	0

0	The	study	2
1	present	study	2
2	study	demonstrates	3
3	demonstrates	secreted	24
4	that	demonstrates	3
5	human	cells	8
6	THP-1	cells	8
7	promonocytic	cells	8
8	cells	that	4
9	,	demonstrates	3
10	engineered	demonstrates	3
11	by	engineered	10
12	gene	transfer	13
13	transfer	by	11
14	to	transfer	13
15	constitutively	human	17
16	produce	constitutively	15
17	human	transfer	13
18	growth	hormone	19
19	hormone	(	20
20	(	demonstrates	3
21	hGH	demonstrates	3
22	)	demonstrates	3
23	,	secreted	24
24	secreted	<ROOT>	-1
25	depressed	secreted	24
26	amounts	depressed	25
27	of	amounts	26
28	TNF-alpha	of	27
29	in	depressed	25
30	response	in	29
31	to	response	30
32	challenge	to	31
33	by	challenge	32
34	LPS	challenge	32
35	.	secreted	24

0	In	was	4
1	contrast	In	0
2	,	was	4
3	POS-1	was	4
4	was	<ROOT>	-1
5	not	was	4
6	found	was	4
7	in	found	6
8	nuclear	extracts	9
9	extracts	human	11
10	of	human	11
11	human	in	7
12	Th1	human	11
13	clones	was	4
14	.	was	4

0	Reconstitution	restored	7
1	of	Jak1	2
2	Jak1	Reconstitution	0
3	expression	Reconstitution	0
4	in	E1C3	5
5	E1C3	expression	3
6	cells	Reconstitution	0
7	restored	<ROOT>	-1
8	the	ability	9
9	ability	restored	7
10	of	ability	9
11	IL-4	of	10
12	to	ability	9
13	induce	tyrosine	17
14	IRS	and	15
15	and	tyrosine	17
16	Stat6	and	15
17	tyrosine	to	12
18	phosphorylation	tyrosine	17
19	.	restored	7

0	An	complex	2
1	additional	complex	2
2	complex	composed	3
3	composed	appeared	10
4	of	(	6
5	p50/RelA	of	4
6	(	composed	3
7	p65	(	6
8	)	composed	3
9	heterodimers	composed	3
10	appeared	<ROOT>	-1
11	only	in	12
12	in	appeared	10
13	nuclear	extracts	14
14	extracts	in	12
15	from	extracts	14
16	7-day	MDMs	17
17	MDMs	from	15
18	.	appeared	10

0	Both	primers	1
1	primers	detected	2
2	detected	<ROOT>	-1
3	a	copy	5
4	single	copy	5
5	copy	detected	2
6	of	adenovirus	8
7	the	adenovirus	8
8	adenovirus	type	9
9	type	copy	5
10	2	detected	2
11	genome	detected	2
12	but	detected	2
13	were	but	12
14	less	sensitive	15
15	sensitive	were	13
16	for	were	13
17	the	group	18
18	group	for	16
19	B	type	20
20	type	were	13
21	35	type	20
22	.	detected	2

0	We	conclude	1
1	conclude	functions	12
2	that	conclude	1
3	:	that	2
4	(	:	3
5	i	(	4
6	)	of	8
7	suppression	of	8
8	of	factor	11
9	specific	factor	11
10	transcription	factor	11
11	factor	i	5
12	functions	<ROOT>	-1
13	can	functions	12
14	potentially	serve	15
15	serve	can	13
16	as	serve	15
17	a	as	16
18	marker	of	19
19	of	a	17
20	exposure	of	19
21	to	exposure	20
22	oxidative	to	21
23	stress	oxidative	22
24	and	of	19
25	its	effects	26
26	effects	and	24
27	on	human	28
28	human	effects	26
29	lymphocytes	functions	12
30	;	functions	12
31	(	ii	32
32	ii	peroxidation	35
33	)	ii	32
34	lipid	peroxidation	35
35	peroxidation	is	36
36	is	functions	12
37	only	is	36
38	detectable	is	36
39	in	detectable	38
40	human	functions	12
41	lymphocytes	functions	12
42	upon	functions	12
43	exposure	functions	12
44	to	functions	12
45	weak	to	44
46	oxidative	to	44
47	stress	which	48
48	which	functions	12
49	does	which	48
50	not	does	49
51	induce	catalase	52
52	catalase	does	49
53	activity	catalase	52
54	;	functions	12
55	(	iii	56
56	iii	activities	63
57	)	iii	56
58	therefore	factor	61
59	,	factor	61
60	transcription	factor	61
61	factor	iii	56
62	DNA-binding	activities	63
63	activities	are	64
64	are	functions	12
65	more	sensitive	66
66	sensitive	are	64
67	to	sensitive	66
68	oxidative	stress	69
69	stress	lipid	71
70	than	stress	69
71	lipid	to	67
72	peroxidation	sensitive	66
73	.	functions	12

0	Of	type	15
1	the	carriers	4
2	5	carriers	4
3	virus	carriers	4
4	carriers	Of	0
5	,	were	7
6	4	,	5
7	were	Of	0
8	infected	were	7
9	with	infected	8
10	type	with	9
11	A	with	9
12	and	with	14
13	1	and	12
14	with	Of	0
15	type	<ROOT>	-1
16	B	type	15
17	EBV	type	15
18	.	type	15

0	In	show	6
1	the	report	3
2	present	report	3
3	report	In	0
4	,	show	6
5	we	show	6
6	show	<ROOT>	-1
7	that	costimulated	9
8	A6H	costimulated	9
9	costimulated	show	6
10	cell	costimulated	9
11	proliferation	show	6
12	and	show	6
13	cytokine	show	6
14	production	cytokine	13
15	in	production	14
16	purified	in	15
17	CD4+	show	6
18	T	show	6
19	cells	show	6
20	.	show	6

0	Since	<ROOT>	-1
1	LPS	Since	0
2	and	Since	0
3	anti-IgM	Since	0
4	were	Since	0
5	unable	were	4
6	to	unable	5
7	activate	to	6
8	RelB	activate	7
9	,	Since	0
10	CD40	appears	11
11	appears	Since	0
12	to	appears	11
13	trigger	to	12
14	a	program	16
15	special	program	16
16	program	trigger	13
17	of	gene	18
18	gene	program	16
19	expression	Since	0
20	involved	expression	19
21	in	expression	19
22	the	proliferation	23
23	proliferation	in	21
24	and/or	differentiation	25
25	differentiation	proliferation	23
26	of	B	27
27	B	proliferation	23
28	lymphocytes	Since	0
29	.	Since	0

0	Bipotential	killer	2
1	T/natural	killer	2
2	killer	cells	7
3	(	NK	4
4	NK	killer	2
5	)	NK	4
6	progenitor	killer	2
7	cells	<ROOT>	-1
8	are	cells	7
9	present	are	8
10	in	present	9
11	the	in	10
12	human	the	11
13	thymus	.	14
14	.	human	12

0	We	demonstrate	2
1	further	demonstrate	2
2	demonstrate	which	18
3	that	demonstrate	2
4	Tax1	activated	6
5	specifically	activated	6
6	activated	that	3
7	the	promoter	10
8	NF-Y-responsive	promoter	10
9	DQbeta	promoter	10
10	promoter	activated	6
11	,	activated	6
12	as	activated	6
13	well	activated	6
14	as	minimal	16
15	a	minimal	16
16	minimal	activated	6
17	promoter	which	18
18	which	<ROOT>	-1
19	contains	which	18
20	only	element	23
21	the	element	23
22	Y-box	element	23
23	element	contains	19
24	.	which	18

0	By	identified	11
1	using	By	0
2	high	screening	4
3	throughput	screening	4
4	screening	using	1
5	of	screening	4
6	microbial	broths	7
7	broths	of	5
8	,	identified	11
9	we	identified	11
10	have	identified	11
11	identified	<ROOT>	-1
12	a	identified	11
13	compound	identified	11
14	,	identified	11
15	designated	09-2210	17
16	Ro	09-2210	17
17	09-2210	,	14
18	,	which	19
19	which	09-2210	17
20	is	which	19
21	able	is	20
22	to	able	21
23	block	T	28
24	anti-CD3	induced	25
25	induced	block	23
26	peripheral	T	28
27	blood	T	28
28	T	to	22
29	cell	to	22
30	activation	identified	11
31	with	identified	11
32	an	with	31
33	IC50	an	32
34	=	IC50	33
35	40	.	37
36	nM	.	37
37	.	=	34

0	While	<ROOT>	-1
1	ICN	appeared	2
2	appeared	While	0
3	primarily	in	4
4	in	appeared	2
5	the	in	4
6	nucleus	,	7
7	,	the	5
8	DeltaE	to	10
9	localized	to	10
10	to	While	0
11	cytoplasmic	to	10
12	and	cytoplasmic	11
13	nuclear	membranes	14
14	membranes	cytoplasmic	11
15	,	While	0
16	suggesting	that	17
17	that	While	0
18	intranuclear	localization	19
19	localization	is	20
20	is	that	17
21	not	is	20
22	essential	is	20
23	for	is	20
24	oncogenesis	for	23
25	or	transcriptional	26
26	transcriptional	oncogenesis	24
27	activation	While	0
28	.	While	0

0	When	was	2
1	18C7	was	2
2	was	inhibited	13
3	incubated	with	4
4	with	MR	5
5	MR	was	2
6	before	MR	5
7	aldosterone	before	6
8	or	aldosterone	7
9	progesterone	was	2
10	,	inhibited	13
11	the	antibody	12
12	antibody	inhibited	13
13	inhibited	<ROOT>	-1
14	75-80	%	15
15	%	inhibited	13
16	of	%	15
17	the	binding	18
18	binding	of	16
19	.	inhibited	13

0	Isoforms	<ROOT>	-1
1	Pax-5b	Isoforms	0
2	and	Pax-5b	1
3	Pax-5e	Isoforms	0
4	have	Isoforms	0
5	spliced	have	4
6	out	spliced	5
7	their	exon	9
8	second	exon	9
9	exon	spliced	5
10	,	Isoforms	0
11	resulting	in	12
12	in	Isoforms	0
13	proteins	Isoforms	0
14	with	DNA-binding	18
15	only	DNA-binding	18
16	a	DNA-binding	18
17	partial	DNA-binding	18
18	DNA-binding	Isoforms	0
19	domain	Isoforms	0
20	.	Isoforms	0

0	Using	<ROOT>	-1
1	deletion	constructs	2
2	constructs	Using	0
3	,	Using	0
4	we	Using	0
5	have	we	4
6	defined	have	5
7	an	defined	6
8	active	of	11
9	promoter	of	11
10	region	of	11
11	of	an	7
12	1056	of	11
13	bp	.	14
14	.	1056	12

0	Intragenic	were	6
1	TSG101	Intragenic	0
2	deletions	TSG101	1
3	in	deletions	2
4	RNA	transcripts	5
5	transcripts	in	3
6	were	<ROOT>	-1
7	frequently	were	6
8	found	were	6
9	in	found	8
10	all	types	11
11	types	in	9
12	of	types	11
13	samples	of	12
14	.	were	6

0	In	investigated	6
1	the	study	3
2	present	study	3
3	study	In	0
4	,	investigated	6
5	we	investigated	6
6	investigated	<ROOT>	-1
7	the	mechanism	9
8	induction	mechanism	9
9	mechanism	investigated	6
10	of	in	13
11	SAA	in	13
12	gene	in	13
13	in	mechanism	9
14	THP-1	investigated	6
15	monocyte/macrophage	cells	16
16	cells	investigated	6
17	which	play	18
18	play	critical	20
19	a	critical	20
20	critical	investigated	6
21	role	critical	20
22	in	fatty	27
23	the	development	24
24	development	fatty	27
25	of	fatty	27
26	atherosclerotic	fatty	27
27	fatty	role	21
28	streak	investigated	6
29	and	investigated	6
30	plaque	and	29
31	formation	investigated	6
32	.	investigated	6

0	Characterization	B1	4
1	of	B1	4
2	the	B1	4
3	NF-kappa	B1	4
4	B1	identified	6
5	promoter	B1	4
6	identified	<ROOT>	-1
7	an	site	9
8	Egr-1	site	9
9	site	identified	6
10	which	was	11
11	was	site	9
12	found	was	11
13	to	found	12
14	be	to	13
15	essential	be	14
16	for	be	14
17	both	induction	20
18	the	induction	20
19	PMA/PHA-mediated	induction	20
20	induction	for	16
21	as	induction	20
22	well	induction	20
23	as	the	24
24	the	induction	20
25	synergistic	the	24
26	activation	observed	27
27	observed	the	24
28	after	the	29
29	the	observed	27
30	expression	subunit	34
31	of	subunit	34
32	the	subunit	34
33	RelA	subunit	34
34	subunit	the	29
35	of	NF-kappa	36
36	NF-kappa	subunit	34
37	B	identified	6
38	and	identified	6
39	Egr-1	identified	6
40	.	identified	6

0	Disruption	abolished	15
1	of	Disruption	0
2	the	spacing	4
3	conserved	spacing	4
4	spacing	of	1
5	between	spacing	4
6	the	site	9
7	proximal	site	9
8	AP-1	site	9
9	site	B	13
10	and	B	13
11	the	B	13
12	kappa	B	13
13	B	between	5
14	site	Disruption	0
15	abolished	<ROOT>	-1
16	LPS	abolished	15
17	induction	.	18
18	.	LPS	16

0	CIF	failed	1
1	failed	<ROOT>	-1
2	to	failed	1
3	inhibit	to	2
4	several	inhibit	3
5	other	several	4
6	enhancer	.	8
7	elements	.	8
8	.	other	5

0	BACKGROUND	<ROOT>	-1
1	:	BACKGROUND	0
2	The	reduction	3
3	reduction	BACKGROUND	0
4	of	reduction	3
5	symptoms	of	4
6	due	reduction	3
7	to	with	9
8	treatment	with	9
9	with	due	6
10	corticosteroids	reduction	3
11	varies	reduction	3
12	among	BACKGROUND	0
13	patients	among	12
14	with	patients	13
15	perennial	rhinitis	16
16	rhinitis	with	14
17	.	BACKGROUND	0

0	The	effect	1
1	effect	<ROOT>	-1
2	of	effect	1
3	temperature	of	2
4	,	beta	5
5	beta	effect	1
6	2-microglobulin	(	7
7	(	beta	5
8	beta	beta	5
9	2-m	effect	1
10	)	serum	14
11	and	calf	13
12	fetal	calf	13
13	calf	)	10
14	serum	2-m	9
15	(	serum	14
16	FCS	effect	1
17	)	effect	1
18	on	effect	1
19	the	binding	20
20	binding	on	18
21	and	binding	20
22	the	stability	23
23	stability	was	28
24	of	stability	23
25	the	complex	27
26	HLA/peptide	complex	27
27	complex	of	24
28	was	and	21
29	studied	was	28
30	.	effect	1

0	NB4	cells	1
1	cells	pulse-exposed	2
2	pulse-exposed	<ROOT>	-1
3	(	pulse-exposed	2
4	30	minutes	5
5	minutes	(	3
6	)	minutes	5
7	to	pulse-exposed	2
8	all-trans	to	7
9	retinoic	all-trans	8
10	acid	(	11
11	(	retinoic	9
12	ATRA	retinoic	9
13	)	ATRA	12
14	,	all-trans	8
15	washed	all-trans	8
16	,	all-trans	8
17	and	pulse-exposed	2
18	cultured	(	19
19	(	pulse-exposed	2
20	3	pulse-exposed	2
21	days	pulse-exposed	2
22	)	pulse-exposed	2
23	with	pulse-exposed	2
24	either	with	23
25	dimethylsulfoxide	had	35
26	(	DMSO	27
27	DMSO	dimethylsulfoxide	25
28	)	DMSO	27
29	or	dimethylsulfoxide	25
30	hexamethylene	bisacetamide	31
31	bisacetamide	or	29
32	(	bisacetamide	31
33	HMBA	bisacetamide	31
34	)	bisacetamide	31
35	had	either	24
36	a	increase	38
37	prominent	increase	38
38	increase	had	35
39	in	increase	38
40	levels	in	39
41	of	levels	40
42	C/EBP	mRNA	44
43	epsilon	mRNA	44
44	mRNA	of	41
45	and	of	41
46	an	increase	47
47	increase	and	45
48	in	granulocytic	49
49	granulocytic	increase	47
50	differentiation	granulocytic	49
51	,	of	41
52	but	of	41
53	exposure	had	60
54	to	exposure	53
55	either	DMSO	56
56	DMSO	to	54
57	or	DMSO	56
58	HMBA	or	57
59	alone	HMBA	58
60	had	but	52
61	no	effect	62
62	effect	had	60
63	on	effect	62
64	base	on	63
65	levels	base	64
66	of	levels	65
67	C/EBP	epsilon	68
68	epsilon	of	66
69	and	of	66
70	did	and	69
71	not	differentiation	73
72	induce	not	71
73	differentiation	did	70
74	.	differentiation	73

0	The	production	2
1	coordinated	production	2
2	production	a	8
3	of	production	2
4	all	cells	6
5	blood	cells	6
6	cells	of	3
7	from	a	8
8	a	is	12
9	common	a	8
10	stem	a	8
11	cell	a	8
12	is	<ROOT>	-1
13	a	process	16
14	highly	regulated	15
15	regulated	process	16
16	process	is	12
17	involving	process	16
18	successive	stages	19
19	stages	involving	17
20	of	stages	19
21	commitment	and	22
22	and	of	20
23	differentiation	and	22
24	.	is	12

0	eTh2	<ROOT>	-1
1	cells	eTh2	0
2	are	cells	1
3	the	source	5
4	major	source	5
5	source	are	2
6	of	source	5
7	IL-4	of	6
8	,	eTh2	0
9	while	eTh2	0
10	gamma	interferon	11
11	interferon	while	9
12	is	interferon	11
13	produced	is	12
14	by	produced	13
15	eTh1	cells	16
16	cells	by	14
17	.	cells	16

0	Tepoxalin	<ROOT>	-1
1	,	Tepoxalin	0
2	a	inhibitor	5
3	dual	inhibitor	5
4	enzyme	inhibitor	5
5	inhibitor	Tepoxalin	0
6	of	inhibitor	5
7	cyclooxygenase	of	6
8	and	cyclooxygenase	7
9	5-lipoxygenase	and	8
10	has	5-lipoxygenase	9
11	been	cyclooxygenase	7
12	shown	been	11
13	to	shown	12
14	inhibit	T-cell	15
15	T-cell	to	13
16	activation	T-cell	15
17	.	activation	16

0	Serum	A	2
1	amyloid	A	2
2	A	has	6
3	(	SAA	4
4	SAA	A	2
5	)	SAA	4
6	has	<ROOT>	-1
7	been	has	6
8	linked	been	7
9	to	linked	8
10	atherosclerosis	to	9
11	because	linked	8
12	of	because	11
13	its	ability	14
14	ability	because	11
15	to	ability	14
16	remodel	high-density	17
17	high-density	to	15
18	lipoprotein	high-density	17
19	by	the	20
20	the	lipoprotein	18
21	depletion	the	20
22	of	depletion	21
23	apolipoprotein	A1	24
24	A1	of	22
25	,	A1	24
26	its	ability	27
27	ability	A1	24
28	to	ability	27
29	bind	to	28
30	cholesterol	bind	29
31	,	cholesterol	30
32	and	,	31
33	its	and	32
34	presence	its	33
35	in	presence	34
36	the	plaques	38
37	atherosclerotic	plaques	38
38	plaques	in	35
39	of	plaques	38
40	coronary	and	41
41	and	of	39
42	carotid	arteries	43
43	arteries	A1	24
44	.	has	6

0	In	<ROOT>	-1
1	addition	In	0
2	,	CIITA	4
3	no	CIITA	4
4	CIITA	In	0
5	protein	is	6
6	is	detectable	7
7	detectable	CIITA	4
8	in	detectable	7
9	clone	In	0
10	13	extracts	12
11	nuclear	extracts	12
12	extracts	In	0
13	.	In	0

0	OCA-B	interacts	4
1	,	interacts	4
2	however	interacts	4
3	,	interacts	4
4	interacts	<ROOT>	-1
5	with	interacts	4
6	a	with	5
7	different	a	6
8	surface	different	7
9	of	surface	8
10	the	domain	14
11	DNA-bound	domain	14
12	Oct-1	domain	14
13	POU	domain	14
14	domain	of	9
15	,	different	7
16	interacting	different	7
17	with	interacting	16
18	both	POU-LRB-S-RRB-	20
19	the	POU-LRB-S-RRB-	20
20	POU-LRB-S-RRB-	with	17
21	and	POU-LRB-S-RRB-	20
22	POU-LRB-H-RRB-	and	21
23	domains	POU-LRB-H-RRB-	22
24	and	domains	23
25	the	center	26
26	center	and	24
27	of	center	26
28	the	sequence	31
29	ATGCAAAT	sequence	31
30	octamer	sequence	31
31	sequence	of	27
32	.	interacts	4

0	Mutations	<ROOT>	-1
1	in	Mutations	0
2	the	box	4
3	AT	box	4
4	box	in	1
5	or	Mutations	0
6	in	BSAP	8
7	the	BSAP	8
8	BSAP	or	5
9	sites	Mutations	0
10	did	Mutations	0
11	not	reporter	14
12	affect	not	11
13	CD19	reporter	14
14	reporter	did	10
15	construct	Mutations	0
16	activity	Mutations	0
17	,	Mutations	0
18	while	Mutations	0
19	a	modestly	27
20	mutation	a	19
21	of	mutation	20
22	the	of	21
23	GC	reduced	25
24	box	reduced	25
25	reduced	the	22
26	it	modestly	27
27	modestly	while	18
28	,	Mutations	0
29	and	box	32
30	a	box	32
31	PyG	box	32
32	box	Mutations	0
33	mutation	Mutations	0
34	reduced	Mutations	0
35	it	Mutations	0
36	dramatically	Mutations	0
37	.	Mutations	0

0	The	selectivity	2
1	greater	selectivity	2
2	selectivity	<ROOT>	-1
3	of	selectivity	2
4	PF	of	3
5	,	selectivity	2
6	compared	selectivity	2
7	with	compared	6
8	FK506	with	7
9	,	selectivity	2
10	at	molecular	13
11	both	molecular	13
12	the	molecular	13
13	molecular	selectivity	2
14	and	molecular	13
15	cellular	levels	16
16	levels	may	17
17	may	selectivity	2
18	prove	may	17
19	advantageous	prove	18
20	in	advantageous	19
21	manipulating	in	20
22	T	responses	24
23	cell	responses	24
24	responses	manipulating	21
25	in	prove	18
26	vivo	in	25
27	.	selectivity	2

0	The	enzyme	1
1	enzyme	might	2
2	might	<ROOT>	-1
3	therefore	might	2
4	be	might	2
5	a	target	7
6	potential	target	7
7	target	be	4
8	for	target	7
9	drug	therapy	10
10	therapy	for	8
11	under	be	4
12	conditions	DNA	15
13	of	DNA	15
14	active	of	13
15	DNA	under	11
16	replication	might	2
17	.	might	2

0	The	role	1
1	role	has	22
2	of	role	1
3	H2O2	of	2
4	and	H2O2	3
5	other	species	8
6	reactive	species	8
7	oxygen	species	8
8	species	and	4
9	(	ROS	10
10	ROS	species	8
11	)	ROS	10
12	as	role	1
13	an	messenger	16
14	integratory	messenger	16
15	secondary	messenger	16
16	messenger	as	12
17	for	messenger	16
18	divergent	signals	21
19	T	signals	21
20	cell	signals	21
21	signals	for	17
22	has	<ROOT>	-1
23	been	has	22
24	complicated	been	23
25	by	complicated	24
26	the	fact	27
27	fact	by	25
28	that	fact	27
29	various	lines	32
30	T	lines	32
31	cell	lines	32
32	lines	that	28
33	and	blood	35
34	peripheral	and	33
35	blood	T	36
36	T	lines	32
37	cells	has	22
38	differ	has	22
39	markedly	has	22
40	in	markedly	39
41	the	in	40
42	levels	the	41
43	of	NF-kappaB	44
44	NF-kappaB	levels	42
45	activation	NF-kappaB	44
46	induced	by	47
47	by	activation	45
48	oxidant	has	22
49	stress	has	22
50	.	has	22

0	All	clones	1
1	clones	showed	7
2	derived	clones	1
3	from	B	5
4	K46	B	5
5	B	derived	2
6	cells	clones	1
7	showed	<ROOT>	-1
8	increased	showed	7
9	expression	increased	8
10	of	expression	9
11	CD44	of	10
12	.	showed	7

0	DNA	binding	1
1	binding	<ROOT>	-1
2	studies	binding	1
3	and	studies	2
4	Ab	assays	6
5	supershift	assays	6
6	assays	and	3
7	revealed	and	3
8	that	revealed	7
9	different	combinations	10
10	combinations	that	8
11	of	combinations	10
12	factors	of	11
13	interact	factors	12
14	with	interact	13
15	these	in	17
16	motifs	in	17
17	in	with	14
18	B	cells	19
19	cells	in	17
20	vs	T	21
21	T	with	14
22	cells	binding	1
23	.	binding	1

0	The	plays	15
1	class	The	0
2	II	trans-activator	3
3	trans-activator	(	4
4	(	class	1
5	CIITA	)	6
6	)	(	4
7	is	The	0
8	a	bi-	9
9	bi-	is	7
10	or	multi-functional	11
11	multi-functional	domain	12
12	domain	bi-	9
13	protein	which	14
14	which	The	0
15	plays	<ROOT>	-1
16	a	critical	17
17	critical	in	19
18	role	in	19
19	in	plays	15
20	the	expression	21
21	expression	MHC	23
22	of	MHC	23
23	MHC	in	19
24	class	II	25
25	II	plays	15
26	genes	plays	15
27	.	plays	15

0	Clone	C3/5	1
1	C3/5	showed	2
2	showed	tumor	11
3	specific	proliferation	4
4	proliferation	showed	2
5	,	showed	2
6	cytotoxicity	,	5
7	,	showed	2
8	and	cytokine	9
9	cytokine	tumor	11
10	(	tumor	11
11	tumor	<ROOT>	-1
12	necrosis	factor	13
13	factor	tumor	11
14	alpha	tumor	11
15	,	tumor	11
16	granulocyte-macrophage	tumor	11
17	colony-stimulating	granulocyte-macrophage	16
18	factor	)	19
19	)	granulocyte-macrophage	16
20	production	tumor	11
21	when	challenged	22
22	challenged	tumor	11
23	with	challenged	22
24	autologous	with	23
25	lymphoblastic	lines	27
26	cell	lines	27
27	lines	autologous	24
28	pulsed	with	29
29	with	autologous	24
30	peptide	tumor	11
31	BCR1/25	tumor	11
32	.	tumor	11

0	Upon	were	21
1	activation	Upon	0
2	of	T	4
3	Jurkat	T	4
4	T	activation	1
5	cells	murine	8
6	and	murine	8
7	primary	murine	8
8	murine	Upon	0
9	thymocytes	phorbol	11
10	with	phorbol	11
11	phorbol	Upon	0
12	esters	Upon	0
13	and	Upon	0
14	ionomycin	Upon	0
15	,	Upon	0
16	BOB.1/OBF.1	Upon	0
17	expression	and	18
18	and	Upon	0
19	transactivation	Upon	0
20	function	Upon	0
21	were	<ROOT>	-1
22	induced	were	21
23	.	were	21

0	We	describe	2
1	now	describe	2
2	describe	(	5
3	another	series	4
4	series	(	5
5	(	<ROOT>	-1
6	B	(	5
7	)	(	5
8	of	(	5
9	such	variants	10
10	variants	of	8
11	,	of	8
12	which	of	8
13	differ	from	14
14	from	of	8
15	A	cells	17
16	series	cells	17
17	cells	from	14
18	grown	from	14
19	in	similar	20
20	similar	grown	18
21	concentrations	similar	20
22	of	concentrations	21
23	1,25D3	of	22
24	in	similar	20
25	that	in	24
26	they	in	24
27	express	in	24
28	the	express	27
29	CD14	antigen	30
30	antigen	express	27
31	and	antigen	30
32	nonspecific	similar	20
33	esterase	similar	20
34	,	(	5
35	characteristic	(	5
36	of	characteristic	35
37	the	monocyte	38
38	monocyte	of	36
39	,	(	5
40	while	(	5
41	continuing	while	40
42	to	continuing	41
43	proliferate	(	5
44	and	(	5
45	they	develop	46
46	develop	and	44
47	hypotetraploid	DNA	48
48	DNA	(	49
49	(	develop	46
50	4C	(	49
51	)	4C	50
52	content	)	51
53	at	higher	54
54	higher	content	52
55	concentrations	higher	54
56	of	ambient	57
57	ambient	concentrations	55
58	1,25D3	higher	54
59	than	1,25D3	58
60	the	cells	63
61	A	cells	63
62	series	cells	63
63	cells	than	59
64	.	(	5

0	Analysis	commonly	26
1	of	Analysis	0
2	the	sequence	3
3	sequence	of	1
4	immediately	of	1
5	upstream	immediately	4
6	from	site	10
7	the	site	10
8	transcription	site	10
9	initiation	site	10
10	site	showed	14
11	(	site	10
12	TIS	site	10
13	)	TIS	12
14	showed	immediately	4
15	no	TATA	17
16	canonical	TATA	17
17	TATA	showed	14
18	or	showed	14
19	CAAT	or	18
20	elements	showed	14
21	,	Analysis	0
22	however	Analysis	0
23	an	element	25
24	initiator	element	25
25	element	Analysis	0
26	commonly	found	27
27	found	<ROOT>	-1
28	in	found	27
29	TATA-less	promoters	30
30	promoters	in	28
31	encompassed	found	27
32	the	TIS	33
33	TIS	encompassed	31
34	.	found	27

0	To	findings	3
1	substantiate	To	0
2	these	substantiate	1
3	findings	<ROOT>	-1
4	we	an	6
5	initiated	an	6
6	an	procedure	9
7	intensified	procedure	9
8	culturing	procedure	9
9	procedure	findings	3
10	and	findings	3
11	were	and	10
12	able	were	11
13	to	able	12
14	establish	to	13
15	LCLs	to	13
16	from	MS	22
17	5	MS	22
18	out	MS	22
19	of	out	18
20	21	of	19
21	consecutive	21	20
22	MS	LCLs	15
23	patients	and	24
24	and	LCLs	15
25	1	LCLs	15
26	out	were	11
27	of	out	26
28	13	were	11
29	consecutive	were	11
30	healthy	were	11
31	controls	were	11
32	.	findings	3

0	Thus	should	8
1	,	should	8
2	the	availability	3
3	availability	should	8
4	of	availability	3
5	these	cells	7
6	variant	cells	7
7	cells	of	4
8	should	<ROOT>	-1
9	provide	should	8
10	a	system	11
11	system	provide	9
12	for	provide	9
13	studying	the	14
14	the	for	12
15	link	the	14
16	between	link	15
17	differentiation	between	16
18	and	cycle	20
19	cell	cycle	20
20	cycle	differentiation	17
21	arrest	should	8
22	.	should	8

0	The	factor	2
1	cellular	factor	2
2	factor	is	9
3	that	binds	4
4	binds	factor	2
5	to	binds	4
6	the	element	8
7	GAS	element	8
8	element	to	5
9	is	<ROOT>	-1
10	present	is	9
11	from	present	10
12	5	min	13
13	min	from	11
14	to	present	10
15	14	h	16
16	h	to	14
17	after	stimulation	18
18	stimulation	present	10
19	with	present	10
20	IFN-gamma	is	9
21	.	is	9

0	Consistent	<ROOT>	-1
1	with	Consistent	0
2	these	observations	3
3	observations	with	1
4	,	Consistent	0
5	coexpression	of	6
6	of	,	4
7	constitutively	active	8
8	active	of	6
9	forms	of	6
10	of	forms	9
11	Raf-1	Consistent	0
12	and	Consistent	0
13	calcineurin	Consistent	0
14	synergistically	Consistent	0
15	induced	Consistent	0
16	kappaB-dependent	reporter	17
17	reporter	Consistent	0
18	activity	Consistent	0
19	,	Consistent	0
20	suggesting	Consistent	0
21	a	interaction	25
22	physiologically	relevant	23
23	relevant	interaction	25
24	functional	interaction	25
25	interaction	suggesting	20
26	between	interaction	25
27	the	kinase	28
28	kinase	between	26
29	and	kinase	28
30	the	phosphatase	31
31	phosphatase	and	29
32	.	Consistent	0

0	In	were	17
1	healthy	subjects	2
2	subjects	In	0
3	,	were	17
4	the	were	17
5	mean	the	4
6	GC-R	mean	5
7	Bmax	and	8
8	and	GC-R	6
9	Kd	and	8
10	in	and	8
11	quiescent	in	10
12	PBMC	quiescent	11
13	of	quiescent	11
14	the	group	16
15	GC-sensitive	group	16
16	group	of	13
17	were	<ROOT>	-1
18	2.89	+/-	19
19	+/-	fmol/10-LRB-6-RRB-	21
20	1.23	fmol/10-LRB-6-RRB-	21
21	fmol/10-LRB-6-RRB-	were	17
22	cells	were	17
23	and	were	17
24	4.00	were	17
25	+/-	4.00	24
26	2.24	+/-	25
27	nM	were	17
28	,	were	17
29	respectively	were	17
30	.	were	17

0	Lymphocytes	have	1
1	have	<ROOT>	-1
2	been	have	1
3	postulated	been	2
4	to	postulated	3
5	serve	to	4
6	as	serve	5
7	a	site	8
8	site	as	6
9	of	site	8
10	adenoviral	of	9
11	persistence	adenoviral	10
12	based	persistence	11
13	upon	based	12
14	the	ability	15
15	ability	upon	13
16	to	ability	15
17	isolate	to	16
18	adenovirus	isolate	17
19	from	adenovirus	18
20	tonsils	from	19
21	and	ability	15
22	to	and	21
23	detect	to	22
24	adenovirus	detect	23
25	DNA	by	26
26	by	adenovirus	24
27	Southern	adenovirus	24
28	blot	in	30
29	hybridization	in	30
30	in	ability	15
31	peripheral	ability	15
32	blood	ability	15
33	mononuclear	persistence	11
34	cells	have	1
35	(	have	1
36	PBMC	have	1
37	)	have	1
38	.	have	1

0	Further	are	4
1	,	are	4
2	B-1	cells	3
3	cells	are	4
4	are	<ROOT>	-1
5	characterized	are	4
6	by	characterized	5
7	aberrant	signaling	9
8	intracellular	signaling	9
9	signaling	by	6
10	,	are	4
11	including	are	4
12	hyperresponsiveness	including	11
13	to	hyperresponsiveness	12
14	phorbol	ester	15
15	ester	PKC	16
16	PKC	to	13
17	agonists	are	4
18	.	are	4

0	This	defect	1
1	defect	resulted	4
2	in	defect	1
3	maturation	in	2
4	resulted	<ROOT>	-1
5	in	dose-dependent	8
6	a	dose-dependent	8
7	transgene	dose-dependent	8
8	dose-dependent	resulted	4
9	reduction	dose-dependent	8
10	in	T	12
11	peripheral	T	12
12	T	reduction	9
13	lymphocytes	resulted	4
14	,	resulted	4
15	with	,	14
16	the	lineage	18
17	CD8	lineage	18
18	lineage	with	15
19	being	lineage	18
20	more	being	19
21	severely	affected	22
22	affected	more	20
23	.	resulted	4

0	In	investigated	5
1	this	paper	2
2	paper	In	0
3	we	investigated	5
4	have	investigated	5
5	investigated	<ROOT>	-1
6	the	investigated	5
7	role	of	8
8	of	the	6
9	Egr-1	of	8
10	in	Egr-1	9
11	B	the	6
12	cell	investigated	5
13	growth	investigated	5
14	regulation	by	15
15	by	investigated	5
16	examining	by	15
17	the	by	15
18	gene	the	17
19	expression	in	20
20	in	gene	18
21	a	panel	22
22	panel	B	24
23	of	B	24
24	B	by	15
25	cell	investigated	5
26	lines	investigated	5
27	,	including	28
28	including	investigated	5
29	both	including	28
30	EBV	both	29
31	genome	EBV	30
32	negative	genome	31
33	and	negative	32
34	EBV	carrying	35
35	carrying	cell	36
36	cell	and	33
37	lines	cell	36
38	.	lines	37

0	Activation	<ROOT>	-1
1	of	Activation	0
2	the	factor	5
3	NF-kappaB	factor	5
4	transcription	factor	5
5	factor	of	1
6	in	cell	9
7	a	cell	9
8	T-lymphocytic	cell	9
9	cell	of	1
10	line	Activation	0
11	by	Activation	0
12	hypochlorous	acid	13
13	acid	by	11
14	.	Activation	0

0	In	beta	13
1	those	In	0
2	cocultures	alpha	5
3	,	cocultures	2
4	TNF	alpha	5
5	alpha	those	1
6	concentrations	In	0
7	peaked	In	0
8	at	peaked	7
9	3	h	10
10	h	at	8
11	whereas	In	0
12	IL-1	In	0
13	beta	rose	16
14	levels	beta	13
15	progressively	rose	16
16	rose	<ROOT>	-1
17	until	rose	16
18	24	h	19
19	h	until	17
20	.	rose	16

0	Using	<ROOT>	-1
1	limiting-dilution	Using	0
2	analysis	limiting-dilution	1
3	of	analysis	2
4	peripheral	mononuclear	6
5	blood	mononuclear	6
6	mononuclear	of	3
7	cells	limiting-dilution	1
8	,	Using	0
9	a	,	8
10	high	a	9
11	RAKFKQLLQ-specific	high	10
12	CTL	RAKFKQLLQ-specific	11
13	precursor	lymphoblastoid	22
14	frequency	was	15
15	was	precursor	13
16	demonstrated	was	15
17	after	lymphoblastoid	22
18	specific	lymphoblastoid	22
19	peptide	lymphoblastoid	22
20	or	autologous	21
21	autologous	lymphoblastoid	22
22	lymphoblastoid	CTL	12
23	cell	lymphoblastoid	22
24	line	lymphoblastoid	22
25	stimulation	Using	0
26	in	Using	0
27	both	in	26
28	type	both	27
29	A	type	28
30	and	type	31
31	type	EBV	33
32	B	EBV	33
33	EBV	A	29
34	carriers	EBV	33
35	.	carriers	34

0	In	was	5
1	monocytes	In	0
2	,	was	5
3	the	virus	4
4	virus	was	5
5	was	<ROOT>	-1
6	bound	was	5
7	to	bound	6
8	the	surface	9
9	surface	to	7
10	without	bound	6
11	being	without	10
12	internalized	being	11
13	.	was	5

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	the	level	5
3	high	level	5
4	expression	level	5
5	level	,	1
6	of	level	5
7	c-myc	of	6
8	,	level	5
9	characteristic	,	8
10	of	characteristic	9
11	the	of	10
12	parental	the	11
13	MPC11	parental	12
14	cells	carrying	15
15	carrying	MPC11	13
16	the	carrying	15
17	t-LRB-12;15-RRB-	,	19
18	translocation	,	19
19	,	the	16
20	is	level	5
21	down-regulated	level	5
22	in	down-regulated	21
23	the	hybrids	24
24	hybrids	in	22
25	to	hybrids	24
26	that	to	25
27	in	that	26
28	unfused	in	27
29	fibroblasts	.	30
30	.	unfused	28

0	There	was	1
1	was	<ROOT>	-1
2	,	was	1
3	however	was	1
4	,	was	1
5	a	decrease	7
6	significant	decrease	7
7	decrease	was	1
8	in	decrease	7
9	the	sialyltransferase	11
10	plasma	sialyltransferase	11
11	sialyltransferase	in	8
12	:	was	1
13	cortisol	ratio	14
14	ratio	was	1
15	in	ratio	14
16	the	in	15
17	depressed	suggesting	19
18	group	suggesting	19
19	suggesting	the	16
20	an	inability	21
21	inability	suggesting	19
22	of	inability	21
23	the	of	22
24	raised	the	23
25	cortisol	raised	24
26	levels	to	27
27	to	cortisol	25
28	induce	cortisol	25
29	enzyme	expression	30
30	expression	induce	28
31	and	cortisol	25
32	this	ratio	33
33	ratio	may	34
34	may	and	31
35	provide	cortisol	41
36	a	marker	39
37	useful	marker	39
38	biochemical	marker	39
39	marker	cortisol	41
40	of	cortisol	41
41	cortisol	may	34
42	receptor	may	34
43	function	was	1
44	.	was	1

0	These	results	1
1	results	suggest	2
2	suggest	regions	24
3	that	binding	6
4	the	binding	6
5	NF-kappaB	binding	6
6	binding	site	7
7	site	suggest	2
8	located	suggest	2
9	around	located	8
10	120	around	9
11	bp	120	10
12	upstream	bp	11
13	of	upstream	12
14	the	of	13
15	transcription	in	18
16	initiation	in	18
17	site	in	18
18	in	the	14
19	murine	in	18
20	and	suggest	2
21	human	suggest	2
22	p40	suggest	2
23	promoter	regions	24
24	regions	could	25
25	could	<ROOT>	-1
26	be	could	25
27	important	be	26
28	for	be	26
29	the	p40	30
30	p40	for	28
31	induction	by	32
32	by	p40	30
33	CD40	ligation	34
34	ligation	could	25
35	via	could	25
36	activation	of	37
37	of	via	35
38	NF-kappaB	of	37
39	.	could	25

0	There	appears	1
1	appears	<ROOT>	-1
2	to	appears	1
3	be	to	2
4	no	relationship	5
5	relationship	be	3
6	between	relationship	5
7	the	number	8
8	number	between	6
9	of	number	8
10	AML1/ETO	transcripts	11
11	transcripts	of	9
12	found	number	8
13	in	found	12
14	the	harvests	17
15	infused	harvests	17
16	PBSC	harvests	17
17	harvests	in	13
18	and	the	19
19	the	found	12
20	incidence	leukemic	22
21	of	leukemic	22
22	leukemic	the	19
23	relapse	be	3
24	following	autologous	25
25	autologous	appears	1
26	PBSCT	autologous	25
27	in	our	28
28	our	PBSCT	26
29	study	appears	1
30	.	appears	1

0	Consistent	<ROOT>	-1
1	with	Consistent	0
2	theses	results	3
3	results	with	1
4	,	Consistent	0
5	nuclear	prepared	7
6	extracts	prepared	7
7	prepared	Consistent	0
8	from	quiescent	9
9	quiescent	prepared	7
10	cells	Consistent	0
11	formed	Consistent	0
12	a	complex	14
13	specific	complex	14
14	complex	formed	11
15	with	this	16
16	this	formed	11
17	element	Consistent	0
18	,	Consistent	0
19	whereas	cells	23
20	extracts	prepared	21
21	prepared	cells	23
22	from	cells	23
23	cells	Consistent	0
24	treated	cells	23
25	with	treated	24
26	anti	CD2	27
27	CD2	treated	24
28	+	CD2	27
29	anti	+	28
30	CD28	anti	29
31	failed	Consistent	0
32	to	failed	31
33	do	to	32
34	so	do	33
35	after	Consistent	0
36	cells	entered	37
37	entered	Consistent	0
38	a	state	40
39	proliferative	state	40
40	state	entered	37
41	.	Consistent	0

0	Purification	<ROOT>	-1
1	and	Purification	0
2	characterization	and	1
3	of	characterization	2
4	the	characterization	2
5	human	protein	8
6	SR	protein	8
7	31747A-binding	protein	8
8	protein	the	4
9	.	Purification	0

0	Plasma	levels	2
1	sialyltransferase	levels	2
2	levels	<ROOT>	-1
3	in	psychiatric	4
4	psychiatric	levels	2
5	disorders	levels	2
6	as	levels	2
7	a	as	6
8	possible	of	10
9	indicator	of	10
10	of	a	7
11	HPA	of	10
12	axis	.	14
13	function	.	14
14	.	HPA	11

0	By	the	3
1	contrast	By	0
2	,	the	3
3	the	<ROOT>	-1
4	binding	the	3
5	activity	the	3
6	of	activity	5
7	the	of	6
8	NF-kappa	the	7
9	(	B	10
10	B	NF-kappa	8
11	)	B	10
12	and	the	3
13	EGR-1	the	3
14	transcription	factors	15
15	factors	the	3
16	was	the	3
17	little	affected	18
18	affected	was	16
19	.	the	3

0	More	interestingly	1
1	interestingly	<ROOT>	-1
2	,	interestingly	1
3	transfection	experiments	4
4	experiments	,	2
5	with	experiments	4
6	CRE-CAT	show	8
7	plasmide	show	8
8	show	with	5
9	that	show	8
10	PGE2	activates	11
11	activates	that	9
12	the	transcription	13
13	transcription	activates	11
14	of	transcription	13
15	a	of	14
16	CRE-containing	.	18
17	promoter	.	18
18	.	a	15

0	Thus	is	10
1	,	is	10
2	a	component	3
3	component	is	10
4	of	component	3
5	LDL-enhanced	recruitment	7
6	endothelial	recruitment	7
7	recruitment	of	4
8	of	recruitment	7
9	monocytes	of	8
10	is	<ROOT>	-1
11	attributed	is	10
12	to	attributed	11
13	VCAM-1	expression	14
14	expression	to	12
15	,	is	10
16	which	appears	17
17	appears	is	10
18	to	appears	17
19	be	to	18
20	mediated	be	19
21	through	mediated	20
22	AP-1	mediated	20
23	and	appears	17
24	GATA	and	23
25	.	is	10

0	Upon	<ROOT>	-1
1	treatment	with	2
2	with	Upon	0
3	a	variety	5
4	large	variety	5
5	variety	with	2
6	of	variety	5
7	inducers	of	6
8	,	Upon	0
9	I	B	11
10	kappa	I	9
11	B	,	8
12	alpha	Upon	0
13	,	Upon	0
14	I	B	16
15	kappa	I	14
16	B	,	13
17	beta	are	18
18	are	,	13
19	proteolytically	Upon	0
20	degraded	Upon	0
21	,	Upon	0
22	resulting	in	23
23	in	Upon	0
24	NF-kappa	B	25
25	B	in	23
26	translocation	Upon	0
27	into	translocation	26
28	the	nucleus	29
29	nucleus	into	27
30	.	Upon	0

0	In	transcript	6
1	the	embryo	3
2	mouse	embryo	3
3	embryo	In	0
4	,	transcript	6
5	mNFATc	transcript	6
6	transcript	was	7
7	was	<ROOT>	-1
8	strongly	was	7
9	expressed	was	7
10	in	expressed	9
11	thymus	was	7
12	,	was	7
13	lung	was	7
14	and	lung	13
15	submandibular	gland	16
16	gland	and	14
17	and	gland	16
18	weakly	was	7
19	in	weakly	18
20	skeletal	was	7
21	muscle	was	7
22	and	was	7
23	heart	and	22
24	suggesting	that	25
25	that	was	7
26	mNFATc	may	27
27	may	that	25
28	have	a	29
29	a	may	27
30	role	both	31
31	both	may	27
32	in	both	31
33	embryogenesis	in	32
34	and	embryogenesis	33
35	in	T	37
36	mature	T	37
37	T	and	34
38	cells	was	7
39	.	was	7

0	Bcl-6	protein	1
1	protein	is	2
2	is	transcription	7
3	a	recently	4
4	recently	transcription	7
5	identified	novel	6
6	novel	transcription	7
7	transcription	<ROOT>	-1
8	factor	B	17
9	whose	expression	11
10	deregulated	expression	11
11	expression	is	12
12	is	B	17
13	associated	B	17
14	with	B	17
15	diffuse	B	17
16	large	B	17
17	B	transcription	7
18	cell	B	17
19	lymphomas	transcription	7
20	.	transcription	7

0	These	findings	1
1	findings	have	2
2	have	<ROOT>	-1
3	important	implications	4
4	implications	have	2
5	in	have	2
6	regulation	in	5
7	of	regulation	6
8	germline	transcription	9
9	transcription	of	7
10	as	of	7
11	well	of	7
12	as	concomitant	13
13	concomitant	of	7
14	activation	V-J	17
15	of	V-J	17
16	the	V-J	17
17	V-J	concomitant	13
18	recombination	regulation	6
19	of	chain	23
20	the	chain	23
21	kappa	chain	23
22	light	chain	23
23	chain	recombination	18
24	locus	have	2
25	.	have	2

0	Using	mobility	2
1	electrophoretic	Using	0
2	mobility	were	35
3	shift	mobility	2
4	assays	mobility	2
5	,	mobility	2
6	the	,	5
7	levels	the	6
8	of	regulatory	10
9	nuclear	regulatory	10
10	regulatory	levels	7
11	proteins	mobility	2
12	recognizing	TRE	16
13	the	TRE	16
14	AP-1	consensus	15
15	consensus	TRE	16
16	TRE	mobility	2
17	motif	mobility	2
18	,	proximal	20
19	the	proximal	20
20	proximal	mobility	2
21	c-jun	TRE-like	22
22	TRE-like	proximal	20
23	promoter	mobility	2
24	element	promoter	23
25	,	the	27
26	and	the	27
27	the	element	24
28	c-fos	mobility	2
29	serum	mobility	2
30	response	mobility	2
31	element	mobility	2
32	(	mobility	2
33	SRE	mobility	2
34	)	mobility	2
35	were	<ROOT>	-1
36	determined	were	35
37	in	determined	36
38	resting	in	37
39	and	in	37
40	stimulated	T	41
41	T	and	39
42	cells	were	35
43	.	were	35

0	In	JNK	3
1	contrast	In	0
2	,	In	0
3	JNK	<ROOT>	-1
4	activation	JNK	3
5	in	activation	4
6	calcineurin-stimulated	cells	7
7	cells	caused	8
8	caused	in	5
9	nuclear	exclusion	10
10	exclusion	caused	8
11	of	exclusion	10
12	NFAT4	of	11
13	.	JNK	3

0	Based	upon	1
1	upon	<ROOT>	-1
2	these	upon	1
3	results	upon	1
4	we	propose	5
5	propose	upon	1
6	that	propose	5
7	alpha-interferon	that	6
8	through	receptor	10
9	its	receptor	10
10	receptor	alpha-interferon	7
11	initiates	alpha-interferon	7
12	phosphatidic	dependent	14
13	acid	dependent	14
14	dependent	alpha-interferon	7
15	signalling	dependent	14
16	which	signalling	15
17	in	47	23
18	turn	47	23
19	regulates	affinity	21
20	the	regulates	19
21	affinity	47	23
22	of	47	23
23	47	which	16
24	kDa	sterol	25
25	sterol	element	27
26	regulatory	element	27
27	element	47	23
28	binding	upon	1
29	factor	upon	1
30	as	upon	1
31	well	upon	1
32	as	upon	1
33	LDL-receptor	as	32
34	gene	transcription	35
35	transcription	LDL-receptor	33
36	in	transcription	35
37	lymphocytes	upon	1
38	from	upon	1
39	CML	upon	1
40	patients	upon	1
41	.	upon	1

0	Activated	expression	3
1	viral	expression	3
2	gene	expression	3
3	expression	associated	4
4	associated	<ROOT>	-1
5	with	associated	4
6	phenotypic	with	5
7	conversion	phenotypic	6
8	of	gene	22
9	group	of	8
10	I	group	9
11	cell	I	10
12	lines	cell	11
13	in	lines	12
14	to	in	13
15	group	II	16
16	II	to	14
17	or	II	16
18	III	of	8
19	restores	of	8
20	the	of	8
21	Egr-1	of	8
22	gene	conversion	7
23	expression	gene	22
24	.	associated	4

0	Here	show	2
1	we	show	2
2	show	<ROOT>	-1
3	that	show	2
4	in	that	3
5	E29.1	cell	7
6	T	cell	7
7	cell	in	4
8	hybridoma	I	9
9	I	in	4
10	kappa	I	9
11	B	alpha	12
12	alpha	that	3
13	and	show	2
14	I	B	16
15	kappa	I	14
16	B	beta	17
17	beta	and	13
18	are	show	2
19	equally	show	2
20	associated	equally	19
21	with	associated	20
22	p65	with	21
23	and	show	2
24	that	and	23
25	I	B	27
26	kappa	I	25
27	B	beta	28
28	beta	that	24
29	is	beta	28
30	degraded	is	29
31	in	beta	28
32	response	in	31
33	to	response	32
34	TNF	show	2
35	alpha	show	2
36	in	show	2
37	contrast	in	36
38	to	contrast	37
39	what	has	40
40	has	to	38
41	been	has	40
42	originally	been	41
43	published	originally	42
44	.	show	2

0	The	forms	1
1	forms	have	6
2	produced	forms	1
3	in	B	4
4	B	produced	2
5	lymphocytes	forms	1
6	have	<ROOT>	-1
7	a	effect	10
8	predominantly	activating	9
9	activating	effect	10
10	effect	have	6
11	on	gene	12
12	gene	effect	10
13	expression	gene	12
14	whereas	gene	12
15	those	whereas	14
16	produced	those	15
17	in	neuronal	18
18	neuronal	produced	16
19	cells	have	6
20	have	have	6
21	a	effect	24
22	predominantly	inhibitory	23
23	inhibitory	effect	24
24	effect	have	20
25	and	have	6
26	can	and	25
27	repress	can	26
28	the	expression	29
29	expression	repress	27
30	of	expression	29
31	both	of	30
32	the	both	31
33	herpes	the	32
34	simplex	herpes	33
35	virus	simplex	34
36	immediate-early	virus	35
37	genes	immediate-early	36
38	and	genes	37
39	the	and	38
40	cellular	tyrosine	41
41	tyrosine	the	39
42	hydroxylase	gene	43
43	gene	tyrosine	41
44	.	have	6

0	Sterol	<ROOT>	-1
1	dependent	Sterol	0
2	LDL-receptor	dependent	1
3	gene	transcription	4
4	transcription	LDL-receptor	2
5	in	transcription	4
6	lymphocytes	Sterol	0
7	from	Sterol	0
8	normal	from	7
9	and	Sterol	0
10	CML	and	9
11	patients	and	9
12	.	Sterol	0

0	Alternatively	might	9
1	,	Alternatively	0
2	another	factor	3
3	factor	Alternatively	0
4	,	Alternatively	0
5	distinct	Alternatively	0
6	from	distinct	5
7	CIITA	from	6
8	,	Alternatively	0
9	might	<ROOT>	-1
10	control	might	9
11	HLA-DQ	might	9
12	expression	might	9
13	.	might	9

0	Here	<ROOT>	-1
1	we	evaluated	2
2	evaluated	Here	0
3	whether	evaluated	2
4	xenogeneic	whether	3
5	serum	xenogeneic	4
6	,	induced	17
7	as	induced	17
8	a	source	9
9	source	as	7
10	of	source	9
11	xenoreactive	antibodies	13
12	natural	antibodies	13
13	antibodies	of	10
14	and	as	7
15	complement	and	14
16	,	induced	17
17	induced	serum	5
18	endothelial	induced	17
19	cell	endothelial	18
20	activation	with	21
21	with	cell	19
22	consequent	flow	26
23	leukocyte	flow	26
24	adhesion	flow	26
25	under	flow	26
26	flow	cell	19
27	conditions	flow	26
28	.	Here	0

0	These	results	1
1	results	suggests	2
2	suggests	<ROOT>	-1
3	that	suggests	2
4	both	steps	6
5	proximal	steps	6
6	steps	are	17
7	in	steps	6
8	CD8+	activation	10
9	T-cell	activation	10
10	activation	in	7
11	as	steps	6
12	well	as	11
13	as	as	11
14	the	phases	16
15	later	phases	16
16	phases	as	11
17	are	that	3
18	unresponsive	are	17
19	to	unresponsive	18
20	A6H	ligation	21
21	ligation	to	19
22	.	suggests	2

0	Inhibition	<ROOT>	-1
1	of	by	5
2	monocyte	induction	4
3	TF	induction	4
4	induction	of	1
5	by	Inhibition	0
6	CsA	by	5
7	may	contribute	8
8	contribute	Inhibition	0
9	to	contribute	8
10	its	use	12
11	successful	use	12
12	use	to	9
13	in	use	12
14	cardiac	medicine	16
15	transplant	medicine	16
16	medicine	in	13
17	and	to	9
18	might	and	17
19	be	might	18
20	useful	be	19
21	in	be	19
22	managing	settings	24
23	further	settings	24
24	settings	in	21
25	of	settings	24
26	vascular	pathology	27
27	pathology	settings	24
28	also	pathology	27
29	known	also	28
30	to	involve	31
31	involve	known	29
32	TF	expression	33
33	expression	involve	31
34	and	expression	33
35	NF-kappaB	activation	36
36	activation	and	34
37	.	Inhibition	0

0	The	protein-tyrosine	1
1	protein-tyrosine	is	4
2	kinase	ZAP-70	3
3	ZAP-70	protein-tyrosine	1
4	is	<ROOT>	-1
5	implicated	is	4
6	,	implicated	5
7	together	implicated	5
8	with	implicated	5
9	the	p56-LRB-lck-RRB-	12
10	Src	p56-LRB-lck-RRB-	12
11	kinase	p56-LRB-lck-RRB-	12
12	p56-LRB-lck-RRB-	with	8
13	,	implicated	5
14	in	implicated	5
15	controlling	in	14
16	the	steps	18
17	early	steps	18
18	steps	controlling	15
19	of	steps	18
20	the	receptor	23
21	T-cell	receptor	23
22	antigen	receptor	23
23	receptor	(	24
24	(	signaling	27
25	TCR	signaling	27
26	)	signaling	27
27	signaling	of	19
28	cascade	is	4
29	.	is	4

0	In	neither	3
1	contrast	In	0
2	,	In	0
3	neither	<ROOT>	-1
4	ascorbate	neither	3
5	nor	ascorbate	4
6	AZT	affected	7
7	affected	nor	5
8	NF-kappa	activity	10
9	B	activity	10
10	activity	affected	7
11	under	nor	5
12	all	under	11
13	three	conditions	15
14	induction	conditions	15
15	conditions	under	11
16	in	conditions	15
17	the	cell	19
18	ACH-2	cell	19
19	cell	in	16
20	line	cell	19
21	.	line	20

0	In	blot	15
1	order	In	0
2	to	In	0
3	investigate	to	2
4	the	factors	5
5	factors	investigate	3
6	that	influence	7
7	influence	factors	5
8	the	induction	9
9	induction	influence	7
10	of	induction	9
11	ICAM-1	molecules	12
12	molecules	of	10
13	,	blot	15
14	Northern	blot	15
15	blot	were	43
16	analysis	blot	15
17	to	blot	15
18	measure	expression	20
19	the	expression	20
20	expression	to	17
21	level	of	22
22	of	expression	20
23	ICAM-1	mRNAs	24
24	mRNAs	of	22
25	and	mRNAs	24
26	Southern	mRNAs	24
27	blot	Southern	26
28	hybridization	blot	27
29	to	hybridization	28
30	analyze	to	29
31	the	integration	32
32	integration	virus	36
33	of	virus	36
34	human	virus	36
35	T-cell-leukemia	virus	36
36	virus	analyze	30
37	type	blot	15
38	1	blot	15
39	(	HTLV-1	40
40	HTLV-1	1	38
41	)	HTLV-1	40
42	provirus	)	41
43	were	<ROOT>	-1
44	done	were	43
45	.	were	43

0	Both	within	1
1	within	reactivations	10
2	and	within	1
3	among	within	1
4	these	polyomavirus	9
5	SLE	polyomavirus	9
6	patients	polyomavirus	9
7	,	patients	6
8	frequent	polyomavirus	9
9	polyomavirus	among	3
10	reactivations	were	11
11	were	<ROOT>	-1
12	observed	were	11
13	that	could	14
14	could	observed	12
15	not	could	14
16	be	could	14
17	explained	be	16
18	by	explained	17
19	certain	by	18
20	rearrangements	certain	19
21	of	rearrangements	20
22	the	of	21
23	noncoding	,	26
24	control	,	26
25	regions	,	26
26	,	the	22
27	nor	were	11
28	by	were	11
29	corticosteroid	treatment	30
30	treatment	by	28
31	.	were	11

0	This	is	1
1	is	<ROOT>	-1
2	the	study	4
3	first	study	4
4	study	is	1
5	of	study	4
6	expression	of	5
7	of	of	5
8	all	family	9
9	family	members	10
10	members	of	5
11	at	is	1
12	the	protein	13
13	protein	at	11
14	level	protein	13
15	in	normal	16
16	normal	protein	13
17	human	is	1
18	T	is	1
19	cells	is	1
20	.	is	1

0	During	with	8
1	15	days	2
2	days	During	0
3	of	days	2
4	treatment	of	3
5	of	treatment	4
6	K562	cells	7
7	cells	of	5
8	with	observed	13
9	sodium	phenylacetate	10
10	phenylacetate	observed	13
11	,	observed	13
12	we	observed	13
13	observed	<ROOT>	-1
14	an	increase	15
15	increase	observed	13
16	in	increase	15
17	the	concentration	20
18	cellular	concentration	20
19	hemoglobin	concentration	20
20	concentration	in	16
21	with	observed	13
22	a	increase	24
23	similar	increase	24
24	increase	with	21
25	in	increase	24
26	the	expression	27
27	expression	in	25
28	of	expression	27
29	gamma-globin	mRNA	30
30	mRNA	of	28
31	.	observed	13

0	HLA	<ROOT>	-1
1	binding	HLA	0
2	characteristics	binding	1
3	and	characteristics	2
4	generation	cytotoxic	6
5	of	cytotoxic	6
6	cytotoxic	and	3
7	lymphocytes	HLA	0
8	against	HLA	0
9	peptides	against	8
10	derived	peptides	9
11	from	oncogenic	12
12	oncogenic	derived	10
13	proteins	HLA	0
14	.	HLA	0

0	Characterization	<ROOT>	-1
1	of	Characterization	0
2	the	factors	5
3	cellular	factors	5
4	transcription	factors	5
5	factors	of	1
6	interacting	factors	5
7	with	interacting	6
8	the	with	7
9	human	cell	11
10	T	cell	11
11	cell	the	8
12	lymphotropic	the	8
13	virus	lymphotropic	12
14	type	virus	13
15	I	(	16
16	(	)	18
17	HTLV-I	(	16
18	)	long	19
19	long	type	14
20	terminal	long	19
21	repeat	terminal	20
22	(	repeat	21
23	LTR	(	22
24	)	is	25
25	is	LTR	23
26	essential	is	25
27	to	essential	26
28	dissecting	to	27
29	the	mechanisms	30
30	mechanisms	dissecting	28
31	involved	in	32
32	in	mechanisms	30
33	viral	that	35
34	transcription	that	35
35	that	in	32
36	may	(	22
37	be	may	36
38	pertinent	be	37
39	to	pertinent	38
40	the	to	39
41	oncogenic	the	40
42	and	neuropathogenic	43
43	neuropathogenic	with	46
44	processes	with	46
45	associated	processes	44
46	with	oncogenic	41
47	HTLV-I	oncogenic	41
48	infection	Characterization	0
49	in	Characterization	0
50	both	immune	52
51	the	immune	52
52	immune	in	49
53	and	immune	52
54	nervous	and	53
55	systems	Characterization	0
56	.	Characterization	0

0	Using	<ROOT>	-1
1	this	Using	0
2	assay	,	3
3	,	this	1
4	we	Using	0
5	also	Using	0
6	showed	that	7
7	that	also	5
8	Pax-5d	was	9
9	was	that	7
10	present	was	9
11	in	present	10
12	nuclear	extracts	13
13	extracts	in	11
14	of	extracts	13
15	some	of	14
16	(	some	15
17	but	(	16
18	not	but	17
19	all	not	18
20	)	not	18
21	B-lymphoid	lines	22
22	lines	)	20
23	and	lines	22
24	interacts	protein-binding	29
25	with	protein-binding	29
26	the	protein-binding	29
27	B-cell-specific	activator	28
28	activator	protein-binding	29
29	protein-binding	and	23
30	site	Using	0
31	.	Using	0

0	The	alterations	2
1	multiple	alterations	2
2	alterations	may	9
3	observed	alterations	2
4	on	observed	3
5	the	pathways	8
6	various	pathways	8
7	biochemical	pathways	8
8	pathways	on	4
9	may	<ROOT>	-1
10	appear	may	9
11	as	appear	10
12	a	consequence	13
13	consequence	as	11
14	of	consequence	13
15	a	mechanism	18
16	unique	mechanism	18
17	deleterious	mechanism	18
18	mechanism	of	14
19	more	fundamentally	20
20	fundamentally	appear	10
21	related	fundamentally	20
22	to	related	21
23	the	process	24
24	process	to	22
25	of	process	24
26	senescence	of	25
27	such	as	28
28	as	senescence	26
29	the	inability	30
30	inability	as	28
31	to	inability	30
32	cope	to	31
33	with	cope	32
34	oxidative	with	33
35	stress	may	9
36	.	may	9

0	Tolerant	cells	1
1	cells	express	3
2	still	express	3
3	express	<ROOT>	-1
4	the	receptor	6
5	CD14	receptor	6
6	receptor	express	3
7	and	express	3
8	they	can	9
9	can	and	7
10	still	can	9
11	be	can	9
12	activated	be	11
13	to	activated	12
14	mobilize	to	13
15	NF-kappa	mobilize	14
16	B	NF-kappa	15
17	into	B	16
18	nucleus	.	19
19	.	into	17

0	Finally	has	5
1	,	has	5
2	a	protein	4
3	110-kDa	protein	4
4	protein	has	5
5	has	<ROOT>	-1
6	been	has	5
7	identified	been	6
8	in	identified	7
9	the	nuclei	10
10	nuclei	in	8
11	of	the	13
12	all	the	13
13	the	nuclei	10
14	B	in	8
15	,	has	5
16	but	has	5
17	not	but	16
18	T	but	16
19	,	has	5
20	cell	has	5
21	lines	has	5
22	that	lines	21
23	specifically	binds	24
24	binds	N-terminal	28
25	to	binds	24
26	this	A-MYB	27
27	A-MYB	to	25
28	N-terminal	domain	29
29	domain	that	22
30	.	domain	29

0	The	role	1
1	role	<ROOT>	-1
2	of	role	1
3	E-proteins	of	2
4	in	B-	5
5	B-	role	1
6	and	B-	5
7	T-lymphocyte	role	1
8	development	role	1
9	.	role	1

0	Finally	are	4
1	,	are	4
2	these	studies	3
3	studies	are	4
4	are	<ROOT>	-1
5	consistent	are	4
6	with	consistent	5
7	the	hypothesis	8
8	hypothesis	with	6
9	that	hypothesis	8
10	the	pathogenesis	12
11	molecular	pathogenesis	12
12	pathogenesis	is	15
13	of	pathogenesis	12
14	X-SCID	of	13
15	is	that	9
16	due	is	15
17	primarily	due	16
18	to	gamma-LRB-c-RRB--mediated	19
19	gamma-LRB-c-RRB--mediated	due	16
20	defects	gamma-LRB-c-RRB--mediated	19
21	in	defects	20
22	the	system	24
23	IL-7/IL-7R	system	24
24	system	in	21
25	.	are	4

0	We	find	1
1	find	motif	38
2	that	find	1
3	,	find	1
4	although	variant	6
5	the	variant	6
6	variant	find	1
7	octamer	motif	8
8	motif	binds	9
9	binds	find	1
10	Oct-1	binds	9
11	and	binds	9
12	Oct-2	find	1
13	in	find	1
14	vitro	find	1
15	with	vitro	14
16	5-fold	with	15
17	lower	affinity	18
18	affinity	5-fold	16
19	than	the	20
20	the	5-fold	16
21	consensus	the	20
22	octamer	find	1
23	motif	octamer	22
24	,	mutation	25
25	mutation	octamer	29
26	of	mutation	25
27	the	variant	28
28	variant	of	26
29	octamer	find	1
30	motif	octamer	29
31	to	octamer	29
32	either	a	33
33	a	octamer	35
34	consensus	a	33
35	octamer	to	31
36	or	find	1
37	non-octamer	find	1
38	motif	has	39
39	has	<ROOT>	-1
40	no	effect	41
41	effect	has	39
42	on	effect	41
43	transcriptional	activation	44
44	activation	on	42
45	from	activation	44
46	the	promoter	48
47	germline	promoter	48
48	promoter	from	45
49	.	has	39

0	In	<ROOT>	-1
1	vivo	In	0
2	footprinting	and	3
3	and	vivo	1
4	mutational	and	3
5	analysis	mutational	4
6	of	analysis	5
7	the	promoter	10
8	proximal	promoter	10
9	CD19	promoter	10
10	promoter	of	6
11	reveal	and	3
12	important	roles	13
13	roles	reveal	11
14	for	reveal	11
15	an	binding	17
16	SP1/Egr-1	binding	17
17	binding	for	14
18	site	binding	17
19	and	novel	21
20	a	novel	21
21	novel	reveal	11
22	site	In	0
23	termed	site	22
24	the	PyG	25
25	PyG	termed	23
26	box	PyG	25
27	.	In	0

0	The	positioning	2
1	three-dimensional	positioning	2
2	positioning	was	15
3	of	positioning	2
4	immunoglobulin	of	3
5	(	Ig	6
6	Ig	genes	8
7	)	Ig	6
8	genes	positioning	2
9	within	positioning	2
10	the	nucleus	11
11	nucleus	within	9
12	of	human	13
13	human	nucleus	11
14	cells	positioning	2
15	was	<ROOT>	-1
16	investigated	was	15
17	using	investigated	16
18	in	using	17
19	situ	in	18
20	hybridization	situ	19
21	and	confocal	22
22	confocal	hybridization	20
23	microscopy	.	24
24	.	hybridization	20

0	The	aim	1
1	aim	was	5
2	of	aim	1
3	this	study	4
4	study	of	2
5	was	<ROOT>	-1
6	to	was	5
7	explore	to	6
8	the	explore	7
9	kinetics	the	8
10	of	kinetics	9
11	the	development	12
12	development	of	10
13	of	development	12
14	alterations	of	13
15	in	transduction	17
16	signal	transduction	17
17	transduction	of	13
18	molecules	(	19
19	(	TCR	20
20	TCR	was	5
21	zeta	was	5
22	chain	was	5
23	,	was	5
24	NF	family	26
25	kappaB	family	26
26	family	was	5
27	proteins	was	5
28	,	was	5
29	and	(	33
30	tyrosine	and	29
31	kinase	p56	32
32	p56	(	33
33	(	was	5
34	lck	was	5
35	)	was	5
36	)	)	35
37	in	)	36
38	mice	in	37
39	bearing	mice	38
40	MC38	adenocarcinoma	42
41	colon	adenocarcinoma	42
42	adenocarcinoma	bearing	39
43	.	was	5

0	To	an	11
1	find	To	0
2	genes	find	1
3	that	protect	4
4	protect	find	1
5	cells	from	6
6	from	protect	4
7	apoptosis	To	0
8	,	an	11
9	we	an	11
10	used	an	11
11	an	<ROOT>	-1
12	expression	strategy	14
13	cloning	strategy	14
14	strategy	an	11
15	and	strategy	14
16	identified	and	15
17	BHRF1	identified	16
18	,	early-lytic-cycle	25
19	an	virus	21
20	Epstein-Barr	virus	21
21	virus	early-lytic-cycle	25
22	(	EBV	23
23	EBV	virus	21
24	)	EBV	23
25	early-lytic-cycle	BHRF1	17
26	protein	an	11
27	with	an	11
28	distant	an	11
29	homology	an	11
30	to	Bcl-2	31
31	Bcl-2	homology	29
32	,	homology	29
33	as	homology	29
34	an	protein	36
35	anti-apoptosis	protein	36
36	protein	as	33
37	.	an	11

0	Human	cells	3
1	leukemia	cells	3
2	HL60	cells	3
3	cells	respond	4
4	respond	<ROOT>	-1
5	to	respond	4
6	the	to	5
7	presence	the	6
8	of	D3	10
9	1,25-dihydroxyvitamin	D3	10
10	D3	presence	7
11	(	D3	10
12	1,25D3	respond	4
13	)	respond	4
14	by	respond	4
15	expressing	by	14
16	a	number	17
17	number	expressing	15
18	of	number	17
19	markers	of	18
20	of	markers	19
21	the	phenotype	23
22	monocyte/macrophage	phenotype	23
23	phenotype	of	20
24	and	of	20
25	become	and	24
26	arrested	become	25
27	predominantly	in	28
28	in	become	25
29	the	in	28
30	G1	of	32
31	phase	of	32
32	of	the	29
33	the	in	28
34	cell	cycle	35
35	cycle	in	28
36	.	respond	4

0	These	insights	1
1	insights	may	15
2	in	insights	1
3	the	events	5
4	molecular	events	5
5	events	in	2
6	that	events	5
7	are	that	6
8	involved	are	7
9	in	involved	8
10	TCF/LEF	function	11
11	function	in	9
12	in	in	9
13	these	organisms	14
14	organisms	in	12
15	may	<ROOT>	-1
16	eventually	may	15
17	lead	may	15
18	to	lead	17
19	the	understanding	20
20	understanding	to	18
21	of	understanding	20
22	the	function	23
23	function	of	21
24	of	function	23
25	these	of	24
26	HMG	box	27
27	box	these	25
28	proteins	box	27
29	in	these	25
30	lymphoid	development	31
31	development	in	29
32	.	may	15

0	Also	receptor	26
1	no	Also	0
2	significant	no	1
3	partial	significant	2
4	correlations	partial	3
5	of	correlations	4
6	the	of	5
7	levels	of	8
8	of	leukotriene	9
9	leukotriene	the	6
10	B4	leukotriene	9
11	(	leukotriene	9
12	45.6	Also	0
13	+/-	45.6	12
14	105.3	+/-	13
15	ng/10-LRB-6-RRB-	+/-	13
16	cells	)	17
17	)	ng/10-LRB-6-RRB-	15
18	produced	ng/10-LRB-6-RRB-	15
19	by	Also	0
20	monocytes	Also	0
21	in	Also	0
22	vitro	Also	0
23	,	interleukin-2	25
24	soluble	interleukin-2	25
25	interleukin-2	Also	0
26	receptor	)	33
27	(	receptor	26
28	734	)	33
29	+/-	)	33
30	237	+/-	29
31	ng/10-LRB-6-RRB-	)	33
32	cells	)	33
33	)	were	57
34	released	)	33
35	by	)	33
36	lymphocytes	)	33
37	in	)	33
38	vitro	)	33
39	and	cortisol	40
40	cortisol	vitro	38
41	levels	(	42
42	(	)	33
43	571	)	33
44	+/-	571	43
45	236	+/-	44
46	ng/mL	+/-	44
47	)	ng/mL	46
48	in	)	47
49	plasma	in	48
50	with	)	47
51	the	score	53
52	symptom	score	53
53	score	with	50
54	after	active	55
55	active	score	53
56	treatment	score	53
57	were	<ROOT>	-1
58	found	were	57
59	.	were	57

0	To	<ROOT>	-1
1	identify	To	0
2	such	genes	4
3	target	genes	4
4	genes	identify	1
5	,	To	0
6	we	,	5
7	established	Egr-1-overexpressing	8
8	Egr-1-overexpressing	we	6
9	transfectants	Egr-1-overexpressing	8
10	from	line	15
11	the	line	15
12	murine	line	15
13	B	line	15
14	cell	line	15
15	line	transfectants	9
16	K46	To	0
17	and	To	0
18	from	To	0
19	human	To	0
20	Ramos	To	0
21	B	cells	22
22	cells	To	0
23	.	To	0

0	Transgenic	mice	1
1	mice	were	9
2	with	mice	1
3	a	defect	5
4	lymphocyte-specific	defect	5
5	defect	with	2
6	in	NF-kappaB	7
7	NF-kappaB	defect	5
8	activation	mice	1
9	were	<ROOT>	-1
10	produced	were	9
11	by	produced	10
12	targeted	expression	13
13	expression	by	11
14	of	expression	13
15	human	alpha	17
16	IkappaB	alpha	17
17	alpha	of	14
18	.	were	9

0	The	existence	1
1	existence	was	6
2	of	existence	1
3	alternative	transcripts	5
4	Pax-5	transcripts	5
5	transcripts	of	2
6	was	<ROOT>	-1
7	confirmed	was	6
8	using	confirmed	7
9	RNase	using	8
10	protection	.	12
11	assays	.	12
12	.	RNase	9

0	We	showed	2
1	further	showed	2
2	showed	09-2210	5
3	that	09-2210	5
4	Ro	09-2210	5
5	09-2210	<ROOT>	-1
6	was	09-2210	5
7	unable	was	6
8	to	was	6
9	inhibit	c-jun	10
10	c-jun	induced	11
11	induced	to	8
12	expression	induced	11
13	of	reporter	15
14	AP1-dependent	reporter	15
15	reporter	expression	12
16	constructs	09-2210	5
17	(	constructs	16
18	IC50	(	17
19	&gt;	nM	21
20	500	nM	21
21	nM	IC50	18
22	)	IC50	18
23	,	09-2210	5
24	but	09-2210	5
25	was	but	24
26	able	was	25
27	to	able	26
28	potently	to	27
29	inhibit	AP1	31
30	ras-induced	AP1	31
31	AP1	to	27
32	activation	AP1	31
33	(	was	25
34	IC50	was	25
35	=	20	36
36	20	IC50	34
37	nM	)	38
38	)	20	36
39	.	09-2210	5

0	The	domain	3
1	DNA	binding	2
2	binding	domain	3
3	domain	is	9
4	of	domain	3
5	the	factor	8
6	A-MYB	factor	8
7	transcription	factor	8
8	factor	of	4
9	is	<ROOT>	-1
10	responsible	B	13
11	for	B	13
12	its	B	13
13	B	is	9
14	cell-specific	B	13
15	activity	is	9
16	and	is	9
17	binds	and	16
18	to	binds	17
19	a	to	18
20	B	cell	21
21	cell	.	25
22	110-kDa	.	25
23	nuclear	.	25
24	protein	.	25
25	.	a	19

0	This	sequence	1
1	sequence	named	3
2	,	sequence	1
3	named	has	8
4	the	element	6
5	A	element	6
6	element	has	8
7	,	has	8
8	has	<ROOT>	-1
9	an	role	11
10	active	role	11
11	role	has	8
12	on	role	11
13	GM-CSF	transcription	14
14	transcription	on	12
15	and	transcription	14
16	is	and	15
17	responsive	is	16
18	to	promoter	21
19	the	promoter	21
20	tumor	promoter	21
21	promoter	responsive	17
22	PMA	has	8
23	in	has	8
24	transient	in	23
25	transfection	experiments	26
26	experiments	has	8
27	.	has	8

0	Human	neutrophils	1
1	neutrophils	express	2
2	express	<ROOT>	-1
3	GH-N	transcripts	5
4	gene	transcripts	5
5	transcripts	express	2
6	and	transcripts	5
7	the	and	6
8	pituitary	the	7
9	transcription	pituitary	8
10	factor	Pit-1b	11
11	Pit-1b	pituitary	8
12	.	express	2

0	Characterization	<ROOT>	-1
1	of	Characterization	0
2	the	protein	4
3	DNA-binding	protein	4
4	protein	of	1
5	by	Characterization	0
6	UV	cross-linking	7
7	cross-linking	by	5
8	,	revealed	16
9	Southwestern	blot	10
10	blot	revealed	16
11	,	blot	10
12	and	blot	10
13	antibody	and	12
14	ablation/supershift	antibody	13
15	assays	ablation/supershift	14
16	revealed	Characterization	0
17	that	revealed	16
18	it	is	19
19	is	that	17
20	similar	is	19
21	to	similar	20
22	a	designated	27
23	recently	designated	27
24	reported	nuclear	25
25	nuclear	designated	27
26	factor	designated	27
27	designated	to	21
28	SAF	designated	27
29	.	Characterization	0

0	Furthermore	<ROOT>	-1
1	a	form	4
2	dominant	form	4
3	negative	form	4
4	form	Furthermore	0
5	of	form	4
6	AML1	of	5
7	,	AML1	6
8	AML1a	totally	10
9	,	totally	10
10	totally	AML1	6
11	suppressed	differentiation	13
12	granulocytic	differentiation	13
13	differentiation	induced	15
14	otherwise	differentiation	13
15	induced	form	4
16	by	induced	15
17	granulocyte	factor	19
18	colony-stimulating	factor	19
19	factor	by	16
20	when	was	22
21	AML1a	was	22
22	was	factor	19
23	overexpressed	was	22
24	in	overexpressed	23
25	32Dc13	cells	28
26	murine	cells	28
27	myeloid	cells	28
28	cells	in	24
29	.	cells	28

0	Dominant	lymphocyte	3
1	cytotoxic	T	2
2	T	lymphocyte	3
3	lymphocyte	virus	20
4	response	lymphocyte	3
5	to	response	4
6	the	to	5
7	immediate-early	,	10
8	trans-activator	,	10
9	protein	,	10
10	,	the	6
11	BZLF1	the	6
12	,	type	15
13	in	,	12
14	persistent	,	12
15	type	BZLF1	11
16	A	type	15
17	or	lymphocyte	3
18	B	lymphocyte	3
19	Epstein-Barr	virus	20
20	virus	<ROOT>	-1
21	infection	virus	20
22	.	infection	21

0	The	factor	3
1	Oct-2	factor	3
2	transcription	factor	3
3	factor	is	4
4	is	<ROOT>	-1
5	a	member	6
6	member	is	4
7	of	member	6
8	the	POU	9
9	POU	of	7
10	(	Pit-Oct-Unc	11
11	Pit-Oct-Unc	member	6
12	)	Pit-Oct-Unc	11
13	family	of	14
14	of	member	6
15	transcription	factors	16
16	factors	member	6
17	and	factors	16
18	is	factors	16
19	expressed	is	18
20	only	in	21
21	in	expressed	19
22	B	in	21
23	lymphocytes	B	22
24	and	in	21
25	in	neuronal	26
26	neuronal	and	24
27	cells	is	4
28	but	is	4
29	not	in	30
30	in	is	4
31	other	types	33
32	cell	types	33
33	types	in	30
34	.	is	4

0	In	cells	13
1	conclusion	In	0
2	,	In	0
3	the	regulation	5
4	long-term	regulation	5
5	regulation	,	2
6	of	gene	9
7	transcription	of	6
8	factor	of	6
9	gene	regulation	5
10	expression	in	11
11	in	gene	9
12	non-proliferating	In	0
13	cells	<ROOT>	-1
14	seems	cells	13
15	to	seems	14
16	be	to	15
17	of	be	16
18	minor	importance	19
19	importance	of	17
20	after	influenza	21
21	influenza	be	16
22	infection	influenza	21
23	since	influenza	21
24	in	influenza	21
25	apoptosisprone	cells	26
26	cells	in	24
27	an	availability	29
28	immediate	availability	29
29	availability	in	24
30	of	availability	29
31	transcription	of	30
32	factor	of	30
33	proteins	factor	32
34	is	influenza	21
35	required	be	16
36	.	cells	13

0	Addition	had	5
1	of	Addition	0
2	untreated	cells	4
3	THP-1	cells	4
4	cells	of	1
5	had	<ROOT>	-1
6	little	effect	7
7	effect	had	5
8	on	effect	7
9	HUVEC	adhesiveness	10
10	adhesiveness	on	8
11	.	adhesiveness	10

0	Oxidants	<ROOT>	-1
1	,	Oxidants	0
2	transcription	factors	3
3	factors	Oxidants	0
4	,	Oxidants	0
5	and	Oxidants	0
6	intestinal	inflammation	7
7	inflammation	and	5
8	.	Oxidants	0

0	Different	cocktails	1
1	cocktails	were	6
2	of	cocktails	1
3	the	ligands	5
4	identified	ligands	5
5	ligands	of	2
6	were	<ROOT>	-1
7	added	were	6
8	to	added	7
9	sorted	cells	12
10	CD34+Thy-1+	cells	12
11	single	cells	12
12	cells	to	8
13	.	cells	12

0	All	molecules	2
1	other	molecules	2
2	molecules	were	4
3	studied	molecules	2
4	were	<ROOT>	-1
5	found	were	4
6	to	found	5
7	be	to	6
8	expressed	be	7
9	at	expressed	8
10	this	stage	11
11	stage	at	9
12	of	stage	11
13	differentiation	of	12
14	.	were	4

0	Although	IL-2-induced	1
1	IL-2-induced	IL-2R	4
2	phosphorylation	IL-2-induced	1
3	of	phosphorylation	2
4	IL-2R	did	32
5	beta	IL-2R	4
6	,	beta	5
7	JAK1	IL-2R	4
8	,	JAK1	7
9	and	STAT5	10
10	STAT5	JAK1	7
11	all	JAK1	7
12	required	the	13
13	the	all	11
14	presence	of	15
15	of	the	13
16	JAK3	of	15
17	,	JAK3	16
18	IL-4-mediated	the	13
19	phosphorylation	of	20
20	of	IL-2R	4
21	JAK1	of	20
22	,	IL-2R	4
23	STAT6	,	24
24	,	insulin	26
25	and	insulin	26
26	insulin	IL-2R	4
27	receptor	IL-2R	4
28	substrates	IL-2R	4
29	1	IL-2R	4
30	and	IL-2R	4
31	2	and	30
32	did	<ROOT>	-1
33	not	did	32
34	.	did	32

0	We	<ROOT>	-1
1	have	We	0
2	examined	have	1
3	the	examined	2
4	5'-regulatory	that	6
5	sequences	that	6
6	that	the	3
7	are	important	8
8	important	that	6
9	for	important	8
10	the	regulation	12
11	transcriptional	regulation	12
12	regulation	important	8
13	of	regulation	12
14	this	gene	15
15	gene	of	13
16	in	T	17
17	T	the	3
18	cells	We	0
19	.	We	0

0	HMG	box	1
1	box	<ROOT>	-1
2	containing	factors	4
3	transcription	factors	4
4	factors	box	1
5	in	box	1
6	lymphocyte	in	5
7	differentiation	lymphocyte	6
8	.	differentiation	7

0	When	tested	1
1	tested	was	27
2	in	tested	1
3	cytotoxicity	in	2
4	assays	cytotoxicity	3
5	using	assays	4
6	T-lymphocytes	tested	1
7	from	tested	1
8	VZV	tested	1
9	immune	tested	1
10	human	tested	1
11	donors	tested	1
12	,	was	27
13	the	range	14
14	range	was	27
15	of	range	14
16	precursor	frequencies	17
17	frequencies	of	15
18	for	frequencies	17
19	T-lymphocytes	of	15
20	that	recognized	21
21	recognized	T-lymphocytes	19
22	VZV	recognized	21
23	gE	or	24
24	or	IE62	26
25	VZV	IE62	26
26	IE62	VZV	22
27	was	<ROOT>	-1
28	similar	was	27
29	whether	similar	28
30	these	whether	29
31	proteins	were	32
32	were	expressed	33
33	expressed	these	30
34	by	expressed	33
35	HSV-1	by	34
36	or	HSV-1	35
37	a	or	36
38	vaccinia	.	40
39	vector	.	40
40	.	a	37

0	The	concentration	1
1	concentration	mRNAs	13
2	of	concentration	1
3	c-fos	of	2
4	,	concentration	1
5	c-jun	concentration	1
6	,	concentration	1
7	c-myc	concentration	1
8	,	concentration	1
9	junB	concentration	1
10	,	concentration	1
11	and	concentration	1
12	fra-1	and	11
13	mRNAs	was	14
14	was	<ROOT>	-1
15	increased	was	14
16	in	activated	17
17	activated	increased	15
18	peripheral	activated	17
19	blood	activated	17
20	lymphocytes	incubated	21
21	incubated	activated	17
22	with	incubated	21
23	ciprofloxacin	with	22
24	compared	activated	17
25	to	compared	24
26	that	in	27
27	in	to	25
28	untreated	in	27
29	controls	was	14
30	.	was	14

0	No	modification	1
1	modification	c-myc	3
2	of	c-myc	3
3	c-myc	expression	4
4	expression	<ROOT>	-1
5	could	expression	4
6	be	could	5
7	detected	be	6
8	on	detected	7
9	treatment	with	10
10	with	detected	7
11	histamine	with	10
12	or	be	6
13	its	analogues	14
14	analogues	or	12
15	.	expression	4

0	Anti-Ehrlichia	antibody	2
1	chaffeensis	antibody	2
2	antibody	induces	7
3	complexed	antibody	2
4	with	complexed	3
5	E.	chaffeensis	6
6	chaffeensis	with	4
7	induces	<ROOT>	-1
8	potent	cytokine	10
9	proinflammatory	cytokine	10
10	cytokine	mRNA	11
11	mRNA	induces	7
12	expression	in	13
13	in	induces	7
14	human	induces	7
15	monocytes	induces	7
16	through	induces	7
17	sustained	reduction	18
18	reduction	induces	7
19	of	reduction	18
20	IkappaB-alpha	of	19
21	and	induces	7
22	activation	induces	7
23	of	induces	7
24	NF-kappaB	induces	7
25	.	induces	7

0	5	is	12
1	.	5	0
2	One	5	0
3	of	mediates	8
4	the	molecules	6
5	signaling	molecules	6
6	molecules	of	3
7	which	molecules	6
8	mediates	cell	10
9	programmed	cell	10
10	cell	One	2
11	death	is	12
12	is	<ROOT>	-1
13	nuclear	factor	14
14	factor	is	12
15	Kappa-B	is	12
16	(	NF-kappa	17
17	NF-kappa	Kappa-B	15
18	B	NF-kappa	17
19	)	NF-kappa	17
20	.	is	12

0	We	demonstrate	1
1	demonstrate	<ROOT>	-1
2	here	demonstrate	1
3	that	demonstrate	1
4	TRAIL	apoptosis-inducing	7
5	(	apoptosis-inducing	7
6	TNF-related	apoptosis-inducing	7
7	apoptosis-inducing	identified	13
8	ligand	apoptosis-inducing	7
9	)	apoptosis-inducing	7
10	,	identified	13
11	a	recently	12
12	recently	identified	13
13	identified	lymphoid	20
14	DIL	identified	13
15	,	identified	13
16	also	identified	13
17	activates	lymphoid	20
18	NFkappaB	activates	17
19	in	lymphoid	20
20	lymphoid	that	3
21	cell	lymphoid	20
22	lines	demonstrate	1
23	in	lines	22
24	a	kinetic	25
25	kinetic	in	23
26	similar	kinetic	25
27	to	similar	26
28	TNFalpha	demonstrate	1
29	.	demonstrate	1

0	The	objectives	1
1	objectives	were	5
2	of	objectives	1
3	this	study	4
4	study	of	2
5	were	define	48
6	to	were	5
7	(	1	8
8	1	to	6
9	)	1	8
10	determine	that	28
11	the	time	12
12	time	determine	10
13	course	time	12
14	of	neutrophil	15
15	neutrophil	course	13
16	adhesion	course	13
17	to	adhesion	16
18	monolayers	to	17
19	of	monolayers	18
20	human	of	19
21	umbilical	human	20
22	vein	(	25
23	endothelial	(	25
24	cells	(	25
25	(	umbilical	21
26	HUVECs	human	20
27	)	time	12
28	that	1	8
29	were	exposed	30
30	exposed	that	28
31	to	exposed	30
32	60	to	31
33	minutes	followed	36
34	of	minutes	33
35	anoxia	of	34
36	followed	were	5
37	by	followed	36
38	30	by	37
39	to	30	38
40	600	to	39
41	minutes	followed	36
42	of	minutes	41
43	reoxygenation	of	42
44	and	(	45
45	(	reoxygenation	43
46	2	(	45
47	)	were	5
48	define	<ROOT>	-1
49	the	mechanisms	50
50	mechanisms	define	48
51	responsible	mechanisms	50
52	for	responsible	51
53	both	the	54
54	the	for	52
55	early	define	48
56	(	minutes	57
57	minutes	early	55
58	)	minutes	57
59	and	early	55
60	late	hyperadhesivity	64
61	(	hours	62
62	hours	hyperadhesivity	64
63	)	hours	62
64	hyperadhesivity	and	59
65	of	early	55
66	postanoxic	HUVECs	67
67	HUVECs	of	65
68	to	define	48
69	human	to	68
70	neutrophils	.	71
71	.	human	69

0	This	may	1
1	may	<ROOT>	-1
2	be	may	1
3	due	be	2
4	to	due	3
5	the	fact	6
6	fact	to	4
7	that	fact	6
8	T	cells	9
9	cells	treated	10
10	treated	that	7
11	with	treated	10
12	IL-2	contained	13
13	contained	those	14
14	those	with	11
15	located	those	14
16	in	located	15
17	S	phases	20
18	+	S	17
19	G2/M	phases	20
20	phases	in	16
21	of	located	15
22	the	cycle	24
23	cell	cycle	24
24	cycle	of	21
25	,	may	1
26	whereas	may	1
27	the	majority	29
28	vast	majority	29
29	majority	whereas	26
30	of	T	31
31	T	majority	29
32	cells	with	34
33	treated	with	34
34	with	may	1
35	IFN-alpha/beta	may	1
36	were	located	37
37	located	may	1
38	in	located	37
39	G0/G1	may	1
40	phase	may	1
41	.	may	1

0	Conversely	chain	6
1	,	chain	6
2	the	chain	6
3	murine	kappa	4
4	kappa	chain	6
5	light	chain	6
6	chain	enhancer	7
7	enhancer	does	12
8	motif	(	9
9	(	enhancer	7
10	GGGGACTTTCCG	(	9
11	)	(	9
12	does	<ROOT>	-1
13	not	does	12
14	efficiently	does	12
15	bind	does	12
16	the	p50p50	18
17	nuclear	p50p50	18
18	p50p50	bind	15
19	from	tolerant	20
20	tolerant	p50p50	18
21	murine	P388	22
22	P388	tolerant	20
23	macrophages	does	12
24	.	does	12

0	Reactive	species	2
1	oxygen	species	2
2	species	<ROOT>	-1
3	(	ROS	4
4	ROS	species	2
5	)	ROS	4
6	such	as	7
7	as	species	2
8	hydrogen	peroxide	9
9	peroxide	as	7
10	serve	species	2
11	as	species	2
12	second	messengers	13
13	messengers	as	11
14	in	the	15
15	the	species	2
16	induction	the	15
17	of	induction	16
18	the	of	17
19	transcription	the	18
20	factor	transcription	19
21	NF-kappaB	transcription	19
22	,	NF-kappaB	21
23	and	species	2
24	hence	species	2
25	in	species	2
26	the	in	25
27	activation	and	28
28	and	virus	33
29	replication	virus	33
30	of	virus	33
31	human	virus	33
32	immunodeficiency	virus	33
33	virus	the	26
34	type	species	2
35	1	species	2
36	(	1	35
37	HIV-1	)	38
38	)	1	35
39	in	human	40
40	human	species	2
41	cells	species	2
42	.	species	2

0	ZEBRA	initiates	6
1	,	ZEBRA	0
2	a	activator	4
3	transcriptional	activator	4
4	activator	ZEBRA	0
5	,	ZEBRA	0
6	initiates	<ROOT>	-1
7	the	initiates	6
8	EBV	by	11
9	lytic	by	11
10	cascade	by	11
11	by	the	7
12	activating	by	11
13	viral	activating	12
14	gene	viral	13
15	expression	.	16
16	.	gene	14

0	CD40	induced	1
1	induced	translocation	5
2	not	translocation	5
3	only	not	2
4	nuclear	translocation	5
5	translocation	<ROOT>	-1
6	but	translocation	5
7	also	translocation	5
8	de	translocation	5
9	novo	synthesis	10
10	synthesis	de	8
11	of	synthesis	10
12	RelB	and	14
13	RNA	and	14
14	and	synthesis	10
15	protein	translocation	5
16	.	translocation	5

0	It	is	1
1	is	<ROOT>	-1
2	concluded	is	1
3	that	concluded	2
4	topoisomerase	inhibitors	6
5	II	inhibitors	6
6	inhibitors	may	7
7	may	that	3
8	induce	may	7
9	the	differentiation	10
10	differentiation	induce	8
11	of	promonocytic	12
12	promonocytic	differentiation	10
13	cells	is	1
14	,	is	1
15	independently	,	14
16	of	their	17
17	their	independently	15
18	capacity	independently	15
19	to	capacity	18
20	cause	DNA	21
21	DNA	to	19
22	strand	DNA	21
23	breaks	independently	15
24	.	is	1

0	This	suggested	1
1	suggested	was	12
2	that	09-2210	4
3	Ro	09-2210	4
4	09-2210	was	5
5	was	an	7
6	inhibiting	an	7
7	an	suggested	1
8	activator	suggested	1
9	of	activator	8
10	AP-1	which	11
11	which	suggested	1
12	was	<ROOT>	-1
13	upstream	was	12
14	of	upstream	13
15	c-jun	of	14
16	and	of	14
17	downstream	of	18
18	of	was	12
19	ras	of	18
20	signaling	was	12
21	.	was	12

0	Each	group	2
1	subject	group	2
2	group	was	3
3	was	<ROOT>	-1
4	divided	was	3
5	into	divided	4
6	two	subgroups	7
7	subgroups	into	5
8	according	subgroups	7
9	to	PBMC	10
10	PBMC	according	8
11	sensitivity	PBMC	10
12	to	sensitivity	11
13	prednisolone	PBMC	10
14	in	PBMC	10
15	a	procedure	18
16	mitogen	procedure	18
17	assay	procedure	18
18	procedure	in	14
19	;	PBMC	10
20	i.e.	PBMC	10
21	,	was	3
22	sensitive	was	3
23	(	was	3
24	IC50	was	3
25	&lt;	IC50	24
26	381	&lt;	25
27	ng/mL	)	28
28	)	381	26
29	and	(	31
30	resistant	and	29
31	(	)	28
32	IC50	&gt;	33
33	&gt;	)	28
34	381	&gt;	33
35	ng/mL	)	36
36	)	381	34
37	groups	&gt;	33
38	.	was	3

0	Although	<ROOT>	-1
1	the	rate	3
2	growth	rate	3
3	rate	was	4
4	was	Although	0
5	normal	was	4
6	,	Although	0
7	the	XP-B	8
8	XP-B	,	6
9	and	XP-B	8
10	XP-D	and	9
11	cells	contained	12
12	contained	XP-D	10
13	reduced	XP-B	8
14	amounts	XP-B	8
15	of	amounts	14
16	TFIIH	amounts	14
17	.	TFIIH	16

0	First	describe	3
1	,	describe	3
2	we	describe	3
3	describe	<ROOT>	-1
4	results	demonstrating	5
5	demonstrating	describe	3
6	that	mice	7
7	mice	demonstrating	5
8	inoculated	mice	7
9	with	produced	12
10	T-antigen-expressing	plasmids	11
11	plasmids	produced	12
12	produced	inoculated	8
13	antibodies	describe	3
14	,	describe	3
15	not	describe	3
16	only	not	15
17	to	not	15
18	T-antigen	to	17
19	and	T-antigen	18
20	DNA	and	19
21	,	describe	3
22	but	describe	3
23	also	but	22
24	to	transcription	28
25	the	transcription	28
26	DNA-binding	transcription	28
27	eukaryotic	transcription	28
28	transcription	but	22
29	factors	transcription	28
30	TATA-binding	describe	3
31	protein	describe	3
32	(	describe	3
33	TBP	(	32
34	)	TBP	33
35	,	)	34
36	and	,	35
37	to	and	36
38	the	protein	40
39	cAMP-response-element-binding	protein	40
40	protein	to	37
41	(	CREB	42
42	CREB	to	37
43	)	CREB	42
44	.	describe	3

0	Their	activities	2
1	different	activities	2
2	activities	might	8
3	on	activities	2
4	the	pathway	7
5	RA	pathway	7
6	signalling	pathway	7
7	pathway	on	3
8	might	<ROOT>	-1
9	underlie	might	8
10	the	responses	12
11	different	responses	12
12	responses	of	13
13	of	underlie	9
14	PML-RAR	of	13
15	alpha	of	13
16	and	of	13
17	PLZF-RAR	of	13
18	alpha	of	13
19	APLs	of	13
20	to	RA	21
21	RA	APLs	19
22	treatment	of	13
23	.	might	8

0	The	biochemical	1
1	biochemical	modifications	2
2	modifications	<ROOT>	-1
3	responsible	modifications	2
4	for	responsible	3
5	the	defect	6
6	defect	for	4
7	in	defect	6
8	transduction	in	7
9	and	transduction	8
10	execution	and	9
11	of	execution	10
12	the	of	11
13	proliferative	are	15
14	signal	are	15
15	are	the	12
16	analyzed	the	12
17	as	analyzed	16
18	a	function	19
19	function	as	17
20	of	function	19
21	age	of	20
22	.	modifications	2

0	However	death	14
1	,	However	0
2	the	,	1
3	cellular	or	4
4	or	the	2
5	molecular	or	4
6	factors	molecular	5
7	responsible	or	4
8	for	responsible	7
9	a	delay	10
10	delay	cell	13
11	in	cell	13
12	B-CLL	cell	13
13	cell	for	8
14	death	are	15
15	are	<ROOT>	-1
16	unknown	are	15
17	.	are	15

0	The	ZAP-70	1
1	ZAP-70	could	5
2	mutant	studied	3
3	studied	ZAP-70	1
4	here	studied	3
5	could	<ROOT>	-1
6	be	could	5
7	phosphorylated	be	6
8	on	phosphorylated	7
9	tyrosine	on	8
10	when	associated	11
11	associated	phosphorylated	7
12	to	associated	11
13	the	TCR	14
14	TCR	to	12
15	zeta	could	5
16	chain	and	17
17	and	could	5
18	was	could	5
19	able	was	18
20	to	able	19
21	bind	to	20
22	p56-LRB-lck-RRB-	bind	21
23	.	p56-LRB-lck-RRB-	22

0	DR3	transduction	2
1	signal	transduction	2
2	transduction	is	3
3	is	<ROOT>	-1
4	mediated	is	3
5	by	mediated	4
6	a	by	5
7	complex	molecules	11
8	of	intracellular	9
9	intracellular	molecules	11
10	signaling	molecules	11
11	molecules	a	6
12	including	a	6
13	TRADD	a	6
14	,	is	3
15	TRAF2	is	3
16	,	is	3
17	FADD	is	3
18	,	is	3
19	and	is	3
20	FLICE	and	19
21	.	is	3

0	In	mediated	8
1	transfection	In	0
2	assays	,	3
3	,	transfection	1
4	TRADD	In	0
5	and	TRADD	4
6	TES2	and	5
7	synergistically	mediated	8
8	mediated	<ROOT>	-1
9	high-level	NF-kappaB	10
10	NF-kappaB	activation	11
11	activation	mediated	8
12	.	activation	11

0	Recent	analysis	1
1	analysis	has	5
2	of	analysis	1
3	gene-targeted	mice	4
4	mice	of	2
5	has	<ROOT>	-1
6	allowed	has	5
7	a	assessment	9
8	direct	assessment	9
9	assessment	allowed	6
10	of	assessment	9
11	the	roles	13
12	functional	roles	13
13	roles	of	10
14	of	roles	13
15	several	members	18
16	E-protein	members	18
17	family	members	18
18	members	of	14
19	in	roles	13
20	hematopoiesis	in	19
21	.	hematopoiesis	20

0	In	demonstrate	6
1	the	study	3
2	current	study	3
3	study	In	0
4	,	demonstrate	6
5	we	demonstrate	6
6	demonstrate	<ROOT>	-1
7	that	demonstrate	6
8	GC-insensitive	asthma	9
9	asthma	is	10
10	is	that	7
11	associated	is	10
12	with	associated	11
13	a	number	16
14	significantly	higher	15
15	higher	number	16
16	number	blood	22
17	of	number	16
18	GCR-beta-immunoreactive	of	17
19	cells	in	20
20	in	GCR-beta-immunoreactive	18
21	peripheral	number	16
22	blood	with	12
23	than	demonstrate	6
24	GC-sensitive	demonstrate	6
25	asthmatics	demonstrate	6
26	or	demonstrate	6
27	normal	or	26
28	controls	demonstrate	6
29	.	demonstrate	6

0	In	<ROOT>	-1
1	resting	In	0
2	Raji	,	4
3	cells	,	4
4	,	resting	1
5	little	resting	1
6	to	little	5
7	no	to	6
8	binding	the	10
9	to	the	10
10	the	no	7
11	X2	was	13
12	box	was	13
13	was	the	10
14	observed	the	10
15	.	In	0

0	Cell-to-cell	activation	2
1	contact	activation	2
2	activation	was	5
3	of	activation	2
4	NF-kappaB	of	3
5	was	<ROOT>	-1
6	only	was	15
7	partially	only	6
8	inhibited	was	15
9	by	inhibited	8
10	100	microM	11
11	microM	by	9
12	pyrrolidine	microM	11
13	dithiocarbamate	and	14
14	and	microM	11
15	was	was	5
16	not	was	15
17	correlated	with	18
18	with	was	15
19	a	with	18
20	significant	of	22
21	decrease	of	22
22	of	a	19
23	cellular	inhibitor	24
24	inhibitor	of	22
25	kappaB	alpha	26
26	alpha	inhibitor	24
27	.	was	5

0	Two	pathways	2
1	distinct	pathways	2
2	pathways	are	11
3	of	pathways	2
4	interleukin-5	synthesis	5
5	synthesis	of	3
6	in	pathways	2
7	allergen-specific	T-cell	9
8	human	T-cell	9
9	T-cell	in	6
10	clones	pathways	2
11	are	<ROOT>	-1
12	suppressed	are	11
13	by	suppressed	12
14	glucocorticoids	by	13
15	.	are	11

0	Here	show	2
1	we	show	2
2	show	<ROOT>	-1
3	that	show	2
4	the	that	3
5	IL-12	receptor	6
6	receptor	(	7
7	(	the	4
8	IL-12R	(	7
9	)	beta	10
10	beta	2	11
11	2	show	2
12	subunit	is	26
13	,	is	26
14	a	binding	17
15	recently	binding	17
16	cloned	binding	17
17	binding	is	26
18	and	binding	17
19	signal	transducing	20
20	transducing	and	18
21	component	transducing	20
22	of	binding	17
23	the	IL-12R	24
24	IL-12R	of	22
25	,	binding	17
26	is	2	11
27	expressed	is	26
28	on	expressed	27
29	human	on	28
30	Th1	human	29
31	but	on	28
32	not	on	28
33	Th2	on	28
34	clones	Th2	33
35	and	Th2	33
36	is	and	35
37	induced	is	36
38	during	induced	37
39	differentiation	during	38
40	of	naive	42
41	human	naive	42
42	naive	during	38
43	cells	show	2
44	along	show	2
45	the	show	2
46	Th1	the	45
47	but	the	45
48	not	the	49
49	the	but	47
50	Th2	show	2
51	pathway	show	2
52	.	show	2

0	Transcription	factors	1
1	factors	are	2
2	are	<ROOT>	-1
3	DNA-binding	proteins	4
4	proteins	are	2
5	that	regulate	6
6	regulate	proteins	4
7	gene	are	2
8	expression	.	9
9	.	gene	7

0	Separate	epitopes	1
1	epitopes	were	4
2	in	epitopes	1
3	VP22	in	2
4	were	<ROOT>	-1
5	defined	T-cell	7
6	for	T-cell	7
7	T-cell	were	4
8	clones	were	4
9	from	were	4
10	each	from	9
11	of	three	12
12	three	each	10
13	patients	were	4
14	.	were	4

0	TSC2	RNA	2
1	messenger	RNA	2
2	RNA	was	3
3	was	widely	4
4	widely	types	9
5	expressed	various	7
6	in	various	7
7	various	widely	4
8	cell	various	7
9	types	<ROOT>	-1
10	throughout	the	11
11	the	types	9
12	body	types	9
13	,	types	9
14	including	,	13
15	epithelia	including	14
16	,	epithelia	15
17	lymphocytes	types	9
18	,	types	9
19	and	types	9
20	cells	types	9
21	with	types	9
22	endocrine	types	9
23	functions	types	9
24	,	types	9
25	e.g.	types	9
26	,	adrenal	27
27	adrenal	e.g.	25
28	cortex	types	9
29	and	types	9
30	anterior	types	9
31	pituitary	types	9
32	.	types	9

0	The	resistance	2
1	inherent	resistance	2
2	resistance	T	5
3	of	T	5
4	naive	of	3
5	T	provides	21
6	cells	T	5
7	to	T	5
8	productive	infection	10
9	HIV	infection	10
10	infection	to	7
11	,	T	5
12	coupled	T	5
13	with	coupled	12
14	their	advantage	16
15	proliferative	advantage	16
16	advantage	with	13
17	as	advantage	16
18	demonstrated	as	17
19	here	T	5
20	,	T	5
21	provides	<ROOT>	-1
22	a	provides	21
23	sound	a	22
24	basis	sound	23
25	for	basis	24
26	proposed	for	25
27	clinical	proposed	26
28	therapies	using	29
29	using	clinical	27
30	ex	clinical	27
31	vivo	ex	30
32	expansion	vivo	31
33	and	expansion	32
34	reinfusion	T	37
35	of	reinfusion	34
36	CD4	T	37
37	T	expansion	32
38	cells	provides	21
39	from	provides	21
40	HIV-infected	provides	21
41	adults	provides	21
42	.	provides	21

0	Transcription	crucial	4
1	factor	Transcription	0
2	NF-kappaB	is	3
3	is	crucial	4
4	crucial	<ROOT>	-1
5	in	crucial	4
6	activating	the	7
7	the	crucial	4
8	transcription	the	7
9	of	transcription	8
10	genes	cytokines	13
11	encoding	cytokines	13
12	proinflammatory	cytokines	13
13	cytokines	crucial	4
14	.	crucial	4

0	However	becomes	4
1	,	becomes	4
2	its	activity	3
3	activity	becomes	4
4	becomes	<ROOT>	-1
5	lower	becomes	4
6	in	becomes	4
7	the	double-positive	8
8	double-positive	in	6
9	and	double-positive	8
10	a	fraction	11
11	fraction	CD8int/-	15
12	of	CD8int/-	15
13	the	CD8int/-	15
14	CD4+	CD8int/-	15
15	CD8int/-	and	9
16	cell	population	17
17	population	becomes	4
18	,	population	17
19	indicating	population	17
20	that	indicating	19
21	an	enhancer	23
22	additional	enhancer	23
23	enhancer	that	20
24	,	enhancer	23
25	located	enhancer	23
26	in	located	25
27	either	first	29
28	the	first	29
29	first	in	26
30	or	first	29
31	the	intron	33
32	third	the	31
33	intron	or	30
34	of	the	35
35	the	intron	33
36	CD4	the	35
37	gene	CD4	36
38	,	is	39
39	is	gene	37
40	required	is	39
41	for	required	40
42	CD4	for	41
43	gene	CD4	42
44	expression	gene	43
45	in	this	46
46	this	expression	44
47	population	becomes	4
48	.	becomes	4

0	Although	resulted	9
1	the	Although	0
2	stimulation	the	1
3	of	T	4
4	T	stimulation	2
5	cells	Although	0
6	from	young	7
7	young	Although	0
8	subjects	Although	0
9	resulted	complexes	16
10	in	protein	15
11	coordinated	increases	12
12	increases	protein	15
13	of	protein	15
14	nuclear	protein	15
15	protein	resulted	9
16	complexes	<ROOT>	-1
17	binding	complexes	16
18	the	TRE	20
19	AP-1	TRE	20
20	TRE	complexes	16
21	,	TRE	20
22	c-jun	complexes	16
23	TRE	complexes	16
24	,	complexes	16
25	and	complexes	16
26	c-fos	complexes	16
27	SRE	complexes	16
28	DNA	complexes	16
29	sequence	complexes	16
30	motifs	complexes	16
31	,	complexes	16
32	age-related	,	31
33	reductions	were	39
34	in	reductions	33
35	the	activation	36
36	activation	in	34
37	of	activation	36
38	AP-1	of	37
39	were	age-related	32
40	accompanied	were	39
41	by	accompanied	40
42	decreased	of	44
43	levels	decreased	42
44	of	by	41
45	c-jun	of	44
46	TRE	of	44
47	and	TRE	46
48	c-fos	complexes	16
49	SRE	complexes	16
50	binding	complexes	16
51	complexes	complexes	16
52	.	complexes	16

0	Electrophoretic	pretreatment	21
1	mobility-shift	revealed	7
2	assays	of	3
3	of	mobility-shift	1
4	HUVEC	proteins	6
5	nuclear	proteins	6
6	proteins	of	3
7	revealed	Electrophoretic	0
8	a	decrease	9
9	decrease	Electrophoretic	0
10	in	Electrophoretic	0
11	TNF-alpha-stimulated	in	10
12	nuclear	TNF-alpha-stimulated	11
13	factor-kappa	B	14
14	B	(	15
15	(	in	10
16	NF-kappa	B	17
17	B	(	15
18	)	Electrophoretic	0
19	activation	Electrophoretic	0
20	after	Electrophoretic	0
21	pretreatment	TCP	32
22	of	pretreatment	21
23	HUVEC	pretreatment	21
24	with	pretreatment	21
25	TCP	with	24
26	succinate	pretreatment	21
27	but	pretreatment	21
28	not	pretreatment	21
29	with	pretreatment	21
30	TCP	with	29
31	,	pretreatment	21
32	TCP	<ROOT>	-1
33	acetate	TCP	32
34	,	acetate	33
35	or	,	34
36	succinate	TCP	32
37	alone	TCP	32
38	.	TCP	32

0	In	was	4
1	addition	In	0
2	,	was	4
3	there	was	4
4	was	<ROOT>	-1
5	no	was	4
6	detectable	no	5
7	activation	in	8
8	in	detectable	6
9	neutrophils	cloned	13
10	of	cloned	13
11	the	cloned	13
12	recently	cloned	13
13	cloned	detectable	6
14	Jak3	cloned	13
15	kinase	detectable	6
16	,	has	18
17	which	has	18
18	has	was	4
19	been	has	18
20	reported	been	19
21	to	reported	20
22	be	to	21
23	expressed	be	22
24	at	high	25
25	high	expressed	23
26	levels	be	22
27	as	to	21
28	myeloid	as	27
29	cells	undergo	30
30	undergo	as	27
31	terminal	neutrophilic	32
32	neutrophilic	was	4
33	maturation	neutrophilic	32
34	.	maturation	33

0	However	<ROOT>	-1
1	,	However	0
2	in	,	1
3	vivo	in	2
4	,	in	2
5	not	CSF	7
6	only	not	5
7	CSF	in	2
8	but	CSF	7
9	also	are	13
10	many	cytokines	12
11	other	cytokines	12
12	cytokines	are	13
13	are	CSF	7
14	produced	are	13
15	under	produced	14
16	various	conditions	17
17	conditions	under	15
18	.	However	0

0	The	method	1
1	method	is	2
2	is	<ROOT>	-1
3	based	is	2
4	on	based	3
5	the	coamplification	6
6	coamplification	of	7
7	of	on	4
8	VDR	of	7
9	cDNA	is	2
10	and	cDNA	9
11	an	internal	12
12	internal	and	10
13	standard	cDNA	9
14	consisting	standard	13
15	of	known	16
16	known	consisting	14
17	concentrations	consisting	14
18	of	concentrations	17
19	a	VDR	21
20	human	VDR	21
21	VDR	of	18
22	CDNA	mutated	23
23	mutated	VDR	21
24	at	consisting	14
25	a	site	28
26	BglII	site	28
27	restriction	site	28
28	site	at	24
29	;	consisting	14
30	the	coefficient	32
31	interassay	coefficient	32
32	coefficient	is	35
33	of	coefficient	32
34	variation	of	33
35	is	consisting	14
36	11	%	37
37	%	is	35
38	.	is	2

0	In	occurring	4
1	particular	In	0
2	,	occurring	4
3	naturally	occurring	4
4	occurring	transcription	8
5	sequence	transcription	8
6	variation	transcription	8
7	impacted	transcription	8
8	transcription	response	16
9	factor	transcription	8
10	binding	transcription	8
11	to	binding	10
12	an	binding	10
13	activating	response	16
14	transcription	response	16
15	factor/cAMP	response	16
16	response	)	21
17	element	binding	18
18	binding	(	19
19	(	ATF/CREB	20
20	ATF/CREB	)	21
21	)	<ROOT>	-1
22	binding	site	23
23	site	located	25
24	(	located	25
25	located	)	21
26	between	located	25
27	the	LEF-1	28
28	LEF-1	between	26
29	and	LEF-1	28
30	distal	and	29
31	NF-kappaB	distal	30
32	transcription	)	21
33	factor	)	21
34	binding	)	21
35	sites	)	21
36	)	)	21
37	that	we	38
38	we	)	36
39	identified	we	38
40	in	previous	41
41	previous	identified	39
42	studies	)	21
43	of	studies	42
44	the	LTR	46
45	HIV-1	LTR	46
46	LTR	of	43
47	.	)	21

0	The	results	1
1	results	<ROOT>	-1
2	of	results	1
3	reporter	of	2
4	gene	reporter	3
5	analyses	revealed	6
6	revealed	gene	4
7	that	of	2
8	the	that	7
9	insulin	the	8
10	gene	insulin	9
11	promoter	gene	10
12	is	promoter	11
13	more	sensitive	14
14	sensitive	is	12
15	to	glycation	16
16	glycation	sensitive	14
17	than	glycation	16
18	the	glycation	16
19	control	;	23
20	beta-actin	;	23
21	gene	;	23
22	promoter	;	23
23	;	glycation	16
24	approximately	gene	10
25	50	approximately	24
26	and	the	8
27	80	%	28
28	%	was	35
29	of	%	28
30	the	activity	34
31	insulin	activity	34
32	gene	activity	34
33	promoter	activity	34
34	activity	of	29
35	was	and	26
36	lost	was	35
37	when	were	40
38	the	cells	39
39	cells	were	40
40	were	lost	36
41	kept	were	40
42	for	kept	41
43	3	d	44
44	d	for	42
45	in	the	46
46	the	kept	41
47	presence	the	46
48	of	presence	47
49	40	of	48
50	and	40	49
51	60	mM	52
52	mM	and	50
53	D-ribose	mM	52
54	,	D-ribose	53
55	respectively	D-ribose	53
56	.	results	1

0	Differences	LTR	2
1	in	LTR	2
2	LTR	also	4
3	sequence	LTR	2
4	also	<ROOT>	-1
5	resulted	also	4
6	in	resulted	5
7	differences	in	6
8	in	factor	10
9	transcription	in	8
10	factor	differences	7
11	recruitment	in	6
12	to	cis-acting	13
13	cis-acting	recruitment	11
14	sites	also	4
15	within	also	4
16	the	within	15
17	U3	the	16
18	region	U3	17
19	of	region	18
20	the	of	19
21	LTR	the	20
22	,	LTR	21
23	as	,	22
24	demonstrated	as	23
25	by	demonstrated	24
26	electrophoretic	mobility	27
27	mobility	by	25
28	shift	mobility	27
29	assays	demonstrated	24
30	.	also	4

0	Effects	<ROOT>	-1
1	of	Effects	0
2	glucocorticoids	of	1
3	on	lymphocyte	4
4	lymphocyte	Effects	0
5	activation	Effects	0
6	in	activation	5
7	patients	in	6
8	with	patients	7
9	steroid-sensitive	patients	7
10	and	steroid-sensitive	9
11	steroid-resistant	Effects	0
12	asthma	Effects	0
13	.	Effects	0

0	We	<ROOT>	-1
1	screened	We	0
2	TSG101	screened	1
3	for	TSG101	2
4	somatic	for	3
5	mutations	somatic	4
6	in	mutations	5
7	DNA	in	6
8	and	somatic	4
9	RNA	and	8
10	samples	We	0
11	isolated	from	12
12	from	samples	10
13	a	variety	14
14	variety	from	12
15	of	variety	14
16	common	malignancies	18
17	human	malignancies	18
18	malignancies	of	15
19	,	EBV-immortalised	20
20	EBV-immortalised	from	12
21	B-cells	We	0
22	,	We	0
23	and	normal	24
24	normal	We	0
25	lung	We	0
26	parenchyma	We	0
27	.	We	0

0	IL-4	enhanced	1
1	enhanced	<ROOT>	-1
2	CD11b	enhanced	1
3	,	enhanced	1
4	but	inhibited	5
5	inhibited	enhanced	1
6	CD26	expression	7
7	expression	inhibited	5
8	and	expression	7
9	delayed	and	8
10	CD13	delayed	9
11	loss	.	12
12	.	CD13	10

0	The	parameters	2
1	same	parameters	2
2	parameters	have	3
3	have	<ROOT>	-1
4	been	have	3
5	examined	been	4
6	in	examined	5
7	a	group	8
8	group	in	6
9	of	group	8
10	soccer	players	11
11	players	of	9
12	for	group	8
13	comparison	for	12
14	with	comparison	13
15	the	group	17
16	sedentary	group	17
17	group	with	14
18	.	have	3

0	It	has	1
1	has	<ROOT>	-1
2	been	has	1
3	proposed	been	2
4	that	proposed	3
5	their	expression	6
6	expression	is	7
7	is	that	4
8	controlled	is	7
9	by	controlled	8
10	the	non-clonal	11
11	non-clonal	by	9
12	,	by	9
13	or	by	9
14	innate	or	13
15	,	by	9
16	component	by	9
17	of	component	16
18	immunity	of	17
19	that	immunity	18
20	preceded	that	19
21	in	preceded	20
22	evolution	that	19
23	the	development	24
24	development	evolution	22
25	of	development	24
26	an	system	29
27	adaptive	system	29
28	immune	system	29
29	system	of	25
30	in	evolution	22
31	vertebrates	in	30
32	.	has	1

0	Neither	condensation	2
1	chromatin	condensation	2
2	condensation	was	6
3	nor	condensation	2
4	DNA	fragmentation	5
5	fragmentation	nor	3
6	was	<ROOT>	-1
7	detected	was	6
8	in	cells	10
9	Kit225	cells	10
10	cells	detected	7
11	cultured	was	6
12	with	was	6
13	V3-BH10	was	6
14	and	was	6
15	IL-2	was	6
16	.	was	6

0	We	examined	1
1	examined	<ROOT>	-1
2	the	effects	3
3	effects	examined	1
4	of	effects	3
5	histamine	of	4
6	and	its	7
7	its	examined	1
8	agonists	its	7
9	on	the	10
10	the	examined	1
11	expression	the	13
12	of	the	13
13	the	the	10
14	c-fos	examined	1
15	and	examined	1
16	c-myc	examined	1
17	proto-oncogenes	examined	1
18	at	examined	1
19	the	transcriptional	20
20	transcriptional	at	18
21	and	U937	28
22	translational	U937	28
23	levels	U937	28
24	in	U937	28
25	the	U937	28
26	human	U937	28
27	promonocytic	U937	28
28	U937	examined	1
29	cell	examined	1
30	line	examined	1
31	.	examined	1

0	However	<ROOT>	-1
1	,	However	0
2	the	effect	4
3	real	effect	4
4	effect	,	1
5	of	effect	4
6	hormones	of	5
7	involved	of	5
8	in	involved	7
9	ovulation	is	10
10	is	However	0
11	expressed	is	10
12	by	expressed	11
13	biological	modifications	14
14	modifications	by	12
15	on	modifications	14
16	target	tissues	17
17	tissues	on	15
18	.	However	0

0	In	were	11
1	comparison	In	0
2	,	PBMC	3
3	PBMC	In	0
4	from	two	5
5	two	PBMC	3
6	children	PBMC	3
7	with	children	6
8	fatal	infection	10
9	adenoviral	infection	10
10	infection	with	7
11	were	<ROOT>	-1
12	both	were	11
13	strongly	both	12
14	positive	for	15
15	for	strongly	13
16	adenovirus	for	15
17	DNA	.	18
18	.	adenovirus	16

0	Various	can	11
1	extracellular	signals	2
2	signals	Various	0
3	,	Various	0
4	often	converging	5
5	converging	Various	0
6	in	converging	5
7	common	pathways	9
8	intracellular	pathways	9
9	pathways	in	6
10	,	Various	0
11	can	<ROOT>	-1
12	induce	can	11
13	apoptosis	induce	12
14	in	induce	12
15	a	fashion	17
16	cell-type-specific	fashion	17
17	fashion	in	14
18	.	can	11

0	In	cell	2
1	T	cell	2
2	cell	RelB	10
3	areas	cell	2
4	,	areas	3
5	p50	areas	3
6	,	p50	5
7	p52	p50	5
8	,	p50	5
9	and	p50	5
10	RelB	were	11
11	were	<ROOT>	-1
12	found	were	11
13	in	found	12
14	the	nuclei	15
15	nuclei	in	13
16	of	nuclei	15
17	HLA-DR+	cells	18
18	cells	of	16
19	with	of	16
20	an	with	19
21	antigen-presenting	cell	22
22	cell	an	20
23	(	were	11
24	APC	were	11
25	)	were	11
26	morphology	.	27
27	.	were	11

0	Human	monocytes	1
1	monocytes	<ROOT>	-1
2	and	monocytes	1
3	monocyte-derived	and	2
4	macrophages	monocyte-derived	3
5	cultured	macrophages	4
6	for	monocyte-derived	3
7	6	monocytes	1
8	days	monocytes	1
9	in	days	8
10	5	%	11
11	%	in	9
12	human	%	11
13	serum	mRNA	16
14	expressed	serum	13
15	PPARgamma	mRNA	16
16	mRNA	human	12
17	and	mRNA	16
18	protein	monocytes	1
19	by	monocytes	1
20	reverse	Western	25
21	transcription-polymerase	Western	25
22	chain	Western	25
23	reaction	Western	25
24	and	Western	25
25	Western	by	19
26	blotting	Western	25
27	,	monocytes	1
28	respectively	monocytes	1
29	.	monocytes	1

0	At	were	8
1	the	end	2
2	end	At	0
3	of	end	2
4	both	periods	6
5	treatment	periods	6
6	periods	symptoms	7
7	symptoms	of	3
8	were	<ROOT>	-1
9	scored	were	8
10	after	were	8
11	allergen	provocation	12
12	provocation	10000	18
13	(	provocation	12
14	100	(	13
15	,	(	13
16	1000	(	13
17	,	(	13
18	10000	BU/mL	19
19	BU/mL	after	10
20	)	were	8
21	and	were	8
22	during	and	21
23	the	hours	25
24	9.5	hours	25
25	hours	during	22
26	after	during	22
27	this	challenge	28
28	challenge	after	26
29	.	were	8

0	PIEC	clones	1
1	clones	stably	2
2	stably	transfected	3
3	transfected	<ROOT>	-1
4	with	transfected	3
5	one	with	4
6	of	these	7
7	these	one	5
8	constructs	transfected	3
9	showed	transfected	3
10	up	showed	9
11	to	up	10
12	99	suppression	14
13	%	99	12
14	suppression	to	11
15	of	suppression	14
16	SLA-DR	of	15
17	and	SLA-DR	16
18	SLA-DQ	and	17
19	antigen	SLA-DQ	18
20	induction	and	21
21	and	SLA-DQ	18
22	marked	suppression	23
23	suppression	and	21
24	of	mRNA	26
25	SLA-DRA	mRNA	26
26	mRNA	suppression	23
27	induction	transfected	3
28	.	transfected	3

0	As	serves	3
1	such	As	0
2	it	serves	3
3	serves	<ROOT>	-1
4	as	serves	3
5	a	prototype	7
6	good	prototype	7
7	prototype	as	4
8	for	prototype	7
9	B	genes	11
10	cell-specific	genes	11
11	genes	for	8
12	whose	expression	13
13	expression	begins	14
14	begins	genes	11
15	shortly	begins	14
16	after	lineage	17
17	lineage	serves	3
18	commitment	lineage	17
19	.	serves	3

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	Interleukin-6	protein	3
3	protein	were	7
4	and	protein	3
5	mRNA	production	6
6	production	and	4
7	were	RESULTS	0
8	significantly	were	7
9	increased	significantly	8
10	in	increased	9
11	cells	transfected	12
12	transfected	in	10
13	with	in	10
14	the	genes	17
15	CMV	genes	17
16	IE	genes	17
17	genes	with	13
18	and	genes	17
19	stimulated	and	18
20	with	stimulated	19
21	LPS	with	20
22	compared	LPS-stimulated	24
23	to	LPS-stimulated	24
24	LPS-stimulated	stimulated	19
25	control	LPS-stimulated	24
26	cells	RESULTS	0
27	.	RESULTS	0

0	In	show	5
1	this	study	2
2	study	In	0
3	,	show	5
4	we	show	5
5	show	<ROOT>	-1
6	that	show	5
7	HNF-3alpha	are	17
8	,	HNF-3alpha	7
9	-3beta	HNF-3alpha	7
10	,	-3beta	9
11	-3gamma	-3beta	9
12	,	-3gamma	11
13	-4gamma	-3gamma	11
14	,	-4gamma	13
15	and	-4gamma	13
16	-6	and	15
17	are	that	6
18	expressed	are	17
19	in	expressed	18
20	pancreatic	beta-cells	21
21	beta-cells	in	19
22	.	show	5

0	B-1	lymphocytes	1
1	lymphocytes	are	2
2	are	<ROOT>	-1
3	self-renewing	B	6
4	,	self-renewing	3
5	CD5+	B	6
6	B	are	2
7	cells	are	2
8	that	are	2
9	display	are	2
10	a	propensity	11
11	propensity	display	9
12	for	display	9
13	malignant	transformation	14
14	transformation	for	12
15	and	for	12
16	are	and	15
17	the	are	16
18	normal	to	20
19	counterpart	to	20
20	to	the	17
21	human	to	20
22	chronic	.	25
23	lymphocytic	.	25
24	leukemias	.	25
25	.	human	21

0	Furthermore	show	3
1	,	show	3
2	we	show	3
3	show	<ROOT>	-1
4	that	inhibitory	10
5	exogenous	PGE2	6
6	PGE2	mimics	7
7	mimics	inhibitory	10
8	the	inhibitory	10
9	NF-kappaB	inhibitory	10
10	inhibitory	show	3
11	effect	inhibitory	10
12	of	effect	11
13	FCM	show	3
14	.	show	3

0	We	found	1
1	found	<ROOT>	-1
2	that	induces	4
3	erythropoietin	induces	4
4	induces	tyrosine	5
5	tyrosine	found	1
6	phosphorylation	tyrosine	5
7	of	phosphorylation	6
8	Jak2	found	1
9	,	found	1
10	STAT5A	found	1
11	,	found	1
12	and	found	1
13	STAT5B	and	12
14	.	found	1

0	Recently	has	3
1	,	has	3
2	it	has	3
3	has	<ROOT>	-1
4	been	has	3
5	shown	been	4
6	that	been	4
7	RelB	knockout	8
8	knockout	mice	9
9	mice	have	10
10	have	that	6
11	no	cells	13
12	dendritic	cells	13
13	cells	have	10
14	(	DC	15
15	DC	cells	13
16	)	DC	15
17	.	has	3

0	For	<ROOT>	-1
1	this	pattern	3
2	expression	pattern	3
3	pattern	For	0
4	the	For	0
5	first	the	4
6	280	first	5
7	bp	280	6
8	upstream	bp	7
9	of	upstream	8
10	the	of	9
11	major	the	10
12	transcriptional	major	11
13	start	transcriptional	12
14	site	start	13
15	seems	site	14
16	to	seems	15
17	be	to	16
18	sufficient	be	17
19	.	For	0

0	V3-BH10	blocked	2
1	neither	blocked	2
2	blocked	binding	5
3	radiolabeled	binding	5
4	IL-2	binding	5
5	binding	<ROOT>	-1
6	to	IL-2	7
7	IL-2	binding	5
8	receptors	binding	5
9	nor	tyrosyl	11
10	affected	nor	9
11	tyrosyl	binding	5
12	phosphorylation	several	14
13	of	several	14
14	several	tyrosyl	11
15	cellular	several	14
16	proteins	cellular	15
17	(	p120	18
18	p120	proteins	16
19	,	p120	18
20	p98	p120	18
21	,	p120	18
22	p96	p120	18
23	,	p96	22
24	p54	p96	22
25	,	p54	24
26	and	p54	24
27	p38	and	26
28	)	p38	27
29	,	p38	27
30	which	is	31
31	is	p38	27
32	immediately	is	31
33	induced	immediately	32
34	by	IL-2	35
35	IL-2	induced	33
36	stimulation	binding	5
37	.	binding	5

0	Mutation	<ROOT>	-1
1	of	CBF1/RBP-Jkappa	3
2	the	CBF1/RBP-Jkappa	3
3	CBF1/RBP-Jkappa	Mutation	0
4	binding	site	5
5	site	CBF1/RBP-Jkappa	3
6	in	site	5
7	EBNA3C	in	6
8	abrogated	repression	9
9	repression	CBF1/RBP-Jkappa	3
10	,	CBF1/RBP-Jkappa	3
11	strongly	that	13
12	suggesting	that	13
13	that	CBF1/RBP-Jkappa	3
14	CBF1/RBP-Jkappa	that	13
15	is	CBF1/RBP-Jkappa	14
16	necessary	is	15
17	for	necessary	16
18	targeting	protein	21
19	the	protein	21
20	viral	protein	21
21	protein	for	17
22	to	protein	21
23	Cp	to	22
24	.	Mutation	0

0	Induction	requires	13
1	of	Induction	0
2	the	of	1
3	CD11b	the	2
4	gene	CD11b	3
5	during	activation	6
6	activation	gene	4
7	of	cell	10
8	the	cell	10
9	monocytic	cell	10
10	cell	activation	6
11	line	Induction	0
12	U937	Induction	0
13	requires	<ROOT>	-1
14	a	factor	17
15	novel	factor	17
16	nuclear	factor	17
17	factor	requires	13
18	MS-2	requires	13
19	[	requires	13
20	published	[	19
21	erratum	requires	13
22	appears	erratum	21
23	in	requires	13
24	J	Jul	27
25	Immunol	Jul	27
26	1999	Jul	27
27	Jul	in	23
28	15	requires	13
29	;	requires	13
30	163	requires	13
31	(	2	32
32	2	163	30
33	)	2	32
34	:	163	30
35	1091	163	30
36	]	1091	35

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	the	function	5
5	function	may	9
6	of	function	5
7	adrenal	cortex	8
8	cortex	of	6
9	may	that	3
10	be	may	9
11	improved	be	10
12	by	be	10
13	the	mechanism	15
14	compensation	mechanism	15
15	mechanism	by	12
16	of	the	17
17	the	mechanism	15
18	patients	the	17
19	,	patients	18
20	but	GCR	23
21	the	GCR	23
22	lower	GCR	23
23	GCR	number	24
24	number	patients	18
25	was	number	24
26	the	result	27
27	result	was	25
28	of	result	27
29	lacking	of	28
30	of	lacking	29
31	oxygen	was	25
32	in	oxygen	31
33	the	patients	34
34	patients	in	32
35	.	indicate	2

0	The	phenomenon	4
1	most	extensively	2
2	extensively	studied	3
3	studied	phenomenon	4
4	phenomenon	is	5
5	is	<ROOT>	-1
6	the	decline	8
7	progressive	decline	8
8	decline	is	5
9	in	decline	8
10	the	capacities	12
11	proliferative	capacities	12
12	capacities	in	9
13	of	T	14
14	T	capacities	12
15	lymphocytes	is	5
16	with	is	5
17	aging	with	16
18	.	is	5

0	We	confirm	1
1	confirm	is	9
2	that	confirm	1
3	binding	that	2
4	of	endogenous	5
5	endogenous	binding	3
6	NFkappaB	confirm	1
7	and	NFkappaB	6
8	AP1	and	7
9	is	<ROOT>	-1
10	induced	is	9
11	following	induced	10
12	PMA/ionomycin	treatment	13
13	treatment	following	11
14	of	T	15
15	T	treatment	13
16	cells	is	9
17	.	is	9

0	In	<ROOT>	-1
1	contrast	In	0
2	to	contrast	1
3	their	to	2
4	inhibitory	cytokine	12
5	effects	cytokine	7
6	on	cytokine	7
7	cytokine	inhibitory	4
8	expression	inhibitory	4
9	,	GCS	10
10	GCS	expression	8
11	up-regulate	inhibitory	4
12	cytokine	receptor	13
13	receptor	their	3
14	expression	to	2
15	that	correlates	16
16	correlates	expression	14
17	with	correlates	16
18	enhanced	cytokine	19
19	cytokine	with	17
20	effects	cytokine	19
21	on	target	22
22	target	effects	20
23	cells	In	0
24	.	In	0

0	From	are	14
1	AML1	gene	2
2	gene	From	0
3	,	are	14
4	two	are	14
5	representative	two	4
6	forms	representative	5
7	of	forms	6
8	proteins	of	7
9	,	are	14
10	AML1a	are	14
11	and	AML1a	10
12	AML1b	and	11
13	,	are	14
14	are	<ROOT>	-1
15	produced	are	14
16	by	produced	15
17	an	splicing	19
18	alternative	splicing	19
19	splicing	by	16
20	.	are	14

0	However	are	3
1	,	are	3
2	there	are	3
3	are	other	4
4	other	effects	5
5	effects	<ROOT>	-1
6	,	effects	5
7	such	as	8
8	as	effects	5
9	the	activation	11
10	early	activation	11
11	activation	as	8
12	of	kinase	14
13	protein	of	12
14	kinase	activation	11
15	C	effects	5
16	,	C	15
17	which	are	18
18	are	C	15
19	probably	are	18
20	derived	are	18
21	from	derived	20
22	the	production	23
23	production	from	21
24	of	production	23
25	primary	breakage	27
26	DNA	breakage	27
27	breakage	of	24
28	by	anti-topoisomerase	30
29	some	anti-topoisomerase	30
30	anti-topoisomerase	from	21
31	drugs	effects	5
32	.	effects	5

0	These	studies	1
1	studies	confirm	3
2	also	confirm	3
3	confirm	<ROOT>	-1
4	that	confirm	3
5	AAV	is	6
6	is	that	4
7	an	vehicle	10
8	efficient	vehicle	10
9	delivery	vehicle	10
10	vehicle	is	6
11	for	vehicle	10
12	cytokines	cells	15
13	to	cytokines	12
14	leukemic	cells	15
15	cells	for	11
16	.	cells	15

0	Regulation	<ROOT>	-1
1	of	Regulation	0
2	B-cell	commitment	3
3	commitment	of	1
4	to	commitment	3
5	plasma	cells	6
6	cells	to	4
7	or	cells	6
8	to	or	7
9	memory	B	10
10	B	to	8
11	cells	Regulation	0
12	.	Regulation	0

0	Specific	formation	2
1	complex	formation	2
2	formation	<ROOT>	-1
3	between	formation	2
4	the	type	5
5	type	between	3
6	II	formation	2
7	bare	syndrome-associated	9
8	lymphocyte	syndrome-associated	9
9	syndrome-associated	formation	2
10	transactivators	syndrome-associated	9
11	CIITA	transactivators	10
12	and	CIITA	11
13	RFX5	and	12
14	.	syndrome-associated	9

0	Our	results	1
1	results	identify	2
2	identify	<ROOT>	-1
3	a	switch	5
4	molecular	switch	5
5	switch	lineage	7
6	for	lineage	7
7	lineage	identify	2
8	specification	identify	2
9	in	lymphoid	11
10	early	lymphoid	11
11	lymphoid	identify	2
12	precursors	identify	2
13	of	identify	2
14	humans	identify	2
15	.	identify	2

0	RESULTS	(	36
1	:	RESULTS	0
2	The	number	3
3	number	RESULTS	0
4	of	glucocorticoid	5
5	glucocorticoid	number	3
6	receptors	RESULTS	0
7	from	RESULTS	0
8	the	nonresponders	10
9	six	nonresponders	10
10	nonresponders	from	7
11	,	nonresponders	10
12	five	responders	13
13	responders	nonresponders	10
14	,	responders	13
15	and	responders	13
16	ten	healthy	17
17	healthy	and	15
18	controls	were	19
19	were	(	21
20	4922	were	19
21	(	RESULTS	0
22	range	(	21
23	,	RESULTS	0
24	4484-5643	RESULTS	0
25	)	RESULTS	0
26	,	(	28
27	3413	(	28
28	(	RESULTS	0
29	range	RESULTS	0
30	,	RESULTS	0
31	3183-4450	,	30
32	)	RESULTS	0
33	,	RESULTS	0
34	and	RESULTS	0
35	3610	(	36
36	(	<ROOT>	-1
37	range	(	36
38	,	(	36
39	2594-3979	,	38
40	)	(	36
41	binding	(	36
42	sites/cell	(	36
43	,	(	36
44	respectively	(	36
45	.	(	36

0	Cyclosporin	<ROOT>	-1
1	A	Cyclosporin	0
2	inhibits	early	3
3	early	mRNA	4
4	mRNA	A	1
5	expression	of	6
6	of	Cyclosporin	0
7	G0/G1	of	6
8	switch	of	6
9	gene	Cyclosporin	0
10	2	Cyclosporin	0
11	(	Cyclosporin	0
12	G0S2	Cyclosporin	0
13	)	Cyclosporin	0
14	in	mononuclear	18
15	cultured	mononuclear	18
16	human	mononuclear	18
17	blood	mononuclear	18
18	mononuclear	Cyclosporin	0
19	cells	Cyclosporin	0
20	.	Cyclosporin	0

0	Involvement	<ROOT>	-1
1	of	Involvement	0
2	nuclear	B	4
3	factor-kappa	B	4
4	B	of	1
5	activation	B	4
6	in	IgE	7
7	IgE	Involvement	0
8	synthesis	IgE	7
9	in	B	11
10	human	B	11
11	B	synthesis	8
12	cells	Involvement	0
13	.	Involvement	0

0	The	<ROOT>	-1
1	Pax-5	is	3
2	gene	is	3
3	is	The	0
4	alternatively	is	3
5	spliced	alternatively	4
6	during	spliced	5
7	B-cell	spliced	5
8	development	.	9
9	.	B-cell	7

0	Thus	is	5
1	,	is	5
2	the	mechanism	4
3	extinguishing	mechanism	4
4	mechanism	is	5
5	is	<ROOT>	-1
6	effective	is	5
7	very	early	8
8	early	is	5
9	after	is	5
10	fusion	after	9
11	.	fusion	10

0	It	is	1
1	is	<ROOT>	-1
2	now	is	1
3	well	is	1
4	appreciated	well	3
5	that	appreciated	4
6	chronic	that	5
7	gut	is	9
8	inflammation	is	9
9	is	chronic	6
10	characterized	is	9
11	by	characterized	10
12	enhanced	by	11
13	production	enhanced	12
14	of	production	13
15	reactive	of	14
16	metabolites	reactive	15
17	of	metabolites	16
18	oxygen	of	17
19	and	oxygen	18
20	nitrogen	and	19
21	.	is	1

0	When	were	3
1	the	cells	2
2	cells	were	3
3	were	receptor	16
4	exposed	were	3
5	to	increasing	6
6	increasing	exposed	4
7	concentrations	increasing	6
8	of	tetracyclines	9
9	tetracyclines	concentrations	7
10	,	tetracyclines	9
11	surface	tetracyclines	9
12	expression	the	14
13	of	the	14
14	the	were	3
15	chimeric	were	3
16	receptor	was	17
17	was	<ROOT>	-1
18	suppressed	was	17
19	in	suppressed	18
20	a	manner	22
21	dose-dependent	manner	22
22	manner	in	19
23	,	suppressed	18
24	and	suppressed	18
25	this	suppression	26
26	suppression	was	27
27	was	and	24
28	sufficient	was	27
29	to	sufficient	28
30	result	to	29
31	in	result	30
32	complete	in	31
33	loss	complete	32
34	of	loss	33
35	responsiveness	of	34
36	to	responsiveness	35
37	the	Ag	39
38	targeted	Ag	39
39	Ag	to	36
40	.	Ag	39

0	However	,	11
1	,	However	0
2	the	,	1
3	experimentally	the	2
4	derived	experimentally	3
5	B-lymphoblastoid	derived	4
6	cell	line	7
7	line	B-lymphoblastoid	5
8	,	line	7
9	clone	However	0
10	13	However	0
11	,	expresses	12
12	expresses	<ROOT>	-1
13	high	expresses	12
14	levels	expresses	12
15	of	levels	14
16	HLADQ	of	15
17	in	expresses	12
18	the	absence	19
19	absence	in	17
20	of	absence	19
21	HLA-DR	of	20
22	and	expresses	12
23	HLA-DP	and	22
24	,	expresses	12
25	despite	expresses	12
26	its	mapping	27
27	mapping	despite	25
28	by	mapping	27
29	complementation	analysis	30
30	analysis	by	28
31	to	analysis	30
32	this	group	33
33	group	analysis	30
34	.	expresses	12

0	Bcd	transcripts	2
1	mRNA	transcripts	2
2	transcripts	kb	8
3	of	transcripts	2
4	&lt;	or	5
5	or	of	3
6	=	or	5
7	2.6	=	6
8	kb	were	9
9	were	<ROOT>	-1
10	selectively	were	9
11	expressed	selectively	10
12	in	expressed	11
13	PBL	in	12
14	and	in	12
15	testis	were	9
16	of	testis	15
17	healthy	individuals	18
18	individuals	of	16
19	.	were	9

0	Electrophoretic	shift	2
1	mobility	shift	2
2	shift	,	30
3	(	EMS	4
4	EMS	shift	2
5	)	EMS	4
6	analyses	reacted	18
7	utilizing	analyses	6
8	oligonucleotides	homologous	9
9	homologous	utilizing	7
10	to	homologous	9
11	each	to	10
12	of	each	11
13	the	elements	17
14	21	elements	17
15	bp	elements	17
16	repeat	elements	17
17	elements	of	12
18	reacted	EMS	4
19	with	reacted	18
20	nuclear	derived	22
21	extracts	derived	22
22	derived	with	19
23	from	derived	22
24	cell	from	23
25	lines	of	26
26	of	from	23
27	lymphocytic	of	26
28	,	shift	2
29	monocytic	,	30
30	,	have	37
31	neuronal	,	30
32	,	,	30
33	and	,	30
34	glial	,	30
35	cell	,	30
36	origin	,	30
37	have	<ROOT>	-1
38	demonstrated	have	37
39	differential	binding	40
40	binding	demonstrated	38
41	of	cellular	42
42	cellular	demonstrated	38
43	factors	cellular	42
44	to	21	47
45	the	21	47
46	three	21	47
47	21	cellular	42
48	bp	repeats	49
49	repeats	21	47
50	(	1-4	51
51	1-4	repeats	49
52	)	1-4	51
53	.	have	37

0	Importantly	acted	15
1	,	Importantly	0
2	despite	binding	5
3	high	binding	5
4	ligand	binding	5
5	binding	Importantly	0
6	affinity	Importantly	0
7	,	Importantly	0
8	the	prototypic	9
9	prototypic	dissociated	10
10	dissociated	Importantly	0
11	compound	dissociated	10
12	,	Importantly	0
13	RU24858	Importantly	0
14	,	Importantly	0
15	acted	<ROOT>	-1
16	as	acted	15
17	a	agonist	19
18	weak	agonist	19
19	agonist	as	16
20	and	agonist	19
21	did	and	20
22	not	did	21
23	efficiently	did	21
24	antagonize	did	21
25	dexamethasone-induced	in	27
26	transcription	in	27
27	in	antagonize	24
28	transfected	acted	15
29	cells	acted	15
30	.	acted	15

0	HIV	does	1
1	does	<ROOT>	-1
2	not	does	1
3	replicate	does	1
4	in	T	7
5	naive	T	7
6	CD4	T	7
7	T	replicate	3
8	cells	stimulated	9
9	stimulated	does	1
10	with	stimulated	9
11	CD3/CD28	with	10
12	.	does	1

0	These	<ROOT>	-1
1	results	These	0
2	demonstrate	that	3
3	that	results	1
4	RXR-alpha	that	3
5	has	a	6
6	a	RXR-alpha	4
7	role	in	8
8	in	a	6
9	mediating	inhibition	11
10	growth	inhibition	11
11	inhibition	in	8
12	and	cell	13
13	cell	inhibition	11
14	adhesion	cell	13
15	during	myelomonocytic	16
16	myelomonocytic	adhesion	14
17	differentiation	These	0
18	,	and	19
19	and	differentiation	17
20	suggest	These	0
21	that	These	0
22	different	RXR-alpha	27
23	species	RXR-alpha	27
24	of	heterodimers	25
25	heterodimers	RXR-alpha	27
26	involving	RXR-alpha	27
27	RXR-alpha	may	28
28	may	that	21
29	control	different	33
30	the	acquisition	31
31	acquisition	different	33
32	of	different	33
33	different	These	0
34	features	These	0
35	of	These	0
36	mature	These	0
37	monocyte/macrophage	These	0
38	function	These	0
39	.	These	0

0	In	analyzed	4
1	this	study	2
2	study	In	0
3	we	analyzed	4
4	analyzed	<ROOT>	-1
5	the	effect	6
6	effect	analyzed	4
7	of	effect	6
8	CD40	stimulation	9
9	stimulation	of	7
10	on	analyzed	4
11	the	activity	12
12	activity	on	10
13	and	activity	12
14	nuclear	and	13
15	appearance	factor	18
16	of	factor	18
17	Rel/nuclear	factor	18
18	factor	kappaB	19
19	kappaB	nuclear	14
20	(	activity	12
21	NF-kappaB	activity	12
22	)	analyzed	4
23	factors	)	22
24	in	murine	26
25	primary	murine	26
26	murine	)	22
27	B	analyzed	4
28	lymphocytes	analyzed	4
29	.	analyzed	4

0	CD15	cross-linking	1
1	cross-linking	interleukin-1	5
2	also	interleukin-1	5
3	concomitantly	interleukin-1	5
4	increased	interleukin-1	5
5	interleukin-1	was	17
6	beta	interleukin-1	5
7	(	IL-1	8
8	IL-1	interleukin-1	5
9	beta	IL-1	8
10	)	IL-1	8
11	mRNA	,	12
12	,	)	10
13	while	)	10
14	no	change	16
15	apparent	change	16
16	change	)	10
17	was	<ROOT>	-1
18	observed	was	17
19	in	observed	18
20	the	levels	21
21	levels	in	19
22	of	levels	21
23	beta-actin	mRNA	24
24	mRNA	of	22
25	,	was	17
26	indicating	was	17
27	specificity	indicating	26
28	.	was	17

0	Transcription	factors	1
1	factors	<ROOT>	-1
2	required	lineage	5
3	for	lineage	5
4	lymphoid	lineage	5
5	lineage	factors	1
6	commitment	factors	1
7	.	factors	1

0	Following	were	39
1	an	screening	4
2	initial	screening	4
3	genotype	screening	4
4	screening	Following	0
5	of	normal	7
6	85	normal	7
7	normal	screening	4
8	volunteers	by	9
9	by	Following	0
10	polymerase	reaction	12
11	chain	reaction	12
12	reaction	Following	0
13	or	reaction	12
14	restriction	or	13
15	fragment	restriction	14
16	length	fragment	15
17	polymorphism	length	16
18	analysis	,	19
19	,	polymorphism	17
20	14	,	19
21	individuals	restriction	14
22	with	individuals	21
23	the	genotype	25
24	Bb	genotype	25
25	genotype	with	22
26	,	Following	0
27	12	Following	0
28	with	Following	0
29	the	genotype	31
30	bb	genotype	31
31	genotype	with	28
32	,	Following	0
33	and	Following	0
34	12	and	33
35	with	and	33
36	the	genotype	38
37	BB	genotype	38
38	genotype	with	35
39	were	<ROOT>	-1
40	selected	were	39
41	.	were	39

0	In	<ROOT>	-1
1	this	study	2
2	study	In	0
3	,	In	0
4	we	,	3
5	investigated	alpha	10
6	the	effect	7
7	effect	of	8
8	of	investigated	5
9	ER	of	8
10	alpha	we	4
11	(	alpha	10
12	referred	alpha	10
13	to	referred	12
14	throughout	to	13
15	as	alpha	10
16	ER	alpha	10
17	)	alpha	10
18	on	DNA-binding	19
19	DNA-binding	we	4
20	activities	of	21
21	of	DNA-binding	19
22	transcription	factors	23
23	factors	of	21
24	involved	of	21
25	in	involved	24
26	regulating	in	25
27	the	expression	28
28	expression	in	25
29	of	expression	28
30	erythroid-specific	genes	31
31	genes	of	29
32	,	In	0
33	and	In	0
34	,	In	0
35	in	In	0
36	particular	in	35
37	,	In	0
38	the	gene	41
39	histone	gene	41
40	H5	gene	41
41	gene	In	0
42	.	In	0

0	Hypermethylation	appear	7
1	within	Hypermethylation	0
2	the	promoters	3
3	promoters	within	1
4	of	promoters	3
5	some	genes	6
6	genes	of	4
7	appear	<ROOT>	-1
8	to	appear	7
9	be	to	8
10	an	event	12
11	early	event	12
12	event	be	9
13	in	be	9
14	the	pathogenesis	15
15	pathogenesis	(	18
16	of	(	18
17	neoplasia	(	18
18	(	in	13
19	ER	(	18
20	,	appear	7
21	P15	appear	7
22	)	appear	7
23	,	appear	7
24	while	appear	7
25	other	genes	26
26	genes	seem	27
27	seem	while	24
28	to	seem	27
29	become	to	28
30	methylated	become	29
31	during	the	32
32	the	become	29
33	progression	the	32
34	of	progression	33
35	leukemias	progression	33
36	(	leukemias	35
37	HIC1	(	36
38	,	HIC1	37
39	c-abl	)	40
40	)	HIC1	37
41	.	)	40

0	The	proto-oncogene	2
1	Bcd	proto-oncogene	2
2	proto-oncogene	was	3
3	was	<ROOT>	-1
4	activated	was	3
5	by	activated	4
6	a	truncation	7
7	truncation	by	5
8	in	truncation	7
9	the	UTR	11
10	5'	UTR	11
11	UTR	in	8
12	.	was	3

0	The	activity	1
1	activity	was	10
2	of	activity	1
3	A-MYB	of	2
4	in	activity	1
5	B	in	4
6	and	B	5
7	not	T	8
8	T	and	6
9	cells	activity	1
10	was	<ROOT>	-1
11	observed	was	10
12	when	was	21
13	either	artificial	15
14	an	artificial	15
15	artificial	was	21
16	construct	artificial	15
17	or	construct	16
18	the	promoter	20
19	c-MYC	promoter	20
20	promoter	or	17
21	was	observed	11
22	used	was	21
23	as	used	22
24	a	reporter	25
25	reporter	as	23
26	.	was	10

0	We	<ROOT>	-1
1	have	We	0
2	previously	shown	3
3	shown	have	1
4	that	shown	3
5	NF-AT1	that	4
6	is	constitutively	7
7	constitutively	active	8
8	active	in	9
9	in	NF-AT1	5
10	Jurkat	T	11
11	T	in	9
12	cells	We	0
13	stably	transfected	14
14	transfected	We	0
15	with	transfected	14
16	the	cDNA	18
17	Tax	cDNA	18
18	cDNA	with	15
19	,	We	0
20	although	We	0
21	the	mechanism	24
22	underlying	mechanism	24
23	molecular	mechanism	24
24	mechanism	and	25
25	and	although	20
26	physiological	and	25
27	relevance	of	28
28	of	We	0
29	this	finding	30
30	finding	of	28
31	remain	We	0
32	unclear	remain	31
33	.	We	0

0	Our	studies	1
1	studies	reported	2
2	reported	<ROOT>	-1
3	here	reported	2
4	demonstrate	that	5
5	that	here	3
6	GATA-3	is	7
7	is	that	5
8	critical	for	9
9	for	expression	10
10	expression	is	7
11	of	expression	10
12	the	of	11
13	IL-5	the	12
14	gene	IL-5	13
15	in	Th2	18
16	bona	Th2	18
17	fide	Th2	18
18	Th2	gene	14
19	cells	reported	2
20	.	reported	2

0	Whereas	mutations	1
1	mutations	abolished	6
2	in	GATA-3	4
3	the	GATA-3	4
4	GATA-3	mutations	1
5	site	mutations	1
6	abolished	<ROOT>	-1
7	antigen-	abolished	6
8	or	antigen-	7
9	cAMP-stimulated	activation	12
10	IL-5	activation	12
11	promoter	activation	12
12	activation	or	8
13	in	abolished	6
14	Th2	abolished	6
15	cells	abolished	6
16	,	abolished	6
17	ectopic	expression	18
18	expression	abolished	6
19	of	expression	18
20	GATA-3	Th1	22
21	in	GATA-3	20
22	Th1	of	19
23	cells	Th1	22
24	or	abolished	6
25	in	cell	30
26	a	cell	30
27	non-lymphoid	cell	30
28	,	non-lymphoid	27
29	non-IL-5-producing	cell	30
30	cell	abolished	6
31	line	abolished	6
32	activated	abolished	6
33	the	promoter	35
34	IL-5	promoter	35
35	promoter	abolished	6
36	.	abolished	6

0	Death-inducing	ligands	1
1	ligands	tumor	7
2	(	DILs	3
3	DILs	ligands	1
4	)	DILs	3
5	such	as	6
6	as	tumor	7
7	tumor	have	19
8	necrosis	factor	9
9	factor	tumor	7
10	alpha	tumor	7
11	(	alpha	10
12	TNFalpha	tumor	7
13	)	tumor	7
14	or	)	13
15	the	or	14
16	cytotoxic	drug	17
17	drug	doxorubicin	18
18	doxorubicin	the	15
19	have	<ROOT>	-1
20	been	have	19
21	shown	been	20
22	to	shown	21
23	activate	to	22
24	a	activate	23
25	nuclear	kappaB	27
26	factor	nuclear	25
27	kappaB	(	28
28	(	a	24
29	NFkappaB	have	19
30	)	have	19
31	-dependent	have	19
32	program	that	33
33	that	may	34
34	may	have	19
35	rescue	may	34
36	cells	from	37
37	from	rescue	35
38	apoptosis	have	19
39	induction	have	19
40	.	have	19

0	Taken	<ROOT>	-1
1	together	Taken	0
2	,	Taken	0
3	these	,	2
4	data	these	3
5	indicate	data	4
6	that	indicate	5
7	Tax1	that	6
8	interacts	Tax1	7
9	with	NF-Y	10
10	NF-Y	interacts	8
11	through	NF-Y	10
12	the	subunit	14
13	B	subunit	14
14	subunit	through	11
15	and	subunit	14
16	that	and	15
17	this	that	16
18	interaction	this	17
19	results	interaction	18
20	in	results	19
21	activation	in	20
22	of	activation	21
23	the	of	22
24	major	the	23
25	histocompatibility	II	28
26	complex	II	28
27	class	II	28
28	II	the	23
29	promoter	of	22
30	.	of	22

0	These	studies	1
1	studies	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	A-myb	plays	5
5	plays	that	3
6	a	plays	5
7	role	during	8
8	during	a	6
9	a	window	11
10	narrow	window	11
11	window	during	8
12	of	window	11
13	normal	of	12
14	B	cell	15
15	cell	normal	13
16	differentiation	cell	15
17	.	differentiation	16

0	Following	<ROOT>	-1
1	PCr	administration	2
2	administration	Following	0
3	we	administration	2
4	observed	lower	5
5	lower	we	3
6	blood	concentrations	8
7	lactate	concentrations	8
8	concentrations	lower	5
9	and	different	10
10	different	administration	2
11	patterns	Following	0
12	of	patterns	11
13	some	activities	15
14	enzyme	activities	15
15	activities	patterns	11
16	,	Following	0
17	less	pronounced	18
18	pronounced	Following	0
19	changes	Following	0
20	in	and	23
21	plasma	ACTH	22
22	ACTH	and	23
23	and	changes	19
24	cortisol	Following	0
25	concentrations	Following	0
26	and	glucocorticoid	28
27	in	glucocorticoid	28
28	glucocorticoid	Following	0
29	binding	Following	0
30	in	Following	0
31	lymphocytes	Following	0
32	,	Following	0
33	but	Following	0
34	no	changes	35
35	changes	growth	38
36	in	growth	38
37	plasma	growth	38
38	growth	but	33
39	hormone	growth	38
40	concentrations	hormone	39
41	compared	concentrations	40
42	to	compared	41
43	the	to	42
44	placebo	the	43
45	.	placebo	44

0	We	is	16
1	have	shown	2
2	shown	We	0
3	that	shown	2
4	the	affinity	7
5	apparent	affinity	7
6	binding	affinity	7
7	affinity	that	3
8	of	glucocorticoid	10
9	the	glucocorticoid	10
10	glucocorticoid	affinity	7
11	receptor	in	12
12	in	glucocorticoid	10
13	squirrel	We	0
14	monkey	We	0
15	lymphocytes	We	0
16	is	<ROOT>	-1
17	5-fold	lower	18
18	lower	is	16
19	than	lower	18
20	that	than	19
21	in	human	22
22	human	that	20
23	lymphocytes	is	16
24	(	lymphocytes	23
25	apparent	is	16
26	Kd	is	16
27	,	is	16
28	20.9	is	16
29	+/-	20.9	28
30	1.8	+/-	29
31	and	is	16
32	4.3	+/-	33
33	+/-	is	16
34	0.2	+/-	33
35	nmol/L	+/-	33
36	,	is	16
37	respectively	is	16
38	;	is	16
39	n	=	40
40	=	previous	46
41	3	=	40
42	)	3	41
43	,	=	40
44	consistent	previous	46
45	with	previous	46
46	previous	is	16
47	studies	previous	46
48	in	previous	46
49	mononuclear	previous	46
50	leukocytes	is	16
51	isolated	is	16
52	from	isolated	51
53	the	species	55
54	two	species	55
55	species	from	52
56	.	is	16

0	Such	hypermethylation-associated	1
1	hypermethylation-associated	expression	5
2	silencing	hypermethylation-associated	1
3	of	gene	4
4	gene	hypermethylation-associated	1
5	expression	has	6
6	has	<ROOT>	-1
7	been	has	6
8	shown	been	7
9	for	shown	8
10	several	genes	11
11	genes	regulating	12
12	regulating	for	9
13	the	growth	14
14	growth	regulating	12
15	and	growth	14
16	differentiation	and	15
17	of	hematopoietic	18
18	hematopoietic	growth	14
19	cells	has	6
20	,	has	6
21	including	,	20
22	the	receptor	24
23	estrogen	receptor	24
24	receptor	including	21
25	(	receptor	24
26	ER	receptor	24
27	)	ER	26
28	gene	,	29
29	,	ER	26
30	P15	receptor	24
31	,	P15	30
32	P16	P15	30
33	and	P16	32
34	others	and	33
35	.	has	6

0	RANTES	is	13
1	(	RANTES	0
2	regulated	(	1
3	upon	RANTES	0
4	activation	RANTES	0
5	,	T	7
6	normal	,	5
7	T	RANTES	0
8	cell	RANTES	0
9	expressed	RANTES	0
10	and	RANTES	0
11	secreted	and	10
12	)	RANTES	0
13	is	is	32
14	a	cytokine	15
15	cytokine	is	13
16	that	belongs	17
17	belongs	cytokine	15
18	to	belongs	17
19	the	family	21
20	beta-chemokine	family	21
21	family	to	18
22	;	is	13
23	it	is	24
24	is	is	13
25	chemoattractant	is	24
26	for	T	28
27	CD4+/CD45RO	T	28
28	T	chemoattractant	25
29	cells	is	13
30	,	is	32
31	it	is	32
32	is	<ROOT>	-1
33	produced	is	32
34	by	produced	33
35	various	types	37
36	cell	types	37
37	types	by	34
38	including	produced	33
39	CD8+	including	38
40	and	T	42
41	CD4+	T	42
42	T	CD8+	39
43	cells	is	32
44	as	is	32
45	well	is	32
46	as	is	32
47	monocytes/macrophages	as	46
48	,	is	32
49	and	is	32
50	has	and	49
51	recently	and	49
52	been	recently	51
53	shown	been	52
54	to	shown	53
55	suppress	to	54
56	replication	macrophage-tropic	58
57	of	macrophage-tropic	58
58	macrophage-tropic	to	54
59	strains	is	32
60	of	strains	59
61	HIV	in	62
62	in	is	32
63	CD4+	T	64
64	T	is	32
65	cells	is	32
66	.	is	32

0	Various	levels	1
1	levels	were	4
2	of	levels	1
3	expression	of	2
4	were	was	18
5	found	were	4
6	on	found	5
7	seborrheic	keratoses	8
8	keratoses	on	6
9	,	were	4
10	while	expression	12
11	the	expression	12
12	expression	level	13
13	level	were	4
14	on	level	13
15	basal	cell	16
16	cell	on	14
17	epitheliomas	were	4
18	was	<ROOT>	-1
19	low	was	18
20	.	was	18

0	Through	could	10
1	this	Through	0
2	mechanism	Through	0
3	of	mechanism	2
4	gene	regulation	5
5	regulation	of	3
6	,	could	10
7	YY1	could	10
8	and	YY1	7
9	LSF	and	8
10	could	<ROOT>	-1
11	contribute	could	10
12	to	contribute	11
13	the	establishment	14
14	establishment	to	12
15	and	to	12
16	maintenance	could	10
17	of	a	18
18	a	maintenance	16
19	population	a	18
20	of	population	19
21	cells	of	20
22	stably	of	20
23	but	stably	22
24	nonproductively	with	26
25	infected	nonproductively	24
26	with	but	23
27	HIV-1	with	26
28	.	HIV-1	27

0	In	observed	4
1	addition	In	0
2	,	observed	4
3	we	observed	4
4	observed	<ROOT>	-1
5	an	expression	7
6	altered	expression	7
7	expression	observed	4
8	level	of	9
9	of	AML1	10
10	AML1	observed	4
11	along	observed	4
12	with	observed	4
13	the	with	12
14	myeloid	the	13
15	differentiation	myeloid	14
16	in	differentiation	15
17	several	in	16
18	hemopoietic	several	17
19	cell	hemopoietic	18
20	lines	cell	19
21	.	lines	20

0	Here	report	2
1	we	report	2
2	report	<ROOT>	-1
3	a	study	5
4	real-time	study	5
5	study	report	2
6	of	study	5
7	factor/DNA	interactions	8
8	interactions	of	6
9	using	a	10
10	a	plasmon	12
11	surface	plasmon	12
12	plasmon	interactions	8
13	resonance	interactions	8
14	approach	study	5
15	and	approach	14
16	further	and	15
17	characterization	of	18
18	of	report	2
19	recovered	proteins	20
20	proteins	report	2
21	involved	proteins	20
22	in	this	23
23	this	involved	21
24	interaction	report	2
25	.	report	2

0	However	demonstrated	8
1	,	However	0
2	using	ATL-16T	3
3	ATL-16T	,	1
4	nuclear	extract	5
5	extract	ATL-16T	3
6	,	ATL-16T	3
7	we	demonstrated	8
8	demonstrated	<ROOT>	-1
9	that	demonstrated	8
10	GATA-4	is	11
11	is	that	9
12	the	is	11
13	only	the	12
14	GATA-binding	that	16
15	protein	that	16
16	that	only	13
17	forms	specific	18
18	specific	that	16
19	DNA-protein	with	21
20	complex	with	21
21	with	specific	18
22	the	is	11
23	-70	the	22
24	GATA	site	25
25	site	-70	23
26	.	site	25

0	Here	an	3
1	we	an	3
2	identified	an	3
3	an	<ROOT>	-1
4	inducible	T	5
5	T	an	3
6	cell-specific	enhancer	7
7	enhancer	T	5
8	14	enhancer	7
9	kb	upstream	10
10	upstream	14	8
11	of	upstream	10
12	the	of	11
13	IL-3	that	15
14	gene	that	15
15	that	the	12
16	responded	that	15
17	to	the	12
18	activation	T	20
19	of	T	20
20	T	to	17
21	cell	an	3
22	receptor	an	3
23	signaling	an	3
24	pathways	an	3
25	.	an	3

0	During	<ROOT>	-1
1	recent	years	2
2	years	During	0
3	,	During	0
4	studies	,	3
5	of	studies	4
6	insulin-gene	regulation	7
7	regulation	of	5
8	and	regulation	7
9	,	and	8
10	in	transcriptional	15
11	particular	in	10
12	,	transcriptional	15
13	the	transcriptional	15
14	tissue-specific	transcriptional	15
15	transcriptional	and	8
16	control	transcriptional	15
17	of	control	16
18	insulin-gene	activity	19
19	activity	of	17
20	have	transcriptional	15
21	provided	have	20
22	information	provided	21
23	on	information	22
24	pancreas	on	23
25	development	pancreas	24
26	in	development	25
27	general	in	26
28	.	During	0

0	These	<ROOT>	-1
1	results	These	0
2	link	regulatory	3
3	regulatory	results	1
4	factors	critical	5
5	critical	regulatory	3
6	to	critical	5
7	T	commitment	9
8	cell	commitment	9
9	commitment	critical	5
10	directly	critical	5
11	to	HIV-1	12
12	HIV-1	critical	5
13	replication	These	0
14	.	These	0

0	All	motifs	2
1	these	motifs	2
2	motifs	are	3
3	are	<ROOT>	-1
4	essential	are	3
5	and	are	3
6	collectively	activity	9
7	control	activity	9
8	transcriptional	activity	9
9	activity	and	5
10	.	activity	9

0	IL-4	treatment	1
1	treatment	tyrosine	4
2	rapidly	induced	3
3	induced	tyrosine	4
4	tyrosine	receptor	8
5	phosphorylation	tyrosine	4
6	of	insulin	7
7	insulin	receptor	8
8	receptor	<ROOT>	-1
9	substrate	(	10
10	(	receptor	8
11	IRS	(	10
12	)	-1	13
13	-1	receptor	8
14	and	receptor	8
15	IRS-2	receptor	8
16	in	receptor	8
17	1D4	in	16
18	but	in	20
19	not	in	20
20	in	receptor	8
21	E1C3	cells	22
22	cells	in	20
23	.	cells	22

0	We	reported	1
1	reported	mutant	7
2	here	reported	1
3	that	mutant	7
4	the	E1B	5
5	E1B	19K	6
6	19K	mutant	7
7	mutant	viruses	8
8	viruses	<ROOT>	-1
9	were	viruses	8
10	unable	were	9
11	to	unable	10
12	replicate	to	11
13	efficiently	to	11
14	in	efficiently	13
15	a	in	14
16	monocyte	,	19
17	cell	,	19
18	line	,	19
19	,	a	15
20	U937	in	14
21	.	viruses	8

0	Reactivity	protein	4
1	with	protein	4
2	the	protein	4
3	tegument	protein	4
4	protein	was	8
5	encoded	protein	4
6	by	encoded	5
7	UL21	by	6
8	was	<ROOT>	-1
9	identified	was	8
10	for	identified	9
11	an	patient	13
12	additional	patient	13
13	patient	for	10
14	.	was	8

0	This	reversal	1
1	reversal	level	8
2	of	reversal	1
3	apoptosis	of	2
4	almost	to	5
5	to	level	8
6	the	level	8
7	control	level	8
8	level	indicate	16
9	by	level	8
10	inhibitor	level	8
11	of	level	8
12	NF-kappa	level	8
13	B	level	8
14	activation	level	8
15	may	level	8
16	indicate	<ROOT>	-1
17	involvement	indicate	16
18	of	involvement	17
19	this	of	18
20	signaling	in	22
21	molecule	in	22
22	in	this	19
23	MTBE	indicate	16
24	and	indicate	16
25	benzene	indicate	16
26	induction	indicate	16
27	of	cell	29
28	programmed	cell	29
29	cell	induction	26
30	death	indicate	16
31	.	indicate	16

0	Results	were	1
1	were	<ROOT>	-1
2	expressed	were	1
3	as	were	1
4	a	median	5
5	median	as	3
6	(	range	8
7	interquartile	range	8
8	range	median	5
9	)	range	8
10	.	were	1

0	NF-kappa	B-independent	1
1	B-independent	suppression	2
2	suppression	<ROOT>	-1
3	of	suppression	2
4	HIV	expression	5
5	expression	of	3
6	by	suppression	2
7	ascorbic	acid	8
8	acid	by	6
9	.	suppression	2

0	To	<ROOT>	-1
1	explore	To	0
2	long-term	mechanisms	4
3	regulatory	mechanisms	4
4	mechanisms	explore	1
5	,	mechanisms	4
6	we	mechanisms	4
7	investigated	may	19
8	the	induction	9
9	induction	may	19
10	of	induction	9
11	transcription	factors	12
12	factors	of	10
13	on	expression	16
14	the	expression	16
15	gene	expression	16
16	expression	induction	9
17	level	which	18
18	which	induction	9
19	may	we	6
20	be	may	19
21	important	be	20
22	to	important	21
23	substitute	to	22
24	for	factor	27
25	metabolized	factor	27
26	transcription	factor	27
27	factor	substitute	23
28	proteins	may	19
29	after	their	30
30	their	activation	31
31	activation	may	19
32	.	activation	31

0	We	<ROOT>	-1
1	have	We	0
2	shown	have	1
3	elsewhere	shown	2
4	that	elsewhere	3
5	both	elsewhere	3
6	the	both	5
7	major	the	6
8	immediate-early	(	10
9	gene	(	10
10	(	major	7
11	MIE	(	10
12	)	major	7
13	and	major	7
14	lytic	and	13
15	cycle	and	13
16	infectious	cycle	15
17	progeny	infectious	16
18	virus	progeny	17
19	expression	virus	18
20	can	expression	19
21	be	can	20
22	induced	in	23
23	in	be	21
24	otherwise	in	23
25	nonpermissive	in	23
26	monocyte-like	can	20
27	U-937	human	33
28	cell	human	33
29	cultures	infected	30
30	infected	cell	28
31	with	human	33
32	either	human	33
33	human	monocyte-like	26
34	CMV	elsewhere	3
35	(	HCMV	36
36	HCMV	CMV	34
37	)	HCMV	36
38	or	CMV	34
39	simian	or	38
40	CMV	simian	39
41	(	CMV	40
42	SCMV	(	41
43	)	SCMV	42
44	by	)	43
45	treatment	with	46
46	with	by	44
47	the	with	46
48	phorbol	(	41
49	ester	CMV	40
50	12-O-tetradecanoylphorbol-13-acetate	ester	49
51	(	12-O-tetradecanoylphorbol-13-acetate	50
52	TPA	)	53
53	)	(	51
54	.	)	53

0	Therefore	share	5
1	,	share	5
2	the	genes	4
3	DM	genes	4
4	genes	share	5
5	share	<ROOT>	-1
6	a	mechanism	8
7	common	mechanism	8
8	mechanism	share	5
9	of	mechanism	8
10	regulation	of	9
11	with	share	5
12	the	with	11
13	class	II	14
14	II	the	12
15	genes	.	16
16	.	II	14

0	Finally	are	3
1	,	are	3
2	oxidants	are	3
3	are	<ROOT>	-1
4	believed	are	3
5	to	believed	4
6	promote	to	5
7	intestinal	promote	6
8	epithelial	promote	6
9	cell	epithelial	8
10	apoptosis	,	11
11	,	cell	9
12	and	to	5
13	the	product	17
14	B-cell	product	17
15	lymphoma/leukemia-2	product	17
16	gene	product	17
17	product	and	12
18	is	to	5
19	believed	is	18
20	to	believed	19
21	inhibit	to	20
22	this	inhibit	21
23	phenomenon	in	24
24	in	this	22
25	an	this	22
26	antioxidant-dependent	.	28
27	manner	.	28
28	.	an	25

0	Here	<ROOT>	-1
1	we	Here	0
2	have	used	3
3	used	we	1
4	reporter	used	3
5	transgenic	reporter	4
6	mice	transgenic	5
7	to	mice	6
8	show	that	9
9	that	to	7
10	DNA	binding	11
11	binding	that	9
12	and	mice	6
13	transcriptional	used	3
14	activities	are	17
15	of	activities	14
16	NFAT	of	15
17	are	transcriptional	13
18	transiently	are	17
19	induced	transiently	18
20	during	induced	19
21	the	differentiation	22
22	differentiation	during	20
23	of	differentiation	22
24	pTh	of	23
25	cells	into	26
26	into	pTh	24
27	either	eTh1	28
28	eTh1	differentiation	22
29	or	eTh1	28
30	eTh2	or	29
31	cells	eTh2	30
32	to	cells	31
33	mediate	the	34
34	the	to	32
35	expression	the	34
36	of	expression	35
37	IL-2	of	36
38	as	to	32
39	a	as	38
40	common	a	39
41	growth	common	40
42	factor	growth	41
43	in	factor	42
44	both	pathways	45
45	pathways	in	43
46	.	factor	42

0	There	were	1
1	were	<ROOT>	-1
2	no	differences	4
3	notable	differences	4
4	differences	were	1
5	in	differences	4
6	the	transcripts	8
7	ER	transcripts	8
8	transcripts	in	5
9	between	differences	4
10	patients	between	9
11	and	patients	10
12	healthy	and	11
13	controls	were	1
14	.	were	1

0	In	<ROOT>	-1
1	exerting	In	0
2	their	effects	4
3	antiproliferative	effects	4
4	effects	exerting	1
5	,	In	0
6	GCS	diffuse	7
7	diffuse	,	5
8	into	diffuse	7
9	target	into	8
10	cells	where	11
11	where	target	9
12	they	bind	13
13	bind	into	8
14	their	cytoplasmic	15
15	cytoplasmic	bind	13
16	receptor	cytoplasmic	15
17	,	receptor	16
18	which	receptor	16
19	in	which	18
20	turn	in	19
21	translocates	turn	20
22	to	the	23
23	the	turn	20
24	nucleus	where	25
25	where	the	23
26	it	transcription	28
27	inhibits	transcription	28
28	transcription	where	25
29	of	cytokine	30
30	cytokine	transcription	28
31	genes	In	0
32	through	In	0
33	direct	through	32
34	binding	direct	33
35	to	binding	34
36	the	to	35
37	glucocorticoid	(	40
38	response	(	40
39	elements	(	40
40	(	the	36
41	GRE	)	42
42	)	(	40
43	,	to	35
44	which	are	45
45	are	to	35
46	located	are	45
47	in	located	46
48	the	in	47
49	promoter	the	48
50	region	promoter	49
51	of	cytokine	52
52	cytokine	region	50
53	genes	In	0
54	or	In	0
55	,	alternatively	56
56	alternatively	In	0
57	,	alternatively	56
58	through	alternatively	56
59	antagonism	through	58
60	of	antagonism	59
61	the	action	62
62	action	of	60
63	of	action	62
64	transcription	required	66
65	factors	required	66
66	required	of	63
67	for	In	0
68	optimal	transcriptional	69
69	transcriptional	for	67
70	activation	In	0
71	.	In	0

0	Molecular	of	2
1	actions	of	2
2	of	<ROOT>	-1
3	prolactin	of	2
4	in	prolactin	3
5	the	prolactin	3
6	immune	.	8
7	system	.	8
8	.	the	5

0	Cis-acting	elements	1
1	elements	have	10
2	with	elements	1
3	NFkappaB	with	2
4	,	elements	1
5	AP1	,	4
6	and	AP1	5
7	ETS-like	motifs	9
8	binding	motifs	9
9	motifs	and	6
10	have	<ROOT>	-1
11	been	have	10
12	identified	been	11
13	in	identified	12
14	the	in	13
15	promoter	the	14
16	region	promoter	15
17	of	region	16
18	the	gene	20
19	GM-CSF	gene	20
20	gene	of	17
21	,	have	10
22	and	have	10
23	are	and	22
24	important	are	23
25	or	important	24
26	essential	transcriptional	28
27	for	transcriptional	28
28	transcriptional	or	25
29	activity	transcriptional	28
30	following	T	31
31	T	cell	32
32	cell	are	23
33	activation	cell	32
34	.	activation	33

0	Five	<ROOT>	-1
1	healthy	Five	0
2	human	healthy	1
3	leukocyte	antigen-B8	4
4	antigen-B8	human	2
5	(	HLA-B8	6
6	HLA-B8	antigen-B8	4
7	)	HLA-B8	6
8	-positive	carriers	10
9	virus	carriers	10
10	carriers	were	11
11	were	antigen-B8	4
12	studied	were	11
13	to	studied	12
14	investigate	to	13
15	the	investigate	14
16	CD8+	T	18
17	cytotoxic	T	18
18	T	the	15
19	lymphocyte	T	18
20	(	CTL	21
21	CTL	lymphocyte	19
22	)	CTL	21
23	response	CTL	21
24	to	response	23
25	an	to	24
26	HLA-B8-restricted	located	31
27	peptide	located	31
28	,	located	31
29	RAKFKQLLQ	located	31
30	,	located	31
31	located	an	25
32	in	located	31
33	the	virus	35
34	Epstein-Barr	virus	35
35	virus	in	32
36	(	EBV	37
37	EBV	,	42
38	)	EBV	37
39	immediate-early	,	42
40	trans-activator	,	42
41	protein	,	42
42	,	located	31
43	BZLF1	located	31
44	.	Five	0

0	OCA-B	is	1
1	is	<ROOT>	-1
2	a	is	1
3	B-cell-specific	a	2
4	coregulator	B-cell-specific	3
5	of	domain	10
6	the	domain	10
7	broadly	expressed	8
8	expressed	domain	10
9	POU	domain	10
10	domain	coregulator	4
11	transcription	factor	12
12	factor	is	1
13	Oct-1	is	1
14	.	is	1

0	The	gene	2
1	Bcd	gene	2
2	gene	may	3
3	may	<ROOT>	-1
4	therefore	may	3
5	play	may	3
6	an	role	8
7	important	role	8
8	role	play	5
9	in	play	5
10	B-cell	growth	11
11	growth	in	9
12	and	growth	11
13	development	may	3
14	.	may	3

0	Synergistic	interactions	1
1	interactions	mediate	14
2	between	interactions	1
3	overlapping	sites	5
4	binding	sites	5
5	sites	between	2
6	for	interactions	1
7	the	factor	10
8	serum	response	9
9	response	factor	10
10	factor	for	6
11	and	interactions	1
12	ELK-1	proteins	13
13	proteins	and	11
14	mediate	<ROOT>	-1
15	both	enhancement	17
16	basal	enhancement	17
17	enhancement	and	18
18	and	mediate	14
19	phorbol	ester	20
20	ester	and	18
21	responsiveness	mediate	14
22	of	responsiveness	21
23	primate	of	22
24	cytomegalovirus	primate	23
25	major	cytomegalovirus	24
26	immediate-early	major	25
27	promoters	in	28
28	in	immediate-early	26
29	monocyte	immediate-early	26
30	and	monocyte	29
31	T-lymphocyte	types	33
32	cell	types	33
33	types	and	30
34	.	mediate	14

0	Treatment	human	2
1	of	human	2
2	human	leukemia	4
3	promyelocytic	human	2
4	leukemia	<ROOT>	-1
5	HL-60	leukemia	4
6	cells	phorbol	8
7	with	phorbol	8
8	phorbol	esters	9
9	esters	leukemia	4
10	ultimately	induces	11
11	induces	leukemia	4
12	the	differentiation	13
13	differentiation	induces	11
14	of	these	15
15	these	differentiation	13
16	cells	leukemia	4
17	along	the	18
18	the	leukemia	4
19	monocyte/macrophage	leukemia	4
20	lineage	leukemia	4
21	,	leukemia	4
22	whereas	leukemia	4
23	treatment	with	24
24	with	leukemia	4
25	retinoic	acid	26
26	acid	with	24
27	or	acid	26
28	DMSO	or	27
29	induces	leukemia	4
30	granulocytic/neutrophillic	differentiation	31
31	differentiation	induces	29
32	.	differentiation	31

0	The	properties	2
1	immunoregulatory	properties	2
2	properties	peptide	8
3	of	properties	2
4	prolactin	of	3
5	,	properties	2
6	a	peptide	8
7	pituitary	peptide	8
8	peptide	<ROOT>	-1
9	hormone	peptide	8
10	,	peptide	8
11	have	peptide	8
12	received	have	11
13	renewed	received	12
14	attention	.	15
15	.	renewed	13

0	In	factor	5
1	comparison	In	0
2	,	In	0
3	platelet	activating	4
4	activating	factor	5
5	factor	<ROOT>	-1
6	(	factor	5
7	PAF	contributed	9
8	)	PAF	7
9	contributed	factor	5
10	to	contributed	9
11	both	phases	12
12	phases	adhesion	15
13	of	neutrophil	14
14	neutrophil	adhesion	15
15	adhesion	to	10
16	.	adhesion	15

0	Monoclonal	anti-D	1
1	anti-D	antibodies	2
2	antibodies	were	10
3	submitted	antibodies	2
4	to	submitted	3
5	the	International	8
6	Third	International	8
7	Monoclonal	International	8
8	International	to	4
9	Workshop	International	8
10	were	<ROOT>	-1
11	evaluated	were	10
12	against	evaluated	11
13	a	number	14
14	number	against	12
15	of	number	14
16	D	of	15
17	variant	of	15
18	cells	using	19
19	using	variant	17
20	standard	using	19
21	serological	techniques	22
22	techniques	standard	20
23	.	techniques	22

0	They	are	1
1	are	<ROOT>	-1
2	particularly	abundant	3
3	abundant	are	1
4	in	lymphoid	5
5	lymphoid	are	1
6	tissues	are	1
7	and	are	1
8	are	and	7
9	thought	are	8
10	to	thought	9
11	be	to	10
12	critical	be	11
13	for	be	11
14	the	transcription	15
15	transcription	for	13
16	of	transcription	15
17	genes	of	16
18	involved	of	16
19	in	involved	18
20	immune	in	19
21	and	immune	20
22	inflammatory	and	21
23	responses	are	1
24	.	are	1

0	Subsequently	a	2
1	,	a	2
2	a	(	5
3	1.8	kilobase	4
4	kilobase	(	5
5	(	<ROOT>	-1
6	kb	(	5
7	)	kb	6
8	fragment	was	13
9	of	fragment	8
10	the	promoter	12
11	CIITA	promoter	12
12	promoter	of	9
13	was	)	7
14	isolated	and	15
15	and	(	5
16	sequenced	(	5
17	.	(	5

0	Rather	affinity	4
1	,	binding	3
2	the	binding	3
3	binding	Rather	0
4	affinity	influenced	7
5	is	affinity	4
6	probably	affinity	4
7	influenced	<ROOT>	-1
8	by	influenced	7
9	the	expression	10
10	expression	by	8
11	of	expression	10
12	cytosolic	factors	13
13	factors	of	11
14	that	of	11
15	affect	that	14
16	glucocorticoid	affect	15
17	receptor	glucocorticoid	16
18	function	.	19
19	.	receptor	17

0	The	requirement	1
1	requirement	was	18
2	of	requirement	1
3	another	element	5
4	regulatory	element	5
5	element	of	2
6	called	element	5
7	CLE0	called	6
8	,	element	5
9	which	lies	10
10	lies	element	5
11	downstream	lies	10
12	of	lies	10
13	the	site	16
14	-70	site	16
15	GATA	site	16
16	site	of	12
17	,	element	5
18	was	<ROOT>	-1
19	also	was	18
20	demonstrated	was	18
21	.	was	18

0	Flow	<ROOT>	-1
1	cytometry	analyses	2
2	analyses	Flow	0
3	on	cultured	4
4	cultured	Flow	0
5	cells	were	7
6	that	were	7
7	were	Flow	0
8	treated	were	7
9	with	treated	8
10	tepoxalin	with	9
11	or	tepoxalin	10
12	antisense	oligonucleotides	13
13	oligonucleotides	or	11
14	to	or	11
15	the	subunit	17
16	P65/p50	subunit	17
17	subunit	to	14
18	of	NF-kappa	19
19	NF-kappa	subunit	17
20	B	Flow	0
21	,	Flow	0
22	and	Flow	0
23	then	Flow	0
24	stimulated	Flow	0
25	with	Flow	0
26	PMA	Flow	0
27	,	Flow	0
28	revealed	Flow	0
29	a	expression	31
30	reduced	expression	31
31	expression	revealed	28
32	of	expression	31
33	CD11b/CD18	of	32
34	on	HL60	36
35	monocytic	HL60	36
36	HL60	revealed	28
37	cells	Flow	0
38	,	Flow	0
39	and	adhesion	41
40	endothelial	adhesion	41
41	adhesion	Flow	0
42	molecule-1	Flow	0
43	(	Flow	0
44	CD62E	Flow	0
45	)	Flow	0
46	and	Flow	0
47	vascular	and	46
48	adhesion	molecule-1	49
49	molecule-1	vascular	47
50	(	CD106	51
51	CD106	molecule-1	49
52	)	CD106	51
53	on	vascular	47
54	human	on	53
55	umbilical	cells	58
56	vein	cells	58
57	endothelial	cells	58
58	cells	human	54
59	.	cells	58

0	We	is	43
1	have	We	0
2	shown	have	1
3	previously	amplified	5
4	that	previously	3
5	amplified	shown	2
6	expression	the	8
7	of	the	8
8	the	amplified	5
9	B2	shown	2
10	subunit	B2	9
11	of	subunit	10
12	the	V-ATPase	13
13	V-ATPase	occurs	14
14	occurs	of	11
15	solely	by	16
16	by	occurs	14
17	increased	by	16
18	transcription	by	16
19	,	of	11
20	and	of	11
21	that	and	20
22	the	that	21
23	5'-untranslated	the	26
24	region	the	26
25	of	the	26
26	the	the	22
27	B2	,	29
28	gene	,	29
29	,	the	26
30	containing	multiple	31
31	multiple	the	26
32	consensus	We	0
33	binding	sites	34
34	sites	We	0
35	for	We	0
36	the	factors	38
37	transcription	factors	38
38	factors	for	35
39	AP-2	for	35
40	and	AP-2	39
41	Sp1	and	40
42	,	We	0
43	is	<ROOT>	-1
44	required	this	46
45	for	this	46
46	this	is	43
47	expression	is	43
48	.	is	43

0	The	cells	2
1	malignant	cells	2
2	cells	acute	4
3	of	acute	4
4	acute	leukemia	6
5	promyelocytic	acute	4
6	leukemia	contain	10
7	(	APL	8
8	APL	leukemia	6
9	)	APL	8
10	contain	<ROOT>	-1
11	a	contain	10
12	reciprocal	a	11
13	chromosomal	that	15
14	translocation	that	15
15	that	reciprocal	12
16	fuses	reciprocal	12
17	the	fuses	16
18	promyelocytic	(	21
19	leukemia	(	21
20	gene	(	21
21	(	the	17
22	PML	(	21
23	)	contain	10
24	with	alpha	29
25	the	retinoic	26
26	retinoic	with	24
27	acid	receptor	28
28	receptor	retinoic	26
29	alpha	contain	10
30	gene	(	31
31	(	contain	10
32	RAR	contain	10
33	alpha	contain	10
34	)	contain	10
35	.	contain	10

0	Furthermore	was	7
1	,	was	7
2	the	inhibition	6
3	degree	of	4
4	of	inhibition	6
5	CN	inhibition	6
6	inhibition	was	7
7	was	<ROOT>	-1
8	reflected	was	7
9	by	reflected	8
10	a	degree	12
11	similar	degree	12
12	degree	by	9
13	of	degree	12
14	reduction	of	13
15	in	degree	12
16	lymphocyte	degree	12
17	proliferation	lymphocyte	16
18	and	proliferation	17
19	IFN-gamma	by	9
20	production	by	9
21	in	production	20
22	the	allogeneic	23
23	allogeneic	in	21
24	mixed	allogeneic	23
25	lymphocyte	.	27
26	cultures	.	27
27	.	mixed	24

0	The	function	2
1	additional	function	2
2	function	is	14
3	that	is	4
4	is	function	2
5	required	is	4
6	for	required	5
7	initiation	for	6
8	of	initiation	7
9	the	cycle	13
10	lytic	cycle	13
11	viral	cycle	13
12	life	cycle	13
13	cycle	of	8
14	is	<ROOT>	-1
15	likely	is	14
16	to	likely	15
17	require	to	16
18	phosphorylation	require	17
19	of	phosphorylation	18
20	serine	of	19
21	186	phosphorylation	18
22	of	186	21
23	the	of	22
24	ZEBRA	the	23
25	protein	,	26
26	,	ZEBRA	24
27	which	of	22
28	may	which	27
29	influence	may	28
30	either	DNA	31
31	DNA	influence	29
32	recognition	DNA	31
33	or	transcriptional	34
34	transcriptional	recognition	32
35	activation	of	36
36	of	transcriptional	34
37	lytic	promoters	39
38	viral	promoters	39
39	promoters	of	36
40	in	transcriptional	34
41	a	episome	44
42	chromatinized	episome	44
43	viral	episome	44
44	episome	in	40
45	.	is	14

0	Two	sets	1
1	sets	are	5
2	of	sets	1
3	independent	evidences	4
4	evidences	of	2
5	are	<ROOT>	-1
6	presented	are	5
7	here	presented	6
8	that	demonstrate	9
9	demonstrate	are	5
10	a	relevance	12
11	biological	relevance	12
12	relevance	demonstrate	9
13	for	this	14
14	this	relevance	12
15	model	this	14
16	.	are	5

0	RESULTS	<ROOT>	-1
1	:	RESULTS	0
2	In	demonstrated	7
3	preliminary	studies	4
4	studies	In	2
5	,	demonstrated	7
6	we	demonstrated	7
7	demonstrated	RESULTS	0
8	that	demonstrated	7
9	transfection	resulted	19
10	of	transfection	9
11	the	line	13
12	PIEC	line	13
13	line	of	10
14	with	transfection	9
15	full-length	constructs	18
16	human	constructs	18
17	CIITA	constructs	18
18	constructs	with	14
19	resulted	that	8
20	in	resulted	19
21	strong	expression	22
22	expression	in	20
23	of	expression	22
24	SLA-DR	and	25
25	and	of	23
26	SLA-DQ	and	25
27	antigens	demonstrated	7
28	,	thus	29
29	thus	demonstrated	7
30	establishing	effectiveness	33
31	the	effectiveness	33
32	cross-species	effectiveness	33
33	effectiveness	thus	29
34	of	human	35
35	human	effectiveness	33
36	CIITA	thus	29
37	in	CIITA	36
38	the	pig	39
39	pig	in	37
40	.	RESULTS	0

0	Liberated	B	2
1	NF-kappa	B	2
2	B	migrates	3
3	migrates	<ROOT>	-1
4	to	the	5
5	the	migrates	3
6	nucleus	migrates	3
7	,	migrates	3
8	where	it	9
9	it	migrates	3
10	binds	specific	12
11	to	specific	12
12	specific	it	9
13	promoter	and	15
14	sites	and	15
15	and	specific	12
16	activates	and	15
17	gene	activates	16
18	transcription	migrates	3
19	.	migrates	3

0	Identification	might	11
1	of	Identification	0
2	more	specific	3
3	specific	of	1
4	and	specific	3
5	efficacious	inhibitors	6
6	inhibitors	and	4
7	of	NF-kappa	8
8	NF-kappa	specific	3
9	B	of	1
10	activation	Identification	0
11	might	<ROOT>	-1
12	prove	might	11
13	beneficial	prove	12
14	for	beneficial	13
15	the	treatment	16
16	treatment	for	14
17	of	treatment	16
18	cytokine-mediated	of	17
19	inflammatory	cytokine-mediated	18
20	diseases	.	21
21	.	inflammatory	19

0	They	demonstrate	2
1	also	demonstrate	2
2	demonstrate	responses	12
3	for	demonstrate	2
4	the	time	6
5	first	time	6
6	time	for	3
7	the	occurrence	8
8	occurrence	T	10
9	of	T	10
10	T	demonstrate	2
11	cell	demonstrate	2
12	responses	<ROOT>	-1
13	against	transactivating	15
14	EBV	transactivating	15
15	transactivating	responses	12
16	factors	responses	12
17	,	responses	12
18	which	might	19
19	might	,	17
20	be	might	19
21	central	be	20
22	in	be	20
23	the	in	22
24	control	the	23
25	of	control	24
26	virus	of	25
27	reactivation	virus	26
28	.	reactivation	27

0	Of	encode	8
1	these	Of	0
2	,	encode	8
3	the	XPB	4
4	XPB	genes	7
5	and	XPB	4
6	XPD	and	5
7	genes	encode	8
8	encode	<ROOT>	-1
9	proteins	that	10
10	that	encode	8
11	are	of	13
12	subunits	of	13
13	of	that	10
14	a	factor	17
15	general	factor	17
16	transcription	factor	17
17	factor	of	13
18	,	of	13
19	TFIIH	encode	8
20	,	encode	8
21	involved	encode	8
22	in	involved	21
23	both	repair	26
24	nucleotide	excision	25
25	excision	repair	26
26	repair	in	22
27	(	NER	28
28	NER	encode	8
29	)	NER	28
30	and	encode	8
31	initiation	of	32
32	of	and	30
33	mRNA	of	32
34	transcription	encode	8
35	by	encode	8
36	RNA	by	35
37	polymerase	II	38
38	II	RNA	36
39	.	encode	8

0	We	conclude	1
1	conclude	<ROOT>	-1
2	that	conclude	1
3	increased	is	7
4	expression	is	7
5	of	expression	4
6	GCR-beta	of	5
7	is	cytokine	8
8	cytokine	that	2
9	inducible	conclude	1
10	and	conclude	1
11	may	account	12
12	account	and	10
13	for	account	12
14	GC	for	13
15	insensitivity	GC	14
16	in	insensitivity	15
17	this	condition	20
18	common	condition	20
19	inflammatory	condition	20
20	condition	in	16
21	.	conclude	1

0	Using	<ROOT>	-1
1	a	probe	4
2	radiolabeled	probe	4
3	chemical	probe	4
4	probe	Using	0
5	,	Using	0
6	we	,	5
7	here	we	6
8	purified	here	7
9	a	target	10
10	target	SR	12
11	of	SR	12
12	SR	purified	8
13	31747A	Using	0
14	and	Using	0
15	called	and	14
16	it	(	20
17	SR	(	20
18	31747A-binding	protein	19
19	protein	(	20
20	(	called	15
21	SR-BP	Using	0
22	)	Using	0
23	.	Using	0

0	After	,	3
1	4	hours	2
2	hours	After	0
3	,	had	13
4	IL-1	,	3
5	beta	IL-8	7
6	and	beta	5
7	IL-8	,	3
8	concentration	,	3
9	of	concentration	8
10	the	supernatant	12
11	cell-free	supernatant	12
12	supernatant	of	9
13	had	<ROOT>	-1
14	increased	268	16
15	by	268	16
16	268	had	13
17	+/-	%	19
18	36	%	19
19	%	268	16
20	and	had	13
21	210	had	13
22	+/-	had	13
23	7	%	24
24	%	had	13
25	,	had	13
26	respectively	had	13
27	,	had	13
28	and	had	13
29	cellular	and	28
30	MCP-1	had	32
31	content	MCP-1	30
32	had	and	28
33	increased	170	35
34	by	170	35
35	170	had	32
36	+/-	had	13
37	8	%	38
38	%	had	13
39	.	had	13

0	Expression	<ROOT>	-1
1	of	Expression	0
2	NFAT-family	proteins	3
3	proteins	of	1
4	in	normal	5
5	normal	of	1
6	human	Expression	0
7	T	cells	8
8	cells	human	6
9	.	cells	8

0	These	ES	2
1	EKLF-/-	ES	2
2	ES	cells	3
3	cells	were	4
4	were	<ROOT>	-1
5	capable	were	4
6	of	in	8
7	undergoing	in	8
8	in	capable	5
9	vitro	in	8
10	differentiation	were	4
11	to	were	4
12	form	were	4
13	definitive	that	16
14	erythroid	that	16
15	colonies	that	16
16	that	were	17
17	were	form	12
18	similar	were	17
19	in	similar	18
20	size	in	19
21	and	size	20
22	number	and	21
23	to	similar	18
24	those	to	23
25	formed	those	24
26	by	ES	28
27	wild-type	ES	28
28	ES	formed	25
29	cells	were	4
30	.	were	4

0	The	expression	2
1	selective	expression	2
2	expression	<ROOT>	-1
3	and	expression	2
4	regulation	and	3
5	of	IL-12R	7
6	the	IL-12R	7
7	IL-12R	expression	2
8	beta	may	11
9	2	subunit	10
10	subunit	may	11
11	may	IL-12R	7
12	help	expression	2
13	to	help	12
14	understand	to	13
15	the	basis	16
16	basis	understand	14
17	of	basis	16
18	Th1/Th2	differentiation	19
19	differentiation	of	17
20	and	to	13
21	may	and	20
22	provide	may	21
23	therapeutic	options	24
24	options	provide	22
25	for	provide	22
26	altering	for	25
27	the	balance	29
28	Th1/Th2	balance	29
29	balance	altering	26
30	in	immuno-pathological	32
31	several	immuno-pathological	32
32	immuno-pathological	altering	26
33	conditions	to	13
34	such	as	35
35	as	to	13
36	autoimmune	diseases	37
37	diseases	as	35
38	and	diseases	37
39	allergies	and	38
40	.	expression	2

0	Analysis	revealed	17
1	of	Analysis	0
2	the	proteins	4
3	binding	proteins	4
4	proteins	of	1
5	employing	of	1
6	the	motif	8
7	-605	motif	8
8	motif	employing	5
9	of	motif	8
10	the	of	9
11	human	the	10
12	TNF	(	14
13	promoter	(	14
14	(	human	11
15	GGGGCTGTCCC	Analysis	0
16	)	Analysis	0
17	revealed	cell	26
18	that	revealed	17
19	in	tolerant	20
20	tolerant	that	18
21	cells	revealed	17
22	of	cell	26
23	the	cell	26
24	human	cell	26
25	monocytic	cell	26
26	cell	<ROOT>	-1
27	line	cell	26
28	Mono	cell	26
29	Mac	6	30
30	6	cell	26
31	there	is	32
32	is	cell	26
33	a	predominance	34
34	predominance	is	32
35	of	predominance	34
36	p50p50	of	35
37	of	NF-kappa	38
38	NF-kappa	p50p50	36
39	B	cell	26
40	.	cell	26

0	When	studying	1
1	studying	yeast	10
2	the	binding	3
3	binding	SR	5
4	of	SR	5
5	SR	studying	1
6	31747A	studying	1
7	on	studying	1
8	membranes	on	7
9	from	membranes	8
10	yeast	found	15
11	expressing	yeast	10
12	SR-BP	yeast	10
13	,	found	15
14	we	found	15
15	found	<ROOT>	-1
16	a	profile	18
17	pharmacological	profile	18
18	profile	found	15
19	of	profile	18
20	sigma	of	19
21	1	sigma	20
22	receptors	;	23
23	;	binding	24
24	binding	1	21
25	was	found	15
26	displaced	found	15
27	by	displaced	26
28	-LRB-+-RRB--pentazocine	by	27
29	,	-LRB-+-RRB--pentazocine	28
30	haloperidol	-LRB-+-RRB--pentazocine	28
31	,	haloperidol	30
32	and	haloperidol	30
33	-LRB-+-RRB--SKF	10,047	34
34	10,047	and	32
35	,	10,047	34
36	with	10,047	34
37	-LRB-+-RRB--SKF	10,047	38
38	10,047	with	36
39	being	10,047	38
40	a	competitor	43
41	more	potent	42
42	potent	competitor	43
43	competitor	being	39
44	than	competitor	43
45	-LRB---RRB--SKF	10,047	46
46	10,047	than	44
47	.	found	15

0	Therefore	<ROOT>	-1
1	we	Therefore	0
2	studied	pattern	5
3	the	pattern	5
4	expression	pattern	5
5	pattern	we	1
6	of	pattern	5
7	LAZ3/BCL6	of	6
8	by	Therefore	0
9	in	by	8
10	situ	in	9
11	hybridization	with	12
12	with	situ	10
13	synthetic	with	12
14	oligonucleotide	probes	15
15	probes	synthetic	13
16	in	probes	15
17	frozen	with	12
18	tissue	with	12
19	sections	Therefore	0
20	from	five	21
21	five	Therefore	0
22	reactive	lymph	23
23	lymph	Therefore	0
24	nodes	and	25
25	and	Therefore	0
26	38	Therefore	0
27	B	cell	28
28	cell	Therefore	0
29	and	non-B	30
30	non-B	Therefore	0
31	NHL	Therefore	0
32	.	Therefore	0

0	Two	sets	1
1	sets	were	5
2	of	sets	1
3	nested	primers	4
4	primers	of	2
5	were	<ROOT>	-1
6	designed	to	7
7	to	were	5
8	conserved	to	7
9	sequences	in	10
10	in	the	11
11	the	were	5
12	adenovirus	were	5
13	E1A	adenovirus	12
14	and	were	5
15	hexon	were	5
16	genes	were	5
17	.	were	5

0	Finally	<ROOT>	-1
1	,	Finally	0
2	a	interaction	4
3	direct	interaction	4
4	interaction	,	1
5	between	interaction	4
6	RFX5	between	5
7	and	RFX5	6
8	CIITA	was	9
9	was	and	7
10	detected	was	9
11	with	detected	10
12	the	with	11
13	yeast	the	12
14	two-hybrid	yeast	13
15	and	two-hybrid	14
16	far-Western	and	15
17	blot	.	19
18	assays	.	19
19	.	far-Western	16

0	Furthermore	<ROOT>	-1
1	,	Furthermore	0
2	no	,	1
3	induction	of	4
4	of	AP-1	5
5	AP-1	was	6
6	was	no	2
7	seen	was	6
8	in	T	12
9	A6H	in	8
10	costimulated	in	8
11	CD8+	T	12
12	T	seen	7
13	cells	Furthermore	0
14	.	Furthermore	0

0	MATERIALS	proteins	8
1	AND	MATERIALS	0
2	METHODS	AND	1
3	:	METHODS	2
4	Peptides	MATERIALS	0
5	derived	Peptides	4
6	from	oncogenic	7
7	oncogenic	derived	5
8	proteins	were	9
9	were	the	12
10	screened	the	12
11	for	the	12
12	the	<ROOT>	-1
13	presence	HLA	15
14	of	HLA	15
15	HLA	the	12
16	binding	the	12
17	motifs	the	12
18	;	the	12
19	actual	binding	20
20	binding	were	21
21	were	the	12
22	evaluated	were	21
23	by	evaluated	22
24	HLA	experiments	26
25	stabilization	experiments	26
26	experiments	by	23
27	using	anti-HLA	31
28	transfectants	anti-HLA	31
29	and	transfectants	28
30	specific	anti-HLA	31
31	anti-HLA	evaluated	22
32	antibodies	the	12
33	.	the	12

0	As	became	5
1	a	consequence	2
2	consequence	As	0
3	,	became	5
4	they	became	5
5	became	<ROOT>	-1
6	resistant	became	5
7	to	resistant	6
8	apoptosis	induced	9
9	induced	to	7
10	by	induced	9
11	anti-CD95	treatment	13
12	Ab	treatment	13
13	treatment	by	10
14	.	became	5

0	The	expression	1
1	expression	<ROOT>	-1
2	of	expression	1
3	anti-sense	RNA	4
4	RNA	of	2
5	to	SRG3	6
6	SRG3	expression	1
7	mRNA	expression	1
8	in	mRNA	7
9	a	in	8
10	thymoma	a	9
11	cell	thymoma	10
12	line	cell	11
13	,	line	12
14	S49.1	expression	18
15	,	S49.1	14
16	reduced	the	17
17	the	expression	18
18	expression	,	13
19	level	the	21
20	of	the	21
21	the	expression	18
22	SRG3	the	21
23	protein	SRG3	22
24	,	and	25
25	and	protein	23
26	decreased	the	27
27	the	the	21
28	apoptotic	the	27
29	cell	expression	1
30	death	expression	1
31	induced	expression	1
32	by	expression	1
33	glucocorticoids	by	32
34	.	expression	1

0	Mutation	<ROOT>	-1
1	of	the	5
2	either	site	3
3	site	of	1
4	reduced	the	5
5	the	Mutation	0
6	expression	the	5
7	in	expression	6
8	transient	in	7
9	transfection	Mutation	0
10	experiments	Mutation	0
11	.	Mutation	0

0	GR	capacity	2
1	binding	capacity	2
2	capacity	was	3
3	was	<ROOT>	-1
4	higher	was	3
5	in	younger	6
6	younger	was	3
7	subjects	was	3
8	than	subjects	7
9	in	than	8
10	older	in	9
11	ones	in	9
12	,	was	3
13	and	was	3
14	lower	and	13
15	in	and	13
16	the	group	17
17	group	in	15
18	of	group	17
19	athletes	of	18
20	than	and	13
21	in	than	20
22	the	younger	23
23	younger	in	21
24	and	younger	23
25	older	and	24
26	sedentary	subjects	27
27	subjects	was	3
28	.	was	3

0	These	heterozygous	1
1	heterozygous	mutant	2
2	mutant	mice	3
3	mice	developed	5
4	usually	developed	5
5	developed	<ROOT>	-1
6	normally	developed	5
7	,	developed	5
8	but	developed	5
9	they	began	10
10	began	but	8
11	to	began	10
12	die	to	11
13	after	to	11
14	5	months	15
15	months	after	13
16	.	developed	5

0	Finally	show	3
1	,	show	3
2	we	show	3
3	show	<ROOT>	-1
4	that	kappaB	12
5	two	molecules	9
6	other	molecules	9
7	I	molecules	9
8	kappaB	molecules	9
9	molecules	kappaB	12
10	,	molecules	9
11	I	kappaB	12
12	kappaB	show	3
13	beta	kappaB	12
14	and	beta	13
15	the	recently	16
16	recently	identified	17
17	identified	,	21
18	I	identified	17
19	kappaB	epsilon	20
20	epsilon	identified	17
21	,	and	14
22	are	and	14
23	not	show	3
24	degraded	show	3
25	in	cell	28
26	the	cell	28
27	1.3E2	cell	28
28	cell	degraded	24
29	line	show	3
30	following	show	3
31	stimulation	show	3
32	.	show	3

0	The	model	1
1	model	should	2
2	should	<ROOT>	-1
3	be	should	2
4	useful	be	3
5	for	be	3
6	exploring	for	5
7	the	pathogenesis	9
8	molecular	pathogenesis	9
9	pathogenesis	exploring	6
10	of	pathogenesis	9
11	APL	of	10
12	and	of	10
13	the	mechanisms	14
14	mechanisms	and	12
15	of	mechanisms	14
16	the	response	18
17	therapeutic	response	18
18	response	of	15
19	to	response	18
20	retinoic	acid	21
21	acid	to	19
22	,	acid	21
23	as	exploring	6
24	well	as	23
25	as	as	23
26	for	preclinical	27
27	preclinical	as	23
28	studies	should	2
29	of	studies	28
30	therapeutic	regimens	31
31	regimens	of	29
32	.	should	2

0	Surprisingly	was	12
1	,	was	12
2	the	synthesis	4
3	PMA-ionomycin-induced	synthesis	4
4	synthesis	was	12
5	of	synthesis	4
6	NFATc	of	5
7	that	was	8
8	was	synthesis	4
9	detected	was	8
10	by	detected	9
11	immunoprecipitation	by	10
12	was	<ROOT>	-1
13	not	was	12
14	mirrored	was	12
15	in	binding	18
16	the	binding	18
17	DNA	binding	18
18	binding	mirrored	14
19	assays	was	12
20	:	was	12
21	nearly	was	26
22	all	nearly	21
23	of	nearly	21
24	the	activity	25
25	activity	of	23
26	was	was	12
27	due	was	26
28	to	due	27
29	NFATp	to	28
30	.	was	12

0	However	limit	6
1	,	limit	6
2	major	effects	4
3	side	effects	4
4	effects	limit	6
5	severely	limit	6
6	limit	<ROOT>	-1
7	their	use	9
8	therapeutic	use	9
9	use	limit	6
10	.	limit	6

0	To	induced	39
1	determine	To	0
2	the	mechanism	3
3	mechanism	determine	1
4	of	mechanism	3
5	action	of	4
6	of	action	5
7	Ro	of	6
8	09-2210	To	0
9	,	To	0
10	we	To	0
11	set	we	10
12	up	set	11
13	a	system	16
14	transient	system	16
15	expression	system	16
16	system	set	11
17	in	T	19
18	Jurkat	T	19
19	T	set	11
20	cells	To	0
21	using	To	0
22	a	variety	23
23	variety	using	21
24	of	variety	23
25	reporter	constructs	27
26	gene	constructs	27
27	constructs	of	24
28	and	To	0
29	showed	effective	30
30	effective	and	28
31	inhibition	effective	30
32	of	inhibition	31
33	phorbol	of	32
34	ester/ionomycin-induced	activation	36
35	NF-AT	activation	36
36	activation	phorbol	33
37	and	of	32
38	anti-CD3	To	0
39	induced	<ROOT>	-1
40	NF-AT	induced	39
41	with	IC50	42
42	IC50	NF-AT	40
43	=	7.7	44
44	7.7	IC50	42
45	and	7.7	44
46	10	and	45
47	nM	induced	39
48	,	induced	39
49	respectively	induced	39
50	.	induced	39

0	In	IFN-gamma	3
1	astrocytes	In	0
2	,	In	0
3	IFN-gamma	<ROOT>	-1
4	treatment	induced	5
5	induced	IFN-gamma	3
6	increased	occupancy	7
7	occupancy	induced	5
8	of	these	9
9	these	occupancy	7
10	sites	IFN-gamma	3
11	.	IFN-gamma	3

0	These	results	1
1	results	show	2
2	show	RelB	16
3	that	show	2
4	,	that	3
5	physiologically	,	4
6	,	physiologically	5
7	high	,	6
8	levels	,	6
9	of	levels	8
10	nuclear	of	9
11	of	nuclear	10
12	p50	of	11
13	,	of	11
14	p52	,	13
15	and	p52	14
16	RelB	<ROOT>	-1
17	are	RelB	16
18	restricted	are	17
19	to	accessory	20
20	accessory	restricted	18
21	cells	accessory	20
22	of	cells	21
23	the	system	25
24	immune	system	25
25	system	of	22
26	,	include	28
27	which	include	28
28	include	RelB	16
29	FDC	include	28
30	in	include	28
31	GC	in	30
32	,	RelB	16
33	and	RelB	16
34	DC	RelB	16
35	and	RelB	16
36	macrophages	RelB	16
37	in	macrophages	36
38	the	cell	40
39	T	cell	40
40	cell	in	37
41	zone	cell	40
42	,	RelB	16
43	that	,	42
44	specialized	do	49
45	scavenger	macrophages	46
46	macrophages	specialized	44
47	from	macrophages	46
48	GC	from	47
49	do	that	43
50	not	do	49
51	have	do	49
52	detectable	have	51
53	levels	detectable	52
54	of	detectable	52
55	p52	of	54
56	and	of	54
57	RelB	RelB	16
58	,	RelB	16
59	whereas	RelB	16
60	macrophages	whereas	59
61	from	cell	64
62	the	cell	64
63	T	cell	64
64	cell	macrophages	60
65	area	RelB	16
66	,	RelB	16
67	known	RelB	16
68	to	known	67
69	present	to	68
70	the	antigen	71
71	antigen	present	69
72	to	T	73
73	T	present	69
74	cells	RelB	16
75	,	RelB	16
76	do	both	78
77	have	both	78
78	both	,	75
79	nuclear	both	78
80	p52	nuclear	79
81	and	nuclear	79
82	RelB	RelB	16
83	,	RelB	16
84	and	RelB	16
85	that	and	84
86	in	RelB	94
87	the	cell	89
88	T	cell	89
89	cell	in	86
90	zone	cell	89
91	,	in	86
92	p52	in	86
93	and	p52	92
94	RelB	are	95
95	are	that	85
96	located	are	95
97	in	located	96
98	nuclei	of	99
99	of	in	97
100	both	CD1a+	101
101	CD1a+	located	96
102	,	CD1a+	101
103	CD68+	CD1a+	101
104	or	CD68+	103
105	both	or	104
106	,	CD1a+	101
107	cells	located	96
108	APC	located	96
109	,	located	96
110	whereas	located	96
111	p50	whereas	110
112	is	p50	111
113	restricted	p50	111
114	to	restricted	113
115	CD1a-	to	114
116	and	CD1a-	115
117	CD68-	APC	118
118	APC	and	116
119	.	RelB	16

0	These	are	1
1	are	<ROOT>	-1
2	known	are	1
3	to	known	2
4	bind	to	3
5	to	bind	4
6	seven-transmembrane-domain	to	5
7	containing	seven-transmembrane-domain	6
8	receptors	containing	7
9	.	containing	7

0	These	<ROOT>	-1
1	data	These	0
2	suggest	that	3
3	that	data	1
4	inhibition	of	5
5	of	NFkappaB	6
6	NFkappaB	may	8
7	activation	NFkappaB	6
8	may	that	3
9	provide	may	8
10	a	approach	12
11	molecular	approach	12
12	approach	provide	9
13	to	provide	9
14	increase	apoptosis	15
15	apoptosis	to	13
16	sensitivity	apoptosis	15
17	in	sensitivity	16
18	anticancer	treatment	19
19	treatment	in	17
20	.	These	0

0	The	production	1
1	production	was	11
2	of	production	1
3	both	cytokines	4
4	cytokines	of	2
5	,	production	1
6	measured	production	1
7	by	measured	6
8	ELISA	tests	9
9	tests	by	7
10	,	production	1
11	was	<ROOT>	-1
12	enhanced	was	11
13	in	enhanced	12
14	monocytes	in	13
15	.	was	11

0	Neither	inhibition	1
1	inhibition	<ROOT>	-1
2	of	inhibition	1
3	translocation	inhibition	1
4	of	translocation	3
5	Rap1	of	4
6	to	inhibition	1
7	the	cytoskeleton	8
8	cytoskeleton	to	6
9	nor	inhibition	1
10	inhibition	nor	9
11	of	inhibition	10
12	platelet	aggregation	13
13	aggregation	of	11
14	affected	aggregation	13
15	thrombin-induced	inhibition	1
16	activation	thrombin-induced	15
17	of	activation	16
18	Rap1	of	17
19	.	inhibition	1

0	Subsequent	cross-linking	1
1	cross-linking	<ROOT>	-1
2	of	cross-linking	1
3	CD15	of	2
4	increased	cross-linking	1
5	CAT	activity	6
6	activity	increased	4
7	.	activity	6

0	Intravenous	injection	2
1	PCr	injection	2
2	injection	led	3
3	led	to	4
4	to	<ROOT>	-1
5	smaller	to	4
6	changes	to	4
7	in	changes	6
8	ACTH	and	9
9	and	changes	6
10	cortisol	to	4
11	concentrations	to	4
12	as	to	4
13	well	to	4
14	as	to	4
15	to	lower	17
16	a	lower	17
17	lower	as	14
18	activation	lower	17
19	of	glucocorticoid	20
20	glucocorticoid	activation	18
21	binding	to	4
22	in	to	4
23	lymphocytes	to	4
24	.	to	4

0	The	tumour	1
1	tumour	<ROOT>	-1
2	associated	tumour	1
3	cell	T	15
4	surface	cell	3
5	antigen	surface	4
6	A6H	surface	4
7	is	A6H	6
8	costimulatory	human	10
9	for	costimulatory	8
10	human	is	7
11	CD4+	is	7
12	but	surface	4
13	not	surface	4
14	CD8+	T	15
15	T	associated	2
16	cells	tumour	1
17	.	tumour	1

0	Northern	blot	1
1	blot	analysis	2
2	analysis	<ROOT>	-1
3	of	analysis	2
4	SR-BP	analysis	2
5	gene	analysis	2
6	expression	analysis	2
7	revealed	analysis	2
8	a	transcript	10
9	single	transcript	10
10	transcript	revealed	7
11	of	transcript	10
12	2	kilobases	13
13	kilobases	of	11
14	which	was	15
15	was	transcript	10
16	widely	was	15
17	expressed	widely	16
18	among	expressed	17
19	organs	among	18
20	,	organs	19
21	with	organs	19
22	the	with	21
23	highest	the	22
24	abundance	highest	23
25	in	abundance	24
26	liver	in	25
27	and	liver	26
28	the	and	27
29	lowest	the	28
30	abundance	lowest	29
31	in	abundance	30
32	brain	in	31
33	.	analysis	2

0	Thus	<ROOT>	-1
1	,	Thus	0
2	the	,	1
3	quantitative	of	5
4	analysis	of	5
5	of	AML1/ETO	6
6	AML1/ETO	the	2
7	transcripts	may	8
8	may	Thus	0
9	be	may	8
10	clinically	be	9
11	useful	clinically	10
12	in	clinically	10
13	patients	in	12
14	with	patients	13
15	t-LRB-8;21-RRB-	AML	16
16	AML	with	14
17	.	Thus	0

0	The	serum	1
1	serum	detected	3
2	also	serum	1
3	detected	<ROOT>	-1
4	a	protein	6
5	170-kD	protein	6
6	protein	detected	3
7	that	seems	8
8	seems	protein	6
9	to	seems	8
10	be	to	9
11	a	homologue	13
12	mouse	homologue	13
13	homologue	be	10
14	of	homologue	13
15	human	BAF170	16
16	BAF170	of	14
17	.	detected	3

0	Furthermore	proteins	5
1	,	Furthermore	0
2	Pax-5a	and	3
3	and	,	1
4	Pax-5b	and	3
5	proteins	<ROOT>	-1
6	were	proteins	5
7	detected	were	6
8	using	detected	7
9	Western	using	8
10	blot	.	12
11	analysis	.	12
12	.	Western	9

0	In	produced	6
1	the	group	3
2	control	group	3
3	group	In	0
4	,	produced	6
5	dexamethasone	produced	6
6	produced	which	28
7	a	depression	9
8	significant	depression	9
9	depression	produced	6
10	of	depression	9
11	Type	receptors	13
12	I	receptors	13
13	receptors	of	10
14	(	receptors	13
15	from	(	14
16	267	+/-	17
17	+/-	from	15
18	72	+/-	17
19	to	169	20
20	169	from	15
21	+/-	169	20
22	71	+/-	21
23	receptors	cell	25
24	per	cell	25
25	cell	produced	6
26	)	produced	6
27	,	which	28
28	which	can	29
29	can	<ROOT>	-1
30	be	can	29
31	interpreted	be	30
32	as	interpreted	31
33	a	as	32
34	primary	of	36
35	involvement	of	36
36	of	a	33
37	Type	receptors	39
38	I	receptors	39
39	receptors	of	36
40	in	a	33
41	the	response	42
42	response	in	40
43	to	response	42
44	dexamethasone	to	43
45	;	can	29
46	Type	can	29
47	II	receptors	48
48	receptors	Type	46
49	decreased	in	50
50	in	Type	46
51	half	subjects	53
52	the	half	51
53	subjects	Type	46
54	(	subjects	53
55	from	(	54
56	2849	from	55
57	+/-	2849	56
58	703	+/-	57
59	to	+/-	57
60	2345	+/-	57
61	+/-	2345	60
62	569	receptors	63
63	receptors	cell	65
64	per	cell	65
65	cell	+/-	61
66	)	(	54
67	.	can	29

0	The	immunization	3
1	in	immunization	3
2	vitro	in	1
3	immunization	remission	12
4	of	blood	6
5	peripheral	blood	6
6	blood	immunization	3
7	lymphocytes	immunization	3
8	from	four	9
9	four	immunization	3
10	patients	immunization	3
11	in	patients	10
12	remission	did	30
13	(	remission	12
14	S.R.	remission	12
15	,	remission	12
16	F.R.	remission	12
17	,	remission	12
18	M.M.	remission	12
19	,	remission	12
20	P.	remission	12
21	G.	P.	20
22	)	G.	21
23	with	P.	20
24	BCR1/25	with	23
25	,	did	30
26	a	pml/RAR-alpha	28
27	25-mer	pml/RAR-alpha	28
28	pml/RAR-alpha	did	30
29	,	pml/RAR-alpha	28
30	did	<ROOT>	-1
31	not	did	30
32	elicit	did	30
33	either	did	30
34	a	either	33
35	polyclonal	a	34
36	or	response	40
37	a	or	36
38	clonal	a	37
39	immune	response	40
40	response	polyclonal	35
41	specific	response	40
42	to	the	43
43	the	specific	41
44	peptide	the	43
45	.	did	30

0	In	demonstrate	5
1	this	study	2
2	study	In	0
3	,	demonstrate	5
4	we	demonstrate	5
5	demonstrate	<ROOT>	-1
6	the	demonstrate	5
7	disparate	the	6
8	fates	disparate	7
9	of	fates	8
10	HL-60	cells	11
11	cells	treated	12
12	treated	of	9
13	with	phorbol	15
14	the	phorbol	15
15	phorbol	treated	12
16	ester	phorbol	15
17	12,13-phorbol	dibutyric	18
18	dibutyric	acid	19
19	acid	(	20
20	(	ester	16
21	PDBu	(	20
22	)	phorbol	15
23	or	)	22
24	DMSO	)	22
25	.	DMSO	24

0	The	mechanism	4
1	deranged	mechanism	4
2	cholesterol	mechanism	4
3	feedback	mechanism	4
4	mechanism	has	5
5	has	<ROOT>	-1
6	been	has	5
7	widely	recognised	8
8	recognised	been	6
9	in	recognised	8
10	initiation	in	9
11	as	been	6
12	well	as	11
13	as	as	11
14	progression	types	17
15	of	progression	14
16	various	of	15
17	types	as	11
18	of	cancers	19
19	cancers	types	17
20	including	cancers	19
21	chronic	including	20
22	myeloid	cancers	19
23	leukaemia	CML	25
24	(	CML	25
25	CML	myeloid	22
26	)	CML	25
27	.	has	5

0	In	was	4
1	contrast	In	0
2	,	was	4
3	it	was	4
4	was	<ROOT>	-1
5	found	was	4
6	to	found	5
7	be	to	6
8	TNF-alpha	independent	9
9	independent	be	7
10	in	be	7
11	the	point	14
12	early	point	14
13	time	point	14
14	point	in	10
15	.	was	4

0	Relative	affinities	1
1	affinities	<ROOT>	-1
2	of	regulatory	4
3	transcriptional	regulatory	4
4	regulatory	affinities	1
5	elements	for	6
6	for	affinities	1
7	their	factor	9
8	respective	their	7
9	factor	for	6
10	have	affinities	1
11	been	affinities	1
12	essentially	been	11
13	studied	essentially	12
14	by	studied	13
15	bandshift	by	14
16	analysis	.	17
17	.	bandshift	15

0	The	CRE	1
1	CRE	conferred	9
2	and	CRE	1
3	kappaB3	sites	4
4	sites	and	2
5	in	region	6
6	region	CRE	1
7	II	CRE	1
8	together	CRE	1
9	conferred	LPS	11
10	strong	conferred	9
11	LPS	responsiveness	12
12	responsiveness	<ROOT>	-1
13	to	responsiveness	12
14	a	promoter	16
15	heterologous	promoter	16
16	promoter	to	13
17	,	responsiveness	12
18	whereas	responsiveness	12
19	individually	whereas	18
20	they	failed	21
21	failed	individually	19
22	to	failed	21
23	provide	transcriptional	24
24	transcriptional	to	22
25	activation	to	22
26	.	activation	25

0	PRRII	is	1
1	is	<ROOT>	-1
2	a	enhancer	4
3	T-cell-specific	enhancer	4
4	enhancer	is	1
5	,	is	1
6	located	is	1
7	between	located	6
8	nucleotides	-137	9
9	-137	between	7
10	and	-137	9
11	-64	is	1
12	,	is	1
13	which	binds	14
14	binds	is	1
15	the	protein	18
16	T-cell-specific	protein	18
17	Ets	protein	18
18	protein	binds	14
19	Elf-1	and	20
20	and	binds	14
21	HMG-I-LRB-Y-RRB-	proteins	22
22	proteins	and	20
23	.	is	1

0	Role	<ROOT>	-1
1	of	Role	0
2	AP-1	of	1
3	,	NF-kappa	4
4	NF-kappa	Role	0
5	B/Rel	,	6
6	,	Role	0
7	and	,	6
8	Sp1	Role	0
9	proteins	Role	0
10	in	Role	0
11	uninduced	Role	0
12	and	lipopolysaccharide-induced	13
13	lipopolysaccharide-induced	uninduced	11
14	expression	Role	0
15	.	Role	0

0	Phase-2	adhesion	2
1	neutrophil	adhesion	2
2	adhesion	was	3
3	was	<ROOT>	-1
4	attenuated	was	3
5	by	attenuated	4
6	an	anti-E-selectin	7
7	anti-E-selectin	by	5
8	mAb	anti-E-selectin	7
9	,	was	3
10	indicating	was	3
11	a	indicating	10
12	dominant	of	14
13	role	of	14
14	of	a	11
15	this	of	14
16	adhesion	molecule	17
17	molecule	late	20
18	in	late	20
19	the	late	20
20	late	of	14
21	phase	late	20
22	response	was	3
23	.	was	3

0	The	mutant	1
1	mutant	promoters	29
2	,	mutant	1
3	containing	mutant	1
4	a	substitution	6
5	serine-to-alanine	substitution	6
6	substitution	containing	3
7	in	substitution	6
8	the	domain	10
9	DNA-binding	domain	10
10	domain	in	7
11	of	domain	10
12	the	of	11
13	protein	bound	15
14	,	bound	15
15	bound	the	12
16	to	bound	15
17	several	to	16
18	known	sites	20
19	ZEBRA-binding	sites	20
20	sites	several	17
21	and	bound	15
22	activated	bound	15
23	transcription	from	24
24	from	bound	15
25	reporters	mutant	1
26	bearing	known	27
27	known	reporters	25
28	ZEBRA-responsive	promoters	29
29	promoters	<ROOT>	-1
30	but	promoters	29
31	did	but	30
32	not	did	31
33	disrupt	did	31
34	latency	disrupt	33
35	in	latency	34
36	EBV-infected	cell	37
37	cell	in	35
38	lines	promoters	29
39	.	promoters	29

0	Inhibition	of	1
1	of	<ROOT>	-1
2	GATA-3	of	1
3	activity	of	1
4	has	of	1
5	therapeutic	potential	6
6	potential	has	4
7	in	has	4
8	the	treatment	9
9	treatment	in	7
10	of	treatment	9
11	asthma	of	10
12	and	has	4
13	other	diseases	15
14	hypereosinophilic	diseases	15
15	diseases	and	12
16	.	of	1

0	Some	are	4
1	of	Some	0
2	these	oxidants	3
3	oxidants	of	1
4	are	<ROOT>	-1
5	known	are	4
6	to	known	5
7	modulate	to	6
8	the	expression	9
9	expression	modulate	7
10	of	expression	9
11	a	variety	12
12	variety	of	10
13	of	variety	12
14	genes	of	13
15	that	variety	12
16	are	that	15
17	involved	are	16
18	in	involved	17
19	the	immune	20
20	immune	in	18
21	and	immune	20
22	inflammatory	and	21
23	responses	are	4
24	.	are	4

0	Our	results	1
1	results	suggest	2
2	suggest	surface	10
3	that	suggest	2
4	by	that	3
5	inhibiting	NF-kappa	6
6	NF-kappa	by	4
7	B	suggest	2
8	activation	suggest	2
9	,	suggest	2
10	surface	molecules	15
11	expression	surface	10
12	of	adhesion	14
13	several	adhesion	14
14	adhesion	expression	11
15	molecules	events	30
16	can	molecules	15
17	be	molecules	15
18	modulated	be	17
19	and	molecules	15
20	that	and	19
21	tepoxalin	may	22
22	may	that	20
23	be	mediated	29
24	useful	be	23
25	in	mediated	29
26	treating	mediated	29
27	selected	adhesion	28
28	adhesion	mediated	29
29	mediated	may	22
30	events	<ROOT>	-1
31	such	as	32
32	as	events	30
33	leukocyte	as	32
34	migration	atherosclerotic	36
35	or	atherosclerotic	36
36	atherosclerotic	leukocyte	33
37	plaque	events	30
38	formation	events	30
39	.	events	30

0	The	<ROOT>	-1
1	parallel	The	0
2	induction	parallel	1
3	of	induction	2
4	I	of	3
5	kappa	B	6
6	B	of	3
7	alpha	The	0
8	synthesis	alpha	7
9	may	allow	10
10	allow	synthesis	8
11	for	alpha	7
12	the	for	11
13	continuous	the	12
14	presence	continuous	13
15	of	presence	14
16	a	reservoir	18
17	cytoplasmic	reservoir	18
18	reservoir	of	15
19	of	(	21
20	p50/RelA	of	19
21	(	reservoir	18
22	p65	(	21
23	)	The	0
24	complexes	The	0
25	that	are	26
26	are	complexes	24
27	readily	available	28
28	available	are	26
29	for	available	28
30	inducer-mediated	stimulation	31
31	stimulation	for	29
32	.	The	0

0	In	describe	5
1	this	report	2
2	report	In	0
3	,	describe	5
4	we	describe	5
5	describe	<ROOT>	-1
6	the	cloning	7
7	cloning	human	9
8	of	human	9
9	human	describe	5
10	GATA-4	hGATA-4	12
11	(	GATA-4	10
12	hGATA-4	describe	5
13	)	hGATA-4	12
14	and	describe	5
15	show	that	16
16	that	describe	5
17	hGATA-4	describe	5
18	selectively	interacts	19
19	interacts	describe	5
20	with	describe	5
21	the	site	24
22	-70	site	24
23	GATA	site	24
24	site	with	20
25	within	proximal	28
26	the	proximal	28
27	IL-5	proximal	28
28	proximal	with	20
29	promoter	describe	5
30	region	describe	5
31	.	describe	5

0	We	characterised	3
1	have	We	0
2	recently	characterised	3
3	characterised	<ROOT>	-1
4	a	factor	6
5	new	factor	6
6	factor	characterised	3
7	called	which	9
8	IK	called	7
9	which	factor	6
10	is	efficient	12
11	an	efficient	12
12	efficient	which	9
13	inhibitor	IFN-gamma	15
14	of	inhibitor	13
15	IFN-gamma	efficient	12
16	induction	which	9
17	of	MHC	18
18	MHC	induction	16
19	class	MHC	18
20	II	antigens	21
21	antigens	class	19
22	expression	antigens	21
23	.	MHC	18

0	We	identified	1
1	identified	<ROOT>	-1
2	an	fragment	4
3	86-nucleotide	fragment	4
4	fragment	identified	1
5	that	is	6
6	is	fragment	4
7	90	%	8
8	%	is	6
9	identical	is	6
10	to	identical	9
11	the	element	16
12	recently	characterized	13
13	characterized	element	16
14	murine	element	16
15	IL-2-responsive	element	16
16	element	to	10
17	(	mIL-2rE	18
18	mIL-2rE	fragment	4
19	)	mIL-2rE	18
20	.	identified	1

0	Clonal	analysis	1
1	analysis	revealed	2
2	revealed	<ROOT>	-1
3	individual	responses	4
4	responses	revealed	2
5	to	responses	4
6	the	proteins	10
7	two	proteins	10
8	immediate	proteins	10
9	early	proteins	10
10	proteins	to	5
11	BZLF1	proteins	10
12	and	proteins	10
13	BRLF1	and	12
14	,	revealed	2
15	and	revealed	2
16	to	and	15
17	three	(	18
18	(	to	16
19	BMLF1	BMRF1	21
20	,	BMRF1	21
21	BMRF1	(	18
22	,	BMRF1	21
23	and	revealed	2
24	BALF2	and	23
25	)	of	26
26	of	BALF2	24
27	the	six	28
28	six	of	26
29	early	proteins	30
30	proteins	of	26
31	tested	revealed	2
32	.	revealed	2

0	The	protein	2
1	SRG3	protein	2
2	protein	is	3
3	is	<ROOT>	-1
4	expressed	is	3
5	about	times	7
6	three	times	7
7	times	expressed	4
8	higher	times	7
9	in	times	7
10	thymocytes	in	9
11	than	times	7
12	in	than	11
13	peripheral	lymphocytes	14
14	lymphocytes	in	12
15	.	is	3

0	Defective	survival	1
1	survival	<ROOT>	-1
2	and	survival	1
3	activation	and	2
4	of	and	2
5	thymocytes	survival	1
6	in	thymocytes	5
7	transgenic	survival	1
8	mice	survival	1
9	expressing	survival	1
10	a	form	13
11	catalytically	form	13
12	inactive	form	13
13	form	expressing	9
14	of	protein	16
15	Ca2+/calmodulin-dependent	protein	16
16	protein	form	13
17	kinase	survival	1
18	IV	survival	1
19	.	survival	1

0	Detection	<ROOT>	-1
1	of	Detection	0
2	adenovirus	DNA	3
3	DNA	of	1
4	in	peripheral	5
5	peripheral	of	1
6	blood	Detection	0
7	mononuclear	Detection	0
8	cells	Detection	0
9	by	Detection	0
10	polymerase	assay	13
11	chain	assay	13
12	reaction	assay	13
13	assay	by	9
14	.	Detection	0

0	In	and	5
1	CRF	patients	2
2	patients	In	0
3	,	and	5
4	Bmax	and	5
5	and	were	14
6	Kd	and	5
7	in	Kd	6
8	quiescent	and	5
9	PBMC	quiescent	8
10	of	quiescent	8
11	the	group	13
12	GC-sensitive	group	13
13	group	of	10
14	were	<ROOT>	-1
15	6.04	were	14
16	+/-	6.04	15
17	2.35	+/-	16
18	fmol/10-LRB-6-RRB-	and	20
19	cells	and	20
20	and	+/-	16
21	3.49	were	14
22	+/-	3.49	21
23	1.72	+/-	22
24	nM	were	14
25	,	were	14
26	respectively	were	14
27	,	were	14
28	while	were	14
29	those	were	36
30	in	those	29
31	PBMC	in	30
32	of	those	29
33	the	group	35
34	GC-resistant	group	35
35	group	of	32
36	were	while	28
37	5.13	were	36
38	+/-	5.13	37
39	2.31	+/-	38
40	fmol/10-LRB-6-RRB-	and	42
41	cells	and	42
42	and	+/-	38
43	4.04	were	14
44	+/-	4.04	43
45	1.62	+/-	44
46	nM	were	14
47	,	were	14
48	respectively	were	14
49	.	were	14

0	We	were	1
1	were	<ROOT>	-1
2	,	were	1
3	therefore	were	1
4	,	were	1
5	interested	were	1
6	in	interested	5
7	examining	in	6
8	mutated	constructs	10
9	CIITA	constructs	10
10	constructs	in	6
11	for	their	12
12	their	in	6
13	effect	their	12
14	on	II	18
15	porcine	II	18
16	MHC	II	18
17	class	II	18
18	II	effect	13
19	expression	were	1
20	.	were	1

0	Using	<ROOT>	-1
1	various	constructs	2
2	constructs	expressing	3
3	expressing	reporter	6
4	a	reporter	6
5	lacZ	reporter	6
6	reporter	Using	0
7	gene	Using	0
8	under	gene	7
9	the	under	8
10	control	the	9
11	of	control	10
12	the	of	11
13	intact	the	12
14	or	intact	13
15	three	deleted	16
16	deleted	or	14
17	forms	deleted	16
18	of	deleted	16
19	HIV-1	LTR	20
20	LTR	deleted	16
21	,	Using	0
22	we	Using	0
23	obtained	Using	0
24	evidence	that	25
25	that	obtained	23
26	the	elements	29
27	kappaB	elements	29
28	regulatory	elements	29
29	elements	that	25
30	located	elements	29
31	in	located	30
32	the	in	31
33	U3	the	32
34	region	U3	33
35	are	region	34
36	involved	are	35
37	in	cell-to-cell	38
38	cell-to-cell	involved	36
39	activation	Using	0
40	of	HIV-1	41
41	HIV-1	Using	0
42	LTR	Using	0
43	.	Using	0

0	Thus	<ROOT>	-1
1	,	Thus	0
2	such	,	1
3	unique	result	15
4	activation	result	15
5	of	activation	4
6	the	of	5
7	inhibitory	by	10
8	p50/p50	by	10
9	homodimer	by	10
10	by	the	6
11	acute	the	6
12	ethanol	may	14
13	treatment	may	14
14	may	acute	11
15	result	such	2
16	in	result	15
17	inhibition	in	16
18	rather	result	15
19	than	rather	18
20	activation	rather	18
21	of	NF-kappa	22
22	NF-kappa	activation	20
23	B-regulated	result	15
24	inflammatory	result	15
25	cytokine	result	15
26	genes	result	15
27	.	Thus	0

0	Relationship	<ROOT>	-1
1	between	receptor	3
2	glucocorticoid	receptor	3
3	receptor	Relationship	0
4	and	receptor	3
5	response	and	4
6	to	glucocorticoid	7
7	glucocorticoid	response	5
8	therapy	glucocorticoid	7
9	in	ulcerative	10
10	ulcerative	therapy	8
11	colitis	Relationship	0
12	.	Relationship	0

0	T	cell	1
1	cell	response	2
2	response	<ROOT>	-1
3	to	response	2
4	Epstein-Barr	virus	5
5	virus	to	3
6	transactivators	virus	5
7	in	transactivators	6
8	chronic	arthritis	10
9	rheumatoid	arthritis	10
10	arthritis	in	7
11	.	response	2

0	From	conclude	5
1	our	From	0
2	results	From	0
3	,	conclude	5
4	we	conclude	5
5	conclude	<ROOT>	-1
6	that	Rap1	7
7	Rap1	conclude	5
8	activation	conclude	5
9	in	conclude	5
10	platelets	conclude	5
11	is	platelets	10
12	an	event	15
13	important	event	15
14	common	event	15
15	event	platelets	10
16	in	event	15
17	early	in	16
18	agonist-induced	conclude	5
19	signalling	conclude	5
20	,	conclude	5
21	and	conclude	5
22	that	and	21
23	this	activation	24
24	activation	is	25
25	is	that	22
26	mediated	is	25
27	by	mediated	26
28	an	concentration	32
29	increased	concentration	32
30	intracellular	concentration	32
31	Ca2+	concentration	32
32	concentration	by	27
33	.	conclude	5

0	A	form	2
1	novel	form	2
2	form	<ROOT>	-1
3	of	protein	8
4	the	protein	8
5	myeloid-specific	protein	8
6	zinc	protein	8
7	finger	protein	8
8	protein	form	2
9	(	protein	8
10	MZF-2	form	2
11	)	MZF-2	10
12	.	)	11

0	By	constructed	17
1	using	By	0
2	a	sequence	5
3	partial	sequence	5
4	nucleotide	sequence	5
5	sequence	using	1
6	from	using	1
7	the	reaction	13
8	cloned	reaction	13
9	TSC2	and	10
10	and	cloned	8
11	polymerase	reaction	13
12	chain	reaction	13
13	reaction	from	6
14	methodology	By	0
15	,	constructed	17
16	we	constructed	17
17	constructed	<ROOT>	-1
18	a	probe	22
19	digoxigenin-labeled	probe	22
20	complementary	probe	22
21	DNA	probe	22
22	probe	constructed	17
23	to	constructed	17
24	examine	to	23
25	TSC2	examine	24
26	gene	TSC2	25
27	expression	in	28
28	in	gene	26
29	autopsy-	constructed	17
30	or	autopsy-	29
31	biopsy-derived	or	30
32	human	constructed	17
33	tissues	constructed	17
34	by	tissues	33
35	in	tissues	33
36	situ	.	38
37	hybridization	.	38
38	.	constructed	17

0	HLA-DMA	gene	3
1	and	HLA-DMA	0
2	HLA-DMB	and	1
3	gene	<ROOT>	-1
4	expression	conserved	8
5	functions	conserved	8
6	through	conserved	8
7	the	through	6
8	conserved	gene	3
9	S-X-Y	region	10
10	region	gene	3
11	.	gene	3

0	A	inhibitor	4
1	specific	inhibitor	4
2	p38	inhibitor	4
3	MAPk	inhibitor	4
4	inhibitor	blocked	9
5	(	86002	7
6	SK&amp;F	86002	7
7	86002	inhibitor	4
8	)	86002	7
9	blocked	<ROOT>	-1
10	superoxide	anion	11
11	anion	blocked	9
12	production	blocked	9
13	in	production	12
14	response	in	13
15	to	response	14
16	FMLP	to	15
17	and	FMLP	16
18	reduced	adhesion	19
19	adhesion	and	17
20	and	adhesion	19
21	chemotaxis	adhesion	19
22	in	chemotaxis	21
23	response	in	22
24	to	response	23
25	PAF	to	24
26	or	PAF	25
27	FMLP	or	26
28	.	FMLP	27

0	Nuclear	B	2
1	factor-kappa	B	2
2	B	proteins	8
3	(	NF-kappa	4
4	NF-kappa	B	2
5	B	NF-kappa	4
6	)	NF-kappa	4
7	/Rel	B	2
8	proteins	are	9
9	are	transcriptional	11
10	inducible	transcriptional	11
11	transcriptional	<ROOT>	-1
12	regulators	transcriptional	11
13	of	regulators	12
14	numerous	genes	16
15	cellular	genes	16
16	genes	of	13
17	.	transcriptional	11

0	The	affinity	3
1	GCR	affinity	3
2	binding	affinity	3
3	affinity	was	6
4	for	affinity	3
5	budesonide	for	4
6	was	<ROOT>	-1
7	significantly	higher	8
8	higher	was	6
9	in	was	6
10	both	groups	11
11	groups	in	9
12	(	groups	11
13	i.e.	)	18
14	,	)	18
15	lower	)	18
16	dissociation	)	18
17	constant	)	18
18	)	groups	11
19	than	)	18
20	that	than	19
21	obtained	for	22
22	for	that	20
23	dexamethasone	for	22
24	.	was	6

0	To	<ROOT>	-1
1	investigate	To	0
2	the	mechanisms	3
3	mechanisms	investigate	1
4	responsible	mechanisms	3
5	for	responsible	4
6	tissue-specific	expression	7
7	expression	for	5
8	of	expression	7
9	the	gene	11
10	IL-4	gene	11
11	gene	of	8
12	,	To	0
13	we	,	12
14	analyzed	we	13
15	nuclear	analyzed	14
16	factors	nuclear	15
17	binding	factors	16
18	to	binding	17
19	the	site	21
20	PRE-I	site	21
21	site	to	18
22	and	nuclear	15
23	compared	analyzed	14
24	the	activities	26
25	binding	activities	26
26	activities	analyzed	14
27	of	activities	26
28	these	factors	29
29	factors	of	27
30	to	analyzed	14
31	the	promoter	33
32	IL-4	promoter	33
33	promoter	to	30
34	of	promoter	33
35	Th1	of	34
36	and	Th2	37
37	Th2	Th1	35
38	cells	To	0
39	.	To	0

0	After	had	11
1	its	proteins	3
2	associated	proteins	3
3	proteins	After	0
4	,	protein	8
5	especially	protein	8
6	the	protein	8
7	heat-shock	protein	8
8	protein	had	11
9	hsp90	protein	8
10	,	protein	8
11	had	<ROOT>	-1
12	been	had	11
13	cross-linked	been	12
14	with	cross-linked	13
15	the	hMR	16
16	hMR	with	14
17	by	cross-linked	13
18	dimethylpimelimidate	by	17
19	,	dimethylpimelimidate	18
20	18C7	was	21
21	was	had	11
22	still	was	21
23	able	was	21
24	to	able	23
25	react	to	24
26	with	react	25
27	the	receptor	28
28	receptor	with	26
29	.	had	11

0	CONCLUSIONS	<ROOT>	-1
1	:	CONCLUSIONS	0
2	In	is	9
3	patients	In	2
4	with	patients	3
5	AMI	with	4
6	,	is	9
7	leukocyte-platelet	adhesion	8
8	adhesion	is	9
9	is	CONCLUSIONS	0
10	increased	is	9
11	.	CONCLUSIONS	0

0	In	have	3
1	cells	In	0
2	that	have	3
3	have	is	12
4	been	have	3
5	preincubated	to	6
6	to	been	4
7	lower	to	6
8	mRNA	have	3
9	levels	have	3
10	,	is	12
11	there	is	12
12	is	<ROOT>	-1
13	a	increase	15
14	transient	increase	15
15	increase	is	12
16	in	increase	15
17	G0S2	mRNA	18
18	mRNA	in	16
19	,	is	12
20	peaking	is	12
21	between	h	23
22	1-2	h	23
23	h	is	12
24	,	h	23
25	in	,	24
26	response	in	25
27	to	response	26
28	Concanavalin-A	to	27
29	(	ConA	30
30	ConA	Concanavalin-A	28
31	)	ConA	30
32	,	in	25
33	or	in	25
34	to	the	35
35	the	or	33
36	combination	phorbol	38
37	of	phorbol	38
38	phorbol	the	35
39	ester	phorbol	38
40	(	phorbol	38
41	TPA	the	35
42	)	TPA	41
43	,	in	25
44	and	the	45
45	the	in	25
46	calcium	is	12
47	ionophore	is	12
48	,	is	12
49	ionomycin	is	12
50	.	is	12

0	The	ability	1
1	ability	was	14
2	of	ability	1
3	BHRF1	of	2
4	to	ability	1
5	protect	to	4
6	MCF-Fas	cells	7
7	cells	protect	5
8	from	protect	5
9	apoptosis	induced	10
10	induced	from	8
11	by	various	12
12	various	induced	10
13	stimuli	ability	1
14	was	<ROOT>	-1
15	identical	was	14
16	to	identical	15
17	that	to	16
18	of	that	17
19	Bcl-2	of	18
20	and	of	18
21	Bcl-xL	was	14
22	.	was	14

0	These	<ROOT>	-1
1	data	These	0
2	may	expand	3
3	expand	data	1
4	the	understanding	5
5	understanding	expand	3
6	of	understanding	5
7	the	anti-thrombotic	8
8	anti-thrombotic	of	6
9	and	anti-thrombotic	8
10	anti-inflammatory	and	9
11	effects	understanding	5
12	of	these	13
13	these	effects	11
14	drugs	when	15
15	when	these	13
16	activation	monocytes	18
17	of	monocytes	18
18	monocytes	occurs	19
19	occurs	These	0
20	.	These	0

0	This	hypothesis	1
1	hypothesis	is	2
2	is	<ROOT>	-1
3	supported	is	2
4	by	supported	3
5	evidence	by	4
6	of	evidence	5
7	hypertension	of	6
8	and	renin	10
9	low	renin	10
10	renin	of	6
11	activity	is	2
12	,	which	13
13	which	is	2
14	others	which	13
15	have	others	14
16	described	have	15
17	in	described	16
18	patients	primary	20
19	with	primary	20
20	primary	in	17
21	glucocorticoid	in	17
22	resistance	glucocorticoid	21
23	due	resistance	22
24	to	due	23
25	mutations	to	24
26	of	glucocorticoid	28
27	the	glucocorticoid	28
28	glucocorticoid	mutations	25
29	receptor	resistance	22
30	.	resistance	22

0	We	have	1
1	have	<ROOT>	-1
2	developed	have	1
3	a	assay	5
4	novel	assay	5
5	assay	developed	2
6	to	developed	2
7	monitor	to	6
8	the	form	12
9	active	form	12
10	,	form	12
11	GTP-bound	form	12
12	form	monitor	7
13	of	form	12
14	Rap1	of	13
15	based	form	12
16	on	based	15
17	the	affinity	19
18	differential	affinity	19
19	affinity	binding	27
20	of	affinity	19
21	Rap1GTP	of	20
22	and	Rap1GTP	21
23	Rap1GDP	and	22
24	for	binding	27
25	the	binding	27
26	Rap	binding	27
27	binding	on	16
28	domain	have	1
29	of	domain	28
30	RalGDS	of	29
31	(	RBD	32
32	RBD	domain	28
33	)	RBD	32
34	.	have	1

0	These	properties	1
1	properties	<ROOT>	-1
2	of	properties	1
3	OCA-B	those	5
4	parallel	OCA-B	3
5	those	displayed	6
6	displayed	of	2
7	by	displayed	6
8	the	VP16	14
9	herpes	VP16	14
10	simplex	VP16	14
11	virus	VP16	14
12	Oct-1	VP16	14
13	coregulator	VP16	14
14	VP16	by	7
15	.	properties	1

0	Nuclear	NF-ATp	1
1	NF-ATp	is	2
2	is	<ROOT>	-1
3	a	hallmark	4
4	hallmark	is	2
5	of	hallmark	4
6	unstimulated	of	5
7	B	cells	8
8	cells	of	5
9	from	B-CLL	10
10	B-CLL	of	5
11	patients	is	2
12	.	is	2

0	NF-Y	is	1
1	is	<ROOT>	-1
2	formed	is	1
3	by	formed	2
4	three	subunits	5
5	subunits	by	3
6	,	subunits	5
7	A	subunits	5
8	,	A	7
9	B	,	8
10	,	B	9
11	and	,	10
12	C	,	10
13	,	C	12
14	all	C	12
15	of	all	14
16	which	are	17
17	are	of	15
18	necessary	for	19
19	for	are	17
20	DNA	binding	21
21	binding	for	19
22	.	is	1

0	There	are	1
1	are	<ROOT>	-1
2	other	elements	3
3	elements	are	1
4	regulating	elements	3
5	IL-4	regulating	4
6	gene	expression	7
7	expression	regulating	4
8	,	are	1
9	however	are	1
10	,	are	1
11	and	are	1
12	the	relative	13
13	relative	recently	17
14	importance	relative	13
15	of	importance	14
16	these	of	15
17	recently	and	11
18	identified	recently	17
19	proteins	are	1
20	has	are	1
21	yet	are	1
22	to	are	1
23	be	to	22
24	determined	be	23
25	.	are	1

0	In	(	23
1	order	In	0
2	to	In	0
3	inquire	to	2
4	into	inquire	3
5	the	into	4
6	functional	the	5
7	state	functional	6
8	of	state	7
9	adrenal	cortex	10
10	cortex	of	8
11	in	cortex	10
12	patients	in	11
13	with	patients	12
14	pulmonary	disease	16
15	heart	disease	16
16	disease	with	13
17	,	functional	6
18	the	number	19
19	number	,	17
20	of	glucocorticoid	21
21	glucocorticoid	number	19
22	receptors	(	23
23	(	was	37
24	GCR	(	23
25	)	(	23
26	of	(	23
27	peripheral	(	23
28	blood	(	23
29	leukocytes	(	23
30	in	leukocytes	29
31	patients	pulmonary	34
32	with	pulmonary	34
33	chronic	pulmonary	34
34	pulmonary	in	30
35	heart	(	23
36	disease	(	23
37	was	<ROOT>	-1
38	determined	was	37
39	with	determined	38
40	radioligand-binding	assay	41
41	assay	with	39
42	and	assay	41
43	the	and	42
44	corresponding	plasma	45
45	plasma	the	43
46	cortisol	were	48
47	levels	were	48
48	were	assessed	49
49	assessed	plasma	45
50	with	assessed	49
51	radioimmune	with	50
52	assays	.	53
53	.	radioimmune	51

0	Constitutive	appearance	2
1	nuclear	appearance	2
2	appearance	was	3
3	was	<ROOT>	-1
4	also	was	3
5	observed	was	3
6	for	observed	5
7	NF-kB2/p52	for	6
8	.	was	3

0	These	observations	1
1	observations	suggest	2
2	suggest	critical	22
3	that	play	8
4	p65	play	8
5	and	p65	4
6	c-Rel	complexes	7
7	complexes	and	5
8	play	distinct	9
9	distinct	suggest	2
10	roles	suggest	2
11	in	gene	12
12	gene	roles	10
13	expression	suggest	2
14	and	expression	13
15	that	and	14
16	both	forms	17
17	forms	that	15
18	of	NF-kappa	19
19	NF-kappa	forms	17
20	B	suggest	2
21	play	suggest	2
22	critical	<ROOT>	-1
23	roles	critical	22
24	during	late	25
25	late	roles	23
26	stages	late	25
27	of	intrathymic	29
28	the	intrathymic	29
29	intrathymic	stages	26
30	maturation	intrathymic	29
31	of	T	32
32	T	maturation	30
33	cells	critical	22
34	.	critical	22

0	NFAT3	protein	1
1	protein	was	2
2	was	<ROOT>	-1
3	not	was	2
4	observed	was	2
5	under	observed	4
6	any	conditions	7
7	conditions	under	5
8	.	was	2

0	The	oligodeoxynucleotide	3
1	AML1	antisense	2
2	antisense	oligodeoxynucleotide	3
3	oligodeoxynucleotide	<ROOT>	-1
4	but	oligodeoxynucleotide	3
5	not	sense	7
6	the	not	5
7	sense	oligomer	8
8	oligomer	but	4
9	recovered	oligomer	8
10	its	oligomer	8
11	differentiation-inducing	in	13
12	capacity	in	13
13	in	its	10
14	the	in	13
15	presence	the	14
16	of	presence	15
17	butyrate	of	16
18	.	oligodeoxynucleotide	3

0	We	overexpressed	1
1	overexpressed	<ROOT>	-1
2	in	overexpressed	1
3	the	line	6
4	Jurkat	line	6
5	T-cell	line	6
6	line	in	2
7	ZAP-70	overexpressed	1
8	mutated	ZAP-70	7
9	on	mutated	8
10	Tyr-492	on	9
11	and	Tyr-492	10
12	Tyr-493	and	11
13	in	Tyr-492	10
14	the	putative	15
15	putative	in	13
16	regulatory	of	18
17	loop	of	18
18	of	putative	15
19	its	domain	21
20	kinase	domain	21
21	domain	of	18
22	.	overexpressed	1

0	Cells	did	4
1	within	Cells	0
2	each	category	3
3	category	within	1
4	did	<ROOT>	-1
5	not	did	4
6	give	did	4
7	any	results	9
8	aberrant	results	9
9	results	give	6
10	.	did	4

0	The	mechanisms	2
1	molecular	mechanisms	2
2	mechanisms	<ROOT>	-1
3	of	the	4
4	the	mechanisms	2
5	effects	mechanisms	2
6	of	effects	5
7	IL-4	of	6
8	and	of	6
9	IL-13	mechanisms	2
10	on	HIV	11
11	HIV	mechanisms	2
12	infection	mechanisms	2
13	in	human	14
14	human	mechanisms	2
15	monocytes	mechanisms	2
16	as	mechanisms	2
17	they	as	16
18	matured	into	19
19	into	they	17
20	monocyte-derived	into	19
21	macrophages	over	22
22	over	were	25
23	7	over	22
24	days	were	25
25	were	monocyte-derived	20
26	investigated	mechanisms	2
27	using	investigated	26
28	HIV-1	BaL	30
29	(	HIV-1	28
30	BaL	using	27
31	)	BaL	30
32	,	mechanisms	2
33	and	clinical	36
34	low	clinical	36
35	passage	clinical	36
36	clinical	mechanisms	2
37	strains	mechanisms	2
38	.	mechanisms	2

0	In	RelB	10
1	germinal	centers	2
2	centers	In	0
3	GC	In	0
4	,	GC	3
5	p50	,	4
6	,	p50	5
7	p52	,	4
8	,	In	0
9	and	,	8
10	RelB	were	11
11	were	<ROOT>	-1
12	found	were	11
13	in	found	12
14	the	nuclei	15
15	nuclei	in	13
16	of	nuclei	15
17	FDC	of	16
18	only	in	13
19	and	only	18
20	were	in	13
21	not	were	20
22	detected	in	13
23	in	detected	22
24	the	nuclei	25
25	nuclei	in	23
26	of	nuclei	25
27	CD68+	cells	28
28	cells	of	26
29	.	cells	28

0	Moreover	was	9
1	,	Moreover	0
2	in	,	1
3	contrast	in	2
4	to	healthy	5
5	healthy	contrast	3
6	subjects	Moreover	0
7	,	was	9
8	there	was	9
9	was	<ROOT>	-1
10	no	correlation	11
11	correlation	was	9
12	between	correlation	11
13	IC50	parameters	16
14	and	IC50	13
15	GC-R	and	14
16	parameters	between	12
17	in	parameters	16
18	CRF	in	17
19	.	was	9

0	IL-2	occurred	4
1	superinduction	Tat	3
2	by	Tat	3
3	Tat	IL-2	0
4	occurred	was	10
5	at	transcriptional	7
6	the	transcriptional	7
7	transcriptional	occurred	4
8	level	occurred	4
9	,	occurred	4
10	was	<ROOT>	-1
11	mediated	was	10
12	by	mediated	11
13	the	by	12
14	CD28-responsive	the	13
15	element	CD28-responsive	14
16	in	IL-2	18
17	the	IL-2	18
18	IL-2	element	15
19	promoter	was	10
20	,	was	10
21	and	was	10
22	was	exclusively	23
23	exclusively	dependent	24
24	dependent	and	21
25	on	dependent	24
26	the	on	25
27	29	the	26
28	amino	29	27
29	acids	amino	28
30	encoded	acids	29
31	by	encoded	30
32	the	exon	34
33	second	exon	34
34	exon	by	31
35	of	Tat	36
36	Tat	exon	34
37	.	was	10

0	This	expression	2
1	widespread	expression	2
2	expression	supports	7
3	of	expression	2
4	the	gene	6
5	TSC2	gene	6
6	gene	of	3
7	supports	<ROOT>	-1
8	the	view	9
9	view	supports	7
10	that	view	9
11	it	encodes	12
12	encodes	that	10
13	a	protein	14
14	protein	encodes	12
15	vital	protein	14
16	to	vital	15
17	cell	growth	18
18	growth	to	16
19	and	supports	7
20	metabolism	and	19
21	or	and	19
22	one	or	21
23	that	one	22
24	functions	that	23
25	as	functions	24
26	a	as	25
27	tumor/growth	.	29
28	suppressor	.	29
29	.	a	26

0	Despite	<ROOT>	-1
1	increasing	Despite	0
2	evidence	that	3
3	that	increasing	1
4	the	outcome	5
5	outcome	determined	10
6	of	outcome	5
7	many	of	6
8	diseases	is	9
9	is	many	7
10	determined	that	3
11	by	determined	10
12	the	ratio	13
13	ratio	by	11
14	of	ratio	13
15	the	of	14
16	two	of	18
17	subsets	of	18
18	of	the	15
19	CD4-LRB-+-RRB-	of	18
20	T	,	23
21	helper	,	23
22	cells	,	23
23	,	CD4-LRB-+-RRB-	19
24	Th1	the	15
25	and	Th1	24
26	Th2	and	25
27	,	Despite	0
28	the	remains	37
29	molecular	for	31
30	basis	for	31
31	for	the	28
32	Th1-	for	31
33	and	Th1-	32
34	Th2-specific	expression	36
35	gene	expression	36
36	expression	and	33
37	remains	,	27
38	to	remains	37
39	be	to	38
40	elucidated	be	39
41	.	Despite	0

0	The	inhibitor	3
1	cyclin-dependent	inhibitor	3
2	kinase	inhibitor	3
3	inhibitor	p27Kip1	4
4	p27Kip1	plays	5
5	plays	<ROOT>	-1
6	an	role	8
7	important	role	8
8	role	plays	5
9	in	plays	5
10	regulating	in	9
11	cell-cycle	progression	12
12	progression	regulating	10
13	.	plays	5

0	In	substrate	10
1	fact	In	0
2	,	substrate	10
3	by	substrate	10
4	employing	synthetic	9
5	a	synthetic	9
6	novel	synthetic	9
7	haptenized	lysis	8
8	lysis	synthetic	9
9	synthetic	by	3
10	substrate	we	21
11	which	allows	12
12	allows	substrate	10
13	the	isolation	14
14	isolation	allows	12
15	of	isolation	14
16	glutaminyl-tTG	substrates	17
17	substrates	of	15
18	in	allows	12
19	vivo	in	18
20	,	substrate	10
21	we	identified	22
22	identified	<ROOT>	-1
23	pRB	identified	22
24	as	identified	22
25	a	substrate	28
26	potential	substrate	28
27	tTG	substrate	28
28	substrate	as	24
29	in	U937	30
30	U937	identified	22
31	cells	identified	22
32	undergoing	identified	22
33	apoptosis	identified	22
34	.	identified	22

0	Allelic	variations	1
1	variations	<ROOT>	-1
2	of	variations	1
3	the	receptor	6
4	vitamin	receptor	6
5	D	receptor	6
6	receptor	of	2
7	(	VDR	8
8	VDR	receptor	6
9	)	VDR	8
10	gene	receptor	6
11	have	gene	10
12	been	have	11
13	associated	been	12
14	with	associated	13
15	the	risk	16
16	risk	with	14
17	of	risk	16
18	developing	of	17
19	prostate	cancer	20
20	cancer	developing	18
21	in	cancer	20
22	men	cancer	20
23	and	men	22
24	osteoporosis	and	23
25	in	men	22
26	postmenopausal	women	27
27	women	in	25
28	.	variations	1

0	Previous	<ROOT>	-1
1	data	Previous	0
2	are	consistent	3
3	consistent	data	1
4	with	consistent	3
5	a	with	4
6	model	a	5
7	that	model	6
8	LMP1	that	7
9	is	a	10
10	a	LMP1	8
11	constitutively	that	14
12	activated	that	14
13	receptor	that	14
14	that	a	10
15	transduces	a	10
16	signals	transduces	15
17	for	signals	16
18	transformation	for	17
19	through	for	17
20	its	through	19
21	carboxyl-terminal	its	20
22	cytoplasmic	tail	23
23	tail	through	19
24	.	Previous	0

0	Cells	<ROOT>	-1
1	in	Cells	0
2	the	series	4
3	B	series	4
4	series	in	1
5	with	Cells	0
6	4C	content	8
7	DNA	content	8
8	content	with	5
9	(	content	8
10	100B	(	9
11	and	100B	10
12	200B	differed	15
13	)	200B	12
14	also	differed	15
15	differed	and	11
16	from	differed	15
17	the	4C	20
18	A	4C	20
19	series	4C	20
20	4C	from	16
21	cells	by	22
22	by	100B	10
23	the	absence	24
24	absence	DNA	26
25	of	DNA	26
26	DNA	by	22
27	binding	(	9
28	by	(	9
29	the	Sp1	31
30	full-length	Sp1	31
31	Sp1	by	28
32	transcription	Sp1	31
33	factor	Sp1	31
34	.	Cells	0

0	None	<ROOT>	-1
1	of	None	0
2	these	the	5
3	polymorphisms	these	2
4	change	polymorphisms	3
5	the	of	1
6	translated	.	8
7	protein	.	8
8	.	the	5

0	Cells	were	4
1	with	Cells	0
2	nuclear	p50	3
3	p50	with	1
4	were	<ROOT>	-1
5	negative	were	4
6	for	were	4
7	the	CD38	8
8	CD38	for	6
9	,	were	4
10	CD20	and	11
11	and	were	4
12	CD2	and	11
13	markers	were	4
14	.	were	4

0	The	area	3
1	putative	area	3
2	promoter	area	3
3	area	is	4
4	is	<ROOT>	-1
5	similar	is	4
6	to	similar	5
7	those	to	6
8	of	those	7
9	several	genes	12
10	other	genes	12
11	myeloid-cell-specific	genes	12
12	genes	of	8
13	in	is	4
14	that	in	13
15	it	contains	16
16	contains	in	13
17	no	box	19
18	TATAAA	box	19
19	box	contains	16
20	but	in	13
21	has	but	20
22	a	number	23
23	number	has	21
24	of	number	23
25	purine-rich	stretches	26
26	stretches	of	24
27	with	stretches	26
28	multiple	sites	29
29	sites	with	27
30	for	sites	29
31	the	factors	32
32	factors	for	30
33	of	factors	32
34	the	family	36
35	Ets	family	36
36	family	of	33
37	of	transcriptional	38
38	transcriptional	family	36
39	regulators	has	21
40	.	is	4

0	Slight	differences	1
1	differences	<ROOT>	-1
2	in	differences	1
3	the	in	2
4	sequence	of	5
5	of	the	3
6	the	site	10
7	core	site	10
8	SRF	site	10
9	binding	site	10
10	site	of	5
11	compared	the	3
12	with	compared	11
13	that	with	12
14	of	that	13
15	the	element	21
16	classical	element	21
17	c-Fos	element	21
18	promoter	element	21
19	serum	element	21
20	response	element	21
21	element	of	14
22	,	differences	1
23	together	differences	1
24	with	differences	1
25	differences	with	24
26	in	differences	25
27	the	spacing	28
28	spacing	in	26
29	between	spacing	28
30	the	between	29
31	SRF	and	32
32	and	ETS	33
33	ETS	the	30
34	motifs	ETS	33
35	,	differences	1
36	appear	differences	1
37	to	appear	36
38	account	to	37
39	for	account	38
40	the	inability	41
41	inability	for	39
42	of	inability	41
43	the	of	42
44	SCMV	to	46
45	SNEs	to	46
46	to	the	43
47	respond	the	43
48	to	serum	49
49	serum	respond	47
50	induction	.	51
51	.	serum	49

0	The	domain	2
1	ligand-binding	domain	2
2	domain	<ROOT>	-1
3	(	domain	2
4	amino	(	3
5	acids	amino	4
6	528-777	acids	5
7	)	528-777	6
8	of	)	7
9	the	of	8
10	squirrel	the	9
11	monkey	acid	17
12	glucocorticoid	monkey	11
13	receptor	amino	16
14	contains	amino	16
15	four	contains	14
16	amino	glucocorticoid	12
17	acid	squirrel	10
18	differences	acid	17
19	(	differences	18
20	Ser551	(	19
21	to	Ser551	20
22	Thr	to	21
23	,	Ser551	20
24	Ser616	,	23
25	to	Ser616	24
26	Ala	to	25
27	,	Ser616	24
28	Ala618	,	27
29	to	Ala618	28
30	Ser	to	29
31	,	Ala618	28
32	and	Ala618	28
33	Ile761	and	32
34	to	Ile761	33
35	Leu	to	34
36	)	Leu	35
37	,	)	36
38	all	of	39
39	of	Ile761	33
40	which	of	39
41	are	which	40
42	present	Ile761	33
43	in	present	42
44	owl	in	43
45	monkey	and	46
46	and	owl	44
47	cotton-top	owl	44
48	tamarin	cotton-top	47
49	receptors	tamarin	48
50	.	receptors	49

0	However	account	7
1	,	account	7
2	none	account	7
3	of	none	2
4	these	regions	6
5	proximal	regions	6
6	regions	of	3
7	account	<ROOT>	-1
8	for	the	9
9	the	account	7
10	induction	of	11
11	of	alpha	13
12	IL-2R	alpha	13
13	alpha	the	9
14	transcription	account	7
15	by	transcription	14
16	IL-2	account	7
17	.	account	7

0	Pretreatment	<ROOT>	-1
1	with	Pretreatment	0
2	actinomycin	D	3
3	D	with	1
4	and	D	3
5	cycloheximide	Pretreatment	0
6	or	cycloheximide	5
7	with	Pretreatment	0
8	competing	Pretreatment	0
9	ds-oligonucleotides	Pretreatment	0
10	containing	ds-oligonucleotides	9
11	the	containing	10
12	nuclear	the	11
13	factor-kappa	B	14
14	B	nuclear	12
15	or	B	14
16	activator	the	11
17	protein-1	Pretreatment	0
18	cognate	Pretreatment	0
19	DNA	Pretreatment	0
20	sequences	Pretreatment	0
21	significantly	sequences	20
22	attenuated	Pretreatment	0
23	phase-2	response	24
24	response	Pretreatment	0
25	,	Pretreatment	0
26	suggesting	Pretreatment	0
27	a	suggesting	26
28	role	a	27
29	for	role	28
30	de	synthesis	33
31	novo	synthesis	33
32	macromolecule	synthesis	33
33	synthesis	for	29
34	.	synthesis	33

0	Thus	is	3
1	,	is	3
2	PPARgamma	is	3
3	is	<ROOT>	-1
4	present	is	3
5	in	present	4
6	macrophages	in	5
7	in	macrophages	6
8	human	lesions	10
9	atherosclerotic	lesions	10
10	lesions	in	7
11	and	is	3
12	may	and	11
13	regulate	may	12
14	expression	may	12
15	and	expression	14
16	activity	is	3
17	of	activity	16
18	MMP-9	is	3
19	,	is	3
20	an	,	19
21	enzyme	implicated	22
22	implicated	rupture	25
23	in	implicated	22
24	plaque	rupture	25
25	rupture	an	20
26	.	is	3

0	Low	capacity	2
1	proliferative	capacity	2
2	capacity	was	3
3	was	<ROOT>	-1
4	observed	was	3
5	after	observed	4
6	1	after	5
7	week	1	6
8	in	1	6
9	culture	the	11
10	in	the	11
11	the	in	8
12	presence	stem	14
13	of	stem	14
14	stem	the	11
15	cell	was	3
16	factor	ligand	22
17	(	SCF	18
18	SCF	ligand	22
19	)	SCF	18
20	+	ligand	22
21	Flt-3	+	20
22	ligand	was	3
23	(	FL	24
24	FL	ligand	22
25	)	FL	24
26	+	ligand	22
27	G-CSF	+	26
28	.	was	3

0	Ciprofloxacin	<ROOT>	-1
1	increased	Ciprofloxacin	0
2	CAT	in	4
3	activity	in	4
4	in	increased	1
5	stimulated	in	4
6	lymphocytes	stimulated	5
7	transfected	lymphocytes	6
8	with	transfected	7
9	plasmids	with	8
10	containing	plasmids	9
11	either	containing	10
12	the	either	11
13	IL-2	or	14
14	or	the	12
15	metallothionein	or	14
16	enhancer	metallothionein	15
17	.	Ciprofloxacin	0

0	Multiple	functionally	1
1	functionally	were	8
2	important	functionally	1
3	EBF	and	4
4	and	sites	7
5	E47	sites	7
6	binding	sites	7
7	sites	important	2
8	were	<ROOT>	-1
9	identified	were	8
10	in	identified	9
11	the	in	10
12	lambda5	the	11
13	promoter/enhancer	lambda5	12
14	region	promoter/enhancer	13
15	,	region	14
16	indicating	region	14
17	that	indicating	16
18	lambda5	is	19
19	is	that	17
20	a	target	23
21	direct	target	23
22	genetic	target	23
23	target	is	19
24	for	transcription	26
25	these	transcription	26
26	transcription	target	23
27	factors	transcription	26
28	.	were	8

0	The	product	3
1	ERG2	product	3
2	gene	product	3
3	product	has	4
4	has	<ROOT>	-1
5	been	has	4
6	identified	been	5
7	recently	identified	6
8	as	identified	6
9	the	target	11
10	molecular	target	11
11	target	as	8
12	of	SR	13
13	SR	target	11
14	31747A	has	4
15	that	has	4
16	mediates	antiproliferative	17
17	antiproliferative	has	4
18	effects	of	19
19	of	antiproliferative	17
20	the	drug	21
21	drug	antiproliferative	17
22	in	antiproliferative	17
23	yeast	in	22
24	.	has	4

0	Estrogen	and	1
1	and	<ROOT>	-1
2	progesterone	and	1
3	receptors	and	1
4	in	and	1
5	vernal	keratoconjunctivitis	6
6	keratoconjunctivitis	in	4
7	.	and	1

0	LEF-1	is	1
1	is	alpha	14
2	a	factor	4
3	transcription	factor	4
4	factor	is	1
5	that	factor	4
6	participates	that	5
7	in	the	8
8	the	participates	6
9	regulation	of	10
10	of	receptor	13
11	the	receptor	13
12	T-cell	receptor	13
13	receptor	the	8
14	alpha	TCR	16
15	(	TCR	16
16	TCR	<ROOT>	-1
17	alpha	)	18
18	)	TCR	16
19	enhancer	TCR	16
20	by	enhancer	19
21	facilitating	multiple	25
22	the	assembly	23
23	assembly	multiple	25
24	of	multiple	25
25	multiple	by	20
26	proteins	TCR	16
27	into	proteins	26
28	a	higher	29
29	higher	into	27
30	order	nucleoprotein	31
31	nucleoprotein	complex	32
32	complex	higher	29
33	.	complex	32

0	In	was	27
1	the	investigation	3
2	present	investigation	3
3	investigation	In	0
4	,	In	0
5	the	effect	6
6	effect	,	4
7	of	effect	6
8	ciprofloxacin	of	7
9	at	effect	6
10	supratherapeutic	concentrations	11
11	concentrations	at	9
12	on	effect	6
13	immediate-early	on	12
14	(	&lt;	15
15	&lt;	immediate-early	13
16	2	&lt;	15
17	h	gene	19
18	)	h	17
19	gene	2	16
20	expression	immediate-early	13
21	in	primary	22
22	primary	expression	20
23	human	effect	6
24	peripheral	effect	6
25	blood	effect	6
26	lymphocytes	In	0
27	was	<ROOT>	-1
28	studied	was	27
29	with	studied	28
30	Northern	with	29
31	blots	.	32
32	.	Northern	30

0	TF	activity	1
1	activity	generated	2
2	generated	<ROOT>	-1
3	by	generated	2
4	both	by	3
5	unstimulated	both	4
6	and	unstimulated	5
7	endotoxin-stimulated	and	6
8	cells	unstimulated	5
9	was	cells	8
10	significantly	higher	11
11	higher	was	9
12	in	transplant	13
13	transplant	was	9
14	recipients	transplant	13
15	than	recipients	14
16	in	than	15
17	control	in	16
18	subjects	control	17
19	(	generated	2
20	P	generated	2
21	&lt;	P	20
22	.05	)	23
23	)	&lt;	21
24	.	)	23

0	The	region	1
1	region	was	11
2	of	region	1
3	A-MYB	of	2
4	responsible	region	1
5	for	cell	8
6	the	cell	8
7	B	cell	8
8	cell	responsible	4
9	specific	cell	8
10	activity	region	1
11	was	<ROOT>	-1
12	defined	was	11
13	to	defined	12
14	be	to	13
15	the	be	14
16	N-terminal	containing	20
17	218	containing	20
18	amino	containing	20
19	acids	containing	20
20	containing	binding	23
21	the	binding	23
22	DNA	binding	23
23	binding	the	15
24	domain	was	11
25	.	was	11

0	Both	truncated	1
1	truncated	forms	2
2	forms	bound	4
3	also	bound	4
4	bound	<ROOT>	-1
5	to	bound	4
6	the	RBP-Jkappa	9
7	transcription	RBP-Jkappa	9
8	factor	transcription	7
9	RBP-Jkappa	to	5
10	in	RBP-Jkappa	9
11	extracts	in	10
12	prepared	murine	16
13	from	murine	16
14	human	murine	16
15	and	murine	16
16	murine	bound	4
17	T-ALL	bound	4
18	cell	bound	4
19	lines	bound	4
20	.	bound	4

0	The	development	1
1	development	will	6
2	of	development	1
3	improved	glucocorticoid-based	4
4	glucocorticoid-based	of	2
5	drugs	glucocorticoid-based	4
6	will	<ROOT>	-1
7	require	will	6
8	the	separation	9
9	separation	require	7
10	of	separation	9
11	beneficial	of	10
12	from	deleterious	13
13	deleterious	require	7
14	effects	will	6
15	.	will	6

0	We	<ROOT>	-1
1	have	We	0
2	selected	sequences	4
3	16	sequences	4
4	sequences	have	1
5	and	sequences	4
6	confirmed	and	5
7	their	down-regulation	8
8	down-regulation	confirmed	6
9	along	confirmed	6
10	the	along	9
11	TPA-induced	confirmed	6
12	monocytic	differentiation	13
13	differentiation	confirmed	6
14	of	HL60	15
15	HL60	differentiation	13
16	cells	We	0
17	.	We	0

0	Consequently	T	2
1	,	Consequently	0
2	T	spleen	7
3	lymphocytes	present	4
4	present	T	2
5	in	the	6
6	the	T	2
7	spleen	can	8
8	can	<ROOT>	-1
9	be	can	8
10	activated	be	9
11	normally	activated	10
12	in	be	9
13	response	in	12
14	to	response	13
15	either	stimulus	16
16	stimulus	mentioned	17
17	mentioned	to	14
18	above	mentioned	17
19	,	can	8
20	demonstrating	can	8
21	that	demonstrating	20
22	the	effects	23
23	effects	are	30
24	of	effects	23
25	the	inactive	26
26	inactive	of	24
27	CaMKIV	inactive	26
28	on	inactive	26
29	activation	on	28
30	are	that	21
31	reversible	are	30
32	.	can	8

0	Antibodies	were	4
1	recognizing	Antibodies	0
2	double-stranded	DNA	3
3	DNA	recognizing	1
4	were	<ROOT>	-1
5	confined	were	4
6	to	confined	5
7	patients	polyomavirus	10
8	with	polyomavirus	10
9	frequent	polyomavirus	10
10	polyomavirus	to	6
11	reactivations	were	4
12	.	were	4

0	Expression	appears	3
1	of	Expression	0
2	DR3	of	1
3	appears	<ROOT>	-1
4	to	appears	3
5	be	to	4
6	restricted	be	5
7	to	restricted	6
8	tissues	enriched	9
9	enriched	to	7
10	in	enriched	9
11	lymphocytes	appears	3
12	.	appears	3

0	The	<ROOT>	-1
1	gene	of	3
2	consists	of	3
3	of	The	0
4	at	of	3
5	least	exons	7
6	three	exons	7
7	exons	of	3
8	and	of	3
9	spans	of	3
10	more	5.6	12
11	than	5.6	12
12	5.6	kb	13
13	kb	spans	9
14	of	kb	13
15	DNA	of	14
16	.	The	0

0	Chicken	factor	3
1	NF-M	factor	3
2	transcription	factor	3
3	factor	is	13
4	,	factor	3
5	in	factor	3
6	cooperation	in	5
7	with	cooperation	6
8	either	c-Myb	9
9	c-Myb	with	7
10	or	c-Myb	9
11	v-Myb	c-Myb	9
12	,	is	13
13	is	<ROOT>	-1
14	active	is	13
15	in	is	13
16	the	in	15
17	combinatorial	the	16
18	activation	combinatorial	17
19	of	activation	18
20	myeloid-cell-specific	genes	21
21	genes	of	19
22	in	of	19
23	heterologous	types	25
24	cell	types	25
25	types	in	22
26	,	combinatorial	17
27	such	as	28
28	as	combinatorial	17
29	embryonic	fibroblasts	30
30	fibroblasts	as	28
31	.	is	13

0	The	CIITA	4
1	class	CIITA	4
2	II	CIITA	4
3	trans-activator	CIITA	4
4	CIITA	interacts	5
5	interacts	<ROOT>	-1
6	with	interacts	5
7	the	with	6
8	TBP-associated	factor	9
9	factor	the	7
10	TAFII32	the	7
11	.	TAFII32	10

0	The	mechanisms	1
1	mechanisms	are	12
2	that	control	3
3	control	mechanisms	1
4	the	induction	6
5	initial	induction	6
6	induction	control	3
7	of	induction	6
8	these	of	7
9	signals	mechanisms	1
10	upon	signals	9
11	infection	mechanisms	1
12	are	<ROOT>	-1
13	poorly	understood	14
14	understood	are	12
15	.	are	12

0	PPARgamma	is	1
1	is	<ROOT>	-1
2	likely	is	1
3	to	likely	2
4	be	to	3
5	an	regulator	7
6	important	regulator	7
7	regulator	be	4
8	of	regulator	7
9	monocyte/macrophage	function	10
10	function	of	8
11	with	function	10
12	relevance	with	11
13	for	relevance	12
14	human	disease	16
15	atherosclerotic	disease	16
16	disease	for	13
17	.	is	1

0	Quantitative	reverse	1
1	reverse	reaction	4
2	transcriptase-polymerase	reaction	4
3	chain	reaction	4
4	reaction	showed	8
5	(	RT-PCR	6
6	RT-PCR	reaction	4
7	)	RT-PCR	6
8	showed	<ROOT>	-1
9	an	increase	10
10	increase	showed	8
11	in	increase	10
12	steady-state	mRNA	14
13	TNF-alpha	mRNA	14
14	mRNA	in	11
15	after	showed	8
16	3	hours	19
17	to	3	16
18	4	to	17
19	hours	after	15
20	of	hours	19
21	cross-linking	of	20
22	.	showed	8

0	Differentiation	<ROOT>	-1
1	of	Differentiation	0
2	T-helper	lymphocytes	3
3	lymphocytes	of	1
4	:	Differentiation	0
5	selective	regulation	6
6	regulation	Differentiation	0
7	by	regulation	6
8	members	by	7
9	of	members	8
10	the	family	12
11	STAT	family	12
12	family	of	9
13	of	family	12
14	transcription	factors	15
15	factors	of	13
16	.	Differentiation	0

0	TRAF1	bind	6
1	,	TRAF1	0
2	TRAF2	TRAF1	0
3	,	TRAF1	0
4	and	TRAF1	0
5	TRAF3	and	4
6	bind	is	30
7	to	bind	6
8	a	site	10
9	single	site	10
10	site	to	7
11	in	site	10
12	the	in	11
13	LMP1	the	12
14	CT	corresponding	15
15	corresponding	(	19
16	to	corresponding	15
17	amino	acids	18
18	acids	corresponding	15
19	(	LMP1	13
20	aa	(	19
21	)	(	19
22	199	(	19
23	to	199	22
24	214	to	23
25	,	199	22
26	within	a	27
27	a	199	22
28	domain	which	29
29	which	a	27
30	is	<ROOT>	-1
31	important	is	30
32	for	important	31
33	B-lymphocyte	for	32
34	growth	B-lymphocyte	33
35	transformation	growth	34
36	(	187	38
37	aa	(	36
38	187	transformation	35
39	to	187	38
40	231	)	41
41	)	to	39
42	.	)	41

0	CD40	leads	13
1	,	CD40	0
2	but	CD40	0
3	not	but	2
4	lipopolysaccharide	not	3
5	and	not	3
6	anti-IgM	and	5
7	stimulation	not	3
8	of	B	10
9	primary	B	10
10	B	stimulation	7
11	lymphocytes	CD40	0
12	,	CD40	0
13	leads	<ROOT>	-1
14	to	leads	13
15	a	accumulation	18
16	persistent	accumulation	18
17	nuclear	accumulation	18
18	accumulation	to	14
19	of	accumulation	18
20	RelB	of	19
21	.	leads	13

0	These	included	1
1	included	<ROOT>	-1
2	both	p50/p50	3
3	p50/p50	included	1
4	and	p50/p50	3
5	p50/p65	dimers	6
6	dimers	and	4
7	,	p50/p50	3
8	recognized	specific	10
9	by	specific	10
10	specific	p50/p50	3
11	antibodies	included	1
12	in	included	1
13	EMSA	in	12
14	.	included	1

0	Transcription	<ROOT>	-1
1	factor	Transcription	0
2	Egr-1	activity	3
3	activity	factor	1
4	down-regulates	activity	3
5	Fas	Transcription	0
6	and	Transcription	0
7	CD23	and	6
8	expression	CD23	7
9	in	Transcription	0
10	B	cells	11
11	cells	in	9
12	.	Transcription	0

0	beta	2-m	1
1	2-m	increased	2
2	increased	<ROOT>	-1
3	the	binding	4
4	binding	increased	2
5	to	HLA-A3	7
6	the	HLA-A3	7
7	HLA-A3	increased	2
8	molecule	increased	2
9	but	increased	2
10	did	but	9
11	not	did	10
12	influence	did	10
13	the	binding	14
14	binding	influence	12
15	to	binding	14
16	the	HLA-Cw*0702	17
17	HLA-Cw*0702	to	15
18	.	increased	2

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	underlying	aberrancies	5
5	aberrancies	that	3
6	in	the	7
7	the	aberrancies	5
8	induction	the	7
9	of	induction	8
10	c-fos/c-jun	of	9
11	as	induction	8
12	well	the	7
13	as	the	7
14	their	regulatory	16
15	nuclear	regulatory	16
16	regulatory	as	13
17	proteins	regulatory	16
18	may	contribute	19
19	contribute	regulatory	16
20	to	contribute	19
21	the	age-related	22
22	age-related	to	20
23	impairments	to	20
24	of	AP-1	25
25	AP-1	impairments	23
26	activation	suggest	2
27	in	human	28
28	human	suggest	2
29	T	cells	30
30	cells	human	28
31	.	cells	30

0	Both	forms	1
1	forms	lacks	8
2	have	forms	1
3	DNA-binding	domain	4
4	domain	have	2
5	,	forms	1
6	but	forms	1
7	AML1a	but	6
8	lacks	activation	12
9	a	putative	10
10	putative	activation	12
11	transcriptional	activation	12
12	activation	<ROOT>	-1
13	domain	activation	12
14	which	has	16
15	AML1b	has	16
16	has	domain	13
17	.	activation	12

0	NF-kappa	activation	2
1	B	activation	2
2	activation	involves	3
3	involves	<ROOT>	-1
4	signaled	involves	3
5	phosphorylation	signaled	4
6	,	signaled	4
7	ubiquitination	signaled	4
8	,	ubiquitination	7
9	and	ubiquitination	7
10	proteolysis	and	9
11	of	ubiquitination	7
12	I	of	11
13	kappa	B	14
14	B	of	11
15	.	involves	3

0	We	propose	1
1	propose	<ROOT>	-1
2	that	functions	4
3	BEAD-1	functions	4
4	functions	propose	1
5	as	functions	4
6	a	boundary	7
7	boundary	as	5
8	that	separates	9
9	separates	boundary	7
10	the	TCR	11
11	TCR	separates	9
12	alpha/delta	separates	9
13	locus	distinct	15
14	into	distinct	15
15	distinct	alpha/delta	12
16	regulatory	distinct	15
17	domains	regulatory	16
18	controlled	domains	17
19	by	controlled	18
20	Edelta	by	19
21	and	TCR	23
22	the	TCR	23
23	TCR	Edelta	20
24	alpha	enhancer	25
25	enhancer	propose	1
26	,	enhancer	25
27	and	,	26
28	that	and	27
29	it	prevents	30
30	prevents	that	28
31	Edelta	prevents	30
32	from	Edelta	31
33	opening	from	32
34	the	opening	33
35	chromatin	the	34
36	of	TCR	38
37	the	TCR	38
38	TCR	chromatin	35
39	alpha	propose	1
40	joining	propose	1
41	gene	propose	1
42	segments	propose	1
43	for	propose	1
44	VDJ	recombination	45
45	recombination	for	43
46	at	propose	1
47	an	at	46
48	early	of	50
49	stage	of	50
50	of	cell	52
51	T	cell	52
52	cell	an	47
53	development	propose	1
54	.	propose	1

0	We	report	1
1	report	<ROOT>	-1
2	that	Rel	6
3	certain	NF-AT	4
4	NF-AT	(	5
5	(	that	2
6	Rel	report	1
7	)	Rel	6
8	family	bind	11
9	members	bind	11
10	productively	bind	11
11	bind	report	1
12	the	elements	15
13	kappaB	elements	15
14	regulatory	elements	15
15	elements	bind	11
16	,	report	1
17	synergize	report	1
18	with	report	1
19	NF-kappaB	report	1
20	and	NF-kappaB	19
21	Tat	NF-kappaB	19
22	in	report	1
23	transcriptional	report	1
24	activation	report	1
25	of	activation	24
26	HIV-1	of	25
27	,	report	1
28	and	report	1
29	enhance	and	28
30	HIV-1	replication	31
31	replication	enhance	29
32	in	T	33
33	T	enhance	29
34	cells	report	1
35	.	report	1

0	We	report	1
1	report	genomic	10
2	here	report	1
3	the	cloning	4
4	cloning	report	1
5	of	cloning	4
6	p27Kip1	gene	7
7	gene	of	5
8	from	murine	9
9	murine	report	1
10	genomic	<ROOT>	-1
11	DNA	genomic	10
12	and	genomic	10
13	the	analysis	15
14	functional	analysis	15
15	analysis	and	12
16	of	analysis	15
17	the	promoter	18
18	promoter	of	16
19	of	promoter	18
20	the	gene	22
21	p27Kip1	gene	22
22	gene	of	19
23	.	genomic	10

0	Likewise	did	28
1	,	Likewise	0
2	the	level	3
3	level	,	1
4	of	level	3
5	expression	of	4
6	of	erythroid	8
7	the	erythroid	8
8	erythroid	of	4
9	transcription	erythroid	8
10	factors	transcription	9
11	GATA-1	Likewise	0
12	,	Likewise	0
13	GATA-2	,	12
14	,	GATA-2	13
15	NF-E2	,	14
16	,	NF-E2	15
17	SCL	NF-E2	15
18	and	SCL	17
19	RBTN2	Likewise	0
20	,	Likewise	0
21	all	Likewise	0
22	expressed	Likewise	0
23	in	K562	25
24	untreated	K562	25
25	K562	expressed	22
26	cells	Likewise	0
27	,	did	28
28	did	<ROOT>	-1
29	not	did	28
30	increase	did	28
31	during	increase	30
32	sodium	phenylacetate	33
33	phenylacetate	induced	34
34	induced	during	31
35	erythroid	differentiation	36
36	differentiation	induced	34
37	.	did	28

0	Currently	available	1
1	available	data	2
2	data	indicate	3
3	indicate	pathways	9
4	that	erythroid	5
5	erythroid	pathways	9
6	and	erythroid	5
7	megakaryocytic	pathways	9
8	differentiation	pathways	9
9	pathways	are	10
10	are	may	28
11	closely	are	10
12	related	are	10
13	to	related	12
14	each	other	15
15	other	to	13
16	,	are	10
17	and	are	10
18	there	may	19
19	may	and	17
20	exist	progenitor	21
21	progenitor	may	19
22	cells	common	23
23	common	are	10
24	to	are	10
25	those	lineages	27
26	two	lineages	27
27	lineages	to	24
28	may	<ROOT>	-1
29	exist	may	28
30	.	may	28

0	Glucocorticoid	responsiveness	1
1	responsiveness	was	4
2	of	responsiveness	1
3	HML	of	2
4	was	<ROOT>	-1
5	evaluated	was	4
6	as	evaluated	5
7	IC50	as	6
8	values	nmol/L	10
9	(	nmol/L	10
10	nmol/L	IC50	7
11	)	IC50	7
12	for	evaluated	5
13	dexamethasone	for	12
14	and	evaluated	5
15	cortisol	and	14
16	for	and	14
17	the	inhibition	18
18	inhibition	for	16
19	of	inhibition	18
20	lysozyme	release	21
21	release	of	19
22	.	was	4

0	From	has	21
1	analyses	From	0
2	of	analyses	1
3	mice	deficient	4
4	deficient	transcription	6
5	in	deficient	4
6	transcription	of	2
7	factor	From	0
8	genes	From	0
9	and	From	0
10	from	From	0
11	the	characterizations	12
12	characterizations	from	10
13	of	characterizations	12
14	chromosome	of	13
15	breakpoints	chromosome	14
16	in	breakpoints	15
17	human	leukemias	18
18	leukemias	breakpoints	15
19	,	has	21
20	it	has	21
21	has	<ROOT>	-1
22	become	has	21
23	evident	become	22
24	that	become	22
25	transcription	factors	26
26	factors	are	27
27	are	that	24
28	important	are	27
29	regulators	important	28
30	of	regulators	29
31	hematopoiesis	of	30
32	.	hematopoiesis	31

0	Differential	interaction	1
1	interaction	<ROOT>	-1
2	of	interaction	1
3	nuclear	factors	4
4	factors	of	2
5	with	factors	4
6	the	promoter	9
7	leukocyte-specific	promoter	9
8	pp52	promoter	9
9	promoter	factors	4
10	in	promoter	9
11	B	in	10
12	and	T	13
13	T	B	11
14	cells	interaction	1
15	.	interaction	1

0	Differanisole	A	1
1	A	inhibited	10
2	and	A	1
3	9-cis	(	6
4	retinoic	(	6
5	acid	(	6
6	(	and	2
7	9cisRA	A	1
8	)	A	1
9	synergistically	inhibited	10
10	inhibited	<ROOT>	-1
11	the	growth	12
12	growth	inhibited	10
13	and	growth	12
14	induced	functional	15
15	functional	and	16
16	and	and	13
17	morphologic	differentiation	18
18	differentiation	and	16
19	of	differentiation	18
20	HL-60	of	19
21	and	of	19
22	NB4	and	16
23	cells	inhibited	10
24	,	inhibited	10
25	whereas	inhibited	10
26	the	treatment	28
27	combined	treatment	28
28	treatment	whereas	25
29	with	treatment	28
30	differanisole	A	31
31	A	with	29
32	and	A	31
33	all-trans	acid	35
34	retinoic	acid	35
35	acid	1alpha,25-dihydroxyvitamin	37
36	or	1alpha,25-dihydroxyvitamin	37
37	1alpha,25-dihydroxyvitamin	D3	38
38	D3	was	39
39	was	and	32
40	less	effective	41
41	effective	was	39
42	.	inhibited	10

0	Association	<ROOT>	-1
1	of	Association	0
2	glucocorticoid	insensitivity	3
3	insensitivity	of	1
4	with	insensitivity	3
5	increased	with	4
6	expression	of	7
7	of	glucocorticoid	8
8	glucocorticoid	receptor	9
9	receptor	increased	5
10	beta	increased	5
11	.	Association	0

0	Serum	ACTH	1
1	ACTH	were	20
2	and	ACTH	1
3	IgE	and	2
4	were	IgE	3
5	measured	IgE	3
6	by	measured	5
7	immunoradiometric	by	6
8	assay	,	9
9	,	immunoradiometric	7
10	and	,	9
11	IL-2	and	10
12	,	measured	5
13	IL-4	ACTH	1
14	,	ACTH	1
15	and	ACTH	1
16	IL-10	ACTH	1
17	cytokines	ACTH	1
18	and	ACTH	1
19	interferon-gamma	and	18
20	were	<ROOT>	-1
21	measured	were	20
22	by	measured	21
23	enzyme-linked	immunosorbent	24
24	immunosorbent	by	22
25	assay	immunosorbent	24
26	.	were	20

0	To	was	17
1	test	To	0
2	this	hypothesis	3
3	hypothesis	test	1
4	,	was	17
5	a	was	17
6	more	sensitive	7
7	sensitive	was	17
8	and	sensitive	7
9	specific	assay	16
10	polymerase	reaction	12
11	chain	reaction	12
12	reaction	assay	16
13	(	PCR	14
14	PCR	reaction	12
15	)	PCR	14
16	assay	and	8
17	was	<ROOT>	-1
18	developed	was	17
19	to	developed	18
20	detect	to	19
21	adenovirus	detect	20
22	DNA	.	23
23	.	adenovirus	21

0	The	protein	1
1	protein	<ROOT>	-1
2	from	converted	6
3	E.	coli	4
4	coli	converted	6
5	specifically	converted	6
6	converted	protein	1
7	dUTP	protein	1
8	to	dUTP	7
9	dUMP	to	8
10	and	dUMP	9
11	did	and	10
12	not	did	11
13	react	did	11
14	with	react	13
15	other	dNTPs	16
16	dNTPs	with	14
17	or	dNTPs	16
18	NTPs	or	17
19	.	protein	1

0	Taken	increased	4
1	together	Taken	0
2	,	increased	4
3	ciprofloxacin	increased	4
4	increased	promoter	15
5	the	increased	4
6	levels	the	5
7	of	levels	6
8	immediate-early	transcripts	9
9	transcripts	levels	6
10	,	increased	4
11	enhanced	increased	4
12	IL-2	enhanced	11
13	and	enhanced	11
14	metallothionein	increased	4
15	promoter	<ROOT>	-1
16	induction	promoter	15
17	,	induction	16
18	and	,	17
19	upregulated	concentrations	21
20	AP-1	concentrations	21
21	concentrations	and	18
22	in	primary	23
23	primary	and	18
24	lymphocytes	promoter	15
25	,	promoter	15
26	reflecting	promoter	15
27	a	program	28
28	program	reflecting	26
29	commonly	observed	30
30	observed	program	28
31	in	observed	30
32	mammalian	in	31
33	stress	promoter	15
34	responses	promoter	15
35	.	promoter	15

0	The	inhibition	1
1	inhibition	<ROOT>	-1
2	of	inhibition	1
3	apoptosis	of	2
4	by	inhibition	1
5	curcumin	by	4
6	in	curcumin	5
7	rat	curcumin	5
8	thymocytes	was	9
9	was	rat	7
10	accompanied	curcumin	5
11	by	accompanied	10
12	partial	by	11
13	suppression	of	14
14	of	partial	12
15	AP-1	of	14
16	activity	inhibition	1
17	.	inhibition	1

0	Here	report	2
1	we	report	2
2	report	<ROOT>	-1
3	that	report	2
4	tepoxalin	inhibits	6
5	selectively	inhibits	6
6	inhibits	that	3
7	intercellular	molecule-1	9
8	adhesion	molecule-1	9
9	molecule-1	inhibits	6
10	(	molecule-1	9
11	ICAM-1	,	12
12	,	molecule-1	9
13	CD54	,	12
14	)	(	16
15	/MAC-1	)	14
16	(	,	12
17	CD11b/CD18	(	16
18	)	(	16
19	dependent	adhesion	20
20	adhesion	)	18
21	of	,	12
22	polymorphonuclear	molecule-1	9
23	cells	report	2
24	to	report	2
25	IL-1	activated	26
26	activated	to	24
27	human	activated	26
28	umbilical	cells	31
29	vein	cells	31
30	endothelial	cells	31
31	cells	human	27
32	.	cells	31

0	OBJECTIVE	<ROOT>	-1
1	:	OBJECTIVE	0
2	To	OBJECTIVE	0
3	investigate	To	2
4	the	association	5
5	association	investigate	3
6	in	reduction	7
7	reduction	association	5
8	of	reduction	7
9	symptoms	of	8
10	due	reduction	7
11	to	due	10
12	glucocorticoids	due	10
13	and	glucocorticoids	12
14	glucocorticoid	receptor	15
15	receptor	and	13
16	characteristics	glucocorticoids	12
17	in	glucocorticoids	12
18	patients	in	17
19	with	receptor	27
20	perennial	receptor	27
21	allergic	rhinitis	22
22	rhinitis	perennial	20
23	,	rhinitis	22
24	in	vitro	25
25	vitro	glucocorticoid	26
26	glucocorticoid	rhinitis	22
27	receptor	patients	18
28	binding	peripheral	33
29	studies	peripheral	33
30	were	peripheral	33
31	performed	peripheral	33
32	with	peripheral	33
33	peripheral	blood	34
34	blood	OBJECTIVE	0
35	mononuclear	OBJECTIVE	0
36	cells	OBJECTIVE	0
37	using	OBJECTIVE	0
38	dexamethasone	OBJECTIVE	0
39	and	OBJECTIVE	0
40	in	OBJECTIVE	0
41	vitro	OBJECTIVE	0
42	production	of	43
43	of	OBJECTIVE	0
44	mediators	of	43
45	were	of	43
46	measured	were	45
47	.	measured	46

0	Cotransfection	substituted	9
1	of	Cotransfection	0
2	a	form	5
3	constitutively	active	4
4	active	form	5
5	form	of	1
6	of	form	5
7	calcineurin	of	6
8	largely	substituted	9
9	substituted	<ROOT>	-1
10	for	substituted	9
11	the	requirement	13
12	Ca2+	requirement	13
13	requirement	for	10
14	and	requirement	13
15	reversed	and	14
16	the	blockade	17
17	blockade	reversed	15
18	by	reversed	15
19	SK&amp;F	96365	20
20	96365	by	18
21	.	substituted	9

0	To	sequences	20
1	examine	To	0
2	transcriptional	regulation	3
3	regulation	cytokine	5
4	of	cytokine	5
5	cytokine	examine	1
6	genes	To	0
7	by	To	0
8	CD15	engagement	9
9	engagement	by	7
10	,	reporter	14
11	a	reporter	14
12	CAT	reporter	14
13	plasmid	reporter	14
14	reporter	To	0
15	construct	containing	16
16	containing	beta	18
17	IL-1	containing	16
18	beta	To	0
19	promoter/enhancer	To	0
20	sequences	was	21
21	was	<ROOT>	-1
22	introduced	was	21
23	into	introduced	22
24	MM6	into	23
25	.	was	21

0	It	was	1
1	was	<ROOT>	-1
2	matched	was	1
3	by	matched	2
4	an	correlation	6
5	inverse	correlation	6
6	correlation	by	3
7	between	correlation	6
8	lymphocyte	infiltration	9
9	infiltration	between	7
10	and	infiltration	9
11	blood-thyroid	concentration	13
12	hormone	concentration	13
13	concentration	and	10
14	,	was	1
15	urine	catecholamines	16
16	catecholamines	free	18
17	and	free	18
18	free	was	1
19	cortisol	body	23
20	excretion	and	21
21	and	cortisol	19
22	fat/lean	body	23
23	body	ratio	25
24	mass	ratio	25
25	ratio	free	18
26	.	was	1

0	The	<ROOT>	-1
1	ferritin	The	0
2	H-chain	was	6
3	gene	was	6
4	promoter	was	6
5	regulation	was	6
6	was	ferritin	1
7	analyzed	The	0
8	in	analyzed	7
9	heme-treated	in	8
10	Friend	heme-treated	9
11	leukemia	(	13
12	cells	(	13
13	(	Friend	10
14	FLCs	in	8
15	)	in	8
16	and	during	17
17	during	in	8
18	monocyte-to-macrophage	in	8
19	differentiation	The	0
20	.	The	0

0	To	<ROOT>	-1
1	assess	To	0
2	whether	assess	1
3	this	inhibition	4
4	inhibition	was	5
5	was	whether	2
6	mediated	via	7
7	via	was	5
8	modulation	via	7
9	of	modulation	8
10	the	factor	13
11	cellular	factor	13
12	transcription	factor	13
13	factor	of	9
14	,	via	7
15	NF-kappa	via	7
16	B	To	0
17	,	To	0
18	we	,	17
19	carried	we	18
20	out	carried	19
21	gel	on	24
22	shift	on	24
23	analysis	on	24
24	on	out	20
25	nuclear	out	20
26	extracts	nuclear	25
27	prepared	extracts	26
28	under	prepared	27
29	different	conditions	30
30	conditions	under	28
31	of	cell	32
32	cell	conditions	30
33	stimulation	carried	19
34	in	the	35
35	the	stimulation	33
36	presence	or	37
37	or	the	35
38	absence	the	35
39	of	absence	38
40	ascorbate	of	39
41	,	To	0
42	N-acetylcysteine	(	43
43	(	To	0
44	NAC	(	43
45	)	To	0
46	,	To	0
47	or	To	0
48	zidovudine	or	47
49	(	zidovudine	48
50	AZT	)	51
51	)	(	49
52	.	)	51

0	Our	data	1
1	data	<ROOT>	-1
2	also	data	1
3	suggest	that	4
4	that	also	2
5	,	data	1
6	unlike	I	7
7	I	,	5
8	kappa	I	7
9	B	alpha	10
10	alpha	I	7
11	,	I	7
12	I	B	14
13	kappa	I	12
14	B	,	11
15	beta	,	11
16	is	constitutively	17
17	constitutively	beta	15
18	phosphorylated	constitutively	17
19	and	phosphorylated	18
20	resynthesized	and	19
21	as	constitutively	17
22	a	form	24
23	hypophosphorylated	form	24
24	form	as	21
25	.	data	1

0	SAC	exhibited	2
1	consistently	exhibited	2
2	exhibited	<ROOT>	-1
3	a	inhibition	5
4	dose-dependent	inhibition	5
5	inhibition	exhibited	2
6	of	NF-kappa	7
7	NF-kappa	inhibition	5
8	B	exhibited	2
9	activation	by	11
10	induced	by	11
11	by	exhibited	2
12	both	exhibited	2
13	TNF-alpha	exhibited	2
14	and	exhibited	2
15	H2O2	exhibited	2
16	.	exhibited	2

0	Neither	FMLP	1
1	FMLP	activated	4
2	nor	FMLP	1
3	PAF	nor	2
4	activated	<ROOT>	-1
5	c-jun	activated	4
6	NH2-terminal	(	8
7	MAPk	(	8
8	(	activated	4
9	JNKs	)	10
10	)	activated	4
11	.	)	10

0	We	created	2
1	therefore	created	2
2	created	<ROOT>	-1
3	and	line	8
4	studied	line	8
5	a	studied	4
6	T	line	8
7	cell	line	8
8	line	created	2
9	expressing	(	14
10	the	receptor	13
11	cloned	receptor	13
12	delta-opioid	receptor	13
13	receptor	expressing	9
14	(	line	8
15	DOR1	(	14
16	)	(	14
17	.	created	2

0	However	proved	9
1	,	proved	9
2	the	responsiveness	4
3	TPA	responsiveness	4
4	responsiveness	proved	9
5	of	responsiveness	4
6	both	elements	8
7	CMV	elements	8
8	elements	of	5
9	proved	<ROOT>	-1
10	to	proved	9
11	involve	to	10
12	synergistic	interactions	13
13	interactions	involve	11
14	between	interactions	13
15	the	site	19
16	core	site	19
17	SRF	site	19
18	binding	site	19
19	site	between	14
20	(	CCATATATGG	21
21	CCATATATGG	proved	9
22	)	CCATATATGG	21
23	and	binding	28
24	the	binding	28
25	adjacent	binding	28
26	inverted	binding	28
27	ETS	binding	28
28	binding	proved	9
29	motifs	(	30
30	(	proved	9
31	TTCC	proved	9
32	)	,	33
33	,	which	34
34	which	TTCC	31
35	correlated	which	34
36	directly	which	34
37	with	directly	36
38	formation	with	37
39	of	formation	38
40	a	of	39
41	bound	tripartite	42
42	tripartite	complex	43
43	complex	a	40
44	containing	complex	43
45	both	containing	44
46	the	both	45
47	cellular	ELK-1	50
48	SRF	and	49
49	and	cellular	47
50	ELK-1	the	46
51	proteins	proved	9
52	.	proved	9

0	Selective	expression	1
1	expression	<ROOT>	-1
2	of	expression	1
3	an	component	6
4	interleukin-12	component	6
5	receptor	component	6
6	component	of	2
7	by	human	8
8	human	expression	1
9	T	helper	10
10	helper	human	8
11	1	human	8
12	cells	expression	1
13	.	expression	1

0	Dose-dependence	studies	1
1	studies	showed	6
2	using	studies	1
3	histamine	using	2
4	and	histamine	3
5	dimaprit	and	4
6	showed	<ROOT>	-1
7	that	showed	6
8	the	values	10
9	EC50	values	10
10	values	increase	16
11	for	cAMP	12
12	cAMP	values	10
13	production	cAMP	12
14	and	values	10
15	c-fos	and	14
16	increase	similar	18
17	were	increase	16
18	similar	that	7
19	,	similar	18
20	suggesting	that	21
21	that	similar	18
22	cAMP	might	23
23	might	that	21
24	be	might	23
25	involved	be	24
26	in	c-fos	27
27	c-fos	involved	25
28	induction	involved	25
29	via	H2	30
30	H2	be	24
31	receptors	showed	6
32	.	showed	6

0	Phorbol	<ROOT>	-1
1	ester	Phorbol	0
2	treatment	ester	1
3	of	cell	6
4	a	cell	6
5	pre-B	cell	6
6	cell	treatment	2
7	line	Phorbol	0
8	up-regulated	Phorbol	0
9	CD19	expression	10
10	expression	Phorbol	0
11	,	Phorbol	0
12	induced	Phorbol	0
13	Egr-1	Phorbol	0
14	,	Phorbol	0
15	and	Phorbol	0
16	enhanced	and	15
17	the	enhanced	16
18	footprint	the	17
19	over	footprint	18
20	the	box	22
21	GC	box	22
22	box	over	19
23	.	box	22

0	Tepoxalin	inhibited	2
1	also	inhibited	2
2	inhibited	<ROOT>	-1
3	the	secretion	4
4	secretion	inhibited	2
5	of	secretion	4
6	a	B	8
7	NF-kappa	B	8
8	B	chemokine	10
9	regulated	chemokine	10
10	chemokine	of	5
11	,	inhibited	2
12	IL-8	inhibited	2
13	,	IL-8	12
14	a	IL-8	12
15	known	a	14
16	inducer	of	17
17	of	known	15
18	CD11b/CD18	of	17
19	expression	.	20
20	.	CD11b/CD18	18

0	The	translocated	1
1	translocated	gene	3
2	PAX-5	gene	3
3	gene	is	4
4	is	<ROOT>	-1
5	deregulated	is	4
6	by	deregulated	5
7	the	insertion	8
8	insertion	by	6
9	of	insertion	8
10	IgH	elements	12
11	regulatory	elements	12
12	elements	of	9
13	into	insertion	8
14	its	region	16
15	5'	region	16
16	region	into	13
17	,	which	18
18	which	region	16
19	may	contribute	20
20	contribute	deregulated	5
21	to	contribute	20
22	tumorigenesis	to	21
23	by	tumorigenesis	22
24	interfering	to	21
25	with	interfering	24
26	the	shut-down	27
27	shut-down	with	25
28	of	shut-down	27
29	PAX-5	transcription	30
30	transcription	of	28
31	and	transcription	30
32	thus	and	31
33	with	thus	32
34	the	completion	35
35	completion	plasma	37
36	of	plasma	37
37	plasma	with	33
38	cell	plasma	37
39	differentiation	cell	38
40	.	differentiation	39

0	Mutational	removal	1
1	removal	phosphorylation	5
2	of	phosphorylation	5
3	the	phosphorylation	5
4	JNK	phosphorylation	5
5	phosphorylation	caused	7
6	sites	phosphorylation	5
7	caused	<ROOT>	-1
8	constitutive	localization	10
9	nuclear	localization	10
10	localization	caused	7
11	of	localization	10
12	NFAT4	of	11
13	.	caused	7

0	Isolated	T	2
1	thymic	T	2
2	T	show	9
3	cells	from	4
4	from	T	2
5	the	T	2
6	transgenic	T	2
7	mice	show	9
8	also	show	9
9	show	<ROOT>	-1
10	a	rate	14
11	dramatically	decreased	12
12	decreased	rate	14
13	survival	rate	14
14	rate	show	9
15	when	evaluated	16
16	evaluated	rate	14
17	in	evaluated	16
18	culture	in	17
19	under	culture	18
20	conditions	under	19
21	that	do	22
22	do	conditions	20
23	not	do	22
24	favor	do	22
25	activation	favor	24
26	.	activation	25

0	In	rescues	17
1	both	types	3
2	cell	types	3
3	types	In	0
4	,	In	0
5	the	cytokine	6
6	cytokine	,	4
7	that	inhibits	8
8	inhibits	cytokine	6
9	the	induction	10
10	induction	inhibits	8
11	of	induction	10
12	IkappaBalpha	of	11
13	by	inhibits	8
14	DEX	In	0
15	,	rescues	17
16	also	rescues	17
17	rescues	<ROOT>	-1
18	these	rescues	17
19	cells	from	20
20	from	these	18
21	DEX-induced	from	20
22	apoptosis	,	23
23	,	DEX-induced	21
24	although	rescues	17
25	the	rescues	17
26	rescue	the	25
27	cytokine	rescue	26
28	is	cytokine	27
29	different	is	28
30	in	different	29
31	Th1	in	30
32	and	Th2	33
33	Th2	Th1	31
34	cells	rescues	17
35	.	rescues	17

0	Confirmation	provides	10
1	of	Confirmation	0
2	the	significance	4
3	unique	significance	4
4	significance	of	1
5	of	significance	4
6	zinc	of	5
7	for	Confirmation	0
8	immune	function	9
9	function	for	7
10	provides	<ROOT>	-1
11	a	understanding	13
12	better	understanding	13
13	understanding	provides	10
14	of	understanding	13
15	the	mechanisms	16
16	mechanisms	of	14
17	of	mechanisms	16
18	specific	modulation	21
19	zinc-mediated	modulation	21
20	immune	modulation	21
21	modulation	of	17
22	.	provides	10

0	It	is	1
1	is	<ROOT>	-1
2	becoming	is	1
3	increasingly	apparent	4
4	apparent	becoming	2
5	that	becoming	2
6	the	inflammation	9
7	chronic	inflammation	9
8	gut	inflammation	9
9	inflammation	that	5
10	observed	inflammation	9
11	in	observed	10
12	the	in	11
13	idiopathic	the	12
14	inflammatory	idiopathic	13
15	bowel	(	17
16	diseases	(	17
17	(	inflammatory	14
18	e.g.	is	1
19	ulcerative	colitis	20
20	colitis	is	1
21	,	is	1
22	Crohn	disease	24
23	's	Crohn	22
24	disease	is	26
25	)	disease	24
26	is	is	1
27	associated	is	26
28	with	associated	27
29	enhanced	with	28
30	production	enhanced	29
31	of	production	30
32	leukocyte-derived	oxidants	33
33	oxidants	of	31
34	.	is	1

0	Secreted	TNF-alpha	1
1	TNF-alpha	mediated	2
2	mediated	protein-1	16
3	the	enhancement	4
4	enhancement	mediated	2
5	of	NF-kappa	11
6	nuclear	B	9
7	factor	B	9
8	kappa	B	9
9	B	of	5
10	(	NF-kappa	11
11	NF-kappa	enhancement	4
12	B	NF-kappa	11
13	)	enhancement	4
14	and	mediated	2
15	activator	mediated	2
16	protein-1	)	19
17	(	protein-1	16
18	AP-1	protein-1	16
19	)	antibodies	37
20	binding	)	19
21	activity	)	19
22	;	)	19
23	in	)	19
24	fact	in	23
25	,	the	26
26	the	)	19
27	triggering	the	26
28	of	HLA-DR	29
29	HLA-DR	triggering	27
30	antigens	the	26
31	in	the	32
32	the	antigens	30
33	presence	the	32
34	of	TNF-alpha-neutralizing	36
35	antihuman	TNF-alpha-neutralizing	36
36	TNF-alpha-neutralizing	presence	33
37	antibodies	<ROOT>	-1
38	did	antibodies	37
39	not	did	38
40	upregulate	did	38
41	NF-kappa	B	42
42	B	upregulate	40
43	and	upregulate	40
44	AP-1	antibodies	37
45	.	antibodies	37

0	The	regulation	1
1	regulation	is	4
2	of	regulation	1
3	IL-6	of	2
4	is	<ROOT>	-1
5	dependent	is	4
6	on	various	7
7	various	dependent	5
8	stimuli	various	7
9	that	include	10
10	include	stimuli	8
11	lipopolysaccharide	LPS	13
12	(	LPS	13
13	LPS	include	10
14	)	is	4
15	,	is	4
16	viruses	is	4
17	,	viruses	16
18	and	,	17
19	other	cytokines	20
20	cytokines	and	18
21	.	is	4

0	The	stimulation	2
1	maximal	stimulation	2
2	stimulation	was	25
3	of	stimulation	2
4	the	lymphocytes	5
5	lymphocytes	of	3
6	,	stimulation	2
7	as	stimulation	2
8	measured	as	7
9	by	maximal	11
10	the	maximal	11
11	maximal	measured	8
12	thymidine	maximal	11
13	incorporation	maximal	11
14	(	in	21
15	in	(	14
16	the	absence	17
17	absence	in	15
18	of	absence	17
19	cortisol	of	18
20	)	(	14
21	in	incorporation	13
22	the	group	24
23	FMS	group	24
24	group	in	21
25	was	<ROOT>	-1
26	approximately	was	25
27	1.5	times	28
28	times	higher	29
29	higher	was	25
30	(	was	25
31	p	(	30
32	&lt;	p	31
33	.05	&lt;	32
34	)	.05	33
35	than	)	34
36	in	than	35
37	the	in	36
38	control	the	37
39	or	control	38
40	LBP	group	41
41	group	or	39
42	.	was	25

0	Complete	was	5
1	suppression	of	2
2	of	Complete	0
3	AP-1	of	2
4	activity	Complete	0
5	was	<ROOT>	-1
6	observed	was	5
7	in	observed	6
8	Con	A-treated	9
9	A-treated	in	7
10	,	was	5
11	proliferating	was	5
12	thymocytes	was	5
13	.	was	5

0	Differanisole	<ROOT>	-1
1	A	Differanisole	0
2	in	A	1
3	combination	in	2
4	with	combination	3
5	9cisRA	with	4
6	may	Differanisole	0
7	have	may	6
8	implications	have	7
9	for	implications	8
10	therapy	for	9
11	of	acute	12
12	acute	therapy	10
13	promyelocytic	.	16
14	leukemia	.	16
15	patients	.	16
16	.	acute	12

0	BACKGROUND	<ROOT>	-1
1	:	BACKGROUND	0
2	Glucocorticoids	are	3
3	are	BACKGROUND	0
4	important	are	3
5	medications	important	4
6	used	medications	5
7	to	used	6
8	control	to	7
9	the	control	8
10	airway	the	9
11	inflammation	associated	12
12	associated	airway	10
13	with	airway	10
14	asthma	with	13
15	.	BACKGROUND	0

0	Unlike	<ROOT>	-1
1	classical	sites	3
2	NFkappaB	sites	3
3	sites	Unlike	0
4	,	Unlike	0
5	neither	SNE	7
6	the	SNE	7
7	SNE	nor	8
8	nor	,	4
9	the	motif	11
10	SEE	motif	11
11	motif	responded	12
12	responded	nor	8
13	to	phosphatase	14
14	phosphatase	responded	12
15	inhibition	by	16
16	by	Unlike	0
17	okadaic	acid	18
18	acid	Unlike	0
19	.	Unlike	0

0	These	isoforms	1
1	isoforms	<ROOT>	-1
2	(	isoforms	1
3	elf-2a	identical	8
4	and	elf-2a	3
5	elf-2b	and	4
6	)	elf-2b	5
7	contain	elf-2b	5
8	identical	isoforms	1
9	RBTN-2	isoforms	1
10	binding	and	12
11	regions	and	12
12	and	isoforms	1
13	DNA-binding	isoforms	1
14	domains	.	15
15	.	DNA-binding	13

0	We	examined	1
1	examined	<ROOT>	-1
2	the	expression	4
3	allele-specific	expression	4
4	expression	examined	1
5	of	expression	4
6	WT1	of	5
7	in	human	9
8	cultured	human	9
9	human	expression	4
10	fibroblasts	examined	1
11	from	examined	1
12	15	examined	1
13	individuals	examined	1
14	.	examined	1

0	METHODS	<ROOT>	-1
1	:	METHODS	0
2	We	METHODS	0
3	compared	We	2
4	hydrocortisone	compared	3
5	,	hydrocortisone	4
6	beclomethasone	dipropionate	7
7	dipropionate	,	5
8	,	dipropionate	7
9	triamcinolone	acetonide	10
10	acetonide	dipropionate	7
11	,	acetonide	10
12	flunisolide	acetonide	10
13	,	flunisolide	12
14	and	flunisolide	12
15	budesonide	and	14
16	with	regard	17
17	regard	budesonide	15
18	to	regard	17
19	their	capacity	20
20	capacity	to	18
21	to	capacity	20
22	inhibit	to	21
23	phytohemagglutinin-induced	peripheral	24
24	peripheral	inhibit	22
25	blood	cell	27
26	mononuclear	cell	27
27	cell	inhibit	22
28	proliferation	cell	27
29	from	proliferation	28
30	six	patients	31
31	patients	from	29
32	with	patients	31
33	steroid-sensitive	asthma	34
34	asthma	with	32
35	and	METHODS	0
36	seven	patients	37
37	patients	and	35
38	with	patients	37
39	steroid-resistant	with	38
40	asthma	steroid-resistant	39
41	.	METHODS	0

0	When	expressed	1
1	expressed	<ROOT>	-1
2	in	expressed	1
3	the	System	5
4	TNT	System	5
5	System	in	2
6	,	squirrel	7
7	squirrel	expressed	1
8	monkey	and	9
9	and	expressed	1
10	human	and	9
11	glucocorticoid	human	10
12	receptors	glucocorticoid	11
13	had	receptors	12
14	similar	had	13
15	,	affinity	17
16	high	affinity	17
17	affinity	similar	14
18	binding	dexamethasone	20
19	for	dexamethasone	20
20	dexamethasone	affinity	17
21	(	dexamethasone	20
22	apparent	(	21
23	Kd	5.9	25
24	,	5.9	25
25	5.9	(	21
26	+/-	5.9	25
27	1.2	and	28
28	and	affinity	17
29	4.3	+/-	30
30	+/-	affinity	17
31	0.5	+/-	30
32	nmol/L	+/-	30
33	,	nmol/L	32
34	respectively	nmol/L	32
35	;	affinity	17
36	n	=	37
37	=	affinity	17
38	3	=	37
39	)	3	38
40	,	affinity	17
41	whereas	affinity	17
42	the	receptor	46
43	squirrel	receptor	46
44	monkey	receptor	46
45	F774L	receptor	46
46	receptor	had	47
47	had	whereas	41
48	lower	had	47
49	affinity	lower	48
50	binding	affinity	49
51	(	binding	50
52	apparent	binding	50
53	Kd	binding	50
54	,	affinity	17
55	20.4	affinity	17
56	+/-	affinity	17
57	2.0	affinity	17
58	nmol/L	affinity	17
59	;	affinity	17
60	n	=	61
61	=	affinity	17
62	3	=	61
63	)	3	62
64	.	receptors	12

0	That	<ROOT>	-1
1	the	That	0
2	signal	the	1
3	transduction	pathways	4
4	pathways	used	5
5	used	would	14
6	by	used	5
7	the	by	6
8	cytokines	IL-2	9
9	IL-2	the	7
10	and	IL-2	9
11	IL-15	are	12
12	are	the	7
13	identical	are	12
14	would	signal	2
15	suggest	That	0
16	that	suggest	15
17	these	cytokines	18
18	cytokines	have	19
19	have	that	16
20	redundant	roles	21
21	roles	have	19
22	in	roles	21
23	lymphoid	in	22
24	development	lymphoid	23
25	;	development	24
26	instead	,	27
27	,	is	29
28	IL-2	,	27
29	is	;	25
30	the	guardian	31
31	guardian	T-cell	34
32	of	T-cell	34
33	thymus-derived	T-cell	34
34	T-cell	is	29
35	homeostasis	;	25
36	,	;	25
37	while	;	25
38	interleukin-15	promotes	39
39	promotes	while	37
40	extrathymic	promotes	39
41	development	extrathymic	40
42	of	development	41
43	T	of	42
44	and	NK	45
45	NK	of	42
46	cells	That	0
47	.	That	0

0	Physical	<ROOT>	-1
1	and	Physical	0
2	functional	interaction	3
3	interaction	and	1
4	between	interaction	3
5	the	between	4
6	human	1	11
7	T-cell	1	11
8	lymphotropic	1	11
9	virus	1	11
10	type	1	11
11	1	the	5
12	Tax1	protein	13
13	protein	the	5
14	and	the	5
15	the	and	14
16	CCAAT	the	15
17	binding	protein	18
18	protein	CCAAT	16
19	NF-Y	.	20
20	.	protein	18

0	A	screen	3
1	yeast	screen	3
2	two-hybrid	screen	3
3	screen	identified	4
4	identified	protein	17
5	TES2	interacting	6
6	interacting	identified	4
7	proteins	interacting	6
8	,	identified	4
9	including	factor	13
10	the	tumor	11
11	tumor	necrosis	12
12	necrosis	factor	13
13	factor	,	8
14	receptor-associated	death	15
15	death	factor	13
16	domain	identified	4
17	protein	<ROOT>	-1
18	(	TRADD	19
19	TRADD	protein	17
20	)	TRADD	19
21	.	protein	17

0	On	conferred	6
1	the	hand	3
2	other	hand	3
3	hand	On	0
4	,	conferred	6
5	AML1b	conferred	6
6	conferred	<ROOT>	-1
7	a	conferred	6
8	similar	a	7
9	differentiation-inducing	upon	11
10	capacity	upon	11
11	upon	similar	8
12	K562	transfected	14
13	cells	transfected	14
14	transfected	upon	11
15	with	transfected	14
16	vector	with	15
17	alone	vector	16
18	.	conferred	6

0	Sensitivity	<ROOT>	-1
1	(	ID50	2
2	ID50	Sensitivity	0
3	)	ID50	2
4	of	Sensitivity	0
5	the	lymphocytes	6
6	lymphocytes	of	4
7	for	inhibitory	9
8	the	inhibitory	9
9	inhibitory	Sensitivity	0
10	effect	of	11
11	of	inhibitory	9
12	dexamethasone	same	15
13	was	dexamethasone	12
14	the	same	15
15	same	of	11
16	in	Sensitivity	0
17	all	groups	18
18	groups	in	16
19	.	Sensitivity	0

0	We	show	1
1	show	<ROOT>	-1
2	that	bind	5
3	B-CLL	bind	5
4	cells	bind	5
5	bind	show	1
6	IL-10	show	1
7	with	significant	8
8	significant	IL-10	6
9	specificity	significant	8
10	and	show	1
11	express	127	15
12	between	47	13
13	47	express	11
14	and	47	13
15	127	and	10
16	IL-10	show	1
17	receptor	IL-10	16
18	sites	show	1
19	per	show	1
20	cell	show	1
21	,	a	23
22	with	a	23
23	a	show	1
24	dissociation	show	1
25	constant	show	1
26	in	constant	25
27	the	range	28
28	range	in	26
29	of	range	28
30	168	of	29
31	to	168	30
32	426	10-LRB--12-RRB-	34
33	x	10-LRB--12-RRB-	34
34	10-LRB--12-RRB-	to	31
35	mol/L	10-LRB--12-RRB-	34
36	.	show	1

0	We	<ROOT>	-1
1	calculated	We	0
2	binding	calculated	1
3	affinity	(	4
4	(	;	6
5	Kd	;	6
6	;	binding	2
7	nmol/L	calculated	1
8	)	calculated	1
9	and	(	11
10	capacity	and	9
11	(	)	8
12	Bmax	(	11
13	;	(	11
14	sites/cell	for	16
15	)	for	16
16	for	We	0
17	dexamethasone	We	0
18	and	We	0
19	cortisol	We	0
20	from	We	0
21	homologous	from	20
22	and	homologous	21
23	heterologous	and	22
24	competition	heterologous	23
25	curves	competition	24
26	for	competition	24
27	specific	for	26
28	-LSB-3H-RSB-dexamethasone	on	31
29	binding	on	31
30	sites	on	31
31	on	specific	27
32	HML	We	0
33	isolated	the	35
34	from	the	35
35	the	We	0
36	blood	We	0
37	of	normotensive	38
38	normotensive	blood	36
39	volunteers	normotensive	38
40	and	volunteers	39
41	subjects	We	0
42	with	We	0
43	essential	hypertension	44
44	hypertension	with	42
45	.	We	0

0	Further	deletional	1
1	deletional	TRAF	9
2	and	alanine	3
3	alanine	deletional	1
4	mutagenesis	TRAF	9
5	analyses	TRAF	9
6	and	TRAF	9
7	comparison	TRAF	9
8	with	TRAF	9
9	TRAF	<ROOT>	-1
10	binding	TRAF	9
11	sequences	TRAF	9
12	in	sequences	11
13	CD40	TRAF	9
14	,	TRAF	9
15	in	TRAF	9
16	CD30	TRAF	9
17	,	TRAF	9
18	and	TRAF	9
19	in	and	18
20	the	in	19
21	LMP1	of	22
22	of	the	20
23	other	lymphycryptoviruses	24
24	lymphycryptoviruses	of	22
25	provide	lymphycryptoviruses	24
26	the	evidence	28
27	first	evidence	28
28	evidence	provide	25
29	that	evidence	28
30	PXQXT/S	is	31
31	is	that	29
32	a	is	31
33	core	binding	35
34	TRAF	binding	35
35	binding	a	32
36	motif	evidence	28
37	.	TRAF	9

0	Pertussis	toxin	1
1	toxin	blocked	2
2	blocked	FMLP-induced	3
3	FMLP-induced	<ROOT>	-1
4	activation	FMLP-induced	3
5	of	activation	4
6	the	p42/44	7
7	p42/44	of	5
8	(	ERK	9
9	ERK	p42/44	7
10	)	ERK	9
11	MAPk	FMLP-induced	3
12	cascade	FMLP-induced	3
13	,	FMLP-induced	3
14	but	FMLP-induced	3
15	not	but	14
16	that	not	15
17	of	that	16
18	p38	of	17
19	MAPk	.	20
20	.	p38	18

0	These	receptor	8
1	data	These	0
2	suggest	that	3
3	that	data	1
4	cortisol	binding	5
5	binding	glucocorticoid	7
6	to	glucocorticoid	7
7	glucocorticoid	that	3
8	receptor	<ROOT>	-1
9	is	receptor	8
10	slightly	receptor	8
11	impaired	receptor	8
12	in	impaired	11
13	patients	in	12
14	with	patients	13
15	essential	hypertension	16
16	hypertension	with	14
17	.	receptor	8

0	The	test	3
1	dexamethasone	test	3
2	suppression	test	3
3	test	is	7
4	(	DST	5
5	DST	test	3
6	)	DST	5
7	is	<ROOT>	-1
8	considered	is	7
9	an	indicator	10
10	indicator	considered	8
11	of	indicator	10
12	the	function	13
13	function	of	11
14	of	function	13
15	the	axis	18
16	adrenal	axis	18
17	pituitary	axis	18
18	axis	of	14
19	.	is	7

0	Further	inhibited	19
1	,	Further	0
2	in	,	1
3	consecutive	samples	4
4	samples	in	2
5	of	samples	4
6	fresh	of	5
7	blood	fresh	6
8	obtained	blood	7
9	from	blood	7
10	patients	from	9
11	with	patients	10
12	B-CLL	with	11
13	cells	B-CLL	12
14	,	inhibited	19
15	the	addition	16
16	addition	inhibited	19
17	of	addition	16
18	IL-10	of	17
19	inhibited	<ROOT>	-1
20	B-CLL	inhibited	19
21	proliferation	inhibited	19
22	,	inhibited	19
23	enhanced	inhibited	19
24	B-CLL	inhibited	19
25	differentiation	inhibited	19
26	,	inhibited	19
27	but	inhibited	19
28	did	but	27
29	not	did	28
30	induce	not	29
31	apoptosis	not	29
32	.	apoptosis	31

0	However	must	8
1	,	must	8
2	in	must	8
3	differentiating	cells	5
4	erythroid	cells	5
5	cells	in	2
6	,	must	8
7	which	must	8
8	must	seemed	32
9	incorporate	high	10
10	high	must	8
11	levels	high	10
12	of	levels	11
13	iron	of	12
14	to	of	12
15	sustain	to	14
16	hemoglobin	synthesis	17
17	synthesis	sustain	15
18	,	must	8
19	and	must	8
20	in	and	19
21	macrophages	in	20
22	,	which	23
23	which	must	8
24	are	which	23
25	involved	are	24
26	in	iron	27
27	iron	involved	25
28	storage	iron	27
29	,	which	23
30	transcriptional	regulation	31
31	regulation	must	8
32	seemed	<ROOT>	-1
33	to	seemed	32
34	be	to	33
35	a	mechanism	37
36	relevant	mechanism	37
37	mechanism	be	34
38	.	seemed	32

0	Lipopolysaccharide	human	9
1	induction	human	9
2	of	human	9
3	the	tumor	4
4	tumor	necrosis	5
5	necrosis	of	2
6	factor-alpha	promoter	7
7	promoter	necrosis	5
8	in	necrosis	5
9	human	<ROOT>	-1
10	monocytic	human	9
11	cells	human	9
12	.	human	9

0	The	structure	4
1	tissue-specific	structure	4
2	core	structure	4
3	promoter	structure	4
4	structure	is	5
5	is	<ROOT>	-1
6	apparently	is	5
7	conserved	is	5
8	in	conserved	7
9	other	in	8
10	T-cell-specifically	expressed	11
11	expressed	other	9
12	genes	such	13
13	such	expressed	11
14	as	CD4	16
15	the	CD4	16
16	CD4	such	13
17	gene	is	5
18	.	is	5

0	The	capacity	1
1	capacity	pathways	14
2	of	capacity	1
3	GH	of	2
4	to	capacity	1
5	inhibit	LPS-induced	6
6	LPS-induced	to	4
7	TNF-alpha	production	8
8	production	LPS-induced	6
9	by	LPS-induced	6
10	monocytes	capacity	1
11	without	monocytes	10
12	altering	without	11
13	other	altering	12
14	pathways	<ROOT>	-1
15	leading	pathways	14
16	to	TNF-alpha	17
17	TNF-alpha	leading	15
18	production	pathways	14
19	may	production	18
20	be	may	19
21	of	be	20
22	potential	relevance	23
23	relevance	of	21
24	in	relevance	23
25	septic	shock	26
26	shock	in	24
27	,	be	20
28	since	be	20
29	GH	is	30
30	is	since	28
31	available	is	30
32	for	available	31
33	clinical	use	34
34	use	for	32
35	.	pathways	14

0	The	importance	1
1	importance	has	8
2	of	importance	1
3	NF-kappaB	complexes	4
4	complexes	of	2
5	in	importance	1
6	viral	functions	7
7	functions	in	5
8	has	<ROOT>	-1
9	been	has	8
10	established	been	9
11	comparing	level	13
12	the	level	13
13	level	established	10
14	of	NF-kappaB	15
15	NF-kappaB	level	13
16	DNA-binding	complexes	17
17	complexes	NF-kappaB	15
18	with	complexes	17
19	syncytia-forming	with	18
20	activity	has	8
21	of	activity	20
22	8e51	cells	23
23	cells	of	21
24	.	cells	23

0	Patients	<ROOT>	-1
1	with	Patients	0
2	one	type	3
3	type	with	1
4	of	type	3
5	major	of	4
6	histocompatibility	major	5
7	complex	have	12
8	class	II	9
9	II	have	12
10	combined	II	9
11	immunodeficiency	combined	10
12	have	histocompatibility	6
13	mutations	type	3
14	in	mutations	13
15	a	transactivator	20
16	gene	transactivator	20
17	termed	class	18
18	class	transactivator	20
19	II	transactivator	20
20	transactivator	in	14
21	(	type	3
22	CIITA	Patients	0
23	)	CIITA	22
24	,	Patients	0
25	which	controls	27
26	coordinately	controls	27
27	controls	,	24
28	the	transcription	29
29	transcription	controls	27
30	of	transcription	29
31	the	II	36
32	three	II	36
33	major	II	36
34	human	II	36
35	class	II	36
36	II	of	30
37	genes	Patients	0
38	,	Patients	0
39	HLA-DR	,	38
40	,	-DQ	41
41	-DQ	Patients	0
42	,	-DQ	41
43	and	-DQ	41
44	-DP	and	43
45	.	Patients	0

0	Interferon-gamma	is	4
1	(	IFN-gamma	2
2	IFN-gamma	Interferon-gamma	0
3	)	IFN-gamma	2
4	is	<ROOT>	-1
5	produced	is	4
6	by	killer	8
7	natural	killer	8
8	killer	produced	5
9	cells	is	4
10	and	is	4
11	certain	subsets	12
12	subsets	and	10
13	of	T	14
14	T	subsets	12
15	cells	is	4
16	,	is	4
17	but	is	4
18	the	basis	19
19	basis	is	24
20	for	basis	19
21	its	expression	23
22	selective	expression	23
23	expression	for	20
24	is	but	17
25	unknown	is	24
26	.	is	4

0	This	detection	1
1	detection	suggested	2
2	suggested	p50/p65	13
3	a	activation	5
4	preferential	activation	5
5	activation	suggested	2
6	of	activation	5
7	p50/c-Rel	of	6
8	in	activation	5
9	medullary	thymocytes	10
10	thymocytes	in	8
11	,	suggested	2
12	whereas	p50/p65	13
13	p50/p65	<ROOT>	-1
14	was	p50/p65	13
15	present	in	16
16	in	p50/p65	13
17	both	cortical	18
18	cortical	in	16
19	and	cortical	18
20	medullary	and	19
21	regions	medullary	20
22	of	human	23
23	human	regions	21
24	thymus	p50/p65	13
25	lobules	p50/p65	13
26	.	p50/p65	13

0	Endothelial	and	3
1	cell	and	3
2	activation	and	3
3	and	are	6
4	leukocyte	infiltration	5
5	infiltration	and	3
6	are	<ROOT>	-1
7	a	feature	9
8	consistent	feature	9
9	feature	are	6
10	of	feature	9
11	discordant	of	10
12	xenograft	rejection	13
13	rejection	are	6
14	.	are	6

0	Peripheral	cell	3
1	blood	cell	3
2	mononuclear	cell	3
3	cell	affinities	6
4	GCR	cell	3
5	binding	affinities	6
6	affinities	were	11
7	for	affinities	6
8	dexamethasone	affinities	6
9	and	affinities	6
10	budesonide	affinities	6
11	were	<ROOT>	-1
12	also	were	11
13	determined	were	11
14	for	determined	13
15	both	groups	17
16	patient	groups	17
17	groups	for	14
18	by	determined	13
19	using	by	18
20	a	using	19
21	radioligand	and	24
22	binding	and	24
23	assay	and	24
24	and	a	20
25	Scatchard	a	20
26	analysis	.	27
27	.	Scatchard	25

0	Furthermore	is	7
1	,	is	7
2	the	MRD	3
3	MRD	is	7
4	in	MRD	3
5	PBSC	harvests	6
6	harvests	in	4
7	is	<ROOT>	-1
8	less	is	7
9	than	less	8
10	in	than	9
11	the	bone	13
12	corresponding	bone	13
13	bone	in	10
14	marrow	bone	13
15	obtained	marrow	14
16	on	obtained	15
17	the	day	18
18	day	on	16
19	of	day	18
20	the	collection	22
21	PBSC	collection	22
22	collection	of	19
23	.	collection	22

0	Relief	<ROOT>	-1
1	of	Relief	0
2	cyclin	of	1
3	A	cyclin	2
4	gene	transcriptional	5
5	transcriptional	A	3
6	inhibition	Relief	0
7	during	activation	8
8	activation	human	10
9	of	human	10
10	human	inhibition	6
11	primary	T	12
12	T	Relief	0
13	lymphocytes	Relief	0
14	via	Relief	0
15	CD2	Relief	0
16	and	Relief	0
17	CD28	Relief	0
18	adhesion	molecules	19
19	molecules	Relief	0
20	.	Relief	0

0	ZEBRA	is	1
1	is	<ROOT>	-1
2	also	is	1
3	indispensable	binds	8
4	for	indispensable	3
5	viral	replication	6
6	replication	for	4
7	and	replication	6
8	binds	is	1
9	directly	is	1
10	to	directly	9
11	the	to	10
12	EBV	the	11
13	lytic	of	15
14	origin	of	15
15	of	EBV	12
16	replication	is	1
17	.	is	1

0	Large	TSG101	1
1	TSG101	intragenic	4
2	and	TSG101	1
3	FHIT	and	2
4	intragenic	transcript	5
5	transcript	were	7
6	deletions	transcript	5
7	were	and	9
8	detected	were	7
9	and	<ROOT>	-1
10	these	and	9
11	appeared	and	9
12	to	appeared	11
13	be	to	12
14	the	predominant	15
15	predominant	be	13
16	transcript	predominant	15
17	in	transcript	16
18	'	in	17
19	aged	transcript	16
20	'	aged	19
21	lymphocytes	.	22
22	.	aged	19

0	Previous	promoters	6
1	analyses	Previous	0
2	of	V	4
3	immunoglobulin	V	4
4	V	analyses	1
5	region	Previous	0
6	promoters	has	7
7	has	<ROOT>	-1
8	led	has	7
9	to	led	8
10	the	discovery	11
11	discovery	to	9
12	of	discovery	11
13	a	octamer	15
14	common	octamer	15
15	octamer	of	12
16	motif	octamer	15
17	which	octamer	15
18	is	functionally	19
19	functionally	which	17
20	important	functionally	19
21	in	important	20
22	the	in	21
23	tissue-specific	the	22
24	and	tissue-specific	23
25	developmentally	activation	28
26	regulated	developmentally	25
27	transcriptional	activation	28
28	activation	and	24
29	of	immunoglobulin	30
30	immunoglobulin	activation	28
31	genes	has	7
32	.	has	7

0	BACKGROUND	<ROOT>	-1
1	:	BACKGROUND	0
2	Activated	BACKGROUND	0
3	platelets	Activated	2
4	tether	platelets	3
5	and	activate	6
6	activate	tether	4
7	myeloid	activate	6
8	leukocytes	BACKGROUND	0
9	.	BACKGROUND	0

0	Electrophoretic	analysis	4
1	mobility	analysis	4
2	shift	analysis	4
3	assay	analysis	4
4	analysis	showed	5
5	showed	<ROOT>	-1
6	that	showed	5
7	Tax	increased	8
8	increased	that	6
9	the	increased	8
10	DNA	binding	11
11	binding	the	9
12	activity	the	9
13	of	activity	12
14	both	Sp1	15
15	Sp1	of	13
16	and	Sp1	15
17	NGFI-A/Egr-1	and	16
18	using	the	9
19	a	probe	21
20	TRE1	probe	21
21	probe	using	18
22	.	showed	5

0	Estrogen	<ROOT>	-1
1	receptor	Estrogen	0
2	diminishes	receptor	1
3	DNA-binding	diminishes	2
4	activities	DNA-binding	3
5	of	chicken	6
6	chicken	activities	4
7	GATA-1	chicken	6
8	and	GATA-1	7
9	CACCC-binding	proteins	10
10	proteins	chicken	6
11	.	Estrogen	0

0	We	demonstrate	1
1	demonstrate	alpha	22
2	that	upon	3
3	upon	demonstrate	1
4	stimulation	demonstrate	1
5	by	stimulation	4
6	lipopolysaccharide	by	5
7	,	myristate	11
8	Taxol	myristate	11
9	,	Taxol	8
10	phorbol	myristate	11
11	myristate	by	5
12	acetate	demonstrate	1
13	,	interleukin-1	14
14	interleukin-1	demonstrate	1
15	,	demonstrate	1
16	or	demonstrate	1
17	double-stranded	RNA	18
18	RNA	or	16
19	,	demonstrate	1
20	I	alpha	22
21	kappaB	alpha	22
22	alpha	is	23
23	is	<ROOT>	-1
24	not	is	23
25	degraded	is	23
26	,	is	23
27	as	is	23
28	a	result	29
29	result	as	27
30	of	an	31
31	an	result	29
32	absence	of	33
33	of	induced	34
34	induced	an	31
35	phosphorylation	is	23
36	on	is	23
37	serines	on	36
38	32	serines	37
39	and	serines	37
40	36	and	39
41	.	is	23

0	In	resulted	13
1	DNA	binding	2
2	binding	In	0
3	assays	In	0
4	,	In	0
5	both	PMA	6
6	PMA	,	4
7	plus	PMA	6
8	anti-CD28	plus	7
9	and	anti-CD28	8
10	PMA	and	9
11	plus	and	9
12	ionomycin	In	0
13	resulted	<ROOT>	-1
14	in	resulted	13
15	nuclear	NFAT	16
16	NFAT	in	14
17	.	resulted	13

0	In	was	5
1	contrast	In	0
2	,	NK	3
3	NK	In	0
4	activity	was	5
5	was	<ROOT>	-1
6	not	was	5
7	affected	by	8
8	by	was	5
9	pretreatment	was	5
10	of	pretreatment	9
11	the	cells	13
12	effector	cells	13
13	cells	of	10
14	with	proteasome	16
15	the	proteasome	16
16	proteasome	was	5
17	inhibitor	proteasome	16
18	N-acetyl-leu-leu-norleucinal	selectively	20
19	which	selectively	20
20	selectively	inhibitor	17
21	inhibits	was	5
22	NF-kappa	was	5
23	B	was	5
24	activation	was	5
25	.	was	5

0	These	indicate	1
1	indicate	<ROOT>	-1
2	where	has	5
3	base	order	4
4	order	has	5
5	has	indicate	1
6	been	has	5
7	adapted	been	6
8	for	adapted	7
9	purposes	for	8
10	other	purposes	9
11	than	stability	13
12	stem-loop	than	11
13	stability	other	10
14	(	indicate	1
15	e.g.	,	16
16	,	(	14
17	encoding	or	19
18	proteins	or	19
19	or	,	16
20	gene	,	16
21	regulation	indicate	1
22	)	indicate	1
23	.	indicate	1

0	PHA-induced	reporter	2
1	kappaB-dependent	reporter	2
2	reporter	was	4
3	activity	reporter	2
4	was	<ROOT>	-1
5	,	was	4
6	however	was	4
7	,	was	4
8	effectively	blocked	9
9	blocked	was	4
10	by	blocked	9
11	a	form	14
12	dominant	form	14
13	negative	form	14
14	form	by	10
15	of	form	14
16	Raf-1	of	15
17	,	form	14
18	suggesting	form	14
19	a	critical	20
20	critical	suggesting	18
21	role	suggesting	18
22	for	role	21
23	a	kinase	25
24	Raf	kinase	25
25	kinase	for	22
26	.	was	4

0	However	produced	19
1	,	However	0
2	continuous	treatments	3
3	treatments	,	1
4	with	treatments	3
5	subcytotoxic	concentrations	6
6	concentrations	with	4
7	of	(	9
8	etoposide	(	9
9	(	concentrations	6
10	0.15	(	9
11	microM	)	12
12	)	(	9
13	and	However	0
14	ICRF-193	However	0
15	(	microM	17
16	0.3	microM	17
17	microM	ICRF-193	14
18	)	microM	17
19	produced	cell	37
20	several	effects	22
21	similar	effects	22
22	effects	produced	19
23	,	produced	19
24	namely	produced	19
25	decreased	,	28
26	cell	,	28
27	proliferation	,	28
28	,	produced	19
29	accumulation	of	30
30	of	produced	19
31	cells	produced	19
32	at	produced	19
33	G2	at	32
34	,	produced	19
35	increase	cell	37
36	in	cell	37
37	cell	<ROOT>	-1
38	mass	cell	37
39	,	cell	37
40	and	cell	37
41	induction	and	40
42	of	induction	41
43	differentiation	of	42
44	.	cell	37

0	This	protein	1
1	protein	was	2
2	was	<ROOT>	-1
3	named	was	2
4	elf-2	named	3
5	because	named	3
6	its	because	5
7	DNA-binding	its	6
8	domain	is	9
9	is	virtually	10
10	virtually	DNA-binding	7
11	identical	virtually	10
12	to	identical	11
13	that	to	12
14	of	that	13
15	ets	elf-1	18
16	family	elf-1	18
17	member	elf-1	18
18	elf-1	of	14
19	.	was	2

0	Inhibitory	effect	1
1	effect	<ROOT>	-1
2	of	effect	1
3	growth	hormone	4
4	hormone	of	2
5	on	effect	1
6	TNF-alpha	secretion	7
7	secretion	on	5
8	and	secretion	7
9	nuclear	factor-kappaB	10
10	factor-kappaB	and	8
11	translocation	effect	1
12	in	translocation	11
13	lipopolysaccharide-stimulated	human	14
14	human	in	12
15	monocytes	effect	1
16	.	effect	1

0	Reverse	<ROOT>	-1
1	transcriptase	Reverse	0
2	(	RT	3
3	RT	transcriptase	1
4	)	RT	3
5	assays	RT	3
6	were	assays	5
7	positive	in	8
8	in	were	6
9	purified	in	8
10	viral	purified	9
11	material	both	13
12	from	both	13
13	both	viral	10
14	LCLs	both	13
15	.	LCLs	14

0	Furthermore	interacts	3
1	,	interacts	3
2	Elf-1	interacts	3
3	interacts	<ROOT>	-1
4	specifically	interacts	3
5	with	target	8
6	the	target	8
7	E74	target	8
8	target	interacts	3
9	sequence	interacts	3
10	and	interacts	3
11	can	and	10
12	stimulate	can	11
13	transcription	driven	14
14	driven	stimulate	12
15	by	driven	14
16	the	site	18
17	E74	site	18
18	site	by	15
19	independent	driven	14
20	of	mitogenic	21
21	mitogenic	independent	19
22	signaling	interacts	3
23	.	interacts	3

0	Regulation	<ROOT>	-1
1	of	Regulation	0
2	nuclear	B	4
3	factor-kappa	B	4
4	B	of	1
5	and	kappa	9
6	its	inhibitor	7
7	inhibitor	kappa	9
8	I	kappa	9
9	kappa	of	1
10	B-alpha/MAD-3	Regulation	0
11	in	Regulation	0
12	monocytes	Regulation	0
13	by	Regulation	0
14	Mycobacterium	tuberculosis	15
15	tuberculosis	by	13
16	and	Regulation	0
17	during	human	18
18	human	and	16
19	tuberculosis	Regulation	0
20	.	Regulation	0

0	Four	elements	2
1	NFAT-like	elements	2
2	elements	exist	3
3	exist	<ROOT>	-1
4	within	exist	3
5	the	enhancer	6
6	enhancer	within	4
7	.	exist	3

0	During	<ROOT>	-1
1	monocyte-to-macrophage	,	3
2	differentiation	,	3
3	,	During	0
4	the	content	6
5	cellular	content	6
6	content	,	3
7	of	content	6
8	vacuolar	H+-ATPase	9
9	H+-ATPase	increases	13
10	(	H+-ATPase	9
11	V-ATPase	H+-ATPase	9
12	)	H+-ATPase	9
13	increases	of	7
14	more	increases	13
15	than	more	14
16	4-fold	than	15
17	.	During	0

0	The	gene	3
1	human	gene	3
2	C/EBPepsilon	gene	3
3	gene	is	4
4	is	<ROOT>	-1
5	transcribed	is	4
6	by	transcribed	5
7	two	promoters	9
8	alternative	promoters	9
9	promoters	by	6
10	,	transcribed	5
11	Palpha	transcribed	5
12	and	Palpha	11
13	Pbeta	and	12
14	.	is	4

0	We	upstream	6
1	have	We	0
2	recently	cloned	3
3	cloned	upstream	6
4	the	upstream	6
5	carboxylesterase	upstream	6
6	upstream	<ROOT>	-1
7	sequence	upstream	6
8	and	upstream	6
9	showed	upstream	6
10	its	showed	9
11	basal	showed	9
12	promoter	upstream	6
13	activity	in	14
14	in	CHO	15
15	CHO	upstream	6
16	cells	upstream	6
17	.	upstream	6

0	Binding	is	1
1	is	<ROOT>	-1
2	,	is	1
3	however	is	1
4	,	is	1
5	readily	is	1
6	detected	readily	5
7	when	is	11
8	the	G	10
9	3'	G	10
10	G	is	11
11	is	detected	6
12	replaced	is	11
13	by	replaced	12
14	a	by	13
15	C	a	14
16	.	C	15

0	When	were	4
1	the	cells	3
2	EKLF-/-	cells	3
3	cells	were	4
4	were	<ROOT>	-1
5	injected	were	4
6	into	injected	5
7	blastocysts	did	10
8	,	did	10
9	they	did	10
10	did	into	6
11	not	did	10
12	contribute	did	10
13	at	contribute	12
14	a	level	16
15	detectable	level	16
16	level	at	13
17	to	contribute	12
18	the	compartment	21
19	mature	compartment	21
20	erythrocyte	compartment	21
21	compartment	to	17
22	of	the	23
23	the	compartment	21
24	chimeric	animals	25
25	animals	into	6
26	,	were	4
27	based	,	26
28	on	based	27
29	analysis	on	28
30	of	analysis	29
31	glucose	isomerase-1	33
32	phosphate	isomerase-1	33
33	isomerase-1	of	30
34	(	GPI-1	35
35	GPI-1	isomerase-1	33
36	)	GPI-1	35
37	isozymes	analysis	29
38	and	isozymes	37
39	hemoglobins	analysis	29
40	that	ES	42
41	distinguish	ES	42
42	ES	hemoglobins	39
43	cell-derived	ES	42
44	erythrocytes	cell-derived	43
45	from	erythrocytes	44
46	host	erythrocytes	48
47	blastocyst-derived	erythrocytes	48
48	erythrocytes	from	45
49	.	were	4

0	It	has	1
1	has	<ROOT>	-1
2	been	has	1
3	shown	been	2
4	that	eosinophil	5
5	eosinophil	cytokines	9
6	stimulation	eosinophil	5
7	by	these	8
8	these	eosinophil	5
9	cytokines	been	2
10	is	cytokines	9
11	associated	is	10
12	with	associated	11
13	increases	with	12
14	in	tyrosine	15
15	tyrosine	increases	13
16	phosphorylation	several	18
17	of	several	18
18	several	has	1
19	cellular	has	1
20	substrates	has	1
21	.	has	1

0	Bcd	transcripts	1
1	transcripts	were	2
2	were	<ROOT>	-1
3	detected	were	2
4	in	detected	3
5	all	in	4
6	normal	all	5
7	PBL	normal	6
8	samples	PBL	7
9	tested	samples	8
10	but	tested	9
11	not	in	12
12	in	but	10
13	several	lines	17
14	malignant	lines	17
15	human	lines	17
16	B-cell	lines	17
17	lines	in	12
18	and	in	12
19	not	in	20
20	in	and	18
21	50	%	22
22	%	in	20
23	of	%	22
24	B-cells	of	23
25	from	B-CLL	26
26	B-CLL	in	20
27	patients	were	2
28	.	were	2

0	Association	intercellular	4
1	between	Association	0
2	expression	between	1
3	of	expression	2
4	intercellular	molecule-1	6
5	adhesion	intercellular	4
6	molecule-1	virus	12
7	and	virus	12
8	integration	virus	12
9	of	virus	12
10	human	virus	12
11	T-cell-leukemia	virus	12
12	virus	adult	16
13	type	virus	12
14	1	virus	12
15	in	adult	16
16	adult	<ROOT>	-1
17	T-cell	leukemia	18
18	leukemia	adult	16
19	cells	adult	16
20	.	adult	16

0	In	impairs	10
1	humans	In	0
2	,	mutation	3
3	mutation	impairs	10
4	of	mutation	3
5	the	XPB	6
6	XPB	of	4
7	or	XPB	6
8	XPD	or	7
9	gene	XPD	8
10	impairs	<ROOT>	-1
11	NER	impairs	10
12	,	impairs	10
13	resulting	impairs	10
14	in	resulting	13
15	hyper-sensitivity	in	14
16	to	hyper-sensitivity	15
17	sunlight	to	16
18	and	sunlight	17
19	greatly	tumor	22
20	increased	tumor	22
21	skin	tumor	22
22	tumor	and	18
23	formation	impairs	10
24	.	impairs	10

0	Our	data	1
1	data	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	SAC	may	5
5	may	that	3
6	act	may	5
7	via	act	6
8	antioxidant	mechanisms	9
9	mechanisms	via	7
10	to	mechanisms	9
11	block	mechanisms	9
12	NF-kappa	B	13
13	B	block	11
14	activation	B	13
15	in	block	11
16	Jurkat	cells	17
17	cells	in	15
18	.	cells	17

0	We	propose	1
1	propose	<ROOT>	-1
2	that	propose	1
3	ALY	mediates	4
4	mediates	transcriptional	6
5	context-dependent	transcriptional	6
6	transcriptional	that	2
7	activation	by	8
8	by	transcriptional	6
9	facilitating	by	8
10	the	facilitating	9
11	functional	the	10
12	collaboration	multiple	14
13	of	multiple	14
14	multiple	functional	11
15	proteins	propose	1
16	in	TCR	18
17	the	TCR	18
18	TCR	proteins	15
19	alpha	propose	1
20	enhancer	propose	1
21	complex	propose	1
22	.	propose	1

0	Hence	do	4
1	,	do	4
2	these	cytokines	3
3	cytokines	do	4
4	do	<ROOT>	-1
5	not	do	4
6	simply	do	4
7	enhance	do	4
8	monocyte	enhance	7
9	differentiation	,	10
10	,	monocyte	8
11	but	,	10
12	have	but	11
13	complex	have	12
14	and	complex	13
15	slightly	impact	19
16	divergent	that	18
17	effects	that	18
18	that	slightly	15
19	impact	and	14
20	on	HIV	21
21	HIV	impact	19
22	replication	do	4
23	probably	through	24
24	through	replication	22
25	cell	pathways	27
26	signaling	pathways	27
27	pathways	through	24
28	and	do	4
29	nuclear	factor-kappaB	30
30	factor-kappaB	do	4
31	translocation	do	4
32	.	do	4

0	Western	using	3
1	Blot	using	3
2	analysis	using	3
3	using	antibodies	4
4	antibodies	<ROOT>	-1
5	against	antibodies	4
6	subunits	against	5
7	of	GTP-binding	8
8	GTP-binding	subunits	6
9	proteins	antibodies	4
10	indicated	antibodies	4
11	that	indicated	10
12	Gq/G11	richly	13
13	richly	existed	14
14	existed	that	11
15	in	existed	14
16	Jurkat	cells	17
17	cells	in	15
18	.	cells	17

0	Indeed	was	22
1	,	Indeed	0
2	addition	,	1
3	of	addition	2
4	inhibitors	of	3
5	of	NF-kappa	6
6	NF-kappa	inhibitors	4
7	B	of	3
8	activation	Indeed	0
9	pyrrolidine	Indeed	0
10	dithiocarbamate	Indeed	0
11	(	dithiocarbamate	10
12	PDTC	Indeed	0
13	)	Indeed	0
14	,	Indeed	0
15	to	,	14
16	the	lymphocytes	17
17	lymphocytes	to	15
18	of	lymphocytes	17
19	the	group	21
20	chemically-exposed	group	21
21	group	of	18
22	was	<ROOT>	-1
23	capable	was	22
24	of	inhibiting	25
25	inhibiting	capable	23
26	programmed	inhibiting	25
27	cell	was	22
28	death	was	22
29	by	was	22
30	40	%	31
31	%	by	29
32	.	was	22

0	No	clone	5
1	peptide-specific	T-cell	2
2	T-cell	No	0
3	line	or	4
4	or	T-cell	2
5	clone	could	6
6	could	<ROOT>	-1
7	be	could	6
8	generated	be	7
9	from	generated	8
10	both	donors	11
11	donors	from	9
12	and	donors	11
13	patients	and	12
14	.	could	6

0	In	<ROOT>	-1
1	elderly	In	0
2	healthy	subjects	3
3	subjects	In	0
4	,	Type	5
5	Type	In	0
6	II	receptors	7
7	receptors	Type	5
8	were	In	0
9	also	were	8
10	significantly	decreased	11
11	decreased	were	8
12	(	decreased	11
13	from	(	12
14	1796	from	13
15	+/-	1796	14
16	671	+/-	15
17	to	+/-	15
18	720	+/-	15
19	+/-	345	20
20	345	720	18
21	)	345	20
22	.	In	0

0	p52	were	3
1	and	p52	0
2	RelB	p52	0
3	were	p50	21
4	detected	were	3
5	in	detected	4
6	the	nuclei	7
7	nuclei	in	5
8	in	detected	4
9	both	CD1a+	10
10	CD1a+	cells	13
11	and	CD1a+	10
12	CD68+	and	11
13	cells	in	8
14	from	cell	17
15	the	cell	17
16	T	cell	17
17	cell	cells	13
18	area	were	3
19	,	were	3
20	whereas	p50	21
21	p50	was	22
22	was	<ROOT>	-1
23	found	was	22
24	only	in	25
25	in	found	23
26	CD68-	in	25
27	and	CD68-	26
28	CD1a-	and	27
29	cells	and	27
30	.	cells	29

0	Analysis	of	1
1	of	<ROOT>	-1
2	DNA	of	1
3	failed	of	1
4	to	failed	3
5	show	containing	11
6	genomic	show	5
7	rearrangements	transcripts	10
8	corresponding	to	9
9	to	transcripts	10
10	transcripts	genomic	6
11	containing	to	4
12	deletions	to	4
13	in	of	1
14	the	samples	16
15	same	samples	16
16	samples	in	13
17	.	of	1

0	The	gamma-herpesvirus	4
1	unique	gamma-herpesvirus	4
2	capacity	of	3
3	of	unique	1
4	gamma-herpesvirus	may	17
5	to	gamma-herpesvirus	4
6	amplify	to	5
7	the	load	9
8	viral	load	9
9	load	amplify	6
10	in	amplify	6
11	vivo	in	10
12	through	vivo	11
13	a	growth-transforming	15
14	latent	growth-transforming	15
15	growth-transforming	in	10
16	infection	growth-transforming	15
17	may	<ROOT>	-1
18	have	may	17
19	rendered	have	18
20	these	agents	21
21	agents	rendered	19
22	less	agents	21
23	dependent	rendered	19
24	upon	rendered	19
25	viral	replication	26
26	replication	upon	24
27	as	rendered	19
28	a	means	29
29	means	as	27
30	of	means	29
31	successfully	colonizing	32
32	colonizing	of	30
33	their	hosts	34
34	hosts	colonizing	32
35	.	may	17

0	The	elements	5
1	two	elements	5
2	most	active	3
3	active	elements	5
4	NFAT-like	elements	5
5	elements	were	6
6	were	<ROOT>	-1
7	located	were	6
8	at	located	7
9	the	center	10
10	center	at	8
11	of	I-hypersensitive	14
12	the	I-hypersensitive	14
13	DNase	I-hypersensitive	14
14	I-hypersensitive	center	10
15	site	were	6
16	.	were	6

0	The	system	4
1	NFAT-controlled	system	4
2	luciferase	system	4
3	gene	system	4
4	system	distinguishes	5
5	distinguishes	<ROOT>	-1
6	CIF	distinguishes	5
7	from	cell	10
8	other	cell	10
9	T	cell	10
10	cell	CIF	6
11	inhibitory	distinguishes	5
12	activities	distinguishes	5
13	present	activities	12
14	in	present	13
15	colostrum	in	14
16	,	colostrum	15
17	in	colostrum	15
18	particular	in	17
19	,	colostrum	15
20	TGF	distinguishes	5
21	beta	distinguishes	5
22	1	distinguishes	5
23	and	distinguishes	5
24	TGF	and	23
25	beta	2	26
26	2	distinguishes	5
27	and	the	28
28	the	distinguishes	5
29	glucocorticoids	distinguishes	5
30	.	distinguishes	5

0	Screening	using	6
1	of	Screening	0
2	a	library	3
3	library	of	1
4	of	library	3
5	compounds	of	4
6	using	transrepression	10
7	transactivation	using	6
8	and	transactivation	7
9	AP-1	transrepression	10
10	transrepression	<ROOT>	-1
11	models	transrepression	10
12	in	models	11
13	transiently	in	12
14	transfected	transiently	13
15	cells	identified	16
16	identified	transfected	14
17	dissociated	identified	16
18	glucocorticoids	,	19
19	,	identified	16
20	which	exert	21
21	exert	,	19
22	strong	exert	21
23	AP-1	inhibition	24
24	inhibition	exert	21
25	but	or	27
26	little	or	27
27	or	inhibition	24
28	no	transactivation	29
29	transactivation	inhibition	24
30	.	transactivation	29

0	CONCLUSIONS	MZF-2	4
1	:	CONCLUSIONS	0
2	MZF-1	CONCLUSIONS	0
3	and	MZF-1	2
4	MZF-2	mRNAs	5
5	mRNAs	seem	6
6	seem	<ROOT>	-1
7	to	seem	6
8	be	to	7
9	produced	be	8
10	by	produced	9
11	the	by	10
12	alternative	initiation	18
13	use	initiation	18
14	of	initiation	18
15	two	initiation	18
16	different	initiation	18
17	transcription	initiation	18
18	initiation	the	11
19	sites	seem	6
20	.	seem	6

0	To	<ROOT>	-1
1	examine	To	0
2	the	factors	3
3	factors	vascular-specific	5
4	controlling	vascular-specific	5
5	vascular-specific	examine	1
6	expression	of	7
7	of	To	0
8	PECAM-1	of	7
9	,	To	0
10	we	To	0
11	cloned	the	12
12	the	5'-flanking	13
13	5'-flanking	we	10
14	region	5'-flanking	13
15	of	region	14
16	the	of	15
17	PECAM-1	and	19
18	gene	and	19
19	and	the	16
20	analyzed	the	16
21	its	transcriptional	22
22	transcriptional	To	0
23	activity	To	0
24	.	To	0

0	These	<ROOT>	-1
1	results	These	0
2	demonstrate	the	3
3	the	of	6
4	selective	of	6
5	role	of	6
6	of	results	1
7	GATA-4	results	1
8	in	results	1
9	the	regulation	11
10	transcriptional	regulation	11
11	regulation	in	8
12	of	regulation	11
13	the	of	12
14	IL-5	the	13
15	gene	IL-5	14
16	in	gene	15
17	a	circumstance	18
18	circumstance	in	16
19	where	are	26
20	multiple	members	21
21	members	are	26
22	of	members	21
23	the	proteins	25
24	GATA-binding	proteins	25
25	proteins	of	22
26	are	circumstance	18
27	expressed	are	26
28	.	These	0

0	By	was	21
1	competition	with	3
2	analysis	with	3
3	with	By	0
4	transcription	factor	5
5	factor	with	3
6	consensus	By	0
7	sequence	By	0
8	oligonucleotides	sequence	7
9	and	By	0
10	by	factor	14
11	immunosupershift	by	10
12	,	immunosupershift	11
13	transcription	factor	14
14	factor	By	0
15	SP-1	By	0
16	or	By	0
17	a	protein	20
18	closely	related	19
19	related	protein	20
20	protein	or	16
21	was	<ROOT>	-1
22	shown	was	21
23	to	shown	22
24	bind	to	23
25	to	bind	24
26	this	element	28
27	regulatory	element	28
28	element	to	25
29	.	was	21

0	However	has	5
1	,	has	5
2	no	deficiency	4
3	transcription	deficiency	4
4	deficiency	has	5
5	has	<ROOT>	-1
6	been	has	5
7	demonstrated	been	6
8	in	demonstrated	7
9	either	XP-B	10
10	XP-B	demonstrated	7
11	or	XP-B	10
12	XP-D	or	11
13	.	has	5

0	Repression	virus	4
1	of	virus	4
2	human	virus	4
3	immunodeficiency	virus	4
4	virus	<ROOT>	-1
5	type	virus	4
6	1	virus	4
7	through	virus	4
8	the	cooperation	10
9	novel	cooperation	10
10	cooperation	human	12
11	of	human	12
12	human	through	7
13	factors	virus	4
14	YY1	virus	4
15	and	virus	4
16	LSF	virus	4
17	[	virus	4
18	published	[	17
19	erratum	virus	4
20	appears	erratum	19
21	in	virus	4
22	J	Feb	25
23	Virol	Feb	25
24	1998	Feb	25
25	Feb	in	21
26	;	virus	4
27	72	(	28
28	(	virus	4
29	2	(	28
30	)	(	28
31	:	(	28
32	1709	(	28
33	]	1709	32

0	No	was	4
1	constitutive	tyrosine	2
2	tyrosine	phosphorylation	3
3	phosphorylation	was	4
4	was	<ROOT>	-1
5	detected	was	4
6	on	detected	5
7	any	STAT	8
8	STAT	on	6
9	in	STAT	8
10	CLL	cells	11
11	cells	in	9
12	.	was	4

0	The	region	1
1	region	terminal	12
2	downstream	region	1
3	of	region	1
4	the	enhancer	5
5	enhancer	of	3
6	(	DEN	7
7	DEN	region	1
8	)	DEN	7
9	of	terminal	12
10	the	terminal	12
11	long	terminal	12
12	terminal	is	22
13	repeat	terminal	12
14	of	mink	16
15	the	mink	16
16	mink	repeat	13
17	cell	terminal	12
18	focus-forming	terminal	12
19	murine	terminal	12
20	leukemia	terminal	12
21	virus	terminal	12
22	is	<ROOT>	-1
23	important	is	22
24	for	important	23
25	viral	pathogenicity	26
26	pathogenicity	for	24
27	.	is	22

0	Nonsteroidal	drugs	2
1	anti-inflammatory	drugs	2
2	drugs	have	6
3	such	as	4
4	as	drugs	2
5	salicylates	as	4
6	have	<ROOT>	-1
7	been	have	6
8	used	been	7
9	to	used	8
10	treat	to	9
11	symptoms	treat	10
12	of	symptoms	11
13	inflammation	of	12
14	,	inflammation	13
15	and	inflammation	13
16	a	mechanism	18
17	new	mechanism	18
18	mechanism	was	22
19	of	mechanism	18
20	drug	action	21
21	action	of	19
22	was	and	15
23	suggested	was	22
24	recently	suggested	23
25	.	have	6

0	The	mechanism	1
1	mechanism	reduced	3
2	of	reduced	3
3	reduced	could	13
4	GR	reduced	3
5	levels	reduced	3
6	in	reduced	3
7	relation	in	6
8	to	relation	7
9	age	to	8
10	and	sport	11
11	sport	age	9
12	activity	could	13
13	could	<ROOT>	-1
14	involve	could	13
15	a	loss	16
16	loss	involve	14
17	or	loss	16
18	an	involution	19
19	involution	or	17
20	of	involution	19
21	receptor	involution	19
22	synthesis	receptor	21
23	.	synthesis	22

0	These	<ROOT>	-1
1	data	These	0
2	support	data	1
3	the	support	2
4	positive	for	6
5	role	for	6
6	for	the	3
7	PGE2	for	6
8	on	PGE2	7
9	some	functions	11
10	immune	functions	11
11	functions	for	6
12	.	These	0

0	Because	play	2
1	monocytes	play	2
2	play	asked	25
3	a	play	2
4	pivotal	a	3
5	role	pivotal	4
6	in	role	5
7	the	pathophysiology	8
8	pathophysiology	in	6
9	of	pathophysiology	8
10	intravascular	of	9
11	coagulation	intravascular	10
12	activation	coagulation	11
13	through	activation	12
14	their	ability	15
15	ability	through	13
16	to	ability	15
17	synthesize	factor	19
18	tissue	factor	19
19	factor	to	16
20	(	factor	19
21	TF	role	5
22	)	play	2
23	,	asked	25
24	we	asked	25
25	asked	<ROOT>	-1
26	(	1	27
27	1	asked	25
28	)	1	27
29	whether	asked	25
30	monocyte	TF	31
31	TF	activation	32
32	activation	whether	29
33	occurs	activation	32
34	in	activation	32
35	cardiac	in	34
36	transplant	recipients	37
37	recipients	cardiac	35
38	and	(	39
39	(	recipients	37
40	2	(	39
41	)	TF	44
42	whether	TF	44
43	monocyte	TF	44
44	TF	cardiac	35
45	expression	cardiac	35
46	is	expression	45
47	affected	is	46
48	by	affected	47
49	treatment	by	48
50	with	treatment	49
51	cyclosporin	with	50
52	A	with	50
53	(	expression	45
54	CsA	asked	25
55	)	asked	25
56	.	asked	25

0	An	event	2
1	unknown	event	2
2	event	might	3
3	might	<ROOT>	-1
4	be	might	3
5	involved	be	4
6	in	involved	5
7	GC-resistance	in	6
8	of	GC-resistance	7
9	CRF	of	8
10	.	might	3

0	Therefore	investigated	4
1	,	investigated	4
2	we	investigated	4
3	additionally	investigated	4
4	investigated	<ROOT>	-1
5	other	factors	7
6	transcription	factors	7
7	factors	investigated	4
8	of	factors	7
9	possible	importance	10
10	importance	of	8
11	such	as	12
12	as	factors	7
13	CREB	as	12
14	,	CREB	13
15	CTF	,	14
16	,	CTF	15
17	OTF-1	,	16
18	,	,	16
19	and	,	16
20	OTF-2	and	19
21	.	investigated	4

0	Recently	has	3
1	,	has	3
2	there	has	3
3	has	<ROOT>	-1
4	been	has	3
5	some	progress	6
6	progress	been	4
7	in	the	8
8	the	progress	6
9	understanding	the	8
10	of	understanding	9
11	the	of	10
12	signal	the	11
13	transduction	pathways	14
14	pathways	activated	15
15	activated	signal	12
16	by	these	17
17	these	the	11
18	cytokines	the	11
19	in	the	11
20	eosinophils	the	11
21	.	has	3

0	We	isolated	2
1	first	isolated	2
2	isolated	<ROOT>	-1
3	two	isolated	2
4	overlapping	two	3
5	cosmids	overlapping	4
6	encoding	human	7
7	human	cosmids	5
8	CIITA	which	9
9	which	human	7
10	,	which	9
11	when	,	10
12	co-transfected	isolated	2
13	,	isolated	2
14	are	isolated	2
15	able	are	14
16	to	able	15
17	restore	to	16
18	MHC	II	20
19	class	II	20
20	II	restore	17
21	expression	in	22
22	in	isolated	2
23	a	isolated	2
24	B-lymphoblastoid	a	23
25	cell	(	27
26	line	(	27
27	(	B-lymphoblastoid	24
28	B-LCL	isolated	2
29	)	isolated	2
30	defective	isolated	2
31	for	defective	30
32	CIITA	for	31
33	.	isolated	2

0	Altogether	the	2
1	,	the	2
2	the	is	5
3	CD4	gene	4
4	gene	the	2
5	is	come	15
6	regulated	is	5
7	by	regulated	6
8	several	which	14
9	positive	and	10
10	and	several	8
11	negative	which	14
12	regulatory	which	14
13	mechanisms	which	14
14	which	by	7
15	come	<ROOT>	-1
16	into	play	17
17	play	come	15
18	in	play	17
19	a	in	18
20	developmentally	a	19
21	coordinated	a	19
22	manner	.	23
23	.	coordinated	21

0	A	span	3
1	shortened	span	3
2	life	span	3
3	span	<ROOT>	-1
4	of	span	3
5	EKLF-/-	erythrocytes	7
6	adult	erythrocytes	7
7	erythrocytes	of	4
8	,	span	3
9	due	span	3
10	to	due	9
11	a	deficiency	12
12	deficiency	to	10
13	of	deficiency	12
14	beta-globin	is	17
15	chains	is	17
16	,	is	17
17	is	of	13
18	ameliorated	deficiency	12
19	by	ameliorated	18
20	human	chains	22
21	gamma-globin	chains	22
22	chains	by	19
23	.	span	3

0	Tyrosine	phosphorylation	1
1	phosphorylation	was	5
2	STAT1	or	3
3	or	STAT3	4
4	STAT3	phosphorylation	1
5	was	<ROOT>	-1
6	not	was	5
7	detected	human	9
8	in	human	9
9	human	was	5
10	erythroid	was	5
11	precursors	was	5
12	after	was	5
13	stimulation	was	5
14	with	stimulation	13
15	erythropoietin	with	14
16	.	erythropoietin	15

0	DNA	changes	2
1	methylation	changes	2
2	changes	are	3
3	are	<ROOT>	-1
4	among	the	5
5	the	detectable	8
6	most	common	7
7	common	the	5
8	detectable	are	3
9	abnormalities	detectable	8
10	in	human	11
11	human	abnormalities	9
12	neoplasia	are	3
13	.	are	3

0	Pharmacological	<ROOT>	-1
1	control	Pharmacological	0
2	of	antigen	3
3	antigen	control	1
4	responsiveness	Pharmacological	0
5	in	responsiveness	4
6	genetically	lymphocytes	9
7	modified	lymphocytes	9
8	T	lymphocytes	9
9	lymphocytes	in	5
10	.	Pharmacological	0

0	A-myb	expression	1
1	expression	has	2
2	has	<ROOT>	-1
3	also	has	2
4	been	has	2
5	studied	been	4
6	in	studied	5
7	a	range	9
8	wide	range	9
9	range	in	6
10	of	B	12
11	neoplastic	of	10
12	B	range	9
13	cells	B	12
14	,	has	2
15	representing	has	2
16	the	representing	15
17	whole	the	16
18	spectrum	B	20
19	of	B	20
20	B	whole	17
21	cell	the	16
22	differentiation	the	16
23	.	has	2

0	This	indicated	1
1	indicated	<ROOT>	-1
2	that	indicated	1
3	the	dUTPase	4
4	dUTPase	is	5
5	is	that	2
6	expressed	is	5
7	during	expressed	6
8	EBV	replication	9
9	replication	during	7
10	and	replication	9
11	reactivation	indicated	1
12	.	indicated	1

0	Despite	develop	7
1	their	capacity	3
2	bipotential	capacity	3
3	capacity	Despite	0
4	,	develop	7
5	these	progenitors	6
6	progenitors	develop	7
7	develop	<ROOT>	-1
8	predominantly	develop	7
9	to	predominantly	8
10	T	cells	11
11	cells	predominantly	8
12	in	develop	7
13	the	in	12
14	thymus	.	15
15	.	the	13

0	Involvement	of	1
1	of	<ROOT>	-1
2	TNF	of	1
3	alpha	of	1
4	.	of	1

0	HIV-1	LTR	1
1	LTR	activity	2
2	activity	is	8
3	in	B	6
4	human	B	6
5	CD40-activated	B	6
6	B	activity	2
7	lymphocytes	activity	2
8	is	<ROOT>	-1
9	dependent	is	8
10	on	dependent	9
11	NF-kappaB	on	10
12	.	is	8

0	Proerythroblasts	was	31
1	and	Proerythroblasts	0
2	megakaryocytes	accumulated	4
3	massively	megakaryocytes	2
4	accumulated	Proerythroblasts	0
5	in	accumulated	4
6	the	spleens	7
7	spleens	in	5
8	of	spleens	7
9	the	heterozygotes	10
10	heterozygotes	of	8
11	,	Proerythroblasts	0
12	and	Proerythroblasts	0
13	we	showed	14
14	showed	and	12
15	that	showed	14
16	the	gene	19
17	neomycin	gene	19
18	resistance	gene	19
19	gene	that	15
20	(	is	22
21	which	is	22
22	is	gene	19
23	the	marker	26
24	positive	marker	26
25	selection	marker	26
26	marker	is	22
27	in	ES	28
28	ES	is	22
29	cells	Proerythroblasts	0
30	)	Proerythroblasts	0
31	was	expressed	32
32	expressed	<ROOT>	-1
33	profusely	expressed	32
34	in	expressed	32
35	the	abnormally	36
36	abnormally	cells	38
37	abundant	cells	38
38	cells	in	34
39	generated	cells	38
40	in	mutant	43
41	the	mutant	43
42	GATA-1.05	mutant	43
43	mutant	generated	39
44	females	mutant	43
45	.	expressed	32

0	Using	murine	8
1	homologous	recombination	2
2	recombination	Using	0
3	,	murine	8
4	both	alleles	6
5	EKLF	alleles	6
6	alleles	murine	8
7	in	murine	8
8	murine	<ROOT>	-1
9	embryonic	stem	10
10	stem	murine	8
11	(	ES	12
12	ES	cells	14
13	)	ES	12
14	cells	stem	10
15	were	inactivated	16
16	inactivated	cells	14
17	.	murine	8

0	The	oncogene	3
1	Epstein-Barr	oncogene	3
2	virus	oncogene	3
3	oncogene	membrane	6
4	product	latent	5
5	latent	oncogene	3
6	membrane	protein	7
7	protein	<ROOT>	-1
8	1	protein	7
9	engages	protein	7
10	the	tumor	11
11	tumor	necrosis	12
12	necrosis	factor	13
13	factor	engages	9
14	receptor-associated	death	15
15	death	factor	13
16	domain	protein	7
17	protein	protein	7
18	to	protein	7
19	mediate	to	18
20	B	transformation	23
21	lymphocyte	transformation	23
22	growth	transformation	23
23	transformation	mediate	19
24	and	transformation	23
25	activate	and	24
26	NF-kappaB	activate	25
27	.	NF-kappaB	26

0	Visceral	expression	2
1	TSC2	expression	2
2	expression	was	3
3	was	expression	18
4	comparable	in	5
5	in	was	3
6	autopsy	in	5
7	tissues	from	8
8	from	autopsy	6
9	patients	from	8
10	with	patients	9
11	and	with	10
12	without	and	11
13	TSC	without	12
14	;	TSC	13
15	TSC2	in	5
16	messenger	RNA	17
17	RNA	in	5
18	expression	<ROOT>	-1
19	was	expression	18
20	most	prominent	21
21	prominent	was	19
22	in	was	19
23	cells	expression	18
24	with	expression	18
25	a	rate	28
26	rapid	rate	28
27	mitotic	rate	28
28	rate	with	24
29	and	rate	28
30	turnover	and	29
31	,	expression	18
32	e.g.	expression	18
33	,	e.g.	32
34	epithelia	,	33
35	and	epithelia	34
36	lymphocytes	expression	18
37	,	expression	18
38	with	central	39
39	central	expression	18
40	nervous	central	39
41	system	expression	18
42	pyramidal	expression	18
43	cells	expression	18
44	and	expression	18
45	other	neurons	46
46	neurons	an	48
47	being	an	48
48	an	and	44
49	obvious	exception	50
50	exception	expression	18
51	,	expression	18
52	and/or	expression	18
53	in	and/or	52
54	cells	in	53
55	with	secretory/transport	57
56	important	secretory/transport	57
57	secretory/transport	in	53
58	functions	expression	18
59	.	expression	18

0	Further	<ROOT>	-1
1	,	Further	0
2	we	,	1
3	have	we	2
4	found	have	3
5	that	found	4
6	these	factors	7
7	factors	cooperate	8
8	cooperate	that	5
9	in	cooperate	8
10	the	repression	11
11	repression	in	9
12	of	LTR	13
13	LTR	repression	11
14	expression	in	9
15	and	expression	14
16	viral	replication	17
17	replication	and	15
18	.	Further	0

0	It	was	1
1	was	)	11
2	prominently	was	1
3	and	prominently	2
4	selectively	and	3
5	(	within	6
6	within	central	8
7	the	central	8
8	central	was	1
9	nervous	was	1
10	system	was	1
11	)	<ROOT>	-1
12	expressed	)	11
13	in	expressed	12
14	pyramidal	in	13
15	cells	pyramidal	14
16	of	cells	15
17	the	cerebral	18
18	cerebral	of	16
19	cortex	cerebral	18
20	and	cortex	19
21	other	neurons	23
22	motor	neurons	23
23	neurons	and	20
24	,	)	11
25	e.g.	)	11
26	,	e.g.	25
27	in	,	26
28	spinal	cord	29
29	cord	in	27
30	and	brainstem	31
31	brainstem	cord	29
32	nuclei	brainstem	31
33	.	)	11

0	Stimulation	myelomonocytic	5
1	of	myelomonocytic	5
2	the	myelomonocytic	5
3	latently	HIV-infected	4
4	HIV-infected	myelomonocytic	5
5	myelomonocytic	line	7
6	cell	line	7
7	line	<ROOT>	-1
8	OM-10.1	line	7
9	with	line	7
10	C.	line	7
11	neoformans	line	7
12	and	neoformans	11
13	C.	albicans	14
14	albicans	and	12
15	in	the	16
16	the	line	7
17	presence	of	18
18	of	the	16
19	pooled	line	7
20	human	serum	21
21	serum	caused	22
22	caused	line	7
23	a	increase	25
24	ratio-dependent	increase	25
25	increase	caused	22
26	in	HIV	27
27	HIV	increase	25
28	production	increase	25
29	.	line	7

0	This	was	1
1	was	isolated	14
2	in	was	1
3	contrast	peripheral	6
4	to	peripheral	6
5	normal	peripheral	6
6	peripheral	blood	7
7	blood	in	2
8	B	was	1
9	lymphocytes	was	1
10	or	was	1
11	CD5+-RRB-	was	1
12	B	was	1
13	cells	was	1
14	isolated	<ROOT>	-1
15	from	isolated	14
16	tonsils	isolated	14
17	,	isolated	14
18	in	was	22
19	which	in	18
20	this	phosphorylation	21
21	phosphorylation	was	22
22	was	isolated	14
23	absent	was	22
24	.	isolated	14

0	Early	studies	1
1	studies	<ROOT>	-1
2	concentrated	studies	1
3	on	concentrated	2
4	the	histogenesis	5
5	histogenesis	on	3
6	of	histogenesis	5
7	the	lesion	9
8	endometriotic	lesion	9
9	lesion	of	6
10	.	studies	1

0	The	binding	2
1	actual	binding	2
2	binding	was	6
3	of	binding	2
4	these	peptides	5
5	peptides	of	3
6	was	<ROOT>	-1
7	analysed	was	6
8	in	analysed	7
9	a	stabilization	10
10	stabilization	in	8
11	assay	stabilization	10
12	.	was	6

0	These	<ROOT>	-1
1	data	These	0
2	support	data	1
3	the	conclusion	4
4	conclusion	support	2
5	that	conclusion	4
6	CN	activity	7
7	activity	is	8
8	is	that	5
9	rate-limiting	is	8
10	for	rate-limiting	9
11	the	activation	12
12	activation	T	16
13	of	T	16
14	primary	T	16
15	human	T	16
16	T	for	10
17	lymphocytes	These	0
18	.	These	0

0	Replacement	<ROOT>	-1
1	of	Replacement	0
2	the	sites	5
3	two	sites	5
4	AP-1	sites	5
5	sites	of	1
6	with	sites	5
7	intrinsically	bent	8
8	bent	with	6
9	DNA	bent	8
10	partially	Replacement	0
11	restored	Replacement	0
12	LPS	induction	13
13	induction	Replacement	0
14	,	Replacement	0
15	suggesting	Replacement	0
16	an	suggesting	15
17	additional	an	16
18	structural	additional	17
19	role	structural	18
20	for	role	19
21	the	sites	23
22	AP-1	sites	23
23	sites	for	20
24	.	Replacement	0

0	Sox-4	is	1
1	is	<ROOT>	-1
2	important	is	1
3	for	important	2
4	very	for	3
5	early	very	4
6	B-cell	,	8
7	differentiation	,	8
8	,	early	5
9	while	for	3
10	TCF-1/LEF-1	play	11
11	play	for	3
12	a	play	11
13	crucial	in	15
14	role	in	15
15	in	a	12
16	early	play	11
17	thymocyte	.	19
18	development	.	19
19	.	early	16

0	Treatment	cell	4
1	of	cell	4
2	a	cell	4
3	T-lymphocytic	cell	4
4	cell	<ROOT>	-1
5	line	cell	4
6	with	micromolar	7
7	micromolar	cell	4
8	concentrations	cell	4
9	of	concentrations	8
10	HOCl	cell	4
11	promoted	of	14
12	the	appearance	13
13	appearance	of	14
14	of	cell	4
15	transcription	of	14
16	factor	cell	4
17	NF-kappaB	heterodimer	20
18	(	heterodimer	20
19	the	heterodimer	20
20	heterodimer	cell	4
21	p50/p65	heterodimer	20
22	)	cell	4
23	in	the	24
24	the	cell	4
25	nucleus	of	26
26	of	cell	4
27	the	of	26
28	cells	,	29
29	,	the	27
30	even	in	31
31	in	cell	4
32	the	absence	33
33	absence	in	31
34	of	absence	33
35	de	synthesis	38
36	novo	synthesis	38
37	protein	synthesis	38
38	synthesis	of	34
39	.	synthesis	38

0	Mutation	indicated	4
1	of	Mutation	0
2	these	elements	3
3	elements	of	1
4	indicated	<ROOT>	-1
5	that	indicated	4
6	two	are	12
7	,	are	12
8	MS-2beta	are	12
9	and	MS-2beta	8
10	MS-2gamma	and	9
11	,	are	12
12	are	that	5
13	critical	are	12
14	to	the	15
15	the	critical	13
16	induction	the	15
17	of	induction	16
18	the	of	17
19	CD11b	the	18
20	gene	CD11b	19
21	during	cell	26
22	differentiation	during	21
23	of	cell	26
24	the	cell	26
25	pro-monocytic	cell	26
26	cell	gene	20
27	line	that	5
28	U937	indicated	4
29	.	indicated	4

0	A	member	2
1	novel	member	2
2	member	has	17
3	of	receptor	11
4	the	tumor	5
5	tumor	necrosis	6
6	necrosis	of	3
7	factor	necrosis	6
8	(	of	3
9	TNF	receptor	11
10	)	receptor	11
11	receptor	member	2
12	family	member	2
13	,	member	2
14	designated	member	2
15	TRAMP	designated	14
16	,	member	2
17	has	<ROOT>	-1
18	been	has	17
19	identified	been	18
20	.	has	17

0	Oncogenic	forms	1
1	forms	<ROOT>	-1
2	of	forms	1
3	NOTCH1	of	2
4	lacking	NOTCH1	3
5	either	of	2
6	the	of	2
7	primary	site	9
8	binding	site	9
9	site	of	2
10	for	of	2
11	RBP-Jkappa	for	10
12	or	RBP-Jkappa	11
13	nuclear	RBP-Jkappa	11
14	localization	retain	16
15	sequences	retain	16
16	retain	nuclear	13
17	the	retain	16
18	ability	of	2
19	to	ability	18
20	associate	with	21
21	with	to	19
22	RBP-Jkappa	with	21
23	and	RBP-Jkappa	22
24	activate	and	23
25	transcription	activate	24
26	.	forms	1

0	Further	B	9
1	,	Further	0
2	by	,	1
3	electrophoretic	shift	5
4	mobility	shift	5
5	shift	by	2
6	assay	,	7
7	,	shift	5
8	NF-kappa	shift	5
9	B	was	10
10	was	<ROOT>	-1
11	activated	was	10
12	in	activated	11
13	monocytes	in	12
14	from	tuberculous	15
15	tuberculous	activated	11
16	patients	was	10
17	.	was	10

0	B-myb	is	1
1	is	<ROOT>	-1
2	also	is	1
3	involved	is	1
4	in	involved	3
5	the	in	4
6	control	the	5
7	of	control	6
8	proliferation	of	7
9	and	of	7
10	differentiation	is	1
11	,	is	1
12	but	is	1
13	,	is	18
14	unlike	is	18
15	c-myb	unlike	14
16	,	is	18
17	it	is	18
18	is	but	12
19	expressed	is	18
20	in	expressed	19
21	many	types	23
22	cell	types	23
23	types	in	20
24	.	is	1

0	[	<ROOT>	-1
1	Molecular	[	0
2	mechanisms	of	3
3	of	age-related	4
4	age-related	lymphocyte	5
5	lymphocyte	Molecular	1
6	dysfunction	]	7
7	]	Molecular	1

0	In	investigated	5
1	this	manuscript	2
2	manuscript	In	0
3	we	investigated	5
4	have	investigated	5
5	investigated	<ROOT>	-1
6	the	mechanisms	8
7	molecular	mechanisms	8
8	mechanisms	investigated	5
9	by	investigated	5
10	which	by	9
11	T	by	9
12	cell	T	11
13	lines	cell	12
14	stimulated	lines	13
15	with	12-myristate	17
16	phorbol	12-myristate	17
17	12-myristate	stimulated	14
18	13-acetate	(	19
19	(	12-myristate	17
20	PMA	(	19
21	)	stimulated	14
22	and	stimulated	14
23	phytohemagglutin	(	24
24	(	stimulated	14
25	PHA	investigated	5
26	)	investigated	5
27	display	investigated	5
28	significantly	higher	29
29	higher	investigated	5
30	levels	of	31
31	of	investigated	5
32	NF-kappa	B1	33
33	B1	encoding	34
34	encoding	investigated	5
35	transcripts	investigated	5
36	than	transcripts	35
37	cells	investigated	5
38	stimulated	investigated	5
39	with	necrosis	41
40	tumor	necrosis	41
41	necrosis	investigated	5
42	factor-alpha	investigated	5
43	,	investigated	5
44	despite	investigated	5
45	the	fact	46
46	fact	despite	44
47	that	both	48
48	both	activate	50
49	stimuli	activate	50
50	activate	fact	46
51	NF-kappa	activate	50
52	B	fact	46
53	.	investigated	5

0	Activation	requires	8
1	of	Activation	0
2	nuclear	factor-kappaB	3
3	factor-kappaB	of	1
4	via	Activation	0
5	T	receptor	7
6	cell	receptor	7
7	receptor	via	4
8	requires	<ROOT>	-1
9	a	kinase	11
10	Raf	kinase	11
11	kinase	requires	8
12	and	influx	14
13	Ca2+	and	12
14	influx	requires	8
15	.	requires	8

0	Substitution	mutations	1
1	mutations	<ROOT>	-1
2	in	mutations	1
3	this	in	2
4	consensus	eliminate	6
5	sequence	eliminate	6
6	eliminate	this	3
7	binding	this	3
8	of	binding	7
9	the	factor	11
10	inducible	factor	11
11	factor	of	8
12	.	mutations	1

0	However	did	3
1	,	did	3
2	NAC	did	3
3	did	<ROOT>	-1
4	not	did	3
5	significantly	did	3
6	affect	significantly	5
7	the	affect	6
8	spontaneous	atopic	13
9	production	spontaneous	8
10	of	production	9
11	IgE	of	10
12	by	spontaneous	8
13	atopic	the	7
14	B	cells	15
15	cells	atopic	13
16	.	did	3

0	In	inhibits	6
1	clinical	use	2
2	use	In	0
3	,	inhibits	6
4	CsA	treatment	5
5	treatment	inhibits	6
6	inhibits	<ROOT>	-1
7	50-75	%	8
8	%	inhibits	6
9	of	%	8
10	CN	activity	11
11	activity	of	9
12	in	circulating	13
13	circulating	inhibits	6
14	leukocytes	inhibits	6
15	.	inhibits	6

0	Altogether	,	1
1	,	involved	13
2	these	results	3
3	results	,	1
4	support	,	1
5	the	hypothesis	6
6	hypothesis	support	4
7	that	hypothesis	6
8	the	activation	9
9	activation	that	7
10	of	NK	11
11	NK	activation	9
12	cells	,	1
13	involved	<ROOT>	-1
14	transcriptional	involved	13
15	and	transcriptional	14
16	post-transcriptional	and	15
17	events	involved	13
18	,	involved	13
19	and	,	18
20	that	and	19
21	reactive	intermediates	22
22	intermediates	may	23
23	may	that	20
24	play	may	23
25	an	role	27
26	important	role	27
27	role	play	24
28	in	play	24
29	the	processes	31
30	molecular	processes	31
31	processes	in	28
32	related	processes	31
33	with	related	32
34	the	generation	35
35	generation	with	33
36	of	generation	35
37	a	response	39
38	cytotoxic	response	39
39	response	of	36
40	by	response	39
41	NK	cells	42
42	cells	by	40
43	.	cells	42

0	Sequence	analysis	1
1	analysis	promoter	5
2	of	promoter	5
3	the	promoter	5
4	p40	promoter	5
5	promoter	region	6
6	region	(	12
7	identified	(	12
8	two	(	12
9	potential	(	12
10	nuclear	factor	11
11	factor	(	12
12	(	conserved	18
13	NF	-kappaB	15
14	)	-kappaB	15
15	-kappaB	(	12
16	binding	(	12
17	sites	(	12
18	conserved	<ROOT>	-1
19	between	conserved	18
20	mouse	and	21
21	and	between	19
22	human	and	21
23	.	conserved	18

0	T	cell	1
1	cell	activation	7
2	activation	and	3
3	and	cell	1
4	ensuing	activation	7
5	cellular	activation	7
6	gene	activation	7
7	activation	<ROOT>	-1
8	can	be	9
9	be	activation	7
10	critical	be	9
11	for	HIV-1	12
12	HIV-1	critical	10
13	replication	activation	7
14	.	activation	7

0	IL-4	induced	2
1	also	induced	2
2	induced	binding	5
3	Stat6	induced	2
4	DNA	binding	5
5	binding	<ROOT>	-1
6	activity	binding	5
7	from	binding	5
8	lysates	from	7
9	of	cells	14
10	1D4	of	9
11	but	of	9
12	not	of	9
13	E1C3	cells	14
14	cells	lysates	8
15	utilizing	cells	14
16	a	epsilon	22
17	radiolabeled	epsilon	22
18	immunoglobulin	heavy	19
19	heavy	chain	20
20	chain	epsilon	22
21	germline	epsilon	22
22	epsilon	lysates	8
23	promotor	binding	5
24	sequence	(	25
25	(	binding	5
26	Iepsilon	(	25
27	)	binding	5
28	in	binding	5
29	an	assay	33
30	electrophoretic	assay	33
31	mobility	assay	33
32	shift	assay	33
33	assay	in	28
34	.	binding	5

0	We	established	2
1	previously	established	2
2	established	critical	4
3	a	critical	4
4	critical	<ROOT>	-1
5	role	critical	4
6	for	role	5
7	the	factor	9
8	transcription	factor	9
9	factor	for	6
10	GATA-3	critical	4
11	in	GATA-3	10
12	IL-5	critical	4
13	promoter	activation	14
14	activation	critical	4
15	in	EL-4	16
16	EL-4	critical	4
17	cells	critical	4
18	,	which	19
19	which	critical	4
20	express	both	21
21	both	which	19
22	Th1-	both	21
23	and	Th2-type	24
24	Th2-type	Th1-	22
25	cytokines	critical	4
26	.	critical	4

0	A	survey	1
1	survey	has	4
2	of	survey	1
3	promoters	of	2
4	has	<ROOT>	-1
5	revealed	has	4
6	that	revealed	5
7	the	wild-type	8
8	wild-type	that	6
9	,	wild-type	8
10	unfused	EBNA3C	11
11	EBNA3C	can	12
12	can	wild-type	8
13	specifically	can	12
14	repress	can	12
15	expression	repress	14
16	from	reporter	17
17	reporter	expression	15
18	plasmids	wild-type	8
19	containing	wild-type	8
20	the	containing	19
21	Epstein-Barr	the	20
22	virus	Epstein-Barr	21
23	Cp	virus	22
24	latency-associated	.	26
25	promoter	.	26
26	.	Cp	23

0	Similar	results	1
1	results	were	2
2	were	<ROOT>	-1
3	obtained	were	2
4	in	obtained	3
5	primary	culture	6
6	culture	in	4
7	of	culture	6
8	leukemia	from	10
9	cells	from	10
10	from	of	7
11	a	patient	12
12	patient	were	2
13	with	promyelocytic	15
14	acute	promyelocytic	15
15	promyelocytic	were	2
16	leukemia	were	2
17	.	were	2

0	However	was	3
1	,	was	3
2	it	was	3
3	was	<ROOT>	-1
4	still	was	3
5	lower	was	3
6	than	lower	5
7	that	than	6
8	in	that	7
9	healthy	subjects	10
10	subjects	in	8
11	(	subjects	10
12	P	in	8
13	&lt;	in	8
14	0.01	)	15
15	)	&lt;	13
16	.	)	15

0	We	have	1
1	have	<ROOT>	-1
2	previously	have	1
3	identified	new	4
4	new	sites	6
5	binding	sites	6
6	sites	have	1
7	for	have	1
8	transcription	factors	9
9	factors	have	1
10	downstream	have	1
11	of	downstream	10
12	the	of	11
13	transcription	(	16
14	start	(	16
15	site	(	16
16	(	the	12
17	nt	(	16
18	465	nt	17
19	to	465	18
20	720	to	19
21	)	720	20
22	:	have	1
23	three	sites	25
24	AP-1	sites	25
25	sites	have	1
26	(	sites	25
27	I	(	26
28	,	I	27
29	II	(	26
30	,	sites	25
31	and	sites	25
32	III	sites	25
33	)	sites	25
34	,	motif	37
35	an	motif	37
36	AP3-like	motif	37
37	motif	sites	25
38	(	motif	37
39	AP3-L	motif	37
40	)	motif	37
41	,	sites	25
42	a	sites	25
43	downstream	binding	44
44	binding	factor	45
45	factor	(	46
46	(	a	42
47	DBF	)	48
48	)	(	46
49	site	)	48
50	,	have	1
51	and	have	1
52	juxtaposed	have	1
53	Sp1	sites	54
54	sites	have	1
55	.	have	1

0	These	results	1
1	results	emphasize	2
2	emphasize	<ROOT>	-1
3	the	versatility	5
4	structural	versatility	5
5	versatility	emphasize	2
6	of	versatility	5
7	the	domain	10
8	Oct-1	domain	10
9	POU	domain	10
10	domain	of	6
11	in	its	12
12	its	emphasize	2
13	interaction	its	12
14	with	interaction	13
15	coregulators	emphasize	2
16	.	emphasize	2

0	By	<ROOT>	-1
1	screening	cell	4
2	a	cell	4
3	T	cell	4
4	cell	By	0
5	cDNA	By	0
6	library	we	8
7	,	we	8
8	we	ets	12
9	identified	we	8
10	a	ets	12
11	novel	ets	12
12	ets	cDNA	5
13	transcription	factor	14
14	factor	ets	12
15	that	factor	14
16	binds	RBTN-2	17
17	RBTN-2	factor	14
18	.	By	0

0	Like	<ROOT>	-1
1	Drosophila	Toll	2
2	Toll	Like	0
3	,	Like	0
4	human	Toll	5
5	Toll	Like	0
6	is	a	7
7	a	Like	0
8	type	transmembrane	10
9	I	transmembrane	10
10	transmembrane	a	7
11	protein	with	12
12	with	transmembrane	10
13	an	domain	15
14	extracellular	domain	15
15	domain	with	12
16	consisting	domain	15
17	of	consisting	16
18	a	repeat	20
19	leucine-rich	repeat	20
20	repeat	of	17
21	(	LRR	22
22	LRR	repeat	20
23	)	LRR	22
24	domain	repeat	20
25	,	and	26
26	and	domain	24
27	a	domain	29
28	cytoplasmic	domain	29
29	domain	and	26
30	homologous	domain	24
31	to	homologous	30
32	the	domain	34
33	cytoplasmic	domain	34
34	domain	to	31
35	of	domain	34
36	the	human	37
37	human	of	35
38	interleukin	consisting	16
39	(	IL	40
40	IL	receptor	43
41	)	IL	40
42	-1	receptor	43
43	receptor	consisting	16
44	.	Like	0

0	Both	alpha	2
1	U	alpha	2
2	alpha	failed	8
3	A	alpha	2
4	and	A	3
5	alpha	B5A	6
6	B5A	and	4
7	also	failed	8
8	failed	<ROOT>	-1
9	to	failed	8
10	respond	to	9
11	to	respond	10
12	another	agent	14
13	modulating	agent	14
14	agent	to	11
15	,	agent	14
16	1	agent	14
17	alpha,25-dihydroxycholecalciferol	agent	14
18	(	DHCC	19
19	DHCC	alpha,25-dihydroxycholecalciferol	17
20	)	DHCC	19
21	,	agent	14
22	but	agent	14
23	only	but	22
24	U	agent	14
25	alpha	failed	8
26	S	alpha	25
27	and	S	26
28	not	alpha	29
29	alpha	and	27
30	G2S	an	32
31	showed	G2S	30
32	an	alpha	29
33	enhanced	an	32
34	response	enhanced	33
35	to	response	34
36	DHCC	to	35
37	.	S	26

0	Latent	infection	1
1	infection	can	11
2	of	B	3
3	B	infection	1
4	lymphocytes	infection	1
5	by	infection	1
6	Epstein-Barr	virus	7
7	virus	by	5
8	(	EBV	9
9	EBV	virus	7
10	)	EBV	9
11	can	<ROOT>	-1
12	be	can	11
13	disrupted	be	12
14	by	disrupted	13
15	expression	by	14
16	of	ZEBRA	19
17	the	ZEBRA	19
18	EBV	ZEBRA	19
19	ZEBRA	expression	15
20	protein	can	11
21	.	can	11

0	Prolonged	poor	1
1	poor	glycemic	2
2	glycemic	pancreatic	18
3	control	glycemic	2
4	in	control	3
5	non-insulin-dependent	in	4
6	diabetes	non-insulin-dependent	5
7	mellitus	diabetes	6
8	patients	leads	10
9	often	leads	10
10	leads	mellitus	7
11	to	leads	10
12	a	decline	13
13	decline	to	11
14	in	insulin	15
15	insulin	secretion	16
16	secretion	decline	13
17	from	secretion	16
18	pancreatic	<ROOT>	-1
19	beta	pancreatic	18
20	cells	pancreatic	18
21	,	pancreatic	18
22	accompanied	pancreatic	18
23	by	accompanied	22
24	a	decrease	25
25	decrease	by	23
26	in	decrease	25
27	the	in	26
28	insulin	the	27
29	content	insulin	28
30	of	content	29
31	the	cells	32
32	cells	of	30
33	.	cells	32

0	A	high	1
1	high	expression	4
2	and	high	1
3	frequent	and	2
4	expression	was	9
5	of	expression	4
6	these	proteins	8
7	two	proteins	8
8	proteins	of	5
9	was	<ROOT>	-1
10	found	was	9
11	both	found	10
12	in	both	11
13	MM	in	12
14	and	in	12
15	MGUS	in	12
16	patients	(	17
17	(	was	9
18	31/33	was	9
19	patients	31/33	18
20	positive	patients	19
21	for	positive	20
22	c-Jun	for	21
23	and	for	21
24	29/33	and	23
25	patients	29/33	24
26	positive	patients	25
27	for	positive	26
28	GST-pi	for	27
29	)	29/33	24
30	and	29/33	24
31	in	not	33
32	controls	in	31
33	not	affected	34
34	affected	and	30
35	by	monoclonal	36
36	monoclonal	affected	34
37	gammopathy	was	9
38	(	7/8	39
39	7/8	gammopathy	37
40	patients	7/8	39
41	positive	for	42
42	for	patients	40
43	both	c-Jun	44
44	c-Jun	was	9
45	and	was	9
46	GST-pi	was	9
47	)	was	9
48	.	was	9

0	Finally	were	18
1	,	were	18
2	although	were	18
3	it	has	4
4	has	although	2
5	been	has	4
6	reported	been	5
7	that	reported	6
8	EBNA3C	can	9
9	can	that	7
10	upregulate	can	9
11	CD21	upregulate	10
12	in	upregulate	10
13	some	cells	15
14	B	cells	15
15	cells	in	12
16	,	were	18
17	we	were	18
18	were	<ROOT>	-1
19	unable	were	18
20	to	unable	19
21	demonstrate	any	22
22	any	to	20
23	effect	any	22
24	of	effect	23
25	EBNA3C	were	18
26	on	reporter	27
27	reporter	EBNA3C	25
28	plasmids	were	18
29	which	the	31
30	contain	the	31
31	the	were	18
32	CD21	promoter	33
33	promoter	the	31
34	.	were	18

0	The	effect	1
1	effect	appears	4
2	of	effect	1
3	GH	of	2
4	appears	<ROOT>	-1
5	to	appears	4
6	occur	to	5
7	in	occur	6
8	an	fashion	10
9	autocrine	fashion	10
10	fashion	in	7
11	,	appears	4
12	since	inhibitory	14
13	the	inhibitory	14
14	inhibitory	appears	4
15	effect	inhibitory	14
16	on	effect	15
17	TNF-alpha	appears	4
18	secretion	by	19
19	by	appears	4
20	constitutive	appears	4
21	GH	appears	4
22	production	could	23
23	could	appears	4
24	be	could	23
25	abolished	be	24
26	in	the	27
27	the	abolished	25
28	presence	the	27
29	of	anti-hGH	30
30	anti-hGH	presence	28
31	mAb	appears	4
32	.	appears	4

0	Accumulating	<ROOT>	-1
1	data	have	7
2	from	data	1
3	a	number	4
4	number	from	2
5	of	number	4
6	laboratories	of	5
7	have	Accumulating	0
8	recently	have	7
9	indicated	have	7
10	that	indicated	9
11	the	may	25
12	response	of	13
13	of	transcription	14
14	transcription	the	11
15	factor	transcription	14
16	NF-kappaB	transcription	14
17	to	the	11
18	alterations	to	17
19	in	alterations	18
20	the	homeostasis	22
21	redox	homeostasis	22
22	homeostasis	in	19
23	of	homeostasis	22
24	cells	of	23
25	may	that	10
26	play	indicated	9
27	an	role	29
28	important	role	29
29	role	play	26
30	in	play	26
31	modulating	function	33
32	immune	function	33
33	function	in	30
34	.	Accumulating	0

0	Pax-5	codes	1
1	codes	<ROOT>	-1
2	for	codes	1
3	the	for	2
4	transcription	the	3
5	factor	transcription	4
6	BSAP	factor	5
7	which	is	8
8	is	BSAP	6
9	expressed	throughout	10
10	throughout	B	11
11	B	cell	12
12	cell	is	8
13	development	codes	1
14	except	codes	1
15	in	except	14
16	terminally	plasma	18
17	differentiated	terminally	16
18	plasma	in	15
19	cells	codes	1
20	.	codes	1

0	Thus	is	7
1	,	of	4
2	constitutive	activation	3
3	activation	of	4
4	of	Thus	0
5	Egr-1	gene	6
6	gene	is	7
7	is	group	19
8	invariably	associated	9
9	associated	is	7
10	with	associated	9
11	unrestricted	expression	12
12	expression	with	10
13	of	viral	14
14	viral	expression	12
15	latent	expression	12
16	genes	is	7
17	in	is	7
18	all	is	7
19	group	<ROOT>	-1
20	III	group	19
21	EBV	genome	22
22	genome	carrying	23
23	carrying	cell	24
24	cell	group	19
25	lines	cell	24
26	.	lines	25

0	CCAAT/enhancer	protein	2
1	binding	protein	2
2	protein	(	3
3	(	C/EBP	4
4	C/EBP	epsilon	6
5	)	C/EBP	4
6	epsilon	is	7
7	is	<ROOT>	-1
8	a	member	11
9	recently	member	11
10	cloned	member	11
11	member	is	7
12	of	member	11
13	the	of	12
14	C/EBP	of	16
15	family	of	16
16	of	the	13
17	transcription	factors	18
18	factors	of	16
19	and	is	7
20	is	and	19
21	expressed	is	20
22	exclusively	expressed	21
23	in	exclusively	22
24	cells	in	23
25	of	hematopoietic	26
26	hematopoietic	expressed	21
27	origin	is	7
28	.	is	7

0	The	suppression	1
1	suppression	is	10
2	of	suppression	1
3	productive	replication	5
4	LAI	replication	5
5	replication	of	2
6	in	T	8
7	naive	T	8
8	T	suppression	1
9	cells	suppression	1
10	is	<ROOT>	-1
11	not	is	10
12	due	is	10
13	to	differential	14
14	differential	due	12
15	expression	due	12
16	of	expression	15
17	viral	coreceptors	18
18	coreceptors	of	16
19	,	is	10
20	nor	is	10
21	is	nor	20
22	it	is	21
23	due	is	21
24	to	due	23
25	inhibition	to	24
26	of	inhibition	25
27	activation	of	26
28	of	of	26
29	the	factors	33
30	important	factors	33
31	HIV	factors	33
32	transcription	HIV	31
33	factors	of	28
34	,	nuclear	35
35	nuclear	factor-kappaB	36
36	factor-kappaB	is	10
37	and	factor-kappaB	36
38	activator	is	10
39	protein-1	is	10
40	.	is	10

0	The	state	1
1	state	<ROOT>	-1
2	of	state	1
3	maturation	of	2
4	of	state	1
5	monocytes	of	4
6	into	state	1
7	macrophages	into	6
8	determines	macrophages	7
9	the	effects	10
10	effects	determines	8
11	of	effects	10
12	IL-4	of	11
13	and	of	11
14	IL-13	HIV	16
15	on	HIV	16
16	HIV	state	1
17	replication	HIV	16
18	.	state	1

0	Furthermore	were	4
1	,	were	4
2	these	plasmids	3
3	plasmids	were	4
4	were	<ROOT>	-1
5	not	were	4
6	active	were	4
7	in	active	6
8	RJ2.2.5	in	7
9	,	were	4
10	an	derivative	14
11	in	derivative	14
12	vitro	in	11
13	mutagenized	derivative	14
14	derivative	,	9
15	of	derivative	14
16	Raji	of	15
17	in	are	23
18	which	in	17
19	both	copies	20
20	copies	are	23
21	of	copies	20
22	CIITA	of	21
23	are	Raji	16
24	defective	are	23
25	.	were	4

0	NF-kappaB	activation	1
1	activation	is	4
2	by	activation	1
3	LMP1-LRB-1-231-RRB-	by	2
4	is	mutant	28
5	likely	is	4
6	to	likely	5
7	be	to	6
8	mediated	be	7
9	by	mediated	8
10	TRAF1/TRAF2	heteroaggregates	11
11	heteroaggregates	mediated	8
12	since	heteroaggregates	11
13	TRAF1	since	12
14	is	TRAF1	13
15	unique	among	16
16	among	heteroaggregates	11
17	the	TRAFs	18
18	TRAFs	among	16
19	in	TRAFs	18
20	coactivating	NF-kappaB	21
21	NF-kappaB	in	19
22	with	TRAF2	26
23	LMP1-LRB-1-231-RRB-	TRAF2	26
24	,	LMP1-LRB-1-231-RRB-	23
25	a	TRAF2	26
26	TRAF2	TRAFs	18
27	dominant-negative	is	4
28	mutant	<ROOT>	-1
29	can	mutant	28
30	block	can	29
31	LMP1-LRB-1-231-RRB--mediated	activation	33
32	NF-kappaB	activation	33
33	activation	block	30
34	as	block	30
35	well	as	34
36	as	as	34
37	TRAF1	coactivation	38
38	coactivation	as	34
39	,	coactivation	38
40	and	coactivation	38
41	30	%	42
42	%	is	45
43	of	%	42
44	TRAF2	of	43
45	is	and	40
46	associated	is	45
47	with	associated	46
48	TRAF1	with	47
49	in	TRAF1	48
50	EBV-transformed	with	47
51	B	mutant	28
52	cells	mutant	28
53	.	mutant	28

0	Mutants	<ROOT>	-1
1	of	Mutants	0
2	type	of	1
3	5	adenovirus	4
4	adenovirus	type	2
5	(	adenovirus	4
6	Ad5	adenovirus	4
7	)	adenovirus	4
8	with	adenovirus	4
9	reiterated	with	8
10	DNA	sequences	11
11	sequences	reiterated	9
12	in	sequences	11
13	the	in	12
14	E1a	appeared	16
15	region	appeared	16
16	appeared	the	13
17	in	the	13
18	a	in	17
19	human	a	18
20	T-lymphocyte	cell	21
21	cell	human	19
22	line	cell	21
23	,	line	22
24	Molt-4	,	23
25	,	Molt-4	24
26	persistently	Molt-4	24
27	infected	persistently	26
28	with	persistently	26
29	H5sub304	with	28
30	,	H5sub304	29
31	a	mutant	33
32	deletion/substitution	mutant	33
33	mutant	H5sub304	29
34	that	has	35
35	has	wild-type	37
36	a	wild-type	37
37	wild-type	mutant	33
38	phenotype	H5sub304	29
39	in	H5sub304	29
40	viral	replication	41
41	replication	in	39
42	.	cell	21

0	Receptors	were	1
1	were	<ROOT>	-1
2	measured	were	1
3	by	measured	2
4	radioreceptor	.	6
5	assay	.	6
6	.	by	3

0	Several	studies	1
1	studies	have	2
2	have	<ROOT>	-1
3	pointed	have	2
4	to	pointed	3
5	a	link	6
6	link	to	4
7	between	and	9
8	immune	and	9
9	and	link	6
10	endocrine	systems	11
11	systems	pointed	3
12	,	pointed	3
13	including	pointed	3
14	a	function	16
15	regulatory	function	16
16	function	including	13
17	of	function	16
18	GH	of	17
19	on	monocyte	20
20	monocyte	function	16
21	activation	monocyte	20
22	.	activation	21

0	Deletional	analysis	1
1	analysis	indicated	2
2	indicated	<ROOT>	-1
3	that	indicated	2
4	five	sites	6
5	Sp1	sites	6
6	sites	that	3
7	mediated	sites	6
8	basal	expression	9
9	expression	mediated	7
10	in	expression	9
11	uninduced	mediated	7
12	cells	indicated	2
13	.	indicated	2

0	Nuclear	Rel-A	1
1	Rel-A	protein	4
2	and	protein	4
3	c-Rel	protein	4
4	protein	are	6
5	complexes	protein	4
6	are	<ROOT>	-1
7	differentially	are	6
8	distributed	differentially	7
9	within	distributed	8
10	human	thymocytes	11
11	thymocytes	distributed	8
12	.	are	6

0	Although	is	14
1	the	Although	0
2	CD8+	T	4
3	cytotoxic	T	4
4	T	the	1
5	lymphocyte	T	4
6	(	CTL	7
7	CTL	lymphocyte	5
8	)	CTL	7
9	response	CTL	7
10	to	infected	12
11	latently	infected	12
12	infected	response	9
13	cells	Although	0
14	is	<ROOT>	-1
15	well	characterized	16
16	characterized	is	20
17	,	characterized	16
18	very	little	19
19	little	characterized	16
20	is	T	23
21	known	T	23
22	about	T	23
23	T	is	14
24	cell	is	14
25	controls	is	14
26	over	controls	25
27	lytic	over	26
28	infection	lytic	27
29	;	infection	28
30	this	imbalance	31
31	imbalance	our	33
32	in	our	33
33	our	infection	28
34	understanding	belies	35
35	belies	our	33
36	the	importance	37
37	importance	belies	35
38	of	importance	37
39	virus-replicative	lesions	40
40	lesions	of	38
41	in	several	42
42	several	of	38
43	aspects	of	44
44	of	several	42
45	EBV	of	44
46	disease	pathogenesis	47
47	pathogenesis	EBV	45
48	.	pathogenesis	47

0	Stably	transfected	1
1	transfected	Jurkat	2
2	Jurkat	cells	3
3	cells	<ROOT>	-1
4	behaved	cells	3
5	similarly	behaved	4
6	to	similarly	5
7	the	ones	10
8	transiently	transfected	9
9	transfected	ones	10
10	ones	to	6
11	with	similarly	5
12	respect	with	11
13	to	respect	12
14	inhibition	to	13
15	by	inhibition	14
16	CIF	inhibition	14
17	and	CIF	16
18	cyclosporine	and	17
19	.	cells	3

0	We	describe	2
1	here	describe	2
2	describe	<ROOT>	-1
3	the	organisation	5
4	genomic	organisation	5
5	organisation	describe	2
6	(	3	7
7	3	organisation	5
8	exons	3	7
9	of	exons	8
10	132	of	9
11	,	exons	8
12	112	3	7
13	and	542	14
14	542	3	7
15	bp	describe	2
16	and	2	17
17	2	describe	2
18	introns	describe	2
19	of	introns	18
20	1211	of	19
21	and	378	22
22	378	1211	20
23	bp	describe	2
24	)	describe	2
25	and	describe	2
26	sequence	including	27
27	including	describe	2
28	3	including	27
29	kb	3	28
30	of	including	27
31	DNA	of	30
32	from	immediate	34
33	the	immediate	34
34	immediate	of	30
35	5'	describe	2
36	upstream	describe	2
37	region	describe	2
38	of	region	37
39	the	gene	42
40	human	gene	42
41	eotaxin	gene	42
42	gene	of	38
43	.	of	38

0	By	was	9
1	Northern	By	0
2	and	By	0
3	in	and	2
4	situ	hybridization	5
5	hybridization	in	3
6	,	hybridization	5
7	mNFATc	transcript	8
8	transcript	hybridization	5
9	was	<ROOT>	-1
10	detected	was	9
11	from	detected	10
12	the	from	11
13	early	of	15
14	stage	of	15
15	of	the	12
16	development	.	17
17	.	of	15

0	Use	<ROOT>	-1
1	of	Use	0
2	new	of	1
3	biologic	new	2
4	markers	biologic	3
5	in	markers	4
6	the	in	5
7	ovulation	the	6
8	induction	.	9
9	.	ovulation	7

0	The	expression	2
1	allele-specific	expression	2
2	expression	profiles	3
3	profiles	were	17
4	of	profiles	3
5	other	genes	7
6	imprinted	genes	7
7	genes	of	4
8	,	profiles	3
9	IGF2	profiles	3
10	and	IGF2	9
11	H19	and	10
12	,	profiles	3
13	on	profiles	3
14	human	on	13
15	chromosome	human	14
16	11	profiles	3
17	were	<ROOT>	-1
18	constant	were	17
19	and	constant	18
20	consistent	and	19
21	with	consistent	20
22	those	with	21
23	in	those	22
24	other	tissues	25
25	tissues	in	23
26	.	were	17

0	The	differentiation	1
1	differentiation	of	2
2	of	is	9
3	myeloid	of	2
4	precursors	of	2
5	into	of	2
6	mature	myelomonocytic	7
7	myelomonocytic	into	5
8	cells	myelomonocytic	7
9	is	<ROOT>	-1
10	characterized	is	9
11	by	characterized	10
12	the	induction	13
13	induction	by	11
14	of	induction	13
15	the	of	14
16	gene	the	15
17	encoding	gene	16
18	the	CD11b	21
19	beta2	CD11b	21
20	integrin	CD11b	21
21	CD11b	encoding	17
22	.	is	9

0	Through	<ROOT>	-1
1	activation	Through	0
2	of	Through	0
3	this	of	2
4	and	driven	7
5	other	NF-Y	6
6	NF-Y	driven	7
7	driven	this	3
8	promoters	driven	7
9	,	driven	7
10	the	interaction	12
11	Tax1-NF-Y	interaction	12
12	interaction	may	13
13	may	driven	7
14	play	critical	16
15	a	critical	16
16	critical	may	13
17	role	may	13
18	in	role	17
19	causing	in	18
20	cellular	transformation	21
21	transformation	causing	19
22	and	causing	19
23	HTLV-1	pathogenesis	24
24	pathogenesis	and	22
25	.	Through	0

0	Lymphocyte	infiltration	1
1	infiltration	was	4
2	of	infiltration	1
3	tumor	of	2
4	was	<ROOT>	-1
5	studied	metabolic	8
6	vis-a-vis	hormone	7
7	hormone	metabolic	8
8	metabolic	was	4
9	status	was	4
10	,	hormone	13
11	tumor	hormone	13
12	tissue	hormone	13
13	hormone	status	9
14	sensitivity	hormone	13
15	and	tobacco	16
16	tobacco	sensitivity	14
17	smoking	was	4
18	,	was	4
19	in	cancer	22
20	113	breast	21
21	breast	cancer	22
22	cancer	was	4
23	patients	was	4
24	,	was	4
25	aged	was	4
26	25-77	was	4
27	.	was	4

0	Transcription	factor	1
1	factor	GATA-3	2
2	GATA-3	is	3
3	is	<ROOT>	-1
4	differentially	is	3
5	expressed	differentially	4
6	in	murine	7
7	murine	expressed	5
8	Th1	murine	7
9	and	Th2	10
10	Th2	Th1	8
11	cells	is	3
12	and	is	3
13	controls	is	3
14	Th2-specific	expression	15
15	expression	is	3
16	of	expression	15
17	the	of	16
18	interleukin-5	gene	19
19	gene	the	17
20	.	gene	19

0	Collectively	suggest	4
1	,	suggest	4
2	these	results	3
3	results	suggest	4
4	suggest	<ROOT>	-1
5	that	suggest	4
6	HOCl	should	7
7	should	that	5
8	be	should	7
9	considered	be	8
10	as	considered	9
11	an	species	13
12	oxidative	species	13
13	species	as	10
14	capable	species	13
15	of	capable	14
16	inducing	NF-kappaB	17
17	NF-kappaB	of	15
18	in	cell	21
19	a	cell	21
20	T-lymphocytic	cell	21
21	cell	capable	14
22	line	that	5
23	through	line	22
24	a	transduction	25
25	transduction	through	23
26	mechanism	transduction	25
27	involving	transduction	25
28	ROS	involving	27
29	,	ROS	28
30	and	ROS	28
31	having	and	30
32	a	having	31
33	long-distance	through	35
34	effect	through	35
35	through	a	32
36	subsequent	release	38
37	TNF-alpha	release	38
38	release	through	35
39	.	suggest	4

0	In	<ROOT>	-1
1	addition	In	0
2	Spi-B	In	0
3	as	In	0
4	well	as	3
5	as	as	3
6	PU.1	were	7
7	were	as	3
8	able	were	7
9	to	able	8
10	transactivate	to	9
11	Btk	expression	12
12	expression	transactivate	10
13	.	In	0

0	Xenogeneic	<ROOT>	-1
1	human	Xenogeneic	0
2	serum	human	1
3	significantly	serum	2
4	(	serum	2
5	P	human	1
6	&lt;	)	8
7	0.01	)	8
8	)	human	1
9	increased	)	8
10	the	number	11
11	number	increased	9
12	of	number	11
13	adherent	of	12
14	leukocytes	as	15
15	as	adherent	13
16	compared	increased	9
17	with	porcine	18
18	porcine	compared	16
19	serum	Xenogeneic	0
20	.	Xenogeneic	0

0	Comparison	<ROOT>	-1
1	of	genomic	4
2	cDNA	of	1
3	and	of	1
4	genomic	Comparison	0
5	sequences	Comparison	0
6	reveals	Comparison	0
7	a	reveals	6
8	4-exon	a	7
9	structure	characteristic	10
10	characteristic	4-exon	8
11	of	characteristic	10
12	the	of	11
13	FOS	the	12
14	family	FOS	13
15	of	family	14
16	genes	of	15
17	.	of	15

0	Platelet/endothelial	is	7
1	cell	Platelet/endothelial	0
2	adhesion	molecule-1	3
3	molecule-1	(	4
4	(	cell	1
5	PECAM-1	(	4
6	)	(	4
7	is	<ROOT>	-1
8	a	member	10
9	130-kD	member	10
10	member	is	7
11	of	member	10
12	the	of	11
13	Ig	superfamily	15
14	gene	superfamily	15
15	superfamily	the	12
16	that	is	17
17	is	is	7
18	expressed	is	17
19	on	expressed	18
20	platelets	on	19
21	,	platelets	20
22	endothelial	platelets	20
23	cells	,	24
24	,	endothelial	22
25	and	,	24
26	certain	subsets	28
27	leukocyte	subsets	28
28	subsets	and	25
29	.	is	7

0	The	data	1
1	data	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	RelB	expression	5
5	expression	is	6
6	is	that	3
7	regulated	transcriptionally	9
8	both	transcriptionally	9
9	transcriptionally	is	6
10	and	transcriptionally	9
11	post-translationally	indicate	2
12	in	myeloid	13
13	myeloid	post-translationally	11
14	cells	indicate	2
15	.	indicate	2

0	In	is	5
1	contrast	In	0
2	,	is	5
3	Egr-1	expression	4
4	expression	is	5
5	is	<ROOT>	-1
6	abrogated	is	5
7	in	abrogated	6
8	group	in	7
9	I	group	8
10	Burkitt	I	9
11	tumor	Burkitt	10
12	cells	,	13
13	,	tumor	11
14	irrespective	tumor	11
15	of	irrespective	14
16	the	of	15
17	EBV	genome	18
18	genome	carrying	19
19	carrying	the	16
20	status	carrying	19
21	.	status	20

0	We	investigated	2
1	have	investigated	2
2	investigated	<ROOT>	-1
3	the	effect	4
4	effect	investigated	2
5	of	effect	4
6	adenovirus	of	5
7	2	adenovirus	6
8	(	2	7
9	Ad2	(	8
10	)	infection	11
11	infection	Ad2	9
12	on	human	13
13	human	(	8
14	monocytes	investigated	2
15	and	investigated	2
16	monocyte-derived	investigated	2
17	macrophages	investigated	2
18	with	regard	19
19	regard	investigated	2
20	to	regard	19
21	expression	of	22
22	of	to	20
23	TNF-alpha	of	22
24	and	of	22
25	IL-1	of	22
26	beta	investigated	2
27	.	investigated	2

0	Expression	can	9
1	of	Expression	0
2	the	protein	5
3	stimulatory	protein	5
4	G	protein	5
5	protein	of	1
6	,	G-LRB-S-RRB-alpha	7
7	G-LRB-S-RRB-alpha	Expression	0
8	,	can	9
9	can	<ROOT>	-1
10	vary	can	9
11	over	vary	10
12	a	over	11
13	3-fold	in	15
14	range	in	15
15	in	a	12
16	human	can	9
17	tissues	can	9
18	and	can	9
19	in	central	21
20	rodent	in	19
21	central	and	18
22	nervous	central	21
23	system	central	21
24	.	can	9

0	In	factors	7
1	most	cells	2
2	cells	In	0
3	,	factors	7
4	Rel/NF-kappa	B	5
5	B	factors	7
6	transcription	B	5
7	factors	<ROOT>	-1
8	appear	factors	7
9	to	mediate	10
10	mediate	appear	8
11	survival	signals	12
12	signals	appear	8
13	that	protect	14
14	protect	signals	12
15	cells	from	16
16	from	protect	14
17	apoptosis	factors	7
18	;	factors	7
19	however	factors	7
20	,	factors	7
21	under	some	22
22	some	factors	7
23	circumstances	,	24
24	,	some	22
25	activation	may	29
26	of	activation	25
27	these	factors	28
28	factors	of	26
29	may	factors	7
30	also	may	29
31	promote	may	29
32	apoptosis	promote	31
33	.	factors	7

0	These	<ROOT>	-1
1	experiments	that	3
2	demonstrate	that	3
3	that	These	0
4	HSV-1	that	3
5	is	HSV-1	4
6	a	is	5
7	competent	for	9
8	vector	for	9
9	for	a	6
10	expression	for	9
11	of	expression	10
12	these	of	11
13	VZV	and	15
14	proteins	and	15
15	and	these	12
16	support	These	0
17	the	feasibility	18
18	feasibility	support	16
19	of	feasibility	18
20	engineering	of	19
21	a	engineering	20
22	combined	for	24
23	vaccine	for	24
24	for	a	21
25	these	for	24
26	closely	.	29
27	related	alpha-herpesviruses	28
28	alpha-herpesviruses	.	29
29	.	these	25

0	The	cells	3
1	AML1a-transfected	cells	3
2	K562	cells	3
3	cells	had	4
4	had	<ROOT>	-1
5	a	capacity	7
6	reduced	capacity	7
7	capacity	had	4
8	to	capacity	7
9	differentiate	to	8
10	in	the	11
11	the	of	13
12	presence	of	13
13	of	differentiate	9
14	sodium	n-butyrate	15
15	n-butyrate	had	4
16	but	n-butyrate	15
17	not	in	18
18	in	the	19
19	the	but	16
20	presence	the	19
21	of	presence	20
22	other	inducers	23
23	inducers	of	21
24	,	such	25
25	such	had	4
26	as	such	25
27	hemin	had	4
28	,	had	4
29	1-beta-D-arabinofuranosylcytosine	,	28
30	,	1-beta-D-arabinofuranosylcytosine	29
31	and	1-beta-D-arabinofuranosylcytosine	29
32	herbimycin	A	33
33	A	and	31
34	.	had	4

0	The	I-EVI1	2
1	Ribophorin	I-EVI1	2
2	I-EVI1	fusion	3
3	fusion	<ROOT>	-1
4	in	fusion	3
5	particular	in	4
6	may	fusion	3
7	be	may	6
8	a	occurrence	10
9	common	occurrence	10
10	occurrence	be	7
11	in	be	7
12	t-LRB-3;3-RRB-	in	11
13	.	fusion	3

0	Octamer	independent	1
1	independent	<ROOT>	-1
2	activation	independent	1
3	of	activation	2
4	transcription	of	3
5	from	transcription	4
6	the	from	5
7	kappa	promoter	10
8	immunoglobulin	promoter	10
9	germline	promoter	10
10	promoter	from	5
11	.	independent	1

0	To	8.5	11
1	find	To	0
2	new	regions	4
3	regulatory	regions	4
4	regions	find	1
5	of	alpha	8
6	the	alpha	8
7	IL-2R	alpha	8
8	alpha	regions	4
9	gene	To	0
10	,	To	0
11	8.5	have	24
12	kb	noncoding	17
13	of	noncoding	17
14	the	noncoding	17
15	5'	end	16
16	end	noncoding	17
17	noncoding	8.5	11
18	sequence	of	19
19	of	alpha	22
20	the	alpha	22
21	IL-2R	alpha	22
22	alpha	8.5	11
23	gene	8.5	11
24	have	<ROOT>	-1
25	been	have	24
26	sequenced	been	25
27	.	have	24

0	Thus	can	5
1	,	can	5
2	human	precursors	4
3	erythroid	precursors	4
4	precursors	can	5
5	can	<ROOT>	-1
6	be	can	5
7	expanded	be	6
8	in	expanded	7
9	vitro	in	8
10	in	expanded	7
11	sufficient	numbers	12
12	numbers	in	10
13	and	numbers	12
14	purity	and	13
15	to	purity	14
16	allow	to	15
17	its	allow	16
18	usage	its	17
19	in	usage	18
20	signal	transduction	21
21	transduction	in	19
22	studies	transduction	21
23	.	studies	22

0	As	expressed	6
1	in	As	0
2	MDMs	in	1
3	,	constitutively	5
4	AMs	constitutively	5
5	constitutively	expressed	6
6	expressed	<ROOT>	-1
7	p50/p65	expressed	6
8	and	p50/p65	7
9	p50/RelB	and	8
10	although	p50/RelB	9
11	at	and	8
12	lower	at	11
13	levels	lower	12
14	.	levels	13

0	Our	investigation	1
1	investigation	Vbeta	18
2	of	investigation	1
3	the	of	2
4	human	the	3
5	TCR	beta	6
6	beta	human	4
7	gene	beta	6
8	uncovers	tissue-specific	13
9	a	complex	11
10	surprisingly	complex	11
11	complex	uncovers	8
12	and	tissue-specific	13
13	tissue-specific	gene	7
14	structure	investigation	1
15	at	investigation	1
16	the	TCR	17
17	TCR	at	15
18	Vbeta	<ROOT>	-1
19	8.1	promoter	20
20	promoter	Vbeta	18
21	.	Vbeta	18

0	A	molecular	1
1	molecular	<ROOT>	-1
2	basis	molecular	1
3	for	basis	2
4	the	pathogenesis	5
5	pathogenesis	for	3
6	of	pathogenesis	5
7	X-linked	immunodeficiency	10
8	severe	immunodeficiency	10
9	combined	immunodeficiency	10
10	immunodeficiency	of	6
11	.	molecular	1

0	Diminished	NF-kappaB	1
1	NF-kappaB	has	3
2	activity	NF-kappaB	1
3	has	<ROOT>	-1
4	been	has	3
5	shown	been	4
6	to	shown	5
7	occur	to	6
8	in	T	9
9	T	occur	7
10	cells	with	11
11	with	to	6
12	aging	with	11
13	,	has	3
14	suggesting	that	15
15	that	has	3
16	impaired	has	3
17	activation	has	3
18	of	has	3
19	NF-kappaB	has	3
20	might	NF-kappaB	19
21	occur	during	22
22	during	might	20
23	cellular	has	3
24	senescence	has	3
25	.	has	3

0	This	suggests	1
1	suggests	<ROOT>	-1
2	that	suggests	1
3	CHEMR1	that	2
4	may	CHEMR1	3
5	be	may	4
6	a	receptor	7
7	receptor	be	5
8	for	receptor	7
9	unidentified	chemokine	11
10	C-C	chemokine	11
11	chemokine	for	8
12	or	chemokine	11
13	a	receptor	15
14	low-affinity	receptor	15
15	receptor	chemokine	11
16	for	receptor	15
17	MIP-1alpha	for	16
18	.	suggests	1

0	In	induced	11
1	THP-1	In	0
2	cells	transfected	3
3	transfected	THP-1	1
4	with	In	0
5	HIV	constructs	7
6	plasmid	constructs	7
7	constructs	with	4
8	,	induced	11
9	both	organisms	10
10	organisms	induced	11
11	induced	terminal	17
12	transcription	induced	11
13	from	terminal	17
14	the	terminal	17
15	HIV	terminal	17
16	long	terminal	17
17	terminal	<ROOT>	-1
18	repeat	that	19
19	that	terminal	17
20	was	NF-kappaB	24
21	dependent	NF-kappaB	24
22	on	NF-kappaB	24
23	intact	NF-kappaB	24
24	NF-kappaB	that	19
25	binding	terminal	17
26	sequences	terminal	17
27	.	terminal	17

0	We	conclude	1
1	conclude	<ROOT>	-1
2	that	conclude	1
3	FMS	patients	4
4	patients	have	5
5	have	that	2
6	a	hypocortisolemia	8
7	mild	hypocortisolemia	8
8	hypocortisolemia	have	5
9	,	conclude	1
10	increased	cortisol	11
11	cortisol	feedback	12
12	feedback	conclude	1
13	resistance	in	14
14	in	feedback	12
15	combination	in	14
16	probably	in	14
17	with	conclude	1
18	a	with	17
19	reduced	a	18
20	CRH	reduced	19
21	synthesis	CRH	20
22	or	synthesis	21
23	release	synthesis	21
24	in	release	23
25	the	hypothalamus	26
26	hypothalamus	in	24
27	.	conclude	1

0	To	showed	17
1	confirm	To	0
2	the	relevance	4
3	physiological	relevance	4
4	relevance	of	5
5	of	confirm	1
6	these	of	5
7	findings	To	0
8	,	showed	17
9	we	showed	17
10	carried	we	9
11	out	carried	10
12	in	carried	10
13	vivo	in	12
14	footprinting	which	16
15	experiments	which	16
16	which	vivo	13
17	showed	<ROOT>	-1
18	that	showed	17
19	stimulation	alpha	22
20	of	alpha	22
21	IL-2R	of	20
22	alpha	expression	23
23	expression	that	18
24	correlated	with	25
25	with	showed	17
26	occupancy	showed	17
27	of	occupancy	26
28	the	element	30
29	GASd	element	30
30	element	of	27
31	.	showed	17

0	Using	<ROOT>	-1
1	electrophoretic	Using	0
2	mobility	Using	0
3	shift	mobility	2
4	assay	,	5
5	,	shift	3
6	we	Using	0
7	demonstrated	Using	0
8	that	demonstrated	7
9	a	treatment	11
10	short	treatment	11
11	treatment	that	8
12	of	human	13
13	human	T	14
14	T	treatment	11
15	lymphocytes	Using	0
16	with	specific	19
17	PGE2	specific	19
18	induces	PGE2	17
19	specific	Using	0
20	binding	Using	0
21	activity	Using	0
22	to	Using	0
23	CRE	Using	0
24	and	Using	0
25	AP-2	Using	0
26	,	AP-2	25
27	but	,	26
28	not	,	26
29	AP-1	Using	0
30	,	Using	0
31	DNA	Using	0
32	elements	Using	0
33	.	Using	0

0	Proinflammatory	<ROOT>	-1
1	neutrophil	stimuli	2
2	stimuli	Proinflammatory	0
3	also	Proinflammatory	0
4	promoted	the	5
5	the	Proinflammatory	0
6	accumulation	of	7
7	of	the	5
8	IkappaB-alpha	transcripts	10
9	mRNA	transcripts	10
10	transcripts	of	7
11	,	Proinflammatory	0
12	resulting	Proinflammatory	0
13	in	resulting	12
14	the	reexpression	15
15	reexpression	in	13
16	of	reexpression	15
17	the	of	16
18	IkappaB-alpha	.	20
19	protein	.	20
20	.	the	17

0	Constitutive	was	8
1	DNA	binding	2
2	binding	Constitutive	0
3	activity	Constitutive	0
4	consisting	Constitutive	0
5	of	consisting	4
6	p50	homodimers	7
7	homodimers	of	5
8	was	<ROOT>	-1
9	detected	was	8
10	in	detected	9
11	nuclear	extracts	12
12	extracts	in	10
13	from	in	10
14	both	types	16
15	cell	types	16
16	types	in	10
17	.	was	8

0	Gel-shift	assays	1
1	assays	revealed	2
2	revealed	<ROOT>	-1
3	that	revealed	2
4	transcriptional	factor	5
5	factor	(	6
6	(	induced	9
7	s	(	6
8	)	(	6
9	induced	that	3
10	only	induced	9
11	in	only	10
12	response	revealed	2
13	to	response	12
14	IL-13	revealed	2
15	treatment	of	16
16	of	peripheral	18
17	human	peripheral	18
18	peripheral	revealed	2
19	blood	revealed	2
20	monocytes	revealed	2
21	bind	revealed	2
22	to	bind	21
23	the	to	22
24	15-LO	.	27
25	promoter	.	27
26	DNA	.	27
27	.	the	23

0	We	<ROOT>	-1
1	have	We	0
2	set	have	1
3	out	set	2
4	to	set	2
5	test	to	4
6	a	model	7
7	model	test	5
8	for	model	7
9	tissue-specific	for	8
10	gene	tissue-specific	9
11	expression	gene	10
12	that	relies	13
13	relies	expression	11
14	on	relies	13
15	the	replication	17
16	early	replication	17
17	replication	on	14
18	of	replication	17
19	expressed	genes	20
20	genes	of	18
21	to	sequester	22
22	sequester	transcription	25
23	limiting	sequester	22
24	activating	transcription	25
25	transcription	relies	13
26	factors	We	0
27	.	We	0

0	The	levels	1
1	levels	<ROOT>	-1
2	of	levels	1
3	secreted	of	2
4	IL-1beta	secreted	3
5	,	IL-1beta	4
6	TNF-alpha	,	5
7	,	TNF-alpha	6
8	and	,	7
9	IL-6	and	8
10	during	IL-6	9
11	24	during	10
12	h	24	11
13	of	24	11
14	stimulation	were	15
15	were	of	13
16	comparable	were	15
17	to	comparable	16
18	those	to	17
19	induced	by	20
20	by	those	18
21	Escherichia	lipopolysaccharide	23
22	coli	lipopolysaccharide	23
23	lipopolysaccharide	to	17
24	at	to	17
25	1	microg/ml	26
26	microg/ml	at	24
27	.	levels	1

0	We	evaluated	1
1	evaluated	<ROOT>	-1
2	the	evaluated	1
3	expression	and	4
4	and	the	2
5	DNA	binding	6
6	binding	and	4
7	activity	evaluated	1
8	of	(	11
9	nuclear	factor	10
10	factor	of	8
11	(	activity	7
12	NF	(	11
13	)	evaluated	1
14	-kappa	evaluated	1
15	B	subunits	16
16	subunits	evaluated	1
17	in	peripheral	19
18	human	peripheral	19
19	peripheral	evaluated	1
20	blood	evaluated	1
21	monocytes	evaluated	1
22	and	evaluated	1
23	in	evaluated	1
24	monocyte-derived	macrophages	25
25	macrophages	in	23
26	(	MDMs	27
27	MDMs	macrophages	25
28	)	MDMs	27
29	.	evaluated	1

0	A	homologue	2
1	human	homologue	2
2	homologue	comments	15
3	of	homologue	2
4	the	Drosophila	5
5	Drosophila	Toll	6
6	Toll	activation	9
7	protein	Toll	6
8	signals	protein	7
9	activation	of	3
10	of	activation	9
11	adaptive	of	10
12	immunity	[	13
13	[	adaptive	11
14	see	homologue	2
15	comments	<ROOT>	-1
16	]	comments	15

0	Nuclear	B	3
1	factor	B	3
2	kappa	B	3
3	B	proteins	14
4	(	NF-kappa	5
5	NF-kappa	B	3
6	B	NF-kappa	5
7	;	NF-kappa	5
8	heterodimer	of	9
9	of	NF-kappa	5
10	p50	of	9
11	and	p50	10
12	p65	B	3
13	)	B	3
14	proteins	have	15
15	have	<ROOT>	-1
16	been	have	15
17	suggested	been	16
18	to	suggested	17
19	play	to	18
20	an	role	22
21	important	role	22
22	role	play	19
23	in	gene	24
24	gene	play	19
25	transcription	gene	24
26	of	transcription	25
27	inflammatory	have	15
28	mediators	monocytes	30
29	when	monocytes	30
30	monocytes	have	15
31	are	have	15
32	stimulated	are	31
33	with	stimulated	32
34	lipopolysaccharide	have	15
35	.	have	15

0	The	assay	2
1	NFAT-luc	assay	2
2	assay	is	3
3	is	<ROOT>	-1
4	a	technique	6
5	useful	technique	6
6	technique	is	3
7	for	technique	6
8	the	rapid	9
9	rapid	for	7
10	,	rapid	9
11	sensitive	rapid	9
12	measurement	sensitive	11
13	of	measurement	12
14	CIF	of	13
15	or	CIF	14
16	other	immunosuppressants	17
17	immunosuppressants	or	15
18	with	measurement	12
19	a	mode	21
20	similar	mode	21
21	mode	with	18
22	of	mode	21
23	action	of	22
24	.	is	3

0	TCP	<ROOT>	-1
1	succinate	TCP	0
2	(	succinate	1
3	20	(	2
4	microM	20	3
5	,	microM	4
6	72	h	7
7	h	,	5
8	)	microM	4
9	,	TCP	0
10	but	TCP	0
11	not	TCP	12
12	TCP	but	10
13	(	but	10
14	200	(	13
15	microM	200	14
16	,	microM	15
17	72	h	18
18	h	,	16
19	)	microM	15
20	,	200	14
21	reduced	to	25
22	U-937	to	25
23	cell	to	25
24	adhesion	to	25
25	to	200	14
26	TNF-alpha-stimulated	200	14
27	(	200	14
28	10	,	30
29	U/ml	,	30
30	,	200	14
31	6	,	30
32	h	6	31
33	)	h	32
34	HUVEC	TCP	0
35	by	TCP	0
36	30	%	37
37	%	by	35
38	(	P	39
39	P	%	37
40	&lt;	P	39
41	0.025	&lt;	40
42	)	0.025	41
43	and	)	42
44	to	IL-1	45
45	IL-1	and	43
46	beta-stimulated	HUVEC	47
47	HUVEC	and	43
48	by	and	43
49	56	%	50
50	%	by	48
51	(	P	52
52	P	%	50
53	&lt;	P	52
54	0.010	)	55
55	)	P	52
56	.	)	55

0	The	number	1
1	number	<ROOT>	-1
2	and	number	1
3	apparent	and	2
4	dissociation	of	6
5	constant	of	6
6	of	receptor	8
7	glucocorticoid	of	6
8	receptor	were	9
9	were	apparent	3
10	measured	were	9
11	using	measured	10
12	a	using	11
13	whole-cell	binding	14
14	binding	.	16
15	assay	.	16
16	.	a	12

0	However	remains	6
1	,	remains	6
2	the	problem	4
3	major	problem	4
4	problem	remains	6
5	still	remains	6
6	remains	<ROOT>	-1
7	the	incidence	9
8	high	incidence	9
9	incidence	leukemic	11
10	of	leukemic	11
11	leukemic	remains	6
12	relapse	remains	6
13	following	autologous	14
14	autologous	remains	6
15	PBSCT	remains	6
16	,	remains	6
17	which	may	18
18	may	remains	6
19	be	may	18
20	caused	be	19
21	by	caused	20
22	the	reinfusion	23
23	reinfusion	by	21
24	of	reinfusion	23
25	PBSC	of	24
26	contaminated	cells	29
27	by	cells	29
28	leukemic	cells	29
29	cells	remains	6
30	.	cells	29

0	We	conclude	1
1	conclude	<ROOT>	-1
2	that	conclude	1
3	cytokines	that	2
4	,	which	5
5	which	cytokines	3
6	signal	which	5
7	through	interferon	9
8	the	interferon	9
9	interferon	signal	6
10	family	cytokines	3
11	of	family	10
12	receptors	conclude	1
13	,	conclude	1
14	have	conclude	1
15	comparable	have	14
16	functional	effects	17
17	effects	comparable	15
18	on	effects	17
19	B-CLL	on	18
20	cells	B-CLL	19
21	.	conclude	1

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	are	9
4	additional	factor	5
5	factor	(	6
6	(	that	3
7	s	(	6
8	)	that	3
9	are	suggest	2
10	necessary	are	9
11	for	necessary	10
12	full	for	11
13	ER	.	15
14	function	.	15
15	.	full	12

0	These	abnormalities	1
1	abnormalities	can	2
2	can	<ROOT>	-1
3	be	can	2
4	reproduced	be	3
5	by	reproduced	4
6	transfection	by	5
7	of	transfection	6
8	cell	lines	9
9	lines	of	7
10	with	transfection	6
11	the	gene	13
12	GCR-beta	gene	13
13	gene	DNA	21
14	resulting	gene	13
15	in	DNA	21
16	significant	reduction	17
17	reduction	DNA	21
18	of	DNA	21
19	their	DNA	21
20	GCR-alpha	DNA	21
21	DNA	with	10
22	binding	.	24
23	capacity	.	24
24	.	DNA	21

0	Consistent	<ROOT>	-1
1	with	Consistent	0
2	this	result	3
3	result	with	1
4	,	mutation	5
5	mutation	Consistent	0
6	of	response	9
7	the	response	9
8	EBNA2	response	9
9	response	mutation	5
10	element	CBF1/RBP-Jkappa	13
11	(	CBF1/RBP-Jkappa	13
12	a	CBF1/RBP-Jkappa	13
13	CBF1/RBP-Jkappa	site	15
14	binding	site	15
15	site	Consistent	0
16	)	in	17
17	in	site	15
18	Cp	Consistent	0
19	also	Consistent	0
20	prevented	Consistent	0
21	significant	repression	22
22	repression	prevented	20
23	.	Consistent	0

0	Expression	<ROOT>	-1
1	of	Expression	0
2	LAZ3/BCL6	of	1
3	in	(	6
4	follicular	center	5
5	center	in	3
6	(	cells	10
7	FC	(	6
8	)	(	6
9	B	cells	10
10	cells	Expression	0
11	of	lymph	13
12	reactive	lymph	13
13	lymph	Expression	0
14	nodes	Expression	0
15	and	nodes	14
16	FC-derived	non-Hodgkin	17
17	non-Hodgkin	and	15
18	lymphomas	Expression	0
19	.	Expression	0

0	Exposure	<ROOT>	-1
1	of	Exposure	0
2	cells	to	3
3	to	of	1
4	adverse	conditions	6
5	environmental	conditions	6
6	conditions	Exposure	0
7	invokes	conditions	6
8	a	series	11
9	genetically	programmed	10
10	programmed	series	11
11	series	invokes	7
12	of	series	11
13	events	of	12
14	resulting	events	13
15	in	the	16
16	the	resulting	14
17	induction	of	18
18	of	the	16
19	specific	of	18
20	genes	.	21
21	.	specific	19

0	Department	hematopoietic	4
1	of	hematopoietic	4
2	lymphocytes	of	1
3	from	of	1
4	hematopoietic	is	7
5	stem	hematopoietic	4
6	cells	hematopoietic	4
7	is	<ROOT>	-1
8	controlled	is	7
9	,	is	7
10	in	is	7
11	part	in	10
12	,	is	7
13	by	is	7
14	the	activity	15
15	activity	by	13
16	of	activity	15
17	transcriptional	proteins	19
18	regulatory	proteins	19
19	proteins	of	16
20	.	is	7

0	Mutations	are	8
1	in	Mutations	0
2	the	gene	4
3	TSC2	gene	4
4	gene	in	1
5	on	Mutations	0
6	chromosome	16p13.3	7
7	16p13.3	on	5
8	are	<ROOT>	-1
9	responsible	are	8
10	for	responsible	9
11	approximately	%	13
12	50	%	13
13	%	for	10
14	of	%	13
15	familial	sclerosis	17
16	tuberous	sclerosis	17
17	sclerosis	of	14
18	(	TSC	19
19	TSC	sclerosis	17
20	)	TSC	19
21	.	are	8

0	They	bind	1
1	bind	<ROOT>	-1
2	in	bind	1
3	vitro	in	2
4	respectively	bind	1
5	ATF-1	respectively	4
6	and	ATF-1	5
7	NF-Y	proteins	8
8	proteins	ATF-1	5
9	.	bind	1

0	The	factor	2
1	nuclear	factor	2
2	factor	<ROOT>	-1
3	of	T	5
4	activated	T	5
5	T	factor	2
6	cells	(	7
7	(	factor	2
8	NFAT	factor	2
9	)	of	11
10	group	of	11
11	of	NFAT	8
12	transcription	factors	13
13	factors	of	11
14	is	factor	2
15	retained	factor	2
16	in	retained	15
17	the	in	16
18	cytoplasm	of	19
19	of	quiescent	20
20	quiescent	the	17
21	cells	quiescent	20
22	.	cells	21

0	In	was	5
1	previous	In	0
2	studies	In	0
3	,	was	5
4	it	was	5
5	was	can	26
6	shown	was	5
7	that	shown	6
8	the	region	10
9	fusion	region	10
10	region	that	7
11	of	region	10
12	the	protein	14
13	pml/RAR-alpha	protein	14
14	protein	of	11
15	,	region	10
16	expressed	promyelocytic	19
17	by	promyelocytic	19
18	acute	promyelocytic	19
19	promyelocytic	region	10
20	leukemia	(	21
21	(	region	10
22	APL	(	21
23	)	that	7
24	cells	that	7
25	,	was	5
26	can	<ROOT>	-1
27	be	can	26
28	specifically	recognized	29
29	recognized	be	27
30	in	recognized	29
31	vitro	in	30
32	by	recognized	29
33	donor	by	32
34	(	D.	35
35	D.	T	39
36	E.	D.	35
37	)	D.	35
38	CD4	T	39
39	T	recognized	29
40	cells	in	41
41	in	can	26
42	a	in	41
43	HLA	a	42
44	class	DR11-restricted	46
45	II	DR11-restricted	46
46	DR11-restricted	HLA	43
47	fashion	can	26
48	.	can	26

0	We	demonstrated	3
1	have	demonstrated	3
2	previously	demonstrated	3
3	demonstrated	acts	26
4	that	mutated	6
5	a	mutated	6
6	mutated	demonstrated	3
7	form	mutated	6
8	of	form	7
9	the	gene	12
10	human	gene	12
11	CIITA	gene	12
12	gene	of	8
13	,	demonstrated	3
14	coding	for	15
15	for	,	13
16	a	for	15
17	protein	151	22
18	lacking	151	22
19	the	151	22
20	amino	151	22
21	terminal	151	22
22	151	a	16
23	amino	demonstrated	3
24	acids	amino	23
25	,	acts	26
26	acts	<ROOT>	-1
27	as	potent	29
28	a	potent	29
29	potent	acts	26
30	dominant-negative	suppressor	31
31	suppressor	acts	26
32	of	II	35
33	HLA	II	35
34	class	II	35
35	II	suppressor	31
36	expression	suppressor	31
37	.	acts	26

0	Here	discuss	2
1	we	discuss	2
2	discuss	<ROOT>	-1
3	recent	advances	4
4	advances	discuss	2
5	in	transcriptional	6
6	transcriptional	advances	4
7	regulation	transcriptional	6
8	during	regulation	7
9	myelopoiesis	during	8
10	.	discuss	2

0	In	line	4
1	the	cell	3
2	erythroleukemia	cell	3
3	cell	In	0
4	line	<ROOT>	-1
5	K562	line	4
6	,	K562	5
7	due	line	4
8	to	due	7
9	the	absence	10
10	absence	to	8
11	of	absence	10
12	Spi-B	of	11
13	,	line	4
14	only	bound	16
15	PU.1	bound	16
16	bound	line	4
17	to	line	4
18	the	promoter	20
19	Btk	promoter	20
20	promoter	to	17
21	.	line	4

0	During	is	7
1	humoral	responses	3
2	immune	responses	3
3	responses	During	0
4	,	is	7
5	B-lymphocyte	activation	6
6	activation	is	7
7	is	<ROOT>	-1
8	followed	is	7
9	by	followed	8
10	differentiation	along	11
11	along	plasma	14
12	either	plasma	14
13	the	plasma	14
14	plasma	by	9
15	cell	plasma	14
16	pathway	is	7
17	or	pathway	16
18	the	pathway	21
19	memory	pathway	21
20	B-cell	pathway	21
21	pathway	or	17
22	.	is	7

0	Like	induced	5
1	G-CSF	Like	0
2	,	induced	5
3	SB	247464	4
4	247464	induced	5
5	induced	<ROOT>	-1
6	tyrosine	phosphorylation	7
7	phosphorylation	induced	5
8	of	phosphorylation	7
9	multiple	of	8
10	signaling	and	12
11	proteins	and	12
12	and	multiple	9
13	stimulated	and	12
14	primary	murine	15
15	murine	and	12
16	bone	induced	5
17	marrow	bone	16
18	cells	to	19
19	to	marrow	17
20	form	to	19
21	granulocytic	induced	5
22	colonies	induced	5
23	in	induced	5
24	vitro	induced	5
25	.	induced	5

0	Cytomegalovirus	products	3
1	IE	products	3
2	gene	products	3
3	products	IL-6	14
4	significantly	products	3
5	enhanced	products	3
6	LPS	enhanced	5
7	stimulation	LPS	6
8	of	IL-6	9
9	IL-6	stimulation	7
10	promoter	products	3
11	activity	products	3
12	in	activity	11
13	both	in	12
14	IL-6	luciferase	18
15	CAT	IL-6	17
16	and	IL-6	17
17	IL-6	IL-6	14
18	luciferase	<ROOT>	-1
19	assays	luciferase	18
20	.	luciferase	18

0	The	IL-3	1
1	IL-3	share	7
2	,	IL-3	1
3	IL-5	and	4
4	and	IL-3	1
5	GM-CSF	and	4
6	receptors	IL-3	1
7	share	<ROOT>	-1
8	a	signal	10
9	common	signal	10
10	signal	share	7
11	transducer	signal	10
12	that	possesses	13
13	possesses	signal	10
14	no	intrinsic	15
15	intrinsic	possesses	13
16	kinase	domain	17
17	domain	possesses	13
18	.	share	7

0	By	were	5
1	contrast	By	0
2	,	were	5
3	these	effects	4
4	effects	were	5
5	were	<ROOT>	-1
6	not	were	5
7	observed	were	5
8	upon	were	5
9	pulse-treatment	were	5
10	with	pulse-treatment	9
11	6	ICRF-193	13
12	microM	ICRF-193	13
13	ICRF-193	with	10
14	.	were	5

0	p65	<ROOT>	-1
1	,	were	7
2	p50	were	7
3	,	p50	2
4	and	p50	2
5	c-Rel	activities	6
6	activities	and	4
7	were	p65	0
8	found	p65	0
9	in	p65	0
10	both	CD4-	11
11	CD4-	p65	0
12	and	CD8-positive	13
13	CD8-positive	CD4-	11
14	thymocytes	p65	0
15	.	p65	0

0	Transcriptional	regulation	1
1	regulation	<ROOT>	-1
2	of	regulation	1
3	the	gene	6
4	ferritin	gene	6
5	heavy-chain	gene	6
6	gene	of	2
7	:	regulation	1
8	the	activity	9
9	activity	is	16
10	of	activity	9
11	the	NF-Y	15
12	CCAAT	NF-Y	15
13	binding	NF-Y	15
14	factor	NF-Y	15
15	NF-Y	of	10
16	is	regulation	1
17	modulated	is	16
18	in	modulated	17
19	heme-treated	cells	22
20	Friend	cells	22
21	leukemia	cells	22
22	cells	in	18
23	and	cells	22
24	during	monocyte-to-macrophage	25
25	monocyte-to-macrophage	is	16
26	differentiation	regulation	1
27	.	regulation	1

0	Northern	blot	1
1	blot	analysis	2
2	analysis	showed	3
3	showed	<ROOT>	-1
4	that	showed	3
5	the	hybridized	8
6	cDNA	hybridized	8
7	probe	hybridized	8
8	hybridized	that	4
9	with	hybridized	8
10	a	with	9
11	4.5	kb	12
12	kb	transcript	13
13	transcript	a	10
14	which	a	10
15	is	highly	16
16	highly	in	18
17	inducible	in	18
18	in	which	14
19	murine	T	20
20	T	a	10
21	cells	showed	3
22	.	showed	3

0	Shared	subunit	2
1	gamma-LRB-c-RRB-	subunit	2
2	subunit	receptor	7
3	within	receptor	7
4	the	receptor	7
5	human	receptor	7
6	interleukin-7	receptor	7
7	receptor	<ROOT>	-1
8	complex	receptor	7
9	.	receptor	7

0	Pretreatment	<ROOT>	-1
1	of	NK	2
2	NK	Pretreatment	0
3	cells	Pretreatment	0
4	with	Pretreatment	0
5	the	leads	12
6	antioxidant	leads	12
7	pyrrolidine	antioxidant	6
8	dithiocarbarmate	antioxidant	6
9	(	dithiocarbarmate	8
10	PDTC	dithiocarbarmate	8
11	)	dithiocarbarmate	8
12	leads	with	4
13	to	leads	12
14	the	inhibition	15
15	inhibition	NF-kappa	17
16	of	NF-kappa	17
17	NF-kappa	to	13
18	B	to	13
19	activation	Pretreatment	0
20	but	Pretreatment	0
21	the	binding	23
22	AP-1	binding	23
23	binding	Pretreatment	0
24	to	DNA	25
25	DNA	binding	23
26	was	DNA	25
27	superinduced	was	26
28	.	Pretreatment	0

0	The	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	the	protein	6
5	SRG3	protein	6
6	protein	associates	7
7	associates	that	3
8	with	mouse	10
9	a	mouse	10
10	mouse	associates	7
11	SWI2	mouse	10
12	.	suggest	2

0	We	suggest	1
1	suggest	<ROOT>	-1
2	that	suggest	1
3	extinction	is	7
4	of	extinction	3
5	Ig	genes	6
6	genes	of	4
7	is	that	2
8	part	is	7
9	of	part	8
10	a	mechanism	12
11	global	mechanism	12
12	mechanism	of	9
13	that	suppresses	14
14	suppresses	mechanism	12
15	the	program	17
16	differentiation	program	17
17	program	suppresses	14
18	foreign	suppresses	14
19	to	HeLa	21
20	the	HeLa	21
21	HeLa	foreign	18
22	phenotype	suggest	1
23	.	suggest	1

0	Although	is	25
1	Stat	Although	0
2	binding	Stat	1
3	to	intracellular	5
4	the	intracellular	5
5	intracellular	binding	2
6	domain	Although	0
7	of	cytokine	9
8	the	cytokine	9
9	cytokine	domain	6
10	receptor	depends	12
11	strongly	depends	12
12	depends	Although	0
13	on	Although	0
14	the	residue	16
15	phosphotyrosine	residue	16
16	residue	on	13
17	,	is	25
18	the	recruitment	19
19	recruitment	is	25
20	of	recruitment	19
21	a	Stat	23
22	specific	Stat	23
23	Stat	of	20
24	protein	Stat	23
25	is	<ROOT>	-1
26	dictated	by	27
27	by	is	25
28	amino	by	27
29	acid	residues	30
30	residues	amino	28
31	C-terminal	is	25
32	to	C-terminal	31
33	the	phosphotyrosine	34
34	phosphotyrosine	to	32
35	.	is	25

0	We	found	1
1	found	IFN-beta	11
2	that	IL-2	3
3	IL-2	found	1
4	,	found	1
5	interferon-alpha	,	4
6	(	IFN-alpha	7
7	IFN-alpha	interferon-alpha	5
8	)	IFN-alpha	7
9	,	interferon-alpha	5
10	and	interferon-alpha	5
11	IFN-beta	IL-2	13
12	inhibited	IFN-beta	11
13	IL-2	<ROOT>	-1
14	deprivation	IL-2	13
15	apoptosis	in	16
16	in	IL-2	13
17	Th0	IL-2	13
18	,	Th0	17
19	Th1	IL-2	13
20	,	IL-2	13
21	and	IL-2	13
22	Th2	IL-2	13
23	clones	IL-2	13
24	.	IL-2	13

0	One	clone	1
1	clone	<ROOT>	-1
2	(	C3/5	3
3	C3/5	clone	1
4	,	C3/5	3
5	CD3-LRB-+-RRB-	selected	12
6	,	CD3-LRB-+-RRB-	5
7	CD4-LRB-+-RRB-	CD3-LRB-+-RRB-	5
8	,	CD8-LRB---RRB-	9
9	CD8-LRB---RRB-	CD4-LRB-+-RRB-	7
10	)	CD8-LRB---RRB-	9
11	was	CD4-LRB-+-RRB-	7
12	selected	C3/5	3
13	for	selected	12
14	further	for	13
15	analysis	.	16
16	.	further	14

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	LMP1	that	3
5	appropriates	LMP1	4
6	TRADD	appropriates	5
7	to	TRADD	6
8	enable	to	7
9	efficient	lymphoblastoid	11
10	long-term	lymphoblastoid	11
11	lymphoblastoid	enable	8
12	cell	.	14
13	outgrowth	.	14
14	.	lymphoblastoid	11

0	A	understanding	2
1	better	understanding	2
2	understanding	may	13
3	of	transcriptional	4
4	transcriptional	understanding	2
5	regulation	at	6
6	at	important	8
7	this	important	8
8	important	understanding	2
9	stage	of	10
10	of	T-cell	11
11	T-cell	important	8
12	maturation	understanding	2
13	may	<ROOT>	-1
14	yield	may	13
15	new	insights	16
16	insights	yield	14
17	into	T-cell	18
18	T-cell	yield	14
19	development	may	13
20	and	development	19
21	new	targets	23
22	immunotherapeutic	targets	23
23	targets	and	20
24	.	may	13

0	Our	result	1
1	result	is	2
2	is	<ROOT>	-1
3	different	is	2
4	from	different	3
5	the	properties	7
6	reported	properties	7
7	properties	from	4
8	of	properties	7
9	human	CCR-4	10
10	CCR-4	of	8
11	.	is	2

0	Role	<ROOT>	-1
1	of	Role	0
2	the	X2	3
3	X2	of	1
4	box	X2	3
5	in	Role	0
6	activated	transcription	7
7	transcription	in	5
8	from	the	9
9	the	Role	0
10	DRA	Role	0
11	promoter	in	12
12	in	Role	0
13	B	Role	0
14	cells	Role	0
15	.	Role	0

0	Decreased	expression	3
1	adhesion	Decreased	0
2	molecule	expression	3
3	expression	was	4
4	was	<ROOT>	-1
5	associated	was	4
6	with	associated	5
7	a	reduction	8
8	reduction	with	6
9	of	reduction	8
10	monocytic	.	13
11	cell	.	13
12	adhesion	.	13
13	.	of	9

0	Salicylates	have	1
1	have	<ROOT>	-1
2	been	have	1
3	shown	been	2
4	to	shown	3
5	inhibit	to	4
6	lipopolysaccharide-induced	gene	7
7	gene	inhibit	5
8	transcription	gene	7
9	via	inhibit	5
10	inhibition	of	11
11	of	via	9
12	NF-kappa	B	13
13	B	of	11
14	activation	B	13
15	by	of	11
16	preventing	the	17
17	the	by	15
18	degradation	the	17
19	of	NF-kappa	20
20	NF-kappa	degradation	18
21	B	to	4
22	inhibitor	to	4
23	``	to	4
24	I	to	4
25	kappa	I	24
26	B	to	4
27	,	to	4
28	blocking	the	29
29	the	to	4
30	translocation	of	31
31	of	the	29
32	NF-kappa	of	31
33	B	into	34
34	into	NF-kappa	32
35	the	compartment	37
36	nuclear	compartment	37
37	compartment	have	1
38	.	have	1

0	These	results	1
1	results	may	2
2	may	<ROOT>	-1
3	lead	may	2
4	to	lead	3
5	an	improvement	6
6	improvement	to	4
7	of	and	9
8	antiinflammatory	and	9
9	and	improvement	6
10	immunosuppressive	and	9
11	therapies	may	2
12	and	therapies	11
13	provide	and	12
14	a	concept	16
15	novel	concept	16
16	concept	provide	13
17	for	concept	16
18	drug	discovery	19
19	discovery	for	17
20	.	may	2

0	Tyrosine	phosphorylation	1
1	phosphorylation	is	4
2	of	phosphorylation	1
3	STAT5	of	2
4	is	<ROOT>	-1
5	accompanied	is	4
6	by	accompanied	5
7	the	translocation	8
8	translocation	by	6
9	of	translocation	8
10	activated	STAT5	11
11	STAT5	of	9
12	to	the	13
13	the	translocation	8
14	nucleus	is	4
15	as	is	4
16	shown	as	15
17	by	STAT5	27
18	electrophoretic	(	22
19	mobility	(	22
20	shift	(	22
21	assay	(	22
22	(	by	17
23	EMSA	)	24
24	)	by	17
25	using	STAT5	27
26	32Pi-labeled	STAT5	27
27	STAT5	shown	16
28	binding	is	4
29	site	is	4
30	in	beta-casein	32
31	the	beta-casein	32
32	beta-casein	is	4
33	promoter	is	4
34	.	is	4

0	Recent	studies	1
1	studies	suggest	2
2	suggest	<ROOT>	-1
3	that	CD40-CD40	4
4	CD40-CD40	ligand	5
5	ligand	suggest	2
6	,	suggest	2
7	OX-OX40	ligand	8
8	ligand	suggest	2
9	,	ligand	8
10	a	group	11
11	group	factors	17
12	of	group	11
13	cytokines	intracellular	15
14	and	intracellular	15
15	intracellular	of	12
16	transcriptional	factors	17
17	factors	ligand	8
18	may	suggest	2
19	all	may	18
20	contribute	may	18
21	to	B-lymphocyte	22
22	B-lymphocyte	differentiation	23
23	differentiation	contribute	20
24	control	contribute	20
25	.	suggest	2

0	Human	<ROOT>	-1
1	cytomegalovirus	cell	9
2	induces	cell	9
3	interleukin-8	production	4
4	production	induces	2
5	by	cell	9
6	a	cell	9
7	human	cell	9
8	monocytic	cell	9
9	cell	Human	0
10	line	cell	9
11	,	Human	0
12	THP-1	,	11
13	,	through	14
14	through	Human	0
15	acting	through	14
16	concurrently	through	14
17	on	concurrently	16
18	AP-1-	on	17
19	and	AP-1-	18
20	NF-kappaB-binding	and	19
21	sites	NF-kappaB-binding	20
22	of	sites	21
23	the	of	22
24	interleukin-8	gene	25
25	gene	the	23
26	.	gene	25

0	Another	<ROOT>	-1
1	important	Another	0
2	activity	is	5
3	of	activity	2
4	DEN	of	3
5	is	important	1
6	its	control	7
7	control	is	5
8	of	control	7
9	transcription	of	8
10	in	activated	11
11	activated	of	8
12	T	Another	0
13	cells	,	14
14	,	T	12
15	and	,	14
16	we	determined	18
17	have	determined	18
18	determined	and	15
19	that	determined	18
20	an	site	22
21	NF-kappaB	site	22
22	site	is	23
23	is	that	19
24	critical	is	23
25	for	critical	24
26	this	activity	27
27	activity	for	25
28	.	Another	0

0	The	purpose	1
1	purpose	was	5
2	of	purpose	1
3	these	studies	4
4	studies	of	2
5	was	<ROOT>	-1
6	to	was	5
7	identify	to	6
8	whether	identify	7
9	transcription	factors	10
10	factors	affected	17
11	,	factors	10
12	associated	with	13
13	with	cytokine	14
14	cytokine	factors	10
15	signalling	factors	10
16	,	affected	17
17	affected	whether	8
18	promoter	affected	17
19	activity	promoter	18
20	of	activity	19
21	the	of	20
22	corticotropin	the	21
23	releasing	hormone	24
24	hormone	(	25
25	(	CRH	26
26	CRH	)	27
27	)	corticotropin	22
28	gene	corticotropin	22
29	.	was	5

0	Hypermethylation	genes	6
1	within	Hypermethylation	0
2	the	promoters	3
3	promoters	within	1
4	of	selected	5
5	selected	promoters	3
6	genes	appears	7
7	appears	<ROOT>	-1
8	to	appears	7
9	be	to	8
10	especially	common	11
11	common	be	9
12	in	be	9
13	all	types	14
14	types	in	12
15	of	human	16
16	human	hematopoietic	17
17	hematopoietic	types	14
18	neoplasms	appears	7
19	,	appears	7
20	and	appears	7
21	is	and	20
22	usually	is	21
23	associated	is	21
24	with	associated	23
25	inactivation	with	24
26	of	inactivation	25
27	the	of	26
28	involved	s	31
29	gene	involved	28
30	(	gene	29
31	s	the	27
32	)	s	31
33	.	appears	7

0	These	markers	1
1	markers	will	2
2	will	<ROOT>	-1
3	be	will	2
4	useful	be	3
5	to	be	3
6	study	to	5
7	the	study	6
8	role	the	7
9	of	genetic	10
10	genetic	role	8
11	variation	genetic	10
12	in	these	13
13	these	variation	11
14	genes	these	13
15	in	genes	14
16	the	pathogenesis	17
17	pathogenesis	type	19
18	of	type	19
19	type	in	15
20	2	diabetes	21
21	diabetes	in	15
22	.	diabetes	21

0	We	found	2
1	also	found	2
2	found	<ROOT>	-1
3	that	IL-2	4
4	IL-2	protects	5
5	protects	found	2
6	T	cell	7
7	cell	protects	5
8	clones	found	2
9	from	IL-2	10
10	IL-2	found	2
11	deprivation	found	2
12	apoptosis	active	14
13	accompanying	active	14
14	active	found	2
15	proliferation	found	2
16	and	found	2
17	enhanced	and	16
18	expression	enhanced	17
19	of	expression	18
20	P53	of	19
21	,	P53	20
22	Rb	,	21
23	and	Bcl-xL	24
24	Bcl-xL	Rb	22
25	proteins	found	2
26	.	found	2

0	Such	pathway	3
1	a	pathway	3
2	diverse	pathway	3
3	pathway	may	7
4	of	pathway	3
5	monocyte	differentiation	6
6	differentiation	of	4
7	may	<ROOT>	-1
8	constitute	may	7
9	one	constitute	8
10	of	one	9
11	the	mechanisms	13
12	basic	mechanisms	13
13	mechanisms	of	10
14	of	mechanisms	13
15	immune	regulation	16
16	regulation	of	14
17	.	may	7

0	Although	<ROOT>	-1
1	a	number	2
2	number	Although	0
3	of	number	2
4	transcription	factors	5
5	factors	of	3
6	involved	of	3
7	in	involved	6
8	the	in	7
9	control	the	8
10	of	control	9
11	the	cycle	13
12	cell	cycle	13
13	cycle	of	10
14	or	DNA	15
15	DNA	control	9
16	replication	have	17
17	have	Although	0
18	been	have	17
19	shown	been	18
20	to	shown	19
21	peak	to	20
22	in	peak	21
23	S	phase	24
24	phase	in	22
25	,	phase	24
26	this	is	27
27	is	phase	24
28	the	example	30
29	first	example	30
30	example	DNA	39
31	of	example	30
32	a	factor	35
33	lineage-restricted	factor	35
34	transcription	factor	35
35	factor	of	31
36	displaying	DNA	39
37	S	DNA	39
38	phase-specific	DNA	39
39	DNA	is	27
40	binding	in	22
41	activity	Although	0
42	.	Although	0

0	Our	studies	1
1	studies	showed	2
2	showed	<ROOT>	-1
3	that	showed	2
4	levels	were	9
5	of	levels	4
6	C/EBP	mRNA	8
7	epsilon	mRNA	8
8	mRNA	of	5
9	were	that	3
10	markedly	were	9
11	increased	(	15
12	in	(	15
13	NB4	in	12
14	cells	(	15
15	(	showed	2
16	promyelocytic	showed	2
17	leukemia	showed	2
18	line	showed	2
19	)	showed	2
20	,	showed	2
21	because	showed	2
22	they	were	23
23	were	because	21
24	induced	were	23
25	by	induced	24
26	9-cis	(	29
27	retinoic	(	29
28	acid	(	29
29	(	by	25
30	9-cis	(	29
31	RA	(	29
32	)	(	29
33	to	)	32
34	differentiate	towards	35
35	towards	to	33
36	granulocytes	(	29
37	.	showed	2

0	An	activator	2
1	isotype-specific	activator	2
2	activator	class	10
3	of	class	10
4	major	class	10
5	histocompatibility	complex	6
6	complex	(	7
7	(	class	10
8	MHC	class	10
9	)	class	10
10	class	<ROOT>	-1
11	II	class	10
12	genes	class	10
13	that	is	14
14	is	class	10
15	independent	is	14
16	of	independent	15
17	class	transactivator	19
18	II	transactivator	19
19	transactivator	of	16
20	.	class	10

0	Genetic	evidence	1
1	evidence	suggests	2
2	suggests	<ROOT>	-1
3	that	mutations	4
4	mutations	suggests	2
5	in	receptor	8
6	the	receptor	8
7	gamma-LRB-c-RRB-	receptor	8
8	receptor	mutations	4
9	subunit	suggests	2
10	cause	subunit	9
11	X-linked	immunodeficiency	14
12	severe	immunodeficiency	14
13	combined	immunodeficiency	14
14	immunodeficiency	cause	10
15	(	X-SCID	16
16	X-SCID	immunodeficiency	14
17	)	X-SCID	16
18	.	suggests	2

0	Infection	peripheral	3
1	of	peripheral	3
2	human	peripheral	3
3	peripheral	blood	4
4	blood	resulted	10
5	lymphocytes	blood	4
6	with	blood	4
7	HIV-1	with	6
8	in	blood	4
9	vitro	in	8
10	resulted	<ROOT>	-1
11	in	resulted	10
12	increased	in	11
13	interleukin-2	increased	12
14	(	IL-2	15
15	IL-2	interleukin-2	13
16	)	in	18
17	secretion	in	18
18	in	IL-2	15
19	response	interleukin-2	13
20	to	cell	22
21	T	cell	22
22	cell	response	19
23	activation	resulted	10
24	via	the	25
25	the	resulted	10
26	CD3	resulted	10
27	and	resulted	10
28	CD28	resulted	10
29	receptors	resulted	10
30	.	resulted	10

0	The	OCA-B	1
1	OCA-B	<ROOT>	-1
2	and	OCA-B	1
3	VP16	are	10
4	interactions	are	10
5	with	interactions	4
6	the	domain	9
7	Oct-1	domain	9
8	POU	domain	9
9	domain	with	5
10	are	and	2
11	sufficiently	different	12
12	different	are	10
13	to	different	12
14	permit	to	13
15	OCA-B	permit	14
16	and	OCA-B	15
17	VP16	and	16
18	to	VP16	17
19	bind	simultaneously	24
20	the	domain	23
21	Oct-1	domain	23
22	POU	domain	23
23	domain	bind	19
24	simultaneously	to	18
25	.	simultaneously	24

0	In	<ROOT>	-1
1	the	study	3
2	present	study	3
3	study	In	0
4	,	In	0
5	we	,	4
6	have	cell	12
7	utilized	cell	12
8	a	HeLa	11
9	mutant	HeLa	11
10	Jak1-deficient	HeLa	11
11	HeLa	utilized	7
12	cell	we	5
13	line	cell	12
14	,	,	4
15	E1C3	,	4
16	,	,	4
17	and	,	4
18	its	counterpart	21
19	parental	counterpart	21
20	Jak1-expressing	counterpart	21
21	counterpart	and	17
22	,	,	4
23	1D4	,	4
24	,	In	0
25	to	,	24
26	analyze	,	24
27	the	mediating	32
28	role	of	29
29	of	the	27
30	Jak1	of	29
31	in	Jak1	30
32	mediating	analyze	26
33	IL-4-induced	tyrosine	34
34	tyrosine	phosphorylation	35
35	phosphorylation	mediating	32
36	events	mediating	32
37	.	In	0

0	PURPOSE	<ROOT>	-1
1	:	PURPOSE	0
2	Sex-related	influences	3
3	influences	PURPOSE	0
4	have	influences	3
5	been	have	4
6	implicated	been	5
7	in	implicated	6
8	the	pathogenesis	9
9	pathogenesis	implicated	6
10	of	pathogenesis	9
11	vernal	keratoconjunctivitis	12
12	keratoconjunctivitis	of	10
13	(	VKC	14
14	VKC	keratoconjunctivitis	12
15	)	VKC	14
16	,	keratoconjunctivitis	12
17	an	disease	20
18	allergic	disease	20
19	eosinophilic	disease	20
20	disease	keratoconjunctivitis	12
21	.	PURPOSE	0

0	These	mutants	3
1	E1a	mutants	3
2	reiteration	mutants	3
3	mutants	could	4
4	could	<ROOT>	-1
5	be	could	4
6	propagated	be	5
7	in	propagated	6
8	HeLa	in	7
9	,	A549	10
10	A549	in	7
11	,	A549	10
12	and	A549	10
13	KB	and	12
14	cells	A549	10
15	;	could	4
16	they	were	17
17	were	could	4
18	genetically	stable	19
19	stable	were	17
20	;	were	17
21	and	were	17
22	they	killed	23
23	killed	and	21
24	CREF	cells	25
25	cells	killed	23
26	at	killed	23
27	a	frequency	30
28	strikingly	high	29
29	high	frequency	30
30	frequency	at	26
31	.	could	4

0	Thus	is	3
1	,	is	3
2	Elf-1	is	3
3	is	<ROOT>	-1
4	able	is	3
5	to	able	4
6	stimulate	gene	7
7	gene	to	5
8	transcription	gene	7
9	which	gene	7
10	may	be	11
11	be	required	12
12	required	is	3
13	for	is	3
14	the	development	15
15	development	for	13
16	and	development	15
17	activity	and	16
18	of	activity	17
19	lymphocytes	is	3
20	.	is	3

0	We	show	2
1	also	show	2
2	show	<ROOT>	-1
3	that	show	2
4	in	that	3
5	vitro-translated	in	4
6	NF-YB	bound	8
7	specifically	bound	8
8	bound	vitro-translated	5
9	to	bound	8
10	a	protein	14
11	glutathione	protein	14
12	S-transferase-Tax1	protein	14
13	fusion	protein	14
14	protein	to	9
15	.	show	2

0	One	<ROOT>	-1
1	gene	One	0
2	encodes	a	3
3	a	protein	4
4	protein	gene	1
5	,	protein	4
6	RFX5	One	0
7	,	One	0
8	that	is	9
9	is	One	0
10	a	member	11
11	member	is	9
12	of	the	13
13	the	member	11
14	RFX	One	0
15	family	RFX	14
16	of	DNA	17
17	DNA	family	15
18	binding	.	20
19	proteins	.	20
20	.	DNA	17

0	In	have	6
1	the	study	3
2	present	study	3
3	study	In	0
4	,	have	6
5	we	have	6
6	have	<ROOT>	-1
7	characterized	have	6
8	the	induction	10
9	transcriptional	induction	10
10	induction	characterized	7
11	of	induction	10
12	p40	of	11
13	by	CD40	14
14	CD40	characterized	7
15	ligation	B	19
16	in	B	19
17	a	B	19
18	human	B	19
19	B	have	6
20	lymphoblastoid	have	6
21	cell	,	23
22	line	,	23
23	,	Daudi	24
24	Daudi	have	6
25	,	have	6
26	and	leukemia	31
27	a	leukemia	31
28	human	leukemia	31
29	acute	leukemia	31
30	monocytic	leukemia	31
31	leukemia	have	6
32	cell	have	6
33	line	have	6
34	,	have	6
35	THP-1	have	6
36	.	have	6

0	Immunological	<ROOT>	-1
1	studies	Immunological	0
2	in	studies	1
3	human	in	2
4	immunodeficiency	human	3
5	virus	(	6
6	(	immunodeficiency	4
7	HIV	)	8
8	)	(	6
9	-positive	(	6
10	patients	(	6
11	suggest	Immunological	0
12	that	cytokines	41
13	the	progression	15
14	disease	progression	15
15	progression	is	16
16	is	that	12
17	accompanied	is	16
18	by	accompanied	17
19	a	production	21
20	defective	production	21
21	production	type	23
22	of	type	23
23	type	by	18
24	1	type	23
25	cytokines	interleukin-2	27
26	(	interleukin-2	27
27	interleukin-2	(	28
28	(	by	18
29	IL-2	that	12
30	)	that	12
31	and	that	12
32	IL-12	that	12
33	]	that	12
34	,	an	35
35	an	that	12
36	increased	type	39
37	production	increased	36
38	of	increased	36
39	type	an	35
40	2	that	12
41	cytokines	suggest	11
42	(	cytokines	41
43	IL-4	cytokines	41
44	,	cytokines	41
45	IL-6	cytokines	41
46	,	cytokines	41
47	and	cytokines	41
48	IL-10	Immunological	0
49	)	Immunological	0
50	,	Immunological	0
51	and	Immunological	0
52	an	and	51
53	increased	an	52
54	production	increased	53
55	of	IgE	56
56	IgE	increased	53
57	.	Immunological	0

0	A	<ROOT>	-1
1	constitutive	A	0
2	NF-kappa	constitutive	1
3	B	has	5
4	activity	has	5
5	has	NF-kappa	2
6	been	has	5
7	reported	been	6
8	in	reported	7
9	mature	in	8
10	macrophages	mature	9
11	.	macrophages	10

0	The	element	2
1	proximal	element	2
2	element	is	3
3	is	<ROOT>	-1
4	a	site	6
5	composite	site	6
6	site	is	3
7	that	binds	8
8	binds	site	6
9	members	binds	8
10	of	members	9
11	the	of	10
12	CREB/ATF	the	11
13	,	CREB/ATF	12
14	AP-1	,	15
15	,	CREB/ATF	12
16	and	,	15
17	octamer	families	18
18	families	,	15
19	of	,	15
20	transcription	factors	21
21	factors	is	3
22	.	is	3

0	MTBE	is	4
1	and	MTBE	0
2	benzene-induced	and	1
3	apoptosis	benzene-induced	2
4	is	<ROOT>	-1
5	attributed	is	4
6	to	attributed	5
7	a	block	9
8	discrete	block	9
9	block	cycle	13
10	within	cycle	13
11	the	cycle	13
12	cell	cycle	13
13	cycle	to	6
14	progression	is	4
15	.	is	4

0	This	report	1
1	report	<ROOT>	-1
2	sets	report	1
3	a	basis	4
4	basis	sets	2
5	for	further	6
6	further	sets	2
7	studies	primary	11
8	on	studies	7
9	signaling	on	8
10	in	primary	11
11	primary	further	6
12	cultured	report	1
13	human	precursors	15
14	erythroid	precursors	15
15	precursors	report	1
16	,	report	1
17	which	,	16
18	in	contribute	20
19	turn	in	18
20	contribute	which	17
21	to	better	23
22	our	better	23
23	better	contribute	20
24	understanding	better	23
25	in	understanding	24
26	the	differentiation	27
27	differentiation	in	25
28	processes	differentiation	27
29	of	processes	28
30	erythrocytes	of	29
31	and	erythrocytes	30
32	their	precursors	33
33	precursors	and	31
34	.	report	1

0	These	findings	1
1	findings	support	2
2	support	<ROOT>	-1
3	a	model	4
4	model	support	2
5	in	serves	8
6	which	in	5
7	gamma-LRB-c-RRB-	serves	8
8	serves	model	4
9	primarily	to	10
10	to	serves	8
11	activate	to	10
12	signal	activate	11
13	transduction	signal	12
14	by	transduction	13
15	the	by	14
16	IL-7R	,	18
17	complex	,	18
18	,	the	15
19	while	the	15
20	IL-7R	alpha	21
21	alpha	specific	23
22	determines	specific	23
23	specific	signaling	24
24	signaling	while	19
25	events	support	2
26	through	support	2
27	its	association	28
28	association	through	26
29	with	cytoplasmic	30
30	cytoplasmic	association	28
31	signaling	molecules	32
32	molecules	cytoplasmic	30
33	.	support	2

0	TRAMP-induced	cell	1
1	cell	death	2
2	death	is	3
3	is	<ROOT>	-1
4	inhibited	is	3
5	by	inhibited	4
6	an	inhibitor	7
7	inhibitor	by	5
8	of	inhibitor	7
9	ICE-like	proteases	10
10	proteases	of	8
11	,	proteases	10
12	but	,	11
13	not	by	14
14	by	,	11
15	Bcl-2	by	14
16	.	is	3

0	Viral	synthesis	2
1	DNA	synthesis	2
2	synthesis	were	7
3	and	synthesis	2
4	late	expression	6
5	gene	expression	6
6	expression	and	3
7	were	<ROOT>	-1
8	found	were	7
9	to	found	8
10	be	to	9
11	defective	be	10
12	in	U937	13
13	U937	be	10
14	cells	were	7
15	infected	were	7
16	with	E1B	17
17	E1B	were	7
18	19K	were	7
19	mutants	were	7
20	compared	with	21
21	with	were	7
22	wild-type	virus	23
23	virus	with	21
24	.	virus	23

0	These	results	1
1	results	show	2
2	show	<ROOT>	-1
3	that	show	2
4	the	steps	6
5	initial	steps	6
6	steps	that	3
7	in	steps	6
8	the	in	7
9	1,25D3	the	8
10	signaling	are	12
11	pathway	are	12
12	are	1,25D3	9
13	intact	steps	6
14	in	B	15
15	B	series	16
16	series	steps	6
17	resistant	steps	6
18	cells	show	2
19	and	show	2
20	lead	and	19
21	to	lead	20
22	the	appearance	23
23	appearance	to	21
24	of	appearance	23
25	early	markers	26
26	markers	of	24
27	of	monocytic	28
28	monocytic	markers	26
29	differentiation	of	24
30	.	differentiation	29

0	The	control	2
1	sophisticated	control	2
2	control	is	7
3	of	control	2
4	Rel/NF-kappa	B	5
5	B	of	3
6	activity	B	5
7	is	<ROOT>	-1
8	not	surprising	9
9	surprising	is	7
10	since	transcription	12
11	this	transcription	12
12	transcription	is	7
13	factor	is	7
14	is	factor	13
15	involved	is	14
16	in	involved	15
17	a	in	16
18	wide	of	20
19	array	of	20
20	of	a	17
21	cellular	of	20
22	responses	cellular	21
23	to	cellular	21
24	extracellular	cues	25
25	cues	to	23
26	,	cues	25
27	associated	cues	25
28	with	associated	27
29	growth	with	28
30	,	cues	25
31	development	cues	25
32	,	is	7
33	apoptosis	is	7
34	,	is	7
35	and	is	7
36	pathogen	is	7
37	invasion	is	7
38	.	is	7

0	Synthetic	glucocorticoids	1
1	glucocorticoids	exhibit	8
2	that	glucocorticoids	1
3	dissociate	that	2
4	transactivation	dissociate	3
5	and	transactivation	4
6	AP-1	transrepression	7
7	transrepression	glucocorticoids	1
8	exhibit	<ROOT>	-1
9	antiinflammatory	activity	10
10	activity	exhibit	8
11	in	activity	10
12	vivo	in	11
13	.	exhibit	8

0	Addition	<ROOT>	-1
1	of	Addition	0
2	GM-CSF	of	1
3	to	Addition	0
4	this	cocktail	6
5	basic	cocktail	6
6	cocktail	to	3
7	consistently	cocktail	6
8	increased	Addition	0
9	the	increased	8
10	clonogenic	of	12
11	capacity	of	12
12	of	the	9
13	single	of	12
14	CD34+Thy-1+	single	13
15	cells	,	16
16	,	CD34+Thy-1+	14
17	and	this	18
18	this	Addition	0
19	effect	was	20
20	was	this	18
21	further	was	20
22	enhanced	was	20
23	(	enhanced	22
24	up	(	23
25	to	72.3	26
26	72.3	up	24
27	+/-	%	29
28	4.3	+/-	27
29	%	72.3	26
30	on	(	23
31	day	(	23
32	7	day	31
33	)	7	32
34	by	)	33
35	the	inclusion	36
36	inclusion	by	34
37	of	inclusion	36
38	TNF-alpha	of	37
39	.	Addition	0

0	Upon	<ROOT>	-1
1	stimulation	Upon	0
2	by	stimulation	1
3	various	agents	4
4	agents	by	2
5	,	agents	4
6	I	is	8
7	kappaB	is	8
8	is	agents	4
9	proteolyzed	is	8
10	and	proteolyzed	9
11	NF-kappaB	and	10
12	translocates	NF-kappaB	11
13	to	the	14
14	the	translocates	12
15	nucleus	stimulation	1
16	,	Upon	0
17	where	activates	19
18	it	activates	19
19	activates	Upon	0
20	its	genes	22
21	target	genes	22
22	genes	activates	19
23	.	Upon	0

0	Glucocorticoids	<ROOT>	-1
1	and	Glucocorticoids	0
2	the	function	4
3	immune	function	4
4	function	and	1
5	in	function	4
6	the	in	5
7	human	:	11
8	immunodeficiency	:	11
9	virus	:	11
10	infection	:	11
11	:	the	6
12	a	Glucocorticoids	0
13	study	in	14
14	in	Glucocorticoids	0
15	hypercortisolemic	in	14
16	and	hypercortisolemic	15
17	cortisol-resistant	patients	18
18	patients	and	16
19	.	Glucocorticoids	0

0	Certain	subpopulations	1
1	subpopulations	<ROOT>	-1
2	of	subpopulations	1
3	lymphocytes	of	2
4	synthesize	of	2
5	and	synthesize	4
6	secrete	active	8
7	biologically	active	8
8	active	and	5
9	prolactin	active	8
10	,	suggests	12
11	which	,	10
12	suggests	subpopulations	1
13	that	prolactin	14
14	prolactin	can	15
15	can	suggests	12
16	act	can	15
17	as	act	16
18	an	autocrine	19
19	autocrine	as	17
20	and/or	autocrine	19
21	paracrine	factor	22
22	factor	autocrine	19
23	to	factor	22
24	modulate	the	25
25	the	to	23
26	activities	the	25
27	of	activities	26
28	cells	subpopulations	1
29	of	subpopulations	1
30	the	of	29
31	immune	.	33
32	system	.	33
33	.	the	30

0	However	did	14
1	,	did	14
2	the	pathway	5
3	NF-kappaB	pathway	5
4	activation	pathway	5
5	pathway	did	14
6	involving	pathway	5
7	the	sphingomyelinase	9
8	acidic	sphingomyelinase	9
9	sphingomyelinase	involving	6
10	of	sphingomyelinase	9
11	the	membrane	13
12	endolysosomial	membrane	13
13	membrane	of	10
14	did	<ROOT>	-1
15	not	did	14
16	seem	did	14
17	to	seem	16
18	participate	to	17
19	in	participate	18
20	the	activation	23
21	LPS-induced	activation	23
22	NF-kappaB	activation	23
23	activation	in	19
24	in	U937	25
25	U937	in	19
26	cells	did	14
27	.	did	14

0	Furthermore	demonstrated	3
1	,	demonstrated	3
2	we	demonstrated	3
3	demonstrated	<ROOT>	-1
4	by	demonstrated	3
5	western	by	4
6	blot	that	8
7	analysis	that	8
8	that	western	5
9	neutrophils	western	5
10	express	an	11
11	an	neutrophils	9
12	alternatively	an	11
13	spliced	variant	14
14	variant	alternatively	12
15	of	variant	14
16	the	of	15
17	pituitary	factor	19
18	transcription	pituitary	17
19	factor	the	16
20	Pit-1	demonstrated	3
21	,	demonstrated	3
22	designated	Pit-1b	23
23	Pit-1b	demonstrated	3
24	.	demonstrated	3

0	To	RelB	22
1	further	To	0
2	elucidate	To	0
3	the	elucidate	2
4	role	of	5
5	of	the	3
6	RelB	of	5
7	in	RelB	6
8	DC	of	5
9	differentiation	,	10
10	,	DC	8
11	mRNA	,	10
12	,	To	0
13	intracellular	,	12
14	protein	intracellular	13
15	expression	To	0
16	,	and	17
17	and	expression	15
18	DNA	To	0
19	binding	To	0
20	activity	To	0
21	of	activity	20
22	RelB	were	23
23	were	<ROOT>	-1
24	examined	in	25
25	in	were	23
26	immature	and	27
27	and	in	25
28	differentiated	and	27
29	human	in	25
30	DC	were	23
31	,	were	23
32	as	mononuclear	37
33	well	as	32
34	as	as	32
35	other	mononuclear	37
36	PB	mononuclear	37
37	mononuclear	were	23
38	cell	were	23
39	populations	were	23
40	.	were	23

0	Western	blot	1
1	blot	raised	9
2	and	blot	1
3	immunoprecipitation	studies	4
4	studies	and	2
5	using	studies	4
6	rabbit	antibodies	8
7	anti-C/EBP-epsilon	antibodies	8
8	antibodies	using	5
9	raised	<ROOT>	-1
10	against	raised	9
11	the	portion	13
12	N-terminal	portion	13
13	portion	against	10
14	of	portion	13
15	C/EBP-epsilon	of	14
16	(	acids	18
17	amino	acids	18
18	acids	C/EBP-epsilon	15
19	1	acids	18
20	to	portion	13
21	115	to	20
22	)	raised	9
23	showed	raised	9
24	that	showed	23
25	C/EBP-epsilon	showed	23
26	is	raised	9
27	a	phosphoprotein	30
28	32-kDa	phosphoprotein	30
29	nuclear	phosphoprotein	30
30	phosphoprotein	is	26
31	.	raised	9

0	The	activation	1
1	activation	<ROOT>	-1
2	of	NF-kappa	3
3	NF-kappa	activation	1
4	B	initiates	5
5	initiates	activation	1
6	both	extracellular	7
7	extracellular	activation	1
8	and	extracellular	7
9	intracellular	events	11
10	regulatory	events	11
11	events	and	8
12	that	result	13
13	result	extracellular	7
14	in	result	13
15	autoregulation	in	14
16	of	inflammatory	18
17	the	inflammatory	18
18	inflammatory	autoregulation	15
19	cascade	activation	1
20	through	activation	1
21	modulation	NF-kappa	23
22	of	NF-kappa	23
23	NF-kappa	through	20
24	B	activation	1
25	activation	activation	1
26	.	activation	1

0	Lymphocytes	lack	4
1	from	Lymphocytes	0
2	CML	patients	3
3	patients	from	1
4	lack	<ROOT>	-1
5	a	factor	8
6	47	factor	8
7	kDa	factor	8
8	factor	lack	4
9	having	affinity	10
10	affinity	a	12
11	for	a	12
12	a	factor	8
13	genomic	sterol	14
14	sterol	a	12
15	regulatory	a	12
16	sequence	lack	4
17	.	lack	4

0	These	animals	2
1	affected	animals	2
2	animals	displayed	3
3	displayed	<ROOT>	-1
4	marked	splenomegaly	5
5	splenomegaly	displayed	3
6	,	splenomegaly	5
7	anemia	splenomegaly	5
8	,	anemia	7
9	and	anemia	7
10	thrombocytopenia	and	9
11	.	displayed	3

0	Alternative	splicing	1
1	splicing	<ROOT>	-1
2	of	(	6
3	the	receptor	5
4	GC	receptor	5
5	receptor	of	2
6	(	splicing	1
7	R	(	6
8	)	pre-messenger	9
9	pre-messenger	splicing	1
10	RNA	splicing	1
11	generates	splicing	1
12	a	GCR	14
13	second	GCR	14
14	GCR	generates	11
15	,	splicing	1
16	termed	,	15
17	GCR-beta	splicing	1
18	,	which	19
19	which	splicing	1
20	does	which	19
21	not	does	20
22	bind	does	20
23	GCs	bind	22
24	but	does	20
25	antagonizes	but	24
26	the	activity	28
27	transactivating	activity	28
28	activity	antagonizes	25
29	of	activity	28
30	the	GCR	32
31	classic	GCR	32
32	GCR	of	29
33	,	antagonizes	25
34	termed	antagonizes	25
35	GCR-alpha	termed	34
36	.	splicing	1

0	CONCLUSIONS	<ROOT>	-1
1	:	CONCLUSIONS	0
2	Although	CONCLUSIONS	0
3	binding	Although	2
4	motifs	binding	3
5	and	binding	3
6	actual	binding	8
7	HLA	binding	8
8	binding	and	5
9	can	binding	8
10	be	binding	8
11	detected	and	5
12	in	detected	11
13	several	cases	14
14	cases	in	12
15	,	binding	3
16	the	generation	17
17	generation	,	15
18	of	generation	17
19	a	of	18
20	cellular	is	22
21	response	is	22
22	is	a	19
23	infrequent	CONCLUSIONS	0
24	,	CONCLUSIONS	0
25	confirming	CONCLUSIONS	0
26	that	CONCLUSIONS	0
27	HLA	binding	28
28	binding	is	29
29	is	that	26
30	necessary	is	29
31	but	is	29
32	not	sufficient	33
33	sufficient	but	31
34	to	sufficient	33
35	obtain	to	34
36	an	obtain	35
37	in	an	36
38	vitro	in	37
39	response	in	37
40	.	CONCLUSIONS	0

0	Dexamethasone	test	2
1	suppression	test	2
2	test	receptors	5
3	:	test	2
4	corticosteroid	receptors	5
5	receptors	<ROOT>	-1
6	regulation	receptors	5
7	in	mononuclear	8
8	mononuclear	regulation	6
9	leukocytes	receptors	5
10	of	leukocytes	9
11	young	subjects	14
12	and	young	11
13	aged	and	12
14	subjects	of	10
15	.	receptors	5

0	With	determined	8
1	the	use	2
2	use	specific	4
3	of	specific	4
4	specific	With	0
5	antibodies	With	0
6	we	determined	8
7	have	determined	8
8	determined	<ROOT>	-1
9	the	composition	10
10	composition	determined	8
11	of	composition	10
12	each	complex	13
13	complex	of	11
14	using	determined	8
15	electrophoretic	mobility	16
16	mobility	using	14
17	shift	mobility	16
18	assays	using	14
19	.	determined	8

0	Prompted	by	1
1	by	investigated	7
2	these	by	1
3	results	by	1
4	,	investigated	7
5	we	investigated	7
6	have	investigated	7
7	investigated	<ROOT>	-1
8	in	investigated	7
9	man	investigated	7
10	a	man	9
11	possible	investigated	7
12	relationship	possible	11
13	between	relationship	12
14	GR	between	13
15	binding	in	17
16	capacity	in	17
17	in	GR	14
18	the	PBMCs	19
19	PBMCs	in	17
20	and	PBMCs	19
21	age	and	20
22	,	relationship	12
23	in	relationship	12
24	relation	in	23
25	also	in	23
26	to	plasma	27
27	plasma	in	23
28	testosterone	plasma	27
29	and	testosterone	28
30	cortisol	investigated	7
31	.	investigated	7

0	We	reported	2
1	recently	reported	2
2	reported	<ROOT>	-1
3	that	reported	2
4	a	cysteine	9
5	garlic	compound	6
6	compound	cysteine	9
7	,	compound	6
8	S-allyl	cysteine	9
9	cysteine	artery	17
10	(	SAC	11
11	SAC	cysteine	9
12	)	SAC	11
13	,	cysteine	9
14	protects	cysteine	9
15	bovine	artery	17
16	pulmonary	artery	17
17	artery	that	3
18	endothelial	artery	17
19	cells	from	20
20	from	endothelial	18
21	oxidant	artery	17
22	injury	induced	23
23	induced	oxidant	21
24	by	artery	17
25	hydrogen	artery	17
26	peroxide	artery	17
27	(	peroxide	26
28	H2O2	reported	2
29	)	reported	2
30	.	reported	2

0	S107	plasmacytoma	1
1	plasmacytoma	cells	2
2	cells	<ROOT>	-1
3	,	cells	2
4	which	express	5
5	express	cells	2
6	CD40	express	5
7	but	express	5
8	are	but	7
9	defective	are	8
10	for	defective	9
11	the	defective	9
12	nuclear	the	11
13	appearance	nuclear	12
14	of	appearance	13
15	p50/p65-NF-kappaB	do	17
16	,	do	17
17	do	of	14
18	not	do	17
19	express	do	17
20	RelB	express	19
21	after	CD40	22
22	CD40	express	19
23	stimulation	cells	2
24	.	cells	2

0	V3-BH10	<ROOT>	-1
1	,	V3-BH10	0
2	which	consists	3
3	consists	amino	6
4	of	amino	6
5	42	amino	6
6	amino	V3-BH10	0
7	acids	V3-BH10	0
8	and	V3-BH10	0
9	has	and	8
10	a	structure	12
11	loop	structure	12
12	structure	has	9
13	,	V3-BH10	0
14	suppressed	V3-BH10	0
15	IL-2-driven	proliferation	16
16	proliferation	suppressed	14
17	of	proliferation	16
18	all	of	17
19	IL-2-dependent	all	18
20	cells	[	21
21	[	IL-2-dependent	19
22	Kit225	V3-BH10	0
23	,	V3-BH10	0
24	ED-40515-LRB-+-RRB-	V3-BH10	0
25	,	V3-BH10	0
26	KT-3	V3-BH10	0
27	,	V3-BH10	0
28	7-day	PHA-blasts	29
29	PHA-blasts	V3-BH10	0
30	,	PHA-blasts	29
31	and	PHA-blasts	29
32	fresh	mononuclear	35
33	peripheral	mononuclear	35
34	blood	mononuclear	35
35	mononuclear	and	31
36	cells	]	37
37	]	V3-BH10	0
38	tested	]	37
39	,	V3-BH10	0
40	whereas	V3-BH10	0
41	it	did	42
42	did	whereas	40
43	not	did	42
44	suppress	did	42
45	the	growth	47
46	cell	growth	47
47	growth	suppress	44
48	of	growth	47
49	IL-2-independent	cell	50
50	cell	of	48
51	lines	cell	50
52	(	lines	51
53	Hut102	(	52
54	,	Hut102	53
55	Molt-4	Hut102	53
56	,	Molt-4	55
57	and	Molt-4	55
58	Jurkat	and	57
59	)	(	52
60	.	V3-BH10	0

0	In	<ROOT>	-1
1	freshly	In	0
2	isolated	freshly	1
3	cells	,	4
4	,	isolated	2
5	both	isolated	2
6	FOS	and	7
7	and	both	5
8	FOSB	in	12
9	mRNAs	dramatically	11
10	increase	mRNAs	9
11	dramatically	in	12
12	in	and	7
13	response	and	7
14	to	response	13
15	the	inhibitor	18
16	protein	the	15
17	synthesis	inhibitor	18
18	inhibitor	to	14
19	cycloheximide	inhibitor	18
20	.	cycloheximide	19

0	Moreover	increased	6
1	,	Moreover	0
2	induction	,	1
3	of	G-LRB-S-RRB-alpha	4
4	G-LRB-S-RRB-alpha	induction	2
5	expression	Moreover	0
6	increased	<ROOT>	-1
7	events	distal	8
8	distal	increased	6
9	to	the	10
10	the	distal	8
11	accumulation	the	10
12	of	accumulation	11
13	cAMP	increased	6
14	including	element	24
15	the	phosphorylation	16
16	phosphorylation	element	24
17	of	phosphorylation	16
18	the	factor	20
19	transcription	factor	20
20	factor	of	17
21	,	cAMP	22
22	cAMP	element	24
23	response	element	24
24	element	cAMP	13
25	binding	element	24
26	protein	binding	25
27	and	element	24
28	transcriptional	increased	6
29	activation	increased	6
30	of	increased	6
31	cAMP-dependent	increased	6
32	reporter	increased	6
33	genes	increased	6
34	.	increased	6

0	Neither	<ROOT>	-1
1	a	mutation	2
2	mutation	Neither	0
3	in	mutation	2
4	I	alpha	6
5	kappaB	alpha	6
6	alpha	in	3
7	nor	Neither	0
8	a	mutation	9
9	mutation	nor	7
10	in	mutation	9
11	p50	in	10
12	or	p50	11
13	relA	or	12
14	,	Neither	0
15	the	subunits	18
16	two	subunits	18
17	major	subunits	18
18	subunits	,	14
19	of	subunits	18
20	NF-kappaB	of	19
21	in	subunits	18
22	this	in	21
23	cell	this	22
24	line	cell	23
25	,	line	24
26	accounts	this	28
27	for	this	28
28	this	cell	23
29	phosphorylation	Neither	0
30	defect	Neither	0
31	.	Neither	0

0	Control	nuclear	3
1	of	nuclear	3
2	NFATx1	nuclear	3
3	nuclear	<ROOT>	-1
4	translocation	by	5
5	by	inhibitory	8
6	a	inhibitory	8
7	calcineurin-regulated	inhibitory	8
8	inhibitory	nuclear	3
9	domain	inhibitory	8
10	.	domain	9

0	Cyclosporin	may	5
1	A	CsA	3
2	(	CsA	3
3	CsA	may	5
4	)	CsA	3
5	may	factor	40
6	achieve	may	5
7	its	achieve	6
8	immunosuppressive	its	7
9	effects	inhibiting	11
10	by	inhibiting	11
11	inhibiting	immunosuppressive	8
12	the	calcium-	13
13	calcium-	immunosuppressive	8
14	and	calmodulin-dependent	15
15	calmodulin-dependent	calcium-	13
16	phosphatase	is	19
17	calcineurin	which	18
18	which	phosphatase	16
19	is	its	7
20	required	is	19
21	for	required	20
22	activation	for	21
23	of	activation	22
24	target	of	23
25	genes	target	24
26	by	genes	25
27	members	by	26
28	of	members	27
29	the	of	28
30	NFAT	the	29
31	(	NFAT	30
32	nuclear	factor	33
33	factor	(	31
34	of	T	36
35	activated	T	36
36	T	factor	33
37	cells	may	5
38	)	may	5
39	transcription	factor	40
40	factor	<ROOT>	-1
41	family	factor	40
42	.	factor	40

0	In	I	7
1	the	study	3
2	present	study	3
3	study	In	0
4	,	I	7
5	corticosteroid	I	7
6	Type	I	7
7	I	were	15
8	and	I	7
9	Type	I	7
10	II	I	7
11	receptors	I	7
12	in	mononuclear	13
13	mononuclear	I	7
14	leukocytes	I	7
15	were	<ROOT>	-1
16	measured	10	18
17	in	10	18
18	10	were	15
19	elderly	were	15
20	subjects	were	15
21	and	were	15
22	in	and	21
23	9	young	24
24	young	in	22
25	adults	were	15
26	,	adults	25
27	before	adults	25
28	and	before	27
29	after	and	28
30	overnight	before	27
31	DST	adults	25
32	(	1	33
33	1	DST	31
34	mg	1	33
35	)	1	33
36	.	were	15

0	Tax1	<ROOT>	-1
1	,	Tax1	0
2	a	activator	4
3	potent	activator	4
4	activator	human	6
5	of	human	6
6	human	Tax1	0
7	T-cell	Tax1	0
8	lymphotropic	T-cell	7
9	virus	lymphotropic	8
10	type	virus	9
11	1	has	17
12	(	HTLV-1	13
13	HTLV-1	1	11
14	)	HTLV-1	13
15	transcription	,	16
16	,	HTLV-1	13
17	has	type	10
18	been	has	17
19	shown	been	18
20	to	shown	19
21	modulate	to	20
22	expression	modulate	21
23	of	expression	22
24	many	genes	26
25	cellular	genes	26
26	genes	of	23
27	.	Tax1	0

0	We	<ROOT>	-1
1	have	We	0
2	identified	have	1
3	a	identified	2
4	novel	,	6
5	gene	,	6
6	,	a	3
7	GR6	identified	2
8	,	We	0
9	located	,	8
10	within	located	9
11	the	within	10
12	leukemia	of	15
13	breakpoint	of	15
14	region	of	15
15	of	the	11
16	3q21	We	0
17	,	is	19
18	that	is	19
19	is	We	0
20	normally	is	19
21	expressed	is	19
22	in	expressed	21
23	early	in	22
24	fetal	early	23
25	development	fetal	24
26	but	development	25
27	not	but	26
28	in	peripheral	30
29	adult	peripheral	30
30	peripheral	not	27
31	blood	but	26
32	.	We	0

0	Elf-1	is	1
1	is	<ROOT>	-1
2	a	factor	5
3	lymphoid-specific	factor	5
4	transcription	factor	5
5	factor	is	1
6	that	belongs	7
7	belongs	protein	11
8	to	protein	11
9	the	protein	11
10	ETS	protein	11
11	protein	factor	5
12	family	is	1
13	.	is	1

0	The	effects	2
1	negative	effects	2
2	effects	<ROOT>	-1
3	of	effects	2
4	point	of	3
5	mutations	point	4
6	in	mutations	5
7	the	in	6
8	LMP1-LRB-1-231-RRB-	core	9
9	core	binding	11
10	TRAF	binding	11
11	binding	the	7
12	motif	effects	2
13	on	effects	2
14	TRAF	binding	15
15	binding	and	16
16	and	on	13
17	NF-kappaB	activation	18
18	activation	and	16
19	genetically	effects	2
20	link	effects	2
21	the	TRAFs	22
22	TRAFs	effects	2
23	to	effects	2
24	LMP1-LRB-1-231-RRB--mediated	activation	26
25	NF-kappaB	activation	26
26	activation	to	23
27	.	effects	2

0	We	lymphocyte	4
1	have	lymphocyte	4
2	measured	lymphocyte	4
3	both	lymphocyte	4
4	lymphocyte	receptor	6
5	GR	lymphocyte	4
6	receptor	and	9
7	binding	and	9
8	parameters	and	9
9	and	sialyltransferase	11
10	plasma	and	9
11	sialyltransferase	<ROOT>	-1
12	activity	sialyltransferase	11
13	,	sialyltransferase	11
14	as	sialyltransferase	11
15	a	marker	17
16	biochemical	marker	17
17	marker	as	14
18	of	GR	19
19	GR	marker	17
20	function	GR	19
21	,	function	20
22	in	,	21
23	two	groups	24
24	groups	in	22
25	of	groups	24
26	patients	of	25
27	suffering	patients	26
28	from	suffering	27
29	depression	from	28
30	or	depression	29
31	schizophrenia	or	30
32	and	schizophrenia	31
33	in	and	32
34	a	group	35
35	group	in	33
36	of	group	35
37	age-	of	36
38	and	age-	37
39	sex-matched	and	38
40	controls	sex-matched	39
41	.	controls	40

0	Tax	activation	1
1	activation	is	5
2	of	activation	1
3	the	CD28RE	4
4	CD28RE	of	2
5	is	<ROOT>	-1
6	partially	is	5
7	mediated	partially	6
8	by	mediated	7
9	a	member	10
10	member	by	8
11	of	member	10
12	the	factor	14
13	nuclear	factor	14
14	factor	of	11
15	of	T	17
16	activated	T	17
17	T	factor	14
18	cells	is	5
19	,	is	5
20	NF-AT1	is	5
21	.	is	5

0	Furthermore	was	10
1	,	was	10
2	among	was	10
3	the	factors	5
4	transcription	factors	5
5	factors	among	2
6	tested	factors	5
7	,	activity	9
8	AP-1	,	7
9	activity	among	2
10	was	<ROOT>	-1
11	increased	was	10
12	in	lymphocytes	17
13	stimulated	lymphocytes	17
14	purified	T	15
15	T	stimulated	13
16	helper	lymphocytes	17
17	lymphocytes	increased	11
18	incubated	with	19
19	with	lymphocytes	17
20	ciprofloxacin	with	19
21	compared	lymphocytes	17
22	to	compared	21
23	drug-free	was	10
24	controls	was	10
25	.	was	10

0	Cytokine	receptor	4
1	and	receptor	4
2	growth	receptor	4
3	factor	receptor	4
4	receptor	engagement	5
5	engagement	<ROOT>	-1
6	leads	engagement	5
7	to	leads	6
8	the	phosphorylation	10
9	rapid	phosphorylation	10
10	phosphorylation	to	7
11	and	engagement	5
12	activation	of	13
13	of	engagement	5
14	latent	of	13
15	,	engagement	5
16	cytosolic	,	15
17	signal	,	15
18	transducers	signal	17
19	and	transducers	18
20	activators	and	19
21	of	activators	20
22	transcription	of	21
23	(	of	21
24	STAT	)	25
25	)	of	21
26	proteins	engagement	5
27	,	engagement	5
28	which	,	27
29	then	which	28
30	translocate	then	29
31	to	the	32
32	the	translocate	30
33	nucleus	where	34
34	where	engagement	5
35	they	transcriptional	37
36	regulate	transcriptional	37
37	transcriptional	engagement	5
38	events	promoter	41
39	from	specific	40
40	specific	events	38
41	promoter	transcriptional	37
42	sequences	engagement	5
43	.	engagement	5

0	Moreover	<ROOT>	-1
1	,	Moreover	0
2	the	changes	4
3	inverse	changes	4
4	changes	,	1
5	in	changes	4
6	the	expression	7
7	expression	in	5
8	of	expression	7
9	CRH	of	8
10	in	changes	4
11	the	hypothalamus	12
12	hypothalamus	in	10
13	and	hypothalamus	12
14	spleens	and	13
15	of	spleens	14
16	arthritic	were	18
17	rats	were	18
18	were	of	15
19	paralleled	spleens	14
20	by	paralleled	19
21	similar	changes	23
22	inverse	changes	23
23	changes	by	20
24	in	changes	23
25	NF-IL6beta	expression	26
26	expression	in	24
27	in	these	28
28	these	changes	23
29	organs	Moreover	0
30	.	Moreover	0

0	Therefore	<ROOT>	-1
1	we	examined	3
2	first	examined	3
3	examined	Therefore	0
4	the	examined	3
5	participation	NF-kappa	7
6	of	NF-kappa	7
7	NF-kappa	the	4
8	B	in	9
9	in	NF-kappa	7
10	germline	the	4
11	C	epsilon	12
12	epsilon	the	4
13	transcription	epsilon	12
14	in	lymphoma	18
15	a	lymphoma	18
16	human	lymphoma	18
17	Burkitt	lymphoma	18
18	lymphoma	epsilon	12
19	B	Therefore	0
20	cell	line	21
21	line	B	19
22	,	line	21
23	DND39	Therefore	0
24	.	Therefore	0

0	Following	translocated	38
1	neutrophil	stimulation	2
2	stimulation	Following	0
3	with	stimulation	2
4	proinflammatory	agonists	5
5	agonists	[	10
6	(	as	8
7	such	as	8
8	as	agonists	5
9	lipopolysaccharide	as	8
10	[	that	24
11	LPS	[	10
12	]	LPS	11
13	,	necrosis	15
14	tumor	necrosis	15
15	necrosis	]	12
16	factor-alpha	[	17
17	[	]	12
18	TNF-alpha	]	12
19	]	TNF-alpha	18
20	,	]	19
21	and	]	12
22	fMet-Leu-Phe	[	10
23	)	[	10
24	that	with	3
25	induce	the	26
26	the	that	24
27	production	the	26
28	of	production	27
29	cytokines	of	28
30	and	cytokines	29
31	chemokines	of	28
32	in	these	33
33	these	chemokines	31
34	cells	Following	0
35	,	translocated	38
36	NF-kappaB/Rel	proteins	37
37	proteins	translocated	38
38	translocated	<ROOT>	-1
39	to	translocated	38
40	nuclear	fractions	41
41	fractions	to	39
42	,	translocated	38
43	resulting	translocated	38
44	in	resulting	43
45	a	induction	47
46	transient	induction	47
47	induction	in	44
48	of	induction	47
49	NF-kappaB	of	48
50	DNA	binding	51
51	binding	NF-kappaB	49
52	activity	translocated	38
53	,	translocated	38
54	as	translocated	38
55	determined	mobility	58
56	in	mobility	58
57	gel	in	56
58	mobility	as	54
59	shift	mobility	58
60	assays	translocated	38
61	.	translocated	38

0	Neutral	sphingomyelinase	1
1	sphingomyelinase	can	5
2	(	SMase	3
3	SMase	sphingomyelinase	1
4	)	SMase	3
5	can	<ROOT>	-1
6	be	can	5
7	activated	be	6
8	by	activated	7
9	extracellular	signals	10
10	signals	by	8
11	to	signals	10
12	produce	to	11
13	ceramide	produce	12
14	,	ceramide	13
15	which	produce	12
16	may	which	15
17	affect	may	16
18	mitogen-activated	affect	17
19	protein	(	21
20	kinase	(	21
21	(	mitogen-activated	18
22	MAPK	)	23
23	)	activities	24
24	activities	mitogen-activated	18
25	.	can	5

0	DOR1	ligation	1
1	ligation	IL-2	11
2	by	ligation	1
3	a	agonist	6
4	specific	DOR1	5
5	DOR1	agonist	6
6	agonist	by	2
7	,	ligation	1
8	deltorphin	ligation	1
9	,	ligation	1
10	augmented	IL-2	11
11	IL-2	<ROOT>	-1
12	secretion	by	13
13	by	IL-2	11
14	synergizing	by	13
15	with	synergizing	14
16	signals	with	15
17	from	signals	16
18	TCR-CD3	from	17
19	and	TCR-CD3	18
20	CD28	TCR-CD3	18
21	.	IL-2	11

0	Expression	after	5
1	of	Expression	0
2	transcription	of	1
3	factor	of	1
4	genes	Expression	0
5	after	virus	8
6	influenza	after	5
7	A	virus	8
8	virus	<ROOT>	-1
9	infection	virus	8
10	.	infection	9

0	The	transactivator	3
1	class	transactivator	3
2	II	transactivator	3
3	transactivator	is	7
4	(	CIITA	5
5	CIITA	transactivator	3
6	)	CIITA	5
7	is	<ROOT>	-1
8	necessary	is	7
9	for	necessary	8
10	both	constitutive	11
11	constitutive	and	12
12	and	for	9
13	IFN-gamma	and	12
14	induced	MHC	15
15	MHC	for	9
16	class	expressions	18
17	II	expressions	18
18	expressions	is	7
19	.	is	7

0	Prostaglandins	are	5
1	of	Prostaglandins	0
2	the	series	4
3	E	series	4
4	series	of	1
5	are	<ROOT>	-1
6	immunomodulatory	agents	7
7	agents	are	5
8	which	agents	7
9	exert	which	8
10	inhibitory	exert	9
11	as	inhibitory	10
12	well	inhibitory	10
13	as	inhibitory	10
14	stimulatory	inhibitory	10
15	effects	stimulatory	14
16	on	immune	20
17	a	variety	18
18	variety	immune	20
19	of	immune	20
20	immune	effects	15
21	responses	are	5
22	.	are	5

0	Three	recombinants	2
1	HSV/VZV	recombinants	2
2	recombinants	were	3
3	were	<ROOT>	-1
4	generated	were	3
5	:	were	3
6	(	1	7
7	1	coding	12
8	)	1	7
9	VZV	coding	12
10	gE	coding	12
11	protein	coding	12
12	coding	sequences	13
13	sequences	were	19
14	along	sequences	13
15	with	along	14
16	the	region	18
17	promoter	region	18
18	region	with	15
19	were	were	3
20	inserted	the	22
21	into	the	22
22	the	were	19
23	thymidine	the	22
24	kinase	(	25
25	(	were	3
26	TK	(	25
27	)	were	3
28	gene	were	3
29	of	HSV-1	30
30	HSV-1	gene	28
31	strain	were	3
32	KOS	were	3
33	;	were	3
34	(	2	35
35	2	was	45
36	)	2	35
37	VZV	promoter	44
38	gE	VZV	37
39	expressed	HSV-1	42
40	from	HSV-1	42
41	the	HSV-1	42
42	HSV-1	gE	38
43	ICP4	promoter	44
44	promoter	was	45
45	was	were	3
46	inserted	were	3
47	into	inserted	46
48	the	into	47
49	glycoprotein	(	51
50	C	(	51
51	(	the	48
52	gC	(	51
53	)	gC	52
54	gene	)	53
55	of	HSV-1	56
56	HSV-1	gene	54
57	strain	were	3
58	F	were	3
59	;	were	3
60	and	were	3
61	(	3	62
62	3	coding	67
63	)	3	62
64	VZV	coding	67
65	IE62	coding	67
66	protein	coding	67
67	coding	and	60
68	sequences	under	69
69	under	were	3
70	the	under	69
71	control	the	70
72	of	HSV-1	74
73	the	HSV-1	74
74	HSV-1	control	71
75	ICP4	were	3
76	promoter	were	3
77	were	were	3
78	inserted	were	77
79	into	inserted	78
80	the	into	79
81	gC	the	80
82	gene	gC	81
83	of	HSV-1	84
84	HSV-1	gene	82
85	strain	were	3
86	F	were	3
87	.	were	3

0	Effects	<ROOT>	-1
1	of	Effects	0
2	Ara-C	of	1
3	on	Effects	0
4	neutral	sphingomyelinase	5
5	sphingomyelinase	on	3
6	and	Effects	0
7	mitogen-	and	6
8	and	mitogen-	7
9	stress-activated	and	8
10	protein	T-lymphocyte	13
11	kinases	T-lymphocyte	13
12	in	T-lymphocyte	13
13	T-lymphocyte	Effects	0
14	cell	Effects	0
15	lines	Effects	0
16	.	Effects	0

0	In	allows	5
1	addition	In	0
2	,	allows	5
3	new	technology	4
4	technology	allows	5
5	allows	<ROOT>	-1
6	the	identification	8
7	sensitive	identification	8
8	identification	allows	5
9	of	identification	8
10	gene	hypermethylation	11
11	hypermethylation	of	9
12	in	identification	8
13	a	background	14
14	background	in	12
15	of	normal	16
16	normal	background	14
17	cells	allows	5
18	,	allows	5
19	suggesting	allows	5
20	possible	strategies	22
21	new	strategies	22
22	strategies	suggesting	19
23	for	strategies	22
24	the	detection	25
25	detection	residual	28
26	of	residual	28
27	minimal	residual	28
28	residual	for	23
29	disease	allows	5
30	.	allows	5

0	The	promoter	2
1	pp52	promoter	2
2	promoter	contains	3
3	contains	<ROOT>	-1
4	an	contains	3
5	initiator	an	4
6	specifying	initiator	5
7	the	specifying	6
8	unique	of	11
9	5'	of	11
10	terminus	of	11
11	of	the	7
12	pp52	an	4
13	mRNA	contains	3
14	,	contains	3
15	tandem	and	19
16	pairs	of	17
17	of	tandem	15
18	Ets	and	19
19	and	,	14
20	SP1	contains	3
21	motifs	contains	3
22	,	contains	3
23	and	C/EBP	26
24	a	C/EBP	26
25	lone	C/EBP	26
26	C/EBP	contains	3
27	motif	contains	3
28	.	contains	3

0	The	role	1
1	role	human	5
2	of	role	1
3	PPARgamma	of	2
4	in	human	5
5	human	<ROOT>	-1
6	atherosclerosis	is	7
7	is	human	5
8	unexplored	is	7
9	.	human	5

0	However	is	3
1	,	is	3
2	it	is	3
3	is	<ROOT>	-1
4	not	is	3
5	clear	is	3
6	which	clear	5
7	,	if	8
8	if	which	6
9	any	if	8
10	,	if	8
11	of	these	12
12	these	if	8
13	kinases	clear	5
14	are	is	3
15	responsible	are	14
16	for	responsible	15
17	initiating	for	16
18	IL-4-induced	tyrosine	19
19	tyrosine	initiating	17
20	phosphorylation	initiating	17
21	of	phosphorylation	20
22	intracellular	substrates	23
23	substrates	of	21
24	in	initiating	17
25	vivo	in	24
26	.	is	3

0	However	<ROOT>	-1
1	,	However	0
2	treatment	,	1
3	of	treatment	2
4	HL-60	cells	5
5	cells	of	3
6	with	the	9
7	PDBu	induced	8
8	induced	the	9
9	the	treatment	2
10	rapid	However	0
11	expression	However	0
12	of	suppressor	15
13	the	suppressor	15
14	apoptosis	suppressor	15
15	suppressor	expression	11
16	protein	However	0
17	Bcl-xL	However	0
18	,	However	0
19	whereas	However	0
20	the	expression	21
21	expression	whereas	19
22	of	expression	21
23	this	of	22
24	protein	this	23
25	remained	protein	24
26	unaltered	protein	24
27	in	unaltered	26
28	DMSO-treated	cells	29
29	cells	in	27
30	.	cells	29

0	This	induction	1
1	induction	<ROOT>	-1
2	of	induction	1
3	C/EBP	of	2
4	epsilon	C/EBP	3
5	mRNA	epsilon	4
6	expression	occurs	11
7	is	transcriptionally	8
8	transcriptionally	mediated	9
9	mediated	and	10
10	and	expression	6
11	occurs	mRNA	5
12	in	occurs	11
13	the	absence	14
14	absence	in	12
15	of	absence	14
16	synthesis	of	15
17	of	synthesis	16
18	additional	of	17
19	protein	.	21
20	factors	.	21
21	.	of	17

0	Following	<ROOT>	-1
1	intracranial	inoculation	2
2	inoculation	Following	0
3	in	inoculation	2
4	mice	in	3
5	,	inoculation	2
6	both	inoculation	2
7	VZV	(	9
8	gE-HSV	(	9
9	(	both	6
10	TK	(	9
11	)	and	12
12	and	TK	10
13	VZV	(	9
14	IE62-HSV	(	15
15	(	VZV	13
16	gC	induced	18
17	)	induced	18
18	induced	Following	0
19	an	IgG	20
20	IgG	induced	18
21	response	induced	18
22	against	response	21
23	VZV	against	22
24	gE	or	25
25	or	VZV	23
26	VZV	or	25
27	IE62	.	28
28	.	VZV	26

0	In	was	9
1	macrophages	In	0
2	,	was	9
3	a	enhancement	5
4	slight	enhancement	5
5	enhancement	was	9
6	of	enhancement	5
7	TNF-alpha	production	8
8	production	of	6
9	was	<ROOT>	-1
10	seen	was	9
11	,	was	9
12	whereas	was	9
13	IL-1	beta	14
14	beta	was	15
15	was	whereas	12
16	not	was	15
17	detected	was	15
18	.	was	9

0	The	<ROOT>	-1
1	class	The	0
2	II	trans-activator	3
3	trans-activator	(	4
4	(	class	1
5	CIITA	)	6
6	)	(	4
7	is	The	0
8	the	is	7
9	main	the	8
10	transcriptional	main	9
11	co-activator	transcriptional	10
12	for	the	13
13	the	co-activator	11
14	expression	the	13
15	of	MHC	16
16	MHC	expression	14
17	class	.	20
18	II	.	20
19	proteins	.	20
20	.	MHC	16

0	Nuclear	levels	1
1	levels	correlate	4
2	of	levels	1
3	NF-kappaB	of	2
4	correlate	<ROOT>	-1
5	with	correlate	4
6	syncytium-forming	capacity	7
7	capacity	with	5
8	of	capacity	7
9	8e51	of	8
10	cells	,	11
11	,	8e51	9
12	expressing	capacity	7
13	a	virus	16
14	defective	virus	16
15	HIV	virus	16
16	virus	expressing	12
17	.	virus	16

0	Interleukin-4	is	1
1	is	<ROOT>	-1
2	an	is	1
3	immunomodulatory	cytokine	4
4	cytokine	an	2
5	which	plays	6
6	plays	cytokine	4
7	a	plays	6
8	central	a	7
9	role	central	8
10	in	the	11
11	the	role	9
12	regulation	the	11
13	of	regulation	12
14	allergic	is	1
15	and	is	1
16	atopic	is	1
17	immune	is	1
18	responses	is	1
19	.	is	1

0	Using	<ROOT>	-1
1	as	Using	0
2	a	as	1
3	probe	a	2
4	cysteamine	probe	3
5	,	cysteamine	4
6	an	cysteamine	4
7	aminothiol	with	9
8	compound	with	9
9	with	probe	3
10	both	with	9
11	antioxidant	and	12
12	and	antiproliferative	13
13	antiproliferative	both	10
14	activity	Using	0
15	,	identified	18
16	we	identified	18
17	have	identified	18
18	identified	Using	0
19	erk2	Using	0
20	,	Using	0
21	a	element	23
22	key	element	23
23	element	,	20
24	of	the	25
25	the	element	23
26	MAP	the	25
27	kinase	Using	0
28	pathway	Using	0
29	,	Using	0
30	as	Using	0
31	being	as	30
32	responsive	being	31
33	to	oxidative	34
34	oxidative	responsive	32
35	signalling	responsive	32
36	during	Using	0
37	lymphocyte	Using	0
38	activation	Using	0
39	.	Using	0

0	alpha-Tocopheryl	succinate	1
1	succinate	inhibits	2
2	inhibits	to	6
3	monocytic	to	6
4	cell	to	6
5	adhesion	to	6
6	to	<ROOT>	-1
7	endothelial	to	6
8	cells	to	6
9	by	to	6
10	suppressing	NF-kappa	11
11	NF-kappa	by	9
12	B	to	6
13	mobilization	to	6
14	.	to	6

0	Within	was	7
1	the	expression	6
2	PBL	expression	6
3	,	PBL	2
4	Bcd	expression	6
5	gene	expression	6
6	expression	Within	0
7	was	<ROOT>	-1
8	restricted	CD19+	10
9	to	CD19+	10
10	CD19+	was	7
11	B-cells	was	7
12	and	B-cells	11
13	absent	and	12
14	from	absent	13
15	CD14+	from	14
16	monocytes	and	17
17	and	CD14+	15
18	T-cells	was	7
19	.	was	7

0	To	<ROOT>	-1
1	gain	To	0
2	a	understanding	4
3	better	understanding	4
4	understanding	gain	1
5	of	understanding	4
6	the	mechanism	7
7	mechanism	of	5
8	of	mechanism	7
9	binding	of	8
10	to	binding	9
11	the	to	10
12	human	the	11
13	mineralocorticoid	receptor	14
14	receptor	(	15
15	(	human	12
16	hMR	understanding	4
17	)	raised	28
18	,	raised	28
19	we	raised	28
20	developed	we	19
21	a	(	25
22	new	(	25
23	monoclonal	(	25
24	antibody	(	25
25	(	developed	20
26	mAb	)	27
27	)	(	25
28	raised	hMR	16
29	against	hMR	16
30	the	domain	32
31	hormone-binding	domain	32
32	domain	against	29
33	(	HBD	34
34	HBD	hMR	16
35	)	HBD	34
36	.	To	0

0	5'-Rapid	amplification	1
1	amplification	204	22
2	of	amplification	1
3	cDNA	of	2
4	ends	cDNA	3
5	(	5'-RACE	6
6	5'-RACE	ends	4
7	)	5'-RACE	6
8	analysis	showed	9
9	showed	that	10
10	that	5'-RACE	6
11	transcription	occurred	13
12	initiation	occurred	13
13	occurred	that	10
14	at	5'-RACE	6
15	several	at	14
16	closely	spaced	17
17	spaced	originating	20
18	nearby	originating	20
19	sites	originating	20
20	originating	several	15
21	approximately	204	22
22	204	<ROOT>	-1
23	bp	204	22
24	upstream	bp	23
25	from	the	26
26	the	start	28
27	translation	start	28
28	start	upstream	24
29	site	start	28
30	.	site	29

0	However	enhanced	3
1	,	enhanced	3
2	V3-BH10	enhanced	3
3	enhanced	<ROOT>	-1
4	IL-2-induced	enhanced	3
5	mRNA	of	7
6	expression	of	7
7	of	IL-2-induced	4
8	c-fos	of	7
9	but	c-fos	8
10	not	of	7
11	c-myc	of	7
12	or	c-myc	11
13	junB	or	12
14	.	enhanced	3

0	HIV	infection	1
1	infection	failed	5
2	of	fresh	3
3	fresh	infection	1
4	monocytes	infection	1
5	failed	<ROOT>	-1
6	to	failed	5
7	induce	to	6
8	p50/p65	induce	7
9	as	induce	7
10	seen	induce	7
11	in	seen	10
12	MDMs	in	11
13	.	MDMs	12

0	Differanisole	A	1
1	A	enhances	8
2	,	A	1
3	a	antibiotic	6
4	novel	antitumor	5
5	antitumor	antibiotic	6
6	antibiotic	A	1
7	,	A	1
8	enhances	<ROOT>	-1
9	growth	inhibition	10
10	inhibition	enhances	8
11	and	enhances	8
12	differentiation	and	11
13	of	human	14
14	human	and	11
15	myeloid	enhances	8
16	leukemia	enhances	8
17	cells	enhances	8
18	induced	enhances	8
19	by	retinoic	21
20	9-cis	retinoic	21
21	retinoic	induced	18
22	acid	retinoic	21
23	.	acid	22

0	In	undertook	6
1	the	study	3
2	current	study	3
3	study	In	0
4	,	undertook	6
5	we	undertook	6
6	undertook	<ROOT>	-1
7	a	analysis	9
8	biochemical	analysis	9
9	analysis	receptor	12
10	of	receptor	12
11	IL-10	of	10
12	receptor	undertook	6
13	expression	undertook	6
14	on	expression	13
15	freshly	undertook	6
16	isolated	freshly	15
17	B-CLL	isolated	16
18	cells	B-CLL	17
19	and	undertook	6
20	characterized	undertook	6
21	the	responsiveness	23
22	functional	responsiveness	23
23	responsiveness	of	24
24	of	characterized	20
25	IL-10	of	24
26	binding	undertook	6
27	to	its	28
28	its	undertook	6
29	constitutively	expressed	30
30	expressed	its	28
31	receptor	undertook	6
32	.	undertook	6

0	Second	the	4
1	,	the	4
2	we	the	4
3	studied	the	4
4	the	<ROOT>	-1
5	effect	of	6
6	of	the	4
7	NAC	IgE	9
8	on	IgE	9
9	IgE	the	4
10	synthesis	IgE	9
11	in	synthesis	10
12	human	cells	15
13	normal	cells	15
14	B	cells	15
15	cells	in	11
16	costimulated	the	4
17	with	the	4
18	IL-4	the	4
19	and	the	4
20	anti-CD40	the	4
21	mAb	the	4
22	.	the	4

0	BACKGROUND	<ROOT>	-1
1	:	BACKGROUND	0
2	The	genes	5
3	immediate	genes	5
4	early	genes	5
5	genes	BACKGROUND	0
6	(	IE	7
7	IE	genes	5
8	)	IE	7
9	of	human	10
10	human	genes	5
11	cytomegalovirus	genes	5
12	(	cytomegalovirus	11
13	CMV	(	12
14	)	can	15
15	can	CMV	13
16	be	can	15
17	expressed	be	16
18	in	monocytic	19
19	monocytic	expressed	17
20	cells	BACKGROUND	0
21	and	BACKGROUND	0
22	are	and	21
23	known	are	22
24	to	known	23
25	regulate	viral	26
26	viral	and	27
27	and	to	24
28	cellular	and	27
29	genes	BACKGROUND	0
30	.	BACKGROUND	0

0	Understanding	should	13
1	the	cis-	2
2	cis-	Understanding	0
3	and	cis-	2
4	transacting	factors	5
5	factors	and	3
6	that	regulate	7
7	regulate	cis-	2
8	the	expression	10
9	tissue-specific	expression	10
10	expression	regulate	7
11	of	expression	10
12	PECAM-1	of	11
13	should	<ROOT>	-1
14	increase	should	13
15	our	understanding	16
16	understanding	increase	14
17	of	understanding	16
18	the	mechanisms	19
19	mechanisms	of	17
20	by	vascular-specific	22
21	which	by	20
22	vascular-specific	mechanisms	19
23	gene	expression	24
24	expression	vascular-specific	22
25	is	of	17
26	achieved	is	25
27	.	should	13

0	Signals	<ROOT>	-1
1	transduced	Signals	0
2	via	the	3
3	the	transduced	1
4	TCR	the	3
5	activate	(	11
6	the	factor	8
7	transcription	factor	8
8	factor	activate	5
9	nuclear	(	11
10	factor-kappaB	nuclear	9
11	(	the	3
12	NF-kappaB	)	13
13	)	the	3
14	,	which	15
15	which	the	3
16	,	is	20
17	in	is	20
18	turn	in	17
19	,	is	20
20	is	which	15
21	critical	is	20
22	to	critical	21
23	the	induction	25
24	transcriptional	induction	25
25	induction	to	22
26	of	induction	25
27	many	genes	28
28	genes	of	26
29	important	induction	25
30	for	the	31
31	the	important	29
32	proliferation	the	31
33	and	proliferation	32
34	expression	Signals	0
35	of	expression	34
36	a	phenotype	38
37	differentiated	phenotype	38
38	phenotype	of	35
39	.	Signals	0

0	We	show	1
1	show	complexes	9
2	here	show	1
3	by	DNA-binding	8
4	mobility-shift	DNA-binding	8
5	assay	that	6
6	that	DNA-binding	8
7	E2F-containing	DNA-binding	8
8	DNA-binding	show	1
9	complexes	<ROOT>	-1
10	were	complexes	9
11	detected	were	10
12	in	detected	11
13	HTLV-I-infected	in	12
14	T-cell	and	16
15	lines	and	16
16	and	HTLV-I-infected	13
17	leukemic	detected	11
18	cells	detected	11
19	obtained	complexes	9
20	from	ATL	21
21	ATL	obtained	19
22	patients	complexes	9
23	but	patients	22
24	not	but	23
25	in	T-cell	28
26	an	T-cell	28
27	uninfected	T-cell	28
28	T-cell	not	24
29	line	but	23
30	,	complexes	9
31	Jurkat	complexes	9
32	,	complexes	9
33	and	peripheral	35
34	normal	peripheral	35
35	peripheral	complexes	9
36	blood	complexes	9
37	mononuclear	complexes	9
38	cells	complexes	9
39	.	complexes	9

0	Histamine	transiently	1
1	transiently	<ROOT>	-1
2	increased	transiently	1
3	cAMP	increased	2
4	and	c-fos	5
5	c-fos	cAMP	3
6	expression	through	7
7	through	cAMP	3
8	H2	transiently	1
9	receptors	transiently	1
10	.	transiently	1

0	The	characterization	1
1	characterization	cells	5
2	of	pro-B	4
3	Pax-5-deficient	pro-B	4
4	pro-B	characterization	1
5	cells	<ROOT>	-1
6	demonstrated	cells	5
7	an	role	9
8	important	role	9
9	role	demonstrated	6
10	of	role	9
11	BSAP	of	10
12	in	the	13
13	the	demonstrated	6
14	regulation	of	15
15	of	the	13
16	the	CD19	17
17	CD19	of	15
18	,	CD19	17
19	mb-1	(	20
20	(	cells	5
21	Ig	(	20
22	alpha	Ig	21
23	)	cells	5
24	and	cells	5
25	N-myc	cells	5
26	genes	cells	5
27	as	cells	5
28	well	as	27
29	as	as	27
30	in	developmental	32
31	the	developmental	32
32	developmental	as	27
33	pathway	controlling	34
34	controlling	cells	5
35	VH-to-DHJH	recombination	36
36	recombination	cells	5
37	at	cells	5
38	the	immunoglobulin	39
39	immunoglobulin	at	37
40	heavy-chain	(	41
41	(	cells	5
42	IgH	)	43
43	)	(	41
44	locus	cells	5
45	.	cells	5

0	Response	<ROOT>	-1
1	to	Response	0
2	intranasal	propionate	4
3	fluticasone	propionate	4
4	propionate	to	1
5	in	propionate	4
6	perennial	in	5
7	allergic	perennial	6
8	rhinitis	not	9
9	not	allergic	7
10	associated	perennial	6
11	with	to	1
12	glucocorticoid	to	1
13	receptor	to	1
14	characteristics	to	1
15	.	Response	0

0	Overexpression	leads	3
1	of	Overexpression	0
2	TRAMP	of	1
3	leads	<ROOT>	-1
4	to	leads	3
5	two	responses	7
6	major	responses	7
7	responses	to	4
8	,	leads	3
9	NF-kappaB	activation	10
10	activation	leads	3
11	and	activation	10
12	apoptosis	leads	3
13	.	leads	3

0	The	was	11
1	gene	The	0
2	encoding	the	3
3	the	virus	5
4	Epstein-Barr	virus	5
5	virus	gene	1
6	(	virus	5
7	EBV	dUTPase	10
8	)	EBV	7
9	-specific	dUTPase	10
10	dUTPase	virus	5
11	was	<ROOT>	-1
12	amplified	was	11
13	from	amplified	12
14	virus	from	13
15	DNA	virus	14
16	by	DNA	15
17	PCR	by	16
18	.	was	11

0	The	Jak1	1
1	Jak1	tyrosine	9
2	,	Jak1	1
3	Jak2	Jak1	1
4	,	Jak2	3
5	Jak3	Jak2	3
6	,	Jak1	1
7	and	tyrosine	9
8	Fes	tyrosine	9
9	tyrosine	kinases	10
10	kinases	have	11
11	have	<ROOT>	-1
12	been	have	11
13	demonstrated	been	12
14	to	tyrosine	16
15	undergo	to	14
16	tyrosine	demonstrated	13
17	phosphorylation	have	11
18	in	have	11
19	response	have	11
20	to	have	11
21	interleukin	to	20
22	(	IL	23
23	IL	interleukin	21
24	)	IL	23
25	-4	IL	23
26	stimulation	have	11
27	in	have	11
28	different	systems	30
29	cell	systems	30
30	systems	in	27
31	.	have	11

0	In	<ROOT>	-1
1	the	cells	5
2	mouse	cells	5
3	Th2	cells	5
4	D10	cells	5
5	cells	In	0
6	and	In	0
7	in	human	9
8	the	human	9
9	human	and	6
10	Th2	In	0
11	clones	In	0
12	,	In	0
13	POS-1	)	17
14	(	)	17
15	designated	)	17
16	POS-1b	)	17
17	)	In	0
18	contains	)	17
19	NF-IL6beta	In	0
20	,	In	0
21	Jun	In	0
22	,	In	0
23	and	In	0
24	NF-ATc/p	and	23
25	.	In	0

0	The	results	1
1	results	described	2
2	described	indicate	4
3	here	described	2
4	indicate	antigen	21
5	that	indicate	4
6	cognate	interaction	7
7	interaction	that	5
8	of	B	9
9	B	interaction	7
10	cells	indicate	4
11	recognizing	indicate	4
12	DNA	recognizing	11
13	or	DNA-associated	14
14	DNA-associated	DNA	12
15	proteins	indicate	4
16	and	indicate	4
17	T	indicate	4
18	cells	T	20
19	recognizing	T	20
20	T	indicate	4
21	antigen	had	22
22	had	<ROOT>	-1
23	taken	had	22
24	place	had	22
25	as	had	22
26	a	consequence	27
27	consequence	as	25
28	of	complex	29
29	complex	consequence	27
30	formation	T	32
31	between	T	32
32	T	had	22
33	ag	and	34
34	and	had	22
35	DNA	and	34
36	in	and	34
37	vivo	had	22
38	in	vivo	37
39	the	context	40
40	context	in	38
41	of	context	40
42	polyomavirus	reactivations	43
43	reactivations	of	41
44	.	had	22

0	In	<ROOT>	-1
1	particular	In	0
2	,	In	0
3	Western	,	2
4	,	Western	3
5	supershift	,	4
6	,	supershift	5
7	and	,	6
8	promoter	,	6
9	deletion	analyses	10
10	analyses	promoter	8
11	suggested	analyses	10
12	a	,	6
13	role	for	14
14	for	a	12
15	CCAAT/enhancer-binding	for	14
16	protein-beta	CCAAT/enhancer-binding	15
17	(	C/EBP-beta	18
18	C/EBP-beta	site	21
19	)	C/EBP-beta	18
20	binding	site	21
21	site	protein-beta	16
22	between	protein-beta	16
23	-2010	between	22
24	and	-2010	23
25	-1954	and	24
26	in	protein-beta	16
27	regulating	in	26
28	transcription	in	26
29	of	protein-beta	16
30	collagenase-1	in	31
31	in	of	29
32	monocytic	In	0
33	cells	In	0
34	.	In	0

0	Cloning	the	2
1	of	the	2
2	the	cDNA	3
3	cDNA	encoding	4
4	encoding	<ROOT>	-1
5	human	encoding	4
6	SR-BP	human	5
7	shows	encoding	4
8	an	frame	11
9	open	frame	11
10	reading	frame	11
11	frame	shows	7
12	for	frame	11
13	a	for	12
14	223-amino	,	17
15	acid	,	17
16	protein	,	17
17	,	a	13
18	which	is	19
19	is	shows	7
20	homologous	is	19
21	to	homologous	20
22	the	to	21
23	recently	the	22
24	cloned	recently	23
25	sigma	cloned	24
26	1	receptor	27
27	receptor	sigma	25
28	.	encoding	4

0	In	insulin	11
1	agreement	In	0
2	with	agreement	1
3	this	with	2
4	,	In	0
5	decrease	,	4
6	in	insulin	8
7	the	insulin	8
8	insulin	decrease	5
9	mRNA	In	0
10	and	insulin	11
11	insulin	was	13
12	content	insulin	11
13	was	<ROOT>	-1
14	observed	was	13
15	in	observed	14
16	the	cells	18
17	glycation-induced	cells	18
18	cells	in	15
19	.	cells	18

0	We	have	1
1	have	<ROOT>	-1
2	reported	have	1
3	previously	reported	2
4	that	reported	2
5	a	B	8
6	nuclear	B	8
7	NF-kappa	B	8
8	B	was	10
9	activity	B	8
10	was	that	4
11	present	was	10
12	in	human	15
13	freshly	human	15
14	extracted	human	15
15	human	present	11
16	thymocytes	have	1
17	in	thymocytes	16
18	the	absence	19
19	absence	in	17
20	of	absence	19
21	in	treatment	23
22	vitro	in	21
23	treatment	of	20
24	of	these	25
25	these	treatment	23
26	cells	have	1
27	.	have	1

0	The	RANTES	2
1	chemokine	RANTES	2
2	RANTES	has	3
3	has	<ROOT>	-1
4	been	has	3
5	implicated	been	4
6	in	implicated	5
7	the	pathogenesis	8
8	pathogenesis	implicated	5
9	of	pathogenesis	8
10	allergic	diseases	12
11	inflammatory	diseases	12
12	diseases	of	9
13	including	of	9
14	asthma	including	13
15	and	asthma	14
16	rhinitis	and	15
17	which	are	18
18	are	asthma	14
19	frequently	are	18
20	treated	frequently	19
21	with	treated	20
22	glucocorticoids	with	21
23	.	has	3

0	In	have	14
1	mammalian	cells	2
2	cells	In	0
3	,	cells	2
4	I	B	6
5	kappa	I	4
6	B	,	3
7	alpha	and	8
8	and	B	11
9	I	and	8
10	kappa	I	9
11	B	In	0
12	beta	proteins	13
13	proteins	have	14
14	have	<ROOT>	-1
15	been	have	14
16	purified	been	15
17	and	been	15
18	shown	and	17
19	to	shown	18
20	be	to	19
21	the	inhibitors	22
22	inhibitors	NF-kappa	24
23	of	NF-kappa	24
24	NF-kappa	be	20
25	B	through	26
26	through	to	19
27	their	association	28
28	association	through	26
29	with	the	30
30	the	association	28
31	p65	the	30
32	or	c-Rel	33
33	c-Rel	p65	31
34	subunits	have	14
35	.	have	14

0	No	replication	2
1	virus	replication	2
2	replication	observed	12
3	and	replication	2
4	no	transcription	5
5	transcription	was	11
6	of	transcription	5
7	the	Ad2	8
8	Ad2	of	6
9	early	genes	10
10	genes	was	11
11	was	and	3
12	observed	<ROOT>	-1
13	in	observed	12
14	either	in	13
15	of	either	14
16	the	cells	17
17	cells	of	15
18	.	cells	17

0	Freshly	isolated	1
1	isolated	<ROOT>	-1
2	cells	contain	3
3	contain	high	4
4	high	isolated	1
5	levels	of	6
6	of	high	4
7	G0S2	of	6
8	mRNA	which	9
9	which	G0S2	7
10	rapidly	isolated	1
11	decline	isolated	1
12	.	isolated	1

0	Elucidation	<ROOT>	-1
1	of	Elucidation	0
2	the	nature	4
3	biochemical	nature	4
4	nature	of	1
5	of	nature	4
6	the	pathway	9
7	signal	pathway	9
8	transduction	pathway	9
9	pathway	of	5
10	that	regulate	11
11	regulate	pathway	9
12	transcription	and	13
13	and	regulate	11
14	replication	Elucidation	0
15	is	replication	14
16	the	focus	17
17	focus	replication	14
18	of	focus	17
19	attention	of	18
20	in	replication	14
21	molecular	biology	22
22	biology	in	20
23	.	Elucidation	0

0	NFAT4/x	was	1
1	was	<ROOT>	-1
2	very	weakly	3
3	weakly	was	1
4	expressed	weakly	3
5	in	expressed	4
6	unstimulated	in	5
7	cells	,	8
8	,	unstimulated	6
9	and	was	1
10	its	and	9
11	level	did	12
12	did	its	10
13	not	did	12
14	increase	did	12
15	upon	increase	14
16	treatment	upon	15
17	with	treatment	16
18	activating	with	17
19	agents	.	20
20	.	activating	18

0	These	effects	1
1	effects	seemed	4
2	of	effects	1
3	D-ribose	of	2
4	seemed	<ROOT>	-1
5	almost	irreversible	6
6	irreversible	seemed	4
7	but	seemed	4
8	could	but	7
9	be	could	8
10	prevented	by	11
11	by	be	9
12	addition	by	11
13	of	1	14
14	1	by	11
15	mM	be	9
16	aminoguanidine	be	9
17	or	10	18
18	10	be	9
19	mM	be	9
20	N-acetylcysteine	seemed	4
21	,	seemed	4
22	thus	seemed	4
23	suggesting	thus	22
24	that	suggesting	23
25	glycation	and	26
26	and	that	24
27	reactive	species	29
28	oxygen	species	29
29	species	and	26
30	,	and	26
31	generated	and	26
32	through	generated	31
33	the	reaction	35
34	glycation	reaction	35
35	reaction	through	32
36	,	and	26
37	serve	and	26
38	as	serve	37
39	mediators	as	38
40	of	mediators	39
41	the	phenomena	42
42	phenomena	of	40
43	.	seemed	4

0	Expression	<ROOT>	-1
1	of	transactivator	4
2	the	transactivator	4
3	HIV-1	transactivator	4
4	transactivator	Expression	0
5	Tat	recapitulated	6
6	recapitulated	Expression	0
7	this	phenotype	8
8	phenotype	recapitulated	6
9	and	Expression	0
10	was	and	9
11	associated	was	10
12	with	IL-2	14
13	increased	IL-2	14
14	IL-2	associated	11
15	secretion	in	16
16	in	Expression	0
17	response	Expression	0
18	to	Expression	0
19	costimulation	Expression	0
20	with	Expression	0
21	CD3	with	20
22	plus	CD3	21
23	CD28	plus	22
24	.	CD28	23

0	In	was	24
1	contrast	In	0
2	to	contrast	1
3	the	increase	4
4	increase	to	2
5	of	increase	4
6	C/EBP	epsilon	7
7	epsilon	of	5
8	in	granulocytic	11
9	9-cis	RA-mediated	10
10	RA-mediated	granulocytic	11
11	granulocytic	increase	4
12	differentiation	In	0
13	,	was	24
14	the	differentiation	16
15	DMSO-induced	differentiation	16
16	differentiation	down	20
17	of	differentiation	16
18	HL-60	cells	19
19	cells	of	17
20	down	was	24
21	the	pathway	23
22	granulocytic	pathway	23
23	pathway	down	20
24	was	<ROOT>	-1
25	associated	was	24
26	with	associated	25
27	an	reduction	29
28	initial	reduction	29
29	reduction	with	26
30	of	reduction	29
31	C/EBP	of	30
32	epsilon	C/EBP	31
33	mRNA	epsilon	32
34	levels	mRNA	33
35	.	levels	34

0	Stimulation	<ROOT>	-1
1	with	Stimulation	0
2	either	PAF	3
3	PAF	resulted	6
4	or	PAF	3
5	FMLP	or	4
6	resulted	with	1
7	in	equivalent	8
8	equivalent	resulted	6
9	phosphorylation	equivalent	8
10	and	phosphorylation	9
11	activation	of	12
12	of	Stimulation	0
13	the	mitogen-activated	14
14	mitogen-activated	protein	15
15	protein	of	12
16	kinase	Stimulation	0
17	(	murine	22
18	MAPk	)	19
19	)	(	17
20	homologue	murine	22
21	38-kD	murine	22
22	murine	kinase	16
23	MAP	Stimulation	0
24	kinase	Stimulation	0
25	homologous	Stimulation	0
26	to	homologous	25
27	HOG-1	to	26
28	(	p38	29
29	p38	.	32
30	)	p38	29
31	MAPk	.	32
32	.	HOG-1	27

0	A	role	1
1	role	has	11
2	in	role	1
3	thymic	maturation	4
4	maturation	in	2
5	for	role	1
6	factors	for	5
7	of	factors	6
8	the	family	10
9	NF-kappaB	family	10
10	family	of	7
11	has	<ROOT>	-1
12	long	has	11
13	been	has	11
14	suspected	been	13
15	,	has	11
16	but	has	11
17	not	but	16
18	yet	but	16
19	proven	but	16
20	.	has	11

0	The	<ROOT>	-1
1	mechanisms	The	0
2	controlling	this	3
3	this	developmental	4
4	developmental	mechanisms	1
5	choice	developmental	4
6	are	unknown	7
7	unknown	The	0
8	.	The	0

0	SRG3	encodes	1
1	encodes	<ROOT>	-1
2	1,100	amino	3
3	amino	encodes	1
4	acids	amino	3
5	and	encodes	1
6	has	%	8
7	33-47	%	8
8	%	and	5
9	identity	and	5
10	with	identity	9
11	SWI3	protein	12
12	protein	with	10
13	over	with	10
14	three	regions	15
15	regions	over	13
16	.	encodes	1

0	Whether	remains	10
1	the	Whether	0
2	detected	the	1
3	transcripts	are	4
4	are	detected	2
5	translated	are	4
6	into	receptor	8
7	functional	receptor	8
8	receptor	translated	5
9	proteins	Whether	0
10	remains	<ROOT>	-1
11	to	remains	10
12	be	to	11
13	determined	be	12
14	.	remains	10

0	These	clones	1
1	clones	were	2
2	were	<ROOT>	-1
3	tested	were	2
4	for	tested	3
5	their	recognition	6
6	recognition	for	4
7	of	recognition	6
8	BCR1/25	of	7
9	.	were	2

0	We	considered	2
1	also	considered	2
2	considered	<ROOT>	-1
3	associations	considered	2
4	of	associations	3
5	these	variables	6
6	variables	of	4
7	with	renin	9
8	plasma	renin	9
9	renin	considered	2
10	activity	considered	2
11	,	activity	10
12	aldosterone	,	11
13	,	aldosterone	12
14	cortisol	,	13
15	,	cortisol	14
16	corticotropin	cortisol	14
17	,	corticotropin	16
18	and	electrolyte	19
19	electrolyte	corticotropin	16
20	concentrations	considered	2
21	.	considered	2

0	Receptor	binding	1
1	binding	were	5
2	studies	binding	1
3	with	studies	2
4	dexamethasone	with	3
5	were	<ROOT>	-1
6	performed	peripheral	8
7	with	peripheral	8
8	peripheral	were	5
9	blood	mononuclear	10
10	mononuclear	were	5
11	cells	were	5
12	.	were	5

0	Binding	sites	1
1	sites	<ROOT>	-1
2	at	sites	1
3	the	region	5
4	core	region	5
5	region	at	2
6	show	region	5
7	little	show	6
8	conservation	little	7
9	with	conservation	8
10	consensus	with	9
11	sites	consensus	10
12	.	sites	11

0	Furthermore	could	7
1	,	could	7
2	the	defect	3
3	defect	could	7
4	in	defect	3
5	viral	replication	6
6	replication	in	4
7	could	defective	37
8	be	could	7
9	complemented	be	8
10	by	virus	12
11	dl312	virus	12
12	virus	complemented	9
13	defective	E1A	15
14	in	E1A	15
15	E1A	virus	12
16	expression	4	17
17	4	be	8
18	days	4	17
19	after	4	17
20	infection	could	7
21	with	could	7
22	E1B	with	21
23	mutants	could	7
24	,	suggesting	25
25	suggesting	mutants	23
26	persistence	could	7
27	of	persistence	26
28	the	of	27
29	E1B	the	28
30	mutant	E1B	29
31	genome	mutant	30
32	in	genome	31
33	the	in	32
34	infected	the	33
35	cells	despite	36
36	despite	infected	34
37	defective	<ROOT>	-1
38	onset	defective	37
39	of	late	41
40	the	late	41
41	late	onset	38
42	phase	late	41
43	of	phase	42
44	replication	defective	37
45	.	defective	37

0	Most	patients	1
1	patients	will	2
2	will	<ROOT>	-1
3	respond	will	2
4	but	respond	3
5	a	but	4
6	few	respond	8
7	patients	respond	8
8	respond	a	5
9	less	respond	8
10	to	respond	8
11	these	to	10
12	drugs	.	13
13	.	these	11

0	Transcription	mediated	1
1	mediated	is	4
2	by	mediated	1
3	NFAT	mediated	1
4	is	<ROOT>	-1
5	highly	inducible	6
6	inducible	is	4
7	in	inducible	6
8	effector	T	10
9	CD4+	T	10
10	T	in	7
11	helper	T	10
12	2	helper	11
13	(	Th2	14
14	Th2	helper	11
15	)	Th2	14
16	cells	is	4
17	but	is	4
18	not	is	4
19	in	Th1	20
20	Th1	is	4
21	cells	is	4
22	.	is	4

0	Three	cases	1
1	cases	were	2
2	were	showed	21
3	predicted	were	2
4	to	predicted	3
5	be	to	4
6	TSC2	mutations	7
7	mutations	be	5
8	on	mutations	7
9	the	basis	10
10	basis	on	8
11	of	basis	10
12	linkage	of	11
13	analysis	or	14
14	or	linkage	12
15	because	or	14
16	a	hamartoma	17
17	hamartoma	linkage	12
18	from	linkage	12
19	the	patient	20
20	patient	from	18
21	showed	<ROOT>	-1
22	loss	showed	21
23	of	loss	22
24	heterozygosity	of	23
25	for	of	23
26	16p13.3	markers	27
27	markers	for	25
28	.	showed	21

0	Immunohistochemical	staining	1
1	staining	demonstrated	2
2	demonstrated	interdigitating	9
3	RelB	demonstrated	2
4	within	interdigitating	9
5	the	interdigitating	9
6	differentiated	lymph	7
7	lymph	interdigitating	9
8	node	interdigitating	9
9	interdigitating	<ROOT>	-1
10	DC	interdigitating	9
11	and	interdigitating	9
12	follicular	interdigitating	9
13	DC	interdigitating	9
14	,	interdigitating	9
15	but	interdigitating	9
16	not	undifferentiated	17
17	undifferentiated	but	15
18	DC	undifferentiated	17
19	in	normal	20
20	normal	DC	18
21	skin	undifferentiated	17
22	.	interdigitating	9

0	Tyrosine	phosphorylation	1
1	phosphorylation	<ROOT>	-1
2	of	phosphorylation	1
3	Stat3	of	2
4	and	phosphorylation	1
5	,	phosphorylation	1
6	to	phosphorylation	1
7	a	lesser	8
8	lesser	to	6
9	extent	to	6
10	,	to	6
11	Stat1	,	10
12	was	Stat1	11
13	also	detected	14
14	detected	phosphorylation	1
15	following	G-CSF	16
16	G-CSF	detected	14
17	stimulation	G-CSF	16
18	.	phosphorylation	1

0	33	had	3
1	of	33	0
2	them	of	1
3	had	<ROOT>	-1
4	ovulation	had	3
5	and	had	3
6	9	developed	7
7	developed	and	5
8	a	syndrome	10
9	LUF	syndrome	10
10	syndrome	developed	7
11	,	had	3
12	constituting	had	3
13	two	models	15
14	biological	models	15
15	models	constituting	12
16	of	an	17
17	an	situation	19
18	opposite	an	17
19	situation	models	15
20	for	situation	19
21	the	markers	23
22	three	markers	23
23	markers	for	20
24	observed	markers	23
25	.	had	3

0	The	transcript	2
1	LAZ3/BCL6	transcript	2
2	transcript	was	3
3	was	<ROOT>	-1
4	found	was	3
5	in	found	4
6	a	variety	7
7	variety	in	5
8	of	variety	7
9	tissues	of	8
10	,	was	3
11	including	skeletal	12
12	skeletal	was	3
13	muscle	peripheral	15
14	,	peripheral	15
15	peripheral	skeletal	12
16	blood	,	18
17	leukocytes	,	18
18	,	peripheral	15
19	and	was	3
20	weakly	was	3
21	in	normal	22
22	normal	was	3
23	lymph	was	3
24	nodes	was	3
25	.	was	3

0	Here	lineage	24
1	we	loop	16
2	present	we	1
3	evidence	that	4
4	that	present	2
5	a	member	6
6	member	that	4
7	(	member	6
8	s	member	6
9	)	member	6
10	of	that	4
11	the	family	12
12	family	basic	14
13	of	basic	14
14	basic	of	10
15	helix	we	1
16	loop	helix	17
17	helix	Here	0
18	(	bHLH	19
19	bHLH	)	20
20	)	helix	17
21	transcription	factors	22
22	factors	Here	0
23	determines	factors	22
24	lineage	<ROOT>	-1
25	specification	lineage	24
26	of	cell	28
27	NK/T	cell	28
28	cell	specification	25
29	progenitors	lineage	24
30	.	lineage	24

0	Expression	<ROOT>	-1
1	of	Expression	0
2	erythroid-specific	genes	3
3	genes	of	1
4	in	Expression	0
5	megakaryoblastic	in	4
6	disorders	.	7
7	.	megakaryoblastic	5

0	Taken	indicate	5
1	together	Taken	0
2	,	indicate	5
3	our	data	4
4	data	indicate	5
5	indicate	<ROOT>	-1
6	that	indicate	5
7	MS-2	that	6
8	mediates	MS-2	7
9	induction	mediates	8
10	of	induction	9
11	the	of	10
12	CD11b	the	11
13	gene	CD11b	12
14	as	gene	13
15	cells	as	14
16	of	lineage	19
17	the	lineage	19
18	monocytic	lineage	19
19	lineage	cells	15
20	mature	the	11
21	.	indicate	5

0	Using	demonstrate	21
1	anti-C/EBPbeta	Using	0
2	(	NF-IL6	3
3	NF-IL6	anti-C/EBPbeta	1
4	)	NF-IL6	3
5	,	anti-C/EBPbeta	1
6	anti-C/EBPdelta	(	7
7	(	anti-C/EBPbeta	1
8	NF-IL6beta	(	7
9	)	anti-C/EBPbeta	1
10	,	anti-C/EBPbeta	1
11	anti-NF-ATc	,	10
12	,	anti-NF-ATc	11
13	anti-NF-ATp	anti-NF-ATc	11
14	,	anti-NF-ATp	13
15	anti-Fos	anti-NF-ATp	13
16	,	anti-Fos	15
17	and	anti-Fos	15
18	anti-Jun	Abs	19
19	Abs	and	17
20	we	demonstrate	21
21	demonstrate	<ROOT>	-1
22	that	identified	25
23	the	previously	24
24	previously	identified	25
25	identified	demonstrate	21
26	PRE-I	identified	25
27	binding	identified	25
28	factor	binding	27
29	POS-1	factor	28
30	is	composed	31
31	composed	POS-1	29
32	of	composed	31
33	different	factors	35
34	transcription	factors	35
35	factors	of	32
36	in	of	32
37	different	subsets	40
38	Th	subsets	40
39	cell	subsets	40
40	subsets	of	32
41	.	demonstrate	21

0	However	showed	14
1	,	showed	14
2	ILT-mat	cells	3
3	cells	showed	14
4	and	cells	3
5	ATL16T-LRB---RRB-	and	4
6	cells	,	7
7	,	and	4
8	although	cells	3
9	they	were	10
10	were	although	8
11	ATL	cells	12
12	cells	were	10
13	,	cells	3
14	showed	<ROOT>	-1
15	rather	low	16
16	low	showed	14
17	surface	and	20
18	ICAM-1	and	20
19	expression	and	20
20	and	low	16
21	ICAM-1	showed	14
22	mRNA	showed	14
23	expression	showed	14
24	.	showed	14

0	Recently	have	3
1	,	have	3
2	we	have	3
3	have	<ROOT>	-1
4	developed	have	3
5	a	assay	7
6	quantitative	assay	7
7	assay	developed	4
8	using	assay	7
9	competitive	reverse	10
10	reverse	using	8
11	transcriptase	reverse	10
12	polymerase	that	15
13	chain	that	15
14	reaction	that	15
15	that	transcriptase	11
16	estimates	transcriptase	11
17	the	number	18
18	number	leukemia	26
19	of	number	18
20	AML1/ETO	of	19
21	transcripts	in	22
22	in	AML1/ETO	20
23	t-LRB-8;21-RRB-	number	18
24	acute	number	18
25	myelogenous	leukemia	26
26	leukemia	estimates	16
27	(	AML	28
28	AML	reverse	10
29	)	AML	28
30	,	have	3
31	in	have	3
32	order	in	31
33	to	in	31
34	determine	to	33
35	the	determine	34
36	degree	of	37
37	of	the	35
38	leukemic	of	37
39	cell	in	41
40	contamination	in	41
41	in	leukemic	38
42	PBSC	harvests	43
43	harvests	the	35
44	,	have	3
45	and	have	3
46	to	and	45
47	monitor	residual	49
48	minimal	residual	49
49	residual	disease	50
50	disease	to	46
51	(	MRD	52
52	MRD	disease	50
53	)	MRD	52
54	quantitatively	disease	50
55	in	quantitatively	54
56	patients	in	55
57	with	patients	56
58	t-LRB-8;21-RRB-	AML	59
59	AML	with	57
60	.	have	3

0	Using	<ROOT>	-1
1	the	system	4
2	yeast	system	4
3	two-hybrid	system	4
4	system	Using	0
5	to	Using	0
6	screen	to	5
7	for	screen	6
8	proteins	for	7
9	which	interact	10
10	interact	proteins	8
11	with	interact	10
12	Tax1	with	11
13	,	Using	0
14	we	Using	0
15	isolated	the	16
16	the	Using	0
17	B	subunit	18
18	subunit	the	16
19	of	subunit	18
20	the	of	19
21	CCAAT	the	20
22	binding	CCAAT	21
23	protein	binding	22
24	NF-Y	protein	23
25	from	HeLa	27
26	a	HeLa	27
27	HeLa	NF-Y	24
28	cDNA	library	29
29	library	Using	0
30	.	library	29

0	Ara-C	had	19
1	activated	Ara-C	0
2	SMase	activated	1
3	with	SMase	2
4	10	minutes	5
5	minutes	with	3
6	in	both	7
7	both	minutes	5
8	Jurkat	both	7
9	and	Jurkat	8
10	EL4	both	7
11	cells	Ara-C	0
12	,	Ara-C	0
13	while	(	16
14	phorbol	ester	15
15	ester	(	16
16	(	Ara-C	0
17	PMA	Ara-C	0
18	)	Ara-C	0
19	had	<ROOT>	-1
20	no	effect	21
21	effect	had	19
22	.	had	19

0	In	may	10
1	addition	In	0
2	,	may	10
3	assay	may	10
4	of	assay	3
5	PBMC	of	4
6	by	assay	3
7	the	PCR	9
8	adenovirus-specific	PCR	9
9	PCR	by	6
10	may	<ROOT>	-1
11	help	may	10
12	detect	help	11
13	early	disease	15
14	invasive	disease	15
15	disease	detect	12
16	and	further	18
17	warrants	and	16
18	further	detect	12
19	evaluation	may	10
20	.	may	10

0	These	results	1
1	results	suggest	2
2	suggest	monoclonal	4
3	that	monoclonal	4
4	monoclonal	<ROOT>	-1
5	integration	monoclonal	4
6	of	HTLV-1	7
7	HTLV-1	integration	5
8	provirus	monoclonal	4
9	to	provirus	8
10	the	genome	11
11	genome	T	13
12	of	T	13
13	T	to	9
14	cell	monoclonal	4
15	,	monoclonal	4
16	especially	,	15
17	the	number	18
18	number	especially	16
19	of	number	18
20	integration	sites	21
21	sites	of	19
22	,	one	24
23	is	,	22
24	one	number	18
25	of	one	24
26	the	factors	27
27	factors	of	25
28	for	factors	27
29	induction	for	28
30	of	induction	29
31	ICAM-1	of	30
32	molecules	.	33
33	.	ICAM-1	31

0	Thymocytes	<ROOT>	-1
1	control	CD4	3
2	the	CD4	3
3	CD4	Thymocytes	0
4	gene	Thymocytes	0
5	differently	gene	4
6	from	T	8
7	mature	T	8
8	T	differently	5
9	lymphocytes	Thymocytes	0
10	.	Thymocytes	0

0	ALY	is	10
1	,	ALY	0
2	a	coactivator	4
3	context-dependent	coactivator	4
4	coactivator	ALY	0
5	of	coactivator	4
6	LEF-1	of	5
7	and	LEF-1	6
8	AML-1	LEF-1	6
9	,	ALY	0
10	is	<ROOT>	-1
11	required	is	10
12	for	required	11
13	TCRalpha	.	16
14	enhancer	.	16
15	function	.	16
16	.	for	12

0	Retinoic	<ROOT>	-1
1	acid	treatment	2
2	treatment	Retinoic	0
3	of	treatment	2
4	HL60	of	3
5	promyelocytic	for	8
6	leukemia	for	8
7	cells	for	8
8	for	HL60	4
9	24	Retinoic	0
10	hr	induced	11
11	induced	24	9
12	C/EBPepsilon	Retinoic	0
13	mRNA	Retinoic	0
14	levels	Retinoic	0
15	by	Retinoic	0
16	4-fold	by	15
17	,	4-fold	16
18	while	4-fold	16
19	prolonged	treatment	20
20	treatment	reduced	22
21	gradually	reduced	22
22	reduced	while	18
23	mRNA	reduced	22
24	expression	mRNA	23
25	to	expression	24
26	pretreatment	to	25
27	levels	pretreatment	26
28	.	levels	27

0	In	cell	5
1	particular	In	0
2	the	cell	5
3	best	cell	5
4	responder	cell	5
5	cell	line	6
6	line	line	12
7	was	line	6
8	the	Burkitt	9
9	Burkitt	line	12
10	's	Burkitt	9
11	cell	line	12
12	line	<ROOT>	-1
13	Namalwa	line	12
14	.	line	12

0	We	<ROOT>	-1
1	have	We	0
2	previously	shown	3
3	shown	have	1
4	that	shown	3
5	a	element	7
6	70-bp	element	7
7	element	is	8
8	is	that	4
9	necessary	is	8
10	and	necessary	9
11	sufficient	and	10
12	for	sufficient	11
13	the	for	12
14	response	of	15
15	of	the	13
16	the	LTR	18
17	CAEV	LTR	18
18	LTR	of	15
19	to	this	20
20	this	of	15
21	cytokine	shown	3
22	.	We	0

0	Adenovirus	E1B	1
1	E1B	19K	2
2	19K	protein	3
3	protein	is	4
4	is	<ROOT>	-1
5	required	is	4
6	for	required	5
7	efficient	replication	9
8	DNA	replication	9
9	replication	for	6
10	in	U937	11
11	U937	required	5
12	cells	is	4
13	.	is	4

0	To	have	7
1	extend	To	0
2	these	observations	4
3	initial	observations	4
4	observations	extend	1
5	,	have	7
6	we	have	7
7	have	<ROOT>	-1
8	examined	have	7
9	the	effect	10
10	effect	examined	8
11	of	antioxidant	12
12	antioxidant	effect	10
13	treatment	antioxidant	12
14	on	treatment	13
15	the	activity	16
16	activity	of	17
17	of	on	14
18	the	mitogen-activated	19
19	mitogen-activated	protein	20
20	protein	of	17
21	kinases	have	7
22	erk1	kinases	21
23	and	erk1	22
24	erk2	and	23
25	,	erk1	22
26	as	erk1	22
27	members	as	26
28	of	members	27
29	a	pathway	32
30	signal	pathway	32
31	transduction	pathway	32
32	pathway	of	28
33	known	pathway	32
34	to	known	33
35	directly	factor	38
36	regulate	factor	38
37	transcription	factor	38
38	factor	to	34
39	function	factor	38
40	.	have	7

0	Glycation-dependent	<ROOT>	-1
1	,	Glycation-dependent	0
2	reactive	Glycation-dependent	0
3	oxygen	reactive	2
4	species-mediated	oxygen	3
5	suppression	species-mediated	4
6	of	suppression	5
7	the	of	6
8	insulin	the	7
9	gene	insulin	8
10	promoter	gene	9
11	activity	promoter	10
12	in	activity	11
13	HIT	cells	14
14	cells	in	12
15	.	cells	14

0	These	studies	1
1	studies	indicate	2
2	indicate	promoter	10
3	that	LPS	5
4	maximal	LPS	5
5	LPS	indicate	2
6	induction	LPS	5
7	of	TNF-alpha	9
8	the	TNF-alpha	9
9	TNF-alpha	induction	6
10	promoter	is	11
11	is	<ROOT>	-1
12	mediated	is	11
13	by	mediated	12
14	concerted	participation	15
15	participation	by	13
16	of	participation	15
17	at	two	19
18	least	two	19
19	two	elements	23
20	separate	elements	23
21	cis-acting	elements	23
22	regulatory	elements	23
23	elements	of	16
24	.	is	11

0	In	demonstrate	5
1	this	report	2
2	report	In	0
3	,	demonstrate	5
4	we	demonstrate	5
5	demonstrate	does	17
6	that	demonstrate	5
7	the	that	6
8	T	cell	9
9	cell	the	7
10	tropic	cell	9
11	strain	demonstrate	5
12	of	strain	11
13	HIV	of	12
14	,	demonstrate	5
15	LAI	demonstrate	5
16	,	demonstrate	5
17	does	<ROOT>	-1
18	not	does	17
19	replicate	does	17
20	in	T	23
21	naive	T	23
22	CD4	T	23
23	T	replicate	19
24	cells	stimulated	25
25	stimulated	does	17
26	by	does	17
27	cross-linking	by	26
28	CD3	cross-linking	27
29	and	CD3	28
30	CD28	and	29
31	.	does	17

0	In	alpha	26
1	MDMs	In	0
2	,	In	0
3	an	upregulation	4
4	upregulation	,	2
5	of	upregulation	4
6	I	of	5
7	kappa	B	8
8	B	of	5
9	alpha	of	5
10	synthesis	alpha	9
11	as	synthesis	10
12	well	as	11
13	as	as	11
14	the	appearance	15
15	appearance	as	11
16	of	appearance	15
17	a	of	16
18	novel	a	17
19	M-LRB-r-RRB-	novel	18
20	40,000	form	21
21	form	M-LRB-r-RRB-	19
22	of	form	21
23	I	of	22
24	kappa	B	25
25	B	of	22
26	alpha	<ROOT>	-1
27	were	alpha	26
28	also	observed	29
29	observed	alpha	26
30	.	alpha	26

0	In	remain	16
1	contrast	In	0
2	,	In	0
3	the	activities	5
4	binding	activities	5
5	activities	,	2
6	of	activities	5
7	two	factors	10
8	ubiquitous	factors	10
9	transcription	factors	10
10	factors	of	6
11	,	activities	5
12	Oct1	activities	5
13	and	Oct1	12
14	Sp1	In	0
15	,	remain	16
16	remain	<ROOT>	-1
17	high	remain	16
18	in	remain	16
19	G2/M	in	18
20	.	remain	16

0	With	<ROOT>	-1
1	the	exception	2
2	exception	With	0
3	of	exception	2
4	LEF1	of	3
5	,	LEF1	4
6	these	LEF1	4
7	factors	activate	8
8	activate	these	6
9	transcription	in	10
10	in	activate	8
11	T	cells	12
12	cells	activate	8
13	.	cells	12

0	In	lipopolysaccharide	3
1	contrast	In	0
2	,	In	0
3	lipopolysaccharide	<ROOT>	-1
4	stimulation	lipopolysaccharide	3
5	primarily	induced	6
6	induced	stimulation	4
7	the	heterodimer	9
8	p65/p50	heterodimer	9
9	heterodimer	induced	6
10	that	has	11
11	has	induced	6
12	been	has	11
13	shown	been	12
14	to	shown	13
15	result	to	14
16	in	gene	17
17	gene	result	15
18	activation	lipopolysaccharide	3
19	.	lipopolysaccharide	3

0	However	appeared	4
1	,	appeared	4
2	this	factor	3
3	factor	appeared	4
4	appeared	<ROOT>	-1
5	when	appeared	4
6	the	patients	8
7	CML	patients	8
8	patients	when	5
9	achieved	patients	8
10	complete	haematological	11
11	haematological	achieved	9
12	remission	(	13
13	(	patients	8
14	CHR	patients	8
15	)	CHR	14
16	through	)	15
17	alpha-interferon	therapy	18
18	therapy	through	16
19	.	appeared	4

0	These	results	1
1	results	indicate	2
2	indicate	<ROOT>	-1
3	that	indicate	2
4	stimulation	pathways	8
5	of	signaling	7
6	CD40	of	5
7	signaling	stimulation	4
8	pathways	that	3
9	exerts	stimulatory	12
10	a	stimulatory	12
11	long-lasting	stimulatory	12
12	stimulatory	pathways	8
13	effect	stimulatory	12
14	on	effect	13
15	both	on	14
16	the	both	15
17	transcription	and	18
18	and	the	16
19	nuclear	translocation	20
20	translocation	and	18
21	of	translocation	20
22	RelB	indicate	2
23	.	indicate	2

0	In	suggests	5
1	addition	In	0
2	,	suggests	5
3	our	data	4
4	data	suggests	5
5	suggests	<ROOT>	-1
6	that	suggests	5
7	the	induction	10
8	rapid	induction	10
9	PMA-mediated	induction	10
10	induction	of	11
11	of	that	6
12	collagenase-1	of	11
13	transcription	is	14
14	is	controlled	15
15	controlled	suggests	5
16	by	controlled	15
17	a	by	16
18	mechanism	a	17
19	distinct	mechanism	18
20	from	distinct	19
21	that	from	20
22	regulating	sustained	24
23	the	sustained	24
24	sustained	that	21
25	expression	sustained	24
26	of	expression	25
27	this	proteinase	28
28	proteinase	of	26
29	in	activated	30
30	activated	sustained	24
31	macrophages	suggests	5
32	.	suggests	5

0	B-lymphoblastoid	<ROOT>	-1
1	cell	B-lymphoblastoid	0
2	lines	cell	1
3	from	lines	2
4	multiple	patients	6
5	sclerosis	patients	6
6	patients	from	3
7	and	B-lymphoblastoid	0
8	a	and	7
9	healthy	control	10
10	control	a	8
11	producing	control	10
12	a	producing	11
13	putative	new	14
14	new	a	12
15	human	new	14
16	retrovirus	human	15
17	and	retrovirus	16
18	Epstein-Barr	virus	19
19	virus	and	17
20	.	virus	19

0	Inhibition	is	13
1	of	Inhibition	0
2	TNF-alpha	production	3
3	production	of	1
4	by	cells	6
5	THP-1-hGH-transfected	cells	6
6	cells	of	1
7	cultured	Inhibition	0
8	in	the	9
9	the	Inhibition	0
10	presence	Inhibition	0
11	of	presence	10
12	LPS	of	11
13	is	<ROOT>	-1
14	dependent	is	13
15	on	dependent	14
16	a	pathway	18
17	selective	pathway	18
18	pathway	on	15
19	,	is	13
20	since	is	13
21	no	inhibition	22
22	inhibition	was	26
23	of	inhibition	22
24	TNF-alpha	production	25
25	production	of	23
26	was	since	20
27	observed	was	26
28	when	observed	27
29	cells	when	28
30	were	cells	29
31	cultured	the	33
32	in	the	33
33	the	were	30
34	presence	of	35
35	of	were	30
36	PMA	is	13
37	.	is	13

0	It	was	1
1	was	that	3
2	observed	was	1
3	that	expression	7
4	induction	that	3
5	of	G-LRB-S-RRB-alpha	6
6	G-LRB-S-RRB-alpha	induction	4
7	expression	<ROOT>	-1
8	increased	expression	7
9	constitutive	expression	7
10	as	expression	7
11	well	expression	7
12	as	stimulated	13
13	stimulated	expression	7
14	cAMP	expression	7
15	accumulation	expression	7
16	.	expression	7

0	We	isolated	1
1	isolated	<ROOT>	-1
2	a	subline	4
3	novel	subline	4
4	subline	isolated	1
5	,	isolated	1
6	UT-7/GMT	isolated	1
7	,	isolated	1
8	from	UT-7/GM	14
9	the	UT-7/GM	14
10	human	UT-7/GM	14
11	leukemia	UT-7/GM	14
12	cell	UT-7/GM	14
13	line	UT-7/GM	14
14	UT-7/GM	isolated	1
15	(	UT-7/GM	14
16	N.	Komatsu	17
17	Komatsu	(	15
18	,	Komatsu	17
19	et	Komatsu	17
20	al.	et	19
21	,	Komatsu	17
22	Blood	Komatsu	17
23	,	Blood	22
24	89	Blood	22
25	:	(	15
26	4021-4033	:	25
27	,	:	25
28	1997	:	25
29	)	(	15
30	.	isolated	1

0	Western	blot	1
1	blot	)	10
2	analysis	inhibitory	6
3	of	inhibitory	6
4	the	inhibitory	6
5	NF-kappaB	inhibitory	6
6	inhibitory	blot	1
7	subunits	blot	1
8	(	subunits	7
9	IkappaB	blot	1
10	)	demonstrated	11
11	demonstrated	<ROOT>	-1
12	that	demonstrated	11
13	both	proteolysis	15
14	IkappaB-alpha	proteolysis	15
15	proteolysis	were	19
16	and	proteolysis	15
17	p105	processing	18
18	processing	and	16
19	were	that	12
20	induced	were	19
21	by	induced	20
22	the	treatment	23
23	treatment	by	21
24	.	demonstrated	11

0	We	find	2
1	also	find	2
2	find	<ROOT>	-1
3	significant	differences	4
4	differences	find	2
5	in	differences	4
6	activation	in	5
7	of	activation	6
8	germline	of	7
9	and	germline	8
10	V	and	9
11	region	by	13
12	promoters	region	11
13	by	V	10
14	kappa	enhancers	15
15	enhancers	find	2
16	.	find	2

0	In	<ROOT>	-1
1	addition	In	0
2	,	In	0
3	a	,	2
4	significant	a	3
5	correlation	was	6
6	was	significant	4
7	noted	was	6
8	between	noted	7
9	the	between	8
10	degree	of	11
11	of	the	9
12	inhibition	of	11
13	of	lymphocyte	14
14	lymphocyte	inhibition	12
15	proliferation	lymphocyte	14
16	(	the	9
17	IC50	(	16
18	)	IC50	17
19	and	binding	21
20	the	binding	21
21	binding	)	18
22	affinity	of	23
23	of	IC50	17
24	dexamethasone	of	23
25	to	the	26
26	the	dexamethasone	24
27	GCR	significant	4
28	.	significant	4

0	Few	are	4
1	of	Few	0
2	these	factors	3
3	factors	of	1
4	are	<ROOT>	-1
5	expressed	are	4
6	exclusively	expressed	5
7	in	myeloid	8
8	myeloid	exclusively	6
9	cells	are	4
10	;	are	4
11	instead	are	4
12	it	appears	13
13	appears	instead	11
14	that	appears	13
15	they	that	14
16	cooperatively	they	15
17	regulate	of	19
18	transcription	of	19
19	of	cooperatively	16
20	myeloid-specific	genes	21
21	genes	of	19
22	.	are	4

0	Redox	signals	1
1	signals	<ROOT>	-1
2	and	signals	1
3	NF-kappaB	activation	4
4	activation	and	2
5	in	T	6
6	T	signals	1
7	cells	signals	1
8	.	signals	1

0	Transient	site	22
1	expression	with	3
2	assays	with	3
3	with	Transient	0
4	plasmids	with	3
5	containing	plasmids	4
6	deleted	containing	5
7	parts	deleted	6
8	of	deleted	6
9	the	region	11
10	LTR	region	11
11	region	of	8
12	linked	with	3
13	to	a	14
14	a	linked	12
15	reporter	gene	16
16	gene	showed	17
17	showed	binding	21
18	that	binding	21
19	the	binding	21
20	NF-kappaB	binding	21
21	binding	a	14
22	site	<ROOT>	-1
23	was	site	22
24	essential	for	25
25	for	site	22
26	HIV-1	LTR	27
27	LTR	for	25
28	activity	for	25
29	in	B	31
30	CD40-stimulated	B	31
31	B	activity	28
32	lymphocytes	site	22
33	.	site	22

0	The	ability	1
1	ability	may	11
2	of	ability	1
3	CMV	products	6
4	IE	products	6
5	gene	products	6
6	products	of	2
7	to	ability	1
8	enhance	to	7
9	IL-6	production	10
10	production	enhance	8
11	may	<ROOT>	-1
12	play	may	11
13	an	role	15
14	important	role	15
15	role	play	12
16	in	play	12
17	immune	states	19
18	inflammatory	states	19
19	states	in	16
20	associated	states	19
21	with	associated	20
22	CMV	with	21
23	infection	CMV	22
24	.	infection	23

0	PCR	shifts	4
1	products	shifts	4
2	showing	shifts	4
3	PTT	showing	2
4	shifts	were	5
5	were	<ROOT>	-1
6	directly	were	5
7	sequenced	directly	6
8	,	sequenced	7
9	and	sequenced	7
10	mutations	and	9
11	confirmed	were	5
12	by	confirmed	11
13	restriction	by	12
14	enzyme	restriction	13
15	digestion	enzyme	14
16	where	possible	17
17	possible	digestion	15
18	.	were	5

0	The	site	3
1	double	site	3
2	NF-kappaB	site	3
3	site	has	16
4	identified	site	3
5	in	identified	4
6	the	LTR	7
7	LTR	in	5
8	of	LTR	7
9	the	virus-1	12
10	human	virus-1	12
11	immunodeficiency	virus-1	12
12	virus-1	of	8
13	(	HIV-1	14
14	HIV-1	virus-1	12
15	)	HIV-1	14
16	has	<ROOT>	-1
17	been	has	16
18	demonstrated	been	17
19	to	demonstrated	18
20	be	to	19
21	necessary	be	20
22	for	viral	24
23	efficient	viral	24
24	viral	be	20
25	transcription	has	16
26	.	has	16

0	These	results	1
1	results	suggest	2
2	suggest	<ROOT>	-1
3	that	suggest	2
4	the	mechanism	6
5	molecular	mechanism	6
6	mechanism	is	12
7	of	mechanism	6
8	HIV	inhibition	9
9	inhibition	of	7
10	by	inhibition	9
11	ascorbate	by	10
12	is	that	3
13	not	is	12
14	mediated	B	17
15	via	NF-kappa	16
16	NF-kappa	mediated	14
17	B	is	12
18	inhibition	suggest	2
19	,	inhibition	18
20	unlike	that	21
21	that	,	19
22	seen	that	21
23	with	seen	22
24	other	antioxidants	25
25	antioxidants	with	23
26	.	suggest	2

0	In	<ROOT>	-1
1	all	subjects	3
2	the	subjects	3
3	subjects	In	0
4	,	In	0
5	dexamethasone	able	7
6	was	dexamethasone	5
7	able	,	4
8	to	suppress	9
9	suppress	able	7
10	plasma	cortisol	11
11	cortisol	suppress	9
12	.	In	0

0	Activation	B	3
1	of	NF-kappa	2
2	NF-kappa	Activation	0
3	B	<ROOT>	-1
4	can	B	3
5	be	can	4
6	inhibited	be	5
7	in	inhibited	6
8	vivo	in	7
9	by	inhibited	6
10	treatment	with	11
11	with	by	9
12	antioxidants	with	11
13	,	B	3
14	corticosteroids	B	3
15	,	B	3
16	and	the	17
17	the	B	3
18	induction	of	19
19	of	endotoxin	20
20	endotoxin	the	17
21	tolerance	B	3
22	.	B	3

0	Structurally	cations	3
1	related	divalent	2
2	divalent	Structurally	0
3	cations	<ROOT>	-1
4	like	cations	3
5	cobalt	like	4
6	,	cations	3
7	nickel	increase	13
8	,	nickel	7
9	and	nickel	7
10	mercury	and	9
11	also	increase	13
12	partially	increase	13
13	increase	cations	3
14	monokine	secretion	15
15	secretion	increase	13
16	but	increase	13
17	to	increase	13
18	a	to	17
19	much	lower	20
20	lower	a	18
21	and	lower	20
22	thus	extent	24
23	insignificant	extent	24
24	extent	and	21
25	.	cations	3

0	Because	<ROOT>	-1
1	antioxidants	been	3
2	have	antioxidants	1
3	been	Because	0
4	considered	been	3
5	to	considered	4
6	be	to	5
7	of	be	6
8	antiatherosclerotic	potential	9
9	potential	of	7
10	,	been	3
11	we	been	3
12	investigated	the	13
13	the	we	11
14	effects	of	15
15	of	alpha-tocopherol	16
16	alpha-tocopherol	the	13
17	(	alpha-tocopherol	16
18	TCP	alpha-tocopherol	16
19	)	alpha-tocopherol	16
20	and	its	21
21	its	been	3
22	acetate	Because	0
23	and	acetate	22
24	succinate	acetate	22
25	esters	succinate	24
26	on	monocyte	27
27	monocyte	acetate	22
28	adhesion	monocyte	27
29	to	Because	0
30	cytokine-stimulated	(	36
31	human	(	36
32	umbilical	(	36
33	vein	(	36
34	endothelial	(	36
35	cells	(	36
36	(	to	29
37	HUVEC	Because	0
38	)	Because	0
39	.	Because	0

0	Pax-5a	was	1
1	was	<ROOT>	-1
2	detectable	was	1
3	in	detectable	2
4	pro-	in	3
5	,	pro-	4
6	pre-	pro-	4
7	,	pre-	6
8	and	pre-	6
9	mature	lines	11
10	B-cell	lines	11
11	lines	and	8
12	,	was	1
13	but	was	1
14	not	in	15
15	in	but	13
16	two	plasmacytomas	17
17	plasmacytomas	in	15
18	;	in	15
19	Pax-5b	was	20
20	was	in	15
21	shown	was	20
22	to	shown	21
23	be	to	22
24	present	be	23
25	at	present	24
26	low	levels	27
27	levels	at	25
28	in	present	24
29	mature	lines	31
30	B-cell	lines	31
31	lines	in	28
32	and	to	22
33	,	and	32
34	unexpectedly	plasma	38
35	,	plasma	38
36	in	plasma	38
37	one	plasma	38
38	plasma	,	33
39	cell	plasma	38
40	line	cell	39
41	,	line	40
42	but	,	41
43	not	line	40
44	in	line	40
45	pro-B-cell	in	44
46	or	pro-B-cell	45
47	T-cell	was	1
48	lines	was	1
49	.	was	1

0	However	was	8
1	,	was	8
2	a	decrease	4
3	substantial	decrease	4
4	decrease	was	8
5	of	decrease	4
6	AML1/ETO	transcripts	7
7	transcripts	of	5
8	was	<ROOT>	-1
9	seen	was	8
10	following	autologous	11
11	autologous	seen	9
12	PBSCT	seen	9
13	.	was	8

0	Its	domain	2
1	extracellular	domain	2
2	domain	is	3
3	is	and	10
4	composed	is	3
5	of	composed	4
6	four	domains	8
7	cysteine-rich	domains	8
8	domains	of	5
9	,	is	3
10	and	<ROOT>	-1
11	the	region	13
12	cytoplasmic	region	13
13	region	and	10
14	contains	death	16
15	a	death	16
16	death	and	10
17	domain	and	10
18	known	domain	17
19	to	known	18
20	signal	to	19
21	apoptosis	and	10
22	.	and	10

0	Northern	blot	1
1	blot	analysis	2
2	analysis	suggests	7
3	in	analysis	2
4	mouse	lines	6
5	cell	lines	6
6	lines	in	3
7	suggests	<ROOT>	-1
8	that	suggests	7
9	its	expression	10
10	expression	is	11
11	is	that	8
12	found	is	11
13	in	found	12
14	a	variety	15
15	variety	in	13
16	of	variety	15
17	cells	of	16
18	,	suggests	7
19	including	T	20
20	T	suggests	7
21	cells	suggests	7
22	,	suggests	7
23	B	cells	24
24	cells	suggests	7
25	,	suggests	7
26	and	suggests	7
27	macrophages	suggests	7
28	.	suggests	7

0	Delta-opioid	receptors	1
1	receptors	<ROOT>	-1
2	expressed	receptors	1
3	by	T	5
4	Jurkat	T	5
5	T	expressed	2
6	cells	receptors	1
7	enhance	receptors	1
8	IL-2	by	10
9	secretion	by	10
10	by	enhance	7
11	increasing	complexes	13
12	AP-1	complexes	13
13	complexes	by	10
14	and	complexes	13
15	activity	and	14
16	of	activity	15
17	the	element	20
18	NF-AT/AP-1-binding	element	20
19	promoter	element	20
20	element	of	16
21	.	receptors	1

0	We	detected	2
1	previously	detected	2
2	detected	promoter	5
3	a	promoter	5
4	tissue-specific	promoter	5
5	promoter	<ROOT>	-1
6	preceding	encoding	9
7	the	exon	8
8	exon	encoding	9
9	encoding	N	11
10	the	N	11
11	N	promoter	5
12	terminus	promoter	5
13	of	leukocyte	16
14	the	leukocyte	16
15	pp52	leukocyte	16
16	leukocyte	terminus	12
17	protein	promoter	5
18	.	promoter	5

0	Transcriptional	activation	1
1	activation	required	2
2	required	<ROOT>	-1
3	the	required	2
4	presence	the	3
5	of	presence	4
6	a	site	9
7	weak	site	9
8	RBP-Jkappa-binding	site	9
9	site	of	5
10	within	presence	4
11	the	within	10
12	NOTCH1	ankyrin	13
13	ankyrin	the	11
14	repeat	ankyrin	13
15	region	repeat	14
16	of	intracellular	18
17	the	intracellular	18
18	intracellular	region	15
19	domain	required	2
20	.	required	2

0	Immunofluorescence	colocalization	1
1	colocalization	receptors	7
2	of	colocalization	1
3	both	estrogen	4
4	estrogen	of	2
5	and	estrogen	4
6	progesterone	and	5
7	receptors	showed	12
8	with	receptors	7
9	eosinophil	protein	11
10	cationic	protein	11
11	protein	with	8
12	showed	were	20
13	that	showed	12
14	approximately	70	15
15	70	%	16
16	%	that	13
17	of	positive	18
18	positive	%	16
19	cells	showed	12
20	were	<ROOT>	-1
21	eosinophils	were	20
22	.	were	20

0	A	Fv	2
1	single-chain	Fv	2
2	Fv	was	6
3	(	sFv	4
4	sFv	Fv	2
5	)	sFv	4
6	was	<ROOT>	-1
7	expressed	was	6
8	from	variable	10
9	the	variable	10
10	variable	expressed	7
11	regions	was	6
12	of	mAb	15
13	the	mAb	15
14	CD40-specific	mAb	15
15	mAb	regions	11
16	G28-5	was	6
17	.	was	6

0	Although	failed	19
1	cadmium	caused	2
2	caused	Although	0
3	an	caused	2
4	early	an	3
5	,	of	8
6	transient	of	8
7	stimulation	of	8
8	of	early	4
9	c-jun	of	8
10	and	c-jun	9
11	c-fos	expression	12
12	expression	of	8
13	and	of	8
14	AP-1	binding	15
15	binding	Although	0
16	activity	Although	0
17	,	failed	19
18	heat-shock	failed	19
19	failed	<ROOT>	-1
20	to	failed	19
21	alter	to	20
22	both	expression	24
23	protooncogene	expression	24
24	expression	alter	21
25	and	expression	24
26	transcription	and	25
27	factor	binding	28
28	binding	and	25
29	,	failed	19
30	indicating	failed	19
31	that	indicating	30
32	the	increase	35
33	stress-induced	increase	35
34	vimentin	increase	35
35	increase	was	36
36	was	that	31
37	not	was	36
38	the	result	39
39	result	was	36
40	of	result	39
41	AP-1-mediated	activation	43
42	transcriptional	activation	43
43	activation	of	40
44	.	failed	19

0	One	encompassed	5
1	of	One	0
2	these	elements	4
3	NFAT-like	elements	4
4	elements	of	1
5	encompassed	<ROOT>	-1
6	overlapping	Oct-	7
7	Oct-	encompassed	5
8	and	Oct-	7
9	NFATp/c-binding	sites	10
10	sites	and	8
11	,	Oct-	7
12	which	functioned	13
13	functioned	Oct-	7
14	in	functioned	13
15	a	manner	18
16	highly	synergistic	17
17	synergistic	manner	18
18	manner	in	14
19	.	encompassed	5

0	Engagement	<ROOT>	-1
1	of	Engagement	0
2	the	antigen	5
3	Lewis	antigen	5
4	X	antigen	5
5	antigen	of	1
6	(	CD15	7
7	CD15	antigen	5
8	)	CD15	7
9	results	antigen	5
10	in	monocyte	11
11	monocyte	of	1
12	activation	Engagement	0
13	.	Engagement	0

0	Transcription	factor	1
1	factor	binding	2
2	binding	sites	3
3	sites	transcription	12
4	downstream	virus	9
5	of	virus	9
6	the	virus	9
7	human	virus	9
8	immunodeficiency	virus	9
9	virus	sites	3
10	type	transcription	12
11	1	transcription	12
12	transcription	<ROOT>	-1
13	start	transcription	12
14	site	are	15
15	are	start	13
16	important	are	15
17	for	virus	18
18	virus	important	16
19	infectivity	virus	18
20	.	infectivity	19

0	Intragenic	<ROOT>	-1
1	deletions	Intragenic	0
2	of	deletions	1
3	TSG101	of	2
4	,	human	6
5	the	human	6
6	human	Intragenic	0
7	homolog	Intragenic	0
8	of	homolog	7
9	a	of	8
10	mouse	(	12
11	gene	(	12
12	(	a	9
13	tsg101	a	9
14	)	that	15
15	that	tsg101	13
16	acts	that	15
17	to	acts	16
18	suppress	cell	20
19	malignant	cell	20
20	cell	to	17
21	growth	Intragenic	0
22	,	Intragenic	0
23	were	Intragenic	0
24	reported	human	26
25	in	human	26
26	human	were	23
27	breast	Intragenic	0
28	tumours	Intragenic	0
29	.	Intragenic	0

0	This	function	2
1	cooperative	function	2
2	function	may	3
3	may	<ROOT>	-1
4	account	may	3
5	for	account	4
6	the	for	5
7	divergent	the	6
8	effects	of	9
9	of	divergent	7
10	LSF	of	9
11	previously	may	3
12	observed	in	13
13	in	may	3
14	vitro	in	13
15	and	may	3
16	in	and	15
17	vivo	may	3
18	.	may	3

0	We	show	1
1	show	<ROOT>	-1
2	here	show	1
3	that	show	1
4	in	pRB	11
5	the	phases	7
6	early	phases	7
7	phases	in	4
8	of	phases	7
9	apoptosis	of	8
10	,	pRB	11
11	pRB	is	12
12	is	that	3
13	posttranslationally	is	12
14	modified	is	12
15	by	modified	14
16	a	by	15
17	tissue	transglutaminase	18
18	transglutaminase	(	19
19	(	a	16
20	tTG	(	19
21	)	a	16
22	-catalyzed	reaction	23
23	reaction	a	16
24	.	show	1

0	The	factor	2
1	nuclear	factor	2
2	factor	cis-acting	18
3	of	T	5
4	activated	T	5
5	T	factor	2
6	cells	(	7
7	(	factor	2
8	NFAT	)	9
9	)	factor	2
10	regulates	)	9
11	cytokine	factor	2
12	gene	factor	2
13	expression	factor	2
14	in	T	15
15	T	expression	13
16	cells	through	17
17	through	factor	2
18	cis-acting	<ROOT>	-1
19	elements	cis-acting	18
20	located	elements	19
21	in	located	20
22	the	promoters	23
23	promoters	in	21
24	of	several	25
25	several	promoters	23
26	cytokine	.	28
27	genes	.	28
28	.	several	25

0	Proteins	<ROOT>	-1
1	exist	Proteins	0
2	in	exist	1
3	leukocytes	in	2
4	able	exist	1
5	to	able	4
6	modify	to	5
7	GTP-binding	modify	6
8	protein	in	10
9	function	in	10
10	in	GTP-binding	7
11	this	in	10
12	manner	,	13
13	,	this	11
14	and	,	13
15	their	and	14
16	activity	Proteins	0
17	may	be	18
18	be	regulated	19
19	regulated	Proteins	0
20	by	Proteins	0
21	signals	by	20
22	generated	signals	21
23	on	generated	22
24	phagocyte	stimulation	25
25	stimulation	on	23
26	.	Proteins	0

0	Cloning	<ROOT>	-1
1	and	Cloning	0
2	expression	Cloning	0
3	of	glucocorticoid	5
4	the	glucocorticoid	5
5	glucocorticoid	expression	2
6	receptor	the	8
7	from	the	8
8	the	Cloning	0
9	squirrel	Cloning	0
10	monkey	Cloning	0
11	(	Cloning	0
12	Saimiri	Cloning	0
13	boliviensis	Cloning	0
14	boliviensis	Cloning	0
15	)	Cloning	0
16	,	primate	19
17	a	primate	19
18	glucocorticoid-resistant	primate	19
19	primate	Cloning	0
20	.	Cloning	0

0	The	motifs	2
1	Ets	motifs	2
2	motifs	are	3
3	are	<ROOT>	-1
4	preferentially	bound	5
5	bound	are	3
6	by	bound	5
7	PU-1	by	6
8	in	B	9
9	B	bound	5
10	cell	extracts	11
11	extracts	B	9
12	from	B	9
13	all	development	16
14	stages	of	15
15	of	all	13
16	development	from	12
17	,	are	3
18	whereas	are	3
19	a	member	23
20	different	member	23
21	Ets	member	23
22	family	member	23
23	member	reacts	24
24	reacts	T	29
25	with	T	29
26	these	T	29
27	motifs	T	29
28	in	T	29
29	T	whereas	18
30	cell	are	3
31	extracts	are	3
32	.	are	3

0	Other	variables	1
1	variables	were	15
2	,	variables	1
3	including	variables	1
4	plasma	hormone	5
5	hormone	including	3
6	and	hormone	5
7	electrolyte	values	8
8	values	and	6
9	and	binding	10
10	binding	values	8
11	characteristics	hormone	5
12	for	characteristics	11
13	dexamethasone	,	14
14	,	for	12
15	were	<ROOT>	-1
16	not	were	15
17	different	were	15
18	.	were	15

0	ATL-16T	cells	1
1	cells	has	19
2	express	cells	1
3	mRNA	express	2
4	of	mRNA	3
5	three	proteins	7
6	GATA-binding	proteins	7
7	proteins	of	4
8	,	proteins	7
9	hGATA-2	proteins	7
10	,	hGATA-2	9
11	hGATA-3	hGATA-2	9
12	and	hGATA-3	11
13	hGATA-4	and	12
14	,	cells	1
15	and	cells	1
16	each	and	15
17	of	each	16
18	them	cells	1
19	has	<ROOT>	-1
20	a	potential	21
21	potential	has	19
22	to	potential	21
23	bind	to	22
24	to	bind	23
25	the	consensus	26
26	consensus	to	24
27	-LRB-A/T-RRB-GATA-LRB-G/A-RRB-	motif	28
28	motif	consensus	26
29	.	has	19

0	CONCLUSIONS	<ROOT>	-1
1	:	CONCLUSIONS	0
2	The	reduction	3
3	reduction	is	21
4	of	reduction	3
5	symptoms	of	4
6	due	reduction	3
7	to	due	6
8	topical	propionate	10
9	fluticasone	propionate	10
10	propionate	to	7
11	in	propionate	10
12	patients	in	11
13	with	patients	12
14	rhinitis	with	13
15	and	rhinitis	14
16	allergy	and	15
17	to	and	15
18	house	mite	20
19	dust	mite	20
20	mite	to	17
21	is	CONCLUSIONS	0
22	not	is	21
23	correlated	is	21
24	with	correlated	23
25	the	characteristics	26
26	characteristics	with	24
27	of	glucocorticoid	29
28	the	glucocorticoid	29
29	glucocorticoid	characteristics	26
30	receptor	glucocorticoid	29
31	.	CONCLUSIONS	0

0	Here	show	3
1	,	show	3
2	we	show	3
3	show	<ROOT>	-1
4	that	show	3
5	OCA-B	alters	6
6	alters	that	4
7	the	activity	8
8	activity	alters	6
9	of	activity	8
10	Oct-1	of	9
11	in	alters	6
12	two	ways	13
13	ways	in	11
14	.	show	3

0	In	are	16
1	contrast	In	0
2	,	In	0
3	the	activities	5
4	binding	activities	5
5	activities	,	2
6	of	activities	5
7	AP-1	of	6
8	and	of	6
9	GATA	In	0
10	,	In	0
11	on	In	0
12	the	hand	14
13	other	hand	14
14	hand	on	11
15	,	In	0
16	are	<ROOT>	-1
17	increased	are	16
18	by	increased	17
19	LDL	by	18
20	.	are	16

0	Nuclear	B	2
1	factor-kappa	B	2
2	B	is	7
3	(	NF-kappa	4
4	NF-kappa	B	2
5	B	NF-kappa	4
6	)	NF-kappa	4
7	is	<ROOT>	-1
8	a	factor	11
9	critical	factor	11
10	transcription	factor	11
11	factor	is	7
12	for	maximal	13
13	maximal	is	7
14	expression	is	7
15	of	expression	14
16	many	cytokines	17
17	cytokines	of	15
18	that	is	7
19	are	that	18
20	involved	are	19
21	in	involved	20
22	the	pathogenesis	23
23	pathogenesis	in	21
24	of	inflammatory	25
25	inflammatory	pathogenesis	23
26	diseases	are	19
27	,	such	28
28	such	diseases	26
29	as	respiratory	31
30	adult	respiratory	31
31	respiratory	distress	32
32	distress	such	28
33	syndrome	are	19
34	(	ARDS	35
35	ARDS	are	19
36	)	ARDS	35
37	and	sepsis	38
38	sepsis	are	19
39	syndrome	sepsis	38
40	.	is	7

0	In	showed	7
1	addition	In	0
2	,	showed	7
3	in	,	2
4	vivo	analysis	6
5	footprint	analysis	6
6	analysis	in	3
7	showed	<ROOT>	-1
8	the	X	10
9	putative	X	10
10	X	showed	7
11	and	showed	7
12	Y	boxes	13
13	boxes	and	11
14	to	and	11
15	be	to	14
16	occupied	be	15
17	by	transcription	18
18	transcription	occupied	16
19	factors	showed	7
20	in	wild-type	21
21	wild-type	showed	7
22	B	showed	7
23	cells	showed	7
24	,	showed	7
25	but	showed	7
26	not	but	25
27	in	B	29
28	RFX-deficient	B	29
29	B	not	26
30	cells	B	29
31	.	showed	7

0	Indeed	was	8
1	,	was	8
2	secretion	was	8
3	of	secretion	2
4	the	interleukin-1beta	7
5	proinflammatory	lymphokine	6
6	lymphokine	interleukin-1beta	7
7	interleukin-1beta	of	3
8	was	THP	17
9	severely	was	8
10	inhibited	severely	9
11	by	inhibited	10
12	dissociated	by	11
13	glucocorticoids	in	14
14	in	dissociated	12
15	human	in	14
16	monocytic	THP	17
17	THP	<ROOT>	-1
18	1	cells	19
19	cells	THP	17
20	.	cells	19

0	Impaired	cortisol	1
1	cortisol	<ROOT>	-1
2	binding	cortisol	1
3	to	glucocorticoid	4
4	glucocorticoid	binding	2
5	receptors	cortisol	1
6	in	cortisol	1
7	hypertensive	patients	8
8	patients	in	6
9	.	cortisol	1

0	The	-326	1
1	-326	contained	5
2	to	region	4
3	-615	region	4
4	region	-326	1
5	contained	<ROOT>	-1
6	positive	elements	8
7	regulatory	elements	8
8	elements	contained	5
9	.	contained	5

0	Both	GATA-1	1
1	GATA-1	CACCC-binding	3
2	and	GATA-1	1
3	CACCC-binding	proteins	4
4	proteins	<ROOT>	-1
5	are	critical	6
6	critical	proteins	4
7	for	critical	6
8	the	developmentally	9
9	developmentally	for	7
10	regulated	expression	11
11	expression	developmentally	9
12	of	expression	11
13	erythroid-specific	genes	14
14	genes	of	12
15	.	proteins	4

0	Furthermore	can	5
1	,	can	5
2	the	NF-AT1	4
3	dephosphorylated	NF-AT1	4
4	NF-AT1	can	5
5	can	<ROOT>	-1
6	be	can	5
7	rapidly	be	6
8	rephosphorylated	rapidly	7
9	when	rephosphorylated	8
10	the	when	9
11	cells	cyclosporin	15
12	are	cyclosporin	15
13	incubated	with	14
14	with	cyclosporin	15
15	cyclosporin	the	10
16	A	cyclosporin	15
17	,	A	16
18	an	immunosuppressant	19
19	immunosuppressant	,	17
20	inhibiting	the	21
21	the	the	10
22	serine/threonine	phosphatase	23
23	phosphatase	the	21
24	calcineurin	phosphatase	23
25	.	calcineurin	24

0	We	identified	1
1	identified	genes	18
2	a	response	5
3	cell-type-specific	differential	4
4	differential	response	5
5	response	identified	1
6	:	response	5
7	CREB	:	6
8	,	response	5
9	CTF	response	5
10	,	response	5
11	OTF-1	response	5
12	,	identified	1
13	OFT-2	,	12
14	,	OFT-2	13
15	and	B	17
16	NF-kappa	B	17
17	B	OFT-2	13
18	genes	hours	25
19	were	genes	18
20	strongly	were	19
21	induced	genes	18
22	1	induced	21
23	to	genes	18
24	4	genes	18
25	hours	cell	34
26	after	influenza	27
27	influenza	A	28
28	A	hours	25
29	virus	hours	25
30	infection	hours	25
31	in	cell	34
32	the	cell	34
33	monocytic	cell	34
34	cell	<ROOT>	-1
35	line	cell	34
36	Mono	cell	34
37	Mac	cell	34
38	6	cell	34
39	,	cell	34
40	while	cell	34
41	in	while	40
42	freshly	prepared	43
43	prepared	human	44
44	human	in	41
45	monocytes	human	44
46	no	changes	48
47	significant	changes	48
48	changes	were	49
49	were	monocytes	45
50	detected	were	49
51	.	cell	34

0	Remixing	<ROOT>	-1
1	of	T	3
2	purified	T	3
3	T	Remixing	0
4	cells	Remixing	0
5	showed	that	6
6	that	Remixing	0
7	naive	that	6
8	T	Remixing	0
9	cells	do	10
10	do	Remixing	0
11	not	do	10
12	suppress	do	10
13	LAI	replication	14
14	replication	suppress	12
15	in	T	17
16	memory	T	17
17	T	suppress	12
18	cells	Remixing	0
19	and	Remixing	0
20	that	T	22
21	memory	T	22
22	T	and	19
23	cells	do	24
24	do	restore	26
25	not	restore	26
26	restore	Remixing	0
27	LAI	Remixing	0
28	expression	in	29
29	in	Remixing	0
30	naive	Remixing	0
31	T	Remixing	0
32	cells	Remixing	0
33	.	Remixing	0

0	Here	show	2
1	we	show	2
2	show	<ROOT>	-1
3	that	show	2
4	a	fraction	6
5	large	fraction	6
6	fraction	that	3
7	of	T	8
8	T	fraction	6
9	cells	show	2
10	infiltrating	show	2
11	affected	infiltrating	10
12	joints	affected	11
13	from	a	14
14	a	patient	15
15	patient	joints	12
16	with	affected	11
17	chronic	with	16
18	rheumatoid	chronic	17
19	arthritis	recognizes	20
20	recognizes	rheumatoid	18
21	two	recognizes	20
22	EBV	(	24
23	transactivators	(	24
24	(	two	21
25	BZLF1	and	26
26	and	BMLF1	27
27	BMLF1	(	24
28	)	rheumatoid	18
29	in	)	28
30	a	complex-restricted	33
31	major	complex-restricted	33
32	histocompatibility	complex-restricted	33
33	complex-restricted	in	29
34	fashion	in	29
35	.	show	2

0	The	promoters	2
1	germline	promoters	2
2	promoters	<ROOT>	-1
3	(	Ko	4
4	Ko	promoters	2
5	)	Ko	4
6	located	promoters	2
7	upstream	located	6
8	of	upstream	7
9	the	of	8
10	J	the	9
11	region	J	10
12	gene	region	11
13	segments	gene	12
14	of	segments	13
15	the	locus	17
16	kappa	locus	17
17	locus	of	14
18	also	contain	19
19	contain	the	9
20	an	motif	22
21	octamer	motif	22
22	motif	contain	19
23	(	containing	24
24	containing	motif	22
25	a	base	27
26	single	base	27
27	base	containing	24
28	pair	base	27
29	mutation	and	30
30	and	pair	28
31	referred	contain	19
32	to	referred	31
33	as	variant	35
34	the	variant	35
35	variant	referred	31
36	octamer	which	38
37	)	octamer	36
38	which	promoters	2
39	has	promoters	2
40	been	promoters	2
41	shown	been	40
42	previously	been	40
43	to	previously	42
44	bind	to	43
45	Oct-1	to	43
46	and	Oct-1	45
47	Oct-2	factors	49
48	transcription	factors	49
49	factors	to	43
50	in	factors	49
51	vitro	in	50
52	.	promoters	2

0	Glucocorticoid	receptors	1
1	receptors	<ROOT>	-1
2	in	blood	4
3	cord	blood	4
4	blood	receptors	1
5	lymphocytes	receptors	1
6	of	lymphocytes	5
7	healthy	neonates	8
8	neonates	of	6
9	and	neonates	8
10	of	neonates	8
11	preterms	suffering	12
12	suffering	of	10
13	from	suffering	12
14	respiratory	distress	15
15	distress	syndrome	16
16	syndrome	from	13
17	.	receptors	1

0	Both	of	1
1	of	did	7
2	these	of	1
3	parameters	of	1
4	,	did	7
5	however	did	7
6	,	did	7
7	did	<ROOT>	-1
8	not	did	7
9	change	did	7
10	significantly	change	9
11	after	change	9
12	mitogen	stimulation	13
13	stimulation	after	11
14	.	did	7

0	The	activation	1
1	activation	is	7
2	of	c-Fos/c-Jun	5
3	transcriptional	factor	4
4	factor	of	2
5	c-Fos/c-Jun	activation	1
6	AP-1	c-Fos/c-Jun	5
7	is	<ROOT>	-1
8	essential	T	11
9	for	T	11
10	normal	T	11
11	T	is	7
12	cell	is	7
13	responsiveness	is	7
14	and	responsiveness	13
15	is	and	14
16	often	is	15
17	impaired	is	15
18	in	T	19
19	T	impaired	17
20	cells	is	7
21	during	is	7
22	aging	is	7
23	.	is	7

0	More	50	2
1	than	50	2
2	50	%	3
3	%	<ROOT>	-1
4	of	UT-7/GMT	6
5	TPO-treated	UT-7/GMT	6
6	UT-7/GMT	%	3
7	cells	stained	9
8	positively	stained	9
9	stained	UT-7/GMT	6
10	for	stained	9
11	Hb	for	10
12	.	%	3

0	Under	produced	5
1	these	conditions	2
2	conditions	Under	0
3	,	produced	5
4	etoposide	produced	5
5	produced	<ROOT>	-1
6	a	activation	8
7	biphasic	activation	8
8	activation	produced	5
9	of	kinase	11
10	protein	of	9
11	kinase	activation	8
12	C	produced	5
13	,	C	12
14	which	consisted	15
15	consisted	C	12
16	in	consisted	15
17	an	in	16
18	early	transient	19
19	transient	activation	20
20	activation	an	17
21	(	from	22
22	from	in	16
23	hours	from	22
24	1	hours	23
25	to	from	22
26	6	produced	5
27	)	produced	5
28	of	membrane-bound	30
29	the	membrane-bound	30
30	membrane-bound	produced	5
31	enzyme	followed	32
32	followed	membrane-bound	30
33	by	later	35
34	a	later	35
35	later	followed	32
36	activation	later	35
37	(	activation	36
38	hour	(	37
39	48	)	40
40	)	hour	38
41	of	later	35
42	the	of	41
43	total	,	44
44	,	membrane-bound	45
45	membrane-bound	the	42
46	and	membrane-bound	45
47	cytosolic	enzyme	48
48	enzyme	and	46
49	.	produced	5

0	Surprisingly	<ROOT>	-1
1	,	Surprisingly	0
2	expression	Surprisingly	0
3	of	expression	2
4	neither	BHRF1	5
5	BHRF1	of	3
6	nor	BHRF1	5
7	Bcl-2	nor	6
8	in	BHRF1	5
9	a	line	11
10	B-cell	line	11
11	line	in	8
12	,	Surprisingly	0
13	BJAB	Surprisingly	0
14	,	Surprisingly	0
15	protected	Surprisingly	0
16	the	cells	17
17	cells	protected	15
18	from	cells	17
19	anti-Fas-mediated	from	18
20	apoptosis	though	22
21	even	though	22
22	though	anti-Fas-mediated	19
23	they	increased	24
24	increased	though	22
25	the	survival	26
26	survival	increased	24
27	of	survival	26
28	serum-starved	cells	29
29	cells	of	27
30	.	cells	29

0	Among	mRNA	23
1	genes	Among	0
2	that	respond	3
3	respond	genes	1
4	to	transcription	6
5	these	transcription	6
6	transcription	respond	3
7	factors	was	12
8	,	was	12
9	IL-2	induction	11
10	mRNA	induction	11
11	induction	was	12
12	was	transcription	6
13	suppressed	transcription	6
14	by	transcription	6
15	PF	by	14
16	,	Among	0
17	whereas	IL-2R	18
18	IL-2R	(	19
19	(	Among	0
20	alpha	(	19
21	)	chain	22
22	chain	Among	0
23	mRNA	induction	24
24	induction	was	25
25	was	<ROOT>	-1
26	not	was	25
27	affected	was	25
28	.	was	25

0	In	was	5
1	contrast	In	0
2	,	was	5
3	released	TNF-alpha	4
4	TNF-alpha	was	5
5	was	<ROOT>	-1
6	not	was	5
7	responsible	was	5
8	for	responsible	7
9	the	aggregation	11
10	homotypic	aggregation	11
11	aggregation	for	8
12	of	aggregation	11
13	Ri-I	of	12
14	,	Ri-I	13
15	Ci-I	Ri-I	13
16	,	Ci-I	15
17	Sc-I	Ci-I	15
18	,	Sc-I	17
19	and	Raji	20
20	Raji	Sc-I	17
21	cells	was	5
22	induced	by	23
23	by	was	5
24	mAb	was	5
25	L243	was	5
26	,	was	5
27	and	was	5
28	it	did	29
29	did	and	27
30	not	did	29
31	affect	did	29
32	the	proliferation	33
33	proliferation	affect	31
34	of	B	35
35	B	proliferation	33
36	cells	was	5
37	investigated	was	5
38	.	was	5

0	In	<ROOT>	-1
1	vivo	In	0
2	genomic	vivo	1
3	DMS	genomic	2
4	footprinting	DMS	3
5	revealed	footprinting	4
6	upstream	revealed	5
7	of	upstream	6
8	the	of	7
9	major	transcription	10
10	transcription	the	8
11	initiation	transcription	10
12	sites	initiation	11
13	,	sites	12
14	the	,	13
15	presence	the	14
16	of	presence	15
17	at	three	19
18	least	three	19
19	three	of	16
20	protein	were	27
21	binding	were	27
22	sites	were	27
23	,	were	27
24	two	were	27
25	of	two	24
26	which	of	25
27	were	three	19
28	constitutively	were	27
29	occupied	constitutively	28
30	.	occupied	29

0	Endonuclease	analyses	1
1	analyses	revealed	5
2	and	analyses	1
3	DNA	sequencing	4
4	sequencing	and	2
5	revealed	<ROOT>	-1
6	DNA	reiteration	7
7	reiteration	revealed	5
8	in	reiteration	7
9	each	mutant	10
10	mutant	in	8
11	.	revealed	5

0	In	<ROOT>	-1
1	the	report	3
2	present	report	3
3	report	In	0
4	,	we	5
5	we	B	8
6	identified	we	5
7	NF-kappa	we	5
8	B	In	0
9	proteins	In	0
10	extracted	In	0
11	from	In	0
12	human	In	0
13	thymocyte	nuclei	14
14	nuclei	In	0
15	as	being	16
16	being	In	0
17	p50/p65	In	0
18	and	In	0
19	p50/c-Rel	In	0
20	complexes	In	0
21	.	In	0

